{"PMID":10047461,"re_id":0,"annotated sentence":"<e1>Tomudex<\\e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in <e2>cyclin E<\\e2> and cdk2 protein expression and kinase activities 24 h after a 2-h exposure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"cyclin E","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in <e2>GENE-Y<\\e2> and cdk2 protein expression and kinase activities 24 h after a 2-h exposure","sentence":"Tomudex treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure"}
{"PMID":10047461,"re_id":1,"annotated sentence":"<e1>Tomudex<\\e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and <e2>cdk2<\\e2> protein expression and kinase activities 24 h after a 2-h exposure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"cdk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and <e2>GENE-Y<\\e2> protein expression and kinase activities 24 h after a 2-h exposure","sentence":"Tomudex treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure"}
{"PMID":10047461,"re_id":2,"annotated sentence":"<e1>Tomudex<\\e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and <e2>kinase<\\e2> activities 24 h after a 2-h exposure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and <e2>GENE-N<\\e2> activities 24 h after a 2-h exposure","sentence":"Tomudex treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure"}
{"PMID":10047461,"re_id":3,"annotated sentence":"The studies with dThyd rescue from <e2>cyclin E<\\e2> cdk2 protein overexpression and growth inhibition by <e1>Tomudex<\\e1> indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"cyclin E","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The studies with dThyd rescue from <e2>GENE-Y<\\e2> cdk2 protein overexpression and growth inhibition by <e1>CHEMICAL<\\e1> indicate that increased GENE-Y-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","sentence":"The studies with dThyd rescue from cyclin E cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance"}
{"PMID":10047461,"re_id":4,"annotated sentence":"The studies with dThyd rescue from cyclin E-<e2>cdk2<\\e2> protein overexpression and growth inhibition by <e1>Tomudex<\\e1> indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"cdk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The studies with dThyd rescue from cyclin E-<e2>GENE-Y<\\e2> protein overexpression and growth inhibition by <e1>CHEMICAL<\\e1> indicate that increased cyclin E-GENE-Y protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","sentence":"The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance"}
{"PMID":10047461,"re_id":5,"annotated sentence":"The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by <e1>Tomudex<\\e1> indicate that increased <e2>cyclin E<\\e2> cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"cyclin E","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The studies with dThyd rescue from GENE-Y-cdk2 protein overexpression and growth inhibition by <e1>CHEMICAL<\\e1> indicate that increased <e2>GENE-Y<\\e2> cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","sentence":"The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance"}
{"PMID":10047461,"re_id":6,"annotated sentence":"The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by <e1>Tomudex<\\e1> indicate that increased cyclin E-<e2>cdk2<\\e2> protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"cdk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The studies with dThyd rescue from cyclin E-GENE-Y protein overexpression and growth inhibition by <e1>CHEMICAL<\\e1> indicate that increased cyclin E-<e2>GENE-Y<\\e2> protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","sentence":"The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance"}
{"PMID":10047461,"re_id":7,"annotated sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by <e1>Tomudex<\\e1> and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in <e2>cyclin E<\\e2> and cdk2 kinase activities","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"cyclin E","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by <e1>CHEMICAL<\\e1> and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in <e2>GENE-Y<\\e2> and cdk2 kinase activities","sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities"}
{"PMID":10047461,"re_id":8,"annotated sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by <e1>Tomudex<\\e1> and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and <e2>cdk2<\\e2> kinase activities","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"cdk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by <e1>CHEMICAL<\\e1> and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and <e2>GENE-Y<\\e2> kinase activities","sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities"}
{"PMID":10047461,"re_id":9,"annotated sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by <e1>Tomudex<\\e1> and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 <e2>kinase<\\e2> activities","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by <e1>CHEMICAL<\\e1> and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 <e2>GENE-N<\\e2> activities","sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities"}
{"PMID":10047461,"re_id":10,"annotated sentence":"Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of <e2>thymidylate synthase<\\e2> by <e1>Tomudex<\\e1>  Twenty-four hours following the initial 2-h treatment with Tomudex, human A253 head and neck squamous carcinoma cells, not expressing p53 and p21(WAF1), were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2\/M phases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1>  Twenty-four hours following the initial 2-h treatment with CHEMICAL, human A253 head and neck squamous carcinoma cells, not expressing p53 and p21(WAF1), were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2\/M phases","sentence":"Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of thymidylate synthase by Tomudex  Twenty-four hours following the initial 2-h treatment with Tomudex, human A253 head and neck squamous carcinoma cells, not expressing p53 and p21(WAF1), were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2\/M phases"}
{"PMID":10047461,"re_id":11,"annotated sentence":"<e1>Tomudex<\\e1> treatment resulted in the decrease in <e2>p27(kip1)<\\e2> expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"p27(kip1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment resulted in the decrease in <e2>GENE-Y<\\e2> expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure","sentence":"Tomudex treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure"}
{"PMID":10047461,"re_id":12,"annotated sentence":"Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the <e2>thymidylate synthase<\\e2> inhibitor <e1>Tomudex<\\e1>  Tomudex (ZD1694) is a specific antifolate-based thymidylate synthase inhibitor active in a variety of solid tumor malignancies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  CHEMICAL (ZD1694) is a specific antifolate-based GENE-Y inhibitor active in a variety of solid tumor malignancies","sentence":"Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex  Tomudex (ZD1694) is a specific antifolate-based thymidylate synthase inhibitor active in a variety of solid tumor malignancies"}
{"PMID":10047461,"re_id":13,"annotated sentence":"<e1>Tomudex<\\e1> (ZD1694) is a specific antifolate-based <e2>thymidylate synthase<\\e2> inhibitor active in a variety of solid tumor malignancies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (ZD1694) is a specific antifolate-based <e2>GENE-Y<\\e2> inhibitor active in a variety of solid tumor malignancies","sentence":"Tomudex (ZD1694) is a specific antifolate-based thymidylate synthase inhibitor active in a variety of solid tumor malignancies"}
{"PMID":10047461,"re_id":14,"annotated sentence":"The studies with dThyd rescue from <e2>cyclin E<\\e2> cdk2 protein overexpression and growth inhibition by <e1>Tomudex<\\e1> indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"cyclin E","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The studies with dThyd rescue from <e2>GENE-Y<\\e2> cdk2 protein overexpression and growth inhibition by <e1>CHEMICAL<\\e1> indicate that increased GENE-Y-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","sentence":"The studies with dThyd rescue from cyclin E cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance"}
{"PMID":10047461,"re_id":15,"annotated sentence":"The studies with dThyd rescue from cyclin E-<e2>cdk2<\\e2> protein overexpression and growth inhibition by <e1>Tomudex<\\e1> indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"cdk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The studies with dThyd rescue from cyclin E-<e2>GENE-Y<\\e2> protein overexpression and growth inhibition by <e1>CHEMICAL<\\e1> indicate that increased cyclin E-GENE-Y protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance","sentence":"The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance"}
{"PMID":10047461,"re_id":16,"annotated sentence":"The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by <e1>Tomudex<\\e1> indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of <e2>thymidylate synthase<\\e2> and resultant dNTP pool imbalance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by <e1>CHEMICAL<\\e1> indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of <e2>GENE-Y<\\e2> and resultant dNTP pool imbalance","sentence":"The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance"}
{"PMID":10047461,"re_id":17,"annotated sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of <e2>thymidylate synthase<\\e2> by <e1>Tomudex<\\e1> and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities","sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities"}
{"PMID":10047461,"re_id":18,"annotated sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by <e1>Tomudex<\\e1> and kilobase DNA fragmentation may correlate with the reduction of <e2>p27(kip1)<\\e2> expression and the increase in cyclin E and cdk2 kinase activities","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tomudex","object":"p27(kip1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by <e1>CHEMICAL<\\e1> and kilobase DNA fragmentation may correlate with the reduction of <e2>GENE-Y<\\e2> expression and the increase in cyclin E and cdk2 kinase activities","sentence":"These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities"}
{"PMID":10095983,"re_id":0,"annotated sentence":"In the long term, <e1>orlistat<\\e1> has been shown to be more effective than placebo in reducing body weight and serum total and <e2>low-density lipoprotein<\\e2> cholesterol levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"orlistat","object":"low-density lipoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the long term, <e1>CHEMICAL<\\e1> has been shown to be more effective than placebo in reducing body weight and serum total and <e2>GENE-N<\\e2> cholesterol levels","sentence":"In the long term, orlistat has been shown to be more effective than placebo in reducing body weight and serum total and low-density lipoprotein cholesterol levels"}
{"PMID":10095983,"re_id":1,"annotated sentence":"<e1>Orlistat<\\e1> is a new inhibitor of <e2>pancreatic lipase<\\e2> enzyme","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Orlistat","object":"pancreatic lipase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a new inhibitor of <e2>GENE-Y<\\e2> enzyme","sentence":"Orlistat is a new inhibitor of pancreatic lipase enzyme"}
{"PMID":10200320,"re_id":0,"annotated sentence":"<e1>Cyclopentenone prostaglandins<\\e1> were potent inhibitors of <e2>iNOS<\\e2> induction and were more effective than their precursors, prostaglandins E2 and D2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cyclopentenone prostaglandins","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> were potent inhibitors of <e2>GENE-Y<\\e2> induction and were more effective than their precursors, prostaglandins E2 and D2","sentence":"Cyclopentenone prostaglandins were potent inhibitors of iNOS induction and were more effective than their precursors, prostaglandins E2 and D2"}
{"PMID":10200320,"re_id":1,"annotated sentence":"Cyclopentenone prostaglandins were potent inhibitors of <e2>iNOS<\\e2> induction and were more effective than their precursors, <e1>prostaglandins E2 and D2<\\e1>  15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) was the most potent prostaglandin among those tested","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prostaglandins E2 and D2","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cyclopentenone prostaglandins were potent inhibitors of <e2>GENE-Y<\\e2> induction and were more effective than their precursors, <e1>CHEMICAL<\\e1>  15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) was the most potent prostaglandin among those tested","sentence":"Cyclopentenone prostaglandins were potent inhibitors of iNOS induction and were more effective than their precursors, prostaglandins E2 and D2  15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) was the most potent prostaglandin among those tested"}
{"PMID":10200320,"re_id":2,"annotated sentence":"In activated microglia, <e1>15d-PGJ2<\\e1> suppressed <e2>iNOS promoter<\\e2> activity, iNOS mRNA, and protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"15d-PGJ2","object":"iNOS promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In activated microglia, <e1>CHEMICAL<\\e1> suppressed <e2>GENE-N<\\e2> activity, iNOS mRNA, and protein levels","sentence":"In activated microglia, 15d-PGJ2 suppressed iNOS promoter activity, iNOS mRNA, and protein levels"}
{"PMID":10200320,"re_id":3,"annotated sentence":"In activated microglia, <e1>15d-PGJ2<\\e1> suppressed iNOS promoter activity, <e2>iNOS<\\e2> mRNA, and protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"15d-PGJ2","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In activated microglia, <e1>CHEMICAL<\\e1> suppressed GENE-Y promoter activity, <e2>GENE-Y<\\e2> mRNA, and protein levels","sentence":"In activated microglia, 15d-PGJ2 suppressed iNOS promoter activity, iNOS mRNA, and protein levels"}
{"PMID":10200320,"re_id":4,"annotated sentence":"<e1>Cyclopentenone prostaglandins<\\e1> suppress activation of microglia: down-regulation of <e2>inducible nitric-oxide synthase<\\e2> by 15-deoxy-Delta12,14-prostaglandin J2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cyclopentenone prostaglandins","object":"inducible nitric-oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppress activation of microglia: down-regulation of <e2>GENE-Y<\\e2> by 15-deoxy-Delta12,14-prostaglandin J2","sentence":"Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2"}
{"PMID":10200320,"re_id":5,"annotated sentence":"Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of <e2>inducible nitric-oxide synthase<\\e2> by <e1>15-deoxy-Delta12,14-prostaglandin J2<\\e1>  Mechanisms leading to down-regulation of activated microglia and astrocytes are poorly understood, in spite of the potentially detrimental role of activated glia in neurodegeneration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"15-deoxy-Delta12,14-prostaglandin J2","object":"inducible nitric-oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1>  Mechanisms leading to down-regulation of activated microglia and astrocytes are poorly understood, in spite of the potentially detrimental role of activated glia in neurodegeneration","sentence":"Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2  Mechanisms leading to down-regulation of activated microglia and astrocytes are poorly understood, in spite of the potentially detrimental role of activated glia in neurodegeneration"}
{"PMID":10200320,"re_id":6,"annotated sentence":"<e1>15d-PGJ2<\\e1> did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an <e2>NFkappaB<\\e2> reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"15d-PGJ2","object":"NFkappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> did not block nuclear translocation or DNA-binding activity of the transcription factor GENE-N, but it did inhibit the activity of an <e2>GENE-N<\\e2> reporter construct, suggesting that the mechanism of suppression of microglial iNOS by CHEMICAL may involve interference with GENE-N transcriptional activity in the nucleus","sentence":"15d-PGJ2 did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus"}
{"PMID":10200320,"re_id":7,"annotated sentence":"15d-PGJ2 did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial <e2>iNOS<\\e2> by <e1>15d-PGJ2<\\e1> may involve interference with NFkappaB transcriptional activity in the nucleus","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"15d-PGJ2","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICAL did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> may involve interference with NFkappaB transcriptional activity in the nucleus","sentence":"15d-PGJ2 did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus"}
{"PMID":10207608,"re_id":0,"annotated sentence":"<e2>Phospholipase A2<\\e2> inhibitors <e1>p-bromophenacyl bromide<\\e1> and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"p-bromophenacyl bromide","object":"Phospholipase A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1> and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes","sentence":"Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes"}
{"PMID":10207608,"re_id":1,"annotated sentence":"Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed <e1>phorbol 12-myristate 13-acetate<\\e1> plus ionomycin-induced <e2>IL-2<\\e2> secretion in a concentration-dependent manner","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phorbol 12-myristate 13-acetate","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed <e1>CHEMICAL<\\e1> plus ionomycin-induced <e2>GENE-Y<\\e2> secretion in a concentration-dependent manner","sentence":"Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner"}
{"PMID":10207608,"re_id":2,"annotated sentence":"Likewise, <e2>IL-2<\\e2> steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM <e1>BPB<\\e1> and 20 microM AACOCF3","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPB","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Likewise, <e2>GENE-Y<\\e2> steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM <e1>CHEMICAL<\\e1> and 20 microM AACOCF3","sentence":"Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3"}
{"PMID":10207608,"re_id":3,"annotated sentence":"Likewise, IL-2 steady-state mRNA expression was inhibited by both <e2>PLA2<\\e2> inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM <e1>BPB<\\e1> and 20 microM AACOCF3","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPB","object":"PLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Likewise, IL-2 steady-state mRNA expression was inhibited by both <e2>GENE-Y<\\e2> inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM <e1>CHEMICAL<\\e1> and 20 microM AACOCF3","sentence":"Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3"}
{"PMID":10207608,"re_id":4,"annotated sentence":"Likewise, <e2>IL-2<\\e2> steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM <e1>AACOCF3<\\e1>  Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AACOCF3","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Likewise, <e2>GENE-Y<\\e2> steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM <e1>CHEMICAL<\\e1>  Taken together, these data demonstrated that PLA2 inhibitors BPB and CHEMICAL are robust inhibitors of GENE-Y expression at both the mRNA and protein levels in murine splenocytes","sentence":"Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3  Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes"}
{"PMID":10207608,"re_id":5,"annotated sentence":"Likewise, IL-2 steady-state mRNA expression was inhibited by both <e2>PLA2<\\e2> inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM <e1>AACOCF3<\\e1>  Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AACOCF3","object":"PLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Likewise, IL-2 steady-state mRNA expression was inhibited by both <e2>GENE-Y<\\e2> inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM <e1>CHEMICAL<\\e1>  Taken together, these data demonstrated that GENE-Y inhibitors BPB and CHEMICAL are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes","sentence":"Likewise, IL-2 steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM AACOCF3  Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes"}
{"PMID":10207608,"re_id":6,"annotated sentence":"Taken together, these data demonstrated that <e2>PLA2<\\e2> inhibitors <e1>BPB<\\e1> and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPB","object":"PLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, these data demonstrated that <e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1> and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes","sentence":"Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes"}
{"PMID":10207608,"re_id":7,"annotated sentence":"Taken together, these data demonstrated that PLA2 inhibitors <e1>BPB<\\e1> and AACOCF3 are robust inhibitors of <e2>IL-2<\\e2> expression at both the mRNA and protein levels in murine splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPB","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, these data demonstrated that PLA2 inhibitors <e1>CHEMICAL<\\e1> and AACOCF3 are robust inhibitors of <e2>GENE-Y<\\e2> expression at both the mRNA and protein levels in murine splenocytes","sentence":"Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes"}
{"PMID":10207608,"re_id":8,"annotated sentence":"Taken together, these data demonstrated that <e2>PLA2<\\e2> inhibitors BPB and <e1>AACOCF3<\\e1> are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AACOCF3","object":"PLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, these data demonstrated that <e2>GENE-Y<\\e2> inhibitors BPB and <e1>CHEMICAL<\\e1> are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes","sentence":"Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes"}
{"PMID":10207608,"re_id":9,"annotated sentence":"Taken together, these data demonstrated that PLA2 inhibitors BPB and <e1>AACOCF3<\\e1> are robust inhibitors of <e2>IL-2<\\e2> expression at both the mRNA and protein levels in murine splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AACOCF3","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, these data demonstrated that PLA2 inhibitors BPB and <e1>CHEMICAL<\\e1> are robust inhibitors of <e2>GENE-Y<\\e2> expression at both the mRNA and protein levels in murine splenocytes","sentence":"Taken together, these data demonstrated that PLA2 inhibitors BPB and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes"}
{"PMID":10207608,"re_id":10,"annotated sentence":"Phospholipase A2 inhibitors <e1>p-bromophenacyl bromide<\\e1> and arachidonyl trifluoromethyl ketone suppressed <e2>interleukin-2<\\e2> (IL-2) expression in murine primary splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-bromophenacyl bromide","object":"interleukin-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phospholipase A2 inhibitors <e1>CHEMICAL<\\e1> and arachidonyl trifluoromethyl ketone suppressed <e2>GENE-Y<\\e2> (IL-2) expression in murine primary splenocytes","sentence":"Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes"}
{"PMID":10207608,"re_id":11,"annotated sentence":"Phospholipase A2 inhibitors <e1>p-bromophenacyl bromide<\\e1> and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (<e2>IL-2<\\e2>  expression in murine primary splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-bromophenacyl bromide","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phospholipase A2 inhibitors <e1>CHEMICAL<\\e1> and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (<e2>GENE-Y<\\e2>  expression in murine primary splenocytes","sentence":"Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2  expression in murine primary splenocytes"}
{"PMID":10207608,"re_id":12,"annotated sentence":"<e2>Phospholipase A2<\\e2> inhibitors p-bromophenacyl bromide and <e1>arachidonyl trifluoromethyl ketone<\\e1> suppressed interleukin-2 (IL-2) expression in murine primary splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"arachidonyl trifluoromethyl ketone","object":"Phospholipase A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors p-bromophenacyl bromide and <e1>CHEMICAL<\\e1> suppressed interleukin-2 (IL-2) expression in murine primary splenocytes","sentence":"Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes"}
{"PMID":10207608,"re_id":13,"annotated sentence":"Phospholipase A2 inhibitors p-bromophenacyl bromide and <e1>arachidonyl trifluoromethyl ketone<\\e1> suppressed <e2>interleukin-2<\\e2> (IL-2) expression in murine primary splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"arachidonyl trifluoromethyl ketone","object":"interleukin-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phospholipase A2 inhibitors p-bromophenacyl bromide and <e1>CHEMICAL<\\e1> suppressed <e2>GENE-Y<\\e2> (IL-2) expression in murine primary splenocytes","sentence":"Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes"}
{"PMID":10207608,"re_id":14,"annotated sentence":"Phospholipase A2 inhibitors p-bromophenacyl bromide and <e1>arachidonyl trifluoromethyl ketone<\\e1> suppressed interleukin-2 (<e2>IL-2<\\e2>  expression in murine primary splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"arachidonyl trifluoromethyl ketone","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phospholipase A2 inhibitors p-bromophenacyl bromide and <e1>CHEMICAL<\\e1> suppressed interleukin-2 (<e2>GENE-Y<\\e2>  expression in murine primary splenocytes","sentence":"Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2  expression in murine primary splenocytes"}
{"PMID":10207608,"re_id":15,"annotated sentence":"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2<\\e2> inhibitors <e1>p-bromophenacyl bromide<\\e1> (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-bromophenacyl bromide","object":"PLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Therefore, the objective of the present study was to investigate the effects of <e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1> (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes","sentence":"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes"}
{"PMID":10207608,"re_id":16,"annotated sentence":"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2<\\e2> inhibitors p-bromophenacyl bromide (<e1>BPB<\\e1>  and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPB","object":"PLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Therefore, the objective of the present study was to investigate the effects of <e2>GENE-Y<\\e2> inhibitors p-bromophenacyl bromide (<e1>CHEMICAL<\\e1>  and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes","sentence":"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB  and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes"}
{"PMID":10207608,"re_id":17,"annotated sentence":"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2<\\e2> inhibitors p-bromophenacyl bromide (BPB) and <e1>arachidonyl trifluoromethyl ketone<\\e1> (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"arachidonyl trifluoromethyl ketone","object":"PLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Therefore, the objective of the present study was to investigate the effects of <e2>GENE-Y<\\e2> inhibitors p-bromophenacyl bromide (BPB) and <e1>CHEMICAL<\\e1> (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes","sentence":"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes"}
{"PMID":10207608,"re_id":18,"annotated sentence":"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2<\\e2> inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>AACOCF3<\\e1>  on interleukin-2 (IL-2) expression in murine primary splenocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AACOCF3","object":"PLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Therefore, the objective of the present study was to investigate the effects of <e2>GENE-Y<\\e2> inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>CHEMICAL<\\e1>  on interleukin-2 (IL-2) expression in murine primary splenocytes","sentence":"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3  on interleukin-2 (IL-2) expression in murine primary splenocytes"}
{"PMID":10207608,"re_id":19,"annotated sentence":"Pretreatment of the splenocytes with both <e1>BPB<\\e1> and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced <e2>IL-2<\\e2> secretion in a concentration-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPB","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment of the splenocytes with both <e1>CHEMICAL<\\e1> and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced <e2>GENE-Y<\\e2> secretion in a concentration-dependent manner","sentence":"Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner"}
{"PMID":10207608,"re_id":20,"annotated sentence":"Pretreatment of the splenocytes with both BPB and <e1>AACOCF3<\\e1> suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced <e2>IL-2<\\e2> secretion in a concentration-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AACOCF3","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment of the splenocytes with both BPB and <e1>CHEMICAL<\\e1> suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced <e2>GENE-Y<\\e2> secretion in a concentration-dependent manner","sentence":"Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced IL-2 secretion in a concentration-dependent manner"}
{"PMID":10207608,"re_id":21,"annotated sentence":"Inhibition > 90% of <e2>IL-2<\\e2> secretion was observed at 1 microM <e1>BPB<\\e1> and 10 microM AACOCF3 compared to the respective vehicle control","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPB","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition > 90% of <e2>GENE-Y<\\e2> secretion was observed at 1 microM <e1>CHEMICAL<\\e1> and 10 microM AACOCF3 compared to the respective vehicle control","sentence":"Inhibition > 90% of IL-2 secretion was observed at 1 microM BPB and 10 microM AACOCF3 compared to the respective vehicle control"}
{"PMID":10207608,"re_id":22,"annotated sentence":"Inhibition > 90% of <e2>IL-2<\\e2> secretion was observed at 1 microM BPB and 10 microM <e1>AACOCF3<\\e1> compared to the respective vehicle control","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AACOCF3","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition > 90% of <e2>GENE-Y<\\e2> secretion was observed at 1 microM BPB and 10 microM <e1>CHEMICAL<\\e1> compared to the respective vehicle control","sentence":"Inhibition > 90% of IL-2 secretion was observed at 1 microM BPB and 10 microM AACOCF3 compared to the respective vehicle control"}
{"PMID":10225363,"re_id":0,"annotated sentence":"<e2>c-fos<\\e2> expression was induced in urethane-anaesthetized rats by intracisternal <e1>capsaicin<\\e1> administration","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"capsaicin","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> expression was induced in urethane-anaesthetized rats by intracisternal <e1>CHEMICAL<\\e1> administration","sentence":"c-fos expression was induced in urethane-anaesthetized rats by intracisternal capsaicin administration"}
{"PMID":10225363,"re_id":1,"annotated sentence":"Sumatriptan and LY 344864 decreased the number of <e1>capsaicin<\\e1> induced <e2>c-fos<\\e2> like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"capsaicin","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sumatriptan and LY 344864 decreased the number of <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))","sentence":"Sumatriptan and LY 344864 decreased the number of capsaicin induced c-fos like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))"}
{"PMID":10225363,"re_id":2,"annotated sentence":"<e1>Sumatriptan<\\e1> and LY 344864 decreased the number of capsaicin-induced <e2>c-fos<\\e2> like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sumatriptan","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and LY 344864 decreased the number of capsaicin-induced <e2>GENE-Y<\\e2> like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))","sentence":"Sumatriptan and LY 344864 decreased the number of capsaicin-induced c-fos like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))"}
{"PMID":10225363,"re_id":3,"annotated sentence":"Sumatriptan and <e1>LY 344864<\\e1> decreased the number of capsaicin-induced <e2>c-fos<\\e2> like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LY 344864","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sumatriptan and <e1>CHEMICAL<\\e1> decreased the number of capsaicin-induced <e2>GENE-Y<\\e2> like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))","sentence":"Sumatriptan and LY 344864 decreased the number of capsaicin-induced c-fos like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))"}
{"PMID":10225363,"re_id":4,"annotated sentence":"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective <e2>5-HT1F<\\e2> receptor agonist (<e1>LY 344864<\\e1>  on c-fos protein expression in the trigeminal nucleus caudalis","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"LY 344864","object":"5-HT1F","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective <e2>GENE-Y<\\e2> receptor agonist (<e1>CHEMICAL<\\e1>  on c-fos protein expression in the trigeminal nucleus caudalis","sentence":"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist (LY 344864  on c-fos protein expression in the trigeminal nucleus caudalis"}
{"PMID":10225363,"re_id":5,"annotated sentence":"The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist <e1>SDZ 21-009<\\e1>  which displays high affinity for <e2>rat 5-HT1B<\\e2> receptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SDZ 21-009","object":"rat 5-HT1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist <e1>CHEMICAL<\\e1>  which displays high affinity for <e2>GENE-Y<\\e2> receptors","sentence":"The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist SDZ 21-009  which displays high affinity for rat 5-HT1B receptors"}
{"PMID":10328230,"re_id":0,"annotated sentence":"Both <e1>BB-94<\\e1> and captopril also prevented substrate degradation by <e2>gelatinase A and B<\\e2> released in conditioned medium by cultured cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BB-94","object":"gelatinase A and B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both <e1>CHEMICAL<\\e1> and captopril also prevented substrate degradation by <e2>GENE-N<\\e2> released in conditioned medium by cultured cells","sentence":"Both BB-94 and captopril also prevented substrate degradation by gelatinase A and B released in conditioned medium by cultured cells"}
{"PMID":10328230,"re_id":1,"annotated sentence":"We have examined the effects of the synthetic <e2>matrix metalloproteinase<\\e2> inhibitor, <e1>batimastat<\\e1> (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL\/6 mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"batimastat","object":"matrix metalloproteinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have examined the effects of the synthetic <e2>GENE-N<\\e2> inhibitor, <e1>CHEMICAL<\\e1> (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL\/6 mice","sentence":"We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL\/6 mice"}
{"PMID":10328230,"re_id":2,"annotated sentence":"We have examined the effects of the synthetic <e2>matrix metalloproteinase<\\e2> inhibitor, batimastat (<e1>BB-94<\\e1>  and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL\/6 mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BB-94","object":"matrix metalloproteinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have examined the effects of the synthetic <e2>GENE-N<\\e2> inhibitor, batimastat (<e1>CHEMICAL<\\e1>  and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL\/6 mice","sentence":"We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94  and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL\/6 mice"}
{"PMID":10328230,"re_id":3,"annotated sentence":"Inhibition of <e2>gelatinase A<\\e2> (MMP-2) by <e1>batimastat<\\e1> and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"batimastat","object":"gelatinase A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> (MMP-2) by <e1>CHEMICAL<\\e1> and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma","sentence":"Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma"}
{"PMID":10328230,"re_id":4,"annotated sentence":"Inhibition of gelatinase A (<e2>MMP-2<\\e2>  by <e1>batimastat<\\e1> and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"batimastat","object":"MMP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of gelatinase A (<e2>GENE-Y<\\e2>  by <e1>CHEMICAL<\\e1> and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma","sentence":"Inhibition of gelatinase A (MMP-2  by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma"}
{"PMID":10328230,"re_id":5,"annotated sentence":"Inhibition of <e2>gelatinase A<\\e2> (MMP-2) by batimastat and <e1>captopril<\\e1> reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"captopril","object":"gelatinase A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> (MMP-2) by batimastat and <e1>CHEMICAL<\\e1> reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma","sentence":"Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma"}
{"PMID":10328230,"re_id":6,"annotated sentence":"Inhibition of gelatinase A (<e2>MMP-2<\\e2>  by batimastat and <e1>captopril<\\e1> reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"captopril","object":"MMP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of gelatinase A (<e2>GENE-Y<\\e2>  by batimastat and <e1>CHEMICAL<\\e1> reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma","sentence":"Inhibition of gelatinase A (MMP-2  by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma"}
{"PMID":10328230,"re_id":7,"annotated sentence":"We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the <e2>angiotensin-converting enzyme<\\e2> inhibitor, <e1>captopril<\\e1>  on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL\/6 mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"captopril","object":"angiotensin-converting enzyme","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL\/6 mice","sentence":"We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the angiotensin-converting enzyme inhibitor, captopril  on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL\/6 mice"}
{"PMID":10328230,"re_id":8,"annotated sentence":"Here we report that <e1>captopril<\\e1> treatment resulted in decreased transcription and protein levels of <e2>gelatinase A<\\e2> by 3LL cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"captopril","object":"gelatinase A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we report that <e1>CHEMICAL<\\e1> treatment resulted in decreased transcription and protein levels of <e2>GENE-Y<\\e2> by 3LL cells","sentence":"Here we report that captopril treatment resulted in decreased transcription and protein levels of gelatinase A by 3LL cells"}
{"PMID":10340919,"re_id":0,"annotated sentence":"Thus our data suggest that the <e2>COX-2<\\e2> preference of <e1>meloxicam<\\e1> observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus our data suggest that the <e2>GENE-Y<\\e2> preference of <e1>CHEMICAL<\\e1> observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed","sentence":"Thus our data suggest that the COX-2 preference of meloxicam observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed"}
{"PMID":10340919,"re_id":1,"annotated sentence":"The effects of <e1>meloxicam<\\e1> were compared with those of diclofenac, a nonselective <e2>COX<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The effects of <e1>CHEMICAL<\\e1> were compared with those of diclofenac, a nonselective <e2>GENE-N<\\e2> inhibitor","sentence":"The effects of meloxicam were compared with those of diclofenac, a nonselective COX inhibitor"}
{"PMID":10340919,"re_id":2,"annotated sentence":"The effects of meloxicam were compared with those of <e1>diclofenac<\\e1>  a nonselective <e2>COX<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diclofenac","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The effects of meloxicam were compared with those of <e1>CHEMICAL<\\e1>  a nonselective <e2>GENE-N<\\e2> inhibitor","sentence":"The effects of meloxicam were compared with those of diclofenac  a nonselective COX inhibitor"}
{"PMID":10340919,"re_id":3,"annotated sentence":"METHODS: <e2>COX-1<\\e2> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg <e1>meloxicam<\\e1> and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: <e2>GENE-Y<\\e2> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg <e1>CHEMICAL<\\e1> and 75 mg diclofenac and at steady state (15 mg CHEMICAL daily and 150 mg diclofenac daily)","sentence":"METHODS: COX-1 inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily)"}
{"PMID":10340919,"re_id":4,"annotated sentence":"METHODS: <e2>COX-1<\\e2> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg <e1>diclofenac<\\e1> and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diclofenac","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: <e2>GENE-Y<\\e2> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg <e1>CHEMICAL<\\e1> and at steady state (15 mg meloxicam daily and 150 mg CHEMICAL daily)","sentence":"METHODS: COX-1 inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily)"}
{"PMID":10340919,"re_id":5,"annotated sentence":"METHODS: <e2>COX-1<\\e2> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg <e1>meloxicam<\\e1> daily and 150 mg diclofenac daily)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: <e2>GENE-Y<\\e2> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg CHEMICAL and 75 mg diclofenac and at steady state (15 mg <e1>CHEMICAL<\\e1> daily and 150 mg diclofenac daily)","sentence":"METHODS: COX-1 inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily)"}
{"PMID":10340919,"re_id":6,"annotated sentence":"METHODS: <e2>COX-1<\\e2> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg <e1>diclofenac<\\e1> daily)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diclofenac","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: <e2>GENE-Y<\\e2> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg CHEMICAL and at steady state (15 mg meloxicam daily and 150 mg <e1>CHEMICAL<\\e1> daily)","sentence":"METHODS: COX-1 inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily)"}
{"PMID":10340919,"re_id":7,"annotated sentence":"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by <e1>meloxicam<\\e1>  which has been reported to preferentially inhibit <e2>cyclooxygenase-2<\\e2> (COX-2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by <e1>CHEMICAL<\\e1>  which has been reported to preferentially inhibit <e2>GENE-Y<\\e2> (COX-2)","sentence":"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by meloxicam  which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2)"}
{"PMID":10340919,"re_id":8,"annotated sentence":"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by <e1>meloxicam<\\e1>  which has been reported to preferentially inhibit cyclooxygenase-2 (<e2>COX-2<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by <e1>CHEMICAL<\\e1>  which has been reported to preferentially inhibit cyclooxygenase-2 (<e2>GENE-Y<\\e2> ","sentence":"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by meloxicam  which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2 "}
{"PMID":10340919,"re_id":9,"annotated sentence":"OBJECTIVE: To evaluate the extent of <e2>human cyclooxygenase-1<\\e2> (COX-1) inhibition by <e1>meloxicam<\\e1>  which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"human cyclooxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: To evaluate the extent of <e2>GENE-Y<\\e2> (COX-1) inhibition by <e1>CHEMICAL<\\e1>  which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2)","sentence":"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by meloxicam  which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2)"}
{"PMID":10340919,"re_id":10,"annotated sentence":"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (<e2>COX-1<\\e2>  inhibition by <e1>meloxicam<\\e1>  which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (<e2>GENE-Y<\\e2>  inhibition by <e1>CHEMICAL<\\e1>  which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2)","sentence":"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1  inhibition by meloxicam  which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2)"}
{"PMID":10373451,"re_id":0,"annotated sentence":"Of the <e2>PDE<\\e2> inhibitors tested, <e1>dipyridamole<\\e1> was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dipyridamole","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Of the <e2>GENE-N<\\e2> inhibitors tested, <e1>CHEMICAL<\\e1> was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively","sentence":"Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively"}
{"PMID":10373451,"re_id":1,"annotated sentence":"Of the <e2>PDE<\\e2> inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of <e1>cAMP<\\e1> and cGMP hydrolysis, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Of the <e2>GENE-N<\\e2> inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of <e1>CHEMICAL<\\e1> and cGMP hydrolysis, respectively","sentence":"Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively"}
{"PMID":10373451,"re_id":2,"annotated sentence":"Of the <e2>PDE<\\e2> inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and <e1>cGMP<\\e1> hydrolysis, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cGMP","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Of the <e2>GENE-N<\\e2> inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and <e1>CHEMICAL<\\e1> hydrolysis, respectively","sentence":"Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively"}
{"PMID":10373451,"re_id":3,"annotated sentence":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both <e1>cAMP<\\e1> and cGMP (<e2>PDE10A<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"PDE10A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both <e1>CHEMICAL<\\e1> and cGMP (<e2>GENE-Y<\\e2> ","sentence":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A "}
{"PMID":10373451,"re_id":4,"annotated sentence":"Cloning and characterization of a novel <e2>human phosphodiesterase<\\e2> that hydrolyzes both <e1>cAMP<\\e1> and cGMP (PDE10A)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"human phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cloning and characterization of a novel <e2>GENE-N<\\e2> that hydrolyzes both <e1>CHEMICAL<\\e1> and cGMP (PDE10A)","sentence":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)"}
{"PMID":10373451,"re_id":5,"annotated sentence":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and <e1>cGMP<\\e1> (<e2>PDE10A<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cGMP","object":"PDE10A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> ","sentence":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A "}
{"PMID":10373451,"re_id":6,"annotated sentence":"Cloning and characterization of a novel <e2>human phosphodiesterase<\\e2> that hydrolyzes both cAMP and <e1>cGMP<\\e1> (PDE10A)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cGMP","object":"human phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cloning and characterization of a novel <e2>GENE-N<\\e2> that hydrolyzes both cAMP and <e1>CHEMICAL<\\e1> (PDE10A)","sentence":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)"}
{"PMID":10373451,"re_id":7,"annotated sentence":"Recombinant <e2>PDE10A<\\e2> transfected and expressed in COS-7 cells hydrolyzed <e1>cAMP<\\e1> and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"PDE10A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recombinant <e2>GENE-Y<\\e2> transfected and expressed in COS-7 cells hydrolyzed <e1>CHEMICAL<\\e1> and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with CHEMICAL","sentence":"Recombinant PDE10A transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP"}
{"PMID":10373451,"re_id":8,"annotated sentence":"Recombinant <e2>PDE10A<\\e2> transfected and expressed in COS-7 cells hydrolyzed cAMP and <e1>cGMP<\\e1> with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cGMP","object":"PDE10A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recombinant <e2>GENE-Y<\\e2> transfected and expressed in COS-7 cells hydrolyzed cAMP and <e1>CHEMICAL<\\e1> with Km values of 0.26 and 7.2 microM, respectively, and Vmax with CHEMICAL was almost twice that with cAMP","sentence":"Recombinant PDE10A transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP"}
{"PMID":10373451,"re_id":9,"annotated sentence":"Recombinant <e2>PDE10A<\\e2> transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with <e1>cGMP<\\e1> was almost twice that with cAMP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cGMP","object":"PDE10A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recombinant <e2>GENE-Y<\\e2> transfected and expressed in COS-7 cells hydrolyzed cAMP and CHEMICAL with Km values of 0.26 and 7.2 microM, respectively, and Vmax with <e1>CHEMICAL<\\e1> was almost twice that with cAMP","sentence":"Recombinant PDE10A transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP"}
{"PMID":10373451,"re_id":10,"annotated sentence":"Recombinant <e2>PDE10A<\\e2> transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with <e1>cAMP<\\e1>  Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"PDE10A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recombinant <e2>GENE-Y<\\e2> transfected and expressed in COS-7 cells hydrolyzed CHEMICAL and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with <e1>CHEMICAL<\\e1>  Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of CHEMICAL and cGMP hydrolysis, respectively","sentence":"Recombinant PDE10A transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with cAMP  Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively"}
{"PMID":10381000,"re_id":0,"annotated sentence":"To begin to examine whether these changes are mediated by alterations in gene expression for <e2>tryptophan hydroxylase<\\e2> (TPH), the rate-limiting enzyme in <e1>5-HT<\\e1> biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-HT","object":"tryptophan hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To begin to examine whether these changes are mediated by alterations in gene expression for <e2>GENE-Y<\\e2> (TPH), the rate-limiting enzyme in <e1>CHEMICAL<\\e1> biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)","sentence":"To begin to examine whether these changes are mediated by alterations in gene expression for tryptophan hydroxylase (TPH), the rate-limiting enzyme in 5-HT biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)"}
{"PMID":10381000,"re_id":1,"annotated sentence":"To begin to examine whether these changes are mediated by alterations in gene expression for tryptophan hydroxylase (<e2>TPH<\\e2> , the rate-limiting enzyme in <e1>5-HT<\\e1> biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-HT","object":"TPH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To begin to examine whether these changes are mediated by alterations in gene expression for tryptophan hydroxylase (<e2>GENE-Y<\\e2> , the rate-limiting enzyme in <e1>CHEMICAL<\\e1> biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)","sentence":"To begin to examine whether these changes are mediated by alterations in gene expression for tryptophan hydroxylase (TPH , the rate-limiting enzyme in 5-HT biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)"}
{"PMID":10381000,"re_id":2,"annotated sentence":"In contrast, there was little change in mRNA levels for <e2>GTP cyclohydrolase I<\\e2> (GTPCH), the rate limiting enzyme in synthesis of the <e1>tetrahydrobiopterin<\\e1> (BH4), the obligate cofactor for TPH","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tetrahydrobiopterin","object":"GTP cyclohydrolase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, there was little change in mRNA levels for <e2>GENE-Y<\\e2> (GTPCH), the rate limiting enzyme in synthesis of the <e1>CHEMICAL<\\e1> (BH4), the obligate cofactor for TPH","sentence":"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin (BH4), the obligate cofactor for TPH"}
{"PMID":10381000,"re_id":3,"annotated sentence":"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (<e2>GTPCH<\\e2> , the rate limiting enzyme in synthesis of the <e1>tetrahydrobiopterin<\\e1> (BH4), the obligate cofactor for TPH","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tetrahydrobiopterin","object":"GTPCH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (<e2>GENE-Y<\\e2> , the rate limiting enzyme in synthesis of the <e1>CHEMICAL<\\e1> (BH4), the obligate cofactor for TPH","sentence":"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH , the rate limiting enzyme in synthesis of the tetrahydrobiopterin (BH4), the obligate cofactor for TPH"}
{"PMID":10381000,"re_id":4,"annotated sentence":"In contrast, there was little change in mRNA levels for <e2>GTP cyclohydrolase I<\\e2> (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin (<e1>BH4<\\e1> , the obligate cofactor for TPH","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BH4","object":"GTP cyclohydrolase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, there was little change in mRNA levels for <e2>GENE-Y<\\e2> (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin (<e1>CHEMICAL<\\e1> , the obligate cofactor for TPH","sentence":"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin (BH4 , the obligate cofactor for TPH"}
{"PMID":10381000,"re_id":5,"annotated sentence":"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (<e2>GTPCH<\\e2> , the rate limiting enzyme in synthesis of the tetrahydrobiopterin (<e1>BH4<\\e1> , the obligate cofactor for TPH","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BH4","object":"GTPCH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (<e2>GENE-Y<\\e2> , the rate limiting enzyme in synthesis of the tetrahydrobiopterin (<e1>CHEMICAL<\\e1> , the obligate cofactor for TPH","sentence":"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH , the rate limiting enzyme in synthesis of the tetrahydrobiopterin (BH4 , the obligate cofactor for TPH"}
{"PMID":10398211,"re_id":0,"annotated sentence":"We evaluated the effects of <e2>angiotensin II<\\e2> and an angiotensin-converting enzyme inhibitor (<e1>cilazapril<\\e1>  on nerve blood flow (NBF) and electrophysiology in control and diabetic rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilazapril","object":"angiotensin II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We evaluated the effects of <e2>GENE-Y<\\e2> and an angiotensin-converting enzyme inhibitor (<e1>CHEMICAL<\\e1>  on nerve blood flow (NBF) and electrophysiology in control and diabetic rats","sentence":"We evaluated the effects of angiotensin II and an angiotensin-converting enzyme inhibitor (cilazapril  on nerve blood flow (NBF) and electrophysiology in control and diabetic rats"}
{"PMID":10398211,"re_id":1,"annotated sentence":"We evaluated the effects of angiotensin II and an <e2>angiotensin-converting enzyme<\\e2> inhibitor (<e1>cilazapril<\\e1>  on nerve blood flow (NBF) and electrophysiology in control and diabetic rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilazapril","object":"angiotensin-converting enzyme","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We evaluated the effects of angiotensin II and an <e2>GENE-Y<\\e2> inhibitor (<e1>CHEMICAL<\\e1>  on nerve blood flow (NBF) and electrophysiology in control and diabetic rats","sentence":"We evaluated the effects of angiotensin II and an angiotensin-converting enzyme inhibitor (cilazapril  on nerve blood flow (NBF) and electrophysiology in control and diabetic rats"}
{"PMID":10398211,"re_id":2,"annotated sentence":"We topically applied the nitric oxide synthase (<e2>NOS<\\e2>  inhibitor, <e1>NG-nitro-L-arginine<\\e1>  on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NG-nitro-L-arginine","object":"NOS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We topically applied the nitric oxide synthase (<e2>GENE-N<\\e2>  inhibitor, <e1>CHEMICAL<\\e1>  on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet","sentence":"We topically applied the nitric oxide synthase (NOS  inhibitor, NG-nitro-L-arginine  on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet"}
{"PMID":10398211,"re_id":3,"annotated sentence":"We topically applied the <e2>nitric oxide synthase<\\e2> (NOS) inhibitor, <e1>NG-nitro-L-arginine<\\e1>  on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NG-nitro-L-arginine","object":"nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We topically applied the <e2>GENE-N<\\e2> (NOS) inhibitor, <e1>CHEMICAL<\\e1>  on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet","sentence":"We topically applied the nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine  on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet"}
{"PMID":10401556,"re_id":0,"annotated sentence":"The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +\/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +\/- 0.10) and against the selective <e2>alpha 1A-adrenoceptor<\\e2> agonist <e1>A-61603<\\e1> (pKB = 8.40 +\/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"A-61603","object":"alpha 1A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +\/- 0.13) and of the selective GENE-Y antagonist RS-17053 against noradrenaline (pKB = 8.35 +\/- 0.10) and against the selective <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> (pKB = 8.40 +\/- 0.09) were too low to account for alpha 1D- and GENE-Y involvement","sentence":"The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +\/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +\/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +\/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement"}
{"PMID":10401556,"re_id":1,"annotated sentence":"The putative <e2>alpha 1L-adrenoceptor<\\e2> antagonist <e1>JTH-601<\\e1>  but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"JTH-601","object":"alpha 1L-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The putative <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1>  but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA","sentence":"The putative alpha 1L-adrenoceptor antagonist JTH-601  but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA"}
{"PMID":10401556,"re_id":2,"annotated sentence":"The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the <e2>alpha 1B-adrenoceptor<\\e2> antagonist <e1>chloroethylclonidine<\\e1> (10 microM) antagonized noradrenaline-induced contractions of SMA","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"chloroethylclonidine","object":"alpha 1B-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (10 microM) antagonized noradrenaline-induced contractions of SMA","sentence":"The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA"}
{"PMID":10401556,"re_id":3,"annotated sentence":"The potency of the selective <e2>alpha 1D-adrenoceptor<\\e2> antagonist <e1>BMY 7378<\\e1> against noradrenaline (pA2 = 6.16 +\/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +\/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +\/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"BMY 7378","object":"alpha 1D-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potency of the selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> against noradrenaline (pA2 = 6.16 +\/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +\/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +\/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement","sentence":"The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +\/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +\/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +\/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement"}
{"PMID":10401556,"re_id":4,"annotated sentence":"The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +\/- 0.13) and of the selective <e2>alpha 1A-adrenoceptor<\\e2> antagonist <e1>RS-17053<\\e1> against noradrenaline (pKB = 8.35 +\/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +\/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"RS-17053","object":"alpha 1A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +\/- 0.13) and of the selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> against noradrenaline (pKB = 8.35 +\/- 0.10) and against the selective GENE-Y agonist A-61603 (pKB = 8.40 +\/- 0.09) were too low to account for alpha 1D- and GENE-Y involvement","sentence":"The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +\/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +\/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +\/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement"}
{"PMID":10403635,"re_id":0,"annotated sentence":"In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher <e1>sarin<\\e1> dose, respectively, was needed to cause a 50% inhibition of brain <e2>AChE<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sarin","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher <e1>CHEMICAL<\\e1> dose, respectively, was needed to cause a 50% inhibition of brain <e2>GENE-Y<\\e2> activity","sentence":"In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher sarin dose, respectively, was needed to cause a 50% inhibition of brain AChE activity"}
{"PMID":10403635,"re_id":1,"annotated sentence":"The acute toxicity of <e1>organophosphorus<\\e1> (OP) compounds in mammals is due to their irreversible inhibition of <e2>acetylcholinesterase<\\e2> (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"organophosphorus","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The acute toxicity of <e1>CHEMICAL<\\e1> (OP) compounds in mammals is due to their irreversible inhibition of <e2>GENE-N<\\e2> (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels","sentence":"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels"}
{"PMID":10403635,"re_id":2,"annotated sentence":"The acute toxicity of <e1>organophosphorus<\\e1> (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (<e2>AChE<\\e2>  in the nervous system, which leads to increased synaptic acetylcholine levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"organophosphorus","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The acute toxicity of <e1>CHEMICAL<\\e1> (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (<e2>GENE-N<\\e2>  in the nervous system, which leads to increased synaptic acetylcholine levels","sentence":"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (AChE  in the nervous system, which leads to increased synaptic acetylcholine levels"}
{"PMID":10403635,"re_id":3,"annotated sentence":"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of <e2>acetylcholinesterase<\\e2> (AChE) in the nervous system, which leads to increased synaptic <e1>acetylcholine<\\e1> levels","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetylcholine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of <e2>CHEMICALsterase<\\e2> (AChE) in the nervous system, which leads to increased synaptic <e1>CHEMICAL<\\e1> levels","sentence":"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels"}
{"PMID":10403635,"re_id":4,"annotated sentence":"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (<e2>AChE<\\e2>  in the nervous system, which leads to increased synaptic <e1>acetylcholine<\\e1> levels","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetylcholine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of CHEMICALsterase (<e2>GENE-N<\\e2>  in the nervous system, which leads to increased synaptic <e1>CHEMICAL<\\e1> levels","sentence":"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (AChE  in the nervous system, which leads to increased synaptic acetylcholine levels"}
{"PMID":10406837,"re_id":0,"annotated sentence":"<e1>Torasemide<\\e1> inhibits <e2>angiotensin II<\\e2> induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Torasemide","object":"angiotensin II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats","sentence":"Torasemide inhibits angiotensin II induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats"}
{"PMID":10406837,"re_id":1,"annotated sentence":"Isometric contraction induced by a submaximal concentration of <e2>Ang II<\\e2> (10(-7) mol\/L) was reduced in a dose-dependent way by <e1>torasemide<\\e1> (IC(50)=0.5+\/-0.04 micromol\/L)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"torasemide","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Isometric contraction induced by a submaximal concentration of <e2>GENE-Y<\\e2> (10(-7) mol\/L) was reduced in a dose-dependent way by <e1>CHEMICAL<\\e1> (IC(50)=0.5+\/-0.04 micromol\/L)","sentence":"Isometric contraction induced by a submaximal concentration of Ang II (10(-7) mol\/L) was reduced in a dose-dependent way by torasemide (IC(50)=0.5+\/-0.04 micromol\/L)"}
{"PMID":10406837,"re_id":2,"annotated sentence":"The stimulatory effect of [Ca(2+)](i) induced by a submaximal concentration of <e2>Ang II<\\e2> (10(-7) mol\/L) was blocked by <e1>torasemide<\\e1> (IC(50)=0.5+\/-0.3 nmol\/L)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"torasemide","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The stimulatory effect of [Ca(2+)](i) induced by a submaximal concentration of <e2>GENE-Y<\\e2> (10(-7) mol\/L) was blocked by <e1>CHEMICAL<\\e1> (IC(50)=0.5+\/-0.3 nmol\/L)","sentence":"The stimulatory effect of [Ca(2+)](i) induced by a submaximal concentration of Ang II (10(-7) mol\/L) was blocked by torasemide (IC(50)=0.5+\/-0.3 nmol\/L)"}
{"PMID":10406837,"re_id":3,"annotated sentence":"Our findings suggest that <e1>torasemide<\\e1> blocks the vasoconstrictor action of <e2>Ang II<\\e2> in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"torasemide","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our findings suggest that <e1>CHEMICAL<\\e1> blocks the vasoconstrictor action of <e2>GENE-Y<\\e2> in vitro","sentence":"Our findings suggest that torasemide blocks the vasoconstrictor action of Ang II in vitro"}
{"PMID":10406837,"re_id":4,"annotated sentence":"This action can be related to the ability of <e1>torasemide<\\e1> to block the increase of [Ca(2+)](i) induced by <e2>Ang II<\\e2> in VSMCs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"torasemide","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This action can be related to the ability of <e1>CHEMICAL<\\e1> to block the increase of [Ca(2+)](i) induced by <e2>GENE-Y<\\e2> in VSMCs","sentence":"This action can be related to the ability of torasemide to block the increase of [Ca(2+)](i) induced by Ang II in VSMCs"}
{"PMID":10411647,"re_id":0,"annotated sentence":"On phosphorylation of <e1>Ser40<\\e1> by <e2>protein kinase A<\\e2>  the affinity for H4biopterin increased ([S]0.5 = 11 +\/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +\/- 0.03)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Ser40","object":"protein kinase A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"On phosphorylation of <e1>CHEMICAL<\\e1> by <e2>GENE-N<\\e2>  the affinity for H4biopterin increased ([S]0.5 = 11 +\/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +\/- 0.03)","sentence":"On phosphorylation of Ser40 by protein kinase A  the affinity for H4biopterin increased ([S]0.5 = 11 +\/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +\/- 0.03)"}
{"PMID":10444166,"re_id":0,"annotated sentence":"<e2>Ribonucleotide reductase<\\e2> activity was found to be strongly increased in the <e1>gemcitabine<\\e1> selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gemcitabine","object":"Ribonucleotide reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> activity was found to be strongly increased in the <e1>CHEMICAL<\\e1> selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line","sentence":"Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line"}
{"PMID":10444166,"re_id":1,"annotated sentence":"Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine-selected line and <e2>purine nucleoside phosphorylase<\\e2> was increased in the <e1>2-chlorodeoxyadenosine<\\e1> selected line","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2-chlorodeoxyadenosine","object":"purine nucleoside phosphorylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine-selected line and <e2>GENE-Y<\\e2> was increased in the <e1>CHEMICAL<\\e1> selected line","sentence":"Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine-selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine selected line"}
{"PMID":10446934,"re_id":0,"annotated sentence":"<e2>Endothelial NO synthase<\\e2> expression was increased by <e1>cilazapril<\\e1> but not by losartan","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cilazapril","object":"Endothelial NO synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> expression was increased by <e1>CHEMICAL<\\e1> but not by losartan","sentence":"Endothelial NO synthase expression was increased by cilazapril but not by losartan"}
{"PMID":10446934,"re_id":1,"annotated sentence":"<e2>Human and rat renin<\\e2> and angiotensinogen genes were downregulated in dTGR and were increased by <e1>losartan<\\e1> and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"losartan","object":"Human and rat renin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> and angiotensinogen genes were downregulated in dTGR and were increased by <e1>CHEMICAL<\\e1> and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed","sentence":"Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by losartan and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed"}
{"PMID":10446934,"re_id":2,"annotated sentence":"Human and rat renin and <e2>angiotensinogen<\\e2> genes were downregulated in dTGR and were increased by <e1>losartan<\\e1> and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"losartan","object":"angiotensinogen","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human and rat renin and <e2>GENE-N<\\e2> genes were downregulated in dTGR and were increased by <e1>CHEMICAL<\\e1> and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed","sentence":"Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by losartan and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed"}
{"PMID":10446934,"re_id":3,"annotated sentence":"<e2>Human and rat renin<\\e2> and angiotensinogen genes were downregulated in dTGR and were increased by losartan and <e1>cilazapril<\\e1> treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cilazapril","object":"Human and rat renin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> and angiotensinogen genes were downregulated in dTGR and were increased by losartan and <e1>CHEMICAL<\\e1> treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed","sentence":"Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by losartan and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed"}
{"PMID":10446934,"re_id":4,"annotated sentence":"Human and rat renin and <e2>angiotensinogen<\\e2> genes were downregulated in dTGR and were increased by losartan and <e1>cilazapril<\\e1> treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cilazapril","object":"angiotensinogen","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human and rat renin and <e2>GENE-N<\\e2> genes were downregulated in dTGR and were increased by losartan and <e1>CHEMICAL<\\e1> treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed","sentence":"Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by losartan and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed"}
{"PMID":10462128,"re_id":0,"annotated sentence":"Combination treatment with the selective <e2>5-HT1A<\\e2> antagonist <e1>WAY100635<\\e1> produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg\/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"WAY100635","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Combination treatment with the selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg\/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone","sentence":"Combination treatment with the selective 5-HT1A antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg\/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone"}
{"PMID":10462128,"re_id":1,"annotated sentence":"The beta-adrenergic\/<e2>5-HT1A<\\e2> receptor antagonist <e1>(+\/-)pindolol<\\e1> and the selective 5-HT1B\/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(+\/-)pindolol","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The beta-adrenergic\/<e2>GENE-Y<\\e2> receptor antagonist <e1>CHEMICAL<\\e1> and the selective 5-HT1B\/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA","sentence":"The beta-adrenergic\/5-HT1A receptor antagonist (+\/-)pindolol and the selective 5-HT1B\/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA"}
{"PMID":10480573,"re_id":0,"annotated sentence":"The <e2>kinase<\\e2> activity of EGFR was little inhibited by <e1>TT-B<\\e1> in a cell-free system.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TT-B","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> activity of EGFR was little inhibited by <e1>CHEMICAL<\\e1> in a cell-free system.","sentence":"The kinase activity of EGFR was little inhibited by TT-B in a cell-free system."}
{"PMID":10480573,"re_id":1,"annotated sentence":"The kinase activity of <e2>EGFR<\\e2> was little inhibited by <e1>TT-B<\\e1> in a cell-free system.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TT-B","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The kinase activity of <e2>GENE-Y<\\e2> was little inhibited by <e1>CHEMICAL<\\e1> in a cell-free system.","sentence":"The kinase activity of EGFR was little inhibited by TT-B in a cell-free system."}
{"PMID":10493852,"re_id":0,"annotated sentence":"We report here that <e1>lovastatin<\\e1>  a drug clinically used for lowering cholesterol levels, inhibits the interaction of <e2>human LFA-1<\\e2> with its counter-receptor intercellular adhesion molecule-1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lovastatin","object":"human LFA-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report here that <e1>CHEMICAL<\\e1>  a drug clinically used for lowering cholesterol levels, inhibits the interaction of <e2>GENE-Y<\\e2> with its counter-receptor intercellular adhesion molecule-1","sentence":"We report here that lovastatin  a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor intercellular adhesion molecule-1"}
{"PMID":10493852,"re_id":1,"annotated sentence":"We report here that <e1>lovastatin<\\e1>  a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor <e2>intercellular adhesion molecule-1<\\e2>  Using nuclear magnetic resonance spectroscopy and X-ray crystallography we show that the inhibitor binds to a highly conserved domain of the LFA-1 alpha-chain called the I-domain","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lovastatin","object":"intercellular adhesion molecule-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report here that <e1>CHEMICAL<\\e1>  a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor <e2>GENE-Y<\\e2>  Using nuclear magnetic resonance spectroscopy and X-ray crystallography we show that the inhibitor binds to a highly conserved domain of the LFA-1 alpha-chain called the I-domain","sentence":"We report here that lovastatin  a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor intercellular adhesion molecule-1  Using nuclear magnetic resonance spectroscopy and X-ray crystallography we show that the inhibitor binds to a highly conserved domain of the LFA-1 alpha-chain called the I-domain"}
{"PMID":10493852,"re_id":2,"annotated sentence":"Structural basis for <e2>LFA-1<\\e2> inhibition upon <e1>lovastatin<\\e1> binding to the CD11a I-domain","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lovastatin","object":"LFA-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Structural basis for <e2>GENE-Y<\\e2> inhibition upon <e1>CHEMICAL<\\e1> binding to the CD11a I-domain","sentence":"Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain"}
{"PMID":10522750,"re_id":0,"annotated sentence":"The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the <e2>endothelin ET(B) receptor<\\e2> antagonist <e1>RES 701-1<\\e1>  by indomethacin, or by glibenclamide","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"RES 701-1","object":"endothelin ET(B) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  by indomethacin, or by glibenclamide","sentence":"The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist RES 701-1  by indomethacin, or by glibenclamide"}
{"PMID":10522750,"re_id":1,"annotated sentence":"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the <e2>thromboxane A2 receptor<\\e2> antagonists <e1>GR32191<\\e1> and ridogrel","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"GR32191","object":"thromboxane A2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the <e2>GENE-Y<\\e2> antagonists <e1>CHEMICAL<\\e1> and ridogrel","sentence":"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the thromboxane A2 receptor antagonists GR32191 and ridogrel"}
{"PMID":10522750,"re_id":2,"annotated sentence":"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the <e2>thromboxane A2 receptor<\\e2> antagonists GR32191 and <e1>ridogrel<\\e1>  U46619 potentiates the 5-HT-effect in mesenteric arteries","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ridogrel","object":"thromboxane A2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the <e2>GENE-Y<\\e2> antagonists GR32191 and <e1>CHEMICAL<\\e1>  U46619 potentiates the 5-HT-effect in mesenteric arteries","sentence":"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the thromboxane A2 receptor antagonists GR32191 and ridogrel  U46619 potentiates the 5-HT-effect in mesenteric arteries"}
{"PMID":10530931,"re_id":0,"annotated sentence":"This work showed that appropriate structural modification of <e1>diphenidol<\\e1> can lead to <e2>M2<\\e2> selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"diphenidol","object":"M2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This work showed that appropriate structural modification of <e1>CHEMICAL<\\e1> can lead to <e2>GENE-Y<\\e2> selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.","sentence":"This work showed that appropriate structural modification of diphenidol can lead to M2 selective muscarinic antagonists of possible interest in the field of Alzheimer's disease."}
{"PMID":10530931,"re_id":1,"annotated sentence":"A series of 2-carbonyl analogues of the muscarinic antagonist <e1>diphenidol<\\e1> bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the <e2>M2 and M3 muscarinic receptor<\\e2> subtypes was evaluated by functional tests","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"diphenidol","object":"M2 and M3 muscarinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of 2-carbonyl analogues of the muscarinic antagonist <e1>CHEMICAL<\\e1> bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the <e2>GENE-N<\\e2> subtypes was evaluated by functional tests","sentence":"A series of 2-carbonyl analogues of the muscarinic antagonist diphenidol bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the M2 and M3 muscarinic receptor subtypes was evaluated by functional tests"}
{"PMID":10530931,"re_id":2,"annotated sentence":"Synthesis and antagonistic activity at <e2>muscarinic receptor<\\e2> subtypes of some 2-carbonyl derivatives of <e1>diphenidol<\\e1>  A series of 2-carbonyl analogues of the muscarinic antagonist diphenidol bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the M2 and M3 muscarinic receptor subtypes was evaluated by functional tests","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"diphenidol","object":"muscarinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Synthesis and antagonistic activity at <e2>GENE-N<\\e2> subtypes of some 2-carbonyl derivatives of <e1>CHEMICAL<\\e1>  A series of 2-carbonyl analogues of the muscarinic antagonist CHEMICAL bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the M2 and M3 GENE-N subtypes was evaluated by functional tests","sentence":"Synthesis and antagonistic activity at muscarinic receptor subtypes of some 2-carbonyl derivatives of diphenidol  A series of 2-carbonyl analogues of the muscarinic antagonist diphenidol bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the M2 and M3 muscarinic receptor subtypes was evaluated by functional tests"}
{"PMID":10530931,"re_id":3,"annotated sentence":"Synthesis and antagonistic activity at <e2>muscarinic receptor<\\e2> subtypes of some <e1>2-carbonyl<\\e1> derivatives of diphenidol","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"2-carbonyl","object":"muscarinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Synthesis and antagonistic activity at <e2>GENE-N<\\e2> subtypes of some <e1>CHEMICAL<\\e1> derivatives of diphenidol","sentence":"Synthesis and antagonistic activity at muscarinic receptor subtypes of some 2-carbonyl derivatives of diphenidol"}
{"PMID":10583449,"re_id":0,"annotated sentence":"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific <e2>renin<\\e2> angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor <e1>remikiren<\\e1> could be predicted from pretreatment renal vascular tone","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"remikiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific <e2>GENE-Y<\\e2> angiotensin-aldosterone system (RAAS) blockade by GENE-Y-inhibitor <e1>CHEMICAL<\\e1> could be predicted from pretreatment renal vascular tone","sentence":"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor remikiren could be predicted from pretreatment renal vascular tone"}
{"PMID":10583449,"re_id":1,"annotated sentence":"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-<e2>angiotensin<\\e2> aldosterone system (RAAS) blockade by renin-inhibitor <e1>remikiren<\\e1> could be predicted from pretreatment renal vascular tone","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"remikiren","object":"angiotensin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-<e2>GENE-Y<\\e2> aldosterone system (RAAS) blockade by renin-inhibitor <e1>CHEMICAL<\\e1> could be predicted from pretreatment renal vascular tone","sentence":"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-angiotensin aldosterone system (RAAS) blockade by renin-inhibitor remikiren could be predicted from pretreatment renal vascular tone"}
{"PMID":10583449,"re_id":2,"annotated sentence":"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-angiotensin-aldosterone system (RAAS) blockade by <e2>renin<\\e2> inhibitor <e1>remikiren<\\e1> could be predicted from pretreatment renal vascular tone","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"remikiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific GENE-Y-angiotensin-aldosterone system (RAAS) blockade by <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> could be predicted from pretreatment renal vascular tone","sentence":"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-angiotensin-aldosterone system (RAAS) blockade by renin inhibitor remikiren could be predicted from pretreatment renal vascular tone"}
{"PMID":10617684,"re_id":0,"annotated sentence":"Compared with WT, <e2>DeltaKPQ<\\e2> I(Na) was more sensitive to <e1>flecainide<\\e1>  and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"flecainide","object":"DeltaKPQ","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with WT, <e2>GENE-Y<\\e2> I(Na) was more sensitive to <e1>CHEMICAL<\\e1>  and CHEMICAL preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)","sentence":"Compared with WT, DeltaKPQ I(Na) was more sensitive to flecainide  and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)"}
{"PMID":10617684,"re_id":1,"annotated sentence":"Compared with WT, <e2>DeltaKPQ<\\e2> I(Na) was more sensitive to flecainide, and <e1>flecainide<\\e1> preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"flecainide","object":"DeltaKPQ","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with WT, <e2>GENE-Y<\\e2> I(Na) was more sensitive to CHEMICAL, and <e1>CHEMICAL<\\e1> preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)","sentence":"Compared with WT, DeltaKPQ I(Na) was more sensitive to flecainide, and flecainide preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)"}
{"PMID":10617684,"re_id":2,"annotated sentence":"<e1>Flecainide<\\e1> block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (<e2>DeltaKPQ<\\e2>  stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Flecainide","object":"DeltaKPQ","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (<e2>GENE-Y<\\e2>  stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings","sentence":"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ  stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings"}
{"PMID":10617684,"re_id":3,"annotated sentence":"<e1>Flecainide<\\e1> block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the <e2>long QT syndrome 3 (LQT3) sodium channel alpha<\\e2> subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Flecainide","object":"long QT syndrome 3 (LQT3) sodium channel alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the <e2>GENE-Y<\\e2> subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings","sentence":"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings"}
{"PMID":10617684,"re_id":4,"annotated sentence":"Preferential block of late sodium current in the <e2>LQT3 DeltaKPQ mutant<\\e2> by the class I(C) antiarrhythmic <e1>flecainide<\\e1>  Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"flecainide","object":"LQT3 DeltaKPQ mutant","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preferential block of late sodium current in the <e2>GENE-Y<\\e2> by the class I(C) antiarrhythmic <e1>CHEMICAL<\\e1>  Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings","sentence":"Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide  Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings"}
{"PMID":10617684,"re_id":5,"annotated sentence":"We conclude that <e2>DeltaKPQ<\\e2> interacts differently with <e1>flecainide<\\e1> than with WT, leading to increased block and slowed recovery, especially for late I(Na)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"flecainide","object":"DeltaKPQ","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that <e2>GENE-Y<\\e2> interacts differently with <e1>CHEMICAL<\\e1> than with WT, leading to increased block and slowed recovery, especially for late I(Na)","sentence":"We conclude that DeltaKPQ interacts differently with flecainide than with WT, leading to increased block and slowed recovery, especially for late I(Na)"}
{"PMID":10617684,"re_id":6,"annotated sentence":"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the <e2>long QT syndrome 3 (LQ<e1>sodium<\\e1> ium channel alpha<\\e2> subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sodium","object":"long QT syndrome 3 (LQT3) sodium channel alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the <e2>long QT syndrome 3 (LQ<e1>CHEMICAL<\\e1> ium channel alpha<\\e2> subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings","sentence":"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQsodium ium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings"}
{"PMID":10626810,"re_id":0,"annotated sentence":"In this report, we evaluated the growth-inhibitory effects of <e1>sulindac sulfide<\\e1>  a <e2>COX-1<\\e2> and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulindac sulfide","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this report, we evaluated the growth-inhibitory effects of <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines","sentence":"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide  a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines"}
{"PMID":10626810,"re_id":1,"annotated sentence":"In this report, we evaluated the growth-inhibitory effects of <e1>sulindac sulfide<\\e1>  a COX-1 and <e2>COX-2<\\e2> inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulindac sulfide","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this report, we evaluated the growth-inhibitory effects of <e1>CHEMICAL<\\e1>  a COX-1 and <e2>GENE-Y<\\e2> inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines","sentence":"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide  a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines"}
{"PMID":10626810,"re_id":2,"annotated sentence":"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and <e1>nordihydroguaiaretic acid<\\e1> (NDGA), a <e2>lipoxygenase<\\e2> inhibitor on human lung cancer cell lines","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nordihydroguaiaretic acid","object":"lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and <e1>CHEMICAL<\\e1> (NDGA), a <e2>GENE-N<\\e2> inhibitor on human lung cancer cell lines","sentence":"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines"}
{"PMID":10626810,"re_id":3,"annotated sentence":"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (<e1>NDGA<\\e1> , a <e2>lipoxygenase<\\e2> inhibitor on human lung cancer cell lines","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NDGA","object":"lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (<e1>CHEMICAL<\\e1> , a <e2>GENE-N<\\e2> inhibitor on human lung cancer cell lines","sentence":"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA , a lipoxygenase inhibitor on human lung cancer cell lines"}
{"PMID":10626836,"re_id":0,"annotated sentence":"Science, 9(266) (1994) 1709-1713) greatly attenuates the <e1>lithium<\\e1> induced potentiation of <e2>GluR3<\\e2>  Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"lithium","object":"GluR3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Science, 9(266) (1994) 1709-1713) greatly attenuates the <e1>CHEMICAL<\\e1> induced potentiation of <e2>GENE-Y<\\e2>  Additionally, experiments with the non-desensitizing site-directed mutant GENE-Y(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M","sentence":"Science, 9(266) (1994) 1709-1713) greatly attenuates the lithium induced potentiation of GluR3  Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M"}
{"PMID":10626836,"re_id":1,"annotated sentence":"Neuron, 21 (1998) 907-918) further confirms that <e1>lithium<\\e1> enhances <e2>GluR3<\\e2> responses by reducing desensitization, since lithium's effects are reversed in this mutant","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"lithium","object":"GluR3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Neuron, 21 (1998) 907-918) further confirms that <e1>CHEMICAL<\\e1> enhances <e2>GENE-Y<\\e2> responses by reducing desensitization, since CHEMICAL's effects are reversed in this mutant","sentence":"Neuron, 21 (1998) 907-918) further confirms that lithium enhances GluR3 responses by reducing desensitization, since lithium's effects are reversed in this mutant"}
{"PMID":10626836,"re_id":2,"annotated sentence":"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that <e1>lithium<\\e1> produces a large potentiation of the <e2>GluR3 flop<\\e2> splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"lithium","object":"GluR3 flop","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that <e1>CHEMICAL<\\e1> produces a large potentiation of the <e2>GENE-Y<\\e2> splice variant and suggested that CHEMICAL might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N","sentence":"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N"}
{"PMID":10626836,"re_id":3,"annotated sentence":"Specifically, <e1>aniracetam<\\e1>  which potentiates wild-type <e2>AMPA receptors<\\e2>  is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"aniracetam","object":"AMPA receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Specifically, <e1>CHEMICAL<\\e1>  which potentiates wild-type <e2>GENE-N<\\e2>  is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.","sentence":"Specifically, aniracetam  which potentiates wild-type AMPA receptors  is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors."}
{"PMID":10626836,"re_id":4,"annotated sentence":"Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing <e2>GluR3<\\e2> L507Y) mutant, but has synergistic effects with <e1>lithium<\\e1> on wild-type receptors.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"lithium","object":"GluR3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing <e2>GENE-Y<\\e2> L507Y) mutant, but has synergistic effects with <e1>CHEMICAL<\\e1> on wild-type receptors.","sentence":"Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3 L507Y) mutant, but has synergistic effects with lithium on wild-type receptors."}
{"PMID":10626836,"re_id":5,"annotated sentence":"Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3(<e2>L507Y<\\e2>  mutant, but has synergistic effects with <e1>lithium<\\e1> on wild-type receptors.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"lithium","object":"L507Y","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3(<e2>GENE-N<\\e2>  mutant, but has synergistic effects with <e1>CHEMICAL<\\e1> on wild-type receptors.","sentence":"Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3(L507Y  mutant, but has synergistic effects with lithium on wild-type receptors."}
{"PMID":10626836,"re_id":6,"annotated sentence":"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the <e2>GluR3 flop<\\e2> splice variant and suggested that <e1>lithium<\\e1> might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"lithium","object":"GluR3 flop","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that CHEMICAL produces a large potentiation of the <e2>GENE-Y<\\e2> splice variant and suggested that <e1>CHEMICAL<\\e1> might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N","sentence":"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N"}
{"PMID":10670413,"re_id":0,"annotated sentence":"It was concluded that <e1>PGE1<\\e1> selectively reduces both N- and R-type Ca2+ currents by activating a <e2>G-protein<\\e2> probably through the EP3 receptor in paratracheal ganglion cells.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PGE1","object":"G-protein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It was concluded that <e1>CHEMICAL<\\e1> selectively reduces both N- and R-type Ca2+ currents by activating a <e2>GENE-N<\\e2> probably through the EP3 receptor in paratracheal ganglion cells.","sentence":"It was concluded that PGE1 selectively reduces both N- and R-type Ca2+ currents by activating a G-protein probably through the EP3 receptor in paratracheal ganglion cells."}
{"PMID":10670413,"re_id":1,"annotated sentence":"Prostaglandin E1, E2, <e1>STA2<\\e1> (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels<\\e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"STA2","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prostaglandin E1, E2, <e1>CHEMICAL<\\e1> (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>GENE-N<\\e2> was sulprostone>PGE2, PGE1>CHEMICAL>>17-phenyl-trinor-PGE2","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2"}
{"PMID":10670413,"re_id":2,"annotated sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of <e1>thromboxane A2<\\e1> , 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels<\\e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"thromboxane A2","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of <e1>CHEMICAL<\\e1> , 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>GENE-N<\\e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2 , 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2"}
{"PMID":10670413,"re_id":3,"annotated sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), <e1>17-phenyl-trinor-PGE2<\\e1> (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels<\\e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"17-phenyl-trinor-PGE2","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), <e1>CHEMICAL<\\e1> (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>GENE-N<\\e2> was sulprostone>PGE2, PGE1>STA2>>CHEMICAL","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2"}
{"PMID":10670413,"re_id":4,"annotated sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and <e1>sulprostone<\\e1> (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels<\\e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulprostone","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and <e1>CHEMICAL<\\e1> (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>GENE-N<\\e2> was CHEMICAL>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2"}
{"PMID":10670413,"re_id":5,"annotated sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels<\\e2> was <e1>sulprostone<\\e1> PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulprostone","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and CHEMICAL (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>GENE-N<\\e2> was <e1>CHEMICAL<\\e1> PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2"}
{"PMID":10670413,"re_id":6,"annotated sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels<\\e2> was sulprostone><e1>PGE2<\\e1>  PGE1>STA2>>17-phenyl-trinor-PGE2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PGE2","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-CHEMICAL (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>GENE-N<\\e2> was sulprostone><e1>CHEMICAL<\\e1>  PGE1>STA2>>17-phenyl-trinor-CHEMICAL","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2  PGE1>STA2>>17-phenyl-trinor-PGE2"}
{"PMID":10670413,"re_id":7,"annotated sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels<\\e2> was sulprostone>PGE2, <e1>PGE1<\\e1> STA2>>17-phenyl-trinor-PGE2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PGE1","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>GENE-N<\\e2> was sulprostone>PGE2, <e1>CHEMICAL<\\e1> STA2>>17-phenyl-trinor-PGE2","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1 STA2>>17-phenyl-trinor-PGE2"}
{"PMID":10670413,"re_id":8,"annotated sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels<\\e2> was sulprostone>PGE2, PGE1><e1>STA2<\\e1> >17-phenyl-trinor-PGE2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"STA2","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prostaglandin E1, E2, CHEMICAL (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>GENE-N<\\e2> was sulprostone>PGE2, PGE1><e1>CHEMICAL<\\e1> >17-phenyl-trinor-PGE2","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2 >17-phenyl-trinor-PGE2"}
{"PMID":10670413,"re_id":9,"annotated sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels<\\e2> was sulprostone>PGE2, PGE1>STA2>><e1>17-phenyl-trinor-PGE2<\\e1>  SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"17-phenyl-trinor-PGE2","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), CHEMICAL (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>GENE-N<\\e2> was sulprostone>PGE2, PGE1>STA2>><e1>CHEMICAL<\\e1>  SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the GENE-N is possibly mediated by the EP3 receptor","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2  SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor"}
{"PMID":10670413,"re_id":10,"annotated sentence":"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that <e1>PGE1<\\e1>  and PGE2-induced inhibition of the <e2>HVA Ca2+ channels<\\e2> is possibly mediated by the EP3 receptor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PGE1","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the CHEMICAL- or PGE2-induced inhibition of the HVA ICa, thereby indicating that <e1>CHEMICAL<\\e1>  and PGE2-induced inhibition of the <e2>GENE-N<\\e2> is possibly mediated by the EP3 receptor","sentence":"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1  and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor"}
{"PMID":10670413,"re_id":11,"annotated sentence":"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and <e1>PGE2<\\e1> induced inhibition of the <e2>HVA Ca2+ channels<\\e2> is possibly mediated by the EP3 receptor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PGE2","object":"HVA Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or CHEMICAL-induced inhibition of the HVA ICa, thereby indicating that PGE1- and <e1>CHEMICAL<\\e1> induced inhibition of the <e2>GENE-N<\\e2> is possibly mediated by the EP3 receptor","sentence":"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2 induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor"}
{"PMID":10670413,"re_id":12,"annotated sentence":"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the <e2>protein kinase C<\\e2> (PKC) inhibitor <e1>chelerythrine<\\e1> blocked the action of PMA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"chelerythrine","object":"protein kinase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the <e2>GENE-N<\\e2> (PKC) inhibitor <e1>CHEMICAL<\\e1> blocked the action of PMA","sentence":"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the protein kinase C (PKC) inhibitor chelerythrine blocked the action of PMA"}
{"PMID":10670413,"re_id":13,"annotated sentence":"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the protein kinase C (<e2>PKC<\\e2>  inhibitor <e1>chelerythrine<\\e1> blocked the action of PMA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"chelerythrine","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the protein kinase C (<e2>GENE-N<\\e2>  inhibitor <e1>CHEMICAL<\\e1> blocked the action of PMA","sentence":"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the protein kinase C (PKC  inhibitor chelerythrine blocked the action of PMA"}
{"PMID":10670413,"re_id":14,"annotated sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), <e1>17-phenyl-trinor-PGE2<\\e1> (an <e2>EP1<\\e2> selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"17-phenyl-trinor-PGE2","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), <e1>CHEMICAL<\\e1> (an <e2>GENE-Y<\\e2> selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>CHEMICAL","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1 selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2"}
{"PMID":10670413,"re_id":15,"annotated sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and <e1>sulprostone<\\e1> (an <e2>EP3<\\e2> selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"sulprostone","object":"EP3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and <e1>CHEMICAL<\\e1> (an <e2>GENE-Y<\\e2> selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was CHEMICAL>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2","sentence":"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3 selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2"}
{"PMID":10670413,"re_id":16,"annotated sentence":"<e1>SC-51089<\\e1> (10(-5) M), a selective <e2>EP1-receptor<\\e2> antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SC-51089","object":"EP1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (10(-5) M), a selective <e2>GENE-Y<\\e2> antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor","sentence":"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor"}
{"PMID":10682471,"re_id":0,"annotated sentence":"<e2>PR mRNA<\\e2> abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing <e1>mifepristone<\\e1> treatment before the operation but not in the other 2 patients stopping RU486 1 month before operation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mifepristone","object":"PR mRNA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing <e1>CHEMICAL<\\e1> treatment before the operation but not in the other 2 patients stopping RU486 1 month before operation","sentence":"PR mRNA abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing mifepristone treatment before the operation but not in the other 2 patients stopping RU486 1 month before operation"}
{"PMID":10682471,"re_id":1,"annotated sentence":"One of the mechanism of <e1>mifepristone<\\e1> action on decreasing leiomyomata volume may be related to suppression on expression of <e2>PR gene<\\e2>  It seems that suppression on transcription of PR gene is reversible, but on translation of PR gene may maintain in a relatively longer period.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mifepristone","object":"PR gene","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the mechanism of <e1>CHEMICAL<\\e1> action on decreasing leiomyomata volume may be related to suppression on expression of <e2>GENE-Y<\\e2>  It seems that suppression on transcription of GENE-Y is reversible, but on translation of GENE-Y may maintain in a relatively longer period.","sentence":"One of the mechanism of mifepristone action on decreasing leiomyomata volume may be related to suppression on expression of PR gene  It seems that suppression on transcription of PR gene is reversible, but on translation of PR gene may maintain in a relatively longer period."}
{"PMID":10690753,"re_id":0,"annotated sentence":"To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of <e1>felbamate<\\e1> block of recombinant <e2>NMDA receptors<\\e2> composed of the NR1a subunit and various NR2 subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felbamate","object":"NMDA receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To investigate the possibility that CHEMICAL's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of <e1>CHEMICAL<\\e1> block of recombinant <e2>GENE-N<\\e2> composed of the NR1a subunit and various NR2 subunits","sentence":"To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the NR1a subunit and various NR2 subunits"}
{"PMID":10690753,"re_id":1,"annotated sentence":"To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of <e1>felbamate<\\e1> block of recombinant NMDA receptors composed of the <e2>NR1a<\\e2> subunit and various NR2 subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felbamate","object":"NR1a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To investigate the possibility that CHEMICAL's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of <e1>CHEMICAL<\\e1> block of recombinant NMDA receptors composed of the <e2>GENE-Y<\\e2> subunit and various NR2 subunits","sentence":"To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the NR1a subunit and various NR2 subunits"}
{"PMID":10690753,"re_id":2,"annotated sentence":"To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of <e1>felbamate<\\e1> block of recombinant NMDA receptors composed of the NR1a subunit and various <e2>NR2<\\e2> subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felbamate","object":"NR2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To investigate the possibility that CHEMICAL's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of <e1>CHEMICAL<\\e1> block of recombinant NMDA receptors composed of the NR1a subunit and various <e2>GENE-N<\\e2> subunits","sentence":"To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the NR1a subunit and various NR2 subunits"}
{"PMID":10690753,"re_id":3,"annotated sentence":"<e1>Felbamate<\\e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the <e2>rat NR1a<\\e2> subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felbamate","object":"rat NR1a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the <e2>GENE-Y<\\e2> subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)","sentence":"Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)"}
{"PMID":10690753,"re_id":4,"annotated sentence":"<e1>Felbamate<\\e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the <e2>NR2A<\\e2>  NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felbamate","object":"NR2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the <e2>GENE-Y<\\e2>  NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)","sentence":"Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A  NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)"}
{"PMID":10690753,"re_id":5,"annotated sentence":"<e1>Felbamate<\\e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, <e2>NR2B<\\e2> or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felbamate","object":"NR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, <e2>GENE-Y<\\e2> or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)","sentence":"Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)"}
{"PMID":10690753,"re_id":6,"annotated sentence":"<e1>Felbamate<\\e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or <e2>NR2C<\\e2> subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felbamate","object":"NR2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or <e2>GENE-Y<\\e2> subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)","sentence":"Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)"}
{"PMID":10690753,"re_id":7,"annotated sentence":"<e1>Felbamate<\\e1> block of recombinant <e2>N-methyl-D-aspartate receptors<\\e2>  selectivity for the NR2B subunit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felbamate","object":"N-methyl-D-aspartate receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> block of recombinant <e2>GENE-N<\\e2>  selectivity for the NR2B subunit","sentence":"Felbamate block of recombinant N-methyl-D-aspartate receptors  selectivity for the NR2B subunit"}
{"PMID":10690753,"re_id":8,"annotated sentence":"<e1>Felbamate<\\e1> block of recombinant N-methyl-D-aspartate receptors: selectivity for the <e2>NR2B<\\e2> subunit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felbamate","object":"NR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> block of recombinant N-methyl-D-aspartate receptors: selectivity for the <e2>GENE-Y<\\e2> subunit","sentence":"Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit"}
{"PMID":10690753,"re_id":9,"annotated sentence":"The higher affinity of <e1>felbamate<\\e1> block of <e2>NMDA receptors<\\e2> containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felbamate","object":"NMDA receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The higher affinity of <e1>CHEMICAL<\\e1> block of <e2>GENE-N<\\e2> containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites","sentence":"The higher affinity of felbamate block of NMDA receptors containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites"}
{"PMID":10690753,"re_id":10,"annotated sentence":"The higher affinity of <e1>felbamate<\\e1> block of NMDA receptors containing the <e2>NR2B<\\e2> subunit could be accounted for by more rapid association and slower dissociation from these sites","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felbamate","object":"NR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The higher affinity of <e1>CHEMICAL<\\e1> block of NMDA receptors containing the <e2>GENE-Y<\\e2> subunit could be accounted for by more rapid association and slower dissociation from these sites","sentence":"The higher affinity of felbamate block of NMDA receptors containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites"}
{"PMID":10690753,"re_id":11,"annotated sentence":"We conclude that <e1>felbamate<\\e1> exhibits modest selectivity for <e2>NMDA receptors<\\e2> composed of NR1a\/NR2B subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felbamate","object":"NMDA receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We conclude that <e1>CHEMICAL<\\e1> exhibits modest selectivity for <e2>GENE-N<\\e2> composed of NR1a\/NR2B subunits","sentence":"We conclude that felbamate exhibits modest selectivity for NMDA receptors composed of NR1a\/NR2B subunits"}
{"PMID":10690753,"re_id":12,"annotated sentence":"We conclude that <e1>felbamate<\\e1> exhibits modest selectivity for NMDA receptors composed of <e2>NR1a<\\e2> NR2B subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felbamate","object":"NR1a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that <e1>CHEMICAL<\\e1> exhibits modest selectivity for NMDA receptors composed of <e2>GENE-Y<\\e2> NR2B subunits","sentence":"We conclude that felbamate exhibits modest selectivity for NMDA receptors composed of NR1a NR2B subunits"}
{"PMID":10690753,"re_id":13,"annotated sentence":"We conclude that <e1>felbamate<\\e1> exhibits modest selectivity for NMDA receptors composed of NR1a\/<e2>NR2B<\\e2> subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felbamate","object":"NR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that <e1>CHEMICAL<\\e1> exhibits modest selectivity for NMDA receptors composed of NR1a\/<e2>GENE-Y<\\e2> subunits","sentence":"We conclude that felbamate exhibits modest selectivity for NMDA receptors composed of NR1a\/NR2B subunits"}
{"PMID":10690753,"re_id":14,"annotated sentence":"The anticonvulsant <e1>felbamate<\\e1> blocks <e2>N-methyl-D-asparate (NMDA) receptors<\\e2> but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felbamate","object":"N-methyl-D-asparate (NMDA) receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The anticonvulsant <e1>CHEMICAL<\\e1> blocks <e2>GENE-N<\\e2> but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists","sentence":"The anticonvulsant felbamate blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists"}
{"PMID":10690753,"re_id":15,"annotated sentence":"This selectivity could, in part, account for the more favorable clinical profile of <e1>felbamate<\\e1> in comparison with <e2>NMDA receptor<\\e2> antagonists that do not show subunit selectivity.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"felbamate","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This selectivity could, in part, account for the more favorable clinical profile of <e1>CHEMICAL<\\e1> in comparison with <e2>GENE-N<\\e2> antagonists that do not show subunit selectivity.","sentence":"This selectivity could, in part, account for the more favorable clinical profile of felbamate in comparison with NMDA receptor antagonists that do not show subunit selectivity."}
{"PMID":10690753,"re_id":16,"annotated sentence":"The anticonvulsant <e1>felbamate<\\e1> blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other <e2>NMDA receptor<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"felbamate","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The anticonvulsant <e1>CHEMICAL<\\e1> blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other <e2>GENE-N<\\e2> antagonists","sentence":"The anticonvulsant felbamate blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists"}
{"PMID":10693877,"re_id":0,"annotated sentence":"Comparison of the effect of <e1>rofecoxib<\\e1> (a <e2>cyclooxygenase 2<\\e2> inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"cyclooxygenase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Comparison of the effect of <e1>CHEMICAL<\\e1> (a <e2>GENE-Y<\\e2> inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial","sentence":"Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial"}
{"PMID":10693877,"re_id":1,"annotated sentence":"OBJECTIVE: This randomized, double-blind study tested the hypothesis that <e1>rofecoxib<\\e1>  a drug that specifically inhibits <e2>cyclooxygenase 2<\\e2>  would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"cyclooxygenase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: This randomized, double-blind study tested the hypothesis that <e1>CHEMICAL<\\e1>  a drug that specifically inhibits <e2>GENE-Y<\\e2>  would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design)","sentence":"OBJECTIVE: This randomized, double-blind study tested the hypothesis that rofecoxib  a drug that specifically inhibits cyclooxygenase 2  would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design)"}
{"PMID":10694244,"re_id":0,"annotated sentence":"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of <e1>zileuton<\\e1>  a specific inhibitor of <e2>5-lipoxygenase<\\e2> (5-LOX) and a clinically used anti-asthmatic drug","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zileuton","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of <e1>CHEMICAL<\\e1>  a specific inhibitor of <e2>GENE-Y<\\e2> (5-LOX) and a clinically used anti-asthmatic drug","sentence":"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of zileuton  a specific inhibitor of 5-lipoxygenase (5-LOX) and a clinically used anti-asthmatic drug"}
{"PMID":10694244,"re_id":1,"annotated sentence":"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of <e1>zileuton<\\e1>  a specific inhibitor of 5-lipoxygenase (<e2>5-LOX<\\e2>  and a clinically used anti-asthmatic drug","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zileuton","object":"5-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of <e1>CHEMICAL<\\e1>  a specific inhibitor of 5-lipoxygenase (<e2>GENE-Y<\\e2>  and a clinically used anti-asthmatic drug","sentence":"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of zileuton  a specific inhibitor of 5-lipoxygenase (5-LOX  and a clinically used anti-asthmatic drug"}
{"PMID":10694244,"re_id":2,"annotated sentence":"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to <e1>zileuton<\\e1>  suggesting that troglitazone inhibits LT production by direct inhibition of <e2>5-LOX<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zileuton","object":"5-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to <e1>CHEMICAL<\\e1>  suggesting that troglitazone inhibits LT production by direct inhibition of <e2>GENE-Y<\\e2> activity","sentence":"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton  suggesting that troglitazone inhibits LT production by direct inhibition of 5-LOX activity"}
{"PMID":10694244,"re_id":3,"annotated sentence":"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that <e1>troglitazone<\\e1> inhibits LT production by direct inhibition of <e2>5-LOX<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"troglitazone","object":"5-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that <e1>CHEMICAL<\\e1> inhibits LT production by direct inhibition of <e2>GENE-Y<\\e2> activity","sentence":"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that troglitazone inhibits LT production by direct inhibition of 5-LOX activity"}
{"PMID":10694244,"re_id":4,"annotated sentence":"These findings suggest that <e1>troglitazone<\\e1> inhibits antigen-induced LT production in the IgE-sensitized RBL-2H3 cells and A23187-stimulated rat peritoneal neutrophils by direct inhibition of <e2>5-LOX<\\e2> activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"troglitazone","object":"5-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> inhibits antigen-induced LT production in the IgE-sensitized RBL-2H3 cells and A23187-stimulated rat peritoneal neutrophils by direct inhibition of <e2>GENE-Y<\\e2> activity.","sentence":"These findings suggest that troglitazone inhibits antigen-induced LT production in the IgE-sensitized RBL-2H3 cells and A23187-stimulated rat peritoneal neutrophils by direct inhibition of 5-LOX activity."}
{"PMID":10712236,"re_id":0,"annotated sentence":"The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that <e1>polyamines<\\e1> might be involved in the <e2>caspase<\\e2> activating signal cascade.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"polyamines","object":"caspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that <e1>CHEMICAL<\\e1> might be involved in the <e2>GENE-N<\\e2> activating signal cascade.","sentence":"The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that polyamines might be involved in the caspase activating signal cascade."}
{"PMID":10712236,"re_id":1,"annotated sentence":"Addition of <e1>putrescine<\\e1> restored the induction of apoptosis as indicated by an increase in the number of detached cells and <e2>caspase 3<\\e2> activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"putrescine","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Addition of <e1>CHEMICAL<\\e1> restored the induction of apoptosis as indicated by an increase in the number of detached cells and <e2>GENE-Y<\\e2> activity","sentence":"Addition of putrescine restored the induction of apoptosis as indicated by an increase in the number of detached cells and caspase 3 activity"}
{"PMID":10712236,"re_id":2,"annotated sentence":"Depletion of putrescine, spermidine, and spermine by <e1>DL-alpha-difluoromethylornithine<\\e1> (DFMO), a specific inhibitor of <e2>ornithine decarboxylase<\\e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DL-alpha-difluoromethylornithine","object":"ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depletion of putrescine, spermidine, and spermine by <e1>CHEMICAL<\\e1> (DFMO), a specific inhibitor of <e2>GENE-Y<\\e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","sentence":"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index"}
{"PMID":10712236,"re_id":3,"annotated sentence":"Depletion of putrescine, spermidine, and spermine by <e1>DL-alpha-difluoromethylornithine<\\e1> (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>ODC<\\e2>  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DL-alpha-difluoromethylornithine","object":"ODC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depletion of putrescine, spermidine, and spermine by <e1>CHEMICAL<\\e1> (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>GENE-Y<\\e2>  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","sentence":"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index"}
{"PMID":10712236,"re_id":4,"annotated sentence":"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (<e1>DFMO<\\e1> , a specific inhibitor of <e2>ornithine decarboxylase<\\e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DFMO","object":"ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (<e1>CHEMICAL<\\e1> , a specific inhibitor of <e2>GENE-Y<\\e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","sentence":"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO , a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index"}
{"PMID":10712236,"re_id":5,"annotated sentence":"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (<e1>DFMO<\\e1> , a specific inhibitor of ornithine decarboxylase (<e2>ODC<\\e2>  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DFMO","object":"ODC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (<e1>CHEMICAL<\\e1> , a specific inhibitor of ornithine decarboxylase (<e2>GENE-Y<\\e2>  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","sentence":"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO , a specific inhibitor of ornithine decarboxylase (ODC  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index"}
{"PMID":10712236,"re_id":6,"annotated sentence":"Inhibition of <e2>S-adenosylmethionine decarboxylase<\\e2> by a specific inhibitor [<e1>diethylglyoxal bis-(guanylhydrazone)<\\e1>  DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diethylglyoxal bis-(guanylhydrazone)","object":"S-adenosylmethionine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> by a specific inhibitor [<e1>CHEMICAL<\\e1>  DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC","sentence":"Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone)  DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC"}
{"PMID":10712236,"re_id":7,"annotated sentence":"Inhibition of <e2>S-adenosylmethionine decarboxylase<\\e2> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); <e1>DEGBG<\\e1>  led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEGBG","object":"S-adenosylmethionine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); <e1>CHEMICAL<\\e1>  led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC","sentence":"Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG  led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC"}
{"PMID":10712236,"re_id":8,"annotated sentence":"Depletion of <e1>putrescine<\\e1>  spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of <e2>ornithine decarboxylase<\\e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"putrescine","object":"ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depletion of <e1>CHEMICAL<\\e1>  spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of <e2>GENE-Y<\\e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","sentence":"Depletion of putrescine  spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index"}
{"PMID":10712236,"re_id":9,"annotated sentence":"Depletion of <e1>putrescine<\\e1>  spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>ODC<\\e2>  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"putrescine","object":"ODC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depletion of <e1>CHEMICAL<\\e1>  spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>GENE-Y<\\e2>  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","sentence":"Depletion of putrescine  spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index"}
{"PMID":10712236,"re_id":10,"annotated sentence":"Depletion of putrescine, <e1>spermidine<\\e1>  and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of <e2>ornithine decarboxylase<\\e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermidine","object":"ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depletion of putrescine, <e1>CHEMICAL<\\e1>  and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of <e2>GENE-Y<\\e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","sentence":"Depletion of putrescine, spermidine  and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index"}
{"PMID":10712236,"re_id":11,"annotated sentence":"Depletion of putrescine, <e1>spermidine<\\e1>  and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>ODC<\\e2>  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermidine","object":"ODC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depletion of putrescine, <e1>CHEMICAL<\\e1>  and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>GENE-Y<\\e2>  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","sentence":"Depletion of putrescine, spermidine  and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index"}
{"PMID":10712236,"re_id":12,"annotated sentence":"Depletion of putrescine, spermidine, and <e1>spermine<\\e1> by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of <e2>ornithine decarboxylase<\\e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depletion of putrescine, spermidine, and <e1>CHEMICAL<\\e1> by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of <e2>GENE-Y<\\e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","sentence":"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index"}
{"PMID":10712236,"re_id":13,"annotated sentence":"Depletion of putrescine, spermidine, and <e1>spermine<\\e1> by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>ODC<\\e2>  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"ODC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depletion of putrescine, spermidine, and <e1>CHEMICAL<\\e1> by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>GENE-Y<\\e2>  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index","sentence":"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (ODC  that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index"}
{"PMID":10712236,"re_id":14,"annotated sentence":"Inhibition of <e2>S-adenosylmethionine decarboxylase<\\e2> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of <e1>spermidine<\\e1> and spermine with a significant accumulation of putrescine and induction of ODC","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermidine","object":"S-adenosylmethionine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of <e1>CHEMICAL<\\e1> and spermine with a significant accumulation of putrescine and induction of ODC","sentence":"Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC"}
{"PMID":10712236,"re_id":15,"annotated sentence":"Inhibition of <e2>S-adenosylmethionine decarboxylase<\\e2> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and <e1>spermine<\\e1> with a significant accumulation of putrescine and induction of ODC","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"S-adenosylmethionine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and <e1>CHEMICAL<\\e1> with a significant accumulation of putrescine and induction of ODC","sentence":"Inhibition of S-adenosylmethionine decarboxylase by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC"}
{"PMID":10727715,"re_id":0,"annotated sentence":"In addition, by comparing the combined administration of (+\/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that <e1>(+\/-)pindolol<\\e1> produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B\/D) receptor in addition to any activity it has at the presynaptic <e2>5-HT(1A)<\\e2> receptor.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(+\/-)pindolol","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, by comparing the combined administration of CHEMICAL with either WAY100635, GR127935 or isamoltane, we have determined that <e1>CHEMICAL<\\e1> produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B\/D) receptor in addition to any activity it has at the presynaptic <e2>GENE-Y<\\e2> receptor.","sentence":"In addition, by comparing the combined administration of (+\/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that (+\/-)pindolol produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B\/D) receptor in addition to any activity it has at the presynaptic 5-HT(1A) receptor."}
{"PMID":10727715,"re_id":1,"annotated sentence":"This effect has been attributed to the antagonist effects of <e1>pindolol<\\e1> at the <e2>5-HT(1A)<\\e2> receptor","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"pindolol","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This effect has been attributed to the antagonist effects of <e1>CHEMICAL<\\e1> at the <e2>GENE-Y<\\e2> receptor","sentence":"This effect has been attributed to the antagonist effects of pindolol at the 5-HT(1A) receptor"}
{"PMID":10727715,"re_id":2,"annotated sentence":"In the present study, we compared the pharmacology of <e1>(+\/-)pindolol<\\e1>  WAY-100635 (a <e2>5-HT(1A)<\\e2> antagonist), GR127935 (a 5-HT(1B\/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(+\/-)pindolol","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the present study, we compared the pharmacology of <e1>CHEMICAL<\\e1>  WAY-100635 (a <e2>GENE-Y<\\e2> antagonist), GR127935 (a 5-HT(1B\/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat","sentence":"In the present study, we compared the pharmacology of (+\/-)pindolol  WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B\/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat"}
{"PMID":10727715,"re_id":3,"annotated sentence":"In the present study, we compared the pharmacology of (+\/-)pindolol, <e1>WAY-100635<\\e1> (a <e2>5-HT(1A)<\\e2> antagonist), GR127935 (a 5-HT(1B\/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"WAY-100635","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the present study, we compared the pharmacology of (+\/-)pindolol, <e1>CHEMICAL<\\e1> (a <e2>GENE-Y<\\e2> antagonist), GR127935 (a 5-HT(1B\/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat","sentence":"In the present study, we compared the pharmacology of (+\/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B\/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat"}
{"PMID":10727715,"re_id":4,"annotated sentence":"In the present study, we compared the pharmacology of (+\/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B\/1D) antagonist), and <e1>isamoltane<\\e1> (a <e2>5-HT(1B)<\\e2> antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"isamoltane","object":"5-HT(1B)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the present study, we compared the pharmacology of (+\/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B\/1D) antagonist), and <e1>CHEMICAL<\\e1> (a <e2>GENE-Y<\\e2> antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat","sentence":"In the present study, we compared the pharmacology of (+\/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B\/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat"}
{"PMID":10730683,"re_id":0,"annotated sentence":"<e1>Orlistat<\\e1> treatment also results in modest improvements in total cholesterol, <e2>low-density lipoprotein<\\e2>  blood pressure, and fasting glucose and insulin concentrations","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Orlistat","object":"low-density lipoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment also results in modest improvements in total cholesterol, <e2>GENE-N<\\e2>  blood pressure, and fasting glucose and insulin concentrations","sentence":"Orlistat treatment also results in modest improvements in total cholesterol, low-density lipoprotein  blood pressure, and fasting glucose and insulin concentrations"}
{"PMID":10730683,"re_id":1,"annotated sentence":"<e1>Orlistat<\\e1> treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting glucose and <e2>insulin<\\e2> concentrations","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Orlistat","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting glucose and <e2>GENE-Y<\\e2> concentrations","sentence":"Orlistat treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting glucose and insulin concentrations"}
{"PMID":10730683,"re_id":2,"annotated sentence":"<e1>Orlistat<\\e1>  a new <e2>lipase<\\e2> inhibitor for the management of obesity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Orlistat","object":"lipase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a new <e2>GENE-N<\\e2> inhibitor for the management of obesity","sentence":"Orlistat  a new lipase inhibitor for the management of obesity"}
{"PMID":10752671,"re_id":0,"annotated sentence":"In the liver of rats given <e1>flutamide<\\e1> as initiating agent at the dose of 500 mg\/kg\/week for 6 successive weeks, <e2>gamma-glutamyltraspeptidase<\\e2> positive foci were detected only in 3 of 10 rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"flutamide","object":"gamma-glutamyltraspeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the liver of rats given <e1>CHEMICAL<\\e1> as initiating agent at the dose of 500 mg\/kg\/week for 6 successive weeks, <e2>GENE-N<\\e2> positive foci were detected only in 3 of 10 rats","sentence":"In the liver of rats given flutamide as initiating agent at the dose of 500 mg\/kg\/week for 6 successive weeks, gamma-glutamyltraspeptidase positive foci were detected only in 3 of 10 rats"}
{"PMID":10752671,"re_id":1,"annotated sentence":"<e1>Flutamide<\\e1>  an effective competitive inhibitor of the <e2>androgen receptor<\\e2> used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Flutamide","object":"androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an effective competitive inhibitor of the <e2>GENE-Y<\\e2> used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes","sentence":"Flutamide  an effective competitive inhibitor of the androgen receptor used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes"}
{"PMID":10839989,"re_id":0,"annotated sentence":"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: <e1>N(5)-methyl<\\e1>  and N(5)-hydroxymethyl H(4)biopterin inhibited <e2>phenylalanine hydroxylase<\\e2>  whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N(5)-methyl","object":"phenylalanine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of GENE-Y: <e1>CHEMICAL<\\e1>  and N(5)-hydroxymethyl H(4)biopterin inhibited <e2>GENE-Y<\\e2>  whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect","sentence":"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl  and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase  whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect"}
{"PMID":10839989,"re_id":1,"annotated sentence":"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and <e1>N(5)-hydroxymethyl H(4)biopterin<\\e1> inhibited <e2>phenylalanine hydroxylase<\\e2>  whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N(5)-hydroxymethyl H(4)biopterin","object":"phenylalanine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of GENE-Y: N(5)-methyl- and <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2>  whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect","sentence":"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase  whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect"}
{"PMID":10839989,"re_id":2,"annotated sentence":"Our data demonstrate differences in the mechanism of stimulation of <e2>phenylalanine hydroxylase<\\e2> and nitric oxide synthase by <e1>H(4)biopterin<\\e1>  They are compatible with a novel, non-classical, redox-active contribution of H(4)biopterin to the catalysis of the nitric oxide synthase reaction.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"H(4)biopterin","object":"phenylalanine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our data demonstrate differences in the mechanism of stimulation of <e2>GENE-Y<\\e2> and nitric oxide synthase by <e1>CHEMICAL<\\e1>  They are compatible with a novel, non-classical, redox-active contribution of CHEMICAL to the catalysis of the nitric oxide synthase reaction.","sentence":"Our data demonstrate differences in the mechanism of stimulation of phenylalanine hydroxylase and nitric oxide synthase by H(4)biopterin  They are compatible with a novel, non-classical, redox-active contribution of H(4)biopterin to the catalysis of the nitric oxide synthase reaction."}
{"PMID":10839989,"re_id":3,"annotated sentence":"<e1>N(5)-Substituted H(4)biopterin<\\e1> derivatives were not oxidized to products serving as substrates for <e2>dihydropteridine reductase<\\e2> and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N(5)-Substituted H(4)biopterin","object":"dihydropteridine reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> derivatives were not oxidized to products serving as substrates for <e2>GENE-Y<\\e2> and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect","sentence":"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect"}
{"PMID":10864881,"re_id":0,"annotated sentence":"In this study, we examined whether <e1>betaxolol<\\e1> and other <e2>beta-adrenoceptor<\\e2> antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"betaxolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, we examined whether <e1>CHEMICAL<\\e1> and other <e2>GENE-N<\\e2> antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes","sentence":"In this study, we examined whether betaxolol and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes"}
{"PMID":10864881,"re_id":1,"annotated sentence":"<e1>Betaxolol<\\e1>  a <e2>beta(1)-adrenoceptor<\\e2> antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia\/excitotoxicity","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Betaxolol","object":"beta(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia\/excitotoxicity","sentence":"Betaxolol  a beta(1)-adrenoceptor antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia\/excitotoxicity"}
{"PMID":10864881,"re_id":2,"annotated sentence":"Comparison of all the <e2>beta-adrenoceptor<\\e2> antagonists tested revealed a potency order of <e1>propranolol<\\e1> betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=timolol>atenolol","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"propranolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of all the <e2>GENE-N<\\e2> antagonists tested revealed a potency order of <e1>CHEMICAL<\\e1> betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=timolol>atenolol","sentence":"Comparison of all the beta-adrenoceptor antagonists tested revealed a potency order of propranolol betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=timolol>atenolol"}
{"PMID":10864881,"re_id":3,"annotated sentence":"Comparison of all the <e2>beta-adrenoceptor<\\e2> antagonists tested revealed a potency order of propranolol><e1>betaxolol<\\e1> approximately levobetaxolol>levobunolol approximately carteolol>\/=timolol>atenolol","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"betaxolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of all the <e2>GENE-N<\\e2> antagonists tested revealed a potency order of propranolol><e1>CHEMICAL<\\e1> approximately levoCHEMICAL>levobunolol approximately carteolol>\/=timolol>atenolol","sentence":"Comparison of all the beta-adrenoceptor antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=timolol>atenolol"}
{"PMID":10864881,"re_id":4,"annotated sentence":"Comparison of all the <e2>beta-adrenoceptor<\\e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately <e1>levobetaxolol<\\e1> levobunolol approximately carteolol>\/=timolol>atenolol","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"levobetaxolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of all the <e2>GENE-N<\\e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately <e1>CHEMICAL<\\e1> levobunolol approximately carteolol>\/=timolol>atenolol","sentence":"Comparison of all the beta-adrenoceptor antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol levobunolol approximately carteolol>\/=timolol>atenolol"}
{"PMID":10864881,"re_id":5,"annotated sentence":"Comparison of all the <e2>beta-adrenoceptor<\\e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol><e1>levobunolol<\\e1> approximately carteolol>\/=timolol>atenolol","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"levobunolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of all the <e2>GENE-N<\\e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol><e1>CHEMICAL<\\e1> approximately carteolol>\/=timolol>atenolol","sentence":"Comparison of all the beta-adrenoceptor antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=timolol>atenolol"}
{"PMID":10864881,"re_id":6,"annotated sentence":"Comparison of all the <e2>beta-adrenoceptor<\\e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately <e1>carteolol<\\e1> \/=timolol>atenolol","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"carteolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of all the <e2>GENE-N<\\e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately <e1>CHEMICAL<\\e1> \/=timolol>atenolol","sentence":"Comparison of all the beta-adrenoceptor antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol \/=timolol>atenolol"}
{"PMID":10864881,"re_id":7,"annotated sentence":"Comparison of all the <e2>beta-adrenoceptor<\\e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=<e1>timolol<\\e1> atenolol","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"timolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of all the <e2>GENE-N<\\e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=<e1>CHEMICAL<\\e1> atenolol","sentence":"Comparison of all the beta-adrenoceptor antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=timolol atenolol"}
{"PMID":10864881,"re_id":8,"annotated sentence":"Comparison of all the <e2>beta-adrenoceptor<\\e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=timolol><e1>atenolol<\\e1>  None of the drugs caused a significant inhibition of [(3)H]-saxitoxin binding to neurotoxin receptor site 1, even at concentrations as high as 250 microM","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"atenolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of all the <e2>GENE-N<\\e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=timolol><e1>CHEMICAL<\\e1>  None of the drugs caused a significant inhibition of [(3)H]-saxitoxin binding to neurotoxin receptor site 1, even at concentrations as high as 250 microM","sentence":"Comparison of all the beta-adrenoceptor antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>\/=timolol>atenolol  None of the drugs caused a significant inhibition of [(3)H]-saxitoxin binding to neurotoxin receptor site 1, even at concentrations as high as 250 microM"}
{"PMID":10864881,"re_id":9,"annotated sentence":"<e1>Betaxolol<\\e1>  a <e2>beta(1)-adrenoceptor<\\e2> antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Betaxolol","object":"beta(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists","sentence":"Betaxolol  a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists"}
{"PMID":10864881,"re_id":10,"annotated sentence":"<e1>Betaxolol<\\e1>  a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other <e2>beta-adrenoceptor<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Betaxolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other <e2>GENE-N<\\e2> antagonists","sentence":"Betaxolol  a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists"}
{"PMID":10891536,"re_id":0,"annotated sentence":"5-Fluorouracil (<e1>5-FU<\\e1> , 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase<\\e2> (TS)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-FU","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-Fluorouracil (<e1>CHEMICAL<\\e1> , 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>GENE-Y<\\e2> (TS)","sentence":"5-Fluorouracil (5-FU , 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS)"}
{"PMID":10891536,"re_id":1,"annotated sentence":"5-Fluorouracil (<e1>5-FU<\\e1> , 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-FU","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-Fluorouracil (<e1>CHEMICAL<\\e1> , 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>GENE-Y<\\e2> ","sentence":"5-Fluorouracil (5-FU , 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS "}
{"PMID":10891536,"re_id":2,"annotated sentence":"<e1>5-Fluorouracil<\\e1> (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase<\\e2> (TS)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-Fluorouracil","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>GENE-Y<\\e2> (TS)","sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS)"}
{"PMID":10891536,"re_id":3,"annotated sentence":"<e1>5-Fluorouracil<\\e1> (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-Fluorouracil","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>GENE-Y<\\e2> ","sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS "}
{"PMID":10891536,"re_id":4,"annotated sentence":"When DLD-1\/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1\/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to <e1>F3(d)Thd<\\e1> is due to a mechanism other than <e2>TS<\\e2> inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"F3(d)Thd","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When DLD-1\/FdUrd cells expressing increased GENE-Y mRNA were treated with FdUrd and CHEMICAL for only 4 h, the resistance ratios of DLD-1\/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and CHEMICAL, suggesting that the cytotoxicity with short-time exposure to <e1>CHEMICAL<\\e1> is due to a mechanism other than <e2>GENE-Y<\\e2> inhibition, although the cytotoxicity of CHEMICAL in the short-time is low compared to that of long-time exposure","sentence":"When DLD-1\/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1\/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure"}
{"PMID":10891536,"re_id":5,"annotated sentence":"In conclusion, <e1>F3(d)Thd<\\e1>  an antimetabolite that inhibits <e2>TS<\\e2> activity, may be effective against 5-FU and\/or FdUrd-resistance in colorectal cancer cells caused by amplification of TS and\/or deletion of orotate phosphoribosyltransferase.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"F3(d)Thd","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1>  an antimetabolite that inhibits <e2>GENE-Y<\\e2> activity, may be effective against 5-FU and\/or FdUrd-resistance in colorectal cancer cells caused by amplification of GENE-Y and\/or deletion of orotate phosphoribosyltransferase.","sentence":"In conclusion, F3(d)Thd  an antimetabolite that inhibits TS activity, may be effective against 5-FU and\/or FdUrd-resistance in colorectal cancer cells caused by amplification of TS and\/or deletion of orotate phosphoribosyltransferase."}
{"PMID":10891536,"re_id":6,"annotated sentence":"5-Fluorouracil (5-FU), <e1>5-fluoro-2'-deoxyuridine<\\e1> (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase<\\e2> (TS)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-fluoro-2'-deoxyuridine","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-Fluorouracil (5-FU), <e1>CHEMICAL<\\e1> (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>GENE-Y<\\e2> (TS)","sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS)"}
{"PMID":10891536,"re_id":7,"annotated sentence":"5-Fluorouracil (5-FU), <e1>5-fluoro-2'-deoxyuridine<\\e1> (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-fluoro-2'-deoxyuridine","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-Fluorouracil (5-FU), <e1>CHEMICAL<\\e1> (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>GENE-Y<\\e2> ","sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS "}
{"PMID":10891536,"re_id":8,"annotated sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (<e1>FdUrd<\\e1>  and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase<\\e2> (TS)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"FdUrd","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (<e1>CHEMICAL<\\e1>  and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>GENE-Y<\\e2> (TS)","sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd  and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS)"}
{"PMID":10891536,"re_id":9,"annotated sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (<e1>FdUrd<\\e1>  and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"FdUrd","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (<e1>CHEMICAL<\\e1>  and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>GENE-Y<\\e2> ","sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd  and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS "}
{"PMID":10891536,"re_id":10,"annotated sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and <e1>5-trifluorothymidine<\\e1> (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase<\\e2> (TS)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-trifluorothymidine","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and <e1>CHEMICAL<\\e1> (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>GENE-Y<\\e2> (TS)","sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS)"}
{"PMID":10891536,"re_id":11,"annotated sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and <e1>5-trifluorothymidine<\\e1> (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-trifluorothymidine","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and <e1>CHEMICAL<\\e1> (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>GENE-Y<\\e2> ","sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS "}
{"PMID":10891536,"re_id":12,"annotated sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (<e1>F3(d)Thd<\\e1>  are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase<\\e2> (TS)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"F3(d)Thd","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (<e1>CHEMICAL<\\e1>  are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>GENE-Y<\\e2> (TS)","sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd  are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS)"}
{"PMID":10891536,"re_id":13,"annotated sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (<e1>F3(d)Thd<\\e1>  are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"F3(d)Thd","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (<e1>CHEMICAL<\\e1>  are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>GENE-Y<\\e2> ","sentence":"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd  are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS "}
{"PMID":10947967,"re_id":0,"annotated sentence":"Stereochemical studies established that <e2>PAM<\\e2> inactivation by <e1>4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid<\\e1> is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid","object":"PAM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Stereochemical studies established that <e2>GENE-Y<\\e2> inactivation by <e1>CHEMICAL<\\e1> is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors","sentence":"Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors"}
{"PMID":10947967,"re_id":1,"annotated sentence":"In contrast, <e1>2, 4-dioxo-5-acetamido-6-phenylhexanoic acid<\\e1>  which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both <e2>PAM<\\e2> and dopamine-beta-hydroxylase.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2, 4-dioxo-5-acetamido-6-phenylhexanoic acid","object":"PAM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1>  which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both <e2>GENE-Y<\\e2> and dopamine-beta-hydroxylase.","sentence":"In contrast, 2, 4-dioxo-5-acetamido-6-phenylhexanoic acid  which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and dopamine-beta-hydroxylase."}
{"PMID":10947967,"re_id":2,"annotated sentence":"In contrast, <e1>2, 4-dioxo-5-acetamido-6-phenylhexanoic acid<\\e1>  which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and <e2>dopamine-beta-hydroxylase<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2, 4-dioxo-5-acetamido-6-phenylhexanoic acid","object":"dopamine-beta-hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1>  which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and <e2>GENE-Y<\\e2> ","sentence":"In contrast, 2, 4-dioxo-5-acetamido-6-phenylhexanoic acid  which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and dopamine-beta-hydroxylase "}
{"PMID":10947967,"re_id":3,"annotated sentence":"Kinetic parameters for <e2>PAM<\\e2> inactivation by <e1>4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid<\\e1> were obtained by using both the conventional dilution assay method and the more complex progress curve method","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid","object":"PAM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic parameters for <e2>GENE-Y<\\e2> inactivation by <e1>CHEMICAL<\\e1> were obtained by using both the conventional dilution assay method and the more complex progress curve method","sentence":"Kinetic parameters for PAM inactivation by 4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid were obtained by using both the conventional dilution assay method and the more complex progress curve method"}
{"PMID":10950934,"re_id":0,"annotated sentence":"Endogenously produced asymmetrically methylated <e1>arginine<\\e1> residues are competitive inhibitors of all three isoforms of <e2>nitric oxide synthase<\\e2> (NOS)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"arginine","object":"nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Endogenously produced asymmetrically methylated <e1>CHEMICAL<\\e1> residues are competitive inhibitors of all three isoforms of <e2>GENE-N<\\e2> (NOS)","sentence":"Endogenously produced asymmetrically methylated arginine residues are competitive inhibitors of all three isoforms of nitric oxide synthase (NOS)"}
{"PMID":10950934,"re_id":1,"annotated sentence":"Endogenously produced asymmetrically methylated <e1>arginine<\\e1> residues are competitive inhibitors of all three isoforms of nitric oxide synthase (<e2>NOS<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"arginine","object":"NOS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Endogenously produced asymmetrically methylated <e1>CHEMICAL<\\e1> residues are competitive inhibitors of all three isoforms of nitric oxide synthase (<e2>GENE-N<\\e2> ","sentence":"Endogenously produced asymmetrically methylated arginine residues are competitive inhibitors of all three isoforms of nitric oxide synthase (NOS "}
{"PMID":10950934,"re_id":2,"annotated sentence":"The enzyme <e2>dimethylarginine dimethylaminohydrolase<\\e2> (DDAH) specifically hydrolyzes these asymmetrically methylated <e1>arginine<\\e1> residues to citrulline and methylamines","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arginine","object":"dimethylarginine dimethylaminohydrolase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The enzyme <e2>dimethylCHEMICAL dimethylaminohydrolase<\\e2> (DDAH) specifically hydrolyzes these asymmetrically methylated <e1>CHEMICAL<\\e1> residues to citrulline and methylamines","sentence":"The enzyme dimethylarginine dimethylaminohydrolase (DDAH) specifically hydrolyzes these asymmetrically methylated arginine residues to citrulline and methylamines"}
{"PMID":10950934,"re_id":3,"annotated sentence":"The enzyme dimethylarginine dimethylaminohydrolase (<e2>DDAH<\\e2>  specifically hydrolyzes these asymmetrically methylated <e1>arginine<\\e1> residues to citrulline and methylamines","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arginine","object":"DDAH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The enzyme dimethylCHEMICAL dimethylaminohydrolase (<e2>GENE-N<\\e2>  specifically hydrolyzes these asymmetrically methylated <e1>CHEMICAL<\\e1> residues to citrulline and methylamines","sentence":"The enzyme dimethylarginine dimethylaminohydrolase (DDAH  specifically hydrolyzes these asymmetrically methylated arginine residues to citrulline and methylamines"}
{"PMID":10950934,"re_id":4,"annotated sentence":"Previously we have proposed that regulation of asymmetric <e1>methylarginine<\\e1> concentration by <e2>DDAH<\\e2> may provide a novel mechanism for the regulation of NOS activity in vivo","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methylarginine","object":"DDAH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previously we have proposed that regulation of asymmetric <e1>CHEMICAL<\\e1> concentration by <e2>GENE-N<\\e2> may provide a novel mechanism for the regulation of NOS activity in vivo","sentence":"Previously we have proposed that regulation of asymmetric methylarginine concentration by DDAH may provide a novel mechanism for the regulation of NOS activity in vivo"}
{"PMID":10954021,"re_id":0,"annotated sentence":"Experimental cystathioninuria was induced in rats by administration of the <e2>cystathionine gamma-lyase<\\e2> inhibitor, <e1>D,L-propargylglycine<\\e1>  The cystathionine metabolites, cystathionine ketimine (CK) and perhydro-1,4-thiazepine-3,5-dicarboxylic acid (PHTZDC), were identified in whole brain and various regions of the brain in D,L-propargylglycine-treated rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"D,L-propargylglycine","object":"cystathionine gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Experimental cystathioninuria was induced in rats by administration of the <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  The cystathionine metabolites, cystathionine ketimine (CK) and perhydro-1,4-thiazepine-3,5-dicarboxylic acid (PHTZDC), were identified in whole brain and various regions of the brain in CHEMICAL-treated rats","sentence":"Experimental cystathioninuria was induced in rats by administration of the cystathionine gamma-lyase inhibitor, D,L-propargylglycine  The cystathionine metabolites, cystathionine ketimine (CK) and perhydro-1,4-thiazepine-3,5-dicarboxylic acid (PHTZDC), were identified in whole brain and various regions of the brain in D,L-propargylglycine-treated rats"}
{"PMID":10988273,"re_id":0,"annotated sentence":"A prerequisite for this hypothesis was the unproved assumption that rabbit and human <e2>alpha(2A)-adrenoceptors<\\e2> are equally activated by <e1>rilmenidine<\\e1>  Because alpha(2A)-adrenoceptors in the brain and on cardiovascular sympathetic nerve terminals are identical, the latter were used as a model for the former to confirm or disprove this assumption","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rilmenidine","object":"alpha(2A)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A prerequisite for this hypothesis was the unproved assumption that rabbit and human <e2>GENE-N<\\e2> are equally activated by <e1>CHEMICAL<\\e1>  Because GENE-N in the brain and on cardiovascular sympathetic nerve terminals are identical, the latter were used as a model for the former to confirm or disprove this assumption","sentence":"A prerequisite for this hypothesis was the unproved assumption that rabbit and human alpha(2A)-adrenoceptors are equally activated by rilmenidine  Because alpha(2A)-adrenoceptors in the brain and on cardiovascular sympathetic nerve terminals are identical, the latter were used as a model for the former to confirm or disprove this assumption"}
{"PMID":10988273,"re_id":1,"annotated sentence":"On the basis of data obtained in rabbits, the imidazoline receptor ligand <e1>rilmenidine<\\e1> has been suggested to decrease blood pressure in humans by activating central <e2>alpha(2A)-adrenoceptors<\\e2>  A prerequisite for this hypothesis was the unproved assumption that rabbit and human alpha(2A)-adrenoceptors are equally activated by rilmenidine","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rilmenidine","object":"alpha(2A)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the basis of data obtained in rabbits, the imidazoline receptor ligand <e1>CHEMICAL<\\e1> has been suggested to decrease blood pressure in humans by activating central <e2>GENE-Y<\\e2>  A prerequisite for this hypothesis was the unproved assumption that rabbit and human GENE-Y are equally activated by CHEMICAL","sentence":"On the basis of data obtained in rabbits, the imidazoline receptor ligand rilmenidine has been suggested to decrease blood pressure in humans by activating central alpha(2A)-adrenoceptors  A prerequisite for this hypothesis was the unproved assumption that rabbit and human alpha(2A)-adrenoceptors are equally activated by rilmenidine"}
{"PMID":10988273,"re_id":2,"annotated sentence":"Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the <e2>alpha(2)-adrenoceptor<\\e2> mediated inhibition induced by <e1>moxonidine<\\e1>  In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors, sharing this property with rauwolscine, phentolamine, and idazoxan","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"moxonidine","object":"alpha(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of GENE-N agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the <e2>GENE-N<\\e2> mediated inhibition induced by <e1>CHEMICAL<\\e1>  In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors, sharing this property with rauwolscine, phentolamine, and idazoxan","sentence":"Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the alpha(2)-adrenoceptor mediated inhibition induced by moxonidine  In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors, sharing this property with rauwolscine, phentolamine, and idazoxan"}
{"PMID":10988273,"re_id":3,"annotated sentence":"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with <e2>alpha(2A)-autoreceptors<\\e2>  at which, however, both rilmenidine and <e1>oxymetazoline<\\e1> exhibit different properties (antagonism and agonism, respectively)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"oxymetazoline","object":"alpha(2A)-autoreceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with <e2>GENE-N<\\e2>  at which, however, both rilmenidine and <e1>CHEMICAL<\\e1> exhibit different properties (antagonism and agonism, respectively)","sentence":"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with alpha(2A)-autoreceptors  at which, however, both rilmenidine and oxymetazoline exhibit different properties (antagonism and agonism, respectively)"}
{"PMID":10988273,"re_id":4,"annotated sentence":"In the rabbit pulmonary artery, <e1>rilmenidine<\\e1> and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>alpha(2)-autoreceptors<\\e2>  sharing this property with rauwolscine, phentolamine, and idazoxan","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"rilmenidine","object":"alpha(2)-autoreceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the rabbit pulmonary artery, <e1>CHEMICAL<\\e1> and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>GENE-N<\\e2>  sharing this property with rauwolscine, phentolamine, and idazoxan","sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors  sharing this property with rauwolscine, phentolamine, and idazoxan"}
{"PMID":10988273,"re_id":5,"annotated sentence":"In the rabbit pulmonary artery, rilmenidine and <e1>oxymetazoline<\\e1> are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>alpha(2)-autoreceptors<\\e2>  sharing this property with rauwolscine, phentolamine, and idazoxan","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"oxymetazoline","object":"alpha(2)-autoreceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the rabbit pulmonary artery, rilmenidine and <e1>CHEMICAL<\\e1> are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>GENE-N<\\e2>  sharing this property with rauwolscine, phentolamine, and idazoxan","sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors  sharing this property with rauwolscine, phentolamine, and idazoxan"}
{"PMID":10988273,"re_id":6,"annotated sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>alpha(2)-autoreceptors<\\e2>  sharing this property with <e1>rauwolscine<\\e1>  phentolamine, and idazoxan","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"rauwolscine","object":"alpha(2)-autoreceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>GENE-N<\\e2>  sharing this property with <e1>CHEMICAL<\\e1>  phentolamine, and idazoxan","sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors  sharing this property with rauwolscine  phentolamine, and idazoxan"}
{"PMID":10988273,"re_id":7,"annotated sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>alpha(2)-autoreceptors<\\e2>  sharing this property with rauwolscine, <e1>phentolamine<\\e1>  and idazoxan","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"phentolamine","object":"alpha(2)-autoreceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>GENE-N<\\e2>  sharing this property with rauwolscine, <e1>CHEMICAL<\\e1>  and idazoxan","sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors  sharing this property with rauwolscine, phentolamine  and idazoxan"}
{"PMID":10988273,"re_id":8,"annotated sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>alpha(2)-autoreceptors<\\e2>  sharing this property with rauwolscine, phentolamine, and <e1>idazoxan<\\e1>  In contrast, prazosin is ineffective","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"idazoxan","object":"alpha(2)-autoreceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>GENE-N<\\e2>  sharing this property with rauwolscine, phentolamine, and <e1>CHEMICAL<\\e1>  In contrast, prazosin is ineffective","sentence":"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors  sharing this property with rauwolscine, phentolamine, and idazoxan  In contrast, prazosin is ineffective"}
{"PMID":10988273,"re_id":9,"annotated sentence":"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with <e2>alpha(2A)-autoreceptors<\\e2>  at which, however, both <e1>rilmenidine<\\e1> and oxymetazoline exhibit different properties (antagonism and agonism, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"rilmenidine","object":"alpha(2A)-autoreceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with <e2>GENE-N<\\e2>  at which, however, both <e1>CHEMICAL<\\e1> and oxymetazoline exhibit different properties (antagonism and agonism, respectively)","sentence":"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with alpha(2A)-autoreceptors  at which, however, both rilmenidine and oxymetazoline exhibit different properties (antagonism and agonism, respectively)"}
{"PMID":10988273,"re_id":10,"annotated sentence":"The antagonistic property of <e1>rilmenidine<\\e1> at <e2>human alpha(2A)-adrenoceptors<\\e2> indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"rilmenidine","object":"human alpha(2A)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antagonistic property of <e1>CHEMICAL<\\e1> at <e2>GENE-Y<\\e2> indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved.","sentence":"The antagonistic property of rilmenidine at human alpha(2A)-adrenoceptors indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved."}
{"PMID":10999950,"re_id":0,"annotated sentence":"<e1>U50, 488H<\\e1> caused a significant down-regulation of the <e2>hkor<\\e2>  although etorphine did not","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U50, 488H","object":"hkor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> caused a significant down-regulation of the <e2>GENE-Y<\\e2>  although etorphine did not","sentence":"U50, 488H caused a significant down-regulation of the hkor  although etorphine did not"}
{"PMID":10999950,"re_id":1,"annotated sentence":"Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced <e1>U50,488H<\\e1> induced down-regulation of the <e2>hkor<\\e2>  Coexpression of GRK2 or GRK2 and arrestin-2 permitted etorphine to induce down-regulation of the hkor, although expression of arrestin-2 or dynamin I alone did not","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U50,488H","object":"hkor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced <e1>CHEMICAL<\\e1> induced down-regulation of the <e2>GENE-Y<\\e2>  Coexpression of GRK2 or GRK2 and arrestin-2 permitted etorphine to induce down-regulation of the GENE-Y, although expression of arrestin-2 or dynamin I alone did not","sentence":"Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced U50,488H induced down-regulation of the hkor  Coexpression of GRK2 or GRK2 and arrestin-2 permitted etorphine to induce down-regulation of the hkor, although expression of arrestin-2 or dynamin I alone did not"}
{"PMID":10999950,"re_id":2,"annotated sentence":"Coexpression of GRK2 or GRK2 and arrestin-2 permitted <e1>etorphine<\\e1> to induce down-regulation of the <e2>hkor<\\e2>  although expression of arrestin-2 or dynamin I alone did not","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"etorphine","object":"hkor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coexpression of GRK2 or GRK2 and arrestin-2 permitted <e1>CHEMICAL<\\e1> to induce down-regulation of the <e2>GENE-Y<\\e2>  although expression of arrestin-2 or dynamin I alone did not","sentence":"Coexpression of GRK2 or GRK2 and arrestin-2 permitted etorphine to induce down-regulation of the hkor  although expression of arrestin-2 or dynamin I alone did not"}
{"PMID":10999950,"re_id":3,"annotated sentence":"Expression of the dominant negative mutants <e2>rab5A<\\e2> N133I or rab7-N125I blunted <e1>U50,488H<\\e1> induced down-regulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U50,488H","object":"rab5A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Expression of the dominant negative mutants <e2>GENE-Y<\\e2> N133I or rab7-N125I blunted <e1>CHEMICAL<\\e1> induced down-regulation","sentence":"Expression of the dominant negative mutants rab5A N133I or rab7-N125I blunted U50,488H induced down-regulation"}
{"PMID":10999950,"re_id":4,"annotated sentence":"Expression of the dominant negative mutants rab5A-<e2>N133I<\\e2> or rab7-N125I blunted <e1>U50,488H<\\e1> induced down-regulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U50,488H","object":"N133I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Expression of the dominant negative mutants rab5A-<e2>GENE-N<\\e2> or rab7-N125I blunted <e1>CHEMICAL<\\e1> induced down-regulation","sentence":"Expression of the dominant negative mutants rab5A-N133I or rab7-N125I blunted U50,488H induced down-regulation"}
{"PMID":10999950,"re_id":5,"annotated sentence":"Expression of the dominant negative mutants rab5A-N133I or <e2>rab7<\\e2> N125I blunted <e1>U50,488H<\\e1> induced down-regulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U50,488H","object":"rab7","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Expression of the dominant negative mutants rab5A-N133I or <e2>GENE-N<\\e2> N125I blunted <e1>CHEMICAL<\\e1> induced down-regulation","sentence":"Expression of the dominant negative mutants rab5A-N133I or rab7 N125I blunted U50,488H induced down-regulation"}
{"PMID":10999950,"re_id":6,"annotated sentence":"Expression of the dominant negative mutants rab5A-N133I or rab7-<e2>N125I<\\e2> blunted <e1>U50,488H<\\e1> induced down-regulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U50,488H","object":"N125I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Expression of the dominant negative mutants rab5A-N133I or rab7-<e2>GENE-N<\\e2> blunted <e1>CHEMICAL<\\e1> induced down-regulation","sentence":"Expression of the dominant negative mutants rab5A-N133I or rab7-N125I blunted U50,488H induced down-regulation"}
{"PMID":10999950,"re_id":7,"annotated sentence":"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (<e2>proteasome<\\e2> inhibitor I, <e1>MG-132<\\e1>  or lactacystin) decreased the extent of U50,488H-induced down-regulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MG-132","object":"proteasome","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or GENE-N inhibitors (<e2>GENE-N<\\e2> inhibitor I, <e1>CHEMICAL<\\e1>  or lactacystin) decreased the extent of U50,488H-induced down-regulation","sentence":"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (proteasome inhibitor I, MG-132  or lactacystin) decreased the extent of U50,488H-induced down-regulation"}
{"PMID":10999950,"re_id":8,"annotated sentence":"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (<e2>proteasome<\\e2> inhibitor I, MG-132, or <e1>lactacystin<\\e1>  decreased the extent of U50,488H-induced down-regulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lactacystin","object":"proteasome","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or GENE-N inhibitors (<e2>GENE-N<\\e2> inhibitor I, MG-132, or <e1>CHEMICAL<\\e1>  decreased the extent of U50,488H-induced down-regulation","sentence":"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (proteasome inhibitor I, MG-132, or lactacystin  decreased the extent of U50,488H-induced down-regulation"}
{"PMID":10999950,"re_id":9,"annotated sentence":"These results indicate that <e1>U50,488H<\\e1> induced down-regulation of the <e2>hkor<\\e2> involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U50,488H","object":"hkor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> induced down-regulation of the <e2>GENE-Y<\\e2> involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation","sentence":"These results indicate that U50,488H induced down-regulation of the hkor involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation"}
{"PMID":10999950,"re_id":10,"annotated sentence":"Thus, <e1>U50,488H<\\e1> induced internalization and down-regulation of the <e2>hkor<\\e2> share initial common mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U50,488H","object":"hkor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> induced internalization and down-regulation of the <e2>GENE-Y<\\e2> share initial common mechanisms","sentence":"Thus, U50,488H induced internalization and down-regulation of the hkor share initial common mechanisms"}
{"PMID":10999950,"re_id":11,"annotated sentence":"Previously, we showed that the <e2>human kappa-opioid receptor<\\e2> (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <e1>U50,488H<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U50,488H","object":"human kappa-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Previously, we showed that the <e2>GENE-Y<\\e2> (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <e1>CHEMICAL<\\e1> treatment","sentence":"Previously, we showed that the human kappa-opioid receptor (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged U50,488H treatment"}
{"PMID":10999950,"re_id":12,"annotated sentence":"Previously, we showed that the human kappa-opioid receptor (<e2>hkor<\\e2>  stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <e1>U50,488H<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U50,488H","object":"hkor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Previously, we showed that the human kappa-opioid receptor (<e2>GENE-Y<\\e2>  stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <e1>CHEMICAL<\\e1> treatment","sentence":"Previously, we showed that the human kappa-opioid receptor (hkor  stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged U50,488H treatment"}
{"PMID":11009561,"re_id":0,"annotated sentence":"The <e1>BH(4)<\\e1> treatment was associated with a 2-fold increase in <e2>eNOS<\\e2> activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BH(4)","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> treatment was associated with a 2-fold increase in <e2>GENE-Y<\\e2> activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats","sentence":"The BH(4) treatment was associated with a 2-fold increase in eNOS activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats"}
{"PMID":11009561,"re_id":1,"annotated sentence":"The <e1>BH(4)<\\e1> treatment also partially improved the <e2>insulin<\\e2> sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BH(4)","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e1>CHEMICAL<\\e1> treatment also partially improved the <e2>GENE-N<\\e2> sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats","sentence":"The BH(4) treatment also partially improved the insulin sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats"}
{"PMID":11009561,"re_id":2,"annotated sentence":"Moreover, BH(4) treatment of the <e1>fructose<\\e1> fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <e2>nuclear factor-kappaB<\\e2> and activating protein-1, which were increased in fructose-fed rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fructose","object":"nuclear factor-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, BH(4) treatment of the <e1>CHEMICAL<\\e1> fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <e2>GENE-N<\\e2> and activating protein-1, which were increased in CHEMICAL-fed rats","sentence":"Moreover, BH(4) treatment of the fructose fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and activating protein-1, which were increased in fructose-fed rats"}
{"PMID":11009561,"re_id":3,"annotated sentence":"Moreover, BH(4) treatment of the <e1>fructose<\\e1> fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <e2>activating protein-1<\\e2>  which were increased in fructose-fed rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fructose","object":"activating protein-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, BH(4) treatment of the <e1>CHEMICAL<\\e1> fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <e2>GENE-Y<\\e2>  which were increased in CHEMICAL-fed rats","sentence":"Moreover, BH(4) treatment of the fructose fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and activating protein-1  which were increased in fructose-fed rats"}
{"PMID":11009561,"re_id":4,"annotated sentence":"Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <e2>nuclear factor-kappaB<\\e2> and activating protein-1, which were increased in <e1>fructose<\\e1> fed rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fructose","object":"nuclear factor-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, BH(4) treatment of the CHEMICAL-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <e2>GENE-N<\\e2> and activating protein-1, which were increased in <e1>CHEMICAL<\\e1> fed rats","sentence":"Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and activating protein-1, which were increased in fructose fed rats"}
{"PMID":11009561,"re_id":5,"annotated sentence":"Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <e2>activating protein-1<\\e2>  which were increased in <e1>fructose<\\e1> fed rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fructose","object":"activating protein-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, BH(4) treatment of the CHEMICAL-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <e2>GENE-Y<\\e2>  which were increased in <e1>CHEMICAL<\\e1> fed rats","sentence":"Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and activating protein-1  which were increased in fructose fed rats"}
{"PMID":11009561,"re_id":6,"annotated sentence":"Moreover, <e1>BH(4)<\\e1> treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <e2>nuclear factor-kappaB<\\e2> and activating protein-1, which were increased in fructose-fed rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BH(4)","object":"nuclear factor-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <e2>GENE-N<\\e2> and activating protein-1, which were increased in fructose-fed rats","sentence":"Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and activating protein-1, which were increased in fructose-fed rats"}
{"PMID":11009561,"re_id":7,"annotated sentence":"Moreover, <e1>BH(4)<\\e1> treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <e2>activating protein-1<\\e2>  which were increased in fructose-fed rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BH(4)","object":"activating protein-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <e2>GENE-Y<\\e2>  which were increased in fructose-fed rats","sentence":"Moreover, BH(4) treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and activating protein-1  which were increased in fructose-fed rats"}
{"PMID":11031122,"re_id":0,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"morantel","object":"FRD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":11031122,"re_id":1,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"oxantel","object":"FRD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":11031122,"re_id":2,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"thiabendazole","object":"FRD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":11031122,"re_id":3,"annotated sentence":"Fumarate reductase (<e2>FRD<\\e2>  is the key enzyme in <e1>fumarate<\\e1> respiration induced by anaerobic growth of bacteria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"fumarate","object":"FRD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Fumarate reductase (<e2>GENE-N<\\e2>  is the key enzyme in <e1>CHEMICAL<\\e1> respiration induced by anaerobic growth of bacteria","sentence":"Fumarate reductase (FRD  is the key enzyme in fumarate respiration induced by anaerobic growth of bacteria"}
{"PMID":11031122,"re_id":4,"annotated sentence":"<e2>Fumarate reductase<\\e2> (FRD) is the key enzyme in <e1>fumarate<\\e1> respiration induced by anaerobic growth of bacteria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"fumarate","object":"Fumarate reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (FRD) is the key enzyme in <e1>CHEMICAL<\\e1> respiration induced by anaerobic growth of bacteria","sentence":"Fumarate reductase (FRD) is the key enzyme in fumarate respiration induced by anaerobic growth of bacteria"}
{"PMID":11031122,"re_id":5,"annotated sentence":"The frdA gene coding for subunit A of FRD, and two control genes, <e2>copA<\\e2> and copP associated with the export of <e1>copper<\\e1> out of H","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"copper","object":"copA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The frdA gene coding for subunit A of FRD, and two control genes, <e2>GENE-Y<\\e2> and copP associated with the export of <e1>CHEMICAL<\\e1> out of H","sentence":"The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H"}
{"PMID":11031122,"re_id":6,"annotated sentence":"The frdA gene coding for subunit A of FRD, and two control genes, copA and <e2>copP<\\e2> associated with the export of <e1>copper<\\e1> out of H","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"copper","object":"copP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The frdA gene coding for subunit A of FRD, and two control genes, copA and <e2>GENE-Y<\\e2> associated with the export of <e1>CHEMICAL<\\e1> out of H","sentence":"The frdA gene coding for subunit A of FRD, and two control genes, copA and copP associated with the export of copper out of H"}
{"PMID":11034583,"re_id":0,"annotated sentence":"METHODS: Part A compared the effects of placebo to four doses of a <e2>5-HT(4)<\\e2> receptor antagonist (SB-207266) on the <e1>cisapride<\\e1> mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"cisapride","object":"5-HT(4)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: Part A compared the effects of placebo to four doses of a <e2>GENE-Y<\\e2> receptor antagonist (SB-207266) on the <e1>CHEMICAL<\\e1> mediated increase in plasma aldosterone (a GENE-Y mediated response) and orocaecal transit in 18 subjects","sentence":"METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (SB-207266) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects"}
{"PMID":11034583,"re_id":1,"annotated sentence":"Effects of a <e2>serotonin 5-HT(4) receptor<\\e2> antagonist <e1>SB-207266<\\e1> on gastrointestinal motor and sensory function in humans","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB-207266","object":"serotonin 5-HT(4) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effects of a <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> on gastrointestinal motor and sensory function in humans","sentence":"Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans"}
{"PMID":11034583,"re_id":2,"annotated sentence":"METHODS: Part A compared the effects of placebo to four doses of a <e2>5-HT(4)<\\e2> receptor antagonist (<e1>SB-207266<\\e1>  on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB-207266","object":"5-HT(4)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: Part A compared the effects of placebo to four doses of a <e2>GENE-Y<\\e2> receptor antagonist (<e1>CHEMICAL<\\e1>  on the cisapride mediated increase in plasma aldosterone (a GENE-Y mediated response) and orocaecal transit in 18 subjects","sentence":"METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (SB-207266  on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects"}
{"PMID":11034583,"re_id":3,"annotated sentence":"METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (<e1>SB-207266<\\e1>  on the cisapride mediated increase in plasma aldosterone (a <e2>5-HT(4)<\\e2> mediated response) and orocaecal transit in 18 subjects","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB-207266","object":"5-HT(4)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: Part A compared the effects of placebo to four doses of a GENE-Y receptor antagonist (<e1>CHEMICAL<\\e1>  on the cisapride mediated increase in plasma aldosterone (a <e2>GENE-Y<\\e2> mediated response) and orocaecal transit in 18 subjects","sentence":"METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (SB-207266  on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects"}
{"PMID":11089538,"re_id":0,"annotated sentence":"Moreover, <e2>IGFBP-rP2<\\e2> noticeably increased in response to TGF-beta1 and <e1>all-trans retinoic acid<\\e1> (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"all-trans retinoic acid","object":"IGFBP-rP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e2>GENE-Y<\\e2> noticeably increased in response to TGF-beta1 and <e1>CHEMICAL<\\e1> (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC","sentence":"Moreover, IGFBP-rP2 noticeably increased in response to TGF-beta1 and all-trans retinoic acid (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC"}
{"PMID":11089538,"re_id":1,"annotated sentence":"Moreover, <e2>IGFBP-rP2<\\e2> noticeably increased in response to TGF-beta1 and all-trans retinoic acid (<e1>atRA<\\e1>  in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"atRA","object":"IGFBP-rP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e2>GENE-Y<\\e2> noticeably increased in response to TGF-beta1 and all-trans retinoic acid (<e1>CHEMICAL<\\e1>  in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC","sentence":"Moreover, IGFBP-rP2 noticeably increased in response to TGF-beta1 and all-trans retinoic acid (atRA  in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC"}
{"PMID":11089538,"re_id":2,"annotated sentence":"Although the data collected on <e2>IGFBP-rP3<\\e2> in prostate are modest, its role as a growth stimulator and\/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by <e1>atRA<\\e1> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"atRA","object":"IGFBP-rP3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although the data collected on <e2>GENE-Y<\\e2> in prostate are modest, its role as a growth stimulator and\/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by <e1>CHEMICAL<\\e1> ","sentence":"Although the data collected on IGFBP-rP3 in prostate are modest, its role as a growth stimulator and\/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by atRA "}
{"PMID":11160515,"re_id":0,"annotated sentence":"Activation of endogenous <e2>somatostatin receptor subtype 2<\\e2> (sst2) by <e1>somatostatin-14<\\e1> or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"somatostatin-14","object":"somatostatin receptor subtype 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of endogenous <e2>GENE-Y<\\e2> (sst2) by <e1>CHEMICAL<\\e1> or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect","sentence":"Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect"}
{"PMID":11160515,"re_id":1,"annotated sentence":"Activation of endogenous somatostatin receptor subtype 2 (<e2>sst2<\\e2>  by <e1>somatostatin-14<\\e1> or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"somatostatin-14","object":"sst2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of endogenous somatostatin receptor subtype 2 (<e2>GENE-Y<\\e2>  by <e1>CHEMICAL<\\e1> or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect","sentence":"Activation of endogenous somatostatin receptor subtype 2 (sst2  by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect"}
{"PMID":11160515,"re_id":2,"annotated sentence":"Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected <e2>rat D2 dopamine receptors<\\e2> (rD2(long)) by <e1>quinpirole<\\e1> had no effect","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"rat D2 dopamine receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected <e2>GENE-N<\\e2> (rD2(long)) by <e1>CHEMICAL<\\e1> had no effect","sentence":"Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect"}
{"PMID":11160515,"re_id":3,"annotated sentence":"Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (<e2>rD2<\\e2> long)) by <e1>quinpirole<\\e1> had no effect","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"rD2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (<e2>GENE-N<\\e2> long)) by <e1>CHEMICAL<\\e1> had no effect","sentence":"Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (rD2 long)) by quinpirole had no effect"}
{"PMID":11160515,"re_id":4,"annotated sentence":"In contrast, in the same system, <e1>N<\\e1> type currents, formed from transiently transfected alpha(1B)\/alpha(2)delta-1\/beta(3), showed strong <e2>G-protein<\\e2> mediated inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"G-protein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, in the same system, <e1>CHEMICAL<\\e1> type currents, formed from transiently transfected alpha(1B)\/alpha(2)delta-1\/beta(3), showed strong <e2>GENE-N<\\e2> mediated inhibition","sentence":"In contrast, in the same system, N type currents, formed from transiently transfected alpha(1B)\/alpha(2)delta-1\/beta(3), showed strong G-protein mediated inhibition"}
{"PMID":11166732,"re_id":0,"annotated sentence":"High <e2>p53<\\e2> protein levels, but not genetic or functional p53 status, were associated with increased <e1>topotecan<\\e1> induced DNA\/topoisomerase I complex formation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"topotecan","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"High <e2>GENE-Y<\\e2> protein levels, but not genetic or functional GENE-Y status, were associated with increased <e1>CHEMICAL<\\e1> induced DNA\/topoisomerase I complex formation","sentence":"High p53 protein levels, but not genetic or functional p53 status, were associated with increased topotecan induced DNA\/topoisomerase I complex formation"}
{"PMID":11166732,"re_id":1,"annotated sentence":"<e1>Topotecan<\\e1> is a <e2>topoisomerase I<\\e2> inhibitor which is currently evaluated as an adjuvant agent for malignant glioma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Topotecan","object":"topoisomerase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a <e2>GENE-Y<\\e2> inhibitor which is currently evaluated as an adjuvant agent for malignant glioma","sentence":"Topotecan is a topoisomerase I inhibitor which is currently evaluated as an adjuvant agent for malignant glioma"}
{"PMID":11264758,"re_id":0,"annotated sentence":"<e1>Pranlukast<\\e1> is a new, orally active, selective inhibitor of <e2>CysLt1<\\e2> leukotriene receptor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pranlukast","object":"CysLt1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a new, orally active, selective inhibitor of <e2>GENE-Y<\\e2> leukotriene receptor","sentence":"Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor"}
{"PMID":11264758,"re_id":1,"annotated sentence":"<e1>Pranlukast<\\e1> is a new, orally active, selective inhibitor of CysLt1 <e2>leukotriene receptor<\\e2>  The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pranlukast","object":"leukotriene receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a new, orally active, selective inhibitor of CysLt1 <e2>GENE-N<\\e2>  The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma","sentence":"Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor  The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma"}
{"PMID":11264758,"re_id":2,"annotated sentence":"Clinical effects of <e1>pranlukast<\\e1>  an oral <e2>leukotriene receptor<\\e2> antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"leukotriene receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Clinical effects of <e1>CHEMICAL<\\e1>  an oral <e2>GENE-N<\\e2> antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial","sentence":"Clinical effects of pranlukast  an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial"}
{"PMID":11278845,"re_id":0,"annotated sentence":"In addition, ADP was shown to strongly antagonize <e2>TOP2<\\e2> mediated DNA cleavage induced by <e1>ATP<\\e1> sensitive but not ATP-insensitive TOP2 poisons","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ATP","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, ADP was shown to strongly antagonize <e2>GENE-Y<\\e2> mediated DNA cleavage induced by <e1>CHEMICAL<\\e1> sensitive but not CHEMICAL-insensitive GENE-Y poisons","sentence":"In addition, ADP was shown to strongly antagonize TOP2 mediated DNA cleavage induced by ATP sensitive but not ATP-insensitive TOP2 poisons"}
{"PMID":11278845,"re_id":1,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"doxorubicin","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":2,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"doxorubicin","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":3,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"etoposide","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":4,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"etoposide","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":5,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mitoxantrone","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":6,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mitoxantrone","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":7,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4'-(9-acridinylamino)methanesulfon-m-anisidide","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":8,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4'-(9-acridinylamino)methanesulfon-m-anisidide","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":9,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amonafide","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":10,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"batracylin","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":11,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"menadione","object":"TOP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11278845,"re_id":12,"annotated sentence":"Second, C427A mutant human TOP2alpha, which exhibits reduced <e2>ATPase<\\e2> activity, was shown to exhibit cross-resistance to all ATP-sensitive but not <e1>ATP<\\e1> insensitive TOP2 poisons","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATP","object":"ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Second, C427A mutant human TOP2alpha, which exhibits reduced <e2>CHEMICALase<\\e2> activity, was shown to exhibit cross-resistance to all CHEMICAL-sensitive but not <e1>CHEMICAL<\\e1> insensitive TOP2 poisons","sentence":"Second, C427A mutant human TOP2alpha, which exhibits reduced ATPase activity, was shown to exhibit cross-resistance to all ATP-sensitive but not ATP insensitive TOP2 poisons"}
{"PMID":11287128,"re_id":0,"annotated sentence":"In contrast, in the presence of <e1>Ca<\\e1> UFH accelerated the inhibition of <e2>factor Xa<\\e2> by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ca","object":"factor Xa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, in the presence of <e1>CHEMICAL<\\e1> UFH accelerated the inhibition of <e2>GENE-Y<\\e2> by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin","sentence":"In contrast, in the presence of Ca UFH accelerated the inhibition of factor Xa by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin"}
{"PMID":11287128,"re_id":1,"annotated sentence":"In contrast, in the presence of <e1>Ca<\\e1> UFH accelerated the inhibition of factor Xa by <e2>antithrombin<\\e2> 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ca","object":"antithrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, in the presence of <e1>CHEMICAL<\\e1> UFH accelerated the inhibition of factor Xa by <e2>GENE-Y<\\e2> 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin","sentence":"In contrast, in the presence of Ca UFH accelerated the inhibition of factor Xa by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin"}
{"PMID":11299519,"re_id":0,"annotated sentence":"<e2>Follicle-stimulating hormone<\\e2> (FSH), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex <e1>steroids<\\e1> and gametes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"steroids","object":"Follicle-stimulating hormone","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (FSH), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex <e1>CHEMICAL<\\e1> and gametes","sentence":"Follicle-stimulating hormone (FSH), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex steroids and gametes"}
{"PMID":11299519,"re_id":1,"annotated sentence":"Follicle-stimulating hormone (<e2>FSH<\\e2> , a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex <e1>steroids<\\e1> and gametes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"steroids","object":"FSH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Follicle-stimulating hormone (<e2>GENE-N<\\e2> , a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex <e1>CHEMICAL<\\e1> and gametes","sentence":"Follicle-stimulating hormone (FSH , a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex steroids and gametes"}
{"PMID":11299519,"re_id":2,"annotated sentence":"Humans with <e2>FSH beta<\\e2> gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex <e1>steroid<\\e1> production occur in both types of mutations","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"steroid","object":"FSH beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Humans with <e2>GENE-Y<\\e2> gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex <e1>CHEMICAL<\\e1> production occur in both types of mutations","sentence":"Humans with FSH beta gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex steroid production occur in both types of mutations"}
{"PMID":11319232,"re_id":0,"annotated sentence":"Re-feeding normal chow or a high <e1>sucrose<\\e1> diet for 24 h after a 48-h fast increased both <e2>ACS1<\\e2> and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sucrose","object":"ACS1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Re-feeding normal chow or a high <e1>CHEMICAL<\\e1> diet for 24 h after a 48-h fast increased both <e2>GENE-Y<\\e2> and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies","sentence":"Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies"}
{"PMID":11319232,"re_id":1,"annotated sentence":"Re-feeding normal chow or a high <e1>sucrose<\\e1> diet for 24 h after a 48-h fast increased both ACS1 and <e2>ACS4<\\e2> protein expression 1.5-2.0-fold, consistent with inhibition studies","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sucrose","object":"ACS4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Re-feeding normal chow or a high <e1>CHEMICAL<\\e1> diet for 24 h after a 48-h fast increased both ACS1 and <e2>GENE-Y<\\e2> protein expression 1.5-2.0-fold, consistent with inhibition studies","sentence":"Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies"}
{"PMID":11319232,"re_id":2,"annotated sentence":"Consistent with these locations, <e1>N-ethylmaleimide<\\e1>  an inhibitor of <e2>ACS4<\\e2>  inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-ethylmaleimide","object":"ACS4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Consistent with these locations, <e1>CHEMICAL<\\e1>  an inhibitor of <e2>GENE-Y<\\e2>  inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum","sentence":"Consistent with these locations, N-ethylmaleimide  an inhibitor of ACS4  inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum"}
{"PMID":11319232,"re_id":3,"annotated sentence":"Consistent with these locations, <e1>N-ethylmaleimide<\\e1>  an inhibitor of ACS4, inhibited <e2>ACS<\\e2> activity 47% in MAM and 28% in endoplasmic reticulum","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-ethylmaleimide","object":"ACS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Consistent with these locations, <e1>CHEMICAL<\\e1>  an inhibitor of GENE-N4, inhibited <e2>GENE-N<\\e2> activity 47% in MAM and 28% in endoplasmic reticulum","sentence":"Consistent with these locations, N-ethylmaleimide  an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum"}
{"PMID":11319232,"re_id":4,"annotated sentence":"<e1>Troglitazone<\\e1>  a second <e2>ACS4<\\e2> inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Troglitazone","object":"ACS4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a second <e2>GENE-Y<\\e2> inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM","sentence":"Troglitazone  a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM"}
{"PMID":11319232,"re_id":5,"annotated sentence":"<e1>Troglitazone<\\e1>  a second ACS4 inhibitor, inhibited <e2>ACS<\\e2> activity <10% in microsomes and mitochondria and 45% in MAM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Troglitazone","object":"ACS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a second GENE-N4 inhibitor, inhibited <e2>GENE-N<\\e2> activity <10% in microsomes and mitochondria and 45% in MAM","sentence":"Troglitazone  a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM"}
{"PMID":11319232,"re_id":6,"annotated sentence":"<e1>Triacsin C<\\e1>  a competitive inhibitor of both <e2>ACS1<\\e2> and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Triacsin C","object":"ACS1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a competitive inhibitor of both <e2>GENE-Y<\\e2> and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria","sentence":"Triacsin C  a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria"}
{"PMID":11319232,"re_id":7,"annotated sentence":"<e1>Triacsin C<\\e1>  a competitive inhibitor of both ACS1 and <e2>ACS4<\\e2>  inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Triacsin C","object":"ACS4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a competitive inhibitor of both ACS1 and <e2>GENE-Y<\\e2>  inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria","sentence":"Triacsin C  a competitive inhibitor of both ACS1 and ACS4  inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria"}
{"PMID":11319232,"re_id":8,"annotated sentence":"<e1>Triacsin C<\\e1>  a competitive inhibitor of both ACS1 and ACS4, inhibited <e2>ACS<\\e2> activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Triacsin C","object":"ACS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a competitive inhibitor of both GENE-N1 and GENE-N4, inhibited <e2>GENE-N<\\e2> activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive GENE-N is present in mitochondria","sentence":"Triacsin C  a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria"}
{"PMID":11319232,"re_id":9,"annotated sentence":"These results suggest that <e2>ACS1<\\e2> and ACS4 may be linked to <e1>triacylglycerol<\\e1> synthesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"triacylglycerol","object":"ACS1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e2>GENE-Y<\\e2> and ACS4 may be linked to <e1>CHEMICAL<\\e1> synthesis","sentence":"These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis"}
{"PMID":11319232,"re_id":10,"annotated sentence":"These results suggest that ACS1 and <e2>ACS4<\\e2> may be linked to <e1>triacylglycerol<\\e1> synthesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"triacylglycerol","object":"ACS4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that ACS1 and <e2>GENE-Y<\\e2> may be linked to <e1>CHEMICAL<\\e1> synthesis","sentence":"These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis"}
{"PMID":11330337,"re_id":0,"annotated sentence":"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase<\\e2> (ambenonium>neostigmine=physostigmine =tacrine><e1>pyridostigmine<\\e1> edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyridostigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting <e2>GENE-Y<\\e2> (ambenonium>neostigmine=physostigmine =tacrine><e1>CHEMICAL<\\e1> edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of GENE-Y also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":1,"annotated sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine><e1>pyridostigmine<\\e1> edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>acetylcholinesterase<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyridostigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting GENE-Y (ambenonium>neostigmine=physostigmine =tacrine><e1>CHEMICAL<\\e1> edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>GENE-Y<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":2,"annotated sentence":"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase<\\e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=<e1>edrophonium<\\e1> galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"edrophonium","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting <e2>GENE-Y<\\e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=<e1>CHEMICAL<\\e1> galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of GENE-Y also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":3,"annotated sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=<e1>edrophonium<\\e1> galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>acetylcholinesterase<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"edrophonium","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting GENE-Y (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=<e1>CHEMICAL<\\e1> galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>GENE-Y<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":4,"annotated sentence":"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase<\\e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=<e1>galanthamine<\\e1> >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"galanthamine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting <e2>GENE-Y<\\e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=<e1>CHEMICAL<\\e1> >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of GENE-Y also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":5,"annotated sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=<e1>galanthamine<\\e1> >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>acetylcholinesterase<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"galanthamine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting GENE-Y (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=<e1>CHEMICAL<\\e1> >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>GENE-Y<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":6,"annotated sentence":"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase<\\e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine ><e1>desoxypeganine<\\e1> parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"desoxypeganine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting <e2>GENE-Y<\\e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine ><e1>CHEMICAL<\\e1> parathion>gramine) indicated that the most effective inhibitors of GENE-Y also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":7,"annotated sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine ><e1>desoxypeganine<\\e1> parathion>gramine) indicated that the most effective inhibitors of <e2>acetylcholinesterase<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"desoxypeganine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting GENE-Y (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine ><e1>CHEMICAL<\\e1> parathion>gramine) indicated that the most effective inhibitors of <e2>GENE-Y<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":8,"annotated sentence":"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase<\\e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine><e1>parathion<\\e1> gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"parathion","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting <e2>GENE-Y<\\e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine><e1>CHEMICAL<\\e1> gramine) indicated that the most effective inhibitors of GENE-Y also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":9,"annotated sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine><e1>parathion<\\e1> gramine) indicated that the most effective inhibitors of <e2>acetylcholinesterase<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"parathion","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting GENE-Y (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine><e1>CHEMICAL<\\e1> gramine) indicated that the most effective inhibitors of <e2>GENE-Y<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":10,"annotated sentence":"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase<\\e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion><e1>gramine<\\e1>  indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gramine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting <e2>GENE-Y<\\e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion><e1>CHEMICAL<\\e1>  indicated that the most effective inhibitors of GENE-Y also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine  indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":11,"annotated sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion><e1>gramine<\\e1>  indicated that the most effective inhibitors of <e2>acetylcholinesterase<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gramine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting GENE-Y (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion><e1>CHEMICAL<\\e1>  indicated that the most effective inhibitors of <e2>GENE-Y<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine  indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":12,"annotated sentence":"The capacity of <e2>acetylcholinesterase<\\e2> inhibitors, with the exception of <e1>tacrine<\\e1> and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tacrine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The capacity of <e2>GENE-Y<\\e2> inhibitors, with the exception of <e1>CHEMICAL<\\e1> and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors","sentence":"The capacity of acetylcholinesterase inhibitors, with the exception of tacrine and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors"}
{"PMID":11330337,"re_id":13,"annotated sentence":"The capacity of <e2>acetylcholinesterase<\\e2> inhibitors, with the exception of tacrine and <e1>ambenonium<\\e1>  to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ambenonium","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The capacity of <e2>GENE-Y<\\e2> inhibitors, with the exception of tacrine and <e1>CHEMICAL<\\e1>  to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors","sentence":"The capacity of acetylcholinesterase inhibitors, with the exception of tacrine and ambenonium  to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors"}
{"PMID":11330337,"re_id":14,"annotated sentence":"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase<\\e2> (<e1>ambenonium<\\e1> neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ambenonium","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1> neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of GENE-Y also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":15,"annotated sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (<e1>ambenonium<\\e1> neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>acetylcholinesterase<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ambenonium","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting GENE-Y (<e1>CHEMICAL<\\e1> neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>GENE-Y<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":16,"annotated sentence":"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase<\\e2> (ambenonium><e1>neostigmine<\\e1> physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neostigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting <e2>GENE-Y<\\e2> (ambenonium><e1>CHEMICAL<\\e1> physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of GENE-Y also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":17,"annotated sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium><e1>neostigmine<\\e1> physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>acetylcholinesterase<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neostigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting GENE-Y (ambenonium><e1>CHEMICAL<\\e1> physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>GENE-Y<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":18,"annotated sentence":"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase<\\e2> (ambenonium>neostigmine=<e1>physostigmine<\\e1> =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"physostigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting <e2>GENE-Y<\\e2> (ambenonium>neostigmine=<e1>CHEMICAL<\\e1> =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of GENE-Y also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":19,"annotated sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=<e1>physostigmine<\\e1> =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>acetylcholinesterase<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"physostigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting GENE-Y (ambenonium>neostigmine=<e1>CHEMICAL<\\e1> =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>GENE-Y<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":20,"annotated sentence":"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase<\\e2> (ambenonium>neostigmine=physostigmine =<e1>tacrine<\\e1> pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tacrine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting <e2>GENE-Y<\\e2> (ambenonium>neostigmine=physostigmine =<e1>CHEMICAL<\\e1> pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of GENE-Y also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11330337,"re_id":21,"annotated sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =<e1>tacrine<\\e1> pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>acetylcholinesterase<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tacrine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the rank order for potency in inhibiting GENE-Y (ambenonium>neostigmine=physostigmine =<e1>CHEMICAL<\\e1> pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of <e2>GENE-Y<\\e2> also displaced [3H]-oxotremorine-M to the greatest extent","sentence":"Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent"}
{"PMID":11401111,"re_id":0,"annotated sentence":"<e1>Carvedilol<\\e1> reduced the risk of death or heart failure in patients with above-median levels of <e2>N-BNP<\\e2> or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Carvedilol","object":"N-BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the risk of death or heart failure in patients with above-median levels of <e2>GENE-Y<\\e2> or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value","sentence":"Carvedilol reduced the risk of death or heart failure in patients with above-median levels of N-BNP or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value"}
{"PMID":11401111,"re_id":1,"annotated sentence":"<e1>Carvedilol<\\e1> reduced the risk of death or heart failure in patients with above-median levels of N-BNP or <e2>adrenomedullin<\\e2>  or both, to rates not significantly different from those observed in patients with levels below the median value","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Carvedilol","object":"adrenomedullin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the risk of death or heart failure in patients with above-median levels of N-BNP or <e2>GENE-Y<\\e2>  or both, to rates not significantly different from those observed in patients with levels below the median value","sentence":"Carvedilol reduced the risk of death or heart failure in patients with above-median levels of N-BNP or adrenomedullin  or both, to rates not significantly different from those observed in patients with levels below the median value"}
{"PMID":11401111,"re_id":2,"annotated sentence":"<e1>Carvedilol<\\e1> reduced mortality and heart failure in patients with higher pre-treatment plasma <e2>N-BNP<\\e2> and adrenomedullin.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Carvedilol","object":"N-BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced mortality and heart failure in patients with higher pre-treatment plasma <e2>GENE-Y<\\e2> and adrenomedullin.","sentence":"Carvedilol reduced mortality and heart failure in patients with higher pre-treatment plasma N-BNP and adrenomedullin."}
{"PMID":11401111,"re_id":3,"annotated sentence":"<e1>Carvedilol<\\e1> reduced mortality and heart failure in patients with higher pre-treatment plasma N-BNP and <e2>adrenomedullin<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Carvedilol","object":"adrenomedullin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced mortality and heart failure in patients with higher pre-treatment plasma N-BNP and <e2>GENE-Y<\\e2> ","sentence":"Carvedilol reduced mortality and heart failure in patients with higher pre-treatment plasma N-BNP and adrenomedullin "}
{"PMID":11430635,"re_id":0,"annotated sentence":"<e1>Indomethacin<\\e1> completely antagonizes <e2>CA<\\e2> activity, i.e","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMIGENE-NL<\\e1> completely antagonizes <e2>GENE-N<\\e2> activity, i.e","sentence":"Indomethacin completely antagonizes CA activity, i.e"}
{"PMID":11430635,"re_id":1,"annotated sentence":"none","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":11430635,"re_id":2,"annotated sentence":"<e1>Indomethacin<\\e1> activates <e2>carbonic anhydrase<\\e2> and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> activates <e2>GENE-N<\\e2> and antagonizes the effect of the specific GENE-N inhibitor acetazolamide, by a direct mechanism of action","sentence":"Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action"}
{"PMID":11430635,"re_id":3,"annotated sentence":"<e1>Indomethacin<\\e1> activates carbonic anhydrase and antagonizes the effect of the specific <e2>carbonic anhydrase<\\e2> inhibitor acetazolamide, by a direct mechanism of action","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> activates GENE-N and antagonizes the effect of the specific <e2>GENE-N<\\e2> inhibitor acetazolamide, by a direct mechanism of action","sentence":"Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action"}
{"PMID":11430635,"re_id":4,"annotated sentence":"CONCLUSIONS: Our results show that <e1>indomethacin<\\e1>  a known cyclooxygenase (COX) inhibitor, is also an activator of <e2>CA<\\e2>  Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"indomethacin","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: Our results show that <e1>CHEMIGENE-NL<\\e1>  a known cyclooxygenase (COX) inhibitor, is also an activator of <e2>GENE-N<\\e2>  Our data also prove that CHEMIGENE-NL is not only an activator of GENE-N but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme","sentence":"CONCLUSIONS: Our results show that indomethacin  a known cyclooxygenase (COX) inhibitor, is also an activator of CA  Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme"}
{"PMID":11430635,"re_id":5,"annotated sentence":"Our data also prove that <e1>indomethacin<\\e1> is not only an activator of <e2>CA<\\e2> but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"indomethacin","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our data also prove that <e1>CHEMIGENE-NL<\\e1> is not only an activator of <e2>GENE-N<\\e2> but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme","sentence":"Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme"}
{"PMID":11430635,"re_id":6,"annotated sentence":"In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, <e2>CA<\\e2> activation induced by <e1>indomethacin<\\e1> might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"indomethacin","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In view of the role of GENE-N in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, <e2>GENE-N<\\e2> activation induced by <e1>CHEMIGENE-NL<\\e1> might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.","sentence":"In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, CA activation induced by indomethacin might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study."}
{"PMID":11430635,"re_id":7,"annotated sentence":"none","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"CA I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11430635,"re_id":8,"annotated sentence":"none","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":11430635,"re_id":9,"annotated sentence":"<e1>Acetazolamide<\\e1>  a specific inhibitor of <e2>CA<\\e2>  reduces the activity of CA I and CA II from red cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Acetazolamide","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMIGENE-NL<\\e1>  a specific inhibitor of <e2>GENE-N<\\e2>  reduces the activity of GENE-N I and GENE-N II from red cells","sentence":"Acetazolamide  a specific inhibitor of CA  reduces the activity of CA I and CA II from red cells"}
{"PMID":11430635,"re_id":10,"annotated sentence":"<e1>Acetazolamide<\\e1>  a specific inhibitor of CA, reduces the activity of <e2>CA I<\\e2> and CA II from red cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Acetazolamide","object":"CA I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a specific inhibitor of CA, reduces the activity of <e2>GENE-Y<\\e2> and GENE-YI from red cells","sentence":"Acetazolamide  a specific inhibitor of CA, reduces the activity of CA I and CA II from red cells"}
{"PMID":11430635,"re_id":11,"annotated sentence":"<e1>Acetazolamide<\\e1>  a specific inhibitor of CA, reduces the activity of CA I and <e2>CA II<\\e2> from red cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Acetazolamide","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a specific inhibitor of CA, reduces the activity of CA I and <e2>GENE-Y<\\e2> from red cells","sentence":"Acetazolamide  a specific inhibitor of CA, reduces the activity of CA I and CA II from red cells"}
{"PMID":11430635,"re_id":12,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":11430635,"re_id":13,"annotated sentence":"abolishes the inhibitory effect of <e1>acetazolamide<\\e1> on <e2>CA<\\e2>  In humans, an increase or decrease in erythrocyte CA II activity is correlated with an increase or decrease in gastric acid secretion","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"abolishes the inhibitory effect of <e1>CHEMIGENE-NL<\\e1> on <e2>GENE-N<\\e2>  In humans, an increase or decrease in erythrocyte GENE-N II activity is correlated with an increase or decrease in gastric acid secretion","sentence":"abolishes the inhibitory effect of acetazolamide on CA  In humans, an increase or decrease in erythrocyte CA II activity is correlated with an increase or decrease in gastric acid secretion"}
{"PMID":11430635,"re_id":14,"annotated sentence":"Indomethacin activates <e2>carbonic anhydrase<\\e2> and antagonizes the effect of the specific carbonic anhydrase inhibitor <e1>acetazolamide<\\e1>  by a direct mechanism of action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Indomethacin activates <e2>GENE-N<\\e2> and antagonizes the effect of the specific GENE-N inhibitor <e1>CHEMICAL<\\e1>  by a direct mechanism of action","sentence":"Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide  by a direct mechanism of action"}
{"PMID":11430635,"re_id":15,"annotated sentence":"Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific <e2>carbonic anhydrase<\\e2> inhibitor <e1>acetazolamide<\\e1>  by a direct mechanism of action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Indomethacin activates GENE-N and antagonizes the effect of the specific <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1>  by a direct mechanism of action","sentence":"Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide  by a direct mechanism of action"}
{"PMID":11430635,"re_id":16,"annotated sentence":"CONCLUSIONS: Our results show that <e1>indomethacin<\\e1>  a known <e2>cyclooxygenase<\\e2> (COX) inhibitor, is also an activator of CA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indomethacin","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: Our results show that <e1>CHEMICAL<\\e1>  a known <e2>GENE-N<\\e2> (COX) inhibitor, is also an activator of CA","sentence":"CONCLUSIONS: Our results show that indomethacin  a known cyclooxygenase (COX) inhibitor, is also an activator of CA"}
{"PMID":11430635,"re_id":17,"annotated sentence":"CONCLUSIONS: Our results show that <e1>indomethacin<\\e1>  a known cyclooxygenase (<e2>COX<\\e2>  inhibitor, is also an activator of CA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indomethacin","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: Our results show that <e1>CHEMICAL<\\e1>  a known cyclooxygenase (<e2>GENE-N<\\e2>  inhibitor, is also an activator of CA","sentence":"CONCLUSIONS: Our results show that indomethacin  a known cyclooxygenase (COX  inhibitor, is also an activator of CA"}
{"PMID":11430635,"re_id":18,"annotated sentence":"Our data also prove that indomethacin is not only an activator of <e2>CA<\\e2> but also antagonizes the effect of <e1>acetazolamide<\\e1>  a specific inhibitor of this enzyme","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our data also prove that indomethacin is not only an activator of <e2>GENE-N<\\e2> but also antagonizes the effect of <e1>CHEMIGENE-NL<\\e1>  a specific inhibitor of this enzyme","sentence":"Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide  a specific inhibitor of this enzyme"}
{"PMID":11511086,"re_id":0,"annotated sentence":"The antipsychotic drugs <e1>sertindole<\\e1> and pimozide block <e2>erg3<\\e2>  a human brain K(+) channel","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sertindole","object":"erg3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antipsychotic drugs <e1>CHEMICAL<\\e1> and pimozide block <e2>GENE-Y<\\e2>  a human brain K(+) channel","sentence":"The antipsychotic drugs sertindole and pimozide block erg3  a human brain K(+) channel"}
{"PMID":11511086,"re_id":1,"annotated sentence":"The antipsychotic drugs <e1>sertindole<\\e1> and pimozide block erg3, a <e2>human brain K(+) channel<\\e2>  The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sertindole","object":"human brain K(+) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The antipsychotic drugs <e1>CHEMICAL<\\e1> and pimozide block erg3, a <e2>GENE-N<\\e2>  The antipsychotic drugs CHEMICAL and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)","sentence":"The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel  The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)"}
{"PMID":11511086,"re_id":2,"annotated sentence":"The antipsychotic drugs sertindole and <e1>pimozide<\\e1> block <e2>erg3<\\e2>  a human brain K(+) channel","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pimozide","object":"erg3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antipsychotic drugs sertindole and <e1>CHEMICAL<\\e1> block <e2>GENE-Y<\\e2>  a human brain K(+) channel","sentence":"The antipsychotic drugs sertindole and pimozide block erg3  a human brain K(+) channel"}
{"PMID":11511086,"re_id":3,"annotated sentence":"The antipsychotic drugs sertindole and <e1>pimozide<\\e1> block erg3, a <e2>human brain K(+) channel<\\e2>  The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pimozide","object":"human brain K(+) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The antipsychotic drugs sertindole and <e1>CHEMICAL<\\e1> block erg3, a <e2>GENE-N<\\e2>  The antipsychotic drugs sertindole and CHEMICAL are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)","sentence":"The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel  The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)"}
{"PMID":11511086,"re_id":4,"annotated sentence":"Block of <e2>erg3<\\e2> by <e1>sertindole<\\e1> also displayed a positive voltage-dependence","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sertindole","object":"erg3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Block of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> also displayed a positive voltage-dependence","sentence":"Block of erg3 by sertindole also displayed a positive voltage-dependence"}
{"PMID":11511086,"re_id":5,"annotated sentence":"<e1>Pimozide<\\e1> blocked <e2>erg3<\\e2> channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pimozide","object":"erg3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> blocked <e2>GENE-Y<\\e2> channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher","sentence":"Pimozide blocked erg3 channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher"}
{"PMID":11511086,"re_id":6,"annotated sentence":"We conclude that <e2>erg3<\\e2> can be blocked by certain antipsychotic drugs like <e1>sertindole<\\e1> and pimozide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sertindole","object":"erg3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that <e2>GENE-Y<\\e2> can be blocked by certain antipsychotic drugs like <e1>CHEMICAL<\\e1> and pimozide","sentence":"We conclude that erg3 can be blocked by certain antipsychotic drugs like sertindole and pimozide"}
{"PMID":11511086,"re_id":7,"annotated sentence":"We conclude that <e2>erg3<\\e2> can be blocked by certain antipsychotic drugs like sertindole and <e1>pimozide<\\e1>  Inhibition of erg3 or related K(+) channels in the brain may contribute to the efficacy\/side effect profiles of some antipsychotic drugs.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pimozide","object":"erg3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that <e2>GENE-Y<\\e2> can be blocked by certain antipsychotic drugs like sertindole and <e1>CHEMICAL<\\e1>  Inhibition of GENE-Y or related K(+) channels in the brain may contribute to the efficacy\/side effect profiles of some antipsychotic drugs.","sentence":"We conclude that erg3 can be blocked by certain antipsychotic drugs like sertindole and pimozide  Inhibition of erg3 or related K(+) channels in the brain may contribute to the efficacy\/side effect profiles of some antipsychotic drugs."}
{"PMID":11511086,"re_id":8,"annotated sentence":"The antipsychotic drugs <e1>sertindole<\\e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the <e2>cardiac K(+) channel<\\e2> known as HERG (human ether-a-go-go-related gene; erg1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sertindole","object":"cardiac K(+) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The antipsychotic drugs <e1>CHEMICAL<\\e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the <e2>GENE-N<\\e2> known as HERG (human ether-a-go-go-related gene; erg1)","sentence":"The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)"}
{"PMID":11511086,"re_id":9,"annotated sentence":"The antipsychotic drugs <e1>sertindole<\\e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as <e2>HERG<\\e2> (human ether-a-go-go-related gene; erg1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sertindole","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antipsychotic drugs <e1>CHEMICAL<\\e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as <e2>GENE-Y<\\e2> (human ether-a-go-go-related gene; erg1)","sentence":"The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)"}
{"PMID":11511086,"re_id":10,"annotated sentence":"The antipsychotic drugs <e1>sertindole<\\e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (<e2>human ether-a-go-go-related gene<\\e2>  erg1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sertindole","object":"human ether-a-go-go-related gene","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antipsychotic drugs <e1>CHEMICAL<\\e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (<e2>GENE-Y<\\e2>  erg1)","sentence":"The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene  erg1)"}
{"PMID":11511086,"re_id":11,"annotated sentence":"The antipsychotic drugs <e1>sertindole<\\e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; <e2>erg1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sertindole","object":"erg1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antipsychotic drugs <e1>CHEMICAL<\\e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; <e2>GENE-Y<\\e2> ","sentence":"The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1 "}
{"PMID":11511086,"re_id":12,"annotated sentence":"The antipsychotic drugs sertindole and <e1>pimozide<\\e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the <e2>cardiac K(+) channel<\\e2> known as HERG (human ether-a-go-go-related gene; erg1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pimozide","object":"cardiac K(+) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The antipsychotic drugs sertindole and <e1>CHEMICAL<\\e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the <e2>GENE-N<\\e2> known as HERG (human ether-a-go-go-related gene; erg1)","sentence":"The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)"}
{"PMID":11511086,"re_id":13,"annotated sentence":"The antipsychotic drugs sertindole and <e1>pimozide<\\e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as <e2>HERG<\\e2> (human ether-a-go-go-related gene; erg1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pimozide","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antipsychotic drugs sertindole and <e1>CHEMICAL<\\e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as <e2>GENE-Y<\\e2> (human ether-a-go-go-related gene; erg1)","sentence":"The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)"}
{"PMID":11511086,"re_id":14,"annotated sentence":"The antipsychotic drugs sertindole and <e1>pimozide<\\e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (<e2>human ether-a-go-go-related gene<\\e2>  erg1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pimozide","object":"human ether-a-go-go-related gene","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antipsychotic drugs sertindole and <e1>CHEMICAL<\\e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (<e2>GENE-Y<\\e2>  erg1)","sentence":"The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene  erg1)"}
{"PMID":11511086,"re_id":15,"annotated sentence":"The antipsychotic drugs sertindole and <e1>pimozide<\\e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; <e2>erg1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pimozide","object":"erg1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antipsychotic drugs sertindole and <e1>CHEMICAL<\\e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; <e2>GENE-Y<\\e2> ","sentence":"The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1 "}
{"PMID":11562773,"re_id":0,"annotated sentence":"<e1>Amiloride<\\e1> is a specific inhibitor of <e2>uPA<\\e2> but does not inhibit tPA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Amiloride","object":"uPA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a specific inhibitor of <e2>GENE-N<\\e2> but does not inhibit tPA","sentence":"Amiloride is a specific inhibitor of uPA but does not inhibit tPA"}
{"PMID":11585753,"re_id":0,"annotated sentence":"<e1>ZD1839<\\e1> (\"Iressa\"), a quinazoline <e2>tyrosine kinase<\\e2> inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ZD1839","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (\"Iressa\"), a quinazoline <e2>GENE-N<\\e2> inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials","sentence":"ZD1839 (\"Iressa\"), a quinazoline tyrosine kinase inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials"}
{"PMID":11585753,"re_id":1,"annotated sentence":"<e1>ZD1839<\\e1> (\"Iressa\"), a quinazoline tyrosine kinase inhibitor selective for the <e2>EGFR<\\e2>  has shown good activity in preclinical studies and in the early phase of clinical trials","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ZD1839","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (\"Iressa\"), a quinazoline tyrosine kinase inhibitor selective for the <e2>GENE-Y<\\e2>  has shown good activity in preclinical studies and in the early phase of clinical trials","sentence":"ZD1839 (\"Iressa\"), a quinazoline tyrosine kinase inhibitor selective for the EGFR  has shown good activity in preclinical studies and in the early phase of clinical trials"}
{"PMID":11585753,"re_id":2,"annotated sentence":"ZD1839 (\"<e1>Iressa<\\e1> ), a quinazoline <e2>tyrosine kinase<\\e2> inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Iressa","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"ZD1839 (\"<e1>CHEMICAL<\\e1> ), a quinazoline <e2>GENE-N<\\e2> inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials","sentence":"ZD1839 (\"Iressa ), a quinazoline tyrosine kinase inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials"}
{"PMID":11585753,"re_id":3,"annotated sentence":"ZD1839 (\"<e1>Iressa<\\e1> ), a quinazoline tyrosine kinase inhibitor selective for the <e2>EGFR<\\e2>  has shown good activity in preclinical studies and in the early phase of clinical trials","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Iressa","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"ZD1839 (\"<e1>CHEMICAL<\\e1> ), a quinazoline tyrosine kinase inhibitor selective for the <e2>GENE-Y<\\e2>  has shown good activity in preclinical studies and in the early phase of clinical trials","sentence":"ZD1839 (\"Iressa ), a quinazoline tyrosine kinase inhibitor selective for the EGFR  has shown good activity in preclinical studies and in the early phase of clinical trials"}
{"PMID":11585753,"re_id":4,"annotated sentence":"The <e2>tyrosine kinase<\\e2> inhibitor <e1>ZD1839<\\e1> (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ZD1839","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells","sentence":"The tyrosine kinase inhibitor ZD1839 (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells"}
{"PMID":11585753,"re_id":5,"annotated sentence":"The tyrosine kinase inhibitor <e1>ZD1839<\\e1> (\"Iressa\") inhibits <e2>HER2<\\e2> driven signaling and suppresses the growth of HER2-overexpressing tumor cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ZD1839","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The tyrosine kinase inhibitor <e1>CHEMICAL<\\e1> (\"Iressa\") inhibits <e2>GENE-Y<\\e2> driven signaling and suppresses the growth of GENE-Y-overexpressing tumor cells","sentence":"The tyrosine kinase inhibitor ZD1839 (\"Iressa\") inhibits HER2 driven signaling and suppresses the growth of HER2-overexpressing tumor cells"}
{"PMID":11585753,"re_id":6,"annotated sentence":"The tyrosine kinase inhibitor ZD1839 (\"<e1>Iressa<\\e1> ) inhibits HER2-driven signaling and suppresses the growth of <e2>HER2<\\e2> overexpressing tumor cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Iressa","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The tyrosine kinase inhibitor ZD1839 (\"<e1>CHEMICAL<\\e1> ) inhibits GENE-Y-driven signaling and suppresses the growth of <e2>GENE-Y<\\e2> overexpressing tumor cells","sentence":"The tyrosine kinase inhibitor ZD1839 (\"Iressa ) inhibits HER2-driven signaling and suppresses the growth of HER2 overexpressing tumor cells"}
{"PMID":11585753,"re_id":7,"annotated sentence":"The <e2>tyrosine kinase<\\e2> inhibitor ZD1839 (\"<e1>Iressa<\\e1> ) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Iressa","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> inhibitor ZD1839 (\"<e1>CHEMICAL<\\e1> ) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells","sentence":"The tyrosine kinase inhibitor ZD1839 (\"Iressa ) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells"}
{"PMID":11585753,"re_id":8,"annotated sentence":"The tyrosine kinase inhibitor ZD1839 (\"<e1>Iressa<\\e1> ) inhibits <e2>HER2<\\e2> driven signaling and suppresses the growth of HER2-overexpressing tumor cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Iressa","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The tyrosine kinase inhibitor ZD1839 (\"<e1>CHEMICAL<\\e1> ) inhibits <e2>GENE-Y<\\e2> driven signaling and suppresses the growth of GENE-Y-overexpressing tumor cells","sentence":"The tyrosine kinase inhibitor ZD1839 (\"Iressa ) inhibits HER2 driven signaling and suppresses the growth of HER2-overexpressing tumor cells"}
{"PMID":11585753,"re_id":9,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tyrosine","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":11585753,"re_id":10,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tyrosine","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":11585753,"re_id":11,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"quinazoline tyrosine","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":11585753,"re_id":12,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phosphatidylinositol","object":"phosphatidylinositol 3-kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":11692072,"re_id":0,"annotated sentence":"In an earlier report, DRD2 E8 A\/A genotype was associated with reduced responsiveness to the <e2>dopamine D2<\\e2> agonist <e1>apomorphine<\\e1>  however, it is not clear whether both findings share the same biological basis","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"apomorphine","object":"dopamine D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In an earlier report, DRD2 E8 A\/A genotype was associated with reduced responsiveness to the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1>  however, it is not clear whether both findings share the same biological basis","sentence":"In an earlier report, DRD2 E8 A\/A genotype was associated with reduced responsiveness to the dopamine D2 agonist apomorphine  however, it is not clear whether both findings share the same biological basis"}
{"PMID":11716850,"re_id":0,"annotated sentence":"Mitiglinide (<e1>KAD-1229<\\e1> , a new anti-diabetic drug, is thought to stimulate <e2>insulin<\\e2> secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"KAD-1229","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mitiglinide (<e1>CHEMICAL<\\e1> , a new anti-diabetic drug, is thought to stimulate <e2>GENE-Y<\\e2> secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells","sentence":"Mitiglinide (KAD-1229 , a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells"}
{"PMID":11716850,"re_id":1,"annotated sentence":"<e1>Mitiglinide<\\e1> (KAD-1229), a new anti-diabetic drug, is thought to stimulate <e2>insulin<\\e2> secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Mitiglinide","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (KAD-1229), a new anti-diabetic drug, is thought to stimulate <e2>GENE-Y<\\e2> secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells","sentence":"Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells"}
{"PMID":11716850,"re_id":2,"annotated sentence":"Mitiglinide (<e1>KAD-1229<\\e1> , a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the <e2>ATP-sensitive K+ (K(ATP)) channels<\\e2> in pancreatic beta-cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"KAD-1229","object":"ATP-sensitive K+ (K(ATP)) channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Mitiglinide (<e1>CHEMICAL<\\e1> , a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the <e2>GENE-N<\\e2> in pancreatic beta-cells","sentence":"Mitiglinide (KAD-1229 , a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells"}
{"PMID":11716850,"re_id":3,"annotated sentence":"<e1>Mitiglinide<\\e1> (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the <e2>ATP-sensitive K+ (K(ATP)) channels<\\e2> in pancreatic beta-cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Mitiglinide","object":"ATP-sensitive K+ (K(ATP)) channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the <e2>GENE-N<\\e2> in pancreatic beta-cells","sentence":"Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells"}
{"PMID":11716850,"re_id":4,"annotated sentence":"Patch-clamp analysis using inside-out recording configuration showed that <e1>mitiglinide<\\e1> inhibits the <e2>Kir6.2<\\e2> SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2\/SUR2A or Kir6.2\/SUR2B channel currents even at high doses (more than 10 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mitiglinide","object":"Kir6.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patch-clamp analysis using inside-out recording configuration showed that <e1>CHEMICAL<\\e1> inhibits the <e2>GENE-Y<\\e2> SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either GENE-Y\/SUR2A or GENE-Y\/SUR2B channel currents even at high doses (more than 10 microM)","sentence":"Patch-clamp analysis using inside-out recording configuration showed that mitiglinide inhibits the Kir6.2 SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2\/SUR2A or Kir6.2\/SUR2B channel currents even at high doses (more than 10 microM)"}
{"PMID":11716850,"re_id":5,"annotated sentence":"Patch-clamp analysis using inside-out recording configuration showed that <e1>mitiglinide<\\e1> inhibits the Kir6.2\/<e2>SUR1<\\e2> channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2\/SUR2A or Kir6.2\/SUR2B channel currents even at high doses (more than 10 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mitiglinide","object":"SUR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patch-clamp analysis using inside-out recording configuration showed that <e1>CHEMICAL<\\e1> inhibits the Kir6.2\/<e2>GENE-Y<\\e2> channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2\/SUR2A or Kir6.2\/SUR2B channel currents even at high doses (more than 10 microM)","sentence":"Patch-clamp analysis using inside-out recording configuration showed that mitiglinide inhibits the Kir6.2\/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2\/SUR2A or Kir6.2\/SUR2B channel currents even at high doses (more than 10 microM)"}
{"PMID":11716850,"re_id":6,"annotated sentence":"<e1>Nateglinide<\\e1> inhibits <e2>Kir6.2<\\e2> SUR1 and Kir6.2\/SUR2B channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nateglinide","object":"Kir6.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> SUR1 and GENE-Y\/SUR2B channels at 100 nM, and inhibits GENE-Y\/SUR2A channels at high concentrations (1 microM)","sentence":"Nateglinide inhibits Kir6.2 SUR1 and Kir6.2\/SUR2B channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)"}
{"PMID":11716850,"re_id":7,"annotated sentence":"<e1>Nateglinide<\\e1> inhibits Kir6.2\/<e2>SUR1<\\e2> and Kir6.2\/SUR2B channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nateglinide","object":"SUR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits Kir6.2\/<e2>GENE-Y<\\e2> and Kir6.2\/SUR2B channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)","sentence":"Nateglinide inhibits Kir6.2\/SUR1 and Kir6.2\/SUR2B channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)"}
{"PMID":11716850,"re_id":8,"annotated sentence":"<e1>Nateglinide<\\e1> inhibits Kir6.2\/SUR1 and <e2>Kir6.2<\\e2> SUR2B channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nateglinide","object":"Kir6.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits GENE-Y\/SUR1 and <e2>GENE-Y<\\e2> SUR2B channels at 100 nM, and inhibits GENE-Y\/SUR2A channels at high concentrations (1 microM)","sentence":"Nateglinide inhibits Kir6.2\/SUR1 and Kir6.2 SUR2B channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)"}
{"PMID":11716850,"re_id":9,"annotated sentence":"<e1>Nateglinide<\\e1> inhibits Kir6.2\/SUR1 and Kir6.2\/<e2>SUR2B<\\e2> channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nateglinide","object":"SUR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits Kir6.2\/SUR1 and Kir6.2\/<e2>GENE-Y<\\e2> channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)","sentence":"Nateglinide inhibits Kir6.2\/SUR1 and Kir6.2\/SUR2B channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)"}
{"PMID":11716850,"re_id":10,"annotated sentence":"<e1>Nateglinide<\\e1> inhibits Kir6.2\/SUR1 and Kir6.2\/SUR2B channels at 100 nM, and inhibits <e2>Kir6.2<\\e2> SUR2A channels at high concentrations (1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nateglinide","object":"Kir6.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits GENE-Y\/SUR1 and GENE-Y\/SUR2B channels at 100 nM, and inhibits <e2>GENE-Y<\\e2> SUR2A channels at high concentrations (1 microM)","sentence":"Nateglinide inhibits Kir6.2\/SUR1 and Kir6.2\/SUR2B channels at 100 nM, and inhibits Kir6.2 SUR2A channels at high concentrations (1 microM)"}
{"PMID":11716850,"re_id":11,"annotated sentence":"<e1>Nateglinide<\\e1> inhibits Kir6.2\/SUR1 and Kir6.2\/SUR2B channels at 100 nM, and inhibits Kir6.2\/<e2>SUR2A<\\e2> channels at high concentrations (1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nateglinide","object":"SUR2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits Kir6.2\/SUR1 and Kir6.2\/SUR2B channels at 100 nM, and inhibits Kir6.2\/<e2>GENE-Y<\\e2> channels at high concentrations (1 microM)","sentence":"Nateglinide inhibits Kir6.2\/SUR1 and Kir6.2\/SUR2B channels at 100 nM, and inhibits Kir6.2\/SUR2A channels at high concentrations (1 microM)"}
{"PMID":11716850,"re_id":12,"annotated sentence":"These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2\/SUR1 complex, i.e., the pancreatic beta-cell <e2>K(ATP) channel<\\e2>  and suggest that <e1>mitiglinide<\\e1> may be a clinically useful anti-diabetic drug.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"mitiglinide","object":"K(ATP) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results indicate that, similar to the sulfonylureas, CHEMICAL is highly specific to the Kir6.2\/SUR1 complex, i.e., the pancreatic beta-cell <e2>GENE-N<\\e2>  and suggest that <e1>CHEMICAL<\\e1> may be a clinically useful anti-diabetic drug.","sentence":"These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2\/SUR1 complex, i.e., the pancreatic beta-cell K(ATP) channel  and suggest that mitiglinide may be a clinically useful anti-diabetic drug."}
{"PMID":11730729,"re_id":0,"annotated sentence":"In the present study, we investigated the effect of <e1>fenoterol<\\e1> induced constitutive <e2>beta(2)-adrenoceptor<\\e2> activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fenoterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the present study, we investigated the effect of <e1>CHEMICAL<\\e1> induced constitutive <e2>GENE-Y<\\e2> activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions","sentence":"In the present study, we investigated the effect of fenoterol induced constitutive beta(2)-adrenoceptor activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions"}
{"PMID":11730729,"re_id":1,"annotated sentence":"Effect of <e1>fenoterol<\\e1> induced constitutive <e2>beta(2)-adrenoceptor<\\e2> activity on contractile receptor function in airway smooth muscle","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fenoterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effect of <e1>CHEMICAL<\\e1> induced constitutive <e2>GENE-Y<\\e2> activity on contractile receptor function in airway smooth muscle","sentence":"Effect of fenoterol induced constitutive beta(2)-adrenoceptor activity on contractile receptor function in airway smooth muscle"}
{"PMID":11730729,"re_id":2,"annotated sentence":"In conclusion, <e1>fenoterol<\\e1> induced constitutive <e2>beta(2)-adrenoceptor<\\e2> activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fenoterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> induced constitutive <e2>GENE-Y<\\e2> activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol","sentence":"In conclusion, fenoterol induced constitutive beta(2)-adrenoceptor activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol"}
{"PMID":11730729,"re_id":3,"annotated sentence":"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial <e2>muscarinic receptor<\\e2> agonist <e1>4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium<\\e1> (McN-A-343) and histamine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium","object":"muscarinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full GENE-N agonist methacholine, the partial <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1> (McN-A-343) and histamine","sentence":"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine"}
{"PMID":11730729,"re_id":4,"annotated sentence":"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial <e2>muscarinic receptor<\\e2> agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and <e1>histamine<\\e1>  Fenoterol treatment significantly reduced the sensitivity (pEC(50)) to methacholine in a time-dependent manner, without affecting maximal contraction (E(max))","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"histamine","object":"muscarinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full GENE-N agonist methacholine, the partial <e2>GENE-N<\\e2> agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and <e1>CHEMICAL<\\e1>  Fenoterol treatment significantly reduced the sensitivity (pEC(50)) to methacholine in a time-dependent manner, without affecting maximal contraction (E(max))","sentence":"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine  Fenoterol treatment significantly reduced the sensitivity (pEC(50)) to methacholine in a time-dependent manner, without affecting maximal contraction (E(max))"}
{"PMID":11730729,"re_id":5,"annotated sentence":"In conclusion, fenoterol-induced constitutive <e2>beta(2)-adrenoceptor<\\e2> activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist <e1>timolol<\\e1>  Moreover, after beta(2)-adrenoceptor agonist treatment, inverse agonism by beta-adrenoceptor antagonists may cause enhanced airway reactivity to contractile mediators.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"timolol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, fenoterol-induced constitutive <e2>GENE-Y<\\e2> activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist <e1>CHEMICAL<\\e1>  Moreover, after GENE-Y agonist treatment, inverse agonism by beta-adrenoceptor antagonists may cause enhanced airway reactivity to contractile mediators.","sentence":"In conclusion, fenoterol-induced constitutive beta(2)-adrenoceptor activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol  Moreover, after beta(2)-adrenoceptor agonist treatment, inverse agonism by beta-adrenoceptor antagonists may cause enhanced airway reactivity to contractile mediators."}
{"PMID":11730729,"re_id":6,"annotated sentence":"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full <e2>muscarinic receptor<\\e2> agonist <e1>methacholine<\\e1>  the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"methacholine","object":"muscarinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1>  the partial GENE-N agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine","sentence":"After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine  the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine"}
{"PMID":11732752,"re_id":0,"annotated sentence":"The inhibition of <e2>aminopeptidase<\\e2> activity in the presence of <e1>bestatin<\\e1> and puromycin inhibitors was also investigated","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bestatin","object":"aminopeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibition of <e2>GENE-N<\\e2> activity in the presence of <e1>CHEMICAL<\\e1> and puromycin inhibitors was also investigated","sentence":"The inhibition of aminopeptidase activity in the presence of bestatin and puromycin inhibitors was also investigated"}
{"PMID":11732752,"re_id":1,"annotated sentence":"The inhibition of <e2>aminopeptidase<\\e2> activity in the presence of bestatin and <e1>puromycin<\\e1> inhibitors was also investigated","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"puromycin","object":"aminopeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibition of <e2>GENE-N<\\e2> activity in the presence of bestatin and <e1>CHEMICAL<\\e1> inhibitors was also investigated","sentence":"The inhibition of aminopeptidase activity in the presence of bestatin and puromycin inhibitors was also investigated"}
{"PMID":11732752,"re_id":2,"annotated sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of <e1>L-arginine<\\e1> for <e2>aminopeptidase B<\\e2>  The vaginal aminopeptidase enzymatic activity of different species was determined spectrofluorometrically","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-arginine","object":"aminopeptidase B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of <e1>CHEMICAL<\\e1> for <e2>GENE-N<\\e2>  The vaginal aminopeptidase enzymatic activity of different species was determined spectrofluorometrically","sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B  The vaginal aminopeptidase enzymatic activity of different species was determined spectrofluorometrically"}
{"PMID":11732752,"re_id":3,"annotated sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: <e1>4-methoxy-2-naphthylamide<\\e1> of L-alanine for <e2>aminopeptidase N<\\e2>  4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-methoxy-2-naphthylamide","object":"aminopeptidase N","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: <e1>CHEMICAL<\\e1> of L-alanine for <e2>GENE-N<\\e2>  CHEMICAL of L-leucine for leucine aminopeptidase, CHEMICAL of L-glutamic acid for aminopeptidase A and CHEMICAL of L-arginine for aminopeptidase B","sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N  4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B"}
{"PMID":11732752,"re_id":4,"annotated sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of <e1>L-alanine<\\e1> for <e2>aminopeptidase N<\\e2>  4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-alanine","object":"aminopeptidase N","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of <e1>CHEMICAL<\\e1> for <e2>GENE-N<\\e2>  4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B","sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N  4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B"}
{"PMID":11732752,"re_id":5,"annotated sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, <e1>4-methoxy-2-naphthylamide<\\e1> of L-leucine for <e2>leucine aminopeptidase<\\e2>  4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-methoxy-2-naphthylamide","object":"leucine aminopeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: CHEMICAL of L-alanine for aminopeptidase N, <e1>CHEMICAL<\\e1> of L-leucine for <e2>GENE-N<\\e2>  CHEMICAL of L-glutamic acid for aminopeptidase A and CHEMICAL of L-arginine for aminopeptidase B","sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase  4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B"}
{"PMID":11732752,"re_id":6,"annotated sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of <e1>L-leucine<\\e1> for <e2>leucine aminopeptidase<\\e2>  4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-leucine","object":"leucine aminopeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of <e1>CHEMICAL<\\e1> for <e2>GENE-N<\\e2>  4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B","sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase  4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B"}
{"PMID":11732752,"re_id":7,"annotated sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, <e1>4-methoxy-2-naphthylamide<\\e1> of L-glutamic acid for <e2>aminopeptidase A<\\e2> and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-methoxy-2-naphthylamide","object":"aminopeptidase A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: CHEMICAL of L-alanine for aminopeptidase N, CHEMICAL of L-leucine for leucine aminopeptidase, <e1>CHEMICAL<\\e1> of L-glutamic acid for <e2>GENE-N<\\e2> and CHEMICAL of L-arginine for aminopeptidase B","sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B"}
{"PMID":11732752,"re_id":8,"annotated sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of <e1>L-glutamic acid<\\e1> for <e2>aminopeptidase A<\\e2> and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-glutamic acid","object":"aminopeptidase A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of <e1>CHEMICAL<\\e1> for <e2>GENE-N<\\e2> and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B","sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B"}
{"PMID":11732752,"re_id":9,"annotated sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and <e1>4-methoxy-2-naphthylamide<\\e1> of L-arginine for <e2>aminopeptidase B<\\e2>  The vaginal aminopeptidase enzymatic activity of different species was determined spectrofluorometrically","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-methoxy-2-naphthylamide","object":"aminopeptidase B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: CHEMICAL of L-alanine for aminopeptidase N, CHEMICAL of L-leucine for leucine aminopeptidase, CHEMICAL of L-glutamic acid for aminopeptidase A and <e1>CHEMICAL<\\e1> of L-arginine for <e2>GENE-N<\\e2>  The vaginal aminopeptidase enzymatic activity of different species was determined spectrofluorometrically","sentence":"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B  The vaginal aminopeptidase enzymatic activity of different species was determined spectrofluorometrically"}
{"PMID":11792932,"re_id":0,"annotated sentence":"PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the <e2>aromatase<\\e2> inhibitor, <e1>testolactone<\\e1>  and resulting changes in semen parameters","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"testolactone","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  and resulting changes in semen parameters","sentence":"PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the aromatase inhibitor, testolactone  and resulting changes in semen parameters"}
{"PMID":11792932,"re_id":1,"annotated sentence":"We evaluated the effect of <e1>anastrozole<\\e1>  a more selective <e2>aromatase<\\e2> inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"anastrozole","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We evaluated the effect of <e1>CHEMICAL<\\e1>  a more selective <e2>GENE-Y<\\e2> inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios","sentence":"We evaluated the effect of anastrozole  a more selective aromatase inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios"}
{"PMID":11861820,"re_id":0,"annotated sentence":"Also in contrast to effects of multiple <e1>METH<\\e1> injections, 1) MDMA caused little or no decrease in binding of the <e2>DAT<\\e2> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"METH","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also in contrast to effects of multiple <e1>CHEMICAL<\\e1> injections, 1) MDMA caused little or no decrease in binding of the <e2>GENE-Y<\\e2> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport","sentence":"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the DAT ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport"}
{"PMID":11861820,"re_id":1,"annotated sentence":"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the <e2>DAT<\\e2> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the <e1>MDMA<\\e1> induced reduction in plasmalemmal DA transport","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MDMA","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also in contrast to effects of multiple METH injections, 1) CHEMICAL caused little or no decrease in binding of the <e2>GENE-Y<\\e2> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the <e1>CHEMICAL<\\e1> induced reduction in plasmalemmal DA transport","sentence":"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the DAT ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA induced reduction in plasmalemmal DA transport"}
{"PMID":11861820,"re_id":2,"annotated sentence":"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the <e2>DAT<\\e2> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal <e1>DA<\\e1> transport","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DA","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the <e2>CHEMICALT<\\e2> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of CHEMICAL prevented the MDMA-induced reduction in plasmalemmal <e1>CHEMICAL<\\e1> transport","sentence":"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the DAT ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport"}
{"PMID":11861820,"re_id":3,"annotated sentence":"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the <e2>DAT<\\e2> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of <e1>DA<\\e1> prevented the MDMA-induced reduction in plasmalemmal DA transport","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DA","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the <e2>CHEMICALT<\\e2> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of <e1>CHEMICAL<\\e1> prevented the MDMA-induced reduction in plasmalemmal CHEMICAL transport","sentence":"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the DAT ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport"}
{"PMID":11861820,"re_id":4,"annotated sentence":"In addition to affecting <e2>DAT<\\e2> function, MDMA rapidly decreased vesicular <e1>DA<\\e1> transport as assessed in striatal vesicles prepared from treated rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DA","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to affecting <e2>CHEMICALT<\\e2> function, MDMA rapidly decreased vesicular <e1>CHEMICAL<\\e1> transport as assessed in striatal vesicles prepared from treated rats","sentence":"In addition to affecting DAT function, MDMA rapidly decreased vesicular DA transport as assessed in striatal vesicles prepared from treated rats"}
{"PMID":11906441,"re_id":0,"annotated sentence":"It is not yet clear whether <e1>tamoxifen<\\e1> can reduce breast cancer incidence in women with BRCA1 and <e2>BRCA2<\\e2> mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tamoxifen","object":"BRCA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It is not yet clear whether <e1>CHEMICAL<\\e1> can reduce breast cancer incidence in women with BRCA1 and <e2>GENE-Y<\\e2> mutations, although preliminary evidence favors benefit for at least those with a GENE-Y mutation","sentence":"It is not yet clear whether tamoxifen can reduce breast cancer incidence in women with BRCA1 and BRCA2 mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation"}
{"PMID":11906441,"re_id":1,"annotated sentence":"It is not yet clear whether <e1>tamoxifen<\\e1> can reduce breast cancer incidence in women with BRCA1 and BRCA2 mutations, although preliminary evidence favors benefit for at least those with a <e2>BRCA2<\\e2> mutation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tamoxifen","object":"BRCA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It is not yet clear whether <e1>CHEMICAL<\\e1> can reduce breast cancer incidence in women with BRCA1 and GENE-Y mutations, although preliminary evidence favors benefit for at least those with a <e2>GENE-Y<\\e2> mutation","sentence":"It is not yet clear whether tamoxifen can reduce breast cancer incidence in women with BRCA1 and BRCA2 mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation"}
{"PMID":11936838,"re_id":0,"annotated sentence":"In addition, we found that <e2>MCP-1<\\e2> transcription and translation was completely inhibited by <e1>mimosine<\\e1>  while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mimosine","object":"MCP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we found that <e2>GENE-Y<\\e2> transcription and translation was completely inhibited by <e1>CHEMICAL<\\e1>  while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T","sentence":"In addition, we found that MCP-1 transcription and translation was completely inhibited by mimosine  while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T"}
{"PMID":11936838,"re_id":1,"annotated sentence":"In addition, we found that MCP-1 transcription and translation was completely inhibited by <e1>mimosine<\\e1>  while <e2>MIP-2<\\e2> transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mimosine","object":"MIP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we found that MCP-1 transcription and translation was completely inhibited by <e1>CHEMICAL<\\e1>  while <e2>GENE-Y<\\e2> transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T","sentence":"In addition, we found that MCP-1 transcription and translation was completely inhibited by mimosine  while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T"}
{"PMID":11936838,"re_id":2,"annotated sentence":"Inhibition of <e2>MCP-1<\\e2> and MIP-2 transcription and translation by <e1>mimosine<\\e1> in muscle tissue infected with the parasite Trichinella spiralis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mimosine","object":"MCP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> and MIP-2 transcription and translation by <e1>CHEMICAL<\\e1> in muscle tissue infected with the parasite Trichinella spiralis","sentence":"Inhibition of MCP-1 and MIP-2 transcription and translation by mimosine in muscle tissue infected with the parasite Trichinella spiralis"}
{"PMID":11936838,"re_id":3,"annotated sentence":"Inhibition of MCP-1 and <e2>MIP-2<\\e2> transcription and translation by <e1>mimosine<\\e1> in muscle tissue infected with the parasite Trichinella spiralis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mimosine","object":"MIP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of MCP-1 and <e2>GENE-Y<\\e2> transcription and translation by <e1>CHEMICAL<\\e1> in muscle tissue infected with the parasite Trichinella spiralis","sentence":"Inhibition of MCP-1 and MIP-2 transcription and translation by mimosine in muscle tissue infected with the parasite Trichinella spiralis"}
{"PMID":11969359,"re_id":0,"annotated sentence":"The selective <e2>PDE 4<\\e2> inhibitors, and to a certain extent the PDE3 inhibitors amrinone and <e1>milrinone<\\e1>  reduced the GM-CSF release in a concentration dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"PDE 4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The selective <e2>GENE-N<\\e2> inhibitors, and to a certain extent the PDE3 inhibitors amrinone and <e1>CHEMICAL<\\e1>  reduced the GM-CSF release in a concentration dependent manner","sentence":"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and milrinone  reduced the GM-CSF release in a concentration dependent manner"}
{"PMID":11969359,"re_id":1,"annotated sentence":"The selective PDE 4 inhibitors, and to a certain extent the <e2>PDE3<\\e2> inhibitors amrinone and <e1>milrinone<\\e1>  reduced the GM-CSF release in a concentration dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The selective PDE 4 inhibitors, and to a certain extent the <e2>GENE-N<\\e2> inhibitors amrinone and <e1>CHEMICAL<\\e1>  reduced the GM-CSF release in a concentration dependent manner","sentence":"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and milrinone  reduced the GM-CSF release in a concentration dependent manner"}
{"PMID":11969359,"re_id":2,"annotated sentence":"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and <e1>milrinone<\\e1>  reduced the <e2>GM-CSF<\\e2> release in a concentration dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"GM-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and <e1>CHEMICAL<\\e1>  reduced the <e2>GENE-Y<\\e2> release in a concentration dependent manner","sentence":"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and milrinone  reduced the GM-CSF release in a concentration dependent manner"}
{"PMID":11969359,"re_id":3,"annotated sentence":"<e1>Amrinone<\\e1> and milrinone, selective <e2>PDE3<\\e2> inhibitors, suppressed TNF secretion to a lesser extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Amrinone","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and milrinone, selective <e2>GENE-N<\\e2> inhibitors, suppressed TNF secretion to a lesser extent","sentence":"Amrinone and milrinone, selective PDE3 inhibitors, suppressed TNF secretion to a lesser extent"}
{"PMID":11969359,"re_id":4,"annotated sentence":"<e1>Amrinone<\\e1> and milrinone, selective PDE3 inhibitors, suppressed <e2>TNF<\\e2> secretion to a lesser extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Amrinone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and milrinone, selective PDE3 inhibitors, suppressed <e2>GENE-Y<\\e2> secretion to a lesser extent","sentence":"Amrinone and milrinone, selective PDE3 inhibitors, suppressed TNF secretion to a lesser extent"}
{"PMID":11969359,"re_id":5,"annotated sentence":"Amrinone and <e1>milrinone<\\e1>  selective <e2>PDE3<\\e2> inhibitors, suppressed TNF secretion to a lesser extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Amrinone and <e1>CHEMICAL<\\e1>  selective <e2>GENE-N<\\e2> inhibitors, suppressed TNF secretion to a lesser extent","sentence":"Amrinone and milrinone  selective PDE3 inhibitors, suppressed TNF secretion to a lesser extent"}
{"PMID":11969359,"re_id":6,"annotated sentence":"Amrinone and <e1>milrinone<\\e1>  selective PDE3 inhibitors, suppressed <e2>TNF<\\e2> secretion to a lesser extent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Amrinone and <e1>CHEMICAL<\\e1>  selective PDE3 inhibitors, suppressed <e2>GENE-Y<\\e2> secretion to a lesser extent","sentence":"Amrinone and milrinone  selective PDE3 inhibitors, suppressed TNF secretion to a lesser extent"}
{"PMID":11969359,"re_id":7,"annotated sentence":"The effects of <e1>theophylline<\\e1> (unspecific <e2>PDE<\\e2> inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"theophylline","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The effects of <e1>CHEMICAL<\\e1> (unspecific <e2>GENE-N<\\e2> inhibitor), vinpocetine (GENE-N1 inhibitor), EHNA (GENE-N2 inhibitor) and the GENE-N5 inhibitors zaprinast and E 4021 were weak","sentence":"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak"}
{"PMID":11969359,"re_id":8,"annotated sentence":"The effects of theophylline (unspecific PDE inhibitor), <e1>vinpocetine<\\e1> (<e2>PDE1<\\e2> inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vinpocetine","object":"PDE1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The effects of theophylline (unspecific PDE inhibitor), <e1>CHEMICAL<\\e1> (<e2>GENE-N<\\e2> inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak","sentence":"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak"}
{"PMID":11969359,"re_id":9,"annotated sentence":"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the <e2>PDE5<\\e2> inhibitors <e1>zaprinast<\\e1> and E 4021 were weak","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zaprinast","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the <e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1> and E 4021 were weak","sentence":"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak"}
{"PMID":11969359,"re_id":10,"annotated sentence":"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the <e2>PDE5<\\e2> inhibitors zaprinast and <e1>E 4021<\\e1> were weak","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"E 4021","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the <e2>GENE-Y<\\e2> inhibitors zaprinast and <e1>CHEMICAL<\\e1> were weak","sentence":"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak"}
{"PMID":11969359,"re_id":11,"annotated sentence":"In human blood, the tested glucocorticoids <e1>beclomethasone<\\e1>  dexamethasone and fluticasone inhibited the LPS induced <e2>TNF<\\e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"beclomethasone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In human blood, the tested glucocorticoids <e1>CHEMICAL<\\e1>  dexamethasone and fluticasone inhibited the LPS induced <e2>GENE-Y<\\e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced GENE-Y release, with the exception of dexamethasone, was much less pronounced","sentence":"In human blood, the tested glucocorticoids beclomethasone  dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced"}
{"PMID":11969359,"re_id":12,"annotated sentence":"In human blood, the tested glucocorticoids <e1>beclomethasone<\\e1>  dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced <e2>TNF<\\e2> release, with the exception of dexamethasone, was much less pronounced","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"beclomethasone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In human blood, the tested glucocorticoids <e1>CHEMICAL<\\e1>  dexamethasone and fluticasone inhibited the LPS induced GENE-Y release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced <e2>GENE-Y<\\e2> release, with the exception of dexamethasone, was much less pronounced","sentence":"In human blood, the tested glucocorticoids beclomethasone  dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced"}
{"PMID":11969359,"re_id":13,"annotated sentence":"In human blood, the tested glucocorticoids beclomethasone, <e1>dexamethasone<\\e1> and fluticasone inhibited the LPS induced <e2>TNF<\\e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dexamethasone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In human blood, the tested glucocorticoids beclomethasone, <e1>CHEMICAL<\\e1> and fluticasone inhibited the LPS induced <e2>GENE-Y<\\e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced GENE-Y release, with the exception of CHEMICAL, was much less pronounced","sentence":"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced"}
{"PMID":11969359,"re_id":14,"annotated sentence":"In human blood, the tested glucocorticoids beclomethasone, <e1>dexamethasone<\\e1> and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced <e2>TNF<\\e2> release, with the exception of dexamethasone, was much less pronounced","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dexamethasone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In human blood, the tested glucocorticoids beclomethasone, <e1>CHEMICAL<\\e1> and fluticasone inhibited the LPS induced GENE-Y release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced <e2>GENE-Y<\\e2> release, with the exception of CHEMICAL, was much less pronounced","sentence":"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced"}
{"PMID":11969359,"re_id":15,"annotated sentence":"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and <e1>fluticasone<\\e1> inhibited the LPS induced <e2>TNF<\\e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fluticasone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and <e1>CHEMICAL<\\e1> inhibited the LPS induced <e2>GENE-Y<\\e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced GENE-Y release, with the exception of dexamethasone, was much less pronounced","sentence":"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced"}
{"PMID":11969359,"re_id":16,"annotated sentence":"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and <e1>fluticasone<\\e1> inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced <e2>TNF<\\e2> release, with the exception of dexamethasone, was much less pronounced","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fluticasone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and <e1>CHEMICAL<\\e1> inhibited the LPS induced GENE-Y release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced <e2>GENE-Y<\\e2> release, with the exception of dexamethasone, was much less pronounced","sentence":"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced"}
{"PMID":11969359,"re_id":17,"annotated sentence":"The selective <e2>PDE 4<\\e2> inhibitors, and to a certain extent the PDE3 inhibitors <e1>amrinone<\\e1> and milrinone, reduced the GM-CSF release in a concentration dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amrinone","object":"PDE 4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The selective <e2>GENE-N<\\e2> inhibitors, and to a certain extent the PDE3 inhibitors <e1>CHEMICAL<\\e1> and milrinone, reduced the GM-CSF release in a concentration dependent manner","sentence":"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and milrinone, reduced the GM-CSF release in a concentration dependent manner"}
{"PMID":11969359,"re_id":18,"annotated sentence":"The selective PDE 4 inhibitors, and to a certain extent the <e2>PDE3<\\e2> inhibitors <e1>amrinone<\\e1> and milrinone, reduced the GM-CSF release in a concentration dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amrinone","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The selective PDE 4 inhibitors, and to a certain extent the <e2>GENE-N<\\e2> inhibitors <e1>CHEMICAL<\\e1> and milrinone, reduced the GM-CSF release in a concentration dependent manner","sentence":"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and milrinone, reduced the GM-CSF release in a concentration dependent manner"}
{"PMID":11969359,"re_id":19,"annotated sentence":"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors <e1>amrinone<\\e1> and milrinone, reduced the <e2>GM-CSF<\\e2> release in a concentration dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amrinone","object":"GM-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors <e1>CHEMICAL<\\e1> and milrinone, reduced the <e2>GENE-Y<\\e2> release in a concentration dependent manner","sentence":"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and milrinone, reduced the GM-CSF release in a concentration dependent manner"}
{"PMID":11972287,"re_id":0,"annotated sentence":"Central <e2>5-HT3<\\e2> receptor stimulation by <e1>m-CPBG<\\e1> increases blood glucose in rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"m-CPBG","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Central <e2>GENE-Y<\\e2> receptor stimulation by <e1>CHEMICAL<\\e1> increases blood glucose in rats","sentence":"Central 5-HT3 receptor stimulation by m-CPBG increases blood glucose in rats"}
{"PMID":11972287,"re_id":1,"annotated sentence":"Injections of <e1>m-CPBG<\\e1>  a selective <e2>5-HT3<\\e2> receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"m-CPBG","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Injections of <e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states","sentence":"Injections of m-CPBG  a selective 5-HT3 receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states"}
{"PMID":11972287,"re_id":2,"annotated sentence":"The hyperglycemic effect of <e1>m-CPBG<\\e1> central administration was blocked by pretreatment with ondansetron, a specific <e2>5-HT3<\\e2> receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"m-CPBG","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The hyperglycemic effect of <e1>CHEMICAL<\\e1> central administration was blocked by pretreatment with ondansetron, a specific <e2>GENE-Y<\\e2> receptor antagonist, indicating that the effects here obtained with CHEMICAL were a result of its interaction with GENE-Y receptors","sentence":"The hyperglycemic effect of m-CPBG central administration was blocked by pretreatment with ondansetron, a specific 5-HT3 receptor antagonist, indicating that the effects here obtained with m-CPBG were a result of its interaction with 5-HT3 receptors"}
{"PMID":11972613,"re_id":0,"annotated sentence":"CONCLUSIONS: <e1>CysLTs<\\e1> produced after antigen provocation sequentially induced IL-5 production from some immune component cells via <e2>CysLT1<\\e2> receptor activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CysLTs","object":"CysLT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> produced after antigen provocation sequentially induced IL-5 production from some immune component cells via <e2>GENE-Y<\\e2> receptor activation","sentence":"CONCLUSIONS: CysLTs produced after antigen provocation sequentially induced IL-5 production from some immune component cells via CysLT1 receptor activation"}
{"PMID":11972613,"re_id":1,"annotated sentence":"Increased <e2>IL-5<\\e2> activity in the serum was inhibited by both <e1>pranlukast<\\e1> and MCI-826 by over 90%","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"IL-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased <e2>GENE-Y<\\e2> activity in the serum was inhibited by both <e1>CHEMICAL<\\e1> and MCI-826 by over 90%","sentence":"Increased IL-5 activity in the serum was inhibited by both pranlukast and MCI-826 by over 90%"}
{"PMID":11972613,"re_id":2,"annotated sentence":"Increased <e2>IL-5<\\e2> activity in the serum was inhibited by both pranlukast and <e1>MCI-826<\\e1> by over 90%","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MCI-826","object":"IL-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased <e2>GENE-Y<\\e2> activity in the serum was inhibited by both pranlukast and <e1>CHEMICAL<\\e1> by over 90%","sentence":"Increased IL-5 activity in the serum was inhibited by both pranlukast and MCI-826 by over 90%"}
{"PMID":11986668,"re_id":0,"annotated sentence":"<e1>Minocycline<\\e1> inhibits <e2>cytochrome c<\\e2> release and delays progression of amyotrophic lateral sclerosis in mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Minocycline","object":"cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> release and delays progression of amyotrophic lateral sclerosis in mice","sentence":"Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice"}
{"PMID":11986668,"re_id":1,"annotated sentence":"We find that <e1>minocycline<\\e1> inhibits mitochondrial permeability-transition-mediated <e2>cytochrome c<\\e2> release","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"minocycline","object":"cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We find that <e1>CHEMICAL<\\e1> inhibits mitochondrial permeability-transition-mediated <e2>GENE-Y<\\e2> release","sentence":"We find that minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release"}
{"PMID":11986668,"re_id":2,"annotated sentence":"<e1>Minocycline<\\e1> mediated inhibition of <e2>cytochrome c<\\e2> release is demonstrated in vivo, in cells, and in isolated mitochondria","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Minocycline","object":"cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> mediated inhibition of <e2>GENE-Y<\\e2> release is demonstrated in vivo, in cells, and in isolated mitochondria","sentence":"Minocycline mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria"}
{"PMID":12003347,"re_id":0,"annotated sentence":"We also shortly discuss the ongoing debate on whether <e1>NO<\\e1> is the actual reaction product of <e2>NOS<\\e2> catalysis, as well as the phenomenon of NO-mediated autoinhibition","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"NOS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We also shortly discuss the ongoing debate on whether <e1>CHEMICAL<\\e1> is the actual reaction product of <e2>CHEMICALS<\\e2> catalysis, as well as the phenomenon of CHEMICAL-mediated autoinhibition","sentence":"We also shortly discuss the ongoing debate on whether NO is the actual reaction product of NOS catalysis, as well as the phenomenon of NO-mediated autoinhibition"}
{"PMID":12047490,"re_id":0,"annotated sentence":"CONCLUSIONS: In the maximum registered dosage, <e1>nabumetone<\\e1> inhibits thromboxane production much more than meloxicam, signifying less <e2>COX-2<\\e2> selectivity of the former","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nabumetone","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: In the maximum registered dosage, <e1>CHEMICAL<\\e1> inhibits thromboxane production much more than meloxicam, signifying less <e2>GENE-Y<\\e2> selectivity of the former","sentence":"CONCLUSIONS: In the maximum registered dosage, nabumetone inhibits thromboxane production much more than meloxicam, signifying less COX-2 selectivity of the former"}
{"PMID":12047490,"re_id":1,"annotated sentence":"<e2>COX-1<\\e2> inhibition was measured as percentage inhibition of serum <e1>TXB2<\\e1> generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"TXB2","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibition was measured as percentage inhibition of serum <e1>CHEMICAL<\\e1> generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100","sentence":"COX-1 inhibition was measured as percentage inhibition of serum TXB2 generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100"}
{"PMID":12065695,"re_id":0,"annotated sentence":"<e1>N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide<\\e1> (NS-398), a selective <e2>cyclooxygenase-2<\\e2> inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (NS-398), a selective <e2>GENE-Y<\\e2> inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis","sentence":"N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis"}
{"PMID":12065695,"re_id":1,"annotated sentence":"N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide (<e1>NS-398<\\e1> , a selective <e2>cyclooxygenase-2<\\e2> inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NS-398","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide (<e1>CHEMICAL<\\e1> , a selective <e2>GENE-Y<\\e2> inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis","sentence":"N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide (NS-398 , a selective cyclooxygenase-2 inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis"}
{"PMID":12067524,"re_id":0,"annotated sentence":"BACKGROUND AND AIMS: <e2>Glutamic acid decarboxylase<\\e2> (GAD, EC 4.1.1.15) catalyses the conversion of <e1>glutamate<\\e1> to gamma-aminobutyric acid (GABA)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"Glutamic acid decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND AND AIMS: <e2>GENE-N<\\e2> (GAD, EC 4.1.1.15) catalyses the conversion of <e1>CHEMICAL<\\e1> to gamma-aminobutyric acid (GABA)","sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)"}
{"PMID":12067524,"re_id":1,"annotated sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (<e2>GAD<\\e2>  EC 4.1.1.15) catalyses the conversion of <e1>glutamate<\\e1> to gamma-aminobutyric acid (GABA)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"GAD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (<e2>GENE-N<\\e2>  EC 4.1.1.15) catalyses the conversion of <e1>CHEMICAL<\\e1> to gamma-aminobutyric acid (GABA)","sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD  EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)"}
{"PMID":12067524,"re_id":2,"annotated sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, <e2>EC 4.1.1.15<\\e2>  catalyses the conversion of <e1>glutamate<\\e1> to gamma-aminobutyric acid (GABA)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"EC 4.1.1.15","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, <e2>GENE-Y<\\e2>  catalyses the conversion of <e1>CHEMICAL<\\e1> to gamma-aminobutyric acid (GABA)","sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, EC 4.1.1.15  catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)"}
{"PMID":12067524,"re_id":3,"annotated sentence":"BACKGROUND AND AIMS: <e2>Glutamic acid decarboxylase<\\e2> (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to <e1>gamma-aminobutyric acid<\\e1> (GABA)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"gamma-aminobutyric acid","object":"Glutamic acid decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND AND AIMS: <e2>GENE-N<\\e2> (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to <e1>CHEMICAL<\\e1> (GABA)","sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)"}
{"PMID":12067524,"re_id":4,"annotated sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (<e2>GAD<\\e2>  EC 4.1.1.15) catalyses the conversion of glutamate to <e1>gamma-aminobutyric acid<\\e1> (GABA)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"gamma-aminobutyric acid","object":"GAD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (<e2>GENE-N<\\e2>  EC 4.1.1.15) catalyses the conversion of glutamate to <e1>CHEMICAL<\\e1> (GABA)","sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD  EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)"}
{"PMID":12067524,"re_id":5,"annotated sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, <e2>EC 4.1.1.15<\\e2>  catalyses the conversion of glutamate to <e1>gamma-aminobutyric acid<\\e1> (GABA)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"gamma-aminobutyric acid","object":"EC 4.1.1.15","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, <e2>GENE-Y<\\e2>  catalyses the conversion of glutamate to <e1>CHEMICAL<\\e1> (GABA)","sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, EC 4.1.1.15  catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA)"}
{"PMID":12067524,"re_id":6,"annotated sentence":"BACKGROUND AND AIMS: <e2>Glutamic acid decarboxylase<\\e2> (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (<e1>GABA<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"GABA","object":"Glutamic acid decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND AND AIMS: <e2>GENE-N<\\e2> (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (<e1>CHEMICAL<\\e1> ","sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA "}
{"PMID":12067524,"re_id":7,"annotated sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (<e2>GAD<\\e2>  EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (<e1>GABA<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"GABA","object":"GAD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (<e2>GENE-N<\\e2>  EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (<e1>CHEMICAL<\\e1> ","sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD  EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA "}
{"PMID":12067524,"re_id":8,"annotated sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, <e2>EC 4.1.1.15<\\e2>  catalyses the conversion of glutamate to gamma-aminobutyric acid (<e1>GABA<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"GABA","object":"EC 4.1.1.15","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, <e2>GENE-Y<\\e2>  catalyses the conversion of glutamate to gamma-aminobutyric acid (<e1>CHEMICAL<\\e1> ","sentence":"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, EC 4.1.1.15  catalyses the conversion of glutamate to gamma-aminobutyric acid (GABA "}
{"PMID":12093311,"re_id":0,"annotated sentence":"OBJECTIVE: Celecoxib and <e1>rofecoxib<\\e1> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the <e2>cyclo-oxygenase-2<\\e2> (COX-2) isoenzyme at therapeutic concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"cyclo-oxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: Celecoxib and <e1>CHEMICAL<\\e1> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the <e2>GENE-Y<\\e2> (COX-2) isoenzyme at therapeutic concentrations","sentence":"OBJECTIVE: Celecoxib and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (COX-2) isoenzyme at therapeutic concentrations"}
{"PMID":12093311,"re_id":1,"annotated sentence":"OBJECTIVE: Celecoxib and <e1>rofecoxib<\\e1> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (<e2>COX-2<\\e2>  isoenzyme at therapeutic concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: Celecoxib and <e1>CHEMICAL<\\e1> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (<e2>GENE-Y<\\e2>  isoenzyme at therapeutic concentrations","sentence":"OBJECTIVE: Celecoxib and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (COX-2  isoenzyme at therapeutic concentrations"}
{"PMID":12093311,"re_id":2,"annotated sentence":"This study was conducted in order to understand the association between acute renal failure and the two <e2>COX-2<\\e2> inhibitors <e1>celecoxib<\\e1> and rofecoxib","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"celecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study was conducted in order to understand the association between acute renal failure and the two <e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1> and rofecoxib","sentence":"This study was conducted in order to understand the association between acute renal failure and the two COX-2 inhibitors celecoxib and rofecoxib"}
{"PMID":12093311,"re_id":3,"annotated sentence":"This study was conducted in order to understand the association between acute renal failure and the two <e2>COX-2<\\e2> inhibitors celecoxib and <e1>rofecoxib<\\e1>  METHODS: A search was performed in the US Food and Drug Administration's (FDA) Adverse Event Reporting System (AERS) to identify cases of renal failure submitted to the FDA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study was conducted in order to understand the association between acute renal failure and the two <e2>GENE-Y<\\e2> inhibitors celecoxib and <e1>CHEMICAL<\\e1>  METHODS: A search was performed in the US Food and Drug Administration's (FDA) Adverse Event Reporting System (AERS) to identify cases of renal failure submitted to the FDA","sentence":"This study was conducted in order to understand the association between acute renal failure and the two COX-2 inhibitors celecoxib and rofecoxib  METHODS: A search was performed in the US Food and Drug Administration's (FDA) Adverse Event Reporting System (AERS) to identify cases of renal failure submitted to the FDA"}
{"PMID":12093311,"re_id":4,"annotated sentence":"OBJECTIVE: <e1>Celecoxib<\\e1> and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the <e2>cyclo-oxygenase-2<\\e2> (COX-2) isoenzyme at therapeutic concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Celecoxib","object":"cyclo-oxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: <e1>CHEMICAL<\\e1> and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the <e2>GENE-Y<\\e2> (COX-2) isoenzyme at therapeutic concentrations","sentence":"OBJECTIVE: Celecoxib and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (COX-2) isoenzyme at therapeutic concentrations"}
{"PMID":12093311,"re_id":5,"annotated sentence":"OBJECTIVE: <e1>Celecoxib<\\e1> and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (<e2>COX-2<\\e2>  isoenzyme at therapeutic concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Celecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: <e1>CHEMICAL<\\e1> and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (<e2>GENE-Y<\\e2>  isoenzyme at therapeutic concentrations","sentence":"OBJECTIVE: Celecoxib and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (COX-2  isoenzyme at therapeutic concentrations"}
{"PMID":12110374,"re_id":0,"annotated sentence":"The results reinforce previous assumptions that <e1>dopamine<\\e1> may interact with eicosanoid metabolism by means of <e2>D(2) receptor<\\e2> activation, and implicate an involvement of cPLA(2) and COX-2 in this effect","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"dopamine","object":"D(2) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results reinforce previous assumptions that <e1>CHEMICAL<\\e1> may interact with eicosanoid metabolism by means of <e2>GENE-Y<\\e2> activation, and implicate an involvement of cPLA(2) and COX-2 in this effect","sentence":"The results reinforce previous assumptions that dopamine may interact with eicosanoid metabolism by means of D(2) receptor activation, and implicate an involvement of cPLA(2) and COX-2 in this effect"}
{"PMID":12110374,"re_id":1,"annotated sentence":"It was also antagonized by the non-specific <e2>cyclooxygenase<\\e2> (COX) inhibitor, <e1>indomethacin<\\e1>  and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indomethacin","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It was also antagonized by the non-specific <e2>GENE-N<\\e2> (COX) inhibitor, <e1>CHEMICAL<\\e1>  and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate","sentence":"It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin  and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate"}
{"PMID":12110374,"re_id":2,"annotated sentence":"It was also antagonized by the non-specific cyclooxygenase (<e2>COX<\\e2>  inhibitor, <e1>indomethacin<\\e1>  and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indomethacin","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It was also antagonized by the non-specific cyclooxygenase (<e2>GENE-N<\\e2>  inhibitor, <e1>CHEMICAL<\\e1>  and by the selective GENE-N-2 inhibitor, NS-398, but not by the specific GENE-N-1 inhibitor, valeryl salicylate","sentence":"It was also antagonized by the non-specific cyclooxygenase (COX  inhibitor, indomethacin  and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate"}
{"PMID":12110374,"re_id":3,"annotated sentence":"It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective <e2>COX-2<\\e2> inhibitor, <e1>NS-398<\\e1>  but not by the specific COX-1 inhibitor, valeryl salicylate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NS-398","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  but not by the specific COX-1 inhibitor, valeryl salicylate","sentence":"It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398  but not by the specific COX-1 inhibitor, valeryl salicylate"}
{"PMID":12110374,"re_id":4,"annotated sentence":"It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific <e2>COX-1<\\e2> inhibitor, <e1>valeryl salicylate<\\e1>  Both the non-specific phospholipase A(2) inhibitor, quinacrine, and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"valeryl salicylate","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  Both the non-specific phospholipase A(2) inhibitor, quinacrine, and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective","sentence":"It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate  Both the non-specific phospholipase A(2) inhibitor, quinacrine, and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective"}
{"PMID":12110374,"re_id":5,"annotated sentence":"Both the non-specific <e2>phospholipase A(2)<\\e2> inhibitor, <e1>quinacrine<\\e1>  and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinacrine","object":"phospholipase A(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both the non-specific <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective","sentence":"Both the non-specific phospholipase A(2) inhibitor, quinacrine  and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective"}
{"PMID":12110374,"re_id":6,"annotated sentence":"The effect was counteracted by the <e2>D(2)<\\e2> antagonist <e1>eticlopride<\\e1>  pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"eticlopride","object":"D(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effect was counteracted by the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA","sentence":"The effect was counteracted by the D(2) antagonist eticlopride  pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA"}
{"PMID":12110374,"re_id":7,"annotated sentence":"Dopamine D(2) receptor-induced <e2>COX-2<\\e2> mediated production of <e1>prostaglandin E(2)<\\e1> in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin E(2)","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dopamine D(2) receptor-induced <e2>GENE-Y<\\e2> mediated production of <e1>CHEMICAL<\\e1> in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent","sentence":"Dopamine D(2) receptor-induced COX-2 mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent"}
{"PMID":12112047,"re_id":0,"annotated sentence":"<e1>Minocycline<\\e1> treatment prevents the formation of activated <e2>caspase-3<\\e2>  a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic\/necrotic cell death","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Minocycline","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment prevents the formation of activated <e2>GENE-Y<\\e2>  a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic\/necrotic cell death","sentence":"Minocycline treatment prevents the formation of activated caspase-3  a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic\/necrotic cell death"}
{"PMID":12123767,"re_id":0,"annotated sentence":"In addition to this pronounced loss of function, <e2>M1766L<\\e2> also showed a 10-fold increase in the persistent late <e1>sodium<\\e1> current","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sodium","object":"M1766L","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition to this pronounced loss of function, <e2>GENE-N<\\e2> also showed a 10-fold increase in the persistent late <e1>CHEMICAL<\\e1> current","sentence":"In addition to this pronounced loss of function, M1766L also showed a 10-fold increase in the persistent late sodium current"}
{"PMID":12167567,"re_id":0,"annotated sentence":"<e1>Valdecoxib<\\e1> is a potent and specific inhibitor of <e2>cyclooxygenase-2<\\e2>  which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Valdecoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a potent and specific inhibitor of <e2>GENE-Y<\\e2>  which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain","sentence":"Valdecoxib is a potent and specific inhibitor of cyclooxygenase-2  which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain"}
{"PMID":12167567,"re_id":1,"annotated sentence":"Disposition of a specific <e2>cyclooxygenase-2<\\e2> inhibitor, <e1>valdecoxib<\\e1>  in human","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"valdecoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Disposition of a specific <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  in human","sentence":"Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib  in human"}
{"PMID":12183670,"re_id":0,"annotated sentence":"Thus, <e1>bupropion<\\e1> acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits <e2>DAT<\\e2> and NET function","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bupropion","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits <e2>GENE-Y<\\e2> and NET function","sentence":"Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function"}
{"PMID":12183670,"re_id":1,"annotated sentence":"Thus, <e1>bupropion<\\e1> acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and <e2>NET<\\e2> function","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bupropion","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and <e2>GENE-Y<\\e2> function","sentence":"Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function"}
{"PMID":12183670,"re_id":2,"annotated sentence":"The combination of <e2>nAChR<\\e2> and transporter inhibition produced by <e1>bupropion<\\e1> may contribute to its clinical efficacy as a smoking cessation agent.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bupropion","object":"nAChR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The combination of <e2>GENE-N<\\e2> and transporter inhibition produced by <e1>CHEMICAL<\\e1> may contribute to its clinical efficacy as a smoking cessation agent.","sentence":"The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent."}
{"PMID":12183670,"re_id":3,"annotated sentence":"<e1>Bupropion<\\e1>  an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (<e2>DAT<\\e2> and NET, respectively)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Bupropion","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (<e2>GENE-Y<\\e2> and NET, respectively)","sentence":"Bupropion  an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively)"}
{"PMID":12183670,"re_id":4,"annotated sentence":"<e1>Bupropion<\\e1>  an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and <e2>NET<\\e2>  respectively)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Bupropion","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and <e2>GENE-Y<\\e2>  respectively)","sentence":"Bupropion  an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET  respectively)"}
{"PMID":12183670,"re_id":5,"annotated sentence":"To eliminate the interaction of <e1>bupropion<\\e1> with <e2>DAT<\\e2> or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bupropion","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To eliminate the interaction of <e1>CHEMICAL<\\e1> with <e2>GENE-Y<\\e2> or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer","sentence":"To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer"}
{"PMID":12183670,"re_id":6,"annotated sentence":"To eliminate the interaction of <e1>bupropion<\\e1> with DAT or <e2>NET<\\e2>  nomifensine or desipramine, respectively, was included in the superfusion buffer","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bupropion","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To eliminate the interaction of <e1>CHEMICAL<\\e1> with DAT or <e2>GENE-Y<\\e2>  nomifensine or desipramine, respectively, was included in the superfusion buffer","sentence":"To eliminate the interaction of bupropion with DAT or NET  nomifensine or desipramine, respectively, was included in the superfusion buffer"}
{"PMID":12184062,"re_id":0,"annotated sentence":"The clinical profile of the <e2>angiotensin II receptor<\\e2> blocker <e1>eprosartan<\\e1>  Angiotensin II receptor antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of angiotensin in the vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"eprosartan","object":"angiotensin II receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The clinical profile of the <e2>GENE-N<\\e2> blocker <e1>CHEMICAL<\\e1>  Angiotensin II receptor antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of angiotensin in the vasculature","sentence":"The clinical profile of the angiotensin II receptor blocker eprosartan  Angiotensin II receptor antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of angiotensin in the vasculature"}
{"PMID":12184062,"re_id":1,"annotated sentence":"In clinical trials <e1>eprosartan<\\e1> has proven to be at least as effective as the <e2>ACE<\\e2> inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"eprosartan","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In clinical trials <e1>CHEMICAL<\\e1> has proven to be at least as effective as the <e2>GENE-Y<\\e2> inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects","sentence":"In clinical trials eprosartan has proven to be at least as effective as the ACE inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects"}
{"PMID":12188035,"re_id":0,"annotated sentence":"The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with <e2>rat GR<\\e2>  whereas <e1>BM<\\e1> and esterified-DEX had full transactivation agonistic activity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"BM","object":"rat GR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The esterified-CHEMICAL, however, had only partial transactivation agonistic activity in cells transfected with <e2>GENE-Y<\\e2>  whereas <e1>CHEMICAL<\\e1> and esterified-DEX had full transactivation agonistic activity","sentence":"The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with rat GR  whereas BM and esterified-DEX had full transactivation agonistic activity"}
{"PMID":12188035,"re_id":1,"annotated sentence":"The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with <e2>rat GR<\\e2>  whereas BM and esterified-<e1>DEX<\\e1> had full transactivation agonistic activity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DEX","object":"rat GR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with <e2>GENE-Y<\\e2>  whereas BM and esterified-<e1>CHEMICAL<\\e1> had full transactivation agonistic activity","sentence":"The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with rat GR  whereas BM and esterified-DEX had full transactivation agonistic activity"}
{"PMID":12188035,"re_id":2,"annotated sentence":"Moreover, in rat hepatoma H4-II-E cells, the esterified-<e1>BM<\\e1> failed to induce tyrosine aminotransferase, which is regulated by <e2>GR<\\e2> mediated transactivation activity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"BM","object":"GR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, in rat hepatoma H4-II-E cells, the esterified-<e1>CHEMICAL<\\e1> failed to induce tyrosine aminotransferase, which is regulated by <e2>GENE-Y<\\e2> mediated transactivation activity","sentence":"Moreover, in rat hepatoma H4-II-E cells, the esterified-BM failed to induce tyrosine aminotransferase, which is regulated by GR mediated transactivation activity"}
{"PMID":12188035,"re_id":3,"annotated sentence":"Consistent with the weak transactivation activity of esterified-<e1>BM<\\e1> mediated by <e2>rat GR<\\e2>  there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"BM","object":"rat GR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Consistent with the weak transactivation activity of esterified-<e1>CHEMICAL<\\e1> mediated by <e2>GENE-Y<\\e2>  there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats","sentence":"Consistent with the weak transactivation activity of esterified-BM mediated by rat GR  there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats"}
{"PMID":12188035,"re_id":4,"annotated sentence":"<e1>Dexamethasone<\\e1> (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>human or rat GR<\\e2>  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Dexamethasone","object":"human or rat GR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>GENE-N<\\e2>  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR","sentence":"Dexamethasone (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either human or rat GR  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR"}
{"PMID":12188035,"re_id":5,"annotated sentence":"Dexamethasone (<e1>DEX<\\e1> , betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>human or rat GR<\\e2>  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DEX","object":"human or rat GR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Dexamethasone (<e1>CHEMICAL<\\e1> , betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>GENE-N<\\e2>  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR","sentence":"Dexamethasone (DEX , betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either human or rat GR  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR"}
{"PMID":12188035,"re_id":6,"annotated sentence":"Dexamethasone (DEX), <e1>betamethasone<\\e1> (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>human or rat GR<\\e2>  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"betamethasone","object":"human or rat GR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Dexamethasone (DEX), <e1>CHEMICAL<\\e1> (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>GENE-N<\\e2>  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR","sentence":"Dexamethasone (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either human or rat GR  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR"}
{"PMID":12188035,"re_id":7,"annotated sentence":"Dexamethasone (DEX), betamethasone (<e1>BM<\\e1> , and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>human or rat GR<\\e2>  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"BM","object":"human or rat GR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Dexamethasone (DEX), betamethasone (<e1>CHEMICAL<\\e1> , and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>GENE-N<\\e2>  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR","sentence":"Dexamethasone (DEX), betamethasone (BM , and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either human or rat GR  These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR"}
{"PMID":12188035,"re_id":8,"annotated sentence":"The esterified-<e1>BM<\\e1>  however, had only partial transactivation agonistic activity in cells transfected with <e2>rat GR<\\e2>  whereas BM and esterified-DEX had full transactivation agonistic activity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"BM","object":"rat GR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The esterified-<e1>CHEMICAL<\\e1>  however, had only partial transactivation agonistic activity in cells transfected with <e2>GENE-Y<\\e2>  whereas CHEMICAL and esterified-DEX had full transactivation agonistic activity","sentence":"The esterified-BM  however, had only partial transactivation agonistic activity in cells transfected with rat GR  whereas BM and esterified-DEX had full transactivation agonistic activity"}
{"PMID":12196163,"re_id":0,"annotated sentence":"Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (<e2>NifS<\\e2>  that is involved in the activation of sulphur from <e1>l-cysteine<\\e1>  and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"l-cysteine","object":"NifS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (<e2>GENE-Y<\\e2>  that is involved in the activation of sulphur from <e1>CHEMICAL<\\e1>  and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed","sentence":"Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (NifS  that is involved in the activation of sulphur from l-cysteine  and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed"}
{"PMID":12213053,"re_id":0,"annotated sentence":"<e1>Mazindol<\\e1> analogues as potential inhibitors of the <e2>cocaine binding site<\\e2> at the dopamine transporter","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Mazindol","object":"cocaine binding site","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> analogues as potential inhibitors of the <e2>GENE-N<\\e2> at the dopamine transporter","sentence":"Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter"}
{"PMID":12213053,"re_id":1,"annotated sentence":"<e1>Mazindol<\\e1> analogues as potential inhibitors of the cocaine binding site at the <e2>dopamine transporter<\\e2>  A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (DAT) on rat or guinea pig striatal membranes were determined","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Mazindol","object":"dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> analogues as potential inhibitors of the cocaine binding site at the <e2>GENE-Y<\\e2>  A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the GENE-Y (DAT) on rat or guinea pig striatal membranes were determined","sentence":"Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter  A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (DAT) on rat or guinea pig striatal membranes were determined"}
{"PMID":12213053,"re_id":2,"annotated sentence":"Several active analogues were also evaluated for their ability to block uptake of DA, <e1>5-HT<\\e1>  and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-<e2>hSERT<\\e2>  and HEK-hNET cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-HT","object":"hSERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Several active analogues were also evaluated for their ability to block uptake of DA, <e1>CHEMICAL<\\e1>  and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-<e2>GENE-Y<\\e2>  and HEK-hNET cells","sentence":"Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT  and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT  and HEK-hNET cells"}
{"PMID":12213053,"re_id":3,"annotated sentence":"Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and <e1>NE<\\e1> and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK-<e2>hNET<\\e2> cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NE","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and <e1>CHEMICAL<\\e1> and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK-<e2>hCHEMICALT<\\e2> cells","sentence":"Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK-hNET cells"}
{"PMID":12213053,"re_id":4,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dopamine","object":"dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":12213053,"re_id":5,"annotated sentence":"Several active analogues were also evaluated for their ability to block uptake of <e1>DA<\\e1>  5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-<e2>hDAT<\\e2>  HEK-hSERT, and HEK-hNET cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DA","object":"hDAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Several active analogues were also evaluated for their ability to block uptake of <e1>CHEMICAL<\\e1>  5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-<e2>hCHEMICALT<\\e2>  HEK-hSERT, and HEK-hNET cells","sentence":"Several active analogues were also evaluated for their ability to block uptake of DA  5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT  HEK-hSERT, and HEK-hNET cells"}
{"PMID":12213829,"re_id":0,"annotated sentence":"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the <e1>ATP<\\e1> inhibition of <e2>K(IR)6.2<\\e2> SUR1, but had no effect on homomeric K(IR)6.2 channels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATP","object":"K(IR)6.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the <e1>CHEMICAL<\\e1> inhibition of <e2>GENE-Y<\\e2> SUR1, but had no effect on homomeric GENE-Y channels","sentence":"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the ATP inhibition of K(IR)6.2 SUR1, but had no effect on homomeric K(IR)6.2 channels"}
{"PMID":12213829,"re_id":1,"annotated sentence":"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the <e1>ATP<\\e1> inhibition of K(IR)6.2\/<e2>SUR1<\\e2>  but had no effect on homomeric K(IR)6.2 channels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATP","object":"SUR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the <e1>CHEMICAL<\\e1> inhibition of K(IR)6.2\/<e2>GENE-Y<\\e2>  but had no effect on homomeric K(IR)6.2 channels","sentence":"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the ATP inhibition of K(IR)6.2\/SUR1  but had no effect on homomeric K(IR)6.2 channels"}
{"PMID":12213829,"re_id":2,"annotated sentence":"These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to <e2>DeltaNK(ATP) channels<\\e2> decreased their P(O(max)) and apparent IC(50) for <e1>ATP<\\e1> in the absence of Mg(2+)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATP","object":"DeltaNK(ATP) channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to <e2>DeltaNK(CHEMICAL) channels<\\e2> decreased their P(O(max)) and apparent IC(50) for <e1>CHEMICAL<\\e1> in the absence of Mg(2+)","sentence":"These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+)"}
{"PMID":12244038,"re_id":0,"annotated sentence":"Since <e1>gemfibrozil<\\e1> is known to activate <e2>peroxisome proliferator-activated receptor-alpha<\\e2> (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"peroxisome proliferator-activated receptor-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since <e1>CHEMICAL<\\e1> is known to activate <e2>GENE-Y<\\e2> (PPAR-alpha), we investigated the role of PPAR-alpha in CHEMICAL-mediated inhibition of iNOS","sentence":"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS"}
{"PMID":12244038,"re_id":1,"annotated sentence":"Since <e1>gemfibrozil<\\e1> is known to activate peroxisome proliferator-activated receptor-alpha (<e2>PPAR-alpha<\\e2> , we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"PPAR-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since <e1>CHEMICAL<\\e1> is known to activate peroxisome proliferator-activated receptor-alpha (<e2>GENE-Y<\\e2> , we investigated the role of GENE-Y in CHEMICAL-mediated inhibition of iNOS","sentence":"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha , we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS"}
{"PMID":12244038,"re_id":2,"annotated sentence":"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of <e2>PPAR-alpha<\\e2> in <e1>gemfibrozil<\\e1> mediated inhibition of iNOS","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"PPAR-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since CHEMICAL is known to activate peroxisome proliferator-activated receptor-alpha (GENE-Y), we investigated the role of <e2>GENE-Y<\\e2> in <e1>CHEMICAL<\\e1> mediated inhibition of iNOS","sentence":"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil mediated inhibition of iNOS"}
{"PMID":12244038,"re_id":3,"annotated sentence":"<e1>Gemfibrozil<\\e1> induced <e2>peroxisome proliferator-responsive element<\\e2> (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Gemfibrozil","object":"peroxisome proliferator-responsive element","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha","sentence":"Gemfibrozil induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha"}
{"PMID":12244038,"re_id":4,"annotated sentence":"<e1>Gemfibrozil<\\e1> induced peroxisome proliferator-responsive element (<e2>PPRE<\\e2> -dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Gemfibrozil","object":"PPRE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced peroxisome proliferator-responsive element (<e2>GENE-N<\\e2> -dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha","sentence":"Gemfibrozil induced peroxisome proliferator-responsive element (PPRE -dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha"}
{"PMID":12244038,"re_id":5,"annotated sentence":"Inhibition of <e2>human iNOS promoter<\\e2> driven luciferase activity by <e1>gemfibrozil<\\e1> in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"human iNOS promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of <e2>GENE-N<\\e2> driven luciferase activity by <e1>CHEMICAL<\\e1> in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS","sentence":"Inhibition of human iNOS promoter driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS"}
{"PMID":12244038,"re_id":6,"annotated sentence":"Inhibition of human iNOS promoter-driven luciferase activity by <e1>gemfibrozil<\\e1> in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of <e2>iNOS<\\e2>  Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of human GENE-Y promoter-driven luciferase activity by <e1>CHEMICAL<\\e1> in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of <e2>GENE-Y<\\e2>  Since CHEMICAL is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in CHEMICAL-mediated inhibition of GENE-Y","sentence":"Inhibition of human iNOS promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS  Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS"}
{"PMID":12244038,"re_id":7,"annotated sentence":"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in <e1>gemfibrozil<\\e1> mediated inhibition of <e2>iNOS<\\e2>  Gemfibrozil induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since CHEMICAL is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in <e1>CHEMICAL<\\e1> mediated inhibition of <e2>GENE-Y<\\e2>  Gemfibrozil induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha","sentence":"Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil mediated inhibition of iNOS  Gemfibrozil induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha"}
{"PMID":12244038,"re_id":8,"annotated sentence":"However, DeltahPPAR-alpha was unable to abrogate <e1>gemfibrozil<\\e1> mediated inhibition of <e2>iNOS<\\e2> suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, DeltahPPAR-alpha was unable to abrogate <e1>CHEMICAL<\\e1> mediated inhibition of <e2>GENE-Y<\\e2> suggesting that CHEMICAL inhibits GENE-Y independent of PPAR-alpha","sentence":"However, DeltahPPAR-alpha was unable to abrogate gemfibrozil mediated inhibition of iNOS suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha"}
{"PMID":12244038,"re_id":9,"annotated sentence":"However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that <e1>gemfibrozil<\\e1> inhibits <e2>iNOS<\\e2> independent of PPAR-alpha","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, DeltahPPAR-alpha was unable to abrogate CHEMICAL-mediated inhibition of GENE-Y suggesting that <e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> independent of PPAR-alpha","sentence":"However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha"}
{"PMID":12244038,"re_id":10,"annotated sentence":"<e1>Gemfibrozil<\\e1>  a lipid-lowering drug, inhibits the induction of <e2>nitric-oxide synthase<\\e2> in human astrocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Gemfibrozil","object":"nitric-oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a lipid-lowering drug, inhibits the induction of <e2>GENE-N<\\e2> in human astrocytes","sentence":"Gemfibrozil  a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes"}
{"PMID":12244038,"re_id":11,"annotated sentence":"<e1>Gemfibrozil<\\e1>  a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of <e2>inducible nitric-oxide synthase<\\e2> (iNOS) in human U373MG astroglial cells and primary astrocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Gemfibrozil","object":"inducible nitric-oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of <e2>GENE-Y<\\e2> (iNOS) in human U373MG astroglial cells and primary astrocytes","sentence":"Gemfibrozil  a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes"}
{"PMID":12244038,"re_id":12,"annotated sentence":"<e1>Gemfibrozil<\\e1>  a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (<e2>iNOS<\\e2>  in human U373MG astroglial cells and primary astrocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Gemfibrozil","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (<e2>GENE-Y<\\e2>  in human U373MG astroglial cells and primary astrocytes","sentence":"Gemfibrozil  a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS  in human U373MG astroglial cells and primary astrocytes"}
{"PMID":12244038,"re_id":13,"annotated sentence":"<e1>Gemfibrozil<\\e1>  a lipid-lowering drug, inhibited <e2>cytokine<\\e2> induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Gemfibrozil","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a lipid-lowering drug, inhibited <e2>GENE-N<\\e2> induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes","sentence":"Gemfibrozil  a lipid-lowering drug, inhibited cytokine induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes"}
{"PMID":12244038,"re_id":14,"annotated sentence":"Interestingly, <e1>gemfibrozil<\\e1> strongly inhibited the activation of <e2>NF-kappaB<\\e2>  AP-1, and C\/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> strongly inhibited the activation of <e2>GENE-N<\\e2>  AP-1, and C\/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells","sentence":"Interestingly, gemfibrozil strongly inhibited the activation of NF-kappaB  AP-1, and C\/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells"}
{"PMID":12244038,"re_id":15,"annotated sentence":"Interestingly, <e1>gemfibrozil<\\e1> strongly inhibited the activation of NF-kappaB, <e2>AP-1<\\e2>  and C\/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"AP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> strongly inhibited the activation of NF-kappaB, <e2>GENE-Y<\\e2>  and C\/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells","sentence":"Interestingly, gemfibrozil strongly inhibited the activation of NF-kappaB, AP-1  and C\/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells"}
{"PMID":12244038,"re_id":16,"annotated sentence":"Interestingly, <e1>gemfibrozil<\\e1> strongly inhibited the activation of NF-kappaB, AP-1, and <e2>C\/EBPbeta<\\e2> but not that of GAS in cytokine-stimulated astroglial cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"C\/EBPbeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> strongly inhibited the activation of NF-kappaB, AP-1, and <e2>GENE-Y<\\e2> but not that of GAS in cytokine-stimulated astroglial cells","sentence":"Interestingly, gemfibrozil strongly inhibited the activation of NF-kappaB, AP-1, and C\/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells"}
{"PMID":12244038,"re_id":17,"annotated sentence":"These results suggest that <e1>gemfibrozil<\\e1> inhibits the induction of <e2>iNOS<\\e2> probably by inhibiting the activation of NF-kappaB, AP-1, and C\/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> inhibits the induction of <e2>GENE-Y<\\e2> probably by inhibiting the activation of NF-kappaB, AP-1, and C\/EBPbeta and that CHEMICAL, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.","sentence":"These results suggest that gemfibrozil inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and C\/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases."}
{"PMID":12244038,"re_id":18,"annotated sentence":"These results suggest that <e1>gemfibrozil<\\e1> inhibits the induction of iNOS probably by inhibiting the activation of <e2>NF-kappaB<\\e2>  AP-1, and C\/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> inhibits the induction of iNOS probably by inhibiting the activation of <e2>GENE-N<\\e2>  AP-1, and C\/EBPbeta and that CHEMICAL, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.","sentence":"These results suggest that gemfibrozil inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB  AP-1, and C\/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases."}
{"PMID":12244038,"re_id":19,"annotated sentence":"These results suggest that <e1>gemfibrozil<\\e1> inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, <e2>AP-1<\\e2>  and C\/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"AP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, <e2>GENE-Y<\\e2>  and C\/EBPbeta and that CHEMICAL, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.","sentence":"These results suggest that gemfibrozil inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1  and C\/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases."}
{"PMID":12244038,"re_id":20,"annotated sentence":"These results suggest that <e1>gemfibrozil<\\e1> inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and <e2>C\/EBPbeta<\\e2> and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"C\/EBPbeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and <e2>GENE-Y<\\e2> and that CHEMICAL, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.","sentence":"These results suggest that gemfibrozil inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and C\/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases."}
{"PMID":12244038,"re_id":21,"annotated sentence":"Similar to <e1>gemfibrozil<\\e1>  clofibrate, another fibrate drug, also inhibited the expression of <e2>iNOS<\\e2>  Inhibition of human iNOS promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemfibrozil","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to <e1>CHEMICAL<\\e1>  clofibrate, another fibrate drug, also inhibited the expression of <e2>GENE-Y<\\e2>  Inhibition of human GENE-Y promoter-driven luciferase activity by CHEMICAL in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of GENE-Y","sentence":"Similar to gemfibrozil  clofibrate, another fibrate drug, also inhibited the expression of iNOS  Inhibition of human iNOS promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS"}
{"PMID":12244038,"re_id":22,"annotated sentence":"Similar to gemfibrozil, <e1>clofibrate<\\e1>  another fibrate drug, also inhibited the expression of <e2>iNOS<\\e2>  Inhibition of human iNOS promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clofibrate","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to gemfibrozil, <e1>CHEMICAL<\\e1>  another fibrate drug, also inhibited the expression of <e2>GENE-Y<\\e2>  Inhibition of human GENE-Y promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of GENE-Y","sentence":"Similar to gemfibrozil, clofibrate  another fibrate drug, also inhibited the expression of iNOS  Inhibition of human iNOS promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS"}
{"PMID":12244038,"re_id":23,"annotated sentence":"Similar to gemfibrozil, clofibrate, another <e1>fibrate<\\e1> drug, also inhibited the expression of <e2>iNOS<\\e2>  Inhibition of human iNOS promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fibrate","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to gemfibrozil, cloCHEMICAL, another <e1>CHEMICAL<\\e1> drug, also inhibited the expression of <e2>GENE-Y<\\e2>  Inhibition of human GENE-Y promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of GENE-Y","sentence":"Similar to gemfibrozil, clofibrate, another fibrate drug, also inhibited the expression of iNOS  Inhibition of human iNOS promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS"}
{"PMID":12244038,"re_id":24,"annotated sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of <e1>NO<\\e1> and the expression of <e2>inducible nitric-oxide synthase<\\e2> (iNOS) in human U373MG astroglial cells and primary astrocytes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"inducible nitric-oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of <e1>CHEMICAL<\\e1> and the expression of <e2>GENE-Y<\\e2> (iCHEMICALS) in human U373MG astroglial cells and primary astrocytes","sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes"}
{"PMID":12244038,"re_id":25,"annotated sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of <e1>NO<\\e1> and the expression of inducible nitric-oxide synthase (<e2>iNOS<\\e2>  in human U373MG astroglial cells and primary astrocytes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of <e1>CHEMICAL<\\e1> and the expression of inducible nitric-oxide synthase (<e2>iCHEMICALS<\\e2>  in human U373MG astroglial cells and primary astrocytes","sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS  in human U373MG astroglial cells and primary astrocytes"}
{"PMID":12244038,"re_id":26,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitric-oxide","object":"nitric-oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":12244038,"re_id":27,"annotated sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of <e2>induci<e1>nitric-oxide<\\e1> ide synthase<\\e2> (iNOS) in human U373MG astroglial cells and primary astrocytes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitric-oxide","object":"inducible nitric-oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of <e2>induci<e1>CHEMICAL<\\e1> ide synthase<\\e2> (iNOS) in human U373MG astroglial cells and primary astrocytes","sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducinitric-oxide ide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes"}
{"PMID":12244038,"re_id":28,"annotated sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible <e1>nitric-oxide<\\e1> synthase (<e2>iNOS<\\e2>  in human U373MG astroglial cells and primary astrocytes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitric-oxide","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible <e1>CHEMICAL<\\e1> synthase (<e2>GENE-Y<\\e2>  in human U373MG astroglial cells and primary astrocytes","sentence":"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS  in human U373MG astroglial cells and primary astrocytes"}
{"PMID":12373423,"re_id":0,"annotated sentence":"Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective <e2>5-HT(1A)<\\e2> agonist <e1>LY 293284<\\e1>  The hypothermic effect of lisuride was prevented by pre-injection of pMPPI, but not by ketanserin or haloperidol","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"LY 293284","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1>  The hypothermic effect of lisuride was prevented by pre-injection of pMPPI, but not by ketanserin or haloperidol","sentence":"Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective 5-HT(1A) agonist LY 293284  The hypothermic effect of lisuride was prevented by pre-injection of pMPPI, but not by ketanserin or haloperidol"}
{"PMID":12373423,"re_id":1,"annotated sentence":"RESULTS: In drug discrimination studies, <e1>lisuride<\\e1> fully mimicked the <e2>5-HT(1A)<\\e2> agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"lisuride","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: In drug discrimination studies, <e1>CHEMICAL<\\e1> fully mimicked the <e2>GENE-Y<\\e2> agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine","sentence":"RESULTS: In drug discrimination studies, lisuride fully mimicked the 5-HT(1A) agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine"}
{"PMID":12373423,"re_id":2,"annotated sentence":"RESULTS: In drug discrimination studies, lisuride fully mimicked the <e2>5-HT(1A)<\\e2> agonist <e1>LY 293284<\\e1>  only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"LY 293284","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: In drug discrimination studies, lisuride fully mimicked the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1>  only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine","sentence":"RESULTS: In drug discrimination studies, lisuride fully mimicked the 5-HT(1A) agonist LY 293284  only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine"}
{"PMID":12373423,"re_id":3,"annotated sentence":"Only pMPPI [<e1>4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride<\\e1> , a selective <e2>5-HT(1A)<\\e2> antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Only pMPPI [<e1>CHEMICAL<\\e1> , a selective <e2>GENE-Y<\\e2> antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD","sentence":"Only pMPPI [4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride , a selective 5-HT(1A) antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD"}
{"PMID":12373557,"re_id":0,"annotated sentence":"We hypothesized that the <e1>HED<\\e1> compounds would be most potent at the <e2>norepinephrine transporter<\\e2> (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HED","object":"norepinephrine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We hypothesized that the <e1>CHEMICAL<\\e1> compounds would be most potent at the <e2>GENE-Y<\\e2> (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers","sentence":"We hypothesized that the HED compounds would be most potent at the norepinephrine transporter (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers"}
{"PMID":12373557,"re_id":1,"annotated sentence":"We hypothesized that the <e1>HED<\\e1> compounds would be most potent at the norepinephrine transporter (<e2>NET<\\e2>  compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HED","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We hypothesized that the <e1>CHEMICAL<\\e1> compounds would be most potent at the norepinephrine transporter (<e2>GENE-Y<\\e2>  compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers","sentence":"We hypothesized that the HED compounds would be most potent at the norepinephrine transporter (NET  compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers"}
{"PMID":12373557,"re_id":2,"annotated sentence":"Stereospecific inhibition of <e2>monoamine uptake transporters<\\e2> by <e1>meta-hydroxyephedrine<\\e1> isomers","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meta-hydroxyephedrine","object":"monoamine uptake transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Stereospecific inhibition of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1> isomers","sentence":"Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers"}
{"PMID":12373557,"re_id":3,"annotated sentence":"To extend structure-activity analyses of binding sites within <e2>monoamine transporters<\\e2> and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the <e1>HED<\\e1> compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HED","object":"monoamine transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To extend structure-activity analyses of binding sites within <e2>GENE-N<\\e2> and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the <e1>CHEMICAL<\\e1> compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles","sentence":"To extend structure-activity analyses of binding sites within monoamine transporters and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the HED compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles"}
{"PMID":12388748,"re_id":0,"annotated sentence":"Culture of HepG2 cells with <e1>griseofulvin<\\e1> has now been shown to induce both the formation of intracellular aggregates containing <e2>K18<\\e2> as well as an increase in the abundance of K18 mRNA","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"griseofulvin","object":"K18","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Culture of HepG2 cells with <e1>CHEMICAL<\\e1> has now been shown to induce both the formation of intracellular aggregates containing <e2>GENE-Y<\\e2> as well as an increase in the abundance of GENE-Y mRNA","sentence":"Culture of HepG2 cells with griseofulvin has now been shown to induce both the formation of intracellular aggregates containing K18 as well as an increase in the abundance of K18 mRNA"}
{"PMID":12388748,"re_id":1,"annotated sentence":"Culture of HepG2 cells with <e1>griseofulvin<\\e1> has now been shown to induce both the formation of intracellular aggregates containing K18 as well as an increase in the abundance of <e2>K18<\\e2> mRNA","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"griseofulvin","object":"K18","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Culture of HepG2 cells with <e1>CHEMICAL<\\e1> has now been shown to induce both the formation of intracellular aggregates containing GENE-Y as well as an increase in the abundance of <e2>GENE-Y<\\e2> mRNA","sentence":"Culture of HepG2 cells with griseofulvin has now been shown to induce both the formation of intracellular aggregates containing K18 as well as an increase in the abundance of K18 mRNA"}
{"PMID":12392782,"re_id":0,"annotated sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the <e2>5-LOX<\\e2> inhibitor <e1>REV 5901<\\e1>  and the 5-LOX activating protein (FLAP) inhibitor MK-886","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"REV 5901","object":"5-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  and the GENE-Y activating protein (FLAP) inhibitor MK-886","sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901  and the 5-LOX activating protein (FLAP) inhibitor MK-886"}
{"PMID":12392782,"re_id":1,"annotated sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the <e2>5-LOX activating protein<\\e2> (FLAP) inhibitor <e1>MK-886<\\e1>  The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MK-886","object":"5-LOX activating protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the <e2>GENE-Y<\\e2> (FLAP) inhibitor <e1>CHEMICAL<\\e1>  The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin","sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886  The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin"}
{"PMID":12392782,"re_id":2,"annotated sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (<e2>FLAP<\\e2>  inhibitor <e1>MK-886<\\e1>  The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MK-886","object":"FLAP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (<e2>GENE-Y<\\e2>  inhibitor <e1>CHEMICAL<\\e1>  The GENE-Y inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin","sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP  inhibitor MK-886  The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin"}
{"PMID":12392782,"re_id":3,"annotated sentence":"They included the COX-1 inhibitor indomethacin; the <e2>COX-2<\\e2> inhibitor <e1>NS-398<\\e1>  the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NS-398","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"They included the COX-1 inhibitor indomethacin; the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  the mixed COX-1\/GENE-Y inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886","sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398  the mixed COX-1\/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886"}
{"PMID":12392782,"re_id":4,"annotated sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed <e2>COX-1<\\e2> COX-2 inhibitor <e1>ibuprofen<\\e1>  the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibuprofen","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"They included the GENE-Y inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed <e2>GENE-Y<\\e2> COX-2 inhibitor <e1>CHEMICAL<\\e1>  the nitric oxide (NO) derivatives of indomethacin, CHEMICAL and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886","sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1 COX-2 inhibitor ibuprofen  the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886"}
{"PMID":12392782,"re_id":5,"annotated sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/<e2>COX-2<\\e2> inhibitor <e1>ibuprofen<\\e1>  the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibuprofen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"They included the COX-1 inhibitor indomethacin; the GENE-Y inhibitor NS-398; the mixed COX-1\/<e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  the nitric oxide (NO) derivatives of indomethacin, CHEMICAL and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886","sentence":"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1\/COX-2 inhibitor ibuprofen  the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886"}
{"PMID":12392782,"re_id":6,"annotated sentence":"The <e2>COX<\\e2> pathway generates inflammatory <e1>prostaglandins<\\e1>  while the 5-LOX pathway generates inflammatory leukotrienes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandins","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> pathway generates inflammatory <e1>CHEMICAL<\\e1>  while the 5-LOX pathway generates inflammatory leukotrienes","sentence":"The COX pathway generates inflammatory prostaglandins  while the 5-LOX pathway generates inflammatory leukotrienes"}
{"PMID":12392782,"re_id":7,"annotated sentence":"The COX pathway generates inflammatory prostaglandins, while the <e2>5-LOX<\\e2> pathway generates inflammatory <e1>leukotrienes<\\e1>  We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"leukotrienes","object":"5-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The COX pathway generates inflammatory prostaglandins, while the <e2>GENE-Y<\\e2> pathway generates inflammatory <e1>CHEMICAL<\\e1>  We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion","sentence":"The COX pathway generates inflammatory prostaglandins, while the 5-LOX pathway generates inflammatory leukotrienes  We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion"}
{"PMID":12398910,"re_id":0,"annotated sentence":"This observation suggests that <e1>MDMA<\\e1> induced reductions in <e2>SERT<\\e2> density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MDMA","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This observation suggests that <e1>CHEMICAL<\\e1> induced reductions in <e2>GENE-Y<\\e2> density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of CHEMICAL.","sentence":"This observation suggests that MDMA induced reductions in SERT density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of MDMA."}
{"PMID":12398910,"re_id":1,"annotated sentence":"Low levels of <e1>serotonin<\\e1> may reduce the density of the <e2>serotonin transporter<\\e2> (SERT) by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\"","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"serotonin","object":"serotonin transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Low levels of <e1>CHEMICAL<\\e1> may reduce the density of the <e2>CHEMICAL transporter<\\e2> (SERT) by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\"","sentence":"Low levels of serotonin may reduce the density of the serotonin transporter (SERT) by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\""}
{"PMID":12398910,"re_id":2,"annotated sentence":"Low levels of <e1>serotonin<\\e1> may reduce the density of the serotonin transporter (<e2>SERT<\\e2>  by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\"","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"serotonin","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Low levels of <e1>CHEMICAL<\\e1> may reduce the density of the CHEMICAL transporter (<e2>GENE-Y<\\e2>  by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\"","sentence":"Low levels of serotonin may reduce the density of the serotonin transporter (SERT  by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\""}
{"PMID":12398910,"re_id":3,"annotated sentence":"To determine whether <e1>3,4-methylenedioxymethamphetamine<\\e1> (MDMA)-induced reductions in <e2>SERT<\\e2> density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"3,4-methylenedioxymethamphetamine","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether <e1>CHEMICAL<\\e1> (MDMA)-induced reductions in <e2>GENE-Y<\\e2> density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and GENE-Y density were measured","sentence":"To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured"}
{"PMID":12398910,"re_id":4,"annotated sentence":"To determine whether 3,4-methylenedioxymethamphetamine (<e1>MDMA<\\e1> -induced reductions in <e2>SERT<\\e2> density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MDMA","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether 3,4-methylenedioxymethamphetamine (<e1>CHEMICAL<\\e1> -induced reductions in <e2>GENE-Y<\\e2> density could be related to such a mechanism, p-chlorophenylalanine or CHEMICAL was administered to rats, and brain serotonin and GENE-Y density were measured","sentence":"To determine whether 3,4-methylenedioxymethamphetamine (MDMA -induced reductions in SERT density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured"}
{"PMID":12398910,"re_id":5,"annotated sentence":"However, only <e1>MDMA<\\e1> reduced <e2>SERT<\\e2> density","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MDMA","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, only <e1>CHEMICAL<\\e1> reduced <e2>GENE-Y<\\e2> density","sentence":"However, only MDMA reduced SERT density"}
{"PMID":12431845,"re_id":0,"annotated sentence":"The selective <e2>norepinephrine (NE) transporter<\\e2> inhibitor <e1>atomoxetine<\\e1> (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit\/Hyperactivity Disorder (ADHD)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"atomoxetine","object":"norepinephrine (NE) transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit\/Hyperactivity Disorder (ADHD)","sentence":"The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit\/Hyperactivity Disorder (ADHD)"}
{"PMID":12431845,"re_id":1,"annotated sentence":"The selective <e2>norepinephrine (NE) transporter<\\e2> inhibitor atomoxetine (formerly called <e1>tomoxetine<\\e1> or LY139603) has been shown to alleviate symptoms in Attention Deficit\/Hyperactivity Disorder (ADHD)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tomoxetine","object":"norepinephrine (NE) transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> inhibitor aCHEMICAL (formerly called <e1>CHEMICAL<\\e1> or LY139603) has been shown to alleviate symptoms in Attention Deficit\/Hyperactivity Disorder (ADHD)","sentence":"The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit\/Hyperactivity Disorder (ADHD)"}
{"PMID":12431845,"re_id":2,"annotated sentence":"The selective <e2>norepinephrine (NE) transporter<\\e2> inhibitor atomoxetine (formerly called tomoxetine or <e1>LY139603<\\e1>  has been shown to alleviate symptoms in Attention Deficit\/Hyperactivity Disorder (ADHD)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LY139603","object":"norepinephrine (NE) transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> inhibitor atomoxetine (formerly called tomoxetine or <e1>CHEMICAL<\\e1>  has been shown to alleviate symptoms in Attention Deficit\/Hyperactivity Disorder (ADHD)","sentence":"The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomoxetine or LY139603  has been shown to alleviate symptoms in Attention Deficit\/Hyperactivity Disorder (ADHD)"}
{"PMID":12504917,"re_id":0,"annotated sentence":"<e1>Rasagiline<\\e1> does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit <e2>MAO-B<\\e2> but not MAO-A.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rasagiline","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit <e2>GENE-Y<\\e2> but not MAO-A.","sentence":"Rasagiline does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not MAO-A."}
{"PMID":12504917,"re_id":1,"annotated sentence":"<e1>Rasagiline<\\e1> does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not <e2>MAO-A<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rasagiline","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not <e2>GENE-Y<\\e2> ","sentence":"Rasagiline does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not MAO-A "}
{"PMID":12504917,"re_id":2,"annotated sentence":"<e1>Rasagiline<\\e1> [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible <e2>monoamine oxidase<\\e2> (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rasagiline","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible <e2>GENE-N<\\e2> (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","sentence":"Rasagiline [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible monoamine oxidase (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease"}
{"PMID":12504917,"re_id":3,"annotated sentence":"<e1>Rasagiline<\\e1> [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible monoamine oxidase (<e2>MAO<\\e2>  inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rasagiline","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible monoamine oxidase (<e2>GENE-N<\\e2>  inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","sentence":"Rasagiline [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible monoamine oxidase (MAO  inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease"}
{"PMID":12504917,"re_id":4,"annotated sentence":"Rasagiline [N-propargyl-1R(+)-aminoindan; <e1>TVP1012<\\e1>  is a potent irreversible <e2>monoamine oxidase<\\e2> (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TVP1012","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rasagiline [N-propargyl-1R(+)-aminoindan; <e1>CHEMICAL<\\e1>  is a potent irreversible <e2>GENE-N<\\e2> (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","sentence":"Rasagiline [N-propargyl-1R(+)-aminoindan; TVP1012  is a potent irreversible monoamine oxidase (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease"}
{"PMID":12504917,"re_id":5,"annotated sentence":"Rasagiline [N-propargyl-1R(+)-aminoindan; <e1>TVP1012<\\e1>  is a potent irreversible monoamine oxidase (<e2>MAO<\\e2>  inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TVP1012","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rasagiline [N-propargyl-1R(+)-aminoindan; <e1>CHEMICAL<\\e1>  is a potent irreversible monoamine oxidase (<e2>GENE-N<\\e2>  inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","sentence":"Rasagiline [N-propargyl-1R(+)-aminoindan; TVP1012  is a potent irreversible monoamine oxidase (MAO  inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease"}
{"PMID":12504917,"re_id":6,"annotated sentence":"Reserpine-induced ptosis was reversed by <e1>rasagiline<\\e1> at doses above 2 mg x kg(-1) i.p., which inhibit <e2>MAO-A<\\e2> as well as MAO-B, but not at MAO-B-selective doses","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rasagiline","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reserpine-induced ptosis was reversed by <e1>CHEMICAL<\\e1> at doses above 2 mg x kg(-1) i.p., which inhibit <e2>GENE-Y<\\e2> as well as MAO-B, but not at MAO-B-selective doses","sentence":"Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at MAO-B-selective doses"}
{"PMID":12504917,"re_id":7,"annotated sentence":"Reserpine-induced ptosis was reversed by <e1>rasagiline<\\e1> at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as <e2>MAO-B<\\e2>  but not at MAO-B-selective doses","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rasagiline","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reserpine-induced ptosis was reversed by <e1>CHEMICAL<\\e1> at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as <e2>GENE-Y<\\e2>  but not at GENE-Y-selective doses","sentence":"Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B  but not at MAO-B-selective doses"}
{"PMID":12504917,"re_id":8,"annotated sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both <e2>MAO-A<\\e2> and MAO-B by <e1>tranylcypromine<\\e1> together with the monoamine precursors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both <e2>GENE-Y<\\e2> and MAO-B by <e1>CHEMICAL<\\e1> together with the monoamine precursors","sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and MAO-B by tranylcypromine together with the monoamine precursors"}
{"PMID":12504917,"re_id":9,"annotated sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and <e2>MAO-B<\\e2> by <e1>tranylcypromine<\\e1> together with the monoamine precursors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> together with the monoamine precursors","sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and MAO-B by tranylcypromine together with the monoamine precursors"}
{"PMID":12504917,"re_id":10,"annotated sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both <e2>MAO-A<\\e2> and MAO-B by tranylcypromine together with the <e1>monoamine<\\e1> precursors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"monoamine","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both <e2>GENE-Y<\\e2> and MAO-B by tranylcypromine together with the <e1>CHEMICAL<\\e1> precursors","sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and MAO-B by tranylcypromine together with the monoamine precursors"}
{"PMID":12504917,"re_id":11,"annotated sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and <e2>MAO-B<\\e2> by tranylcypromine together with the <e1>monoamine<\\e1> precursors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"monoamine","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and <e2>GENE-Y<\\e2> by tranylcypromine together with the <e1>CHEMICAL<\\e1> precursors","sentence":"However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and MAO-B by tranylcypromine together with the monoamine precursors"}
{"PMID":12504917,"re_id":12,"annotated sentence":"Rasagiline [<e1>N-propargyl-1R(+)-aminoindan<\\e1>  TVP1012] is a potent irreversible <e2>monoamine oxidase<\\e2> (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-propargyl-1R(+)-aminoindan","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rasagiline [<e1>CHEMICAL<\\e1>  TVP1012] is a potent irreversible <e2>GENE-N<\\e2> (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","sentence":"Rasagiline [N-propargyl-1R(+)-aminoindan  TVP1012] is a potent irreversible monoamine oxidase (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease"}
{"PMID":12504917,"re_id":13,"annotated sentence":"Rasagiline [<e1>N-propargyl-1R(+)-aminoindan<\\e1>  TVP1012] is a potent irreversible monoamine oxidase (<e2>MAO<\\e2>  inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-propargyl-1R(+)-aminoindan","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rasagiline [<e1>CHEMICAL<\\e1>  TVP1012] is a potent irreversible monoamine oxidase (<e2>GENE-N<\\e2>  inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease","sentence":"Rasagiline [N-propargyl-1R(+)-aminoindan  TVP1012] is a potent irreversible monoamine oxidase (MAO  inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease"}
{"PMID":12513997,"re_id":0,"annotated sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of <e2>gamma-glutamyl kinase<\\e2> and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of <e1>L-proline<\\e1> synthesis from L-glutamate and which together may form a complex in vivo","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-proline","object":"gamma-glutamyl kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of <e2>GENE-Y<\\e2> and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of <e1>CHEMICAL<\\e1> synthesis from L-glutamate and which together may form a complex in vivo","sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo"}
{"PMID":12513997,"re_id":1,"annotated sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and <e2>gamma-glutamyl phosphate reductase<\\e2>  both of which catalyze the first two steps of <e1>L-proline<\\e1> synthesis from L-glutamate and which together may form a complex in vivo","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-proline","object":"gamma-glutamyl phosphate reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and <e2>GENE-Y<\\e2>  both of which catalyze the first two steps of <e1>CHEMICAL<\\e1> synthesis from L-glutamate and which together may form a complex in vivo","sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase  both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo"}
{"PMID":12513997,"re_id":2,"annotated sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of <e2>gamma-glutamyl kinase<\\e2> and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from <e1>L-glutamate<\\e1> and which together may form a complex in vivo","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-glutamate","object":"gamma-glutamyl kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of <e2>GENE-Y<\\e2> and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from <e1>CHEMICAL<\\e1> and which together may form a complex in vivo","sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo"}
{"PMID":12513997,"re_id":3,"annotated sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and <e2>gamma-glutamyl phosphate reductase<\\e2>  both of which catalyze the first two steps of L-proline synthesis from <e1>L-glutamate<\\e1> and which together may form a complex in vivo","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-glutamate","object":"gamma-glutamyl phosphate reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and <e2>GENE-Y<\\e2>  both of which catalyze the first two steps of L-proline synthesis from <e1>CHEMICAL<\\e1> and which together may form a complex in vivo","sentence":"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and gamma-glutamyl phosphate reductase  both of which catalyze the first two steps of L-proline synthesis from L-glutamate and which together may form a complex in vivo"}
{"PMID":12513997,"re_id":4,"annotated sentence":"<e1>L-proline<\\e1> accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding <e2>gamma-glutamyl kinase<\\e2>  We previously isolated a mutant which showed a high tolerance to freezing that correlated with higher levels of intracellular L-proline derived from L-proline analogue-resistant mutants","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-proline","object":"gamma-glutamyl kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding <e2>GENE-Y<\\e2>  We previously isolated a mutant which showed a high tolerance to freezing that correlated with higher levels of intracellular CHEMICAL derived from CHEMICAL analogue-resistant mutants","sentence":"L-proline accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding gamma-glutamyl kinase  We previously isolated a mutant which showed a high tolerance to freezing that correlated with higher levels of intracellular L-proline derived from L-proline analogue-resistant mutants"}
{"PMID":12513997,"re_id":5,"annotated sentence":"When cultured in liquid minimal medium, yeast cells expressing the mutated <e2>gamma-glutamyl kinase<\\e2> were found to accumulate intracellular <e1>L-proline<\\e1> and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type PRO1 gene","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-proline","object":"gamma-glutamyl kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When cultured in liquid minimal medium, yeast cells expressing the mutated <e2>GENE-Y<\\e2> were found to accumulate intracellular <e1>CHEMICAL<\\e1> and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type PRO1 gene","sentence":"When cultured in liquid minimal medium, yeast cells expressing the mutated gamma-glutamyl kinase were found to accumulate intracellular L-proline and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type PRO1 gene"}
{"PMID":12513997,"re_id":6,"annotated sentence":"These results suggest that the altered <e2>gamma-glutamyl kinase<\\e2> results in stabilization of the complex or has an indirect effect on gamma-glutamyl phosphate reductase activity, which leads to an increase in <e1>L-proline<\\e1> production in Saccharomyces cerevisiae","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-proline","object":"gamma-glutamyl kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that the altered <e2>GENE-Y<\\e2> results in stabilization of the complex or has an indirect effect on gamma-glutamyl phosphate reductase activity, which leads to an increase in <e1>CHEMICAL<\\e1> production in Saccharomyces cerevisiae","sentence":"These results suggest that the altered gamma-glutamyl kinase results in stabilization of the complex or has an indirect effect on gamma-glutamyl phosphate reductase activity, which leads to an increase in L-proline production in Saccharomyces cerevisiae"}
{"PMID":12513997,"re_id":7,"annotated sentence":"These results suggest that the altered gamma-glutamyl kinase results in stabilization of the complex or has an indirect effect on <e2>gamma-glutamyl phosphate reductase<\\e2> activity, which leads to an increase in <e1>L-proline<\\e1> production in Saccharomyces cerevisiae","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-proline","object":"gamma-glutamyl phosphate reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that the altered gamma-glutamyl kinase results in stabilization of the complex or has an indirect effect on <e2>GENE-Y<\\e2> activity, which leads to an increase in <e1>CHEMICAL<\\e1> production in Saccharomyces cerevisiae","sentence":"These results suggest that the altered gamma-glutamyl kinase results in stabilization of the complex or has an indirect effect on gamma-glutamyl phosphate reductase activity, which leads to an increase in L-proline production in Saccharomyces cerevisiae"}
{"PMID":12517247,"re_id":0,"annotated sentence":"Within the class of <e2>AII<\\e2> blockers, <e1>eprosartan<\\e1> differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"eprosartan","object":"AII","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Within the class of <e2>GENE-Y<\\e2> blockers, <e1>CHEMICAL<\\e1> differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action","sentence":"Within the class of AII blockers, eprosartan differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action"}
{"PMID":12517247,"re_id":1,"annotated sentence":"In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the <e2>ACE<\\e2> inhibitor <e1>enalapril<\\e1>  and has significantly lower side effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"enalapril","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  and has significantly lower side effects","sentence":"In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the ACE inhibitor enalapril  and has significantly lower side effects"}
{"PMID":12560076,"re_id":0,"annotated sentence":"<e1>D-Serine<\\e1> was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the <e2>N-methyl-D-aspartate (NMDA)-type receptors<\\e2>  Racemization of serine is catalyzed by serine racemase, a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"D-Serine","object":"N-methyl-D-aspartate (NMDA)-type receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the <e2>GENE-N<\\e2>  Racemization of serine is catalyzed by serine racemase, a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver","sentence":"D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the N-methyl-D-aspartate (NMDA)-type receptors  Racemization of serine is catalyzed by serine racemase, a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver"}
{"PMID":12560076,"re_id":1,"annotated sentence":"<e2>Mouse brain serine racemase<\\e2> catalyzes specific elimination of <e1>L-serine<\\e1> to pyruvate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-serine","object":"Mouse brain serine racemase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> catalyzes specific elimination of <e1>CHEMICAL<\\e1> to pyruvate","sentence":"Mouse brain serine racemase catalyzes specific elimination of L-serine to pyruvate"}
{"PMID":12560076,"re_id":2,"annotated sentence":"<e2>Mouse brain serine racemase<\\e2> catalyzes specific elimination of L-serine to <e1>pyruvate<\\e1>  D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the N-methyl-D-aspartate (NMDA)-type receptors","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyruvate","object":"Mouse brain serine racemase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> catalyzes specific elimination of L-serine to <e1>CHEMICAL<\\e1>  D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the N-methyl-D-aspartate (NMDA)-type receptors","sentence":"Mouse brain serine racemase catalyzes specific elimination of L-serine to pyruvate  D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the N-methyl-D-aspartate (NMDA)-type receptors"}
{"PMID":12560076,"re_id":3,"annotated sentence":"Racemization of <e1>serine<\\e1> is catalyzed by <e2>serine racemase<\\e2>  a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"serine","object":"serine racemase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Racemization of <e1>CHEMICAL<\\e1> is catalyzed by <e2>CHEMICAL racemase<\\e2>  a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver","sentence":"Racemization of serine is catalyzed by serine racemase  a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver"}
{"PMID":12566304,"re_id":0,"annotated sentence":"EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with <e1>U0126<\\e1>  a selective <e2>MAP kinase kinase (MKK)1\/2<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U0126","object":"MAP kinase kinase (MKK)1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with <e1>CHEMICAL<\\e1>  a selective <e2>GENE-N<\\e2> inhibitor","sentence":"EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with U0126  a selective MAP kinase kinase (MKK)1\/2 inhibitor"}
{"PMID":12566304,"re_id":1,"annotated sentence":"<e2>EGF<\\e2> stimulated phosphorylation of ERK and Bad is blocked by pretreatment with <e1>U0126<\\e1>  a selective MAP kinase kinase (MKK)1\/2 inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U0126","object":"EGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> stimulated phosphorylation of ERK and Bad is blocked by pretreatment with <e1>CHEMICAL<\\e1>  a selective MAP kinase kinase (MKK)1\/2 inhibitor","sentence":"EGF stimulated phosphorylation of ERK and Bad is blocked by pretreatment with U0126  a selective MAP kinase kinase (MKK)1\/2 inhibitor"}
{"PMID":12566304,"re_id":2,"annotated sentence":"EGF-stimulated phosphorylation of <e2>ERK<\\e2> and Bad is blocked by pretreatment with <e1>U0126<\\e1>  a selective MAP kinase kinase (MKK)1\/2 inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U0126","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"EGF-stimulated phosphorylation of <e2>GENE-N<\\e2> and Bad is blocked by pretreatment with <e1>CHEMICAL<\\e1>  a selective MAP kinase kinase (MKK)1\/2 inhibitor","sentence":"EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with U0126  a selective MAP kinase kinase (MKK)1\/2 inhibitor"}
{"PMID":12566304,"re_id":3,"annotated sentence":"EGF-stimulated phosphorylation of ERK and <e2>Bad<\\e2> is blocked by pretreatment with <e1>U0126<\\e1>  a selective MAP kinase kinase (MKK)1\/2 inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U0126","object":"Bad","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"EGF-stimulated phosphorylation of ERK and <e2>GENE-Y<\\e2> is blocked by pretreatment with <e1>CHEMICAL<\\e1>  a selective MAP kinase kinase (MKK)1\/2 inhibitor","sentence":"EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with U0126  a selective MAP kinase kinase (MKK)1\/2 inhibitor"}
{"PMID":12566304,"re_id":4,"annotated sentence":"Similarly, pretreatment with <e1>sulindac sulfide<\\e1> blocks the ability of <e2>EGF<\\e2> to induce ERK1\/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1\/2 protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulindac sulfide","object":"EGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, pretreatment with <e1>CHEMICAL<\\e1> blocks the ability of <e2>GENE-Y<\\e2> to induce ERK1\/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1\/2 protein levels","sentence":"Similarly, pretreatment with sulindac sulfide blocks the ability of EGF to induce ERK1\/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1\/2 protein levels"}
{"PMID":12566304,"re_id":5,"annotated sentence":"Similarly, pretreatment with <e1>sulindac sulfide<\\e1> blocks the ability of EGF to induce ERK1\/2 and <e2>Bad<\\e2> phosphorylation, but also down-regulates total Bad but not ERK1\/2 protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulindac sulfide","object":"Bad","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, pretreatment with <e1>CHEMICAL<\\e1> blocks the ability of EGF to induce ERK1\/2 and <e2>GENE-Y<\\e2> phosphorylation, but also down-regulates total GENE-Y but not ERK1\/2 protein levels","sentence":"Similarly, pretreatment with sulindac sulfide blocks the ability of EGF to induce ERK1\/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1\/2 protein levels"}
{"PMID":12566304,"re_id":6,"annotated sentence":"Similarly, pretreatment with <e1>sulindac sulfide<\\e1> blocks the ability of EGF to induce ERK1\/2 and Bad phosphorylation, but also down-regulates total <e2>Bad<\\e2> but not ERK1\/2 protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulindac sulfide","object":"Bad","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, pretreatment with <e1>CHEMICAL<\\e1> blocks the ability of EGF to induce ERK1\/2 and GENE-Y phosphorylation, but also down-regulates total <e2>GENE-Y<\\e2> but not ERK1\/2 protein levels","sentence":"Similarly, pretreatment with sulindac sulfide blocks the ability of EGF to induce ERK1\/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1\/2 protein levels"}
{"PMID":12566304,"re_id":7,"annotated sentence":"The ability of <e1>sulindac<\\e1> to block <e2>ERK1\/2<\\e2> signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulindac","object":"ERK1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The ability of <e1>CHEMICAL<\\e1> to block <e2>GENE-N<\\e2> signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells.","sentence":"The ability of sulindac to block ERK1\/2 signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells."}
{"PMID":12566304,"re_id":8,"annotated sentence":"The ability of <e1>sulindac<\\e1> to block ERK1\/2 signaling by the <e2>EGF receptor<\\e2> may account for at least part of its potent growth-inhibitory effects against cancer cells.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulindac","object":"EGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ability of <e1>CHEMICAL<\\e1> to block ERK1\/2 signaling by the <e2>GENE-Y<\\e2> may account for at least part of its potent growth-inhibitory effects against cancer cells.","sentence":"The ability of sulindac to block ERK1\/2 signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells."}
{"PMID":12566304,"re_id":9,"annotated sentence":"<e1>Sulindac<\\e1> and selective <e2>cyclooxygenase (COX)-2<\\e2> inhibitors cause regression of colonic polyps in familial polyposis patients","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sulindac","object":"cyclooxygenase (COX)-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and selective <e2>GENE-Y<\\e2> inhibitors cause regression of colonic polyps in familial polyposis patients","sentence":"Sulindac and selective cyclooxygenase (COX)-2 inhibitors cause regression of colonic polyps in familial polyposis patients"}
{"PMID":12566304,"re_id":10,"annotated sentence":"<e1>Sulindac<\\e1> metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit <e2>ERK1\/2<\\e2> phosphorylation in human colon cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sulindac","object":"ERK1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit <e2>GENE-N<\\e2> phosphorylation in human colon cancer cells","sentence":"Sulindac metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit ERK1\/2 phosphorylation in human colon cancer cells"}
{"PMID":12566304,"re_id":11,"annotated sentence":"<e1>Sulindac sulfide<\\e1> inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1\/2 and <e2>Bad<\\e2> in human colon cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sulindac sulfide","object":"Bad","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1\/2 and <e2>GENE-Y<\\e2> in human colon cancer cells","sentence":"Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1\/2 and Bad in human colon cancer cells"}
{"PMID":12566304,"re_id":12,"annotated sentence":"<e1>Sulindac sulfide<\\e1> inhibits <e2>epidermal growth factor<\\e2> induced phosphorylation of extracellular-regulated kinase 1\/2 and Bad in human colon cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sulindac sulfide","object":"epidermal growth factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> induced phosphorylation of extracellular-regulated kinase 1\/2 and Bad in human colon cancer cells","sentence":"Sulindac sulfide inhibits epidermal growth factor induced phosphorylation of extracellular-regulated kinase 1\/2 and Bad in human colon cancer cells"}
{"PMID":12582227,"re_id":0,"annotated sentence":"db\/db mice treated with <e1>DRF 2655<\\e1> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes <e2>carnitine palmitoyltransferase<\\e2> and carnitine acetyltransferase, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DRF 2655","object":"carnitine palmitoyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"db\/db mice treated with <e1>CHEMICAL<\\e1> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes <e2>GENE-N<\\e2> and carnitine acetyltransferase, respectively","sentence":"db\/db mice treated with DRF 2655 showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively"}
{"PMID":12582227,"re_id":1,"annotated sentence":"db\/db mice treated with <e1>DRF 2655<\\e1> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and <e2>carnitine acetyltransferase<\\e2>  respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DRF 2655","object":"carnitine acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"db\/db mice treated with <e1>CHEMICAL<\\e1> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and <e2>GENE-Y<\\e2>  respectively","sentence":"db\/db mice treated with DRF 2655 showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase  respectively"}
{"PMID":12582227,"re_id":2,"annotated sentence":"db\/db mice treated with <e1>DRF 2655<\\e1> showed 5- and 3.6-fold inhibition in <e2>phosphoenolpyruvate carboxykinase<\\e2> and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DRF 2655","object":"phosphoenolpyruvate carboxykinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"db\/db mice treated with <e1>CHEMICAL<\\e1> showed 5- and 3.6-fold inhibition in <e2>GENE-Y<\\e2> and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively","sentence":"db\/db mice treated with DRF 2655 showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively"}
{"PMID":12582227,"re_id":3,"annotated sentence":"db\/db mice treated with <e1>DRF 2655<\\e1> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and <e2>glucose 6-phosphatase<\\e2> activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DRF 2655","object":"glucose 6-phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"db\/db mice treated with <e1>CHEMICAL<\\e1> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and <e2>GENE-Y<\\e2> activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively","sentence":"db\/db mice treated with DRF 2655 showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively"}
{"PMID":12582227,"re_id":4,"annotated sentence":"OBJECTIVE: Preclinical evaluation of <e1>DRF 2655<\\e1>  a peroxisome proliferator-activated receptor alpha (PPARalpha) and <e2>PPARgamma<\\e2> agonist, as a body-weight lowering, hypolipidemic and euglycemic agent","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DRF 2655","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: Preclinical evaluation of <e1>CHEMICAL<\\e1>  a peroxisome proliferator-activated receptor alpha (PPARalpha) and <e2>GENE-Y<\\e2> agonist, as a body-weight lowering, hypolipidemic and euglycemic agent","sentence":"OBJECTIVE: Preclinical evaluation of DRF 2655  a peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent"}
{"PMID":12582227,"re_id":5,"annotated sentence":"OBJECTIVE: Preclinical evaluation of <e1>DRF 2655<\\e1>  a <e2>peroxisome proliferator-activated receptor alpha<\\e2> (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DRF 2655","object":"peroxisome proliferator-activated receptor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: Preclinical evaluation of <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent","sentence":"OBJECTIVE: Preclinical evaluation of DRF 2655  a peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent"}
{"PMID":12582227,"re_id":6,"annotated sentence":"OBJECTIVE: Preclinical evaluation of <e1>DRF 2655<\\e1>  a peroxisome proliferator-activated receptor alpha (<e2>PPARalpha<\\e2>  and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DRF 2655","object":"PPARalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: Preclinical evaluation of <e1>CHEMICAL<\\e1>  a peroxisome proliferator-activated receptor alpha (<e2>GENE-Y<\\e2>  and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent","sentence":"OBJECTIVE: Preclinical evaluation of DRF 2655  a peroxisome proliferator-activated receptor alpha (PPARalpha  and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent"}
{"PMID":12582227,"re_id":7,"annotated sentence":"RESULTS: <e1>DRF 2655<\\e1> showed concentration-dependent transactivation of <e2>PPARalpha<\\e2> and PPARgamma","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DRF 2655","object":"PPARalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> showed concentration-dependent transactivation of <e2>GENE-Y<\\e2> and PPARgamma","sentence":"RESULTS: DRF 2655 showed concentration-dependent transactivation of PPARalpha and PPARgamma"}
{"PMID":12582227,"re_id":8,"annotated sentence":"RESULTS: <e1>DRF 2655<\\e1> showed concentration-dependent transactivation of PPARalpha and <e2>PPARgamma<\\e2>  In the 3T3L1 cell-differentiation study, DRF 2655 and rosiglitazone showed 369% and 471% increases, respectively, in triglyceride accumulation","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DRF 2655","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> showed concentration-dependent transactivation of PPARalpha and <e2>GENE-Y<\\e2>  In the 3T3L1 cell-differentiation study, CHEMICAL and rosiglitazone showed 369% and 471% increases, respectively, in triglyceride accumulation","sentence":"RESULTS: DRF 2655 showed concentration-dependent transactivation of PPARalpha and PPARgamma  In the 3T3L1 cell-differentiation study, DRF 2655 and rosiglitazone showed 369% and 471% increases, respectively, in triglyceride accumulation"}
{"PMID":12606421,"re_id":0,"annotated sentence":"<e1>Cetrorelix<\\e1> completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the <e2>GnRH-R<\\e2> mRNA, during both the infantile and the juvenile periods","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cetrorelix","object":"GnRH-R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the <e2>GENE-Y<\\e2> mRNA, during both the infantile and the juvenile periods","sentence":"Cetrorelix completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the GnRH-R mRNA, during both the infantile and the juvenile periods"}
{"PMID":12606421,"re_id":1,"annotated sentence":"<e1>Cetrorelix<\\e1> also abolished the developmental rise of the <e2>gonadotropin beta<\\e2> subunit mRNAs during the two periods of the study","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cetrorelix","object":"gonadotropin beta","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also abolished the developmental rise of the <e2>GENE-N<\\e2> subunit mRNAs during the two periods of the study","sentence":"Cetrorelix also abolished the developmental rise of the gonadotropin beta subunit mRNAs during the two periods of the study"}
{"PMID":12614192,"re_id":0,"annotated sentence":"With the use of <e1>sildenafil<\\e1>  it has been clearly, clinically demonstrated that the selective inhibition of <e2>PDE5<\\e2> is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sildenafil","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With the use of <e1>CHEMICAL<\\e1>  it has been clearly, clinically demonstrated that the selective inhibition of <e2>GENE-Y<\\e2> is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.","sentence":"With the use of sildenafil  it has been clearly, clinically demonstrated that the selective inhibition of PDE5 is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities."}
{"PMID":12614192,"re_id":1,"annotated sentence":"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of <e1>sildenafil<\\e1> (Viagra, Pfizer) - the first approved selective <e2>PDE<\\e2> inhibitor for the treatment of ED","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sildenafil","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of <e1>CHEMICAL<\\e1> (Viagra, Pfizer) - the first approved selective <e2>GENE-N<\\e2> inhibitor for the treatment of ED","sentence":"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (Viagra, Pfizer) - the first approved selective PDE inhibitor for the treatment of ED"}
{"PMID":12614192,"re_id":2,"annotated sentence":"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (<e1>Viagra<\\e1>  Pfizer) - the first approved selective <e2>PDE<\\e2> inhibitor for the treatment of ED","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Viagra","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (<e1>CHEMICAL<\\e1>  Pfizer) - the first approved selective <e2>GENE-N<\\e2> inhibitor for the treatment of ED","sentence":"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (Viagra  Pfizer) - the first approved selective PDE inhibitor for the treatment of ED"}
{"PMID":12614192,"re_id":3,"annotated sentence":"<e1>Sildenafil<\\e1> is inhibitory of <e2>PDE5<\\e2> at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sildenafil","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is inhibitory of <e2>GENE-Y<\\e2> at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods","sentence":"Sildenafil is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods"}
{"PMID":12614192,"re_id":4,"annotated sentence":"<e1>Sildenafil<\\e1> is inhibitory of PDE5 at a rate tenfold higher than for the next <e2>PDE<\\e2> (PDE6), which produces visual changes through the retinal rods","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sildenafil","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is inhibitory of GENE-N5 at a rate tenfold higher than for the next <e2>GENE-N<\\e2> (GENE-N6), which produces visual changes through the retinal rods","sentence":"Sildenafil is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods"}
{"PMID":12614192,"re_id":5,"annotated sentence":"<e1>Sildenafil<\\e1> is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (<e2>PDE6<\\e2> , which produces visual changes through the retinal rods","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sildenafil","object":"PDE6","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (<e2>GENE-N<\\e2> , which produces visual changes through the retinal rods","sentence":"Sildenafil is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (PDE6 , which produces visual changes through the retinal rods"}
{"PMID":12614192,"re_id":6,"annotated sentence":"The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of <e2>PDE5<\\e2> that breaks down <e1>cGMP<\\e1>  the key pathway for the production of erectile function in humans","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cGMP","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of <e2>GENE-Y<\\e2> that breaks down <e1>CHEMICAL<\\e1>  the key pathway for the production of erectile function in humans","sentence":"The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of PDE5 that breaks down cGMP  the key pathway for the production of erectile function in humans"}
{"PMID":12650833,"re_id":0,"annotated sentence":"administration of very low doses of <e1>okadaic acid<\\e1> (0.001-1 pg\/mouse) and cantharidin (0.001-1 ng\/mouse), which inhibit <e2>PP2A<\\e2>  produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"okadaic acid","object":"PP2A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"administration of very low doses of <e1>CHEMICAL<\\e1> (0.001-1 pg\/mouse) and cantharidin (0.001-1 ng\/mouse), which inhibit <e2>GENE-N<\\e2>  produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.)","sentence":"administration of very low doses of okadaic acid (0.001-1 pg\/mouse) and cantharidin (0.001-1 ng\/mouse), which inhibit PP2A  produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.)"}
{"PMID":12650833,"re_id":1,"annotated sentence":"administration of very low doses of okadaic acid (0.001-1 pg\/mouse) and <e1>cantharidin<\\e1> (0.001-1 ng\/mouse), which inhibit <e2>PP2A<\\e2>  produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cantharidin","object":"PP2A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"administration of very low doses of okadaic acid (0.001-1 pg\/mouse) and <e1>CHEMICAL<\\e1> (0.001-1 ng\/mouse), which inhibit <e2>GENE-N<\\e2>  produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.)","sentence":"administration of very low doses of okadaic acid (0.001-1 pg\/mouse) and cantharidin (0.001-1 ng\/mouse), which inhibit PP2A  produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.)"}
{"PMID":12650833,"re_id":2,"annotated sentence":"On the other hand, high doses of <e1>okadaic acid<\\e1> (10 ng\/mouse, i.c.v.) and cantharidin (1 microg\/mouse, i.c.v.), which also block <e2>PP1<\\e2>  and calyculin-A (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"okadaic acid","object":"PP1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"On the other hand, high doses of <e1>CHEMICAL<\\e1> (10 ng\/mouse, i.c.v.) and cantharidin (1 microg\/mouse, i.c.v.), which also block <e2>GENE-N<\\e2>  and calyculin-A (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both GENE-N and PP2A, did not modify the morphine-induced antinociception","sentence":"On the other hand, high doses of okadaic acid (10 ng\/mouse, i.c.v.) and cantharidin (1 microg\/mouse, i.c.v.), which also block PP1  and calyculin-A (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception"}
{"PMID":12650833,"re_id":3,"annotated sentence":"On the other hand, high doses of okadaic acid (10 ng\/mouse, i.c.v.) and <e1>cantharidin<\\e1> (1 microg\/mouse, i.c.v.), which also block <e2>PP1<\\e2>  and calyculin-A (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cantharidin","object":"PP1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"On the other hand, high doses of okadaic acid (10 ng\/mouse, i.c.v.) and <e1>CHEMICAL<\\e1> (1 microg\/mouse, i.c.v.), which also block <e2>GENE-N<\\e2>  and calyculin-A (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both GENE-N and PP2A, did not modify the morphine-induced antinociception","sentence":"On the other hand, high doses of okadaic acid (10 ng\/mouse, i.c.v.) and cantharidin (1 microg\/mouse, i.c.v.), which also block PP1  and calyculin-A (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception"}
{"PMID":12650833,"re_id":4,"annotated sentence":"On the other hand, high doses of okadaic acid (10 ng\/mouse, i.c.v.) and cantharidin (1 microg\/mouse, i.c.v.), which also block PP1, and <e1>calyculin-A<\\e1> (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both <e2>PP1<\\e2> and PP2A, did not modify the morphine-induced antinociception","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"calyculin-A","object":"PP1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"On the other hand, high doses of okadaic acid (10 ng\/mouse, i.c.v.) and cantharidin (1 microg\/mouse, i.c.v.), which also block GENE-N, and <e1>CHEMICAL<\\e1> (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both <e2>GENE-N<\\e2> and PP2A, did not modify the morphine-induced antinociception","sentence":"On the other hand, high doses of okadaic acid (10 ng\/mouse, i.c.v.) and cantharidin (1 microg\/mouse, i.c.v.), which also block PP1, and calyculin-A (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception"}
{"PMID":12650833,"re_id":5,"annotated sentence":"On the other hand, high doses of okadaic acid (10 ng\/mouse, i.c.v.) and cantharidin (1 microg\/mouse, i.c.v.), which also block PP1, and <e1>calyculin-A<\\e1> (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both PP1 and <e2>PP2A<\\e2>  did not modify the morphine-induced antinociception","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"calyculin-A","object":"PP2A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"On the other hand, high doses of okadaic acid (10 ng\/mouse, i.c.v.) and cantharidin (1 microg\/mouse, i.c.v.), which also block PP1, and <e1>CHEMICAL<\\e1> (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both PP1 and <e2>GENE-N<\\e2>  did not modify the morphine-induced antinociception","sentence":"On the other hand, high doses of okadaic acid (10 ng\/mouse, i.c.v.) and cantharidin (1 microg\/mouse, i.c.v.), which also block PP1, and calyculin-A (0.1 fg\/mouse-1 ng\/mouse, i.c.v.), which inhibits equally both PP1 and PP2A  did not modify the morphine-induced antinociception"}
{"PMID":12668769,"re_id":0,"annotated sentence":"The ratio between the GDC\/<e2>SHMT<\\e2> and C1-THF synthase\/SHMT pathways of <e1>Ser<\\e1> synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Ser","object":"SHMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The ratio between the GDC\/<e2>GENE-N<\\e2> and C1-THF synthase\/GENE-N pathways of <e1>CHEMICAL<\\e1> synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1","sentence":"The ratio between the GDC\/SHMT and C1-THF synthase\/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1"}
{"PMID":12668769,"re_id":1,"annotated sentence":"The ratio between the GDC\/SHMT and C1-THF synthase\/<e2>SHMT<\\e2> pathways of <e1>Ser<\\e1> synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Ser","object":"SHMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The ratio between the GDC\/GENE-N and C1-THF synthase\/<e2>GENE-N<\\e2> pathways of <e1>CHEMICAL<\\e1> synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1","sentence":"The ratio between the GDC\/SHMT and C1-THF synthase\/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1"}
{"PMID":12668769,"re_id":2,"annotated sentence":"The ratio between the <e2>GDC<\\e2> SHMT and C1-THF synthase\/SHMT pathways of Ser synthesis from <e1>[alpha-(13)C]Gly<\\e1> and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[alpha-(13)C]Gly","object":"GDC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The ratio between the <e2>GENE-N<\\e2> SHMT and C1-THF synthase\/SHMT pathways of Ser synthesis from <e1>CHEMICAL<\\e1> and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1","sentence":"The ratio between the GDC SHMT and C1-THF synthase\/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1"}
{"PMID":12668769,"re_id":3,"annotated sentence":"The ratio between the GDC\/SHMT and <e2>C1-THF synthase<\\e2> SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and <e1>[(13)C]formate<\\e1>  respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[(13)C]formate","object":"C1-THF synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ratio between the GDC\/SHMT and <e2>GENE-Y<\\e2> SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and <e1>CHEMICAL<\\e1>  respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1","sentence":"The ratio between the GDC\/SHMT and C1-THF synthase SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate  respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1"}
{"PMID":12668769,"re_id":4,"annotated sentence":"On the other hand, the accumulation of <e1>Ser<\\e1> through the C1-THF synthase\/<e2>SHMT<\\e2> pathway in glyD plants was 2.5-fold greater than that in WT plants","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Ser","object":"SHMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"On the other hand, the accumulation of <e1>CHEMICAL<\\e1> through the C1-THF synthase\/<e2>GENE-N<\\e2> pathway in glyD plants was 2.5-fold greater than that in WT plants","sentence":"On the other hand, the accumulation of Ser through the C1-THF synthase\/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants"}
{"PMID":12668769,"re_id":5,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e2>glycine decarboxylase complex<\\e2> (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with <e1>glycine<\\e1> (Gly) as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"glycine decarboxylase complex","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e2>CHEMICAL decarboxylase complex<\\e2> (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with <e1>CHEMICAL<\\e1> (Gly) as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":6,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (<e2>GDC<\\e2>  EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with <e1>glycine<\\e1> (Gly) as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"GDC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the CHEMICAL decarboxylase complex (<e2>GENE-N<\\e2>  EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with <e1>CHEMICAL<\\e1> (Gly) as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC  EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":7,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, <e2>EC 2.1.1.10<\\e2>  and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with <e1>glycine<\\e1> (Gly) as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"EC 2.1.1.10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the CHEMICAL decarboxylase complex (GDC, <e2>GENE-Y<\\e2>  and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with <e1>CHEMICAL<\\e1> (Gly) as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10  and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":8,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and <e2>serine hydroxymethyltransferase<\\e2> (SHMT, EC 2.1.2.1) with <e1>glycine<\\e1> (Gly) as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"serine hydroxymethyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the CHEMICAL decarboxylase complex (GDC, EC 2.1.1.10) and <e2>GENE-N<\\e2> (SHMT, EC 2.1.2.1) with <e1>CHEMICAL<\\e1> (Gly) as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":9,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (<e2>SHMT<\\e2>  EC 2.1.2.1) with <e1>glycine<\\e1> (Gly) as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"SHMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the CHEMICAL decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (<e2>GENE-N<\\e2>  EC 2.1.2.1) with <e1>CHEMICAL<\\e1> (Gly) as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT  EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":10,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, <e2>EC 2.1.2.1<\\e2>  with <e1>glycine<\\e1> (Gly) as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glycine","object":"EC 2.1.2.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the CHEMICAL decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, <e2>GENE-Y<\\e2>  with <e1>CHEMICAL<\\e1> (Gly) as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1  with glycine (Gly) as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":11,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e2>glycine decarboxylase complex<\\e2> (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<e1>Gly<\\e1>  as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Gly","object":"glycine decarboxylase complex","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e2>GENE-N<\\e2> (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<e1>CHEMICAL<\\e1>  as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly  as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":12,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (<e2>GDC<\\e2>  EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<e1>Gly<\\e1>  as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Gly","object":"GDC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (<e2>GENE-N<\\e2>  EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<e1>CHEMICAL<\\e1>  as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC  EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly  as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":13,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, <e2>EC 2.1.1.10<\\e2>  and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<e1>Gly<\\e1>  as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Gly","object":"EC 2.1.1.10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, <e2>GENE-Y<\\e2>  and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<e1>CHEMICAL<\\e1>  as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10  and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly  as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":14,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and <e2>serine hydroxymethyltransferase<\\e2> (SHMT, EC 2.1.2.1) with glycine (<e1>Gly<\\e1>  as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Gly","object":"serine hydroxymethyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and <e2>GENE-N<\\e2> (SHMT, EC 2.1.2.1) with glycine (<e1>CHEMICAL<\\e1>  as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly  as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":15,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (<e2>SHMT<\\e2>  EC 2.1.2.1) with glycine (<e1>Gly<\\e1>  as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Gly","object":"SHMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (<e2>GENE-N<\\e2>  EC 2.1.2.1) with glycine (<e1>CHEMICAL<\\e1>  as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT  EC 2.1.2.1) with glycine (Gly  as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":16,"annotated sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, <e2>EC 2.1.2.1<\\e2>  with glycine (<e1>Gly<\\e1>  as one-carbon (1-C) source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Gly","object":"EC 2.1.2.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, <e2>GENE-Y<\\e2>  with glycine (<e1>CHEMICAL<\\e1>  as one-carbon (1-C) source","sentence":"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1  with glycine (Gly  as one-carbon (1-C) source"}
{"PMID":12668769,"re_id":17,"annotated sentence":"An alternative THF-dependent pathway involves the <e2>C1-THF synthase<\\e2> SHMT activities with <e1>formate<\\e1> as 1-C source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"formate","object":"C1-THF synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An alternative THF-dependent pathway involves the <e2>GENE-Y<\\e2> SHMT activities with <e1>CHEMICAL<\\e1> as 1-C source","sentence":"An alternative THF-dependent pathway involves the C1-THF synthase SHMT activities with formate as 1-C source"}
{"PMID":12668769,"re_id":18,"annotated sentence":"An alternative THF-dependent pathway involves the C1-THF synthase\/<e2>SHMT<\\e2> activities with <e1>formate<\\e1> as 1-C source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"formate","object":"SHMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"An alternative THF-dependent pathway involves the C1-THF synthase\/<e2>GENE-N<\\e2> activities with <e1>CHEMICAL<\\e1> as 1-C source","sentence":"An alternative THF-dependent pathway involves the C1-THF synthase\/SHMT activities with formate as 1-C source"}
{"PMID":12668769,"re_id":19,"annotated sentence":"Firstly, transgenic plants overexpressing <e2>formate dehydrogenase<\\e2> (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in <e1>formate<\\e1> metabolism","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"formate","object":"formate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, transgenic plants overexpressing <e2>CHEMICAL dehydrogenase<\\e2> (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in <e1>CHEMICAL<\\e1> metabolism","sentence":"Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism"}
{"PMID":12668769,"re_id":20,"annotated sentence":"Firstly, transgenic plants overexpressing formate dehydrogenase (<e2>FDH<\\e2>  EC 1.2.1.2) were used to continue our previous studies on the function of FDH in <e1>formate<\\e1> metabolism","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"formate","object":"FDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, transgenic plants overexpressing CHEMICAL dehydrogenase (<e2>GENE-Y<\\e2>  EC 1.2.1.2) were used to continue our previous studies on the function of GENE-Y in <e1>CHEMICAL<\\e1> metabolism","sentence":"Firstly, transgenic plants overexpressing formate dehydrogenase (FDH  EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism"}
{"PMID":12668769,"re_id":21,"annotated sentence":"Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, <e2>EC 1.2.1.2<\\e2>  were used to continue our previous studies on the function of FDH in <e1>formate<\\e1> metabolism","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"formate","object":"EC 1.2.1.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, transgenic plants overexpressing CHEMICAL dehydrogenase (FDH, <e2>GENE-Y<\\e2>  were used to continue our previous studies on the function of FDH in <e1>CHEMICAL<\\e1> metabolism","sentence":"Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, EC 1.2.1.2  were used to continue our previous studies on the function of FDH in formate metabolism"}
{"PMID":12668769,"re_id":22,"annotated sentence":"Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of <e2>FDH<\\e2> in <e1>formate<\\e1> metabolism","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"formate","object":"FDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, transgenic plants overexpressing CHEMICAL dehydrogenase (GENE-Y, EC 1.2.1.2) were used to continue our previous studies on the function of <e2>GENE-Y<\\e2> in <e1>CHEMICAL<\\e1> metabolism","sentence":"Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism"}
{"PMID":12668769,"re_id":23,"annotated sentence":"We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of <e1>formate<\\e1> to CO(2) by the <e2>FDH<\\e2> reaction is the primary and preferred fate of the organic acid in Arabidopsis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"formate","object":"FDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We concluded that GENE-Y has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of <e1>CHEMICAL<\\e1> to CO(2) by the <e2>GENE-Y<\\e2> reaction is the primary and preferred fate of the organic acid in Arabidopsis","sentence":"We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to CO(2) by the FDH reaction is the primary and preferred fate of the organic acid in Arabidopsis"}
{"PMID":12668769,"re_id":24,"annotated sentence":"We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to <e1>CO(2)<\\e1> by the <e2>FDH<\\e2> reaction is the primary and preferred fate of the organic acid in Arabidopsis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"CO(2)","object":"FDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We concluded that GENE-Y has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to <e1>CHEMICAL<\\e1> by the <e2>GENE-Y<\\e2> reaction is the primary and preferred fate of the organic acid in Arabidopsis","sentence":"We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to CO(2) by the FDH reaction is the primary and preferred fate of the organic acid in Arabidopsis"}
{"PMID":12671891,"re_id":0,"annotated sentence":"The beta subunit has been cloned and shown to lower the K(m) of <e2>methionine adenosyltransferase II alpha2<\\e2> (the MAT2A product) for methionine and to render the enzyme more susceptible to <e1>S-adenosylmethionine<\\e1> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"S-adenosylmethionine","object":"methionine adenosyltransferase II alpha2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The beta subunit has been cloned and shown to lower the K(m) of <e2>GENE-Y<\\e2> (the MAT2A product) for methionine and to render the enzyme more susceptible to <e1>CHEMICAL<\\e1> inhibition","sentence":"The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the MAT2A product) for methionine and to render the enzyme more susceptible to S-adenosylmethionine inhibition"}
{"PMID":12671891,"re_id":1,"annotated sentence":"The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the <e2>MAT2A<\\e2> product) for methionine and to render the enzyme more susceptible to <e1>S-adenosylmethionine<\\e1> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"S-adenosylmethionine","object":"MAT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the <e2>GENE-Y<\\e2> product) for methionine and to render the enzyme more susceptible to <e1>CHEMICAL<\\e1> inhibition","sentence":"The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the MAT2A product) for methionine and to render the enzyme more susceptible to S-adenosylmethionine inhibition"}
{"PMID":12671891,"re_id":2,"annotated sentence":"BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes <e1>S-adenosylmethionine<\\e1>  <e2>MAT1A<\\e2>  is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"S-adenosylmethionine","object":"MAT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND & AIMS: Of the 2 genes (GENE-Y, MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes <e1>CHEMICAL<\\e1>  <e2>GENE-Y<\\e2>  is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues","sentence":"BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes S-adenosylmethionine  MAT1A  is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues"}
{"PMID":12671891,"re_id":3,"annotated sentence":"BACKGROUND & AIMS: Of the 2 genes (<e2>MAT1A<\\e2>  MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes <e1>S-adenosylmethionine<\\e1>  MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"S-adenosylmethionine","object":"MAT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND & AIMS: Of the 2 genes (<e2>GENE-Y<\\e2>  MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes <e1>CHEMICAL<\\e1>  GENE-Y, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues","sentence":"BACKGROUND & AIMS: Of the 2 genes (MAT1A  MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes S-adenosylmethionine  MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues"}
{"PMID":12671891,"re_id":4,"annotated sentence":"BACKGROUND & AIMS: Of the 2 genes (MAT1A, <e2>MAT2A<\\e2>  encoding methionine adenosyltransferase, the enzyme that synthesizes <e1>S-adenosylmethionine<\\e1>  MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"S-adenosylmethionine","object":"MAT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND & AIMS: Of the 2 genes (MAT1A, <e2>GENE-Y<\\e2>  encoding methionine adenosyltransferase, the enzyme that synthesizes <e1>CHEMICAL<\\e1>  MAT1A, is expressed in liver, whereas GENE-Y is expressed in extrahepatic tissues","sentence":"BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A  encoding methionine adenosyltransferase, the enzyme that synthesizes S-adenosylmethionine  MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues"}
{"PMID":12671891,"re_id":5,"annotated sentence":"BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding <e2>methionine adenosyltransferase<\\e2>  the enzyme that synthesizes <e1>S-adenosylmethionine<\\e1>  MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"S-adenosylmethionine","object":"methionine adenosyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding <e2>GENE-N<\\e2>  the enzyme that synthesizes <e1>CHEMICAL<\\e1>  MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues","sentence":"BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding methionine adenosyltransferase  the enzyme that synthesizes S-adenosylmethionine  MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues"}
{"PMID":12671891,"re_id":6,"annotated sentence":"The beta subunit has been cloned and shown to lower the K(m) of <e2>methionine adenosyltransferase II alpha2<\\e2> (the MAT2A product) for <e1>methionine<\\e1> and to render the enzyme more susceptible to S-adenosylmethionine inhibition","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methionine","object":"methionine adenosyltransferase II alpha2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The beta subunit has been cloned and shown to lower the K(m) of <e2>CHEMICAL adenosyltransferase II alpha2<\\e2> (the MAT2A product) for <e1>CHEMICAL<\\e1> and to render the enzyme more susceptible to S-adenosylCHEMICAL inhibition","sentence":"The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the MAT2A product) for methionine and to render the enzyme more susceptible to S-adenosylmethionine inhibition"}
{"PMID":12671891,"re_id":7,"annotated sentence":"The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the <e2>MAT2A<\\e2> product) for <e1>methionine<\\e1> and to render the enzyme more susceptible to S-adenosylmethionine inhibition","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methionine","object":"MAT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The beta subunit has been cloned and shown to lower the K(m) of CHEMICAL adenosyltransferase II alpha2 (the <e2>GENE-Y<\\e2> product) for <e1>CHEMICAL<\\e1> and to render the enzyme more susceptible to S-adenosylCHEMICAL inhibition","sentence":"The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the MAT2A product) for methionine and to render the enzyme more susceptible to S-adenosylmethionine inhibition"}
{"PMID":12699699,"re_id":0,"annotated sentence":"The protein exhibited modest <e1>H(2)O(2)<\\e1> dependent <e2>peroxidase<\\e2> activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"H(2)O(2)","object":"peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The protein exhibited modest <e1>CHEMICAL<\\e1> dependent <e2>GENE-N<\\e2> activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)","sentence":"The protein exhibited modest H(2)O(2) dependent peroxidase activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)"}
{"PMID":12699699,"re_id":1,"annotated sentence":"The protein exhibited modest H(2)O(2)-dependent <e2>peroxidase<\\e2> activities with <e1>guaiacol<\\e1>  potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"guaiacol","object":"peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The protein exhibited modest H(2)O(2)-dependent <e2>GENE-N<\\e2> activities with <e1>CHEMICAL<\\e1>  potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)","sentence":"The protein exhibited modest H(2)O(2)-dependent peroxidase activities with guaiacol  potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)"}
{"PMID":12699699,"re_id":2,"annotated sentence":"The protein exhibited modest H(2)O(2)-dependent <e2>peroxidase<\\e2> activities with guaiacol, <e1>potassium iodide<\\e1>  and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"potassium iodide","object":"peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The protein exhibited modest H(2)O(2)-dependent <e2>GENE-N<\\e2> activities with guaiacol, <e1>CHEMICAL<\\e1>  and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)","sentence":"The protein exhibited modest H(2)O(2)-dependent peroxidase activities with guaiacol, potassium iodide  and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)"}
{"PMID":12699699,"re_id":3,"annotated sentence":"The protein exhibited modest H(2)O(2)-dependent <e2>peroxidase<\\e2> activities with guaiacol, potassium iodide, and <e1>2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid<\\e1> (ABTS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid","object":"peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The protein exhibited modest H(2)O(2)-dependent <e2>GENE-N<\\e2> activities with guaiacol, potassium iodide, and <e1>CHEMICAL<\\e1> (ABTS)","sentence":"The protein exhibited modest H(2)O(2)-dependent peroxidase activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)"}
{"PMID":12699699,"re_id":4,"annotated sentence":"The protein exhibited modest H(2)O(2)-dependent <e2>peroxidase<\\e2> activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (<e1>ABTS<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ABTS","object":"peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The protein exhibited modest H(2)O(2)-dependent <e2>GENE-N<\\e2> activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (<e1>CHEMICAL<\\e1> ","sentence":"The protein exhibited modest H(2)O(2)-dependent peroxidase activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS "}
{"PMID":12724156,"re_id":0,"annotated sentence":"However, <e1>topiramate<\\e1> at low concentrations causes slow inhibition of <e2>GluR5<\\e2> kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"topiramate","object":"GluR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, <e1>CHEMICAL<\\e1> at low concentrations causes slow inhibition of <e2>GENE-Y<\\e2> kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GENE-Y kainate receptor responses.","sentence":"However, topiramate at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses."}
{"PMID":12724156,"re_id":1,"annotated sentence":"However, <e1>topiramate<\\e1> at low concentrations causes slow inhibition of GluR5 <e2>kainate receptor<\\e2> mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"topiramate","object":"kainate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, <e1>CHEMICAL<\\e1> at low concentrations causes slow inhibition of GluR5 <e2>GENE-N<\\e2> mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 GENE-N responses.","sentence":"However, topiramate at low concentrations causes slow inhibition of GluR5 kainate receptor mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses."}
{"PMID":12724156,"re_id":2,"annotated sentence":"However, <e1>topiramate<\\e1> at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of <e2>GluR5<\\e2> kainate receptor responses.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"topiramate","object":"GluR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, <e1>CHEMICAL<\\e1> at low concentrations causes slow inhibition of GENE-Y kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of <e2>GENE-Y<\\e2> kainate receptor responses.","sentence":"However, topiramate at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses."}
{"PMID":12724156,"re_id":3,"annotated sentence":"However, <e1>topiramate<\\e1> at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 <e2>kainate receptor<\\e2> responses.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"topiramate","object":"kainate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, <e1>CHEMICAL<\\e1> at low concentrations causes slow inhibition of GluR5 GENE-N-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 <e2>GENE-N<\\e2> responses.","sentence":"However, topiramate at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses."}
{"PMID":12724156,"re_id":4,"annotated sentence":"The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the <e2>GluR5<\\e2> kainate receptor antagonist <e1>LY293558<\\e1>  Intra-amygdala infusion of ATPA in the rat induces limbic status epilepticus; in some animals, recurrent spontaneous seizures occur for months after the ATPA treatment","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY293558","object":"GluR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective GENE-Y kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the <e2>GENE-Y<\\e2> kainate receptor antagonist <e1>CHEMICAL<\\e1>  Intra-amygdala infusion of ATPA in the rat induces limbic status epilepticus; in some animals, recurrent spontaneous seizures occur for months after the ATPA treatment","sentence":"The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist LY293558  Intra-amygdala infusion of ATPA in the rat induces limbic status epilepticus; in some animals, recurrent spontaneous seizures occur for months after the ATPA treatment"}
{"PMID":12724156,"re_id":5,"annotated sentence":"The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 <e2>kainate receptor<\\e2> antagonist <e1>LY293558<\\e1>  Intra-amygdala infusion of ATPA in the rat induces limbic status epilepticus; in some animals, recurrent spontaneous seizures occur for months after the ATPA treatment","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY293558","object":"kainate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The selective GluR5 GENE-N agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1>  Intra-amygdala infusion of ATPA in the rat induces limbic status epilepticus; in some animals, recurrent spontaneous seizures occur for months after the ATPA treatment","sentence":"The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist LY293558  Intra-amygdala infusion of ATPA in the rat induces limbic status epilepticus; in some animals, recurrent spontaneous seizures occur for months after the ATPA treatment"}
{"PMID":12727196,"re_id":0,"annotated sentence":"Purified <e2>PAOh1<\\e2> SMO oxidizes both <e1>spermine<\\e1> (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"PAOh1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Purified <e2>GENE-Y<\\e2> SMO oxidizes both <e1>CHEMICAL<\\e1> (K(m)=1.6 microM) and N(1)-acetylCHEMICAL (K(m)=51 microM), but does not oxidize spermidine","sentence":"Purified PAOh1 SMO oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine"}
{"PMID":12727196,"re_id":1,"annotated sentence":"Purified PAOh1\/<e2>SMO<\\e2> oxidizes both <e1>spermine<\\e1> (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"SMO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Purified PAOh1\/<e2>GENE-Y<\\e2> oxidizes both <e1>CHEMICAL<\\e1> (K(m)=1.6 microM) and N(1)-acetylCHEMICAL (K(m)=51 microM), but does not oxidize spermidine","sentence":"Purified PAOh1\/SMO oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine"}
{"PMID":12727196,"re_id":2,"annotated sentence":"Purified <e2>PAOh1<\\e2> SMO oxidizes both spermine (K(m)=1.6 microM) and <e1>N(1)-acetylspermine<\\e1> (K(m)=51 microM), but does not oxidize spermidine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N(1)-acetylspermine","object":"PAOh1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Purified <e2>GENE-Y<\\e2> SMO oxidizes both spermine (K(m)=1.6 microM) and <e1>CHEMICAL<\\e1> (K(m)=51 microM), but does not oxidize spermidine","sentence":"Purified PAOh1 SMO oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine"}
{"PMID":12727196,"re_id":3,"annotated sentence":"Purified PAOh1\/<e2>SMO<\\e2> oxidizes both spermine (K(m)=1.6 microM) and <e1>N(1)-acetylspermine<\\e1> (K(m)=51 microM), but does not oxidize spermidine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N(1)-acetylspermine","object":"SMO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Purified PAOh1\/<e2>GENE-Y<\\e2> oxidizes both spermine (K(m)=1.6 microM) and <e1>CHEMICAL<\\e1> (K(m)=51 microM), but does not oxidize spermidine","sentence":"Purified PAOh1\/SMO oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine"}
{"PMID":12727196,"re_id":4,"annotated sentence":"The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of <e1>spermine<\\e1> by <e2>PAOh1<\\e2> SMO","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"PAOh1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of <e1>CHEMICAL<\\e1> by <e2>GENE-Y<\\e2> SMO","sentence":"The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of spermine by PAOh1 SMO"}
{"PMID":12727196,"re_id":5,"annotated sentence":"The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of <e1>spermine<\\e1> by PAOh1\/<e2>SMO<\\e2>  The results of these studies are consistent with the hypothesis that PAOh1\/SMO represents a new addition to the polyamine metabolic pathway that may represent a new target for antineoplastic drug development.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"SMO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of <e1>CHEMICAL<\\e1> by PAOh1\/<e2>GENE-Y<\\e2>  The results of these studies are consistent with the hypothesis that PAOh1\/GENE-Y represents a new addition to the polyamine metabolic pathway that may represent a new target for antineoplastic drug development.","sentence":"The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of spermine by PAOh1\/SMO  The results of these studies are consistent with the hypothesis that PAOh1\/SMO represents a new addition to the polyamine metabolic pathway that may represent a new target for antineoplastic drug development."}
{"PMID":12727196,"re_id":6,"annotated sentence":"The discovery of an inducible <e2>oxidase<\\e2> whose apparent substrate preference is <e1>spermine<\\e1> indicates that polyamine catabolism is more complex than that originally proposed","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The discovery of an inducible <e2>GENE-N<\\e2> whose apparent substrate preference is <e1>CHEMICAL<\\e1> indicates that polyamine catabolism is more complex than that originally proposed","sentence":"The discovery of an inducible oxidase whose apparent substrate preference is spermine indicates that polyamine catabolism is more complex than that originally proposed"}
{"PMID":12742526,"re_id":0,"annotated sentence":"Even though the activities of <e2>MAT<\\e2> and GNMT were elevated, the concentration of liver <e1>S-adenosylmethionine<\\e1> was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"S-adenosylmethionine","object":"MAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Even though the activities of <e2>GENE-N<\\e2> and GNMT were elevated, the concentration of liver <e1>CHEMICAL<\\e1> was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice","sentence":"Even though the activities of MAT and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice"}
{"PMID":12742526,"re_id":1,"annotated sentence":"Even though the activities of MAT and <e2>GNMT<\\e2> were elevated, the concentration of liver <e1>S-adenosylmethionine<\\e1> was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"S-adenosylmethionine","object":"GNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Even though the activities of MAT and <e2>GENE-Y<\\e2> were elevated, the concentration of liver <e1>CHEMICAL<\\e1> was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice","sentence":"Even though the activities of MAT and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice"}
{"PMID":12742526,"re_id":2,"annotated sentence":"Even though the activities of <e2>MAT<\\e2> and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and <e1>S-adenosylhomocysteine<\\e1> increased (113%, p<0.001) in the dwarf mice","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"S-adenosylhomocysteine","object":"MAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Even though the activities of <e2>GENE-N<\\e2> and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and <e1>CHEMICAL<\\e1> increased (113%, p<0.001) in the dwarf mice","sentence":"Even though the activities of MAT and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice"}
{"PMID":12742526,"re_id":3,"annotated sentence":"Even though the activities of MAT and <e2>GNMT<\\e2> were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and <e1>S-adenosylhomocysteine<\\e1> increased (113%, p<0.001) in the dwarf mice","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"S-adenosylhomocysteine","object":"GNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Even though the activities of MAT and <e2>GENE-Y<\\e2> were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and <e1>CHEMICAL<\\e1> increased (113%, p<0.001) in the dwarf mice","sentence":"Even though the activities of MAT and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice"}
{"PMID":12826271,"re_id":0,"annotated sentence":"Treatment with <e1>diclofenac<\\e1> resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated <e2>caspase-3<\\e2> after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"diclofenac","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated <e2>GENE-Y<\\e2> after 6 hr, indicating that CHEMICAL may cause apoptosis of neuronal cells via activation of the caspase cascade","sentence":"Treatment with diclofenac resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated caspase-3 after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade"}
{"PMID":12826271,"re_id":1,"annotated sentence":"Treatment with diclofenac resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated caspase-3 after 6 hr, indicating that <e1>diclofenac<\\e1> may cause apoptosis of neuronal cells via activation of the <e2>caspase<\\e2> cascade","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"diclofenac","object":"caspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment with CHEMICAL resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated GENE-N-3 after 6 hr, indicating that <e1>CHEMICAL<\\e1> may cause apoptosis of neuronal cells via activation of the <e2>GENE-N<\\e2> cascade","sentence":"Treatment with diclofenac resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated caspase-3 after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade"}
{"PMID":12850267,"re_id":0,"annotated sentence":"<e1>Kynurenic acid<\\e1> (KA) is an endogenous <e2>glutamate receptor<\\e2> antagonist at the level of the different ionotropic glutamate receptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Kynurenic acid","object":"glutamate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (KA) is an endogenous <e2>GENE-N<\\e2> antagonist at the level of the different ionotropic GENE-Ns","sentence":"Kynurenic acid (KA) is an endogenous glutamate receptor antagonist at the level of the different ionotropic glutamate receptors"}
{"PMID":12850267,"re_id":1,"annotated sentence":"<e1>Kynurenic acid<\\e1> (KA) is an endogenous glutamate receptor antagonist at the level of the different <e2>ionotropic glutamate receptors<\\e2>  One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Kynurenic acid","object":"ionotropic glutamate receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (KA) is an endogenous glutamate receptor antagonist at the level of the different <e2>GENE-N<\\e2>  One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)","sentence":"Kynurenic acid (KA) is an endogenous glutamate receptor antagonist at the level of the different ionotropic glutamate receptors  One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)"}
{"PMID":12850267,"re_id":2,"annotated sentence":"Kynurenic acid (<e1>KA<\\e1>  is an endogenous <e2>glutamate receptor<\\e2> antagonist at the level of the different ionotropic glutamate receptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"KA","object":"glutamate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kynurenic acid (<e1>CHEMICAL<\\e1>  is an endogenous <e2>GENE-N<\\e2> antagonist at the level of the different ionotropic GENE-Ns","sentence":"Kynurenic acid (KA  is an endogenous glutamate receptor antagonist at the level of the different ionotropic glutamate receptors"}
{"PMID":12850267,"re_id":3,"annotated sentence":"Kynurenic acid (<e1>KA<\\e1>  is an endogenous glutamate receptor antagonist at the level of the different <e2>ionotropic glutamate receptors<\\e2>  One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"KA","object":"ionotropic glutamate receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kynurenic acid (<e1>CHEMICAL<\\e1>  is an endogenous glutamate receptor antagonist at the level of the different <e2>GENE-N<\\e2>  One of the enzymes responsible for the production of CHEMICAL, kynurenine aminotransferase I (CHEMICALTI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)","sentence":"Kynurenic acid (KA  is an endogenous glutamate receptor antagonist at the level of the different ionotropic glutamate receptors  One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)"}
{"PMID":12850267,"re_id":4,"annotated sentence":"One of the enzymes responsible for the production of <e1>KA<\\e1>  <e2>kynurenine aminotransferase I<\\e2> (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"KA","object":"kynurenine aminotransferase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the enzymes responsible for the production of <e1>CHEMICAL<\\e1>  <e2>GENE-Y<\\e2> (CHEMICALTI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)","sentence":"One of the enzymes responsible for the production of KA  kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)"}
{"PMID":12850267,"re_id":5,"annotated sentence":"One of the enzymes responsible for the production of <e1>KA<\\e1>  kynurenine aminotransferase I (<e2>KATI<\\e2> , also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"KA","object":"KATI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the enzymes responsible for the production of <e1>CHEMICAL<\\e1>  kynurenine aminotransferase I (<e2>CHEMICALTI<\\e2> , also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)","sentence":"One of the enzymes responsible for the production of KA  kynurenine aminotransferase I (KATI , also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)"}
{"PMID":12850267,"re_id":6,"annotated sentence":"One of the enzymes responsible for the production of KA, <e2>kynurenine aminotransferase I<\\e2> (KATI), also catalyses the reversible transamination of <e1>glutamine<\\e1> to oxoglutaramic acid (GTK, EC 2.6.1.15)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"kynurenine aminotransferase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the enzymes responsible for the production of KA, <e2>GENE-Y<\\e2> (KATI), also catalyses the reversible transamination of <e1>CHEMICAL<\\e1> to oxoglutaramic acid (GTK, EC 2.6.1.15)","sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)"}
{"PMID":12850267,"re_id":7,"annotated sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (<e2>KATI<\\e2> , also catalyses the reversible transamination of <e1>glutamine<\\e1> to oxoglutaramic acid (GTK, EC 2.6.1.15)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"KATI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (<e2>GENE-Y<\\e2> , also catalyses the reversible transamination of <e1>CHEMICAL<\\e1> to oxoglutaramic acid (GTK, EC 2.6.1.15)","sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI , also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)"}
{"PMID":12850267,"re_id":8,"annotated sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of <e1>glutamine<\\e1> to oxoglutaramic acid (<e2>GTK<\\e2>  EC 2.6.1.15)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"GTK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of <e1>CHEMICAL<\\e1> to oxoglutaramic acid (<e2>GENE-Y<\\e2>  EC 2.6.1.15)","sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK  EC 2.6.1.15)"}
{"PMID":12850267,"re_id":9,"annotated sentence":"One of the enzymes responsible for the production of KA, <e2>kynurenine aminotransferase I<\\e2> (KATI), also catalyses the reversible transamination of glutamine to <e1>oxoglutaramic acid<\\e1> (GTK, EC 2.6.1.15)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxoglutaramic acid","object":"kynurenine aminotransferase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the enzymes responsible for the production of KA, <e2>GENE-Y<\\e2> (KATI), also catalyses the reversible transamination of glutamine to <e1>CHEMICAL<\\e1> (GTK, EC 2.6.1.15)","sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)"}
{"PMID":12850267,"re_id":10,"annotated sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (<e2>KATI<\\e2> , also catalyses the reversible transamination of glutamine to <e1>oxoglutaramic acid<\\e1> (GTK, EC 2.6.1.15)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxoglutaramic acid","object":"KATI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (<e2>GENE-Y<\\e2> , also catalyses the reversible transamination of glutamine to <e1>CHEMICAL<\\e1> (GTK, EC 2.6.1.15)","sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI , also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)"}
{"PMID":12850267,"re_id":11,"annotated sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to <e1>oxoglutaramic acid<\\e1> (<e2>GTK<\\e2>  EC 2.6.1.15)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxoglutaramic acid","object":"GTK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2>  EC 2.6.1.15)","sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK  EC 2.6.1.15)"}
{"PMID":12850267,"re_id":12,"annotated sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to <e1>oxoglutaramic acid<\\e1> (GTK, <e2>EC 2.6.1.15<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxoglutaramic acid","object":"EC 2.6.1.15","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to <e1>CHEMICAL<\\e1> (GTK, <e2>GENE-Y<\\e2> ","sentence":"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15 "}
{"PMID":12871155,"re_id":0,"annotated sentence":"These compounds are competitive and, in a few cases, non-competitive inhibitors for <e2>AChE<\\e2>  the most potent being compound (14), though three-fold less active than <e1>tacrine<\\e1>  The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than tacrine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tacrine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These compounds are competitive and, in a few cases, non-competitive inhibitors for <e2>GENE-Y<\\e2>  the most potent being compound (14), though three-fold less active than <e1>CHEMICAL<\\e1>  The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than CHEMICAL","sentence":"These compounds are competitive and, in a few cases, non-competitive inhibitors for AChE  the most potent being compound (14), though three-fold less active than tacrine  The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than tacrine"}
{"PMID":12871155,"re_id":1,"annotated sentence":"The acetylcholinesterase (<e2>AChE<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of <e1>pyrano[2,3-b]quinolines<\\e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrano[2,3-b]quinolines","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (<e2>GENE-Y<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of <e1>CHEMICAL<\\e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":2,"annotated sentence":"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase<\\e2> (BuChE) inhibitory activities of a series of <e1>pyrano[2,3-b]quinolines<\\e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrano[2,3-b]quinolines","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and <e2>GENE-Y<\\e2> (BuChE) inhibitory activities of a series of <e1>CHEMICAL<\\e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":3,"annotated sentence":"The <e2>acetylcholinesterase<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of <e1>pyrano[2,3-b]quinolines<\\e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrano[2,3-b]quinolines","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of <e1>CHEMICAL<\\e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":4,"annotated sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE<\\e2>  inhibitory activities of a series of <e1>pyrano[2,3-b]quinolines<\\e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrano[2,3-b]quinolines","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>GENE-Y<\\e2>  inhibitory activities of a series of <e1>CHEMICAL<\\e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":5,"annotated sentence":"The <e2>BuChE<\\e2> inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than <e1>tacrine<\\e1>  Furthermore, the products 12 and 13 are selective and moderate AChE inhibitors.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tacrine","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than <e1>CHEMICAL<\\e1>  Furthermore, the products 12 and 13 are selective and moderate AChE inhibitors.","sentence":"The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than tacrine  Furthermore, the products 12 and 13 are selective and moderate AChE inhibitors."}
{"PMID":12871155,"re_id":6,"annotated sentence":"The acetylcholinesterase (<e2>AChE<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>[1,8]naphthyridines<\\e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"[1,8]naphthyridines","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (<e2>GENE-Y<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>CHEMICAL<\\e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":7,"annotated sentence":"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase<\\e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>[1,8]naphthyridines<\\e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"[1,8]naphthyridines","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and <e2>GENE-Y<\\e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>CHEMICAL<\\e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":8,"annotated sentence":"The <e2>acetylcholinesterase<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>[1,8]naphthyridines<\\e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"[1,8]naphthyridines","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>CHEMICAL<\\e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":9,"annotated sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE<\\e2>  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>[1,8]naphthyridines<\\e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"[1,8]naphthyridines","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>GENE-Y<\\e2>  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>CHEMICAL<\\e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":10,"annotated sentence":"The acetylcholinesterase (<e2>AChE<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines<\\e1> (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (<e2>GENE-Y<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>CHEMICAL<\\e1> (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":11,"annotated sentence":"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase<\\e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines<\\e1> (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and <e2>GENE-Y<\\e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>CHEMICAL<\\e1> (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":12,"annotated sentence":"The <e2>acetylcholinesterase<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines<\\e1> (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>CHEMICAL<\\e1> (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":13,"annotated sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE<\\e2>  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines<\\e1> (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>GENE-Y<\\e2>  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>CHEMICAL<\\e1> (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":14,"annotated sentence":"The acetylcholinesterase (<e2>AChE<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine<\\e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (<e2>GENE-Y<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ <e1>CHEMICAL<\\e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":15,"annotated sentence":"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase<\\e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine<\\e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and <e2>GENE-Y<\\e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ <e1>CHEMICAL<\\e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":16,"annotated sentence":"The <e2>acetylcholinesterase<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine<\\e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ <e1>CHEMICAL<\\e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":17,"annotated sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE<\\e2>  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine<\\e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>GENE-Y<\\e2>  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ <e1>CHEMICAL<\\e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":18,"annotated sentence":"The acetylcholinesterase (<e2>AChE<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline<\\e1> (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (<e2>GENE-Y<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>CHEMICAL<\\e1> (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":19,"annotated sentence":"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase<\\e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline<\\e1> (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and <e2>GENE-Y<\\e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>CHEMICAL<\\e1> (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":20,"annotated sentence":"The <e2>acetylcholinesterase<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline<\\e1> (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>CHEMICAL<\\e1> (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":21,"annotated sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE<\\e2>  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline<\\e1> (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>GENE-Y<\\e2>  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>CHEMICAL<\\e1> (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":22,"annotated sentence":"The acetylcholinesterase (<e2>AChE<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine<\\e1> (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (<e2>GENE-Y<\\e2>  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ <e1>CHEMICAL<\\e1> (16) are described","sentence":"The acetylcholinesterase (AChE  and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":23,"annotated sentence":"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase<\\e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine<\\e1> (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and <e2>GENE-Y<\\e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ <e1>CHEMICAL<\\e1> (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":24,"annotated sentence":"The <e2>acetylcholinesterase<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine<\\e1> (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ <e1>CHEMICAL<\\e1> (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12871155,"re_id":25,"annotated sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE<\\e2>  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine<\\e1> (16) are described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>GENE-Y<\\e2>  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ <e1>CHEMICAL<\\e1> (16) are described","sentence":"The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE  inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)\/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described"}
{"PMID":12881227,"re_id":0,"annotated sentence":"Nevertheless, 3 mM <e1>DMA<\\e1>  a higher concentration that inhibits <e2>NHE1<\\e2>  NHE2, and NHE3, significantly increased DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMA","object":"NHE1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nevertheless, 3 mM <e1>CHEMICAL<\\e1>  a higher concentration that inhibits <e2>GENE-Y<\\e2>  NHE2, and NHE3, significantly increased DBS","sentence":"Nevertheless, 3 mM DMA  a higher concentration that inhibits NHE1  NHE2, and NHE3, significantly increased DBS"}
{"PMID":12881227,"re_id":1,"annotated sentence":"Nevertheless, 3 mM <e1>DMA<\\e1>  a higher concentration that inhibits NHE1, <e2>NHE2<\\e2>  and NHE3, significantly increased DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMA","object":"NHE2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nevertheless, 3 mM <e1>CHEMICAL<\\e1>  a higher concentration that inhibits NHE1, <e2>GENE-Y<\\e2>  and NHE3, significantly increased DBS","sentence":"Nevertheless, 3 mM DMA  a higher concentration that inhibits NHE1, NHE2  and NHE3, significantly increased DBS"}
{"PMID":12881227,"re_id":2,"annotated sentence":"Nevertheless, 3 mM <e1>DMA<\\e1>  a higher concentration that inhibits NHE1, NHE2, and <e2>NHE3<\\e2>  significantly increased DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMA","object":"NHE3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nevertheless, 3 mM <e1>CHEMICAL<\\e1>  a higher concentration that inhibits NHE1, NHE2, and <e2>GENE-Y<\\e2>  significantly increased DBS","sentence":"Nevertheless, 3 mM DMA  a higher concentration that inhibits NHE1, NHE2, and NHE3  significantly increased DBS"}
{"PMID":12881227,"re_id":3,"annotated sentence":"Moreover, <e1>S1611<\\e1> and S3226, both specific inhibitors of <e2>NHE3<\\e2> only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"S1611","object":"NHE3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> and S3226, both specific inhibitors of <e2>GENE-Y<\\e2> only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH","sentence":"Moreover, S1611 and S3226, both specific inhibitors of NHE3 only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH"}
{"PMID":12881227,"re_id":4,"annotated sentence":"Moreover, S1611 and <e1>S3226<\\e1>  both specific inhibitors of <e2>NHE3<\\e2> only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"S3226","object":"NHE3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, S1611 and <e1>CHEMICAL<\\e1>  both specific inhibitors of <e2>GENE-Y<\\e2> only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH","sentence":"Moreover, S1611 and S3226  both specific inhibitors of NHE3 only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH"}
{"PMID":12881227,"re_id":5,"annotated sentence":"Nevertheless, coperfusion with 0.1 and 0.3 mM <e1>5-nitro-2-(3-phenylpropylamino) benzoic acid<\\e1>  which inhibits the <e2>cystic fibrosis transmembrane conductor regulator<\\e2> (CFTR), dose dependently inhibited S3226-induced DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-nitro-2-(3-phenylpropylamino) benzoic acid","object":"cystic fibrosis transmembrane conductor regulator","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nevertheless, coperfusion with 0.1 and 0.3 mM <e1>CHEMICAL<\\e1>  which inhibits the <e2>GENE-Y<\\e2> (CFTR), dose dependently inhibited S3226-induced DBS","sentence":"Nevertheless, coperfusion with 0.1 and 0.3 mM 5-nitro-2-(3-phenylpropylamino) benzoic acid  which inhibits the cystic fibrosis transmembrane conductor regulator (CFTR), dose dependently inhibited S3226-induced DBS"}
{"PMID":12881227,"re_id":6,"annotated sentence":"Nevertheless, coperfusion with 0.1 and 0.3 mM <e1>5-nitro-2-(3-phenylpropylamino) benzoic acid<\\e1>  which inhibits the cystic fibrosis transmembrane conductor regulator (<e2>CFTR<\\e2> , dose dependently inhibited S3226-induced DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-nitro-2-(3-phenylpropylamino) benzoic acid","object":"CFTR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nevertheless, coperfusion with 0.1 and 0.3 mM <e1>CHEMICAL<\\e1>  which inhibits the cystic fibrosis transmembrane conductor regulator (<e2>GENE-Y<\\e2> , dose dependently inhibited S3226-induced DBS","sentence":"Nevertheless, coperfusion with 0.1 and 0.3 mM 5-nitro-2-(3-phenylpropylamino) benzoic acid  which inhibits the cystic fibrosis transmembrane conductor regulator (CFTR , dose dependently inhibited S3226-induced DBS"}
{"PMID":12881227,"re_id":7,"annotated sentence":"<e1>5-(N,N-dimethyl)-amiloride<\\e1> (50 microM; DMA), a concentration that selectively inhibits the <e2>NHE<\\e2> isoforms NHE1 and NHE2, but not NHE3, did not affect DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-(N,N-dimethyl)-amiloride","object":"NHE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (50 microM; DMA), a concentration that selectively inhibits the <e2>GENE-N<\\e2> isoforms GENE-N1 and GENE-N2, but not GENE-N3, did not affect DBS","sentence":"5-(N,N-dimethyl)-amiloride (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not NHE3, did not affect DBS"}
{"PMID":12881227,"re_id":8,"annotated sentence":"<e1>5-(N,N-dimethyl)-amiloride<\\e1> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms <e2>NHE1<\\e2> and NHE2, but not NHE3, did not affect DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-(N,N-dimethyl)-amiloride","object":"NHE1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms <e2>GENE-Y<\\e2> and NHE2, but not NHE3, did not affect DBS","sentence":"5-(N,N-dimethyl)-amiloride (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not NHE3, did not affect DBS"}
{"PMID":12881227,"re_id":9,"annotated sentence":"<e1>5-(N,N-dimethyl)-amiloride<\\e1> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and <e2>NHE2<\\e2>  but not NHE3, did not affect DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-(N,N-dimethyl)-amiloride","object":"NHE2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and <e2>GENE-Y<\\e2>  but not NHE3, did not affect DBS","sentence":"5-(N,N-dimethyl)-amiloride (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2  but not NHE3, did not affect DBS"}
{"PMID":12881227,"re_id":10,"annotated sentence":"<e1>5-(N,N-dimethyl)-amiloride<\\e1> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not <e2>NHE3<\\e2>  did not affect DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-(N,N-dimethyl)-amiloride","object":"NHE3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not <e2>GENE-Y<\\e2>  did not affect DBS","sentence":"5-(N,N-dimethyl)-amiloride (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not NHE3  did not affect DBS"}
{"PMID":12881227,"re_id":11,"annotated sentence":"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA<\\e1> , a concentration that selectively inhibits the <e2>NHE<\\e2> isoforms NHE1 and NHE2, but not NHE3, did not affect DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMA","object":"NHE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"5-(N,N-dimethyl)-amiloride (50 microM; <e1>CHEMICAL<\\e1> , a concentration that selectively inhibits the <e2>GENE-N<\\e2> isoforms GENE-N1 and GENE-N2, but not GENE-N3, did not affect DBS","sentence":"5-(N,N-dimethyl)-amiloride (50 microM; DMA , a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not NHE3, did not affect DBS"}
{"PMID":12881227,"re_id":12,"annotated sentence":"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA<\\e1> , a concentration that selectively inhibits the NHE isoforms <e2>NHE1<\\e2> and NHE2, but not NHE3, did not affect DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMA","object":"NHE1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-(N,N-dimethyl)-amiloride (50 microM; <e1>CHEMICAL<\\e1> , a concentration that selectively inhibits the NHE isoforms <e2>GENE-Y<\\e2> and NHE2, but not NHE3, did not affect DBS","sentence":"5-(N,N-dimethyl)-amiloride (50 microM; DMA , a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not NHE3, did not affect DBS"}
{"PMID":12881227,"re_id":13,"annotated sentence":"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA<\\e1> , a concentration that selectively inhibits the NHE isoforms NHE1 and <e2>NHE2<\\e2>  but not NHE3, did not affect DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMA","object":"NHE2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-(N,N-dimethyl)-amiloride (50 microM; <e1>CHEMICAL<\\e1> , a concentration that selectively inhibits the NHE isoforms NHE1 and <e2>GENE-Y<\\e2>  but not NHE3, did not affect DBS","sentence":"5-(N,N-dimethyl)-amiloride (50 microM; DMA , a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2  but not NHE3, did not affect DBS"}
{"PMID":12881227,"re_id":14,"annotated sentence":"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA<\\e1> , a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not <e2>NHE3<\\e2>  did not affect DBS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMA","object":"NHE3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5-(N,N-dimethyl)-amiloride (50 microM; <e1>CHEMICAL<\\e1> , a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not <e2>GENE-Y<\\e2>  did not affect DBS","sentence":"5-(N,N-dimethyl)-amiloride (50 microM; DMA , a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not NHE3  did not affect DBS"}
{"PMID":12881227,"re_id":15,"annotated sentence":"In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-HCO3- cotransporter activation, or intracellular <e1>HCO3<\\e1>  formation by <e2>carbonic anhydrase<\\e2> was not involved","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HCO3","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-CHEMICAL- cotransporter activation, or intracellular <e1>CHEMICAL<\\e1>  formation by <e2>GENE-N<\\e2> was not involved","sentence":"In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-HCO3- cotransporter activation, or intracellular HCO3  formation by carbonic anhydrase was not involved"}
{"PMID":12904467,"re_id":0,"annotated sentence":"Inhibition of <e2>GluR5<\\e2> kainate receptors could represent a key mechanism underlying the anticonvulsant activity of <e1>topiramate<\\e1>  Moreover, these results support the concept that GluR5 kainate receptors represent a novel target for antiepileptic drug development.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"topiramate","object":"GluR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> kainate receptors could represent a key mechanism underlying the anticonvulsant activity of <e1>CHEMICAL<\\e1>  Moreover, these results support the concept that GENE-Y kainate receptors represent a novel target for antiepileptic drug development.","sentence":"Inhibition of GluR5 kainate receptors could represent a key mechanism underlying the anticonvulsant activity of topiramate  Moreover, these results support the concept that GluR5 kainate receptors represent a novel target for antiepileptic drug development."}
{"PMID":12904467,"re_id":1,"annotated sentence":"Inhibition of GluR5 <e2>kainate receptors<\\e2> could represent a key mechanism underlying the anticonvulsant activity of <e1>topiramate<\\e1>  Moreover, these results support the concept that GluR5 kainate receptors represent a novel target for antiepileptic drug development.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"topiramate","object":"kainate receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of GluR5 <e2>GENE-N<\\e2> could represent a key mechanism underlying the anticonvulsant activity of <e1>CHEMICAL<\\e1>  Moreover, these results support the concept that GluR5 GENE-N represent a novel target for antiepileptic drug development.","sentence":"Inhibition of GluR5 kainate receptors could represent a key mechanism underlying the anticonvulsant activity of topiramate  Moreover, these results support the concept that GluR5 kainate receptors represent a novel target for antiepileptic drug development."}
{"PMID":12904467,"re_id":2,"annotated sentence":"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, <e1>topiramate<\\e1> at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by <e2>kainate receptors<\\e2> containing the GluR5 subunit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"topiramate","object":"kainate receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, <e1>CHEMICAL<\\e1> at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by <e2>GENE-N<\\e2> containing the GluR5 subunit","sentence":"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, topiramate at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by kainate receptors containing the GluR5 subunit"}
{"PMID":12904467,"re_id":3,"annotated sentence":"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, <e1>topiramate<\\e1> at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by kainate receptors containing the <e2>GluR5<\\e2> subunit","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"topiramate","object":"GluR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, <e1>CHEMICAL<\\e1> at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by kainate receptors containing the <e2>GENE-Y<\\e2> subunit","sentence":"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, topiramate at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by kainate receptors containing the GluR5 subunit"}
{"PMID":12904467,"re_id":4,"annotated sentence":"<e1>Topiramate<\\e1> also partially depressed predominantly <e2>AMPA-receptor<\\e2> mediated EPSCs, but with lower efficacy","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Topiramate","object":"AMPA-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also partially depressed predominantly <e2>GENE-N<\\e2> mediated EPSCs, but with lower efficacy","sentence":"Topiramate also partially depressed predominantly AMPA-receptor mediated EPSCs, but with lower efficacy"}
{"PMID":12904467,"re_id":5,"annotated sentence":"Selective antagonism of <e2>GluR5<\\e2> kainate-receptor-mediated synaptic currents by <e1>topiramate<\\e1> in rat basolateral amygdala neurons","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"topiramate","object":"GluR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective antagonism of <e2>GENE-Y<\\e2> kainate-receptor-mediated synaptic currents by <e1>CHEMICAL<\\e1> in rat basolateral amygdala neurons","sentence":"Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons"}
{"PMID":12904467,"re_id":6,"annotated sentence":"Selective antagonism of GluR5 <e2>kainate-receptor<\\e2> mediated synaptic currents by <e1>topiramate<\\e1> in rat basolateral amygdala neurons","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"topiramate","object":"kainate-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Selective antagonism of GluR5 <e2>GENE-N<\\e2> mediated synaptic currents by <e1>CHEMICAL<\\e1> in rat basolateral amygdala neurons","sentence":"Selective antagonism of GluR5 kainate-receptor mediated synaptic currents by topiramate in rat basolateral amygdala neurons"}
{"PMID":12907443,"re_id":0,"annotated sentence":"Weekly subcutaneous <e1>decitabine<\\e1> produces cumulative increases in <e2>HbF<\\e2> and total hemoglobin through a noncytotoxic mechanism of action","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"decitabine","object":"HbF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Weekly subcutaneous <e1>CHEMICAL<\\e1> produces cumulative increases in <e2>GENE-N<\\e2> and total hemoglobin through a noncytotoxic mechanism of action","sentence":"Weekly subcutaneous decitabine produces cumulative increases in HbF and total hemoglobin through a noncytotoxic mechanism of action"}
{"PMID":12907443,"re_id":1,"annotated sentence":"Weekly subcutaneous <e1>decitabine<\\e1> produces cumulative increases in HbF and total <e2>hemoglobin<\\e2> through a noncytotoxic mechanism of action","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"decitabine","object":"hemoglobin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Weekly subcutaneous <e1>CHEMICAL<\\e1> produces cumulative increases in HbF and total <e2>GENE-N<\\e2> through a noncytotoxic mechanism of action","sentence":"Weekly subcutaneous decitabine produces cumulative increases in HbF and total hemoglobin through a noncytotoxic mechanism of action"}
{"PMID":12907443,"re_id":2,"annotated sentence":"We examined if subcutaneous <e1>decitabine<\\e1> could increase <e2>HbF<\\e2> levels and improve SSD pathophysiology without cytotoxicity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"decitabine","object":"HbF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We examined if subcutaneous <e1>CHEMICAL<\\e1> could increase <e2>GENE-N<\\e2> levels and improve SSD pathophysiology without cytotoxicity","sentence":"We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity"}
{"PMID":12907443,"re_id":3,"annotated sentence":"The <e1>cytosine<\\e1> analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting <e2>DNA methyltransferase<\\e2>  We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cytosine","object":"DNA methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e1>CHEMICAL<\\e1> analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting <e2>GENE-N<\\e2>  We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity","sentence":"The cytosine analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting DNA methyltransferase  We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity"}
{"PMID":12907443,"re_id":4,"annotated sentence":"The cytosine analog <e1>5-aza-2'-deoxycytidine<\\e1> (decitabine) hypomethylates DNA by inhibiting <e2>DNA methyltransferase<\\e2>  We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-aza-2'-deoxycytidine","object":"DNA methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The cytosine analog <e1>CHEMICAL<\\e1> (decitabine) hypomethylates DNA by inhibiting <e2>GENE-N<\\e2>  We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity","sentence":"The cytosine analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting DNA methyltransferase  We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity"}
{"PMID":12907443,"re_id":5,"annotated sentence":"The cytosine analog 5-aza-2'-deoxycytidine (<e1>decitabine<\\e1>  hypomethylates DNA by inhibiting <e2>DNA methyltransferase<\\e2>  We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"decitabine","object":"DNA methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The cytosine analog 5-aza-2'-deoxycytidine (<e1>CHEMICAL<\\e1>  hypomethylates DNA by inhibiting <e2>GENE-N<\\e2>  We examined if subcutaneous CHEMICAL could increase HbF levels and improve SSD pathophysiology without cytotoxicity","sentence":"The cytosine analog 5-aza-2'-deoxycytidine (decitabine  hypomethylates DNA by inhibiting DNA methyltransferase  We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity"}
{"PMID":12927775,"re_id":0,"annotated sentence":"<e1>Aliskiren<\\e1> represents the first in a novel class of <e2>renin<\\e2> inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aliskiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> represents the first in a novel class of <e2>GENE-Y<\\e2> inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.","sentence":"Aliskiren represents the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases."}
{"PMID":12927775,"re_id":1,"annotated sentence":"This led to the discovery of <e1>aliskiren<\\e1>  a highly potent and selective inhibitor of <e2>human renin<\\e2> in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aliskiren","object":"human renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This led to the discovery of <e1>CHEMICAL<\\e1>  a highly potent and selective inhibitor of <e2>GENE-Y<\\e2> in vitro, and in vivo; once-daily oral doses of CHEMICAL inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients","sentence":"This led to the discovery of aliskiren  a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients"}
{"PMID":12927775,"re_id":2,"annotated sentence":"This led to the discovery of aliskiren, a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of <e1>aliskiren<\\e1> inhibit <e2>renin<\\e2> and lower blood pressure in sodium-depleted marmosets and hypertensive human patients","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aliskiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This led to the discovery of CHEMICAL, a highly potent and selective inhibitor of human GENE-Y in vitro, and in vivo; once-daily oral doses of <e1>CHEMICAL<\\e1> inhibit <e2>GENE-Y<\\e2> and lower blood pressure in sodium-depleted marmosets and hypertensive human patients","sentence":"This led to the discovery of aliskiren, a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients"}
{"PMID":12927775,"re_id":3,"annotated sentence":"Structure-based design of <e1>aliskiren<\\e1>  a novel orally effective <e2>renin<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aliskiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Structure-based design of <e1>CHEMICAL<\\e1>  a novel orally effective <e2>GENE-Y<\\e2> inhibitor","sentence":"Structure-based design of aliskiren  a novel orally effective renin inhibitor"}
{"PMID":12956944,"re_id":0,"annotated sentence":"CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of <e2>CREB<\\e2> in the nucleus accumbens, and those changes can be reversed by <e1>naloxone<\\e1>  which may be one kind of the molecular mechanisms associated with ethanol dependence.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"naloxone","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of <e2>GENE-N<\\e2> in the nucleus accumbens, and those changes can be reversed by <e1>CHEMICAL<\\e1>  which may be one kind of the molecular mechanisms associated with ethanol dependence.","sentence":"CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of CREB in the nucleus accumbens, and those changes can be reversed by naloxone  which may be one kind of the molecular mechanisms associated with ethanol dependence."}
{"PMID":12956944,"re_id":1,"annotated sentence":"The decrement of <e2>p-CREB<\\e2> protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of <e1>ethanol<\\e1> withdrawal, which recovered toward control level after 7 d of ethanol withdrawal","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"p-CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The decrement of <e2>GENE-N<\\e2> protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of <e1>CHEMICAL<\\e1> withdrawal, which recovered toward control level after 7 d of CHEMICAL withdrawal","sentence":"The decrement of p-CREB protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of ethanol withdrawal, which recovered toward control level after 7 d of ethanol withdrawal"}
{"PMID":12956944,"re_id":2,"annotated sentence":"The decrement of <e2>p-CREB<\\e2> protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of ethanol withdrawal, which recovered toward control level after 7 d of <e1>ethanol<\\e1> withdrawal","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"p-CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The decrement of <e2>GENE-N<\\e2> protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of CHEMICAL withdrawal, which recovered toward control level after 7 d of <e1>CHEMICAL<\\e1> withdrawal","sentence":"The decrement of p-CREB protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of ethanol withdrawal, which recovered toward control level after 7 d of ethanol withdrawal"}
{"PMID":12956944,"re_id":3,"annotated sentence":"However, when naloxone was administered concurrently with <e1>ethanol<\\e1> treatment, it antagonized the down-regulation of <e2>p-CREB<\\e2> protein in the nucleus accumbens (142 %) of rats exposed to ethanol","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"p-CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, when naloxone was administered concurrently with <e1>CHEMICAL<\\e1> treatment, it antagonized the down-regulation of <e2>GENE-N<\\e2> protein in the nucleus accumbens (142 %) of rats exposed to CHEMICAL","sentence":"However, when naloxone was administered concurrently with ethanol treatment, it antagonized the down-regulation of p-CREB protein in the nucleus accumbens (142 %) of rats exposed to ethanol"}
{"PMID":12956944,"re_id":4,"annotated sentence":"However, when naloxone was administered concurrently with ethanol treatment, it antagonized the down-regulation of <e2>p-CREB<\\e2> protein in the nucleus accumbens (142 %) of rats exposed to <e1>ethanol<\\e1>  CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of CREB in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"p-CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, when naloxone was administered concurrently with CHEMICAL treatment, it antagonized the down-regulation of <e2>GENE-N<\\e2> protein in the nucleus accumbens (142 %) of rats exposed to <e1>CHEMICAL<\\e1>  CONCLUSION: A long-term intake of CHEMICAL solution down-regulates the phosphorylation of CREB in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with CHEMICAL dependence.","sentence":"However, when naloxone was administered concurrently with ethanol treatment, it antagonized the down-regulation of p-CREB protein in the nucleus accumbens (142 %) of rats exposed to ethanol  CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of CREB in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence."}
{"PMID":12956944,"re_id":5,"annotated sentence":"CONCLUSION: A long-term intake of <e1>ethanol<\\e1> solution down-regulates the phosphorylation of <e2>CREB<\\e2> in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSION: A long-term intake of <e1>CHEMICAL<\\e1> solution down-regulates the phosphorylation of <e2>GENE-N<\\e2> in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with CHEMICAL dependence.","sentence":"CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of CREB in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with ethanol dependence."}
{"PMID":12956944,"re_id":6,"annotated sentence":"RESULTS: <e1>Ethanol<\\e1> given to rats in drinking water decreased the level of <e2>p-CREB<\\e2> protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ethanol","object":"p-CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> given to rats in drinking water decreased the level of <e2>GENE-N<\\e2> protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol","sentence":"RESULTS: Ethanol given to rats in drinking water decreased the level of p-CREB protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol"}
{"PMID":13129570,"re_id":0,"annotated sentence":"<e1>2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid<\\e1> (1) is a potent <e2>AMPA receptor<\\e2> agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid","object":"AMPA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (1) is a potent <e2>GENE-N<\\e2> agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of GENE-Ns","sentence":"2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors"}
{"PMID":1332478,"re_id":0,"annotated sentence":"The failure of the myometrium to respond to <e1>ritodrine<\\e1> (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and <e2>beta 2-adrenergic receptor<\\e2> concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ritodrine","object":"beta 2-adrenergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The failure of the myometrium to respond to <e1>CHEMICAL<\\e1> (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and <e2>GENE-Y<\\e2> concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls","sentence":"The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls"}
{"PMID":1361547,"re_id":0,"annotated sentence":"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the <e1>isoprenaline<\\e1> responses of the atria and the pA2 values were 8.60 and 8.98 at the <e2>beta 1-adrenoceptors<\\e2> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"isoprenaline","object":"beta 1-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the <e1>CHEMICAL<\\e1> responses of the atria and the pA2 values were 8.60 and 8.98 at the <e2>GENE-N<\\e2> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors","sentence":"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors"}
{"PMID":1361547,"re_id":1,"annotated sentence":"<e1>Labetalol<\\e1> (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the <e2>beta 1-adrenoceptors<\\e2> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Labetalol","object":"beta 1-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the <e2>GENE-N<\\e2> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors","sentence":"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors"}
{"PMID":1361547,"re_id":2,"annotated sentence":"Labetalol (> or = 3 x 10(-8) M) and <e1>dilevalol<\\e1> (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the <e2>beta 1-adrenoceptors<\\e2> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"dilevalol","object":"beta 1-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Labetalol (> or = 3 x 10(-8) M) and <e1>CHEMICAL<\\e1> (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the <e2>GENE-N<\\e2> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors","sentence":"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors"}
{"PMID":1361547,"re_id":3,"annotated sentence":"The isoprenaline attenuation responses of the portal vein were inhibited by labetalol and dilevalol (both at > or = 10(-7) M) and the pA2 value for the <e1>labetalol<\\e1> at <e2>beta 2-adrenoceptors<\\e2> was 7.59","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"labetalol","object":"beta 2-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The isoprenaline attenuation responses of the portal vein were inhibited by CHEMICAL and dilevalol (both at > or = 10(-7) M) and the pA2 value for the <e1>CHEMICAL<\\e1> at <e2>GENE-N<\\e2> was 7.59","sentence":"The isoprenaline attenuation responses of the portal vein were inhibited by labetalol and dilevalol (both at > or = 10(-7) M) and the pA2 value for the labetalol at beta 2-adrenoceptors was 7.59"}
{"PMID":1361547,"re_id":4,"annotated sentence":"It is concluded that <e1>labetalol<\\e1> and dilevalol are <e2>beta 1-adrenoceptor<\\e2> selective antagonists.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"labetalol","object":"beta 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is concluded that <e1>CHEMICAL<\\e1> and dilevalol are <e2>GENE-N<\\e2> selective antagonists.","sentence":"It is concluded that labetalol and dilevalol are beta 1-adrenoceptor selective antagonists."}
{"PMID":1361547,"re_id":5,"annotated sentence":"It is concluded that labetalol and <e1>dilevalol<\\e1> are <e2>beta 1-adrenoceptor<\\e2> selective antagonists.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"dilevalol","object":"beta 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is concluded that labetalol and <e1>CHEMICAL<\\e1> are <e2>GENE-N<\\e2> selective antagonists.","sentence":"It is concluded that labetalol and dilevalol are beta 1-adrenoceptor selective antagonists."}
{"PMID":1375507,"re_id":0,"annotated sentence":"These results suggest that <e1>prostacyclin<\\e1> may play a role in downregulating <e2>tissue factor<\\e2> expression in monocytes, at least in part via elevation of intracellular levels of cyclic AMP.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prostacyclin","object":"tissue factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> may play a role in downregulating <e2>GENE-Y<\\e2> expression in monocytes, at least in part via elevation of intracellular levels of cyclic AMP.","sentence":"These results suggest that prostacyclin may play a role in downregulating tissue factor expression in monocytes, at least in part via elevation of intracellular levels of cyclic AMP."}
{"PMID":1375507,"re_id":1,"annotated sentence":"These results suggest that prostacyclin may play a role in downregulating <e2>tissue factor<\\e2> expression in monocytes, at least in part via elevation of intracellular levels of <e1>cyclic AMP<\\e1> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyclic AMP","object":"tissue factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that prostacyclin may play a role in downregulating <e2>GENE-Y<\\e2> expression in monocytes, at least in part via elevation of intracellular levels of <e1>CHEMICAL<\\e1> ","sentence":"These results suggest that prostacyclin may play a role in downregulating tissue factor expression in monocytes, at least in part via elevation of intracellular levels of cyclic AMP "}
{"PMID":1375507,"re_id":2,"annotated sentence":"The present studies were undertaken to determine whether stable analogues of <e1>prostacyclin<\\e1>  a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit <e2>tissue factor<\\e2> expression by human monocytic cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prostacyclin","object":"tissue factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present studies were undertaken to determine whether stable analogues of <e1>CHEMICAL<\\e1>  a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit <e2>GENE-Y<\\e2> expression by human monocytic cells","sentence":"The present studies were undertaken to determine whether stable analogues of prostacyclin  a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit tissue factor expression by human monocytic cells"}
{"PMID":1375507,"re_id":3,"annotated sentence":"Preincubation for 30 minutes with <e1>iloprost<\\e1>  ciprostene, and carbacyclin led to a dose-dependent inhibition of <e2>tissue factor<\\e2> expression induced by all three challenging agents","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"iloprost","object":"tissue factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preincubation for 30 minutes with <e1>CHEMICAL<\\e1>  ciprostene, and carbacyclin led to a dose-dependent inhibition of <e2>GENE-Y<\\e2> expression induced by all three challenging agents","sentence":"Preincubation for 30 minutes with iloprost  ciprostene, and carbacyclin led to a dose-dependent inhibition of tissue factor expression induced by all three challenging agents"}
{"PMID":1375507,"re_id":4,"annotated sentence":"Preincubation for 30 minutes with iloprost, <e1>ciprostene<\\e1>  and carbacyclin led to a dose-dependent inhibition of <e2>tissue factor<\\e2> expression induced by all three challenging agents","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ciprostene","object":"tissue factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preincubation for 30 minutes with iloprost, <e1>CHEMICAL<\\e1>  and carbacyclin led to a dose-dependent inhibition of <e2>GENE-Y<\\e2> expression induced by all three challenging agents","sentence":"Preincubation for 30 minutes with iloprost, ciprostene  and carbacyclin led to a dose-dependent inhibition of tissue factor expression induced by all three challenging agents"}
{"PMID":1375507,"re_id":5,"annotated sentence":"Preincubation for 30 minutes with iloprost, ciprostene, and <e1>carbacyclin<\\e1> led to a dose-dependent inhibition of <e2>tissue factor<\\e2> expression induced by all three challenging agents","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbacyclin","object":"tissue factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preincubation for 30 minutes with iloprost, ciprostene, and <e1>CHEMICAL<\\e1> led to a dose-dependent inhibition of <e2>GENE-Y<\\e2> expression induced by all three challenging agents","sentence":"Preincubation for 30 minutes with iloprost, ciprostene, and carbacyclin led to a dose-dependent inhibition of tissue factor expression induced by all three challenging agents"}
{"PMID":1375507,"re_id":6,"annotated sentence":"<e1>Prostacyclin<\\e1> analogues inhibit <e2>tissue factor<\\e2> expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Prostacyclin","object":"tissue factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> analogues inhibit <e2>GENE-Y<\\e2> expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism","sentence":"Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism"}
{"PMID":1375507,"re_id":7,"annotated sentence":"This effect was potentiated by <e1>isobutylmethylxanthine<\\e1>  an inhibitor of <e2>phosphodiesterase<\\e2>  The inhibitory effects of iloprost on tissue factor expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"isobutylmethylxanthine","object":"phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This effect was potentiated by <e1>CHEMICAL<\\e1>  an inhibitor of <e2>GENE-N<\\e2>  The inhibitory effects of iloprost on tissue factor expression were also potentiated by CHEMICAL and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP","sentence":"This effect was potentiated by isobutylmethylxanthine  an inhibitor of phosphodiesterase  The inhibitory effects of iloprost on tissue factor expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP"}
{"PMID":1375507,"re_id":8,"annotated sentence":"The inhibitory effects of iloprost on <e2>tissue factor<\\e2> expression were also potentiated by <e1>isobutylmethylxanthine<\\e1> and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"isobutylmethylxanthine","object":"tissue factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibitory effects of iloprost on <e2>GENE-Y<\\e2> expression were also potentiated by <e1>CHEMICAL<\\e1> and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP","sentence":"The inhibitory effects of iloprost on tissue factor expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP"}
{"PMID":1375507,"re_id":9,"annotated sentence":"The inhibitory effects of iloprost on <e2>tissue factor<\\e2> expression were also potentiated by isobutylmethylxanthine and mimicked by <e1>forskolin<\\e1> and dibutyryl cyclic AMP but not dibutyryl cyclic GMP","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"forskolin","object":"tissue factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibitory effects of iloprost on <e2>GENE-Y<\\e2> expression were also potentiated by isobutylmethylxanthine and mimicked by <e1>CHEMICAL<\\e1> and dibutyryl cyclic AMP but not dibutyryl cyclic GMP","sentence":"The inhibitory effects of iloprost on tissue factor expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP"}
{"PMID":1375507,"re_id":10,"annotated sentence":"The inhibitory effects of iloprost on <e2>tissue factor<\\e2> expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and d<e1>ibutyryl cyclic AMP<\\e1> but not dibutyryl cyclic GMP","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibutyryl cyclic AMP","object":"tissue factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibitory effects of iloprost on <e2>GENE-Y<\\e2> expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and d<e1>CHEMICAL<\\e1> but not dibutyryl cyclic GMP","sentence":"The inhibitory effects of iloprost on tissue factor expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP"}
{"PMID":1386491,"re_id":0,"annotated sentence":"On study day 1, <e1>candoxatril<\\e1> acutely increased plasma <e2>ANP<\\e2> levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"candoxatril","object":"ANP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On study day 1, <e1>CHEMICAL<\\e1> acutely increased plasma <e2>GENE-Y<\\e2> levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures","sentence":"On study day 1, candoxatril acutely increased plasma ANP levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures"}
{"PMID":1386491,"re_id":1,"annotated sentence":"On study day 10, the acute effects of <e1>candoxatril<\\e1> were similar to those on day 1 (i.e., <e2>ANP<\\e2> was further increased, aldosterone was suppressed, and right and left ventricular filling pressures were decreased)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"candoxatril","object":"ANP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On study day 10, the acute effects of <e1>CHEMICAL<\\e1> were similar to those on day 1 (i.e., <e2>GENE-Y<\\e2> was further increased, aldosterone was suppressed, and right and left ventricular filling pressures were decreased)","sentence":"On study day 10, the acute effects of candoxatril were similar to those on day 1 (i.e., ANP was further increased, aldosterone was suppressed, and right and left ventricular filling pressures were decreased)"}
{"PMID":1386491,"re_id":2,"annotated sentence":"<e1>Candoxatril<\\e1> is a novel, orally active inhibitor of <e2>neutral endopeptidase<\\e2> EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide (ANP)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Candoxatril","object":"neutral endopeptidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a novel, orally active inhibitor of <e2>GENE-Y<\\e2> EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide (ANP)","sentence":"Candoxatril is a novel, orally active inhibitor of neutral endopeptidase EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide (ANP)"}
{"PMID":1386491,"re_id":3,"annotated sentence":"<e1>Candoxatril<\\e1> is a novel, orally active inhibitor of neutral endopeptidase <e2>EC 3.4.24.11<\\e2>  the enzyme that degrades atrial natriuretic peptide (ANP)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Candoxatril","object":"EC 3.4.24.11","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a novel, orally active inhibitor of neutral endopeptidase <e2>GENE-Y<\\e2>  the enzyme that degrades atrial natriuretic peptide (ANP)","sentence":"Candoxatril is a novel, orally active inhibitor of neutral endopeptidase EC 3.4.24.11  the enzyme that degrades atrial natriuretic peptide (ANP)"}
{"PMID":1386491,"re_id":4,"annotated sentence":"Effectiveness of <e2>endopeptidase<\\e2> inhibition (<e1>candoxatril<\\e1>  in congestive heart failure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"candoxatril","object":"endopeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effectiveness of <e2>GENE-N<\\e2> inhibition (<e1>CHEMICAL<\\e1>  in congestive heart failure","sentence":"Effectiveness of endopeptidase inhibition (candoxatril  in congestive heart failure"}
{"PMID":14501155,"re_id":0,"annotated sentence":"These results suggest that <e1>clomipramine<\\e1> induces hyperglycemia in mice by blocking the <e2>5-HT(2B )<\\e2> nd\/or 5-HT(2C) receptors, which results in facilitation of adrenaline release.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clomipramine","object":"5-HT(2B )","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> induces hyperglycemia in mice by blocking the <e2>GENE-Y<\\e2> nd\/or 5-HT(2C) receptors, which results in facilitation of adrenaline release.","sentence":"These results suggest that clomipramine induces hyperglycemia in mice by blocking the 5-HT(2B ) nd\/or 5-HT(2C) receptors, which results in facilitation of adrenaline release."}
{"PMID":14501155,"re_id":1,"annotated sentence":"These results suggest that <e1>clomipramine<\\e1> induces hyperglycemia in mice by blocking the 5-HT(2B )and\/or <e2>5-HT(2C)<\\e2> receptors, which results in facilitation of adrenaline release.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clomipramine","object":"5-HT(2C)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> induces hyperglycemia in mice by blocking the 5-HT(2B )and\/or <e2>GENE-Y<\\e2> receptors, which results in facilitation of adrenaline release.","sentence":"These results suggest that clomipramine induces hyperglycemia in mice by blocking the 5-HT(2B )and\/or 5-HT(2C) receptors, which results in facilitation of adrenaline release."}
{"PMID":14501155,"re_id":2,"annotated sentence":"The 5-HT(1\/2\/5\/7)-receptor antagonist methysergide and the 5-HT(2A\/2B\/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the <e2>5-HT(1A\/1B)-receptor<\\e2> antagonist <e1>(-)-propranolol<\\e1> and the 5-HT(3\/4)-receptor antagonist tropisetron did not affect it","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(-)-propranolol","object":"5-HT(1A\/1B)-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The 5-HT(1\/2\/5\/7)-receptor antagonist methysergide and the 5-HT(2A\/2B\/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> and the 5-HT(3\/4)-receptor antagonist tropisetron did not affect it","sentence":"The 5-HT(1\/2\/5\/7)-receptor antagonist methysergide and the 5-HT(2A\/2B\/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A\/1B)-receptor antagonist (-)-propranolol and the 5-HT(3\/4)-receptor antagonist tropisetron did not affect it"}
{"PMID":14501155,"re_id":3,"annotated sentence":"The 5-HT(1\/2\/5\/7)-receptor antagonist methysergide and the 5-HT(2A\/2B\/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A\/1B)-receptor antagonist (-)-propranolol and the <e2>5-HT(3\/4)-receptor<\\e2> antagonist <e1>tropisetron<\\e1> did not affect it","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tropisetron","object":"5-HT(3\/4)-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The 5-HT(1\/2\/5\/7)-receptor antagonist methysergide and the 5-HT(2A\/2B\/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A\/1B)-receptor antagonist (-)-propranolol and the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> did not affect it","sentence":"The 5-HT(1\/2\/5\/7)-receptor antagonist methysergide and the 5-HT(2A\/2B\/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A\/1B)-receptor antagonist (-)-propranolol and the 5-HT(3\/4)-receptor antagonist tropisetron did not affect it"}
{"PMID":14501155,"re_id":4,"annotated sentence":"The <e2>5-HT(2B\/2C)-receptor<\\e2> antagonist <e1>SB 206553<\\e1> facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB 206553","object":"5-HT(2B\/2C)-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect","sentence":"The 5-HT(2B\/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect"}
{"PMID":14501155,"re_id":5,"annotated sentence":"The 5-HT(2B\/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the <e2>5-HT(2A)<\\e2> receptor antagonist <e1>ketanserin<\\e1> was without effect","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ketanserin","object":"5-HT(2A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The 5-HT(2B\/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the <e2>GENE-Y<\\e2> receptor antagonist <e1>CHEMICAL<\\e1> was without effect","sentence":"The 5-HT(2B\/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A) receptor antagonist ketanserin was without effect"}
{"PMID":14501155,"re_id":6,"annotated sentence":"The 5-HT(1\/2\/5\/7)-receptor antagonist methysergide and the <e2>5-HT(2A\/2B\/2C)-receptor<\\e2> antagonist <e1>LY 53857<\\e1> enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A\/1B)-receptor antagonist (-)-propranolol and the 5-HT(3\/4)-receptor antagonist tropisetron did not affect it","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY 53857","object":"5-HT(2A\/2B\/2C)-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The 5-HT(1\/2\/5\/7)-receptor antagonist methysergide and the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A\/1B)-receptor antagonist (-)-propranolol and the 5-HT(3\/4)-receptor antagonist tropisetron did not affect it","sentence":"The 5-HT(1\/2\/5\/7)-receptor antagonist methysergide and the 5-HT(2A\/2B\/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A\/1B)-receptor antagonist (-)-propranolol and the 5-HT(3\/4)-receptor antagonist tropisetron did not affect it"}
{"PMID":14505791,"re_id":0,"annotated sentence":"The potent <e2>histamine H(1)-receptor<\\e2> antagonist <e1>cetirizine<\\e1> (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"cetirizine","object":"histamine H(1)-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potent <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (Zyrtec) is a racemic mixture of levoCHEMICAL (now available under the trademark Xyzal and dextroCHEMICAL","sentence":"The potent histamine H(1)-receptor antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine"}
{"PMID":14505791,"re_id":1,"annotated sentence":"The potent <e2>histamine H(1)-receptor<\\e2> antagonist cetirizine (<e1>Zyrtec<\\e1>  is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Zyrtec","object":"histamine H(1)-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potent <e2>GENE-Y<\\e2> antagonist cetirizine (<e1>CHEMICAL<\\e1>  is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine","sentence":"The potent histamine H(1)-receptor antagonist cetirizine (Zyrtec  is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine"}
{"PMID":14505791,"re_id":2,"annotated sentence":"The potent <e2>histamine H(1)-receptor<\\e2> antagonist cetirizine (Zyrtec) is a racemic mixture of <e1>levocetirizine<\\e1> (now available under the trademark Xyzal and dextrocetirizine","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"levocetirizine","object":"histamine H(1)-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potent <e2>GENE-Y<\\e2> antagonist cetirizine (Zyrtec) is a racemic mixture of <e1>CHEMICAL<\\e1> (now available under the trademark Xyzal and dextrocetirizine","sentence":"The potent histamine H(1)-receptor antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine"}
{"PMID":14505791,"re_id":3,"annotated sentence":"Compared pharmacological characteristics in humans of racemic <e1>cetirizine<\\e1> and levocetirizine, two <e2>histamine H1-receptor<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"cetirizine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared pharmacological characteristics in humans of racemic <e1>CHEMICAL<\\e1> and levoCHEMICAL, two <e2>GENE-Y<\\e2> antagonists","sentence":"Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists"}
{"PMID":14505791,"re_id":4,"annotated sentence":"Compared pharmacological characteristics in humans of racemic cetirizine and <e1>levocetirizine<\\e1>  two <e2>histamine H1-receptor<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"levocetirizine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared pharmacological characteristics in humans of racemic cetirizine and <e1>CHEMICAL<\\e1>  two <e2>GENE-Y<\\e2> antagonists","sentence":"Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine  two histamine H1-receptor antagonists"}
{"PMID":14505791,"re_id":5,"annotated sentence":"The potent <e2>histamine H(1)-receptor<\\e2> antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark <e1>Xyzal<\\e1> and dextrocetirizine","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Xyzal","object":"histamine H(1)-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potent <e2>GENE-Y<\\e2> antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark <e1>CHEMICAL<\\e1> and dextrocetirizine","sentence":"The potent histamine H(1)-receptor antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine"}
{"PMID":14505791,"re_id":6,"annotated sentence":"The potent <e2>histamine H(1)-receptor<\\e2> antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and <e1>dextrocetirizine<\\e1>  In this Commentary, we examine some biological properties of cetirizine and levocetirizine, namely enantioselectivity in pharmacological activity and pharmacokinetic properties, with emphasis on the possibility of racemization, the compared behavior of the two enantiomers, and the potential for interactions with other drugs","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"dextrocetirizine","object":"histamine H(1)-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potent <e2>GENE-Y<\\e2> antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and <e1>CHEMICAL<\\e1>  In this Commentary, we examine some biological properties of cetirizine and levocetirizine, namely enantioselectivity in pharmacological activity and pharmacokinetic properties, with emphasis on the possibility of racemization, the compared behavior of the two enantiomers, and the potential for interactions with other drugs","sentence":"The potent histamine H(1)-receptor antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine  In this Commentary, we examine some biological properties of cetirizine and levocetirizine, namely enantioselectivity in pharmacological activity and pharmacokinetic properties, with emphasis on the possibility of racemization, the compared behavior of the two enantiomers, and the potential for interactions with other drugs"}
{"PMID":14507109,"re_id":0,"annotated sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor <e1>chloramine T<\\e1> (CT), to destroy <e2>plasmatic PAI-1<\\e2> and alpha2-antiplasmin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"chloramine T","object":"plasmatic PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor <e1>CHEMICAL<\\e1> (CT), to destroy <e2>GENE-Y<\\e2> and alpha2-antiplasmin","sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-antiplasmin"}
{"PMID":14507109,"re_id":1,"annotated sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor <e1>chloramine T<\\e1> (CT), to destroy plasmatic PAI-1 and alpha2-anti<e2>plasmin<\\e2>  After 0 to 80 minutes (37 degrees C), 50-microL samples were withdrawn and added to 100 microL 1.5 M arginine, pH 8.7, and oxidized with 50 microL of 20 mM CT","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"chloramine T","object":"plasmin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor <e1>CHEMICAL<\\e1> (CT), to destroy plasmatic PAI-1 and alpha2-anti<e2>GENE-Y<\\e2>  After 0 to 80 minutes (37 degrees C), 50-microL samples were withdrawn and added to 100 microL 1.5 M arginine, pH 8.7, and oxidized with 50 microL of 20 mM CT","sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-antiplasmin  After 0 to 80 minutes (37 degrees C), 50-microL samples were withdrawn and added to 100 microL 1.5 M arginine, pH 8.7, and oxidized with 50 microL of 20 mM CT"}
{"PMID":14507109,"re_id":2,"annotated sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (<e1>CT<\\e1> , to destroy <e2>plasmatic PAI-1<\\e2> and alpha2-antiplasmin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CT","object":"plasmatic PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (<e1>CHEMICAL<\\e1> , to destroy <e2>GENE-Y<\\e2> and alpha2-antiplasmin","sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (CT , to destroy plasmatic PAI-1 and alpha2-antiplasmin"}
{"PMID":14507109,"re_id":3,"annotated sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (<e1>CT<\\e1> , to destroy plasmatic PAI-1 and alpha2-anti<e2>plasmin<\\e2>  After 0 to 80 minutes (37 degrees C), 50-microL samples were withdrawn and added to 100 microL 1.5 M arginine, pH 8.7, and oxidized with 50 microL of 20 mM CT","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CT","object":"plasmin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (<e1>CHEMICAL<\\e1> , to destroy plasmatic PAI-1 and alpha2-anti<e2>GENE-Y<\\e2>  After 0 to 80 minutes (37 degrees C), 50-microL samples were withdrawn and added to 100 microL 1.5 M arginine, pH 8.7, and oxidized with 50 microL of 20 mM CHEMICAL","sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (CT , to destroy plasmatic PAI-1 and alpha2-antiplasmin  After 0 to 80 minutes (37 degrees C), 50-microL samples were withdrawn and added to 100 microL 1.5 M arginine, pH 8.7, and oxidized with 50 microL of 20 mM CT"}
{"PMID":14507109,"re_id":4,"annotated sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the <e1>singlet oxygen<\\e1> (1O2) donor chloramine T (CT), to destroy <e2>plasmatic PAI-1<\\e2> and alpha2-antiplasmin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"singlet oxygen","object":"plasmatic PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the <e1>CHEMICAL<\\e1> (1O2) donor chloramine T (CT), to destroy <e2>GENE-Y<\\e2> and alpha2-antiplasmin","sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-antiplasmin"}
{"PMID":14507109,"re_id":5,"annotated sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (<e1>1O2<\\e1>  donor chloramine T (CT), to destroy <e2>plasmatic PAI-1<\\e2> and alpha2-antiplasmin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1O2","object":"plasmatic PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (<e1>CHEMICAL<\\e1>  donor chloramine T (CT), to destroy <e2>GENE-Y<\\e2> and alpha2-antiplasmin","sentence":"Ten IU\/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2  donor chloramine T (CT), to destroy plasmatic PAI-1 and alpha2-antiplasmin"}
{"PMID":14507109,"re_id":6,"annotated sentence":"For determination of <e2>plasmin<\\e2> activity, 10 microL thereof was incubated with 150 microL 1.5 M <e1>arginine<\\e1>  pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arginine","object":"plasmin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"For determination of <e2>GENE-Y<\\e2> activity, 10 microL thereof was incubated with 150 microL 1.5 M <e1>CHEMICAL<\\e1>  pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C)","sentence":"For determination of plasmin activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine  pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C)"}
{"PMID":14507109,"re_id":7,"annotated sentence":"For determination of [<e2>PA<\\e2> Pli]-activity, <e1>arginine<\\e1> was added after this incubation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arginine","object":"PA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"For determination of [<e2>GENE-N<\\e2> Pli]-activity, <e1>CHEMICAL<\\e1> was added after this incubation","sentence":"For determination of [PA Pli]-activity, arginine was added after this incubation"}
{"PMID":14507109,"re_id":8,"annotated sentence":"For determination of [PA+<e2>Pli<\\e2> -activity, <e1>arginine<\\e1> was added after this incubation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arginine","object":"Pli","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"For determination of [PA+<e2>GENE-Y<\\e2> -activity, <e1>CHEMICAL<\\e1> was added after this incubation","sentence":"For determination of [PA+Pli -activity, arginine was added after this incubation"}
{"PMID":14507899,"re_id":0,"annotated sentence":"<e2>P2Y(2) receptor<\\e2> agonist <e1>INS37217<\\e1> enhances functional recovery after detachment caused by subretinal injection in normal and rds mice","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"INS37217","object":"P2Y(2) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> enhances functional recovery after detachment caused by subretinal injection in normal and rds mice","sentence":"P2Y(2) receptor agonist INS37217 enhances functional recovery after detachment caused by subretinal injection in normal and rds mice"}
{"PMID":14508322,"re_id":0,"annotated sentence":"Activation of <e2>alpha 2B-adrenoceptors<\\e2> mediates the cardiovascular effects of <e1>etomidate<\\e1>  BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific alpha2-adrenoceptor agonists of the type such as dexmedetomidine","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"etomidate","object":"alpha 2B-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>GENE-Y<\\e2> mediates the cardiovascular effects of <e1>CHEMICAL<\\e1>  BACKGROUND: The intravenous anesthetic CHEMICAL exhibits structural similarities to specific alpha2-adrenoceptor agonists of the type such as dexmedetomidine","sentence":"Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate  BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific alpha2-adrenoceptor agonists of the type such as dexmedetomidine"}
{"PMID":14508322,"re_id":1,"annotated sentence":"In alpha2B-receptor-expressing HEK293 cells, <e1>etomidate<\\e1> rapidly increased phosphorylation of the <e2>extracellular signal-related kinases<\\e2> ERK1\/2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"etomidate","object":"extracellular signal-related kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In alpha2B-receptor-expressing HEK293 cells, <e1>CHEMICAL<\\e1> rapidly increased phosphorylation of the <e2>GENE-N<\\e2> ERK1\/2","sentence":"In alpha2B-receptor-expressing HEK293 cells, etomidate rapidly increased phosphorylation of the extracellular signal-related kinases ERK1\/2"}
{"PMID":14508322,"re_id":2,"annotated sentence":"In alpha2B-receptor-expressing HEK293 cells, <e1>etomidate<\\e1> rapidly increased phosphorylation of the extracellular signal-related kinases <e2>ERK1\/2<\\e2>  CONCLUSIONS: These results indicate that etomidate acts as an agonist at alpha2-adrenoceptors, which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"etomidate","object":"ERK1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In alpha2B-receptor-expressing HEK293 cells, <e1>CHEMICAL<\\e1> rapidly increased phosphorylation of the extracellular signal-related kinases <e2>GENE-N<\\e2>  CONCLUSIONS: These results indicate that CHEMICAL acts as an agonist at alpha2-adrenoceptors, which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure","sentence":"In alpha2B-receptor-expressing HEK293 cells, etomidate rapidly increased phosphorylation of the extracellular signal-related kinases ERK1\/2  CONCLUSIONS: These results indicate that etomidate acts as an agonist at alpha2-adrenoceptors, which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure"}
{"PMID":14508322,"re_id":3,"annotated sentence":"METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist, <e1>dexmedetomidine<\\e1>  were determined in mice deficient in <e2>alpha2-receptor<\\e2> subtypes","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"dexmedetomidine","object":"alpha2-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist, <e1>CHEMICAL<\\e1>  were determined in mice deficient in <e2>GENE-N<\\e2> subtypes","sentence":"METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist, dexmedetomidine  were determined in mice deficient in alpha2-receptor subtypes"}
{"PMID":14508322,"re_id":4,"annotated sentence":"BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific <e2>alpha2-adrenoceptor<\\e2> agonists of the type such as <e1>dexmedetomidine<\\e1>  The current study was performed to elucidate the possible interaction of etomidate with alpha2-adrenoceptors in mice lacking individual alpha2-adrenoceptor subtypes (alpha2-KO)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"dexmedetomidine","object":"alpha2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific <e2>GENE-N<\\e2> agonists of the type such as <e1>CHEMICAL<\\e1>  The current study was performed to elucidate the possible interaction of etomidate with GENE-Ns in mice lacking individual GENE-N subtypes (alpha2-KO)","sentence":"BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific alpha2-adrenoceptor agonists of the type such as dexmedetomidine  The current study was performed to elucidate the possible interaction of etomidate with alpha2-adrenoceptors in mice lacking individual alpha2-adrenoceptor subtypes (alpha2-KO)"}
{"PMID":14508322,"re_id":5,"annotated sentence":"CONCLUSIONS: These results indicate that <e1>etomidate<\\e1> acts as an agonist at <e2>alpha2-adrenoceptors<\\e2>  which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"etomidate","object":"alpha2-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: These results indicate that <e1>CHEMICAL<\\e1> acts as an agonist at <e2>GENE-N<\\e2>  which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure","sentence":"CONCLUSIONS: These results indicate that etomidate acts as an agonist at alpha2-adrenoceptors  which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure"}
{"PMID":14508322,"re_id":6,"annotated sentence":"Inhibition of binding of the <e2>alpha2-receptor<\\e2> antagonist <e1>[3H]RX821002<\\e1> to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"[3H]RX821002","object":"alpha2-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of binding of the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> to recombinant GENE-Ns by etomidate was tested in human embryonic kidney (HEK293) cells in vitro","sentence":"Inhibition of binding of the alpha2-receptor antagonist [3H]RX821002 to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro"}
{"PMID":14508322,"re_id":7,"annotated sentence":"Inhibition of binding of the alpha2-receptor antagonist <e1>[3H]RX821002<\\e1> to recombinant <e2>alpha2-receptors<\\e2> by etomidate was tested in human embryonic kidney (HEK293) cells in vitro","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"[3H]RX821002","object":"alpha2-receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of binding of the alpha2-receptor antagonist <e1>CHEMICAL<\\e1> to recombinant <e2>GENE-N<\\e2> by etomidate was tested in human embryonic kidney (HEK293) cells in vitro","sentence":"Inhibition of binding of the alpha2-receptor antagonist [3H]RX821002 to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro"}
{"PMID":14508322,"re_id":8,"annotated sentence":"In membranes from HEK293 cells transfected with <e2>alpha2-receptors<\\e2>  etomidate inhibited binding of the alpha2-antagonist, <e1>[3H]RX821002<\\e1>  with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"[3H]RX821002","object":"alpha2-receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In membranes from HEK293 cells transfected with <e2>GENE-N<\\e2>  etomidate inhibited binding of the alpha2-antagonist, <e1>CHEMICAL<\\e1>  with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm)","sentence":"In membranes from HEK293 cells transfected with alpha2-receptors  etomidate inhibited binding of the alpha2-antagonist, [3H]RX821002  with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm)"}
{"PMID":14508322,"re_id":9,"annotated sentence":"In membranes from HEK293 cells transfected with alpha2-receptors, etomidate inhibited binding of the alpha2-antagonist, <e1>[3H]RX821002<\\e1>  with higher potency from alpha2B- and alpha2C-receptors than from <e2>alpha2A-receptors<\\e2> (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"[3H]RX821002","object":"alpha2A-receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In membranes from HEK293 cells transfected with alpha2-receptors, etomidate inhibited binding of the alpha2-antagonist, <e1>CHEMICAL<\\e1>  with higher potency from alpha2B- and alpha2C-receptors than from <e2>GENE-Y<\\e2> (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm)","sentence":"In membranes from HEK293 cells transfected with alpha2-receptors, etomidate inhibited binding of the alpha2-antagonist, [3H]RX821002  with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm)"}
{"PMID":14523001,"re_id":0,"annotated sentence":"<e2>Cat-1<\\e2>  the transporter for the essential <e1>amino acids<\\e1>  arginine and lysine, is one of the up-regulated genes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acids","object":"Cat-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2>  the transporter for the essential <e1>CHEMICAL<\\e1>  arginine and lysine, is one of the up-regulated genes","sentence":"Cat-1  the transporter for the essential amino acids  arginine and lysine, is one of the up-regulated genes"}
{"PMID":14523001,"re_id":1,"annotated sentence":"<e2>Cat-1<\\e2>  the transporter for the essential amino acids, <e1>arginine<\\e1> and lysine, is one of the up-regulated genes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arginine","object":"Cat-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2>  the transporter for the essential amino acids, <e1>CHEMICAL<\\e1> and lysine, is one of the up-regulated genes","sentence":"Cat-1  the transporter for the essential amino acids, arginine and lysine, is one of the up-regulated genes"}
{"PMID":14523001,"re_id":2,"annotated sentence":"<e2>Cat-1<\\e2>  the transporter for the essential amino acids, arginine and <e1>lysine<\\e1>  is one of the up-regulated genes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"lysine","object":"Cat-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2>  the transporter for the essential amino acids, arginine and <e1>CHEMICAL<\\e1>  is one of the up-regulated genes","sentence":"Cat-1  the transporter for the essential amino acids, arginine and lysine  is one of the up-regulated genes"}
{"PMID":14530799,"re_id":0,"annotated sentence":"Blockade of <e2>NMDA receptors<\\e2> by <e1>memantine<\\e1> could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"memantine","object":"NMDA receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1> could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia","sentence":"Blockade of NMDA receptors by memantine could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia"}
{"PMID":14530799,"re_id":1,"annotated sentence":"Blockade of NMDA receptors by <e1>memantine<\\e1> could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\" <e2>NMDA receptor<\\e2> dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"memantine","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of GENE-Ns by <e1>CHEMICAL<\\e1> could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\" <e2>GENE-N<\\e2> dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia","sentence":"Blockade of NMDA receptors by memantine could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\" NMDA receptor dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia"}
{"PMID":14530799,"re_id":2,"annotated sentence":"Moreover, recent in vitro studies suggest that <e1>memantine<\\e1> abrogates <e2>beta-amyloid<\\e2> (Abeta) toxicity and possibly inhibits Abeta production","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"memantine","object":"beta-amyloid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, recent in vitro studies suggest that <e1>CHEMICAL<\\e1> abrogates <e2>GENE-Y<\\e2> (Abeta) toxicity and possibly inhibits Abeta production","sentence":"Moreover, recent in vitro studies suggest that memantine abrogates beta-amyloid (Abeta) toxicity and possibly inhibits Abeta production"}
{"PMID":14530799,"re_id":3,"annotated sentence":"Moreover, recent in vitro studies suggest that <e1>memantine<\\e1> abrogates beta-amyloid (<e2>Abeta<\\e2>  toxicity and possibly inhibits Abeta production","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"memantine","object":"Abeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, recent in vitro studies suggest that <e1>CHEMICAL<\\e1> abrogates beta-amyloid (<e2>GENE-Y<\\e2>  toxicity and possibly inhibits GENE-Y production","sentence":"Moreover, recent in vitro studies suggest that memantine abrogates beta-amyloid (Abeta  toxicity and possibly inhibits Abeta production"}
{"PMID":14530799,"re_id":4,"annotated sentence":"Moreover, recent in vitro studies suggest that <e1>memantine<\\e1> abrogates beta-amyloid (Abeta) toxicity and possibly inhibits <e2>Abeta<\\e2> production","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"memantine","object":"Abeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, recent in vitro studies suggest that <e1>CHEMICAL<\\e1> abrogates beta-amyloid (GENE-Y) toxicity and possibly inhibits <e2>GENE-Y<\\e2> production","sentence":"Moreover, recent in vitro studies suggest that memantine abrogates beta-amyloid (Abeta) toxicity and possibly inhibits Abeta production"}
{"PMID":14530799,"re_id":5,"annotated sentence":"<e1>Memantine<\\e1> is an uncompetitive (channel blocking) <e2>NMDA receptor<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Memantine","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is an uncompetitive (channel blocking) <e2>GENE-N<\\e2> antagonist","sentence":"Memantine is an uncompetitive (channel blocking) NMDA receptor antagonist"}
{"PMID":14530799,"re_id":6,"annotated sentence":"Like other <e2>NMDA receptor<\\e2> antagonists, <e1>memantine<\\e1> at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"memantine","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Like other <e2>GENE-N<\\e2> antagonists, <e1>CHEMICAL<\\e1> at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory","sentence":"Like other NMDA receptor antagonists, memantine at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory"}
{"PMID":14530799,"re_id":7,"annotated sentence":"Considerable attention has focused on the investigation of theories to explain the better tolerability of <e1>memantine<\\e1> over other <e2>NMDA receptor<\\e2> antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"memantine","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Considerable attention has focused on the investigation of theories to explain the better tolerability of <e1>CHEMICAL<\\e1> over other <e2>GENE-N<\\e2> antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801)","sentence":"Considerable attention has focused on the investigation of theories to explain the better tolerability of memantine over other NMDA receptor antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801)"}
{"PMID":14587496,"re_id":0,"annotated sentence":"BACKGROUND: <e1>Rivastigmine<\\e1> is a carbamate drug designed to inhibit both <e2>acetylcholinesterase<\\e2> and butyrylcholinesterase by reversibly covalently bonding to these enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rivastigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1> is a carbamate drug designed to inhibit both <e2>GENE-Y<\\e2> and butyrylcholinesterase by reversibly covalently bonding to these enzymes","sentence":"BACKGROUND: Rivastigmine is a carbamate drug designed to inhibit both acetylcholinesterase and butyrylcholinesterase by reversibly covalently bonding to these enzymes"}
{"PMID":14587496,"re_id":1,"annotated sentence":"BACKGROUND: <e1>Rivastigmine<\\e1> is a carbamate drug designed to inhibit both acetylcholinesterase and <e2>butyrylcholinesterase<\\e2> by reversibly covalently bonding to these enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rivastigmine","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1> is a carbamate drug designed to inhibit both acetylcholinesterase and <e2>GENE-Y<\\e2> by reversibly covalently bonding to these enzymes","sentence":"BACKGROUND: Rivastigmine is a carbamate drug designed to inhibit both acetylcholinesterase and butyrylcholinesterase by reversibly covalently bonding to these enzymes"}
{"PMID":14587496,"re_id":2,"annotated sentence":"BACKGROUND: Rivastigmine is a <e1>carbamate<\\e1> drug designed to inhibit both <e2>acetylcholinesterase<\\e2> and butyrylcholinesterase by reversibly covalently bonding to these enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbamate","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Rivastigmine is a <e1>CHEMICAL<\\e1> drug designed to inhibit both <e2>GENE-Y<\\e2> and butyrylcholinesterase by reversibly covalently bonding to these enzymes","sentence":"BACKGROUND: Rivastigmine is a carbamate drug designed to inhibit both acetylcholinesterase and butyrylcholinesterase by reversibly covalently bonding to these enzymes"}
{"PMID":14587496,"re_id":3,"annotated sentence":"BACKGROUND: Rivastigmine is a <e1>carbamate<\\e1> drug designed to inhibit both acetylcholinesterase and <e2>butyrylcholinesterase<\\e2> by reversibly covalently bonding to these enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbamate","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Rivastigmine is a <e1>CHEMICAL<\\e1> drug designed to inhibit both acetylcholinesterase and <e2>GENE-Y<\\e2> by reversibly covalently bonding to these enzymes","sentence":"BACKGROUND: Rivastigmine is a carbamate drug designed to inhibit both acetylcholinesterase and butyrylcholinesterase by reversibly covalently bonding to these enzymes"}
{"PMID":14600253,"re_id":0,"annotated sentence":"Glycylsarcosine coadministration could inhibit the uptake of <e1>cefadroxil<\\e1> in <e2>PEPT2<\\e2> +\/+) mice (p < 0.01) but not PEPT2(-\/-) mice","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cefadroxil","object":"PEPT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Glycylsarcosine coadministration could inhibit the uptake of <e1>CHEMICAL<\\e1> in <e2>GENE-Y<\\e2> +\/+) mice (p < 0.01) but not GENE-Y(-\/-) mice","sentence":"Glycylsarcosine coadministration could inhibit the uptake of cefadroxil in PEPT2 +\/+) mice (p < 0.01) but not PEPT2(-\/-) mice"}
{"PMID":14600253,"re_id":1,"annotated sentence":"Glycylsarcosine coadministration could inhibit the uptake of <e1>cefadroxil<\\e1> in PEPT2(+\/+) mice (p < 0.01) but not <e2>PEPT2<\\e2> -\/-) mice","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cefadroxil","object":"PEPT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Glycylsarcosine coadministration could inhibit the uptake of <e1>CHEMICAL<\\e1> in GENE-Y(+\/+) mice (p < 0.01) but not <e2>GENE-Y<\\e2> -\/-) mice","sentence":"Glycylsarcosine coadministration could inhibit the uptake of cefadroxil in PEPT2(+\/+) mice (p < 0.01) but not PEPT2 -\/-) mice"}
{"PMID":14600253,"re_id":2,"annotated sentence":"Although a proton-stimulated uptake of <e1>cefadroxil<\\e1> was demonstrated in <e2>PEPT2<\\e2> +\/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2(-\/-) mice","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cefadroxil","object":"PEPT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although a proton-stimulated uptake of <e1>CHEMICAL<\\e1> was demonstrated in <e2>GENE-Y<\\e2> +\/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in GENE-Y(-\/-) mice","sentence":"Although a proton-stimulated uptake of cefadroxil was demonstrated in PEPT2 +\/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2(-\/-) mice"}
{"PMID":14600253,"re_id":3,"annotated sentence":"Although a proton-stimulated uptake of <e1>cefadroxil<\\e1> was demonstrated in PEPT2(+\/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in <e2>PEPT2<\\e2> -\/-) mice","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cefadroxil","object":"PEPT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although a proton-stimulated uptake of <e1>CHEMICAL<\\e1> was demonstrated in GENE-Y(+\/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in <e2>GENE-Y<\\e2> -\/-) mice","sentence":"Although a proton-stimulated uptake of cefadroxil was demonstrated in PEPT2(+\/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2 -\/-) mice"}
{"PMID":14600253,"re_id":4,"annotated sentence":"Mechanisms of <e1>cefadroxil<\\e1> uptake in the choroid plexus: studies in wild-type and <e2>PEPT2<\\e2> knockout mice","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cefadroxil","object":"PEPT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mechanisms of <e1>CHEMICAL<\\e1> uptake in the choroid plexus: studies in wild-type and <e2>GENE-Y<\\e2> knockout mice","sentence":"Mechanisms of cefadroxil uptake in the choroid plexus: studies in wild-type and PEPT2 knockout mice"}
{"PMID":14600253,"re_id":5,"annotated sentence":"These findings demonstrate that <e2>PEPT2<\\e2> is the primary transporter responsible for <e1>cefadroxil<\\e1> uptake in the choroid plexus","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cefadroxil","object":"PEPT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings demonstrate that <e2>GENE-Y<\\e2> is the primary transporter responsible for <e1>CHEMICAL<\\e1> uptake in the choroid plexus","sentence":"These findings demonstrate that PEPT2 is the primary transporter responsible for cefadroxil uptake in the choroid plexus"}
{"PMID":14600253,"re_id":6,"annotated sentence":"At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM <e1>cefadroxil<\\e1> was reduced by 83% in <e2>PEPT2<\\e2> -\/-) mice as compared with PEPT2(+\/+) mice (p < 0.001)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cefadroxil","object":"PEPT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM <e1>CHEMICAL<\\e1> was reduced by 83% in <e2>GENE-Y<\\e2> -\/-) mice as compared with GENE-Y(+\/+) mice (p < 0.001)","sentence":"At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM cefadroxil was reduced by 83% in PEPT2 -\/-) mice as compared with PEPT2(+\/+) mice (p < 0.001)"}
{"PMID":14600253,"re_id":7,"annotated sentence":"At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM <e1>cefadroxil<\\e1> was reduced by 83% in PEPT2(-\/-) mice as compared with <e2>PEPT2<\\e2> +\/+) mice (p < 0.001)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cefadroxil","object":"PEPT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM <e1>CHEMICAL<\\e1> was reduced by 83% in GENE-Y(-\/-) mice as compared with <e2>GENE-Y<\\e2> +\/+) mice (p < 0.001)","sentence":"At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM cefadroxil was reduced by 83% in PEPT2(-\/-) mice as compared with PEPT2 +\/+) mice (p < 0.001)"}
{"PMID":14600253,"re_id":8,"annotated sentence":"The choroid plexus uptake of <e1>[(3)H]cefadroxil<\\e1> was studied in <e2>peptide transporter 2<\\e2> (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[(3)H]cefadroxil","object":"peptide transporter 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The choroid plexus uptake of <e1>CHEMICAL<\\e1> was studied in <e2>GENE-Y<\\e2> (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability","sentence":"The choroid plexus uptake of [(3)H]cefadroxil was studied in peptide transporter 2 (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability"}
{"PMID":14600253,"re_id":9,"annotated sentence":"The choroid plexus uptake of <e1>[(3)H]cefadroxil<\\e1> was studied in peptide transporter 2 (<e2>PEPT2<\\e2>  wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[(3)H]cefadroxil","object":"PEPT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The choroid plexus uptake of <e1>CHEMICAL<\\e1> was studied in peptide transporter 2 (<e2>GENE-Y<\\e2>  wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability","sentence":"The choroid plexus uptake of [(3)H]cefadroxil was studied in peptide transporter 2 (PEPT2  wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability"}
{"PMID":14642426,"re_id":0,"annotated sentence":"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and\/or <e1>epinephrine<\\e1> induced increase of <e2>IL-6<\\e2> level in macrophage rather than in the brain","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"epinephrine","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma GENE-Y level would be in periphery; at least in part, mediated by blocking norCHEMICAL- and\/or <e1>CHEMICAL<\\e1> induced increase of <e2>GENE-Y<\\e2> level in macrophage rather than in the brain","sentence":"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and\/or epinephrine induced increase of IL-6 level in macrophage rather than in the brain"}
{"PMID":14642426,"re_id":1,"annotated sentence":"Ginsenosides Rb2, Rd and Rg1 significantly decreased <e1>norepinephrine<\\e1> and\/or epinephrine-induced increase of <e2>IL-6<\\e2> level in macrophage cell line (RAW 264.7)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"norepinephrine","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ginsenosides Rb2, Rd and Rg1 significantly decreased <e1>CHEMICAL<\\e1> and\/or epinephrine-induced increase of <e2>GENE-Y<\\e2> level in macrophage cell line (RAW 264.7)","sentence":"Ginsenosides Rb2, Rd and Rg1 significantly decreased norepinephrine and\/or epinephrine-induced increase of IL-6 level in macrophage cell line (RAW 264.7)"}
{"PMID":14642426,"re_id":2,"annotated sentence":"Ginsenosides Rb2, Rd and Rg1 significantly decreased norepinephrine and\/or <e1>epinephrine<\\e1> induced increase of <e2>IL-6<\\e2> level in macrophage cell line (RAW 264.7)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"epinephrine","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ginsenosides Rb2, Rd and Rg1 significantly decreased norCHEMICAL and\/or <e1>CHEMICAL<\\e1> induced increase of <e2>GENE-Y<\\e2> level in macrophage cell line (RAW 264.7)","sentence":"Ginsenosides Rb2, Rd and Rg1 significantly decreased norepinephrine and\/or epinephrine induced increase of IL-6 level in macrophage cell line (RAW 264.7)"}
{"PMID":14642426,"re_id":3,"annotated sentence":"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking <e1>norepinephrine<\\e1>  and\/or epinephrine-induced increase of <e2>IL-6<\\e2> level in macrophage rather than in the brain","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"norepinephrine","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma GENE-Y level would be in periphery; at least in part, mediated by blocking <e1>CHEMICAL<\\e1>  and\/or epinephrine-induced increase of <e2>GENE-Y<\\e2> level in macrophage rather than in the brain","sentence":"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine  and\/or epinephrine-induced increase of IL-6 level in macrophage rather than in the brain"}
{"PMID":14642426,"re_id":4,"annotated sentence":"The inhibitory effect of <e1>ginseng saponins<\\e1> on the stress-induced plasma <e2>interleukin-6<\\e2> level in mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ginseng saponins","object":"interleukin-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibitory effect of <e1>CHEMICAL<\\e1> on the stress-induced plasma <e2>GENE-Y<\\e2> level in mice","sentence":"The inhibitory effect of ginseng saponins on the stress-induced plasma interleukin-6 level in mice"}
{"PMID":14642426,"re_id":5,"annotated sentence":"Ginseng total <e1>saponins<\\e1>  ginsenosides Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma <e2>IL-6<\\e2> level","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"saponins","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ginseng total <e1>CHEMICAL<\\e1>  ginsenosides Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma <e2>GENE-Y<\\e2> level","sentence":"Ginseng total saponins  ginsenosides Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma IL-6 level"}
{"PMID":14642426,"re_id":6,"annotated sentence":"Ginseng total saponins, <e1>ginsenosides Rb2, Rg1 and Rd<\\e1> administered intraperitoneally attenuated the immobilization stress-induced increase in plasma <e2>IL-6<\\e2> level","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ginsenosides Rb2, Rg1 and Rd","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ginseng total saponins, <e1>CHEMICAL<\\e1> administered intraperitoneally attenuated the immobilization stress-induced increase in plasma <e2>GENE-Y<\\e2> level","sentence":"Ginseng total saponins, ginsenosides Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma IL-6 level"}
{"PMID":14642426,"re_id":7,"annotated sentence":"<e1>Ginsenosides Rb2, Rd and Rg1<\\e1> significantly decreased norepinephrine and\/or epinephrine-induced increase of <e2>IL-6<\\e2> level in macrophage cell line (RAW 264.7)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ginsenosides Rb2, Rd and Rg1","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> significantly decreased norepinephrine and\/or epinephrine-induced increase of <e2>GENE-Y<\\e2> level in macrophage cell line (RAW 264.7)","sentence":"Ginsenosides Rb2, Rd and Rg1 significantly decreased norepinephrine and\/or epinephrine-induced increase of IL-6 level in macrophage cell line (RAW 264.7)"}
{"PMID":14642426,"re_id":8,"annotated sentence":"Thus, it can be suggested that the inhibitory action of <e1>ginseng saponins<\\e1> against the immobilization stress-induced increase of plasma <e2>IL-6<\\e2> level would be in periphery; at least in part, mediated by blocking norepinephrine- and\/or epinephrine-induced increase of IL-6 level in macrophage rather than in the brain","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ginseng saponins","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, it can be suggested that the inhibitory action of <e1>CHEMICAL<\\e1> against the immobilization stress-induced increase of plasma <e2>GENE-Y<\\e2> level would be in periphery; at least in part, mediated by blocking norepinephrine- and\/or epinephrine-induced increase of GENE-Y level in macrophage rather than in the brain","sentence":"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and\/or epinephrine-induced increase of IL-6 level in macrophage rather than in the brain"}
{"PMID":14642426,"re_id":9,"annotated sentence":"Thus, it can be suggested that the inhibitory action of <e1>ginseng saponins<\\e1> against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and\/or epinephrine-induced increase of <e2>IL-6<\\e2> level in macrophage rather than in the brain","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ginseng saponins","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, it can be suggested that the inhibitory action of <e1>CHEMICAL<\\e1> against the immobilization stress-induced increase of plasma GENE-Y level would be in periphery; at least in part, mediated by blocking norepinephrine- and\/or epinephrine-induced increase of <e2>GENE-Y<\\e2> level in macrophage rather than in the brain","sentence":"Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma IL-6 level would be in periphery; at least in part, mediated by blocking norepinephrine- and\/or epinephrine-induced increase of IL-6 level in macrophage rather than in the brain"}
{"PMID":14680444,"re_id":0,"annotated sentence":"The <e2>alpha(1)-adrenoceptor<\\e2> antagonist, <e1>tamsulosin<\\e1>  is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tamsulosin","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1>  is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors","sentence":"The alpha(1)-adrenoceptor antagonist, tamsulosin  is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors"}
{"PMID":14680444,"re_id":1,"annotated sentence":"The alpha(1)-adrenoceptor antagonist, <e1>tamsulosin<\\e1>  is selective for <e2>alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors<\\e2>  Both placebo-controlled and comparative studies with other agents have demonstrated tamsulosin to be an effective treatment for patients with lower urinary symptoms suggestive of benign prostatic hyperplasia","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tamsulosin","object":"alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The alpha(1)-adrenoceptor antagonist, <e1>CHEMICAL<\\e1>  is selective for <e2>GENE-N<\\e2>  Both placebo-controlled and comparative studies with other agents have demonstrated CHEMICAL to be an effective treatment for patients with lower urinary symptoms suggestive of benign prostatic hyperplasia","sentence":"The alpha(1)-adrenoceptor antagonist, tamsulosin  is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors  Both placebo-controlled and comparative studies with other agents have demonstrated tamsulosin to be an effective treatment for patients with lower urinary symptoms suggestive of benign prostatic hyperplasia"}
{"PMID":14692707,"re_id":0,"annotated sentence":"On the other hand, in patients with a mean serum <e1>carvedilol<\\e1> level (Cmin) of less than 2.5 nmol\/l up to 2 weeks after the start ofcarvedilol therapy, the degree of reduction in the <e2>BNP<\\e2> value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol\/l","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the other hand, in patients with a mean serum <e1>CHEMICAL<\\e1> level (Cmin) of less than 2.5 nmol\/l up to 2 weeks after the start ofCHEMICAL therapy, the degree of reduction in the <e2>GENE-Y<\\e2> value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol\/l","sentence":"On the other hand, in patients with a mean serum carvedilol level (Cmin) of less than 2.5 nmol\/l up to 2 weeks after the start ofcarvedilol therapy, the degree of reduction in the BNP value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol\/l"}
{"PMID":14692707,"re_id":1,"annotated sentence":"On the other hand, in patients with a mean serum carvedilol level (Cmin) of less than 2.5 nmol\/l up to 2 weeks after the start of<e1>carvedilol<\\e1> therapy, the degree of reduction in the <e2>BNP<\\e2> value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol\/l","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the other hand, in patients with a mean serum CHEMICAL level (Cmin) of less than 2.5 nmol\/l up to 2 weeks after the start of<e1>CHEMICAL<\\e1> therapy, the degree of reduction in the <e2>GENE-Y<\\e2> value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol\/l","sentence":"On the other hand, in patients with a mean serum carvedilol level (Cmin) of less than 2.5 nmol\/l up to 2 weeks after the start ofcarvedilol therapy, the degree of reduction in the BNP value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol\/l"}
{"PMID":14711372,"re_id":0,"annotated sentence":"<e2>CPT I<\\e2> (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into <e1>palmitoylcarnitine<\\e1> in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"palmitoylcarnitine","object":"CPT I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into <e1>CHEMICAL<\\e1> in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria","sentence":"CPT I (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria"}
{"PMID":14711372,"re_id":1,"annotated sentence":"CPT I (<e2>carnitine palmitoyltransferase I<\\e2>  catalyses the conversion of palmitoyl-CoA into <e1>palmitoylcarnitine<\\e1> in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"palmitoylcarnitine","object":"carnitine palmitoyltransferase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CPT I (<e2>GENE-Y<\\e2>  catalyses the conversion of palmitoyl-CoA into <e1>CHEMICAL<\\e1> in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria","sentence":"CPT I (carnitine palmitoyltransferase I  catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria"}
{"PMID":14711372,"re_id":2,"annotated sentence":"<e2>CPT I<\\e2> (carnitine palmitoyltransferase I) catalyses the conversion of <e1>palmitoyl-CoA<\\e1> into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"palmitoyl-CoA","object":"CPT I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (carnitine palmitoyltransferase I) catalyses the conversion of <e1>CHEMICAL<\\e1> into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria","sentence":"CPT I (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria"}
{"PMID":14711372,"re_id":3,"annotated sentence":"CPT I (<e2>carnitine palmitoyltransferase I<\\e2>  catalyses the conversion of <e1>palmitoyl-CoA<\\e1> into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"palmitoyl-CoA","object":"carnitine palmitoyltransferase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CPT I (<e2>GENE-Y<\\e2>  catalyses the conversion of <e1>CHEMICAL<\\e1> into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria","sentence":"CPT I (carnitine palmitoyltransferase I  catalyses the conversion of palmitoyl-CoA into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria"}
{"PMID":14719072,"re_id":0,"annotated sentence":"<e1>TAS-102<\\e1> currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of <e2>TS<\\e2> and incorporation into DNA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAS-102","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of <e2>GENE-Y<\\e2> and incorporation into DNA","sentence":"TAS-102 currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of TS and incorporation into DNA"}
{"PMID":14719072,"re_id":1,"annotated sentence":"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and <e2>thymidilate synthase<\\e2> (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of <e1>TAS-102<\\e1>  Antitumor activity of TAS-102 appears to be associated with TK, tumor growth and TS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAS-102","object":"thymidilate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and <e2>GENE-Y<\\e2> (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of <e1>CHEMICAL<\\e1>  Antitumor activity of CHEMICAL appears to be associated with TK, tumor growth and TS","sentence":"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102  Antitumor activity of TAS-102 appears to be associated with TK, tumor growth and TS"}
{"PMID":14719072,"re_id":2,"annotated sentence":"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase (<e2>TS<\\e2>  in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of <e1>TAS-102<\\e1>  Antitumor activity of TAS-102 appears to be associated with TK, tumor growth and TS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAS-102","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase (<e2>GENE-Y<\\e2>  in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of <e1>CHEMICAL<\\e1>  Antitumor activity of CHEMICAL appears to be associated with TK, tumor growth and GENE-Y","sentence":"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS  in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of TAS-102  Antitumor activity of TAS-102 appears to be associated with TK, tumor growth and TS"}
{"PMID":14725487,"re_id":0,"annotated sentence":"Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the <e2>beta(2)-adrenoceptor<\\e2> agonist <e1>formoterol<\\e1> [eformoterol]","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"formoterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sepracor in the US is developing arCHEMICAL [R,R-CHEMICAL], a single isomer form of the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> [eCHEMICAL]","sentence":"Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]"}
{"PMID":14725487,"re_id":1,"annotated sentence":"Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the <e2>beta(2)-adrenoceptor<\\e2> agonist formoterol [<e1>eformoterol<\\e1> ","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"eformoterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the <e2>GENE-Y<\\e2> agonist formoterol [<e1>CHEMICAL<\\e1> ","sentence":"Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol "}
{"PMID":14737100,"re_id":0,"annotated sentence":"Increased phosphorylation of <e2>p95ErbB2<\\e2> and AKT in response to HRG was abrogated to varying degrees by <e1>GW572016<\\e1>  In contrast, trastuzumab did not inhibit p95ErbB2 phosphorylation or the expression of downstream phospho-Erk1\/2, phospho-AKT, or cyclin D","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"p95ErbB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased phosphorylation of <e2>GENE-Y<\\e2> and AKT in response to HRG was abrogated to varying degrees by <e1>CHEMICAL<\\e1>  In contrast, trastuzumab did not inhibit GENE-Y phosphorylation or the expression of downstream phospho-Erk1\/2, phospho-AKT, or cyclin D","sentence":"Increased phosphorylation of p95ErbB2 and AKT in response to HRG was abrogated to varying degrees by GW572016  In contrast, trastuzumab did not inhibit p95ErbB2 phosphorylation or the expression of downstream phospho-Erk1\/2, phospho-AKT, or cyclin D"}
{"PMID":14737100,"re_id":1,"annotated sentence":"Increased phosphorylation of p95ErbB2 and <e2>AKT<\\e2> in response to HRG was abrogated to varying degrees by <e1>GW572016<\\e1>  In contrast, trastuzumab did not inhibit p95ErbB2 phosphorylation or the expression of downstream phospho-Erk1\/2, phospho-AKT, or cyclin D","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Increased phosphorylation of p95ErbB2 and <e2>GENE-N<\\e2> in response to HRG was abrogated to varying degrees by <e1>CHEMICAL<\\e1>  In contrast, trastuzumab did not inhibit p95ErbB2 phosphorylation or the expression of downstream phospho-Erk1\/2, phospho-GENE-N, or cyclin D","sentence":"Increased phosphorylation of p95ErbB2 and AKT in response to HRG was abrogated to varying degrees by GW572016  In contrast, trastuzumab did not inhibit p95ErbB2 phosphorylation or the expression of downstream phospho-Erk1\/2, phospho-AKT, or cyclin D"}
{"PMID":14737100,"re_id":2,"annotated sentence":"<e1>GW572016<\\e1>  a reversible small molecule inhibitor of <e2>EGFR<\\e2> and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a reversible small molecule inhibitor of <e2>GENE-Y<\\e2> and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts","sentence":"GW572016  a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts"}
{"PMID":14737100,"re_id":3,"annotated sentence":"<e1>GW572016<\\e1>  a reversible small molecule inhibitor of EGFR and <e2>ErbB2<\\e2> tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"ErbB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a reversible small molecule inhibitor of EGFR and <e2>GENE-Y<\\e2> tyrosine kinases, inhibits baseline p95GENE-Y phosphorylation in BT474 cells and tumor xenografts","sentence":"GW572016  a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts"}
{"PMID":14737100,"re_id":4,"annotated sentence":"<e1>GW572016<\\e1>  a reversible small molecule inhibitor of EGFR and ErbB2 <e2>tyrosine kinases<\\e2>  inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a reversible small molecule inhibitor of EGFR and ErbB2 <e2>GENE-N<\\e2>  inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts","sentence":"GW572016  a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases  inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts"}
{"PMID":14737100,"re_id":5,"annotated sentence":"<e1>GW572016<\\e1>  a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline <e2>p95ErbB2<\\e2> phosphorylation in BT474 cells and tumor xenografts","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"p95ErbB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline <e2>GENE-Y<\\e2> phosphorylation in BT474 cells and tumor xenografts","sentence":"GW572016  a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts"}
{"PMID":14737100,"re_id":6,"annotated sentence":"Inhibition of <e2>p95ErbB2<\\e2>  p185ErbB2, and EGFR phosphorylation by <e1>GW572016<\\e1> resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and cyclin D steady-state protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"p95ErbB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2>  p185ErbB2, and EGFR phosphorylation by <e1>CHEMICAL<\\e1> resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and cyclin D steady-state protein levels","sentence":"Inhibition of p95ErbB2  p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and cyclin D steady-state protein levels"}
{"PMID":14737100,"re_id":7,"annotated sentence":"Inhibition of p95ErbB2, <e2>p185ErbB2<\\e2>  and EGFR phosphorylation by <e1>GW572016<\\e1> resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and cyclin D steady-state protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"p185ErbB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of p95ErbB2, <e2>GENE-Y<\\e2>  and EGFR phosphorylation by <e1>CHEMICAL<\\e1> resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and cyclin D steady-state protein levels","sentence":"Inhibition of p95ErbB2, p185ErbB2  and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and cyclin D steady-state protein levels"}
{"PMID":14737100,"re_id":8,"annotated sentence":"Inhibition of p95ErbB2, p185ErbB2, and <e2>EGFR<\\e2> phosphorylation by <e1>GW572016<\\e1> resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and cyclin D steady-state protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of p95ErbB2, p185ErbB2, and <e2>GENE-Y<\\e2> phosphorylation by <e1>CHEMICAL<\\e1> resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and cyclin D steady-state protein levels","sentence":"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and cyclin D steady-state protein levels"}
{"PMID":14737100,"re_id":9,"annotated sentence":"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by <e1>GW572016<\\e1> resulted in the inhibition of downstream phospho-<e2>Erk1\/2<\\e2>  phospho-AKT, and cyclin D steady-state protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"Erk1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by <e1>CHEMICAL<\\e1> resulted in the inhibition of downstream phospho-<e2>GENE-N<\\e2>  phospho-AKT, and cyclin D steady-state protein levels","sentence":"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1\/2  phospho-AKT, and cyclin D steady-state protein levels"}
{"PMID":14737100,"re_id":10,"annotated sentence":"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by <e1>GW572016<\\e1> resulted in the inhibition of downstream phospho-Erk1\/2, phospho-<e2>AKT<\\e2>  and cyclin D steady-state protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by <e1>CHEMICAL<\\e1> resulted in the inhibition of downstream phospho-Erk1\/2, phospho-<e2>GENE-N<\\e2>  and cyclin D steady-state protein levels","sentence":"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT  and cyclin D steady-state protein levels"}
{"PMID":14737100,"re_id":11,"annotated sentence":"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by <e1>GW572016<\\e1> resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and <e2>cyclin D<\\e2> steady-state protein levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"cyclin D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by <e1>CHEMICAL<\\e1> resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and <e2>GENE-N<\\e2> steady-state protein levels","sentence":"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1\/2, phospho-AKT, and cyclin D steady-state protein levels"}
{"PMID":14737100,"re_id":12,"annotated sentence":"Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR\/<e2>ErbB2<\\e2> kinase inhibitor <e1>GW572016<\\e1>  The expression of the NH2 terminally truncated ErbB2 receptor (p95ErbB2) in breast cancer correlates with metastatic disease progression compared with the expression of full-length p185ErbB2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"ErbB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Truncated GENE-Y receptor (p95GENE-Y) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR\/<e2>GENE-Y<\\e2> kinase inhibitor <e1>CHEMICAL<\\e1>  The expression of the NH2 terminally truncated GENE-Y receptor (p95GENE-Y) in breast cancer correlates with metastatic disease progression compared with the expression of full-length p185GENE-Y","sentence":"Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR\/ErbB2 kinase inhibitor GW572016  The expression of the NH2 terminally truncated ErbB2 receptor (p95ErbB2) in breast cancer correlates with metastatic disease progression compared with the expression of full-length p185ErbB2"}
{"PMID":14757703,"re_id":0,"annotated sentence":"(3)H-CGP 12177A saturation binding, in the presence of <e1>propranolol<\\e1>  increased approximately 5-fold following overexpression of <e2>beta(1)-adrenoceptors<\\e2>  6","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"propranolol","object":"beta(1)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(3)H-CGP 12177A saturation binding, in the presence of <e1>CHEMICAL<\\e1>  increased approximately 5-fold following overexpression of <e2>GENE-Y<\\e2>  6","sentence":"(3)H-CGP 12177A saturation binding, in the presence of propranolol  increased approximately 5-fold following overexpression of beta(1)-adrenoceptors  6"}
{"PMID":14757703,"re_id":1,"annotated sentence":"<e1>CGP 12177A<\\e1> mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor; however, it has recently been reported that disruption of the <e2>beta(1)-adrenoceptor<\\e2> gene abolishes this effect","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CGP 12177A","object":"beta(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor; however, it has recently been reported that disruption of the <e2>GENE-Y<\\e2> gene abolishes this effect","sentence":"CGP 12177A mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor; however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect"}
{"PMID":14757703,"re_id":2,"annotated sentence":"<e1>CGP 12177A<\\e1> mediates cardiostimulation by activation of the 'putative' <e2>beta(4)-adrenoceptor<\\e2>  however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CGP 12177A","object":"beta(4)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> mediates cardiostimulation by activation of the 'putative' <e2>GENE-N<\\e2>  however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect","sentence":"CGP 12177A mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor  however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect"}
{"PMID":14757703,"re_id":3,"annotated sentence":"<e1>CGP 12177A<\\e1> but not isoprenaline initiated arrhythmias at lower concentrations following <e2>beta(1)-adrenoceptor<\\e2> overexpression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CGP 12177A","object":"beta(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> but not isoprenaline initiated arrhythmias at lower concentrations following <e2>GENE-Y<\\e2> overexpression","sentence":"CGP 12177A but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression"}
{"PMID":14757703,"re_id":4,"annotated sentence":"<e1>(125)I-Cyanopindolol<\\e1> saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in <e2>beta(1)-adrenoceptors<\\e2>  (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"(125)I-Cyanopindolol","object":"beta(1)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in <e2>GENE-Y<\\e2>  (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of GENE-Y","sentence":"(125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors  (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors"}
{"PMID":14757703,"re_id":5,"annotated sentence":"<e1>(3)H-CGP 12177A<\\e1> saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of <e2>beta(1)-adrenoceptors<\\e2>  6","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"(3)H-CGP 12177A","object":"beta(1)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of <e2>GENE-Y<\\e2>  6","sentence":"(3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors  6"}
{"PMID":14967461,"re_id":0,"annotated sentence":"Agents that have only begun to undergo clinical evaluation include <e1>CI-1033<\\e1>  an irreversible pan-<e2>erbB<\\e2> tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CI-1033","object":"erbB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agents that have only begun to undergo clinical evaluation include <e1>CHEMICAL<\\e1>  an irreversible pan-<e2>GENE-Y<\\e2> tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)","sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033  an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)"}
{"PMID":14967461,"re_id":1,"annotated sentence":"Agents that have only begun to undergo clinical evaluation include <e1>CI-1033<\\e1>  an irreversible pan-erbB <e2>tyrosine kinase<\\e2> inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CI-1033","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agents that have only begun to undergo clinical evaluation include <e1>CHEMICAL<\\e1>  an irreversible pan-erbB <e2>GENE-N<\\e2> inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)","sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033  an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)"}
{"PMID":14967461,"re_id":2,"annotated sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and <e1>PKI166<\\e1> and GW572016, both examples of dual <e2>kinase<\\e2> inhibitors (inhibiting epidermal growth factor receptor and Her2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PKI166","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine GENE-N inhibitor, and <e1>CHEMICAL<\\e1> and GW572016, both examples of dual <e2>GENE-N<\\e2> inhibitors (inhibiting epidermal growth factor receptor and Her2)","sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)"}
{"PMID":14967461,"re_id":3,"annotated sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and <e1>PKI166<\\e1> and GW572016, both examples of dual kinase inhibitors (inhibiting <e2>epidermal growth factor receptor<\\e2> and Her2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PKI166","object":"epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and <e1>CHEMICAL<\\e1> and GW572016, both examples of dual kinase inhibitors (inhibiting <e2>GENE-Y<\\e2> and Her2)","sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)"}
{"PMID":14967461,"re_id":4,"annotated sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and <e1>PKI166<\\e1> and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and <e2>Her2<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PKI166","object":"Her2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and <e1>CHEMICAL<\\e1> and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and <e2>GENE-Y<\\e2> ","sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2 "}
{"PMID":14967461,"re_id":5,"annotated sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and <e1>GW572016<\\e1>  both examples of dual <e2>kinase<\\e2> inhibitors (inhibiting epidermal growth factor receptor and Her2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine GENE-N inhibitor, and PKI166 and <e1>CHEMICAL<\\e1>  both examples of dual <e2>GENE-N<\\e2> inhibitors (inhibiting epidermal growth factor receptor and Her2)","sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016  both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)"}
{"PMID":14967461,"re_id":6,"annotated sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and <e1>GW572016<\\e1>  both examples of dual kinase inhibitors (inhibiting <e2>epidermal growth factor receptor<\\e2> and Her2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and <e1>CHEMICAL<\\e1>  both examples of dual kinase inhibitors (inhibiting <e2>GENE-Y<\\e2> and Her2)","sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016  both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)"}
{"PMID":14967461,"re_id":7,"annotated sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and <e1>GW572016<\\e1>  both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and <e2>Her2<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW572016","object":"Her2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and <e1>CHEMICAL<\\e1>  both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and <e2>GENE-Y<\\e2> ","sentence":"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016  both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2 "}
{"PMID":14967461,"re_id":8,"annotated sentence":"<e2>Epidermal growth factor receptor<\\e2> inhibitors currently under investigation include the small molecules <e1>gefitinib<\\e1> (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gefitinib","object":"Epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors currently under investigation include the small molecules <e1>CHEMICAL<\\e1> (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","sentence":"Epidermal growth factor receptor inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)"}
{"PMID":14967461,"re_id":9,"annotated sentence":"<e2>Epidermal growth factor receptor<\\e2> inhibitors currently under investigation include the small molecules gefitinib (<e1>Iressa<\\e1>  ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Iressa","object":"Epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors currently under investigation include the small molecules gefitinib (<e1>CHEMICAL<\\e1>  ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","sentence":"Epidermal growth factor receptor inhibitors currently under investigation include the small molecules gefitinib (Iressa  ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)"}
{"PMID":14967461,"re_id":10,"annotated sentence":"<e2>Epidermal growth factor receptor<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, <e1>ZD1839<\\e1>  and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ZD1839","object":"Epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, <e1>CHEMICAL<\\e1>  and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","sentence":"Epidermal growth factor receptor inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839  and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)"}
{"PMID":14967461,"re_id":11,"annotated sentence":"<e2>Epidermal growth factor receptor<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and <e1>erlotinib<\\e1> (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"erlotinib","object":"Epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and <e1>CHEMICAL<\\e1> (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","sentence":"Epidermal growth factor receptor inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)"}
{"PMID":14967461,"re_id":12,"annotated sentence":"<e2>Epidermal growth factor receptor<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (<e1>Tarceva<\\e1>  OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tarceva","object":"Epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (<e1>CHEMICAL<\\e1>  OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","sentence":"Epidermal growth factor receptor inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva  OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)"}
{"PMID":14967461,"re_id":13,"annotated sentence":"<e2>Epidermal growth factor receptor<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, <e1>OSI-774<\\e1> , as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"OSI-774","object":"Epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, <e1>CHEMICAL<\\e1> , as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)","sentence":"Epidermal growth factor receptor inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774 , as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)"}
{"PMID":14967461,"re_id":14,"annotated sentence":"<e2>Epidermal growth factor receptor<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as <e1>cetuximab<\\e1> (IMC-225, Erbitux)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cetuximab","object":"Epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as <e1>CHEMICAL<\\e1> (IMC-225, Erbitux)","sentence":"Epidermal growth factor receptor inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)"}
{"PMID":14967461,"re_id":15,"annotated sentence":"<e2>Epidermal growth factor receptor<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (<e1>IMC-225<\\e1>  Erbitux)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IMC-225","object":"Epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (<e1>CHEMICAL<\\e1>  Erbitux)","sentence":"Epidermal growth factor receptor inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225  Erbitux)"}
{"PMID":14967461,"re_id":16,"annotated sentence":"<e2>Epidermal growth factor receptor<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, <e1>Erbitux<\\e1> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Erbitux","object":"Epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, <e1>CHEMICAL<\\e1> ","sentence":"Epidermal growth factor receptor inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux "}
{"PMID":14984733,"re_id":0,"annotated sentence":"<e1>Phosphatidylserine<\\e1> (PtdSer) is made in mammalian cells by two <e2>PtdSer synthases<\\e2>  PSS1 and PSS2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Phosphatidylserine","object":"PtdSer synthases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (PtdSer) is made in mammalian cells by two <e2>GENE-N<\\e2>  PSS1 and PSS2","sentence":"Phosphatidylserine (PtdSer) is made in mammalian cells by two PtdSer synthases  PSS1 and PSS2"}
{"PMID":14984733,"re_id":1,"annotated sentence":"<e1>Phosphatidylserine<\\e1> (PtdSer) is made in mammalian cells by two PtdSer synthases, <e2>PSS1<\\e2> and PSS2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Phosphatidylserine","object":"PSS1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (PtdSer) is made in mammalian cells by two PtdSer synthases, <e2>GENE-N<\\e2> and PSS2","sentence":"Phosphatidylserine (PtdSer) is made in mammalian cells by two PtdSer synthases, PSS1 and PSS2"}
{"PMID":14984733,"re_id":2,"annotated sentence":"<e1>Phosphatidylserine<\\e1> (PtdSer) is made in mammalian cells by two PtdSer synthases, PSS1 and <e2>PSS2<\\e2>  In the plasma membrane PtdSer is normally localized on the inner leaflet but undergoes transbilayer movement during apoptosis and becomes exposed on the cell surface","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Phosphatidylserine","object":"PSS2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (PtdSer) is made in mammalian cells by two PtdSer synthases, PSS1 and <e2>GENE-N<\\e2>  In the plasma membrane PtdSer is normally localized on the inner leaflet but undergoes transbilayer movement during apoptosis and becomes exposed on the cell surface","sentence":"Phosphatidylserine (PtdSer) is made in mammalian cells by two PtdSer synthases, PSS1 and PSS2  In the plasma membrane PtdSer is normally localized on the inner leaflet but undergoes transbilayer movement during apoptosis and becomes exposed on the cell surface"}
{"PMID":14984733,"re_id":3,"annotated sentence":"Moreover, a normal level of expression of <e2>PSS1<\\e2> and\/or PSS2 is not required for generating the pool of <e1>PtdSer<\\e1> externalized during apoptosis.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PtdSer","object":"PSS1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, a normal level of expression of <e2>GENE-Y<\\e2> and\/or PSS2 is not required for generating the pool of <e1>CHEMICAL<\\e1> externalized during apoptosis.","sentence":"Moreover, a normal level of expression of PSS1 and\/or PSS2 is not required for generating the pool of PtdSer externalized during apoptosis."}
{"PMID":14984733,"re_id":4,"annotated sentence":"Moreover, a normal level of expression of PSS1 and\/or <e2>PSS2<\\e2> is not required for generating the pool of <e1>PtdSer<\\e1> externalized during apoptosis.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PtdSer","object":"PSS2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, a normal level of expression of PSS1 and\/or <e2>GENE-Y<\\e2> is not required for generating the pool of <e1>CHEMICAL<\\e1> externalized during apoptosis.","sentence":"Moreover, a normal level of expression of PSS1 and\/or PSS2 is not required for generating the pool of PtdSer externalized during apoptosis."}
{"PMID":15066664,"re_id":0,"annotated sentence":"In this study, we have synthesized novel <e1>alpha-hydroxyphenylamide<\\e1> analogues of diphenylhydantoin and examined their ability to inhibit <e2>human Na(V)1.5<\\e2> sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-hydroxyphenylamide","object":"human Na(V)1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we have synthesized novel <e1>CHEMICAL<\\e1> analogues of diphenylhydantoin and examined their ability to inhibit <e2>GENE-Y<\\e2> sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells","sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells"}
{"PMID":15066664,"re_id":1,"annotated sentence":"In this study, we have synthesized novel <e1>alpha-hydroxyphenylamide<\\e1> analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 <e2>sodium channels<\\e2> expressed in Chinese Hamster Ovary (CHO-K1) cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-hydroxyphenylamide","object":"sodium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, we have synthesized novel <e1>CHEMICAL<\\e1> analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 <e2>GENE-N<\\e2> expressed in Chinese Hamster Ovary (CHO-K1) cells","sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells"}
{"PMID":15066664,"re_id":2,"annotated sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of <e1>diphenylhydantoin<\\e1> and examined their ability to inhibit <e2>human Na(V)1.5<\\e2> sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diphenylhydantoin","object":"human Na(V)1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of <e1>CHEMICAL<\\e1> and examined their ability to inhibit <e2>GENE-Y<\\e2> sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells","sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells"}
{"PMID":15066664,"re_id":3,"annotated sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of <e1>diphenylhydantoin<\\e1> and examined their ability to inhibit human Na(V)1.5 <e2>sodium channels<\\e2> expressed in Chinese Hamster Ovary (CHO-K1) cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diphenylhydantoin","object":"sodium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of <e1>CHEMICAL<\\e1> and examined their ability to inhibit human Na(V)1.5 <e2>GENE-N<\\e2> expressed in Chinese Hamster Ovary (CHO-K1) cells","sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells"}
{"PMID":15066664,"re_id":4,"annotated sentence":"In comparison to <e1>diphenylhydantoin<\\e1>  the novel chloro-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of <e2>Na(V)1.5<\\e2> channels with an IC(50) value of 14.5 microM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diphenylhydantoin","object":"Na(V)1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In comparison to <e1>CHEMICAL<\\e1>  the novel chloro-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of <e2>GENE-Y<\\e2> channels with an IC(50) value of 14.5 microM","sentence":"In comparison to diphenylhydantoin  the novel chloro-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of Na(V)1.5 channels with an IC(50) value of 14.5 microM"}
{"PMID":15066664,"re_id":5,"annotated sentence":"In comparison to diphenylhydantoin, the novel <e1>chloro<\\e1> substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of <e2>Na(V)1.5<\\e2> channels with an IC(50) value of 14.5 microM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"chloro","object":"Na(V)1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In comparison to diphenylhydantoin, the novel <e1>CHEMICAL<\\e1> substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of <e2>GENE-Y<\\e2> channels with an IC(50) value of 14.5 microM","sentence":"In comparison to diphenylhydantoin, the novel chloro substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of Na(V)1.5 channels with an IC(50) value of 14.5 microM"}
{"PMID":15066664,"re_id":6,"annotated sentence":"In comparison to diphenylhydantoin, the novel chloro-substituted <e1>alpha-hydroxyphenylamide<\\e1> compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of <e2>Na(V)1.5<\\e2> channels with an IC(50) value of 14.5 microM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-hydroxyphenylamide","object":"Na(V)1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In comparison to diphenylhydantoin, the novel chloro-substituted <e1>CHEMICAL<\\e1> compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of <e2>GENE-Y<\\e2> channels with an IC(50) value of 14.5 microM","sentence":"In comparison to diphenylhydantoin, the novel chloro-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of Na(V)1.5 channels with an IC(50) value of 14.5 microM"}
{"PMID":15066664,"re_id":7,"annotated sentence":"<e1>Phenytoin<\\e1> (diphenylhydantoin, DPH) is an established <e2>sodium channel<\\e2> blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenytoin","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (diphenylhydantoin, DPH) is an established <e2>GENE-N<\\e2> blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain","sentence":"Phenytoin (diphenylhydantoin, DPH) is an established sodium channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain"}
{"PMID":15066664,"re_id":8,"annotated sentence":"Block of human NaV1.5 <e2>sodium channels<\\e2> by novel <e1>alpha-hydroxyphenylamide<\\e1> analogues of phenytoin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-hydroxyphenylamide","object":"sodium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Block of human NaV1.5 <e2>GENE-N<\\e2> by novel <e1>CHEMICAL<\\e1> analogues of phenytoin","sentence":"Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin"}
{"PMID":15066664,"re_id":9,"annotated sentence":"Block of <e2>human NaV1.5<\\e2> sodium channels by novel <e1>alpha-hydroxyphenylamide<\\e1> analogues of phenytoin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alpha-hydroxyphenylamide","object":"human NaV1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Block of <e2>GENE-Y<\\e2> sodium channels by novel <e1>CHEMICAL<\\e1> analogues of phenytoin","sentence":"Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin"}
{"PMID":15066664,"re_id":10,"annotated sentence":"Block of human NaV1.5 <e2>sodium channels<\\e2> by novel alpha-hydroxyphenylamide analogues of <e1>phenytoin<\\e1>  Voltage-gated sodium (Na) channels are a critical component of electrically excitable cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenytoin","object":"sodium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Block of human NaV1.5 <e2>GENE-N<\\e2> by novel alpha-hydroxyphenylamide analogues of <e1>CHEMICAL<\\e1>  Voltage-gated sodium (Na) channels are a critical component of electrically excitable cells","sentence":"Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin  Voltage-gated sodium (Na) channels are a critical component of electrically excitable cells"}
{"PMID":15066664,"re_id":11,"annotated sentence":"Block of <e2>human NaV1.5<\\e2> sodium channels by novel alpha-hydroxyphenylamide analogues of <e1>phenytoin<\\e1>  Voltage-gated sodium (Na) channels are a critical component of electrically excitable cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenytoin","object":"human NaV1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Block of <e2>GENE-Y<\\e2> sodium channels by novel alpha-hydroxyphenylamide analogues of <e1>CHEMICAL<\\e1>  Voltage-gated sodium (Na) channels are a critical component of electrically excitable cells","sentence":"Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin  Voltage-gated sodium (Na) channels are a critical component of electrically excitable cells"}
{"PMID":15066664,"re_id":12,"annotated sentence":"Phenytoin (<e1>diphenylhydantoin<\\e1>  DPH) is an established <e2>sodium channel<\\e2> blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diphenylhydantoin","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phenytoin (<e1>CHEMICAL<\\e1>  DPH) is an established <e2>GENE-N<\\e2> blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain","sentence":"Phenytoin (diphenylhydantoin  DPH) is an established sodium channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain"}
{"PMID":15066664,"re_id":13,"annotated sentence":"Phenytoin (diphenylhydantoin, <e1>DPH<\\e1>  is an established <e2>sodium channel<\\e2> blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DPH","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phenytoin (diphenylhydantoin, <e1>CHEMICAL<\\e1>  is an established <e2>GENE-N<\\e2> blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain","sentence":"Phenytoin (diphenylhydantoin, DPH  is an established sodium channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain"}
{"PMID":15066664,"re_id":14,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sodium","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":15066664,"re_id":15,"annotated sentence":"<e2>Voltage-gated sodi<e1>Na<\\e1> (Na) channels<\\e2> are a critical component of electrically excitable cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Na","object":"Voltage-gated sodium (Na) channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>Voltage-gated sodi<e1>CHEMICAL<\\e1> (CHEMICAL) channels<\\e2> are a critical component of electrically excitable cells","sentence":"Voltage-gated sodiNa (Na) channels are a critical component of electrically excitable cells"}
{"PMID":15066664,"re_id":16,"annotated sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit <e2>human Na(V)1.5<\\e2> <e1>sodium<\\e1> channels expressed in Chinese Hamster Ovary (CHO-K1) cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sodium","object":"human Na(V)1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit <e2>GENE-Y<\\e2> <e1>CHEMICAL<\\e1> channels expressed in Chinese Hamster Ovary (CHO-K1) cells","sentence":"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5 sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells"}
{"PMID":15066664,"re_id":17,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sodium","object":"sodium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":15066664,"re_id":18,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sodium","object":"sodium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":15066664,"re_id":19,"annotated sentence":"Block of <e2>human NaV1.5<\\e2> <e1>sodium<\\e1> channels by novel alpha-hydroxyphenylamide analogues of phenytoin","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sodium","object":"human NaV1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Block of <e2>GENE-Y<\\e2> <e1>CHEMICAL<\\e1> channels by novel alpha-hydroxyphenylamide analogues of phenytoin","sentence":"Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin"}
{"PMID":15066664,"re_id":20,"annotated sentence":"<e2>Voltage-ga<e1>sodium<\\e1> ium (Na) channels<\\e2> are a critical component of electrically excitable cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sodium","object":"Voltage-gated sodium (Na) channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>Voltage-ga<e1>CHEMICAL<\\e1> ium (Na) channels<\\e2> are a critical component of electrically excitable cells","sentence":"Voltage-gasodium ium (Na) channels are a critical component of electrically excitable cells"}
{"PMID":15066664,"re_id":21,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"sodium","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":15070163,"re_id":0,"annotated sentence":"Our results indicate that Salix extract 1520L inhibits <e2>COX-2<\\e2> mediated <e1>PGE2<\\e1> release through compounds other than salicin or salicylate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results indicate that Salix extract 1520L inhibits <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> release through compounds other than salicin or salicylate","sentence":"Our results indicate that Salix extract 1520L inhibits COX-2 mediated PGE2 release through compounds other than salicin or salicylate"}
{"PMID":15070163,"re_id":1,"annotated sentence":"The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (PGE2) reflecting <e2>cyclooxygenase (COX)-2<\\e2> mediated <e1>PGE2<\\e1> release were 47 microg\/ml and 0.6 microg\/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE2","object":"cyclooxygenase (COX)-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (CHEMICAL) reflecting <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> release were 47 microg\/ml and 0.6 microg\/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively","sentence":"The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (PGE2) reflecting cyclooxygenase (COX)-2 mediated PGE2 release were 47 microg\/ml and 0.6 microg\/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively"}
{"PMID":15078100,"re_id":0,"annotated sentence":"To investigate the mechanism and consequences of inhibition of <e2>QR2<\\e2> by the <e1>quinolines<\\e1> further, we have used steady-state and transient-state kinetics to define the mechanism of QR2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinolines","object":"QR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To investigate the mechanism and consequences of inhibition of <e2>GENE-Y<\\e2> by the <e1>CHEMICAL<\\e1> further, we have used steady-state and transient-state kinetics to define the mechanism of GENE-Y","sentence":"To investigate the mechanism and consequences of inhibition of QR2 by the quinolines further, we have used steady-state and transient-state kinetics to define the mechanism of QR2"}
{"PMID":15078100,"re_id":1,"annotated sentence":"To investigate the mechanism and consequences of inhibition of QR2 by the <e1>quinolines<\\e1> further, we have used steady-state and transient-state kinetics to define the mechanism of <e2>QR2<\\e2>  Importantly, we have shown that QR2 when isolated from an overproducing strain of E","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinolines","object":"QR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To investigate the mechanism and consequences of inhibition of GENE-Y by the <e1>CHEMICAL<\\e1> further, we have used steady-state and transient-state kinetics to define the mechanism of <e2>GENE-Y<\\e2>  Importantly, we have shown that GENE-Y when isolated from an overproducing strain of E","sentence":"To investigate the mechanism and consequences of inhibition of QR2 by the quinolines further, we have used steady-state and transient-state kinetics to define the mechanism of QR2  Importantly, we have shown that QR2 when isolated from an overproducing strain of E"}
{"PMID":15078100,"re_id":2,"annotated sentence":"Kinetic mechanism of <e2>quinone oxidoreductase 2<\\e2> and its inhibition by the antimalarial <e1>quinolines<\\e1>  Quinone oxidoreductase 2 (QR2) purified from human red blood cells was recently shown to be a potential target of the quinoline antimalarial compounds [Graves et al., (2002) Mol","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinolines","object":"quinone oxidoreductase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic mechanism of <e2>GENE-Y<\\e2> and its inhibition by the antimalarial <e1>CHEMICAL<\\e1>  Quinone oxidoreductase 2 (QR2) purified from human red blood cells was recently shown to be a potential target of the quinoline antimalarial compounds [Graves et al., (2002) Mol","sentence":"Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines  Quinone oxidoreductase 2 (QR2) purified from human red blood cells was recently shown to be a potential target of the quinoline antimalarial compounds [Graves et al., (2002) Mol"}
{"PMID":15078100,"re_id":3,"annotated sentence":"Our studies shed light on the possible in vivo potency of the <e1>quinolines<\\e1> and provide a foundation for future studies aimed at creating more potent <e2>QR2<\\e2> inhibitors and at understanding the physiological significance of QR2.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinolines","object":"QR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our studies shed light on the possible in vivo potency of the <e1>CHEMICAL<\\e1> and provide a foundation for future studies aimed at creating more potent <e2>GENE-Y<\\e2> inhibitors and at understanding the physiological significance of GENE-Y.","sentence":"Our studies shed light on the possible in vivo potency of the quinolines and provide a foundation for future studies aimed at creating more potent QR2 inhibitors and at understanding the physiological significance of QR2."}
{"PMID":15078100,"re_id":4,"annotated sentence":"<e2>QR2<\\e2> catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or <e1>N-ribosylated nicotinamides<\\e1>  To investigate the mechanism and consequences of inhibition of QR2 by the quinolines further, we have used steady-state and transient-state kinetics to define the mechanism of QR2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-ribosylated nicotinamides","object":"QR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or <e1>CHEMICAL<\\e1>  To investigate the mechanism and consequences of inhibition of GENE-Y by the quinolines further, we have used steady-state and transient-state kinetics to define the mechanism of GENE-Y","sentence":"QR2 catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or N-ribosylated nicotinamides  To investigate the mechanism and consequences of inhibition of QR2 by the quinolines further, we have used steady-state and transient-state kinetics to define the mechanism of QR2"}
{"PMID":15078100,"re_id":5,"annotated sentence":"<e2>QR2<\\e2> catalyzes the two-electron reduction of <e1>menadione<\\e1> via the oxidation of N-alkylated or N-ribosylated nicotinamides","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"menadione","object":"QR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> catalyzes the two-electron reduction of <e1>CHEMICAL<\\e1> via the oxidation of N-alkylated or N-ribosylated nicotinamides","sentence":"QR2 catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or N-ribosylated nicotinamides"}
{"PMID":15078100,"re_id":6,"annotated sentence":"<e2>QR2<\\e2> catalyzes the two-electron reduction of menadione via the oxidation of <e1>N-alkylated<\\e1> or N-ribosylated nicotinamides","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-alkylated","object":"QR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> catalyzes the two-electron reduction of menadione via the oxidation of <e1>CHEMICAL<\\e1> or N-ribosylated nicotinamides","sentence":"QR2 catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or N-ribosylated nicotinamides"}
{"PMID":15102890,"re_id":0,"annotated sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (<e1>BLT-4<\\e1> , blocked <e2>ABCA1<\\e2> mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BLT-4","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (<e1>CHEMICAL<\\e1> , blocked <e2>GENE-Y<\\e2> mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)","sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4 , blocked ABCA1 mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)"}
{"PMID":15102890,"re_id":1,"annotated sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (<e1>BLT-4<\\e1> , blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of <e2>SR-BI<\\e2> (IC(50) approximately 55-60 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BLT-4","object":"SR-BI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (<e1>CHEMICAL<\\e1> , blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of <e2>GENE-Y<\\e2> (IC(50) approximately 55-60 microM)","sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4 , blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)"}
{"PMID":15102890,"re_id":2,"annotated sentence":"Reciprocally, <e1>glyburide<\\e1> blocked SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of <e2>ABCA1<\\e2> (IC(50) approximately 275-300 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glyburide","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reciprocally, <e1>CHEMICAL<\\e1> blocked SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of <e2>GENE-Y<\\e2> (IC(50) approximately 275-300 microM)","sentence":"Reciprocally, glyburide blocked SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of ABCA1 (IC(50) approximately 275-300 microM)"}
{"PMID":15102890,"re_id":3,"annotated sentence":"Reciprocally, <e1>glyburide<\\e1> blocked <e2>SR-BI<\\e2> mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of ABCA1 (IC(50) approximately 275-300 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glyburide","object":"SR-BI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reciprocally, <e1>CHEMICAL<\\e1> blocked <e2>GENE-Y<\\e2> mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of ABCA1 (IC(50) approximately 275-300 microM)","sentence":"Reciprocally, glyburide blocked SR-BI mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of ABCA1 (IC(50) approximately 275-300 microM)"}
{"PMID":15102890,"re_id":4,"annotated sentence":"Cross-inhibition of <e2>SR-BI<\\e2>  and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and <e1>glyburide<\\e1>  Scavenger receptor class B type I (SR-BI) and ABCA1 are structurally dissimilar cell surface proteins that play key roles in HDL metabolism","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glyburide","object":"SR-BI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cross-inhibition of <e2>GENE-Y<\\e2>  and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and <e1>CHEMICAL<\\e1>  Scavenger receptor class B type I (GENE-Y) and ABCA1 are structurally dissimilar cell surface proteins that play key roles in HDL metabolism","sentence":"Cross-inhibition of SR-BI  and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide  Scavenger receptor class B type I (SR-BI) and ABCA1 are structurally dissimilar cell surface proteins that play key roles in HDL metabolism"}
{"PMID":15102890,"re_id":5,"annotated sentence":"Cross-inhibition of SR-BI- and <e2>ABCA1<\\e2> mediated cholesterol transport by the small molecules BLT-4 and <e1>glyburide<\\e1>  Scavenger receptor class B type I (SR-BI) and ABCA1 are structurally dissimilar cell surface proteins that play key roles in HDL metabolism","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glyburide","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cross-inhibition of SR-BI- and <e2>GENE-Y<\\e2> mediated cholesterol transport by the small molecules BLT-4 and <e1>CHEMICAL<\\e1>  Scavenger receptor class B type I (SR-BI) and GENE-Y are structurally dissimilar cell surface proteins that play key roles in HDL metabolism","sentence":"Cross-inhibition of SR-BI- and ABCA1 mediated cholesterol transport by the small molecules BLT-4 and glyburide  Scavenger receptor class B type I (SR-BI) and ABCA1 are structurally dissimilar cell surface proteins that play key roles in HDL metabolism"}
{"PMID":15102890,"re_id":6,"annotated sentence":"The reciprocal inhibition of <e2>SR-BI<\\e2> and ABCA1 by BLT-4 and <e1>glyburide<\\e1> raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glyburide","object":"SR-BI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reciprocal inhibition of <e2>GENE-Y<\\e2> and ABCA1 by BLT-4 and <e1>CHEMICAL<\\e1> raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.","sentence":"The reciprocal inhibition of SR-BI and ABCA1 by BLT-4 and glyburide raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport."}
{"PMID":15102890,"re_id":7,"annotated sentence":"The reciprocal inhibition of SR-BI and <e2>ABCA1<\\e2> by BLT-4 and <e1>glyburide<\\e1> raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glyburide","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reciprocal inhibition of SR-BI and <e2>GENE-Y<\\e2> by BLT-4 and <e1>CHEMICAL<\\e1> raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.","sentence":"The reciprocal inhibition of SR-BI and ABCA1 by BLT-4 and glyburide raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport."}
{"PMID":15102890,"re_id":8,"annotated sentence":"The activities of <e2>ABCA1<\\e2> and other ATP binding cassette superfamily members are inhibited by the drug <e1>glyburide<\\e1>  and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glyburide","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activities of <e2>GENE-Y<\\e2> and other ATP binding cassette superfamily members are inhibited by the drug <e1>CHEMICAL<\\e1>  and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs","sentence":"The activities of ABCA1 and other ATP binding cassette superfamily members are inhibited by the drug glyburide  and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs"}
{"PMID":15102890,"re_id":9,"annotated sentence":"The activities of ABCA1 and other <e2>ATP binding cassette superfamily<\\e2> members are inhibited by the drug <e1>glyburide<\\e1>  and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glyburide","object":"ATP binding cassette superfamily","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The activities of ABCA1 and other <e2>GENE-N<\\e2> members are inhibited by the drug <e1>CHEMICAL<\\e1>  and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs","sentence":"The activities of ABCA1 and other ATP binding cassette superfamily members are inhibited by the drug glyburide  and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs"}
{"PMID":15102890,"re_id":10,"annotated sentence":"Here, we show that one <e1>BLT<\\e1>  [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked <e2>ABCA1<\\e2> mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BLT","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that one <e1>CHEMICAL<\\e1>  [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (CHEMICAL-4), blocked <e2>GENE-Y<\\e2> mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)","sentence":"Here, we show that one BLT  [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1 mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)"}
{"PMID":15102890,"re_id":11,"annotated sentence":"Here, we show that one <e1>BLT<\\e1>  [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of <e2>SR-BI<\\e2> (IC(50) approximately 55-60 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BLT","object":"SR-BI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that one <e1>CHEMICAL<\\e1>  [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (CHEMICAL-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of <e2>GENE-Y<\\e2> (IC(50) approximately 55-60 microM)","sentence":"Here, we show that one BLT  [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)"}
{"PMID":15102890,"re_id":12,"annotated sentence":"Here, we show that one BLT, [<e1>1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea<\\e1>  (BLT-4), blocked <e2>ABCA1<\\e2> mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that one BLT, [<e1>CHEMICAL<\\e1>  (BLT-4), blocked <e2>GENE-Y<\\e2> mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)","sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea  (BLT-4), blocked ABCA1 mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)"}
{"PMID":15102890,"re_id":13,"annotated sentence":"Here, we show that one BLT, [<e1>1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea<\\e1>  (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of <e2>SR-BI<\\e2> (IC(50) approximately 55-60 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea","object":"SR-BI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that one BLT, [<e1>CHEMICAL<\\e1>  (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of <e2>GENE-Y<\\e2> (IC(50) approximately 55-60 microM)","sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea  (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)"}
{"PMID":15102890,"re_id":14,"annotated sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked <e2>ABCA1<\\e2> mediated <e1>cholesterol<\\e1> efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)","sentence":"Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1 mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)"}
{"PMID":15102890,"re_id":15,"annotated sentence":"Cross-inhibition of <e2>SR-BI<\\e2>  and ABCA1-mediated <e1>cholesterol<\\e1> transport by the small molecules BLT-4 and glyburide","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"SR-BI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cross-inhibition of <e2>GENE-Y<\\e2>  and ABCA1-mediated <e1>CHEMICAL<\\e1> transport by the small molecules BLT-4 and glyburide","sentence":"Cross-inhibition of SR-BI  and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide"}
{"PMID":15102890,"re_id":16,"annotated sentence":"Cross-inhibition of SR-BI- and <e2>ABCA1<\\e2> mediated <e1>cholesterol<\\e1> transport by the small molecules BLT-4 and glyburide","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cross-inhibition of SR-BI- and <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> transport by the small molecules BLT-4 and glyburide","sentence":"Cross-inhibition of SR-BI- and ABCA1 mediated cholesterol transport by the small molecules BLT-4 and glyburide"}
{"PMID":15102890,"re_id":17,"annotated sentence":"<e2>SR-BI<\\e2> is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of <e1>cholesteryl esters<\\e1> from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesteryl esters","object":"SR-BI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of <e1>CHEMICAL<\\e1> from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL","sentence":"SR-BI is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of cholesteryl esters from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL"}
{"PMID":15102890,"re_id":18,"annotated sentence":"<e2>SR-BI<\\e2> is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of cholesteryl esters from lipid-rich HDL to cells and the efflux of unesterified <e1>cholesterol<\\e1> from cells to HDL","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"SR-BI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of cholesteryl esters from lipid-rich HDL to cells and the efflux of unesterified <e1>CHEMICAL<\\e1> from cells to HDL","sentence":"SR-BI is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of cholesteryl esters from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL"}
{"PMID":15102890,"re_id":19,"annotated sentence":"<e2>ABCA1<\\e2> mediates the efflux of unesterified <e1>cholesterol<\\e1> and phospholipids from cells to lipid-poor apolipoprotein A-I (apoA-I)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> mediates the efflux of unesterified <e1>CHEMICAL<\\e1> and phospholipids from cells to lipid-poor apolipoprotein A-I (apoA-I)","sentence":"ABCA1 mediates the efflux of unesterified cholesterol and phospholipids from cells to lipid-poor apolipoprotein A-I (apoA-I)"}
{"PMID":15110853,"re_id":0,"annotated sentence":"Some of these derivatives showed good inhibitory potency against two <e2>human CA<\\e2> isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and <e1>methazolamide<\\e1>  The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methazolamide","object":"human CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Some of these derivatives showed good inhibitory potency against two <e2>GENE-N<\\e2> isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and <e1>CHEMICAL<\\e1>  The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value","sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and methazolamide  The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value"}
{"PMID":15110853,"re_id":1,"annotated sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, <e2>CA I<\\e2>  and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and <e1>methazolamide<\\e1>  The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methazolamide","object":"CA I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, <e2>GENE-Y<\\e2>  and GENE-YI, of the same order of magnitude as the clinically used drugs acetazolamide and <e1>CHEMICAL<\\e1>  The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value","sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I  and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and methazolamide  The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value"}
{"PMID":15110853,"re_id":2,"annotated sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and <e2>CA II<\\e2>  of the same order of magnitude as the clinically used drugs acetazolamide and <e1>methazolamide<\\e1>  The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methazolamide","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and <e2>GENE-Y<\\e2>  of the same order of magnitude as the clinically used drugs acetazolamide and <e1>CHEMICAL<\\e1>  The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value","sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and CA II  of the same order of magnitude as the clinically used drugs acetazolamide and methazolamide  The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value"}
{"PMID":15110853,"re_id":3,"annotated sentence":"<e2>Carbonic anhydrase<\\e2> inhibitors: <e1>aromatic and heterocyclic sulfonamides<\\e1> incorporating adamantyl moieties with strong anticonvulsant activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aromatic and heterocyclic sulfonamides","object":"Carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> inhibitors: <e1>CHEMICAL<\\e1> incorporating adamantyl moieties with strong anticonvulsant activity","sentence":"Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity"}
{"PMID":15110853,"re_id":4,"annotated sentence":"<e2>Carbonic anhydrase<\\e2> inhibitors: aromatic and heterocyclic sulfonamides incorporating <e1>adamantyl<\\e1> moieties with strong anticonvulsant activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"adamantyl","object":"Carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> inhibitors: aromatic and heterocyclic sulfonamides incorporating <e1>CHEMICAL<\\e1> moieties with strong anticonvulsant activity","sentence":"Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity"}
{"PMID":15110853,"re_id":5,"annotated sentence":"Some of these derivatives showed good inhibitory potency against two <e2>human CA<\\e2> isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs <e1>acetazolamide<\\e1> and methazolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"human CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Some of these derivatives showed good inhibitory potency against two <e2>GENE-N<\\e2> isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs <e1>CHEMICAL<\\e1> and methazolamide","sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and methazolamide"}
{"PMID":15110853,"re_id":6,"annotated sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, <e2>CA I<\\e2>  and CA II, of the same order of magnitude as the clinically used drugs <e1>acetazolamide<\\e1> and methazolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, <e2>GENE-Y<\\e2>  and GENE-YI, of the same order of magnitude as the clinically used drugs <e1>CHEMICAL<\\e1> and methazolamide","sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I  and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and methazolamide"}
{"PMID":15110853,"re_id":7,"annotated sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and <e2>CA II<\\e2>  of the same order of magnitude as the clinically used drugs <e1>acetazolamide<\\e1> and methazolamide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and <e2>GENE-Y<\\e2>  of the same order of magnitude as the clinically used drugs <e1>CHEMICAL<\\e1> and methazolamide","sentence":"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and CA II  of the same order of magnitude as the clinically used drugs acetazolamide and methazolamide"}
{"PMID":15114505,"re_id":0,"annotated sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, <e1>kuraridin<\\e1> ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase<\\e2> (DGAT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kuraridin","object":"diacylglycerol acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, <e1>CHEMICAL<\\e1> ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>GENE-Y<\\e2> (DGAT)","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT)"}
{"PMID":15114505,"re_id":1,"annotated sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, <e1>kuraridin<\\e1> ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kuraridin","object":"DGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, <e1>CHEMICAL<\\e1> ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>GENE-Y<\\e2> ","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT "}
{"PMID":15114505,"re_id":2,"annotated sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), <e1>kurarinol<\\e1> ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase<\\e2> (DGAT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kurarinol","object":"diacylglycerol acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), <e1>CHEMICAL<\\e1> ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>GENE-Y<\\e2> (DGAT)","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT)"}
{"PMID":15114505,"re_id":3,"annotated sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), <e1>kurarinol<\\e1> ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kurarinol","object":"DGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), <e1>CHEMICAL<\\e1> ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>GENE-Y<\\e2> ","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT "}
{"PMID":15114505,"re_id":4,"annotated sentence":"These data suggest that the <e1>lavandulyl<\\e1> side chain and the position of the hydroxy group are important for high <e2>DGAT<\\e2> inhibitory activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lavandulyl","object":"DGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that the <e1>CHEMICAL<\\e1> side chain and the position of the hydroxy group are important for high <e2>GENE-Y<\\e2> inhibitory activity","sentence":"These data suggest that the lavandulyl side chain and the position of the hydroxy group are important for high DGAT inhibitory activity"}
{"PMID":15114505,"re_id":5,"annotated sentence":"These data suggest that the lavandulyl side chain and the position of the <e1>hydroxy<\\e1> group are important for high <e2>DGAT<\\e2> inhibitory activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxy","object":"DGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that the lavandulyl side chain and the position of the <e1>CHEMICAL<\\e1> group are important for high <e2>GENE-Y<\\e2> inhibitory activity","sentence":"These data suggest that the lavandulyl side chain and the position of the hydroxy group are important for high DGAT inhibitory activity"}
{"PMID":15114505,"re_id":6,"annotated sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), <e1>kushenol H<\\e1> ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase<\\e2> (DGAT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kushenol H","object":"diacylglycerol acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), <e1>CHEMICAL<\\e1> ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>GENE-Y<\\e2> (DGAT)","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT)"}
{"PMID":15114505,"re_id":7,"annotated sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), <e1>kushenol H<\\e1> ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kushenol H","object":"DGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), <e1>CHEMICAL<\\e1> ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>GENE-Y<\\e2> ","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT "}
{"PMID":15114505,"re_id":8,"annotated sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and <e1>kushenol K<\\e1> ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase<\\e2> (DGAT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kushenol K","object":"diacylglycerol acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and <e1>CHEMICAL<\\e1> ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>GENE-Y<\\e2> (DGAT)","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT)"}
{"PMID":15114505,"re_id":9,"annotated sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and <e1>kushenol K<\\e1> ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kushenol K","object":"DGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and <e1>CHEMICAL<\\e1> ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>GENE-Y<\\e2> ","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT "}
{"PMID":15114505,"re_id":10,"annotated sentence":"In vitro inhibition of <e2>diacylglycerol acyltransferase<\\e2> by <e1>prenylflavonoids<\\e1> from Sophora flavescens","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prenylflavonoids","object":"diacylglycerol acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro inhibition of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> from Sophora flavescens","sentence":"In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens"}
{"PMID":15114505,"re_id":11,"annotated sentence":"Four prenylflavonoids, <e1>kurarinone<\\e1> ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase<\\e2> (DGAT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kurarinone","object":"diacylglycerol acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, <e1>CHEMICAL<\\e1> ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>GENE-Y<\\e2> (DGAT)","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT)"}
{"PMID":15114505,"re_id":12,"annotated sentence":"Four prenylflavonoids, <e1>kurarinone<\\e1> ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kurarinone","object":"DGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, <e1>CHEMICAL<\\e1> ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>GENE-Y<\\e2> ","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT "}
{"PMID":15114505,"re_id":13,"annotated sentence":"The <e1>flavonoids<\\e1> inhibited <e2>DGAT<\\e2> activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"flavonoids","object":"DGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5)","sentence":"The flavonoids inhibited DGAT activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5)"}
{"PMID":15114505,"re_id":14,"annotated sentence":"Four prenylflavonoids, kurarinone ( 1), a <e1>chalcone<\\e1> of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase<\\e2> (DGAT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"chalcone","object":"diacylglycerol acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, kurarinone ( 1), a <e1>CHEMICAL<\\e1> of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>GENE-Y<\\e2> (DGAT)","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT)"}
{"PMID":15114505,"re_id":15,"annotated sentence":"Four prenylflavonoids, kurarinone ( 1), a <e1>chalcone<\\e1> of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"chalcone","object":"DGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four prenylflavonoids, kurarinone ( 1), a <e1>CHEMICAL<\\e1> of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>GENE-Y<\\e2> ","sentence":"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT "}
{"PMID":15114505,"re_id":16,"annotated sentence":"Four <e1>prenylflavonoids<\\e1>  kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase<\\e2> (DGAT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prenylflavonoids","object":"diacylglycerol acyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four <e1>CHEMICAL<\\e1>  kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>GENE-Y<\\e2> (DGAT)","sentence":"Four prenylflavonoids  kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT)"}
{"PMID":15114505,"re_id":17,"annotated sentence":"Four <e1>prenylflavonoids<\\e1>  kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prenylflavonoids","object":"DGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Four <e1>CHEMICAL<\\e1>  kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>GENE-Y<\\e2> ","sentence":"Four prenylflavonoids  kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT "}
{"PMID":15120421,"re_id":0,"annotated sentence":"At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas <e1>mifepristone<\\e1> and its monodemethylated metabolite manifested slight <e2>glucocorticoid<\\e2> agonist activity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"mifepristone","object":"glucocorticoid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas <e1>CHEMICAL<\\e1> and its monodemethylated metabolite manifested slight <e2>GENE-Y<\\e2> agonist activity","sentence":"At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas mifepristone and its monodemethylated metabolite manifested slight glucocorticoid agonist activity"}
{"PMID":15126366,"re_id":0,"annotated sentence":"<e1>I3A<\\e1> induced a higher level of secretion of the inflammatory cytokine <e2>interleukin 6<\\e2> compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3A","object":"interleukin 6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced a higher level of secretion of the inflammatory cytokine <e2>GENE-Y<\\e2> compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction","sentence":"I3A induced a higher level of secretion of the inflammatory cytokine interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction"}
{"PMID":15126366,"re_id":1,"annotated sentence":"<e1>I3A<\\e1> induced a higher level of secretion of the inflammatory <e2>cytokine<\\e2> interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3A","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced a higher level of secretion of the inflammatory <e2>GENE-N<\\e2> interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction","sentence":"I3A induced a higher level of secretion of the inflammatory cytokine interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction"}
{"PMID":15126366,"re_id":2,"annotated sentence":"I3A induced a higher level of secretion of the inflammatory cytokine <e2>interleukin 6<\\e2> compared with <e1>PMA<\\e1> in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PMA","object":"interleukin 6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"I3A induced a higher level of secretion of the inflammatory cytokine <e2>GENE-Y<\\e2> compared with <e1>CHEMICAL<\\e1> in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction","sentence":"I3A induced a higher level of secretion of the inflammatory cytokine interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction"}
{"PMID":15126366,"re_id":3,"annotated sentence":"I3A induced a higher level of secretion of the inflammatory <e2>cytokine<\\e2> interleukin 6 compared with <e1>PMA<\\e1> in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PMA","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"I3A induced a higher level of secretion of the inflammatory <e2>GENE-N<\\e2> interleukin 6 compared with <e1>CHEMICAL<\\e1> in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction","sentence":"I3A induced a higher level of secretion of the inflammatory cytokine interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction"}
{"PMID":15126366,"re_id":4,"annotated sentence":"The in vitro kinase activity of <e2>PKC-alpha<\\e2> induced by <e1>I3A<\\e1> was lower than that induced by PMA","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"I3A","object":"PKC-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The in vitro kinase activity of <e2>GENE-Y<\\e2> induced by <e1>CHEMICAL<\\e1> was lower than that induced by PMA","sentence":"The in vitro kinase activity of PKC-alpha induced by I3A was lower than that induced by PMA"}
{"PMID":15126366,"re_id":5,"annotated sentence":"The in vitro kinase activity of <e2>PKC-alpha<\\e2> induced by I3A was lower than that induced by <e1>PMA<\\e1>  The novel pattern of behavior of I3A makes it of great interest for further evaluation.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PMA","object":"PKC-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The in vitro kinase activity of <e2>GENE-Y<\\e2> induced by I3A was lower than that induced by <e1>CHEMICAL<\\e1>  The novel pattern of behavior of I3A makes it of great interest for further evaluation.","sentence":"The in vitro kinase activity of PKC-alpha induced by I3A was lower than that induced by PMA  The novel pattern of behavior of I3A makes it of great interest for further evaluation."}
{"PMID":15126366,"re_id":6,"annotated sentence":"<e2>PKC<\\e2> isoforms did show different sensitivity and selectivity for down-regulation by <e1>I3A<\\e1> and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"I3A","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> isoforms did show different sensitivity and selectivity for down-regulation by <e1>CHEMICAL<\\e1> and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells","sentence":"PKC isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells"}
{"PMID":15126366,"re_id":7,"annotated sentence":"<e2>PKC<\\e2> isoforms did show different sensitivity and selectivity for down-regulation by I3A and <e1>phorbol 12-myristate 13-acetate<\\e1> (PMA) in WEHI-231, HOP-92, and Colo-205 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phorbol 12-myristate 13-acetate","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> isoforms did show different sensitivity and selectivity for down-regulation by I3A and <e1>CHEMICAL<\\e1> (PMA) in WEHI-231, HOP-92, and Colo-205 cells","sentence":"PKC isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells"}
{"PMID":15126366,"re_id":8,"annotated sentence":"<e2>PKC<\\e2> isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (<e1>PMA<\\e1>  in WEHI-231, HOP-92, and Colo-205 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PMA","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (<e1>CHEMICAL<\\e1>  in WEHI-231, HOP-92, and Colo-205 cells","sentence":"PKC isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (PMA  in WEHI-231, HOP-92, and Colo-205 cells"}
{"PMID":15132128,"re_id":0,"annotated sentence":"<e1>5-FU<\\e1> interferes with DNA synthesis by blocking <e2>thymidylate synthase<\\e2> (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-FU","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> interferes with DNA synthesis by blocking <e2>GENE-Y<\\e2> (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)","sentence":"5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)"}
{"PMID":15132128,"re_id":1,"annotated sentence":"<e1>5-FU<\\e1> interferes with DNA synthesis by blocking thymidylate synthase (<e2>TS<\\e2>  but is inactivated by dihydropyrimidine dehydrogenase (DPD)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-FU","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> interferes with DNA synthesis by blocking thymidylate synthase (<e2>GENE-Y<\\e2>  but is inactivated by dihydropyrimidine dehydrogenase (DPD)","sentence":"5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS  but is inactivated by dihydropyrimidine dehydrogenase (DPD)"}
{"PMID":15132128,"re_id":2,"annotated sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to <e1>5-fluorouracil<\\e1> (5-FU) by thymidine phosphorylase (<e2>TP<\\e2>  inside target tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-fluorouracil","object":"TP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to <e1>CHEMICAL<\\e1> (5-FU) by thymidine phosphorylase (<e2>GENE-Y<\\e2>  inside target tissues","sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP  inside target tissues"}
{"PMID":15132128,"re_id":3,"annotated sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to <e1>5-fluorouracil<\\e1> (5-FU) by <e2>thymidine phosphorylase<\\e2> (TP) inside target tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-fluorouracil","object":"thymidine phosphorylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to <e1>CHEMICAL<\\e1> (5-FU) by <e2>GENE-Y<\\e2> (TP) inside target tissues","sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues"}
{"PMID":15132128,"re_id":4,"annotated sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (<e1>5-FU<\\e1>  by thymidine phosphorylase (<e2>TP<\\e2>  inside target tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-FU","object":"TP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (<e1>CHEMICAL<\\e1>  by thymidine phosphorylase (<e2>GENE-Y<\\e2>  inside target tissues","sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU  by thymidine phosphorylase (TP  inside target tissues"}
{"PMID":15132128,"re_id":5,"annotated sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (<e1>5-FU<\\e1>  by <e2>thymidine phosphorylase<\\e2> (TP) inside target tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-FU","object":"thymidine phosphorylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (<e1>CHEMICAL<\\e1>  by <e2>GENE-Y<\\e2> (TP) inside target tissues","sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU  by thymidine phosphorylase (TP) inside target tissues"}
{"PMID":15132128,"re_id":6,"annotated sentence":"PURPOSE: The <e1>fluoropyrimidine carbamate<\\e1> (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (<e2>TP<\\e2>  inside target tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"fluoropyrimidine carbamate","object":"TP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: The <e1>CHEMICAL<\\e1> (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (<e2>GENE-Y<\\e2>  inside target tissues","sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP  inside target tissues"}
{"PMID":15132128,"re_id":7,"annotated sentence":"PURPOSE: The <e1>fluoropyrimidine carbamate<\\e1> (capecitabine) is converted to 5-fluorouracil (5-FU) by <e2>thymidine phosphorylase<\\e2> (TP) inside target tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"fluoropyrimidine carbamate","object":"thymidine phosphorylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: The <e1>CHEMICAL<\\e1> (capecitabine) is converted to 5-fluorouracil (5-FU) by <e2>GENE-Y<\\e2> (TP) inside target tissues","sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues"}
{"PMID":15132128,"re_id":8,"annotated sentence":"Favorable enzyme profiles (high <e2>TP<\\e2> and low DPD) generate high intratumor levels of <e1>5-FU<\\e1> that are effective against many tumors, especially those with low TS","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-FU","object":"TP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Favorable enzyme profiles (high <e2>GENE-Y<\\e2> and low DPD) generate high intratumor levels of <e1>CHEMICAL<\\e1> that are effective against many tumors, especially those with low TS","sentence":"Favorable enzyme profiles (high TP and low DPD) generate high intratumor levels of 5-FU that are effective against many tumors, especially those with low TS"}
{"PMID":15132128,"re_id":9,"annotated sentence":"Favorable enzyme profiles (high TP and low <e2>DPD<\\e2>  generate high intratumor levels of <e1>5-FU<\\e1> that are effective against many tumors, especially those with low TS","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-FU","object":"DPD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Favorable enzyme profiles (high TP and low <e2>GENE-Y<\\e2>  generate high intratumor levels of <e1>CHEMICAL<\\e1> that are effective against many tumors, especially those with low TS","sentence":"Favorable enzyme profiles (high TP and low DPD  generate high intratumor levels of 5-FU that are effective against many tumors, especially those with low TS"}
{"PMID":15132128,"re_id":10,"annotated sentence":"PURPOSE: The fluoropyrimidine carbamate (<e1>capecitabine<\\e1>  is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (<e2>TP<\\e2>  inside target tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"capecitabine","object":"TP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: The fluoropyrimidine carbamate (<e1>CHEMICAL<\\e1>  is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (<e2>GENE-Y<\\e2>  inside target tissues","sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine  is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP  inside target tissues"}
{"PMID":15132128,"re_id":11,"annotated sentence":"PURPOSE: The fluoropyrimidine carbamate (<e1>capecitabine<\\e1>  is converted to 5-fluorouracil (5-FU) by <e2>thymidine phosphorylase<\\e2> (TP) inside target tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"capecitabine","object":"thymidine phosphorylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: The fluoropyrimidine carbamate (<e1>CHEMICAL<\\e1>  is converted to 5-fluorouracil (5-FU) by <e2>GENE-Y<\\e2> (TP) inside target tissues","sentence":"PURPOSE: The fluoropyrimidine carbamate (capecitabine  is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues"}
{"PMID":15133083,"re_id":0,"annotated sentence":"<e1>SL-11158<\\e1> inhibited <e2>SSAT<\\e2> activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SL-11158","object":"SSAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited <e2>GENE-N<\\e2> activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine","sentence":"SL-11158 inhibited SSAT activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine"}
{"PMID":15133083,"re_id":1,"annotated sentence":"bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of <e1>BW-1<\\e1>  acted as substrate for <e2>PAO<\\e2>  The Enc","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BW-1","object":"PAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [CHEMICAL, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of <e1>CHEMICAL<\\e1>  acted as substrate for <e2>GENE-N<\\e2>  The Enc","sentence":"bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1  acted as substrate for PAO  The Enc"}
{"PMID":15155769,"re_id":0,"annotated sentence":"The <e2>M564G<\\e2> mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, <e1>acetyl-CoA<\\e1>  Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetyl-CoA","object":"M564G","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, <e1>CHEMICAL<\\e1>  Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates","sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA  Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates"}
{"PMID":15155769,"re_id":1,"annotated sentence":"The M564G mutated <e2>CrAT<\\e2> showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, <e1>acetyl-CoA<\\e1>  Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetyl-CoA","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The M564G mutated <e2>GENE-Y<\\e2> showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type GENE-Y, and lower activity toward its natural substrate, <e1>CHEMICAL<\\e1>  Kinetic constants of the mutant GENE-Y showed modification in favor of longer acyl-CoAs as substrates","sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA  Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates"}
{"PMID":15155769,"re_id":2,"annotated sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type <e2>CrAT<\\e2>  and lower activity toward its natural substrate, <e1>acetyl-CoA<\\e1>  Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetyl-CoA","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The M564G mutated GENE-Y showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type <e2>GENE-Y<\\e2>  and lower activity toward its natural substrate, <e1>CHEMICAL<\\e1>  Kinetic constants of the mutant GENE-Y showed modification in favor of longer acyl-CoAs as substrates","sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT  and lower activity toward its natural substrate, acetyl-CoA  Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates"}
{"PMID":15155769,"re_id":3,"annotated sentence":"Kinetic constants of the mutant <e2>CrAT<\\e2> showed modification in favor of longer <e1>acyl-CoAs<\\e1> as substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl-CoAs","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic constants of the mutant <e2>GENE-Y<\\e2> showed modification in favor of longer <e1>CHEMICAL<\\e1> as substrates","sentence":"Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates"}
{"PMID":15155769,"re_id":4,"annotated sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in <e2>carnitine octanoyltransferase<\\e2> (COT) decreased activity toward its natural substrates, medium- and long-chain <e1>acyl-CoAs<\\e1>  and increased activity toward short-chain acyl-CoAs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl-CoAs","object":"carnitine octanoyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in <e2>GENE-Y<\\e2> (COT) decreased activity toward its natural substrates, medium- and long-chain <e1>CHEMICAL<\\e1>  and increased activity toward short-chain CHEMICAL","sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs  and increased activity toward short-chain acyl-CoAs"}
{"PMID":15155769,"re_id":5,"annotated sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (<e2>COT<\\e2>  decreased activity toward its natural substrates, medium- and long-chain <e1>acyl-CoAs<\\e1>  and increased activity toward short-chain acyl-CoAs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl-CoAs","object":"COT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (<e2>GENE-Y<\\e2>  decreased activity toward its natural substrates, medium- and long-chain <e1>CHEMICAL<\\e1>  and increased activity toward short-chain CHEMICAL","sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (COT  decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs  and increased activity toward short-chain acyl-CoAs"}
{"PMID":15155769,"re_id":6,"annotated sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in <e2>carnitine octanoyltransferase<\\e2> (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain <e1>acyl-CoAs<\\e1>  Another CrAT mutant, M564A, was prepared and tested in the same way, with similar results","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl-CoAs","object":"carnitine octanoyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in <e2>GENE-Y<\\e2> (COT) decreased activity toward its natural substrates, medium- and long-chain CHEMICAL, and increased activity toward short-chain <e1>CHEMICAL<\\e1>  Another CrAT mutant, M564A, was prepared and tested in the same way, with similar results","sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs  Another CrAT mutant, M564A, was prepared and tested in the same way, with similar results"}
{"PMID":15155769,"re_id":7,"annotated sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (<e2>COT<\\e2>  decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain <e1>acyl-CoAs<\\e1>  Another CrAT mutant, M564A, was prepared and tested in the same way, with similar results","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl-CoAs","object":"COT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (<e2>GENE-Y<\\e2>  decreased activity toward its natural substrates, medium- and long-chain CHEMICAL, and increased activity toward short-chain <e1>CHEMICAL<\\e1>  Another CrAT mutant, M564A, was prepared and tested in the same way, with similar results","sentence":"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (COT  decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs  Another CrAT mutant, M564A, was prepared and tested in the same way, with similar results"}
{"PMID":15155769,"re_id":8,"annotated sentence":"We conclude that Met564 blocks the entry of medium- and long-chain <e1>acyl-CoAs<\\e1> to the catalytic site of <e2>CrAT<\\e2>  Three-dimensional models of wild-type and mutated CrAT and COT support this hypothesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl-CoAs","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that Met564 blocks the entry of medium- and long-chain <e1>CHEMICAL<\\e1> to the catalytic site of <e2>GENE-Y<\\e2>  Three-dimensional models of wild-type and mutated GENE-Y and COT support this hypothesis","sentence":"We conclude that Met564 blocks the entry of medium- and long-chain acyl-CoAs to the catalytic site of CrAT  Three-dimensional models of wild-type and mutated CrAT and COT support this hypothesis"}
{"PMID":15155769,"re_id":9,"annotated sentence":"<e2>Carnitine acetyltransferases<\\e2> (CrAT) catalyze the reversible conversion of <e1>acetyl-CoA<\\e1> and carnitine to acetylcarnitine and free CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetyl-CoA","object":"Carnitine acetyltransferases","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CrAT) catalyze the reversible conversion of <e1>CHEMICAL<\\e1> and carnitine to acetylcarnitine and free CoA","sentence":"Carnitine acetyltransferases (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to acetylcarnitine and free CoA"}
{"PMID":15155769,"re_id":10,"annotated sentence":"Carnitine acetyltransferases (<e2>CrAT<\\e2>  catalyze the reversible conversion of <e1>acetyl-CoA<\\e1> and carnitine to acetylcarnitine and free CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetyl-CoA","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Carnitine acetyltransferases (<e2>GENE-Y<\\e2>  catalyze the reversible conversion of <e1>CHEMICAL<\\e1> and carnitine to acetylcarnitine and free CoA","sentence":"Carnitine acetyltransferases (CrAT  catalyze the reversible conversion of acetyl-CoA and carnitine to acetylcarnitine and free CoA"}
{"PMID":15155769,"re_id":11,"annotated sentence":"<e2>Carnitine acetyltransferases<\\e2> (CrAT) catalyze the reversible conversion of acetyl-CoA and <e1>carnitine<\\e1> to acetylcarnitine and free CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"carnitine","object":"Carnitine acetyltransferases","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CrAT) catalyze the reversible conversion of acetyl-CoA and <e1>CHEMICAL<\\e1> to acetylCHEMICAL and free CoA","sentence":"Carnitine acetyltransferases (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to acetylcarnitine and free CoA"}
{"PMID":15155769,"re_id":12,"annotated sentence":"Carnitine acetyltransferases (<e2>CrAT<\\e2>  catalyze the reversible conversion of acetyl-CoA and <e1>carnitine<\\e1> to acetylcarnitine and free CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"carnitine","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Carnitine acetyltransferases (<e2>GENE-Y<\\e2>  catalyze the reversible conversion of acetyl-CoA and <e1>CHEMICAL<\\e1> to acetylCHEMICAL and free CoA","sentence":"Carnitine acetyltransferases (CrAT  catalyze the reversible conversion of acetyl-CoA and carnitine to acetylcarnitine and free CoA"}
{"PMID":15155769,"re_id":13,"annotated sentence":"<e2>Carnitine acetyltransferases<\\e2> (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to <e1>acetylcarnitine<\\e1> and free CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetylcarnitine","object":"Carnitine acetyltransferases","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to <e1>CHEMICAL<\\e1> and free CoA","sentence":"Carnitine acetyltransferases (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to acetylcarnitine and free CoA"}
{"PMID":15155769,"re_id":14,"annotated sentence":"Carnitine acetyltransferases (<e2>CrAT<\\e2>  catalyze the reversible conversion of acetyl-CoA and carnitine to <e1>acetylcarnitine<\\e1> and free CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetylcarnitine","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Carnitine acetyltransferases (<e2>GENE-Y<\\e2>  catalyze the reversible conversion of acetyl-CoA and carnitine to <e1>CHEMICAL<\\e1> and free CoA","sentence":"Carnitine acetyltransferases (CrAT  catalyze the reversible conversion of acetyl-CoA and carnitine to acetylcarnitine and free CoA"}
{"PMID":15155769,"re_id":15,"annotated sentence":"The <e2>M564G<\\e2> mutated CrAT showed higher activity toward longer chain <e1>acyl-CoAs<\\e1>  activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl-CoAs","object":"M564G","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> mutated CrAT showed higher activity toward longer chain <e1>CHEMICAL<\\e1>  activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA","sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs  activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA"}
{"PMID":15155769,"re_id":16,"annotated sentence":"The M564G mutated <e2>CrAT<\\e2> showed higher activity toward longer chain <e1>acyl-CoAs<\\e1>  activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl-CoAs","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The M564G mutated <e2>GENE-Y<\\e2> showed higher activity toward longer chain <e1>CHEMICAL<\\e1>  activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type GENE-Y, and lower activity toward its natural substrate, acetyl-CoA","sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs  activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA"}
{"PMID":15155769,"re_id":17,"annotated sentence":"The M564G mutated CrAT showed higher activity toward longer chain <e1>acyl-CoAs<\\e1>  activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type <e2>CrAT<\\e2>  and lower activity toward its natural substrate, acetyl-CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl-CoAs","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The M564G mutated GENE-Y showed higher activity toward longer chain <e1>CHEMICAL<\\e1>  activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type <e2>GENE-Y<\\e2>  and lower activity toward its natural substrate, acetyl-CoA","sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs  activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT  and lower activity toward its natural substrate, acetyl-CoA"}
{"PMID":15155769,"re_id":18,"annotated sentence":"The <e2>M564G<\\e2> mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward <e1>myristoyl-CoA<\\e1> was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"myristoyl-CoA","object":"M564G","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward <e1>CHEMICAL<\\e1> was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA","sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA"}
{"PMID":15155769,"re_id":19,"annotated sentence":"The M564G mutated <e2>CrAT<\\e2> showed higher activity toward longer chain acyl-CoAs: activity toward <e1>myristoyl-CoA<\\e1> was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"myristoyl-CoA","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The M564G mutated <e2>GENE-Y<\\e2> showed higher activity toward longer chain acyl-CoAs: activity toward <e1>CHEMICAL<\\e1> was 1250-fold higher than that of the wild-type GENE-Y, and lower activity toward its natural substrate, acetyl-CoA","sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA"}
{"PMID":15155769,"re_id":20,"annotated sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward <e1>myristoyl-CoA<\\e1> was 1250-fold higher than that of the wild-type <e2>CrAT<\\e2>  and lower activity toward its natural substrate, acetyl-CoA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"myristoyl-CoA","object":"CrAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The M564G mutated GENE-Y showed higher activity toward longer chain acyl-CoAs: activity toward <e1>CHEMICAL<\\e1> was 1250-fold higher than that of the wild-type <e2>GENE-Y<\\e2>  and lower activity toward its natural substrate, acetyl-CoA","sentence":"The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT  and lower activity toward its natural substrate, acetyl-CoA"}
{"PMID":15177307,"re_id":0,"annotated sentence":"No influence of moderate hepatic impairment on the pharmacokinetics of <e1>lumiracoxib<\\e1>  an oral <e2>COX-2<\\e2> selective inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"No influence of moderate hepatic impairment on the pharmacokinetics of <e1>CHEMICAL<\\e1>  an oral <e2>GENE-Y<\\e2> selective inhibitor","sentence":"No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib  an oral COX-2 selective inhibitor"}
{"PMID":15177307,"re_id":1,"annotated sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel <e2>cyclooxygenase-2<\\e2> (COX-2) selective inhibitor <e1>lumiracoxib<\\e1> (Prexige), so that dose recommendations for clinical use can be provided","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel <e2>GENE-Y<\\e2> (COX-2) selective inhibitor <e1>CHEMICAL<\\e1> (Prexige), so that dose recommendations for clinical use can be provided","sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (COX-2) selective inhibitor lumiracoxib (Prexige), so that dose recommendations for clinical use can be provided"}
{"PMID":15177307,"re_id":2,"annotated sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (<e2>COX-2<\\e2>  selective inhibitor <e1>lumiracoxib<\\e1> (Prexige), so that dose recommendations for clinical use can be provided","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (<e2>GENE-Y<\\e2>  selective inhibitor <e1>CHEMICAL<\\e1> (Prexige), so that dose recommendations for clinical use can be provided","sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (COX-2  selective inhibitor lumiracoxib (Prexige), so that dose recommendations for clinical use can be provided"}
{"PMID":15177307,"re_id":3,"annotated sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel <e2>cyclooxygenase-2<\\e2> (COX-2) selective inhibitor lumiracoxib (<e1>Prexige<\\e1> , so that dose recommendations for clinical use can be provided","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Prexige","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel <e2>GENE-Y<\\e2> (COX-2) selective inhibitor lumiracoxib (<e1>CHEMICAL<\\e1> , so that dose recommendations for clinical use can be provided","sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (COX-2) selective inhibitor lumiracoxib (Prexige , so that dose recommendations for clinical use can be provided"}
{"PMID":15177307,"re_id":4,"annotated sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (<e2>COX-2<\\e2>  selective inhibitor lumiracoxib (<e1>Prexige<\\e1> , so that dose recommendations for clinical use can be provided","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Prexige","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (<e2>GENE-Y<\\e2>  selective inhibitor lumiracoxib (<e1>CHEMICAL<\\e1> , so that dose recommendations for clinical use can be provided","sentence":"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (COX-2  selective inhibitor lumiracoxib (Prexige , so that dose recommendations for clinical use can be provided"}
{"PMID":15224175,"re_id":0,"annotated sentence":"bolus injection of, either physiological saline (0.3 ml\/kg; control), or the antagonists <e1>SB224289<\\e1> (300 microg\/kg; <e2>5-HT1B<\\e2> , BRL15572 (300 microg\/kg; 5-HT1D), rauwolscine (300 microg\/kg; alpha2), SB224289 + BRL15572 (300 microg\/kg each), SB224289 + rauwolscine (300 microg\/kg each), BRL15572 + rauwolscine (300 microg\/kg each), rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg; alpha1), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg), SB224289 (300 microg\/kg) + rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg) + BRL44408 (1,000 microg\/kg; alpha2A), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg)+ imiloxan (1,000 microg\/kg; alpha2B), or SB224289 (300 microg\/kg) + prazosin (100 microg\/kg) + MK912 (300 microg\/kg; alpha2C)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SB224289","object":"5-HT1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"bolus injection of, either physiological saline (0.3 ml\/kg; control), or the antagonists <e1>CHEMICAL<\\e1> (300 microg\/kg; <e2>GENE-Y<\\e2> , BRL15572 (300 microg\/kg; 5-HT1D), rauwolscine (300 microg\/kg; alpha2), CHEMICAL + BRL15572 (300 microg\/kg each), CHEMICAL + rauwolscine (300 microg\/kg each), BRL15572 + rauwolscine (300 microg\/kg each), rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg; alpha1), CHEMICAL (300 microg\/kg) + prazosin (100 microg\/kg), CHEMICAL (300 microg\/kg) + rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg), CHEMICAL (300 microg\/kg) + prazosin (100 microg\/kg) + BRL44408 (1,000 microg\/kg; alpha2A), CHEMICAL (300 microg\/kg) + prazosin (100 microg\/kg)+ imiloxan (1,000 microg\/kg; alpha2B), or CHEMICAL (300 microg\/kg) + prazosin (100 microg\/kg) + MK912 (300 microg\/kg; alpha2C)","sentence":"bolus injection of, either physiological saline (0.3 ml\/kg; control), or the antagonists SB224289 (300 microg\/kg; 5-HT1B , BRL15572 (300 microg\/kg; 5-HT1D), rauwolscine (300 microg\/kg; alpha2), SB224289 + BRL15572 (300 microg\/kg each), SB224289 + rauwolscine (300 microg\/kg each), BRL15572 + rauwolscine (300 microg\/kg each), rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg; alpha1), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg), SB224289 (300 microg\/kg) + rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg) + BRL44408 (1,000 microg\/kg; alpha2A), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg)+ imiloxan (1,000 microg\/kg; alpha2B), or SB224289 (300 microg\/kg) + prazosin (100 microg\/kg) + MK912 (300 microg\/kg; alpha2C)"}
{"PMID":15224175,"re_id":1,"annotated sentence":"bolus injection of, either physiological saline (0.3 ml\/kg; control), or the antagonists SB224289 (300 microg\/kg; 5-HT1B), <e1>BRL15572<\\e1> (300 microg\/kg; <e2>5-HT1D<\\e2> , rauwolscine (300 microg\/kg; alpha2), SB224289 + BRL15572 (300 microg\/kg each), SB224289 + rauwolscine (300 microg\/kg each), BRL15572 + rauwolscine (300 microg\/kg each), rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg; alpha1), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg), SB224289 (300 microg\/kg) + rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg) + BRL44408 (1,000 microg\/kg; alpha2A), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg)+ imiloxan (1,000 microg\/kg; alpha2B), or SB224289 (300 microg\/kg) + prazosin (100 microg\/kg) + MK912 (300 microg\/kg; alpha2C)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"BRL15572","object":"5-HT1D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"bolus injection of, either physiological saline (0.3 ml\/kg; control), or the antagonists SB224289 (300 microg\/kg; 5-HT1B), <e1>CHEMICAL<\\e1> (300 microg\/kg; <e2>GENE-Y<\\e2> , rauwolscine (300 microg\/kg; alpha2), SB224289 + CHEMICAL (300 microg\/kg each), SB224289 + rauwolscine (300 microg\/kg each), CHEMICAL + rauwolscine (300 microg\/kg each), rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg; alpha1), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg), SB224289 (300 microg\/kg) + rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg) + BRL44408 (1,000 microg\/kg; alpha2A), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg)+ imiloxan (1,000 microg\/kg; alpha2B), or SB224289 (300 microg\/kg) + prazosin (100 microg\/kg) + MK912 (300 microg\/kg; alpha2C)","sentence":"bolus injection of, either physiological saline (0.3 ml\/kg; control), or the antagonists SB224289 (300 microg\/kg; 5-HT1B), BRL15572 (300 microg\/kg; 5-HT1D , rauwolscine (300 microg\/kg; alpha2), SB224289 + BRL15572 (300 microg\/kg each), SB224289 + rauwolscine (300 microg\/kg each), BRL15572 + rauwolscine (300 microg\/kg each), rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg; alpha1), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg), SB224289 (300 microg\/kg) + rauwolscine (300 microg\/kg) + prazosin (100 microg\/kg), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg) + BRL44408 (1,000 microg\/kg; alpha2A), SB224289 (300 microg\/kg) + prazosin (100 microg\/kg)+ imiloxan (1,000 microg\/kg; alpha2B), or SB224289 (300 microg\/kg) + prazosin (100 microg\/kg) + MK912 (300 microg\/kg; alpha2C)"}
{"PMID":15336276,"re_id":0,"annotated sentence":"To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of <e1>phenylalkylphosphonamidate<\\e1> derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against <e2>PSMA<\\e2>  Both the phenyl- and benzylphosphonamidates (1a and 1b) exhibited only modest inhibitory potency against","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenylalkylphosphonamidate","object":"PSMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of GENE-Y a series of <e1>CHEMICAL<\\e1> derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against <e2>GENE-Y<\\e2>  Both the phenyl- and benzylphosphonamidates (1a and 1b) exhibited only modest inhibitory potency against","sentence":"To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of phenylalkylphosphonamidate derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against PSMA  Both the phenyl- and benzylphosphonamidates (1a and 1b) exhibited only modest inhibitory potency against"}
{"PMID":15336276,"re_id":1,"annotated sentence":"To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of phenylalkylphosphonamidate derivatives of <e1>glutamic acid<\\e1> were synthesized and evaluated for their inhibitory potencies against <e2>PSMA<\\e2>  Both the phenyl- and benzylphosphonamidates (1a and 1b) exhibited only modest inhibitory potency against","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glutamic acid","object":"PSMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of GENE-Y a series of phenylalkylphosphonamidate derivatives of <e1>CHEMICAL<\\e1> were synthesized and evaluated for their inhibitory potencies against <e2>GENE-Y<\\e2>  Both the phenyl- and benzylphosphonamidates (1a and 1b) exhibited only modest inhibitory potency against","sentence":"To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of phenylalkylphosphonamidate derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against PSMA  Both the phenyl- and benzylphosphonamidates (1a and 1b) exhibited only modest inhibitory potency against"}
{"PMID":15452358,"re_id":0,"annotated sentence":"These findings suggest that the anti-allodynia effect of <e1>CP-101,606<\\e1> is ascribable to blockade of <e2>NR2B<\\e2> receptors at the brain, but not at the spinal cord","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CP-101,606","object":"NR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that the anti-allodynia effect of <e1>CHEMICAL<\\e1> is ascribable to blockade of <e2>GENE-Y<\\e2> receptors at the brain, but not at the spinal cord","sentence":"These findings suggest that the anti-allodynia effect of CP-101,606 is ascribable to blockade of NR2B receptors at the brain, but not at the spinal cord"}
{"PMID":15452358,"re_id":1,"annotated sentence":"In order to examine the site of action of an <e2>NR2B<\\e2> subtype-selective NMDA antagonist <e1>CP-101,606<\\e1>  we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"CP-101,606","object":"NR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In order to examine the site of action of an <e2>GENE-Y<\\e2> subtype-selective NMDA antagonist <e1>CHEMICAL<\\e1>  we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration","sentence":"In order to examine the site of action of an NR2B subtype-selective NMDA antagonist CP-101,606  we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration"}
{"PMID":15452358,"re_id":2,"annotated sentence":"In order to examine the site of action of an NR2B subtype-selective <e2>NMDA<\\e2> antagonist <e1>CP-101,606<\\e1>  we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"CP-101,606","object":"NMDA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In order to examine the site of action of an NR2B subtype-selective <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1>  we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration","sentence":"In order to examine the site of action of an NR2B subtype-selective NMDA antagonist CP-101,606  we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration"}
{"PMID":15452358,"re_id":3,"annotated sentence":"Brain but not spinal <e2>NR2B<\\e2> receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist <e1>CP-101,606<\\e1> in a rat chronic constriction injury model","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"CP-101,606","object":"NR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Brain but not spinal <e2>GENE-Y<\\e2> receptor is responsible for the anti-allodynic effect of an GENE-Y subunit-selective antagonist <e1>CHEMICAL<\\e1> in a rat chronic constriction injury model","sentence":"Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model"}
{"PMID":15452358,"re_id":4,"annotated sentence":"Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an <e2>NR2B<\\e2> subunit-selective antagonist <e1>CP-101,606<\\e1> in a rat chronic constriction injury model","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"CP-101,606","object":"NR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Brain but not spinal GENE-Y receptor is responsible for the anti-allodynic effect of an <e2>GENE-Y<\\e2> subunit-selective antagonist <e1>CHEMICAL<\\e1> in a rat chronic constriction injury model","sentence":"Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model"}
{"PMID":15452358,"re_id":5,"annotated sentence":"In contrast, intrathecal injection of a non-selective <e2>NMDA<\\e2> antagonist, <e1>memantine<\\e1>  significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"memantine","object":"NMDA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, intrathecal injection of a non-selective <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1>  significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective GENE-N antagonist and the NR2B-specific GENE-N antagonist.","sentence":"In contrast, intrathecal injection of a non-selective NMDA antagonist, memantine  significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist."}
{"PMID":15465035,"re_id":0,"annotated sentence":"We demonstrate that among the three nitrates, only <e1>SNP<\\e1> inhibits <e2>HIF-1<\\e2> activation in response to hypoxia","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SNP","object":"HIF-1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We demonstrate that among the three nitrates, only <e1>CHEMICAL<\\e1> inhibits <e2>GENE-N<\\e2> activation in response to hypoxia","sentence":"We demonstrate that among the three nitrates, only SNP inhibits HIF-1 activation in response to hypoxia"}
{"PMID":15465035,"re_id":1,"annotated sentence":"<e1>SNP<\\e1> inhibits the accumulation of <e2>HIF-1alpha<\\e2>  the regulatory subunit of HIF-1, and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SNP","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits the accumulation of <e2>GENE-Y<\\e2>  the regulatory subunit of HIF-1, and the transcriptional activation of GENE-Y via a mechanism that is not dependent on either NO or soluble guanylate cyclase.","sentence":"SNP inhibits the accumulation of HIF-1alpha  the regulatory subunit of HIF-1, and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase."}
{"PMID":15465035,"re_id":2,"annotated sentence":"<e1>SNP<\\e1> inhibits the accumulation of HIF-1alpha, the regulatory subunit of <e2>HIF-1<\\e2>  and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SNP","object":"HIF-1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits the accumulation of GENE-Nalpha, the regulatory subunit of <e2>GENE-N<\\e2>  and the transcriptional activation of GENE-Nalpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase.","sentence":"SNP inhibits the accumulation of HIF-1alpha, the regulatory subunit of HIF-1  and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase."}
{"PMID":15465035,"re_id":3,"annotated sentence":"<e1>SNP<\\e1> inhibits the accumulation of HIF-1alpha, the regulatory subunit of HIF-1, and the transcriptional activation of <e2>HIF-1alpha<\\e2> via a mechanism that is not dependent on either NO or soluble guanylate cyclase.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SNP","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits the accumulation of GENE-Y, the regulatory subunit of HIF-1, and the transcriptional activation of <e2>GENE-Y<\\e2> via a mechanism that is not dependent on either NO or soluble guanylate cyclase.","sentence":"SNP inhibits the accumulation of HIF-1alpha, the regulatory subunit of HIF-1, and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase."}
{"PMID":15465035,"re_id":4,"annotated sentence":"The inhibitory effect of <e1>sodium nitroprusside<\\e1> on <e2>HIF-1<\\e2> activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sodium nitroprusside","object":"HIF-1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-N<\\e2> activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway","sentence":"The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway"}
{"PMID":15561973,"re_id":0,"annotated sentence":"As opposed to the rat and flounder orthologs, <e2>hNaDC-3<\\e2> was hardly inhibited by <e1>lithium<\\e1> concentrations up to 5 mM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lithium","object":"hNaDC-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As opposed to the rat and flounder orthologs, <e2>GENE-Y<\\e2> was hardly inhibited by <e1>CHEMICAL<\\e1> concentrations up to 5 mM","sentence":"As opposed to the rat and flounder orthologs, hNaDC-3 was hardly inhibited by lithium concentrations up to 5 mM"}
{"PMID":15562257,"re_id":0,"annotated sentence":"Using whole-cell voltage clamp, we examined <e1>mibefradil<\\e1> block of four <e2>Na+ channel<\\e2> isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mibefradil","object":"Na+ channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Using whole-cell voltage clamp, we examined <e1>CHEMICAL<\\e1> block of four <e2>GENE-N<\\e2> isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)","sentence":"Using whole-cell voltage clamp, we examined mibefradil block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)"}
{"PMID":15562257,"re_id":1,"annotated sentence":"Using whole-cell voltage clamp, we examined <e1>mibefradil<\\e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: <e2>Nav1.5<\\e2> (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mibefradil","object":"Nav1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using whole-cell voltage clamp, we examined <e1>CHEMICAL<\\e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: <e2>GENE-Y<\\e2> (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)","sentence":"Using whole-cell voltage clamp, we examined mibefradil block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)"}
{"PMID":15562257,"re_id":2,"annotated sentence":"Using whole-cell voltage clamp, we examined <e1>mibefradil<\\e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), <e2>Nav1.4<\\e2> (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mibefradil","object":"Nav1.4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using whole-cell voltage clamp, we examined <e1>CHEMICAL<\\e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), <e2>GENE-Y<\\e2> (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)","sentence":"Using whole-cell voltage clamp, we examined mibefradil block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)"}
{"PMID":15562257,"re_id":3,"annotated sentence":"Using whole-cell voltage clamp, we examined <e1>mibefradil<\\e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), <e2>Nav1.2<\\e2> (brain), and Nav1.7 (peripheral nerve)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mibefradil","object":"Nav1.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using whole-cell voltage clamp, we examined <e1>CHEMICAL<\\e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), <e2>GENE-Y<\\e2> (brain), and Nav1.7 (peripheral nerve)","sentence":"Using whole-cell voltage clamp, we examined mibefradil block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)"}
{"PMID":15562257,"re_id":4,"annotated sentence":"Using whole-cell voltage clamp, we examined <e1>mibefradil<\\e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and <e2>Nav1.7<\\e2> (peripheral nerve)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mibefradil","object":"Nav1.7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using whole-cell voltage clamp, we examined <e1>CHEMICAL<\\e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and <e2>GENE-Y<\\e2> (peripheral nerve)","sentence":"Using whole-cell voltage clamp, we examined mibefradil block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)"}
{"PMID":15562257,"re_id":5,"annotated sentence":"<e1>Mibefradil<\\e1> blocked <e2>Nav1.5<\\e2> in a use\/frequency-dependent manner, indicating preferential binding to states visited during depolarization","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Mibefradil","object":"Nav1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> blocked <e2>GENE-Y<\\e2> in a use\/frequency-dependent manner, indicating preferential binding to states visited during depolarization","sentence":"Mibefradil blocked Nav1.5 in a use\/frequency-dependent manner, indicating preferential binding to states visited during depolarization"}
{"PMID":15562257,"re_id":6,"annotated sentence":"<e1>Mibefradil<\\e1> blocked currents of all <e2>Na+ channel<\\e2> isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024\/s at -130 mV and 0.007\/s at -100 mV for Nav1.5)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Mibefradil","object":"Na+ channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> blocked currents of all <e2>GENE-N<\\e2> isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024\/s at -130 mV and 0.007\/s at -100 mV for Nav1.5)","sentence":"Mibefradil blocked currents of all Na+ channel isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024\/s at -130 mV and 0.007\/s at -100 mV for Nav1.5)"}
{"PMID":15562257,"re_id":7,"annotated sentence":"<e1>Mibefradil<\\e1> blocked currents of all Na+ channel isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024\/s at -130 mV and 0.007\/s at -100 mV for <e2>Nav1.5<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Mibefradil","object":"Nav1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> blocked currents of all Na+ channel isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024\/s at -130 mV and 0.007\/s at -100 mV for <e2>GENE-Y<\\e2> ","sentence":"Mibefradil blocked currents of all Na+ channel isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024\/s at -130 mV and 0.007\/s at -100 mV for Nav1.5 "}
{"PMID":15562257,"re_id":8,"annotated sentence":"State-dependent <e1>mibefradil<\\e1> block of <e2>Na+ channels<\\e2>  Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mibefradil","object":"Na+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"State-dependent <e1>CHEMICAL<\\e1> block of <e2>GENE-N<\\e2>  Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and GENE-N","sentence":"State-dependent mibefradil block of Na+ channels  Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels"}
{"PMID":15562257,"re_id":9,"annotated sentence":"In addition, inhibiting the binding of the fast inactivation lid (<e2>Nav1.5<\\e2> ICM + MTSET) did not alter <e1>mibefradil<\\e1> block, confirming that the drug does not preferentially interact with the fast-inactivated state","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mibefradil","object":"Nav1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, inhibiting the binding of the fast inactivation lid (<e2>GENE-Y<\\e2> ICM + MTSET) did not alter <e1>CHEMICAL<\\e1> block, confirming that the drug does not preferentially interact with the fast-inactivated state","sentence":"In addition, inhibiting the binding of the fast inactivation lid (Nav1.5 ICM + MTSET) did not alter mibefradil block, confirming that the drug does not preferentially interact with the fast-inactivated state"}
{"PMID":15562257,"re_id":10,"annotated sentence":"When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, <e1>mibefradil<\\e1> (1 microM) produced 45% fractional block in <e2>Nav1.5<\\e2> and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mibefradil","object":"Nav1.5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, <e1>CHEMICAL<\\e1> (1 microM) produced 45% fractional block in <e2>GENE-Y<\\e2> and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely","sentence":"When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, mibefradil (1 microM) produced 45% fractional block in Nav1.5 and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely"}
{"PMID":15562257,"re_id":11,"annotated sentence":"When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, <e1>mibefradil<\\e1> (1 microM) produced 45% fractional block in Nav1.5 and greater block (88%) in an isoform (<e2>Nav1.4<\\e2>  that slow-inactivates more completely","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mibefradil","object":"Nav1.4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, <e1>CHEMICAL<\\e1> (1 microM) produced 45% fractional block in Nav1.5 and greater block (88%) in an isoform (<e2>GENE-Y<\\e2>  that slow-inactivates more completely","sentence":"When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, mibefradil (1 microM) produced 45% fractional block in Nav1.5 and greater block (88%) in an isoform (Nav1.4  that slow-inactivates more completely"}
{"PMID":15562257,"re_id":12,"annotated sentence":"Our results suggest that <e1>mibefradil<\\e1> blocks <e2>Na+ channels<\\e2> in a state-dependent manner that does not depend on fast inactivation but probably involves interaction with one or more slow-inactivated state(s).","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mibefradil","object":"Na+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our results suggest that <e1>CHEMICAL<\\e1> blocks <e2>GENE-N<\\e2> in a state-dependent manner that does not depend on fast inactivation but probably involves interaction with one or more slow-inactivated state(s).","sentence":"Our results suggest that mibefradil blocks Na+ channels in a state-dependent manner that does not depend on fast inactivation but probably involves interaction with one or more slow-inactivated state(s)."}
{"PMID":15562257,"re_id":13,"annotated sentence":"<e1>Mibefradil<\\e1> is a <e2>T-type Ca2+ channel<\\e2> antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Mibefradil","object":"T-type Ca2+ channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a <e2>GENE-N<\\e2> antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels","sentence":"Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels"}
{"PMID":15598972,"re_id":0,"annotated sentence":"Extracellular application of meclofenamate (EC(50) = 25 microM) and <e1>diclofenac<\\e1> (EC(50) = 2.6 microM) resulted in the activation of <e2>KCNQ2\/Q3<\\e2> K(+) currents, heterologously expressed in Chinese hamster ovary cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"diclofenac","object":"KCNQ2\/Q3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Extracellular application of meclofenamate (EC(50) = 25 microM) and <e1>CHEMICAL<\\e1> (EC(50) = 2.6 microM) resulted in the activation of <e2>GENE-N<\\e2> K(+) currents, heterologously expressed in Chinese hamster ovary cells","sentence":"Extracellular application of meclofenamate (EC(50) = 25 microM) and diclofenac (EC(50) = 2.6 microM) resulted in the activation of KCNQ2\/Q3 K(+) currents, heterologously expressed in Chinese hamster ovary cells"}
{"PMID":15598972,"re_id":1,"annotated sentence":"Extracellular application of <e1>meclofenamate<\\e1> (EC(50) = 25 microM) and diclofenac (EC(50) = 2.6 microM) resulted in the activation of <e2>KCNQ2\/Q3<\\e2> K(+) currents, heterologously expressed in Chinese hamster ovary cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"meclofenamate","object":"KCNQ2\/Q3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Extracellular application of <e1>CHEMICAL<\\e1> (EC(50) = 25 microM) and diclofenac (EC(50) = 2.6 microM) resulted in the activation of <e2>GENE-N<\\e2> K(+) currents, heterologously expressed in Chinese hamster ovary cells","sentence":"Extracellular application of meclofenamate (EC(50) = 25 microM) and diclofenac (EC(50) = 2.6 microM) resulted in the activation of KCNQ2\/Q3 K(+) currents, heterologously expressed in Chinese hamster ovary cells"}
{"PMID":15650315,"re_id":0,"annotated sentence":"<e1>Pranlukast<\\e1>  a leukotriene receptor antagonist, inhibits <e2>interleukin-5<\\e2> production via a mechanism distinct from leukotriene receptor antagonism","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pranlukast","object":"interleukin-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a leukotriene receptor antagonist, inhibits <e2>GENE-Y<\\e2> production via a mechanism distinct from leukotriene receptor antagonism","sentence":"Pranlukast  a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism"}
{"PMID":15650315,"re_id":1,"annotated sentence":"<e1>Pranlukast<\\e1> induced inhibition of <e2>IL-5<\\e2> mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pranlukast","object":"IL-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced inhibition of <e2>GENE-Y<\\e2> mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status","sentence":"Pranlukast induced inhibition of IL-5 mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status"}
{"PMID":15650315,"re_id":2,"annotated sentence":"CONCLUSION: Our results indicate that <e1>pranlukast<\\e1> inhibits <e2>IL-5<\\e2> synthesis via a mechanism distinct from CysLTR1 antagonism.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"IL-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Our results indicate that <e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> synthesis via a mechanism distinct from CysLTR1 antagonism.","sentence":"CONCLUSION: Our results indicate that pranlukast inhibits IL-5 synthesis via a mechanism distinct from CysLTR1 antagonism."}
{"PMID":15650315,"re_id":3,"annotated sentence":"The aim of this study was to determine the mechanism of <e1>pranlukast<\\e1> induced <e2>interleukin-5<\\e2> (IL-5) inhibition in allergic inflammation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"interleukin-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The aim of this study was to determine the mechanism of <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> (IL-5) inhibition in allergic inflammation","sentence":"The aim of this study was to determine the mechanism of pranlukast induced interleukin-5 (IL-5) inhibition in allergic inflammation"}
{"PMID":15650315,"re_id":4,"annotated sentence":"The aim of this study was to determine the mechanism of <e1>pranlukast<\\e1> induced interleukin-5 (<e2>IL-5<\\e2>  inhibition in allergic inflammation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"IL-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The aim of this study was to determine the mechanism of <e1>CHEMICAL<\\e1> induced interleukin-5 (<e2>GENE-Y<\\e2>  inhibition in allergic inflammation","sentence":"The aim of this study was to determine the mechanism of pranlukast induced interleukin-5 (IL-5  inhibition in allergic inflammation"}
{"PMID":15650315,"re_id":5,"annotated sentence":"RESULTS: Pretreatment of lung tissues with <e1>pranlukast<\\e1> alone significantly decreased the amount of <e2>IL-5<\\e2> protein in the culture medium by 40%","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"IL-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Pretreatment of lung tissues with <e1>CHEMICAL<\\e1> alone significantly decreased the amount of <e2>GENE-Y<\\e2> protein in the culture medium by 40%","sentence":"RESULTS: Pretreatment of lung tissues with pranlukast alone significantly decreased the amount of IL-5 protein in the culture medium by 40%"}
{"PMID":15650315,"re_id":6,"annotated sentence":"<e1>Pranlukast<\\e1>  a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from <e2>leukotriene receptor<\\e2> antagonism","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Pranlukast","object":"leukotriene receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a GENE-N antagonist, inhibits interleukin-5 production via a mechanism distinct from <e2>GENE-N<\\e2> antagonism","sentence":"Pranlukast  a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism"}
{"PMID":15650315,"re_id":7,"annotated sentence":"<e1>Pranlukast<\\e1>  a <e2>leukotriene receptor<\\e2> antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Pranlukast","object":"leukotriene receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> antagonist, inhibits interleukin-5 production via a mechanism distinct from GENE-N antagonism","sentence":"Pranlukast  a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism"}
{"PMID":15650315,"re_id":8,"annotated sentence":"BACKGROUND: <e1>Pranlukast<\\e1>  a <e2>cysteinyl leukotriene receptor 1<\\e2> (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Pranlukast","object":"cysteinyl leukotriene receptor 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation","sentence":"BACKGROUND: Pranlukast  a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation"}
{"PMID":15650315,"re_id":9,"annotated sentence":"BACKGROUND: <e1>Pranlukast<\\e1>  a cysteinyl leukotriene receptor 1 (<e2>CysLTR1<\\e2>  antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Pranlukast","object":"CysLTR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1>  a cysteinyl leukotriene receptor 1 (<e2>GENE-Y<\\e2>  antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation","sentence":"BACKGROUND: Pranlukast  a cysteinyl leukotriene receptor 1 (CysLTR1  antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation"}
{"PMID":15650315,"re_id":10,"annotated sentence":"CONCLUSION: Our results indicate that <e1>pranlukast<\\e1> inhibits IL-5 synthesis via a mechanism distinct from <e2>CysLTR1<\\e2> antagonism.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"CysLTR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Our results indicate that <e1>CHEMICAL<\\e1> inhibits IL-5 synthesis via a mechanism distinct from <e2>GENE-Y<\\e2> antagonism.","sentence":"CONCLUSION: Our results indicate that pranlukast inhibits IL-5 synthesis via a mechanism distinct from CysLTR1 antagonism."}
{"PMID":15673388,"re_id":0,"annotated sentence":"CONCLUSION: Oral <e1>quinidine<\\e1> is effective in suppressing the gain of function in <e2>IKr<\\e2> responsible for some cases of short QT syndrome with a mutation in HERG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia\/ventricular fibrillation noninducible.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinidine","object":"IKr","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSION: Oral <e1>CHEMICAL<\\e1> is effective in suppressing the gain of function in <e2>GENE-N<\\e2> responsible for some cases of short QT syndrome with a mutation in HERG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia\/ventricular fibrillation noninducible.","sentence":"CONCLUSION: Oral quinidine is effective in suppressing the gain of function in IKr responsible for some cases of short QT syndrome with a mutation in HERG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia\/ventricular fibrillation noninducible."}
{"PMID":15673388,"re_id":1,"annotated sentence":"INTRODUCTION: The principal aim of this study was to assess the efficacy of <e1>quinidine<\\e1> in suppressing <e2>IKr<\\e2> in vitro and in modulating the rate dependence of the QT interval in the \"SQT1\" form of the short QT syndrome","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinidine","object":"IKr","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"INTRODUCTION: The principal aim of this study was to assess the efficacy of <e1>CHEMICAL<\\e1> in suppressing <e2>GENE-N<\\e2> in vitro and in modulating the rate dependence of the QT interval in the \"SQT1\" form of the short QT syndrome","sentence":"INTRODUCTION: The principal aim of this study was to assess the efficacy of quinidine in suppressing IKr in vitro and in modulating the rate dependence of the QT interval in the \"SQT1\" form of the short QT syndrome"}
{"PMID":15686475,"re_id":0,"annotated sentence":"Firstly, the V(max) of <e2>GAD<\\e2> was increased when ApoCaM was present whereas the affinity for the substrate, <e1>glutamate<\\e1>  was not affected","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"GAD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, the V(max) of <e2>GENE-Y<\\e2> was increased when ApoCaM was present whereas the affinity for the substrate, <e1>CHEMICAL<\\e1>  was not affected","sentence":"Firstly, the V(max) of GAD was increased when ApoCaM was present whereas the affinity for the substrate, glutamate  was not affected"}
{"PMID":15689518,"re_id":0,"annotated sentence":"<e2>L-serine dehydratase<\\e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of <e1>L-serine<\\e1> and L-threonine to yield pyruvate or 2-oxobutyrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-serine","object":"L-serine dehydratase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>CHEMICAL dehydratase<\\e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of <e1>CHEMICAL<\\e1> and L-threonine to yield pyruvate or 2-oxobutyrate","sentence":"L-serine dehydratase (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate"}
{"PMID":15689518,"re_id":1,"annotated sentence":"L-serine dehydratase (<e2>SDH<\\e2> , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of <e1>L-serine<\\e1> and L-threonine to yield pyruvate or 2-oxobutyrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-serine","object":"SDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICAL dehydratase (<e2>GENE-Y<\\e2> , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of <e1>CHEMICAL<\\e1> and L-threonine to yield pyruvate or 2-oxobutyrate","sentence":"L-serine dehydratase (SDH , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate"}
{"PMID":15689518,"re_id":2,"annotated sentence":"<e2>L-serine dehydratase<\\e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and <e1>L-threonine<\\e1> to yield pyruvate or 2-oxobutyrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-threonine","object":"L-serine dehydratase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and <e1>CHEMICAL<\\e1> to yield pyruvate or 2-oxobutyrate","sentence":"L-serine dehydratase (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate"}
{"PMID":15689518,"re_id":3,"annotated sentence":"L-serine dehydratase (<e2>SDH<\\e2> , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and <e1>L-threonine<\\e1> to yield pyruvate or 2-oxobutyrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-threonine","object":"SDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"L-serine dehydratase (<e2>GENE-Y<\\e2> , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and <e1>CHEMICAL<\\e1> to yield pyruvate or 2-oxobutyrate","sentence":"L-serine dehydratase (SDH , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate"}
{"PMID":15689518,"re_id":4,"annotated sentence":"<e2>L-serine dehydratase<\\e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield <e1>pyruvate<\\e1> or 2-oxobutyrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyruvate","object":"L-serine dehydratase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield <e1>CHEMICAL<\\e1> or 2-oxobutyrate","sentence":"L-serine dehydratase (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate"}
{"PMID":15689518,"re_id":5,"annotated sentence":"L-serine dehydratase (<e2>SDH<\\e2> , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield <e1>pyruvate<\\e1> or 2-oxobutyrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyruvate","object":"SDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"L-serine dehydratase (<e2>GENE-Y<\\e2> , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield <e1>CHEMICAL<\\e1> or 2-oxobutyrate","sentence":"L-serine dehydratase (SDH , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate"}
{"PMID":15689518,"re_id":6,"annotated sentence":"<e2>L-serine dehydratase<\\e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or <e1>2-oxobutyrate<\\e1>  The crystal structure of L-serine dehydratase from human liver (hSDH) has been solved at 2.5 A-resolution by molecular replacement","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"2-oxobutyrate","object":"L-serine dehydratase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or <e1>CHEMICAL<\\e1>  The crystal structure of GENE-Y from human liver (hSDH) has been solved at 2.5 A-resolution by molecular replacement","sentence":"L-serine dehydratase (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate  The crystal structure of L-serine dehydratase from human liver (hSDH) has been solved at 2.5 A-resolution by molecular replacement"}
{"PMID":15689518,"re_id":7,"annotated sentence":"L-serine dehydratase (<e2>SDH<\\e2> , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or <e1>2-oxobutyrate<\\e1>  The crystal structure of L-serine dehydratase from human liver (hSDH) has been solved at 2.5 A-resolution by molecular replacement","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"2-oxobutyrate","object":"SDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"L-serine dehydratase (<e2>GENE-Y<\\e2> , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or <e1>CHEMICAL<\\e1>  The crystal structure of L-serine dehydratase from human liver (hGENE-Y) has been solved at 2.5 A-resolution by molecular replacement","sentence":"L-serine dehydratase (SDH , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate  The crystal structure of L-serine dehydratase from human liver (hSDH) has been solved at 2.5 A-resolution by molecular replacement"}
{"PMID":15714982,"re_id":0,"annotated sentence":"<e1>Docetaxel<\\e1> is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of <e2>bcl-2<\\e2> inactivation, which induce apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Docetaxel","object":"bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of <e2>GENE-Y<\\e2> inactivation, which induce apoptosis","sentence":"Docetaxel is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of bcl-2 inactivation, which induce apoptosis"}
{"PMID":15714982,"re_id":1,"annotated sentence":"Docetaxel is a semisynthetic <e1>taxane<\\e1> that inhibit tumor growth by induction of microtubule stabilization and promotion of <e2>bcl-2<\\e2> inactivation, which induce apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"taxane","object":"bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Docetaxel is a semisynthetic <e1>CHEMICAL<\\e1> that inhibit tumor growth by induction of microtubule stabilization and promotion of <e2>GENE-Y<\\e2> inactivation, which induce apoptosis","sentence":"Docetaxel is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of bcl-2 inactivation, which induce apoptosis"}
{"PMID":15732037,"re_id":0,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and <e2>NGF-beta<\\e2> to the baseline values","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"NGF-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and <e2>GENE-Y<\\e2> to the baseline values","sentence":"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values"}
{"PMID":15732037,"re_id":1,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> reversed both protein and mRNA of <e2>HIF-1alpha<\\e2>  VEGF, BNP, and NGF-beta to the baseline values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> reversed both protein and mRNA of <e2>GENE-Y<\\e2>  VEGF, BNP, and NGF-beta to the baseline values","sentence":"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha  VEGF, BNP, and NGF-beta to the baseline values"}
{"PMID":15732037,"re_id":2,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> reversed both protein and mRNA of HIF-1alpha, <e2>VEGF<\\e2>  BNP, and NGF-beta to the baseline values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> reversed both protein and mRNA of HIF-1alpha, <e2>GENE-Y<\\e2>  BNP, and NGF-beta to the baseline values","sentence":"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF  BNP, and NGF-beta to the baseline values"}
{"PMID":15732037,"re_id":3,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> reversed both protein and mRNA of HIF-1alpha, VEGF, <e2>BNP<\\e2>  and NGF-beta to the baseline values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> reversed both protein and mRNA of HIF-1alpha, VEGF, <e2>GENE-Y<\\e2>  and NGF-beta to the baseline values","sentence":"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP  and NGF-beta to the baseline values"}
{"PMID":15732037,"re_id":4,"annotated sentence":"Increased immunohistochemical labeling of <e2>HIF-1alpha<\\e2>  VEGF, and BNP in the ventricular myocardium was observed in the shunt group and <e1>carvedilol<\\e1> again normalized the labeling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased immunohistochemical labeling of <e2>GENE-Y<\\e2>  VEGF, and BNP in the ventricular myocardium was observed in the shunt group and <e1>CHEMICAL<\\e1> again normalized the labeling","sentence":"Increased immunohistochemical labeling of HIF-1alpha  VEGF, and BNP in the ventricular myocardium was observed in the shunt group and carvedilol again normalized the labeling"}
{"PMID":15732037,"re_id":5,"annotated sentence":"Increased immunohistochemical labeling of HIF-1alpha, <e2>VEGF<\\e2>  and BNP in the ventricular myocardium was observed in the shunt group and <e1>carvedilol<\\e1> again normalized the labeling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased immunohistochemical labeling of HIF-1alpha, <e2>GENE-Y<\\e2>  and BNP in the ventricular myocardium was observed in the shunt group and <e1>CHEMICAL<\\e1> again normalized the labeling","sentence":"Increased immunohistochemical labeling of HIF-1alpha, VEGF  and BNP in the ventricular myocardium was observed in the shunt group and carvedilol again normalized the labeling"}
{"PMID":15732037,"re_id":6,"annotated sentence":"Increased immunohistochemical labeling of HIF-1alpha, VEGF, and <e2>BNP<\\e2> in the ventricular myocardium was observed in the shunt group and <e1>carvedilol<\\e1> again normalized the labeling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased immunohistochemical labeling of HIF-1alpha, VEGF, and <e2>GENE-Y<\\e2> in the ventricular myocardium was observed in the shunt group and <e1>CHEMICAL<\\e1> again normalized the labeling","sentence":"Increased immunohistochemical labeling of HIF-1alpha, VEGF, and BNP in the ventricular myocardium was observed in the shunt group and carvedilol again normalized the labeling"}
{"PMID":15732037,"re_id":7,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> is associated with a reversal of abnormal regulation of <e2>HIF-1alpha<\\e2> and VEGF in the failing ventricular myocardium.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> is associated with a reversal of abnormal regulation of <e2>GENE-Y<\\e2> and VEGF in the failing ventricular myocardium.","sentence":"Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha and VEGF in the failing ventricular myocardium."}
{"PMID":15732037,"re_id":8,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> is associated with a reversal of abnormal regulation of HIF-1alpha and <e2>VEGF<\\e2> in the failing ventricular myocardium.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carvedilol","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> is associated with a reversal of abnormal regulation of HIF-1alpha and <e2>GENE-Y<\\e2> in the failing ventricular myocardium.","sentence":"Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha and VEGF in the failing ventricular myocardium."}
{"PMID":15736931,"re_id":0,"annotated sentence":"Mutation of arginine 228 to <e1>lysine<\\e1> enhances the <e2>glucosyltransferase<\\e2> activity of bovine beta-1,4-galactosyltransferase I","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"lysine","object":"glucosyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Mutation of arginine 228 to <e1>CHEMICAL<\\e1> enhances the <e2>GENE-N<\\e2> activity of bovine beta-1,4-galactosyltransferase I","sentence":"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I"}
{"PMID":15736931,"re_id":1,"annotated sentence":"Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from <e1>UDP-Glc<\\e1> to GlcNAc (<e2>Glc-T<\\e2> activity), albeit at only 0.3% efficiency","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"UDP-Glc","object":"Glc-T","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from <e1>CHEMICAL<\\e1> to GlcNAc (<e2>GENE-N<\\e2> activity), albeit at only 0.3% efficiency","sentence":"Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency"}
{"PMID":15736931,"re_id":2,"annotated sentence":"<e2>Beta-1,4-galactosyltransferase I<\\e2> (beta4Gal-T1) normally transfers Gal from <e1>UDP-Gal<\\e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"UDP-Gal","object":"Beta-1,4-galactosyltransferase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (beta4Gal-T1) normally transfers Gal from <e1>CHEMICAL<\\e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency","sentence":"Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency"}
{"PMID":15736931,"re_id":3,"annotated sentence":"Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from <e1>UDP-Gal<\\e1> to GlcNAc in the presence of Mn(2+) ion (<e2>Gal-T<\\e2> activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"UDP-Gal","object":"Gal-T","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Beta-1,4-galactosyltransferase I (beta4GENE-N1) normally transfers Gal from <e1>CHEMICAL<\\e1> to GlcNAc in the presence of Mn(2+) ion (<e2>GENE-N<\\e2> activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency","sentence":"Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency"}
{"PMID":15736931,"re_id":4,"annotated sentence":"Beta-1,4-galactosyltransferase I (<e2>beta4Gal-T1<\\e2>  normally transfers Gal from <e1>UDP-Gal<\\e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"UDP-Gal","object":"beta4Gal-T1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Beta-1,4-galactosyltransferase I (<e2>GENE-Y<\\e2>  normally transfers Gal from <e1>CHEMICAL<\\e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency","sentence":"Beta-1,4-galactosyltransferase I (beta4Gal-T1  normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency"}
{"PMID":15777622,"re_id":0,"annotated sentence":"In this study, using a model of <e1>gentamicin C<\\e1> (GMC)-induced reduction in <e2>SGLT1<\\e2> activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gentamicin C","object":"SGLT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, using a model of <e1>CHEMICAL<\\e1> (GMC)-induced reduction in <e2>GENE-Y<\\e2> activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in GENE-Y activity","sentence":"In this study, using a model of gentamicin C (GMC)-induced reduction in SGLT1 activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity"}
{"PMID":15777622,"re_id":1,"annotated sentence":"In this study, using a model of gentamicin C (<e1>GMC<\\e1> -induced reduction in <e2>SGLT1<\\e2> activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GMC","object":"SGLT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, using a model of gentamicin C (<e1>CHEMICAL<\\e1> -induced reduction in <e2>GENE-Y<\\e2> activity, we examined whether ligands for megalin protect LLC-PK1 cells from the CHEMICAL-induced reduction in GENE-Y activity","sentence":"In this study, using a model of gentamicin C (GMC -induced reduction in SGLT1 activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity"}
{"PMID":15777622,"re_id":2,"annotated sentence":"In this study, using a model of gentamicin C (GMC)-induced reduction in SGLT1 activity, we examined whether ligands for megalin protect LLC-PK1 cells from the <e1>GMC<\\e1> induced reduction in <e2>SGLT1<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GMC","object":"SGLT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, using a model of gentamicin C (CHEMICAL)-induced reduction in GENE-Y activity, we examined whether ligands for megalin protect LLC-PK1 cells from the <e1>CHEMICAL<\\e1> induced reduction in <e2>GENE-Y<\\e2> activity","sentence":"In this study, using a model of gentamicin C (GMC)-induced reduction in SGLT1 activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC induced reduction in SGLT1 activity"}
{"PMID":15777622,"re_id":3,"annotated sentence":"Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in <e2>SGLT1<\\e2> activity induced by <e1>gentamicin C<\\e1>  Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular aminoglycoside accumulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gentamicin C","object":"SGLT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in <e2>GENE-Y<\\e2> activity induced by <e1>CHEMICAL<\\e1>  Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular aminoglycoside accumulation","sentence":"Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C  Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular aminoglycoside accumulation"}
{"PMID":15777622,"re_id":4,"annotated sentence":"We previously reported that <e1>aminoglycoside<\\e1> antibiotics reduce <e2>SGLT1<\\e2> dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aminoglycoside","object":"SGLT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We previously reported that <e1>CHEMICAL<\\e1> antibiotics reduce <e2>GENE-Y<\\e2> dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity","sentence":"We previously reported that aminoglycoside antibiotics reduce SGLT1 dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity"}
{"PMID":15777622,"re_id":5,"annotated sentence":"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg\/ml of GMC, and the <e2>SGLT1<\\e2> dependent <e1>methyl alpha-D-glucopyranoside<\\e1> (AMG) uptake and levels of SGLT1 expression were determined","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methyl alpha-D-glucopyranoside","object":"SGLT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg\/ml of GMC, and the <e2>GENE-Y<\\e2> dependent <e1>CHEMICAL<\\e1> (AMG) uptake and levels of GENE-Y expression were determined","sentence":"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg\/ml of GMC, and the SGLT1 dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined"}
{"PMID":15777622,"re_id":6,"annotated sentence":"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg\/ml of GMC, and the <e2>SGLT1<\\e2> dependent methyl alpha-D-glucopyranoside (<e1>AMG<\\e1>  uptake and levels of SGLT1 expression were determined","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"AMG","object":"SGLT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg\/ml of GMC, and the <e2>GENE-Y<\\e2> dependent methyl alpha-D-glucopyranoside (<e1>CHEMICAL<\\e1>  uptake and levels of GENE-Y expression were determined","sentence":"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg\/ml of GMC, and the SGLT1 dependent methyl alpha-D-glucopyranoside (AMG  uptake and levels of SGLT1 expression were determined"}
{"PMID":15777622,"re_id":7,"annotated sentence":"Megalin, a family of <e2>endocytic receptors<\\e2> related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular <e1>aminoglycoside<\\e1> accumulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"aminoglycoside","object":"endocytic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Megalin, a family of <e2>GENE-N<\\e2> related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular <e1>CHEMICAL<\\e1> accumulation","sentence":"Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular aminoglycoside accumulation"}
{"PMID":15777622,"re_id":8,"annotated sentence":"Megalin, a family of endocytic receptors related to the <e2>low-density lipoprotein (LDL) receptor<\\e2>  is a major pathway for proximal tubular <e1>aminoglycoside<\\e1> accumulation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"aminoglycoside","object":"low-density lipoprotein (LDL) receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Megalin, a family of endocytic receptors related to the <e2>GENE-N<\\e2>  is a major pathway for proximal tubular <e1>CHEMICAL<\\e1> accumulation","sentence":"Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor  is a major pathway for proximal tubular aminoglycoside accumulation"}
{"PMID":15795320,"re_id":0,"annotated sentence":"Synergistic cytotoxicity was demonstrated, and <e1>pemetrexed<\\e1> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of <e2>dCK<\\e2> in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pemetrexed","object":"dCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synergistic cytotoxicity was demonstrated, and <e1>CHEMICAL<\\e1> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of <e2>GENE-Y<\\e2> in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines","sentence":"Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines"}
{"PMID":15795320,"re_id":1,"annotated sentence":"Synergistic cytotoxicity was demonstrated, and <e1>pemetrexed<\\e1> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the <e2>human nucleoside equilibrative transporter 1<\\e2> (hENT1) in all cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pemetrexed","object":"human nucleoside equilibrative transporter 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synergistic cytotoxicity was demonstrated, and <e1>CHEMICAL<\\e1> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the <e2>GENE-Y<\\e2> (hENT1) in all cell lines","sentence":"Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines"}
{"PMID":15795320,"re_id":2,"annotated sentence":"Synergistic cytotoxicity was demonstrated, and <e1>pemetrexed<\\e1> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (<e2>hENT1<\\e2>  in all cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pemetrexed","object":"hENT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synergistic cytotoxicity was demonstrated, and <e1>CHEMICAL<\\e1> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (<e2>GENE-Y<\\e2>  in all cell lines","sentence":"Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1  in all cell lines"}
{"PMID":15795320,"re_id":3,"annotated sentence":"These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) <e1>pemetrexed<\\e1> enhances <e2>dCK<\\e2> and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pemetrexed","object":"dCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data demonstrated that 1) gemcitabine and CHEMICAL synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) <e1>CHEMICAL<\\e1> enhances <e2>GENE-Y<\\e2> and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.","sentence":"These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations."}
{"PMID":15795320,"re_id":4,"annotated sentence":"These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) <e1>pemetrexed<\\e1> enhances dCK and <e2>hENT1<\\e2> expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pemetrexed","object":"hENT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data demonstrated that 1) gemcitabine and CHEMICAL synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) <e1>CHEMICAL<\\e1> enhances dCK and <e2>GENE-Y<\\e2> expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.","sentence":"These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations."}
{"PMID":15795320,"re_id":5,"annotated sentence":"Synergistic cytotoxicity was demonstrated, and <e1>pemetrexed<\\e1> significantly decreased the amount of <e2>phosphorylated Akt<\\e2>  enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pemetrexed","object":"phosphorylated Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Synergistic cytotoxicity was demonstrated, and <e1>CHEMICAL<\\e1> significantly decreased the amount of <e2>GENE-N<\\e2>  enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines","sentence":"Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt  enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines"}
{"PMID":15795320,"re_id":6,"annotated sentence":"These data demonstrated that 1) <e1>gemcitabine<\\e1> and pemetrexed synergistically interact against NSCLC cells through the suppression of <e2>Akt<\\e2> phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gemcitabine","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These data demonstrated that 1) <e1>CHEMICAL<\\e1> and pemetrexed synergistically interact against NSCLC cells through the suppression of <e2>GENE-N<\\e2> phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.","sentence":"These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations."}
{"PMID":15795320,"re_id":7,"annotated sentence":"These data demonstrated that 1) gemcitabine and <e1>pemetrexed<\\e1> synergistically interact against NSCLC cells through the suppression of <e2>Akt<\\e2> phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pemetrexed","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These data demonstrated that 1) gemcitabine and <e1>CHEMICAL<\\e1> synergistically interact against NSCLC cells through the suppression of <e2>GENE-N<\\e2> phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) CHEMICAL enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.","sentence":"These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations."}
{"PMID":15805193,"re_id":0,"annotated sentence":"<e1>Phenytoin<\\e1> is principally metabolized by <e2>CYP2C9<\\e2>  and both are probable substrates of the drug transporter P-glycoprotein","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Phenytoin","object":"CYP2C9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is principally metabolized by <e2>GENE-Y<\\e2>  and both are probable substrates of the drug transporter P-glycoprotein","sentence":"Phenytoin is principally metabolized by CYP2C9  and both are probable substrates of the drug transporter P-glycoprotein"}
{"PMID":15805193,"re_id":1,"annotated sentence":"<e1>Phenytoin<\\e1> is principally metabolized by CYP2C9, and both are probable substrates of the <e2>drug transporter<\\e2> P-glycoprotein","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Phenytoin","object":"drug transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is principally metabolized by CYP2C9, and both are probable substrates of the <e2>GENE-N<\\e2> P-glycoprotein","sentence":"Phenytoin is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter P-glycoprotein"}
{"PMID":15805193,"re_id":2,"annotated sentence":"<e1>Phenytoin<\\e1> is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter <e2>P-glycoprotein<\\e2>  We therefore assessed whether variation in these genes associates with the clinical use of carbamazepine and phenytoin in cohorts of 425 and 281 patients, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Phenytoin","object":"P-glycoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter <e2>GENE-N<\\e2>  We therefore assessed whether variation in these genes associates with the clinical use of carbamazepine and phenytoin in cohorts of 425 and 281 patients, respectively","sentence":"Phenytoin is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter P-glycoprotein  We therefore assessed whether variation in these genes associates with the clinical use of carbamazepine and phenytoin in cohorts of 425 and 281 patients, respectively"}
{"PMID":15843826,"re_id":0,"annotated sentence":"<e1>Am80<\\e1> inhibited VEGF-induced phosphorylation of <e2>VEGF receptor<\\e2>  In addition, VEGF-induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by Am80","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Am80","object":"VEGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited VEGF-induced phosphorylation of <e2>GENE-N<\\e2>  In addition, VEGF-induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by CHEMICAL","sentence":"Am80 inhibited VEGF-induced phosphorylation of VEGF receptor  In addition, VEGF-induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by Am80"}
{"PMID":15843826,"re_id":1,"annotated sentence":"<e1>Am80<\\e1> inhibited <e2>VEGF<\\e2> induced phosphorylation of VEGF receptor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Am80","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> induced phosphorylation of GENE-Y receptor","sentence":"Am80 inhibited VEGF induced phosphorylation of VEGF receptor"}
{"PMID":15843826,"re_id":2,"annotated sentence":"In addition, <e2>VEGF<\\e2> induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by <e1>Am80<\\e1>  These findings clearly demonstrate that Am80 is a potential inhibitor of angiogenesis caused by the interaction between vascular endothelial cells and myeloma cells, and might be a useful therapeutic agent against MM.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Am80","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e2>GENE-Y<\\e2> induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by <e1>CHEMICAL<\\e1>  These findings clearly demonstrate that CHEMICAL is a potential inhibitor of angiogenesis caused by the interaction between vascular endothelial cells and myeloma cells, and might be a useful therapeutic agent against MM.","sentence":"In addition, VEGF induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by Am80  These findings clearly demonstrate that Am80 is a potential inhibitor of angiogenesis caused by the interaction between vascular endothelial cells and myeloma cells, and might be a useful therapeutic agent against MM."}
{"PMID":15843826,"re_id":3,"annotated sentence":"<e1>Am80<\\e1> slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by <e2>VEGF<\\e2>  Am80 showed little growth inhibition of bone marrow stromal cells (BMSCs), but it markedly inhibited migration of HUVECs by cocultured myeloma cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Am80","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by <e2>GENE-Y<\\e2>  CHEMICAL showed little growth inhibition of bone marrow stromal cells (BMSCs), but it markedly inhibited migration of HUVECs by cocultured myeloma cells","sentence":"Am80 slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by VEGF  Am80 showed little growth inhibition of bone marrow stromal cells (BMSCs), but it markedly inhibited migration of HUVECs by cocultured myeloma cells"}
{"PMID":15866288,"re_id":0,"annotated sentence":"When <e1>amiloride<\\e1> was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment, <e2>u-PA<\\e2> activity in both cornea and tear fluid was strongly inhibited","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amiloride","object":"u-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When <e1>CHEMICAL<\\e1> was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment, <e2>GENE-Y<\\e2> activity in both cornea and tear fluid was strongly inhibited","sentence":"When amiloride was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment, u-PA activity in both cornea and tear fluid was strongly inhibited"}
{"PMID":15866288,"re_id":1,"annotated sentence":"In conclusion, early application of <e1>amiloride<\\e1> inhibited <e2>u-PA<\\e2> activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amiloride","object":"u-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, early application of <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology.","sentence":"In conclusion, early application of amiloride inhibited u-PA activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology."}
{"PMID":15866288,"re_id":2,"annotated sentence":"The purpose of the present study was to test our hypothesis that <e1>amiloride<\\e1>  a specific <e2>u-PA<\\e2> inhibitor, effectively decreases u-PA activity in cornea as well as in tear fluid and favourably affects corneal healing","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amiloride","object":"u-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purpose of the present study was to test our hypothesis that <e1>CHEMICAL<\\e1>  a specific <e2>GENE-Y<\\e2> inhibitor, effectively decreases GENE-Y activity in cornea as well as in tear fluid and favourably affects corneal healing","sentence":"The purpose of the present study was to test our hypothesis that amiloride  a specific u-PA inhibitor, effectively decreases u-PA activity in cornea as well as in tear fluid and favourably affects corneal healing"}
{"PMID":15866288,"re_id":3,"annotated sentence":"The purpose of the present study was to test our hypothesis that <e1>amiloride<\\e1>  a specific u-PA inhibitor, effectively decreases <e2>u-PA<\\e2> activity in cornea as well as in tear fluid and favourably affects corneal healing","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amiloride","object":"u-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purpose of the present study was to test our hypothesis that <e1>CHEMICAL<\\e1>  a specific GENE-Y inhibitor, effectively decreases <e2>GENE-Y<\\e2> activity in cornea as well as in tear fluid and favourably affects corneal healing","sentence":"The purpose of the present study was to test our hypothesis that amiloride  a specific u-PA inhibitor, effectively decreases u-PA activity in cornea as well as in tear fluid and favourably affects corneal healing"}
{"PMID":15866288,"re_id":4,"annotated sentence":"Effects of inhibition of <e2>urokinase-type plasminogen activator<\\e2> (u-PA) by <e1>amiloride<\\e1> in the cornea and tear fluid of eyes irradiated with UVB","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amiloride","object":"urokinase-type plasminogen activator","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effects of inhibition of <e2>GENE-Y<\\e2> (u-PA) by <e1>CHEMICAL<\\e1> in the cornea and tear fluid of eyes irradiated with UVB","sentence":"Effects of inhibition of urokinase-type plasminogen activator (u-PA) by amiloride in the cornea and tear fluid of eyes irradiated with UVB"}
{"PMID":15866288,"re_id":5,"annotated sentence":"Effects of inhibition of urokinase-type plasminogen activator (<e2>u-PA<\\e2>  by <e1>amiloride<\\e1> in the cornea and tear fluid of eyes irradiated with UVB","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amiloride","object":"u-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effects of inhibition of urokinase-type plasminogen activator (<e2>GENE-Y<\\e2>  by <e1>CHEMICAL<\\e1> in the cornea and tear fluid of eyes irradiated with UVB","sentence":"Effects of inhibition of urokinase-type plasminogen activator (u-PA  by amiloride in the cornea and tear fluid of eyes irradiated with UVB"}
{"PMID":15866288,"re_id":6,"annotated sentence":"Therefore, comparative histochemical and biochemical studies of <e2>u-PA<\\e2> and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate <e1>Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin<\\e1>  Rabbit eyes were repeatedly irradiated with UVB for 9 days and during the irradiation topically treated with amiloride (1 mg\/ml saline) or placebo (saline) (dropwise, 5 times daily)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin","object":"u-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Therefore, comparative histochemical and biochemical studies of <e2>GENE-Y<\\e2> and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate <e1>CHEMICAL<\\e1>  Rabbit eyes were repeatedly irradiated with UVB for 9 days and during the irradiation topically treated with amiloride (1 mg\/ml saline) or placebo (saline) (dropwise, 5 times daily)","sentence":"Therefore, comparative histochemical and biochemical studies of u-PA and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin  Rabbit eyes were repeatedly irradiated with UVB for 9 days and during the irradiation topically treated with amiloride (1 mg\/ml saline) or placebo (saline) (dropwise, 5 times daily)"}
{"PMID":15908512,"re_id":0,"annotated sentence":"In contrast, the selective <e2>beta2AR<\\e2> antagonists ICI-118,551 and butoxamine inhibited <e1>isoproterenol<\\e1> mediated enhancement with apparent low affinities (K(b) of 222 +\/- 61 and 9268 +\/- 512 nM, respectively)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"isoproterenol","object":"beta2AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, the selective <e2>GENE-Y<\\e2> antagonists ICI-118,551 and butoxamine inhibited <e1>CHEMICAL<\\e1> mediated enhancement with apparent low affinities (K(b) of 222 +\/- 61 and 9268 +\/- 512 nM, respectively)","sentence":"In contrast, the selective beta2AR antagonists ICI-118,551 and butoxamine inhibited isoproterenol mediated enhancement with apparent low affinities (K(b) of 222 +\/- 61 and 9268 +\/- 512 nM, respectively)"}
{"PMID":15908512,"re_id":1,"annotated sentence":"Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model, <e2>beta1AR<\\e2> activation is responsible for the enhanced hippocampal CA3 network activity initiated by <e1>isoproterenol<\\e1> ","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"isoproterenol","object":"beta1AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model, <e2>GENE-Y<\\e2> activation is responsible for the enhanced hippocampal CA3 network activity initiated by <e1>CHEMICAL<\\e1> ","sentence":"Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model, beta1AR activation is responsible for the enhanced hippocampal CA3 network activity initiated by isoproterenol "}
{"PMID":15908512,"re_id":2,"annotated sentence":"The selective <e2>betaAR<\\e2> agonist <e1>isoproterenol<\\e1> caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"isoproterenol","object":"betaAR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The selective <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1> caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region","sentence":"The selective betaAR agonist isoproterenol caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region"}
{"PMID":15908512,"re_id":3,"annotated sentence":"The selective <e2>beta1AR<\\e2> antagonists atenolol and metoprolol blocked <e1>isoproterenol<\\e1> induced enhancement, with apparent K(b) values of 85 +\/- 36 and 3.9 +\/- 1.7 nM, respectively","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"isoproterenol","object":"beta1AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> antagonists atenolol and metoprolol blocked <e1>CHEMICAL<\\e1> induced enhancement, with apparent K(b) values of 85 +\/- 36 and 3.9 +\/- 1.7 nM, respectively","sentence":"The selective beta1AR antagonists atenolol and metoprolol blocked isoproterenol induced enhancement, with apparent K(b) values of 85 +\/- 36 and 3.9 +\/- 1.7 nM, respectively"}
{"PMID":15908512,"re_id":4,"annotated sentence":"In contrast, the selective <e2>beta2AR<\\e2> antagonists ICI-118,551 and <e1>butoxamine<\\e1> inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +\/- 61 and 9268 +\/- 512 nM, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"butoxamine","object":"beta2AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, the selective <e2>GENE-Y<\\e2> antagonists ICI-118,551 and <e1>CHEMICAL<\\e1> inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +\/- 61 and 9268 +\/- 512 nM, respectively)","sentence":"In contrast, the selective beta2AR antagonists ICI-118,551 and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +\/- 61 and 9268 +\/- 512 nM, respectively)"}
{"PMID":15908512,"re_id":5,"annotated sentence":"The selective <e2>beta1AR<\\e2> antagonists <e1>atenolol<\\e1> and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +\/- 36 and 3.9 +\/- 1.7 nM, respectively","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"atenolol","object":"beta1AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> antagonists <e1>CHEMICAL<\\e1> and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +\/- 36 and 3.9 +\/- 1.7 nM, respectively","sentence":"The selective beta1AR antagonists atenolol and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +\/- 36 and 3.9 +\/- 1.7 nM, respectively"}
{"PMID":15908512,"re_id":6,"annotated sentence":"The selective <e2>beta1AR<\\e2> antagonists atenolol and <e1>metoprolol<\\e1> blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +\/- 36 and 3.9 +\/- 1.7 nM, respectively","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"metoprolol","object":"beta1AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> antagonists atenolol and <e1>CHEMICAL<\\e1> blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +\/- 36 and 3.9 +\/- 1.7 nM, respectively","sentence":"The selective beta1AR antagonists atenolol and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +\/- 36 and 3.9 +\/- 1.7 nM, respectively"}
{"PMID":15908512,"re_id":7,"annotated sentence":"In contrast, the selective <e2>beta2AR<\\e2> antagonists <e1>ICI-118,551<\\e1> and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +\/- 61 and 9268 +\/- 512 nM, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ICI-118,551","object":"beta2AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, the selective <e2>GENE-Y<\\e2> antagonists <e1>CHEMICAL<\\e1> and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +\/- 61 and 9268 +\/- 512 nM, respectively)","sentence":"In contrast, the selective beta2AR antagonists ICI-118,551 and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +\/- 61 and 9268 +\/- 512 nM, respectively)"}
{"PMID":15921304,"re_id":0,"annotated sentence":"On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the <e2>tyrosine kinase<\\e2> inhibitor <e1>imatinib mesylate<\\e1> (Glivec) would be effective.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib mesylate","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (Glivec) would be effective.","sentence":"On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the tyrosine kinase inhibitor imatinib mesylate (Glivec) would be effective."}
{"PMID":15932636,"re_id":0,"annotated sentence":"Furthermore, experiments showed that treatment with <e1>DEC<\\e1> results in a reduction in the amount of <e2>COX-1<\\e2> protein in peritoneal exudate cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEC","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, experiments showed that treatment with <e1>CHEMICAL<\\e1> results in a reduction in the amount of <e2>GENE-Y<\\e2> protein in peritoneal exudate cells","sentence":"Furthermore, experiments showed that treatment with DEC results in a reduction in the amount of COX-1 protein in peritoneal exudate cells"}
{"PMID":15944809,"re_id":0,"annotated sentence":"Experimental as well as clinical reports support the hypothesis that <e2>calcium channel<\\e2> blockers such as <e1>verapamil<\\e1> may be an appropriate therapeutic approach in LQTS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"verapamil","object":"calcium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Experimental as well as clinical reports support the hypothesis that <e2>GENE-N<\\e2> blockers such as <e1>CHEMICAL<\\e1> may be an appropriate therapeutic approach in LQTS","sentence":"Experimental as well as clinical reports support the hypothesis that calcium channel blockers such as verapamil may be an appropriate therapeutic approach in LQTS"}
{"PMID":15944809,"re_id":1,"annotated sentence":"METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts, <e1>veratridine<\\e1> (0.1 microM), an inhibitor of <e2>sodium channel<\\e2> inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"veratridine","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts, <e1>CHEMICAL<\\e1> (0.1 microM), an inhibitor of <e2>GENE-N<\\e2> inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3","sentence":"METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts, veratridine (0.1 microM), an inhibitor of sodium channel inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3"}
{"PMID":15951260,"re_id":0,"annotated sentence":"The positive correlation between <e1>vitamin A<\\e1> and <e2>immunoglobulin A<\\e2> concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vitamin A","object":"immunoglobulin A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The positive correlation between <e1>CHEMICAL<\\e1> and <e2>GENE-N<\\e2> concentrations might be the result of the CHEMICAL inductive effect during immunoglobulins A synthesis","sentence":"The positive correlation between vitamin A and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis"}
{"PMID":15951260,"re_id":1,"annotated sentence":"The positive correlation between <e1>vitamin A<\\e1> and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during <e2>immunoglobulins A<\\e2> synthesis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vitamin A","object":"immunoglobulins A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The positive correlation between <e1>CHEMICAL<\\e1> and immunoglobulin A concentrations might be the result of the CHEMICAL inductive effect during <e2>GENE-N<\\e2> synthesis","sentence":"The positive correlation between vitamin A and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis"}
{"PMID":15951260,"re_id":2,"annotated sentence":"The positive correlation between vitamin A and <e2>immunoglobulin A<\\e2> concentrations might be the result of the <e1>vitamin A<\\e1> inductive effect during immunoglobulins A synthesis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vitamin A","object":"immunoglobulin A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The positive correlation between CHEMICAL and <e2>GENE-N<\\e2> concentrations might be the result of the <e1>CHEMICAL<\\e1> inductive effect during immunoglobulins A synthesis","sentence":"The positive correlation between vitamin A and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis"}
{"PMID":15951260,"re_id":3,"annotated sentence":"The positive correlation between vitamin A and immunoglobulin A concentrations might be the result of the <e1>vitamin A<\\e1> inductive effect during <e2>immunoglobulins A<\\e2> synthesis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vitamin A","object":"immunoglobulins A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The positive correlation between CHEMICAL and immunoglobulin A concentrations might be the result of the <e1>CHEMICAL<\\e1> inductive effect during <e2>GENE-N<\\e2> synthesis","sentence":"The positive correlation between vitamin A and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during immunoglobulins A synthesis"}
{"PMID":15953344,"re_id":0,"annotated sentence":"<e2>Monocarboxylate transporters<\\e2> (MCTs) are proton-linked membrane carriers involved in the transport of <e1>monocarboxylates<\\e1> such as lactate, pyruvate, as well as ketone bodies","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"monocarboxylates","object":"Monocarboxylate transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (MCTs) are proton-linked membrane carriers involved in the transport of <e1>CHEMICAL<\\e1> such as lactate, pyruvate, as well as ketone bodies","sentence":"Monocarboxylate transporters (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as ketone bodies"}
{"PMID":15953344,"re_id":1,"annotated sentence":"Monocarboxylate transporters (<e2>MCTs<\\e2>  are proton-linked membrane carriers involved in the transport of <e1>monocarboxylates<\\e1> such as lactate, pyruvate, as well as ketone bodies","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"monocarboxylates","object":"MCTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Monocarboxylate transporters (<e2>GENE-N<\\e2>  are proton-linked membrane carriers involved in the transport of <e1>CHEMICAL<\\e1> such as lactate, pyruvate, as well as ketone bodies","sentence":"Monocarboxylate transporters (MCTs  are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as ketone bodies"}
{"PMID":15953344,"re_id":2,"annotated sentence":"<e2>Monocarboxylate transporters<\\e2> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as <e1>lactate<\\e1>  pyruvate, as well as ketone bodies","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"lactate","object":"Monocarboxylate transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as <e1>CHEMICAL<\\e1>  pyruvate, as well as ketone bodies","sentence":"Monocarboxylate transporters (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate  pyruvate, as well as ketone bodies"}
{"PMID":15953344,"re_id":3,"annotated sentence":"Monocarboxylate transporters (<e2>MCTs<\\e2>  are proton-linked membrane carriers involved in the transport of monocarboxylates such as <e1>lactate<\\e1>  pyruvate, as well as ketone bodies","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"lactate","object":"MCTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Monocarboxylate transporters (<e2>GENE-N<\\e2>  are proton-linked membrane carriers involved in the transport of monocarboxylates such as <e1>CHEMICAL<\\e1>  pyruvate, as well as ketone bodies","sentence":"Monocarboxylate transporters (MCTs  are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate  pyruvate, as well as ketone bodies"}
{"PMID":15953344,"re_id":4,"annotated sentence":"<e2>Monocarboxylate transporters<\\e2> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, <e1>pyruvate<\\e1>  as well as ketone bodies","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyruvate","object":"Monocarboxylate transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, <e1>CHEMICAL<\\e1>  as well as ketone bodies","sentence":"Monocarboxylate transporters (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate  as well as ketone bodies"}
{"PMID":15953344,"re_id":5,"annotated sentence":"Monocarboxylate transporters (<e2>MCTs<\\e2>  are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, <e1>pyruvate<\\e1>  as well as ketone bodies","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyruvate","object":"MCTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Monocarboxylate transporters (<e2>GENE-N<\\e2>  are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, <e1>CHEMICAL<\\e1>  as well as ketone bodies","sentence":"Monocarboxylate transporters (MCTs  are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate  as well as ketone bodies"}
{"PMID":15953344,"re_id":6,"annotated sentence":"<e2>Monocarboxylate transporters<\\e2> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as <e1>ketone<\\e1> bodies","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ketone","object":"Monocarboxylate transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as <e1>CHEMICAL<\\e1> bodies","sentence":"Monocarboxylate transporters (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as ketone bodies"}
{"PMID":15953344,"re_id":7,"annotated sentence":"Monocarboxylate transporters (<e2>MCTs<\\e2>  are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as <e1>ketone<\\e1> bodies","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ketone","object":"MCTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Monocarboxylate transporters (<e2>GENE-N<\\e2>  are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as <e1>CHEMICAL<\\e1> bodies","sentence":"Monocarboxylate transporters (MCTs  are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as ketone bodies"}
{"PMID":15953344,"re_id":8,"annotated sentence":"Interestingly, part of <e2>MCT2<\\e2> immunoreactivity is located at postsynaptic sites, suggesting a particular role of <e1>monocarboxylates<\\e1> and their transporters in synaptic transmission","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"monocarboxylates","object":"MCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, part of <e2>GENE-Y<\\e2> immunoreactivity is located at postsynaptic sites, suggesting a particular role of <e1>CHEMICAL<\\e1> and their transporters in synaptic transmission","sentence":"Interestingly, part of MCT2 immunoreactivity is located at postsynaptic sites, suggesting a particular role of monocarboxylates and their transporters in synaptic transmission"}
{"PMID":15963471,"re_id":0,"annotated sentence":"<e1>Thiazolidinediones<\\e1> are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of <e2>insulin<\\e2> responsive genes involved in glucose and lipid metabolism","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Thiazolidinediones","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> are a new class of anti-diabetic agents which increase GENE-Y sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of <e2>GENE-Y<\\e2> responsive genes involved in glucose and lipid metabolism","sentence":"Thiazolidinediones are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin responsive genes involved in glucose and lipid metabolism"}
{"PMID":15963471,"re_id":1,"annotated sentence":"<e1>Thiazolidinediones<\\e1> are a new class of anti-diabetic agents which increase <e2>insulin<\\e2> sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Thiazolidinediones","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> are a new class of anti-diabetic agents which increase <e2>GENE-Y<\\e2> sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of GENE-Y-responsive genes involved in glucose and lipid metabolism","sentence":"Thiazolidinediones are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism"}
{"PMID":15963471,"re_id":2,"annotated sentence":"The difference in structure of <e1>troglitazone<\\e1> did not account for its inhibitory effect on <e2>ENT1<\\e2> because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"troglitazone","object":"ENT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The difference in structure of <e1>CHEMICAL<\\e1> did not account for its inhibitory effect on <e2>GENE-Y<\\e2> because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs","sentence":"The difference in structure of troglitazone did not account for its inhibitory effect on ENT1 because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs"}
{"PMID":15963471,"re_id":3,"annotated sentence":"Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that <e1>troglitazone<\\e1> inhibited <e2>ENT1<\\e2> but had no effect on ENT2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"troglitazone","object":"ENT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using the nucleoside transporter deficient PK15NTD cells stably expressing GENE-Y and ENT2, it was found that <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> but had no effect on ENT2","sentence":"Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that troglitazone inhibited ENT1 but had no effect on ENT2"}
{"PMID":15963471,"re_id":4,"annotated sentence":"From these results, it is suggested that <e1>troglitazone<\\e1> may enhance the vasodilatory effect of adenosine by inhibiting <e2>ENT1<\\e2>  Pharmacologically, troglitazone is a novel inhibitor of ENT1.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"troglitazone","object":"ENT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"From these results, it is suggested that <e1>CHEMICAL<\\e1> may enhance the vasodilatory effect of adenosine by inhibiting <e2>GENE-Y<\\e2>  Pharmacologically, CHEMICAL is a novel inhibitor of GENE-Y.","sentence":"From these results, it is suggested that troglitazone may enhance the vasodilatory effect of adenosine by inhibiting ENT1  Pharmacologically, troglitazone is a novel inhibitor of ENT1."}
{"PMID":15963471,"re_id":5,"annotated sentence":"Pharmacologically, <e1>troglitazone<\\e1> is a novel inhibitor of <e2>ENT1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"troglitazone","object":"ENT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacologically, <e1>CHEMICAL<\\e1> is a novel inhibitor of <e2>GENE-Y<\\e2> ","sentence":"Pharmacologically, troglitazone is a novel inhibitor of ENT1 "}
{"PMID":15963471,"re_id":6,"annotated sentence":"The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that <e1>troglitazone<\\e1> was a competitive inhibitor of <e2>ENT1<\\e2>  In contrast, pioglitazone and ciglitazone had minimal effects on [3H]adenosine uptake by HASMCs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"troglitazone","object":"ENT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effect of CHEMICAL on GENE-Y was PPAR(gamma)-independent and kinetic studies revealed that <e1>CHEMICAL<\\e1> was a competitive inhibitor of <e2>GENE-Y<\\e2>  In contrast, pioglitazone and ciglitazone had minimal effects on [3H]adenosine uptake by HASMCs","sentence":"The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1  In contrast, pioglitazone and ciglitazone had minimal effects on [3H]adenosine uptake by HASMCs"}
{"PMID":15974585,"re_id":0,"annotated sentence":"<e1>(R)-Ketoprofen<\\e1> (1) was previously reported to be a potent and specific noncompetitive inhibitor of <e2>CXCL8<\\e2> induced human PMNs chemotaxis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(R)-Ketoprofen","object":"CXCL8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (1) was previously reported to be a potent and specific noncompetitive inhibitor of <e2>GENE-Y<\\e2> induced human PMNs chemotaxis","sentence":"(R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCL8 induced human PMNs chemotaxis"}
{"PMID":15974585,"re_id":1,"annotated sentence":"<e1>2-Arylpropionic<\\e1> CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive <e2>CXCL8<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-Arylpropionic","object":"CXCL8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive <e2>GENE-Y<\\e2> inhibitors","sentence":"2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors"}
{"PMID":15982930,"re_id":0,"annotated sentence":"<e1>Thalidomide<\\e1> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased <e2>cytochrome c<\\e2>  but had no effect on that of COX-1, in MCF-7 and HL-60","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Thalidomide","object":"cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased <e2>GENE-Y<\\e2>  but had no effect on that of COX-1, in MCF-7 and HL-60","sentence":"Thalidomide reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c  but had no effect on that of COX-1, in MCF-7 and HL-60"}
{"PMID":15982930,"re_id":1,"annotated sentence":"<e1>Thalidomide<\\e1> reduced <e2>COX-2<\\e2> expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Thalidomide","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced <e2>GENE-Y<\\e2> expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60","sentence":"Thalidomide reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60"}
{"PMID":15982930,"re_id":2,"annotated sentence":"<e1>Thalidomide<\\e1> reduced COX-2 expression accompanied by a decrease of <e2>bcl-2<\\e2> protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Thalidomide","object":"bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced COX-2 expression accompanied by a decrease of <e2>GENE-Y<\\e2> protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60","sentence":"Thalidomide reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60"}
{"PMID":15982930,"re_id":3,"annotated sentence":"<e1>Thalidomide<\\e1> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, <e2>TNFalpha<\\e2>  VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Thalidomide","object":"TNFalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, <e2>GENE-Y<\\e2>  VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60","sentence":"Thalidomide reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha  VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60"}
{"PMID":15982930,"re_id":4,"annotated sentence":"<e1>Thalidomide<\\e1> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, <e2>VEGF<\\e2>  GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Thalidomide","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, <e2>GENE-Y<\\e2>  GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60","sentence":"Thalidomide reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF  GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60"}
{"PMID":15982930,"re_id":5,"annotated sentence":"<e1>Thalidomide<\\e1> inhibits growth of tumors through <e2>COX-2<\\e2> degradation independent of antiangiogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Thalidomide","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits growth of tumors through <e2>GENE-Y<\\e2> degradation independent of antiangiogenesis","sentence":"Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis"}
{"PMID":15982930,"re_id":6,"annotated sentence":"These results demonstrated that <e1>thalidomide<\\e1> might inhibit growth of tumors through <e2>COX-2<\\e2> degradation independent of antiangiogenesis.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"thalidomide","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results demonstrated that <e1>CHEMICAL<\\e1> might inhibit growth of tumors through <e2>GENE-Y<\\e2> degradation independent of antiangiogenesis.","sentence":"These results demonstrated that thalidomide might inhibit growth of tumors through COX-2 degradation independent of antiangiogenesis."}
{"PMID":16278927,"re_id":0,"annotated sentence":"In conclusion, of the seven NSAIDs investigated, <e1>niflumic acid<\\e1> was the most potent inhibitor of recombinant <e2>UGT1A9<\\e2> via 4-MUG in a competitive manner.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"niflumic acid","object":"UGT1A9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, of the seven NSAIDs investigated, <e1>CHEMICAL<\\e1> was the most potent inhibitor of recombinant <e2>GENE-Y<\\e2> via 4-MUG in a competitive manner.","sentence":"In conclusion, of the seven NSAIDs investigated, niflumic acid was the most potent inhibitor of recombinant UGT1A9 via 4-MUG in a competitive manner."}
{"PMID":16278927,"re_id":1,"annotated sentence":"In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant <e2>human UDP-glucuronosyltransferase 1A9<\\e2> -potent inhibition by <e1>niflumic acid<\\e1>  The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"niflumic acid","object":"human UDP-glucuronosyltransferase 1A9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant <e2>GENE-Y<\\e2> -potent inhibition by <e1>CHEMICAL<\\e1>  The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation","sentence":"In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9 -potent inhibition by niflumic acid  The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation"}
{"PMID":16291873,"re_id":0,"annotated sentence":"We used mutagenesis of these residues, combined with an investigation of <e2>hERG<\\e2> block by close analogs of <e1>clofilium<\\e1> and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clofilium","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We used mutagenesis of these residues, combined with an investigation of <e2>GENE-Y<\\e2> block by close analogs of <e1>CHEMICAL<\\e1> and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions","sentence":"We used mutagenesis of these residues, combined with an investigation of hERG block by close analogs of clofilium and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions"}
{"PMID":16291873,"re_id":1,"annotated sentence":"We used mutagenesis of these residues, combined with an investigation of <e2>hERG<\\e2> block by close analogs of clofilium and <e1>ibutilide<\\e1>  to assess how specific alterations in drug structure affected potency and binding interactions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibutilide","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We used mutagenesis of these residues, combined with an investigation of <e2>GENE-Y<\\e2> block by close analogs of clofilium and <e1>CHEMICAL<\\e1>  to assess how specific alterations in drug structure affected potency and binding interactions","sentence":"We used mutagenesis of these residues, combined with an investigation of hERG block by close analogs of clofilium and ibutilide  to assess how specific alterations in drug structure affected potency and binding interactions"}
{"PMID":16303771,"re_id":0,"annotated sentence":"Tissue-type plasminogen activator (tPA), a <e1>serine<\\e1> protease well known for generating plasmin, has been demonstrated to induce <e2>matrix metalloproteinase-9<\\e2> (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"serine","object":"matrix metalloproteinase-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Tissue-type plasminogen activator (tPA), a <e1>CHEMICAL<\\e1> protease well known for generating plasmin, has been demonstrated to induce <e2>GENE-Y<\\e2> (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts","sentence":"Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts"}
{"PMID":16303771,"re_id":1,"annotated sentence":"Tissue-type plasminogen activator (tPA), a <e1>serine<\\e1> protease well known for generating <e2>plasmin<\\e2>  has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"serine","object":"plasmin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Tissue-type GENE-Yogen activator (tPA), a <e1>CHEMICAL<\\e1> protease well known for generating <e2>GENE-Y<\\e2>  has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts","sentence":"Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin  has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts"}
{"PMID":16303771,"re_id":2,"annotated sentence":"Furthermore, tPA induced rapid <e1>tyrosine<\\e1> phosphorylation on the beta subunit of LRP-1, which was followed by the activation of <e2>Mek1<\\e2> and its downstream Erk-1 and -2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tyrosine","object":"Mek1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, tPA induced rapid <e1>CHEMICAL<\\e1> phosphorylation on the beta subunit of LRP-1, which was followed by the activation of <e2>GENE-Y<\\e2> and its downstream Erk-1 and -2","sentence":"Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2"}
{"PMID":16303771,"re_id":3,"annotated sentence":"Furthermore, tPA induced rapid <e1>tyrosine<\\e1> phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream <e2>Erk-1 and -2<\\e2>  Blockade of Erk-1\/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tyrosine","object":"Erk-1 and -2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, tPA induced rapid <e1>CHEMICAL<\\e1> phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream <e2>GENE-N<\\e2>  Blockade of Erk-1\/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells","sentence":"Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2  Blockade of Erk-1\/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells"}
{"PMID":16365052,"re_id":0,"annotated sentence":"Expression of L-type pyruvate kinase (<e2>L-PK<\\e2>  is upregulated in the liver by dietary <e1>carbohydrate<\\e1>  Previously, 3 carbohydrate\/insulin response elements were identified in the 5'-flanking region of the L-PK gene up to bp -170","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"carbohydrate","object":"L-PK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Expression of L-type pyruvate kinase (<e2>GENE-Y<\\e2>  is upregulated in the liver by dietary <e1>CHEMICAL<\\e1>  Previously, 3 CHEMICAL\/insulin response elements were identified in the 5'-flanking region of the GENE-Y gene up to bp -170","sentence":"Expression of L-type pyruvate kinase (L-PK  is upregulated in the liver by dietary carbohydrate  Previously, 3 carbohydrate\/insulin response elements were identified in the 5'-flanking region of the L-PK gene up to bp -170"}
{"PMID":16365052,"re_id":1,"annotated sentence":"Expression of <e2>L-type pyruvate kinase<\\e2> (L-PK) is upregulated in the liver by dietary <e1>carbohydrate<\\e1>  Previously, 3 carbohydrate\/insulin response elements were identified in the 5'-flanking region of the L-PK gene up to bp -170","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"carbohydrate","object":"L-type pyruvate kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Expression of <e2>GENE-Y<\\e2> (L-PK) is upregulated in the liver by dietary <e1>CHEMICAL<\\e1>  Previously, 3 CHEMICAL\/insulin response elements were identified in the 5'-flanking region of the L-PK gene up to bp -170","sentence":"Expression of L-type pyruvate kinase (L-PK) is upregulated in the liver by dietary carbohydrate  Previously, 3 carbohydrate\/insulin response elements were identified in the 5'-flanking region of the L-PK gene up to bp -170"}
{"PMID":16395286,"re_id":0,"annotated sentence":"Our results have shown that <e2>MMP-9<\\e2> messenger ribonucleic acid (mRNA) expression was inhibited by <e1>doxycycline<\\e1> starting at 10 mg\/kg\/day (P<0.02)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"doxycycline","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results have shown that <e2>GENE-Y<\\e2> messenger ribonucleic acid (mRNA) expression was inhibited by <e1>CHEMICAL<\\e1> starting at 10 mg\/kg\/day (P<0.02)","sentence":"Our results have shown that MMP-9 messenger ribonucleic acid (mRNA) expression was inhibited by doxycycline starting at 10 mg\/kg\/day (P<0.02)"}
{"PMID":16395286,"re_id":1,"annotated sentence":"<e1>Minocycline<\\e1> showed more potent inhibition on <e2>MMP-9<\\e2> mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg\/kg\/day","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Minocycline","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> showed more potent inhibition on <e2>GENE-Y<\\e2> mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg\/kg\/day","sentence":"Minocycline showed more potent inhibition on MMP-9 mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg\/kg\/day"}
{"PMID":16395286,"re_id":2,"annotated sentence":"At the enzymatic activity level, <e1>doxycycline<\\e1> started to suppress <e2>MMP-9<\\e2> activity at 5 mg\/kg\/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg\/kg\/day (P<0.02)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"doxycycline","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At the enzymatic activity level, <e1>CHEMICAL<\\e1> started to suppress <e2>GENE-Y<\\e2> activity at 5 mg\/kg\/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg\/kg\/day (P<0.02)","sentence":"At the enzymatic activity level, doxycycline started to suppress MMP-9 activity at 5 mg\/kg\/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg\/kg\/day (P<0.02)"}
{"PMID":16395286,"re_id":3,"annotated sentence":"We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the <e2>MMP-9<\\e2> inhibition by <e1>tetracyclines<\\e1>  In vitro, minocycline, but not doxycycline, inhibits MMP-9, at least in part, via the extracellular signaling-related kinase 1\/2 (ERK1\/2)-mediated pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tetracyclines","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the <e2>GENE-Y<\\e2> inhibition by <e1>CHEMICAL<\\e1>  In vitro, minocycline, but not doxycycline, inhibits GENE-Y, at least in part, via the extracellular signaling-related kinase 1\/2 (ERK1\/2)-mediated pathway","sentence":"We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the MMP-9 inhibition by tetracyclines  In vitro, minocycline, but not doxycycline, inhibits MMP-9, at least in part, via the extracellular signaling-related kinase 1\/2 (ERK1\/2)-mediated pathway"}
{"PMID":16395286,"re_id":4,"annotated sentence":"In vitro, <e1>minocycline<\\e1>  but not doxycycline, inhibits <e2>MMP-9<\\e2>  at least in part, via the extracellular signaling-related kinase 1\/2 (ERK1\/2)-mediated pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"minocycline","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro, <e1>CHEMICAL<\\e1>  but not doxycycline, inhibits <e2>GENE-Y<\\e2>  at least in part, via the extracellular signaling-related kinase 1\/2 (ERK1\/2)-mediated pathway","sentence":"In vitro, minocycline  but not doxycycline, inhibits MMP-9  at least in part, via the extracellular signaling-related kinase 1\/2 (ERK1\/2)-mediated pathway"}
{"PMID":16395286,"re_id":5,"annotated sentence":"In vitro, minocycline, but not <e1>doxycycline<\\e1>  inhibits <e2>MMP-9<\\e2>  at least in part, via the extracellular signaling-related kinase 1\/2 (ERK1\/2)-mediated pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"doxycycline","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro, minocycline, but not <e1>CHEMICAL<\\e1>  inhibits <e2>GENE-Y<\\e2>  at least in part, via the extracellular signaling-related kinase 1\/2 (ERK1\/2)-mediated pathway","sentence":"In vitro, minocycline, but not doxycycline  inhibits MMP-9  at least in part, via the extracellular signaling-related kinase 1\/2 (ERK1\/2)-mediated pathway"}
{"PMID":16395286,"re_id":6,"annotated sentence":"This study provided the evidence that the <e1>tetracyclines<\\e1> inhibit stimulated cerebral <e2>MMP-9<\\e2> at multiple levels and are effective at very low doses, offering great potential for therapeutic use.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tetracyclines","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study provided the evidence that the <e1>CHEMICAL<\\e1> inhibit stimulated cerebral <e2>GENE-Y<\\e2> at multiple levels and are effective at very low doses, offering great potential for therapeutic use.","sentence":"This study provided the evidence that the tetracyclines inhibit stimulated cerebral MMP-9 at multiple levels and are effective at very low doses, offering great potential for therapeutic use."}
{"PMID":16395286,"re_id":7,"annotated sentence":"<e1>Doxycycline<\\e1> was shown to decrease cerebral <e2>MMP-9<\\e2> activities and angiogenesis induced by vascular endothelial growth factor (VEGF)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Doxycycline","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was shown to decrease cerebral <e2>GENE-Y<\\e2> activities and angiogenesis induced by vascular endothelial growth factor (VEGF)","sentence":"Doxycycline was shown to decrease cerebral MMP-9 activities and angiogenesis induced by vascular endothelial growth factor (VEGF)"}
{"PMID":16395286,"re_id":8,"annotated sentence":"<e1>Doxycycline<\\e1> was shown to decrease cerebral MMP-9 activities and angiogenesis induced by <e2>vascular endothelial growth factor<\\e2> (VEGF)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Doxycycline","object":"vascular endothelial growth factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was shown to decrease cerebral MMP-9 activities and angiogenesis induced by <e2>GENE-Y<\\e2> (VEGF)","sentence":"Doxycycline was shown to decrease cerebral MMP-9 activities and angiogenesis induced by vascular endothelial growth factor (VEGF)"}
{"PMID":16395286,"re_id":9,"annotated sentence":"<e1>Doxycycline<\\e1> was shown to decrease cerebral MMP-9 activities and angiogenesis induced by vascular endothelial growth factor (<e2>VEGF<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Doxycycline","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was shown to decrease cerebral MMP-9 activities and angiogenesis induced by vascular endothelial growth factor (<e2>GENE-Y<\\e2> ","sentence":"Doxycycline was shown to decrease cerebral MMP-9 activities and angiogenesis induced by vascular endothelial growth factor (VEGF "}
{"PMID":16399380,"re_id":0,"annotated sentence":"<e2>Omega class GSTs<\\e2> have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of <e1>monomethylarsonate<\\e1>  an intermediate in the pathway of arsenic biotransformation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"monomethylarsonate","object":"Omega class GSTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of <e1>CHEMICAL<\\e1>  an intermediate in the pathway of arsenic biotransformation","sentence":"Omega class GSTs have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of monomethylarsonate  an intermediate in the pathway of arsenic biotransformation"}
{"PMID":16417577,"re_id":0,"annotated sentence":"Galanin attenuates <e2>cyclic AMP regulatory element-binding protein<\\e2> (CREB) phosphorylation induced by chronic <e1>morphine<\\e1> and naloxone challenge in Cath.a cells and primary striatal cultures","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"morphine","object":"cyclic AMP regulatory element-binding protein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Galanin attenuates <e2>GENE-N<\\e2> (CREB) phosphorylation induced by chronic <e1>CHEMICAL<\\e1> and naloxone challenge in Cath.a cells and primary striatal cultures","sentence":"Galanin attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures"}
{"PMID":16417577,"re_id":1,"annotated sentence":"Galanin attenuates cyclic AMP regulatory element-binding protein (<e2>CREB<\\e2>  phosphorylation induced by chronic <e1>morphine<\\e1> and naloxone challenge in Cath.a cells and primary striatal cultures","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"morphine","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Galanin attenuates cyclic AMP regulatory element-binding protein (<e2>GENE-N<\\e2>  phosphorylation induced by chronic <e1>CHEMICAL<\\e1> and naloxone challenge in Cath.a cells and primary striatal cultures","sentence":"Galanin attenuates cyclic AMP regulatory element-binding protein (CREB  phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures"}
{"PMID":16417577,"re_id":2,"annotated sentence":"Galanin attenuates <e2>cyclic AMP regulatory element-binding protein<\\e2> (CREB) phosphorylation induced by chronic morphine and <e1>naloxone<\\e1> challenge in Cath.a cells and primary striatal cultures","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"naloxone","object":"cyclic AMP regulatory element-binding protein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Galanin attenuates <e2>GENE-N<\\e2> (CREB) phosphorylation induced by chronic morphine and <e1>CHEMICAL<\\e1> challenge in Cath.a cells and primary striatal cultures","sentence":"Galanin attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures"}
{"PMID":16417577,"re_id":3,"annotated sentence":"Galanin attenuates cyclic AMP regulatory element-binding protein (<e2>CREB<\\e2>  phosphorylation induced by chronic morphine and <e1>naloxone<\\e1> challenge in Cath.a cells and primary striatal cultures","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"naloxone","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Galanin attenuates cyclic AMP regulatory element-binding protein (<e2>GENE-N<\\e2>  phosphorylation induced by chronic morphine and <e1>CHEMICAL<\\e1> challenge in Cath.a cells and primary striatal cultures","sentence":"Galanin attenuates cyclic AMP regulatory element-binding protein (CREB  phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures"}
{"PMID":16432501,"re_id":0,"annotated sentence":"A dose of 25 microg kg(-1) day(-1) of <e1>formoterol<\\e1> elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar <e2>beta-adrenoceptor<\\e2> downregulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"formoterol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A dose of 25 microg kg(-1) day(-1) of <e1>CHEMICAL<\\e1> elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar <e2>GENE-N<\\e2> downregulation","sentence":"A dose of 25 microg kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar beta-adrenoceptor downregulation"}
{"PMID":16432501,"re_id":1,"annotated sentence":"A dose of 25 microg kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than <e1>salmeterol<\\e1>  but resulted in similar <e2>beta-adrenoceptor<\\e2> downregulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"salmeterol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A dose of 25 microg kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than <e1>CHEMICAL<\\e1>  but resulted in similar <e2>GENE-N<\\e2> downregulation","sentence":"A dose of 25 microg kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than salmeterol  but resulted in similar beta-adrenoceptor downregulation"}
{"PMID":16432501,"re_id":2,"annotated sentence":"Two beta(2)-agonists, <e1>formoterol<\\e1> and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater <e2>beta(2)-adrenoceptor<\\e2> selectivity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"formoterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two beta(2)-agonists, <e1>CHEMICAL<\\e1> and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater <e2>GENE-Y<\\e2> selectivity","sentence":"Two beta(2)-agonists, formoterol and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater beta(2)-adrenoceptor selectivity"}
{"PMID":16432501,"re_id":3,"annotated sentence":"Two beta(2)-agonists, formoterol and <e1>salmeterol<\\e1>  are approved for treating asthma and have an extended duration of action and increased safety, associated with greater <e2>beta(2)-adrenoceptor<\\e2> selectivity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"salmeterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two beta(2)-agonists, formoterol and <e1>CHEMICAL<\\e1>  are approved for treating asthma and have an extended duration of action and increased safety, associated with greater <e2>GENE-Y<\\e2> selectivity","sentence":"Two beta(2)-agonists, formoterol and salmeterol  are approved for treating asthma and have an extended duration of action and increased safety, associated with greater beta(2)-adrenoceptor selectivity"}
{"PMID":16432501,"re_id":4,"annotated sentence":"Systemic administration of <e2>beta2-adrenoceptor<\\e2> agonists, <e1>formoterol<\\e1> and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"formoterol","object":"beta2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Systemic administration of <e2>GENE-Y<\\e2> agonists, <e1>CHEMICAL<\\e1> and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses","sentence":"Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses"}
{"PMID":16432501,"re_id":5,"annotated sentence":"Systemic administration of <e2>beta2-adrenoceptor<\\e2> agonists, formoterol and <e1>salmeterol<\\e1>  elicit skeletal muscle hypertrophy in rats at micromolar doses","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"salmeterol","object":"beta2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Systemic administration of <e2>GENE-Y<\\e2> agonists, formoterol and <e1>CHEMICAL<\\e1>  elicit skeletal muscle hypertrophy in rats at micromolar doses","sentence":"Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol  elicit skeletal muscle hypertrophy in rats at micromolar doses"}
{"PMID":16434489,"re_id":0,"annotated sentence":"In this study, we demonstrate significant inhibitory activity of <e1>dasatinib<\\e1> against both wild-type <e2>KIT<\\e2> and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we demonstrate significant inhibitory activity of <e1>CHEMICAL<\\e1> against both wild-type <e2>GENE-Y<\\e2> and the GENE-YD816V mutation in the nanomolar range in in vitro and cell-based kinase assays","sentence":"In this study, we demonstrate significant inhibitory activity of dasatinib against both wild-type KIT and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays"}
{"PMID":16434489,"re_id":1,"annotated sentence":"In this study, we demonstrate significant inhibitory activity of <e1>dasatinib<\\e1> against both wild-type KIT and the <e2>KIT<\\e2> 816V mutation in the nanomolar range in in vitro and cell-based kinase assays","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we demonstrate significant inhibitory activity of <e1>CHEMICAL<\\e1> against both wild-type GENE-Y and the <e2>GENE-Y<\\e2> 816V mutation in the nanomolar range in in vitro and cell-based kinase assays","sentence":"In this study, we demonstrate significant inhibitory activity of dasatinib against both wild-type KIT and the KIT 816V mutation in the nanomolar range in in vitro and cell-based kinase assays"}
{"PMID":16434489,"re_id":2,"annotated sentence":"In this study, we demonstrate significant inhibitory activity of <e1>dasatinib<\\e1> against both wild-type KIT and the KIT<e2>D816V<\\e2> mutation in the nanomolar range in in vitro and cell-based kinase assays","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"D816V","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, we demonstrate significant inhibitory activity of <e1>CHEMICAL<\\e1> against both wild-type KIT and the KIT<e2>GENE-N<\\e2> mutation in the nanomolar range in in vitro and cell-based kinase assays","sentence":"In this study, we demonstrate significant inhibitory activity of dasatinib against both wild-type KIT and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays"}
{"PMID":16434489,"re_id":3,"annotated sentence":"Additionally, <e1>dasatinib<\\e1> leads to growth inhibition of a <e2>KIT<\\e2> 816V-harboring human masto-cytosis cell line","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> leads to growth inhibition of a <e2>GENE-Y<\\e2> 816V-harboring human masto-cytosis cell line","sentence":"Additionally, dasatinib leads to growth inhibition of a KIT 816V-harboring human masto-cytosis cell line"}
{"PMID":16434489,"re_id":4,"annotated sentence":"Additionally, <e1>dasatinib<\\e1> leads to growth inhibition of a KIT<e2>D816V<\\e2> harboring human masto-cytosis cell line","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"D816V","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> leads to growth inhibition of a KIT<e2>GENE-N<\\e2> harboring human masto-cytosis cell line","sentence":"Additionally, dasatinib leads to growth inhibition of a KITD816V harboring human masto-cytosis cell line"}
{"PMID":16434489,"re_id":5,"annotated sentence":"<e1>Dasatinib<\\e1> (BMS-354825) inhibits <e2>KIT<\\e2> 816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dasatinib","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (BMS-354825) inhibits <e2>GENE-Y<\\e2> 816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","sentence":"Dasatinib (BMS-354825) inhibits KIT 816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis"}
{"PMID":16434489,"re_id":6,"annotated sentence":"<e1>Dasatinib<\\e1> (BMS-354825) inhibits KIT<e2>D816V<\\e2>  an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dasatinib","object":"D816V","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (BMS-354825) inhibits KIT<e2>GENE-N<\\e2>  an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","sentence":"Dasatinib (BMS-354825) inhibits KITD816V  an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis"}
{"PMID":16434489,"re_id":7,"annotated sentence":"Dasatinib (<e1>BMS-354825<\\e1>  inhibits KIT<e2>D816V<\\e2>  an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"D816V","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Dasatinib (<e1>CHEMICAL<\\e1>  inhibits KIT<e2>GENE-N<\\e2>  an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","sentence":"Dasatinib (BMS-354825  inhibits KITD816V  an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis"}
{"PMID":16434489,"re_id":8,"annotated sentence":"<e1>Dasatinib<\\e1> (BMS-354825) is a novel orally bioavailable <e2>SRC<\\e2> ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dasatinib","object":"SRC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (BMS-354825) is a novel orally bioavailable <e2>GENE-Y<\\e2> ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)","sentence":"Dasatinib (BMS-354825) is a novel orally bioavailable SRC ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)"}
{"PMID":16434489,"re_id":9,"annotated sentence":"<e1>Dasatinib<\\e1> (BMS-354825) is a novel orally bioavailable SRC\/<e2>ABL<\\e2> inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dasatinib","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (BMS-354825) is a novel orally bioavailable SRC\/<e2>GENE-Y<\\e2> inhibitor that has activity against multiple imatinib-resistant BCR-GENE-Y isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)","sentence":"Dasatinib (BMS-354825) is a novel orally bioavailable SRC\/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)"}
{"PMID":16434489,"re_id":10,"annotated sentence":"Dasatinib (<e1>BMS-354825<\\e1>  is a novel orally bioavailable <e2>SRC<\\e2> ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"SRC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dasatinib (<e1>CHEMICAL<\\e1>  is a novel orally bioavailable <e2>GENE-Y<\\e2> ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)","sentence":"Dasatinib (BMS-354825  is a novel orally bioavailable SRC ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)"}
{"PMID":16434489,"re_id":11,"annotated sentence":"Dasatinib (<e1>BMS-354825<\\e1>  is a novel orally bioavailable SRC\/<e2>ABL<\\e2> inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dasatinib (<e1>CHEMICAL<\\e1>  is a novel orally bioavailable SRC\/<e2>GENE-Y<\\e2> inhibitor that has activity against multiple imatinib-resistant BCR-GENE-Y isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)","sentence":"Dasatinib (BMS-354825  is a novel orally bioavailable SRC\/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)"}
{"PMID":16437532,"re_id":0,"annotated sentence":"BACKGROUND: Since the introduction of the first <e2>cholinesterase<\\e2> inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, <e1>donepezil<\\e1>  galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"donepezil","object":"cholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Since the introduction of the first <e2>GENE-Y<\\e2> inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, <e1>CHEMICAL<\\e1>  galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylGENE-Y","sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil  galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase"}
{"PMID":16437532,"re_id":1,"annotated sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, <e1>donepezil<\\e1>  galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme <e2>acetylcholinesterase<\\e2>  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"donepezil","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, <e1>CHEMICAL<\\e1>  galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme <e2>GENE-Y<\\e2>  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease","sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil  galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease"}
{"PMID":16437532,"re_id":2,"annotated sentence":"BACKGROUND: Since the introduction of the first <e2>cholinesterase<\\e2> inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, <e1>galantamine<\\e1> and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"galantamine","object":"cholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Since the introduction of the first <e2>GENE-Y<\\e2> inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, <e1>CHEMICAL<\\e1> and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylGENE-Y","sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase"}
{"PMID":16437532,"re_id":3,"annotated sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, <e1>galantamine<\\e1> and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme <e2>acetylcholinesterase<\\e2>  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"galantamine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, <e1>CHEMICAL<\\e1> and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme <e2>GENE-Y<\\e2>  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease","sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease"}
{"PMID":16437532,"re_id":4,"annotated sentence":"BACKGROUND: Since the introduction of the first <e2>cholinesterase<\\e2> inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and <e1>rivastigmine<\\e1>  to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rivastigmine","object":"cholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Since the introduction of the first <e2>GENE-Y<\\e2> inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and <e1>CHEMICAL<\\e1>  to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylGENE-Y","sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine  to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase"}
{"PMID":16437532,"re_id":5,"annotated sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and <e1>rivastigmine<\\e1>  to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme <e2>acetylcholinesterase<\\e2>  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rivastigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and <e1>CHEMICAL<\\e1>  to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme <e2>GENE-Y<\\e2>  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease","sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine  to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease"}
{"PMID":16437532,"re_id":6,"annotated sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of <e1>acetylcholine<\\e1>  an important neurotransmitter associated with memory, by blocking the enzyme <e2>acetylcholinesterase<\\e2>  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetylcholine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of <e1>CHEMICAL<\\e1>  an important neurotransmitter associated with memory, by blocking the enzyme <e2>CHEMICALsterase<\\e2>  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease","sentence":"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine  an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease"}
{"PMID":16455797,"re_id":0,"annotated sentence":"These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating <e2>SSAT<\\e2> activity or stability as a part of <e1>polyamine<\\e1> homeostasis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"polyamine","object":"SSAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating <e2>GENE-Y<\\e2> activity or stability as a part of <e1>CHEMICAL<\\e1> homeostasis","sentence":"These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating SSAT activity or stability as a part of polyamine homeostasis"}
{"PMID":16455797,"re_id":1,"annotated sentence":"<e2>Spermidine\/spermine N1-acetyltransferase<\\e2> (SSAT) is a key enzyme in the control of <e1>polyamine<\\e1> levels in human cells, as acetylation of spermidine and spermine triggers export or degradation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"polyamine","object":"Spermidine\/spermine N1-acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (SSAT) is a key enzyme in the control of <e1>CHEMICAL<\\e1> levels in human cells, as acetylation of spermidine and spermine triggers export or degradation","sentence":"Spermidine\/spermine N1-acetyltransferase (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation"}
{"PMID":16455797,"re_id":2,"annotated sentence":"<e2>Spermidine\/spermine N1-acetyltransferase<\\e2> (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of <e1>spermidine<\\e1> and spermine triggers export or degradation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermidine","object":"Spermidine\/spermine N1-acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of <e1>CHEMICAL<\\e1> and spermine triggers export or degradation","sentence":"Spermidine\/spermine N1-acetyltransferase (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation"}
{"PMID":16455797,"re_id":3,"annotated sentence":"<e2>Spermidine\/spermine N1-acetyltransferase<\\e2> (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and <e1>spermine<\\e1> triggers export or degradation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"spermine","object":"Spermidine\/spermine N1-acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>Spermidine\/CHEMICAL N1-acetyltransferase<\\e2> (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and <e1>CHEMICAL<\\e1> triggers export or degradation","sentence":"Spermidine\/spermine N1-acetyltransferase (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation"}
{"PMID":16480505,"re_id":0,"annotated sentence":"In general, rifampicin can act on a pattern: <e1>rifampicin<\\e1> activates the <e2>nuclear pregnane X receptor<\\e2> that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rifampicin","object":"nuclear pregnane X receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In general, CHEMICAL can act on a pattern: <e1>CHEMICAL<\\e1> activates the <e2>GENE-Y<\\e2> that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities","sentence":"In general, rifampicin can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities"}
{"PMID":16480505,"re_id":1,"annotated sentence":"In general, <e1>rifampicin<\\e1> can act on a pattern: rifampicin activates the <e2>nuclear pregnane X receptor<\\e2> that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"rifampicin","object":"nuclear pregnane X receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In general, <e1>CHEMICAL<\\e1> can act on a pattern: CHEMICAL activates the <e2>GENE-Y<\\e2> that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities","sentence":"In general, rifampicin can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities"}
{"PMID":16480505,"re_id":2,"annotated sentence":"The concomitantly administered effects of <e1>rifampicin<\\e1> on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by <e2>p-glycoprotein<\\e2> in the gastrointestinal tract and liver","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"rifampicin","object":"p-glycoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The concomitantly administered effects of <e1>CHEMICAL<\\e1> on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by <e2>GENE-N<\\e2> in the gastrointestinal tract and liver","sentence":"The concomitantly administered effects of rifampicin on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by p-glycoprotein in the gastrointestinal tract and liver"}
{"PMID":16480505,"re_id":3,"annotated sentence":"The concomitantly administered effects of <e1>rifampicin<\\e1> on other drugs can result in their altered metabolism or transportation that are metabolised by <e2>cytochromes P450<\\e2> or transported by p-glycoprotein in the gastrointestinal tract and liver","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"rifampicin","object":"cytochromes P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The concomitantly administered effects of <e1>CHEMICAL<\\e1> on other drugs can result in their altered metabolism or transportation that are metabolised by <e2>GENE-N<\\e2> or transported by p-glycoprotein in the gastrointestinal tract and liver","sentence":"The concomitantly administered effects of rifampicin on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by p-glycoprotein in the gastrointestinal tract and liver"}
{"PMID":16484281,"re_id":0,"annotated sentence":"Withdrawal from free-choice <e1>ethanol<\\e1> consumption results in increased packing density of <e2>glutamine synthetase<\\e2> immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ethanol","object":"glutamine synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Withdrawal from free-choice <e1>CHEMICAL<\\e1> consumption results in increased packing density of <e2>GENE-Y<\\e2> immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats","sentence":"Withdrawal from free-choice ethanol consumption results in increased packing density of glutamine synthetase immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats"}
{"PMID":16484281,"re_id":1,"annotated sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released <e1>glutamate<\\e1> and its conversion to glutamine through the enzyme <e2>glutamine synthetase<\\e2> (GS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"glutamine synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released <e1>CHEMICAL<\\e1> and its conversion to glutamine through the enzyme <e2>GENE-Y<\\e2> (GS)","sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to glutamine through the enzyme glutamine synthetase (GS)"}
{"PMID":16484281,"re_id":2,"annotated sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released <e1>glutamate<\\e1> and its conversion to glutamine through the enzyme glutamine synthetase (<e2>GS<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamate","object":"GS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released <e1>CHEMICAL<\\e1> and its conversion to glutamine through the enzyme glutamine synthetase (<e2>GENE-Y<\\e2> ","sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to glutamine through the enzyme glutamine synthetase (GS "}
{"PMID":16484281,"re_id":3,"annotated sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to <e1>glutamine<\\e1> through the enzyme <e2>glutamine synthetase<\\e2> (GS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"glutamine synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to <e1>CHEMICAL<\\e1> through the enzyme <e2>CHEMICAL synthetase<\\e2> (GS)","sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to glutamine through the enzyme glutamine synthetase (GS)"}
{"PMID":16484281,"re_id":4,"annotated sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to <e1>glutamine<\\e1> through the enzyme glutamine synthetase (<e2>GS<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"GS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to <e1>CHEMICAL<\\e1> through the enzyme CHEMICAL synthetase (<e2>GENE-Y<\\e2> ","sentence":"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to glutamine through the enzyme glutamine synthetase (GS "}
{"PMID":16494569,"re_id":0,"annotated sentence":"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired <e2>pyridoxal kinase<\\e2> for the conversion of <e1>pyridoxine<\\e1> and pyridoxal to PLP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyridoxine","object":"pyridoxal kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired <e2>GENE-Y<\\e2> for the conversion of <e1>CHEMICAL<\\e1> and pyridoxal to PLP","sentence":"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired pyridoxal kinase for the conversion of pyridoxine and pyridoxal to PLP"}
{"PMID":16494569,"re_id":1,"annotated sentence":"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired <e2>pyridoxal kinase<\\e2> for the conversion of pyridoxine and <e1>pyridoxal<\\e1> to PLP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyridoxal","object":"pyridoxal kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired <e2>CHEMICAL kinase<\\e2> for the conversion of pyridoxine and <e1>CHEMICAL<\\e1> to PLP","sentence":"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired pyridoxal kinase for the conversion of pyridoxine and pyridoxal to PLP"}
{"PMID":16494569,"re_id":2,"annotated sentence":"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired <e2>pyridoxal kinase<\\e2> for the conversion of pyridoxine and pyridoxal to <e1>PLP<\\e1>  This may explain the many published studies of benefits of high-dose vitamin B6 supplementation in some children and adults with autism.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PLP","object":"pyridoxal kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired <e2>GENE-Y<\\e2> for the conversion of pyridoxine and pyridoxal to <e1>CHEMICAL<\\e1>  This may explain the many published studies of benefits of high-dose vitamin B6 supplementation in some children and adults with autism.","sentence":"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired pyridoxal kinase for the conversion of pyridoxine and pyridoxal to PLP  This may explain the many published studies of benefits of high-dose vitamin B6 supplementation in some children and adults with autism."}
{"PMID":16497876,"re_id":0,"annotated sentence":"In this article, the action of <e1>dasatinib<\\e1> (BMS-354825) is contrasted with that of imatinib, a <e2>kinase<\\e2> inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this article, the action of <e1>CHEMICAL<\\e1> (BMS-354825) is contrasted with that of imatinib, a <e2>GENE-N<\\e2> inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders","sentence":"In this article, the action of dasatinib (BMS-354825) is contrasted with that of imatinib, a kinase inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders"}
{"PMID":16497876,"re_id":1,"annotated sentence":"In this article, the action of dasatinib (<e1>BMS-354825<\\e1>  is contrasted with that of imatinib, a <e2>kinase<\\e2> inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this article, the action of dasatinib (<e1>CHEMICAL<\\e1>  is contrasted with that of imatinib, a <e2>GENE-N<\\e2> inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders","sentence":"In this article, the action of dasatinib (BMS-354825  is contrasted with that of imatinib, a kinase inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders"}
{"PMID":16497876,"re_id":2,"annotated sentence":"In this article, the action of dasatinib (BMS-354825) is contrasted with that of <e1>imatinib<\\e1>  a <e2>kinase<\\e2> inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this article, the action of dasatinib (BMS-354825) is contrasted with that of <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders","sentence":"In this article, the action of dasatinib (BMS-354825) is contrasted with that of imatinib  a kinase inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders"}
{"PMID":16497876,"re_id":3,"annotated sentence":"The work of Chen and colleagues shows that <e1>dasatinib<\\e1> is a particularly potent inhibitor of <e2>PDGFR<\\e2> and that the compound also targets Src kinase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"PDGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The work of Chen and colleagues shows that <e1>CHEMICAL<\\e1> is a particularly potent inhibitor of <e2>GENE-N<\\e2> and that the compound also targets Src kinase","sentence":"The work of Chen and colleagues shows that dasatinib is a particularly potent inhibitor of PDGFR and that the compound also targets Src kinase"}
{"PMID":16497876,"re_id":4,"annotated sentence":"The work of Chen and colleagues shows that <e1>dasatinib<\\e1> is a particularly potent inhibitor of PDGFR and that the compound also targets <e2>Src kinase<\\e2>  The authors suggest that this combination of activities could be useful in the treatment of vascular obstructive diseases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"Src kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The work of Chen and colleagues shows that <e1>CHEMICAL<\\e1> is a particularly potent inhibitor of PDGFR and that the compound also targets <e2>GENE-Y<\\e2>  The authors suggest that this combination of activities could be useful in the treatment of vascular obstructive diseases","sentence":"The work of Chen and colleagues shows that dasatinib is a particularly potent inhibitor of PDGFR and that the compound also targets Src kinase  The authors suggest that this combination of activities could be useful in the treatment of vascular obstructive diseases"}
{"PMID":16516814,"re_id":0,"annotated sentence":"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the <e1>PGE1<\\e1> mediated stimulation of <e2>Na,K-ATPase beta<\\e2> subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PGE1","object":"Na,K-ATPase beta","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the <e1>CHEMICAL<\\e1> mediated stimulation of <e2>GENE-N<\\e2> subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089","sentence":"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089"}
{"PMID":16516814,"re_id":1,"annotated sentence":"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of <e2>Na,K-ATPase beta<\\e2> subunit gene transcription includes the stimulatory effect of <e1>17-phenyl trinor PGE2<\\e1>  as well as the inhibitory effects of SC-51089","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"17-phenyl trinor PGE2","object":"Na,K-ATPase beta","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of <e2>GENE-N<\\e2> subunit gene transcription includes the stimulatory effect of <e1>CHEMICAL<\\e1>  as well as the inhibitory effects of SC-51089","sentence":"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2  as well as the inhibitory effects of SC-51089"}
{"PMID":16516814,"re_id":2,"annotated sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the <e2>PKC<\\e2> inhibitor Go 6976, <e1>thapsigargin<\\e1>  as well as the calmodulin antagonists W7 and W13.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"thapsigargin","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the GENE-NI vector (encoding the GENE-N inhibitory domain), the <e2>GENE-N<\\e2> inhibitor Go 6976, <e1>CHEMICAL<\\e1>  as well as the calmodulin antagonists W7 and W13.","sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin  as well as the calmodulin antagonists W7 and W13."}
{"PMID":16516814,"re_id":3,"annotated sentence":"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of <e2>Na,K-ATPase beta<\\e2> subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of <e1>SC-51089<\\e1>  Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SC-51089","object":"Na,K-ATPase beta","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of <e2>GENE-N<\\e2> subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of <e1>CHEMICAL<\\e1>  Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13.","sentence":"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089  Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13."}
{"PMID":16516814,"re_id":4,"annotated sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the <e2>PKC<\\e2> inhibitor <e1>Go 6976<\\e1>  thapsigargin, as well as the calmodulin antagonists W7 and W13.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Go 6976","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the GENE-NI vector (encoding the GENE-N inhibitory domain), the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1>  thapsigargin, as well as the calmodulin antagonists W7 and W13.","sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976  thapsigargin, as well as the calmodulin antagonists W7 and W13."}
{"PMID":16516814,"re_id":5,"annotated sentence":"The involvement of <e2>EP1<\\e2> and EP2 receptors is indicated by studies with the EP1 selective agonist <e1>17-phenyl trinor PGE2<\\e1>  and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"17-phenyl trinor PGE2","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of <e2>GENE-Y<\\e2> and EP2 receptors is indicated by studies with the GENE-Y selective agonist <e1>CHEMICAL<\\e1>  and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (GENE-Y specific) and AH 6809 (GENE-Y and EP2 specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2  and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":6,"annotated sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the <e2>EP1<\\e2> selective agonist <e1>17-phenyl trinor PGE2<\\e1>  and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"17-phenyl trinor PGE2","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of GENE-Y and EP2 receptors is indicated by studies with the <e2>GENE-Y<\\e2> selective agonist <e1>CHEMICAL<\\e1>  and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (GENE-Y specific) and AH 6809 (GENE-Y and EP2 specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2  and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":7,"annotated sentence":"The involvement of EP1 and <e2>EP2 receptors<\\e2> is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist <e1>butaprost<\\e1> (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"butaprost","object":"EP2 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of EP1 and <e2>GENE-Y<\\e2> is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist <e1>CHEMICAL<\\e1> (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":8,"annotated sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the <e2>EP2<\\e2> selective agonist <e1>butaprost<\\e1> (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"butaprost","object":"EP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of EP1 and GENE-Y receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the <e2>GENE-Y<\\e2> selective agonist <e1>CHEMICAL<\\e1> (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and GENE-Y specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":9,"annotated sentence":"The involvement of <e2>EP1<\\e2> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <e1>SC-51089<\\e1> (EP1 specific) and AH 6809 (EP1 and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"SC-51089","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of <e2>GENE-Y<\\e2> and EP2 receptors is indicated by studies with the GENE-Y selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <e1>CHEMICAL<\\e1> (GENE-Y specific) and AH 6809 (GENE-Y and EP2 specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":10,"annotated sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the <e2>EP1<\\e2> selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <e1>SC-51089<\\e1> (EP1 specific) and AH 6809 (EP1 and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"SC-51089","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of GENE-Y and EP2 receptors is indicated by studies with the <e2>GENE-Y<\\e2> selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <e1>CHEMICAL<\\e1> (GENE-Y specific) and AH 6809 (GENE-Y and EP2 specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":11,"annotated sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <e1>SC-51089<\\e1> (EP1 specific) and AH 6809 (<e2>EP1<\\e2> and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"SC-51089","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of GENE-Y and EP2 receptors is indicated by studies with the GENE-Y selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <e1>CHEMICAL<\\e1> (GENE-Y specific) and AH 6809 (<e2>GENE-Y<\\e2> and EP2 specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":12,"annotated sentence":"The involvement of <e2>EP1<\\e2> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809<\\e1> (EP1 and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AH 6809","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of <e2>GENE-Y<\\e2> and EP2 receptors is indicated by studies with the GENE-Y selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (GENE-Y specific) and <e1>CHEMICAL<\\e1> (GENE-Y and EP2 specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":13,"annotated sentence":"The involvement of EP1 and <e2>EP2 receptors<\\e2> is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809<\\e1> (EP1 and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AH 6809","object":"EP2 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of EP1 and <e2>GENE-Y<\\e2> is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>CHEMICAL<\\e1> (EP1 and EP2 specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":14,"annotated sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the <e2>EP1<\\e2> selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809<\\e1> (EP1 and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AH 6809","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of GENE-Y and EP2 receptors is indicated by studies with the <e2>GENE-Y<\\e2> selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (GENE-Y specific) and <e1>CHEMICAL<\\e1> (GENE-Y and EP2 specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":15,"annotated sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the <e2>EP2<\\e2> selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809<\\e1> (EP1 and EP2 specific)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AH 6809","object":"EP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of EP1 and GENE-Y receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the <e2>GENE-Y<\\e2> selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>CHEMICAL<\\e1> (EP1 and GENE-Y specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":16,"annotated sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the <e2>calmodulin<\\e2> antagonists <e1>W7<\\e1> and W13.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"W7","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the <e2>GENE-N<\\e2> antagonists <e1>CHEMICAL<\\e1> and W13.","sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13."}
{"PMID":16516814,"re_id":17,"annotated sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the <e2>calmodulin<\\e2> antagonists W7 and <e1>W13<\\e1> ","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"W13","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the <e2>GENE-N<\\e2> antagonists W7 and <e1>CHEMICAL<\\e1> ","sentence":"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13 "}
{"PMID":16516814,"re_id":18,"annotated sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809<\\e1> (<e2>EP1<\\e2> and EP2 specific)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"AH 6809","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of GENE-Y and EP2 receptors is indicated by studies with the GENE-Y selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (GENE-Y specific) and <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> and EP2 specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16516814,"re_id":19,"annotated sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809<\\e1> (EP1 and <e2>EP2<\\e2> specific)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"AH 6809","object":"EP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of EP1 and GENE-Y receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the GENE-Y selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>CHEMICAL<\\e1> (EP1 and <e2>GENE-Y<\\e2> specific)","sentence":"The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)"}
{"PMID":16546990,"re_id":0,"annotated sentence":"Cotreatment with <e1>U0126<\\e1> and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, <e2>JNK<\\e2>  and beta-catenin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"U0126","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cotreatment with <e1>CHEMICAL<\\e1> and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, <e2>GENE-N<\\e2>  and beta-catenin","sentence":"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, JNK  and beta-catenin"}
{"PMID":16546990,"re_id":1,"annotated sentence":"Cotreatment with U0126 and <e1>YC-1<\\e1> synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, <e2>JNK<\\e2>  and beta-catenin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"YC-1","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cotreatment with U0126 and <e1>CHEMICAL<\\e1> synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, <e2>GENE-N<\\e2>  and beta-catenin","sentence":"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, JNK  and beta-catenin"}
{"PMID":16546990,"re_id":2,"annotated sentence":"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of <e1>sulindac<\\e1> treatment on ERK1\/2, <e2>JNK<\\e2>  and beta-catenin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sulindac","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of <e1>CHEMICAL<\\e1> treatment on ERK1\/2, <e2>GENE-N<\\e2>  and beta-catenin","sentence":"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, JNK  and beta-catenin"}
{"PMID":16546990,"re_id":3,"annotated sentence":"<e1>Sulindac<\\e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate <e2>cyclic GMP-dependent protein kinase<\\e2> (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Sulindac","object":"cyclic GMP-dependent protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate <e2>GENE-N<\\e2> (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis","sentence":"Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis"}
{"PMID":16546990,"re_id":4,"annotated sentence":"<e1>Sulindac<\\e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (<e2>PKG<\\e2> ; (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Sulindac","object":"PKG","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (<e2>GENE-N<\\e2> ; (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis","sentence":"Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG ; (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis"}
{"PMID":16546990,"re_id":5,"annotated sentence":"Cotreatment with <e1>U0126<\\e1> and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, JNK, and <e2>beta-catenin<\\e2>  These results indicate that sulindac metabolites modulate ERK1\/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U0126","object":"beta-catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cotreatment with <e1>CHEMICAL<\\e1> and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, JNK, and <e2>GENE-Y<\\e2>  These results indicate that sulindac metabolites modulate ERK1\/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway","sentence":"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, JNK, and beta-catenin  These results indicate that sulindac metabolites modulate ERK1\/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway"}
{"PMID":16546990,"re_id":6,"annotated sentence":"Cotreatment with U0126 and <e1>YC-1<\\e1> synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, JNK, and <e2>beta-catenin<\\e2>  These results indicate that sulindac metabolites modulate ERK1\/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"YC-1","object":"beta-catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cotreatment with U0126 and <e1>CHEMICAL<\\e1> synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, JNK, and <e2>GENE-Y<\\e2>  These results indicate that sulindac metabolites modulate ERK1\/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway","sentence":"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, JNK, and beta-catenin  These results indicate that sulindac metabolites modulate ERK1\/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway"}
{"PMID":16546990,"re_id":7,"annotated sentence":"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of <e1>sulindac<\\e1> treatment on ERK1\/2, JNK, and <e2>beta-catenin<\\e2>  These results indicate that sulindac metabolites modulate ERK1\/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulindac","object":"beta-catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of <e1>CHEMICAL<\\e1> treatment on ERK1\/2, JNK, and <e2>GENE-Y<\\e2>  These results indicate that CHEMICAL metabolites modulate ERK1\/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of CHEMICAL is mediated by more than one pathway","sentence":"Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1\/2, JNK, and beta-catenin  These results indicate that sulindac metabolites modulate ERK1\/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway"}
{"PMID":16546990,"re_id":8,"annotated sentence":"<e1>Sulindac<\\e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate <e2>c-jun NH2-terminal kinase<\\e2> (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sulindac","object":"c-jun NH2-terminal kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate <e2>GENE-N<\\e2> (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis","sentence":"Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis"}
{"PMID":16546990,"re_id":9,"annotated sentence":"<e1>Sulindac<\\e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (<e2>JNK<\\e2> ; (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sulindac","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (<e2>GENE-N<\\e2> ; (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis","sentence":"Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK ; (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis"}
{"PMID":16546990,"re_id":10,"annotated sentence":"<e1>Sulindac<\\e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease <e2>beta-catenin<\\e2> protein expression at times and doses consistent with apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sulindac","object":"beta-catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease <e2>GENE-Y<\\e2> protein expression at times and doses consistent with apoptosis","sentence":"Sulindac metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1\/2 (ERK1\/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis"}
{"PMID":16547651,"re_id":0,"annotated sentence":"<e1>Glyphosate<\\e1> affects aromatic amino acid biosynthesis by inhibiting <e2>5-enolpyruvylshikimate-3-phosphate synthase<\\e2> (EPSPS)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Glyphosate","object":"5-enolpyruvylshikimate-3-phosphate synthase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> affects aromatic amino acid biosynthesis by inhibiting <e2>GENE-N<\\e2> (EPSPS)","sentence":"Glyphosate affects aromatic amino acid biosynthesis by inhibiting 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS)"}
{"PMID":16547651,"re_id":1,"annotated sentence":"<e1>Glyphosate<\\e1> affects aromatic amino acid biosynthesis by inhibiting 5-enolpyruvylshikimate-3-phosphate synthase (<e2>EPSPS<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Glyphosate","object":"EPSPS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> affects aromatic amino acid biosynthesis by inhibiting 5-enolpyruvylshikimate-3-phosphate synthase (<e2>GENE-N<\\e2> ","sentence":"Glyphosate affects aromatic amino acid biosynthesis by inhibiting 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS "}
{"PMID":16547651,"re_id":2,"annotated sentence":"<e1>Glufosinate<\\e1> inhibits <e2>glutamine synthetase<\\e2> and blocks biosynthesis of glutamine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Glufosinate","object":"glutamine synthetase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-N<\\e2> and blocks biosynthesis of glutamine","sentence":"Glufosinate inhibits glutamine synthetase and blocks biosynthesis of glutamine"}
{"PMID":16547651,"re_id":3,"annotated sentence":"Glufosinate inhibits <e2>glutamine synthetase<\\e2> and blocks biosynthesis of <e1>glutamine<\\e1>  AHAS gene variants that confer tolerance to AHAS inhibitors have been discovered in plants through selection or mutagenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutamine","object":"glutamine synthetase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Glufosinate inhibits <e2>CHEMICAL synthetase<\\e2> and blocks biosynthesis of <e1>CHEMICAL<\\e1>  AHAS gene variants that confer tolerance to AHAS inhibitors have been discovered in plants through selection or mutagenesis","sentence":"Glufosinate inhibits glutamine synthetase and blocks biosynthesis of glutamine  AHAS gene variants that confer tolerance to AHAS inhibitors have been discovered in plants through selection or mutagenesis"}
{"PMID":16554743,"re_id":0,"annotated sentence":"A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by <e2>NET<\\e2> inhibiting ADs such as <e1>reboxetine<\\e1>  desipramine, and imipramine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"reboxetine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A pronounced GENE-Y knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by <e2>GENE-Y<\\e2> inhibiting ADs such as <e1>CHEMICAL<\\e1>  desipramine, and imipramine","sentence":"A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET inhibiting ADs such as reboxetine  desipramine, and imipramine"}
{"PMID":16554743,"re_id":1,"annotated sentence":"A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by <e2>NET<\\e2> inhibiting ADs such as reboxetine, <e1>desipramine<\\e1>  and imipramine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"desipramine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A pronounced GENE-Y knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by <e2>GENE-Y<\\e2> inhibiting ADs such as reboxetine, <e1>CHEMICAL<\\e1>  and imipramine","sentence":"A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET inhibiting ADs such as reboxetine, desipramine  and imipramine"}
{"PMID":16554743,"re_id":2,"annotated sentence":"A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by <e2>NET<\\e2> inhibiting ADs such as reboxetine, desipramine, and <e1>imipramine<\\e1>  Citalopram, which is devoid of affinity for the NET, exerted a significant reduction of immobility time in the NET-\/- mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imipramine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A pronounced GENE-Y knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by <e2>GENE-Y<\\e2> inhibiting ADs such as reboxetine, desipramine, and <e1>CHEMICAL<\\e1>  Citalopram, which is devoid of affinity for the GENE-Y, exerted a significant reduction of immobility time in the GENE-Y-\/- mice","sentence":"A pronounced NET knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET inhibiting ADs such as reboxetine, desipramine, and imipramine  Citalopram, which is devoid of affinity for the NET, exerted a significant reduction of immobility time in the NET-\/- mice"}
{"PMID":16633143,"re_id":0,"annotated sentence":"<e1>Reboxetine<\\e1>  a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the <e2>human norepinephrine transporter<\\e2>  Inasmuch as PTSD may be associated with dysregulation of noradrenergic activity, the present double-blind randomized clinical trial intended to evaluate reboxetine's efficacy in the management of MVA-related PTSD and to compare its efficacy with a medication commonly used in PTSD, the selective serotonin reuptake inhibitor fluvoxamine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Reboxetine","object":"human norepinephrine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the <e2>GENE-Y<\\e2>  Inasmuch as PTSD may be associated with dysregulation of noradrenergic activity, the present double-blind randomized clinical trial intended to evaluate reboxetine's efficacy in the management of MVA-related PTSD and to compare its efficacy with a medication commonly used in PTSD, the selective serotonin reuptake inhibitor fluvoxamine","sentence":"Reboxetine  a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the human norepinephrine transporter  Inasmuch as PTSD may be associated with dysregulation of noradrenergic activity, the present double-blind randomized clinical trial intended to evaluate reboxetine's efficacy in the management of MVA-related PTSD and to compare its efficacy with a medication commonly used in PTSD, the selective serotonin reuptake inhibitor fluvoxamine"}
{"PMID":1663395,"re_id":0,"annotated sentence":"Evidence has accumulated in the last few years that the expression of the <e2>microsomal\/peroxidase antigen<\\e2> (M\/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular <e1>cAMP<\\e1> accumulation and protein synthesis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cAMP","object":"microsomal\/peroxidase antigen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Evidence has accumulated in the last few years that the expression of the <e2>GENE-Y<\\e2> (M\/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular <e1>CHEMICAL<\\e1> accumulation and protein synthesis","sentence":"Evidence has accumulated in the last few years that the expression of the microsomal\/peroxidase antigen (M\/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular cAMP accumulation and protein synthesis"}
{"PMID":1663395,"re_id":1,"annotated sentence":"Evidence has accumulated in the last few years that the expression of the microsomal\/peroxidase antigen (<e2>M\/TPO-Ag<\\e2>  in thyroid cells is induced by TSH, through pathways which involve intracellular <e1>cAMP<\\e1> accumulation and protein synthesis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cAMP","object":"M\/TPO-Ag","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Evidence has accumulated in the last few years that the expression of the microsomal\/peroxidase antigen (<e2>GENE-Y<\\e2>  in thyroid cells is induced by TSH, through pathways which involve intracellular <e1>CHEMICAL<\\e1> accumulation and protein synthesis","sentence":"Evidence has accumulated in the last few years that the expression of the microsomal\/peroxidase antigen (M\/TPO-Ag  in thyroid cells is induced by TSH, through pathways which involve intracellular cAMP accumulation and protein synthesis"}
{"PMID":1663395,"re_id":2,"annotated sentence":"TSH and <e1>cAMP<\\e1> also increase the levels of the specific mRNA for <e2>TPO<\\e2> in thyroid cells from different species","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cAMP","object":"TPO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TSH and <e1>CHEMICAL<\\e1> also increase the levels of the specific mRNA for <e2>GENE-Y<\\e2> in thyroid cells from different species","sentence":"TSH and cAMP also increase the levels of the specific mRNA for TPO in thyroid cells from different species"}
{"PMID":16636450,"re_id":0,"annotated sentence":"Rats were fed experimental diets containing SPI or <e2>casein<\\e2> as a <e1>nitrogen<\\e1> source","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitrogen","object":"casein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rats were fed experimental diets containing SPI or <e2>GENE-N<\\e2> as a <e1>CHEMICAL<\\e1> source","sentence":"Rats were fed experimental diets containing SPI or casein as a nitrogen source"}
{"PMID":16651698,"re_id":0,"annotated sentence":"<e1>Theophylline<\\e1> exposure resulted in a sustained increase in mRNA expression for <e2>CysS<\\e2> and PDE3A, but PDE4D gene expression was unchanged","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Theophylline","object":"CysS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> exposure resulted in a sustained increase in mRNA expression for <e2>GENE-Y<\\e2> and PDE3A, but PDE4D gene expression was unchanged","sentence":"Theophylline exposure resulted in a sustained increase in mRNA expression for CysS and PDE3A, but PDE4D gene expression was unchanged"}
{"PMID":16651698,"re_id":1,"annotated sentence":"<e1>Theophylline<\\e1> exposure resulted in a sustained increase in mRNA expression for CysS and <e2>PDE3A<\\e2>  but PDE4D gene expression was unchanged","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Theophylline","object":"PDE3A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> exposure resulted in a sustained increase in mRNA expression for CysS and <e2>GENE-Y<\\e2>  but PDE4D gene expression was unchanged","sentence":"Theophylline exposure resulted in a sustained increase in mRNA expression for CysS and PDE3A  but PDE4D gene expression was unchanged"}
{"PMID":16651698,"re_id":2,"annotated sentence":"Multiple exposure to <e1>theophylline<\\e1>  a phosphodiesterase (<e2>PDE<\\e2>  inhibitor, induces acinar hypertrophy in the salivary gland","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"theophylline","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Multiple exposure to <e1>CHEMICAL<\\e1>  a phosphodiesterase (<e2>GENE-N<\\e2>  inhibitor, induces acinar hypertrophy in the salivary gland","sentence":"Multiple exposure to theophylline  a phosphodiesterase (PDE  inhibitor, induces acinar hypertrophy in the salivary gland"}
{"PMID":16651698,"re_id":3,"annotated sentence":"Multiple exposure to <e1>theophylline<\\e1>  a <e2>phosphodiesterase<\\e2> (PDE) inhibitor, induces acinar hypertrophy in the salivary gland","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"theophylline","object":"phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Multiple exposure to <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> (PDE) inhibitor, induces acinar hypertrophy in the salivary gland","sentence":"Multiple exposure to theophylline  a phosphodiesterase (PDE) inhibitor, induces acinar hypertrophy in the salivary gland"}
{"PMID":16686685,"re_id":0,"annotated sentence":"However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and <e1>RSD1235<\\e1>  a novel mixed <e2>ion channel<\\e2> blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RSD1235","object":"ion channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and <e1>CHEMICAL<\\e1>  a novel mixed <e2>GENE-N<\\e2> blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3","sentence":"However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and RSD1235  a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3"}
{"PMID":16686685,"re_id":1,"annotated sentence":"The <e2>Na channel<\\e2> block caused by <e1>lidocaine<\\e1> and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lidocaine","object":"Na channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> block caused by <e1>CHEMICAL<\\e1> and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells","sentence":"The Na channel block caused by lidocaine and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells"}
{"PMID":16686685,"re_id":2,"annotated sentence":"The <e2>Na channel<\\e2> block caused by lidocaine and <e1>RSD1235<\\e1> can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RSD1235","object":"Na channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> block caused by lidocaine and <e1>CHEMICAL<\\e1> can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells","sentence":"The Na channel block caused by lidocaine and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells"}
{"PMID":16702329,"re_id":0,"annotated sentence":"<e1>GW9662<\\e1>  a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced <e2>iNOS<\\e2> mRNA downregulation in HD11 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GW9662","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced <e2>GENE-Y<\\e2> mRNA downregulation in HD11 cells","sentence":"GW9662  a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells"}
{"PMID":16702329,"re_id":1,"annotated sentence":"<e1>GW9662<\\e1>  a <e2>PPARgamma<\\e2> antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"GW9662","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells","sentence":"GW9662  a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells"}
{"PMID":16730121,"re_id":0,"annotated sentence":"Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (<e1>ramelteon<\\e1>  TAK-375), a selective <e2>MT1\/MT2 receptor<\\e2> agonist, on motor coordination was studied using rota-rod performance in mice","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ramelteon","object":"MT1\/MT2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (<e1>CHEMICAL<\\e1>  TAK-375), a selective <e2>GENE-N<\\e2> agonist, on motor coordination was studied using rota-rod performance in mice","sentence":"Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon  TAK-375), a selective MT1\/MT2 receptor agonist, on motor coordination was studied using rota-rod performance in mice"}
{"PMID":16730121,"re_id":1,"annotated sentence":"Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon, <e1>TAK-375<\\e1> , a selective <e2>MT1\/MT2 receptor<\\e2> agonist, on motor coordination was studied using rota-rod performance in mice","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"TAK-375","object":"MT1\/MT2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon, <e1>CHEMICAL<\\e1> , a selective <e2>GENE-N<\\e2> agonist, on motor coordination was studied using rota-rod performance in mice","sentence":"Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon, TAK-375 , a selective MT1\/MT2 receptor agonist, on motor coordination was studied using rota-rod performance in mice"}
{"PMID":16730121,"re_id":2,"annotated sentence":"Effect of <e1>ramelteon<\\e1> (TAK-375), a selective <e2>MT1\/MT2 receptor<\\e2> agonist, on motor performance in mice","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ramelteon","object":"MT1\/MT2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effect of <e1>CHEMICAL<\\e1> (TAK-375), a selective <e2>GENE-N<\\e2> agonist, on motor performance in mice","sentence":"Effect of ramelteon (TAK-375), a selective MT1\/MT2 receptor agonist, on motor performance in mice"}
{"PMID":16730121,"re_id":3,"annotated sentence":"Effect of ramelteon (<e1>TAK-375<\\e1> , a selective <e2>MT1\/MT2 receptor<\\e2> agonist, on motor performance in mice","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"TAK-375","object":"MT1\/MT2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effect of ramelteon (<e1>CHEMICAL<\\e1> , a selective <e2>GENE-N<\\e2> agonist, on motor performance in mice","sentence":"Effect of ramelteon (TAK-375 , a selective MT1\/MT2 receptor agonist, on motor performance in mice"}
{"PMID":16730121,"re_id":4,"annotated sentence":"Effect of <e1>(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide<\\e1> (ramelteon, TAK-375), a selective <e2>MT1\/MT2 receptor<\\e2> agonist, on motor coordination was studied using rota-rod performance in mice","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide","object":"MT1\/MT2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effect of <e1>CHEMICAL<\\e1> (ramelteon, TAK-375), a selective <e2>GENE-N<\\e2> agonist, on motor coordination was studied using rota-rod performance in mice","sentence":"Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon, TAK-375), a selective MT1\/MT2 receptor agonist, on motor coordination was studied using rota-rod performance in mice"}
{"PMID":16757355,"re_id":0,"annotated sentence":"<e1>Sorafenib<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and <e2>tyrosine kinases<\\e2> VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and <e2>GENE-N<\\e2> VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":1,"annotated sentence":"<e1>Sorafenib<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases <e2>VEGFR<\\e2> PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases <e2>GENE-N<\\e2> PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":2,"annotated sentence":"<e1>Sorafenib<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/<e2>PDGFR<\\e2> in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"PDGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/<e2>GENE-N<\\e2> in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":3,"annotated sentence":"<e1>Sorafenib<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets <e2>RAF<\\e2> MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"RAF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets <e2>GENE-N<\\e2> MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":4,"annotated sentence":"<e1>Sorafenib<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/<e2>MEK<\\e2> ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"MEK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/<e2>GENE-N<\\e2> ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":5,"annotated sentence":"<e1>Sorafenib<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/<e2>ERK<\\e2> pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/<e2>GENE-N<\\e2> pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":6,"annotated sentence":"Sorafenib (<e1>BAY 43-9006<\\e1>  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and <e2>tyrosine kinases<\\e2> VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BAY 43-9006","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (<e1>CHEMICAL<\\e1>  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and <e2>GENE-N<\\e2> VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":7,"annotated sentence":"Sorafenib (<e1>BAY 43-9006<\\e1>  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases <e2>VEGFR<\\e2> PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BAY 43-9006","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (<e1>CHEMICAL<\\e1>  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases <e2>GENE-N<\\e2> PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":8,"annotated sentence":"Sorafenib (<e1>BAY 43-9006<\\e1>  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/<e2>PDGFR<\\e2> in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BAY 43-9006","object":"PDGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (<e1>CHEMICAL<\\e1>  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/<e2>GENE-N<\\e2> in tumor vasculature","sentence":"Sorafenib (BAY 43-9006  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":9,"annotated sentence":"Sorafenib (<e1>BAY 43-9006<\\e1>  Nexavar), a dual-action inhibitor that targets <e2>RAF<\\e2> MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BAY 43-9006","object":"RAF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (<e1>CHEMICAL<\\e1>  Nexavar), a dual-action inhibitor that targets <e2>GENE-N<\\e2> MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006  Nexavar), a dual-action inhibitor that targets RAF MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":10,"annotated sentence":"Sorafenib (<e1>BAY 43-9006<\\e1>  Nexavar), a dual-action inhibitor that targets RAF\/<e2>MEK<\\e2> ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BAY 43-9006","object":"MEK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (<e1>CHEMICAL<\\e1>  Nexavar), a dual-action inhibitor that targets RAF\/<e2>GENE-N<\\e2> ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006  Nexavar), a dual-action inhibitor that targets RAF\/MEK ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":11,"annotated sentence":"Sorafenib (<e1>BAY 43-9006<\\e1>  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/<e2>ERK<\\e2> pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BAY 43-9006","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (<e1>CHEMICAL<\\e1>  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/<e2>GENE-N<\\e2> pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006  Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":12,"annotated sentence":"Sorafenib (BAY 43-9006, <e1>Nexavar<\\e1> , a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and <e2>tyrosine kinases<\\e2> VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nexavar","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (BAY 43-9006, <e1>CHEMICAL<\\e1> , a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and <e2>GENE-N<\\e2> VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar , a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":13,"annotated sentence":"Sorafenib (BAY 43-9006, <e1>Nexavar<\\e1> , a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases <e2>VEGFR<\\e2> PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nexavar","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (BAY 43-9006, <e1>CHEMICAL<\\e1> , a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases <e2>GENE-N<\\e2> PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar , a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":14,"annotated sentence":"Sorafenib (BAY 43-9006, <e1>Nexavar<\\e1> , a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/<e2>PDGFR<\\e2> in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nexavar","object":"PDGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (BAY 43-9006, <e1>CHEMICAL<\\e1> , a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/<e2>GENE-N<\\e2> in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar , a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":15,"annotated sentence":"Sorafenib (BAY 43-9006, <e1>Nexavar<\\e1> , a dual-action inhibitor that targets <e2>RAF<\\e2> MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nexavar","object":"RAF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (BAY 43-9006, <e1>CHEMICAL<\\e1> , a dual-action inhibitor that targets <e2>GENE-N<\\e2> MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar , a dual-action inhibitor that targets RAF MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":16,"annotated sentence":"Sorafenib (BAY 43-9006, <e1>Nexavar<\\e1> , a dual-action inhibitor that targets RAF\/<e2>MEK<\\e2> ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nexavar","object":"MEK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (BAY 43-9006, <e1>CHEMICAL<\\e1> , a dual-action inhibitor that targets RAF\/<e2>GENE-N<\\e2> ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar , a dual-action inhibitor that targets RAF\/MEK ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":17,"annotated sentence":"Sorafenib (BAY 43-9006, <e1>Nexavar<\\e1> , a dual-action inhibitor that targets RAF\/MEK\/<e2>ERK<\\e2> pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nexavar","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (BAY 43-9006, <e1>CHEMICAL<\\e1> , a dual-action inhibitor that targets RAF\/MEK\/<e2>GENE-N<\\e2> pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","sentence":"Sorafenib (BAY 43-9006, Nexavar , a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature"}
{"PMID":16757355,"re_id":18,"annotated sentence":"Further characterization of <e1>sorafenib<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the <e2>vascular endothelial growth factor receptor<\\e2> family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"vascular endothelial growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further characterization of <e1>CHEMICAL<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the <e2>GENE-N<\\e2> family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis","sentence":"Further characterization of sorafenib revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis"}
{"PMID":16757355,"re_id":19,"annotated sentence":"Further characterization of <e1>sorafenib<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (<e2>VEGFR-2<\\e2> and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"VEGFR-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further characterization of <e1>CHEMICAL<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (<e2>GENE-Y<\\e2> and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis","sentence":"Further characterization of sorafenib revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis"}
{"PMID":16757355,"re_id":20,"annotated sentence":"Further characterization of <e1>sorafenib<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and <e2>VEGFR-3<\\e2>  and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"VEGFR-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further characterization of <e1>CHEMICAL<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and <e2>GENE-Y<\\e2>  and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis","sentence":"Further characterization of sorafenib revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3  and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis"}
{"PMID":16757355,"re_id":21,"annotated sentence":"Further characterization of <e1>sorafenib<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and <e2>platelet-derived growth factor receptor<\\e2> family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"platelet-derived growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further characterization of <e1>CHEMICAL<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and <e2>GENE-N<\\e2> family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis","sentence":"Further characterization of sorafenib revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis"}
{"PMID":16757355,"re_id":22,"annotated sentence":"Further characterization of <e1>sorafenib<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (<e2>PDGFR-beta<\\e2> and Kit), which play key roles in tumor progression and angiogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"PDGFR-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further characterization of <e1>CHEMICAL<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (<e2>GENE-Y<\\e2> and Kit), which play key roles in tumor progression and angiogenesis","sentence":"Further characterization of sorafenib revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis"}
{"PMID":16757355,"re_id":23,"annotated sentence":"Further characterization of <e1>sorafenib<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and <e2>Kit<\\e2> , which play key roles in tumor progression and angiogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"Kit","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further characterization of <e1>CHEMICAL<\\e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and <e2>GENE-Y<\\e2> , which play key roles in tumor progression and angiogenesis","sentence":"Further characterization of sorafenib revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit , which play key roles in tumor progression and angiogenesis"}
{"PMID":16757355,"re_id":24,"annotated sentence":"Thus, <e1>sorafenib<\\e1> may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of <e2>Raf<\\e2> and Kit signaling) and\/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"Raf","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, <e1>CHEMICAL<\\e1> may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of <e2>GENE-N<\\e2> and Kit signaling) and\/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)","sentence":"Thus, sorafenib may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and\/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)"}
{"PMID":16757355,"re_id":25,"annotated sentence":"Thus, <e1>sorafenib<\\e1> may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and <e2>Kit<\\e2> signaling) and\/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"Kit","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and <e2>GENE-Y<\\e2> signaling) and\/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)","sentence":"Thus, sorafenib may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and\/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)"}
{"PMID":16757355,"re_id":26,"annotated sentence":"Thus, <e1>sorafenib<\\e1> may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and\/or on tumor angiogenesis (through inhibition of <e2>VEGFR<\\e2> and PDGFR signaling)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, <e1>CHEMICAL<\\e1> may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and\/or on tumor angiogenesis (through inhibition of <e2>GENE-N<\\e2> and PDGFR signaling)","sentence":"Thus, sorafenib may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and\/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)"}
{"PMID":16757355,"re_id":27,"annotated sentence":"Thus, <e1>sorafenib<\\e1> may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and\/or on tumor angiogenesis (through inhibition of VEGFR and <e2>PDGFR<\\e2> signaling)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"PDGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, <e1>CHEMICAL<\\e1> may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and\/or on tumor angiogenesis (through inhibition of VEGFR and <e2>GENE-N<\\e2> signaling)","sentence":"Thus, sorafenib may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and\/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)"}
{"PMID":16757355,"re_id":28,"annotated sentence":"A novel class of <e1>biaryl urea<\\e1> that inhibits <e2>C-RAF<\\e2> kinase was discovered using a combination of medicinal and combinatorial chemistry approaches","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"biaryl urea","object":"C-RAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A novel class of <e1>CHEMICAL<\\e1> that inhibits <e2>GENE-Y<\\e2> kinase was discovered using a combination of medicinal and combinatorial chemistry approaches","sentence":"A novel class of biaryl urea that inhibits C-RAF kinase was discovered using a combination of medicinal and combinatorial chemistry approaches"}
{"PMID":16757355,"re_id":29,"annotated sentence":"A novel class of <e1>biaryl urea<\\e1> that inhibits C-RAF <e2>kinase<\\e2> was discovered using a combination of medicinal and combinatorial chemistry approaches","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"biaryl urea","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A novel class of <e1>CHEMICAL<\\e1> that inhibits C-RAF <e2>GENE-N<\\e2> was discovered using a combination of medicinal and combinatorial chemistry approaches","sentence":"A novel class of biaryl urea that inhibits C-RAF kinase was discovered using a combination of medicinal and combinatorial chemistry approaches"}
{"PMID":16757355,"re_id":30,"annotated sentence":"<e1>Sorafenib<\\e1> inhibited the <e2>kinase<\\e2> activity of both C-RAF and B-RAF (wild type and V600E mutant)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the <e2>GENE-N<\\e2> activity of both C-RAF and B-RAF (wild type and V600E mutant)","sentence":"Sorafenib inhibited the kinase activity of both C-RAF and B-RAF (wild type and V600E mutant)"}
{"PMID":16757355,"re_id":31,"annotated sentence":"<e1>Sorafenib<\\e1> inhibited the kinase activity of both <e2>C-RAF<\\e2> and B-RAF (wild type and V600E mutant)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"C-RAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the kinase activity of both <e2>GENE-Y<\\e2> and B-RAF (wild type and V600E mutant)","sentence":"Sorafenib inhibited the kinase activity of both C-RAF and B-RAF (wild type and V600E mutant)"}
{"PMID":16757355,"re_id":32,"annotated sentence":"<e1>Sorafenib<\\e1> inhibited the kinase activity of both C-RAF and <e2>B-RAF<\\e2> (wild type and V600E mutant)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"B-RAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the kinase activity of both C-RAF and <e2>GENE-Y<\\e2> (wild type and V600E mutant)","sentence":"Sorafenib inhibited the kinase activity of both C-RAF and B-RAF (wild type and V600E mutant)"}
{"PMID":16757355,"re_id":33,"annotated sentence":"<e1>Sorafenib<\\e1> inhibited the kinase activity of both C-RAF and B-RAF (wild type and <e2>V600E<\\e2> mutant)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sorafenib","object":"V600E","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the kinase activity of both C-RAF and B-RAF (wild type and <e2>GENE-N<\\e2> mutant)","sentence":"Sorafenib inhibited the kinase activity of both C-RAF and B-RAF (wild type and V600E mutant)"}
{"PMID":16766717,"re_id":0,"annotated sentence":"In the present study, we have evaluated possible participation of <e2>monocarboxylate transporters<\\e2> (MCTs) responsible for the bidirectional membrane transport of <e1>pyruvate<\\e1> in the cytoprotective property in osteoblasts","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyruvate","object":"monocarboxylate transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, we have evaluated possible participation of <e2>GENE-N<\\e2> (MCTs) responsible for the bidirectional membrane transport of <e1>CHEMICAL<\\e1> in the cytoprotective property in osteoblasts","sentence":"In the present study, we have evaluated possible participation of monocarboxylate transporters (MCTs) responsible for the bidirectional membrane transport of pyruvate in the cytoprotective property in osteoblasts"}
{"PMID":16766717,"re_id":1,"annotated sentence":"In the present study, we have evaluated possible participation of monocarboxylate transporters (<e2>MCTs<\\e2>  responsible for the bidirectional membrane transport of <e1>pyruvate<\\e1> in the cytoprotective property in osteoblasts","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyruvate","object":"MCTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, we have evaluated possible participation of monocarboxylate transporters (<e2>GENE-N<\\e2>  responsible for the bidirectional membrane transport of <e1>CHEMICAL<\\e1> in the cytoprotective property in osteoblasts","sentence":"In the present study, we have evaluated possible participation of monocarboxylate transporters (MCTs  responsible for the bidirectional membrane transport of pyruvate in the cytoprotective property in osteoblasts"}
{"PMID":16789740,"re_id":0,"annotated sentence":"Discovery and optimization of <e1>anthranilic acid sulfonamides<\\e1> as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of <e2>albumin<\\e2> binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"anthranilic acid sulfonamides","object":"albumin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery and optimization of <e1>CHEMICAL<\\e1> as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of <e2>GENE-Y<\\e2> binding","sentence":"Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding"}
{"PMID":16801455,"re_id":0,"annotated sentence":"When HUVECs were stimulated by thrombin without extracellular L-arginine, <e1>Nor-NOHA<\\e1> dose-dependently increased the <e2>NOS<\\e2> activity and the NO release with maximal effects at 20 microM","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Nor-NOHA","object":"NOS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When HUVECs were stimulated by thrombin without extracellular L-arginine, <e1>CHEMICAL<\\e1> dose-dependently increased the <e2>GENE-N<\\e2> activity and the NO release with maximal effects at 20 microM","sentence":"When HUVECs were stimulated by thrombin without extracellular L-arginine, Nor-NOHA dose-dependently increased the NOS activity and the NO release with maximal effects at 20 microM"}
{"PMID":16801455,"re_id":1,"annotated sentence":"Extracellular <e1>L-arginine<\\e1> also dose-dependently increased NO release and <e2>arginase<\\e2> activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"L-arginine","object":"arginase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Extracellular <e1>CHEMICAL<\\e1> also dose-dependently increased NO release and <e2>GENE-N<\\e2> activity","sentence":"Extracellular L-arginine also dose-dependently increased NO release and arginase activity"}
{"PMID":16801455,"re_id":2,"annotated sentence":"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive <e2>arginase<\\e2> inhibitor <e1>N(omega)-hydroxy-nor-L-arginine<\\e1> (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N(omega)-hydroxy-nor-L-arginine","object":"arginase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To determine whether GENE-Ns modulate the endothelial NO synthesis, we investigated the effects of the competitive <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (Nor-NOHA) on the activity of NOS, GENE-Ns, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)","sentence":"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)"}
{"PMID":16801455,"re_id":3,"annotated sentence":"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive <e2>arginase<\\e2> inhibitor N(omega)-hydroxy-nor-L-arginine (<e1>Nor-NOHA<\\e1>  on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nor-NOHA","object":"arginase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To determine whether GENE-Ns modulate the endothelial NO synthesis, we investigated the effects of the competitive <e2>GENE-N<\\e2> inhibitor N(omega)-hydroxy-nor-L-arginine (<e1>CHEMICAL<\\e1>  on the activity of NOS, GENE-Ns, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)","sentence":"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA  on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)"}
{"PMID":16801455,"re_id":4,"annotated sentence":"In unstimulated cells, <e1>Nor-NOHA<\\e1> dose-dependently reduced the <e2>arginase<\\e2> activity with maximal inhibition at 20 microM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nor-NOHA","object":"arginase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In unstimulated cells, <e1>CHEMICAL<\\e1> dose-dependently reduced the <e2>GENE-N<\\e2> activity with maximal inhibition at 20 microM","sentence":"In unstimulated cells, Nor-NOHA dose-dependently reduced the arginase activity with maximal inhibition at 20 microM"}
{"PMID":16801455,"re_id":5,"annotated sentence":"However, despite activation of L-arginine uptake, the inhibition of <e2>arginase<\\e2> activity by <e1>Nor-NOHA<\\e1> was still significant","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nor-NOHA","object":"arginase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, despite activation of L-arginine uptake, the inhibition of <e2>GENE-N<\\e2> activity by <e1>CHEMICAL<\\e1> was still significant","sentence":"However, despite activation of L-arginine uptake, the inhibition of arginase activity by Nor-NOHA was still significant"}
{"PMID":16801455,"re_id":6,"annotated sentence":"These data suggest that endothelial <e1>NO<\\e1> synthesis depends on the activity of <e2>arginase II<\\e2> in mitochondria and l-arginine carriers in cell membrane.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"arginase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that endothelial <e1>CHEMICAL<\\e1> synthesis depends on the activity of <e2>GENE-Y<\\e2> in mitochondria and l-arginine carriers in cell membrane.","sentence":"These data suggest that endothelial NO synthesis depends on the activity of arginase II in mitochondria and l-arginine carriers in cell membrane."}
{"PMID":16801455,"re_id":7,"annotated sentence":"Reduced synthesis of <e1>nitric oxide<\\e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of <e2>constitutive nitric-oxide synthase<\\e2> (NOS) and cytosolic arginase I and mitochondrial arginase II","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitric oxide","object":"constitutive nitric-oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reduced synthesis of <e1>CHEMICAL<\\e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of <e2>GENE-Y<\\e2> (NOS) and cytosolic arginase I and mitochondrial arginase II","sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial arginase II"}
{"PMID":16801455,"re_id":8,"annotated sentence":"Reduced synthesis of <e1>nitric oxide<\\e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (<e2>NOS<\\e2>  and cytosolic arginase I and mitochondrial arginase II","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitric oxide","object":"NOS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Reduced synthesis of <e1>CHEMICAL<\\e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (<e2>GENE-N<\\e2>  and cytosolic arginase I and mitochondrial arginase II","sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS  and cytosolic arginase I and mitochondrial arginase II"}
{"PMID":16801455,"re_id":9,"annotated sentence":"Reduced synthesis of <e1>nitric oxide<\\e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic <e2>arginase I<\\e2> and mitochondrial arginase II","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitric oxide","object":"arginase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reduced synthesis of <e1>CHEMICAL<\\e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic <e2>GENE-Y<\\e2> and mitochondrial GENE-YI","sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial arginase II"}
{"PMID":16801455,"re_id":10,"annotated sentence":"Reduced synthesis of <e1>nitric oxide<\\e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and <e2>mitochondrial arginase II<\\e2>  To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitric oxide","object":"mitochondrial arginase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reduced synthesis of <e1>CHEMICAL<\\e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and <e2>GENE-Y<\\e2>  To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)","sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial arginase II  To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)"}
{"PMID":16801455,"re_id":11,"annotated sentence":"To determine whether <e2>arginases<\\e2> modulate the endothelial <e1>NO<\\e1> synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"arginases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To determine whether <e2>GENE-N<\\e2> modulate the endothelial <e1>CHEMICAL<\\e1> synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-CHEMICALHA) on the activity of CHEMICALS, GENE-N, and L-arginine transporter and on CHEMICAL release at surface of human umbilical vein endothelial cells (HUVECs)","sentence":"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)"}
{"PMID":16801455,"re_id":12,"annotated sentence":"Reduced synthesis of nitric oxide (<e1>NO<\\e1>  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of <e2>constitutive nitric-oxide synthase<\\e2> (NOS) and cytosolic arginase I and mitochondrial arginase II","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"constitutive nitric-oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reduced synthesis of nitric oxide (<e1>CHEMICAL<\\e1>  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of <e2>GENE-Y<\\e2> (CHEMICALS) and cytosolic arginase I and mitochondrial arginase II","sentence":"Reduced synthesis of nitric oxide (NO  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial arginase II"}
{"PMID":16801455,"re_id":13,"annotated sentence":"Reduced synthesis of nitric oxide (<e1>NO<\\e1>  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (<e2>NOS<\\e2>  and cytosolic arginase I and mitochondrial arginase II","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"NOS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Reduced synthesis of nitric oxide (<e1>CHEMICAL<\\e1>  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (<e2>CHEMICALS<\\e2>  and cytosolic arginase I and mitochondrial arginase II","sentence":"Reduced synthesis of nitric oxide (NO  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS  and cytosolic arginase I and mitochondrial arginase II"}
{"PMID":16801455,"re_id":14,"annotated sentence":"Reduced synthesis of nitric oxide (<e1>NO<\\e1>  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic <e2>arginase I<\\e2> and mitochondrial arginase II","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"arginase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reduced synthesis of nitric oxide (<e1>CHEMICAL<\\e1>  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (CHEMICALS) and cytosolic <e2>GENE-Y<\\e2> and mitochondrial GENE-YI","sentence":"Reduced synthesis of nitric oxide (NO  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial arginase II"}
{"PMID":16801455,"re_id":15,"annotated sentence":"Reduced synthesis of nitric oxide (<e1>NO<\\e1>  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and <e2>mitochondrial arginase II<\\e2>  To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"mitochondrial arginase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reduced synthesis of nitric oxide (<e1>CHEMICAL<\\e1>  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (CHEMICALS) and cytosolic arginase I and <e2>GENE-Y<\\e2>  To determine whether arginases modulate the endothelial CHEMICAL synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-CHEMICALHA) on the activity of CHEMICALS, arginases, and L-arginine transporter and on CHEMICAL release at surface of human umbilical vein endothelial cells (HUVECs)","sentence":"Reduced synthesis of nitric oxide (NO  contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial arginase II  To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)"}
{"PMID":16801455,"re_id":16,"annotated sentence":"<e2>Mitochondrial arginase II<\\e2> modulates <e1>nitric-oxide<\\e1> synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"nitric-oxide","object":"Mitochondrial arginase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> modulates <e1>CHEMICAL<\\e1> synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells","sentence":"Mitochondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells"}
{"PMID":16801455,"re_id":17,"annotated sentence":"<e2>Mitochondrial arginase II<\\e2> modulates nitric-oxide synthesis through nonfreely exchangeable <e1>L-arginine<\\e1> pools in human endothelial cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-arginine","object":"Mitochondrial arginase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> modulates nitric-oxide synthesis through nonfreely exchangeable <e1>CHEMICAL<\\e1> pools in human endothelial cells","sentence":"Mitochondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells"}
{"PMID":16801455,"re_id":18,"annotated sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>L-arginine<\\e1>  the common substrate of <e2>constitutive nitric-oxide synthase<\\e2> (NOS) and cytosolic arginase I and mitochondrial arginase II","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-arginine","object":"constitutive nitric-oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>CHEMICAL<\\e1>  the common substrate of <e2>GENE-Y<\\e2> (NOS) and cytosolic arginase I and mitochondrial arginase II","sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine  the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial arginase II"}
{"PMID":16801455,"re_id":19,"annotated sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>L-arginine<\\e1>  the common substrate of constitutive nitric-oxide synthase (<e2>NOS<\\e2>  and cytosolic arginase I and mitochondrial arginase II","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-arginine","object":"NOS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>CHEMICAL<\\e1>  the common substrate of constitutive nitric-oxide synthase (<e2>GENE-N<\\e2>  and cytosolic arginase I and mitochondrial arginase II","sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine  the common substrate of constitutive nitric-oxide synthase (NOS  and cytosolic arginase I and mitochondrial arginase II"}
{"PMID":16801455,"re_id":20,"annotated sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>L-arginine<\\e1>  the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic <e2>arginase I<\\e2> and mitochondrial arginase II","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-arginine","object":"arginase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>CHEMICAL<\\e1>  the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic <e2>GENE-Y<\\e2> and mitochondrial GENE-YI","sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine  the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial arginase II"}
{"PMID":16801455,"re_id":21,"annotated sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>L-arginine<\\e1>  the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and <e2>mitochondrial arginase II<\\e2>  To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-arginine","object":"mitochondrial arginase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>CHEMICAL<\\e1>  the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and <e2>GENE-Y<\\e2>  To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-CHEMICAL (Nor-NOHA) on the activity of NOS, arginases, and CHEMICAL transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)","sentence":"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine  the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial arginase II  To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)"}
{"PMID":1680855,"re_id":0,"annotated sentence":"These G-proteins are likely to be involved in the adrenaline-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the <e1>adrenaline<\\e1> induced inhibition of <e2>insulin<\\e2> secretion.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"adrenaline","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These G-proteins are likely to be involved in the CHEMICAL-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the <e1>CHEMICAL<\\e1> induced inhibition of <e2>GENE-Y<\\e2> secretion.","sentence":"These G-proteins are likely to be involved in the adrenaline-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the adrenaline induced inhibition of insulin secretion."}
{"PMID":1680855,"re_id":1,"annotated sentence":"<e1>Somatostatin<\\e1> which also inhibits <e2>insulin<\\e2> secretion was less efficient (inhibition by 20%)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Somatostatin","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> which also inhibits <e2>GENE-Y<\\e2> secretion was less efficient (inhibition by 20%)","sentence":"Somatostatin which also inhibits insulin secretion was less efficient (inhibition by 20%)"}
{"PMID":1680855,"re_id":2,"annotated sentence":"<e1>Adrenaline<\\e1> inhibits <e2>insulin<\\e2> secretion via pertussis toxin-sensitive mechanisms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Adrenaline","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> secretion via pertussis toxin-sensitive mechanisms","sentence":"Adrenaline inhibits insulin secretion via pertussis toxin-sensitive mechanisms"}
{"PMID":1680855,"re_id":3,"annotated sentence":"In contrast to <e1>adrenaline<\\e1> and somatostatin, galanin, another inhibitor of <e2>insulin<\\e2> secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"adrenaline","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast to <e1>CHEMICAL<\\e1> and somatostatin, galanin, another inhibitor of <e2>GENE-Y<\\e2> secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner","sentence":"In contrast to adrenaline and somatostatin, galanin, another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner"}
{"PMID":1680855,"re_id":4,"annotated sentence":"In contrast to adrenaline and <e1>somatostatin<\\e1>  galanin, another inhibitor of <e2>insulin<\\e2> secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"somatostatin","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast to adrenaline and <e1>CHEMICAL<\\e1>  galanin, another inhibitor of <e2>GENE-Y<\\e2> secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner","sentence":"In contrast to adrenaline and somatostatin  galanin, another inhibitor of insulin secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner"}
{"PMID":16835395,"re_id":0,"annotated sentence":"Epididymal tissue from wild-type mice responded in vitro to <e1>noradrenaline<\\e1> and isoprenaline with increased glycerol release, reduced <e2>IL-6<\\e2> release, and increased cAMP accumulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"noradrenaline","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Epididymal tissue from wild-type mice responded in vitro to <e1>CHEMICAL<\\e1> and isoprenaline with increased glycerol release, reduced <e2>GENE-Y<\\e2> release, and increased cAMP accumulation","sentence":"Epididymal tissue from wild-type mice responded in vitro to noradrenaline and isoprenaline with increased glycerol release, reduced IL-6 release, and increased cAMP accumulation"}
{"PMID":16835395,"re_id":1,"annotated sentence":"Epididymal tissue from wild-type mice responded in vitro to noradrenaline and <e1>isoprenaline<\\e1> with increased glycerol release, reduced <e2>IL-6<\\e2> release, and increased cAMP accumulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"isoprenaline","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Epididymal tissue from wild-type mice responded in vitro to noradrenaline and <e1>CHEMICAL<\\e1> with increased glycerol release, reduced <e2>GENE-Y<\\e2> release, and increased cAMP accumulation","sentence":"Epididymal tissue from wild-type mice responded in vitro to noradrenaline and isoprenaline with increased glycerol release, reduced IL-6 release, and increased cAMP accumulation"}
{"PMID":16846546,"re_id":0,"annotated sentence":"Comparison of <e2>cyclooxygenase<\\e2> inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and <e1>bromfenac sodium<\\e1>  OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bromfenac sodium","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of <e2>GENE-N<\\e2> inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and <e1>CHEMICAL<\\e1>  OBJECTIVE: To compare the GENE-N (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and CHEMICAL (bromfenac)","sentence":"Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium  OBJECTIVE: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac)"}
{"PMID":16846546,"re_id":1,"annotated sentence":"Comparison of <e2>cyclooxygenase<\\e2> inhibitory activity and ocular anti-inflammatory effects of <e1>ketorolac tromethamine<\\e1> and bromfenac sodium","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ketorolac tromethamine","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of <e2>GENE-N<\\e2> inhibitory activity and ocular anti-inflammatory effects of <e1>CHEMICAL<\\e1> and bromfenac sodium","sentence":"Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium"}
{"PMID":16846546,"re_id":2,"annotated sentence":"RESULTS: <e1>Ketorolac<\\e1> was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against <e2>COX-2<\\e2> (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ketorolac","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> was six times more active against COX-1 (IC(50) = 0.02 microM) than GENE-Y (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against <e2>GENE-Y<\\e2> (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)","sentence":"RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)"}
{"PMID":16846546,"re_id":3,"annotated sentence":"RESULTS: <e1>Ketorolac<\\e1> was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than <e2>COX-1<\\e2> (IC(50) = 0.210 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ketorolac","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> was six times more active against GENE-Y (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than <e2>GENE-Y<\\e2> (IC(50) = 0.210 microM)","sentence":"RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)"}
{"PMID":16846546,"re_id":4,"annotated sentence":"RESULTS: Ketorolac was six times more active against <e2>COX-1<\\e2> (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while <e1>bromfenac<\\e1> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bromfenac","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Ketorolac was six times more active against <e2>GENE-Y<\\e2> (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while <e1>CHEMICAL<\\e1> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than GENE-Y (IC(50) = 0.210 microM)","sentence":"RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)"}
{"PMID":16846546,"re_id":5,"annotated sentence":"RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than <e2>COX-2<\\e2> (IC(50) = 0.12 microM) while <e1>bromfenac<\\e1> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bromfenac","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than <e2>GENE-Y<\\e2> (IC(50) = 0.12 microM) while <e1>CHEMICAL<\\e1> was approximately 32 times more active against GENE-Y (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)","sentence":"RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)"}
{"PMID":16846546,"re_id":6,"annotated sentence":"METHODS: <e2>Cyclooxygenase<\\e2> activity and selectivity was determined in vitro by measuring <e1>prostaglandin E(2)<\\e1> (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin E(2)","object":"Cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"METHODS: <e2>GENE-N<\\e2> activity and selectivity was determined in vitro by measuring <e1>CHEMICAL<\\e1> (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid","sentence":"METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid"}
{"PMID":16846546,"re_id":7,"annotated sentence":"METHODS: <e2>Cyclooxygenase<\\e2> activity and selectivity was determined in vitro by measuring prostaglandin E(2) (<e1>PGE(2)<\\e1>  production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE(2)","object":"Cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"METHODS: <e2>GENE-N<\\e2> activity and selectivity was determined in vitro by measuring prostaglandin E(2) (<e1>CHEMICAL<\\e1>  production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid","sentence":"METHODS: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E(2) (PGE(2)  production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid"}
{"PMID":16851960,"re_id":0,"annotated sentence":"Density functional theory calculations using the hybrid functional B3LYP have been performed to study the <e1>methyl<\\e1> transfer step in <e2>glycine N-methyltransferase<\\e2> (GNMT)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methyl","object":"glycine N-methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Density functional theory calculations using the hybrid functional B3LYP have been performed to study the <e1>CHEMICAL<\\e1> transfer step in <e2>glycine N-CHEMICALtransferase<\\e2> (GNMT)","sentence":"Density functional theory calculations using the hybrid functional B3LYP have been performed to study the methyl transfer step in glycine N-methyltransferase (GNMT)"}
{"PMID":16851960,"re_id":1,"annotated sentence":"Density functional theory calculations using the hybrid functional B3LYP have been performed to study the <e1>methyl<\\e1> transfer step in glycine N-methyltransferase (<e2>GNMT<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methyl","object":"GNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Density functional theory calculations using the hybrid functional B3LYP have been performed to study the <e1>CHEMICAL<\\e1> transfer step in glycine N-CHEMICALtransferase (<e2>GENE-Y<\\e2> ","sentence":"Density functional theory calculations using the hybrid functional B3LYP have been performed to study the methyl transfer step in glycine N-methyltransferase (GNMT "}
{"PMID":16851960,"re_id":2,"annotated sentence":"The starting point for the calculations is the recent X-ray crystal structure of <e2>GNMT<\\e2> complexed with <e1>SAM<\\e1> and acetate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"SAM","object":"GNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The starting point for the calculations is the recent X-ray crystal structure of <e2>GENE-Y<\\e2> complexed with <e1>CHEMICAL<\\e1> and acetate","sentence":"The starting point for the calculations is the recent X-ray crystal structure of GNMT complexed with SAM and acetate"}
{"PMID":16855178,"re_id":0,"annotated sentence":"In healthy rats, <e1>ATB-429<\\e1> dose dependently (25, 50, or 100 mg\/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal <e2>c-FOS<\\e2> mRNA, whereas mesalamine had no effect","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATB-429","object":"c-FOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In healthy rats, <e1>CHEMICAL<\\e1> dose dependently (25, 50, or 100 mg\/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal <e2>GENE-Y<\\e2> mRNA, whereas mesalamine had no effect","sentence":"In healthy rats, ATB-429 dose dependently (25, 50, or 100 mg\/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal c-FOS mRNA, whereas mesalamine had no effect"}
{"PMID":16855178,"re_id":1,"annotated sentence":"ATB-429-induced antinociception was reversed by <e1>glibenclamide<\\e1>  a <e2>ATP-sensitive K(+) (K(ATP)) channel<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glibenclamide","object":"ATP-sensitive K(+) (K(ATP)) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"ATB-429-induced antinociception was reversed by <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> inhibitor","sentence":"ATB-429-induced antinociception was reversed by glibenclamide  a ATP-sensitive K(+) (K(ATP)) channel inhibitor"}
{"PMID":16855178,"re_id":2,"annotated sentence":"Colonic <e2>cyclooxygenase-2<\\e2> and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by <e1>ATB-429<\\e1>  but not by mesalamine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATB-429","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Colonic <e2>GENE-Y<\\e2> and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by <e1>CHEMICAL<\\e1>  but not by mesalamine","sentence":"Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429  but not by mesalamine"}
{"PMID":16855178,"re_id":3,"annotated sentence":"Colonic cyclooxygenase-2 and <e2>interkeukin-1beta<\\e2> mRNA and spinal c-FOS mRNA expression were significantly down-regulated by <e1>ATB-429<\\e1>  but not by mesalamine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATB-429","object":"interkeukin-1beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Colonic cyclooxygenase-2 and <e2>GENE-Y<\\e2> mRNA and spinal c-FOS mRNA expression were significantly down-regulated by <e1>CHEMICAL<\\e1>  but not by mesalamine","sentence":"Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429  but not by mesalamine"}
{"PMID":16855178,"re_id":4,"annotated sentence":"Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal <e2>c-FOS<\\e2> mRNA expression were significantly down-regulated by <e1>ATB-429<\\e1>  but not by mesalamine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ATB-429","object":"c-FOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal <e2>GENE-Y<\\e2> mRNA expression were significantly down-regulated by <e1>CHEMICAL<\\e1>  but not by mesalamine","sentence":"Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429  but not by mesalamine"}
{"PMID":16920841,"re_id":0,"annotated sentence":"Liver <e2>BHMT<\\e2> activity was 1.3-fold higher in rats fed the Met deficient diet containing <e1>choline<\\e1>  which was reflected in corresponding increases in mRNA content and immunodetectable protein","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"choline","object":"BHMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Liver <e2>GENE-N<\\e2> activity was 1.3-fold higher in rats fed the Met deficient diet containing <e1>CHEMICAL<\\e1>  which was reflected in corresponding increases in mRNA content and immunodetectable protein","sentence":"Liver BHMT activity was 1.3-fold higher in rats fed the Met deficient diet containing choline  which was reflected in corresponding increases in mRNA content and immunodetectable protein"}
{"PMID":16920841,"re_id":1,"annotated sentence":"Independent of dietary <e1>choline<\\e1>  supplemental Met increased hepatic <e2>BHMT<\\e2> activity approximately 30%","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"choline","object":"BHMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Independent of dietary <e1>CHEMICAL<\\e1>  supplemental Met increased hepatic <e2>GENE-N<\\e2> activity approximately 30%","sentence":"Independent of dietary choline  supplemental Met increased hepatic BHMT activity approximately 30%"}
{"PMID":16920841,"re_id":2,"annotated sentence":"Independent of dietary choline, supplemental <e1>Met<\\e1> increased hepatic <e2>BHMT<\\e2> activity approximately 30%","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Met","object":"BHMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Independent of dietary choline, supplemental <e1>CHEMICAL<\\e1> increased hepatic <e2>GENE-N<\\e2> activity approximately 30%","sentence":"Independent of dietary choline, supplemental Met increased hepatic BHMT activity approximately 30%"}
{"PMID":16920841,"re_id":3,"annotated sentence":"<e2>Choline dehydrogenase<\\e2> (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in <e1>choline<\\e1> oxidation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"choline","object":"Choline dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in <e1>CHEMICAL<\\e1> oxidation","sentence":"Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in choline oxidation"}
{"PMID":16920841,"re_id":4,"annotated sentence":"Choline dehydrogenase (<e2>CHDH<\\e2>  and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in <e1>choline<\\e1> oxidation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"choline","object":"CHDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Choline dehydrogenase (<e2>GENE-Y<\\e2>  and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in <e1>CHEMICAL<\\e1> oxidation","sentence":"Choline dehydrogenase (CHDH  and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in choline oxidation"}
{"PMID":16920841,"re_id":5,"annotated sentence":"Choline dehydrogenase (CHDH) and <e2>betaine-homocysteine methyltransferase<\\e2> (BHMT) are 2 enzymes involved in <e1>choline<\\e1> oxidation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"choline","object":"betaine-homocysteine methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Choline dehydrogenase (CHDH) and <e2>GENE-N<\\e2> (BHMT) are 2 enzymes involved in <e1>CHEMICAL<\\e1> oxidation","sentence":"Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in choline oxidation"}
{"PMID":16920841,"re_id":6,"annotated sentence":"Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (<e2>BHMT<\\e2>  are 2 enzymes involved in <e1>choline<\\e1> oxidation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"choline","object":"BHMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (<e2>GENE-N<\\e2>  are 2 enzymes involved in <e1>CHEMICAL<\\e1> oxidation","sentence":"Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (BHMT  are 2 enzymes involved in choline oxidation"}
{"PMID":16973691,"re_id":0,"annotated sentence":"The beta(2)-adrenoceptor (<e2>beta(2)-AR<\\e2>  agonists <e1>clenbuterol<\\e1> and fenoterol have similar beneficial effects in animal models of heart failure","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"clenbuterol","object":"beta(2)-AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The beta(2)-adrenoceptor (<e2>GENE-Y<\\e2>  agonists <e1>CHEMICAL<\\e1> and fenoterol have similar beneficial effects in animal models of heart failure","sentence":"The beta(2)-adrenoceptor (beta(2)-AR  agonists clenbuterol and fenoterol have similar beneficial effects in animal models of heart failure"}
{"PMID":16973691,"re_id":1,"annotated sentence":"The <e2>beta(2)-adrenoceptor<\\e2> (beta(2)-AR) agonists <e1>clenbuterol<\\e1> and fenoterol have similar beneficial effects in animal models of heart failure","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"clenbuterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> (beta(2)-AR) agonists <e1>CHEMICAL<\\e1> and fenoterol have similar beneficial effects in animal models of heart failure","sentence":"The beta(2)-adrenoceptor (beta(2)-AR) agonists clenbuterol and fenoterol have similar beneficial effects in animal models of heart failure"}
{"PMID":16973691,"re_id":2,"annotated sentence":"The beta(2)-adrenoceptor (<e2>beta(2)-AR<\\e2>  agonists clenbuterol and <e1>fenoterol<\\e1> have similar beneficial effects in animal models of heart failure","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"fenoterol","object":"beta(2)-AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The beta(2)-adrenoceptor (<e2>GENE-Y<\\e2>  agonists clenbuterol and <e1>CHEMICAL<\\e1> have similar beneficial effects in animal models of heart failure","sentence":"The beta(2)-adrenoceptor (beta(2)-AR  agonists clenbuterol and fenoterol have similar beneficial effects in animal models of heart failure"}
{"PMID":16973691,"re_id":3,"annotated sentence":"The <e2>beta(2)-adrenoceptor<\\e2> (beta(2)-AR) agonists clenbuterol and <e1>fenoterol<\\e1> have similar beneficial effects in animal models of heart failure","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"fenoterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> (beta(2)-AR) agonists clenbuterol and <e1>CHEMICAL<\\e1> have similar beneficial effects in animal models of heart failure","sentence":"The beta(2)-adrenoceptor (beta(2)-AR) agonists clenbuterol and fenoterol have similar beneficial effects in animal models of heart failure"}
{"PMID":16973691,"re_id":4,"annotated sentence":"<e2>beta(1)-Adrenoceptor<\\e2> antagonism (10 mg kg(-1) <e1>bisoprolol<\\e1>  prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"bisoprolol","object":"beta(1)-Adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> antagonism (10 mg kg(-1) <e1>CHEMICAL<\\e1>  prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551)","sentence":"beta(1)-Adrenoceptor antagonism (10 mg kg(-1) bisoprolol  prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551)"}
{"PMID":16978033,"re_id":0,"annotated sentence":"<e1>CP-690550<\\e1>  a <e2>JAK3<\\e2> inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CP-690550","object":"JAK3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials","sentence":"CP-690550  a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials"}
{"PMID":17000933,"re_id":0,"annotated sentence":"The beneficial role of <e1>17beta-estradiol<\\e1> on blood pressure, cardiac hypertrophy, vascular <e2>osteopontin<\\e2> expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"17beta-estradiol","object":"osteopontin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The beneficial role of <e1>CHEMICAL<\\e1> on blood pressure, cardiac hypertrophy, vascular <e2>GENE-Y<\\e2> expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate","sentence":"The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular osteopontin expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate"}
{"PMID":17000933,"re_id":1,"annotated sentence":"The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular <e2>osteopontin<\\e2> expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of <e1>medroxyprogesterone acetate<\\e1>  In contrast, drospirenone was either neutral or additive to 17beta-estradiol in protecting against aldosterone salt-induced cardiovascular injury and inflammation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"medroxyprogesterone acetate","object":"osteopontin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular <e2>GENE-Y<\\e2> expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of <e1>CHEMICAL<\\e1>  In contrast, drospirenone was either neutral or additive to 17beta-estradiol in protecting against aldosterone salt-induced cardiovascular injury and inflammation","sentence":"The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular osteopontin expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate  In contrast, drospirenone was either neutral or additive to 17beta-estradiol in protecting against aldosterone salt-induced cardiovascular injury and inflammation"}
{"PMID":17015640,"re_id":0,"annotated sentence":"We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of <e2>COX-2<\\e2>  <e1>rofecoxib<\\e1>  We also assessed the antithrombotic effect of licofelone in rabbit platelet-rich plasma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of <e2>GENE-Y<\\e2>  <e1>CHEMICAL<\\e1>  We also assessed the antithrombotic effect of licofelone in rabbit platelet-rich plasma","sentence":"We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of COX-2  rofecoxib  We also assessed the antithrombotic effect of licofelone in rabbit platelet-rich plasma"}
{"PMID":17015640,"re_id":1,"annotated sentence":"<e1>Licofelone<\\e1> reduced intima\/media ratio in injured arteries, the macrophages infiltration in the neointimal area, <e2>monocyte chemoattractant protein-1<\\e2> (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"monocyte chemoattractant protein-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced intima\/media ratio in injured arteries, the macrophages infiltration in the neointimal area, <e2>GENE-Y<\\e2> (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma","sentence":"Licofelone reduced intima\/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma"}
{"PMID":17015640,"re_id":2,"annotated sentence":"<e1>Licofelone<\\e1> reduced intima\/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (<e2>MCP-1<\\e2>  gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"MCP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced intima\/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (<e2>GENE-Y<\\e2>  gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma","sentence":"Licofelone reduced intima\/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1  gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma"}
{"PMID":17015640,"re_id":3,"annotated sentence":"<e1>Licofelone<\\e1> reduced intima\/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1) gene expression, and the activation of <e2>nuclear factor-kappaB<\\e2> in rabbit atheroma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"nuclear factor-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> reduced intima\/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1) gene expression, and the activation of <e2>GENE-N<\\e2> in rabbit atheroma","sentence":"Licofelone reduced intima\/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma"}
{"PMID":17015640,"re_id":4,"annotated sentence":"<e1>Licofelone<\\e1>  a balanced inhibitor of <e2>cyclooxygenase<\\e2> and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a balanced inhibitor of <e2>GENE-N<\\e2> and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis","sentence":"Licofelone  a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis"}
{"PMID":17015640,"re_id":5,"annotated sentence":"<e1>Licofelone<\\e1>  a balanced inhibitor of cyclooxygenase and <e2>5-lipoxygenase<\\e2>  reduces inflammation in a rabbit model of atherosclerosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a balanced inhibitor of cyclooxygenase and <e2>GENE-Y<\\e2>  reduces inflammation in a rabbit model of atherosclerosis","sentence":"Licofelone  a balanced inhibitor of cyclooxygenase and 5-lipoxygenase  reduces inflammation in a rabbit model of atherosclerosis"}
{"PMID":17015640,"re_id":6,"annotated sentence":"<e1>Licofelone<\\e1>  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to <e2>cycloxygenase-1<\\e2> blockade-mediated antithrombotic effect and a better gastrointestinal tolerability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"cycloxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to <e2>GENE-Y<\\e2> blockade-mediated antithrombotic effect and a better gastrointestinal tolerability","sentence":"Licofelone  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability"}
{"PMID":17015640,"re_id":7,"annotated sentence":"<e1>Licofelone<\\e1>  a dual anti-inflammatory drug that inhibits <e2>5-lipoxygenase<\\e2> (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a dual anti-inflammatory drug that inhibits <e2>GENE-Y<\\e2> (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability","sentence":"Licofelone  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability"}
{"PMID":17015640,"re_id":8,"annotated sentence":"<e1>Licofelone<\\e1>  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (<e2>LOX<\\e2>  and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"LOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (<e2>GENE-N<\\e2>  and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability","sentence":"Licofelone  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX  and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability"}
{"PMID":17015640,"re_id":9,"annotated sentence":"<e1>Licofelone<\\e1>  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and <e2>cyclooxygenase<\\e2> (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and <e2>GENE-N<\\e2> (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability","sentence":"Licofelone  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability"}
{"PMID":17015640,"re_id":10,"annotated sentence":"<e1>Licofelone<\\e1>  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (<e2>COX<\\e2>  enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (<e2>GENE-N<\\e2>  enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability","sentence":"Licofelone  a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX  enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability"}
{"PMID":17015640,"re_id":11,"annotated sentence":"Moreover, <e1>licofelone<\\e1> inhibited <e2>COX-2<\\e2> and 5-LOX protein expression in vascular lesions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"licofelone","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> and 5-LOX protein expression in vascular lesions","sentence":"Moreover, licofelone inhibited COX-2 and 5-LOX protein expression in vascular lesions"}
{"PMID":17015640,"re_id":12,"annotated sentence":"Moreover, <e1>licofelone<\\e1> inhibited COX-2 and <e2>5-LOX<\\e2> protein expression in vascular lesions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"licofelone","object":"5-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> inhibited COX-2 and <e2>GENE-Y<\\e2> protein expression in vascular lesions","sentence":"Moreover, licofelone inhibited COX-2 and 5-LOX protein expression in vascular lesions"}
{"PMID":17015640,"re_id":13,"annotated sentence":"<e1>Rofecoxib<\\e1> only diminished <e2>COX-2<\\e2> protein expression and MCP-1 gene expression in vascular atheroma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> only diminished <e2>GENE-Y<\\e2> protein expression and MCP-1 gene expression in vascular atheroma","sentence":"Rofecoxib only diminished COX-2 protein expression and MCP-1 gene expression in vascular atheroma"}
{"PMID":17015640,"re_id":14,"annotated sentence":"<e1>Rofecoxib<\\e1> only diminished COX-2 protein expression and <e2>MCP-1<\\e2> gene expression in vascular atheroma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rofecoxib","object":"MCP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> only diminished COX-2 protein expression and <e2>GENE-Y<\\e2> gene expression in vascular atheroma","sentence":"Rofecoxib only diminished COX-2 protein expression and MCP-1 gene expression in vascular atheroma"}
{"PMID":17015640,"re_id":15,"annotated sentence":"<e1>Licofelone<\\e1> almost abolished <e2>5-LOX<\\e2> activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Licofelone","object":"5-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> almost abolished <e2>GENE-Y<\\e2> activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood","sentence":"Licofelone almost abolished 5-LOX activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood"}
{"PMID":17015640,"re_id":16,"annotated sentence":"Licofelone almost abolished <e2>5-LOX<\\e2> activity by inhibiting <e1>leukotriene B4<\\e1> generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"leukotriene B4","object":"5-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Licofelone almost abolished <e2>GENE-Y<\\e2> activity by inhibiting <e1>CHEMICAL<\\e1> generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood","sentence":"Licofelone almost abolished 5-LOX activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood"}
{"PMID":17015640,"re_id":17,"annotated sentence":"Licofelone almost abolished <e2>5-LOX<\\e2> activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet <e1>thromboxane B2<\\e1> production from whole blood","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"thromboxane B2","object":"5-LOX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Licofelone almost abolished <e2>GENE-Y<\\e2> activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet <e1>CHEMICAL<\\e1> production from whole blood","sentence":"Licofelone almost abolished 5-LOX activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood"}
{"PMID":17018843,"re_id":0,"annotated sentence":"Chronic insulin (24 h) activates NHE3 through the classic <e2>phosphatidylinositol 3-kinase<\\e2> serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor <e1>wortmannin<\\e1> or a dominant-negative SGK1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wortmannin","object":"phosphatidylinositol 3-kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Chronic insulin (24 h) activates NHE3 through the classic <e2>GENE-N<\\e2> serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor <e1>CHEMICAL<\\e1> or a dominant-negative SGK1","sentence":"Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1"}
{"PMID":17018843,"re_id":1,"annotated sentence":"Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (<e2>PI3K<\\e2> SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor <e1>wortmannin<\\e1> or a dominant-negative SGK1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wortmannin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (<e2>GENE-N<\\e2> SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the GENE-N inhibitor <e1>CHEMICAL<\\e1> or a dominant-negative SGK1","sentence":"Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1"}
{"PMID":17018843,"re_id":2,"annotated sentence":"Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the <e2>PI3K<\\e2> inhibitor <e1>wortmannin<\\e1> or a dominant-negative SGK1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wortmannin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (GENE-N-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> or a dominant-negative SGK1","sentence":"Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor wortmannin or a dominant-negative SGK1"}
{"PMID":17020418,"re_id":0,"annotated sentence":"The potent and selective third-generation <e2>aromatase<\\e2> inhibitors anastrozole, <e1>letrozole<\\e1> and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"letrozole","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potent and selective third-generation <e2>GENE-Y<\\e2> inhibitors anastrozole, <e1>CHEMICAL<\\e1> and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies","sentence":"The potent and selective third-generation aromatase inhibitors anastrozole, letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies"}
{"PMID":17020418,"re_id":1,"annotated sentence":"<e1>Anastrozole<\\e1> and letrozole are both non-steroidal <e2>aromatase<\\e2> inhibitors that compete with the substrate for binding to the enzyme active site","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Anastrozole","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and letrozole are both non-steroidal <e2>GENE-Y<\\e2> inhibitors that compete with the substrate for binding to the enzyme active site","sentence":"Anastrozole and letrozole are both non-steroidal aromatase inhibitors that compete with the substrate for binding to the enzyme active site"}
{"PMID":17020418,"re_id":2,"annotated sentence":"Anastrozole and <e1>letrozole<\\e1> are both non-steroidal <e2>aromatase<\\e2> inhibitors that compete with the substrate for binding to the enzyme active site","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"letrozole","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Anastrozole and <e1>CHEMICAL<\\e1> are both non-steroidal <e2>GENE-Y<\\e2> inhibitors that compete with the substrate for binding to the enzyme active site","sentence":"Anastrozole and letrozole are both non-steroidal aromatase inhibitors that compete with the substrate for binding to the enzyme active site"}
{"PMID":17020418,"re_id":3,"annotated sentence":"The potent and selective third-generation <e2>aromatase<\\e2> inhibitors <e1>anastrozole<\\e1>  letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"anastrozole","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potent and selective third-generation <e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1>  letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies","sentence":"The potent and selective third-generation aromatase inhibitors anastrozole  letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies"}
{"PMID":17020418,"re_id":4,"annotated sentence":"<e1>Estrogens<\\e1> are biosynthesised from androgens by the <e2>CYP450<\\e2> enzyme complex called aromatase","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Estrogens","object":"CYP450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> are biosynthesised from androgens by the <e2>GENE-N<\\e2> enzyme complex called aromatase","sentence":"Estrogens are biosynthesised from androgens by the CYP450 enzyme complex called aromatase"}
{"PMID":17020418,"re_id":5,"annotated sentence":"<e1>Estrogens<\\e1> are biosynthesised from androgens by the CYP450 enzyme complex called <e2>aromatase<\\e2>  Aromatase is expressed in the ovary, placenta, brain, bone, adipose tissue and breast tissue","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Estrogens","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> are biosynthesised from androgens by the CYP450 enzyme complex called <e2>GENE-Y<\\e2>  Aromatase is expressed in the ovary, placenta, brain, bone, adipose tissue and breast tissue","sentence":"Estrogens are biosynthesised from androgens by the CYP450 enzyme complex called aromatase  Aromatase is expressed in the ovary, placenta, brain, bone, adipose tissue and breast tissue"}
{"PMID":17020418,"re_id":6,"annotated sentence":"In breast cancer, intratumoural <e2>aromatase<\\e2> is the source for local <e1>estrogen<\\e1> production in the tissue","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"estrogen","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In breast cancer, intratumoural <e2>GENE-Y<\\e2> is the source for local <e1>CHEMICAL<\\e1> production in the tissue","sentence":"In breast cancer, intratumoural aromatase is the source for local estrogen production in the tissue"}
{"PMID":17020418,"re_id":7,"annotated sentence":"Estrogens are biosynthesised from <e1>androgens<\\e1> by the CYP450 enzyme complex called <e2>aromatase<\\e2>  Aromatase is expressed in the ovary, placenta, brain, bone, adipose tissue and breast tissue","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"androgens","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Estrogens are biosynthesised from <e1>CHEMICAL<\\e1> by the CYP450 enzyme complex called <e2>GENE-Y<\\e2>  Aromatase is expressed in the ovary, placenta, brain, bone, adipose tissue and breast tissue","sentence":"Estrogens are biosynthesised from androgens by the CYP450 enzyme complex called aromatase  Aromatase is expressed in the ovary, placenta, brain, bone, adipose tissue and breast tissue"}
{"PMID":17034761,"re_id":0,"annotated sentence":"Furthermore, <e1>auranofin<\\e1> inhibited <e2>NF-kappaB<\\e2> activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> inhibited <e2>GENE-N<\\e2> activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65","sentence":"Furthermore, auranofin inhibited NF-kappaB activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65"}
{"PMID":17034761,"re_id":1,"annotated sentence":"<e1>Auranofin<\\e1>  as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of <e2>TLR4<\\e2>  Toll-like receptors (TLRs), which are activated by invading microorganisms or endogenous molecules, evoke immune and inflammatory responses","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Auranofin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of <e2>GENE-Y<\\e2>  Toll-like receptors (TLRs), which are activated by invading microorganisms or endogenous molecules, evoke immune and inflammatory responses","sentence":"Auranofin  as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4  Toll-like receptors (TLRs), which are activated by invading microorganisms or endogenous molecules, evoke immune and inflammatory responses"}
{"PMID":17034761,"re_id":2,"annotated sentence":"<e2>IRF3<\\e2> activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by <e1>auranofin<\\e1>  Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"IRF3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by <e1>CHEMICAL<\\e1>  Our results first demonstrate that CHEMICAL suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4","sentence":"IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin  Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4"}
{"PMID":17034761,"re_id":3,"annotated sentence":"IRF3 activation induced by MyD88-independent signaling components, <e2>TRIF<\\e2> and TBK1, was also downregulated by <e1>auranofin<\\e1>  Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"TRIF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"IRF3 activation induced by MyD88-independent signaling components, <e2>GENE-Y<\\e2> and TBK1, was also downregulated by <e1>CHEMICAL<\\e1>  Our results first demonstrate that CHEMICAL suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4","sentence":"IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin  Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4"}
{"PMID":17034761,"re_id":4,"annotated sentence":"IRF3 activation induced by MyD88-independent signaling components, TRIF and <e2>TBK1<\\e2>  was also downregulated by <e1>auranofin<\\e1>  Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"TBK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"IRF3 activation induced by MyD88-independent signaling components, TRIF and <e2>GENE-Y<\\e2>  was also downregulated by <e1>CHEMICAL<\\e1>  Our results first demonstrate that CHEMICAL suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4","sentence":"IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1  was also downregulated by auranofin  Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4"}
{"PMID":17034761,"re_id":5,"annotated sentence":"Our results first demonstrate that <e1>auranofin<\\e1> suppresses the multiple steps in <e2>TLR4<\\e2> signaling, especially the homodimerization of TLR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results first demonstrate that <e1>CHEMICAL<\\e1> suppresses the multiple steps in <e2>GENE-Y<\\e2> signaling, especially the homodimerization of GENE-Y","sentence":"Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4"}
{"PMID":17034761,"re_id":6,"annotated sentence":"Our results first demonstrate that <e1>auranofin<\\e1> suppresses the multiple steps in TLR4 signaling, especially the homodimerization of <e2>TLR4<\\e2>  The results suggest that the suppression of TLR4 activity by auranofin may be the molecular mechanism through which auranofin exerts anti-rheumatic activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results first demonstrate that <e1>CHEMICAL<\\e1> suppresses the multiple steps in GENE-Y signaling, especially the homodimerization of <e2>GENE-Y<\\e2>  The results suggest that the suppression of GENE-Y activity by CHEMICAL may be the molecular mechanism through which CHEMICAL exerts anti-rheumatic activity.","sentence":"Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4  The results suggest that the suppression of TLR4 activity by auranofin may be the molecular mechanism through which auranofin exerts anti-rheumatic activity."}
{"PMID":17034761,"re_id":7,"annotated sentence":"The results suggest that the suppression of <e2>TLR4<\\e2> activity by <e1>auranofin<\\e1> may be the molecular mechanism through which auranofin exerts anti-rheumatic activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that the suppression of <e2>GENE-Y<\\e2> activity by <e1>CHEMICAL<\\e1> may be the molecular mechanism through which CHEMICAL exerts anti-rheumatic activity.","sentence":"The results suggest that the suppression of TLR4 activity by auranofin may be the molecular mechanism through which auranofin exerts anti-rheumatic activity."}
{"PMID":17034761,"re_id":8,"annotated sentence":"The results suggest that the suppression of <e2>TLR4<\\e2> activity by auranofin may be the molecular mechanism through which <e1>auranofin<\\e1> exerts anti-rheumatic activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that the suppression of <e2>GENE-Y<\\e2> activity by CHEMICAL may be the molecular mechanism through which <e1>CHEMICAL<\\e1> exerts anti-rheumatic activity.","sentence":"The results suggest that the suppression of TLR4 activity by auranofin may be the molecular mechanism through which auranofin exerts anti-rheumatic activity."}
{"PMID":17034761,"re_id":9,"annotated sentence":"Our results demonstrated that <e1>auranofin<\\e1> suppressed <e2>TLR4<\\e2> mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results demonstrated that <e1>CHEMICAL<\\e1> suppressed <e2>GENE-Y<\\e2> mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme","sentence":"Our results demonstrated that auranofin suppressed TLR4 mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme"}
{"PMID":17034761,"re_id":10,"annotated sentence":"Our results demonstrated that <e1>auranofin<\\e1> suppressed TLR4-mediated activation of transcription factors, <e2>NF-kappaB<\\e2> and IRF3, and expression of COX-2, a pro-inflammatory enzyme","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our results demonstrated that <e1>CHEMICAL<\\e1> suppressed TLR4-mediated activation of transcription factors, <e2>GENE-N<\\e2> and IRF3, and expression of COX-2, a pro-inflammatory enzyme","sentence":"Our results demonstrated that auranofin suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme"}
{"PMID":17034761,"re_id":11,"annotated sentence":"Our results demonstrated that <e1>auranofin<\\e1> suppressed TLR4-mediated activation of transcription factors, NF-kappaB and <e2>IRF3<\\e2>  and expression of COX-2, a pro-inflammatory enzyme","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"IRF3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results demonstrated that <e1>CHEMICAL<\\e1> suppressed TLR4-mediated activation of transcription factors, NF-kappaB and <e2>GENE-Y<\\e2>  and expression of COX-2, a pro-inflammatory enzyme","sentence":"Our results demonstrated that auranofin suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3  and expression of COX-2, a pro-inflammatory enzyme"}
{"PMID":17034761,"re_id":12,"annotated sentence":"Our results demonstrated that <e1>auranofin<\\e1> suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of <e2>COX-2<\\e2>  a pro-inflammatory enzyme","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results demonstrated that <e1>CHEMICAL<\\e1> suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of <e2>GENE-Y<\\e2>  a pro-inflammatory enzyme","sentence":"Our results demonstrated that auranofin suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2  a pro-inflammatory enzyme"}
{"PMID":17034761,"re_id":13,"annotated sentence":"This suppression was well correlated with the inhibitory effect of <e1>auranofin<\\e1> on the homodimerization of <e2>TLR4<\\e2> induced by an agonist","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This suppression was well correlated with the inhibitory effect of <e1>CHEMICAL<\\e1> on the homodimerization of <e2>GENE-Y<\\e2> induced by an agonist","sentence":"This suppression was well correlated with the inhibitory effect of auranofin on the homodimerization of TLR4 induced by an agonist"}
{"PMID":17040106,"re_id":0,"annotated sentence":"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <e1>arylhydroxylamine<\\e1> carcinogens was catalyzed by <e2>NADH cytochrome b5 reductase<\\e2> (b5R) and cytochrome b5 (cyt b5)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arylhydroxylamine","object":"NADH cytochrome b5 reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the basis of our findings with structurally similar CHEMICAL metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <e1>CHEMICAL<\\e1> carcinogens was catalyzed by <e2>GENE-Y<\\e2> (b5R) and cytochrome b5 (cyt b5)","sentence":"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 (cyt b5)"}
{"PMID":17040106,"re_id":1,"annotated sentence":"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <e1>arylhydroxylamine<\\e1> carcinogens was catalyzed by NADH cytochrome b5 reductase (<e2>b5R<\\e2>  and cytochrome b5 (cyt b5)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arylhydroxylamine","object":"b5R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the basis of our findings with structurally similar CHEMICAL metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <e1>CHEMICAL<\\e1> carcinogens was catalyzed by NADH cytochrome b5 reductase (<e2>GENE-Y<\\e2>  and cytochrome b5 (cyt b5)","sentence":"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R  and cytochrome b5 (cyt b5)"}
{"PMID":17040106,"re_id":2,"annotated sentence":"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <e1>arylhydroxylamine<\\e1> carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and <e2>cytochrome b5<\\e2> (cyt b5)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arylhydroxylamine","object":"cytochrome b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the basis of our findings with structurally similar CHEMICAL metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <e1>CHEMICAL<\\e1> carcinogens was catalyzed by NADH GENE-Y reductase (b5R) and <e2>GENE-Y<\\e2> (cyt b5)","sentence":"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 (cyt b5)"}
{"PMID":17040106,"re_id":3,"annotated sentence":"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <e1>arylhydroxylamine<\\e1> carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 (<e2>cyt b5<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arylhydroxylamine","object":"cyt b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the basis of our findings with structurally similar CHEMICAL metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of <e1>CHEMICAL<\\e1> carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 (<e2>GENE-Y<\\e2> ","sentence":"On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 (cyt b5 "}
{"PMID":17040106,"re_id":4,"annotated sentence":"We found that reduction of the carcinogenic <e1>hydroxylamines<\\e1> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R<\\e2> and cyt b5","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"hydroxylamines","object":"human b5R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic <e1>CHEMICAL<\\e1> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>GENE-Y<\\e2> and cyt b5","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5"}
{"PMID":17040106,"re_id":5,"annotated sentence":"We found that reduction of the carcinogenic <e1>hydroxylamines<\\e1> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"hydroxylamines","object":"cyt b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic <e1>CHEMICAL<\\e1> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>GENE-Y<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems"}
{"PMID":17040106,"re_id":6,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the <e1>aromatic amine<\\e1> 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R<\\e2> and cyt b5","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"aromatic amine","object":"human b5R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the <e1>CHEMICAL<\\e1> 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>GENE-Y<\\e2> and cyt b5","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5"}
{"PMID":17040106,"re_id":7,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the <e1>aromatic amine<\\e1> 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"aromatic amine","object":"cyt b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the <e1>CHEMICAL<\\e1> 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>GENE-Y<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems"}
{"PMID":17040106,"re_id":8,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine <e1>4-aminobiphenyl<\\e1> (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R<\\e2> and cyt b5","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-aminobiphenyl","object":"human b5R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine <e1>CHEMICAL<\\e1> (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>GENE-Y<\\e2> and cyt b5","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5"}
{"PMID":17040106,"re_id":9,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine <e1>4-aminobiphenyl<\\e1> (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-aminobiphenyl","object":"cyt b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine <e1>CHEMICAL<\\e1> (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>GENE-Y<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems"}
{"PMID":17040106,"re_id":10,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (<e1>4-ABP<\\e1>  found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R<\\e2> and cyt b5","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-ABP","object":"human b5R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (<e1>CHEMICAL<\\e1>  found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>GENE-Y<\\e2> and cyt b5","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP  found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5"}
{"PMID":17040106,"re_id":11,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (<e1>4-ABP<\\e1>  found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-ABP","object":"cyt b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (<e1>CHEMICAL<\\e1>  found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>GENE-Y<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP  found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems"}
{"PMID":17040106,"re_id":12,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the <e1>heterocyclic amine<\\e1> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R<\\e2> and cyt b5","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"heterocyclic amine","object":"human b5R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the <e1>CHEMICAL<\\e1> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>GENE-Y<\\e2> and cyt b5","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5"}
{"PMID":17040106,"re_id":13,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the <e1>heterocyclic amine<\\e1> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"heterocyclic amine","object":"cyt b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the <e1>CHEMICAL<\\e1> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>GENE-Y<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems"}
{"PMID":17040106,"re_id":14,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine <e1>2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine<\\e1> (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R<\\e2> and cyt b5","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine","object":"human b5R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine <e1>CHEMICAL<\\e1> (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>GENE-Y<\\e2> and cyt b5","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5"}
{"PMID":17040106,"re_id":15,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine <e1>2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine<\\e1> (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine","object":"cyt b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine <e1>CHEMICAL<\\e1> (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>GENE-Y<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems"}
{"PMID":17040106,"re_id":16,"annotated sentence":"Reductive detoxification of <e1>arylhydroxylamine<\\e1> carcinogens by human NADH cytochrome b5 reductase and <e2>cytochrome b5<\\e2>  Heterocyclic and aromatic amine carcinogens are thought to lead to tumor initiation via the formation of DNA adducts, and bioactivation to arylhydroxylamine metabolites is necessary for reactivity with DNA","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arylhydroxylamine","object":"cytochrome b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reductive detoxification of <e1>CHEMICAL<\\e1> carcinogens by human NADH GENE-Y reductase and <e2>GENE-Y<\\e2>  Heterocyclic and aromatic amine carcinogens are thought to lead to tumor initiation via the formation of DNA adducts, and bioactivation to CHEMICAL metabolites is necessary for reactivity with DNA","sentence":"Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5  Heterocyclic and aromatic amine carcinogens are thought to lead to tumor initiation via the formation of DNA adducts, and bioactivation to arylhydroxylamine metabolites is necessary for reactivity with DNA"}
{"PMID":17040106,"re_id":17,"annotated sentence":"Reductive detoxification of <e1>arylhydroxylamine<\\e1> carcinogens by <e2>human NADH cytochrome b5 reductase<\\e2> and cytochrome b5","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arylhydroxylamine","object":"human NADH cytochrome b5 reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reductive detoxification of <e1>CHEMICAL<\\e1> carcinogens by <e2>GENE-Y<\\e2> and cytochrome b5","sentence":"Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5"}
{"PMID":17040106,"re_id":18,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (<e1>PhIP<\\e1>  found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R<\\e2> and cyt b5","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PhIP","object":"human b5R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (<e1>CHEMICAL<\\e1>  found in grilled meats) was indeed catalyzed by a purified system containing only <e2>GENE-Y<\\e2> and cyt b5","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP  found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5"}
{"PMID":17040106,"re_id":19,"annotated sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (<e1>PhIP<\\e1>  found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PhIP","object":"cyt b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (<e1>CHEMICAL<\\e1>  found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>GENE-Y<\\e2>  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems","sentence":"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP  found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and cyt b5  Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems"}
{"PMID":17040106,"re_id":20,"annotated sentence":"Polyclonal antisera to either <e2>b5R<\\e2> or cyt b5 significantly inhibited <e1>N-hydroxy-4-aminobiphenyl<\\e1> (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-hydroxy-4-aminobiphenyl","object":"b5R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Polyclonal antisera to either <e2>GENE-Y<\\e2> or cyt b5 significantly inhibited <e1>CHEMICAL<\\e1> (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)","sentence":"Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)"}
{"PMID":17040106,"re_id":21,"annotated sentence":"Polyclonal antisera to either b5R or <e2>cyt b5<\\e2> significantly inhibited <e1>N-hydroxy-4-aminobiphenyl<\\e1> (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"N-hydroxy-4-aminobiphenyl","object":"cyt b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Polyclonal antisera to either b5R or <e2>GENE-Y<\\e2> significantly inhibited <e1>CHEMICAL<\\e1> (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive GENE-Y protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)","sentence":"Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)"}
{"PMID":17040106,"re_id":22,"annotated sentence":"Polyclonal antisera to either <e2>b5R<\\e2> or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (<e1>NHOH-4-ABP<\\e1>  reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NHOH-4-ABP","object":"b5R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Polyclonal antisera to either <e2>GENE-Y<\\e2> or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (<e1>CHEMICAL<\\e1>  reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both CHEMICAL and N-hydroxy-PhIP (NHOH-PhIP)","sentence":"Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP  reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)"}
{"PMID":17040106,"re_id":23,"annotated sentence":"Polyclonal antisera to either b5R or <e2>cyt b5<\\e2> significantly inhibited N-hydroxy-4-aminobiphenyl (<e1>NHOH-4-ABP<\\e1>  reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NHOH-4-ABP","object":"cyt b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Polyclonal antisera to either b5R or <e2>GENE-Y<\\e2> significantly inhibited N-hydroxy-4-aminobiphenyl (<e1>CHEMICAL<\\e1>  reduction by 95 and 89%, respectively, and immunoreactive GENE-Y protein content in individual HLM was significantly correlated with individual reduction of both CHEMICAL and N-hydroxy-PhIP (NHOH-PhIP)","sentence":"Polyclonal antisera to either b5R or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (NHOH-4-ABP  reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)"}
{"PMID":17049513,"re_id":0,"annotated sentence":"Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that <e1>imatinib<\\e1> may affect mature osteoclasts through the inhibition of <e2>c-FMS<\\e2>  Taken together, these results suggest that imatinib could be of clinical value in treating diseases where bone destruction can occur due to excessive M-CSF production such as osteoporosis, inflammatory-and tumor-induced osteolysis.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"c-FMS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that <e1>CHEMICAL<\\e1> may affect mature osteoclasts through the inhibition of <e2>GENE-Y<\\e2>  Taken together, these results suggest that CHEMICAL could be of clinical value in treating diseases where bone destruction can occur due to excessive M-CSF production such as osteoporosis, inflammatory-and tumor-induced osteolysis.","sentence":"Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS  Taken together, these results suggest that imatinib could be of clinical value in treating diseases where bone destruction can occur due to excessive M-CSF production such as osteoporosis, inflammatory-and tumor-induced osteolysis."}
{"PMID":17049513,"re_id":1,"annotated sentence":"Recent studies have reported that <e1>imatinib mesylate<\\e1>  a kinase inhibitor that targets the intracellular <e2>tyrosine kinase<\\e2> BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib mesylate","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recent studies have reported that <e1>CHEMICAL<\\e1>  a kinase inhibitor that targets the intracellular <e2>GENE-N<\\e2> BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS","sentence":"Recent studies have reported that imatinib mesylate  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS"}
{"PMID":17049513,"re_id":2,"annotated sentence":"Recent studies have reported that <e1>imatinib mesylate<\\e1>  a kinase inhibitor that targets the intracellular tyrosine kinase <e2>BCR<\\e2> ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib mesylate","object":"BCR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recent studies have reported that <e1>CHEMICAL<\\e1>  a kinase inhibitor that targets the intracellular tyrosine kinase <e2>GENE-Y<\\e2> ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS","sentence":"Recent studies have reported that imatinib mesylate  a kinase inhibitor that targets the intracellular tyrosine kinase BCR ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS"}
{"PMID":17049513,"re_id":3,"annotated sentence":"Recent studies have reported that <e1>imatinib mesylate<\\e1>  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-<e2>ABL<\\e2> and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib mesylate","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recent studies have reported that <e1>CHEMICAL<\\e1>  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-<e2>GENE-Y<\\e2> and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS","sentence":"Recent studies have reported that imatinib mesylate  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS"}
{"PMID":17049513,"re_id":4,"annotated sentence":"Recent studies have reported that <e1>imatinib mesylate<\\e1>  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the <e2>platelet derived growth factor (PDGF) receptor<\\e2>  is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib mesylate","object":"platelet derived growth factor (PDGF) receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recent studies have reported that <e1>CHEMICAL<\\e1>  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the <e2>GENE-N<\\e2>  is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS","sentence":"Recent studies have reported that imatinib mesylate  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor  is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS"}
{"PMID":17049513,"re_id":5,"annotated sentence":"Recent studies have reported that <e1>imatinib mesylate<\\e1>  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the <e2>macrophage colony stimulating factor (M-CSF) receptor<\\e2>  c-FMS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib mesylate","object":"macrophage colony stimulating factor (M-CSF) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recent studies have reported that <e1>CHEMICAL<\\e1>  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the <e2>GENE-Y<\\e2>  c-FMS","sentence":"Recent studies have reported that imatinib mesylate  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor  c-FMS"}
{"PMID":17049513,"re_id":6,"annotated sentence":"Recent studies have reported that <e1>imatinib mesylate<\\e1>  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, <e2>c-FMS<\\e2>  Given that M-CSF signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with imatinib may modulate osteoclast activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib mesylate","object":"c-FMS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recent studies have reported that <e1>CHEMICAL<\\e1>  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, <e2>GENE-Y<\\e2>  Given that M-CSF signalling through GENE-Y plays an important role in osteoclast biology, we speculated that blocking such a pathway with imatinib may modulate osteoclast activity","sentence":"Recent studies have reported that imatinib mesylate  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS  Given that M-CSF signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with imatinib may modulate osteoclast activity"}
{"PMID":17049513,"re_id":7,"annotated sentence":"Recent studies have reported that <e1>imatinib mesylate<\\e1>  a <e2>kinase<\\e2> inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib mesylate","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recent studies have reported that <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> inhibitor that targets the intracellular tyrosine GENE-N BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS","sentence":"Recent studies have reported that imatinib mesylate  a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS"}
{"PMID":17049513,"re_id":8,"annotated sentence":"Given that <e2>M-CSF<\\e2> signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with <e1>imatinib<\\e1> may modulate osteoclast activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"M-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given that <e2>GENE-Y<\\e2> signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with <e1>CHEMICAL<\\e1> may modulate osteoclast activity","sentence":"Given that M-CSF signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with imatinib may modulate osteoclast activity"}
{"PMID":17049513,"re_id":9,"annotated sentence":"Given that M-CSF signalling through <e2>c-FMS<\\e2> plays an important role in osteoclast biology, we speculated that blocking such a pathway with <e1>imatinib<\\e1> may modulate osteoclast activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"c-FMS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given that M-CSF signalling through <e2>GENE-Y<\\e2> plays an important role in osteoclast biology, we speculated that blocking such a pathway with <e1>CHEMICAL<\\e1> may modulate osteoclast activity","sentence":"Given that M-CSF signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with imatinib may modulate osteoclast activity"}
{"PMID":17049513,"re_id":10,"annotated sentence":"<e1>Imatinib<\\e1> was also found to inhibit <e2>M-CSF<\\e2> induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Imatinib","object":"M-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was also found to inhibit <e2>GENE-Y<\\e2> induced osteoclast survival as well as GENE-Y-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS","sentence":"Imatinib was also found to inhibit M-CSF induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS"}
{"PMID":17049513,"re_id":11,"annotated sentence":"<e1>Imatinib<\\e1> was also found to inhibit M-CSF-induced osteoclast survival as well as <e2>M-CSF<\\e2> induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Imatinib","object":"M-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was also found to inhibit GENE-Y-induced osteoclast survival as well as <e2>GENE-Y<\\e2> induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS","sentence":"Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS"}
{"PMID":1705137,"re_id":0,"annotated sentence":"Before the next drug intake, <e2>MAO-A<\\e2> inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with <e1>moclobemide<\\e1> but not with toloxatone","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"moclobemide","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Before the next drug intake, <e2>GENE-Y<\\e2> inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with <e1>CHEMICAL<\\e1> but not with toloxatone","sentence":"Before the next drug intake, MAO-A inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with toloxatone"}
{"PMID":1705137,"re_id":1,"annotated sentence":"Before the next drug intake, <e2>MAO-A<\\e2> inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with <e1>toloxatone<\\e1>  5","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"toloxatone","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Before the next drug intake, <e2>GENE-Y<\\e2> inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with <e1>CHEMICAL<\\e1>  5","sentence":"Before the next drug intake, MAO-A inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with toloxatone  5"}
{"PMID":1705137,"re_id":2,"annotated sentence":"The effects of two reversible, predominantly <e2>monoamine oxidase-A<\\e2> (MAO-A) inhibitors, <e1>moclobemide<\\e1> (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"moclobemide","object":"monoamine oxidase-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of two reversible, predominantly <e2>GENE-Y<\\e2> (MAO-A) inhibitors, <e1>CHEMICAL<\\e1> (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects","sentence":"The effects of two reversible, predominantly monoamine oxidase-A (MAO-A) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects"}
{"PMID":1705137,"re_id":3,"annotated sentence":"Comparison of the <e2>monoamine oxidase<\\e2> inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors <e1>moclobemide<\\e1> and toloxatone, and assessment of their effect on psychometric performance in healthy subjects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"moclobemide","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of the <e2>GENE-N<\\e2> inhibiting properties of two reversible and selective GENE-N-A inhibitors <e1>CHEMICAL<\\e1> and toloxatone, and assessment of their effect on psychometric performance in healthy subjects","sentence":"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects"}
{"PMID":1705137,"re_id":4,"annotated sentence":"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective <e2>monoamine oxidase-A<\\e2> inhibitors <e1>moclobemide<\\e1> and toloxatone, and assessment of their effect on psychometric performance in healthy subjects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"moclobemide","object":"monoamine oxidase-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective <e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1> and toloxatone, and assessment of their effect on psychometric performance in healthy subjects","sentence":"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects"}
{"PMID":1705137,"re_id":5,"annotated sentence":"Comparison of the <e2>monoamine oxidase<\\e2> inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and <e1>toloxatone<\\e1>  and assessment of their effect on psychometric performance in healthy subjects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"toloxatone","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comparison of the <e2>GENE-N<\\e2> inhibiting properties of two reversible and selective GENE-N-A inhibitors moclobemide and <e1>CHEMICAL<\\e1>  and assessment of their effect on psychometric performance in healthy subjects","sentence":"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone  and assessment of their effect on psychometric performance in healthy subjects"}
{"PMID":1705137,"re_id":6,"annotated sentence":"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective <e2>monoamine oxidase-A<\\e2> inhibitors moclobemide and <e1>toloxatone<\\e1>  and assessment of their effect on psychometric performance in healthy subjects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"toloxatone","object":"monoamine oxidase-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective <e2>GENE-Y<\\e2> inhibitors moclobemide and <e1>CHEMICAL<\\e1>  and assessment of their effect on psychometric performance in healthy subjects","sentence":"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone  and assessment of their effect on psychometric performance in healthy subjects"}
{"PMID":1705137,"re_id":7,"annotated sentence":"The effects of two reversible, predominantly <e2>monoamine oxidase-A<\\e2> (MAO-A) inhibitors, moclobemide (150 mg three times daily) and <e1>toloxatone<\\e1> (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"toloxatone","object":"monoamine oxidase-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of two reversible, predominantly <e2>GENE-Y<\\e2> (MAO-A) inhibitors, moclobemide (150 mg three times daily) and <e1>CHEMICAL<\\e1> (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects","sentence":"The effects of two reversible, predominantly monoamine oxidase-A (MAO-A) inhibitors, moclobemide (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects"}
{"PMID":1705633,"re_id":0,"annotated sentence":"Clinical pharmacology of <e1>enalkiren<\\e1>  a novel, dipeptide <e2>renin<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"enalkiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical pharmacology of <e1>CHEMICAL<\\e1>  a novel, dipeptide <e2>GENE-Y<\\e2> inhibitor","sentence":"Clinical pharmacology of enalkiren  a novel, dipeptide renin inhibitor"}
{"PMID":1705633,"re_id":1,"annotated sentence":"Clinical pharmacology of enalkiren, a novel, <e1>dipeptide<\\e1> <e2>renin<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dipeptide","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical pharmacology of enalkiren, a novel, <e1>CHEMICAL<\\e1> <e2>GENE-Y<\\e2> inhibitor","sentence":"Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor"}
{"PMID":1705633,"re_id":2,"annotated sentence":"<e1>Enalkiren<\\e1> (A-64662), a potent, dipeptide <e2>renin<\\e2> inhibitor, mimics the transition state of the human renin substrate, angiotensinogen","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Enalkiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (A-64662), a potent, dipeptide <e2>GENE-Y<\\e2> inhibitor, mimics the transition state of the human GENE-Y substrate, angiotensinogen","sentence":"Enalkiren (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate, angiotensinogen"}
{"PMID":1705633,"re_id":3,"annotated sentence":"<e1>Enalkiren<\\e1> (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the <e2>human renin<\\e2> substrate, angiotensinogen","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Enalkiren","object":"human renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the <e2>GENE-Y<\\e2> substrate, angiotensinogen","sentence":"Enalkiren (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate, angiotensinogen"}
{"PMID":1705633,"re_id":4,"annotated sentence":"Enalkiren (<e1>A-64662<\\e1> , a potent, dipeptide <e2>renin<\\e2> inhibitor, mimics the transition state of the human renin substrate, angiotensinogen","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"A-64662","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Enalkiren (<e1>CHEMICAL<\\e1> , a potent, dipeptide <e2>GENE-Y<\\e2> inhibitor, mimics the transition state of the human GENE-Y substrate, angiotensinogen","sentence":"Enalkiren (A-64662 , a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate, angiotensinogen"}
{"PMID":1705633,"re_id":5,"annotated sentence":"Enalkiren (<e1>A-64662<\\e1> , a potent, dipeptide renin inhibitor, mimics the transition state of the <e2>human renin<\\e2> substrate, angiotensinogen","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"A-64662","object":"human renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Enalkiren (<e1>CHEMICAL<\\e1> , a potent, dipeptide renin inhibitor, mimics the transition state of the <e2>GENE-Y<\\e2> substrate, angiotensinogen","sentence":"Enalkiren (A-64662 , a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate, angiotensinogen"}
{"PMID":1705633,"re_id":6,"annotated sentence":"The results of clinical trials with <e1>enalkiren<\\e1> are encouraging, and suggest that <e2>renin<\\e2> inhibitors may be safe, useful therapeutic agents in the management of hypertension.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"enalkiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results of clinical trials with <e1>CHEMICAL<\\e1> are encouraging, and suggest that <e2>GENE-Y<\\e2> inhibitors may be safe, useful therapeutic agents in the management of hypertension.","sentence":"The results of clinical trials with enalkiren are encouraging, and suggest that renin inhibitors may be safe, useful therapeutic agents in the management of hypertension."}
{"PMID":1705633,"re_id":7,"annotated sentence":"<e1>Enalkiren<\\e1> has been shown to produce dose-related suppression of plasma <e2>renin<\\e2> activity (PRA) and angiotensin II when administered intravenously","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Enalkiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has been shown to produce dose-related suppression of plasma <e2>GENE-Y<\\e2> activity (PRA) and angiotensin II when administered intravenously","sentence":"Enalkiren has been shown to produce dose-related suppression of plasma renin activity (PRA) and angiotensin II when administered intravenously"}
{"PMID":1705633,"re_id":8,"annotated sentence":"<e1>Enalkiren<\\e1> has been shown to produce dose-related suppression of plasma renin activity (PRA) and <e2>angiotensin II<\\e2> when administered intravenously","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Enalkiren","object":"angiotensin II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has been shown to produce dose-related suppression of plasma renin activity (PRA) and <e2>GENE-Y<\\e2> when administered intravenously","sentence":"Enalkiren has been shown to produce dose-related suppression of plasma renin activity (PRA) and angiotensin II when administered intravenously"}
{"PMID":1705633,"re_id":9,"annotated sentence":"Enalkiren (A-64662), a potent, <e1>dipeptide<\\e1> <e2>renin<\\e2> inhibitor, mimics the transition state of the human renin substrate, angiotensinogen","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dipeptide","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Enalkiren (A-64662), a potent, <e1>CHEMICAL<\\e1> <e2>GENE-Y<\\e2> inhibitor, mimics the transition state of the human GENE-Y substrate, angiotensinogen","sentence":"Enalkiren (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate, angiotensinogen"}
{"PMID":1705633,"re_id":10,"annotated sentence":"Enalkiren (A-64662), a potent, <e1>dipeptide<\\e1> renin inhibitor, mimics the transition state of the <e2>human renin<\\e2> substrate, angiotensinogen","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dipeptide","object":"human renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Enalkiren (A-64662), a potent, <e1>CHEMICAL<\\e1> renin inhibitor, mimics the transition state of the <e2>GENE-Y<\\e2> substrate, angiotensinogen","sentence":"Enalkiren (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate, angiotensinogen"}
{"PMID":17067304,"re_id":0,"annotated sentence":"Results showed that neonatal <e1>quinpirole<\\e1> treatment induced <e2>D2<\\e2> priming that was eliminated by olanzapine treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results showed that neonatal <e1>CHEMICAL<\\e1> treatment induced <e2>GENE-Y<\\e2> priming that was eliminated by olanzapine treatment","sentence":"Results showed that neonatal quinpirole treatment induced D2 priming that was eliminated by olanzapine treatment"}
{"PMID":17067304,"re_id":1,"annotated sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal <e2>NGF<\\e2>  BDNF and ChAT that was eliminated by <e1>olanzapine<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"olanzapine","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal <e2>GENE-Y<\\e2>  BDNF and ChAT that was eliminated by <e1>CHEMICAL<\\e1> treatment","sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF  BDNF and ChAT that was eliminated by olanzapine treatment"}
{"PMID":17067304,"re_id":2,"annotated sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, <e2>BDNF<\\e2> and ChAT that was eliminated by <e1>olanzapine<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"olanzapine","object":"BDNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, <e2>GENE-Y<\\e2> and ChAT that was eliminated by <e1>CHEMICAL<\\e1> treatment","sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and ChAT that was eliminated by olanzapine treatment"}
{"PMID":17067304,"re_id":3,"annotated sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and <e2>ChAT<\\e2> that was eliminated by <e1>olanzapine<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"olanzapine","object":"ChAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and <e2>GENE-Y<\\e2> that was eliminated by <e1>CHEMICAL<\\e1> treatment","sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and ChAT that was eliminated by olanzapine treatment"}
{"PMID":17067304,"re_id":4,"annotated sentence":"Results showed that neonatal quinpirole treatment induced <e2>D2<\\e2> priming that was eliminated by <e1>olanzapine<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"olanzapine","object":"D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results showed that neonatal quinpirole treatment induced <e2>GENE-Y<\\e2> priming that was eliminated by <e1>CHEMICAL<\\e1> treatment","sentence":"Results showed that neonatal quinpirole treatment induced D2 priming that was eliminated by olanzapine treatment"}
{"PMID":17067304,"re_id":5,"annotated sentence":"Brain tissue analyses revealed that neonatal <e1>quinpirole<\\e1> treatment produced a significant decrease in hippocampal <e2>NGF<\\e2>  BDNF and ChAT that was eliminated by olanzapine treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"NGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Brain tissue analyses revealed that neonatal <e1>CHEMICAL<\\e1> treatment produced a significant decrease in hippocampal <e2>GENE-Y<\\e2>  BDNF and ChAT that was eliminated by olanzapine treatment","sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF  BDNF and ChAT that was eliminated by olanzapine treatment"}
{"PMID":17067304,"re_id":6,"annotated sentence":"Brain tissue analyses revealed that neonatal <e1>quinpirole<\\e1> treatment produced a significant decrease in hippocampal NGF, <e2>BDNF<\\e2> and ChAT that was eliminated by olanzapine treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"BDNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Brain tissue analyses revealed that neonatal <e1>CHEMICAL<\\e1> treatment produced a significant decrease in hippocampal NGF, <e2>GENE-Y<\\e2> and ChAT that was eliminated by olanzapine treatment","sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and ChAT that was eliminated by olanzapine treatment"}
{"PMID":17067304,"re_id":7,"annotated sentence":"Brain tissue analyses revealed that neonatal <e1>quinpirole<\\e1> treatment produced a significant decrease in hippocampal NGF, BDNF and <e2>ChAT<\\e2> that was eliminated by olanzapine treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"ChAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Brain tissue analyses revealed that neonatal <e1>CHEMICAL<\\e1> treatment produced a significant decrease in hippocampal NGF, BDNF and <e2>GENE-Y<\\e2> that was eliminated by olanzapine treatment","sentence":"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and ChAT that was eliminated by olanzapine treatment"}
{"PMID":17067304,"re_id":8,"annotated sentence":"Neonatal <e1>quinpirole<\\e1> treatment produced a significant decrease in <e2>BDNF<\\e2> and ChAT in the frontal cortex that was unaffected by olanzapine treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"BDNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Neonatal <e1>CHEMICAL<\\e1> treatment produced a significant decrease in <e2>GENE-Y<\\e2> and ChAT in the frontal cortex that was unaffected by olanzapine treatment","sentence":"Neonatal quinpirole treatment produced a significant decrease in BDNF and ChAT in the frontal cortex that was unaffected by olanzapine treatment"}
{"PMID":17067304,"re_id":9,"annotated sentence":"Neonatal <e1>quinpirole<\\e1> treatment produced a significant decrease in BDNF and <e2>ChAT<\\e2> in the frontal cortex that was unaffected by olanzapine treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinpirole","object":"ChAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Neonatal <e1>CHEMICAL<\\e1> treatment produced a significant decrease in BDNF and <e2>GENE-Y<\\e2> in the frontal cortex that was unaffected by olanzapine treatment","sentence":"Neonatal quinpirole treatment produced a significant decrease in BDNF and ChAT in the frontal cortex that was unaffected by olanzapine treatment"}
{"PMID":17067304,"re_id":10,"annotated sentence":"These results show that <e1>olanzapine<\\e1> eliminates <e2>D2 receptor<\\e2> priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"olanzapine","object":"D2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results show that <e1>CHEMICAL<\\e1> eliminates <e2>GENE-Y<\\e2> priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus.","sentence":"These results show that olanzapine eliminates D2 receptor priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus."}
{"PMID":17075268,"re_id":0,"annotated sentence":"Histamine content, <e2>HDC<\\e2> activity and HDC mRNA expression in nasal mucosa were also significantly increased after <e1>TDI<\\e1> provocation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TDI","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Histamine content, <e2>GENE-Y<\\e2> activity and GENE-Y mRNA expression in nasal mucosa were also significantly increased after <e1>CHEMICAL<\\e1> provocation","sentence":"Histamine content, HDC activity and HDC mRNA expression in nasal mucosa were also significantly increased after TDI provocation"}
{"PMID":17075268,"re_id":1,"annotated sentence":"Histamine content, HDC activity and <e2>HDC<\\e2> mRNA expression in nasal mucosa were also significantly increased after <e1>TDI<\\e1> provocation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TDI","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Histamine content, GENE-Y activity and <e2>GENE-Y<\\e2> mRNA expression in nasal mucosa were also significantly increased after <e1>CHEMICAL<\\e1> provocation","sentence":"Histamine content, HDC activity and HDC mRNA expression in nasal mucosa were also significantly increased after TDI provocation"}
{"PMID":17075268,"re_id":2,"annotated sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, <e2>HDC<\\e2> activity and HDC mRNA induced by <e1>TDI<\\e1> in TDI-sensitized rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TDI","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, <e2>GENE-Y<\\e2> activity and GENE-Y mRNA induced by <e1>CHEMICAL<\\e1> in CHEMICAL-sensitized rats","sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and HDC mRNA induced by TDI in TDI-sensitized rats"}
{"PMID":17075268,"re_id":3,"annotated sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and <e2>HDC<\\e2> mRNA induced by <e1>TDI<\\e1> in TDI-sensitized rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TDI","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, GENE-Y activity and <e2>GENE-Y<\\e2> mRNA induced by <e1>CHEMICAL<\\e1> in CHEMICAL-sensitized rats","sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and HDC mRNA induced by TDI in TDI-sensitized rats"}
{"PMID":17075268,"re_id":4,"annotated sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and <e2>HDC<\\e2> mRNA induced by TDI in <e1>TDI<\\e1> sensitized rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TDI","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, GENE-Y activity and <e2>GENE-Y<\\e2> mRNA induced by CHEMICAL in <e1>CHEMICAL<\\e1> sensitized rats","sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and HDC mRNA induced by TDI in TDI sensitized rats"}
{"PMID":17075268,"re_id":5,"annotated sentence":"Repression of <e2>HDC<\\e2> gene expression and HDC activity by <e1>dexamethasone<\\e1> may underlie its therapeutic effect in the treatment of allergy.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dexamethasone","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Repression of <e2>GENE-Y<\\e2> gene expression and GENE-Y activity by <e1>CHEMICAL<\\e1> may underlie its therapeutic effect in the treatment of allergy.","sentence":"Repression of HDC gene expression and HDC activity by dexamethasone may underlie its therapeutic effect in the treatment of allergy."}
{"PMID":17075268,"re_id":6,"annotated sentence":"Repression of HDC gene expression and <e2>HDC<\\e2> activity by <e1>dexamethasone<\\e1> may underlie its therapeutic effect in the treatment of allergy.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dexamethasone","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Repression of GENE-Y gene expression and <e2>GENE-Y<\\e2> activity by <e1>CHEMICAL<\\e1> may underlie its therapeutic effect in the treatment of allergy.","sentence":"Repression of HDC gene expression and HDC activity by dexamethasone may underlie its therapeutic effect in the treatment of allergy."}
{"PMID":17075268,"re_id":7,"annotated sentence":"<e1>Dexamethasone<\\e1> suppresses histamine synthesis by repressing both transcription and activity of <e2>HDC<\\e2> in allergic rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dexamethasone","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppresses histamine synthesis by repressing both transcription and activity of <e2>GENE-Y<\\e2> in allergic rats","sentence":"Dexamethasone suppresses histamine synthesis by repressing both transcription and activity of HDC in allergic rats"}
{"PMID":17075268,"re_id":8,"annotated sentence":"Pretreatment with <e1>dexamethasone<\\e1> significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, <e2>HDC<\\e2> activity and HDC mRNA induced by TDI in TDI-sensitized rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dexamethasone","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with <e1>CHEMICAL<\\e1> significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, <e2>GENE-Y<\\e2> activity and GENE-Y mRNA induced by TDI in TDI-sensitized rats","sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and HDC mRNA induced by TDI in TDI-sensitized rats"}
{"PMID":17075268,"re_id":9,"annotated sentence":"Pretreatment with <e1>dexamethasone<\\e1> significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and <e2>HDC<\\e2> mRNA induced by TDI in TDI-sensitized rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dexamethasone","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with <e1>CHEMICAL<\\e1> significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, GENE-Y activity and <e2>GENE-Y<\\e2> mRNA induced by TDI in TDI-sensitized rats","sentence":"Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and HDC mRNA induced by TDI in TDI-sensitized rats"}
{"PMID":17075268,"re_id":10,"annotated sentence":"However the regulatory mechanism of <e1>histamine<\\e1> synthesis by <e2>HDC<\\e2> remains to be elucidated","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"histamine","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However the regulatory mechanism of <e1>CHEMICAL<\\e1> synthesis by <e2>GENE-Y<\\e2> remains to be elucidated","sentence":"However the regulatory mechanism of histamine synthesis by HDC remains to be elucidated"}
{"PMID":17075268,"re_id":11,"annotated sentence":"BACKGROUND: Histamine synthesized by <e2>histidine decarboxylase<\\e2> (HDC) from <e1>L-histidine<\\e1> is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-histidine","object":"histidine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Histamine synthesized by <e2>GENE-Y<\\e2> (HDC) from <e1>CHEMICAL<\\e1> is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity","sentence":"BACKGROUND: Histamine synthesized by histidine decarboxylase (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity"}
{"PMID":17075268,"re_id":12,"annotated sentence":"BACKGROUND: Histamine synthesized by histidine decarboxylase (<e2>HDC<\\e2>  from <e1>L-histidine<\\e1> is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-histidine","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Histamine synthesized by histidine decarboxylase (<e2>GENE-Y<\\e2>  from <e1>CHEMICAL<\\e1> is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity","sentence":"BACKGROUND: Histamine synthesized by histidine decarboxylase (HDC  from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity"}
{"PMID":17075268,"re_id":13,"annotated sentence":"BACKGROUND: <e1>Histamine<\\e1> synthesized by <e2>histidine decarboxylase<\\e2> (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Histamine","object":"histidine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1> synthesized by <e2>GENE-Y<\\e2> (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity","sentence":"BACKGROUND: Histamine synthesized by histidine decarboxylase (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity"}
{"PMID":17075268,"re_id":14,"annotated sentence":"BACKGROUND: <e1>Histamine<\\e1> synthesized by histidine decarboxylase (<e2>HDC<\\e2>  from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Histamine","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: <e1>CHEMICAL<\\e1> synthesized by histidine decarboxylase (<e2>GENE-Y<\\e2>  from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity","sentence":"BACKGROUND: Histamine synthesized by histidine decarboxylase (HDC  from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity"}
{"PMID":17075268,"re_id":15,"annotated sentence":"CONCLUSIONS: These findings indicate that increased synthesis of <e1>histamine<\\e1> through up-regulation of <e2>HDC<\\e2> gene expression and HDC activity in nasal mucosa plays an important role in the development of nasal hypersensitivity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"histamine","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: These findings indicate that increased synthesis of <e1>CHEMICAL<\\e1> through up-regulation of <e2>GENE-Y<\\e2> gene expression and GENE-Y activity in nasal mucosa plays an important role in the development of nasal hypersensitivity","sentence":"CONCLUSIONS: These findings indicate that increased synthesis of histamine through up-regulation of HDC gene expression and HDC activity in nasal mucosa plays an important role in the development of nasal hypersensitivity"}
{"PMID":17075268,"re_id":16,"annotated sentence":"CONCLUSIONS: These findings indicate that increased synthesis of <e1>histamine<\\e1> through up-regulation of HDC gene expression and <e2>HDC<\\e2> activity in nasal mucosa plays an important role in the development of nasal hypersensitivity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"histamine","object":"HDC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: These findings indicate that increased synthesis of <e1>CHEMICAL<\\e1> through up-regulation of GENE-Y gene expression and <e2>GENE-Y<\\e2> activity in nasal mucosa plays an important role in the development of nasal hypersensitivity","sentence":"CONCLUSIONS: These findings indicate that increased synthesis of histamine through up-regulation of HDC gene expression and HDC activity in nasal mucosa plays an important role in the development of nasal hypersensitivity"}
{"PMID":17079868,"re_id":0,"annotated sentence":"Methionine synthase reductase (<e2>MTRR<\\e2>  is an enzyme involved in the conversion of <e1>Hcy<\\e1> to methionine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Hcy","object":"MTRR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methionine synthase reductase (<e2>GENE-Y<\\e2>  is an enzyme involved in the conversion of <e1>CHEMICAL<\\e1> to methionine","sentence":"Methionine synthase reductase (MTRR  is an enzyme involved in the conversion of Hcy to methionine"}
{"PMID":17079868,"re_id":1,"annotated sentence":"<e2>Methionine synthase reductase<\\e2> (MTRR) is an enzyme involved in the conversion of <e1>Hcy<\\e1> to methionine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Hcy","object":"Methionine synthase reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (MTRR) is an enzyme involved in the conversion of <e1>CHEMICAL<\\e1> to methionine","sentence":"Methionine synthase reductase (MTRR) is an enzyme involved in the conversion of Hcy to methionine"}
{"PMID":17079868,"re_id":2,"annotated sentence":"Methionine synthase reductase (<e2>MTRR<\\e2>  is an enzyme involved in the conversion of Hcy to <e1>methionine<\\e1>  We hypothesized that certain genetic polymorphisms of MTRR leading to reduced enzyme activity may cause hyperhomocysteinemia and affect bone metabolism","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methionine","object":"MTRR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methionine synthase reductase (<e2>GENE-Y<\\e2>  is an enzyme involved in the conversion of Hcy to <e1>CHEMICAL<\\e1>  We hypothesized that certain genetic polymorphisms of GENE-Y leading to reduced enzyme activity may cause hyperhomocysteinemia and affect bone metabolism","sentence":"Methionine synthase reductase (MTRR  is an enzyme involved in the conversion of Hcy to methionine  We hypothesized that certain genetic polymorphisms of MTRR leading to reduced enzyme activity may cause hyperhomocysteinemia and affect bone metabolism"}
{"PMID":17079868,"re_id":3,"annotated sentence":"<e2>Methionine synthase reductase<\\e2> (MTRR) is an enzyme involved in the conversion of Hcy to <e1>methionine<\\e1>  We hypothesized that certain genetic polymorphisms of MTRR leading to reduced enzyme activity may cause hyperhomocysteinemia and affect bone metabolism","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"methionine","object":"Methionine synthase reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (MTRR) is an enzyme involved in the conversion of Hcy to <e1>CHEMICAL<\\e1>  We hypothesized that certain genetic polymorphisms of MTRR leading to reduced enzyme activity may cause hyperhomocysteinemia and affect bone metabolism","sentence":"Methionine synthase reductase (MTRR) is an enzyme involved in the conversion of Hcy to methionine  We hypothesized that certain genetic polymorphisms of MTRR leading to reduced enzyme activity may cause hyperhomocysteinemia and affect bone metabolism"}
{"PMID":17081103,"re_id":0,"annotated sentence":"<e2>GPxs<\\e2> reduce hydroperoxides to the corresponding <e1>alcohols<\\e1> by means of glutathione (GSH)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alcohols","object":"GPxs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> reduce hydroperoxides to the corresponding <e1>CHEMICAL<\\e1> by means of glutathione (GSH)","sentence":"GPxs reduce hydroperoxides to the corresponding alcohols by means of glutathione (GSH)"}
{"PMID":17085856,"re_id":0,"annotated sentence":"The non-selective <e2>adenosine receptor<\\e2> antagonist (<e1>caffeine<\\e1> , and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"caffeine","object":"adenosine receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The non-selective <e2>GENE-N<\\e2> antagonist (<e1>CHEMICAL<\\e1> , and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice","sentence":"The non-selective adenosine receptor antagonist (caffeine , and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice"}
{"PMID":17085856,"re_id":1,"annotated sentence":"The non-selective adenosine receptor antagonist (caffeine), and the selective <e2>adenosine A1 receptor<\\e2> antagonist (<e1>DPCPX<\\e1> , injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"DPCPX","object":"adenosine A1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The non-selective adenosine receptor antagonist (caffeine), and the selective <e2>GENE-Y<\\e2> antagonist (<e1>CHEMICAL<\\e1> , injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice","sentence":"The non-selective adenosine receptor antagonist (caffeine), and the selective adenosine A1 receptor antagonist (DPCPX , injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice"}
{"PMID":17085856,"re_id":2,"annotated sentence":"The concomitant application of subconvulsive dose of pentetrazole (55.0 mg\/kg) with low dose of <e1>flumazenil<\\e1> (5.0 mg\/kg) - a <e2>BDZ receptor<\\e2> antagonist, immediately induced BDZ withdrawal signs in these animals","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"flumazenil","object":"BDZ receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The concomitant application of subconvulsive dose of pentetrazole (55.0 mg\/kg) with low dose of <e1>CHEMICAL<\\e1> (5.0 mg\/kg) - a <e2>GENE-N<\\e2> antagonist, immediately induced BDZ withdrawal signs in these animals","sentence":"The concomitant application of subconvulsive dose of pentetrazole (55.0 mg\/kg) with low dose of flumazenil (5.0 mg\/kg) - a BDZ receptor antagonist, immediately induced BDZ withdrawal signs in these animals"}
{"PMID":17159811,"re_id":0,"annotated sentence":"In the interaction of <e1>GAL<\\e1> and CAR, <e2>AChE<\\e2> inhibition was stronger but without any statistical significance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GAL","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the interaction of <e1>CHEMICAL<\\e1> and CAR, <e2>GENE-Y<\\e2> inhibition was stronger but without any statistical significance","sentence":"In the interaction of GAL and CAR, AChE inhibition was stronger but without any statistical significance"}
{"PMID":17159811,"re_id":1,"annotated sentence":"OBJECTIVES: The alkaloid <e1>galantamine<\\e1> (GAL), which exhibits a combined <e2>anticholinesterase<\\e2> and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"galantamine","object":"anticholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVES: The alkaloid <e1>CHEMICAL<\\e1> (GAL), which exhibits a combined <e2>GENE-Y<\\e2> and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases","sentence":"OBJECTIVES: The alkaloid galantamine (GAL), which exhibits a combined anticholinesterase and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases"}
{"PMID":17159811,"re_id":2,"annotated sentence":"OBJECTIVES: The alkaloid galantamine (<e1>GAL<\\e1> , which exhibits a combined <e2>anticholinesterase<\\e2> and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GAL","object":"anticholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVES: The alkaloid galantamine (<e1>CHEMICAL<\\e1> , which exhibits a combined <e2>GENE-Y<\\e2> and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases","sentence":"OBJECTIVES: The alkaloid galantamine (GAL , which exhibits a combined anticholinesterase and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases"}
{"PMID":17159811,"re_id":3,"annotated sentence":"RESULTS: Following administration of the highest of the <e1>GAL<\\e1> doses used (2.5; 5; 10 mg\/kg i.m.), <e2>AChE<\\e2> activity decreased mainly in the frontal cortex, hippocampus and hypophysis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GAL","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Following administration of the highest of the <e1>CHEMICAL<\\e1> doses used (2.5; 5; 10 mg\/kg i.m.), <e2>GENE-Y<\\e2> activity decreased mainly in the frontal cortex, hippocampus and hypophysis","sentence":"RESULTS: Following administration of the highest of the GAL doses used (2.5; 5; 10 mg\/kg i.m.), AChE activity decreased mainly in the frontal cortex, hippocampus and hypophysis"}
{"PMID":17161452,"re_id":0,"annotated sentence":"Pharmacogenetic analysis of two genes, the <e1>warfarin<\\e1> metabolic enzyme <e2>CYP2C9<\\e2> and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"warfarin","object":"CYP2C9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacogenetic analysis of two genes, the <e1>CHEMICAL<\\e1> metabolic enzyme <e2>GENE-Y<\\e2> and CHEMICAL target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on CHEMICAL maintenance dose","sentence":"Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose"}
{"PMID":17161452,"re_id":1,"annotated sentence":"Possession of <e2>CYP2C9<\\e2> 2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean <e1>warfarin<\\e1> dose","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"warfarin","object":"CYP2C9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Possession of <e2>GENE-Y<\\e2> 2 or GENE-Y*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean <e1>CHEMICAL<\\e1> dose","sentence":"Possession of CYP2C9 2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean warfarin dose"}
{"PMID":17161452,"re_id":2,"annotated sentence":"Possession of CYP2C9*2 or <e2>CYP2C9<\\e2> 3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean <e1>warfarin<\\e1> dose","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"warfarin","object":"CYP2C9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Possession of GENE-Y*2 or <e2>GENE-Y<\\e2> 3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean <e1>CHEMICAL<\\e1> dose","sentence":"Possession of CYP2C9*2 or CYP2C9 3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean warfarin dose"}
{"PMID":17192395,"re_id":0,"annotated sentence":"The identification of the <e2>succinate receptor<\\e2> SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of <e1>succinate<\\e1> were shown to potentiate the effect of low doses of a variety of platelet agonists.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"succinate","object":"succinate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The identification of the <e2>CHEMICAL receptor<\\e2> SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of <e1>CHEMICAL<\\e1> were shown to potentiate the effect of low doses of a variety of platelet agonists.","sentence":"The identification of the succinate receptor SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of succinate were shown to potentiate the effect of low doses of a variety of platelet agonists."}
{"PMID":17192395,"re_id":1,"annotated sentence":"The identification of the succinate receptor <e2>SUCNR1<\\e2> in platelets is of particular interest, because physiologically relevant concentrations of <e1>succinate<\\e1> were shown to potentiate the effect of low doses of a variety of platelet agonists.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"succinate","object":"SUCNR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The identification of the CHEMICAL receptor <e2>GENE-Y<\\e2> in platelets is of particular interest, because physiologically relevant concentrations of <e1>CHEMICAL<\\e1> were shown to potentiate the effect of low doses of a variety of platelet agonists.","sentence":"The identification of the succinate receptor SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of succinate were shown to potentiate the effect of low doses of a variety of platelet agonists."}
{"PMID":17197042,"re_id":0,"annotated sentence":"The activity of <e2>polymerases<\\e2> containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of <e1>foscarnet<\\e1> eight to 14 times higher than those required to inhibit wild-type polymerases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"foscarnet","object":"polymerases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The activity of <e2>GENE-N<\\e2> containing mutations known to confer resistance to CHEMICAL (V715M, T700A and N495K) was inhibited by concentrations of <e1>CHEMICAL<\\e1> eight to 14 times higher than those required to inhibit wild-type GENE-N","sentence":"The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases"}
{"PMID":17197042,"re_id":1,"annotated sentence":"The activity of polymerases containing mutations known to confer resistance to foscarnet (<e2>V715M<\\e2>  T700A and N495K) was inhibited by concentrations of <e1>foscarnet<\\e1> eight to 14 times higher than those required to inhibit wild-type polymerases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"foscarnet","object":"V715M","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The activity of polymerases containing mutations known to confer resistance to CHEMICAL (<e2>GENE-N<\\e2>  T700A and N495K) was inhibited by concentrations of <e1>CHEMICAL<\\e1> eight to 14 times higher than those required to inhibit wild-type polymerases","sentence":"The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M  T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases"}
{"PMID":17197042,"re_id":2,"annotated sentence":"The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, <e2>T700A<\\e2> and N495K) was inhibited by concentrations of <e1>foscarnet<\\e1> eight to 14 times higher than those required to inhibit wild-type polymerases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"foscarnet","object":"T700A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The activity of polymerases containing mutations known to confer resistance to CHEMICAL (V715M, <e2>GENE-N<\\e2> and N495K) was inhibited by concentrations of <e1>CHEMICAL<\\e1> eight to 14 times higher than those required to inhibit wild-type polymerases","sentence":"The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases"}
{"PMID":17197042,"re_id":3,"annotated sentence":"The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, T700A and <e2>N495K<\\e2>  was inhibited by concentrations of <e1>foscarnet<\\e1> eight to 14 times higher than those required to inhibit wild-type polymerases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"foscarnet","object":"N495K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The activity of polymerases containing mutations known to confer resistance to CHEMICAL (V715M, T700A and <e2>GENE-N<\\e2>  was inhibited by concentrations of <e1>CHEMICAL<\\e1> eight to 14 times higher than those required to inhibit wild-type polymerases","sentence":"The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K  was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases"}
{"PMID":17197042,"re_id":4,"annotated sentence":"The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of <e1>foscarnet<\\e1> eight to 14 times higher than those required to inhibit wild-type <e2>polymerases<\\e2>  Our in-house non-radioactive phenotypic assay was sensitive and reproducible","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"foscarnet","object":"polymerases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The activity of GENE-N containing mutations known to confer resistance to CHEMICAL (V715M, T700A and N495K) was inhibited by concentrations of <e1>CHEMICAL<\\e1> eight to 14 times higher than those required to inhibit wild-type <e2>GENE-N<\\e2>  Our in-house non-radioactive phenotypic assay was sensitive and reproducible","sentence":"The activity of polymerases containing mutations known to confer resistance to foscarnet (V715M, T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases  Our in-house non-radioactive phenotypic assay was sensitive and reproducible"}
{"PMID":17197042,"re_id":5,"annotated sentence":"Development and validation of a non-radioactive <e2>DNA polymerase<\\e2> assay for studying cytomegalovirus resistance to <e1>foscarnet<\\e1>  Phenotypic characterisation of the human cytomegalovirus (HCMV) pUL54 DNA polymerase is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to foscarnet","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"foscarnet","object":"DNA polymerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Development and validation of a non-radioactive <e2>GENE-N<\\e2> assay for studying cytomegalovirus resistance to <e1>CHEMICAL<\\e1>  Phenotypic characterisation of the human cytomegalovirus (HCMV) pUL54 GENE-N is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to CHEMICAL","sentence":"Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet  Phenotypic characterisation of the human cytomegalovirus (HCMV) pUL54 DNA polymerase is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to foscarnet"}
{"PMID":17199504,"re_id":0,"annotated sentence":"<e2>Adenine phosphoribosyltransferase<\\e2> plays a role in purine salvage by catalyzing the direct conversion of <e1>adenine<\\e1> to adenosine monophosphate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"adenine","object":"Adenine phosphoribosyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> plays a role in purine salvage by catalyzing the direct conversion of <e1>CHEMICAL<\\e1> to adenosine monophosphate","sentence":"Adenine phosphoribosyltransferase plays a role in purine salvage by catalyzing the direct conversion of adenine to adenosine monophosphate"}
{"PMID":17199504,"re_id":1,"annotated sentence":"<e2>Adenine phosphoribosyltransferase<\\e2> plays a role in purine salvage by catalyzing the direct conversion of adenine to <e1>adenosine monophosphate<\\e1>  The involvement of the purine salvage pathway in tumor proliferation and angiogenesis makes adenine phosphoribosyltransferase a potential target for oncology drug discovery","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"adenosine monophosphate","object":"Adenine phosphoribosyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> plays a role in purine salvage by catalyzing the direct conversion of adenine to <e1>CHEMICAL<\\e1>  The involvement of the purine salvage pathway in tumor proliferation and angiogenesis makes adenine phosphoribosyltransferase a potential target for oncology drug discovery","sentence":"Adenine phosphoribosyltransferase plays a role in purine salvage by catalyzing the direct conversion of adenine to adenosine monophosphate  The involvement of the purine salvage pathway in tumor proliferation and angiogenesis makes adenine phosphoribosyltransferase a potential target for oncology drug discovery"}
{"PMID":17205056,"re_id":0,"annotated sentence":"Antitumor activity of <e1>sorafenib<\\e1> in <e2>FLT3<\\e2> driven leukemic cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Antitumor activity of <e1>CHEMICAL<\\e1> in <e2>GENE-Y<\\e2> driven leukemic cells","sentence":"Antitumor activity of sorafenib in FLT3 driven leukemic cells"}
{"PMID":17205056,"re_id":1,"annotated sentence":"The demonstration that <e1>sorafenib<\\e1> exhibits potent target inhibition and efficacy in <e2>FLT3<\\e2> driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The demonstration that <e1>CHEMICAL<\\e1> exhibits potent target inhibition and efficacy in <e2>GENE-Y<\\e2> driven models suggests that this compound may have a therapeutic benefit for patients with GENE-Y-driven leukemias.","sentence":"The demonstration that sorafenib exhibits potent target inhibition and efficacy in FLT3 driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias."}
{"PMID":17205056,"re_id":2,"annotated sentence":"The demonstration that <e1>sorafenib<\\e1> exhibits potent target inhibition and efficacy in FLT3-driven models suggests that this compound may have a therapeutic benefit for patients with <e2>FLT3<\\e2> driven leukemias.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The demonstration that <e1>CHEMICAL<\\e1> exhibits potent target inhibition and efficacy in GENE-Y-driven models suggests that this compound may have a therapeutic benefit for patients with <e2>GENE-Y<\\e2> driven leukemias.","sentence":"The demonstration that sorafenib exhibits potent target inhibition and efficacy in FLT3-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3 driven leukemias."}
{"PMID":17205056,"re_id":3,"annotated sentence":"We show that <e1>sorafenib<\\e1> (BAY 43-9006, Nexavar) potently inhibits <e2>FLT3<\\e2> enzymatic and signaling activities","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We show that <e1>CHEMICAL<\\e1> (BAY 43-9006, Nexavar) potently inhibits <e2>GENE-Y<\\e2> enzymatic and signaling activities","sentence":"We show that sorafenib (BAY 43-9006, Nexavar) potently inhibits FLT3 enzymatic and signaling activities"}
{"PMID":17205056,"re_id":4,"annotated sentence":"We show that sorafenib (<e1>BAY 43-9006<\\e1>  Nexavar) potently inhibits <e2>FLT3<\\e2> enzymatic and signaling activities","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BAY 43-9006","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We show that sorafenib (<e1>CHEMICAL<\\e1>  Nexavar) potently inhibits <e2>GENE-Y<\\e2> enzymatic and signaling activities","sentence":"We show that sorafenib (BAY 43-9006  Nexavar) potently inhibits FLT3 enzymatic and signaling activities"}
{"PMID":17205056,"re_id":5,"annotated sentence":"We show that sorafenib (BAY 43-9006, <e1>Nexavar<\\e1>  potently inhibits <e2>FLT3<\\e2> enzymatic and signaling activities","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nexavar","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We show that sorafenib (BAY 43-9006, <e1>CHEMICAL<\\e1>  potently inhibits <e2>GENE-Y<\\e2> enzymatic and signaling activities","sentence":"We show that sorafenib (BAY 43-9006, Nexavar  potently inhibits FLT3 enzymatic and signaling activities"}
{"PMID":17205056,"re_id":6,"annotated sentence":"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, <e1>sorafenib<\\e1> blocked basal and ligand dependent <e2>FLT3<\\e2> mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1\/2 and Stat5 phosphorylation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In HEK293 cells stably transfected with GENE-Y-WT or GENE-Y-ITD, <e1>CHEMICAL<\\e1> blocked basal and ligand dependent <e2>GENE-Y<\\e2> mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1\/2 and Stat5 phosphorylation","sentence":"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3 mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1\/2 and Stat5 phosphorylation"}
{"PMID":17205056,"re_id":7,"annotated sentence":"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, <e1>sorafenib<\\e1> blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as <e2>extracellular signal-regulated kinase1\/2<\\e2> and Stat5 phosphorylation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"extracellular signal-regulated kinase1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, <e1>CHEMICAL<\\e1> blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as <e2>GENE-N<\\e2> and Stat5 phosphorylation","sentence":"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1\/2 and Stat5 phosphorylation"}
{"PMID":17205056,"re_id":8,"annotated sentence":"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, <e1>sorafenib<\\e1> blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1\/2 and <e2>Stat5<\\e2> phosphorylation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"Stat5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, <e1>CHEMICAL<\\e1> blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1\/2 and <e2>GENE-Y<\\e2> phosphorylation","sentence":"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, sorafenib blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1\/2 and Stat5 phosphorylation"}
{"PMID":17205056,"re_id":9,"annotated sentence":"In leukemia cell lines MV4-11 and EOL-1, <e1>sorafenib<\\e1> treatment resulted in decreased cell proliferation and inhibition of <e2>FLT3<\\e2> signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In leukemia cell lines MV4-11 and EOL-1, <e1>CHEMICAL<\\e1> treatment resulted in decreased cell proliferation and inhibition of <e2>GENE-Y<\\e2> signaling","sentence":"In leukemia cell lines MV4-11 and EOL-1, sorafenib treatment resulted in decreased cell proliferation and inhibition of FLT3 signaling"}
{"PMID":17205056,"re_id":10,"annotated sentence":"The growth of the <e2>FLT3<\\e2> independent RS4-11 cell line was only weakly inhibited by <e1>sorafenib<\\e1>  Cell cycle arrest and induction of apoptosis were observed upon treatment with sorafenib in MV4-11 and EOL-1 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The growth of the <e2>GENE-Y<\\e2> independent RS4-11 cell line was only weakly inhibited by <e1>CHEMICAL<\\e1>  Cell cycle arrest and induction of apoptosis were observed upon treatment with CHEMICAL in MV4-11 and EOL-1 cells","sentence":"The growth of the FLT3 independent RS4-11 cell line was only weakly inhibited by sorafenib  Cell cycle arrest and induction of apoptosis were observed upon treatment with sorafenib in MV4-11 and EOL-1 cells"}
{"PMID":17210712,"re_id":0,"annotated sentence":"They all expressed ASS, but not <e2>ornithine transcarbamylase<\\e2> (OTC), the enzyme that converts <e1>ornithine<\\e1>  the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ornithine","object":"ornithine transcarbamylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"They all expressed ASS, but not <e2>CHEMICAL transcarbamylase<\\e2> (OTC), the enzyme that converts <e1>CHEMICAL<\\e1>  the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS","sentence":"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine  the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS"}
{"PMID":17210712,"re_id":1,"annotated sentence":"They all expressed ASS, but not ornithine transcarbamylase (<e2>OTC<\\e2> , the enzyme that converts <e1>ornithine<\\e1>  the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ornithine","object":"OTC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"They all expressed ASS, but not CHEMICAL transcarbamylase (<e2>GENE-Y<\\e2> , the enzyme that converts <e1>CHEMICAL<\\e1>  the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS","sentence":"They all expressed ASS, but not ornithine transcarbamylase (OTC , the enzyme that converts ornithine  the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS"}
{"PMID":17210712,"re_id":2,"annotated sentence":"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of <e1>arginine<\\e1> with <e2>rhArg<\\e2>  to citrulline, which is converted back to arginine via ASS","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arginine","object":"rhArg","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of <e1>CHEMICAL<\\e1> with <e2>GENE-N<\\e2>  to citrulline, which is converted back to CHEMICAL via ASS","sentence":"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg  to citrulline, which is converted back to arginine via ASS"}
{"PMID":17210712,"re_id":3,"annotated sentence":"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with <e2>rhArg<\\e2>  to <e1>citrulline<\\e1>  which is converted back to arginine via ASS","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"citrulline","object":"rhArg","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with <e2>GENE-N<\\e2>  to <e1>CHEMICAL<\\e1>  which is converted back to arginine via ASS","sentence":"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg  to citrulline  which is converted back to arginine via ASS"}
{"PMID":17210712,"re_id":4,"annotated sentence":"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to <e1>arginine<\\e1> via <e2>ASS<\\e2>  Transfection of HCC cells with OTC resulted in resistance to rhArg","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arginine","object":"ASS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"They all expressed GENE-Y, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of CHEMICAL with rhArg, to citrulline, which is converted back to <e1>CHEMICAL<\\e1> via <e2>GENE-Y<\\e2>  Transfection of HCC cells with OTC resulted in resistance to rhArg","sentence":"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS  Transfection of HCC cells with OTC resulted in resistance to rhArg"}
{"PMID":17210712,"re_id":5,"annotated sentence":"This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to <e2>rhArg<\\e2> mediated <e1>arginine<\\e1> depletion","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arginine","object":"rhArg","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to <e2>GENE-N<\\e2> mediated <e1>CHEMICAL<\\e1> depletion","sentence":"This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to rhArg mediated arginine depletion"}
{"PMID":17210712,"re_id":6,"annotated sentence":"Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to <e1>arginine<\\e1> depletion with <e2>arginine-depleting enzymes<\\e2>  We have also shown that the rhArg native enzyme and the pegylated rhArg (rhArg-peg(5,000mw)) gave similar anticancer efficacy in vitro","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arginine","object":"arginine-depleting enzymes","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to <e1>CHEMICAL<\\e1> depletion with <e2>CHEMICAL-depleting enzymes<\\e2>  We have also shown that the rhArg native enzyme and the pegylated rhArg (rhArg-peg(5,000mw)) gave similar anticancer efficacy in vitro","sentence":"Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to arginine depletion with arginine-depleting enzymes  We have also shown that the rhArg native enzyme and the pegylated rhArg (rhArg-peg(5,000mw)) gave similar anticancer efficacy in vitro"}
{"PMID":17253779,"re_id":0,"annotated sentence":"Unlike mouse RetSat (mRetSat), <e2>zRetSat A<\\e2> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of <e1>all-trans-retinol<\\e1> to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"all-trans-retinol","object":"zRetSat A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unlike mouse RetSat (mRetSat), <e2>GENE-Y<\\e2> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of <e1>CHEMICAL<\\e1> to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively","sentence":"Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively"}
{"PMID":17253779,"re_id":1,"annotated sentence":"Specifically, <e1>all-trans-13,14-dihydroretinol<\\e1> is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by <e2>Cyp26<\\e2> enzymes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"all-trans-13,14-dihydroretinol","object":"Cyp26","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Specifically, <e1>CHEMICAL<\\e1> is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by <e2>GENE-Y<\\e2> enzymes","sentence":"Specifically, all-trans-13,14-dihydroretinol is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by Cyp26 enzymes"}
{"PMID":17253779,"re_id":2,"annotated sentence":"Specificity of <e2>zebrafish retinol saturase<\\e2>  formation of <e1>all-trans-13,14-dihydroretinol<\\e1> and all-trans-7,8- dihydroretinol","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"all-trans-13,14-dihydroretinol","object":"zebrafish retinol saturase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Specificity of <e2>GENE-Y<\\e2>  formation of <e1>CHEMICAL<\\e1> and all-trans-7,8- dihydroretinol","sentence":"Specificity of zebrafish retinol saturase  formation of all-trans-13,14-dihydroretinol and all-trans-7,8- dihydroretinol"}
{"PMID":17253779,"re_id":3,"annotated sentence":"Specificity of <e2>zebrafish retinol saturase<\\e2>  formation of all-trans-13,14-dihydroretinol and <e1>all-trans-7,8- dihydroretinol<\\e1>  Metabolism of vitamin A, all-trans-retinol, leads to the formation of 11-cis-retinaldehyde, the visual chromophore, and all-trans-retinoic acid, which is involved in the regulation of gene expression through the retinoic acid receptor","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"all-trans-7,8- dihydroretinol","object":"zebrafish retinol saturase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Specificity of <e2>GENE-Y<\\e2>  formation of all-trans-13,14-dihydroretinol and <e1>CHEMICAL<\\e1>  Metabolism of vitamin A, all-trans-retinol, leads to the formation of 11-cis-retinaldehyde, the visual chromophore, and all-trans-retinoic acid, which is involved in the regulation of gene expression through the retinoic acid receptor","sentence":"Specificity of zebrafish retinol saturase  formation of all-trans-13,14-dihydroretinol and all-trans-7,8- dihydroretinol  Metabolism of vitamin A, all-trans-retinol, leads to the formation of 11-cis-retinaldehyde, the visual chromophore, and all-trans-retinoic acid, which is involved in the regulation of gene expression through the retinoic acid receptor"}
{"PMID":17253779,"re_id":4,"annotated sentence":"Unlike mouse RetSat (mRetSat), <e2>zRetSat A<\\e2> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either <e1>all-trans-13,14-dihydroretinol<\\e1> or all-trans-7,8-dihydroretinol, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"all-trans-13,14-dihydroretinol","object":"zRetSat A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unlike mouse RetSat (mRetSat), <e2>GENE-Y<\\e2> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either <e1>CHEMICAL<\\e1> or all-trans-7,8-dihydroretinol, respectively","sentence":"Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively"}
{"PMID":17253779,"re_id":5,"annotated sentence":"Unlike mouse RetSat (mRetSat), <e2>zRetSat A<\\e2> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or <e1>all-trans-7,8-dihydroretinol<\\e1>  respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"all-trans-7,8-dihydroretinol","object":"zRetSat A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unlike mouse RetSat (mRetSat), <e2>GENE-Y<\\e2> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or <e1>CHEMICAL<\\e1>  respectively","sentence":"Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol  respectively"}
{"PMID":17253779,"re_id":6,"annotated sentence":"<e2>zRetSat A<\\e2> also saturated the 13-14 or 7-8 double bonds of <e1>all-trans-3,4-didehydroretinol<\\e1> (vitamin A2), a second endogenous form of vitamin A in zebrafish","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"all-trans-3,4-didehydroretinol","object":"zRetSat A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> also saturated the 13-14 or 7-8 double bonds of <e1>CHEMICAL<\\e1> (vitamin A2), a second endogenous form of vitamin A in zebrafish","sentence":"zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish"}
{"PMID":17253779,"re_id":7,"annotated sentence":"<e2>zRetSat A<\\e2> also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (<e1>vitamin A2<\\e1> , a second endogenous form of vitamin A in zebrafish","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"vitamin A2","object":"zRetSat A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (<e1>CHEMICAL<\\e1> , a second endogenous form of vitamin A in zebrafish","sentence":"zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2 , a second endogenous form of vitamin A in zebrafish"}
{"PMID":17254025,"re_id":0,"annotated sentence":"The latter reaction, catalyzed by <e2>aspartoacylase<\\e2> (ASPA), produces <e1>acetyl<\\e1> groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetyl","object":"aspartoacylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The latter reaction, catalyzed by <e2>GENE-Y<\\e2> (ASPA), produces <e1>CHEMICAL<\\e1> groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter","sentence":"The latter reaction, catalyzed by aspartoacylase (ASPA), produces acetyl groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter"}
{"PMID":17254025,"re_id":1,"annotated sentence":"The latter reaction, catalyzed by aspartoacylase (<e2>ASPA<\\e2> , produces <e1>acetyl<\\e1> groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetyl","object":"ASPA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The latter reaction, catalyzed by aspartoacylase (<e2>GENE-Y<\\e2> , produces <e1>CHEMICAL<\\e1> groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter","sentence":"The latter reaction, catalyzed by aspartoacylase (ASPA , produces acetyl groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter"}
{"PMID":17254025,"re_id":2,"annotated sentence":"The latter reaction, catalyzed by <e2>aspartoacylase<\\e2> (ASPA), produces acetyl groups plus <e1>aspartate<\\e1> and has been proposed to occur in both soluble and membranous subfractions of white matter","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"aspartate","object":"aspartoacylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The latter reaction, catalyzed by <e2>GENE-Y<\\e2> (ASPA), produces acetyl groups plus <e1>CHEMICAL<\\e1> and has been proposed to occur in both soluble and membranous subfractions of white matter","sentence":"The latter reaction, catalyzed by aspartoacylase (ASPA), produces acetyl groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter"}
{"PMID":17254025,"re_id":3,"annotated sentence":"The latter reaction, catalyzed by aspartoacylase (<e2>ASPA<\\e2> , produces acetyl groups plus <e1>aspartate<\\e1> and has been proposed to occur in both soluble and membranous subfractions of white matter","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"aspartate","object":"ASPA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The latter reaction, catalyzed by aspartoacylase (<e2>GENE-Y<\\e2> , produces acetyl groups plus <e1>CHEMICAL<\\e1> and has been proposed to occur in both soluble and membranous subfractions of white matter","sentence":"The latter reaction, catalyzed by aspartoacylase (ASPA , produces acetyl groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter"}
{"PMID":17275903,"re_id":0,"annotated sentence":"<e2>LDH<\\e2> is responsible for <e1>pyruvate<\\e1> conversion to lactate through glycolysis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyruvate","object":"LDH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> is responsible for <e1>CHEMICAL<\\e1> conversion to lactate through glycolysis","sentence":"LDH is responsible for pyruvate conversion to lactate through glycolysis"}
{"PMID":17275903,"re_id":1,"annotated sentence":"<e2>LDH<\\e2> is responsible for pyruvate conversion to <e1>lactate<\\e1> through glycolysis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"lactate","object":"LDH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> is responsible for pyruvate conversion to <e1>CHEMICAL<\\e1> through glycolysis","sentence":"LDH is responsible for pyruvate conversion to lactate through glycolysis"}
{"PMID":17284757,"re_id":0,"annotated sentence":"OBJECTIVE: The aim was to test whether the common deletion [T\/-] in the promoter of <e2>FADS2<\\e2> affects the PUFA biosynthetic pathway and consequently modifies the effect of <e1>alpha-linolenic acid<\\e1> (ALA) on myocardial infarction (MI)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-linolenic acid","object":"FADS2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: The aim was to test whether the common deletion [T\/-] in the promoter of <e2>GENE-Y<\\e2> affects the PUFA biosynthetic pathway and consequently modifies the effect of <e1>CHEMICAL<\\e1> (ALA) on myocardial infarction (MI)","sentence":"OBJECTIVE: The aim was to test whether the common deletion [T\/-] in the promoter of FADS2 affects the PUFA biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (ALA) on myocardial infarction (MI)"}
{"PMID":17284757,"re_id":1,"annotated sentence":"OBJECTIVE: The aim was to test whether the common deletion [T\/-] in the promoter of <e2>FADS2<\\e2> affects the PUFA biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (<e1>ALA<\\e1>  on myocardial infarction (MI)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ALA","object":"FADS2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: The aim was to test whether the common deletion [T\/-] in the promoter of <e2>GENE-Y<\\e2> affects the PUFA biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (<e1>CHEMICAL<\\e1>  on myocardial infarction (MI)","sentence":"OBJECTIVE: The aim was to test whether the common deletion [T\/-] in the promoter of FADS2 affects the PUFA biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (ALA  on myocardial infarction (MI)"}
{"PMID":17284757,"re_id":2,"annotated sentence":"OBJECTIVE: The aim was to test whether the common deletion [T\/-] in the promoter of <e2>FADS2<\\e2> affects the <e1>PUFA<\\e1> biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (ALA) on myocardial infarction (MI)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PUFA","object":"FADS2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: The aim was to test whether the common deletion [T\/-] in the promoter of <e2>GENE-Y<\\e2> affects the <e1>CHEMICAL<\\e1> biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (ALA) on myocardial infarction (MI)","sentence":"OBJECTIVE: The aim was to test whether the common deletion [T\/-] in the promoter of FADS2 affects the PUFA biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (ALA) on myocardial infarction (MI)"}
{"PMID":17308037,"re_id":0,"annotated sentence":"These data support the conclusion that renal ecto-<e2>phosphodiesterase<\\e2> activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of <e1>dipyridamole<\\e1>  Ecto-phosphodiesterase has some pharmacological characteristics similar to PDE8.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dipyridamole","object":"phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These data support the conclusion that renal ecto-<e2>GENE-N<\\e2> activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of <e1>CHEMICAL<\\e1>  Ecto-GENE-N has some pharmacological characteristics similar to PDE8.","sentence":"These data support the conclusion that renal ecto-phosphodiesterase activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of dipyridamole  Ecto-phosphodiesterase has some pharmacological characteristics similar to PDE8."}
{"PMID":17308037,"re_id":1,"annotated sentence":"A broad-spectrum <e2>phosphodiesterase<\\e2> (PDE) inhibitor (<e1>1,3-isobutyl-1-methylxanthine<\\e1>  300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,3-isobutyl-1-methylxanthine","object":"phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A broad-spectrum <e2>GENE-N<\\e2> (PDE) inhibitor (<e1>CHEMICAL<\\e1>  300 microM, n=6) and an ecto-GENE-N inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively","sentence":"A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine  300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively"}
{"PMID":17308037,"re_id":2,"annotated sentence":"A broad-spectrum phosphodiesterase (<e2>PDE<\\e2>  inhibitor (<e1>1,3-isobutyl-1-methylxanthine<\\e1>  300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,3-isobutyl-1-methylxanthine","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A broad-spectrum phosphodiesterase (<e2>GENE-N<\\e2>  inhibitor (<e1>CHEMICAL<\\e1>  300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively","sentence":"A broad-spectrum phosphodiesterase (PDE  inhibitor (1,3-isobutyl-1-methylxanthine  300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively"}
{"PMID":17308037,"re_id":3,"annotated sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], <e2>PDE3<\\e2> (<e1>milrinone<\\e1>  10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"milrinone","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], <e2>GENE-N<\\e2> (<e1>CHEMICAL<\\e1>  10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone  10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":4,"annotated sentence":"Blockade of <e2>PDE1<\\e2> (<e1>8-methoxymethyl-3-isobutyl-1-methylxanthine<\\e1>  100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"8-methoxymethyl-3-isobutyl-1-methylxanthine","object":"PDE1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of <e2>GENE-N<\\e2> (<e1>CHEMICAL<\\e1>  100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine  100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":5,"annotated sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), <e2>PDE2<\\e2> [<e1>erythro-9-(2-hydroxy-3-nonyl)adenine<\\e1>  30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"erythro-9-(2-hydroxy-3-nonyl)adenine","object":"PDE2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), <e2>GENE-N<\\e2> [<e1>CHEMICAL<\\e1>  30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine  30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":6,"annotated sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), <e2>PDE4<\\e2> (Ro 20-1724 [<e1>4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one<\\e1> , 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), <e2>GENE-N<\\e2> (Ro 20-1724 [<e1>CHEMICAL<\\e1> , 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one , 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":7,"annotated sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), <e2>PDE5<\\e2> and PDE6 (<e1>zaprinast<\\e1>  30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zaprinast","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), <e2>GENE-Y<\\e2> and PDE6 (<e1>CHEMICAL<\\e1>  30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast  30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":8,"annotated sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and <e2>PDE6<\\e2> (<e1>zaprinast<\\e1>  30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zaprinast","object":"PDE6","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and <e2>GENE-N<\\e2> (<e1>CHEMICAL<\\e1>  30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast  30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":9,"annotated sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and <e2>PDE7<\\e2> [<e1>BRL-50481<\\e1> (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BRL-50481","object":"PDE7","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and <e2>GENE-N<\\e2> [<e1>CHEMICAL<\\e1> (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity","sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":10,"annotated sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and <e2>PDE7<\\e2> [BRL-50481 (<e1>5-nitro-2,N,N-trimethylbenzenesulfonamide<\\e1> , 10 microM] did not alter renal ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-nitro-2,N,N-trimethylbenzenesulfonamide","object":"PDE7","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and <e2>GENE-N<\\e2> [BRL-50481 (<e1>CHEMICAL<\\e1> , 10 microM] did not alter renal ecto-phosphodiesterase activity","sentence":"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide , 10 microM] did not alter renal ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":11,"annotated sentence":"Administration of a concentration (100 microM) of <e1>dipyridamole<\\e1> that blocks <e2>PDE8<\\e2> inhibited ecto-phosphodiesterase activity (by 44%)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dipyridamole","object":"PDE8","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Administration of a concentration (100 microM) of <e1>CHEMICAL<\\e1> that blocks <e2>GENE-N<\\e2> inhibited ecto-phosphodiesterase activity (by 44%)","sentence":"Administration of a concentration (100 microM) of dipyridamole that blocks PDE8 inhibited ecto-phosphodiesterase activity (by 44%)"}
{"PMID":17308037,"re_id":12,"annotated sentence":"Administration of a concentration (100 microM) of <e1>dipyridamole<\\e1> that blocks PDE8 inhibited ecto-<e2>phosphodiesterase<\\e2> activity (by 44%)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dipyridamole","object":"phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Administration of a concentration (100 microM) of <e1>CHEMICAL<\\e1> that blocks PDE8 inhibited ecto-<e2>GENE-N<\\e2> activity (by 44%)","sentence":"Administration of a concentration (100 microM) of dipyridamole that blocks PDE8 inhibited ecto-phosphodiesterase activity (by 44%)"}
{"PMID":17308037,"re_id":13,"annotated sentence":"However, a lower concentration of <e1>dipyridamole<\\e1> (3 microM) that blocks <e2>PDE9<\\e2>  PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dipyridamole","object":"PDE9","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, a lower concentration of <e1>CHEMICAL<\\e1> (3 microM) that blocks <e2>GENE-N<\\e2>  PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity","sentence":"However, a lower concentration of dipyridamole (3 microM) that blocks PDE9  PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":14,"annotated sentence":"However, a lower concentration of <e1>dipyridamole<\\e1> (3 microM) that blocks PDE9, <e2>PDE10<\\e2>  and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dipyridamole","object":"PDE10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, a lower concentration of <e1>CHEMICAL<\\e1> (3 microM) that blocks PDE9, <e2>GENE-Y<\\e2>  and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity","sentence":"However, a lower concentration of dipyridamole (3 microM) that blocks PDE9, PDE10  and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":15,"annotated sentence":"However, a lower concentration of <e1>dipyridamole<\\e1> (3 microM) that blocks PDE9, PDE10, and <e2>PDE11<\\e2>  but not PDE8, did not inhibit ecto-phosphodiesterase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dipyridamole","object":"PDE11","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, a lower concentration of <e1>CHEMICAL<\\e1> (3 microM) that blocks PDE9, PDE10, and <e2>GENE-Y<\\e2>  but not PDE8, did not inhibit ecto-phosphodiesterase activity","sentence":"However, a lower concentration of dipyridamole (3 microM) that blocks PDE9, PDE10, and PDE11  but not PDE8, did not inhibit ecto-phosphodiesterase activity"}
{"PMID":17308037,"re_id":16,"annotated sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of <e1>cAMP<\\e1> to AMP by ecto-<e2>phosphodiesterase<\\e2>  and metabolism of AMP to adenosine by ecto-5'-nucleotidase","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cAMP","object":"phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of CHEMICAL, conversion of <e1>CHEMICAL<\\e1> to AMP by ecto-<e2>GENE-N<\\e2>  and metabolism of AMP to adenosine by ecto-5'-nucleotidase","sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase  and metabolism of AMP to adenosine by ecto-5'-nucleotidase"}
{"PMID":17308037,"re_id":17,"annotated sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to <e1>AMP<\\e1> by ecto-<e2>phosphodiesterase<\\e2>  and metabolism of AMP to adenosine by ecto-5'-nucleotidase","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"AMP","object":"phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cCHEMICAL, conversion of cCHEMICAL to <e1>CHEMICAL<\\e1> by ecto-<e2>GENE-N<\\e2>  and metabolism of CHEMICAL to adenosine by ecto-5'-nucleotidase","sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase  and metabolism of AMP to adenosine by ecto-5'-nucleotidase"}
{"PMID":17308037,"re_id":18,"annotated sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of <e1>AMP<\\e1> to adenosine by <e2>ecto-5'-nucleotidase<\\e2>  Although much is known about ecto-5'-nucleotidase, the renal ecto-phosphodiesterase remains uncharacterized","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"AMP","object":"ecto-5'-nucleotidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cCHEMICAL, conversion of cCHEMICAL to CHEMICAL by ecto-phosphodiesterase, and metabolism of <e1>CHEMICAL<\\e1> to adenosine by <e2>GENE-Y<\\e2>  Although much is known about GENE-Y, the renal ecto-phosphodiesterase remains uncharacterized","sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5'-nucleotidase  Although much is known about ecto-5'-nucleotidase, the renal ecto-phosphodiesterase remains uncharacterized"}
{"PMID":17308037,"re_id":19,"annotated sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to <e1>adenosine<\\e1> by <e2>ecto-5'-nucleotidase<\\e2>  Although much is known about ecto-5'-nucleotidase, the renal ecto-phosphodiesterase remains uncharacterized","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"adenosine","object":"ecto-5'-nucleotidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to <e1>CHEMICAL<\\e1> by <e2>GENE-Y<\\e2>  Although much is known about GENE-Y, the renal ecto-phosphodiesterase remains uncharacterized","sentence":"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5'-nucleotidase  Although much is known about ecto-5'-nucleotidase, the renal ecto-phosphodiesterase remains uncharacterized"}
{"PMID":17325667,"re_id":0,"annotated sentence":"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two <e1>IM<\\e1> resistant GIST patients demonstrated that <e2>KIT<\\e2> is downregulated implying a major role in IM resistance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IM","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two <e1>CHEMICAL<\\e1> resistant GIST patients demonstrated that <e2>GENE-Y<\\e2> is downregulated implying a major role in CHEMICAL resistance","sentence":"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two IM resistant GIST patients demonstrated that KIT is downregulated implying a major role in IM resistance"}
{"PMID":17325667,"re_id":1,"annotated sentence":"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two IM resistant GIST patients demonstrated that <e2>KIT<\\e2> is downregulated implying a major role in <e1>IM<\\e1> resistance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IM","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two CHEMICAL resistant GIST patients demonstrated that <e2>GENE-Y<\\e2> is downregulated implying a major role in <e1>CHEMICAL<\\e1> resistance","sentence":"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two IM resistant GIST patients demonstrated that KIT is downregulated implying a major role in IM resistance"}
{"PMID":17325667,"re_id":2,"annotated sentence":"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to <e1>MP470<\\e1>  a novel <e2>c-Kit<\\e2> AXL kinase inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MP470","object":"c-Kit","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Molecular modeling of the kinase domain of mutant GENE-Y (V654A) and AXL showed no binding to IM but efficient binding to <e1>CHEMICAL<\\e1>  a novel <e2>GENE-Y<\\e2> AXL kinase inhibitor","sentence":"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to MP470  a novel c-Kit AXL kinase inhibitor"}
{"PMID":17325667,"re_id":3,"annotated sentence":"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to <e1>MP470<\\e1>  a novel c-Kit\/<e2>AXL<\\e2> kinase inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MP470","object":"AXL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and GENE-Y showed no binding to IM but efficient binding to <e1>CHEMICAL<\\e1>  a novel c-Kit\/<e2>GENE-Y<\\e2> kinase inhibitor","sentence":"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to MP470  a novel c-Kit\/AXL kinase inhibitor"}
{"PMID":17325667,"re_id":4,"annotated sentence":"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to <e1>MP470<\\e1>  a novel c-Kit\/AXL <e2>kinase<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MP470","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Molecular modeling of the GENE-N domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to <e1>CHEMICAL<\\e1>  a novel c-Kit\/AXL <e2>GENE-N<\\e2> inhibitor","sentence":"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to MP470  a novel c-Kit\/AXL kinase inhibitor"}
{"PMID":17327465,"re_id":0,"annotated sentence":"none","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"leflunomide","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":17327465,"re_id":1,"annotated sentence":"none","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"flutamide","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":17327465,"re_id":2,"annotated sentence":"none","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"nimodipine","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":17333137,"re_id":0,"annotated sentence":"OBJECTIVES: The aim of the current study was to assess the activity of <e1>rolipram<\\e1>  a nonsubtype-selective <e2>PDE4<\\e2> inhibitor, in several animal models predictive of antipsychotic-like efficacy and side-effect liability and to use PDE4B wild-type and knockout mice to begin to understand the subtypes involved in the activity of rolipram","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rolipram","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"OBJECTIVES: The aim of the current study was to assess the activity of <e1>CHEMICAL<\\e1>  a nonsubtype-selective <e2>GENE-N<\\e2> inhibitor, in several animal models predictive of antipsychotic-like efficacy and side-effect liability and to use GENE-NB wild-type and knockout mice to begin to understand the subtypes involved in the activity of CHEMICAL","sentence":"OBJECTIVES: The aim of the current study was to assess the activity of rolipram  a nonsubtype-selective PDE4 inhibitor, in several animal models predictive of antipsychotic-like efficacy and side-effect liability and to use PDE4B wild-type and knockout mice to begin to understand the subtypes involved in the activity of rolipram"}
{"PMID":17333137,"re_id":1,"annotated sentence":"These results suggest that PDE4B mediates the antipsychotic effects of rolipram in CAR and that the <e2>PDE4B<\\e2> regulated <e1>cyclic adenosine monophosphate<\\e1> signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cyclic adenosine monophosphate","object":"PDE4B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that GENE-Y mediates the antipsychotic effects of rolipram in CAR and that the <e2>GENE-Y<\\e2> regulated <e1>CHEMICAL<\\e1> signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.","sentence":"These results suggest that PDE4B mediates the antipsychotic effects of rolipram in CAR and that the PDE4B regulated cyclic adenosine monophosphate signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis."}
{"PMID":17352516,"re_id":0,"annotated sentence":"Improvements from baseline in mean <e2>glycosylated haemoglobin<\\e2> (HbA(1c)) were significantly greater with <e1>sitagliptin<\\e1> monotherapy than with placebo in patients with type 2 diabetes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sitagliptin","object":"glycosylated haemoglobin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Improvements from baseline in mean <e2>GENE-Y<\\e2> (HbA(1c)) were significantly greater with <e1>CHEMICAL<\\e1> monotherapy than with placebo in patients with type 2 diabetes","sentence":"Improvements from baseline in mean glycosylated haemoglobin (HbA(1c)) were significantly greater with sitagliptin monotherapy than with placebo in patients with type 2 diabetes"}
{"PMID":17352516,"re_id":1,"annotated sentence":"Improvements from baseline in mean glycosylated haemoglobin (<e2>HbA(1c)<\\e2>  were significantly greater with <e1>sitagliptin<\\e1> monotherapy than with placebo in patients with type 2 diabetes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sitagliptin","object":"HbA(1c)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Improvements from baseline in mean glycosylated haemoglobin (<e2>GENE-Y<\\e2>  were significantly greater with <e1>CHEMICAL<\\e1> monotherapy than with placebo in patients with type 2 diabetes","sentence":"Improvements from baseline in mean glycosylated haemoglobin (HbA(1c)  were significantly greater with sitagliptin monotherapy than with placebo in patients with type 2 diabetes"}
{"PMID":17352516,"re_id":2,"annotated sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, <e1>sitagliptin<\\e1> improved <e2>HbA(1c)<\\e2> to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sitagliptin","object":"HbA(1c)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, <e1>CHEMICAL<\\e1> improved <e2>GENE-Y<\\e2> to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin","sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved HbA(1c) to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin"}
{"PMID":17352516,"re_id":3,"annotated sentence":"<e1>Sitagliptin<\\e1>  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the <e2>incretin hormones<\\e2> glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Sitagliptin","object":"incretin hormones","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the <e2>GENE-N<\\e2> glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide","sentence":"Sitagliptin  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide"}
{"PMID":17352516,"re_id":4,"annotated sentence":"<e1>Sitagliptin<\\e1>  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones <e2>glucagon-like peptide-1<\\e2> and glucose-dependent insulinotropic polypeptide","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Sitagliptin","object":"glucagon-like peptide-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones <e2>GENE-Y<\\e2> and glucose-dependent insulinotropic polypeptide","sentence":"Sitagliptin  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide"}
{"PMID":17352516,"re_id":5,"annotated sentence":"<e1>Sitagliptin<\\e1>  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and <e2>glucose-dependent insulinotropic polypeptide<\\e2>  This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load glucose excursion","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Sitagliptin","object":"glucose-dependent insulinotropic polypeptide","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and <e2>GENE-Y<\\e2>  This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load glucose excursion","sentence":"Sitagliptin  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide  This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load glucose excursion"}
{"PMID":17352516,"re_id":6,"annotated sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved <e2>HbA(1c)<\\e2> to a significantly greater extent than placebo when added to <e1>metformin<\\e1> or pioglitazone and was noninferior to glipizide when added to metformin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"metformin","object":"HbA(1c)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved <e2>GENE-Y<\\e2> to a significantly greater extent than placebo when added to <e1>CHEMICAL<\\e1> or pioglitazone and was noninferior to glipizide when added to CHEMICAL","sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved HbA(1c) to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin"}
{"PMID":17352516,"re_id":7,"annotated sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved <e2>HbA(1c)<\\e2> to a significantly greater extent than placebo when added to metformin or <e1>pioglitazone<\\e1> and was noninferior to glipizide when added to metformin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pioglitazone","object":"HbA(1c)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved <e2>GENE-Y<\\e2> to a significantly greater extent than placebo when added to metformin or <e1>CHEMICAL<\\e1> and was noninferior to glipizide when added to metformin","sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved HbA(1c) to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin"}
{"PMID":17352516,"re_id":8,"annotated sentence":"<e1>Sitagliptin<\\e1>  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting <e2>DPP-4<\\e2> inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sitagliptin","object":"DPP-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an oral dipeptidyl peptidase-4 (GENE-Y) inhibitor, improves glycaemic control by inhibiting <e2>GENE-Y<\\e2> inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide","sentence":"Sitagliptin  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide"}
{"PMID":17352516,"re_id":9,"annotated sentence":"<e1>Sitagliptin<\\e1>  an oral <e2>dipeptidyl peptidase-4<\\e2> (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sitagliptin","object":"dipeptidyl peptidase-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an oral <e2>GENE-Y<\\e2> (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide","sentence":"Sitagliptin  an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide"}
{"PMID":17352516,"re_id":10,"annotated sentence":"<e1>Sitagliptin<\\e1>  an oral dipeptidyl peptidase-4 (<e2>DPP-4<\\e2>  inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sitagliptin","object":"DPP-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an oral dipeptidyl peptidase-4 (<e2>GENE-Y<\\e2>  inhibitor, improves glycaemic control by inhibiting GENE-Y inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide","sentence":"Sitagliptin  an oral dipeptidyl peptidase-4 (DPP-4  inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide"}
{"PMID":17352516,"re_id":11,"annotated sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved <e2>HbA(1c)<\\e2> to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to <e1>metformin<\\e1>  Sitagliptin was well tolerated when administered alone or in combination with other antihyperglycaemics, with an adverse event profile similar to that shown with placebo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"metformin","object":"HbA(1c)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved <e2>GENE-Y<\\e2> to a significantly greater extent than placebo when added to CHEMICAL or pioglitazone and was noninferior to glipizide when added to <e1>CHEMICAL<\\e1>  Sitagliptin was well tolerated when administered alone or in combination with other antihyperglycaemics, with an adverse event profile similar to that shown with placebo","sentence":"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved HbA(1c) to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin  Sitagliptin was well tolerated when administered alone or in combination with other antihyperglycaemics, with an adverse event profile similar to that shown with placebo"}
{"PMID":17390078,"re_id":0,"annotated sentence":"There was also an increase in <e2>c-kit<\\e2>  Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion<\\e1> treated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"parathion","object":"c-kit","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in <e2>GENE-Y<\\e2>  Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>CHEMICAL<\\e1> treated cells","sentence":"There was also an increase in c-kit  Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the parathion treated cells"}
{"PMID":17390078,"re_id":1,"annotated sentence":"There was also an increase in c-kit, <e2>Trio<\\e2>  Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion<\\e1> treated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"parathion","object":"Trio","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in c-kit, <e2>GENE-Y<\\e2>  Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>CHEMICAL<\\e1> treated cells","sentence":"There was also an increase in c-kit, Trio  Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the parathion treated cells"}
{"PMID":17390078,"re_id":2,"annotated sentence":"There was also an increase in c-kit, Trio, <e2>Rho-A<\\e2>  Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion<\\e1> treated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"parathion","object":"Rho-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in c-kit, Trio, <e2>GENE-Y<\\e2>  Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>CHEMICAL<\\e1> treated cells","sentence":"There was also an increase in c-kit, Trio, Rho-A  Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the parathion treated cells"}
{"PMID":17390078,"re_id":3,"annotated sentence":"There was also an increase in c-kit, Trio, Rho-A, <e2>Rac-3<\\e2>  EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion<\\e1> treated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"parathion","object":"Rac-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in c-kit, Trio, Rho-A, <e2>GENE-Y<\\e2>  EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>CHEMICAL<\\e1> treated cells","sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3  EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the parathion treated cells"}
{"PMID":17390078,"re_id":4,"annotated sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, <e2>Notch-4<\\e2>  Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion<\\e1> treated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"parathion","object":"Notch-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, <e2>GENE-Y<\\e2>  Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>CHEMICAL<\\e1> treated cells","sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4  Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the parathion treated cells"}
{"PMID":17390078,"re_id":5,"annotated sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, <e2>Dvl-2<\\e2>  Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion<\\e1> treated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"parathion","object":"Dvl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, <e2>GENE-Y<\\e2>  Ezrin, beta catenin and mutant p53 protein expression in the <e1>CHEMICAL<\\e1> treated cells","sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2  Ezrin, beta catenin and mutant p53 protein expression in the parathion treated cells"}
{"PMID":17390078,"re_id":6,"annotated sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, <e2>Ezrin<\\e2>  beta catenin and mutant p53 protein expression in the <e1>parathion<\\e1> treated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"parathion","object":"Ezrin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, <e2>GENE-Y<\\e2>  beta catenin and mutant p53 protein expression in the <e1>CHEMICAL<\\e1> treated cells","sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin  beta catenin and mutant p53 protein expression in the parathion treated cells"}
{"PMID":17390078,"re_id":7,"annotated sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, <e2>beta catenin<\\e2> and mutant p53 protein expression in the <e1>parathion<\\e1> treated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"parathion","object":"beta catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, <e2>GENE-Y<\\e2> and mutant p53 protein expression in the <e1>CHEMICAL<\\e1> treated cells","sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the parathion treated cells"}
{"PMID":17390078,"re_id":8,"annotated sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant <e2>p53<\\e2> protein expression in the <e1>parathion<\\e1> treated cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"parathion","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant <e2>GENE-Y<\\e2> protein expression in the <e1>CHEMICAL<\\e1> treated cells","sentence":"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the parathion treated cells"}
{"PMID":17390078,"re_id":9,"annotated sentence":"<e1>Parathion<\\e1> is a <e2>cholinesterase<\\e2> inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Parathion","object":"cholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a <e2>GENE-N<\\e2> inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses","sentence":"Parathion is a cholinesterase inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses"}
{"PMID":17391279,"re_id":0,"annotated sentence":"<e1>Indomethacin<\\e1> treatment led to an increase in lipid peroxidation, <e2>glutathione peroxidase<\\e2> and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"glutathione peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment led to an increase in lipid peroxidation, <e2>GENE-N<\\e2> and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa","sentence":"Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa"}
{"PMID":17391279,"re_id":1,"annotated sentence":"<e1>Indomethacin<\\e1> treatment led to an increase in lipid peroxidation, glutathione peroxidase and <e2>glucose-6-phosphate dehydrogenase<\\e2> activities and to a decrease in catalase activity and glutathione levels in gastric mucosa","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"glucose-6-phosphate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment led to an increase in lipid peroxidation, glutathione peroxidase and <e2>GENE-Y<\\e2> activities and to a decrease in catalase activity and glutathione levels in gastric mucosa","sentence":"Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa"}
{"PMID":17391279,"re_id":2,"annotated sentence":"<e1>Indomethacin<\\e1> treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in <e2>catalase<\\e2> activity and glutathione levels in gastric mucosa","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"catalase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in <e2>GENE-Y<\\e2> activity and glutathione levels in gastric mucosa","sentence":"Indomethacin treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa"}
{"PMID":17409426,"re_id":0,"annotated sentence":"<e1>Sulindac sulfide<\\e1> inhibited <e2>PPARdelta<\\e2> protein expression and PPARdelta transcriptional activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sulindac sulfide","object":"PPARdelta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> protein expression and GENE-Y transcriptional activity","sentence":"Sulindac sulfide inhibited PPARdelta protein expression and PPARdelta transcriptional activity"}
{"PMID":17409426,"re_id":1,"annotated sentence":"<e1>Sulindac sulfide<\\e1> inhibited PPARdelta protein expression and <e2>PPARdelta<\\e2> transcriptional activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sulindac sulfide","object":"PPARdelta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited GENE-Y protein expression and <e2>GENE-Y<\\e2> transcriptional activity","sentence":"Sulindac sulfide inhibited PPARdelta protein expression and PPARdelta transcriptional activity"}
{"PMID":17409426,"re_id":2,"annotated sentence":"<e1>Sulindac sulfide<\\e1> inhibited <e2>14-3-3epsilon proteins<\\e2> in HT-29 and DLD-1 cells in a time- and concentration-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sulindac sulfide","object":"14-3-3epsilon proteins","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> in HT-29 and DLD-1 cells in a time- and concentration-dependent manner","sentence":"Sulindac sulfide inhibited 14-3-3epsilon proteins in HT-29 and DLD-1 cells in a time- and concentration-dependent manner"}
{"PMID":17409426,"re_id":3,"annotated sentence":"<e1>Indomethacin<\\e1> and SC-236, a selective <e2>cyclooxygenase-2<\\e2> (COX-2) inhibitor, exerted a similar effect as sulindac","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and SC-236, a selective <e2>GENE-Y<\\e2> (COX-2) inhibitor, exerted a similar effect as sulindac","sentence":"Indomethacin and SC-236, a selective cyclooxygenase-2 (COX-2) inhibitor, exerted a similar effect as sulindac"}
{"PMID":17409426,"re_id":4,"annotated sentence":"<e1>Indomethacin<\\e1> and SC-236, a selective cyclooxygenase-2 (<e2>COX-2<\\e2>  inhibitor, exerted a similar effect as sulindac","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and SC-236, a selective cyclooxygenase-2 (<e2>GENE-Y<\\e2>  inhibitor, exerted a similar effect as sulindac","sentence":"Indomethacin and SC-236, a selective cyclooxygenase-2 (COX-2  inhibitor, exerted a similar effect as sulindac"}
{"PMID":17409426,"re_id":5,"annotated sentence":"Indomethacin and <e1>SC-236<\\e1>  a selective <e2>cyclooxygenase-2<\\e2> (COX-2) inhibitor, exerted a similar effect as sulindac","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SC-236","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Indomethacin and <e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> (COX-2) inhibitor, exerted a similar effect as sulindac","sentence":"Indomethacin and SC-236  a selective cyclooxygenase-2 (COX-2) inhibitor, exerted a similar effect as sulindac"}
{"PMID":17409426,"re_id":6,"annotated sentence":"Indomethacin and <e1>SC-236<\\e1>  a selective cyclooxygenase-2 (<e2>COX-2<\\e2>  inhibitor, exerted a similar effect as sulindac","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SC-236","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Indomethacin and <e1>CHEMICAL<\\e1>  a selective cyclooxygenase-2 (<e2>GENE-Y<\\e2>  inhibitor, exerted a similar effect as sulindac","sentence":"Indomethacin and SC-236  a selective cyclooxygenase-2 (COX-2  inhibitor, exerted a similar effect as sulindac"}
{"PMID":17418819,"re_id":0,"annotated sentence":"Under isotonic conditions, <e1>N-ethylmaleimide<\\e1> (NEM) produced <e2>KCC<\\e2> activation and transient cell shrinkage","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"N-ethylmaleimide","object":"KCC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Under isotonic conditions, <e1>CHEMICAL<\\e1> (NEM) produced <e2>GENE-N<\\e2> activation and transient cell shrinkage","sentence":"Under isotonic conditions, N-ethylmaleimide (NEM) produced KCC activation and transient cell shrinkage"}
{"PMID":17418819,"re_id":1,"annotated sentence":"Under isotonic conditions, N-ethylmaleimide (<e1>NEM<\\e1>  produced <e2>KCC<\\e2> activation and transient cell shrinkage","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NEM","object":"KCC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Under isotonic conditions, N-ethylmaleimide (<e1>CHEMICAL<\\e1>  produced <e2>GENE-N<\\e2> activation and transient cell shrinkage","sentence":"Under isotonic conditions, N-ethylmaleimide (NEM  produced KCC activation and transient cell shrinkage"}
{"PMID":17418819,"re_id":2,"annotated sentence":"A <e2>KCC<\\e2> inhibitor-<e1>[(dihydroindenyl)oxy] alkanoic acid<\\e1> (DIOA)-blocked RVD more in HCEC than RCEC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"[(dihydroindenyl)oxy] alkanoic acid","object":"KCC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A <e2>GENE-N<\\e2> inhibitor-<e1>CHEMICAL<\\e1> (DIOA)-blocked RVD more in HCEC than RCEC","sentence":"A KCC inhibitor-[(dihydroindenyl)oxy] alkanoic acid (DIOA)-blocked RVD more in HCEC than RCEC"}
{"PMID":17418819,"re_id":3,"annotated sentence":"A <e2>KCC<\\e2> inhibitor-[(dihydroindenyl)oxy] alkanoic acid (<e1>DIOA<\\e1> -blocked RVD more in HCEC than RCEC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DIOA","object":"KCC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A <e2>GENE-N<\\e2> inhibitor-[(dihydroindenyl)oxy] alkanoic acid (<e1>CHEMICAL<\\e1> -blocked RVD more in HCEC than RCEC","sentence":"A KCC inhibitor-[(dihydroindenyl)oxy] alkanoic acid (DIOA -blocked RVD more in HCEC than RCEC"}
{"PMID":17429625,"re_id":0,"annotated sentence":"PURPOSE: <e1>Dasatinib<\\e1> (BMS-354825), a potent oral multi-targeted <e2>kinase<\\e2> inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dasatinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PURPOSE: <e1>CHEMICAL<\\e1> (BMS-354825), a potent oral multi-targeted <e2>GENE-N<\\e2> inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","sentence":"PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance"}
{"PMID":17429625,"re_id":1,"annotated sentence":"PURPOSE: <e1>Dasatinib<\\e1> (BMS-354825), a potent oral multi-targeted kinase inhibitor against <e2>SRC<\\e2> and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dasatinib","object":"SRC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: <e1>CHEMICAL<\\e1> (BMS-354825), a potent oral multi-targeted kinase inhibitor against <e2>GENE-Y<\\e2> and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","sentence":"PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance"}
{"PMID":17429625,"re_id":2,"annotated sentence":"PURPOSE: <e1>Dasatinib<\\e1> (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and <e2>BCR<\\e2> ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dasatinib","object":"BCR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: <e1>CHEMICAL<\\e1> (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and <e2>GENE-Y<\\e2> ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","sentence":"PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance"}
{"PMID":17429625,"re_id":3,"annotated sentence":"PURPOSE: <e1>Dasatinib<\\e1> (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>ABL<\\e2>  has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dasatinib","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: <e1>CHEMICAL<\\e1> (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>GENE-Y<\\e2>  has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","sentence":"PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL  has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance"}
{"PMID":17429625,"re_id":4,"annotated sentence":"Preclinical pharmacokinetics and in vitro metabolism of <e1>dasatinib<\\e1> (BMS-354825): a potent oral multi-targeted <e2>kinase<\\e2> inhibitor against SRC and BCR-ABL","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Preclinical pharmacokinetics and in vitro metabolism of <e1>CHEMICAL<\\e1> (BMS-354825): a potent oral multi-targeted <e2>GENE-N<\\e2> inhibitor against SRC and BCR-ABL","sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL"}
{"PMID":17429625,"re_id":5,"annotated sentence":"Preclinical pharmacokinetics and in vitro metabolism of <e1>dasatinib<\\e1> (BMS-354825): a potent oral multi-targeted kinase inhibitor against <e2>SRC<\\e2> and BCR-ABL","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"SRC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preclinical pharmacokinetics and in vitro metabolism of <e1>CHEMICAL<\\e1> (BMS-354825): a potent oral multi-targeted kinase inhibitor against <e2>GENE-Y<\\e2> and BCR-ABL","sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL"}
{"PMID":17429625,"re_id":6,"annotated sentence":"Preclinical pharmacokinetics and in vitro metabolism of <e1>dasatinib<\\e1> (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and <e2>BCR<\\e2> ABL","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"BCR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preclinical pharmacokinetics and in vitro metabolism of <e1>CHEMICAL<\\e1> (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and <e2>GENE-Y<\\e2> ABL","sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR ABL"}
{"PMID":17429625,"re_id":7,"annotated sentence":"Preclinical pharmacokinetics and in vitro metabolism of <e1>dasatinib<\\e1> (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>ABL<\\e2>  PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dasatinib","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preclinical pharmacokinetics and in vitro metabolism of <e1>CHEMICAL<\\e1> (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>GENE-Y<\\e2>  PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-GENE-Y, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL  PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance"}
{"PMID":17429625,"re_id":8,"annotated sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825<\\e1> : a potent oral multi-targeted <e2>kinase<\\e2> inhibitor against SRC and BCR-ABL","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>CHEMICAL<\\e1> : a potent oral multi-targeted <e2>GENE-N<\\e2> inhibitor against SRC and BCR-ABL","sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825 : a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL"}
{"PMID":17429625,"re_id":9,"annotated sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825<\\e1> : a potent oral multi-targeted kinase inhibitor against <e2>SRC<\\e2> and BCR-ABL","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"SRC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>CHEMICAL<\\e1> : a potent oral multi-targeted kinase inhibitor against <e2>GENE-Y<\\e2> and BCR-ABL","sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825 : a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL"}
{"PMID":17429625,"re_id":10,"annotated sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825<\\e1> : a potent oral multi-targeted kinase inhibitor against SRC and <e2>BCR<\\e2> ABL","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"BCR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>CHEMICAL<\\e1> : a potent oral multi-targeted kinase inhibitor against SRC and <e2>GENE-Y<\\e2> ABL","sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825 : a potent oral multi-targeted kinase inhibitor against SRC and BCR ABL"}
{"PMID":17429625,"re_id":11,"annotated sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825<\\e1> : a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>ABL<\\e2>  PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>CHEMICAL<\\e1> : a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>GENE-Y<\\e2>  PURPOSE: Dasatinib (CHEMICAL), a potent oral multi-targeted kinase inhibitor against SRC and BCR-GENE-Y, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","sentence":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825 : a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL  PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance"}
{"PMID":17429625,"re_id":12,"annotated sentence":"PURPOSE: Dasatinib (<e1>BMS-354825<\\e1> , a potent oral multi-targeted <e2>kinase<\\e2> inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PURPOSE: Dasatinib (<e1>CHEMICAL<\\e1> , a potent oral multi-targeted <e2>GENE-N<\\e2> inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","sentence":"PURPOSE: Dasatinib (BMS-354825 , a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance"}
{"PMID":17429625,"re_id":13,"annotated sentence":"PURPOSE: Dasatinib (<e1>BMS-354825<\\e1> , a potent oral multi-targeted kinase inhibitor against <e2>SRC<\\e2> and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"SRC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: Dasatinib (<e1>CHEMICAL<\\e1> , a potent oral multi-targeted kinase inhibitor against <e2>GENE-Y<\\e2> and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","sentence":"PURPOSE: Dasatinib (BMS-354825 , a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance"}
{"PMID":17429625,"re_id":14,"annotated sentence":"PURPOSE: Dasatinib (<e1>BMS-354825<\\e1> , a potent oral multi-targeted kinase inhibitor against SRC and <e2>BCR<\\e2> ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"BCR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: Dasatinib (<e1>CHEMICAL<\\e1> , a potent oral multi-targeted kinase inhibitor against SRC and <e2>GENE-Y<\\e2> ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","sentence":"PURPOSE: Dasatinib (BMS-354825 , a potent oral multi-targeted kinase inhibitor against SRC and BCR ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance"}
{"PMID":17429625,"re_id":15,"annotated sentence":"PURPOSE: Dasatinib (<e1>BMS-354825<\\e1> , a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>ABL<\\e2>  has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-354825","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: Dasatinib (<e1>CHEMICAL<\\e1> , a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>GENE-Y<\\e2>  has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance","sentence":"PURPOSE: Dasatinib (BMS-354825 , a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL  has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance"}
{"PMID":17434872,"re_id":0,"annotated sentence":"Interestingly, a <e2>Val-349 to Ile<\\e2> mutant was inhibited with equal potency to human COX-2 with <e1>2,6-dichloro<\\e1> , 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2,6-dichloro","object":"Val-349 to Ile","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, a <e2>GENE-N<\\e2> mutant was inhibited with equal potency to human COX-2 with <e1>CHEMICAL<\\e1> , 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro , 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency"}
{"PMID":17434872,"re_id":1,"annotated sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>human COX-2<\\e2> with <e1>2,6-dichloro<\\e1> , 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2,6-dichloro","object":"human COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>GENE-Y<\\e2> with <e1>CHEMICAL<\\e1> , 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro , 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency"}
{"PMID":17434872,"re_id":2,"annotated sentence":"Interestingly, a <e2>Val-349 to Ile<\\e2> mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, <e1>2,6-dimethyl<\\e1> , or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2,6-dimethyl","object":"Val-349 to Ile","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, a <e2>GENE-N<\\e2> mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, <e1>CHEMICAL<\\e1> , or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl , or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency"}
{"PMID":17434872,"re_id":3,"annotated sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>human COX-2<\\e2> with 2,6-dichloro-, <e1>2,6-dimethyl<\\e1> , or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2,6-dimethyl","object":"human COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>GENE-Y<\\e2> with 2,6-dichloro-, <e1>CHEMICAL<\\e1> , or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl , or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency"}
{"PMID":17434872,"re_id":4,"annotated sentence":"Interestingly, a <e2>Val-349 to Ile<\\e2> mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or <e1>2-chloro-6-methyl<\\e1> substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-chloro-6-methyl","object":"Val-349 to Ile","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, a <e2>GENE-N<\\e2> mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or <e1>CHEMICAL<\\e1> substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency"}
{"PMID":17434872,"re_id":5,"annotated sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>human COX-2<\\e2> with 2,6-dichloro-, 2,6-dimethyl-, or <e1>2-chloro-6-methyl<\\e1> substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-chloro-6-methyl","object":"human COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>GENE-Y<\\e2> with 2,6-dichloro-, 2,6-dimethyl-, or <e1>CHEMICAL<\\e1> substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency","sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency"}
{"PMID":17434872,"re_id":6,"annotated sentence":"Interestingly, a <e2>Val-349 to Ile<\\e2> mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of <e1>lumiracoxib<\\e1>  actually showed an increase in potency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"Val-349 to Ile","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, a <e2>GENE-N<\\e2> mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of <e1>CHEMICAL<\\e1>  actually showed an increase in potency","sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib  actually showed an increase in potency"}
{"PMID":17434872,"re_id":7,"annotated sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>human COX-2<\\e2> with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of <e1>lumiracoxib<\\e1>  actually showed an increase in potency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"human COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>GENE-Y<\\e2> with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of <e1>CHEMICAL<\\e1>  actually showed an increase in potency","sentence":"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib  actually showed an increase in potency"}
{"PMID":17434872,"re_id":8,"annotated sentence":"Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant <e2>COX-2s<\\e2> by <e1>lumiracoxib<\\e1> allows the definition of the molecular basis of COX-2 inhibition.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"COX-2s","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together with a recent crystal structure of a CHEMICAL-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> allows the definition of the molecular basis of COX-2 inhibition.","sentence":"Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant COX-2s by lumiracoxib allows the definition of the molecular basis of COX-2 inhibition."}
{"PMID":17434872,"re_id":9,"annotated sentence":"Using standard assays, <e1>lumiracoxib<\\e1> was found to be a poor inhibitor of purified <e2>ovine COX-1<\\e2> and a relatively weak inhibitor of purified human COX-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"ovine COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using standard assays, <e1>CHEMICAL<\\e1> was found to be a poor inhibitor of purified <e2>GENE-Y<\\e2> and a relatively weak inhibitor of purified human COX-2","sentence":"Using standard assays, lumiracoxib was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified human COX-2"}
{"PMID":17434872,"re_id":10,"annotated sentence":"Using standard assays, <e1>lumiracoxib<\\e1> was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified <e2>human COX-2<\\e2>  The extent of COX-2 inhibition plateaued at around 50% and suggested that the inhibitor may be reversibly bound to the enzyme","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"human COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using standard assays, <e1>CHEMICAL<\\e1> was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified <e2>GENE-Y<\\e2>  The extent of COX-2 inhibition plateaued at around 50% and suggested that the inhibitor may be reversibly bound to the enzyme","sentence":"Using standard assays, lumiracoxib was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified human COX-2  The extent of COX-2 inhibition plateaued at around 50% and suggested that the inhibitor may be reversibly bound to the enzyme"}
{"PMID":17434872,"re_id":11,"annotated sentence":"Kinetic studies with <e1>lumiracoxib<\\e1> demonstrated that it was a time-dependent and slowly reversible inhibitor of <e2>human COX-2<\\e2> that exhibited at least two binding steps during inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"human COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic studies with <e1>CHEMICAL<\\e1> demonstrated that it was a time-dependent and slowly reversible inhibitor of <e2>GENE-Y<\\e2> that exhibited at least two binding steps during inhibition","sentence":"Kinetic studies with lumiracoxib demonstrated that it was a time-dependent and slowly reversible inhibitor of human COX-2 that exhibited at least two binding steps during inhibition"}
{"PMID":17434872,"re_id":12,"annotated sentence":"Lumiracoxib is the first example of a marketed <e2>COX-2<\\e2> inhibitor of the <e1>arylacetic acid<\\e1> class, and it is reported to be the most selective COXIB in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"arylacetic acid","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Lumiracoxib is the first example of a marketed <e2>GENE-Y<\\e2> inhibitor of the <e1>CHEMICAL<\\e1> class, and it is reported to be the most selective COXIB in vivo","sentence":"Lumiracoxib is the first example of a marketed COX-2 inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo"}
{"PMID":17434872,"re_id":13,"annotated sentence":"<e1>Lumiracoxib<\\e1> is the first example of a marketed <e2>COX-2<\\e2> inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Lumiracoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is the first example of a marketed <e2>GENE-Y<\\e2> inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo","sentence":"Lumiracoxib is the first example of a marketed COX-2 inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo"}
{"PMID":17434872,"re_id":14,"annotated sentence":"Inhibition studies demonstrated that the <e1>methyl<\\e1> group on the phenylacetic acid ring is required for <e2>COX-2<\\e2> selectivity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methyl","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition studies demonstrated that the <e1>CHEMICAL<\\e1> group on the phenylacetic acid ring is required for <e2>GENE-Y<\\e2> selectivity","sentence":"Inhibition studies demonstrated that the methyl group on the phenylacetic acid ring is required for COX-2 selectivity"}
{"PMID":17434872,"re_id":15,"annotated sentence":"Inhibition studies demonstrated that the methyl group on the <e1>phenylacetic acid<\\e1> ring is required for <e2>COX-2<\\e2> selectivity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenylacetic acid","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition studies demonstrated that the methyl group on the <e1>CHEMICAL<\\e1> ring is required for <e2>GENE-Y<\\e2> selectivity","sentence":"Inhibition studies demonstrated that the methyl group on the phenylacetic acid ring is required for COX-2 selectivity"}
{"PMID":17434872,"re_id":16,"annotated sentence":"Molecular determinants for the selective inhibition of <e2>cyclooxygenase-2<\\e2> by <e1>lumiracoxib<\\e1>  Lumiracoxib is the first example of a marketed COX-2 inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Molecular determinants for the selective inhibition of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1>  Lumiracoxib is the first example of a marketed COX-2 inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo","sentence":"Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib  Lumiracoxib is the first example of a marketed COX-2 inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo"}
{"PMID":17434872,"re_id":17,"annotated sentence":"The chemical identity and position of the substituents on the lower <e1>aniline<\\e1> ring were important in determining the potency and extent of <e2>COX<\\e2> inhibition as well as COX-2 selectivity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aniline","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The chemical identity and position of the substituents on the lower <e1>CHEMICAL<\\e1> ring were important in determining the potency and extent of <e2>GENE-N<\\e2> inhibition as well as GENE-N-2 selectivity","sentence":"The chemical identity and position of the substituents on the lower aniline ring were important in determining the potency and extent of COX inhibition as well as COX-2 selectivity"}
{"PMID":17434872,"re_id":18,"annotated sentence":"Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type <e2>human COX-2<\\e2> and key <e1>lumiracoxib<\\e1> analogs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lumiracoxib","object":"human COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type <e2>GENE-Y<\\e2> and key <e1>CHEMICAL<\\e1> analogs","sentence":"Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs"}
{"PMID":17475673,"re_id":0,"annotated sentence":"Differences in magnitude of <e1>Na(+)<\\e1> dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in <e2>ASCT2<\\e2> protein expression, this being more abundant in WKY PTE cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Na(+)","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Differences in magnitude of <e1>CHEMICAL<\\e1> dependent l-alanine uptake through GENE-Y between WKY and SHR PTE cells correlated positively with differences in <e2>GENE-Y<\\e2> protein expression, this being more abundant in WKY PTE cells","sentence":"Differences in magnitude of Na(+) dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells"}
{"PMID":17475673,"re_id":1,"annotated sentence":"Differences in magnitude of Na(+)-dependent <e1>l-alanine<\\e1> uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in <e2>ASCT2<\\e2> protein expression, this being more abundant in WKY PTE cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"l-alanine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Differences in magnitude of Na(+)-dependent <e1>CHEMICAL<\\e1> uptake through GENE-Y between WKY and SHR PTE cells correlated positively with differences in <e2>GENE-Y<\\e2> protein expression, this being more abundant in WKY PTE cells","sentence":"Differences in magnitude of Na(+)-dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells"}
{"PMID":17475673,"re_id":2,"annotated sentence":"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity <e1>Na(+)<\\e1> dependent amino acid transporter, with functional features of <e2>ASCT2<\\e2> transport","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Na(+)","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity <e1>CHEMICAL<\\e1> dependent amino acid transporter, with functional features of <e2>GENE-Y<\\e2> transport","sentence":"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+) dependent amino acid transporter, with functional features of ASCT2 transport"}
{"PMID":17475673,"re_id":3,"annotated sentence":"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent <e1>amino acid<\\e1> transporter, with functional features of <e2>ASCT2<\\e2> transport","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"amino acid","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent <e1>CHEMICAL<\\e1> transporter, with functional features of <e2>GENE-Y<\\e2> transport","sentence":"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of ASCT2 transport"}
{"PMID":17475673,"re_id":4,"annotated sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by <e1>alanine<\\e1>  serine, and cysteine, which is consistent with amino acid transport through <e2>ASCT2<\\e2>  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alanine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-CHEMICAL uptake in WKY and SHR PTE cells was inhibited by <e1>CHEMICAL<\\e1>  serine, and cysteine, which is consistent with amino acid transport through <e2>GENE-Y<\\e2>  The saturable component of Na(+)-dependent l-CHEMICAL transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values","sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine  serine, and cysteine, which is consistent with amino acid transport through ASCT2  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values"}
{"PMID":17475673,"re_id":5,"annotated sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, <e1>serine<\\e1>  and cysteine, which is consistent with amino acid transport through <e2>ASCT2<\\e2>  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"serine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, <e1>CHEMICAL<\\e1>  and cysteine, which is consistent with amino acid transport through <e2>GENE-Y<\\e2>  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values","sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine  and cysteine, which is consistent with amino acid transport through ASCT2  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values"}
{"PMID":17475673,"re_id":6,"annotated sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and <e1>cysteine<\\e1>  which is consistent with amino acid transport through <e2>ASCT2<\\e2>  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cysteine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and <e1>CHEMICAL<\\e1>  which is consistent with amino acid transport through <e2>GENE-Y<\\e2>  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values","sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine  which is consistent with amino acid transport through ASCT2  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values"}
{"PMID":17475673,"re_id":7,"annotated sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent <e1>l-alanine<\\e1> uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through <e2>ASCT2<\\e2>  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"l-alanine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent <e1>CHEMICAL<\\e1> uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through <e2>GENE-Y<\\e2>  The saturable component of Na(+)-dependent CHEMICAL transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values","sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through ASCT2  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values"}
{"PMID":17475673,"re_id":8,"annotated sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with <e1>amino acid<\\e1> transport through <e2>ASCT2<\\e2>  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amino acid","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with <e1>CHEMICAL<\\e1> transport through <e2>GENE-Y<\\e2>  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values","sentence":"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through ASCT2  The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values"}
{"PMID":17475673,"re_id":9,"annotated sentence":"Differences in magnitude of Na(+)-dependent <e1>l-alanine<\\e1> uptake through <e2>ASCT2<\\e2> between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"l-alanine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Differences in magnitude of Na(+)-dependent <e1>CHEMICAL<\\e1> uptake through <e2>GENE-Y<\\e2> between WKY and SHR PTE cells correlated positively with differences in GENE-Y protein expression, this being more abundant in WKY PTE cells","sentence":"Differences in magnitude of Na(+)-dependent l-alanine uptake through ASCT2 between WKY and SHR PTE cells correlated positively with differences in ASCT2 protein expression, this being more abundant in WKY PTE cells"}
{"PMID":17475673,"re_id":10,"annotated sentence":"In conclusion, immortalized SHR and WKY PTE cells take up <e1>l-alanine<\\e1> mainly through a high-affinity <e2>Na(+)-dependent amino acid transporter<\\e2>  with functional features of ASCT2 transport","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"l-alanine","object":"Na(+)-dependent amino acid transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, immortalized SHR and WKY PTE cells take up <e1>CHEMICAL<\\e1> mainly through a high-affinity <e2>GENE-N<\\e2>  with functional features of ASCT2 transport","sentence":"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent amino acid transporter  with functional features of ASCT2 transport"}
{"PMID":17475673,"re_id":11,"annotated sentence":"In conclusion, immortalized SHR and WKY PTE cells take up <e1>l-alanine<\\e1> mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of <e2>ASCT2<\\e2> transport","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"l-alanine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, immortalized SHR and WKY PTE cells take up <e1>CHEMICAL<\\e1> mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of <e2>GENE-Y<\\e2> transport","sentence":"In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of ASCT2 transport"}
{"PMID":17475673,"re_id":12,"annotated sentence":"This study examined the inward transport of <e1>l-[(14)C]alanine<\\e1>  an <e2>ASCT2<\\e2> preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"l-[(14)C]alanine","object":"ASCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study examined the inward transport of <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats","sentence":"This study examined the inward transport of l-[(14)C]alanine  an ASCT2 preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats"}
{"PMID":17479245,"re_id":0,"annotated sentence":"Intravenous <e1>arginine<\\e1> significantly increased the acute <e2>glucagon<\\e2> response (129 +\/- 12 vs 36 +\/- 6 ng\/l in controls; p < 0.01), notably without affecting plasma glucose","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arginine","object":"glucagon","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Intravenous <e1>CHEMICAL<\\e1> significantly increased the acute <e2>GENE-Y<\\e2> response (129 +\/- 12 vs 36 +\/- 6 ng\/l in controls; p < 0.01), notably without affecting plasma glucose","sentence":"Intravenous arginine significantly increased the acute glucagon response (129 +\/- 12 vs 36 +\/- 6 ng\/l in controls; p < 0.01), notably without affecting plasma glucose"}
{"PMID":17479245,"re_id":1,"annotated sentence":"Isolated islets displayed improved <e1>glucose<\\e1> stimulated <e2>insulin<\\e2> secretion after GRA treatment (0.061 +\/- 0.007 vs 0.030 +\/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol\/l glucose; p < 0.001), without affecting islet glucose oxidation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Isolated islets displayed improved <e1>CHEMICAL<\\e1> stimulated <e2>GENE-N<\\e2> secretion after GRA treatment (0.061 +\/- 0.007 vs 0.030 +\/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol\/l CHEMICAL; p < 0.001), without affecting islet CHEMICAL oxidation","sentence":"Isolated islets displayed improved glucose stimulated insulin secretion after GRA treatment (0.061 +\/- 0.007 vs 0.030 +\/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol\/l glucose; p < 0.001), without affecting islet glucose oxidation"}
{"PMID":17488480,"re_id":0,"annotated sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, <e1>sodium hydrosulphide<\\e1> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in <e2>SP<\\e2> concentration and expression of PPT-A and NK1-R in acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sodium hydrosulphide","object":"SP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, <e1>CHEMICAL<\\e1> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in <e2>GENE-Y<\\e2> concentration and expression of PPT-A and NK1-R in acinar cells","sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and NK1-R in acinar cells"}
{"PMID":17488480,"re_id":1,"annotated sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, <e1>sodium hydrosulphide<\\e1> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of <e2>PPT-A<\\e2> and NK1-R in acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sodium hydrosulphide","object":"PPT-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, <e1>CHEMICAL<\\e1> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of <e2>GENE-Y<\\e2> and NK1-R in acinar cells","sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and NK1-R in acinar cells"}
{"PMID":17488480,"re_id":2,"annotated sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, <e1>sodium hydrosulphide<\\e1> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and <e2>NK1-R<\\e2> in acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sodium hydrosulphide","object":"NK1-R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, <e1>CHEMICAL<\\e1> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and <e2>GENE-Y<\\e2> in acinar cells","sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and NK1-R in acinar cells"}
{"PMID":17488480,"re_id":3,"annotated sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<e1>NaHS<\\e1> , (10, 50 and 100 muM), that resulted in a significant increase in <e2>SP<\\e2> concentration and expression of PPT-A and NK1-R in acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaHS","object":"SP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<e1>CHEMICAL<\\e1> , (10, 50 and 100 muM), that resulted in a significant increase in <e2>GENE-Y<\\e2> concentration and expression of PPT-A and NK1-R in acinar cells","sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (NaHS , (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and NK1-R in acinar cells"}
{"PMID":17488480,"re_id":4,"annotated sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<e1>NaHS<\\e1> , (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of <e2>PPT-A<\\e2> and NK1-R in acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaHS","object":"PPT-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<e1>CHEMICAL<\\e1> , (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of <e2>GENE-Y<\\e2> and NK1-R in acinar cells","sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (NaHS , (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and NK1-R in acinar cells"}
{"PMID":17488480,"re_id":5,"annotated sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<e1>NaHS<\\e1> , (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and <e2>NK1-R<\\e2> in acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaHS","object":"NK1-R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<e1>CHEMICAL<\\e1> , (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and <e2>GENE-Y<\\e2> in acinar cells","sentence":"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (NaHS , (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and NK1-R in acinar cells"}
{"PMID":17488480,"re_id":6,"annotated sentence":"<e1>Caerulein<\\e1> increased the levels of H(2)S and <e2>CSE<\\e2> mRNA expression while CBS mRNA expression was decreased","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Caerulein","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased the levels of H(2)S and <e2>GENE-Y<\\e2> mRNA expression while CBS mRNA expression was decreased","sentence":"Caerulein increased the levels of H(2)S and CSE mRNA expression while CBS mRNA expression was decreased"}
{"PMID":17488480,"re_id":7,"annotated sentence":"Furthermore, <e2>substance P<\\e2> (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein<\\e1> treated acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"caerulein","object":"substance P","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e2>GENE-Y<\\e2> (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>CHEMICAL<\\e1> treated acinar cells","sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein treated acinar cells"}
{"PMID":17488480,"re_id":8,"annotated sentence":"Furthermore, substance P (<e2>SP<\\e2>  concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein<\\e1> treated acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"caerulein","object":"SP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, substance P (<e2>GENE-Y<\\e2>  concentration in the acini and expression of GENE-Y gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for GENE-Y, are increased in secretagogue <e1>CHEMICAL<\\e1> treated acinar cells","sentence":"Furthermore, substance P (SP  concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein treated acinar cells"}
{"PMID":17488480,"re_id":9,"annotated sentence":"Furthermore, substance P (SP) concentration in the acini and expression of <e2>SP<\\e2> gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein<\\e1> treated acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"caerulein","object":"SP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, substance P (GENE-Y) concentration in the acini and expression of <e2>GENE-Y<\\e2> gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for GENE-Y, are increased in secretagogue <e1>CHEMICAL<\\e1> treated acinar cells","sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein treated acinar cells"}
{"PMID":17488480,"re_id":10,"annotated sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (<e2>preprotachykinin-A<\\e2>  PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein<\\e1> treated acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"caerulein","object":"preprotachykinin-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (<e2>GENE-Y<\\e2>  PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>CHEMICAL<\\e1> treated acinar cells","sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A  PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein treated acinar cells"}
{"PMID":17488480,"re_id":11,"annotated sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, <e2>PPT-A<\\e2>  and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein<\\e1> treated acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"caerulein","object":"PPT-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, <e2>GENE-Y<\\e2>  and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>CHEMICAL<\\e1> treated acinar cells","sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A  and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein treated acinar cells"}
{"PMID":17488480,"re_id":12,"annotated sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and <e2>neurokinin-1 receptor<\\e2> (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein<\\e1> treated acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"caerulein","object":"neurokinin-1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and <e2>GENE-Y<\\e2> (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>CHEMICAL<\\e1> treated acinar cells","sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue caerulein treated acinar cells"}
{"PMID":17488480,"re_id":13,"annotated sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (<e2>NK-1R<\\e2> , the primary receptor for SP, are increased in secretagogue <e1>caerulein<\\e1> treated acinar cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"caerulein","object":"NK-1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (<e2>GENE-Y<\\e2> , the primary receptor for SP, are increased in secretagogue <e1>CHEMICAL<\\e1> treated acinar cells","sentence":"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R , the primary receptor for SP, are increased in secretagogue caerulein treated acinar cells"}
{"PMID":17488480,"re_id":14,"annotated sentence":"<e1>Caerulein<\\e1> increased the levels of H(2)S and CSE mRNA expression while <e2>CBS<\\e2> mRNA expression was decreased","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Caerulein","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased the levels of H(2)S and CSE mRNA expression while <e2>GENE-Y<\\e2> mRNA expression was decreased","sentence":"Caerulein increased the levels of H(2)S and CSE mRNA expression while CBS mRNA expression was decreased"}
{"PMID":17488480,"re_id":15,"annotated sentence":"In addition, cells pre-treated with <e1>DL-propargylglycine<\\e1> (PAG, 3 mM), a <e2>CSE<\\e2> inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DL-propargylglycine","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, cells pre-treated with <e1>CHEMICAL<\\e1> (PAG, 3 mM), a <e2>GENE-Y<\\e2> inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that GENE-Y may be the main enzyme involved in H(2)S formation in mouse acinar cells","sentence":"In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells"}
{"PMID":17488480,"re_id":16,"annotated sentence":"In addition, cells pre-treated with DL-propargylglycine (<e1>PAG<\\e1>  3 mM), a <e2>CSE<\\e2> inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PAG","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, cells pre-treated with DL-propargylglycine (<e1>CHEMICAL<\\e1>  3 mM), a <e2>GENE-Y<\\e2> inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that GENE-Y may be the main enzyme involved in H(2)S formation in mouse acinar cells","sentence":"In addition, cells pre-treated with DL-propargylglycine (PAG  3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells"}
{"PMID":17488480,"re_id":17,"annotated sentence":"Inhibition of endogenous production of <e1>H(2)S<\\e1> by PAG significantly suppressed <e2>SP<\\e2> concentration, PPT-A expression and NK1-R expression in the acini","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"SP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of endogenous production of <e1>CHEMICAL<\\e1> by PAG significantly suppressed <e2>GENE-Y<\\e2> concentration, PPT-A expression and NK1-R expression in the acini","sentence":"Inhibition of endogenous production of H(2)S by PAG significantly suppressed SP concentration, PPT-A expression and NK1-R expression in the acini"}
{"PMID":17488480,"re_id":18,"annotated sentence":"Inhibition of endogenous production of <e1>H(2)S<\\e1> by PAG significantly suppressed SP concentration, <e2>PPT-A<\\e2> expression and NK1-R expression in the acini","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"PPT-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of endogenous production of <e1>CHEMICAL<\\e1> by PAG significantly suppressed SP concentration, <e2>GENE-Y<\\e2> expression and NK1-R expression in the acini","sentence":"Inhibition of endogenous production of H(2)S by PAG significantly suppressed SP concentration, PPT-A expression and NK1-R expression in the acini"}
{"PMID":17488480,"re_id":19,"annotated sentence":"Inhibition of endogenous production of <e1>H(2)S<\\e1> by PAG significantly suppressed SP concentration, PPT-A expression and <e2>NK1-R<\\e2> expression in the acini","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"NK1-R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of endogenous production of <e1>CHEMICAL<\\e1> by PAG significantly suppressed SP concentration, PPT-A expression and <e2>GENE-Y<\\e2> expression in the acini","sentence":"Inhibition of endogenous production of H(2)S by PAG significantly suppressed SP concentration, PPT-A expression and NK1-R expression in the acini"}
{"PMID":17488480,"re_id":20,"annotated sentence":"These results suggest that the pro-inflammatory effect of <e1>H(2)S<\\e1> may be mediated by <e2>SP<\\e2> NK-1R related pathway in mouse pancreatic acinar cells.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"SP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that the pro-inflammatory effect of <e1>CHEMICAL<\\e1> may be mediated by <e2>GENE-Y<\\e2> NK-1R related pathway in mouse pancreatic acinar cells.","sentence":"These results suggest that the pro-inflammatory effect of H(2)S may be mediated by SP NK-1R related pathway in mouse pancreatic acinar cells."}
{"PMID":17488480,"re_id":21,"annotated sentence":"These results suggest that the pro-inflammatory effect of <e1>H(2)S<\\e1> may be mediated by SP-<e2>NK-1R<\\e2> related pathway in mouse pancreatic acinar cells.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"NK-1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that the pro-inflammatory effect of <e1>CHEMICAL<\\e1> may be mediated by SP-<e2>GENE-Y<\\e2> related pathway in mouse pancreatic acinar cells.","sentence":"These results suggest that the pro-inflammatory effect of H(2)S may be mediated by SP-NK-1R related pathway in mouse pancreatic acinar cells."}
{"PMID":17488480,"re_id":22,"annotated sentence":"Hydrogen sulphide (<e1>H(2)S<\\e1>  is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (<e2>CSE<\\e2>  and cystathionine-beta-synthase (CBS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulphide (<e1>CHEMICAL<\\e1>  is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (<e2>GENE-Y<\\e2>  and cystathionine-beta-synthase (CBS)","sentence":"Hydrogen sulphide (H(2)S  is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE  and cystathionine-beta-synthase (CBS)"}
{"PMID":17488480,"re_id":23,"annotated sentence":"Hydrogen sulphide (<e1>H(2)S<\\e1>  is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and <e2>cystathionine-beta-synthase<\\e2> (CBS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"cystathionine-beta-synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulphide (<e1>CHEMICAL<\\e1>  is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and <e2>GENE-Y<\\e2> (CBS)","sentence":"Hydrogen sulphide (H(2)S  is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS)"}
{"PMID":17488480,"re_id":24,"annotated sentence":"Hydrogen sulphide (<e1>H(2)S<\\e1>  is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulphide (<e1>CHEMICAL<\\e1>  is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>GENE-Y<\\e2> ","sentence":"Hydrogen sulphide (H(2)S  is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS "}
{"PMID":17488480,"re_id":25,"annotated sentence":"Hydrogen sulphide (<e1>H(2)S<\\e1>  is synthesized from L-cysteine via the action of <e2>cystathionine-gamma-lyase<\\e2> (CSE) and cystathionine-beta-synthase (CBS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"cystathionine-gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulphide (<e1>CHEMICAL<\\e1>  is synthesized from L-cysteine via the action of <e2>GENE-Y<\\e2> (CSE) and cystathionine-beta-synthase (CBS)","sentence":"Hydrogen sulphide (H(2)S  is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS)"}
{"PMID":17488480,"re_id":26,"annotated sentence":"In this study, we investigated the presence of H(2)S and the expression of <e1>H(2)S<\\e1> synthesizing enzymes, <e2>CSE<\\e2> and CBS, in isolated mouse pancreatic acini","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we investigated the presence of CHEMICAL and the expression of <e1>CHEMICAL<\\e1> synthesizing enzymes, <e2>GENE-Y<\\e2> and CBS, in isolated mouse pancreatic acini","sentence":"In this study, we investigated the presence of H(2)S and the expression of H(2)S synthesizing enzymes, CSE and CBS, in isolated mouse pancreatic acini"}
{"PMID":17488480,"re_id":27,"annotated sentence":"In this study, we investigated the presence of H(2)S and the expression of <e1>H(2)S<\\e1> synthesizing enzymes, CSE and <e2>CBS<\\e2>  in isolated mouse pancreatic acini","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we investigated the presence of CHEMICAL and the expression of <e1>CHEMICAL<\\e1> synthesizing enzymes, CSE and <e2>GENE-Y<\\e2>  in isolated mouse pancreatic acini","sentence":"In this study, we investigated the presence of H(2)S and the expression of H(2)S synthesizing enzymes, CSE and CBS  in isolated mouse pancreatic acini"}
{"PMID":17488480,"re_id":28,"annotated sentence":"Hydrogen sulphide (H(2)S) is synthesized from <e1>L-cysteine<\\e1> via the action of cystathionine-gamma-lyase (<e2>CSE<\\e2>  and cystathionine-beta-synthase (CBS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-cysteine","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulphide (H(2)S) is synthesized from <e1>CHEMICAL<\\e1> via the action of cystathionine-gamma-lyase (<e2>GENE-Y<\\e2>  and cystathionine-beta-synthase (CBS)","sentence":"Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE  and cystathionine-beta-synthase (CBS)"}
{"PMID":17488480,"re_id":29,"annotated sentence":"Hydrogen sulphide (H(2)S) is synthesized from <e1>L-cysteine<\\e1> via the action of cystathionine-gamma-lyase (CSE) and <e2>cystathionine-beta-synthase<\\e2> (CBS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-cysteine","object":"cystathionine-beta-synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulphide (H(2)S) is synthesized from <e1>CHEMICAL<\\e1> via the action of cystathionine-gamma-lyase (CSE) and <e2>GENE-Y<\\e2> (CBS)","sentence":"Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS)"}
{"PMID":17488480,"re_id":30,"annotated sentence":"Hydrogen sulphide (H(2)S) is synthesized from <e1>L-cysteine<\\e1> via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-cysteine","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulphide (H(2)S) is synthesized from <e1>CHEMICAL<\\e1> via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>GENE-Y<\\e2> ","sentence":"Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS "}
{"PMID":17488480,"re_id":31,"annotated sentence":"Hydrogen sulphide (H(2)S) is synthesized from <e1>L-cysteine<\\e1> via the action of <e2>cystathionine-gamma-lyase<\\e2> (CSE) and cystathionine-beta-synthase (CBS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"L-cysteine","object":"cystathionine-gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulphide (H(2)S) is synthesized from <e1>CHEMICAL<\\e1> via the action of <e2>GENE-Y<\\e2> (CSE) and cystathionine-beta-synthase (CBS)","sentence":"Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS)"}
{"PMID":17488480,"re_id":32,"annotated sentence":"<e1>Hydrogen sulphide<\\e1> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (<e2>CSE<\\e2>  and cystathionine-beta-synthase (CBS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Hydrogen sulphide","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (<e2>GENE-Y<\\e2>  and cystathionine-beta-synthase (CBS)","sentence":"Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE  and cystathionine-beta-synthase (CBS)"}
{"PMID":17488480,"re_id":33,"annotated sentence":"<e1>Hydrogen sulphide<\\e1> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and <e2>cystathionine-beta-synthase<\\e2> (CBS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Hydrogen sulphide","object":"cystathionine-beta-synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and <e2>GENE-Y<\\e2> (CBS)","sentence":"Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS)"}
{"PMID":17488480,"re_id":34,"annotated sentence":"<e1>Hydrogen sulphide<\\e1> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Hydrogen sulphide","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>GENE-Y<\\e2> ","sentence":"Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS "}
{"PMID":17488480,"re_id":35,"annotated sentence":"<e1>Hydrogen sulphide<\\e1> (H(2)S) is synthesized from L-cysteine via the action of <e2>cystathionine-gamma-lyase<\\e2> (CSE) and cystathionine-beta-synthase (CBS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Hydrogen sulphide","object":"cystathionine-gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (H(2)S) is synthesized from L-cysteine via the action of <e2>GENE-Y<\\e2> (CSE) and cystathionine-beta-synthase (CBS)","sentence":"Hydrogen sulphide (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS)"}
{"PMID":17488480,"re_id":36,"annotated sentence":"In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that <e2>CSE<\\e2> may be the main enzyme involved in <e1>H(2)S<\\e1> formation in mouse acinar cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"H(2)S","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a GENE-Y inhibitor, reduced the formation of CHEMICAL in caerulein treated cells, suggesting that <e2>GENE-Y<\\e2> may be the main enzyme involved in <e1>CHEMICAL<\\e1> formation in mouse acinar cells","sentence":"In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells"}
{"PMID":17494951,"re_id":0,"annotated sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while <e1>1400W dihydrochloride<\\e1> (1400W), a selective inhibitor of <e2>iNOS<\\e2>  decreased the expression of E-selectin, VEGF, and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1400W dihydrochloride","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and GENE-Y induced by reIL-4, while <e1>CHEMICAL<\\e1> (1400W), a selective inhibitor of <e2>GENE-Y<\\e2>  decreased the expression of E-selectin, VEGF, and GENE-Y","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS  decreased the expression of E-selectin, VEGF, and iNOS"}
{"PMID":17494951,"re_id":1,"annotated sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while <e1>1400W dihydrochloride<\\e1> (1400W), a selective inhibitor of iNOS, decreased the expression of <e2>E-selectin<\\e2>  VEGF, and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1400W dihydrochloride","object":"E-selectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while <e1>CHEMICAL<\\e1> (1400W), a selective inhibitor of iNOS, decreased the expression of <e2>GENE-Y<\\e2>  VEGF, and iNOS","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin  VEGF, and iNOS"}
{"PMID":17494951,"re_id":2,"annotated sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while <e1>1400W dihydrochloride<\\e1> (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, <e2>VEGF<\\e2>  and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1400W dihydrochloride","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, GENE-Y, and iNOS induced by reIL-4, while <e1>CHEMICAL<\\e1> (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, <e2>GENE-Y<\\e2>  and iNOS","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF  and iNOS"}
{"PMID":17494951,"re_id":3,"annotated sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while <e1>1400W dihydrochloride<\\e1> (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and <e2>iNOS<\\e2>  DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1400W dihydrochloride","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and GENE-Y induced by reIL-4, while <e1>CHEMICAL<\\e1> (1400W), a selective inhibitor of GENE-Y, decreased the expression of E-selectin, VEGF, and <e2>GENE-Y<\\e2>  DXM and 1400W attenuated the mRNA expression of E-selectin and GENE-Y induced by the costimulation of reIL-4, reTNF-alpha, and LPS","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS  DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS"}
{"PMID":17494951,"re_id":4,"annotated sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (<e1>1400W<\\e1> , a selective inhibitor of <e2>iNOS<\\e2>  decreased the expression of E-selectin, VEGF, and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1400W","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and GENE-Y induced by reIL-4, while CHEMICAL dihydrochloride (<e1>CHEMICAL<\\e1> , a selective inhibitor of <e2>GENE-Y<\\e2>  decreased the expression of E-selectin, VEGF, and GENE-Y","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W , a selective inhibitor of iNOS  decreased the expression of E-selectin, VEGF, and iNOS"}
{"PMID":17494951,"re_id":5,"annotated sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (<e1>1400W<\\e1> , a selective inhibitor of iNOS, decreased the expression of <e2>E-selectin<\\e2>  VEGF, and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1400W","object":"E-selectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while CHEMICAL dihydrochloride (<e1>CHEMICAL<\\e1> , a selective inhibitor of iNOS, decreased the expression of <e2>GENE-Y<\\e2>  VEGF, and iNOS","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W , a selective inhibitor of iNOS, decreased the expression of E-selectin  VEGF, and iNOS"}
{"PMID":17494951,"re_id":6,"annotated sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (<e1>1400W<\\e1> , a selective inhibitor of iNOS, decreased the expression of E-selectin, <e2>VEGF<\\e2>  and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1400W","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, GENE-Y, and iNOS induced by reIL-4, while CHEMICAL dihydrochloride (<e1>CHEMICAL<\\e1> , a selective inhibitor of iNOS, decreased the expression of E-selectin, <e2>GENE-Y<\\e2>  and iNOS","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W , a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF  and iNOS"}
{"PMID":17494951,"re_id":7,"annotated sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (<e1>1400W<\\e1> , a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and <e2>iNOS<\\e2>  DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1400W","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and GENE-Y induced by reIL-4, while CHEMICAL dihydrochloride (<e1>CHEMICAL<\\e1> , a selective inhibitor of GENE-Y, decreased the expression of E-selectin, VEGF, and <e2>GENE-Y<\\e2>  DXM and CHEMICAL attenuated the mRNA expression of E-selectin and GENE-Y induced by the costimulation of reIL-4, reTNF-alpha, and LPS","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W , a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS  DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS"}
{"PMID":17494951,"re_id":8,"annotated sentence":"<e1>DXM<\\e1> and 1400W attenuated the mRNA expression of <e2>E-selectin<\\e2> and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DXM","object":"E-selectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and 1400W attenuated the mRNA expression of <e2>GENE-Y<\\e2> and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS","sentence":"DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS"}
{"PMID":17494951,"re_id":9,"annotated sentence":"<e1>DXM<\\e1> and 1400W attenuated the mRNA expression of E-selectin and <e2>iNOS<\\e2> induced by the costimulation of reIL-4, reTNF-alpha, and LPS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DXM","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and 1400W attenuated the mRNA expression of E-selectin and <e2>GENE-Y<\\e2> induced by the costimulation of reIL-4, reTNF-alpha, and LPS","sentence":"DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS"}
{"PMID":17494951,"re_id":10,"annotated sentence":"DXM and <e1>1400W<\\e1> attenuated the mRNA expression of <e2>E-selectin<\\e2> and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1400W","object":"E-selectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"DXM and <e1>CHEMICAL<\\e1> attenuated the mRNA expression of <e2>GENE-Y<\\e2> and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS","sentence":"DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS"}
{"PMID":17494951,"re_id":11,"annotated sentence":"DXM and <e1>1400W<\\e1> attenuated the mRNA expression of E-selectin and <e2>iNOS<\\e2> induced by the costimulation of reIL-4, reTNF-alpha, and LPS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1400W","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"DXM and <e1>CHEMICAL<\\e1> attenuated the mRNA expression of E-selectin and <e2>GENE-Y<\\e2> induced by the costimulation of reIL-4, reTNF-alpha, and LPS","sentence":"DXM and 1400W attenuated the mRNA expression of E-selectin and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS"}
{"PMID":17494951,"re_id":12,"annotated sentence":"<e1>Dexamethasone<\\e1> (DXM) decreased the expression of <e2>CXCL-8<\\e2>  VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dexamethasone","object":"CXCL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (DXM) decreased the expression of <e2>GENE-Y<\\e2>  VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8  VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS"}
{"PMID":17494951,"re_id":13,"annotated sentence":"<e1>Dexamethasone<\\e1> (DXM) decreased the expression of CXCL-8, <e2>VEGF<\\e2>  and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dexamethasone","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (DXM) decreased the expression of CXCL-8, <e2>GENE-Y<\\e2>  and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, GENE-Y, and iNOS","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF  and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS"}
{"PMID":17494951,"re_id":14,"annotated sentence":"<e1>Dexamethasone<\\e1> (DXM) decreased the expression of CXCL-8, VEGF, and <e2>iNOS<\\e2> induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dexamethasone","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (DXM) decreased the expression of CXCL-8, VEGF, and <e2>GENE-Y<\\e2> induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of GENE-Y, decreased the expression of E-selectin, VEGF, and GENE-Y","sentence":"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS"}
{"PMID":17494951,"re_id":15,"annotated sentence":"Dexamethasone (<e1>DXM<\\e1>  decreased the expression of <e2>CXCL-8<\\e2>  VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DXM","object":"CXCL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (<e1>CHEMICAL<\\e1>  decreased the expression of <e2>GENE-Y<\\e2>  VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS","sentence":"Dexamethasone (DXM  decreased the expression of CXCL-8  VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS"}
{"PMID":17494951,"re_id":16,"annotated sentence":"Dexamethasone (<e1>DXM<\\e1>  decreased the expression of CXCL-8, <e2>VEGF<\\e2>  and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DXM","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (<e1>CHEMICAL<\\e1>  decreased the expression of CXCL-8, <e2>GENE-Y<\\e2>  and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, GENE-Y, and iNOS","sentence":"Dexamethasone (DXM  decreased the expression of CXCL-8, VEGF  and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS"}
{"PMID":17494951,"re_id":17,"annotated sentence":"Dexamethasone (<e1>DXM<\\e1>  decreased the expression of CXCL-8, VEGF, and <e2>iNOS<\\e2> induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DXM","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (<e1>CHEMICAL<\\e1>  decreased the expression of CXCL-8, VEGF, and <e2>GENE-Y<\\e2> induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of GENE-Y, decreased the expression of E-selectin, VEGF, and GENE-Y","sentence":"Dexamethasone (DXM  decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS"}
{"PMID":17497253,"re_id":0,"annotated sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., <e1>sotalol<\\e1> or ibutilide in patients with a mutation in the <e2>IKr<\\e2> coding gene KCNH2 (HERG)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sotalol","object":"IKr","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., <e1>CHEMICAL<\\e1> or ibutilide in patients with a mutation in the <e2>GENE-Y<\\e2> coding gene KCNH2 (HERG)","sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or ibutilide in patients with a mutation in the IKr coding gene KCNH2 (HERG)"}
{"PMID":17497253,"re_id":1,"annotated sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., <e1>sotalol<\\e1> or ibutilide in patients with a mutation in the IKr-coding gene <e2>KCNH2<\\e2> (HERG)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sotalol","object":"KCNH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., <e1>CHEMICAL<\\e1> or ibutilide in patients with a mutation in the IKr-coding gene <e2>GENE-Y<\\e2> (HERG)","sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 (HERG)"}
{"PMID":17497253,"re_id":2,"annotated sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., <e1>sotalol<\\e1> or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 (<e2>HERG<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sotalol","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., <e1>CHEMICAL<\\e1> or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 (<e2>GENE-Y<\\e2> ","sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 (HERG "}
{"PMID":17497253,"re_id":3,"annotated sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or <e1>ibutilide<\\e1> in patients with a mutation in the <e2>IKr<\\e2> coding gene KCNH2 (HERG)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibutilide","object":"IKr","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or <e1>CHEMICAL<\\e1> in patients with a mutation in the <e2>GENE-Y<\\e2> coding gene KCNH2 (HERG)","sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or ibutilide in patients with a mutation in the IKr coding gene KCNH2 (HERG)"}
{"PMID":17497253,"re_id":4,"annotated sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or <e1>ibutilide<\\e1> in patients with a mutation in the IKr-coding gene <e2>KCNH2<\\e2> (HERG)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibutilide","object":"KCNH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or <e1>CHEMICAL<\\e1> in patients with a mutation in the IKr-coding gene <e2>GENE-Y<\\e2> (HERG)","sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 (HERG)"}
{"PMID":17497253,"re_id":5,"annotated sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or <e1>ibutilide<\\e1> in patients with a mutation in the IKr-coding gene KCNH2 (<e2>HERG<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibutilide","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or <e1>CHEMICAL<\\e1> in patients with a mutation in the IKr-coding gene KCNH2 (<e2>GENE-Y<\\e2> ","sentence":"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 (HERG "}
{"PMID":17499824,"re_id":0,"annotated sentence":"The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian <e2>serine racemase<\\e2> activity is increased by <e1>ATP<\\e1>  In addition to the results regarding the effect of ATP on enzyme activity and the phylogenetic analysis of eukaryotic serine racemases, the antiserum against Arabidopsis serine racemase did not form a precipitate with barley and rice serine racemases","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ATP","object":"serine racemase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not CHEMICAL, whereas mammalian <e2>GENE-N<\\e2> activity is increased by <e1>CHEMICAL<\\e1>  In addition to the results regarding the effect of CHEMICAL on enzyme activity and the phylogenetic analysis of eukaryotic GENE-Ns, the antiserum against Arabidopsis GENE-N did not form a precipitate with barley and rice GENE-Ns","sentence":"The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian serine racemase activity is increased by ATP  In addition to the results regarding the effect of ATP on enzyme activity and the phylogenetic analysis of eukaryotic serine racemases, the antiserum against Arabidopsis serine racemase did not form a precipitate with barley and rice serine racemases"}
{"PMID":17545671,"re_id":0,"annotated sentence":"<e2>cAspAT<\\e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the <e1>thiazolidinedione<\\e1> (TZD) rosiglitazone","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"thiazolidinedione","object":"cAspAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the <e1>CHEMICAL<\\e1> (TZD) rosiglitazone","sentence":"cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone"}
{"PMID":17545671,"re_id":1,"annotated sentence":"<e2>cAspAT<\\e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (<e1>TZD<\\e1>  rosiglitazone","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TZD","object":"cAspAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (<e1>CHEMICAL<\\e1>  rosiglitazone","sentence":"cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD  rosiglitazone"}
{"PMID":17545671,"re_id":2,"annotated sentence":"<e2>cAspAT<\\e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) <e1>rosiglitazone<\\e1>  Conversely, the ratio of fatty acid to glycerol released into the medium decreased","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rosiglitazone","object":"cAspAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) <e1>CHEMICAL<\\e1>  Conversely, the ratio of fatty acid to glycerol released into the medium decreased","sentence":"cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone  Conversely, the ratio of fatty acid to glycerol released into the medium decreased"}
{"PMID":17545671,"re_id":3,"annotated sentence":"<e2>RORalpha<\\e2> ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by <e1>rosiglitazone<\\e1> treatment of adipocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rosiglitazone","object":"RORalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> ectopic expression activated the cAspAT gene transcription in absence of CHEMICAL, and its protein amount in nuclear extracts is 1.8-fold increased by <e1>CHEMICAL<\\e1> treatment of adipocytes","sentence":"RORalpha ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by rosiglitazone treatment of adipocytes"}
{"PMID":17545671,"re_id":4,"annotated sentence":"RORalpha ectopic expression activated the <e2>cAspAT<\\e2> gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by <e1>rosiglitazone<\\e1> treatment of adipocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rosiglitazone","object":"cAspAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RORalpha ectopic expression activated the <e2>GENE-Y<\\e2> gene transcription in absence of CHEMICAL, and its protein amount in nuclear extracts is 1.8-fold increased by <e1>CHEMICAL<\\e1> treatment of adipocytes","sentence":"RORalpha ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by rosiglitazone treatment of adipocytes"}
{"PMID":17545671,"re_id":5,"annotated sentence":"Finally, the amounts of <e2>RORalpha<\\e2> and cAspAT mRNAs were similarly increased by <e1>TZD<\\e1> treatment of human adipose tissue explants, confirming coordinated regulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TZD","object":"RORalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, the amounts of <e2>GENE-Y<\\e2> and cAspAT mRNAs were similarly increased by <e1>CHEMICAL<\\e1> treatment of human adipose tissue explants, confirming coordinated regulation","sentence":"Finally, the amounts of RORalpha and cAspAT mRNAs were similarly increased by TZD treatment of human adipose tissue explants, confirming coordinated regulation"}
{"PMID":17545671,"re_id":6,"annotated sentence":"Finally, the amounts of RORalpha and <e2>cAspAT<\\e2> mRNAs were similarly increased by <e1>TZD<\\e1> treatment of human adipose tissue explants, confirming coordinated regulation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TZD","object":"cAspAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, the amounts of RORalpha and <e2>GENE-Y<\\e2> mRNAs were similarly increased by <e1>CHEMICAL<\\e1> treatment of human adipose tissue explants, confirming coordinated regulation","sentence":"Finally, the amounts of RORalpha and cAspAT mRNAs were similarly increased by TZD treatment of human adipose tissue explants, confirming coordinated regulation"}
{"PMID":17545671,"re_id":7,"annotated sentence":"Our data identify <e2>cAspAT<\\e2> as a new member of glyceroneogenesis, transcriptionally regulated by <e1>TZD<\\e1> via the control of RORalpha expression by PPARgamma in adipocytes.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TZD","object":"cAspAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our data identify <e2>GENE-Y<\\e2> as a new member of glyceroneogenesis, transcriptionally regulated by <e1>CHEMICAL<\\e1> via the control of RORalpha expression by PPARgamma in adipocytes.","sentence":"Our data identify cAspAT as a new member of glyceroneogenesis, transcriptionally regulated by TZD via the control of RORalpha expression by PPARgamma in adipocytes."}
{"PMID":17553661,"re_id":0,"annotated sentence":"In summary, our data indicates that over-expression of hGSTA4 at levels conferring high <e2>GST<\\e2> <e1>4-HNE<\\e1> conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-HNE","object":"GST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In summary, our data indicates that over-expression of hGENE-NA4 at levels conferring high <e2>GENE-N<\\e2> <e1>CHEMICAL<\\e1> conjugating activity confers a partial growth advantage to HepG2 cells and protects against CHEMICAL oxidative injury","sentence":"In summary, our data indicates that over-expression of hGSTA4 at levels conferring high GST 4-HNE conjugating activity confers a partial growth advantage to HepG2 cells and protects against 4-HNE oxidative injury"}
{"PMID":17553661,"re_id":1,"annotated sentence":"4-Hydroxynonenal (<e1>4-HNE<\\e1>  is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several <e2>glutathione S-transferase<\\e2> (GST) isoforms","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-HNE","object":"glutathione S-transferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"4-Hydroxynonenal (<e1>CHEMICAL<\\e1>  is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several <e2>GENE-N<\\e2> (GST) isoforms","sentence":"4-Hydroxynonenal (4-HNE  is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST) isoforms"}
{"PMID":17553661,"re_id":2,"annotated sentence":"4-Hydroxynonenal (<e1>4-HNE<\\e1>  is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (<e2>GST<\\e2>  isoforms","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-HNE","object":"GST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"4-Hydroxynonenal (<e1>CHEMICAL<\\e1>  is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (<e2>GENE-N<\\e2>  isoforms","sentence":"4-Hydroxynonenal (4-HNE  is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST  isoforms"}
{"PMID":17553661,"re_id":3,"annotated sentence":"However, the loss of proliferative capacity of <e2>hGSTA4<\\e2> cells challenged with levels of <e1>4-HNE<\\e1> associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and\/or GSH-electrophile transporter proteins, in providing full cellular protection against 4-HNE toxicity.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-HNE","object":"hGSTA4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, the loss of proliferative capacity of <e2>GENE-Y<\\e2> cells challenged with levels of <e1>CHEMICAL<\\e1> associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and\/or GSH-electrophile transporter proteins, in providing full cellular protection against CHEMICAL toxicity.","sentence":"However, the loss of proliferative capacity of hGSTA4 cells challenged with levels of 4-HNE associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and\/or GSH-electrophile transporter proteins, in providing full cellular protection against 4-HNE toxicity."}
{"PMID":17553661,"re_id":4,"annotated sentence":"<e1>4-Hydroxynonenal<\\e1> (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several <e2>glutathione S-transferase<\\e2> (GST) isoforms","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-Hydroxynonenal","object":"glutathione S-transferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several <e2>GENE-N<\\e2> (GST) isoforms","sentence":"4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST) isoforms"}
{"PMID":17553661,"re_id":5,"annotated sentence":"<e1>4-Hydroxynonenal<\\e1> (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (<e2>GST<\\e2>  isoforms","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-Hydroxynonenal","object":"GST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (<e2>GENE-N<\\e2>  isoforms","sentence":"4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST  isoforms"}
{"PMID":17553661,"re_id":6,"annotated sentence":"The alpha class <e2>human GSTA4-4<\\e2> enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward <e1>4-HNE<\\e1> conjugation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-HNE","object":"human GSTA4-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The alpha class <e2>GENE-Y<\\e2> enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward <e1>CHEMICAL<\\e1> conjugation","sentence":"The alpha class human GSTA4-4 enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward 4-HNE conjugation"}
{"PMID":17553661,"re_id":7,"annotated sentence":"The alpha class human GSTA4-4 enzyme (<e2>hGSTA4-4<\\e2>  has a particularly high catalytic efficiency toward <e1>4-HNE<\\e1> conjugation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-HNE","object":"hGSTA4-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The alpha class human GSTA4-4 enzyme (<e2>GENE-Y<\\e2>  has a particularly high catalytic efficiency toward <e1>CHEMICAL<\\e1> conjugation","sentence":"The alpha class human GSTA4-4 enzyme (hGSTA4-4  has a particularly high catalytic efficiency toward 4-HNE conjugation"}
{"PMID":17553661,"re_id":8,"annotated sentence":"4-Hydroxynonenal (4-HNE) is a mutagenic <e1>alpha,beta-unsaturated aldehyde<\\e1> produced during oxidative injury that is conjugated by several <e2>glutathione S-transferase<\\e2> (GST) isoforms","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha,beta-unsaturated aldehyde","object":"glutathione S-transferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"4-Hydroxynonenal (4-HNE) is a mutagenic <e1>CHEMICAL<\\e1> produced during oxidative injury that is conjugated by several <e2>GENE-N<\\e2> (GST) isoforms","sentence":"4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST) isoforms"}
{"PMID":17553661,"re_id":9,"annotated sentence":"4-Hydroxynonenal (4-HNE) is a mutagenic <e1>alpha,beta-unsaturated aldehyde<\\e1> produced during oxidative injury that is conjugated by several glutathione S-transferase (<e2>GST<\\e2>  isoforms","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha,beta-unsaturated aldehyde","object":"GST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"4-Hydroxynonenal (4-HNE) is a mutagenic <e1>CHEMICAL<\\e1> produced during oxidative injury that is conjugated by several glutathione S-transferase (<e2>GENE-N<\\e2>  isoforms","sentence":"4-Hydroxynonenal (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (GST  isoforms"}
{"PMID":17553661,"re_id":10,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-HNE","object":"GST-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":17553661,"re_id":11,"annotated sentence":"Specifically, <e2>hGSTA4<\\e2> cells had significantly higher GSH concentrations when exposed to 5-15 microM <e1>4-HNE<\\e1>  but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-HNE","object":"hGSTA4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Specifically, <e2>GENE-Y<\\e2> cells had significantly higher GSH concentrations when exposed to 5-15 microM <e1>CHEMICAL<\\e1>  but not at 20 microM CHEMICAL, suggesting extensive GSH utilization at high concentrations of CHEMICAL","sentence":"Specifically, hGSTA4 cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE  but not at 20 microM 4-HNE, suggesting extensive GSH utilization at high concentrations of 4-HNE"}
{"PMID":17553661,"re_id":12,"annotated sentence":"Specifically, <e2>hGSTA4<\\e2> cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM <e1>4-HNE<\\e1>  suggesting extensive GSH utilization at high concentrations of 4-HNE","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"4-HNE","object":"hGSTA4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Specifically, <e2>GENE-Y<\\e2> cells had significantly higher GSH concentrations when exposed to 5-15 microM CHEMICAL, but not at 20 microM <e1>CHEMICAL<\\e1>  suggesting extensive GSH utilization at high concentrations of CHEMICAL","sentence":"Specifically, hGSTA4 cells had significantly higher GSH concentrations when exposed to 5-15 microM 4-HNE, but not at 20 microM 4-HNE  suggesting extensive GSH utilization at high concentrations of 4-HNE"}
{"PMID":17567713,"re_id":0,"annotated sentence":"Recently, it has been shown that the activation of particular <e2>T2R<\\e2> bitter taste receptors is partially involved with the bitter aftertaste sensation of <e1>saccharin<\\e1> and acesulfame-K","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"saccharin","object":"T2R","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recently, it has been shown that the activation of particular <e2>GENE-N<\\e2> bitter taste receptors is partially involved with the bitter aftertaste sensation of <e1>CHEMICAL<\\e1> and acesulfame-K","sentence":"Recently, it has been shown that the activation of particular T2R bitter taste receptors is partially involved with the bitter aftertaste sensation of saccharin and acesulfame-K"}
{"PMID":17567713,"re_id":1,"annotated sentence":"Recently, it has been shown that the activation of particular <e2>T2R<\\e2> bitter taste receptors is partially involved with the bitter aftertaste sensation of saccharin and <e1>acesulfame-K<\\e1>  To more fully understand the biology behind these phenomena we have addressed the question of whether AS could stimulate transient receptor potential vanilloid-1 (TRPV1) receptors, as these receptors are activated by a large range of structurally different chemicals","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"acesulfame-K","object":"T2R","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recently, it has been shown that the activation of particular <e2>GENE-N<\\e2> bitter taste receptors is partially involved with the bitter aftertaste sensation of saccharin and <e1>CHEMICAL<\\e1>  To more fully understand the biology behind these phenomena we have addressed the question of whether AS could stimulate transient receptor potential vanilloid-1 (TRPV1) receptors, as these receptors are activated by a large range of structurally different chemicals","sentence":"Recently, it has been shown that the activation of particular T2R bitter taste receptors is partially involved with the bitter aftertaste sensation of saccharin and acesulfame-K  To more fully understand the biology behind these phenomena we have addressed the question of whether AS could stimulate transient receptor potential vanilloid-1 (TRPV1) receptors, as these receptors are activated by a large range of structurally different chemicals"}
{"PMID":17567713,"re_id":2,"annotated sentence":"We also found that <e2>TRPV1<\\e2> receptors are activated by <e1>CuSO(4)<\\e1>  ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CuSO(4)","object":"TRPV1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We also found that <e2>GENE-Y<\\e2> receptors are activated by <e1>CHEMICAL<\\e1>  ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation","sentence":"We also found that TRPV1 receptors are activated by CuSO(4)  ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation"}
{"PMID":17567713,"re_id":3,"annotated sentence":"We also found that <e2>TRPV1<\\e2> receptors are activated by CuSO(4), <e1>ZnSO(4)<\\e1>  and FeSO(4), three salts known to produce a metallic taste sensation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ZnSO(4)","object":"TRPV1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We also found that <e2>GENE-Y<\\e2> receptors are activated by CuSO(4), <e1>CHEMICAL<\\e1>  and FeSO(4), three salts known to produce a metallic taste sensation","sentence":"We also found that TRPV1 receptors are activated by CuSO(4), ZnSO(4)  and FeSO(4), three salts known to produce a metallic taste sensation"}
{"PMID":17567713,"re_id":4,"annotated sentence":"We also found that <e2>TRPV1<\\e2> receptors are activated by CuSO(4), ZnSO(4), and <e1>FeSO(4)<\\e1>  three salts known to produce a metallic taste sensation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"FeSO(4)","object":"TRPV1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We also found that <e2>GENE-Y<\\e2> receptors are activated by CuSO(4), ZnSO(4), and <e1>CHEMICAL<\\e1>  three salts known to produce a metallic taste sensation","sentence":"We also found that TRPV1 receptors are activated by CuSO(4), ZnSO(4), and FeSO(4)  three salts known to produce a metallic taste sensation"}
{"PMID":17570561,"re_id":0,"annotated sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin<\\e1> biosynthesis such as <e2>l-phenylalanine ammonia-lyase<\\e2> (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"anthocyanin","object":"l-phenylalanine ammonia-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>CHEMICAL<\\e1> biosynthesis such as <e2>GENE-Y<\\e2> (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)","sentence":"We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)"}
{"PMID":17570561,"re_id":1,"annotated sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin<\\e1> biosynthesis such as l-phenylalanine ammonia-lyase (<e2>PAL<\\e2>  and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"anthocyanin","object":"PAL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>CHEMICAL<\\e1> biosynthesis such as l-phenylalanine ammonia-lyase (<e2>GENE-Y<\\e2>  and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)","sentence":"We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL  and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)"}
{"PMID":17570561,"re_id":2,"annotated sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin<\\e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and <e2>chalcone synthase<\\e2> (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"anthocyanin","object":"chalcone synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>CHEMICAL<\\e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and <e2>GENE-Y<\\e2> (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)","sentence":"We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)"}
{"PMID":17570561,"re_id":3,"annotated sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin<\\e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (<e2>CHS<\\e2> , and an antioxidant enzyme such as ascorbate peroxidase (APX)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"anthocyanin","object":"CHS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>CHEMICAL<\\e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (<e2>GENE-Y<\\e2> , and an antioxidant enzyme such as ascorbate peroxidase (APX)","sentence":"We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS , and an antioxidant enzyme such as ascorbate peroxidase (APX)"}
{"PMID":17570561,"re_id":4,"annotated sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin<\\e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as <e2>ascorbate peroxidase<\\e2> (APX)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"anthocyanin","object":"ascorbate peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>CHEMICAL<\\e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as <e2>GENE-Y<\\e2> (APX)","sentence":"We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)"}
{"PMID":17570561,"re_id":5,"annotated sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin<\\e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (<e2>APX<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"anthocyanin","object":"APX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We isolated partial cDNAs that codified for enzymes implicated in the <e1>CHEMICAL<\\e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (<e2>GENE-Y<\\e2> ","sentence":"We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX "}
{"PMID":17588737,"re_id":0,"annotated sentence":"These effects were fully counteracted by dietary <e1>phenolics<\\e1> which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of glutathione-associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of <e2>p66Shc<\\e2> signalling molecule","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenolics","object":"p66Shc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These effects were fully counteracted by dietary <e1>CHEMICAL<\\e1> which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of glutathione-associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of <e2>GENE-Y<\\e2> signalling molecule","sentence":"These effects were fully counteracted by dietary phenolics which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of glutathione-associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of p66Shc signalling molecule"}
{"PMID":17593236,"re_id":0,"annotated sentence":"AIM: To assess the efficacy and safety of a 24-week treatment with <e1>sitagliptin<\\e1>  a highly selective once-daily oral <e2>dipeptidyl peptidase-4<\\e2> (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sitagliptin","object":"dipeptidyl peptidase-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"AIM: To assess the efficacy and safety of a 24-week treatment with <e1>CHEMICAL<\\e1>  a highly selective once-daily oral <e2>GENE-Y<\\e2> (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin","sentence":"AIM: To assess the efficacy and safety of a 24-week treatment with sitagliptin  a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin"}
{"PMID":17593236,"re_id":1,"annotated sentence":"AIM: To assess the efficacy and safety of a 24-week treatment with <e1>sitagliptin<\\e1>  a highly selective once-daily oral dipeptidyl peptidase-4 (<e2>DPP-4<\\e2>  inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sitagliptin","object":"DPP-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"AIM: To assess the efficacy and safety of a 24-week treatment with <e1>CHEMICAL<\\e1>  a highly selective once-daily oral dipeptidyl peptidase-4 (<e2>GENE-Y<\\e2>  inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin","sentence":"AIM: To assess the efficacy and safety of a 24-week treatment with sitagliptin  a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4  inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin"}
{"PMID":17593236,"re_id":2,"annotated sentence":"Efficacy and safety of the <e2>dipeptidyl peptidase-4<\\e2> inhibitor, <e1>sitagliptin<\\e1>  in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sitagliptin","object":"dipeptidyl peptidase-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Efficacy and safety of the <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin","sentence":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin  in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin"}
{"PMID":17603755,"re_id":0,"annotated sentence":"<e1>Miglustat<\\e1>  a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits <e2>glucosylceramide synthase<\\e2>  which catalyses the first committed step in glycosphingolipid synthesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Miglustat","object":"glucosylceramide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits <e2>GENE-Y<\\e2>  which catalyses the first committed step in glycosphingolipid synthesis","sentence":"Miglustat  a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits glucosylceramide synthase  which catalyses the first committed step in glycosphingolipid synthesis"}
{"PMID":17611273,"re_id":0,"annotated sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>MPH<\\e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker <e2>tyrosine hydroxylase<\\e2> (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MPH","object":"tyrosine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>CHEMICAL<\\e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker <e2>GENE-Y<\\e2> (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density","sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density"}
{"PMID":17611273,"re_id":1,"annotated sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>MPH<\\e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (<e2>TH<\\e2> , 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MPH","object":"TH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>CHEMICAL<\\e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (<e2>GENE-Y<\\e2> , 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density","sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH , 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density"}
{"PMID":17611273,"re_id":2,"annotated sentence":"In hippocampal dentate gyrus, <e1>MPH<\\e1> receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of <e2>neural cell adhesion molecule<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MPH","object":"neural cell adhesion molecule","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In hippocampal dentate gyrus, <e1>CHEMICAL<\\e1> receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of <e2>GENE-Y<\\e2> ","sentence":"In hippocampal dentate gyrus, MPH receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule "}
{"PMID":17611273,"re_id":3,"annotated sentence":"In hippocampal dentate gyrus, <e1>MPH<\\e1> receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-<e2>NCAM<\\e2> (polysialylated form of neural cell adhesion molecule)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MPH","object":"NCAM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In hippocampal dentate gyrus, <e1>CHEMICAL<\\e1> receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-<e2>GENE-Y<\\e2> (polysialylated form of neural cell adhesion molecule)","sentence":"In hippocampal dentate gyrus, MPH receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule)"}
{"PMID":17611273,"re_id":4,"annotated sentence":"In medial striatum, TH-ir decreased by 21%, and in hypothalamus <e2>neuropeptide Y<\\e2> ir increased by 10% in <e1>MPH<\\e1> exposed rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MPH","object":"neuropeptide Y","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In medial striatum, TH-ir decreased by 21%, and in hypothalamus <e2>GENE-Y<\\e2> ir increased by 10% in <e1>CHEMICAL<\\e1> exposed rats","sentence":"In medial striatum, TH-ir decreased by 21%, and in hypothalamus neuropeptide Y ir increased by 10% in MPH exposed rats"}
{"PMID":17611273,"re_id":5,"annotated sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>MPH<\\e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less <e2>norepinephrine transporter<\\e2> (NET)-ir density","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MPH","object":"norepinephrine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>CHEMICAL<\\e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less <e2>GENE-Y<\\e2> (NET)-ir density","sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density"}
{"PMID":17611273,"re_id":6,"annotated sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>MPH<\\e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (<e2>NET<\\e2> -ir density","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MPH","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>CHEMICAL<\\e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (<e2>GENE-Y<\\e2> -ir density","sentence":"At PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET -ir density"}
{"PMID":17611273,"re_id":7,"annotated sentence":"In hippocampal dentate gyrus, <e1>MPH<\\e1> receiving rats showed a 51% decrease in <e2>NET<\\e2> ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MPH","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In hippocampal dentate gyrus, <e1>CHEMICAL<\\e1> receiving rats showed a 51% decrease in <e2>GENE-Y<\\e2> ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule)","sentence":"In hippocampal dentate gyrus, MPH receiving rats showed a 51% decrease in NET ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule)"}
{"PMID":17611273,"re_id":8,"annotated sentence":"In medial striatum, <e2>TH<\\e2> ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in <e1>MPH<\\e1> exposed rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MPH","object":"TH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In medial striatum, <e2>GENE-Y<\\e2> ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in <e1>CHEMICAL<\\e1> exposed rats","sentence":"In medial striatum, TH ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in MPH exposed rats"}
{"PMID":17658513,"re_id":0,"annotated sentence":"Noradrenaline and <e1>phenylephrine<\\e1> (<e2>alpha(1)-adrenoceptor<\\e2> agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+\/-0.08 and 6.10+\/-0.05, respectively","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"phenylephrine","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Noradrenaline and <e1>CHEMICAL<\\e1> (<e2>GENE-N<\\e2> agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+\/-0.08 and 6.10+\/-0.05, respectively","sentence":"Noradrenaline and phenylephrine (alpha(1)-adrenoceptor agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+\/-0.08 and 6.10+\/-0.05, respectively"}
{"PMID":17658513,"re_id":1,"annotated sentence":"Prazosin (nonselective <e2>alpha(1)-adrenoceptor<\\e2> antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the <e1>phenylephrine<\\e1> induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"phenylephrine","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prazosin (nonselective <e2>GENE-N<\\e2> antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the <e1>CHEMICAL<\\e1> induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)"}
{"PMID":17658513,"re_id":2,"annotated sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective <e2>alpha(1A)-adrenoceptor<\\e2> antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the <e1>phenylephrine<\\e1> induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"phenylephrine","object":"alpha(1A)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective <e2>GENE-N<\\e2> antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the <e1>CHEMICAL<\\e1> induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)"}
{"PMID":17658513,"re_id":3,"annotated sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective <e2>alpha(1D)-adrenoceptor<\\e2> antagonist) competitively antagonized the <e1>phenylephrine<\\e1> induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"phenylephrine","object":"alpha(1D)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective <e2>GENE-N<\\e2> antagonist) competitively antagonized the <e1>CHEMICAL<\\e1> induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)"}
{"PMID":17658513,"re_id":4,"annotated sentence":"alpha(1)-Adrenoceptor antagonists were tested against the <e1>phenylephrine<\\e1> (<e2>alpha(1)-adrenoceptor<\\e2> agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"phenylephrine","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"alpha(1)-Adrenoceptor antagonists were tested against the <e1>CHEMICAL<\\e1> (<e2>GENE-N<\\e2> agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach","sentence":"alpha(1)-Adrenoceptor antagonists were tested against the phenylephrine (alpha(1)-adrenoceptor agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach"}
{"PMID":17658513,"re_id":5,"annotated sentence":"<e1>Noradrenaline<\\e1> and phenylephrine (<e2>alpha(1)-adrenoceptor<\\e2> agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+\/-0.08 and 6.10+\/-0.05, respectively","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Noradrenaline","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and phenylephrine (<e2>GENE-N<\\e2> agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+\/-0.08 and 6.10+\/-0.05, respectively","sentence":"Noradrenaline and phenylephrine (alpha(1)-adrenoceptor agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+\/-0.08 and 6.10+\/-0.05, respectively"}
{"PMID":17658513,"re_id":6,"annotated sentence":"<e1>Prazosin<\\e1> (nonselective <e2>alpha(1)-adrenoceptor<\\e2> antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Prazosin","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (nonselective <e2>GENE-N<\\e2> antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)"}
{"PMID":17658513,"re_id":7,"annotated sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), <e1>silodosin<\\e1> (selective <e2>alpha(1A)-adrenoceptor<\\e2> antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"silodosin","object":"alpha(1A)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), <e1>CHEMICAL<\\e1> (selective <e2>GENE-N<\\e2> antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)"}
{"PMID":17658513,"re_id":8,"annotated sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and <e1>BMY-7378<\\e1> (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective <e2>alpha(1D)-adrenoceptor<\\e2> antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"BMY-7378","object":"alpha(1D)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and <e1>CHEMICAL<\\e1> (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective <e2>GENE-N<\\e2> antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)"}
{"PMID":17658513,"re_id":9,"annotated sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (<e1>8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride<\\e1>  (selective <e2>alpha(1D)-adrenoceptor<\\e2> antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride","object":"alpha(1D)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (<e1>CHEMICAL<\\e1>  (selective <e2>GENE-N<\\e2> antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)","sentence":"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride  (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+\/-0.07, 9.44+\/-0.06 and 5.75+\/-0.07, respectively)"}
{"PMID":17661345,"re_id":0,"annotated sentence":"Indoleamine 2,3-dioxygenase (<e2>IDO<\\e2> , a <e1>tryptophan<\\e1> catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tryptophan","object":"IDO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Indoleamine 2,3-dioxygenase (<e2>GENE-Y<\\e2> , a <e1>CHEMICAL<\\e1> catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders","sentence":"Indoleamine 2,3-dioxygenase (IDO , a tryptophan catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders"}
{"PMID":17661345,"re_id":1,"annotated sentence":"<e2>Indoleamine 2,3-dioxygenase<\\e2> (IDO), a <e1>tryptophan<\\e1> catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tryptophan","object":"Indoleamine 2,3-dioxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (IDO), a <e1>CHEMICAL<\\e1> catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders","sentence":"Indoleamine 2,3-dioxygenase (IDO), a tryptophan catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders"}
{"PMID":17692748,"re_id":0,"annotated sentence":"OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting <e2>alpha2 adrenergic receptor<\\e2> (AR) agonist (<e1>dexmedetomidine<\\e1> ","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"dexmedetomidine","object":"alpha2 adrenergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting <e2>GENE-N<\\e2> (AR) agonist (<e1>CHEMICAL<\\e1> ","sentence":"OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor (AR) agonist (dexmedetomidine "}
{"PMID":17692748,"re_id":1,"annotated sentence":"OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor (<e2>AR<\\e2>  agonist (<e1>dexmedetomidine<\\e1> ","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"dexmedetomidine","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor (<e2>GENE-N<\\e2>  agonist (<e1>CHEMICAL<\\e1> ","sentence":"OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor (AR  agonist (dexmedetomidine "}
{"PMID":17884974,"re_id":0,"annotated sentence":"In vitro, <e1>acetaminophen<\\e1> elicited a 4.4-fold selectivity toward <e2>COX-2<\\e2> inhibition (IC(50)=113.7 micromol\/L for COX-1; IC(50)=25.8 micromol\/L for COX-2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro, <e1>CHEMICAL<\\e1> elicited a 4.4-fold selectivity toward <e2>GENE-Y<\\e2> inhibition (IC(50)=113.7 micromol\/L for COX-1; IC(50)=25.8 micromol\/L for GENE-Y)","sentence":"In vitro, acetaminophen elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol\/L for COX-1; IC(50)=25.8 micromol\/L for COX-2)"}
{"PMID":17884974,"re_id":1,"annotated sentence":"In vitro, <e1>acetaminophen<\\e1> elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol\/L for <e2>COX-1<\\e2>  IC(50)=25.8 micromol\/L for COX-2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro, <e1>CHEMICAL<\\e1> elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol\/L for <e2>GENE-Y<\\e2>  IC(50)=25.8 micromol\/L for COX-2)","sentence":"In vitro, acetaminophen elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol\/L for COX-1  IC(50)=25.8 micromol\/L for COX-2)"}
{"PMID":17884974,"re_id":2,"annotated sentence":"In vitro, <e1>acetaminophen<\\e1> elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol\/L for COX-1; IC(50)=25.8 micromol\/L for <e2>COX-2<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro, <e1>CHEMICAL<\\e1> elicited a 4.4-fold selectivity toward GENE-Y inhibition (IC(50)=113.7 micromol\/L for COX-1; IC(50)=25.8 micromol\/L for <e2>GENE-Y<\\e2> ","sentence":"In vitro, acetaminophen elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol\/L for COX-1; IC(50)=25.8 micromol\/L for COX-2 "}
{"PMID":17884974,"re_id":3,"annotated sentence":"<e1>Acetaminophen<\\e1> plasma concentrations remained above the in vitro IC(50) for <e2>COX-2<\\e2> for at least 5 h postadministration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Acetaminophen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> plasma concentrations remained above the in vitro IC(50) for <e2>GENE-Y<\\e2> for at least 5 h postadministration","sentence":"Acetaminophen plasma concentrations remained above the in vitro IC(50) for COX-2 for at least 5 h postadministration"}
{"PMID":17884974,"re_id":4,"annotated sentence":"<e1>Acetaminophen<\\e1> (paracetamol) is a selective <e2>cyclooxygenase-2<\\e2> inhibitor in man","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Acetaminophen","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (paracetamol) is a selective <e2>GENE-Y<\\e2> inhibitor in man","sentence":"Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man"}
{"PMID":17884974,"re_id":5,"annotated sentence":"Acetaminophen (<e1>paracetamol<\\e1>  is a selective <e2>cyclooxygenase-2<\\e2> inhibitor in man","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"paracetamol","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetaminophen (<e1>CHEMICAL<\\e1>  is a selective <e2>GENE-Y<\\e2> inhibitor in man","sentence":"Acetaminophen (paracetamol  is a selective cyclooxygenase-2 inhibitor in man"}
{"PMID":17884974,"re_id":6,"annotated sentence":"Ex vivo IC(50) values (<e2>COX-1<\\e2>  105.2 micromol\/L; COX-2: 26.3 micromol\/L) of <e1>acetaminophen<\\e1> compared favorably with its in vitro IC(50) values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ex vivo IC(50) values (<e2>GENE-Y<\\e2>  105.2 micromol\/L; COX-2: 26.3 micromol\/L) of <e1>CHEMICAL<\\e1> compared favorably with its in vitro IC(50) values","sentence":"Ex vivo IC(50) values (COX-1  105.2 micromol\/L; COX-2: 26.3 micromol\/L) of acetaminophen compared favorably with its in vitro IC(50) values"}
{"PMID":17884974,"re_id":7,"annotated sentence":"Ex vivo IC(50) values (COX-1: 105.2 micromol\/L; <e2>COX-2<\\e2>  26.3 micromol\/L) of <e1>acetaminophen<\\e1> compared favorably with its in vitro IC(50) values","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ex vivo IC(50) values (COX-1: 105.2 micromol\/L; <e2>GENE-Y<\\e2>  26.3 micromol\/L) of <e1>CHEMICAL<\\e1> compared favorably with its in vitro IC(50) values","sentence":"Ex vivo IC(50) values (COX-1: 105.2 micromol\/L; COX-2  26.3 micromol\/L) of acetaminophen compared favorably with its in vitro IC(50) values"}
{"PMID":17884974,"re_id":8,"annotated sentence":"In contrast to previous concepts, <e1>acetaminophen<\\e1> inhibited <e2>COX-2<\\e2> by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast to previous concepts, <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective GENE-Y inhibitors","sentence":"In contrast to previous concepts, acetaminophen inhibited COX-2 by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors"}
{"PMID":17884974,"re_id":9,"annotated sentence":"In view of its substantial <e2>COX-2<\\e2> inhibition, recently defined cardiovascular warnings for use of COX-2 inhibitors should also be considered for <e1>acetaminophen<\\e1> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In view of its substantial <e2>GENE-Y<\\e2> inhibition, recently defined cardiovascular warnings for use of GENE-Y inhibitors should also be considered for <e1>CHEMICAL<\\e1> ","sentence":"In view of its substantial COX-2 inhibition, recently defined cardiovascular warnings for use of COX-2 inhibitors should also be considered for acetaminophen "}
{"PMID":17884974,"re_id":10,"annotated sentence":"The fact that <e1>acetaminophen<\\e1> acts functionally as a selective <e2>COX-2<\\e2> inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The fact that <e1>CHEMICAL<\\e1> acts functionally as a selective <e2>GENE-Y<\\e2> inhibitor led us to investigate the hypothesis of whether it works via preferential GENE-Y blockade","sentence":"The fact that acetaminophen acts functionally as a selective COX-2 inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade"}
{"PMID":17884974,"re_id":11,"annotated sentence":"Ex vivo <e2>COX<\\e2> inhibition and pharmacokinetics of <e1>acetaminophen<\\e1> were assessed in 5 volunteers receiving single 1000 mg doses orally","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetaminophen","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ex vivo <e2>GENE-N<\\e2> inhibition and pharmacokinetics of <e1>CHEMICAL<\\e1> were assessed in 5 volunteers receiving single 1000 mg doses orally","sentence":"Ex vivo COX inhibition and pharmacokinetics of acetaminophen were assessed in 5 volunteers receiving single 1000 mg doses orally"}
{"PMID":17884974,"re_id":12,"annotated sentence":"Coagulation-induced <e1>thromboxane B(2)<\\e1> and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of <e2>COX-1<\\e2> and COX-2 activity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"thromboxane B(2)","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coagulation-induced <e1>CHEMICAL<\\e1> and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of <e2>GENE-Y<\\e2> and COX-2 activity","sentence":"Coagulation-induced thromboxane B(2) and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of COX-1 and COX-2 activity"}
{"PMID":17884974,"re_id":13,"annotated sentence":"Coagulation-induced thromboxane B(2) and lipopolysaccharide-induced <e1>prostaglandin E(2)<\\e1> were measured ex vivo and in vitro in human whole blood as indices of COX-1 and <e2>COX-2<\\e2> activity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin E(2)","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coagulation-induced thromboxane B(2) and lipopolysaccharide-induced <e1>CHEMICAL<\\e1> were measured ex vivo and in vitro in human whole blood as indices of COX-1 and <e2>GENE-Y<\\e2> activity","sentence":"Coagulation-induced thromboxane B(2) and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of COX-1 and COX-2 activity"}
{"PMID":17896959,"re_id":0,"annotated sentence":"Existing <e2>ion channel<\\e2> blockers, such as amiodarone, dronedarone, bepridil, aprindine, and <e1>cibenzoline<\\e1>  have been found to have an NCX inhibitory action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cibenzoline","object":"ion channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Existing <e2>GENE-N<\\e2> blockers, such as amiodarone, dronedarone, bepridil, aprindine, and <e1>CHEMICAL<\\e1>  have been found to have an NCX inhibitory action","sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and cibenzoline  have been found to have an NCX inhibitory action"}
{"PMID":17896959,"re_id":1,"annotated sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and <e1>cibenzoline<\\e1>  have been found to have an <e2>NCX<\\e2> inhibitory action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cibenzoline","object":"NCX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and <e1>CHEMICAL<\\e1>  have been found to have an <e2>GENE-N<\\e2> inhibitory action","sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and cibenzoline  have been found to have an NCX inhibitory action"}
{"PMID":17896959,"re_id":2,"annotated sentence":"The pharmacology of NCX inhibitors has been studied extensively since the development of <e1>KB-R7943<\\e1>  a prototype benzyloxyphenyl <e2>NCX<\\e2> inhibitor, in 1996","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"KB-R7943","object":"NCX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pharmacology of GENE-N inhibitors has been studied extensively since the development of <e1>CHEMICAL<\\e1>  a prototype benzyloxyphenyl <e2>GENE-N<\\e2> inhibitor, in 1996","sentence":"The pharmacology of NCX inhibitors has been studied extensively since the development of KB-R7943  a prototype benzyloxyphenyl NCX inhibitor, in 1996"}
{"PMID":17896959,"re_id":3,"annotated sentence":"The pharmacology of NCX inhibitors has been studied extensively since the development of KB-R7943, a prototype <e1>benzyloxyphenyl<\\e1> <e2>NCX<\\e2> inhibitor, in 1996","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzyloxyphenyl","object":"NCX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pharmacology of GENE-N inhibitors has been studied extensively since the development of KB-R7943, a prototype <e1>CHEMICAL<\\e1> <e2>GENE-N<\\e2> inhibitor, in 1996","sentence":"The pharmacology of NCX inhibitors has been studied extensively since the development of KB-R7943, a prototype benzyloxyphenyl NCX inhibitor, in 1996"}
{"PMID":17896959,"re_id":4,"annotated sentence":"Intriguingly, the inhibitory potency of <e1>benzyloxyphenyl<\\e1> <e2>NCX<\\e2> inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzyloxyphenyl","object":"NCX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Intriguingly, the inhibitory potency of <e1>CHEMICAL<\\e1> <e2>GENE-N<\\e2> inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation","sentence":"Intriguingly, the inhibitory potency of benzyloxyphenyl NCX inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation"}
{"PMID":17896959,"re_id":5,"annotated sentence":"Existing <e2>ion channel<\\e2> blockers, such as <e1>amiodarone<\\e1>  dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amiodarone","object":"ion channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Existing <e2>GENE-N<\\e2> blockers, such as <e1>CHEMICAL<\\e1>  dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action","sentence":"Existing ion channel blockers, such as amiodarone  dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action"}
{"PMID":17896959,"re_id":6,"annotated sentence":"Existing ion channel blockers, such as <e1>amiodarone<\\e1>  dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an <e2>NCX<\\e2> inhibitory action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"amiodarone","object":"NCX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Existing ion channel blockers, such as <e1>CHEMICAL<\\e1>  dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an <e2>GENE-N<\\e2> inhibitory action","sentence":"Existing ion channel blockers, such as amiodarone  dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action"}
{"PMID":17896959,"re_id":7,"annotated sentence":"Existing <e2>ion channel<\\e2> blockers, such as amiodarone, <e1>dronedarone<\\e1>  bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dronedarone","object":"ion channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Existing <e2>GENE-N<\\e2> blockers, such as amiodarone, <e1>CHEMICAL<\\e1>  bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action","sentence":"Existing ion channel blockers, such as amiodarone, dronedarone  bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action"}
{"PMID":17896959,"re_id":8,"annotated sentence":"Existing ion channel blockers, such as amiodarone, <e1>dronedarone<\\e1>  bepridil, aprindine, and cibenzoline, have been found to have an <e2>NCX<\\e2> inhibitory action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dronedarone","object":"NCX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Existing ion channel blockers, such as amiodarone, <e1>CHEMICAL<\\e1>  bepridil, aprindine, and cibenzoline, have been found to have an <e2>GENE-N<\\e2> inhibitory action","sentence":"Existing ion channel blockers, such as amiodarone, dronedarone  bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action"}
{"PMID":17896959,"re_id":9,"annotated sentence":"Existing <e2>ion channel<\\e2> blockers, such as amiodarone, dronedarone, <e1>bepridil<\\e1>  aprindine, and cibenzoline, have been found to have an NCX inhibitory action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bepridil","object":"ion channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Existing <e2>GENE-N<\\e2> blockers, such as amiodarone, dronedarone, <e1>CHEMICAL<\\e1>  aprindine, and cibenzoline, have been found to have an NCX inhibitory action","sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil  aprindine, and cibenzoline, have been found to have an NCX inhibitory action"}
{"PMID":17896959,"re_id":10,"annotated sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, <e1>bepridil<\\e1>  aprindine, and cibenzoline, have been found to have an <e2>NCX<\\e2> inhibitory action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bepridil","object":"NCX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, <e1>CHEMICAL<\\e1>  aprindine, and cibenzoline, have been found to have an <e2>GENE-N<\\e2> inhibitory action","sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil  aprindine, and cibenzoline, have been found to have an NCX inhibitory action"}
{"PMID":17896959,"re_id":11,"annotated sentence":"Existing <e2>ion channel<\\e2> blockers, such as amiodarone, dronedarone, bepridil, <e1>aprindine<\\e1>  and cibenzoline, have been found to have an NCX inhibitory action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aprindine","object":"ion channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Existing <e2>GENE-N<\\e2> blockers, such as amiodarone, dronedarone, bepridil, <e1>CHEMICAL<\\e1>  and cibenzoline, have been found to have an NCX inhibitory action","sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine  and cibenzoline, have been found to have an NCX inhibitory action"}
{"PMID":17896959,"re_id":12,"annotated sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, <e1>aprindine<\\e1>  and cibenzoline, have been found to have an <e2>NCX<\\e2> inhibitory action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aprindine","object":"NCX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, <e1>CHEMICAL<\\e1>  and cibenzoline, have been found to have an <e2>GENE-N<\\e2> inhibitory action","sentence":"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine  and cibenzoline, have been found to have an NCX inhibitory action"}
{"PMID":17896959,"re_id":13,"annotated sentence":"The <e2>Na(+)\/Ca(2+) exchanger<\\e2> (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings <e1>Ca(2+)<\\e1> into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Ca(2+)","object":"Na(+)\/Ca(2+) exchanger","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>Na(+)\/CHEMICAL exchanger<\\e2> (NCX) is a bidirectional transporter that normally extrudes CHEMICAL from the cell (forward mode), but also brings <e1>CHEMICAL<\\e1> into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization","sentence":"The Na(+)\/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization"}
{"PMID":17896959,"re_id":14,"annotated sentence":"The <e2>Na(+)\/Ca(2+) exchanger<\\e2> (NCX) is a bidirectional transporter that normally extrudes <e1>Ca(2+)<\\e1> from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Ca(2+)","object":"Na(+)\/Ca(2+) exchanger","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>Na(+)\/CHEMICAL exchanger<\\e2> (NCX) is a bidirectional transporter that normally extrudes <e1>CHEMICAL<\\e1> from the cell (forward mode), but also brings CHEMICAL into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization","sentence":"The Na(+)\/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization"}
{"PMID":17919259,"re_id":0,"annotated sentence":"<e1>Conivaptan<\\e1> is a nonpeptide dual <e2>V1a\/V2 AVP receptor<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Conivaptan","object":"V1a\/V2 AVP receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a nonpeptide dual <e2>GENE-N<\\e2> antagonist","sentence":"Conivaptan is a nonpeptide dual V1a\/V2 AVP receptor antagonist"}
{"PMID":17919259,"re_id":1,"annotated sentence":"<e1>Conivaptan<\\e1>  a dual <e2>vasopressin receptor v1a\/v2<\\e2> antagonist [corrected]","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Conivaptan","object":"vasopressin receptor v1a\/v2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a dual <e2>GENE-N<\\e2> antagonist [corrected]","sentence":"Conivaptan  a dual vasopressin receptor v1a\/v2 antagonist [corrected]"}
{"PMID":17929831,"re_id":0,"annotated sentence":"<e1>Phosphate<\\e1>  a product of the reaction, was found to be a potent inhibitor of <e2>MjAdSS<\\e2> showing biphasic inhibition of enzyme activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phosphate","object":"MjAdSS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a product of the reaction, was found to be a potent inhibitor of <e2>GENE-Y<\\e2> showing biphasic inhibition of enzyme activity","sentence":"Phosphate  a product of the reaction, was found to be a potent inhibitor of MjAdSS showing biphasic inhibition of enzyme activity"}
{"PMID":17929831,"re_id":1,"annotated sentence":"Adenylosuccinate synthetase (<e2>AdSS<\\e2>  catalyzes the <e1>Mg2+<\\e1> dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Mg2+","object":"AdSS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adenylosuccinate synthetase (<e2>GENE-Y<\\e2>  catalyzes the <e1>CHEMICAL<\\e1> dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP","sentence":"Adenylosuccinate synthetase (AdSS  catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP"}
{"PMID":17929831,"re_id":2,"annotated sentence":"<e2>Adenylosuccinate synthetase<\\e2> (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form <e1>adenylosuccinate<\\e1>  in a reaction driven by the hydrolysis of GTP to GDP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"adenylosuccinate","object":"Adenylosuccinate synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form <e1>CHEMICAL<\\e1>  in a reaction driven by the hydrolysis of GTP to GDP","sentence":"Adenylosuccinate synthetase (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate  in a reaction driven by the hydrolysis of GTP to GDP"}
{"PMID":17929831,"re_id":3,"annotated sentence":"Adenylosuccinate synthetase (<e2>AdSS<\\e2>  catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form <e1>adenylosuccinate<\\e1>  in a reaction driven by the hydrolysis of GTP to GDP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"adenylosuccinate","object":"AdSS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adenylosuccinate synthetase (<e2>GENE-Y<\\e2>  catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form <e1>CHEMICAL<\\e1>  in a reaction driven by the hydrolysis of GTP to GDP","sentence":"Adenylosuccinate synthetase (AdSS  catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate  in a reaction driven by the hydrolysis of GTP to GDP"}
{"PMID":17959709,"re_id":0,"annotated sentence":"Conformational variations of both <e2>phosphodiesterase-5<\\e2> and inhibitors provide the structural basis for the physiological effects of vardenafil and <e1>sildenafil<\\e1>  Vardenafil has higher affinity to phosphodiesterase-5 (PDE5) than sildenafil and lower administered dosage for the treatment of erectile dysfunction","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sildenafil","object":"phosphodiesterase-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Conformational variations of both <e2>GENE-Y<\\e2> and inhibitors provide the structural basis for the physiological effects of vardenafil and <e1>CHEMICAL<\\e1>  Vardenafil has higher affinity to GENE-Y (PDE5) than CHEMICAL and lower administered dosage for the treatment of erectile dysfunction","sentence":"Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil  Vardenafil has higher affinity to phosphodiesterase-5 (PDE5) than sildenafil and lower administered dosage for the treatment of erectile dysfunction"}
{"PMID":17979301,"re_id":0,"annotated sentence":"Catalytic-site affinities for cGMP, vardenafil, sildenafil, <e1>tadalafil<\\e1>  or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for <e2>Q817A<\\e2>  and 59-, 448-, 71-, 137-, and 93-fold for F820A","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tadalafil","object":"Q817A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Catalytic-site affinities for cGMP, vardenafil, sildenafil, <e1>CHEMICAL<\\e1>  or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for <e2>GENE-N<\\e2>  and 59-, 448-, 71-, 137-, and 93-fold for F820A","sentence":"Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil  or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A  and 59-, 448-, 71-, 137-, and 93-fold for F820A"}
{"PMID":18068977,"re_id":0,"annotated sentence":"In this report, we show that the hypolipidemic agent <e1>atorvastatin<\\e1> is a competitive inhibitor of <e2>porcine DPP-IV<\\e2> in vitro, with K(i)=57.8+\/-2.3 microM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"atorvastatin","object":"porcine DPP-IV","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this report, we show that the hypolipidemic agent <e1>CHEMICAL<\\e1> is a competitive inhibitor of <e2>GENE-Y<\\e2> in vitro, with K(i)=57.8+\/-2.3 microM","sentence":"In this report, we show that the hypolipidemic agent atorvastatin is a competitive inhibitor of porcine DPP-IV in vitro, with K(i)=57.8+\/-2.3 microM"}
{"PMID":18068977,"re_id":1,"annotated sentence":"These results may have implications in the development of novel <e2>DPP-IV<\\e2> inhibitors based on the use of <e1>atorvastatin<\\e1> as a lead compound for the treatment of type 2 diabetes.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"atorvastatin","object":"DPP-IV","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results may have implications in the development of novel <e2>GENE-Y<\\e2> inhibitors based on the use of <e1>CHEMICAL<\\e1> as a lead compound for the treatment of type 2 diabetes.","sentence":"These results may have implications in the development of novel DPP-IV inhibitors based on the use of atorvastatin as a lead compound for the treatment of type 2 diabetes."}
{"PMID":18068977,"re_id":2,"annotated sentence":"Inhibition of <e2>dipeptidyl peptidase-IV<\\e2> (DPP-IV) by <e1>atorvastatin<\\e1>  Dipeptidyl peptidase-IV (DPP-IV) is an enzyme responsible for the inactivation of the glucoregulatory incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"atorvastatin","object":"dipeptidyl peptidase-IV","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> (DPP-IV) by <e1>CHEMICAL<\\e1>  Dipeptidyl peptidase-IV (DPP-IV) is an enzyme responsible for the inactivation of the glucoregulatory incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)","sentence":"Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin  Dipeptidyl peptidase-IV (DPP-IV) is an enzyme responsible for the inactivation of the glucoregulatory incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)"}
{"PMID":18068977,"re_id":3,"annotated sentence":"Inhibition of dipeptidyl peptidase-IV (<e2>DPP-IV<\\e2>  by <e1>atorvastatin<\\e1>  Dipeptidyl peptidase-IV (DPP-IV) is an enzyme responsible for the inactivation of the glucoregulatory incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"atorvastatin","object":"DPP-IV","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of dipeptidyl peptidase-IV (<e2>GENE-Y<\\e2>  by <e1>CHEMICAL<\\e1>  Dipeptidyl peptidase-IV (GENE-Y) is an enzyme responsible for the inactivation of the glucoregulatory incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)","sentence":"Inhibition of dipeptidyl peptidase-IV (DPP-IV  by atorvastatin  Dipeptidyl peptidase-IV (DPP-IV) is an enzyme responsible for the inactivation of the glucoregulatory incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)"}
{"PMID":18093407,"re_id":0,"annotated sentence":"The ARB <e1>eprosartan<\\e1> is a nonbiphenyl nontetrazole <e2>angiotensin II type 1 receptor<\\e2> (AT1) antagonist, which acts to decrease total peripheral resistance","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"eprosartan","object":"angiotensin II type 1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ARB <e1>CHEMICAL<\\e1> is a nonbiphenyl nontetrazole <e2>GENE-Y<\\e2> (AT1) antagonist, which acts to decrease total peripheral resistance","sentence":"The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance"}
{"PMID":18093407,"re_id":1,"annotated sentence":"The ARB <e1>eprosartan<\\e1> is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (<e2>AT1<\\e2>  antagonist, which acts to decrease total peripheral resistance","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"eprosartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ARB <e1>CHEMICAL<\\e1> is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (<e2>GENE-Y<\\e2>  antagonist, which acts to decrease total peripheral resistance","sentence":"The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1  antagonist, which acts to decrease total peripheral resistance"}
{"PMID":18282775,"re_id":0,"annotated sentence":"Inhibitors of <e2>PDE4<\\e2> (<e1>rolipram<\\e1>  0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rolipram","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibitors of <e2>GENE-N<\\e2> (<e1>CHEMICAL<\\e1>  0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively","sentence":"Inhibitors of PDE4 (rolipram  0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively"}
{"PMID":18282775,"re_id":1,"annotated sentence":"Inhibitors of PDE4 (rolipram; 0.1-10 microM) and <e2>PDE3<\\e2> (<e1>cilostazol<\\e1>  0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cilostazol","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibitors of PDE4 (rolipram; 0.1-10 microM) and <e2>GENE-N<\\e2> (<e1>CHEMICAL<\\e1>  0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively","sentence":"Inhibitors of PDE4 (rolipram; 0.1-10 microM) and PDE3 (cilostazol  0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively"}
{"PMID":18282775,"re_id":2,"annotated sentence":"Inhibitor of <e2>cGMP-specific PDE5<\\e2> (<e1>zaprinast<\\e1>  0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zaprinast","object":"cGMP-specific PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibitor of <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1>  0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis","sentence":"Inhibitor of cGMP-specific PDE5 (zaprinast  0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis"}
{"PMID":18381445,"re_id":0,"annotated sentence":"<e1>Statins<\\e1> increase p21 through inhibition of histone deacetylase activity and release of promoter-associated <e2>HDAC1\/2<\\e2>  Statins are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Statins","object":"HDAC1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increase p21 through inhibition of histone deacetylase activity and release of promoter-associated <e2>GENE-N<\\e2>  CHEMICAL are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia","sentence":"Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1\/2  Statins are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia"}
{"PMID":18381445,"re_id":1,"annotated sentence":"<e1>Statins<\\e1> increase <e2>p21<\\e2> through inhibition of histone deacetylase activity and release of promoter-associated HDAC1\/2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Statins","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increase <e2>GENE-Y<\\e2> through inhibition of histone deacetylase activity and release of promoter-associated HDAC1\/2","sentence":"Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1\/2"}
{"PMID":18381445,"re_id":2,"annotated sentence":"<e1>Statins<\\e1> are <e2>3-hydroxy-3-methylglutaryl-CoA reductase<\\e2> inhibitors broadly used for the control of hypercholesterolemia","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Statins","object":"3-hydroxy-3-methylglutaryl-CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> are <e2>GENE-Y<\\e2> inhibitors broadly used for the control of hypercholesterolemia","sentence":"Statins are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia"}
{"PMID":18381445,"re_id":3,"annotated sentence":"In the subsequent enzymatic assay, it was shown that <e1>lovastatin<\\e1> inhibited <e2>HDAC2<\\e2> activity competitively with a K(i) value of 31.6 micromol\/L","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lovastatin","object":"HDAC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the subsequent enzymatic assay, it was shown that <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> activity competitively with a K(i) value of 31.6 micromol\/L","sentence":"In the subsequent enzymatic assay, it was shown that lovastatin inhibited HDAC2 activity competitively with a K(i) value of 31.6 micromol\/L"}
{"PMID":18381445,"re_id":4,"annotated sentence":"<e1>Statins<\\e1> increase p21 through inhibition of <e2>histone deacetylase<\\e2> activity and release of promoter-associated HDAC1\/2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Statins","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increase p21 through inhibition of <e2>GENE-N<\\e2> activity and release of promoter-associated HDAC1\/2","sentence":"Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1\/2"}
{"PMID":18465538,"re_id":0,"annotated sentence":"<e1>Flavopiridol<\\e1>  a <e2>cyclin-dependent kinase<\\e2> inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660]","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Flavopiridol","object":"cyclin-dependent kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660]","sentence":"Flavopiridol  a cyclin-dependent kinase inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660]"}
{"PMID":18465538,"re_id":1,"annotated sentence":"In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent <e2>CDK2<\\e2> inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of <e1>flavopiridol<\\e1>  In vitro pharmacokinetic studies have shown that flavopiridol undergoes hepatic biotransformation to its corresponding glucoronide by uridine diphosphate glucoronosyltransferases [283791]","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"flavopiridol","object":"CDK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent <e2>GENE-Y<\\e2> inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of <e1>CHEMICAL<\\e1>  In vitro pharmacokinetic studies have shown that CHEMICAL undergoes hepatic biotransformation to its corresponding glucoronide by uridine diphosphate glucoronosyltransferases [283791]","sentence":"In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent CDK2 inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of flavopiridol  In vitro pharmacokinetic studies have shown that flavopiridol undergoes hepatic biotransformation to its corresponding glucoronide by uridine diphosphate glucoronosyltransferases [283791]"}
{"PMID":18465538,"re_id":2,"annotated sentence":"<e1>Flavopiridol<\\e1> inhibits <e2>CDK<\\e2> with an IC50 value of 0.4 mM [285707]","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Flavopiridol","object":"CDK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-N<\\e2> with an IC50 value of 0.4 mM [285707]","sentence":"Flavopiridol inhibits CDK with an IC50 value of 0.4 mM [285707]"}
{"PMID":18708991,"re_id":0,"annotated sentence":"Both <e1>risperidone<\\e1> and 9-hydroxyrisperidone are substrates of <e2>P-glycoprotein<\\e2> (P-gp), a transport protein involved in drug absorption, distribution, and elimination","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"risperidone","object":"P-glycoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both <e1>CHEMICAL<\\e1> and 9-hydroxyCHEMICAL are substrates of <e2>GENE-N<\\e2> (P-gp), a transport protein involved in drug absorption, distribution, and elimination","sentence":"Both risperidone and 9-hydroxyrisperidone are substrates of P-glycoprotein (P-gp), a transport protein involved in drug absorption, distribution, and elimination"}
{"PMID":18708991,"re_id":1,"annotated sentence":"Both <e1>risperidone<\\e1> and 9-hydroxyrisperidone are substrates of P-glycoprotein (<e2>P-gp<\\e2> , a transport protein involved in drug absorption, distribution, and elimination","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"risperidone","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both <e1>CHEMICAL<\\e1> and 9-hydroxyCHEMICAL are substrates of P-glycoprotein (<e2>GENE-N<\\e2> , a transport protein involved in drug absorption, distribution, and elimination","sentence":"Both risperidone and 9-hydroxyrisperidone are substrates of P-glycoprotein (P-gp , a transport protein involved in drug absorption, distribution, and elimination"}
{"PMID":18708991,"re_id":2,"annotated sentence":"Both risperidone and <e1>9-hydroxyrisperidone<\\e1> are substrates of <e2>P-glycoprotein<\\e2> (P-gp), a transport protein involved in drug absorption, distribution, and elimination","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"9-hydroxyrisperidone","object":"P-glycoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both risperidone and <e1>CHEMICAL<\\e1> are substrates of <e2>GENE-N<\\e2> (P-gp), a transport protein involved in drug absorption, distribution, and elimination","sentence":"Both risperidone and 9-hydroxyrisperidone are substrates of P-glycoprotein (P-gp), a transport protein involved in drug absorption, distribution, and elimination"}
{"PMID":18708991,"re_id":3,"annotated sentence":"Both risperidone and <e1>9-hydroxyrisperidone<\\e1> are substrates of P-glycoprotein (<e2>P-gp<\\e2> , a transport protein involved in drug absorption, distribution, and elimination","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"9-hydroxyrisperidone","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both risperidone and <e1>CHEMICAL<\\e1> are substrates of P-glycoprotein (<e2>GENE-N<\\e2> , a transport protein involved in drug absorption, distribution, and elimination","sentence":"Both risperidone and 9-hydroxyrisperidone are substrates of P-glycoprotein (P-gp , a transport protein involved in drug absorption, distribution, and elimination"}
{"PMID":18708991,"re_id":4,"annotated sentence":"Risperidone is metabolized to its active metabolite, <e1>9-hydroxyrisperidone<\\e1>  mainly by the <e2>cytochrome P450<\\e2> enzymes CYP2D6 and 3A4","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"9-hydroxyrisperidone","object":"cytochrome P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Risperidone is metabolized to its active metabolite, <e1>CHEMICAL<\\e1>  mainly by the <e2>GENE-N<\\e2> enzymes CYP2D6 and 3A4","sentence":"Risperidone is metabolized to its active metabolite, 9-hydroxyrisperidone  mainly by the cytochrome P450 enzymes CYP2D6 and 3A4"}
{"PMID":18708991,"re_id":5,"annotated sentence":"<e1>Risperidone<\\e1> is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the <e2>cytochrome P450<\\e2> enzymes CYP2D6 and 3A4","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Risperidone","object":"cytochrome P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the <e2>GENE-N<\\e2> enzymes CYP2D6 and 3A4","sentence":"Risperidone is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the cytochrome P450 enzymes CYP2D6 and 3A4"}
{"PMID":18715952,"re_id":0,"annotated sentence":"<e2>EP(1)<\\e2> and EP(3) receptor antagonists <e1>ONO-8713<\\e1> and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ONO-8713","object":"EP(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and EP(3) receptor antagonists <e1>CHEMICAL<\\e1> and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of GENE-Y and EP(3) but not EP(4) for MB growth","sentence":"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth"}
{"PMID":18715952,"re_id":1,"annotated sentence":"EP(1) and <e2>EP(3) receptor<\\e2> antagonists <e1>ONO-8713<\\e1> and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ONO-8713","object":"EP(3) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"EP(1) and <e2>GENE-Y<\\e2> antagonists <e1>CHEMICAL<\\e1> and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth","sentence":"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth"}
{"PMID":18715952,"re_id":2,"annotated sentence":"<e2>EP(1)<\\e2> and EP(3) receptor antagonists ONO-8713 and <e1>ONO-AE3-240<\\e1>  but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ONO-AE3-240","object":"EP(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and EP(3) receptor antagonists ONO-8713 and <e1>CHEMICAL<\\e1>  but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of GENE-Y and EP(3) but not EP(4) for MB growth","sentence":"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240  but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth"}
{"PMID":18715952,"re_id":3,"annotated sentence":"EP(1) and <e2>EP(3) receptor<\\e2> antagonists ONO-8713 and <e1>ONO-AE3-240<\\e1>  but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ONO-AE3-240","object":"EP(3) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"EP(1) and <e2>GENE-Y<\\e2> antagonists ONO-8713 and <e1>CHEMICAL<\\e1>  but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth","sentence":"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240  but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth"}
{"PMID":18715952,"re_id":4,"annotated sentence":"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the <e2>EP(4)<\\e2> antagonists <e1>ONO-AE3-208<\\e1> and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ONO-AE3-208","object":"EP(4)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the <e2>GENE-Y<\\e2> antagonists <e1>CHEMICAL<\\e1> and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not GENE-Y for MB growth","sentence":"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth"}
{"PMID":18715952,"re_id":5,"annotated sentence":"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the <e2>EP(4)<\\e2> antagonists ONO-AE3-208 and <e1>AH 23848<\\e1>  inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"AH 23848","object":"EP(4)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the <e2>GENE-Y<\\e2> antagonists ONO-AE3-208 and <e1>CHEMICAL<\\e1>  inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not GENE-Y for MB growth","sentence":"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848  inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth"}
{"PMID":18715952,"re_id":6,"annotated sentence":"Tumor-growth-promoting <e2>cyclooxygenase-2<\\e2> <e1>prostaglandin E2<\\e1> pathway provides medulloblastoma therapeutic targets","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin E2","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Tumor-growth-promoting <e2>GENE-Y<\\e2> <e1>CHEMICAL<\\e1> pathway provides medulloblastoma therapeutic targets","sentence":"Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets"}
{"PMID":18715952,"re_id":7,"annotated sentence":"<e1>PGE(2)<\\e1> is synthesized from arachidonic acid by <e2>cyclooxygenases<\\e2> (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE(2)","object":"cyclooxygenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is synthesized from arachidonic acid by <e2>GENE-N<\\e2> (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","sentence":"PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)"}
{"PMID":18715952,"re_id":8,"annotated sentence":"<e1>PGE(2)<\\e1> is synthesized from arachidonic acid by cyclooxygenases (<e2>COX<\\e2>  and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE(2)","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is synthesized from arachidonic acid by cyclooxygenases (<e2>GENE-N<\\e2>  and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","sentence":"PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX  and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)"}
{"PMID":18715952,"re_id":9,"annotated sentence":"<e1>PGE(2)<\\e1> is synthesized from arachidonic acid by cyclooxygenases (COX) and <e2>prostaglandin E synthases<\\e2> (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE(2)","object":"prostaglandin E synthases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is synthesized from arachidonic acid by cyclooxygenases (COX) and <e2>GENE-N<\\e2> (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","sentence":"PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)"}
{"PMID":18715952,"re_id":10,"annotated sentence":"<e1>PGE(2)<\\e1> is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (<e2>PGES<\\e2>  and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE(2)","object":"PGES","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (<e2>GENE-N<\\e2>  and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","sentence":"PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES  and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)"}
{"PMID":18715952,"re_id":11,"annotated sentence":"PGE(2) is synthesized from <e1>arachidonic acid<\\e1> by <e2>cyclooxygenases<\\e2> (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"cyclooxygenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PGE(2) is synthesized from <e1>CHEMICAL<\\e1> by <e2>GENE-N<\\e2> (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","sentence":"PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)"}
{"PMID":18715952,"re_id":12,"annotated sentence":"PGE(2) is synthesized from <e1>arachidonic acid<\\e1> by cyclooxygenases (<e2>COX<\\e2>  and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PGE(2) is synthesized from <e1>CHEMICAL<\\e1> by cyclooxygenases (<e2>GENE-N<\\e2>  and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","sentence":"PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX  and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)"}
{"PMID":18715952,"re_id":13,"annotated sentence":"PGE(2) is synthesized from <e1>arachidonic acid<\\e1> by cyclooxygenases (COX) and <e2>prostaglandin E synthases<\\e2> (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"prostaglandin E synthases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PGE(2) is synthesized from <e1>CHEMICAL<\\e1> by cyclooxygenases (COX) and <e2>GENE-N<\\e2> (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","sentence":"PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)"}
{"PMID":18715952,"re_id":14,"annotated sentence":"PGE(2) is synthesized from <e1>arachidonic acid<\\e1> by cyclooxygenases (COX) and prostaglandin E synthases (<e2>PGES<\\e2>  and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"PGES","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PGE(2) is synthesized from <e1>CHEMICAL<\\e1> by cyclooxygenases (COX) and prostaglandin E synthases (<e2>GENE-N<\\e2>  and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)","sentence":"PGE(2) is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES  and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)"}
{"PMID":18847313,"re_id":0,"annotated sentence":"<e1>Plerixafor<\\e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine <e2>stromal cell-derived factor-1<\\e2> (SDF-1) to its cognate receptor CXCR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Plerixafor","object":"stromal cell-derived factor-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine <e2>GENE-Y<\\e2> (SDF-1) to its cognate receptor CXCR4","sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4"}
{"PMID":18847313,"re_id":1,"annotated sentence":"<e1>Plerixafor<\\e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (<e2>SDF-1<\\e2>  to its cognate receptor CXCR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Plerixafor","object":"SDF-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (<e2>GENE-Y<\\e2>  to its cognate receptor CXCR4","sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1  to its cognate receptor CXCR4"}
{"PMID":18847313,"re_id":2,"annotated sentence":"<e1>Plerixafor<\\e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor <e2>CXCR4<\\e2>  Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Plerixafor","object":"CXCR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor <e2>GENE-Y<\\e2>  CHEMICAL results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF","sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4  Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF"}
{"PMID":18847313,"re_id":3,"annotated sentence":"<e1>Plerixafor<\\e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the <e2>chemokine<\\e2> stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Plerixafor","object":"chemokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the <e2>GENE-N<\\e2> stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4","sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4"}
{"PMID":18847313,"re_id":4,"annotated sentence":"Plerixafor (<e1>AMD3100<\\e1>  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine <e2>stromal cell-derived factor-1<\\e2> (SDF-1) to its cognate receptor CXCR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AMD3100","object":"stromal cell-derived factor-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Plerixafor (<e1>CHEMICAL<\\e1>  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine <e2>GENE-Y<\\e2> (SDF-1) to its cognate receptor CXCR4","sentence":"Plerixafor (AMD3100  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4"}
{"PMID":18847313,"re_id":5,"annotated sentence":"Plerixafor (<e1>AMD3100<\\e1>  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (<e2>SDF-1<\\e2>  to its cognate receptor CXCR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AMD3100","object":"SDF-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Plerixafor (<e1>CHEMICAL<\\e1>  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (<e2>GENE-Y<\\e2>  to its cognate receptor CXCR4","sentence":"Plerixafor (AMD3100  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1  to its cognate receptor CXCR4"}
{"PMID":18847313,"re_id":6,"annotated sentence":"Plerixafor (<e1>AMD3100<\\e1>  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor <e2>CXCR4<\\e2>  Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AMD3100","object":"CXCR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Plerixafor (<e1>CHEMICAL<\\e1>  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor <e2>GENE-Y<\\e2>  Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF","sentence":"Plerixafor (AMD3100  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4  Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF"}
{"PMID":18847313,"re_id":7,"annotated sentence":"Plerixafor (<e1>AMD3100<\\e1>  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the <e2>chemokine<\\e2> stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AMD3100","object":"chemokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Plerixafor (<e1>CHEMICAL<\\e1>  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the <e2>GENE-N<\\e2> stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4","sentence":"Plerixafor (AMD3100  Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4"}
{"PMID":18847313,"re_id":8,"annotated sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>bicyclam<\\e1> molecule that antagonizes the binding of the chemokine <e2>stromal cell-derived factor-1<\\e2> (SDF-1) to its cognate receptor CXCR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bicyclam","object":"stromal cell-derived factor-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>CHEMICAL<\\e1> molecule that antagonizes the binding of the chemokine <e2>GENE-Y<\\e2> (SDF-1) to its cognate receptor CXCR4","sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4"}
{"PMID":18847313,"re_id":9,"annotated sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>bicyclam<\\e1> molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (<e2>SDF-1<\\e2>  to its cognate receptor CXCR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bicyclam","object":"SDF-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>CHEMICAL<\\e1> molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (<e2>GENE-Y<\\e2>  to its cognate receptor CXCR4","sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1  to its cognate receptor CXCR4"}
{"PMID":18847313,"re_id":10,"annotated sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>bicyclam<\\e1> molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor <e2>CXCR4<\\e2>  Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bicyclam","object":"CXCR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>CHEMICAL<\\e1> molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor <e2>GENE-Y<\\e2>  Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF","sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4  Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF"}
{"PMID":18847313,"re_id":11,"annotated sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>bicyclam<\\e1> molecule that antagonizes the binding of the <e2>chemokine<\\e2> stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bicyclam","object":"chemokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>CHEMICAL<\\e1> molecule that antagonizes the binding of the <e2>GENE-N<\\e2> stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4","sentence":"Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4"}
{"PMID":18847313,"re_id":12,"annotated sentence":"<e1>Plerixafor<\\e1>  a <e2>CXCR4<\\e2> antagonist for the mobilization of hematopoietic stem cells","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Plerixafor","object":"CXCR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> antagonist for the mobilization of hematopoietic stem cells","sentence":"Plerixafor  a CXCR4 antagonist for the mobilization of hematopoietic stem cells"}
{"PMID":19068776,"re_id":0,"annotated sentence":"[Pharmacological effects of a <e2>mu-opioid receptor<\\e2> antagonist <e1>naltrexone<\\e1> on alcohol dependence]","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"naltrexone","object":"mu-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"[Pharmacological effects of a <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> on alcohol dependence]","sentence":"[Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence]"}
{"PMID":19068776,"re_id":1,"annotated sentence":"In many countries, a <e2>mu-opioid receptor<\\e2> antagonist <e1>naltrexone<\\e1> has been used in the treatment of alcohol dependence","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"naltrexone","object":"mu-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In many countries, a <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> has been used in the treatment of alcohol dependence","sentence":"In many countries, a mu-opioid receptor antagonist naltrexone has been used in the treatment of alcohol dependence"}
{"PMID":19203467,"re_id":0,"annotated sentence":"Pretreatment of rats with the <e2>MAO<\\e2> inhibitor <e1>tranylcypromine<\\e1> prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment of rats with the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA","sentence":"Pretreatment of rats with the MAO inhibitor tranylcypromine prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA"}
{"PMID":19203467,"re_id":1,"annotated sentence":"The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the <e2>MAO<\\e2> inhibitor <e1>tranylcypromine<\\e1>  This pretreament had no effect on the inhibition of GABA-T or the elevation of brain GABA levels produced by VIG","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1>  This pretreament had no effect on the inhibition of GABA-T or the elevation of brain GABA levels produced by VIG","sentence":"The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the MAO inhibitor tranylcypromine  This pretreament had no effect on the inhibition of GABA-T or the elevation of brain GABA levels produced by VIG"}
{"PMID":19203467,"re_id":2,"annotated sentence":"The effects of PLZ on both amino acids and their <e2>transaminases<\\e2> were blocked by pre-treatment with the MAO inhibitor <e1>tranylcypromine<\\e1>  This pretreament had no effect on the inhibition of GABA-T or the elevation of brain GABA levels produced by VIG","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranylcypromine","object":"transaminases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The effects of PLZ on both amino acids and their <e2>GENE-N<\\e2> were blocked by pre-treatment with the MAO inhibitor <e1>CHEMICAL<\\e1>  This pretreament had no effect on the inhibition of GABA-T or the elevation of brain GABA levels produced by VIG","sentence":"The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the MAO inhibitor tranylcypromine  This pretreament had no effect on the inhibition of GABA-T or the elevation of brain GABA levels produced by VIG"}
{"PMID":19203467,"re_id":3,"annotated sentence":"PURPOSE: To compare <e1>phenelzine<\\e1> (PLZ), an antidepressant drug with anxiolytic properties which inhibits <e2>monoamine oxidase<\\e2> (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenelzine","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PURPOSE: To compare <e1>CHEMICAL<\\e1> (PLZ), an antidepressant drug with anxiolytic properties which inhibits <e2>GENE-N<\\e2> (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)"}
{"PMID":19203467,"re_id":4,"annotated sentence":"PURPOSE: To compare <e1>phenelzine<\\e1> (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (<e2>MAO<\\e2>  but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenelzine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PURPOSE: To compare <e1>CHEMICAL<\\e1> (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (<e2>GENE-N<\\e2>  but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of GENE-N, GABA-T and ALA transaminase (ALA-T)","sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO  but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)"}
{"PMID":19203467,"re_id":5,"annotated sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with <e1>vigabatrin<\\e1> (VIG), an anticonvulsant which elevates brain GABA by inhibition of <e2>GABA transaminase<\\e2> (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vigabatrin","object":"GABA transaminase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with <e1>CHEMICAL<\\e1> (VIG), an anticonvulsant which elevates brain GABA by inhibition of <e2>GENE-Y<\\e2> (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)"}
{"PMID":19203467,"re_id":6,"annotated sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with <e1>vigabatrin<\\e1> (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GABA-T<\\e2> , with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vigabatrin","object":"GABA-T","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with <e1>CHEMICAL<\\e1> (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GENE-Y<\\e2> , with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GENE-Y and ALA transaminase (ALA-T)","sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T , with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)"}
{"PMID":19203467,"re_id":7,"annotated sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG<\\e1> , an anticonvulsant which elevates brain GABA by inhibition of <e2>GABA transaminase<\\e2> (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VIG","object":"GABA transaminase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>CHEMICAL<\\e1> , an anticonvulsant which elevates brain GABA by inhibition of <e2>GENE-Y<\\e2> (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG , an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)"}
{"PMID":19203467,"re_id":8,"annotated sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG<\\e1> , an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GABA-T<\\e2> , with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VIG","object":"GABA-T","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>CHEMICAL<\\e1> , an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GENE-Y<\\e2> , with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GENE-Y and ALA transaminase (ALA-T)","sentence":"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG , an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T , with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)"}
{"PMID":19203467,"re_id":9,"annotated sentence":"PURPOSE: To compare phenelzine (<e1>PLZ<\\e1> , an antidepressant drug with anxiolytic properties which inhibits <e2>monoamine oxidase<\\e2> (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PLZ","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PURPOSE: To compare phenelzine (<e1>CHEMICAL<\\e1> , an antidepressant drug with anxiolytic properties which inhibits <e2>GENE-N<\\e2> (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","sentence":"PURPOSE: To compare phenelzine (PLZ , an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)"}
{"PMID":19203467,"re_id":10,"annotated sentence":"PURPOSE: To compare phenelzine (<e1>PLZ<\\e1> , an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (<e2>MAO<\\e2>  but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PLZ","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"PURPOSE: To compare phenelzine (<e1>CHEMICAL<\\e1> , an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (<e2>GENE-N<\\e2>  but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of GENE-N, GABA-T and ALA transaminase (ALA-T)","sentence":"PURPOSE: To compare phenelzine (PLZ , an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO  but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)"}
{"PMID":19203467,"re_id":11,"annotated sentence":"RESULTS: Both <e1>PLZ<\\e1> and VIG inhibited <e2>GABA-T<\\e2> and elevated GABA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PLZ","object":"GABA-T","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Both <e1>CHEMICAL<\\e1> and VIG inhibited <e2>GENE-Y<\\e2> and elevated GABA levels","sentence":"RESULTS: Both PLZ and VIG inhibited GABA-T and elevated GABA levels"}
{"PMID":19203467,"re_id":12,"annotated sentence":"RESULTS: Both PLZ and <e1>VIG<\\e1> inhibited <e2>GABA-T<\\e2> and elevated GABA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VIG","object":"GABA-T","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Both PLZ and <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> and elevated GABA levels","sentence":"RESULTS: Both PLZ and VIG inhibited GABA-T and elevated GABA levels"}
{"PMID":19203467,"re_id":13,"annotated sentence":"Only <e1>PLZ<\\e1> inhibited <e2>MAO<\\e2> and ALA-T and elevated ALA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PLZ","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Only <e1>CHEMICAL<\\e1> inhibited <e2>GENE-N<\\e2> and ALA-T and elevated ALA levels","sentence":"Only PLZ inhibited MAO and ALA-T and elevated ALA levels"}
{"PMID":19203467,"re_id":14,"annotated sentence":"Only <e1>PLZ<\\e1> inhibited MAO and <e2>ALA-T<\\e2> and elevated ALA levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PLZ","object":"ALA-T","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Only <e1>CHEMICAL<\\e1> inhibited MAO and <e2>GENE-N<\\e2> and elevated ALA levels","sentence":"Only PLZ inhibited MAO and ALA-T and elevated ALA levels"}
{"PMID":19203467,"re_id":15,"annotated sentence":"Neurochemical effects of the <e2>monoamine oxidase<\\e2> inhibitor <e1>phenelzine<\\e1> on brain GABA and alanine: A comparison with vigabatrin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenelzine","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Neurochemical effects of the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> on brain GABA and alanine: A comparison with vigabatrin","sentence":"Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin"}
{"PMID":19203467,"re_id":16,"annotated sentence":"This pretreament had no effect on the inhibition of <e2>GABA-T<\\e2> or the elevation of brain GABA levels produced by <e1>VIG<\\e1>  CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike VIG, also inhibited MAO and ALA-T (and increased brain ALA levels)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VIG","object":"GABA-T","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This pretreament had no effect on the inhibition of <e2>GENE-Y<\\e2> or the elevation of brain GABA levels produced by <e1>CHEMICAL<\\e1>  CONCLUSIONS: At the doses studied, PLZ was as effective as CHEMICAL at elevating brain GABA levels, but, unlike CHEMICAL, also inhibited MAO and ALA-T (and increased brain ALA levels)","sentence":"This pretreament had no effect on the inhibition of GABA-T or the elevation of brain GABA levels produced by VIG  CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike VIG, also inhibited MAO and ALA-T (and increased brain ALA levels)"}
{"PMID":19203467,"re_id":17,"annotated sentence":"CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike <e1>VIG<\\e1>  also inhibited <e2>MAO<\\e2> and ALA-T (and increased brain ALA levels)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VIG","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: At the doses studied, PLZ was as effective as CHEMICAL at elevating brain GABA levels, but, unlike <e1>CHEMICAL<\\e1>  also inhibited <e2>GENE-N<\\e2> and ALA-T (and increased brain ALA levels)","sentence":"CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike VIG  also inhibited MAO and ALA-T (and increased brain ALA levels)"}
{"PMID":19203467,"re_id":18,"annotated sentence":"CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike <e1>VIG<\\e1>  also inhibited MAO and <e2>ALA-T<\\e2> (and increased brain ALA levels)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VIG","object":"ALA-T","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: At the doses studied, PLZ was as effective as CHEMICAL at elevating brain GABA levels, but, unlike <e1>CHEMICAL<\\e1>  also inhibited MAO and <e2>GENE-N<\\e2> (and increased brain ALA levels)","sentence":"CONCLUSIONS: At the doses studied, PLZ was as effective as VIG at elevating brain GABA levels, but, unlike VIG  also inhibited MAO and ALA-T (and increased brain ALA levels)"}
{"PMID":19228178,"re_id":0,"annotated sentence":"<e1>Ramelteon<\\e1> (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin <e2>MT(1)<\\e2> MT(2) receptor agonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Ramelteon","object":"MT(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin <e2>GENE-Y<\\e2> MT(2) receptor agonist","sentence":"Ramelteon (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1) MT(2) receptor agonist"}
{"PMID":19228178,"re_id":1,"annotated sentence":"<e1>Ramelteon<\\e1> (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)\/<e2>MT(2)<\\e2> receptor agonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Ramelteon","object":"MT(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)\/<e2>GENE-Y<\\e2> receptor agonist","sentence":"Ramelteon (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)\/MT(2) receptor agonist"}
{"PMID":19228178,"re_id":2,"annotated sentence":"Unlike the sedative hypnotics that target GABA(A) receptor complexes, <e1>ramelteon<\\e1> is a chronohypnotic that acts on the melatonin <e2>MT(1)<\\e2> and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ramelteon","object":"MT(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unlike the sedative hypnotics that target GABA(A) receptor complexes, <e1>CHEMICAL<\\e1> is a chronohypnotic that acts on the melatonin <e2>GENE-Y<\\e2> and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such, CHEMICAL possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades","sentence":"Unlike the sedative hypnotics that target GABA(A) receptor complexes, ramelteon is a chronohypnotic that acts on the melatonin MT(1) and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades"}
{"PMID":19228178,"re_id":3,"annotated sentence":"Unlike the sedative hypnotics that target GABA(A) receptor complexes, <e1>ramelteon<\\e1> is a chronohypnotic that acts on the melatonin MT(1) and <e2>MT(2)<\\e2> receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ramelteon","object":"MT(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unlike the sedative hypnotics that target GABA(A) receptor complexes, <e1>CHEMICAL<\\e1> is a chronohypnotic that acts on the melatonin MT(1) and <e2>GENE-Y<\\e2> receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such, CHEMICAL possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades","sentence":"Unlike the sedative hypnotics that target GABA(A) receptor complexes, ramelteon is a chronohypnotic that acts on the melatonin MT(1) and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades"}
{"PMID":19228178,"re_id":4,"annotated sentence":"Pharmacology of <e1>ramelteon<\\e1>  a selective <e2>MT1<\\e2> MT2 receptor agonist: a novel therapeutic drug for sleep disorders","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ramelteon","object":"MT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacology of <e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> MT2 receptor agonist: a novel therapeutic drug for sleep disorders","sentence":"Pharmacology of ramelteon  a selective MT1 MT2 receptor agonist: a novel therapeutic drug for sleep disorders"}
{"PMID":19228178,"re_id":5,"annotated sentence":"Pharmacology of <e1>ramelteon<\\e1>  a selective MT1\/<e2>MT2<\\e2> receptor agonist: a novel therapeutic drug for sleep disorders","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ramelteon","object":"MT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacology of <e1>CHEMICAL<\\e1>  a selective MT1\/<e2>GENE-Y<\\e2> receptor agonist: a novel therapeutic drug for sleep disorders","sentence":"Pharmacology of ramelteon  a selective MT1\/MT2 receptor agonist: a novel therapeutic drug for sleep disorders"}
{"PMID":19275550,"re_id":0,"annotated sentence":"<e1>Acarbose<\\e1>  an <e2>alpha-glucosidase<\\e2> inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Acarbose","object":"alpha-glucosidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia","sentence":"Acarbose  an alpha-glucosidase inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia"}
{"PMID":19275550,"re_id":1,"annotated sentence":"Clinical utility of <e1>acarbose<\\e1>  an <e2>alpha-glucosidase<\\e2> inhibitor in cardiometabolic disorders","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acarbose","object":"alpha-glucosidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical utility of <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> inhibitor in cardiometabolic disorders","sentence":"Clinical utility of acarbose  an alpha-glucosidase inhibitor in cardiometabolic disorders"}
{"PMID":19337422,"re_id":0,"annotated sentence":"Prolonged use of <e1>tolvaptan<\\e1> leads to increased endogenous levels of <e2>AVP<\\e2> and perhaps over-stimulation of V(1A) receptors","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tolvaptan","object":"AVP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Prolonged use of <e1>CHEMICAL<\\e1> leads to increased endogenous levels of <e2>GENE-Y<\\e2> and perhaps over-stimulation of V(1A) receptors","sentence":"Prolonged use of tolvaptan leads to increased endogenous levels of AVP and perhaps over-stimulation of V(1A) receptors"}
{"PMID":19337422,"re_id":1,"annotated sentence":"Prolonged use of <e1>tolvaptan<\\e1> leads to increased endogenous levels of AVP and perhaps over-stimulation of <e2>V(1A) receptors<\\e2>  Theoretically this activation could lead to increased afterload and cardiac myocyte fibrosis, causing progression of CHF","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tolvaptan","object":"V(1A) receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Prolonged use of <e1>CHEMICAL<\\e1> leads to increased endogenous levels of AVP and perhaps over-stimulation of <e2>GENE-Y<\\e2>  Theoretically this activation could lead to increased afterload and cardiac myocyte fibrosis, causing progression of CHF","sentence":"Prolonged use of tolvaptan leads to increased endogenous levels of AVP and perhaps over-stimulation of V(1A) receptors  Theoretically this activation could lead to increased afterload and cardiac myocyte fibrosis, causing progression of CHF"}
{"PMID":19337422,"re_id":2,"annotated sentence":"<e1>Tolvaptan<\\e1> is a selective <e2>arginine vasopressin (AVP) V(2) receptor<\\e2> blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tolvaptan","object":"arginine vasopressin (AVP) V(2) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a selective <e2>GENE-Y<\\e2> blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia","sentence":"Tolvaptan is a selective arginine vasopressin (AVP) V(2) receptor blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia"}
{"PMID":19337422,"re_id":3,"annotated sentence":"In addition, <e1>tolvaptan<\\e1> is metabolized by the <e2>CYP3A4<\\e2> system; thus physicians should be aware of the potential for increased interactions with other medications","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"tolvaptan","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> is metabolized by the <e2>GENE-Y<\\e2> system; thus physicians should be aware of the potential for increased interactions with other medications","sentence":"In addition, tolvaptan is metabolized by the CYP3A4 system; thus physicians should be aware of the potential for increased interactions with other medications"}
{"PMID":19370562,"re_id":0,"annotated sentence":"<e1>Tacrine<\\e1>  the first of the <e2>cholinesterase<\\e2> inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tacrine","object":"cholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  the first of the <e2>GENE-Y<\\e2> inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity","sentence":"Tacrine  the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity"}
{"PMID":19370562,"re_id":1,"annotated sentence":"Other <e2>cholinesterase<\\e2> inhibitors, including <e1>rivastigmine<\\e1>  with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rivastigmine","object":"cholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Other <e2>GENE-Y<\\e2> inhibitors, including <e1>CHEMICAL<\\e1>  with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced","sentence":"Other cholinesterase inhibitors, including rivastigmine  with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced"}
{"PMID":19389876,"re_id":0,"annotated sentence":"In summary, <e1>ketoconazole<\\e1> had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known <e2>CYP3A4<\\e2> inhibitors.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ketoconazole","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In summary, <e1>CHEMICAL<\\e1> had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known <e2>GENE-Y<\\e2> inhibitors.","sentence":"In summary, ketoconazole had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known CYP3A4 inhibitors."}
{"PMID":19389876,"re_id":1,"annotated sentence":"The potential for <e1>ketoconazole<\\e1>  the archetypal strong inhibitor of <e2>CYP3A4<\\e2>  to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ketoconazole","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potential for <e1>CHEMICAL<\\e1>  the archetypal strong inhibitor of <e2>GENE-Y<\\e2>  to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men","sentence":"The potential for ketoconazole  the archetypal strong inhibitor of CYP3A4  to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men"}
{"PMID":19389876,"re_id":2,"annotated sentence":"<e1>Ambrisentan<\\e1> is an <e2>endothelin type A (ET(A))-selective receptor<\\e2> antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Ambrisentan","object":"endothelin type A (ET(A))-selective receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is an <e2>GENE-Y<\\e2> antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4","sentence":"Ambrisentan is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4"}
{"PMID":19389876,"re_id":3,"annotated sentence":"<e1>Ambrisentan<\\e1> is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by <e2>CYP3A4<\\e2>  The potential for ketoconazole, the archetypal strong inhibitor of CYP3A4, to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Ambrisentan","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by <e2>GENE-Y<\\e2>  The potential for ketoconazole, the archetypal strong inhibitor of GENE-Y, to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men","sentence":"Ambrisentan is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4  The potential for ketoconazole, the archetypal strong inhibitor of CYP3A4, to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men"}
{"PMID":19427182,"re_id":0,"annotated sentence":"Second, <e1>probucol<\\e1>  an antiatherogenic compound reported to be an inactivator of <e2>ABCA1<\\e2> reduced hepatic alpha-tocopherol secretion","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"probucol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Second, <e1>CHEMICAL<\\e1>  an antiatherogenic compound reported to be an inactivator of <e2>GENE-Y<\\e2> reduced hepatic alpha-tocopherol secretion","sentence":"Second, probucol  an antiatherogenic compound reported to be an inactivator of ABCA1 reduced hepatic alpha-tocopherol secretion"}
{"PMID":19427182,"re_id":1,"annotated sentence":"alpha-Tocopherol transfer protein (<e2>alpha-TTP<\\e2> , the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma <e1>alpha-tocopherol<\\e1> level by mediating the secretion of alpha-tocopherol by the liver","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"alpha-TTP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"alpha-Tocopherol transfer protein (<e2>GENE-Y<\\e2> , the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma <e1>CHEMICAL<\\e1> level by mediating the secretion of CHEMICAL by the liver","sentence":"alpha-Tocopherol transfer protein (alpha-TTP , the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver"}
{"PMID":19427182,"re_id":2,"annotated sentence":"<e2>alpha-Tocopherol transfer protein<\\e2> (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma <e1>alpha-tocopherol<\\e1> level by mediating the secretion of alpha-tocopherol by the liver","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"alpha-Tocopherol transfer protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma <e1>CHEMICAL<\\e1> level by mediating the secretion of CHEMICAL by the liver","sentence":"alpha-Tocopherol transfer protein (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver"}
{"PMID":19427182,"re_id":3,"annotated sentence":"alpha-Tocopherol transfer protein (<e2>alpha-TTP<\\e2> , the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of <e1>alpha-tocopherol<\\e1> by the liver","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"alpha-TTP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"alpha-Tocopherol transfer protein (<e2>GENE-Y<\\e2> , the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma CHEMICAL level by mediating the secretion of <e1>CHEMICAL<\\e1> by the liver","sentence":"alpha-Tocopherol transfer protein (alpha-TTP , the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver"}
{"PMID":19427182,"re_id":4,"annotated sentence":"<e2>alpha-Tocopherol transfer protein<\\e2> (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of <e1>alpha-tocopherol<\\e1> by the liver","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"alpha-Tocopherol transfer protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma CHEMICAL level by mediating the secretion of <e1>CHEMICAL<\\e1> by the liver","sentence":"alpha-Tocopherol transfer protein (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma alpha-tocopherol level by mediating the secretion of alpha-tocopherol by the liver"}
{"PMID":19427182,"re_id":5,"annotated sentence":"First, addition of <e2>apolipoprotein A-I<\\e2> (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased <e1>alpha-tocopherol<\\e1> secretion in a dose-dependent manner","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"apolipoprotein A-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"First, addition of <e2>GENE-Y<\\e2> (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased <e1>CHEMICAL<\\e1> secretion in a dose-dependent manner","sentence":"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner"}
{"PMID":19427182,"re_id":6,"annotated sentence":"First, addition of apolipoprotein A-I (<e2>apoA-I<\\e2> , a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased <e1>alpha-tocopherol<\\e1> secretion in a dose-dependent manner","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"apoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"First, addition of apolipoprotein A-I (<e2>GENE-Y<\\e2> , a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased <e1>CHEMICAL<\\e1> secretion in a dose-dependent manner","sentence":"First, addition of apolipoprotein A-I (apoA-I , a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner"}
{"PMID":19427182,"re_id":7,"annotated sentence":"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the <e2>ATP-binding cassette transporter A1<\\e2> (ABCA1)-secreted lipids, increased <e1>alpha-tocopherol<\\e1> secretion in a dose-dependent manner","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"ATP-binding cassette transporter A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the <e2>GENE-Y<\\e2> (ABCA1)-secreted lipids, increased <e1>CHEMICAL<\\e1> secretion in a dose-dependent manner","sentence":"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner"}
{"PMID":19427182,"re_id":8,"annotated sentence":"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (<e2>ABCA1<\\e2> -secreted lipids, increased <e1>alpha-tocopherol<\\e1> secretion in a dose-dependent manner","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (<e2>GENE-Y<\\e2> -secreted lipids, increased <e1>CHEMICAL<\\e1> secretion in a dose-dependent manner","sentence":"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1 -secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner"}
{"PMID":19427182,"re_id":9,"annotated sentence":"<e2>ATP-binding cassette transporter A1<\\e2> is involved in hepatic <e1>alpha-tocopherol<\\e1> secretion","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"ATP-binding cassette transporter A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> is involved in hepatic <e1>CHEMICAL<\\e1> secretion","sentence":"ATP-binding cassette transporter A1 is involved in hepatic alpha-tocopherol secretion"}
{"PMID":19427182,"re_id":10,"annotated sentence":"Third, <e2>ABCA1<\\e2> RNAi suppressed hepatic <e1>alpha-tocopherol<\\e1> secretion","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Third, <e2>GENE-Y<\\e2> RNAi suppressed hepatic <e1>CHEMICAL<\\e1> secretion","sentence":"Third, ABCA1 RNAi suppressed hepatic alpha-tocopherol secretion"}
{"PMID":19427182,"re_id":11,"annotated sentence":"These results strongly suggest that <e2>ABCA1<\\e2> is substantially involved in hepatic <e1>alpha-tocopherol<\\e1> secretion.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alpha-tocopherol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results strongly suggest that <e2>GENE-Y<\\e2> is substantially involved in hepatic <e1>CHEMICAL<\\e1> secretion.","sentence":"These results strongly suggest that ABCA1 is substantially involved in hepatic alpha-tocopherol secretion."}
{"PMID":19428322,"re_id":0,"annotated sentence":"<e2>AMPK<\\e2> activators <e1>metformin<\\e1> and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> activators <e1>CHEMICAL<\\e1> and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C","sentence":"AMPK activators metformin and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C"}
{"PMID":19428322,"re_id":1,"annotated sentence":"<e2>AMPK<\\e2> activators metformin and <e1>AICAR<\\e1> partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AICAR","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> activators metformin and <e1>CHEMICAL<\\e1> partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C","sentence":"AMPK activators metformin and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C"}
{"PMID":19429089,"re_id":0,"annotated sentence":"Moreover, kinetic analysis revealed that inhibition by <e1>reserpine<\\e1>  a typical <e2>VMAT2<\\e2> inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"reserpine","object":"VMAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, kinetic analysis revealed that inhibition by <e1>CHEMICAL<\\e1>  a typical <e2>GENE-Y<\\e2> inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine","sentence":"Moreover, kinetic analysis revealed that inhibition by reserpine  a typical VMAT2 inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine"}
{"PMID":19429089,"re_id":1,"annotated sentence":"These results suggest that fluoxetine inhibited the activity of <e2>VMAT2<\\e2> by a mechanism different from that of <e1>reserpine<\\e1> and did not directly interact with the active site of VMAT2.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"reserpine","object":"VMAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that fluoxetine inhibited the activity of <e2>GENE-Y<\\e2> by a mechanism different from that of <e1>CHEMICAL<\\e1> and did not directly interact with the active site of GENE-Y.","sentence":"These results suggest that fluoxetine inhibited the activity of VMAT2 by a mechanism different from that of reserpine and did not directly interact with the active site of VMAT2."}
{"PMID":19429089,"re_id":2,"annotated sentence":"These results suggest that <e1>fluoxetine<\\e1> inhibited the activity of VMAT2 by a mechanism different from that of reserpine and did not directly interact with the active site of <e2>VMAT2<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fluoxetine","object":"VMAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> inhibited the activity of GENE-Y by a mechanism different from that of reserpine and did not directly interact with the active site of <e2>GENE-Y<\\e2> ","sentence":"These results suggest that fluoxetine inhibited the activity of VMAT2 by a mechanism different from that of reserpine and did not directly interact with the active site of VMAT2 "}
{"PMID":19429089,"re_id":3,"annotated sentence":"These results suggest that <e1>fluoxetine<\\e1> inhibited the activity of <e2>VMAT2<\\e2> by a mechanism different from that of reserpine and did not directly interact with the active site of VMAT2.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fluoxetine","object":"VMAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> inhibited the activity of <e2>GENE-Y<\\e2> by a mechanism different from that of reserpine and did not directly interact with the active site of GENE-Y.","sentence":"These results suggest that fluoxetine inhibited the activity of VMAT2 by a mechanism different from that of reserpine and did not directly interact with the active site of VMAT2."}
{"PMID":19429089,"re_id":4,"annotated sentence":"Moreover, kinetic analysis revealed that inhibition by reserpine, a typical <e2>VMAT2<\\e2> inhibitor, was uncompetitive, decreasing maximum velocity and affinity for <e1>dopamine<\\e1>  Inhibition by fluoxetine was noncompetitive, only decreasing maximum velocity for dopamine","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dopamine","object":"VMAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, kinetic analysis revealed that inhibition by reserpine, a typical <e2>GENE-Y<\\e2> inhibitor, was uncompetitive, decreasing maximum velocity and affinity for <e1>CHEMICAL<\\e1>  Inhibition by fluoxetine was noncompetitive, only decreasing maximum velocity for CHEMICAL","sentence":"Moreover, kinetic analysis revealed that inhibition by reserpine, a typical VMAT2 inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine  Inhibition by fluoxetine was noncompetitive, only decreasing maximum velocity for dopamine"}
{"PMID":19429089,"re_id":5,"annotated sentence":"The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on <e2>VMAT2<\\e2> activity by measuring adenosine triphosphate-dependent <e1>[(3)H]dopamine<\\e1> uptake into synaptic vesicles prepared from rat striatum","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[(3)H]dopamine","object":"VMAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on <e2>GENE-Y<\\e2> activity by measuring adenosine triphosphate-dependent <e1>CHEMICAL<\\e1> uptake into synaptic vesicles prepared from rat striatum","sentence":"The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on VMAT2 activity by measuring adenosine triphosphate-dependent [(3)H]dopamine uptake into synaptic vesicles prepared from rat striatum"}
{"PMID":19549602,"re_id":0,"annotated sentence":"<e1>Amitriptyline<\\e1>  but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes <e2>TrkA<\\e2> autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Amitriptyline","object":"TrkA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes <e2>GENE-Y<\\e2> autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells","sentence":"Amitriptyline  but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes TrkA autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells"}
{"PMID":19549602,"re_id":1,"annotated sentence":"Thus, <e1>amitriptyline<\\e1> acts as a TrkA and <e2>TrkB<\\e2> agonist and possesses marked neurotrophic activity.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"amitriptyline","object":"TrkB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> acts as a TrkA and <e2>GENE-Y<\\e2> agonist and possesses marked neurotrophic activity.","sentence":"Thus, amitriptyline acts as a TrkA and TrkB agonist and possesses marked neurotrophic activity."}
{"PMID":19549602,"re_id":2,"annotated sentence":"Thus, <e1>amitriptyline<\\e1> acts as a <e2>TrkA<\\e2> and TrkB agonist and possesses marked neurotrophic activity.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"amitriptyline","object":"TrkA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> acts as a <e2>GENE-Y<\\e2> and TrkB agonist and possesses marked neurotrophic activity.","sentence":"Thus, amitriptyline acts as a TrkA and TrkB agonist and possesses marked neurotrophic activity."}
{"PMID":19549602,"re_id":3,"annotated sentence":"<e1>Amitriptyline<\\e1> is a <e2>TrkA<\\e2> and TrkB receptor agonist that promotes TrkA\/TrkB heterodimerization and has potent neurotrophic activity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Amitriptyline","object":"TrkA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a <e2>GENE-Y<\\e2> and TrkB receptor agonist that promotes GENE-Y\/TrkB heterodimerization and has potent neurotrophic activity","sentence":"Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA\/TrkB heterodimerization and has potent neurotrophic activity"}
{"PMID":19549602,"re_id":4,"annotated sentence":"<e1>Amitriptyline<\\e1> is a TrkA and <e2>TrkB<\\e2> receptor agonist that promotes TrkA\/TrkB heterodimerization and has potent neurotrophic activity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Amitriptyline","object":"TrkB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a TrkA and <e2>GENE-Y<\\e2> receptor agonist that promotes TrkA\/GENE-Y heterodimerization and has potent neurotrophic activity","sentence":"Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA\/TrkB heterodimerization and has potent neurotrophic activity"}
{"PMID":19568704,"re_id":0,"annotated sentence":"INTRODUCTION: In this study, we examined the effects of the <e2>alpha-glucosidase<\\e2> inhibitors acarbose and <e1>voglibose<\\e1> on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"voglibose","object":"alpha-glucosidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"INTRODUCTION: In this study, we examined the effects of the <e2>GENE-N<\\e2> inhibitors acarbose and <e1>CHEMICAL<\\e1> on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus","sentence":"INTRODUCTION: In this study, we examined the effects of the alpha-glucosidase inhibitors acarbose and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus"}
{"PMID":19568704,"re_id":1,"annotated sentence":"INTRODUCTION: In this study, we examined the effects of the <e2>alpha-glucosidase<\\e2> inhibitors <e1>acarbose<\\e1> and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acarbose","object":"alpha-glucosidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"INTRODUCTION: In this study, we examined the effects of the <e2>GENE-N<\\e2> inhibitors <e1>CHEMICAL<\\e1> and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus","sentence":"INTRODUCTION: In this study, we examined the effects of the alpha-glucosidase inhibitors acarbose and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus"}
{"PMID":19568704,"re_id":2,"annotated sentence":"INTRODUCTION: In this study, we examined the effects of the <e2>alpha-glucosidase<\\e2> inhibitors acarbose and voglibose on postprandial plasma <e1>glucose<\\e1> and serum triglyceride levels in patients with type 2 diabetes mellitus","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucose","object":"alpha-glucosidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"INTRODUCTION: In this study, we examined the effects of the <e2>GENE-N<\\e2> inhibitors acarbose and voglibose on postprandial plasma <e1>CHEMICAL<\\e1> and serum triglyceride levels in patients with type 2 diabetes mellitus","sentence":"INTRODUCTION: In this study, we examined the effects of the alpha-glucosidase inhibitors acarbose and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus"}
{"PMID":1975995,"re_id":0,"annotated sentence":"We evaluated the clinical effectiveness of <e1>esmolol<\\e1>  an ultra-short-acting <e2>beta 1-adrenergic receptor<\\e2> blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"esmolol","object":"beta 1-adrenergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We evaluated the clinical effectiveness of <e1>CHEMICAL<\\e1>  an ultra-short-acting <e2>GENE-Y<\\e2> blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT)","sentence":"We evaluated the clinical effectiveness of esmolol  an ultra-short-acting beta 1-adrenergic receptor blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT)"}
{"PMID":1977506,"re_id":0,"annotated sentence":"<e2>H1-receptor<\\e2> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which histamine is considered to be of pathogenic importance and conversely to help elucidate the role of <e1>histamine<\\e1> in disease, through an evaluation of their influence on disease expression","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"histamine","object":"H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which CHEMICAL is considered to be of pathogenic importance and conversely to help elucidate the role of <e1>CHEMICAL<\\e1> in disease, through an evaluation of their influence on disease expression","sentence":"H1-receptor antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which histamine is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression"}
{"PMID":1977506,"re_id":1,"annotated sentence":"While there is considerable indirect evidence to implicate <e1>histamine<\\e1> in the pathogenesis of asthma, a critical evaluation of <e2>H1-receptor<\\e2> antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"histamine","object":"H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While there is considerable indirect evidence to implicate <e1>CHEMICAL<\\e1> in the pathogenesis of asthma, a critical evaluation of <e2>GENE-Y<\\e2> antagonism in this condition has, until recently, proved difficult, as many of the early GENE-Y antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity","sentence":"While there is considerable indirect evidence to implicate histamine in the pathogenesis of asthma, a critical evaluation of H1-receptor antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity"}
{"PMID":1977506,"re_id":2,"annotated sentence":"While there is considerable indirect evidence to implicate <e1>histamine<\\e1> in the pathogenesis of asthma, a critical evaluation of H1-receptor antagonism in this condition has, until recently, proved difficult, as many of the early <e2>H1-receptor<\\e2> antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"histamine","object":"H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While there is considerable indirect evidence to implicate <e1>CHEMICAL<\\e1> in the pathogenesis of asthma, a critical evaluation of GENE-Y antagonism in this condition has, until recently, proved difficult, as many of the early <e2>GENE-Y<\\e2> antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity","sentence":"While there is considerable indirect evidence to implicate histamine in the pathogenesis of asthma, a critical evaluation of H1-receptor antagonism in this condition has, until recently, proved difficult, as many of the early H1-receptor antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity"}
{"PMID":1977506,"re_id":3,"annotated sentence":"<e2>H1-receptor<\\e2> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which <e1>histamine<\\e1> is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"histamine","object":"H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which <e1>CHEMICAL<\\e1> is considered to be of pathogenic importance and conversely to help elucidate the role of CHEMICAL in disease, through an evaluation of their influence on disease expression","sentence":"H1-receptor antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which histamine is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression"}
{"PMID":1977506,"re_id":4,"annotated sentence":"The recent development of <e2>H1-receptor<\\e2> antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of <e1>histamine<\\e1> in this condition","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"histamine","object":"H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The recent development of <e2>GENE-Y<\\e2> antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antiCHEMICALs which achieve a greater degree of GENE-Y blockade within the airways, thus permitting a better appraisal of the role of <e1>CHEMICAL<\\e1> in this condition","sentence":"The recent development of H1-receptor antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of histamine in this condition"}
{"PMID":1977506,"re_id":5,"annotated sentence":"The recent development of H1-receptor antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of <e2>H1-receptor<\\e2> blockade within the airways, thus permitting a better appraisal of the role of <e1>histamine<\\e1> in this condition","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"histamine","object":"H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The recent development of GENE-Y antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antiCHEMICALs which achieve a greater degree of <e2>GENE-Y<\\e2> blockade within the airways, thus permitting a better appraisal of the role of <e1>CHEMICAL<\\e1> in this condition","sentence":"The recent development of H1-receptor antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-antihistamines which achieve a greater degree of H1-receptor blockade within the airways, thus permitting a better appraisal of the role of histamine in this condition"}
{"PMID":19780818,"re_id":0,"annotated sentence":"Furthermore, the <e2>Panx1<\\e2> channel blockers <e1>carbenoxolone<\\e1> and Probenecid were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbenoxolone","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, the <e2>GENE-Y<\\e2> channel blockers <e1>CHEMICAL<\\e1> and Probenecid were less effective in inhibiting GENE-Y currents when Kvbeta3 was co-expressed","sentence":"Furthermore, the Panx1 channel blockers carbenoxolone and Probenecid were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed"}
{"PMID":19780818,"re_id":1,"annotated sentence":"Furthermore, the <e2>Panx1<\\e2> channel blockers carbenoxolone and <e1>Probenecid<\\e1> were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Probenecid","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, the <e2>GENE-Y<\\e2> channel blockers carbenoxolone and <e1>CHEMICAL<\\e1> were less effective in inhibiting GENE-Y currents when Kvbeta3 was co-expressed","sentence":"Furthermore, the Panx1 channel blockers carbenoxolone and Probenecid were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed"}
{"PMID":20012638,"re_id":0,"annotated sentence":"Terbutaline (Bricanyl) and its prodrug <e1>Bambuterol<\\e1> (Bambec) are highly potent <e2>beta(2)-adrenoceptor<\\e2> agonists often used in asthma patients","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Bambuterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Terbutaline (Bricanyl) and its prodrug <e1>CHEMICAL<\\e1> (Bambec) are highly potent <e2>GENE-Y<\\e2> agonists often used in asthma patients","sentence":"Terbutaline (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent beta(2)-adrenoceptor agonists often used in asthma patients"}
{"PMID":20012638,"re_id":1,"annotated sentence":"Terbutaline (Bricanyl) and its prodrug Bambuterol (<e1>Bambec<\\e1>  are highly potent <e2>beta(2)-adrenoceptor<\\e2> agonists often used in asthma patients","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Bambec","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Terbutaline (Bricanyl) and its prodrug Bambuterol (<e1>CHEMICAL<\\e1>  are highly potent <e2>GENE-Y<\\e2> agonists often used in asthma patients","sentence":"Terbutaline (Bricanyl) and its prodrug Bambuterol (Bambec  are highly potent beta(2)-adrenoceptor agonists often used in asthma patients"}
{"PMID":20012638,"re_id":2,"annotated sentence":"<e1>Terbutaline<\\e1> (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent <e2>beta(2)-adrenoceptor<\\e2> agonists often used in asthma patients","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Terbutaline","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent <e2>GENE-Y<\\e2> agonists often used in asthma patients","sentence":"Terbutaline (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent beta(2)-adrenoceptor agonists often used in asthma patients"}
{"PMID":20012638,"re_id":3,"annotated sentence":"Terbutaline (<e1>Bricanyl<\\e1>  and its prodrug Bambuterol (Bambec) are highly potent <e2>beta(2)-adrenoceptor<\\e2> agonists often used in asthma patients","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Bricanyl","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Terbutaline (<e1>CHEMICAL<\\e1>  and its prodrug Bambuterol (Bambec) are highly potent <e2>GENE-Y<\\e2> agonists often used in asthma patients","sentence":"Terbutaline (Bricanyl  and its prodrug Bambuterol (Bambec) are highly potent beta(2)-adrenoceptor agonists often used in asthma patients"}
{"PMID":20091113,"re_id":0,"annotated sentence":"Polymorphisms in dopamine transporter (<e2>SLC6A3<\\e2>  are associated with stimulant effects of <e1>D-amphetamine<\\e1>  an exploratory pharmacogenetic study using healthy volunteers","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"D-amphetamine","object":"SLC6A3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Polymorphisms in dopamine transporter (<e2>GENE-Y<\\e2>  are associated with stimulant effects of <e1>CHEMICAL<\\e1>  an exploratory pharmacogenetic study using healthy volunteers","sentence":"Polymorphisms in dopamine transporter (SLC6A3  are associated with stimulant effects of D-amphetamine  an exploratory pharmacogenetic study using healthy volunteers"}
{"PMID":20091113,"re_id":1,"annotated sentence":"Polymorphisms in <e2>dopamine transporter<\\e2> (SLC6A3) are associated with stimulant effects of <e1>D-amphetamine<\\e1>  an exploratory pharmacogenetic study using healthy volunteers","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"D-amphetamine","object":"dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Polymorphisms in <e2>GENE-Y<\\e2> (SLC6A3) are associated with stimulant effects of <e1>CHEMICAL<\\e1>  an exploratory pharmacogenetic study using healthy volunteers","sentence":"Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine  an exploratory pharmacogenetic study using healthy volunteers"}
{"PMID":20104269,"re_id":0,"annotated sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the <e1>chenodeoxycholic acid<\\e1> (CDCA)-induced expression of <e2>Cdx2<\\e2> and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"chenodeoxycholic acid","object":"Cdx2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the <e1>CHEMICAL<\\e1> (CDCA)-induced expression of <e2>GENE-Y<\\e2> and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)","sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (CDCA)-induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)"}
{"PMID":20104269,"re_id":1,"annotated sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the <e1>chenodeoxycholic acid<\\e1> (CDCA)-induced expression of Cdx2 and <e2>MUC2<\\e2> in normal rat gastric epithelial cells (RGM-1 cells)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"chenodeoxycholic acid","object":"MUC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the <e1>CHEMICAL<\\e1> (CDCA)-induced expression of Cdx2 and <e2>GENE-Y<\\e2> in normal rat gastric epithelial cells (RGM-1 cells)","sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (CDCA)-induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)"}
{"PMID":20104269,"re_id":2,"annotated sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA<\\e1> -induced expression of <e2>Cdx2<\\e2> and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDCA","object":"Cdx2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CHEMICAL<\\e1> -induced expression of <e2>GENE-Y<\\e2> and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)","sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (CDCA -induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)"}
{"PMID":20104269,"re_id":3,"annotated sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA<\\e1> -induced expression of Cdx2 and <e2>MUC2<\\e2> in normal rat gastric epithelial cells (RGM-1 cells)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDCA","object":"MUC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CHEMICAL<\\e1> -induced expression of Cdx2 and <e2>GENE-Y<\\e2> in normal rat gastric epithelial cells (RGM-1 cells)","sentence":"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (CDCA -induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)"}
{"PMID":20104269,"re_id":4,"annotated sentence":"<e1>CDCA<\\e1> induced dose-dependent expression of <e2>Cdx2<\\e2> and MUC2 at both the mRNA and protein levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDCA","object":"Cdx2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced dose-dependent expression of <e2>GENE-Y<\\e2> and MUC2 at both the mRNA and protein levels","sentence":"CDCA induced dose-dependent expression of Cdx2 and MUC2 at both the mRNA and protein levels"}
{"PMID":20104269,"re_id":5,"annotated sentence":"<e1>CDCA<\\e1> induced dose-dependent expression of Cdx2 and <e2>MUC2<\\e2> at both the mRNA and protein levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDCA","object":"MUC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced dose-dependent expression of Cdx2 and <e2>GENE-Y<\\e2> at both the mRNA and protein levels","sentence":"CDCA induced dose-dependent expression of Cdx2 and MUC2 at both the mRNA and protein levels"}
{"PMID":20104269,"re_id":6,"annotated sentence":"The maximum stimulation of <e2>Cdx2<\\e2> and MUC2 mRNA induced by <e1>CDCA<\\e1> was observed at 3 h and by 6 h, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDCA","object":"Cdx2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The maximum stimulation of <e2>GENE-Y<\\e2> and MUC2 mRNA induced by <e1>CHEMICAL<\\e1> was observed at 3 h and by 6 h, respectively","sentence":"The maximum stimulation of Cdx2 and MUC2 mRNA induced by CDCA was observed at 3 h and by 6 h, respectively"}
{"PMID":20104269,"re_id":7,"annotated sentence":"The maximum stimulation of Cdx2 and <e2>MUC2<\\e2> mRNA induced by <e1>CDCA<\\e1> was observed at 3 h and by 6 h, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CDCA","object":"MUC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The maximum stimulation of Cdx2 and <e2>GENE-Y<\\e2> mRNA induced by <e1>CHEMICAL<\\e1> was observed at 3 h and by 6 h, respectively","sentence":"The maximum stimulation of Cdx2 and MUC2 mRNA induced by CDCA was observed at 3 h and by 6 h, respectively"}
{"PMID":20104269,"re_id":8,"annotated sentence":"The effects of CDCA and GW4064 on expression of <e2>Cdx2<\\e2> and MUC2 were abolished by <e1>guggulsterone<\\e1>  These findings suggest that bile acids may induce gastric intestinal metaplasia and carcinogenesis through the FXR.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"guggulsterone","object":"Cdx2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of CDCA and GW4064 on expression of <e2>GENE-Y<\\e2> and MUC2 were abolished by <e1>CHEMICAL<\\e1>  These findings suggest that bile acids may induce gastric intestinal metaplasia and carcinogenesis through the FXR.","sentence":"The effects of CDCA and GW4064 on expression of Cdx2 and MUC2 were abolished by guggulsterone  These findings suggest that bile acids may induce gastric intestinal metaplasia and carcinogenesis through the FXR."}
{"PMID":20104269,"re_id":9,"annotated sentence":"The effects of CDCA and GW4064 on expression of Cdx2 and <e2>MUC2<\\e2> were abolished by <e1>guggulsterone<\\e1>  These findings suggest that bile acids may induce gastric intestinal metaplasia and carcinogenesis through the FXR.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"guggulsterone","object":"MUC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of CDCA and GW4064 on expression of Cdx2 and <e2>GENE-Y<\\e2> were abolished by <e1>CHEMICAL<\\e1>  These findings suggest that bile acids may induce gastric intestinal metaplasia and carcinogenesis through the FXR.","sentence":"The effects of CDCA and GW4064 on expression of Cdx2 and MUC2 were abolished by guggulsterone  These findings suggest that bile acids may induce gastric intestinal metaplasia and carcinogenesis through the FXR."}
{"PMID":20104269,"re_id":10,"annotated sentence":"RGM-1 cells were treated with <e1>CDCA<\\e1> or GW4064, an <e2>FXR<\\e2> agonist, in the presence or absence of guggulsterone, an FXR antagonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"CDCA","object":"FXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RGM-1 cells were treated with <e1>CHEMICAL<\\e1> or GW4064, an <e2>GENE-Y<\\e2> agonist, in the presence or absence of guggulsterone, an GENE-Y antagonist","sentence":"RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of guggulsterone, an FXR antagonist"}
{"PMID":20104269,"re_id":11,"annotated sentence":"RGM-1 cells were treated with CDCA or <e1>GW4064<\\e1>  an <e2>FXR<\\e2> agonist, in the presence or absence of guggulsterone, an FXR antagonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"GW4064","object":"FXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RGM-1 cells were treated with CDCA or <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> agonist, in the presence or absence of guggulsterone, an GENE-Y antagonist","sentence":"RGM-1 cells were treated with CDCA or GW4064  an FXR agonist, in the presence or absence of guggulsterone, an FXR antagonist"}
{"PMID":20104269,"re_id":12,"annotated sentence":"RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of <e1>guggulsterone<\\e1>  an <e2>FXR<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"guggulsterone","object":"FXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RGM-1 cells were treated with CDCA or GW4064, an GENE-Y agonist, in the presence or absence of <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> antagonist","sentence":"RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of guggulsterone  an FXR antagonist"}
{"PMID":20185318,"re_id":0,"annotated sentence":"A series of phenolic acids and phenol natural products, such as <e1>p-hydroxybenzoic acid<\\e1>  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-hydroxybenzoic acid","object":"metalloenzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as <e1>CHEMICAL<\\e1>  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>GENE-N<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":1,"annotated sentence":"A series of phenolic acids and phenol natural products, such as <e1>p-hydroxybenzoic acid<\\e1>  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-hydroxybenzoic acid","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as <e1>CHEMICAL<\\e1>  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>GENE-N<\\e2> (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":2,"annotated sentence":"A series of phenolic acids and phenol natural products, such as <e1>p-hydroxybenzoic acid<\\e1>  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-hydroxybenzoic acid","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as <e1>CHEMIGENE-NL<\\e1>  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA  EC 4.2.1.1)"}
{"PMID":20185318,"re_id":3,"annotated sentence":"A series of phenolic acids and phenol natural products, such as <e1>p-hydroxybenzoic acid<\\e1>  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-hydroxybenzoic acid","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of phenolic acids and phenol natural products, such as <e1>CHEMICAL<\\e1>  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>GENE-Y<\\e2> ","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid  p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1 "}
{"PMID":20185318,"re_id":4,"annotated sentence":"<e1>Phenols<\\e1> like the ones investigated here possess a <e2>CA<\\e2> inhibition mechanism distinct of that of the sulfonamides\/sulfamates used clinically or the coumarins","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenols","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMIGENE-NL<\\e1> like the ones investigated here possess a <e2>GENE-N<\\e2> inhibition mechanism distinct of that of the sulfonamides\/sulfamates used clinically or the coumarins","sentence":"Phenols like the ones investigated here possess a CA inhibition mechanism distinct of that of the sulfonamides\/sulfamates used clinically or the coumarins"}
{"PMID":20185318,"re_id":5,"annotated sentence":"Phenols like the ones investigated here possess a <e2>CA<\\e2> inhibition mechanism distinct of that of the <e1>sulfonamides<\\e1> sulfamates used clinically or the coumarins","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulfonamides","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phenols like the ones investigated here possess a <e2>GENE-N<\\e2> inhibition mechanism distinct of that of the <e1>CHEMIGENE-NL<\\e1> sulfamates used clinically or the coumarins","sentence":"Phenols like the ones investigated here possess a CA inhibition mechanism distinct of that of the sulfonamides sulfamates used clinically or the coumarins"}
{"PMID":20185318,"re_id":6,"annotated sentence":"Phenols like the ones investigated here possess a <e2>CA<\\e2> inhibition mechanism distinct of that of the sulfonamides\/<e1>sulfamates<\\e1> used clinically or the coumarins","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulfamates","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phenols like the ones investigated here possess a <e2>GENE-N<\\e2> inhibition mechanism distinct of that of the sulfonamides\/<e1>CHEMIGENE-NL<\\e1> used clinically or the coumarins","sentence":"Phenols like the ones investigated here possess a CA inhibition mechanism distinct of that of the sulfonamides\/sulfamates used clinically or the coumarins"}
{"PMID":20185318,"re_id":7,"annotated sentence":"Phenols like the ones investigated here possess a <e2>CA<\\e2> inhibition mechanism distinct of that of the sulfonamides\/sulfamates used clinically or the <e1>coumarins<\\e1>  Unlike the sulfonamides, which bind to the catalytic zinc ion, phenols are anchored at the Zn(II)-coordinated water molecule and bind more externally within the active site cavity, making contacts with various amino acid residues","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"coumarins","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phenols like the ones investigated here possess a <e2>GENE-N<\\e2> inhibition mechanism distinct of that of the sulfonamides\/sulfamates used clinically or the <e1>CHEMIGENE-NL<\\e1>  Unlike the sulfonamides, which bind to the catalytic zinc ion, phenols are anchored at the Zn(II)-coordinated water molecule and bind more externally within the active site cavity, making contacts with various amino acid residues","sentence":"Phenols like the ones investigated here possess a CA inhibition mechanism distinct of that of the sulfonamides\/sulfamates used clinically or the coumarins  Unlike the sulfonamides, which bind to the catalytic zinc ion, phenols are anchored at the Zn(II)-coordinated water molecule and bind more externally within the active site cavity, making contacts with various amino acid residues"}
{"PMID":20185318,"re_id":8,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>p-coumaric acid<\\e1>  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-coumaric acid","object":"metalloenzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>CHEMICAL<\\e1>  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>GENE-N<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":9,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>p-coumaric acid<\\e1>  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-coumaric acid","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>CHEMICAL<\\e1>  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>GENE-N<\\e2> (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":10,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>p-coumaric acid<\\e1>  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-coumaric acid","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>CHEMIGENE-NL<\\e1>  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA  EC 4.2.1.1)"}
{"PMID":20185318,"re_id":11,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>p-coumaric acid<\\e1>  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-coumaric acid","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>CHEMICAL<\\e1>  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>GENE-Y<\\e2> ","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid  caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1 "}
{"PMID":20185318,"re_id":12,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>caffeic acid<\\e1>  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeic acid","object":"metalloenzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>CHEMICAL<\\e1>  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>GENE-N<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":13,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>caffeic acid<\\e1>  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeic acid","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>CHEMICAL<\\e1>  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>GENE-N<\\e2> (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":14,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>caffeic acid<\\e1>  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeic acid","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>CHEMIGENE-NL<\\e1>  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA  EC 4.2.1.1)"}
{"PMID":20185318,"re_id":15,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>caffeic acid<\\e1>  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"caffeic acid","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>CHEMICAL<\\e1>  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>GENE-Y<\\e2> ","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid  ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1 "}
{"PMID":20185318,"re_id":16,"annotated sentence":"Inhibition of <e2>mammalian isoforms I-XIV<\\e2> with a series of natural product <e1>polyphenols<\\e1> and phenolic acids","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"polyphenols","object":"mammalian isoforms I-XIV","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of <e2>GENE-N<\\e2> with a series of natural product <e1>CHEMICAL<\\e1> and phenolic acids","sentence":"Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids"}
{"PMID":20185318,"re_id":17,"annotated sentence":"Inhibition of <e2>mammalian isoforms I-XIV<\\e2> with a series of natural product polyphenols and <e1>phenolic acids<\\e1>  A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenolic acids","object":"mammalian isoforms I-XIV","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of <e2>GENE-N<\\e2> with a series of natural product polyphenols and <e1>CHEMICAL<\\e1>  A series of CHEMICAL and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids  A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":18,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>ferulic acid<\\e1>  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ferulic acid","object":"metalloenzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>CHEMICAL<\\e1>  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>GENE-N<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":19,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>ferulic acid<\\e1>  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ferulic acid","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>CHEMICAL<\\e1>  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>GENE-N<\\e2> (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":20,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>ferulic acid<\\e1>  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ferulic acid","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>CHEMIGENE-NL<\\e1>  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA  EC 4.2.1.1)"}
{"PMID":20185318,"re_id":21,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>ferulic acid<\\e1>  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ferulic acid","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>CHEMICAL<\\e1>  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>GENE-Y<\\e2> ","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid  gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1 "}
{"PMID":20185318,"re_id":22,"annotated sentence":"A series of <e1>phenolic acids<\\e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenolic acids","object":"metalloenzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of <e1>CHEMICAL<\\e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>GENE-N<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":23,"annotated sentence":"A series of <e1>phenolic acids<\\e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenolic acids","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of <e1>CHEMICAL<\\e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>GENE-N<\\e2> (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":24,"annotated sentence":"A series of <e1>phenolic acids<\\e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenolic acids","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of <e1>CHEMIGENE-NL<\\e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA  EC 4.2.1.1)"}
{"PMID":20185318,"re_id":25,"annotated sentence":"A series of <e1>phenolic acids<\\e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenolic acids","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>GENE-Y<\\e2> ","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1 "}
{"PMID":20185318,"re_id":26,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>gallic acid<\\e1>  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gallic acid","object":"metalloenzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>CHEMICAL<\\e1>  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>GENE-N<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":27,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>gallic acid<\\e1>  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gallic acid","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>CHEMICAL<\\e1>  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>GENE-N<\\e2> (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":28,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>gallic acid<\\e1>  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gallic acid","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>CHEMIGENE-NL<\\e1>  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA  EC 4.2.1.1)"}
{"PMID":20185318,"re_id":29,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>gallic acid<\\e1>  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gallic acid","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>CHEMICAL<\\e1>  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>GENE-Y<\\e2> ","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid  syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1 "}
{"PMID":20185318,"re_id":30,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>syringic acid<\\e1>  quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"syringic acid","object":"metalloenzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>CHEMICAL<\\e1>  quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>GENE-N<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid  quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":31,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>syringic acid<\\e1>  quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"syringic acid","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>CHEMICAL<\\e1>  quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>GENE-N<\\e2> (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid  quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":32,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>syringic acid<\\e1>  quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"syringic acid","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>CHEMIGENE-NL<\\e1>  quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid  quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA  EC 4.2.1.1)"}
{"PMID":20185318,"re_id":33,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>syringic acid<\\e1>  quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"syringic acid","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>CHEMICAL<\\e1>  quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>GENE-Y<\\e2> ","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid  quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1 "}
{"PMID":20185318,"re_id":34,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>quercetin<\\e1>  and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quercetin","object":"metalloenzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>CHEMICAL<\\e1>  and ellagic acid, were investigated for their inhibitory effects against the <e2>GENE-N<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin  and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":35,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>quercetin<\\e1>  and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quercetin","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>CHEMICAL<\\e1>  and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>GENE-N<\\e2> (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin  and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":36,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>quercetin<\\e1>  and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quercetin","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>CHEMIGENE-NL<\\e1>  and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin  and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA  EC 4.2.1.1)"}
{"PMID":20185318,"re_id":37,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>quercetin<\\e1>  and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quercetin","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>CHEMICAL<\\e1>  and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>GENE-Y<\\e2> ","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin  and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1 "}
{"PMID":20185318,"re_id":38,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>ellagic acid<\\e1>  were investigated for their inhibitory effects against the <e2>metalloenzyme<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ellagic acid","object":"metalloenzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>CHEMICAL<\\e1>  were investigated for their inhibitory effects against the <e2>GENE-N<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid  were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":39,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>ellagic acid<\\e1>  were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ellagic acid","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>CHEMICAL<\\e1>  were investigated for their inhibitory effects against the metalloenzyme <e2>GENE-N<\\e2> (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid  were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":40,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>ellagic acid<\\e1>  were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ellagic acid","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>CHEMIGENE-NL<\\e1>  were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid  were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA  EC 4.2.1.1)"}
{"PMID":20185318,"re_id":41,"annotated sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>ellagic acid<\\e1>  were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ellagic acid","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>CHEMICAL<\\e1>  were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>GENE-Y<\\e2> ","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid  were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1 "}
{"PMID":20185318,"re_id":42,"annotated sentence":"A series of phenolic acids and <e1>phenol<\\e1> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenol","object":"metalloenzyme","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of CHEMICALic acids and <e1>CHEMICAL<\\e1> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>GENE-N<\\e2> carbonic anhydrase (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":43,"annotated sentence":"A series of phenolic acids and <e1>phenol<\\e1> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase<\\e2> (CA, EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenol","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of CHEMICALic acids and <e1>CHEMICAL<\\e1> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>GENE-N<\\e2> (CA, EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)"}
{"PMID":20185318,"re_id":44,"annotated sentence":"A series of phenolic acids and <e1>phenol<\\e1> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenol","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of CHEMIGENE-NLic acids and <e1>CHEMIGENE-NL<\\e1> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1)","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA  EC 4.2.1.1)"}
{"PMID":20185318,"re_id":45,"annotated sentence":"A series of phenolic acids and <e1>phenol<\\e1> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenol","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of CHEMICALic acids and <e1>CHEMICAL<\\e1> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>GENE-Y<\\e2> ","sentence":"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1 "}
{"PMID":20230007,"re_id":0,"annotated sentence":"Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic <e1>steroids<\\e1> (AAS) were activating <e2>hAR<\\e2> and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"steroids","object":"hAR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, translocation studies using the human androgen receptor (GENE-Y) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic <e1>CHEMICAL<\\e1> (AAS) were activating <e2>GENE-Y<\\e2> and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and GENE-Y","sentence":"Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic steroids (AAS) were activating hAR and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR"}
{"PMID":20347047,"re_id":0,"annotated sentence":"The contractions to 5-HT were inhibited by <e1>ketanserin<\\e1> and alosetron indicating involvement of <e2>5-HT(2A)<\\e2> and 5-HT(3) receptors, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ketanserin","object":"5-HT(2A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The contractions to 5-HT were inhibited by <e1>CHEMICAL<\\e1> and alosetron indicating involvement of <e2>GENE-Y<\\e2> and 5-HT(3) receptors, respectively","sentence":"The contractions to 5-HT were inhibited by ketanserin and alosetron indicating involvement of 5-HT(2A) and 5-HT(3) receptors, respectively"}
{"PMID":20347047,"re_id":1,"annotated sentence":"The contractions to 5-HT were inhibited by ketanserin and <e1>alosetron<\\e1> indicating involvement of 5-HT(2A) and <e2>5-HT(3)<\\e2> receptors, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"alosetron","object":"5-HT(3)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The contractions to 5-HT were inhibited by ketanserin and <e1>CHEMICAL<\\e1> indicating involvement of 5-HT(2A) and <e2>GENE-Y<\\e2> receptors, respectively","sentence":"The contractions to 5-HT were inhibited by ketanserin and alosetron indicating involvement of 5-HT(2A) and 5-HT(3) receptors, respectively"}
{"PMID":20372850,"re_id":0,"annotated sentence":"<e1>TAS-102<\\e1> is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit <e2>TS<\\e2>  TAS-102 has been shown to exhibit antitumor activity in fluoropyrimidine-resistant human cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAS-102","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit <e2>GENE-Y<\\e2>  CHEMICAL has been shown to exhibit antitumor activity in fluoropyrimidine-resistant human cancer cells","sentence":"TAS-102 is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit TS  TAS-102 has been shown to exhibit antitumor activity in fluoropyrimidine-resistant human cancer cells"}
{"PMID":20372850,"re_id":1,"annotated sentence":"<e1>TAS-102<\\e1> is a novel drug containing trifluorothymidine, which is phosphorylated by <e2>TK-1<\\e2> to its active monophosphated form, that in turn can inhibit TS","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"TAS-102","object":"TK-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a novel drug containing trifluorothymidine, which is phosphorylated by <e2>GENE-Y<\\e2> to its active monophosphated form, that in turn can inhibit TS","sentence":"TAS-102 is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit TS"}
{"PMID":20372850,"re_id":2,"annotated sentence":"TAS-102 is a novel drug containing <e1>trifluorothymidine<\\e1>  which is phosphorylated by <e2>TK-1<\\e2> to its active monophosphated form, that in turn can inhibit TS","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"trifluorothymidine","object":"TK-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TAS-102 is a novel drug containing <e1>CHEMICAL<\\e1>  which is phosphorylated by <e2>GENE-Y<\\e2> to its active monophosphated form, that in turn can inhibit TS","sentence":"TAS-102 is a novel drug containing trifluorothymidine  which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit TS"}
{"PMID":20372850,"re_id":3,"annotated sentence":"<e2>Thymidine kinase-1<\\e2> (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo <e1>pyrimidine<\\e1> synthesis, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrimidine","object":"Thymidine kinase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo <e1>CHEMICAL<\\e1> synthesis, respectively","sentence":"Thymidine kinase-1 (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo pyrimidine synthesis, respectively"}
{"PMID":20372850,"re_id":4,"annotated sentence":"Thymidine kinase-1 (<e2>TK-1)<\\e2> and thymidylate synthase (TS) are key enzymes for salvage and de novo <e1>pyrimidine<\\e1> synthesis, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrimidine","object":"TK-1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thymidine kinase-1 (<e2>GENE-Y<\\e2> and thymidylate synthase (TS) are key enzymes for salvage and de novo <e1>CHEMICAL<\\e1> synthesis, respectively","sentence":"Thymidine kinase-1 (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo pyrimidine synthesis, respectively"}
{"PMID":20372850,"re_id":5,"annotated sentence":"Thymidine kinase-1 (TK-1) and <e2>thymidylate synthase<\\e2> (TS) are key enzymes for salvage and de novo <e1>pyrimidine<\\e1> synthesis, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrimidine","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thymidine kinase-1 (TK-1) and <e2>GENE-Y<\\e2> (TS) are key enzymes for salvage and de novo <e1>CHEMICAL<\\e1> synthesis, respectively","sentence":"Thymidine kinase-1 (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo pyrimidine synthesis, respectively"}
{"PMID":20372850,"re_id":6,"annotated sentence":"Thymidine kinase-1 (TK-1) and thymidylate synthase (<e2>TS<\\e2>  are key enzymes for salvage and de novo <e1>pyrimidine<\\e1> synthesis, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrimidine","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thymidine kinase-1 (TK-1) and thymidylate synthase (<e2>GENE-Y<\\e2>  are key enzymes for salvage and de novo <e1>CHEMICAL<\\e1> synthesis, respectively","sentence":"Thymidine kinase-1 (TK-1) and thymidylate synthase (TS  are key enzymes for salvage and de novo pyrimidine synthesis, respectively"}
{"PMID":20372850,"re_id":7,"annotated sentence":"Immunohistochemical characterization of <e1>pyrimidine<\\e1> synthetic enzymes, <e2>thymidine kinase-1<\\e2> and thymidylate synthase, in various types of cancer","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrimidine","object":"thymidine kinase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Immunohistochemical characterization of <e1>CHEMICAL<\\e1> synthetic enzymes, <e2>GENE-Y<\\e2> and thymidylate synthase, in various types of cancer","sentence":"Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer"}
{"PMID":20372850,"re_id":8,"annotated sentence":"Immunohistochemical characterization of <e1>pyrimidine<\\e1> synthetic enzymes, thymidine kinase-1 and <e2>thymidylate synthase<\\e2>  in various types of cancer","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrimidine","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Immunohistochemical characterization of <e1>CHEMICAL<\\e1> synthetic enzymes, thymidine kinase-1 and <e2>GENE-Y<\\e2>  in various types of cancer","sentence":"Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase  in various types of cancer"}
{"PMID":20372850,"re_id":9,"annotated sentence":"Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high <e2>TS<\\e2> expression, indicating activation of <e1>pyrimidine<\\e1> synthesis through both the salvage and de novo pathways","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pyrimidine","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high <e2>GENE-Y<\\e2> expression, indicating activation of <e1>CHEMICAL<\\e1> synthesis through both the salvage and de novo pathways","sentence":"Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high TS expression, indicating activation of pyrimidine synthesis through both the salvage and de novo pathways"}
{"PMID":20421509,"re_id":0,"annotated sentence":"Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at <e1>TFP<\\e1> concentrations that promote <e2>S100A4<\\e2> oligomerization","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TFP","object":"S100A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Assays examining the ability of CHEMICAL to block GENE-Y-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of GENE-Y function occurs only at <e1>CHEMICAL<\\e1> concentrations that promote <e2>GENE-Y<\\e2> oligomerization","sentence":"Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization"}
{"PMID":20421509,"re_id":1,"annotated sentence":"Using a unique biosensor-based assay, <e1>trifluoperazine<\\e1> (TFP) was identified as an inhibitor that disrupts the <e2>S100A4<\\e2> myosin-IIA interaction","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"trifluoperazine","object":"S100A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using a unique biosensor-based assay, <e1>CHEMICAL<\\e1> (TFP) was identified as an inhibitor that disrupts the <e2>GENE-Y<\\e2> myosin-IIA interaction","sentence":"Using a unique biosensor-based assay, trifluoperazine (TFP) was identified as an inhibitor that disrupts the S100A4 myosin-IIA interaction"}
{"PMID":20421509,"re_id":2,"annotated sentence":"Using a unique biosensor-based assay, <e1>trifluoperazine<\\e1> (TFP) was identified as an inhibitor that disrupts the S100A4\/<e2>myosin-IIA<\\e2> interaction","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"trifluoperazine","object":"myosin-IIA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using a unique biosensor-based assay, <e1>CHEMICAL<\\e1> (TFP) was identified as an inhibitor that disrupts the S100A4\/<e2>GENE-Y<\\e2> interaction","sentence":"Using a unique biosensor-based assay, trifluoperazine (TFP) was identified as an inhibitor that disrupts the S100A4\/myosin-IIA interaction"}
{"PMID":20421509,"re_id":3,"annotated sentence":"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP<\\e1>  was identified as an inhibitor that disrupts the <e2>S100A4<\\e2> myosin-IIA interaction","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TFP","object":"S100A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using a unique biosensor-based assay, trifluoperazine (<e1>CHEMICAL<\\e1>  was identified as an inhibitor that disrupts the <e2>GENE-Y<\\e2> myosin-IIA interaction","sentence":"Using a unique biosensor-based assay, trifluoperazine (TFP  was identified as an inhibitor that disrupts the S100A4 myosin-IIA interaction"}
{"PMID":20421509,"re_id":4,"annotated sentence":"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP<\\e1>  was identified as an inhibitor that disrupts the S100A4\/<e2>myosin-IIA<\\e2> interaction","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TFP","object":"myosin-IIA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using a unique biosensor-based assay, trifluoperazine (<e1>CHEMICAL<\\e1>  was identified as an inhibitor that disrupts the S100A4\/<e2>GENE-Y<\\e2> interaction","sentence":"Using a unique biosensor-based assay, trifluoperazine (TFP  was identified as an inhibitor that disrupts the S100A4\/myosin-IIA interaction"}
{"PMID":20421509,"re_id":5,"annotated sentence":"<e1>Phenothiazines<\\e1> inhibit <e2>S100A4<\\e2> function by inducing protein oligomerization","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenothiazines","object":"S100A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibit <e2>GENE-Y<\\e2> function by inducing protein oligomerization","sentence":"Phenothiazines inhibit S100A4 function by inducing protein oligomerization"}
{"PMID":20421509,"re_id":6,"annotated sentence":"Assays examining the ability of <e1>TFP<\\e1> to block <e2>S100A4<\\e2> mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TFP","object":"S100A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Assays examining the ability of <e1>CHEMICAL<\\e1> to block <e2>GENE-Y<\\e2> mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of GENE-Y function occurs only at CHEMICAL concentrations that promote GENE-Y oligomerization","sentence":"Assays examining the ability of TFP to block S100A4 mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization"}
{"PMID":20421509,"re_id":7,"annotated sentence":"Assays examining the ability of <e1>TFP<\\e1> to block S100A4-mediated disassembly of <e2>myosin-IIA<\\e2> filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TFP","object":"myosin-IIA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Assays examining the ability of <e1>CHEMICAL<\\e1> to block S100A4-mediated disassembly of <e2>GENE-Y<\\e2> filaments demonstrate that significant inhibition of S100A4 function occurs only at CHEMICAL concentrations that promote S100A4 oligomerization","sentence":"Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization"}
{"PMID":20421509,"re_id":8,"annotated sentence":"Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of <e2>S100A4<\\e2> function occurs only at <e1>TFP<\\e1> concentrations that promote S100A4 oligomerization","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TFP","object":"S100A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Assays examining the ability of CHEMICAL to block GENE-Y-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of <e2>GENE-Y<\\e2> function occurs only at <e1>CHEMICAL<\\e1> concentrations that promote GENE-Y oligomerization","sentence":"Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization"}
{"PMID":20421509,"re_id":9,"annotated sentence":"Together these studies support a unique mode of inhibition in which <e1>phenothiazines<\\e1> disrupt the <e2>S100A4<\\e2> myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenothiazines","object":"S100A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Together these studies support a unique mode of inhibition in which <e1>CHEMICAL<\\e1> disrupt the <e2>GENE-Y<\\e2> myosin-IIA interaction by sequestering GENE-Y via small molecule-induced oligomerization.","sentence":"Together these studies support a unique mode of inhibition in which phenothiazines disrupt the S100A4 myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization."}
{"PMID":20421509,"re_id":10,"annotated sentence":"Together these studies support a unique mode of inhibition in which <e1>phenothiazines<\\e1> disrupt the S100A4\/<e2>myosin-IIA<\\e2> interaction by sequestering S100A4 via small molecule-induced oligomerization.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenothiazines","object":"myosin-IIA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Together these studies support a unique mode of inhibition in which <e1>CHEMICAL<\\e1> disrupt the S100A4\/<e2>GENE-Y<\\e2> interaction by sequestering S100A4 via small molecule-induced oligomerization.","sentence":"Together these studies support a unique mode of inhibition in which phenothiazines disrupt the S100A4\/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization."}
{"PMID":20427668,"re_id":0,"annotated sentence":"<e1>Prednisolone<\\e1> also inhibited ACTH and cortisol secretion in response to exogenous <e2>CRH<\\e2> stimulation, inferring rapid feedback inhibition at the anterior pituitary","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Prednisolone","object":"CRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also inhibited ACTH and cortisol secretion in response to exogenous <e2>GENE-Y<\\e2> stimulation, inferring rapid feedback inhibition at the anterior pituitary","sentence":"Prednisolone also inhibited ACTH and cortisol secretion in response to exogenous CRH stimulation, inferring rapid feedback inhibition at the anterior pituitary"}
{"PMID":20427668,"re_id":1,"annotated sentence":"Prednisolone also inhibited ACTH and <e1>cortisol<\\e1> secretion in response to exogenous <e2>CRH<\\e2> stimulation, inferring rapid feedback inhibition at the anterior pituitary","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisol","object":"CRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Prednisolone also inhibited ACTH and <e1>CHEMICAL<\\e1> secretion in response to exogenous <e2>GENE-Y<\\e2> stimulation, inferring rapid feedback inhibition at the anterior pituitary","sentence":"Prednisolone also inhibited ACTH and cortisol secretion in response to exogenous CRH stimulation, inferring rapid feedback inhibition at the anterior pituitary"}
{"PMID":20517484,"re_id":0,"annotated sentence":"<e1>Rasagiline<\\e1> is a novel, potent, and irreversible <e2>monoamine oxidase type B<\\e2> (MAO-B) inhibitor which has been approved for treatment of PD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rasagiline","object":"monoamine oxidase type B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a novel, potent, and irreversible <e2>GENE-Y<\\e2> (MAO-B) inhibitor which has been approved for treatment of PD","sentence":"Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD"}
{"PMID":20517484,"re_id":1,"annotated sentence":"<e1>Rasagiline<\\e1> is a novel, potent, and irreversible monoamine oxidase type B (<e2>MAO-B<\\e2>  inhibitor which has been approved for treatment of PD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rasagiline","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a novel, potent, and irreversible monoamine oxidase type B (<e2>GENE-Y<\\e2>  inhibitor which has been approved for treatment of PD","sentence":"Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B  inhibitor which has been approved for treatment of PD"}
{"PMID":20517484,"re_id":2,"annotated sentence":"<e1>Rasagiline<\\e1> inhibits <e2>MAO-B<\\e2> more potently than selegiline and has the advantage of once-daily dosing","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rasagiline","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> more potently than selegiline and has the advantage of once-daily dosing","sentence":"Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing"}
{"PMID":20531964,"re_id":0,"annotated sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the <e2>VEGFR<\\e2> tyrosine kinase inhibitors sunitinib and\/or <e1>sorafenib<\\e1>  The primary endpoint of progression-free survival was increased from median 1.9 to 4.9 months (hazard ratio 0.33, P < 0.001) and 25% were still progression-free after 10 months of everolimus therapy","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the <e2>GENE-N<\\e2> tyrosine kinase inhibitors sunitinib and\/or <e1>CHEMICAL<\\e1>  The primary endpoint of progression-free survival was increased from median 1.9 to 4.9 months (hazard ratio 0.33, P < 0.001) and 25% were still progression-free after 10 months of everolimus therapy","sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR tyrosine kinase inhibitors sunitinib and\/or sorafenib  The primary endpoint of progression-free survival was increased from median 1.9 to 4.9 months (hazard ratio 0.33, P < 0.001) and 25% were still progression-free after 10 months of everolimus therapy"}
{"PMID":20531964,"re_id":1,"annotated sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR <e2>tyrosine kinase<\\e2> inhibitors sunitinib and\/or <e1>sorafenib<\\e1>  The primary endpoint of progression-free survival was increased from median 1.9 to 4.9 months (hazard ratio 0.33, P < 0.001) and 25% were still progression-free after 10 months of everolimus therapy","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sorafenib","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR <e2>GENE-N<\\e2> inhibitors sunitinib and\/or <e1>CHEMICAL<\\e1>  The primary endpoint of progression-free survival was increased from median 1.9 to 4.9 months (hazard ratio 0.33, P < 0.001) and 25% were still progression-free after 10 months of everolimus therapy","sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR tyrosine kinase inhibitors sunitinib and\/or sorafenib  The primary endpoint of progression-free survival was increased from median 1.9 to 4.9 months (hazard ratio 0.33, P < 0.001) and 25% were still progression-free after 10 months of everolimus therapy"}
{"PMID":20531964,"re_id":2,"annotated sentence":"<e1>Everolimus<\\e1> (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of <e2>mTOR<\\e2> (mammalian target of rapamycin) to reach the oncology clinic","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Everolimus","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of <e2>GENE-Y<\\e2> (mammalian target of rapamycin) to reach the oncology clinic","sentence":"Everolimus (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (mammalian target of rapamycin) to reach the oncology clinic"}
{"PMID":20531964,"re_id":3,"annotated sentence":"<e1>Everolimus<\\e1> (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (<e2>mammalian target of rapamycin<\\e2>  to reach the oncology clinic","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Everolimus","object":"mammalian target of rapamycin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (<e2>GENE-Y<\\e2>  to reach the oncology clinic","sentence":"Everolimus (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (mammalian target of rapamycin  to reach the oncology clinic"}
{"PMID":20531964,"re_id":4,"annotated sentence":"Everolimus (<e1>RAD001<\\e1>  Afinitor((R)) Novartis) is the first oral inhibitor of <e2>mTOR<\\e2> (mammalian target of rapamycin) to reach the oncology clinic","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RAD001","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Everolimus (<e1>CHEMICAL<\\e1>  Afinitor((R)) Novartis) is the first oral inhibitor of <e2>GENE-Y<\\e2> (mammalian target of rapamycin) to reach the oncology clinic","sentence":"Everolimus (RAD001  Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (mammalian target of rapamycin) to reach the oncology clinic"}
{"PMID":20531964,"re_id":5,"annotated sentence":"Everolimus (<e1>RAD001<\\e1>  Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (<e2>mammalian target of rapamycin<\\e2>  to reach the oncology clinic","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"RAD001","object":"mammalian target of rapamycin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Everolimus (<e1>CHEMICAL<\\e1>  Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (<e2>GENE-Y<\\e2>  to reach the oncology clinic","sentence":"Everolimus (RAD001  Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (mammalian target of rapamycin  to reach the oncology clinic"}
{"PMID":20531964,"re_id":6,"annotated sentence":"Everolimus (RAD001, <e1>Afinitor((R)) Novartis<\\e1>  is the first oral inhibitor of <e2>mTOR<\\e2> (mammalian target of rapamycin) to reach the oncology clinic","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Afinitor((R)) Novartis","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Everolimus (RAD001, <e1>CHEMICAL<\\e1>  is the first oral inhibitor of <e2>GENE-Y<\\e2> (mammalian target of rapamycin) to reach the oncology clinic","sentence":"Everolimus (RAD001, Afinitor((R)) Novartis  is the first oral inhibitor of mTOR (mammalian target of rapamycin) to reach the oncology clinic"}
{"PMID":20531964,"re_id":7,"annotated sentence":"Everolimus (RAD001, <e1>Afinitor((R)) Novartis<\\e1>  is the first oral inhibitor of mTOR (<e2>mammalian target of rapamycin<\\e2>  to reach the oncology clinic","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Afinitor((R)) Novartis","object":"mammalian target of rapamycin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Everolimus (RAD001, <e1>CHEMICAL<\\e1>  is the first oral inhibitor of mTOR (<e2>GENE-Y<\\e2>  to reach the oncology clinic","sentence":"Everolimus (RAD001, Afinitor((R)) Novartis  is the first oral inhibitor of mTOR (mammalian target of rapamycin  to reach the oncology clinic"}
{"PMID":20531964,"re_id":8,"annotated sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the <e2>VEGFR<\\e2> tyrosine kinase inhibitors <e1>sunitinib<\\e1> and\/or sorafenib","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sunitinib","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the <e2>GENE-N<\\e2> tyrosine kinase inhibitors <e1>CHEMICAL<\\e1> and\/or sorafenib","sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR tyrosine kinase inhibitors sunitinib and\/or sorafenib"}
{"PMID":20531964,"re_id":9,"annotated sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR <e2>tyrosine kinase<\\e2> inhibitors <e1>sunitinib<\\e1> and\/or sorafenib","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sunitinib","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR <e2>GENE-N<\\e2> inhibitors <e1>CHEMICAL<\\e1> and\/or sorafenib","sentence":"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR tyrosine kinase inhibitors sunitinib and\/or sorafenib"}
{"PMID":20573261,"re_id":0,"annotated sentence":"After inflammation was established mice were dosed with the <e2>H4R<\\e2> antagonist, <e1>JNJ 7777120<\\e1>  or anti-IL-13 antibody for comparison","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"JNJ 7777120","object":"H4R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After inflammation was established mice were dosed with the <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1>  or anti-IL-13 antibody for comparison","sentence":"After inflammation was established mice were dosed with the H4R antagonist, JNJ 7777120  or anti-IL-13 antibody for comparison"}
{"PMID":20596674,"re_id":0,"annotated sentence":"Apoptosis studies (DAPI staining and <e2>caspase 3<\\e2> activity) showed a marked increase in the presence of <e1>MXF<\\e1> and VP-16 compared to VP-16 alone","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MXF","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Apoptosis studies (DAPI staining and <e2>GENE-Y<\\e2> activity) showed a marked increase in the presence of <e1>CHEMICAL<\\e1> and VP-16 compared to VP-16 alone","sentence":"Apoptosis studies (DAPI staining and caspase 3 activity) showed a marked increase in the presence of MXF and VP-16 compared to VP-16 alone"}
{"PMID":20596674,"re_id":1,"annotated sentence":"Apoptosis studies (DAPI staining and <e2>caspase 3<\\e2> activity) showed a marked increase in the presence of MXF and <e1>VP-16<\\e1> compared to VP-16 alone","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"VP-16","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Apoptosis studies (DAPI staining and <e2>GENE-Y<\\e2> activity) showed a marked increase in the presence of MXF and <e1>CHEMICAL<\\e1> compared to CHEMICAL alone","sentence":"Apoptosis studies (DAPI staining and caspase 3 activity) showed a marked increase in the presence of MXF and VP-16 compared to VP-16 alone"}
{"PMID":20596674,"re_id":2,"annotated sentence":"Apoptosis studies (DAPI staining and <e2>caspase 3<\\e2> activity) showed a marked increase in the presence of MXF and VP-16 compared to <e1>VP-16<\\e1> alone","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"VP-16","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Apoptosis studies (DAPI staining and <e2>GENE-Y<\\e2> activity) showed a marked increase in the presence of MXF and CHEMICAL compared to <e1>CHEMICAL<\\e1> alone","sentence":"Apoptosis studies (DAPI staining and caspase 3 activity) showed a marked increase in the presence of MXF and VP-16 compared to VP-16 alone"}
{"PMID":20596674,"re_id":3,"annotated sentence":"In conclusion, the results suggest that the enhancement in the reduction of <e2>topo II<\\e2> activity by the combined <e1>MXF<\\e1> VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MXF","object":"topo II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, the results suggest that the enhancement in the reduction of <e2>GENE-Y<\\e2> activity by the combined <e1>CHEMICAL<\\e1> VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs","sentence":"In conclusion, the results suggest that the enhancement in the reduction of topo II activity by the combined MXF VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs"}
{"PMID":20596674,"re_id":4,"annotated sentence":"In conclusion, the results suggest that the enhancement in the reduction of <e2>topo II<\\e2> activity by the combined MXF\/<e1>VP-16<\\e1> treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VP-16","object":"topo II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, the results suggest that the enhancement in the reduction of <e2>GENE-Y<\\e2> activity by the combined MXF\/<e1>CHEMICAL<\\e1> treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs","sentence":"In conclusion, the results suggest that the enhancement in the reduction of topo II activity by the combined MXF\/VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs"}
{"PMID":20596674,"re_id":5,"annotated sentence":"<e1>Etoposide<\\e1> (VP-16) is a <e2>topoisomerase-II<\\e2> (topo II) inhibitor chemotherapeutic agent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Etoposide","object":"topoisomerase-II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (VP-16) is a <e2>GENE-Y<\\e2> (topo II) inhibitor chemotherapeutic agent","sentence":"Etoposide (VP-16) is a topoisomerase-II (topo II) inhibitor chemotherapeutic agent"}
{"PMID":20596674,"re_id":6,"annotated sentence":"<e1>Etoposide<\\e1> (VP-16) is a topoisomerase-II (<e2>topo II<\\e2>  inhibitor chemotherapeutic agent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Etoposide","object":"topo II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (VP-16) is a topoisomerase-II (<e2>GENE-Y<\\e2>  inhibitor chemotherapeutic agent","sentence":"Etoposide (VP-16) is a topoisomerase-II (topo II  inhibitor chemotherapeutic agent"}
{"PMID":20596674,"re_id":7,"annotated sentence":"<e1>MXF<\\e1> or VP-16 slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of <e2>topo II<\\e2>  VP-16 induced cell cycle arrest at G2\/M and the appearance of the subG1 peak which was increased by the addition of MXF","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MXF","object":"topo II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> or VP-16 slightly affected cellular GENE-Y activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of <e2>GENE-Y<\\e2>  VP-16 induced cell cycle arrest at G2\/M and the appearance of the subG1 peak which was increased by the addition of CHEMICAL","sentence":"MXF or VP-16 slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of topo II  VP-16 induced cell cycle arrest at G2\/M and the appearance of the subG1 peak which was increased by the addition of MXF"}
{"PMID":20596674,"re_id":8,"annotated sentence":"MXF or <e1>VP-16<\\e1> slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of <e2>topo II<\\e2>  VP-16 induced cell cycle arrest at G2\/M and the appearance of the subG1 peak which was increased by the addition of MXF","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VP-16","object":"topo II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"MXF or <e1>CHEMICAL<\\e1> slightly affected cellular GENE-Y activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of <e2>GENE-Y<\\e2>  CHEMICAL induced cell cycle arrest at G2\/M and the appearance of the subG1 peak which was increased by the addition of MXF","sentence":"MXF or VP-16 slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of topo II  VP-16 induced cell cycle arrest at G2\/M and the appearance of the subG1 peak which was increased by the addition of MXF"}
{"PMID":20596674,"re_id":9,"annotated sentence":"Etoposide (<e1>VP-16<\\e1>  is a <e2>topoisomerase-II<\\e2> (topo II) inhibitor chemotherapeutic agent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VP-16","object":"topoisomerase-II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Etoposide (<e1>CHEMICAL<\\e1>  is a <e2>GENE-Y<\\e2> (topo II) inhibitor chemotherapeutic agent","sentence":"Etoposide (VP-16  is a topoisomerase-II (topo II) inhibitor chemotherapeutic agent"}
{"PMID":20596674,"re_id":10,"annotated sentence":"Etoposide (<e1>VP-16<\\e1>  is a topoisomerase-II (<e2>topo II<\\e2>  inhibitor chemotherapeutic agent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VP-16","object":"topo II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Etoposide (<e1>CHEMICAL<\\e1>  is a topoisomerase-II (<e2>GENE-Y<\\e2>  inhibitor chemotherapeutic agent","sentence":"Etoposide (VP-16  is a topoisomerase-II (topo II  inhibitor chemotherapeutic agent"}
{"PMID":20624440,"re_id":0,"annotated sentence":"<e1>Rasagiline<\\e1> is a propargylamine and irreversible <e2>monoamine oxidase (MAO) B<\\e2> inhibitor used for the treatment of Parkinson's disease (PD)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rasagiline","object":"monoamine oxidase (MAO) B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a propargylamine and irreversible <e2>GENE-Y<\\e2> inhibitor used for the treatment of Parkinson's disease (PD)","sentence":"Rasagiline is a propargylamine and irreversible monoamine oxidase (MAO) B inhibitor used for the treatment of Parkinson's disease (PD)"}
{"PMID":20624440,"re_id":1,"annotated sentence":"Rasagiline is a <e1>propargylamine<\\e1> and irreversible <e2>monoamine oxidase (MAO) B<\\e2> inhibitor used for the treatment of Parkinson's disease (PD)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"propargylamine","object":"monoamine oxidase (MAO) B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rasagiline is a <e1>CHEMICAL<\\e1> and irreversible <e2>GENE-Y<\\e2> inhibitor used for the treatment of Parkinson's disease (PD)","sentence":"Rasagiline is a propargylamine and irreversible monoamine oxidase (MAO) B inhibitor used for the treatment of Parkinson's disease (PD)"}
{"PMID":2083404,"re_id":0,"annotated sentence":"However, salicylate moiety appears to interfere with <e1>aspirin<\\e1> inhibitory action on platelets and vascular <e2>COX<\\e2>  Such interaction, if present at the level of respiratory tract, may be of interest to pathogenesis of ASA-induced asthma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aspirin","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, salicylate moiety appears to interfere with <e1>CHEMICAL<\\e1> inhibitory action on platelets and vascular <e2>GENE-N<\\e2>  Such interaction, if present at the level of respiratory tract, may be of interest to pathogenesis of ASA-induced asthma","sentence":"However, salicylate moiety appears to interfere with aspirin inhibitory action on platelets and vascular COX  Such interaction, if present at the level of respiratory tract, may be of interest to pathogenesis of ASA-induced asthma"}
{"PMID":2083404,"re_id":1,"annotated sentence":"<e1>Aspirin<\\e1> (ASA) and other non-steroidal anti-inflammatory drugs, which are <e2>cyclooxygenase<\\e2> (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aspirin","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (ASA) and other non-steroidal anti-inflammatory drugs, which are <e2>GENE-N<\\e2> (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients","sentence":"Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients"}
{"PMID":2083404,"re_id":2,"annotated sentence":"<e1>Aspirin<\\e1> (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (<e2>COX<\\e2>  inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Aspirin","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (<e2>GENE-N<\\e2>  inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on GENE-N by itself, is well tolerated by these patients","sentence":"Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX  inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients"}
{"PMID":2083404,"re_id":3,"annotated sentence":"Aspirin (<e1>ASA<\\e1>  and other non-steroidal anti-inflammatory drugs, which are <e2>cyclooxygenase<\\e2> (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ASA","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aspirin (<e1>CHEMICAL<\\e1>  and other non-steroidal anti-inflammatory drugs, which are <e2>GENE-N<\\e2> (COX) inhibitors, precipitate asthmatic attacks in CHEMICAL-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients","sentence":"Aspirin (ASA  and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients"}
{"PMID":2083404,"re_id":4,"annotated sentence":"Aspirin (<e1>ASA<\\e1>  and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (<e2>COX<\\e2>  inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ASA","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aspirin (<e1>CHEMICAL<\\e1>  and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (<e2>GENE-N<\\e2>  inhibitors, precipitate asthmatic attacks in CHEMICAL-intolerant patients, while sodium salicylate, hardly active on GENE-N by itself, is well tolerated by these patients","sentence":"Aspirin (ASA  and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX  inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients"}
{"PMID":2083404,"re_id":5,"annotated sentence":"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between <e1>salicylate<\\e1> and ASA on <e2>cyclo-oxygenase<\\e2> locus in the respiratory tract in ASA-intolerant patients.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"salicylate","object":"cyclo-oxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between <e1>CHEMICAL<\\e1> and ASA on <e2>GENE-N<\\e2> locus in the respiratory tract in ASA-intolerant patients.","sentence":"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and ASA on cyclo-oxygenase locus in the respiratory tract in ASA-intolerant patients."}
{"PMID":2083404,"re_id":6,"annotated sentence":"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and <e1>ASA<\\e1> on <e2>cyclo-oxygenase<\\e2> locus in the respiratory tract in ASA-intolerant patients.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ASA","object":"cyclo-oxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and <e1>CHEMICAL<\\e1> on <e2>GENE-N<\\e2> locus in the respiratory tract in CHEMICAL-intolerant patients.","sentence":"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and ASA on cyclo-oxygenase locus in the respiratory tract in ASA-intolerant patients."}
{"PMID":21262851,"re_id":0,"annotated sentence":"Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (<e2>I1150A<\\e2>  did not affect <e1>diazepam<\\e1> potency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"diazepam","object":"I1150A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (<e2>GENE-N<\\e2>  did not affect <e1>CHEMICAL<\\e1> potency","sentence":"Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (I1150A  did not affect diazepam potency"}
{"PMID":21262851,"re_id":1,"annotated sentence":"Although <e2>L-VGCC<\\e2> inhibition by <e1>BDZs<\\e1> occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, pentobarbital and ethanol inhibited L-VGCCs at clinically relevant concentrations.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BDZs","object":"L-VGCC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although <e2>GENE-N<\\e2> inhibition by <e1>CHEMICAL<\\e1> occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of GENE-Ns during long-term treatment, pentobarbital and ethanol inhibited GENE-Ns at clinically relevant concentrations.","sentence":"Although L-VGCC inhibition by BDZs occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, pentobarbital and ethanol inhibited L-VGCCs at clinically relevant concentrations."}
{"PMID":21262851,"re_id":2,"annotated sentence":"Although L-VGCC inhibition by BDZs occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, <e1>pentobarbital<\\e1> and ethanol inhibited <e2>L-VGCCs<\\e2> at clinically relevant concentrations.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pentobarbital","object":"L-VGCCs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although L-VGCC inhibition by BDZs occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of GENE-N during long-term treatment, <e1>CHEMICAL<\\e1> and ethanol inhibited <e2>GENE-N<\\e2> at clinically relevant concentrations.","sentence":"Although L-VGCC inhibition by BDZs occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, pentobarbital and ethanol inhibited L-VGCCs at clinically relevant concentrations."}
{"PMID":21262851,"re_id":3,"annotated sentence":"BDZs and other positive GABA(A)R modulators, including <e1>barbiturates<\\e1>  ethanol, and neurosteroids, can also inhibit <e2>L-type voltage-gated calcium channels<\\e2> (L-VGCCs), which could contribute to reduced neuronal excitability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"barbiturates","object":"L-type voltage-gated calcium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BDZs and other positive GABA(A)R modulators, including <e1>CHEMICAL<\\e1>  ethanol, and neurosteroids, can also inhibit <e2>GENE-N<\\e2> (L-VGCCs), which could contribute to reduced neuronal excitability","sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates  ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability"}
{"PMID":21262851,"re_id":4,"annotated sentence":"BDZs and other positive GABA(A)R modulators, including <e1>barbiturates<\\e1>  ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>L-VGCCs<\\e2> , which could contribute to reduced neuronal excitability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"barbiturates","object":"L-VGCCs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BDZs and other positive GABA(A)R modulators, including <e1>CHEMICAL<\\e1>  ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>GENE-N<\\e2> , which could contribute to reduced neuronal excitability","sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates  ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs , which could contribute to reduced neuronal excitability"}
{"PMID":21262851,"re_id":5,"annotated sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, <e1>ethanol<\\e1>  and neurosteroids, can also inhibit <e2>L-type voltage-gated calcium channels<\\e2> (L-VGCCs), which could contribute to reduced neuronal excitability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"L-type voltage-gated calcium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, <e1>CHEMICAL<\\e1>  and neurosteroids, can also inhibit <e2>GENE-N<\\e2> (L-VGCCs), which could contribute to reduced neuronal excitability","sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol  and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability"}
{"PMID":21262851,"re_id":6,"annotated sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, <e1>ethanol<\\e1>  and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>L-VGCCs<\\e2> , which could contribute to reduced neuronal excitability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"L-VGCCs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, <e1>CHEMICAL<\\e1>  and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>GENE-N<\\e2> , which could contribute to reduced neuronal excitability","sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol  and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs , which could contribute to reduced neuronal excitability"}
{"PMID":21262851,"re_id":7,"annotated sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and <e1>neurosteroids<\\e1>  can also inhibit <e2>L-type voltage-gated calcium channels<\\e2> (L-VGCCs), which could contribute to reduced neuronal excitability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neurosteroids","object":"L-type voltage-gated calcium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and <e1>CHEMICAL<\\e1>  can also inhibit <e2>GENE-N<\\e2> (L-VGCCs), which could contribute to reduced neuronal excitability","sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids  can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability"}
{"PMID":21262851,"re_id":8,"annotated sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and <e1>neurosteroids<\\e1>  can also inhibit L-type voltage-gated calcium channels (<e2>L-VGCCs<\\e2> , which could contribute to reduced neuronal excitability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neurosteroids","object":"L-VGCCs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and <e1>CHEMICAL<\\e1>  can also inhibit L-type voltage-gated calcium channels (<e2>GENE-N<\\e2> , which could contribute to reduced neuronal excitability","sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids  can also inhibit L-type voltage-gated calcium channels (L-VGCCs , which could contribute to reduced neuronal excitability"}
{"PMID":21262851,"re_id":9,"annotated sentence":"<e2>Ca(v)1.3<\\e2> channels were less sensitive to <e1>pentobarbital<\\e1> inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pentobarbital","object":"Ca(v)1.3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> channels were less sensitive to <e1>CHEMICAL<\\e1> inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists","sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists"}
{"PMID":21262851,"re_id":10,"annotated sentence":"Ca(v)1.3 channels were less sensitive to <e1>pentobarbital<\\e1> inhibition than <e2>Ca(v)1.2<\\e2> channels, similar to dihydropyridine (DHP) L-VGCC antagonists","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pentobarbital","object":"Ca(v)1.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ca(v)1.3 channels were less sensitive to <e1>CHEMICAL<\\e1> inhibition than <e2>GENE-Y<\\e2> channels, similar to dihydropyridine (DHP) L-VGCC antagonists","sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists"}
{"PMID":21262851,"re_id":11,"annotated sentence":"<e2>Ca(v)1.3<\\e2> channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to <e1>dihydropyridine<\\e1> (DHP) L-VGCC antagonists","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydropyridine","object":"Ca(v)1.3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to <e1>CHEMICAL<\\e1> (DHP) L-VGCC antagonists","sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists"}
{"PMID":21262851,"re_id":12,"annotated sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than <e2>Ca(v)1.2<\\e2> channels, similar to <e1>dihydropyridine<\\e1> (DHP) L-VGCC antagonists","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydropyridine","object":"Ca(v)1.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than <e2>GENE-Y<\\e2> channels, similar to <e1>CHEMICAL<\\e1> (DHP) L-VGCC antagonists","sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists"}
{"PMID":21262851,"re_id":13,"annotated sentence":"<e2>Ca(v)1.3<\\e2> channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (<e1>DHP<\\e1>  L-VGCC antagonists","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DHP","object":"Ca(v)1.3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (<e1>CHEMICAL<\\e1>  L-VGCC antagonists","sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP  L-VGCC antagonists"}
{"PMID":21262851,"re_id":14,"annotated sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than <e2>Ca(v)1.2<\\e2> channels, similar to dihydropyridine (<e1>DHP<\\e1>  L-VGCC antagonists","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DHP","object":"Ca(v)1.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than <e2>GENE-Y<\\e2> channels, similar to dihydropyridine (<e1>CHEMICAL<\\e1>  L-VGCC antagonists","sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP  L-VGCC antagonists"}
{"PMID":21262851,"re_id":15,"annotated sentence":"All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only <e1>BDZs<\\e1> and pentobarbital induced a negative shift in <e2>Ca(v)1.2<\\e2> channel inactivation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BDZs","object":"Ca(v)1.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only <e1>CHEMICAL<\\e1> and pentobarbital induced a negative shift in <e2>GENE-Y<\\e2> channel inactivation","sentence":"All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and pentobarbital induced a negative shift in Ca(v)1.2 channel inactivation"}
{"PMID":21262851,"re_id":16,"annotated sentence":"All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and <e1>pentobarbital<\\e1> induced a negative shift in <e2>Ca(v)1.2<\\e2> channel inactivation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pentobarbital","object":"Ca(v)1.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and <e1>CHEMICAL<\\e1> induced a negative shift in <e2>GENE-Y<\\e2> channel inactivation","sentence":"All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and pentobarbital induced a negative shift in Ca(v)1.2 channel inactivation"}
{"PMID":21262851,"re_id":17,"annotated sentence":"<e1>BDZs<\\e1> and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit <e2>L-type voltage-gated calcium channels<\\e2> (L-VGCCs), which could contribute to reduced neuronal excitability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BDZs","object":"L-type voltage-gated calcium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit <e2>GENE-N<\\e2> (L-VGCCs), which could contribute to reduced neuronal excitability","sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability"}
{"PMID":21262851,"re_id":18,"annotated sentence":"<e1>BDZs<\\e1> and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>L-VGCCs<\\e2> , which could contribute to reduced neuronal excitability","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BDZs","object":"L-VGCCs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>GENE-N<\\e2> , which could contribute to reduced neuronal excitability","sentence":"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs , which could contribute to reduced neuronal excitability"}
{"PMID":21262851,"re_id":19,"annotated sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to <e1>dihydropyridine<\\e1> (DHP) <e2>L-VGCC<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"dihydropyridine","object":"L-VGCC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to <e1>CHEMICAL<\\e1> (DHP) <e2>GENE-N<\\e2> antagonists","sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists"}
{"PMID":21262851,"re_id":20,"annotated sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (<e1>DHP<\\e1>  <e2>L-VGCC<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"DHP","object":"L-VGCC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (<e1>CHEMICAL<\\e1>  <e2>GENE-N<\\e2> antagonists","sentence":"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP  L-VGCC antagonists"}
{"PMID":21475861,"re_id":0,"annotated sentence":"In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of <e1>aspirin<\\e1> to acetylate the <e2>tumor suppressor protein p53<\\e2>  In this review, we present current research from the literature on the aspirin-induced acetylation of proteins","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"aspirin","object":"tumor suppressor protein p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of <e1>CHEMICAL<\\e1> to acetylate the <e2>GENE-Y<\\e2>  In this review, we present current research from the literature on the CHEMICAL-induced acetylation of proteins","sentence":"In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of aspirin to acetylate the tumor suppressor protein p53  In this review, we present current research from the literature on the aspirin-induced acetylation of proteins"}
{"PMID":21475861,"re_id":1,"annotated sentence":"Although the inhibition of <e2>cyclooxygenases<\\e2> by <e1>aspirin<\\e1>  which leads to its anti-inflammatory\/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aspirin","object":"cyclooxygenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although the inhibition of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1>  which leads to its anti-inflammatory\/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined","sentence":"Although the inhibition of cyclooxygenases by aspirin  which leads to its anti-inflammatory\/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined"}
{"PMID":21631396,"re_id":0,"annotated sentence":"In addition, PSE inhibited the transcriptional activity of NFAT without interfering with the <e1>calcium<\\e1> induced <e2>NFAT<\\e2> dephosphorylation event, which represents the major signaling pathway for its activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"calcium","object":"NFAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, PSE inhibited the transcriptional activity of GENE-N without interfering with the <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> dephosphorylation event, which represents the major signaling pathway for its activation","sentence":"In addition, PSE inhibited the transcriptional activity of NFAT without interfering with the calcium induced NFAT dephosphorylation event, which represents the major signaling pathway for its activation"}
{"PMID":21631396,"re_id":1,"annotated sentence":"We found that <e1>PSE<\\e1> inhibits interleukin-2 (IL-2) and <e2>tumor necrosis factor (TNF) alpha<\\e2> gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PSE","object":"tumor necrosis factor (TNF) alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> inhibits interleukin-2 (IL-2) and <e2>GENE-Y<\\e2> gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line","sentence":"We found that PSE inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line"}
{"PMID":21631396,"re_id":2,"annotated sentence":"To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that <e1>PSE<\\e1> inhibited <e2>NF-kappaB<\\e2> dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PSE","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To further characterize the inhibitory mechanisms of CHEMICAL at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (GENE-N), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that <e1>CHEMICAL<\\e1> inhibited <e2>GENE-N<\\e2> dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic GENE-N inhibitory protein, IkappaBalpha or the DNA-binding activity","sentence":"To further characterize the inhibitory mechanisms of PSE at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity"}
{"PMID":21631396,"re_id":3,"annotated sentence":"<e1>Pseudoephedrine<\\e1> inhibits T-cell activation by targeting <e2>NF-kappaB<\\e2>  NFAT and AP-1 signaling pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pseudoephedrine","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits T-cell activation by targeting <e2>GENE-N<\\e2>  NFAT and AP-1 signaling pathways","sentence":"Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB  NFAT and AP-1 signaling pathways"}
{"PMID":21631396,"re_id":4,"annotated sentence":"<e1>Pseudoephedrine<\\e1> inhibits T-cell activation by targeting NF-kappaB, <e2>NFAT<\\e2> and AP-1 signaling pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pseudoephedrine","object":"NFAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits T-cell activation by targeting NF-kappaB, <e2>GENE-N<\\e2> and AP-1 signaling pathways","sentence":"Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways"}
{"PMID":21631396,"re_id":5,"annotated sentence":"<e1>Pseudoephedrine<\\e1> inhibits T-cell activation by targeting NF-kappaB, NFAT and <e2>AP-1<\\e2> signaling pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pseudoephedrine","object":"AP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits T-cell activation by targeting NF-kappaB, NFAT and <e2>GENE-Y<\\e2> signaling pathways","sentence":"Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways"}
{"PMID":21631396,"re_id":6,"annotated sentence":"However, phosphorylation of the <e2>p65<\\e2> RelA subunit was clearly inhibited by <e1>PSE<\\e1> in stimulated cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PSE","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, phosphorylation of the <e2>GENE-Y<\\e2> RelA subunit was clearly inhibited by <e1>CHEMICAL<\\e1> in stimulated cells","sentence":"However, phosphorylation of the p65 RelA subunit was clearly inhibited by PSE in stimulated cells"}
{"PMID":21631396,"re_id":7,"annotated sentence":"However, phosphorylation of the p65\/<e2>RelA<\\e2> subunit was clearly inhibited by <e1>PSE<\\e1> in stimulated cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PSE","object":"RelA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, phosphorylation of the p65\/<e2>GENE-Y<\\e2> subunit was clearly inhibited by <e1>CHEMICAL<\\e1> in stimulated cells","sentence":"However, phosphorylation of the p65\/RelA subunit was clearly inhibited by PSE in stimulated cells"}
{"PMID":21631396,"re_id":8,"annotated sentence":"In addition, <e1>PSE<\\e1> inhibited the transcriptional activity of <e2>NFAT<\\e2> without interfering with the calcium-induced NFAT dephosphorylation event, which represents the major signaling pathway for its activation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PSE","object":"NFAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> inhibited the transcriptional activity of <e2>GENE-N<\\e2> without interfering with the calcium-induced GENE-N dephosphorylation event, which represents the major signaling pathway for its activation","sentence":"In addition, PSE inhibited the transcriptional activity of NFAT without interfering with the calcium-induced NFAT dephosphorylation event, which represents the major signaling pathway for its activation"}
{"PMID":21631396,"re_id":9,"annotated sentence":"NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that <e1>PSE<\\e1> inhibited both <e2>JNK<\\e2> activation and AP-1 transcriptional activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PSE","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that <e1>CHEMICAL<\\e1> inhibited both <e2>GENE-N<\\e2> activation and AP-1 transcriptional activity","sentence":"NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that PSE inhibited both JNK activation and AP-1 transcriptional activity"}
{"PMID":21631396,"re_id":10,"annotated sentence":"NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that <e1>PSE<\\e1> inhibited both JNK activation and <e2>AP-1<\\e2> transcriptional activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PSE","object":"AP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"NFAT cooperates with c-Jun, a compound of the GENE-Y complex, to activate target genes, and we also found that <e1>CHEMICAL<\\e1> inhibited both JNK activation and <e2>GENE-Y<\\e2> transcriptional activity","sentence":"NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that PSE inhibited both JNK activation and AP-1 transcriptional activity"}
{"PMID":21631396,"re_id":11,"annotated sentence":"We found that <e1>PSE<\\e1> inhibits <e2>interleukin-2<\\e2> (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PSE","object":"interleukin-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line","sentence":"We found that PSE inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line"}
{"PMID":21631396,"re_id":12,"annotated sentence":"We found that <e1>PSE<\\e1> inhibits interleukin-2 (<e2>IL-2<\\e2>  and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PSE","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> inhibits interleukin-2 (<e2>GENE-Y<\\e2>  and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line","sentence":"We found that PSE inhibits interleukin-2 (IL-2  and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line"}
{"PMID":21712771,"re_id":0,"annotated sentence":"Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the <e2>VMAT<\\e2> inhibitor <e1>reserpine<\\e1> and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"reserpine","object":"VMAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> and a proton ionophore, but not by tetrabenazine, which has a high affinity for GENE-N-2","sentence":"Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the VMAT inhibitor reserpine and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2"}
{"PMID":21838705,"re_id":0,"annotated sentence":"Because clinical studies investigating interactions between garlic and <e2>human immunodeficiency virus protease<\\e2> inhibitors <e1>saquinavir<\\e1> and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"saquinavir","object":"human immunodeficiency virus protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Because clinical studies investigating interactions between garlic and <e2>GENE-N<\\e2> inhibitors <e1>CHEMICAL<\\e1> and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes","sentence":"Because clinical studies investigating interactions between garlic and human immunodeficiency virus protease inhibitors saquinavir and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes"}
{"PMID":21838705,"re_id":1,"annotated sentence":"Because clinical studies investigating interactions between garlic and <e2>human immunodeficiency virus protease<\\e2> inhibitors saquinavir and <e1>ritonavir<\\e1> have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ritonavir","object":"human immunodeficiency virus protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Because clinical studies investigating interactions between garlic and <e2>GENE-N<\\e2> inhibitors saquinavir and <e1>CHEMICAL<\\e1> have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes","sentence":"Because clinical studies investigating interactions between garlic and human immunodeficiency virus protease inhibitors saquinavir and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes"}
{"PMID":2226440,"re_id":0,"annotated sentence":"Catecholamines (<e1>adrenaline<\\e1>  noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (<e2>phenylalanine hydroxylase<\\e2>  EC 1.14.16.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"adrenaline","object":"phenylalanine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Catecholamines (<e1>CHEMICAL<\\e1>  norCHEMICAL and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (<e2>GENE-Y<\\e2>  EC 1.14.16.1)","sentence":"Catecholamines (adrenaline  noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase  EC 1.14.16.1)"}
{"PMID":2226440,"re_id":1,"annotated sentence":"Catecholamines (<e1>adrenaline<\\e1>  noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>EC 1.14.16.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"adrenaline","object":"EC 1.14.16.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Catecholamines (<e1>CHEMICAL<\\e1>  norCHEMICAL and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>GENE-Y<\\e2> ","sentence":"Catecholamines (adrenaline  noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1 "}
{"PMID":2226440,"re_id":2,"annotated sentence":"Catecholamines (<e1>adrenaline<\\e1>  noradrenaline and dopamine) are potent inhibitors of <e2>phenylalanine 4-monooxygenase<\\e2> (phenylalanine hydroxylase, EC 1.14.16.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"adrenaline","object":"phenylalanine 4-monooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Catecholamines (<e1>CHEMICAL<\\e1>  norCHEMICAL and dopamine) are potent inhibitors of <e2>GENE-Y<\\e2> (phenylalanine hydroxylase, EC 1.14.16.1)","sentence":"Catecholamines (adrenaline  noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1)"}
{"PMID":2226440,"re_id":3,"annotated sentence":"Catecholamines (adrenaline, <e1>noradrenaline<\\e1> and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (<e2>phenylalanine hydroxylase<\\e2>  EC 1.14.16.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"noradrenaline","object":"phenylalanine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Catecholamines (adrenaline, <e1>CHEMICAL<\\e1> and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (<e2>GENE-Y<\\e2>  EC 1.14.16.1)","sentence":"Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase  EC 1.14.16.1)"}
{"PMID":2226440,"re_id":4,"annotated sentence":"Catecholamines (adrenaline, <e1>noradrenaline<\\e1> and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>EC 1.14.16.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"noradrenaline","object":"EC 1.14.16.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Catecholamines (adrenaline, <e1>CHEMICAL<\\e1> and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>GENE-Y<\\e2> ","sentence":"Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1 "}
{"PMID":2226440,"re_id":5,"annotated sentence":"Catecholamines (adrenaline, <e1>noradrenaline<\\e1> and dopamine) are potent inhibitors of <e2>phenylalanine 4-monooxygenase<\\e2> (phenylalanine hydroxylase, EC 1.14.16.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"noradrenaline","object":"phenylalanine 4-monooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Catecholamines (adrenaline, <e1>CHEMICAL<\\e1> and dopamine) are potent inhibitors of <e2>GENE-Y<\\e2> (phenylalanine hydroxylase, EC 1.14.16.1)","sentence":"Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1)"}
{"PMID":2226440,"re_id":6,"annotated sentence":"Catecholamines (adrenaline, noradrenaline and <e1>dopamine<\\e1>  are potent inhibitors of phenylalanine 4-monooxygenase (<e2>phenylalanine hydroxylase<\\e2>  EC 1.14.16.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dopamine","object":"phenylalanine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Catecholamines (adrenaline, noradrenaline and <e1>CHEMICAL<\\e1>  are potent inhibitors of phenylalanine 4-monooxygenase (<e2>GENE-Y<\\e2>  EC 1.14.16.1)","sentence":"Catecholamines (adrenaline, noradrenaline and dopamine  are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase  EC 1.14.16.1)"}
{"PMID":2226440,"re_id":7,"annotated sentence":"Catecholamines (adrenaline, noradrenaline and <e1>dopamine<\\e1>  are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>EC 1.14.16.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dopamine","object":"EC 1.14.16.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Catecholamines (adrenaline, noradrenaline and <e1>CHEMICAL<\\e1>  are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>GENE-Y<\\e2> ","sentence":"Catecholamines (adrenaline, noradrenaline and dopamine  are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1 "}
{"PMID":2226440,"re_id":8,"annotated sentence":"Catecholamines (adrenaline, noradrenaline and <e1>dopamine<\\e1>  are potent inhibitors of <e2>phenylalanine 4-monooxygenase<\\e2> (phenylalanine hydroxylase, EC 1.14.16.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dopamine","object":"phenylalanine 4-monooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Catecholamines (adrenaline, noradrenaline and <e1>CHEMICAL<\\e1>  are potent inhibitors of <e2>GENE-Y<\\e2> (phenylalanine hydroxylase, EC 1.14.16.1)","sentence":"Catecholamines (adrenaline, noradrenaline and dopamine  are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1)"}
{"PMID":2226440,"re_id":9,"annotated sentence":"<e1>Catecholamines<\\e1> (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (<e2>phenylalanine hydroxylase<\\e2>  EC 1.14.16.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catecholamines","object":"phenylalanine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (<e2>GENE-Y<\\e2>  EC 1.14.16.1)","sentence":"Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase  EC 1.14.16.1)"}
{"PMID":2226440,"re_id":10,"annotated sentence":"<e1>Catecholamines<\\e1> (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>EC 1.14.16.1<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catecholamines","object":"EC 1.14.16.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>GENE-Y<\\e2> ","sentence":"Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1 "}
{"PMID":2226440,"re_id":11,"annotated sentence":"<e1>Catecholamines<\\e1> (adrenaline, noradrenaline and dopamine) are potent inhibitors of <e2>phenylalanine 4-monooxygenase<\\e2> (phenylalanine hydroxylase, EC 1.14.16.1)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catecholamines","object":"phenylalanine 4-monooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (adrenaline, noradrenaline and dopamine) are potent inhibitors of <e2>GENE-Y<\\e2> (phenylalanine hydroxylase, EC 1.14.16.1)","sentence":"Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1)"}
{"PMID":22301814,"re_id":0,"annotated sentence":"The treatment with <e1>arsenic<\\e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (<e2>alanine aminotransferase<\\e2>  aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arsenic","object":"alanine aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The treatment with <e1>CHEMICAL<\\e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (<e2>GENE-N<\\e2>  aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)","sentence":"The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase  aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)"}
{"PMID":22301814,"re_id":1,"annotated sentence":"The treatment with <e1>arsenic<\\e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, <e2>aspartate aminotransferase<\\e2>  alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arsenic","object":"aspartate aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The treatment with <e1>CHEMICAL<\\e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, <e2>GENE-N<\\e2>  alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)","sentence":"The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase  alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)"}
{"PMID":22301814,"re_id":2,"annotated sentence":"The treatment with <e1>arsenic<\\e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, <e2>alkaline phosphatase<\\e2>  total protein, albumin, bilirubin, cholesterol, urea and creatinine)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arsenic","object":"alkaline phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The treatment with <e1>CHEMICAL<\\e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, <e2>GENE-N<\\e2>  total protein, albumin, bilirubin, cholesterol, urea and creatinine)","sentence":"The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase  total protein, albumin, bilirubin, cholesterol, urea and creatinine)"}
{"PMID":22301814,"re_id":3,"annotated sentence":"The treatment with <e1>arsenic<\\e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, <e2>albumin<\\e2>  bilirubin, cholesterol, urea and creatinine)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"arsenic","object":"albumin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The treatment with <e1>CHEMICAL<\\e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, <e2>GENE-Y<\\e2>  bilirubin, cholesterol, urea and creatinine)","sentence":"The treatment with arsenic exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin  bilirubin, cholesterol, urea and creatinine)"}
{"PMID":22349823,"re_id":0,"annotated sentence":"They display sensitivity to <e2>TK<\\e2> inhibitors, including <e1>gefitinib<\\e1> and erlotinib","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gefitinib","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"They display sensitivity to <e2>GENE-N<\\e2> inhibitors, including <e1>CHEMICAL<\\e1> and erlotinib","sentence":"They display sensitivity to TK inhibitors, including gefitinib and erlotinib"}
{"PMID":22349823,"re_id":1,"annotated sentence":"They display sensitivity to <e2>TK<\\e2> inhibitors, including gefitinib and <e1>erlotinib<\\e1>  In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"erlotinib","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"They display sensitivity to <e2>GENE-N<\\e2> inhibitors, including gefitinib and <e1>CHEMICAL<\\e1>  In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants","sentence":"They display sensitivity to TK inhibitors, including gefitinib and erlotinib  In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants"}
{"PMID":22370641,"re_id":0,"annotated sentence":"<e1>Epi<\\e1> increased the activity of the <e2>human WNT6 promoter<\\e2> through Cav1-dependent binding of \u03b2-catenin to the proximal WNT6 promoter","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Epi","object":"human WNT6 promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increased the activity of the <e2>GENE-N<\\e2> through Cav1-dependent binding of \u03b2-catenin to the proximal WNT6 promoter","sentence":"Epi increased the activity of the human WNT6 promoter through Cav1-dependent binding of \u03b2-catenin to the proximal WNT6 promoter"}
{"PMID":22370641,"re_id":1,"annotated sentence":"<e1>Epi<\\e1> increased the activity of the human WNT6 promoter through Cav1-dependent binding of \u03b2-catenin to the proximal <e2>WNT6 promoter<\\e2>  Epi increased both WNT6\/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Epi","object":"WNT6 promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increased the activity of the human GENE-N through Cav1-dependent binding of \u03b2-catenin to the proximal <e2>GENE-N<\\e2>  CHEMICAL increased both WNT6\/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)","sentence":"Epi increased the activity of the human WNT6 promoter through Cav1-dependent binding of \u03b2-catenin to the proximal WNT6 promoter  Epi increased both WNT6\/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)"}
{"PMID":22370641,"re_id":2,"annotated sentence":"<e1>Epi<\\e1> increased both <e2>WNT6<\\e2> Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Epi","object":"WNT6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased both <e2>GENE-Y<\\e2> Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)","sentence":"Epi increased both WNT6 Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)"}
{"PMID":22370641,"re_id":3,"annotated sentence":"<e1>Epi<\\e1> increased both WNT6\/<e2>Wnt6<\\e2> and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Epi","object":"Wnt6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased both WNT6\/<e2>GENE-Y<\\e2> and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)","sentence":"Epi increased both WNT6\/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)"}
{"PMID":22370641,"re_id":4,"annotated sentence":"<e1>Epi<\\e1> increased both WNT6\/Wnt6 and <e2>Cav1<\\e2> expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Epi","object":"Cav1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased both WNT6\/Wnt6 and <e2>GENE-Y<\\e2> expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)","sentence":"Epi increased both WNT6\/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)"}
{"PMID":22370641,"re_id":5,"annotated sentence":"These results showed that <e2>WNT6<\\e2> and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to <e1>anthracycline<\\e1> drugs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anthracycline","object":"WNT6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results showed that <e2>GENE-Y<\\e2> and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to <e1>CHEMICAL<\\e1> drugs","sentence":"These results showed that WNT6 and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to anthracycline drugs"}
{"PMID":22370641,"re_id":6,"annotated sentence":"These results showed that WNT6 and <e2>Cav1<\\e2> are upregulated by chemotherapeutics and enhance the resistance of GC cells to <e1>anthracycline<\\e1> drugs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anthracycline","object":"Cav1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results showed that WNT6 and <e2>GENE-Y<\\e2> are upregulated by chemotherapeutics and enhance the resistance of GC cells to <e1>CHEMICAL<\\e1> drugs","sentence":"These results showed that WNT6 and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to anthracycline drugs"}
{"PMID":22445601,"re_id":0,"annotated sentence":"Differentiating the roles of mGlu2 and mGlu3 receptors using <e1>LY541850<\\e1>  an <e2>mGlu2<\\e2> agonist\/mGlu3 antagonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"LY541850","object":"mGlu2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Differentiating the roles of GENE-Y and mGlu3 receptors using <e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> agonist\/mGlu3 antagonist","sentence":"Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850  an mGlu2 agonist\/mGlu3 antagonist"}
{"PMID":22445601,"re_id":1,"annotated sentence":"These results confirm the selective <e2>mGlu2<\\e2> agonist and mGlu3 antagonist actions of <e1>LY541850<\\e1>  A similar profile of activity was seen in medial perforant path synapse to the dentate gyrus","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"LY541850","object":"mGlu2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results confirm the selective <e2>GENE-Y<\\e2> agonist and mGlu3 antagonist actions of <e1>CHEMICAL<\\e1>  A similar profile of activity was seen in medial perforant path synapse to the dentate gyrus","sentence":"These results confirm the selective mGlu2 agonist and mGlu3 antagonist actions of LY541850  A similar profile of activity was seen in medial perforant path synapse to the dentate gyrus"}
{"PMID":22445601,"re_id":2,"annotated sentence":"<e1>LY541850<\\e1> was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric <e2>mGlu2<\\e2> agonist and mGlu3 antagonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"LY541850","object":"mGlu2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric <e2>GENE-Y<\\e2> agonist and mGlu3 antagonist","sentence":"LY541850 was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and mGlu3 antagonist"}
{"PMID":22445601,"re_id":3,"annotated sentence":"Differentiating the roles of mGlu2 and mGlu3 receptors using <e1>LY541850<\\e1>  an mGlu2 agonist\/<e2>mGlu3<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY541850","object":"mGlu3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Differentiating the roles of mGlu2 and GENE-Y receptors using <e1>CHEMICAL<\\e1>  an mGlu2 agonist\/<e2>GENE-Y<\\e2> antagonist","sentence":"Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850  an mGlu2 agonist\/mGlu3 antagonist"}
{"PMID":22445601,"re_id":4,"annotated sentence":"These results confirm the selective mGlu2 agonist and <e2>mGlu3<\\e2> antagonist actions of <e1>LY541850<\\e1>  A similar profile of activity was seen in medial perforant path synapse to the dentate gyrus","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY541850","object":"mGlu3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results confirm the selective mGlu2 agonist and <e2>GENE-Y<\\e2> antagonist actions of <e1>CHEMICAL<\\e1>  A similar profile of activity was seen in medial perforant path synapse to the dentate gyrus","sentence":"These results confirm the selective mGlu2 agonist and mGlu3 antagonist actions of LY541850  A similar profile of activity was seen in medial perforant path synapse to the dentate gyrus"}
{"PMID":22445601,"re_id":5,"annotated sentence":"<e1>LY541850<\\e1> was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and <e2>mGlu3<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY541850","object":"mGlu3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and <e2>GENE-Y<\\e2> antagonist","sentence":"LY541850 was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and mGlu3 antagonist"}
{"PMID":22537794,"re_id":0,"annotated sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of <e1>[(3)H] dopamine<\\e1> (DA) uptake and [(3)H]WIN 35428 binding in <e2>human dopamine transporter<\\e2> (DAT) wild-type and mutants with altered conformational equilibria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[(3)H] dopamine","object":"human dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of <e1>CHEMICAL<\\e1> (DA) uptake and [(3)H]WIN 35428 binding in <e2>GENE-Y<\\e2> (DAT) wild-type and mutants with altered conformational equilibria","sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (DAT) wild-type and mutants with altered conformational equilibria"}
{"PMID":22537794,"re_id":1,"annotated sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of <e1>[(3)H] dopamine<\\e1> (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (<e2>DAT<\\e2>  wild-type and mutants with altered conformational equilibria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[(3)H] dopamine","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of <e1>CHEMICAL<\\e1> (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (<e2>GENE-Y<\\e2>  wild-type and mutants with altered conformational equilibria","sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (DAT  wild-type and mutants with altered conformational equilibria"}
{"PMID":22537794,"re_id":2,"annotated sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (<e1>DA<\\e1>  uptake and [(3)H]WIN 35428 binding in <e2>human dopamine transporter<\\e2> (DAT) wild-type and mutants with altered conformational equilibria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DA","object":"human dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (<e1>CHEMICAL<\\e1>  uptake and [(3)H]WIN 35428 binding in <e2>GENE-Y<\\e2> (CHEMICALT) wild-type and mutants with altered conformational equilibria","sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA  uptake and [(3)H]WIN 35428 binding in human dopamine transporter (DAT) wild-type and mutants with altered conformational equilibria"}
{"PMID":22537794,"re_id":3,"annotated sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (<e1>DA<\\e1>  uptake and [(3)H]WIN 35428 binding in human dopamine transporter (<e2>DAT<\\e2>  wild-type and mutants with altered conformational equilibria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DA","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (<e1>CHEMICAL<\\e1>  uptake and [(3)H]WIN 35428 binding in human dopamine transporter (<e2>CHEMICALT<\\e2>  wild-type and mutants with altered conformational equilibria","sentence":"METHODS: (+\/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA  uptake and [(3)H]WIN 35428 binding in human dopamine transporter (DAT  wild-type and mutants with altered conformational equilibria"}
{"PMID":22537794,"re_id":4,"annotated sentence":"RESULTS: (+\/-)-, R-, and S-modafinil bind to the <e2>DAT<\\e2> and inhibit <e1>DA<\\e1> uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DA","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: (+\/-)-, R-, and S-modafinil bind to the <e2>CHEMICALT<\\e2> and inhibit <e1>CHEMICAL<\\e1> uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer","sentence":"RESULTS: (+\/-)-, R-, and S-modafinil bind to the DAT and inhibit DA uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer"}
{"PMID":22619007,"re_id":0,"annotated sentence":"In addition, <e1>Silibinin<\\e1> caused an increase in <e2>p53<\\e2> and p21 protein level as well as mRNA levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Silibinin","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> caused an increase in <e2>GENE-Y<\\e2> and p21 protein level as well as mRNA levels","sentence":"In addition, Silibinin caused an increase in p53 and p21 protein level as well as mRNA levels"}
{"PMID":22619007,"re_id":1,"annotated sentence":"In addition, <e1>Silibinin<\\e1> caused an increase in p53 and <e2>p21<\\e2> protein level as well as mRNA levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Silibinin","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> caused an increase in p53 and <e2>GENE-Y<\\e2> protein level as well as mRNA levels","sentence":"In addition, Silibinin caused an increase in p53 and p21 protein level as well as mRNA levels"}
{"PMID":22619007,"re_id":2,"annotated sentence":"In mechanistic studies, <e1>Silibinin<\\e1> decreased the protein level of <e2>p34cdc2<\\e2>  which might be the possible molecular mechanism of Silibinin efficacy on the growth inhibition in SGC-7901 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Silibinin","object":"p34cdc2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In mechanistic studies, <e1>CHEMICAL<\\e1> decreased the protein level of <e2>GENE-Y<\\e2>  which might be the possible molecular mechanism of CHEMICAL efficacy on the growth inhibition in SGC-7901 cells","sentence":"In mechanistic studies, Silibinin decreased the protein level of p34cdc2  which might be the possible molecular mechanism of Silibinin efficacy on the growth inhibition in SGC-7901 cells"}
{"PMID":22634361,"re_id":0,"annotated sentence":"The anti-hyperthermic effect of Lu AF21934 (5 mg\/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg\/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either <e2>5-HT(1A)<\\e2> receptors by <e1>WAY100635<\\e1>  or 5-HT(2A\/2C) receptors by ritanserin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"WAY100635","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The anti-hyperthermic effect of Lu AF21934 (5 mg\/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg\/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either <e2>GENE-Y<\\e2> receptors by <e1>CHEMICAL<\\e1>  or 5-HT(2A\/2C) receptors by ritanserin","sentence":"The anti-hyperthermic effect of Lu AF21934 (5 mg\/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg\/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635  or 5-HT(2A\/2C) receptors by ritanserin"}
{"PMID":22634361,"re_id":1,"annotated sentence":"The anti-hyperthermic effect of Lu AF21934 (5 mg\/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg\/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or <e2>5-HT(2A\/2C)<\\e2> receptors by <e1>ritanserin<\\e1>  These results suggest that the GABAergic system, but not the serotonergic system, is involved in the mechanism of the anxiolytic-like phenotype of Lu AF21934 in rodents","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ritanserin","object":"5-HT(2A\/2C)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The anti-hyperthermic effect of Lu AF21934 (5 mg\/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg\/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or <e2>GENE-N<\\e2> receptors by <e1>CHEMICAL<\\e1>  These results suggest that the GABAergic system, but not the serotonergic system, is involved in the mechanism of the anxiolytic-like phenotype of Lu AF21934 in rodents","sentence":"The anti-hyperthermic effect of Lu AF21934 (5 mg\/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg\/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A\/2C) receptors by ritanserin  These results suggest that the GABAergic system, but not the serotonergic system, is involved in the mechanism of the anxiolytic-like phenotype of Lu AF21934 in rodents"}
{"PMID":22634361,"re_id":2,"annotated sentence":"Previous studies demonstrated that the <e2>Group III mGlu receptor<\\e2> selective orthosteric agonist, <e1>LSP1-2111<\\e1> produced anxiolytic- but not antidepressant-like effects upon peripheral administration","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"LSP1-2111","object":"Group III mGlu receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previous studies demonstrated that the <e2>GENE-N<\\e2> selective orthosteric agonist, <e1>CHEMICAL<\\e1> produced anxiolytic- but not antidepressant-like effects upon peripheral administration","sentence":"Previous studies demonstrated that the Group III mGlu receptor selective orthosteric agonist, LSP1-2111 produced anxiolytic- but not antidepressant-like effects upon peripheral administration"}
{"PMID":22634361,"re_id":3,"annotated sentence":"The anti-hyperthermic effect of Lu AF21934 (5 mg\/kg) in the SIH test was inhibited by the <e2>benzodiazepine receptor<\\e2> antagonist <e1>flumazenil<\\e1> (10 mg\/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A\/2C) receptors by ritanserin","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"flumazenil","object":"benzodiazepine receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The anti-hyperthermic effect of Lu AF21934 (5 mg\/kg) in the SIH test was inhibited by the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (10 mg\/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A\/2C) receptors by ritanserin","sentence":"The anti-hyperthermic effect of Lu AF21934 (5 mg\/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg\/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A\/2C) receptors by ritanserin"}
{"PMID":22718571,"re_id":0,"annotated sentence":"Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, <e1>Gentianine<\\e1>  that Upregulates <e2>PPAR-\u03b3<\\e2> Gene Expression in 3T3-L1 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Gentianine","object":"PPAR-\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, <e1>CHEMICAL<\\e1>  that Upregulates <e2>GENE-Y<\\e2> Gene Expression in 3T3-L1 cells","sentence":"Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, Gentianine  that Upregulates PPAR-\u03b3 Gene Expression in 3T3-L1 cells"}
{"PMID":22718571,"re_id":1,"annotated sentence":"<e1>Swertiamarin<\\e1> treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-\u03b3 and GLUT-4; however, there was a significant increase in the mRNA expression of <e2>adiponectin<\\e2>  On the other hand, treatment with gentianine significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, GLUT-4 and adiponectin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Swertiamarin","object":"adiponectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-\u03b3 and GLUT-4; however, there was a significant increase in the mRNA expression of <e2>GENE-Y<\\e2>  On the other hand, treatment with gentianine significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, GLUT-4 and GENE-Y","sentence":"Swertiamarin treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-\u03b3 and GLUT-4; however, there was a significant increase in the mRNA expression of adiponectin  On the other hand, treatment with gentianine significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, GLUT-4 and adiponectin"}
{"PMID":22718571,"re_id":2,"annotated sentence":"On the other hand, treatment with <e1>gentianine<\\e1> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of <e2>PPAR-\u03b3<\\e2>  GLUT-4 and adiponectin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gentianine","object":"PPAR-\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the other hand, treatment with <e1>CHEMICAL<\\e1> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of <e2>GENE-Y<\\e2>  GLUT-4 and adiponectin","sentence":"On the other hand, treatment with gentianine significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3  GLUT-4 and adiponectin"}
{"PMID":22718571,"re_id":3,"annotated sentence":"On the other hand, treatment with <e1>gentianine<\\e1> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, <e2>GLUT-4<\\e2> and adiponectin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gentianine","object":"GLUT-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the other hand, treatment with <e1>CHEMICAL<\\e1> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, <e2>GENE-Y<\\e2> and adiponectin","sentence":"On the other hand, treatment with gentianine significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, GLUT-4 and adiponectin"}
{"PMID":22718571,"re_id":4,"annotated sentence":"On the other hand, treatment with <e1>gentianine<\\e1> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, GLUT-4 and <e2>adiponectin<\\e2>  These findings suggest, for the first time, that the anti-diabetic effect of swertiamarin is due to gentianine, an active metabolite of swertiamarin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gentianine","object":"adiponectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the other hand, treatment with <e1>CHEMICAL<\\e1> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, GLUT-4 and <e2>GENE-Y<\\e2>  These findings suggest, for the first time, that the anti-diabetic effect of swertiamarin is due to CHEMICAL, an active metabolite of swertiamarin","sentence":"On the other hand, treatment with gentianine significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, GLUT-4 and adiponectin  These findings suggest, for the first time, that the anti-diabetic effect of swertiamarin is due to gentianine, an active metabolite of swertiamarin"}
{"PMID":22815248,"re_id":0,"annotated sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or <e1>silymarin<\\e1> resulted in significantly increased activities of <e2>ethylmorphine-N-demethylase<\\e2> and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"silymarin","object":"ethylmorphine-N-demethylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or <e1>CHEMICAL<\\e1> resulted in significantly increased activities of <e2>GENE-N<\\e2> and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group","sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group"}
{"PMID":22815248,"re_id":1,"annotated sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or <e1>silymarin<\\e1> resulted in significantly increased activities of ethylmorphine-N-demethylase and <e2>aniline 4-hydroxylase<\\e2> activity and cytochrome P450, compared to the CCl4 only group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"silymarin","object":"aniline 4-hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or <e1>CHEMICAL<\\e1> resulted in significantly increased activities of ethylmorphine-N-demethylase and <e2>GENE-N<\\e2> activity and cytochrome P450, compared to the CCl4 only group","sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group"}
{"PMID":22815248,"re_id":2,"annotated sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or <e1>silymarin<\\e1> resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and <e2>cytochrome P450<\\e2>  compared to the CCl4 only group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"silymarin","object":"cytochrome P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or <e1>CHEMICAL<\\e1> resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and <e2>GENE-N<\\e2>  compared to the CCl4 only group","sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and cytochrome P450  compared to the CCl4 only group"}
{"PMID":22815248,"re_id":3,"annotated sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of <e2>ethylmorphine-N-demethylase<\\e2> and aniline 4-hydroxylase activity and cytochrome P450, compared to the <e1>CCl4<\\e1> only group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl4","object":"ethylmorphine-N-demethylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the CHEMICAL hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of <e2>GENE-N<\\e2> and aniline 4-hydroxylase activity and cytochrome P450, compared to the <e1>CHEMICAL<\\e1> only group","sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group"}
{"PMID":22815248,"re_id":4,"annotated sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and <e2>aniline 4-hydroxylase<\\e2> activity and cytochrome P450, compared to the <e1>CCl4<\\e1> only group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl4","object":"aniline 4-hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the CHEMICAL hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and <e2>GENE-N<\\e2> activity and cytochrome P450, compared to the <e1>CHEMICAL<\\e1> only group","sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group"}
{"PMID":22815248,"re_id":5,"annotated sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and <e2>cytochrome P450<\\e2>  compared to the <e1>CCl4<\\e1> only group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl4","object":"cytochrome P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the CHEMICAL hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and <e2>GENE-N<\\e2>  compared to the <e1>CHEMICAL<\\e1> only group","sentence":"In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and cytochrome P450  compared to the CCl4 only group"}
{"PMID":22815248,"re_id":6,"annotated sentence":"A significant decrease of <e2>aspartate aminotransferase<\\e2>  alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CCl4<\\e1> and PC administration alone","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CCl4","object":"aspartate aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A significant decrease of <e2>GENE-Y<\\e2>  alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CHEMICAL<\\e1> and PC administration alone","sentence":"A significant decrease of aspartate aminotransferase  alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone"}
{"PMID":22815248,"re_id":7,"annotated sentence":"A significant decrease of aspartate aminotransferase, <e2>alanine aminotransferase<\\e2>  lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CCl4<\\e1> and PC administration alone","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CCl4","object":"alanine aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A significant decrease of aspartate aminotransferase, <e2>GENE-N<\\e2>  lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CHEMICAL<\\e1> and PC administration alone","sentence":"A significant decrease of aspartate aminotransferase, alanine aminotransferase  lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone"}
{"PMID":22815248,"re_id":8,"annotated sentence":"A significant decrease of aspartate aminotransferase, alanine aminotransferase, <e2>lactate dehydrogenase<\\e2> (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CCl4<\\e1> and PC administration alone","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CCl4","object":"lactate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A significant decrease of aspartate aminotransferase, alanine aminotransferase, <e2>GENE-N<\\e2> (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CHEMICAL<\\e1> and PC administration alone","sentence":"A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone"}
{"PMID":22815248,"re_id":9,"annotated sentence":"A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (<e2>LDH<\\e2>  activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CCl4<\\e1> and PC administration alone","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CCl4","object":"LDH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (<e2>GENE-N<\\e2>  activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CHEMICAL<\\e1> and PC administration alone","sentence":"A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH  activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone"}
{"PMID":22859660,"re_id":0,"annotated sentence":"For <e2>AII<\\e2> and ET1, MAP was also increased for the <e1>fenofibrate<\\e1> group but not in a dose-dependent fashion","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fenofibrate","object":"AII","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"For <e2>GENE-Y<\\e2> and ET1, MAP was also increased for the <e1>CHEMICAL<\\e1> group but not in a dose-dependent fashion","sentence":"For AII and ET1, MAP was also increased for the fenofibrate group but not in a dose-dependent fashion"}
{"PMID":22859660,"re_id":1,"annotated sentence":"For AII and <e2>ET1<\\e2>  MAP was also increased for the <e1>fenofibrate<\\e1> group but not in a dose-dependent fashion","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"fenofibrate","object":"ET1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"For AII and <e2>GENE-Y<\\e2>  MAP was also increased for the <e1>CHEMICAL<\\e1> group but not in a dose-dependent fashion","sentence":"For AII and ET1  MAP was also increased for the fenofibrate group but not in a dose-dependent fashion"}
{"PMID":22865292,"re_id":0,"annotated sentence":"The lysosomal inhibitor <e1>chloroquine<\\e1> significantly increased <e2>RCAN1<\\e2> accumulation in +\/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1\/NFATc1 ratio and consequently NFATc1 inhibition","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"chloroquine","object":"RCAN1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The lysosomal inhibitor <e1>CHEMICAL<\\e1> significantly increased <e2>GENE-N<\\e2> accumulation in +\/+ cells, consistent with the hypothesis that higher lysosomal pH impairs GENE-N degradation, leading to a higher GENE-N\/NFATc1 ratio and consequently NFATc1 inhibition","sentence":"The lysosomal inhibitor chloroquine significantly increased RCAN1 accumulation in +\/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1\/NFATc1 ratio and consequently NFATc1 inhibition"}
{"PMID":22872607,"re_id":0,"annotated sentence":"Exposure to <e1>PAHs<\\e1>  their metabolites, and ROS further increase <e2>AKRs<\\e2> isoform expression that may amplify oxidative damage","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PAHs","object":"AKRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exposure to <e1>CHEMICAL<\\e1>  their metabolites, and ROS further increase <e2>GENE-N<\\e2> isoform expression that may amplify oxidative damage","sentence":"Exposure to PAHs  their metabolites, and ROS further increase AKRs isoform expression that may amplify oxidative damage"}
{"PMID":22872607,"re_id":1,"annotated sentence":"<e2>Aldo-keto reductases<\\e2> (AKRs) metabolize a wide range of substrates, including <e1>polycyclic aromatic hydrocarbons<\\e1> (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"polycyclic aromatic hydrocarbons","object":"Aldo-keto reductases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (AKRs) metabolize a wide range of substrates, including <e1>CHEMICAL<\\e1> (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","sentence":"Aldo-keto reductases (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis"}
{"PMID":22872607,"re_id":2,"annotated sentence":"Aldo-keto reductases (<e2>AKRs<\\e2>  metabolize a wide range of substrates, including <e1>polycyclic aromatic hydrocarbons<\\e1> (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"polycyclic aromatic hydrocarbons","object":"AKRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aldo-keto reductases (<e2>GENE-N<\\e2>  metabolize a wide range of substrates, including <e1>CHEMICAL<\\e1> (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","sentence":"Aldo-keto reductases (AKRs  metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis"}
{"PMID":22872607,"re_id":3,"annotated sentence":"<e2>Aldo-keto reductases<\\e2> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<e1>PAHs<\\e1> , generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PAHs","object":"Aldo-keto reductases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<e1>CHEMICAL<\\e1> , generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","sentence":"Aldo-keto reductases (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs , generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis"}
{"PMID":22872607,"re_id":4,"annotated sentence":"Aldo-keto reductases (<e2>AKRs<\\e2>  metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<e1>PAHs<\\e1> , generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PAHs","object":"AKRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aldo-keto reductases (<e2>GENE-N<\\e2>  metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<e1>CHEMICAL<\\e1> , generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","sentence":"Aldo-keto reductases (AKRs  metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs , generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis"}
{"PMID":22872607,"re_id":5,"annotated sentence":"<e2>Aldo-keto reductases<\\e2> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (<e1>o-quinones<\\e1>  and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"o-quinones","object":"Aldo-keto reductases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (<e1>CHEMICAL<\\e1>  and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","sentence":"Aldo-keto reductases (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones  and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis"}
{"PMID":22872607,"re_id":6,"annotated sentence":"Aldo-keto reductases (<e2>AKRs<\\e2>  metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (<e1>o-quinones<\\e1>  and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"o-quinones","object":"AKRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aldo-keto reductases (<e2>GENE-N<\\e2>  metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (<e1>CHEMICAL<\\e1>  and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis","sentence":"Aldo-keto reductases (AKRs  metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones  and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis"}
{"PMID":22872607,"re_id":7,"annotated sentence":"<e2>Aldo-keto reductases<\\e2> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive <e1>oxygen<\\e1> species (ROS), which are capable of initiating and promoting carcinogenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxygen","object":"Aldo-keto reductases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive <e1>CHEMICAL<\\e1> species (ROS), which are capable of initiating and promoting carcinogenesis","sentence":"Aldo-keto reductases (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis"}
{"PMID":22872607,"re_id":8,"annotated sentence":"Aldo-keto reductases (<e2>AKRs<\\e2>  metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive <e1>oxygen<\\e1> species (ROS), which are capable of initiating and promoting carcinogenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxygen","object":"AKRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aldo-keto reductases (<e2>GENE-N<\\e2>  metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive <e1>CHEMICAL<\\e1> species (ROS), which are capable of initiating and promoting carcinogenesis","sentence":"Aldo-keto reductases (AKRs  metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis"}
{"PMID":22872607,"re_id":9,"annotated sentence":"Despite the importance of <e2>AKRs<\\e2> in <e1>PAHs<\\e1> metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PAHs","object":"AKRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Despite the importance of <e2>GENE-N<\\e2> in <e1>CHEMICAL<\\e1> metabolism, there are no studies that evaluate, in general human populations, the effect of CHEMICAL on GENE-N expression in peripheral blood lymphocytes (PBLs)","sentence":"Despite the importance of AKRs in PAHs metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs)"}
{"PMID":22878908,"re_id":0,"annotated sentence":"<e1>TZDs<\\e1> also inhibited <e2>alkaline phosphatase<\\e2> activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TZDs","object":"alkaline phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also inhibited <e2>GENE-N<\\e2> activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031)","sentence":"TZDs also inhibited alkaline phosphatase activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031)"}
{"PMID":22878908,"re_id":1,"annotated sentence":"<e1>TZDs<\\e1> also inhibited alkaline phosphatase activity (58-75%, p<0.046) and <e2>osteocalcin<\\e2> production (52-75%, p<0.031)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TZDs","object":"osteocalcin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also inhibited alkaline phosphatase activity (58-75%, p<0.046) and <e2>GENE-Y<\\e2> production (52-75%, p<0.031)","sentence":"TZDs also inhibited alkaline phosphatase activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031)"}
{"PMID":22878908,"re_id":2,"annotated sentence":"<e1>TZD<\\e1> effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on <e2>aromatase<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TZD","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on <e2>GENE-Y<\\e2> ","sentence":"TZD effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on aromatase "}
{"PMID":22878908,"re_id":3,"annotated sentence":"We have previously reported that <e1>TZDs<\\e1> reduce estrogen synthesis by inhibiting <e2>aromatase<\\e2> activity in human granulosa cells (HGC)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TZDs","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have previously reported that <e1>CHEMICAL<\\e1> reduce estrogen synthesis by inhibiting <e2>GENE-Y<\\e2> activity in human granulosa cells (HGC)","sentence":"We have previously reported that TZDs reduce estrogen synthesis by inhibiting aromatase activity in human granulosa cells (HGC)"}
{"PMID":22878908,"re_id":4,"annotated sentence":"We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether <e1>TZD<\\e1> inhibition of <e2>aromatase<\\e2> plays a role in their effects on bone metabolism","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TZD","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether <e1>CHEMICAL<\\e1> inhibition of <e2>GENE-Y<\\e2> plays a role in their effects on bone metabolism","sentence":"We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether TZD inhibition of aromatase plays a role in their effects on bone metabolism"}
{"PMID":22878908,"re_id":5,"annotated sentence":"We have previously reported that TZDs reduce <e1>estrogen<\\e1> synthesis by inhibiting <e2>aromatase<\\e2> activity in human granulosa cells (HGC)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"estrogen","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have previously reported that TZDs reduce <e1>CHEMICAL<\\e1> synthesis by inhibiting <e2>GENE-Y<\\e2> activity in human granulosa cells (HGC)","sentence":"We have previously reported that TZDs reduce estrogen synthesis by inhibiting aromatase activity in human granulosa cells (HGC)"}
{"PMID":22899102,"re_id":0,"annotated sentence":"The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by <e1>glutathione<\\e1> conjugate formation catalyzed by <e2>glutathione S-transferases<\\e2>  In the present study, differentiated human intestinal Caco-2 cells were used as a model for the human small intestine to investigate the detoxification of BPDE and excretion of stereoisomeric glutathione conjugates in the presence of an inhibitor of the glutathione-cleaving enzyme \u03b3-glutamyl transpeptidase at the cell surface","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutathione","object":"glutathione S-transferases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by <e1>CHEMICAL<\\e1> conjugate formation catalyzed by <e2>CHEMICAL S-transferases<\\e2>  In the present study, differentiated human intestinal Caco-2 cells were used as a model for the human small intestine to investigate the detoxification of BPDE and excretion of stereoisomeric CHEMICAL conjugates in the presence of an inhibitor of the CHEMICAL-cleaving enzyme \u03b3-glutamyl transpeptidase at the cell surface","sentence":"The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by glutathione conjugate formation catalyzed by glutathione S-transferases  In the present study, differentiated human intestinal Caco-2 cells were used as a model for the human small intestine to investigate the detoxification of BPDE and excretion of stereoisomeric glutathione conjugates in the presence of an inhibitor of the glutathione-cleaving enzyme \u03b3-glutamyl transpeptidase at the cell surface"}
{"PMID":22899102,"re_id":1,"annotated sentence":"<e2>Multidrug resistance-associated proteins<\\e2> are involved in the transport of the <e1>glutathione<\\e1> conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glutathione","object":"Multidrug resistance-associated proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> are involved in the transport of the <e1>CHEMICAL<\\e1> conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells","sentence":"Multidrug resistance-associated proteins are involved in the transport of the glutathione conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells"}
{"PMID":22899102,"re_id":2,"annotated sentence":"Inhibition studies revealed that the <e2>multidrug resistance-associated proteins<\\e2> (ABCCs) are involved in the transport of <e1>BPDE glutathione<\\e1> conjugates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BPDE glutathione","object":"multidrug resistance-associated proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition studies revealed that the <e2>GENE-N<\\e2> (ABCCs) are involved in the transport of <e1>CHEMICAL<\\e1> conjugates","sentence":"Inhibition studies revealed that the multidrug resistance-associated proteins (ABCCs) are involved in the transport of BPDE glutathione conjugates"}
{"PMID":22899102,"re_id":3,"annotated sentence":"Inhibition studies revealed that the multidrug resistance-associated proteins (<e2>ABCCs<\\e2>  are involved in the transport of <e1>BPDE glutathione<\\e1> conjugates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BPDE glutathione","object":"ABCCs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition studies revealed that the multidrug resistance-associated proteins (<e2>GENE-N<\\e2>  are involved in the transport of <e1>CHEMICAL<\\e1> conjugates","sentence":"Inhibition studies revealed that the multidrug resistance-associated proteins (ABCCs  are involved in the transport of BPDE glutathione conjugates"}
{"PMID":22899102,"re_id":4,"annotated sentence":"Stable <e2>ABCC1<\\e2>  ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of <e1>BPDE glutathione<\\e1> conjugates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BPDE glutathione","object":"ABCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Stable <e2>GENE-Y<\\e2>  ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that GENE-Y mediates the basolateral and ABCC2 the apical excretion of <e1>CHEMICAL<\\e1> conjugates","sentence":"Stable ABCC1  ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of BPDE glutathione conjugates"}
{"PMID":22899102,"re_id":5,"annotated sentence":"Stable ABCC1, <e2>ABCC2<\\e2> and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of <e1>BPDE glutathione<\\e1> conjugates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BPDE glutathione","object":"ABCC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Stable ABCC1, <e2>GENE-Y<\\e2> and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and GENE-Y the apical excretion of <e1>CHEMICAL<\\e1> conjugates","sentence":"Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of BPDE glutathione conjugates"}
{"PMID":22899102,"re_id":6,"annotated sentence":"Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that <e2>ABCC1<\\e2> mediates the basolateral and ABCC2 the apical excretion of <e1>BPDE glutathione<\\e1> conjugates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BPDE glutathione","object":"ABCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Stable GENE-Y, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that <e2>GENE-Y<\\e2> mediates the basolateral and ABCC2 the apical excretion of <e1>CHEMICAL<\\e1> conjugates","sentence":"Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of BPDE glutathione conjugates"}
{"PMID":22899102,"re_id":7,"annotated sentence":"Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and <e2>ABCC2<\\e2> the apical excretion of <e1>BPDE glutathione<\\e1> conjugates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BPDE glutathione","object":"ABCC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Stable ABCC1, GENE-Y and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and <e2>GENE-Y<\\e2> the apical excretion of <e1>CHEMICAL<\\e1> conjugates","sentence":"Stable ABCC1, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of BPDE glutathione conjugates"}
{"PMID":22931530,"re_id":0,"annotated sentence":"<e1>\u03b1-Amino-\u03b1\u00b4-Halomethylketones<\\e1>  Synthetic Methodologies and Pharmaceutical Applications as <e2>Serine and Cysteine Protease<\\e2> Inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"\u03b1-Amino-\u03b1\u00b4-Halomethylketones","object":"Serine and Cysteine Protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  Synthetic Methodologies and Pharmaceutical Applications as <e2>GENE-N<\\e2> Inhibitors","sentence":"\u03b1-Amino-\u03b1\u00b4-Halomethylketones  Synthetic Methodologies and Pharmaceutical Applications as Serine and Cysteine Protease Inhibitors"}
{"PMID":22972179,"re_id":0,"annotated sentence":"Phosphorylation of <e2>AMPK<\\e2> at Thr172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to <e1>2-deoxyglucose<\\e1>  Global rates of protein synthesis declined by 78% of control values","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2-deoxyglucose","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phosphorylation of <e2>GENE-N<\\e2> at Thr172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to <e1>CHEMICAL<\\e1>  Global rates of protein synthesis declined by 78% of control values","sentence":"Phosphorylation of AMPK at Thr172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to 2-deoxyglucose  Global rates of protein synthesis declined by 78% of control values"}
{"PMID":22972179,"re_id":1,"annotated sentence":"Phosphorylation of ER-stress marker <e2>eIF2\u03b1<\\e2> was also increased but only at 30 min of <e1>2-deoxyglucose<\\e1> exposure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2-deoxyglucose","object":"eIF2\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphorylation of ER-stress marker <e2>GENE-Y<\\e2> was also increased but only at 30 min of <e1>CHEMICAL<\\e1> exposure","sentence":"Phosphorylation of ER-stress marker eIF2\u03b1 was also increased but only at 30 min of 2-deoxyglucose exposure"}
{"PMID":22972179,"re_id":2,"annotated sentence":"<e1>2-Deoxyglucose<\\e1> increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to <e2>TSC2<\\e2>  Activation of AMPK did not result in changes in the amount of raptor bound to mTOR","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2-Deoxyglucose","object":"TSC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased phosphorylation of tuberous sclerosis complex 2 (GENE-Y) on AMPK consensus sites but did not change the amount of TSC1 bound to <e2>GENE-Y<\\e2>  Activation of AMPK did not result in changes in the amount of raptor bound to mTOR","sentence":"2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2  Activation of AMPK did not result in changes in the amount of raptor bound to mTOR"}
{"PMID":22972179,"re_id":3,"annotated sentence":"<e1>2-Deoxyglucose<\\e1> increased phosphorylation of <e2>tuberous sclerosis complex 2<\\e2> (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2-Deoxyglucose","object":"tuberous sclerosis complex 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased phosphorylation of <e2>GENE-Y<\\e2> (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2","sentence":"2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2"}
{"PMID":22972179,"re_id":4,"annotated sentence":"<e1>2-Deoxyglucose<\\e1> increased phosphorylation of tuberous sclerosis complex 2 (<e2>TSC2<\\e2>  on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2-Deoxyglucose","object":"TSC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased phosphorylation of tuberous sclerosis complex 2 (<e2>GENE-Y<\\e2>  on AMPK consensus sites but did not change the amount of TSC1 bound to GENE-Y","sentence":"2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 (TSC2  on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2"}
{"PMID":22972179,"re_id":5,"annotated sentence":"<e1>2-Deoxyglucose<\\e1> increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on <e2>AMPK<\\e2> consensus sites but did not change the amount of TSC1 bound to TSC2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2-Deoxyglucose","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on <e2>GENE-N<\\e2> consensus sites but did not change the amount of TSC1 bound to TSC2","sentence":"2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2"}
{"PMID":22981796,"re_id":0,"annotated sentence":"Exposure to <e1>Cu<\\e1> NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and <e2>interleukin-8<\\e2> that mirrored our findings from subacute in vivo inhalation studies in mice","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cu","object":"interleukin-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exposure to <e1>CHEMICAL<\\e1> NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and <e2>GENE-Y<\\e2> that mirrored our findings from subacute in vivo inhalation studies in mice","sentence":"Exposure to Cu NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and interleukin-8 that mirrored our findings from subacute in vivo inhalation studies in mice"}
{"PMID":22981796,"re_id":1,"annotated sentence":"Exposure to <e1>Cu<\\e1> NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of <e2>lactate dehydrogenase<\\e2>  intracellular reactive oxygen species and interleukin-8 that mirrored our findings from subacute in vivo inhalation studies in mice","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cu","object":"lactate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exposure to <e1>CHEMICAL<\\e1> NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of <e2>GENE-N<\\e2>  intracellular reactive oxygen species and interleukin-8 that mirrored our findings from subacute in vivo inhalation studies in mice","sentence":"Exposure to Cu NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase  intracellular reactive oxygen species and interleukin-8 that mirrored our findings from subacute in vivo inhalation studies in mice"}
{"PMID":22982445,"re_id":0,"annotated sentence":"<e1>Leukotriene D4<\\e1> induces cognitive impairment through enhancement of <e2>CysLT\u2081 R<\\e2> mediated amyloid-\u03b2 generation in mice","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Leukotriene D4","object":"CysLT\u2081 R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induces cognitive impairment through enhancement of <e2>GENE-Y<\\e2> mediated amyloid-\u03b2 generation in mice","sentence":"Leukotriene D4 induces cognitive impairment through enhancement of CysLT\u2081 R mediated amyloid-\u03b2 generation in mice"}
{"PMID":22982445,"re_id":1,"annotated sentence":"<e1>Leukotriene D4<\\e1> induces cognitive impairment through enhancement of CysLT\u2081 R-mediated <e2>amyloid-\u03b2<\\e2> generation in mice","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Leukotriene D4","object":"amyloid-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induces cognitive impairment through enhancement of CysLT\u2081 R-mediated <e2>GENE-Y<\\e2> generation in mice","sentence":"Leukotriene D4 induces cognitive impairment through enhancement of CysLT\u2081 R-mediated amyloid-\u03b2 generation in mice"}
{"PMID":22982445,"re_id":2,"annotated sentence":"Moreover, <e1>LTD4<\\e1> induced increases in <e2>CysLT(1)R<\\e2> and NF-\u03baB p65 in the brain were also attenuated by pranlukast","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"CysLT(1)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> induced increases in <e2>GENE-Y<\\e2> and NF-\u03baB p65 in the brain were also attenuated by pranlukast","sentence":"Moreover, LTD4 induced increases in CysLT(1)R and NF-\u03baB p65 in the brain were also attenuated by pranlukast"}
{"PMID":22982445,"re_id":3,"annotated sentence":"Moreover, <e1>LTD4<\\e1> induced increases in CysLT(1)R and <e2>NF-\u03baB<\\e2> p65 in the brain were also attenuated by pranlukast","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> induced increases in CysLT(1)R and <e2>GENE-N<\\e2> p65 in the brain were also attenuated by pranlukast","sentence":"Moreover, LTD4 induced increases in CysLT(1)R and NF-\u03baB p65 in the brain were also attenuated by pranlukast"}
{"PMID":22982445,"re_id":4,"annotated sentence":"Moreover, <e1>LTD4<\\e1> induced increases in CysLT(1)R and NF-\u03baB <e2>p65<\\e2> in the brain were also attenuated by pranlukast","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> induced increases in CysLT(1)R and NF-\u03baB <e2>GENE-Y<\\e2> in the brain were also attenuated by pranlukast","sentence":"Moreover, LTD4 induced increases in CysLT(1)R and NF-\u03baB p65 in the brain were also attenuated by pranlukast"}
{"PMID":22982445,"re_id":5,"annotated sentence":"These results suggest that <e1>LTD4<\\e1> increases <e2>A\u03b2 peptide<\\e2> burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"A\u03b2 peptide","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> increases <e2>GENE-Y<\\e2> burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway","sentence":"These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway"}
{"PMID":22982445,"re_id":6,"annotated sentence":"These results suggest that <e1>LTD4<\\e1> increases A\u03b2 peptide burden via activation of <e2>CysLT(1)R<\\e2>  which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"CysLT(1)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1> increases A\u03b2 peptide burden via activation of <e2>GENE-Y<\\e2>  which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway","sentence":"These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R  which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway"}
{"PMID":22982445,"re_id":7,"annotated sentence":"The results demonstrated that intracerebral infusions of <e1>LTD4<\\e1> (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of <e2>A\u03b21-40<\\e2> and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"A\u03b21-40","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results demonstrated that intracerebral infusions of <e1>CHEMICAL<\\e1> (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of <e2>GENE-Y<\\e2> and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP)","sentence":"The results demonstrated that intracerebral infusions of LTD4 (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP)"}
{"PMID":22982445,"re_id":8,"annotated sentence":"The results demonstrated that intracerebral infusions of <e1>LTD4<\\e1> (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and <e2>A\u03b21-42<\\e2> in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"A\u03b21-42","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results demonstrated that intracerebral infusions of <e1>CHEMICAL<\\e1> (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and <e2>GENE-Y<\\e2> in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP)","sentence":"The results demonstrated that intracerebral infusions of LTD4 (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP)"}
{"PMID":22982445,"re_id":9,"annotated sentence":"The results demonstrated that intracerebral infusions of <e1>LTD4<\\e1> (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of <e2>amyloid precursor protein<\\e2> (APP)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"amyloid precursor protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results demonstrated that intracerebral infusions of <e1>CHEMICAL<\\e1> (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of <e2>GENE-Y<\\e2> (APP)","sentence":"The results demonstrated that intracerebral infusions of LTD4 (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP)"}
{"PMID":22982445,"re_id":10,"annotated sentence":"The results demonstrated that intracerebral infusions of <e1>LTD4<\\e1> (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (<e2>APP<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"APP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results demonstrated that intracerebral infusions of <e1>CHEMICAL<\\e1> (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (<e2>GENE-Y<\\e2> ","sentence":"The results demonstrated that intracerebral infusions of LTD4 (1 ng\/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP "}
{"PMID":22982445,"re_id":11,"annotated sentence":"<e1>LTD4<\\e1> also induced expression of <e2>cysteinyl leukotriene receptor 1<\\e2> (CysLT(1)R) and NF-\u03baB p65 in the hippocampus and cortex","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"cysteinyl leukotriene receptor 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also induced expression of <e2>GENE-Y<\\e2> (CysLT(1)R) and NF-\u03baB p65 in the hippocampus and cortex","sentence":"LTD4 also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-\u03baB p65 in the hippocampus and cortex"}
{"PMID":22982445,"re_id":12,"annotated sentence":"<e1>LTD4<\\e1> also induced expression of cysteinyl leukotriene receptor 1 (<e2>CysLT(1)R<\\e2>  and NF-\u03baB p65 in the hippocampus and cortex","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"CysLT(1)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also induced expression of cysteinyl leukotriene receptor 1 (<e2>GENE-Y<\\e2>  and NF-\u03baB p65 in the hippocampus and cortex","sentence":"LTD4 also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R  and NF-\u03baB p65 in the hippocampus and cortex"}
{"PMID":22982445,"re_id":13,"annotated sentence":"<e1>LTD4<\\e1> also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and <e2>NF-\u03baB<\\e2> p65 in the hippocampus and cortex","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and <e2>GENE-N<\\e2> p65 in the hippocampus and cortex","sentence":"LTD4 also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-\u03baB p65 in the hippocampus and cortex"}
{"PMID":22982445,"re_id":14,"annotated sentence":"<e1>LTD4<\\e1> also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-\u03baB <e2>p65<\\e2> in the hippocampus and cortex","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LTD4","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-\u03baB <e2>GENE-Y<\\e2> in the hippocampus and cortex","sentence":"LTD4 also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-\u03baB p65 in the hippocampus and cortex"}
{"PMID":22982445,"re_id":15,"annotated sentence":"Moreover, LTD4-induced increases in <e2>CysLT(1)R<\\e2> and NF-\u03baB p65 in the brain were also attenuated by <e1>pranlukast<\\e1>  These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"CysLT(1)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, LTD4-induced increases in <e2>GENE-Y<\\e2> and NF-\u03baB p65 in the brain were also attenuated by <e1>CHEMICAL<\\e1>  These results suggest that LTD4 increases A\u03b2 peptide burden via activation of GENE-Y, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway","sentence":"Moreover, LTD4-induced increases in CysLT(1)R and NF-\u03baB p65 in the brain were also attenuated by pranlukast  These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway"}
{"PMID":22982445,"re_id":16,"annotated sentence":"Moreover, LTD4-induced increases in CysLT(1)R and <e2>NF-\u03baB<\\e2> p65 in the brain were also attenuated by <e1>pranlukast<\\e1>  These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, LTD4-induced increases in CysLT(1)R and <e2>GENE-N<\\e2> p65 in the brain were also attenuated by <e1>CHEMICAL<\\e1>  These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the GENE-N pathway","sentence":"Moreover, LTD4-induced increases in CysLT(1)R and NF-\u03baB p65 in the brain were also attenuated by pranlukast  These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway"}
{"PMID":22982445,"re_id":17,"annotated sentence":"Moreover, LTD4-induced increases in CysLT(1)R and NF-\u03baB <e2>p65<\\e2> in the brain were also attenuated by <e1>pranlukast<\\e1>  These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, LTD4-induced increases in CysLT(1)R and NF-\u03baB <e2>GENE-Y<\\e2> in the brain were also attenuated by <e1>CHEMICAL<\\e1>  These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway","sentence":"Moreover, LTD4-induced increases in CysLT(1)R and NF-\u03baB p65 in the brain were also attenuated by pranlukast  These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway"}
{"PMID":22982445,"re_id":18,"annotated sentence":"Pretreatment with <e1>pranlukast<\\e1> (1.5 ng\/mouse, intracerebroventricularly), a <e2>CysLT(1)R<\\e2> antagonist, blocked LTD4-induced amyloidogenesis, memory deficits","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"pranlukast","object":"CysLT(1)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with <e1>CHEMICAL<\\e1> (1.5 ng\/mouse, intracerebroventricularly), a <e2>GENE-Y<\\e2> antagonist, blocked LTD4-induced amyloidogenesis, memory deficits","sentence":"Pretreatment with pranlukast (1.5 ng\/mouse, intracerebroventricularly), a CysLT(1)R antagonist, blocked LTD4-induced amyloidogenesis, memory deficits"}
{"PMID":22983867,"re_id":0,"annotated sentence":"Although the treatment with <e1>MSG<\\e1> increased IRS-1 tyrosine phosphorylation (<e2>pIRS-1<\\e2>  by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; MSG, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIRS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although the treatment with <e1>CHEMICAL<\\e1> increased IRS-1 tyrosine phosphorylation (<e2>GENE-Y<\\e2>  by 96\u00a0% (CHEMICAL, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; CHEMICAL, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)","sentence":"Although the treatment with MSG increased IRS-1 tyrosine phosphorylation (pIRS-1  by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; MSG, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)"}
{"PMID":22983867,"re_id":1,"annotated sentence":"Although the treatment with MSG increased IRS-1 tyrosine phosphorylation (<e2>pIRS-1<\\e2>  by 96\u00a0% (<e1>MSG<\\e1>  17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; MSG, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIRS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although the treatment with CHEMICAL increased IRS-1 tyrosine phosphorylation (<e2>GENE-Y<\\e2>  by 96\u00a0% (<e1>CHEMICAL<\\e1>  17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; CHEMICAL, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)","sentence":"Although the treatment with MSG increased IRS-1 tyrosine phosphorylation (pIRS-1  by 96\u00a0% (MSG  17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; MSG, 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)"}
{"PMID":22983867,"re_id":2,"annotated sentence":"Although the treatment with MSG increased IRS-1 tyrosine phosphorylation (<e2>pIRS-1<\\e2>  by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; <e1>MSG<\\e1>  22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIRS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although the treatment with CHEMICAL increased IRS-1 tyrosine phosphorylation (<e2>GENE-Y<\\e2>  by 96\u00a0% (CHEMICAL, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; <e1>CHEMICAL<\\e1>  22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)","sentence":"Although the treatment with MSG increased IRS-1 tyrosine phosphorylation (pIRS-1  by 96\u00a0% (MSG, 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1; MSG  22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)"}
{"PMID":22983867,"re_id":3,"annotated sentence":"The results showed that IR tyrosine phosphorylation (<e2>pIR<\\e2>  was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (<e1>MSG<\\e1>  11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that IR tyrosine phosphorylation (<e2>GENE-Y<\\e2>  was reduced by 42\u00a0% in CHEMICAL-obese mice (CHEMICAL, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased GENE-Y by 76\u00a0% in CHEMICAL mice without affecting control mice (<e1>CHEMICAL<\\e1>  11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","sentence":"The results showed that IR tyrosine phosphorylation (pIR  was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG  11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)"}
{"PMID":22983867,"re_id":4,"annotated sentence":"The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <e2>pIR<\\e2> by 76\u00a0% in MSG mice without affecting control mice (<e1>MSG<\\e1>  11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that IR tyrosine phosphorylation (GENE-Y) was reduced by 42\u00a0% in CHEMICAL-obese mice (CHEMICAL, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <e2>GENE-Y<\\e2> by 76\u00a0% in CHEMICAL mice without affecting control mice (<e1>CHEMICAL<\\e1>  11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","sentence":"The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG  11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)"}
{"PMID":22983867,"re_id":5,"annotated sentence":"The results showed that IR tyrosine phosphorylation (<e2>pIR<\\e2>  was reduced by 42\u00a0% in <e1>MSG<\\e1> obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that IR tyrosine phosphorylation (<e2>GENE-Y<\\e2>  was reduced by 42\u00a0% in <e1>CHEMICAL<\\e1> obese mice (CHEMICAL, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased GENE-Y by 76\u00a0% in CHEMICAL mice without affecting control mice (CHEMICAL, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","sentence":"The results showed that IR tyrosine phosphorylation (pIR  was reduced by 42\u00a0% in MSG obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)"}
{"PMID":22983867,"re_id":6,"annotated sentence":"The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in <e1>MSG<\\e1> obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <e2>pIR<\\e2> by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that IR tyrosine phosphorylation (GENE-Y) was reduced by 42\u00a0% in <e1>CHEMICAL<\\e1> obese mice (CHEMICAL, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <e2>GENE-Y<\\e2> by 76\u00a0% in CHEMICAL mice without affecting control mice (CHEMICAL, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","sentence":"The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)"}
{"PMID":22983867,"re_id":7,"annotated sentence":"The results showed that IR tyrosine phosphorylation (<e2>pIR<\\e2>  was reduced by 42\u00a0% in MSG-obese mice (<e1>MSG<\\e1>  6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that IR tyrosine phosphorylation (<e2>GENE-Y<\\e2>  was reduced by 42\u00a0% in CHEMICAL-obese mice (<e1>CHEMICAL<\\e1>  6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased GENE-Y by 76\u00a0% in CHEMICAL mice without affecting control mice (CHEMICAL, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","sentence":"The results showed that IR tyrosine phosphorylation (pIR  was reduced by 42\u00a0% in MSG-obese mice (MSG  6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)"}
{"PMID":22983867,"re_id":8,"annotated sentence":"The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (<e1>MSG<\\e1>  6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <e2>pIR<\\e2> by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that IR tyrosine phosphorylation (GENE-Y) was reduced by 42\u00a0% in CHEMICAL-obese mice (<e1>CHEMICAL<\\e1>  6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <e2>GENE-Y<\\e2> by 76\u00a0% in CHEMICAL mice without affecting control mice (CHEMICAL, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","sentence":"The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG  6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)"}
{"PMID":22983867,"re_id":9,"annotated sentence":"The results showed that IR tyrosine phosphorylation (<e2>pIR<\\e2>  was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in <e1>MSG<\\e1> mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that IR tyrosine phosphorylation (<e2>GENE-Y<\\e2>  was reduced by 42\u00a0% in CHEMICAL-obese mice (CHEMICAL, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased GENE-Y by 76\u00a0% in <e1>CHEMICAL<\\e1> mice without affecting control mice (CHEMICAL, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","sentence":"The results showed that IR tyrosine phosphorylation (pIR  was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)"}
{"PMID":22983867,"re_id":10,"annotated sentence":"The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <e2>pIR<\\e2> by 76\u00a0% in <e1>MSG<\\e1> mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MSG","object":"pIR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that IR tyrosine phosphorylation (GENE-Y) was reduced by 42\u00a0% in CHEMICAL-obese mice (CHEMICAL, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased <e2>GENE-Y<\\e2> by 76\u00a0% in <e1>CHEMICAL<\\e1> mice without affecting control mice (CHEMICAL, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)","sentence":"The results showed that IR tyrosine phosphorylation (pIR) was reduced by 42\u00a0% in MSG-obese mice (MSG, 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased pIR by 76\u00a0% in MSG mice without affecting control mice (MSG, 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)"}
{"PMID":22989705,"re_id":0,"annotated sentence":"The obtained results showed that <e1>pioglitazone<\\e1> improved the renal function, structural changes, renal malondialdehyde (MDA), <e2>tumor necrosis factor alpha<\\e2> (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pioglitazone","object":"tumor necrosis factor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> improved the renal function, structural changes, renal malondialdehyde (MDA), <e2>GENE-Y<\\e2> (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats","sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats"}
{"PMID":22989705,"re_id":1,"annotated sentence":"The obtained results showed that <e1>pioglitazone<\\e1> improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (<e2>TNF-\u03b1<\\e2> , nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pioglitazone","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (<e2>GENE-Y<\\e2> , nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats","sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1 , nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats"}
{"PMID":22989705,"re_id":2,"annotated sentence":"The obtained results showed that <e1>pioglitazone<\\e1> improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), <e2>nuclear factor kappa B<\\e2> (NF-\u03baB) genes expression in cisplatin injected rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pioglitazone","object":"nuclear factor kappa B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), <e2>GENE-N<\\e2> (NF-\u03baB) genes expression in cisplatin injected rats","sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats"}
{"PMID":22989705,"re_id":3,"annotated sentence":"The obtained results showed that <e1>pioglitazone<\\e1> improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B (<e2>NF-\u03baB<\\e2>  genes expression in cisplatin injected rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pioglitazone","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that <e1>CHEMICAL<\\e1> improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B (<e2>GENE-N<\\e2>  genes expression in cisplatin injected rats","sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB  genes expression in cisplatin injected rats"}
{"PMID":22989705,"re_id":4,"annotated sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), <e2>tumor necrosis factor alpha<\\e2> (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB) genes expression in <e1>cisplatin<\\e1> injected rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"tumor necrosis factor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), <e2>GENE-Y<\\e2> (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB) genes expression in <e1>CHEMICAL<\\e1> injected rats","sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats"}
{"PMID":22989705,"re_id":5,"annotated sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (<e2>TNF-\u03b1<\\e2> , nuclear factor kappa B (NF-\u03baB) genes expression in <e1>cisplatin<\\e1> injected rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (<e2>GENE-Y<\\e2> , nuclear factor kappa B (NF-\u03baB) genes expression in <e1>CHEMICAL<\\e1> injected rats","sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1 , nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats"}
{"PMID":22989705,"re_id":6,"annotated sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), <e2>nuclear factor kappa B<\\e2> (NF-\u03baB) genes expression in <e1>cisplatin<\\e1> injected rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"nuclear factor kappa B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), <e2>GENE-N<\\e2> (NF-\u03baB) genes expression in <e1>CHEMICAL<\\e1> injected rats","sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats"}
{"PMID":22989705,"re_id":7,"annotated sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B (<e2>NF-\u03baB<\\e2>  genes expression in <e1>cisplatin<\\e1> injected rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cisplatin","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B (<e2>GENE-N<\\e2>  genes expression in <e1>CHEMICAL<\\e1> injected rats","sentence":"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB  genes expression in cisplatin injected rats"}
{"PMID":23000445,"re_id":0,"annotated sentence":"The results showed that <e1>wogonoside<\\e1> promotes the expression of <e2>LC3-II<\\e2> and Beclin-1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"wogonoside","object":"LC3-II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that <e1>CHEMICAL<\\e1> promotes the expression of <e2>GENE-Y<\\e2> and Beclin-1","sentence":"The results showed that wogonoside promotes the expression of LC3-II and Beclin-1"}
{"PMID":23000445,"re_id":1,"annotated sentence":"The results showed that <e1>wogonoside<\\e1> promotes the expression of LC3-II and <e2>Beclin-1<\\e2>  Furthermore, wogonoside inhibited cell growth of MDA-MB-231 cells in a concentration- and time-dependent manner, which was associated with wogonoside-induced autophagy","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"wogonoside","object":"Beclin-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that <e1>CHEMICAL<\\e1> promotes the expression of LC3-II and <e2>GENE-Y<\\e2>  Furthermore, CHEMICAL inhibited cell growth of MDA-MB-231 cells in a concentration- and time-dependent manner, which was associated with CHEMICAL-induced autophagy","sentence":"The results showed that wogonoside promotes the expression of LC3-II and Beclin-1  Furthermore, wogonoside inhibited cell growth of MDA-MB-231 cells in a concentration- and time-dependent manner, which was associated with wogonoside-induced autophagy"}
{"PMID":23000445,"re_id":2,"annotated sentence":"<e1>Wogonoside<\\e1> also suppressed the activation of mammalian target of rapamycin (mTOR) and <e2>p70-S6 kinase<\\e2> (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Wogonoside","object":"p70-S6 kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also suppressed the activation of mammalian target of rapamycin (mTOR) and <e2>GENE-N<\\e2> (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway","sentence":"Wogonoside also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway"}
{"PMID":23000445,"re_id":3,"annotated sentence":"<e1>Wogonoside<\\e1> also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (<e2>p70S6K)<\\e2> by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Wogonoside","object":"p70S6K)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (<e2>GENE-N<\\e2> by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway","sentence":"Wogonoside also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway"}
{"PMID":23000445,"re_id":4,"annotated sentence":"<e1>Wogonoside<\\e1> also suppressed the activation of <e2>mammalian target of rapamycin<\\e2> (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Wogonoside","object":"mammalian target of rapamycin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also suppressed the activation of <e2>GENE-Y<\\e2> (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway","sentence":"Wogonoside also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway"}
{"PMID":23000445,"re_id":5,"annotated sentence":"<e1>Wogonoside<\\e1> also suppressed the activation of mammalian target of rapamycin (<e2>mTOR<\\e2>  and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Wogonoside","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also suppressed the activation of mammalian target of rapamycin (<e2>GENE-Y<\\e2>  and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway","sentence":"Wogonoside also suppressed the activation of mammalian target of rapamycin (mTOR  and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1\/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway"}
{"PMID":23007555,"re_id":0,"annotated sentence":"At a low pH (pH 7.4), but not pH 7.9, <e1>ifenprodil<\\e1> reduces the mean open time of <e2>GluN1<\\e2> GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ifenprodil","object":"GluN1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At a low pH (pH 7.4), but not pH 7.9, <e1>CHEMICAL<\\e1> reduces the mean open time of <e2>GENE-Y<\\e2> GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.","sentence":"At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1 GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic."}
{"PMID":23007555,"re_id":1,"annotated sentence":"At a low pH (pH 7.4), but not pH 7.9, <e1>ifenprodil<\\e1> reduces the mean open time of GluN1\/<e2>GluN2B<\\e2> receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ifenprodil","object":"GluN2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At a low pH (pH 7.4), but not pH 7.9, <e1>CHEMICAL<\\e1> reduces the mean open time of GluN1\/<e2>GENE-Y<\\e2> receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.","sentence":"At a low pH (pH 7.4), but not pH 7.9, ifenprodil reduces the mean open time of GluN1\/GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic."}
{"PMID":23017388,"re_id":0,"annotated sentence":"Also, <e1>SB365<\\e1> showed anti-angiogenic activity by decreasing the expression of <e2>HIF-1\u03b1<\\e2> and VEGF","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB365","object":"HIF-1\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, <e1>CHEMICAL<\\e1> showed anti-angiogenic activity by decreasing the expression of <e2>GENE-Y<\\e2> and VEGF","sentence":"Also, SB365 showed anti-angiogenic activity by decreasing the expression of HIF-1\u03b1 and VEGF"}
{"PMID":23017388,"re_id":1,"annotated sentence":"Also, <e1>SB365<\\e1> showed anti-angiogenic activity by decreasing the expression of HIF-1\u03b1 and <e2>VEGF<\\e2>  These results were confirmed by an in vivo study showing that SB365 significantly inhibited tumor growth by the induction of apoptosis and inhibition of angiogenesis with stronger anticancer activity than 5-FU","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB365","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, <e1>CHEMICAL<\\e1> showed anti-angiogenic activity by decreasing the expression of HIF-1\u03b1 and <e2>GENE-Y<\\e2>  These results were confirmed by an in vivo study showing that CHEMICAL significantly inhibited tumor growth by the induction of apoptosis and inhibition of angiogenesis with stronger anticancer activity than 5-FU","sentence":"Also, SB365 showed anti-angiogenic activity by decreasing the expression of HIF-1\u03b1 and VEGF  These results were confirmed by an in vivo study showing that SB365 significantly inhibited tumor growth by the induction of apoptosis and inhibition of angiogenesis with stronger anticancer activity than 5-FU"}
{"PMID":23017388,"re_id":2,"annotated sentence":"When further examined for its anticancer mechanism, <e1>SB365<\\e1> effectively suppressed the <e2>AKT<\\e2> mTOR pathway both in vitro and in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB365","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When further examined for its anticancer mechanism, <e1>CHEMICAL<\\e1> effectively suppressed the <e2>GENE-N<\\e2> mTOR pathway both in vitro and in vivo","sentence":"When further examined for its anticancer mechanism, SB365 effectively suppressed the AKT mTOR pathway both in vitro and in vivo"}
{"PMID":23017388,"re_id":3,"annotated sentence":"When further examined for its anticancer mechanism, <e1>SB365<\\e1> effectively suppressed the AKT\/<e2>mTOR<\\e2> pathway both in vitro and in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB365","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When further examined for its anticancer mechanism, <e1>CHEMICAL<\\e1> effectively suppressed the AKT\/<e2>GENE-Y<\\e2> pathway both in vitro and in vivo","sentence":"When further examined for its anticancer mechanism, SB365 effectively suppressed the AKT\/mTOR pathway both in vitro and in vivo"}
{"PMID":23017388,"re_id":4,"annotated sentence":"Taken together, our study demonstrated that <e1>SB365<\\e1> inhibits the <e2>AKT<\\e2> mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB365","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, our study demonstrated that <e1>CHEMICAL<\\e1> inhibits the <e2>GENE-N<\\e2> mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis","sentence":"Taken together, our study demonstrated that SB365 inhibits the AKT mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis"}
{"PMID":23017388,"re_id":5,"annotated sentence":"Taken together, our study demonstrated that <e1>SB365<\\e1> inhibits the AKT\/<e2>mTOR<\\e2> pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB365","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, our study demonstrated that <e1>CHEMICAL<\\e1> inhibits the AKT\/<e2>GENE-Y<\\e2> pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis","sentence":"Taken together, our study demonstrated that SB365 inhibits the AKT\/mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis"}
{"PMID":23019138,"re_id":0,"annotated sentence":"In further studies, the diuretic effects of the <e2>CB1<\\e2> agonist <e1>AM4054<\\e1> were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AM4054","object":"CB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In further studies, the diuretic effects of the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]","sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]"}
{"PMID":23019138,"re_id":1,"annotated sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of <e1>WIN 55,212<\\e1> antagonized by the <e2>CB2<\\e2> antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"WIN 55,212","object":"CB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of <e1>CHEMICAL<\\e1> antagonized by the <e2>GENE-Y<\\e2> antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]","sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]"}
{"PMID":23019138,"re_id":2,"annotated sentence":"Direct-acting <e2>CB1<\\e2> agonists, including <e1>\u0394(9)-tetrahydrocannabinol<\\e1>  WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"\u0394(9)-tetrahydrocannabinol","object":"CB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Direct-acting <e2>GENE-Y<\\e2> agonists, including <e1>CHEMICAL<\\e1>  WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","sentence":"Direct-acting CB1 agonists, including \u0394(9)-tetrahydrocannabinol  WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia"}
{"PMID":23019138,"re_id":3,"annotated sentence":"Direct-acting <e2>CB1<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, <e1>WIN 55,212<\\e1> [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"WIN 55,212","object":"CB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Direct-acting <e2>GENE-Y<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, <e1>CHEMICAL<\\e1> [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","sentence":"Direct-acting CB1 agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia"}
{"PMID":23019138,"re_id":4,"annotated sentence":"Direct-acting <e2>CB1<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [<e1>R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate<\\e1> , AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate","object":"CB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Direct-acting <e2>GENE-Y<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [<e1>CHEMICAL<\\e1> , AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","sentence":"Direct-acting CB1 agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate , AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia"}
{"PMID":23019138,"re_id":5,"annotated sentence":"Direct-acting <e2>CB1<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], <e1>AM2389<\\e1> [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AM2389","object":"CB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Direct-acting <e2>GENE-Y<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], <e1>CHEMICAL<\\e1> [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","sentence":"Direct-acting CB1 agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia"}
{"PMID":23019138,"re_id":6,"annotated sentence":"Direct-acting <e2>CB1<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [<e1>9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol<\\e1> , and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol","object":"CB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Direct-acting <e2>GENE-Y<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [<e1>CHEMICAL<\\e1> , and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","sentence":"Direct-acting CB1 agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol , and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia"}
{"PMID":23019138,"re_id":7,"annotated sentence":"Direct-acting <e2>CB1<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and <e1>AM4054<\\e1> [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AM4054","object":"CB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Direct-acting <e2>GENE-Y<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and <e1>CHEMICAL<\\e1> [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","sentence":"Direct-acting CB1 agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia"}
{"PMID":23019138,"re_id":8,"annotated sentence":"Direct-acting <e2>CB1<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [<e1>9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol<\\e1> , produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol","object":"CB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Direct-acting <e2>GENE-Y<\\e2> agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [<e1>CHEMICAL<\\e1> , produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia","sentence":"Direct-acting CB1 agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol , produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia"}
{"PMID":23019138,"re_id":9,"annotated sentence":"Methanandamide (10.0 mg\/kg) had lesser effect than other CB agonists, and the <e2>CB2<\\e2> agonist <e1>AM1241<\\e1> [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AM1241","object":"CB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methanandamide (10.0 mg\/kg) had lesser effect than other CB agonists, and the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects","sentence":"Methanandamide (10.0 mg\/kg) had lesser effect than other CB agonists, and the CB2 agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects"}
{"PMID":23019138,"re_id":10,"annotated sentence":"Methanandamide (10.0 mg\/kg) had lesser effect than other CB agonists, and the <e2>CB2<\\e2> agonist AM1241 [<e1>1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole<\\e1> , the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole","object":"CB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methanandamide (10.0 mg\/kg) had lesser effect than other CB agonists, and the <e2>GENE-Y<\\e2> agonist AM1241 [<e1>CHEMICAL<\\e1> , the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects","sentence":"Methanandamide (10.0 mg\/kg) had lesser effect than other CB agonists, and the CB2 agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole , the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects"}
{"PMID":23019138,"re_id":11,"annotated sentence":"Methanandamide (10.0 mg\/kg) had lesser effect than other CB agonists, and the <e2>CB2<\\e2> agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor <e1>AM404<\\e1>  and the CB antagonist rimonabant did not have diuretic effects","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"AM404","object":"CB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methanandamide (10.0 mg\/kg) had lesser effect than other CB agonists, and the <e2>GENE-Y<\\e2> agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor <e1>CHEMICAL<\\e1>  and the CB antagonist rimonabant did not have diuretic effects","sentence":"Methanandamide (10.0 mg\/kg) had lesser effect than other CB agonists, and the CB2 agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404  and the CB antagonist rimonabant did not have diuretic effects"}
{"PMID":23019138,"re_id":12,"annotated sentence":"In further studies, the diuretic effects of the <e2>CB1<\\e2> agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with <e1>rimonabant<\\e1>  but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"rimonabant","object":"CB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In further studies, the diuretic effects of the <e2>GENE-Y<\\e2> agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with <e1>CHEMICAL<\\e1>  but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]","sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant  but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]"}
{"PMID":23019138,"re_id":13,"annotated sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the <e2>vanilloid receptor type I<\\e2> antagonist <e1>capsazepine<\\e1>  nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"capsazepine","object":"vanilloid receptor type I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]","sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine  nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]"}
{"PMID":23019138,"re_id":14,"annotated sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the <e2>CB2<\\e2> antagonist <e1>AM630<\\e1> [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"AM630","object":"CB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]","sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]"}
{"PMID":23019138,"re_id":15,"annotated sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the <e2>CB2<\\e2> antagonist AM630 [<e1>(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)<\\e1> ","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)","object":"CB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the <e2>GENE-Y<\\e2> antagonist AM630 [<e1>CHEMICAL<\\e1> ","sentence":"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone) "}
{"PMID":23022324,"re_id":0,"annotated sentence":"<e1>NaAsO(2)<\\e1> increased the mRNA levels of the <e2>light and medium subunits of neurofilament<\\e2> and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaAsO(2)","object":"light and medium subunits of neurofilament","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increased the mRNA levels of the <e2>GENE-N<\\e2> and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin","sentence":"NaAsO(2) increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin"}
{"PMID":23022324,"re_id":1,"annotated sentence":"<e1>NaAsO(2)<\\e1> increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of <e2>tau<\\e2> and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NaAsO(2)","object":"tau","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of <e2>GENE-Y<\\e2> and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin","sentence":"NaAsO(2) increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin"}
{"PMID":23022324,"re_id":2,"annotated sentence":"<e1>NaAsO(2)<\\e1> increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and <e2>tubulin<\\e2> in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NaAsO(2)","object":"tubulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and <e2>GENE-N<\\e2> in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin","sentence":"NaAsO(2) increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin"}
{"PMID":23041257,"re_id":0,"annotated sentence":"<e1>DBDCT<\\e1> up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of <e2>Bax<\\e2> Bcl-2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DBDCT","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> up-regulated the expression of GENE-Y, down-regulated the expression of Bcl-2, and significantly increased the ratio of <e2>GENE-Y<\\e2> Bcl-2","sentence":"DBDCT up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax Bcl-2"}
{"PMID":23041257,"re_id":1,"annotated sentence":"<e1>DBDCT<\\e1> up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax\/<e2>Bcl-2<\\e2>  DBDCT also caused the phosphorylation of JNK and p38(MAPK)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DBDCT","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> up-regulated the expression of Bax, down-regulated the expression of GENE-Y, and significantly increased the ratio of Bax\/<e2>GENE-Y<\\e2>  CHEMICAL also caused the phosphorylation of JNK and p38(MAPK)","sentence":"DBDCT up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax\/Bcl-2  DBDCT also caused the phosphorylation of JNK and p38(MAPK)"}
{"PMID":23041257,"re_id":2,"annotated sentence":"<e1>DBDCT<\\e1> up-regulated the expression of <e2>Bax<\\e2>  down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax\/Bcl-2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DBDCT","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> up-regulated the expression of <e2>GENE-Y<\\e2>  down-regulated the expression of Bcl-2, and significantly increased the ratio of GENE-Y\/Bcl-2","sentence":"DBDCT up-regulated the expression of Bax  down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax\/Bcl-2"}
{"PMID":23041257,"re_id":3,"annotated sentence":"<e1>DBDCT<\\e1> also caused the phosphorylation of <e2>JNK<\\e2> and p38(MAPK)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DBDCT","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also caused the phosphorylation of <e2>GENE-N<\\e2> and p38(MAPK)","sentence":"DBDCT also caused the phosphorylation of JNK and p38(MAPK)"}
{"PMID":23041257,"re_id":4,"annotated sentence":"<e1>DBDCT<\\e1> also caused the phosphorylation of JNK and <e2>p38<\\e2> MAPK)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DBDCT","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also caused the phosphorylation of JNK and <e2>GENE-N<\\e2> MAPK)","sentence":"DBDCT also caused the phosphorylation of JNK and p38 MAPK)"}
{"PMID":23041257,"re_id":5,"annotated sentence":"<e1>DBDCT<\\e1> also caused the phosphorylation of JNK and p38(<e2>MAPK<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DBDCT","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also caused the phosphorylation of JNK and p38(<e2>GENE-N<\\e2> ","sentence":"DBDCT also caused the phosphorylation of JNK and p38(MAPK "}
{"PMID":23041257,"re_id":6,"annotated sentence":"<e1>DBDCT<\\e1> up-regulated the expression of Bax, down-regulated the expression of <e2>Bcl-2<\\e2>  and significantly increased the ratio of Bax\/Bcl-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DBDCT","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> up-regulated the expression of Bax, down-regulated the expression of <e2>GENE-Y<\\e2>  and significantly increased the ratio of Bax\/GENE-Y","sentence":"DBDCT up-regulated the expression of Bax, down-regulated the expression of Bcl-2  and significantly increased the ratio of Bax\/Bcl-2"}
{"PMID":23043184,"re_id":0,"annotated sentence":"The results show that CYP2E1 inhibits <e2>CYP2B4<\\e2> mediated metabolism of <e1>benzphetamine<\\e1> (BNZ) with a K(i) of 0.04 \u00b5M","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"benzphetamine","object":"CYP2B4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results show that CYP2E1 inhibits <e2>GENE-Y<\\e2> mediated metabolism of <e1>CHEMICAL<\\e1> (BNZ) with a K(i) of 0.04 \u00b5M","sentence":"The results show that CYP2E1 inhibits CYP2B4 mediated metabolism of benzphetamine (BNZ) with a K(i) of 0.04 \u00b5M"}
{"PMID":23043184,"re_id":1,"annotated sentence":"The results show that CYP2E1 inhibits <e2>CYP2B4<\\e2> mediated metabolism of benzphetamine (<e1>BNZ<\\e1>  with a K(i) of 0.04 \u00b5M","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"BNZ","object":"CYP2B4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results show that CYP2E1 inhibits <e2>GENE-Y<\\e2> mediated metabolism of benzphetamine (<e1>CHEMICAL<\\e1>  with a K(i) of 0.04 \u00b5M","sentence":"The results show that CYP2E1 inhibits CYP2B4 mediated metabolism of benzphetamine (BNZ  with a K(i) of 0.04 \u00b5M"}
{"PMID":23043184,"re_id":2,"annotated sentence":"However, CYP2B4 is not an inhibitor of <e2>CYP2E1<\\e2> mediated <e1>p-nitrophenol<\\e1> hydroxylation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"p-nitrophenol","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, CYP2B4 is not an inhibitor of <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> hydroxylation","sentence":"However, CYP2B4 is not an inhibitor of CYP2E1 mediated p-nitrophenol hydroxylation"}
{"PMID":23046524,"re_id":0,"annotated sentence":"Based on these studies, the frequency of spontaneous tail contractions at 26 hpf - a developmental stage with minimal <e2>AChE<\\e2> expression and activity - was significantly higher following exposure to <e1>paraoxon<\\e1> concentrations as low as 31.2 nM","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paraoxon","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on these studies, the frequency of spontaneous tail contractions at 26 hpf - a developmental stage with minimal <e2>GENE-Y<\\e2> expression and activity - was significantly higher following exposure to <e1>CHEMICAL<\\e1> concentrations as low as 31.2 nM","sentence":"Based on these studies, the frequency of spontaneous tail contractions at 26 hpf - a developmental stage with minimal AChE expression and activity - was significantly higher following exposure to paraoxon concentrations as low as 31.2 nM"}
{"PMID":23046524,"re_id":1,"annotated sentence":"We then showed that static exposure of embryos to <e1>paraoxon<\\e1> (31.2-500 nM) from 5 to 96 hpf resulted in significant stage- and concentration-dependent <e2>AChE<\\e2> inhibition, albeit these effects were fully reversible within 48 h following transfer to clean water","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"paraoxon","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We then showed that static exposure of embryos to <e1>CHEMICAL<\\e1> (31.2-500 nM) from 5 to 96 hpf resulted in significant stage- and concentration-dependent <e2>GENE-Y<\\e2> inhibition, albeit these effects were fully reversible within 48 h following transfer to clean water","sentence":"We then showed that static exposure of embryos to paraoxon (31.2-500 nM) from 5 to 96 hpf resulted in significant stage- and concentration-dependent AChE inhibition, albeit these effects were fully reversible within 48 h following transfer to clean water"}
{"PMID":23046524,"re_id":2,"annotated sentence":"Using <e1>paraoxon<\\e1> as a reference <e2>acetylcholinesterase<\\e2> (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"paraoxon","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using <e1>CHEMICAL<\\e1> as a reference <e2>GENE-Y<\\e2> (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis","sentence":"Using paraoxon as a reference acetylcholinesterase (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis"}
{"PMID":23046524,"re_id":3,"annotated sentence":"Using <e1>paraoxon<\\e1> as a reference acetylcholinesterase (<e2>AChE<\\e2>  inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"paraoxon","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using <e1>CHEMICAL<\\e1> as a reference acetylcholinesterase (<e2>GENE-Y<\\e2>  inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis","sentence":"Using paraoxon as a reference acetylcholinesterase (AChE  inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis"}
{"PMID":23063590,"re_id":0,"annotated sentence":"The mRNA levels of <e2>microphthalmia-associated transcription factor<\\e2> (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by <e1>artemisinic acid<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"microphthalmia-associated transcription factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of <e2>GENE-Y<\\e2> (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by <e1>CHEMICAL<\\e1> treatment","sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by artemisinic acid treatment"}
{"PMID":23063590,"re_id":1,"annotated sentence":"The mRNA levels of microphthalmia-associated transcription factor (<e2>MITF<\\e2>  and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by <e1>artemisinic acid<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"MITF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of microphthalmia-associated transcription factor (<e2>GENE-Y<\\e2>  and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by <e1>CHEMICAL<\\e1> treatment","sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF  and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by artemisinic acid treatment"}
{"PMID":23063590,"re_id":2,"annotated sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes <e2>tyrosinase<\\e2>  tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by <e1>artemisinic acid<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes <e2>GENE-Y<\\e2>  GENE-Y-related protein (TRP)-1, and TRP-2 were reduced by <e1>CHEMICAL<\\e1> treatment","sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase  tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by artemisinic acid treatment"}
{"PMID":23063590,"re_id":3,"annotated sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, <e2>tyrosinase-related protein (TRP)-1<\\e2>  and TRP-2 were reduced by <e1>artemisinic acid<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"tyrosinase-related protein (TRP)-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, <e2>GENE-Y<\\e2>  and TRP-2 were reduced by <e1>CHEMICAL<\\e1> treatment","sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1  and TRP-2 were reduced by artemisinic acid treatment"}
{"PMID":23063590,"re_id":4,"annotated sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and <e2>TRP-2<\\e2> were reduced by <e1>artemisinic acid<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"TRP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and <e2>GENE-Y<\\e2> were reduced by <e1>CHEMICAL<\\e1> treatment","sentence":"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by artemisinic acid treatment"}
{"PMID":23063590,"re_id":5,"annotated sentence":"Additionally, the mRNA levels of melanogenesis-related genes (<e2>c-KIT<\\e2>  stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by <e1>artemisinic acid<\\e1>  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"c-KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, the mRNA levels of melanogenesis-related genes (<e2>GENE-Y<\\e2>  stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by <e1>CHEMICAL<\\e1>  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by CHEMICAL","sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT  stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by artemisinic acid  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid"}
{"PMID":23063590,"re_id":6,"annotated sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, <e2>stem cell factor<\\e2> (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by <e1>artemisinic acid<\\e1>  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"stem cell factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, <e2>GENE-Y<\\e2> (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by <e1>CHEMICAL<\\e1>  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by CHEMICAL","sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by artemisinic acid  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid"}
{"PMID":23063590,"re_id":7,"annotated sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (<e2>SCF<\\e2> , and macrophage migration inhibitory factor (MIF)) were down-regulated by <e1>artemisinic acid<\\e1>  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"SCF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (<e2>GENE-Y<\\e2> , and macrophage migration inhibitory factor (MIF)) were down-regulated by <e1>CHEMICAL<\\e1>  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by CHEMICAL","sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF , and macrophage migration inhibitory factor (MIF)) were down-regulated by artemisinic acid  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid"}
{"PMID":23063590,"re_id":8,"annotated sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and <e2>macrophage migration inhibitory factor<\\e2> (MIF)) were down-regulated by <e1>artemisinic acid<\\e1>  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"macrophage migration inhibitory factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and <e2>GENE-Y<\\e2> (MIF)) were down-regulated by <e1>CHEMICAL<\\e1>  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by CHEMICAL","sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by artemisinic acid  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid"}
{"PMID":23063590,"re_id":9,"annotated sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (<e2>MIF<\\e2> ) were down-regulated by <e1>artemisinic acid<\\e1>  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"MIF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (<e2>GENE-Y<\\e2> ) were down-regulated by <e1>CHEMICAL<\\e1>  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by CHEMICAL","sentence":"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (MIF ) were down-regulated by artemisinic acid  Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid"}
{"PMID":23063590,"re_id":10,"annotated sentence":"Furthermore, cAMP production and <e2>protein kinase A<\\e2> (PKA) activity were suppressed by <e1>artemisinic acid<\\e1>  Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT\/enhancer-binding protein (C\/EBP) \u03b1 gene","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"protein kinase A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, cAMP production and <e2>GENE-N<\\e2> (PKA) activity were suppressed by <e1>CHEMICAL<\\e1>  Moreover, attempts to elucidate a possible mechanism underlying the CHEMICAL-mediated effects revealed that CHEMICAL regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT\/enhancer-binding protein (C\/EBP) \u03b1 gene","sentence":"Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid  Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT\/enhancer-binding protein (C\/EBP) \u03b1 gene"}
{"PMID":23063590,"re_id":11,"annotated sentence":"Furthermore, cAMP production and protein kinase A (<e2>PKA<\\e2>  activity were suppressed by <e1>artemisinic acid<\\e1>  Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT\/enhancer-binding protein (C\/EBP) \u03b1 gene","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, cAMP production and protein kinase A (<e2>GENE-N<\\e2>  activity were suppressed by <e1>CHEMICAL<\\e1>  Moreover, attempts to elucidate a possible mechanism underlying the CHEMICAL-mediated effects revealed that CHEMICAL regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT\/enhancer-binding protein (C\/EBP) \u03b1 gene","sentence":"Furthermore, cAMP production and protein kinase A (PKA  activity were suppressed by artemisinic acid  Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT\/enhancer-binding protein (C\/EBP) \u03b1 gene"}
{"PMID":23063590,"re_id":12,"annotated sentence":"Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that <e1>artemisinic acid<\\e1> regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the <e2>hydroxymethylglutaryl CoA (HMG CoA) reductase<\\e2> gene, which was mediated through reduced expression of the CCAAT\/enhancer-binding protein (C\/EBP) \u03b1 gene","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"hydroxymethylglutaryl CoA (HMG CoA) reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, attempts to elucidate a possible mechanism underlying the CHEMICAL-mediated effects revealed that <e1>CHEMICAL<\\e1> regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the <e2>GENE-Y<\\e2> gene, which was mediated through reduced expression of the CCAAT\/enhancer-binding protein (C\/EBP) \u03b1 gene","sentence":"Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT\/enhancer-binding protein (C\/EBP) \u03b1 gene"}
{"PMID":23063590,"re_id":13,"annotated sentence":"Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that <e1>artemisinic acid<\\e1> regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the <e2>CCAAT\/enhancer-binding protein (C\/EBP) \u03b1<\\e2> gene","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"CCAAT\/enhancer-binding protein (C\/EBP) \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, attempts to elucidate a possible mechanism underlying the CHEMICAL-mediated effects revealed that <e1>CHEMICAL<\\e1> regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the <e2>GENE-Y<\\e2> gene","sentence":"Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT\/enhancer-binding protein (C\/EBP) \u03b1 gene"}
{"PMID":23063590,"re_id":14,"annotated sentence":"<e1>Artemisinic acid<\\e1> inhibits melanogenesis through downregulation of <e2>C\/EBP \u03b1<\\e2> dependent expression of HMG-CoA reductase gene","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Artemisinic acid","object":"C\/EBP \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits melanogenesis through downregulation of <e2>GENE-Y<\\e2> dependent expression of HMG-CoA reductase gene","sentence":"Artemisinic acid inhibits melanogenesis through downregulation of C\/EBP \u03b1 dependent expression of HMG-CoA reductase gene"}
{"PMID":23063590,"re_id":15,"annotated sentence":"<e1>Artemisinic acid<\\e1> inhibits melanogenesis through downregulation of C\/EBP \u03b1-dependent expression of <e2>HMG-CoA reductase<\\e2> gene","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Artemisinic acid","object":"HMG-CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits melanogenesis through downregulation of C\/EBP \u03b1-dependent expression of <e2>GENE-Y<\\e2> gene","sentence":"Artemisinic acid inhibits melanogenesis through downregulation of C\/EBP \u03b1-dependent expression of HMG-CoA reductase gene"}
{"PMID":23063590,"re_id":16,"annotated sentence":"Taken together, these findings indicate that the inhibition of melanogenesis by <e1>artemisinic acid<\\e1> occurs through reduced expression of the <e2>HMG CoA reductase<\\e2> gene, which is mediated by C\/EBP \u03b1 inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"HMG CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, these findings indicate that the inhibition of melanogenesis by <e1>CHEMICAL<\\e1> occurs through reduced expression of the <e2>GENE-Y<\\e2> gene, which is mediated by C\/EBP \u03b1 inhibition and suggest that CHEMICAL may be useful as a hyperpigmentation inhibitor.","sentence":"Taken together, these findings indicate that the inhibition of melanogenesis by artemisinic acid occurs through reduced expression of the HMG CoA reductase gene, which is mediated by C\/EBP \u03b1 inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor."}
{"PMID":23063590,"re_id":17,"annotated sentence":"Taken together, these findings indicate that the inhibition of melanogenesis by <e1>artemisinic acid<\\e1> occurs through reduced expression of the HMG CoA reductase gene, which is mediated by <e2>C\/EBP \u03b1<\\e2> inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"artemisinic acid","object":"C\/EBP \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, these findings indicate that the inhibition of melanogenesis by <e1>CHEMICAL<\\e1> occurs through reduced expression of the HMG CoA reductase gene, which is mediated by <e2>GENE-Y<\\e2> inhibition and suggest that CHEMICAL may be useful as a hyperpigmentation inhibitor.","sentence":"Taken together, these findings indicate that the inhibition of melanogenesis by artemisinic acid occurs through reduced expression of the HMG CoA reductase gene, which is mediated by C\/EBP \u03b1 inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor."}
{"PMID":23071106,"re_id":0,"annotated sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of <e2>insulin<\\e2> secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor <e1>bisindolylmaleimide I<\\e1> (1 \u03bcM)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bisindolylmaleimide I","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of <e2>GENE-N<\\e2> secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor <e1>CHEMICAL<\\e1> (1 \u03bcM)","sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)"}
{"PMID":23071106,"re_id":1,"annotated sentence":"Our data demonstrate that the actions of both tolbutamide and gliclazide are strongly potentiated by 8-pCPT-2'-O-Me-cAMP-AM, that <e1>gliclazide<\\e1> can stimulate <e2>phospholipase C<\\e2> activity via a partially pertussis toxin-sensitive mechanism, and that 8-pCPT-2'-O-Me-cAMP-AM potentiation of tolbutamide action may involve activation of a 2-APB-sensitive Ca(2+) influx.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gliclazide","object":"phospholipase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our data demonstrate that the actions of both tolbutamide and CHEMICAL are strongly potentiated by 8-pCPT-2'-O-Me-cAMP-AM, that <e1>CHEMICAL<\\e1> can stimulate <e2>GENE-N<\\e2> activity via a partially pertussis toxin-sensitive mechanism, and that 8-pCPT-2'-O-Me-cAMP-AM potentiation of tolbutamide action may involve activation of a 2-APB-sensitive Ca(2+) influx.","sentence":"Our data demonstrate that the actions of both tolbutamide and gliclazide are strongly potentiated by 8-pCPT-2'-O-Me-cAMP-AM, that gliclazide can stimulate phospholipase C activity via a partially pertussis toxin-sensitive mechanism, and that 8-pCPT-2'-O-Me-cAMP-AM potentiation of tolbutamide action may involve activation of a 2-APB-sensitive Ca(2+) influx."}
{"PMID":23071106,"re_id":2,"annotated sentence":"<e1>Tolbutamide<\\e1> and gliclazide block the K(ATP) channel K(ir)6.2\/Sur1, causing membrane depolarization and stimulating <e2>insulin<\\e2> secretion in pancreatic beta cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Tolbutamide","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and gliclazide block the K(ATP) channel K(ir)6.2\/Sur1, causing membrane depolarization and stimulating <e2>GENE-Y<\\e2> secretion in pancreatic beta cells","sentence":"Tolbutamide and gliclazide block the K(ATP) channel K(ir)6.2\/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells"}
{"PMID":23071106,"re_id":3,"annotated sentence":"<e2>Insulin<\\e2> secretion stimulated by both 200 \u03bcM <e1>tolbutamide<\\e1> and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tolbutamide","object":"Insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> secretion stimulated by both 200 \u03bcM <e1>CHEMICAL<\\e1> and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells","sentence":"Insulin secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells"}
{"PMID":23071106,"re_id":4,"annotated sentence":"<e2>Insulin<\\e2> secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM <e1>gliclazide<\\e1>  concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gliclazide","object":"Insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM <e1>CHEMICAL<\\e1>  concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells","sentence":"Insulin secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide  concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells"}
{"PMID":23071106,"re_id":5,"annotated sentence":"<e2>Insulin<\\e2> secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by <e1>8-pCPT-2'-O-Me-cAMP-AM<\\e1> at concentrations \u22652 \u03bcM in INS-1 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"8-pCPT-2'-O-Me-cAMP-AM","object":"Insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by <e1>CHEMICAL<\\e1> at concentrations \u22652 \u03bcM in INS-1 cells","sentence":"Insulin secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells"}
{"PMID":23071106,"re_id":6,"annotated sentence":"Both <e1>tolbutamide<\\e1> and gliclazide stimulated <e2>phospholipase C<\\e2> activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tolbutamide","object":"phospholipase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both <e1>CHEMICAL<\\e1> and gliclazide stimulated <e2>GENE-N<\\e2> activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin","sentence":"Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin"}
{"PMID":23071106,"re_id":7,"annotated sentence":"Both tolbutamide and <e1>gliclazide<\\e1> stimulated <e2>phospholipase C<\\e2> activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gliclazide","object":"phospholipase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both tolbutamide and <e1>CHEMICAL<\\e1> stimulated <e2>GENE-N<\\e2> activity; however, only CHEMICAL did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin","sentence":"Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin"}
{"PMID":23071106,"re_id":8,"annotated sentence":"Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only <e1>gliclazide<\\e1> did so independently of its activity at <e2>K(ATP) channels<\\e2>  and this activity was partially inhibited by pertussis toxin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"gliclazide","object":"K(ATP) channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both tolbutamide and CHEMICAL stimulated phospholipase C activity; however, only <e1>CHEMICAL<\\e1> did so independently of its activity at <e2>GENE-N<\\e2>  and this activity was partially inhibited by pertussis toxin","sentence":"Both tolbutamide and gliclazide stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at K(ATP) channels  and this activity was partially inhibited by pertussis toxin"}
{"PMID":23071106,"re_id":9,"annotated sentence":"<e1>8-pCPT-2'-O-Me-cAMP-AM<\\e1> potentiation of <e2>insulin<\\e2> secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"8-pCPT-2'-O-Me-cAMP-AM","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> potentiation of <e2>GENE-N<\\e2> secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)","sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)"}
{"PMID":23071106,"re_id":10,"annotated sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of <e2>insulin<\\e2> secretion stimulated by <e1>tolbutamide<\\e1> was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tolbutamide","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of <e2>GENE-N<\\e2> secretion stimulated by <e1>CHEMICAL<\\e1> was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)","sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)"}
{"PMID":23071106,"re_id":11,"annotated sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the <e2>PKC<\\e2> inhibitor <e1>bisindolylmaleimide I<\\e1> (1 \u03bcM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bisindolylmaleimide I","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (1 \u03bcM)","sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)"}
{"PMID":23071106,"re_id":12,"annotated sentence":"<e1>Tolbutamide<\\e1> and gliclazide block the <e2>K(ATP) channel<\\e2> K(ir)6.2\/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tolbutamide","object":"K(ATP) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and gliclazide block the <e2>GENE-N<\\e2> K(ir)6.2\/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells","sentence":"Tolbutamide and gliclazide block the K(ATP) channel K(ir)6.2\/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells"}
{"PMID":23071106,"re_id":13,"annotated sentence":"<e1>Tolbutamide<\\e1> and gliclazide block the K(ATP) channel <e2>K(ir)6.2<\\e2> Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tolbutamide","object":"K(ir)6.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and gliclazide block the K(ATP) channel <e2>GENE-Y<\\e2> Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells","sentence":"Tolbutamide and gliclazide block the K(ATP) channel K(ir)6.2 Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells"}
{"PMID":23071106,"re_id":14,"annotated sentence":"<e1>Tolbutamide<\\e1> and gliclazide block the K(ATP) channel K(ir)6.2\/<e2>Sur1<\\e2>  causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Tolbutamide","object":"Sur1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and gliclazide block the K(ATP) channel K(ir)6.2\/<e2>GENE-Y<\\e2>  causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells","sentence":"Tolbutamide and gliclazide block the K(ATP) channel K(ir)6.2\/Sur1  causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells"}
{"PMID":23071106,"re_id":15,"annotated sentence":"<e2>Insulin<\\e2> secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by <e1>thapsigargin<\\e1> (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"thapsigargin","object":"Insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by <e1>CHEMICAL<\\e1> (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells","sentence":"Insulin secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells"}
{"PMID":23071106,"re_id":16,"annotated sentence":"<e2>Insulin<\\e2> secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker <e1>nicardipine<\\e1> (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicardipine","object":"Insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker <e1>CHEMICAL<\\e1> (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells","sentence":"Insulin secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells"}
{"PMID":23071106,"re_id":17,"annotated sentence":"Insulin secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the <e2>L-type Ca(2+) channel<\\e2> blocker <e1>nicardipine<\\e1> (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicardipine","object":"L-type Ca(2+) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Insulin secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the <e2>GENE-N<\\e2> blocker <e1>CHEMICAL<\\e1> (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells","sentence":"Insulin secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells"}
{"PMID":23071106,"re_id":18,"annotated sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of <e2>insulin<\\e2> secretion stimulated by tolbutamide was markedly inhibited by <e1>2-APB<\\e1> (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-APB","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of <e2>GENE-N<\\e2> secretion stimulated by tolbutamide was markedly inhibited by <e1>CHEMICAL<\\e1> (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)","sentence":"8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)"}
{"PMID":23074021,"re_id":0,"annotated sentence":"In addition, the number and area of <e2>glutathione S-transferase placental form<\\e2> (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg <e1>MEG<\\e1> compared with the control animals","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MEG","object":"glutathione S-transferase placental form","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, the number and area of <e2>GENE-N<\\e2> (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg <e1>CHEMICAL<\\e1> compared with the control animals","sentence":"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg MEG compared with the control animals"}
{"PMID":23074021,"re_id":1,"annotated sentence":"In addition, the number and area of glutathione S-transferase placental form (<e2>GST-P<\\e2>  positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg <e1>MEG<\\e1> compared with the control animals","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MEG","object":"GST-P","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, the number and area of glutathione S-transferase placental form (<e2>GENE-N<\\e2>  positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg <e1>CHEMICAL<\\e1> compared with the control animals","sentence":"In addition, the number and area of glutathione S-transferase placental form (GST-P  positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg MEG compared with the control animals"}
{"PMID":23074021,"re_id":2,"annotated sentence":"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and <e2>proliferating cell nuclear antigen<\\e2> (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg <e1>MEG<\\e1> compared with the control animals","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MEG","object":"proliferating cell nuclear antigen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and <e2>GENE-Y<\\e2> (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg <e1>CHEMICAL<\\e1> compared with the control animals","sentence":"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg MEG compared with the control animals"}
{"PMID":23074021,"re_id":3,"annotated sentence":"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (<e2>PCNA<\\e2>  positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg <e1>MEG<\\e1> compared with the control animals","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MEG","object":"PCNA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (<e2>GENE-Y<\\e2>  positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg <e1>CHEMICAL<\\e1> compared with the control animals","sentence":"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (PCNA  positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg\/kg MEG compared with the control animals"}
{"PMID":23085435,"re_id":0,"annotated sentence":"Furthermore, <e1>N<\\e1> BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced <e2>Bim<\\e2> expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"N","object":"Bim","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced <e2>GENE-Y<\\e2> expression","sentence":"Furthermore, N BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression"}
{"PMID":23085435,"re_id":1,"annotated sentence":"Furthermore, N-<e1>BPs<\\e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced <e2>Bim<\\e2> expression","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BPs","object":"Bim","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, N-<e1>CHEMICAL<\\e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced <e2>GENE-Y<\\e2> expression","sentence":"Furthermore, N-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression"}
{"PMID":23085435,"re_id":2,"annotated sentence":"The present results indicated that <e1>N<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of <e2>caspase-9<\\e2> and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"N","object":"caspase-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present results indicated that <e1>CHEMICAL<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of <e2>GENE-Y<\\e2> and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","sentence":"The present results indicated that N BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":3,"annotated sentence":"The present results indicated that <e1>N<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and <e2>caspase-3<\\e2>  and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"N","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present results indicated that <e1>CHEMICAL<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and <e2>GENE-Y<\\e2>  and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","sentence":"The present results indicated that N BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3  and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":4,"annotated sentence":"The present results indicated that <e1>N<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing <e2>Bim<\\e2> expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"N","object":"Bim","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present results indicated that <e1>CHEMICAL<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing <e2>GENE-Y<\\e2> expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","sentence":"The present results indicated that N BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":5,"annotated sentence":"The present results indicated that N-<e1>BPs<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of <e2>caspase-9<\\e2> and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BPs","object":"caspase-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present results indicated that N-<e1>CHEMICAL<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of <e2>GENE-Y<\\e2> and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","sentence":"The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":6,"annotated sentence":"The present results indicated that N-<e1>BPs<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and <e2>caspase-3<\\e2>  and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BPs","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present results indicated that N-<e1>CHEMICAL<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and <e2>GENE-Y<\\e2>  and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","sentence":"The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3  and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":7,"annotated sentence":"The present results indicated that N-<e1>BPs<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing <e2>Bim<\\e2> expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BPs","object":"Bim","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present results indicated that N-<e1>CHEMICAL<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing <e2>GENE-Y<\\e2> expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways","sentence":"The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":8,"annotated sentence":"<e1>Nitrogen<\\e1> containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and <e2>Bim<\\e2> mediated activation of the intrinsic apoptotic pathway","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Nitrogen","object":"Bim","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and <e2>GENE-Y<\\e2> mediated activation of the intrinsic apoptotic pathway","sentence":"Nitrogen containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim mediated activation of the intrinsic apoptotic pathway"}
{"PMID":23085435,"re_id":9,"annotated sentence":"Nitrogen-containing <e1>bisphosphonates<\\e1> induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and <e2>Bim<\\e2> mediated activation of the intrinsic apoptotic pathway","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bisphosphonates","object":"Bim","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nitrogen-containing <e1>CHEMICAL<\\e1> induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and <e2>GENE-Y<\\e2> mediated activation of the intrinsic apoptotic pathway","sentence":"Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim mediated activation of the intrinsic apoptotic pathway"}
{"PMID":23085435,"re_id":10,"annotated sentence":"Furthermore, <e1>N<\\e1> BPs decreased the levels of <e2>phosphorylated extracellular signal-regulated kinase<\\e2> (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"phosphorylated extracellular signal-regulated kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> BPs decreased the levels of <e2>GENE-N<\\e2> (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression","sentence":"Furthermore, N BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression"}
{"PMID":23085435,"re_id":11,"annotated sentence":"Furthermore, <e1>N<\\e1> BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (<e2>ERK<\\e2>  and mTOR via suppression of Ras prenylation and enhanced Bim expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (<e2>GENE-N<\\e2>  and mTOR via suppression of Ras prenylation and enhanced Bim expression","sentence":"Furthermore, N BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK  and mTOR via suppression of Ras prenylation and enhanced Bim expression"}
{"PMID":23085435,"re_id":12,"annotated sentence":"Furthermore, <e1>N<\\e1> BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and <e2>mTOR<\\e2> via suppression of Ras prenylation and enhanced Bim expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and <e2>GENE-Y<\\e2> via suppression of Ras prenylation and enhanced Bim expression","sentence":"Furthermore, N BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression"}
{"PMID":23085435,"re_id":13,"annotated sentence":"Furthermore, <e1>N<\\e1> BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of <e2>Ras<\\e2> prenylation and enhanced Bim expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of <e2>GENE-N<\\e2> prenylation and enhanced Bim expression","sentence":"Furthermore, N BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression"}
{"PMID":23085435,"re_id":14,"annotated sentence":"Furthermore, N-<e1>BPs<\\e1> decreased the levels of <e2>phosphorylated extracellular signal-regulated kinase<\\e2> (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPs","object":"phosphorylated extracellular signal-regulated kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, N-<e1>CHEMICAL<\\e1> decreased the levels of <e2>GENE-N<\\e2> (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression","sentence":"Furthermore, N-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression"}
{"PMID":23085435,"re_id":15,"annotated sentence":"Furthermore, N-<e1>BPs<\\e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (<e2>ERK<\\e2>  and mTOR via suppression of Ras prenylation and enhanced Bim expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPs","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, N-<e1>CHEMICAL<\\e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (<e2>GENE-N<\\e2>  and mTOR via suppression of Ras prenylation and enhanced Bim expression","sentence":"Furthermore, N-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK  and mTOR via suppression of Ras prenylation and enhanced Bim expression"}
{"PMID":23085435,"re_id":16,"annotated sentence":"Furthermore, N-<e1>BPs<\\e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and <e2>mTOR<\\e2> via suppression of Ras prenylation and enhanced Bim expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPs","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, N-<e1>CHEMICAL<\\e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and <e2>GENE-Y<\\e2> via suppression of Ras prenylation and enhanced Bim expression","sentence":"Furthermore, N-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression"}
{"PMID":23085435,"re_id":17,"annotated sentence":"Furthermore, N-<e1>BPs<\\e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of <e2>Ras<\\e2> prenylation and enhanced Bim expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPs","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, N-<e1>CHEMICAL<\\e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of <e2>GENE-N<\\e2> prenylation and enhanced Bim expression","sentence":"Furthermore, N-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression"}
{"PMID":23085435,"re_id":18,"annotated sentence":"The present results indicated that <e1>N<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the <e2>Ras<\\e2> MEK\/ERK and Ras\/mTOR pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present results indicated that <e1>CHEMICAL<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the <e2>GENE-N<\\e2> MEK\/ERK and GENE-N\/mTOR pathways","sentence":"The present results indicated that N BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":19,"annotated sentence":"The present results indicated that <e1>N<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/<e2>MEK<\\e2> ERK and Ras\/mTOR pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"MEK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present results indicated that <e1>CHEMICAL<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/<e2>GENE-N<\\e2> ERK and Ras\/mTOR pathways","sentence":"The present results indicated that N BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":20,"annotated sentence":"The present results indicated that <e1>N<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/<e2>ERK<\\e2> and Ras\/mTOR pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present results indicated that <e1>CHEMICAL<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/<e2>GENE-N<\\e2> and Ras\/mTOR pathways","sentence":"The present results indicated that N BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":21,"annotated sentence":"The present results indicated that <e1>N<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and <e2>Ras<\\e2> mTOR pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present results indicated that <e1>CHEMICAL<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the GENE-N\/MEK\/ERK and <e2>GENE-N<\\e2> mTOR pathways","sentence":"The present results indicated that N BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras mTOR pathways"}
{"PMID":23085435,"re_id":22,"annotated sentence":"The present results indicated that <e1>N<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/<e2>mTOR<\\e2> pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present results indicated that <e1>CHEMICAL<\\e1> BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/<e2>GENE-Y<\\e2> pathways","sentence":"The present results indicated that N BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":23,"annotated sentence":"The present results indicated that N-<e1>BPs<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the <e2>Ras<\\e2> MEK\/ERK and Ras\/mTOR pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPs","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present results indicated that N-<e1>CHEMICAL<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the <e2>GENE-N<\\e2> MEK\/ERK and GENE-N\/mTOR pathways","sentence":"The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":24,"annotated sentence":"The present results indicated that N-<e1>BPs<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/<e2>MEK<\\e2> ERK and Ras\/mTOR pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPs","object":"MEK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present results indicated that N-<e1>CHEMICAL<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/<e2>GENE-N<\\e2> ERK and Ras\/mTOR pathways","sentence":"The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":25,"annotated sentence":"The present results indicated that N-<e1>BPs<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/<e2>ERK<\\e2> and Ras\/mTOR pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPs","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present results indicated that N-<e1>CHEMICAL<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/<e2>GENE-N<\\e2> and Ras\/mTOR pathways","sentence":"The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":26,"annotated sentence":"The present results indicated that N-<e1>BPs<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and <e2>Ras<\\e2> mTOR pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPs","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present results indicated that N-<e1>CHEMICAL<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the GENE-N\/MEK\/ERK and <e2>GENE-N<\\e2> mTOR pathways","sentence":"The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras mTOR pathways"}
{"PMID":23085435,"re_id":27,"annotated sentence":"The present results indicated that N-<e1>BPs<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/<e2>mTOR<\\e2> pathways","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPs","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present results indicated that N-<e1>CHEMICAL<\\e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/<e2>GENE-Y<\\e2> pathways","sentence":"The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras\/MEK\/ERK and Ras\/mTOR pathways"}
{"PMID":23085435,"re_id":28,"annotated sentence":"<e1>Nitrogen<\\e1> containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of <e2>Ras<\\e2> signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nitrogen","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of <e2>GENE-N<\\e2> signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway","sentence":"Nitrogen containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway"}
{"PMID":23085435,"re_id":29,"annotated sentence":"Nitrogen-containing <e1>bisphosphonates<\\e1> induce apoptosis of hematopoietic tumor cells via inhibition of <e2>Ras<\\e2> signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bisphosphonates","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Nitrogen-containing <e1>CHEMICAL<\\e1> induce apoptosis of hematopoietic tumor cells via inhibition of <e2>GENE-N<\\e2> signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway","sentence":"Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway"}
{"PMID":23085435,"re_id":30,"annotated sentence":"<e1>Nitrogen<\\e1> containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>G-proteins<\\e2>  However, the details of the apoptosis-inducing mechanism remain obscure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nitrogen","object":"G-proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>GENE-N<\\e2>  However, the details of the apoptosis-inducing mechanism remain obscure","sentence":"Nitrogen containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small G-proteins  However, the details of the apoptosis-inducing mechanism remain obscure"}
{"PMID":23085435,"re_id":31,"annotated sentence":"Nitrogen-containing <e1>bisphosphonates<\\e1> (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>G-proteins<\\e2>  However, the details of the apoptosis-inducing mechanism remain obscure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bisphosphonates","object":"G-proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Nitrogen-containing <e1>CHEMICAL<\\e1> (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>GENE-N<\\e2>  However, the details of the apoptosis-inducing mechanism remain obscure","sentence":"Nitrogen-containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small G-proteins  However, the details of the apoptosis-inducing mechanism remain obscure"}
{"PMID":23085435,"re_id":32,"annotated sentence":"Nitrogen-containing bisphosphonates (<e1>N<\\e1> BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>G-proteins<\\e2>  However, the details of the apoptosis-inducing mechanism remain obscure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"G-proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CHEMICALitrogen-containing bisphosphonates (<e1>CHEMICAL<\\e1> BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>GENE-N<\\e2>  However, the details of the apoptosis-inducing mechanism remain obscure","sentence":"Nitrogen-containing bisphosphonates (N BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small G-proteins  However, the details of the apoptosis-inducing mechanism remain obscure"}
{"PMID":23085435,"re_id":33,"annotated sentence":"Nitrogen-containing bisphosphonates (N-<e1>BPs<\\e1>  induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>G-proteins<\\e2>  However, the details of the apoptosis-inducing mechanism remain obscure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPs","object":"G-proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Nitrogen-containing bisphosphonates (N-<e1>CHEMICAL<\\e1>  induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>GENE-N<\\e2>  However, the details of the apoptosis-inducing mechanism remain obscure","sentence":"Nitrogen-containing bisphosphonates (N-BPs  induce apoptosis in tumor cells by inhibiting the prenylation of small G-proteins  However, the details of the apoptosis-inducing mechanism remain obscure"}
{"PMID":23085979,"re_id":0,"annotated sentence":"Although both intracellular and membrane <e2>Cx43<\\e2> pools were markedly reduced in cells released from contact inhibition by <e1>TCDD<\\e1>  siRNA-mediated Cx43 knock-down was not sufficient to stimulate proliferation in contact-inhibited cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Cx43","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although both intracellular and membrane <e2>GENE-Y<\\e2> pools were markedly reduced in cells released from contact inhibition by <e1>CHEMICAL<\\e1>  siRNA-mediated GENE-Y knock-down was not sufficient to stimulate proliferation in contact-inhibited cells","sentence":"Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by TCDD  siRNA-mediated Cx43 knock-down was not sufficient to stimulate proliferation in contact-inhibited cells"}
{"PMID":23085979,"re_id":1,"annotated sentence":"Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by <e1>TCDD<\\e1>  siRNA-mediated <e2>Cx43<\\e2> knock-down was not sufficient to stimulate proliferation in contact-inhibited cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Cx43","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although both intracellular and membrane GENE-Y pools were markedly reduced in cells released from contact inhibition by <e1>CHEMICAL<\\e1>  siRNA-mediated <e2>GENE-Y<\\e2> knock-down was not sufficient to stimulate proliferation in contact-inhibited cells","sentence":"Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by TCDD  siRNA-mediated Cx43 knock-down was not sufficient to stimulate proliferation in contact-inhibited cells"}
{"PMID":23085979,"re_id":2,"annotated sentence":"Disruption of contact inhibition, which was induced by toxic AhR ligands <e1>2,3,7,8-tetrachlorodibenzo-p-dioxin<\\e1> (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced <e2>Cx43<\\e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2,3,7,8-tetrachlorodibenzo-p-dioxin","object":"Cx43","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Disruption of contact inhibition, which was induced by toxic AhR ligands <e1>CHEMICAL<\\e1> (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced <e2>GENE-Y<\\e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner","sentence":"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner"}
{"PMID":23085979,"re_id":3,"annotated sentence":"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD<\\e1>  or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced <e2>Cx43<\\e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Cx43","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>CHEMICAL<\\e1>  or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced <e2>GENE-Y<\\e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner","sentence":"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD  or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner"}
{"PMID":23085979,"re_id":4,"annotated sentence":"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or <e1>polycyclic aromatic hydrocarbons<\\e1> in epithelial WB-F344 cells, reduced <e2>Cx43<\\e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"polycyclic aromatic hydrocarbons","object":"Cx43","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or <e1>CHEMICAL<\\e1> in epithelial WB-F344 cells, reduced <e2>GENE-Y<\\e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner","sentence":"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner"}
{"PMID":23090712,"re_id":0,"annotated sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) <e1>La(III)<\\e1> could alleviate the effects of UV-B radiation on the activities of <e2>nitrate reductase<\\e2>  glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"La(III)","object":"nitrate reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) <e1>CHEMICAL<\\e1> could alleviate the effects of UV-B radiation on the activities of <e2>GENE-N<\\e2>  glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings","sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase  glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings"}
{"PMID":23090712,"re_id":1,"annotated sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) <e1>La(III)<\\e1> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, <e2>glutamine synthetase<\\e2>  glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"La(III)","object":"glutamine synthetase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) <e1>CHEMICAL<\\e1> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, <e2>GENE-N<\\e2>  glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings","sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase  glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings"}
{"PMID":23090712,"re_id":2,"annotated sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) <e1>La(III)<\\e1> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, <e2>glutamate synthase<\\e2>  and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"La(III)","object":"glutamate synthase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) <e1>CHEMICAL<\\e1> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, <e2>GENE-N<\\e2>  and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings","sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase  and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings"}
{"PMID":23090712,"re_id":3,"annotated sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) <e1>La(III)<\\e1> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and <e2>glutamate dehydrogenase<\\e2>  promoting amino acid conversion and protein synthesis in soybean seedlings","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"La(III)","object":"glutamate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) <e1>CHEMICAL<\\e1> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and <e2>GENE-N<\\e2>  promoting amino acid conversion and protein synthesis in soybean seedlings","sentence":"The pretreatment with 20\u00a0mg\u2009L(-1) La(III) could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and glutamate dehydrogenase  promoting amino acid conversion and protein synthesis in soybean seedlings"}
{"PMID":23100158,"re_id":0,"annotated sentence":"<e1>\u03b2-ionone<\\e1> was also shown to induce the expression of cleaved-<e2>caspase-3<\\e2> and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"\u03b2-ionone","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was also shown to induce the expression of cleaved-<e2>GENE-Y<\\e2> and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner","sentence":"\u03b2-ionone was also shown to induce the expression of cleaved-caspase-3 and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner"}
{"PMID":23100158,"re_id":1,"annotated sentence":"<e1>\u03b2-ionone<\\e1> was also shown to induce the expression of cleaved-caspase-3 and inhibit <e2>bcl-2<\\e2> expression in SGC-7901 cells in a dose-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"\u03b2-ionone","object":"bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was also shown to induce the expression of cleaved-caspase-3 and inhibit <e2>GENE-Y<\\e2> expression in SGC-7901 cells in a dose-dependent manner","sentence":"\u03b2-ionone was also shown to induce the expression of cleaved-caspase-3 and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner"}
{"PMID":23100158,"re_id":2,"annotated sentence":"The significantly decreased levels of <e2>p-PI3K<\\e2> and p-AKT expression were observed in SGC-7901 cells after <e1>\u03b2-ionone<\\e1> treatments in a time- and dose-dependent manner (P\u00a0<\u00a00.01)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"\u03b2-ionone","object":"p-PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The significantly decreased levels of <e2>GENE-N<\\e2> and p-AKT expression were observed in SGC-7901 cells after <e1>CHEMICAL<\\e1> treatments in a time- and dose-dependent manner (P\u00a0<\u00a00.01)","sentence":"The significantly decreased levels of p-PI3K and p-AKT expression were observed in SGC-7901 cells after \u03b2-ionone treatments in a time- and dose-dependent manner (P\u00a0<\u00a00.01)"}
{"PMID":23100158,"re_id":3,"annotated sentence":"The significantly decreased levels of p-PI3K and <e2>p-AKT<\\e2> expression were observed in SGC-7901 cells after <e1>\u03b2-ionone<\\e1> treatments in a time- and dose-dependent manner (P\u00a0<\u00a00.01)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"\u03b2-ionone","object":"p-AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The significantly decreased levels of p-PI3K and <e2>GENE-N<\\e2> expression were observed in SGC-7901 cells after <e1>CHEMICAL<\\e1> treatments in a time- and dose-dependent manner (P\u00a0<\u00a00.01)","sentence":"The significantly decreased levels of p-PI3K and p-AKT expression were observed in SGC-7901 cells after \u03b2-ionone treatments in a time- and dose-dependent manner (P\u00a0<\u00a00.01)"}
{"PMID":23115325,"re_id":0,"annotated sentence":"The concentration response to <e1>levcromakalim<\\e1> (LEVC), a <e2>K(ATP) channel<\\e2> opener, was significantly shifted to the left in the inflamed smooth-muscle cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"levcromakalim","object":"K(ATP) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The concentration response to <e1>CHEMICAL<\\e1> (LEVC), a <e2>GENE-N<\\e2> opener, was significantly shifted to the left in the inflamed smooth-muscle cells","sentence":"The concentration response to levcromakalim (LEVC), a K(ATP) channel opener, was significantly shifted to the left in the inflamed smooth-muscle cells"}
{"PMID":23115325,"re_id":1,"annotated sentence":"The concentration response to levcromakalim (<e1>LEVC<\\e1> , a <e2>K(ATP) channel<\\e2> opener, was significantly shifted to the left in the inflamed smooth-muscle cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LEVC","object":"K(ATP) channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The concentration response to levcromakalim (<e1>CHEMICAL<\\e1> , a <e2>GENE-N<\\e2> opener, was significantly shifted to the left in the inflamed smooth-muscle cells","sentence":"The concentration response to levcromakalim (LEVC , a K(ATP) channel opener, was significantly shifted to the left in the inflamed smooth-muscle cells"}
{"PMID":23115325,"re_id":2,"annotated sentence":"Sulfhydration of <e2>sulfonylurea receptor 2B<\\e2> (SUR2B) was induced by <e1>NaHS<\\e1> and colonic inflammation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaHS","object":"sulfonylurea receptor 2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sulfhydration of <e2>GENE-Y<\\e2> (SUR2B) was induced by <e1>CHEMICAL<\\e1> and colonic inflammation","sentence":"Sulfhydration of sulfonylurea receptor 2B (SUR2B) was induced by NaHS and colonic inflammation"}
{"PMID":23115325,"re_id":3,"annotated sentence":"Sulfhydration of sulfonylurea receptor 2B (<e2>SUR2B<\\e2>  was induced by <e1>NaHS<\\e1> and colonic inflammation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaHS","object":"SUR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sulfhydration of sulfonylurea receptor 2B (<e2>GENE-Y<\\e2>  was induced by <e1>CHEMICAL<\\e1> and colonic inflammation","sentence":"Sulfhydration of sulfonylurea receptor 2B (SUR2B  was induced by NaHS and colonic inflammation"}
{"PMID":23116643,"re_id":0,"annotated sentence":"<e1>CCl(4)<\\e1> administration triggered inflammatory response in mice livers by activating <e2>nuclear factor-kappaB<\\e2> (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl(4)","object":"nuclear factor-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> administration triggered inflammatory response in mice livers by activating <e2>GENE-N<\\e2> (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2)","sentence":"CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2)"}
{"PMID":23116643,"re_id":1,"annotated sentence":"<e1>CCl(4)<\\e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (<e2>NF-\u03baB<\\e2> , which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl(4)","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (<e2>GENE-N<\\e2> , which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2)","sentence":"CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB , which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2)"}
{"PMID":23116643,"re_id":2,"annotated sentence":"<e1>CCl(4)<\\e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of <e2>tumor necrosis factor-alpha<\\e2> (TNF-\u03b1) and cyclooxygenase-2 (COX-2)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl(4)","object":"tumor necrosis factor-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of <e2>GENE-Y<\\e2> (TNF-\u03b1) and cyclooxygenase-2 (COX-2)","sentence":"CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2)"}
{"PMID":23116643,"re_id":3,"annotated sentence":"<e1>CCl(4)<\\e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (<e2>TNF-\u03b1<\\e2>  and cyclooxygenase-2 (COX-2)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl(4)","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (<e2>GENE-Y<\\e2>  and cyclooxygenase-2 (COX-2)","sentence":"CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1  and cyclooxygenase-2 (COX-2)"}
{"PMID":23116643,"re_id":4,"annotated sentence":"<e1>CCl(4)<\\e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and <e2>cyclooxygenase-2<\\e2> (COX-2)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl(4)","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and <e2>GENE-Y<\\e2> (COX-2)","sentence":"CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2)"}
{"PMID":23116643,"re_id":5,"annotated sentence":"<e1>CCl(4)<\\e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (<e2>COX-2<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl(4)","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (<e2>GENE-Y<\\e2> ","sentence":"CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2 "}
{"PMID":23116643,"re_id":6,"annotated sentence":"<e1>CCl(4)<\\e1> intoxication caused hepatic necrosis and increased serum <e2>ALT<\\e2> activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CCl(4)","object":"ALT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> intoxication caused hepatic necrosis and increased serum <e2>GENE-N<\\e2> activity","sentence":"CCl(4) intoxication caused hepatic necrosis and increased serum ALT activity"}
{"PMID":23116643,"re_id":7,"annotated sentence":"Furthermore, RA significantly inhibited the <e1>CCl(4)<\\e1> induced apoptosis, which was evident from decreased cleavage of <e2>caspase-3<\\e2>  The hepatoprotective activity of RA coincided with enhanced NF-E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CCl(4)","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, RA significantly inhibited the <e1>CHEMICAL<\\e1> induced apoptosis, which was evident from decreased cleavage of <e2>GENE-Y<\\e2>  The hepatoprotective activity of RA coincided with enhanced NF-E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) expression","sentence":"Furthermore, RA significantly inhibited the CCl(4) induced apoptosis, which was evident from decreased cleavage of caspase-3  The hepatoprotective activity of RA coincided with enhanced NF-E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) expression"}
{"PMID":23116965,"re_id":0,"annotated sentence":"Antiarrhythmic effects of <e1>(-)-epicatechin-3-gallate<\\e1>  a novel <e2>sodium channel<\\e2> agonist in cultured neonatal rat ventricular myocytes","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"(-)-epicatechin-3-gallate","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Antiarrhythmic effects of <e1>CHEMICAL<\\e1>  a novel <e2>GENE-N<\\e2> agonist in cultured neonatal rat ventricular myocytes","sentence":"Antiarrhythmic effects of (-)-epicatechin-3-gallate  a novel sodium channel agonist in cultured neonatal rat ventricular myocytes"}
{"PMID":23118019,"re_id":0,"annotated sentence":"Both <e1>5'-AMN<\\e1> and 5'-MABN had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and <e2>\u03bc-receptor<\\e2> antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"5'-AMN","object":"\u03bc-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both <e1>CHEMICAL<\\e1> and 5'-MABN had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and <e2>GENE-Y<\\e2> antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum","sentence":"Both 5'-AMN and 5'-MABN had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and \u03bc-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum"}
{"PMID":23118019,"re_id":1,"annotated sentence":"Both 5'-AMN and <e1>5'-MABN<\\e1> had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and <e2>\u03bc-receptor<\\e2> antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"5'-MABN","object":"\u03bc-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both 5'-AMN and <e1>CHEMICAL<\\e1> had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and <e2>GENE-Y<\\e2> antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum","sentence":"Both 5'-AMN and 5'-MABN had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and \u03bc-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum"}
{"PMID":23122079,"re_id":0,"annotated sentence":"Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the <e1>phillyrin<\\e1> enhanced activation of <e2>AMPK<\\e2> in HepG2 hepatocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phillyrin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the <e1>CHEMICAL<\\e1> enhanced activation of <e2>GENE-N<\\e2> in HepG2 hepatocytes","sentence":"Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the phillyrin enhanced activation of AMPK in HepG2 hepatocytes"}
{"PMID":23122079,"re_id":1,"annotated sentence":"These results indicate that <e1>phillyrin<\\e1> prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through <e2>LKB1<\\e2> AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phillyrin","object":"LKB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through <e2>GENE-Y<\\e2> AMPK activation, suggesting that CHEMICAL is a novel AMPK activator with a role in the prevention and treatment of obesity.","sentence":"These results indicate that phillyrin prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1 AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity."}
{"PMID":23122079,"re_id":2,"annotated sentence":"These results indicate that <e1>phillyrin<\\e1> prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1\/<e2>AMPK<\\e2> activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phillyrin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1\/<e2>GENE-N<\\e2> activation, suggesting that CHEMICAL is a novel GENE-N activator with a role in the prevention and treatment of obesity.","sentence":"These results indicate that phillyrin prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1\/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity."}
{"PMID":23122079,"re_id":3,"annotated sentence":"<e1>Phillyrin<\\e1> attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of <e2>LKB1<\\e2> AMP-activated protein kinase-dependent signalling","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Phillyrin","object":"LKB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of <e2>GENE-Y<\\e2> AMP-activated protein kinase-dependent signalling","sentence":"Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1 AMP-activated protein kinase-dependent signalling"}
{"PMID":23122079,"re_id":4,"annotated sentence":"<e1>Phillyrin<\\e1> attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1\/<e2>AMP-activated protein kinase<\\e2> dependent signalling","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Phillyrin","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1\/<e2>GENE-N<\\e2> dependent signalling","sentence":"Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1\/AMP-activated protein kinase dependent signalling"}
{"PMID":23122079,"re_id":5,"annotated sentence":"These results indicate that phillyrin prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1\/AMPK activation, suggesting that <e1>phillyrin<\\e1> is a novel <e2>AMPK<\\e2> activator with a role in the prevention and treatment of obesity.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phillyrin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results indicate that CHEMICAL prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1\/GENE-N activation, suggesting that <e1>CHEMICAL<\\e1> is a novel <e2>GENE-N<\\e2> activator with a role in the prevention and treatment of obesity.","sentence":"These results indicate that phillyrin prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1\/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity."}
{"PMID":23122079,"re_id":6,"annotated sentence":"Phillyrin strongly inhibited high <e1>glucose<\\e1> induced <e2>fatty acid synthase<\\e2> (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"fatty acid synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phillyrin strongly inhibited high <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation","sentence":"Phillyrin strongly inhibited high glucose induced fatty acid synthase (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation"}
{"PMID":23122079,"re_id":7,"annotated sentence":"Phillyrin strongly inhibited high <e1>glucose<\\e1> induced fatty acid synthase (<e2>FAS<\\e2>  expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"FAS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phillyrin strongly inhibited high <e1>CHEMICAL<\\e1> induced fatty acid synthase (<e2>GENE-Y<\\e2>  expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation","sentence":"Phillyrin strongly inhibited high glucose induced fatty acid synthase (FAS  expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation"}
{"PMID":23122079,"re_id":8,"annotated sentence":"Moreover, use of the pharmacological <e2>AMP-activated protein kinase<\\e2> (AMPK) inhibitor <e1>compound C<\\e1> revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"compound C","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, use of the pharmacological <e2>GENE-N<\\e2> (AMPK) inhibitor <e1>CHEMICAL<\\e1> revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells","sentence":"Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells"}
{"PMID":23122079,"re_id":9,"annotated sentence":"Moreover, use of the pharmacological AMP-activated protein kinase (<e2>AMPK<\\e2>  inhibitor <e1>compound C<\\e1> revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"compound C","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, use of the pharmacological AMP-activated protein kinase (<e2>GENE-N<\\e2>  inhibitor <e1>CHEMICAL<\\e1> revealed that GENE-N is essential for suppressing SREBP-1c expression in phillyrin-treated cells","sentence":"Moreover, use of the pharmacological AMP-activated protein kinase (AMPK  inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells"}
{"PMID":23122079,"re_id":10,"annotated sentence":"Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor <e1>compound C<\\e1> revealed that <e2>AMPK<\\e2> is essential for suppressing SREBP-1c expression in phillyrin-treated cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"compound C","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, use of the pharmacological AMP-activated protein kinase (GENE-N) inhibitor <e1>CHEMICAL<\\e1> revealed that <e2>GENE-N<\\e2> is essential for suppressing SREBP-1c expression in phillyrin-treated cells","sentence":"Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells"}
{"PMID":23122079,"re_id":11,"annotated sentence":"These results indicate that <e1>phillyrin<\\e1> prevents lipid accumulation in HepG2 cells by blocking the expression of <e2>SREBP-1c<\\e2> and FAS through LKB1\/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phillyrin","object":"SREBP-1c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> prevents lipid accumulation in HepG2 cells by blocking the expression of <e2>GENE-Y<\\e2> and FAS through LKB1\/AMPK activation, suggesting that CHEMICAL is a novel AMPK activator with a role in the prevention and treatment of obesity.","sentence":"These results indicate that phillyrin prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1\/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity."}
{"PMID":23122079,"re_id":12,"annotated sentence":"These results indicate that <e1>phillyrin<\\e1> prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and <e2>FAS<\\e2> through LKB1\/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phillyrin","object":"FAS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and <e2>GENE-Y<\\e2> through LKB1\/AMPK activation, suggesting that CHEMICAL is a novel AMPK activator with a role in the prevention and treatment of obesity.","sentence":"These results indicate that phillyrin prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1\/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity."}
{"PMID":23122079,"re_id":13,"annotated sentence":"<e1>Phillyrin<\\e1> strongly inhibited high glucose-induced <e2>fatty acid synthase<\\e2> (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phillyrin","object":"fatty acid synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> strongly inhibited high glucose-induced <e2>GENE-Y<\\e2> (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation","sentence":"Phillyrin strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation"}
{"PMID":23122079,"re_id":14,"annotated sentence":"<e1>Phillyrin<\\e1> strongly inhibited high glucose-induced fatty acid synthase (<e2>FAS<\\e2>  expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phillyrin","object":"FAS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> strongly inhibited high glucose-induced fatty acid synthase (<e2>GENE-Y<\\e2>  expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation","sentence":"Phillyrin strongly inhibited high glucose-induced fatty acid synthase (FAS  expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation"}
{"PMID":23123250,"re_id":0,"annotated sentence":"<e1>[-]-Huperzine A<\\e1> ([-]-Hup A), is a naturally occurring potent reversible <e2>AChE<\\e2> inhibitor that penetrates the blood-brain barrier","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"[-]-Huperzine A","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> ([-]-Hup A), is a naturally occurring potent reversible <e2>GENE-Y<\\e2> inhibitor that penetrates the blood-brain barrier","sentence":"[-]-Huperzine A ([-]-Hup A), is a naturally occurring potent reversible AChE inhibitor that penetrates the blood-brain barrier"}
{"PMID":23123250,"re_id":1,"annotated sentence":"[-]-Huperzine A (<e1>[-]-Hup A<\\e1> , is a naturally occurring potent reversible <e2>AChE<\\e2> inhibitor that penetrates the blood-brain barrier","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"[-]-Hup A","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"[-]-Huperzine A (<e1>CHEMICAL<\\e1> , is a naturally occurring potent reversible <e2>GENE-Y<\\e2> inhibitor that penetrates the blood-brain barrier","sentence":"[-]-Huperzine A ([-]-Hup A , is a naturally occurring potent reversible AChE inhibitor that penetrates the blood-brain barrier"}
{"PMID":23123250,"re_id":2,"annotated sentence":"The synthetic stereoisomer, <e1>[+]-Hup A<\\e1>  is less toxic due to poor <e2>AChE<\\e2> inhibition and is suitable for both pre-\/post-exposure treatments of nerve agent toxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"[+]-Hup A","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The synthetic stereoisomer, <e1>CHEMICAL<\\e1>  is less toxic due to poor <e2>GENE-Y<\\e2> inhibition and is suitable for both pre-\/post-exposure treatments of nerve agent toxicity","sentence":"The synthetic stereoisomer, [+]-Hup A  is less toxic due to poor AChE inhibition and is suitable for both pre-\/post-exposure treatments of nerve agent toxicity"}
{"PMID":23123646,"re_id":0,"annotated sentence":"An increase in the <e1>ADP<\\e1> ATP ratio opens <e2>K(ATP) channels<\\e2>  leading to membrane hyperpolarization","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ADP","object":"K(ATP) channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"An increase in the <e1>CHEMICAL<\\e1> ATP ratio opens <e2>GENE-N<\\e2>  leading to membrane hyperpolarization","sentence":"An increase in the ADP ATP ratio opens K(ATP) channels  leading to membrane hyperpolarization"}
{"PMID":23123646,"re_id":1,"annotated sentence":"An increase in the ADP\/<e1>ATP<\\e1> ratio opens <e2>K(ATP) channels<\\e2>  leading to membrane hyperpolarization","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ATP","object":"K(ATP) channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"An increase in the ADP\/<e1>CHEMICAL<\\e1> ratio opens <e2>K(CHEMICAL) channels<\\e2>  leading to membrane hyperpolarization","sentence":"An increase in the ADP\/ATP ratio opens K(ATP) channels  leading to membrane hyperpolarization"}
{"PMID":23125284,"re_id":0,"annotated sentence":"The <e2>mitochondrial respiratory chain complex IV<\\e2> (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular <e1>oxygen<\\e1>  yielding water","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxygen","object":"mitochondrial respiratory chain complex IV","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular <e1>CHEMICAL<\\e1>  yielding water","sentence":"The mitochondrial respiratory chain complex IV (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular oxygen  yielding water"}
{"PMID":23125284,"re_id":1,"annotated sentence":"The mitochondrial respiratory chain complex IV (<e2>cytochrome c oxidase<\\e2>  is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular <e1>oxygen<\\e1>  yielding water","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxygen","object":"cytochrome c oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The mitochondrial respiratory chain complex IV (<e2>GENE-N<\\e2>  is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular <e1>CHEMICAL<\\e1>  yielding water","sentence":"The mitochondrial respiratory chain complex IV (cytochrome c oxidase  is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular oxygen  yielding water"}
{"PMID":23127600,"re_id":0,"annotated sentence":"These findings demonstrate that cinnamon <e1>polyphenols<\\e1> can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of <e2>iNOS<\\e2>  NF-\u03baB activation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"polyphenols","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings demonstrate that cinnamon <e1>CHEMICAL<\\e1> can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of <e2>GENE-Y<\\e2>  NF-\u03baB activation.","sentence":"These findings demonstrate that cinnamon polyphenols can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS  NF-\u03baB activation."}
{"PMID":23127600,"re_id":1,"annotated sentence":"These findings demonstrate that cinnamon <e1>polyphenols<\\e1> can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS, <e2>NF-\u03baB<\\e2> activation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"polyphenols","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings demonstrate that cinnamon <e1>CHEMICAL<\\e1> can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS, <e2>GENE-N<\\e2> activation.","sentence":"These findings demonstrate that cinnamon polyphenols can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS, NF-\u03baB activation."}
{"PMID":23127600,"re_id":2,"annotated sentence":"As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both <e1>dimethyldiguanide<\\e1> (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and <e2>insulin<\\e2> levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dimethyldiguanide","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both <e1>CHEMICAL<\\e1> (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and <e2>GENE-N<\\e2> levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay","sentence":"As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both dimethyldiguanide (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and insulin levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay"}
{"PMID":23127916,"re_id":0,"annotated sentence":"The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and <e1>imatinib<\\e1>  a selective <e2>tyrosine kinase<\\e2> inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable\/metastatic GIST","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imatinib","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and <e1>CHEMICAL<\\e1>  a selective <e2>GENE-N<\\e2> inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable\/metastatic GIST","sentence":"The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and imatinib  a selective tyrosine kinase inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable\/metastatic GIST"}
{"PMID":23131798,"re_id":0,"annotated sentence":"One of the <e2>CB2<\\e2> agonists, <e1>N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine<\\e1> (19, -logEC(50)=7.5, E(max)=255%) was selected for further development","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine","object":"CB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One of the <e2>GENE-Y<\\e2> agonists, <e1>CHEMICAL<\\e1> (19, -logEC(50)=7.5, E(max)=255%) was selected for further development","sentence":"One of the CB2 agonists, N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine (19, -logEC(50)=7.5, E(max)=255%) was selected for further development"}
{"PMID":23131798,"re_id":1,"annotated sentence":"As far as we are aware, the compound's <e1>1,3,5-triazine<\\e1> scaffold represents a new core structure for <e2>CB2<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"1,3,5-triazine","object":"CB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As far as we are aware, the compound's <e1>CHEMICAL<\\e1> scaffold represents a new core structure for <e2>GENE-Y<\\e2> agonists","sentence":"As far as we are aware, the compound's 1,3,5-triazine scaffold represents a new core structure for CB2 agonists"}
{"PMID":23131798,"re_id":2,"annotated sentence":"Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of <e1>2,4,6-trisubstituted 1,3,5-triazines<\\e1> as <e2>CB2<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"2,4,6-trisubstituted 1,3,5-triazines","object":"CB2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of <e1>CHEMICAL<\\e1> as <e2>GENE-Y<\\e2> agonists","sentence":"Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists"}
{"PMID":23139413,"re_id":0,"annotated sentence":"Binding of the agonist angiotensin II (AngII) and inverse agonist <e1>losartan<\\e1> in wild-type <e2>AT1R<\\e2> changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific \"lid\" conformations of ECL2","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"losartan","object":"AT1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Binding of the agonist angiotensin II (AngII) and inverse agonist <e1>CHEMICAL<\\e1> in wild-type <e2>GENE-Y<\\e2> changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific \"lid\" conformations of ECL2","sentence":"Binding of the agonist angiotensin II (AngII) and inverse agonist losartan in wild-type AT1R changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific \"lid\" conformations of ECL2"}
{"PMID":23142538,"re_id":0,"annotated sentence":"In muscle and liver, <e1>TCDD<\\e1> (10 ng\/kg\/day) induced increases in methylation and decreases in mRNA expression of <e2>Igf2r<\\e2>  These results show that the robust effects of TCDD on the mRNA expression of Snrpn, Peg3 and Igf2r genes in the sperm and of Igf2r in the muscle and liver are unrelated to changes in methylation in their respective genes.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Igf2r","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In muscle and liver, <e1>CHEMICAL<\\e1> (10 ng\/kg\/day) induced increases in methylation and decreases in mRNA expression of <e2>GENE-Y<\\e2>  These results show that the robust effects of CHEMICAL on the mRNA expression of Snrpn, Peg3 and GENE-Y genes in the sperm and of GENE-Y in the muscle and liver are unrelated to changes in methylation in their respective genes.","sentence":"In muscle and liver, TCDD (10 ng\/kg\/day) induced increases in methylation and decreases in mRNA expression of Igf2r  These results show that the robust effects of TCDD on the mRNA expression of Snrpn, Peg3 and Igf2r genes in the sperm and of Igf2r in the muscle and liver are unrelated to changes in methylation in their respective genes."}
{"PMID":23145773,"re_id":0,"annotated sentence":"We report here the optimization of <e2>human 17\u03b2-HSD2<\\e2> inhibitors in the <e1>2,5-thiophene amide<\\e1> class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2,5-thiophene amide","object":"human 17\u03b2-HSD2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report here the optimization of <e2>GENE-Y<\\e2> inhibitors in the <e1>CHEMICAL<\\e1> class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group","sentence":"We report here the optimization of human 17\u03b2-HSD2 inhibitors in the 2,5-thiophene amide class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group"}
{"PMID":23145773,"re_id":1,"annotated sentence":"While none of the phenethylamides (n = 2) were active, most of the <e1>anilides<\\e1> (n = 0) turned out to moderately or strongly inhibit <e2>17\u03b2-HSD2<\\e2>  The four most active compounds showed an IC\u2085\u2080 of around 60 nM and a very good selectivity toward 17\u03b2-HSD1, 17\u03b2-HSD4, 17\u03b2-HSD5, 11\u03b2-HSD1, 11\u03b2-HSD2 and the estrogen receptors \u03b1 and \u03b2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"anilides","object":"17\u03b2-HSD2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While none of the phenethylamides (n = 2) were active, most of the <e1>CHEMICAL<\\e1> (n = 0) turned out to moderately or strongly inhibit <e2>GENE-Y<\\e2>  The four most active compounds showed an IC\u2085\u2080 of around 60 nM and a very good selectivity toward 17\u03b2-HSD1, 17\u03b2-HSD4, 17\u03b2-HSD5, 11\u03b2-HSD1, 11\u03b2-HSD2 and the estrogen receptors \u03b1 and \u03b2","sentence":"While none of the phenethylamides (n = 2) were active, most of the anilides (n = 0) turned out to moderately or strongly inhibit 17\u03b2-HSD2  The four most active compounds showed an IC\u2085\u2080 of around 60 nM and a very good selectivity toward 17\u03b2-HSD1, 17\u03b2-HSD4, 17\u03b2-HSD5, 11\u03b2-HSD1, 11\u03b2-HSD2 and the estrogen receptors \u03b1 and \u03b2"}
{"PMID":23145773,"re_id":2,"annotated sentence":"Structural optimization of <e1>2,5-thiophene amides<\\e1> as highly potent and selective <e2>17\u03b2-hydroxysteroid dehydrogenase type 2<\\e2> inhibitors for the treatment of osteoporosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2,5-thiophene amides","object":"17\u03b2-hydroxysteroid dehydrogenase type 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Structural optimization of <e1>CHEMICAL<\\e1> as highly potent and selective <e2>GENE-Y<\\e2> inhibitors for the treatment of osteoporosis","sentence":"Structural optimization of 2,5-thiophene amides as highly potent and selective 17\u03b2-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis"}
{"PMID":23146690,"re_id":0,"annotated sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of <e1>resveratrol<\\e1> and clofarabine is linked to the inhibition of <e2>Akt<\\e2> and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of <e1>CHEMICAL<\\e1> and clofarabine is linked to the inhibition of <e2>GENE-N<\\e2> and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma."}
{"PMID":23146690,"re_id":1,"annotated sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of <e1>resveratrol<\\e1> and clofarabine is linked to the inhibition of Akt and <e2>Sp1<\\e2> activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"Sp1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of <e1>CHEMICAL<\\e1> and clofarabine is linked to the inhibition of Akt and <e2>GENE-Y<\\e2> activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma."}
{"PMID":23146690,"re_id":2,"annotated sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and <e1>clofarabine<\\e1> is linked to the inhibition of <e2>Akt<\\e2> and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clofarabine","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and <e1>CHEMICAL<\\e1> is linked to the inhibition of <e2>GENE-N<\\e2> and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma."}
{"PMID":23146690,"re_id":3,"annotated sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and <e1>clofarabine<\\e1> is linked to the inhibition of Akt and <e2>Sp1<\\e2> activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clofarabine","object":"Sp1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and <e1>CHEMICAL<\\e1> is linked to the inhibition of Akt and <e2>GENE-Y<\\e2> activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","sentence":"Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma."}
{"PMID":23146690,"re_id":4,"annotated sentence":"In combination with <e1>clofarabine<\\e1>  the ability of resveratrol to reduce the contents of <e2>Sp1<\\e2> and its target gene products was also evident in a time- and dose-dependent experiment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clofarabine","object":"Sp1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In combination with <e1>CHEMICAL<\\e1>  the ability of resveratrol to reduce the contents of <e2>GENE-Y<\\e2> and its target gene products was also evident in a time- and dose-dependent experiment","sentence":"In combination with clofarabine  the ability of resveratrol to reduce the contents of Sp1 and its target gene products was also evident in a time- and dose-dependent experiment"}
{"PMID":23146690,"re_id":5,"annotated sentence":"In combination with clofarabine, the ability of <e1>resveratrol<\\e1> to reduce the contents of <e2>Sp1<\\e2> and its target gene products was also evident in a time- and dose-dependent experiment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"Sp1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In combination with clofarabine, the ability of <e1>CHEMICAL<\\e1> to reduce the contents of <e2>GENE-Y<\\e2> and its target gene products was also evident in a time- and dose-dependent experiment","sentence":"In combination with clofarabine, the ability of resveratrol to reduce the contents of Sp1 and its target gene products was also evident in a time- and dose-dependent experiment"}
{"PMID":23146690,"re_id":6,"annotated sentence":"The inhibition of <e2>phosphoinositide 3-kinase<\\e2> using <e1>Ly294002<\\e1> augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ly294002","object":"phosphoinositide 3-kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibition of <e2>GENE-N<\\e2> using <e1>CHEMICAL<\\e1> augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1","sentence":"The inhibition of phosphoinositide 3-kinase using Ly294002 augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1"}
{"PMID":23146690,"re_id":7,"annotated sentence":"The inhibition of phosphoinositide 3-kinase using <e1>Ly294002<\\e1> augmented a decrease in the <e2>p21<\\e2> level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ly294002","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibition of phosphoinositide 3-kinase using <e1>CHEMICAL<\\e1> augmented a decrease in the <e2>GENE-Y<\\e2> level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1","sentence":"The inhibition of phosphoinositide 3-kinase using Ly294002 augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1"}
{"PMID":23146691,"re_id":0,"annotated sentence":"<e1>Emodin-6-O-\u03b2-D-glucoside<\\e1> inhibits <e2>HMGB1<\\e2> induced inflammatory responses in vitro and in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Emodin-6-O-\u03b2-D-glucoside","object":"HMGB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> induced inflammatory responses in vitro and in vivo","sentence":"Emodin-6-O-\u03b2-D-glucoside inhibits HMGB1 induced inflammatory responses in vitro and in vivo"}
{"PMID":23152189,"re_id":0,"annotated sentence":"<e1>TCDD<\\e1> decreased the expression of the <e2>glucose transporter<\\e2>  SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"glucose transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> decreased the expression of the <e2>GENE-N<\\e2>  SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate","sentence":"TCDD decreased the expression of the glucose transporter  SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate"}
{"PMID":23152189,"re_id":1,"annotated sentence":"<e1>TCDD<\\e1> decreased the expression of the glucose transporter, <e2>SLC2A1<\\e2>  and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"SLC2A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased the expression of the glucose transporter, <e2>GENE-Y<\\e2>  and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate","sentence":"TCDD decreased the expression of the glucose transporter, SLC2A1  and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate"}
{"PMID":23152189,"re_id":2,"annotated sentence":"Mitochondrial <e2>glutathione (GSH) reductase<\\e2> activity and the GSH\/glutathione disulfide ratio were decreased by <e1>TCDD<\\e1>  ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"glutathione (GSH) reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Mitochondrial <e2>GENE-N<\\e2> activity and the GSH\/glutathione disulfide ratio were decreased by <e1>CHEMICAL<\\e1>  ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide","sentence":"Mitochondrial glutathione (GSH) reductase activity and the GSH\/glutathione disulfide ratio were decreased by TCDD  ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide"}
{"PMID":23159529,"re_id":0,"annotated sentence":"Nanobody-albumin nanoparticles (NANAPs) for the delivery of a <e2>multikinase<\\e2> inhibitor <e1>17864<\\e1> to EGFR overexpressing tumor cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"17864","object":"multikinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Nanobody-albumin nanoparticles (NANAPs) for the delivery of a <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> to EGFR overexpressing tumor cells","sentence":"Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells"}
{"PMID":23159529,"re_id":1,"annotated sentence":"Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the <e2>multikinase<\\e2> inhibitor <e1>17864<\\e1> L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"17864","object":"multikinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment","sentence":"Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864 L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment"}
{"PMID":23160090,"re_id":0,"annotated sentence":"<e1>HSYA<\\e1> suppressed the expression of TLR-4, <e2>Myd88<\\e2>  ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"Myd88","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed the expression of TLR-4, <e2>GENE-Y<\\e2>  ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","sentence":"HSYA suppressed the expression of TLR-4, Myd88  ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells"}
{"PMID":23160090,"re_id":1,"annotated sentence":"<e1>HSYA<\\e1> suppressed the expression of TLR-4, Myd88, <e2>ICAM-1<\\e2>  TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"ICAM-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed the expression of TLR-4, Myd88, <e2>GENE-Y<\\e2>  TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","sentence":"HSYA suppressed the expression of TLR-4, Myd88, ICAM-1  TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells"}
{"PMID":23160090,"re_id":2,"annotated sentence":"<e1>HSYA<\\e1> suppressed the expression of TLR-4, Myd88, ICAM-1, <e2>TNF\u03b1<\\e2>  IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"TNF\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed the expression of TLR-4, Myd88, ICAM-1, <e2>GENE-Y<\\e2>  IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","sentence":"HSYA suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1  IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells"}
{"PMID":23160090,"re_id":3,"annotated sentence":"<e1>HSYA<\\e1> suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1, <e2>IL-1\u03b2<\\e2> and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"IL-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1, <e2>GENE-Y<\\e2> and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","sentence":"HSYA suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells"}
{"PMID":23160090,"re_id":4,"annotated sentence":"<e1>HSYA<\\e1> suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and <e2>IL-6<\\e2> at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and <e2>GENE-Y<\\e2> at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","sentence":"HSYA suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells"}
{"PMID":23160090,"re_id":5,"annotated sentence":"<e1>HSYA<\\e1> suppressed the expression of <e2>TLR-4<\\e2>  Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"TLR-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed the expression of <e2>GENE-Y<\\e2>  Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells","sentence":"HSYA suppressed the expression of TLR-4  Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells"}
{"PMID":23160090,"re_id":6,"annotated sentence":"<e1>HSYA<\\e1> treatment also decreased <e2>NF-\u03baB<\\e2> p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment also decreased <e2>GENE-N<\\e2> p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)","sentence":"HSYA treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)"}
{"PMID":23160090,"re_id":7,"annotated sentence":"<e1>HSYA<\\e1> treatment also decreased NF-\u03baB <e2>p65<\\e2> nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment also decreased NF-\u03baB <e2>GENE-Y<\\e2> nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)","sentence":"HSYA treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)"}
{"PMID":23160090,"re_id":8,"annotated sentence":"<e1>HSYA<\\e1> treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of <e2>p38<\\e2> mitogen-activated protein kinase (p38 MAPK)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of <e2>GENE-N<\\e2> mitogen-activated protein kinase (GENE-N MAPK)","sentence":"HSYA treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)"}
{"PMID":23160090,"re_id":9,"annotated sentence":"<e1>HSYA<\\e1> treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 <e2>mitogen-activated protein kinase<\\e2> (p38 MAPK)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"mitogen-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 <e2>GENE-N<\\e2> (p38 MAPK)","sentence":"HSYA treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)"}
{"PMID":23160090,"re_id":10,"annotated sentence":"<e1>HSYA<\\e1> treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (<e2>p38<\\e2> MAPK)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of GENE-N mitogen-activated protein kinase (<e2>GENE-N<\\e2> MAPK)","sentence":"HSYA treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)"}
{"PMID":23160090,"re_id":11,"annotated sentence":"<e1>HSYA<\\e1> treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 <e2>MAPK<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"HSYA","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 <e2>GENE-N<\\e2> ","sentence":"HSYA treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK "}
{"PMID":23160530,"re_id":0,"annotated sentence":"First, we showed that intracerebroventricular administration of <e1>glucose<\\e1> in rats increases <e2>DBI<\\e2> expression in hypothalamic glial-like tanycytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"DBI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"First, we showed that intracerebroventricular administration of <e1>CHEMICAL<\\e1> in rats increases <e2>GENE-Y<\\e2> expression in hypothalamic glial-like tanycytes","sentence":"First, we showed that intracerebroventricular administration of glucose in rats increases DBI expression in hypothalamic glial-like tanycytes"}
{"PMID":23164673,"re_id":0,"annotated sentence":"Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of <e1>cinobufagin<\\e1>  while the phosphorylation of <e2>GSK-3\u03b2<\\e2> was simultaneously increased","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cinobufagin","object":"GSK-3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of <e1>CHEMICAL<\\e1>  while the phosphorylation of <e2>GENE-Y<\\e2> was simultaneously increased","sentence":"Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of cinobufagin  while the phosphorylation of GSK-3\u03b2 was simultaneously increased"}
{"PMID":23164673,"re_id":1,"annotated sentence":"Transduction with constitutively active forms of GSK-3\u03b2 could protect against the downregulation of p65 and upregulation of cleaved-<e2>PARP<\\e2> that are induced by <e1>cinobufagin<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cinobufagin","object":"PARP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Transduction with constitutively active forms of GSK-3\u03b2 could protect against the downregulation of p65 and upregulation of cleaved-<e2>GENE-N<\\e2> that are induced by <e1>CHEMICAL<\\e1> treatment","sentence":"Transduction with constitutively active forms of GSK-3\u03b2 could protect against the downregulation of p65 and upregulation of cleaved-PARP that are induced by cinobufagin treatment"}
{"PMID":23164673,"re_id":2,"annotated sentence":"However, combined treatment with <e1>cinobufagin<\\e1> and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-<e2>PARP<\\e2> in U2OS cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cinobufagin","object":"PARP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, combined treatment with <e1>CHEMICAL<\\e1> and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-<e2>GENE-N<\\e2> in U2OS cells","sentence":"However, combined treatment with cinobufagin and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-PARP in U2OS cells"}
{"PMID":23164673,"re_id":3,"annotated sentence":"However, combined treatment with cinobufagin and <e1>SB216367<\\e1> resulted in a significant reduction in p65 and an increase in cleaved-<e2>PARP<\\e2> in U2OS cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SB216367","object":"PARP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, combined treatment with cinobufagin and <e1>CHEMICAL<\\e1> resulted in a significant reduction in p65 and an increase in cleaved-<e2>GENE-N<\\e2> in U2OS cells","sentence":"However, combined treatment with cinobufagin and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-PARP in U2OS cells"}
{"PMID":23164673,"re_id":4,"annotated sentence":"Furthermore, we validated the inhibition of <e2>GSK-3\u03b2<\\e2> NF-\u03baB signaling following <e1>cinobufagin<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cinobufagin","object":"GSK-3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, we validated the inhibition of <e2>GENE-Y<\\e2> NF-\u03baB signaling following <e1>CHEMICAL<\\e1> treatment","sentence":"Furthermore, we validated the inhibition of GSK-3\u03b2 NF-\u03baB signaling following cinobufagin treatment"}
{"PMID":23164673,"re_id":5,"annotated sentence":"Furthermore, we validated the inhibition of GSK-3\u03b2\/<e2>NF-\u03baB<\\e2> signaling following <e1>cinobufagin<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cinobufagin","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, we validated the inhibition of GSK-3\u03b2\/<e2>GENE-N<\\e2> signaling following <e1>CHEMICAL<\\e1> treatment","sentence":"Furthermore, we validated the inhibition of GSK-3\u03b2\/NF-\u03baB signaling following cinobufagin treatment"}
{"PMID":23164673,"re_id":6,"annotated sentence":"Western blots showed a decrease in nuclear <e2>p65<\\e2> protein expression after exposure to different concentrations of <e1>cinobufagin<\\e1>  while the phosphorylation of GSK-3\u03b2 was simultaneously increased","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cinobufagin","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blots showed a decrease in nuclear <e2>GENE-Y<\\e2> protein expression after exposure to different concentrations of <e1>CHEMICAL<\\e1>  while the phosphorylation of GSK-3\u03b2 was simultaneously increased","sentence":"Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of cinobufagin  while the phosphorylation of GSK-3\u03b2 was simultaneously increased"}
{"PMID":23164673,"re_id":7,"annotated sentence":"Transduction with constitutively active forms of GSK-3\u03b2 could protect against the downregulation of <e2>p65<\\e2> and upregulation of cleaved-PARP that are induced by <e1>cinobufagin<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cinobufagin","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Transduction with constitutively active forms of GSK-3\u03b2 could protect against the downregulation of <e2>GENE-Y<\\e2> and upregulation of cleaved-PARP that are induced by <e1>CHEMICAL<\\e1> treatment","sentence":"Transduction with constitutively active forms of GSK-3\u03b2 could protect against the downregulation of p65 and upregulation of cleaved-PARP that are induced by cinobufagin treatment"}
{"PMID":23164673,"re_id":8,"annotated sentence":"However, combined treatment with <e1>cinobufagin<\\e1> and SB216367 resulted in a significant reduction in <e2>p65<\\e2> and an increase in cleaved-PARP in U2OS cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cinobufagin","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, combined treatment with <e1>CHEMICAL<\\e1> and SB216367 resulted in a significant reduction in <e2>GENE-Y<\\e2> and an increase in cleaved-PARP in U2OS cells","sentence":"However, combined treatment with cinobufagin and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-PARP in U2OS cells"}
{"PMID":23164673,"re_id":9,"annotated sentence":"However, combined treatment with cinobufagin and <e1>SB216367<\\e1> resulted in a significant reduction in <e2>p65<\\e2> and an increase in cleaved-PARP in U2OS cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB216367","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, combined treatment with cinobufagin and <e1>CHEMICAL<\\e1> resulted in a significant reduction in <e2>GENE-Y<\\e2> and an increase in cleaved-PARP in U2OS cells","sentence":"However, combined treatment with cinobufagin and SB216367 resulted in a significant reduction in p65 and an increase in cleaved-PARP in U2OS cells"}
{"PMID":23172777,"re_id":0,"annotated sentence":"Based on these suggestions, the rational redesign of <e1>furanopyrimidine<\\e1> 24 (clog\u2009P=7.41; <e2>Aurora\u2005A<\\e2> IC(50) =43\u2005nM; HCT-116 IC(50) =400\u2005nM) led to the identification of quinazoline 67 (clog\u2009P=5.28; Aurora\u2005A IC(50) =25\u2005nM; HCT-116 IC(50) =23\u2005nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"furanopyrimidine","object":"Aurora\u2005A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on these suggestions, the rational redesign of <e1>CHEMICAL<\\e1> 24 (clog\u2009P=7.41; <e2>GENE-Y<\\e2> IC(50) =43\u2005nM; HCT-116 IC(50) =400\u2005nM) led to the identification of quinazoline 67 (clog\u2009P=5.28; GENE-Y IC(50) =25\u2005nM; HCT-116 IC(50) =23\u2005nM)","sentence":"Based on these suggestions, the rational redesign of furanopyrimidine 24 (clog\u2009P=7.41; Aurora\u2005A IC(50) =43\u2005nM; HCT-116 IC(50) =400\u2005nM) led to the identification of quinazoline 67 (clog\u2009P=5.28; Aurora\u2005A IC(50) =25\u2005nM; HCT-116 IC(50) =23\u2005nM)"}
{"PMID":23172777,"re_id":1,"annotated sentence":"Based on these suggestions, the rational redesign of furanopyrimidine 24 (clog\u2009P=7.41; Aurora\u2005A IC(50) =43\u2005nM; HCT-116 IC(50) =400\u2005nM) led to the identification of <e1>quinazoline<\\e1> 67 (clog\u2009P=5.28; <e2>Aurora\u2005A<\\e2> IC(50) =25\u2005nM; HCT-116 IC(50) =23\u2005nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinazoline","object":"Aurora\u2005A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on these suggestions, the rational redesign of furanopyrimidine 24 (clog\u2009P=7.41; GENE-Y IC(50) =43\u2005nM; HCT-116 IC(50) =400\u2005nM) led to the identification of <e1>CHEMICAL<\\e1> 67 (clog\u2009P=5.28; <e2>GENE-Y<\\e2> IC(50) =25\u2005nM; HCT-116 IC(50) =23\u2005nM)","sentence":"Based on these suggestions, the rational redesign of furanopyrimidine 24 (clog\u2009P=7.41; Aurora\u2005A IC(50) =43\u2005nM; HCT-116 IC(50) =400\u2005nM) led to the identification of quinazoline 67 (clog\u2009P=5.28; Aurora\u2005A IC(50) =25\u2005nM; HCT-116 IC(50) =23\u2005nM)"}
{"PMID":23172777,"re_id":2,"annotated sentence":"Three different 3D-QSAR models were built and validated by using a set of 66 <e1>pyrazole<\\e1> (Model\u2005I) and furanopyrimidine (Model\u2005II) compounds with IC(50) values toward <e2>Aurora kinase\u2005A<\\e2> ranging from 33\u2005nM to 10.5\u2005\u03bcM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrazole","object":"Aurora kinase\u2005A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three different 3D-QSAR models were built and validated by using a set of 66 <e1>CHEMICAL<\\e1> (Model\u2005I) and furanopyrimidine (Model\u2005II) compounds with IC(50) values toward <e2>GENE-Y<\\e2> ranging from 33\u2005nM to 10.5\u2005\u03bcM","sentence":"Three different 3D-QSAR models were built and validated by using a set of 66 pyrazole (Model\u2005I) and furanopyrimidine (Model\u2005II) compounds with IC(50) values toward Aurora kinase\u2005A ranging from 33\u2005nM to 10.5\u2005\u03bcM"}
{"PMID":23172777,"re_id":3,"annotated sentence":"Three different 3D-QSAR models were built and validated by using a set of 66 pyrazole (Model\u2005I) and <e1>furanopyrimidine<\\e1> (Model\u2005II) compounds with IC(50) values toward <e2>Aurora kinase\u2005A<\\e2> ranging from 33\u2005nM to 10.5\u2005\u03bcM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"furanopyrimidine","object":"Aurora kinase\u2005A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three different 3D-QSAR models were built and validated by using a set of 66 pyrazole (Model\u2005I) and <e1>CHEMICAL<\\e1> (Model\u2005II) compounds with IC(50) values toward <e2>GENE-Y<\\e2> ranging from 33\u2005nM to 10.5\u2005\u03bcM","sentence":"Three different 3D-QSAR models were built and validated by using a set of 66 pyrazole (Model\u2005I) and furanopyrimidine (Model\u2005II) compounds with IC(50) values toward Aurora kinase\u2005A ranging from 33\u2005nM to 10.5\u2005\u03bcM"}
{"PMID":23172777,"re_id":4,"annotated sentence":"3D-QSAR-assisted drug design: identification of a potent <e1>quinazoline<\\e1> based <e2>Aurora kinase<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinazoline","object":"Aurora kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"3D-QSAR-assisted drug design: identification of a potent <e1>CHEMICAL<\\e1> based <e2>GENE-N<\\e2> inhibitor","sentence":"3D-QSAR-assisted drug design: identification of a potent quinazoline based Aurora kinase inhibitor"}
{"PMID":23177256,"re_id":0,"annotated sentence":"Pharmacophore identification of <e2>c-Myc<\\e2> inhibitor <e1>10074-G5<\\e1>  A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"10074-G5","object":"c-Myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacophore identification of <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  A structure-activity relationship (SAR) study of the GENE-Y (Myc) inhibitor CHEMICAL (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore","sentence":"Pharmacophore identification of c-Myc inhibitor 10074-G5  A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore"}
{"PMID":23177256,"re_id":1,"annotated sentence":"Importantly, the carboxylic acid of <e1>JY-3-094<\\e1> improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance <e2>Myc<\\e2> inhibitory activity further still.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JY-3-094","object":"Myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Importantly, the carboxylic acid of <e1>CHEMICAL<\\e1> improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance <e2>GENE-Y<\\e2> inhibitory activity further still.","sentence":"Importantly, the carboxylic acid of JY-3-094 improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance Myc inhibitory activity further still."}
{"PMID":23177256,"re_id":2,"annotated sentence":"A structure-activity relationship (SAR) study of the <e2>c-Myc<\\e2> (Myc) inhibitor <e1>10074-G5<\\e1> (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"10074-G5","object":"c-Myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A structure-activity relationship (SAR) study of the <e2>GENE-Y<\\e2> (Myc) inhibitor <e1>CHEMICAL<\\e1> (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore","sentence":"A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore"}
{"PMID":23177256,"re_id":3,"annotated sentence":"A structure-activity relationship (SAR) study of the c-Myc (<e2>Myc<\\e2>  inhibitor <e1>10074-G5<\\e1> (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"10074-G5","object":"Myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A structure-activity relationship (SAR) study of the c-GENE-Y (<e2>GENE-Y<\\e2>  inhibitor <e1>CHEMICAL<\\e1> (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the GENE-Y oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore","sentence":"A structure-activity relationship (SAR) study of the c-Myc (Myc  inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore"}
{"PMID":23177256,"re_id":4,"annotated sentence":"A structure-activity relationship (SAR) study of the <e2>c-Myc<\\e2> (Myc) inhibitor 10074-G5 (<e1>N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine<\\e1>  1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine","object":"c-Myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A structure-activity relationship (SAR) study of the <e2>GENE-Y<\\e2> (Myc) inhibitor 10074-G5 (<e1>CHEMICAL<\\e1>  1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore","sentence":"A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine  1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore"}
{"PMID":23177256,"re_id":5,"annotated sentence":"A structure-activity relationship (SAR) study of the c-Myc (<e2>Myc<\\e2>  inhibitor 10074-G5 (<e1>N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine<\\e1>  1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine","object":"Myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A structure-activity relationship (SAR) study of the c-GENE-Y (<e2>GENE-Y<\\e2>  inhibitor 10074-G5 (<e1>CHEMICAL<\\e1>  1) - which targets a hydrophobic domain of the GENE-Y oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore","sentence":"A structure-activity relationship (SAR) study of the c-Myc (Myc  inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine  1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore"}
{"PMID":23178380,"re_id":0,"annotated sentence":"In contrast to parenteral delivery of rBChE, which currently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-<e1>paraoxon<\\e1> (Px) was able to prevent inhibition of circulating <e2>cholinesterase<\\e2> in a dose-dependent manner","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paraoxon","object":"cholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast to parenteral delivery of rBChE, which currently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-<e1>CHEMICAL<\\e1> (Px) was able to prevent inhibition of circulating <e2>GENE-Y<\\e2> in a dose-dependent manner","sentence":"In contrast to parenteral delivery of rBChE, which currently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-paraoxon (Px) was able to prevent inhibition of circulating cholinesterase in a dose-dependent manner"}
{"PMID":23182954,"re_id":0,"annotated sentence":"<e1>Ozone<\\e1> plus PM(2.5) exposure, however, induced <e2>CRP<\\e2>  IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ozone","object":"CRP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> plus PM(2.5) exposure, however, induced <e2>GENE-Y<\\e2>  IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way","sentence":"Ozone plus PM(2.5) exposure, however, induced CRP  IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way"}
{"PMID":23182954,"re_id":1,"annotated sentence":"<e1>Ozone<\\e1> plus PM(2.5) exposure, however, induced CRP, <e2>IL-6<\\e2>  CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ozone","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> plus PM(2.5) exposure, however, induced CRP, <e2>GENE-Y<\\e2>  CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way","sentence":"Ozone plus PM(2.5) exposure, however, induced CRP, IL-6  CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way"}
{"PMID":23182954,"re_id":2,"annotated sentence":"<e1>Ozone<\\e1> plus PM(2.5) exposure, however, induced CRP, IL-6, <e2>CK<\\e2>  LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ozone","object":"CK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> plus PM(2.5) exposure, however, induced CRP, IL-6, <e2>GENE-N<\\e2>  LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way","sentence":"Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK  LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way"}
{"PMID":23182954,"re_id":3,"annotated sentence":"<e1>Ozone<\\e1> plus PM(2.5) exposure, however, induced CRP, IL-6, CK, <e2>LDH<\\e2> and MDA increase, SOD and HRV decrease significantly in a dose-response way","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ozone","object":"LDH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> plus PM(2.5) exposure, however, induced CRP, IL-6, CK, <e2>GENE-N<\\e2> and MDA increase, SOD and HRV decrease significantly in a dose-response way","sentence":"Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way"}
{"PMID":23182954,"re_id":4,"annotated sentence":"<e1>Ozone<\\e1> plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, <e2>SOD<\\e2> and HRV decrease significantly in a dose-response way","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ozone","object":"SOD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, <e2>GENE-N<\\e2> and HRV decrease significantly in a dose-response way","sentence":"Ozone plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way"}
{"PMID":23183186,"re_id":0,"annotated sentence":"This stimulation was attenuated by the <e2>Pak<\\e2> inhibitor <e1>2,2'-dihydroxy-1,1'-dinaphthyldisulfide<\\e1> (IPA3) or dominant-negative Pak1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2,2'-dihydroxy-1,1'-dinaphthyldisulfide","object":"Pak","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This stimulation was attenuated by the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (IPA3) or dominant-negative GENE-N1","sentence":"This stimulation was attenuated by the Pak inhibitor 2,2'-dihydroxy-1,1'-dinaphthyldisulfide (IPA3) or dominant-negative Pak1"}
{"PMID":23183186,"re_id":1,"annotated sentence":"This stimulation was attenuated by the <e2>Pak<\\e2> inhibitor 2,2'-dihydroxy-1,1'-dinaphthyldisulfide (<e1>IPA3<\\e1>  or dominant-negative Pak1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IPA3","object":"Pak","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This stimulation was attenuated by the <e2>GENE-N<\\e2> inhibitor 2,2'-dihydroxy-1,1'-dinaphthyldisulfide (<e1>CHEMICAL<\\e1>  or dominant-negative GENE-N1","sentence":"This stimulation was attenuated by the Pak inhibitor 2,2'-dihydroxy-1,1'-dinaphthyldisulfide (IPA3  or dominant-negative Pak1"}
{"PMID":23194825,"re_id":0,"annotated sentence":"Importantly, pre-treatment with buthionine sulfoximine (BS<e1>BSO<\\e1> an inhibitor of \u03b3-<e2>\u03b3-GCS<\\e2> revented \u03b1-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BSO","object":"\u03b3-GCS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Importantly, pre-treatment with buthionine sulfoximine (BS<e1>CHEMICAL<\\e1> an inhibitor of \u03b3-<e2>GENE-Y<\\e2> revented \u03b1-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity","sentence":"Importantly, pre-treatment with buthionine sulfoximine (BSBSO an inhibitor of \u03b3-\u03b3-GCS revented \u03b1-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity"}
{"PMID":23194825,"re_id":1,"annotated sentence":"Neither the superoxide radical scavenger, tiron, nor the inhibitor of the do<e2>dopamine (DA) transporter<\\e2> B<e1>GBR 12909<\\e1> revented the metabolites' toxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GBR 12909","object":"dopamine (DA) transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Neither the superoxide radical scavenger, tiron, nor the inhibitor of the do<e2>GENE-Y<\\e2> B<e1>CHEMICAL<\\e1> revented the metabolites' toxicity","sentence":"Neither the superoxide radical scavenger, tiron, nor the inhibitor of the dodopamine (DA) transporter BGBR 12909 revented the metabolites' toxicity"}
{"PMID":23194825,"re_id":2,"annotated sentence":"Importantly, pre-treatment with bu<e1>buthionine sulfoximine<\\e1> SO), an inhibitor of \u03b3-<e2>\u03b3-GCS<\\e2> revented \u03b1-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"buthionine sulfoximine","object":"\u03b3-GCS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Importantly, pre-treatment with bu<e1>CHEMICAL<\\e1> SO), an inhibitor of \u03b3-<e2>GENE-Y<\\e2> revented \u03b1-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity","sentence":"Importantly, pre-treatment with bubuthionine sulfoximine SO), an inhibitor of \u03b3-\u03b3-GCS revented \u03b1-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity"}
{"PMID":23200255,"re_id":0,"annotated sentence":"<e1>(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one<\\e1> (KCA-1490) exhibits moderate dual <e2>PDE3\/4<\\e2> inhibitory activity and promises as a combined bronchodilatory\/anti-inflammatory agent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one","object":"PDE3\/4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (KCA-1490) exhibits moderate dual <e2>GENE-N<\\e2> inhibitory activity and promises as a combined bronchodilatory\/anti-inflammatory agent","sentence":"(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3\/4 inhibitory activity and promises as a combined bronchodilatory\/anti-inflammatory agent"}
{"PMID":23200255,"re_id":1,"annotated sentence":"(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (<e1>KCA-1490<\\e1>  exhibits moderate dual <e2>PDE3\/4<\\e2> inhibitory activity and promises as a combined bronchodilatory\/anti-inflammatory agent","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"KCA-1490","object":"PDE3\/4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (<e1>CHEMICAL<\\e1>  exhibits moderate dual <e2>GENE-N<\\e2> inhibitory activity and promises as a combined bronchodilatory\/anti-inflammatory agent","sentence":"(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490  exhibits moderate dual PDE3\/4 inhibitory activity and promises as a combined bronchodilatory\/anti-inflammatory agent"}
{"PMID":23200255,"re_id":2,"annotated sentence":"<e1>N<\\e1> alkylation of the pyridazinone ring markedly enhances potency against <e2>PDE4<\\e2> but suppresses PDE3 inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> alkylation of the pyridazinone ring markedly enhances potency against <e2>GENE-N<\\e2> but suppresses PDE3 inhibition","sentence":"N alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition"}
{"PMID":23200255,"re_id":3,"annotated sentence":"<e1>N<\\e1> alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses <e2>PDE3<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses <e2>GENE-N<\\e2> inhibition","sentence":"N alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition"}
{"PMID":23200255,"re_id":4,"annotated sentence":"N-alkylation of the <e1>pyridazinone<\\e1> ring markedly enhances potency against <e2>PDE4<\\e2> but suppresses PDE3 inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyridazinone","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"N-alkylation of the <e1>CHEMICAL<\\e1> ring markedly enhances potency against <e2>GENE-N<\\e2> but suppresses PDE3 inhibition","sentence":"N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition"}
{"PMID":23200255,"re_id":5,"annotated sentence":"N-alkylation of the <e1>pyridazinone<\\e1> ring markedly enhances potency against PDE4 but suppresses <e2>PDE3<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyridazinone","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"N-alkylation of the <e1>CHEMICAL<\\e1> ring markedly enhances potency against PDE4 but suppresses <e2>GENE-N<\\e2> inhibition","sentence":"N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition"}
{"PMID":23200255,"re_id":6,"annotated sentence":"Addition of a <e1>6-aryl-4,5-dihydropyridazin-3(2H)-one<\\e1> extension to the N-alkyl group facilitates both enhancement of <e2>PDE4<\\e2> inhibitory activity and restoration of potent PDE3 inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"6-aryl-4,5-dihydropyridazin-3(2H)-one","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Addition of a <e1>CHEMICAL<\\e1> extension to the N-alkyl group facilitates both enhancement of <e2>GENE-N<\\e2> inhibitory activity and restoration of potent PDE3 inhibition","sentence":"Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4 inhibitory activity and restoration of potent PDE3 inhibition"}
{"PMID":23200255,"re_id":7,"annotated sentence":"Addition of a <e1>6-aryl-4,5-dihydropyridazin-3(2H)-one<\\e1> extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent <e2>PDE3<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"6-aryl-4,5-dihydropyridazin-3(2H)-one","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Addition of a <e1>CHEMICAL<\\e1> extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent <e2>GENE-N<\\e2> inhibition","sentence":"Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition"}
{"PMID":23200255,"re_id":8,"annotated sentence":"Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the <e1>N<\\e1> alkyl group facilitates both enhancement of <e2>PDE4<\\e2> inhibitory activity and restoration of potent PDE3 inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the <e1>CHEMICAL<\\e1> alkyl group facilitates both enhancement of <e2>GENE-N<\\e2> inhibitory activity and restoration of potent PDE3 inhibition","sentence":"Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N alkyl group facilitates both enhancement of PDE4 inhibitory activity and restoration of potent PDE3 inhibition"}
{"PMID":23200255,"re_id":9,"annotated sentence":"Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the <e1>N<\\e1> alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent <e2>PDE3<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N","object":"PDE3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the <e1>CHEMICAL<\\e1> alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent <e2>GENE-N<\\e2> inhibition","sentence":"Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition"}
{"PMID":23206862,"re_id":0,"annotated sentence":"Identification of a novel <e1>benzimidazole<\\e1> derivative as a highly potent <e2>NPY Y5 receptor<\\e2> antagonist with an anti-obesity profile","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"benzimidazole","object":"NPY Y5 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Identification of a novel <e1>CHEMICAL<\\e1> derivative as a highly potent <e2>GENE-Y<\\e2> antagonist with an anti-obesity profile","sentence":"Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile"}
{"PMID":23219339,"re_id":0,"annotated sentence":"<e1>OMT<\\e1> showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of <e2>Bcl-2<\\e2> family","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"OMT","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of <e2>GENE-Y<\\e2> family","sentence":"OMT showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of Bcl-2 family"}
{"PMID":23219339,"re_id":1,"annotated sentence":"Western blot analysis revealed that <e1>OMT<\\e1> decreased the expression of <e2>Bax<\\e2> and repaired the balance of pro- and anti-apoptotic proteins","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"OMT","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blot analysis revealed that <e1>CHEMICAL<\\e1> decreased the expression of <e2>GENE-Y<\\e2> and repaired the balance of pro- and anti-apoptotic proteins","sentence":"Western blot analysis revealed that OMT decreased the expression of Bax and repaired the balance of pro- and anti-apoptotic proteins"}
{"PMID":23219339,"re_id":2,"annotated sentence":"Furthermore, <e1>OMT<\\e1> significantly reversed the up-regulation of <e2>NR2B<\\e2> and inhibited the calcium overload in the cultured neurons after challenging the NMDA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"OMT","object":"NR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> significantly reversed the up-regulation of <e2>GENE-Y<\\e2> and inhibited the calcium overload in the cultured neurons after challenging the NMDA","sentence":"Furthermore, OMT significantly reversed the up-regulation of NR2B and inhibited the calcium overload in the cultured neurons after challenging the NMDA"}
{"PMID":23219339,"re_id":3,"annotated sentence":"<e1>OMT<\\e1> showed partial protection in the cortical neurons via down-regulation of <e2>NR2B<\\e2> containing NMDA receptors and up-regulation of Bcl-2 family","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"OMT","object":"NR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> showed partial protection in the cortical neurons via down-regulation of <e2>GENE-Y<\\e2> containing NMDA receptors and up-regulation of Bcl-2 family","sentence":"OMT showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of Bcl-2 family"}
{"PMID":23219339,"re_id":4,"annotated sentence":"<e1>OMT<\\e1> showed partial protection in the cortical neurons via down-regulation of NR2B containing <e2>NMDA receptors<\\e2> and up-regulation of Bcl-2 family","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"OMT","object":"NMDA receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> showed partial protection in the cortical neurons via down-regulation of NR2B containing <e2>GENE-N<\\e2> and up-regulation of Bcl-2 family","sentence":"OMT showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of Bcl-2 family"}
{"PMID":23220589,"re_id":0,"annotated sentence":"The reactivation of brain <e2>AChE<\\e2> inhibited with tabun demonstrated better activity of new compound <e1>BT-07-4M<\\e1>  TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BT-07-4M","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reactivation of brain <e2>GENE-Y<\\e2> inhibited with tabun demonstrated better activity of new compound <e1>CHEMICAL<\\e1>  TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure","sentence":"The reactivation of brain AChE inhibited with tabun demonstrated better activity of new compound BT-07-4M  TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure"}
{"PMID":23220589,"re_id":1,"annotated sentence":"The reactivation of brain <e2>AChE<\\e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, <e1>TMB-4<\\e1> and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TMB-4","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reactivation of brain <e2>GENE-Y<\\e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, <e1>CHEMICAL<\\e1> and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure","sentence":"The reactivation of brain AChE inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure"}
{"PMID":23220589,"re_id":2,"annotated sentence":"The reactivation of brain <e2>AChE<\\e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and <e1>obidoxime<\\e1> from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"obidoxime","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reactivation of brain <e2>GENE-Y<\\e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and <e1>CHEMICAL<\\e1> from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure","sentence":"The reactivation of brain AChE inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure"}
{"PMID":23220589,"re_id":3,"annotated sentence":"The reactivation of brain <e2>AChE<\\e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric <e1>oximes<\\e1>  and BT-05 and BT-03 possessing asymmetric structure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oximes","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reactivation of brain <e2>GENE-Y<\\e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric <e1>CHEMICAL<\\e1>  and BT-05 and BT-03 possessing asymmetric structure","sentence":"The reactivation of brain AChE inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes  and BT-05 and BT-03 possessing asymmetric structure"}
{"PMID":23220589,"re_id":4,"annotated sentence":"The reactivation of brain <e2>AChE<\\e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and <e1>BT-05<\\e1> and BT-03 possessing asymmetric structure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BT-05","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reactivation of brain <e2>GENE-Y<\\e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and <e1>CHEMICAL<\\e1> and BT-03 possessing asymmetric structure","sentence":"The reactivation of brain AChE inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure"}
{"PMID":23220589,"re_id":5,"annotated sentence":"The reactivation of brain <e2>AChE<\\e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and <e1>BT-03<\\e1> possessing asymmetric structure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BT-03","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reactivation of brain <e2>GENE-Y<\\e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and <e1>CHEMICAL<\\e1> possessing asymmetric structure","sentence":"The reactivation of brain AChE inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure"}
{"PMID":23220589,"re_id":6,"annotated sentence":"<e2>AChE<\\e2> was easier reactivated after <e1>paraoxon<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"paraoxon","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> was easier reactivated after <e1>CHEMICAL<\\e1> treatment","sentence":"AChE was easier reactivated after paraoxon treatment"}
{"PMID":23220589,"re_id":7,"annotated sentence":"All compounds showed low activity toward inhibition of <e2>AChE<\\e2> caused by <e1>dichlorvos<\\e1>  Comparison of two main structure types (symmetric\/asymmetric) showed that the symmetric compounds reactivated better AChE, inhibited with this OPC, than asymmetric ones.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dichlorvos","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All compounds showed low activity toward inhibition of <e2>GENE-Y<\\e2> caused by <e1>CHEMICAL<\\e1>  Comparison of two main structure types (symmetric\/asymmetric) showed that the symmetric compounds reactivated better GENE-Y, inhibited with this OPC, than asymmetric ones.","sentence":"All compounds showed low activity toward inhibition of AChE caused by dichlorvos  Comparison of two main structure types (symmetric\/asymmetric) showed that the symmetric compounds reactivated better AChE, inhibited with this OPC, than asymmetric ones."}
{"PMID":23220589,"re_id":8,"annotated sentence":"Reactivators showed different activity in the reactivation of <e2>rat brain AChE<\\e2> after <e1>dichlorvos<\\e1>  paraoxon and tabun inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dichlorvos","object":"rat brain AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reactivators showed different activity in the reactivation of <e2>GENE-Y<\\e2> after <e1>CHEMICAL<\\e1>  paraoxon and tabun inhibition","sentence":"Reactivators showed different activity in the reactivation of rat brain AChE after dichlorvos  paraoxon and tabun inhibition"}
{"PMID":23220589,"re_id":9,"annotated sentence":"Reactivators showed different activity in the reactivation of <e2>rat brain AChE<\\e2> after dichlorvos, <e1>paraoxon<\\e1> and tabun inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"paraoxon","object":"rat brain AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reactivators showed different activity in the reactivation of <e2>GENE-Y<\\e2> after dichlorvos, <e1>CHEMICAL<\\e1> and tabun inhibition","sentence":"Reactivators showed different activity in the reactivation of rat brain AChE after dichlorvos, paraoxon and tabun inhibition"}
{"PMID":23220589,"re_id":10,"annotated sentence":"Reactivators showed different activity in the reactivation of <e2>rat brain AChE<\\e2> after dichlorvos, paraoxon and <e1>tabun<\\e1> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tabun","object":"rat brain AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reactivators showed different activity in the reactivation of <e2>GENE-Y<\\e2> after dichlorvos, paraoxon and <e1>CHEMICAL<\\e1> inhibition","sentence":"Reactivators showed different activity in the reactivation of rat brain AChE after dichlorvos, paraoxon and tabun inhibition"}
{"PMID":23221006,"re_id":0,"annotated sentence":"Inhibition by <e1>phenformin<\\e1> of oxygen consumption via <e2>complex I<\\e2> respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenformin","object":"complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition by <e1>CHEMICAL<\\e1> of oxygen consumption via <e2>GENE-N<\\e2> respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of CHEMICAL on GENE-N respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts","sentence":"Inhibition by phenformin of oxygen consumption via complex I respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts"}
{"PMID":23221006,"re_id":1,"annotated sentence":"Role of organic cation\/carnitine transporter 1 in uptake of <e1>phenformin<\\e1> and inhibitory effect on <e2>complex I<\\e2> respiration in mitochondria","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenformin","object":"complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Role of organic cation\/carnitine transporter 1 in uptake of <e1>CHEMICAL<\\e1> and inhibitory effect on <e2>GENE-N<\\e2> respiration in mitochondria","sentence":"Role of organic cation\/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria"}
{"PMID":23221006,"re_id":2,"annotated sentence":"<e1>Phenformin<\\e1> causes lactic acidosis in clinical situations due to inhibition of <e2>mitochondrial respiratory chain complex I<\\e2>  It is reportedly taken up by hepatocytes and exhibits mitochondrial toxicity in the liver","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Phenformin","object":"mitochondrial respiratory chain complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> causes lactic acidosis in clinical situations due to inhibition of <e2>GENE-N<\\e2>  It is reportedly taken up by hepatocytes and exhibits mitochondrial toxicity in the liver","sentence":"Phenformin causes lactic acidosis in clinical situations due to inhibition of mitochondrial respiratory chain complex I  It is reportedly taken up by hepatocytes and exhibits mitochondrial toxicity in the liver"}
{"PMID":23221006,"re_id":3,"annotated sentence":"Inhibition by phenformin of oxygen consumption via complex I respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of <e1>phenformin<\\e1> on <e2>complex I<\\e2> respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenformin","object":"complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition by CHEMICAL of oxygen consumption via GENE-N respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-N<\\e2> respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts","sentence":"Inhibition by phenformin of oxygen consumption via complex I respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts"}
{"PMID":23221006,"re_id":4,"annotated sentence":"These observations suggest that uptake of <e1>phenformin<\\e1> into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of <e2>complex I<\\e2> respiration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenformin","object":"complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These observations suggest that uptake of <e1>CHEMICAL<\\e1> into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of <e2>GENE-N<\\e2> respiration","sentence":"These observations suggest that uptake of phenformin into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of complex I respiration"}
{"PMID":23221006,"re_id":5,"annotated sentence":"In this study, uptake of phenformin and [(14)C]tetraethylammonium (TEA) and <e2>complex I<\\e2> inhibition by <e1>phenformin<\\e1> were examined in isolated liver and heart mitochondria","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenformin","object":"complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, uptake of CHEMICAL and [(14)C]tetraethylammonium (TEA) and <e2>GENE-N<\\e2> inhibition by <e1>CHEMICAL<\\e1> were examined in isolated liver and heart mitochondria","sentence":"In this study, uptake of phenformin and [(14)C]tetraethylammonium (TEA) and complex I inhibition by phenformin were examined in isolated liver and heart mitochondria"}
{"PMID":23221006,"re_id":6,"annotated sentence":"Role of <e2>organic cation\/carnitine transporter 1<\\e2> in uptake of <e1>phenformin<\\e1> and inhibitory effect on complex I respiration in mitochondria","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phenformin","object":"organic cation\/carnitine transporter 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Role of <e2>GENE-Y<\\e2> in uptake of <e1>CHEMICAL<\\e1> and inhibitory effect on complex I respiration in mitochondria","sentence":"Role of organic cation\/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria"}
{"PMID":23221006,"re_id":7,"annotated sentence":"These observations suggest that uptake of <e1>phenformin<\\e1> into liver mitochondria is at least partly mediated by <e2>OCTN1<\\e2> and functionally relevant to its inhibition potential of complex I respiration","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phenformin","object":"OCTN1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These observations suggest that uptake of <e1>CHEMICAL<\\e1> into liver mitochondria is at least partly mediated by <e2>GENE-Y<\\e2> and functionally relevant to its inhibition potential of complex I respiration","sentence":"These observations suggest that uptake of phenformin into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of complex I respiration"}
{"PMID":23223345,"re_id":0,"annotated sentence":"CONCLUSIONS A diet that partially replaces <e1>carbohydrate<\\e1> with unsaturated fat may improve <e2>insulin<\\e2> sensitivity in a population at risk for cardiovascular disease","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"carbohydrate","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS A diet that partially replaces <e1>CHEMICAL<\\e1> with unsaturated fat may improve <e2>GENE-Y<\\e2> sensitivity in a population at risk for cardiovascular disease","sentence":"CONCLUSIONS A diet that partially replaces carbohydrate with unsaturated fat may improve insulin sensitivity in a population at risk for cardiovascular disease"}
{"PMID":23229512,"re_id":0,"annotated sentence":"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for <e1>VK2<\\e1> induced <e2>cytochrome c<\\e2> (cyt c) release and cell death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"VK2","object":"cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> (cyt c) release and cell death","sentence":"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2 induced cytochrome c (cyt c) release and cell death"}
{"PMID":23229512,"re_id":1,"annotated sentence":"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for <e1>VK2<\\e1> induced cytochrome c (<e2>cyt c<\\e2>  release and cell death","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"VK2","object":"cyt c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for <e1>CHEMICAL<\\e1> induced cytochrome c (<e2>GENE-Y<\\e2>  release and cell death","sentence":"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2 induced cytochrome c (cyt c  release and cell death"}
{"PMID":23231502,"re_id":0,"annotated sentence":"Here, we demonstrate that <e2>peptidyl-prolyl cis\/trans-isomerase A1<\\e2> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of <e1>pSer<\\e1> pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pSer","object":"peptidyl-prolyl cis\/trans-isomerase A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we demonstrate that <e2>GENE-Y<\\e2> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of <e1>CHEMICAL<\\e1> pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification"}
{"PMID":23231502,"re_id":1,"annotated sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (<e2>Pin1<\\e2> , an enzyme that catalyzes the conversion of the peptide bond of <e1>pSer<\\e1> pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pSer","object":"Pin1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (<e2>GENE-Y<\\e2> , an enzyme that catalyzes the conversion of the peptide bond of <e1>CHEMICAL<\\e1> pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (Pin1 , an enzyme that catalyzes the conversion of the peptide bond of pSer pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification"}
{"PMID":23231502,"re_id":2,"annotated sentence":"Here, we demonstrate that <e2>peptidyl-prolyl cis\/trans-isomerase A1<\\e2> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer\/<e1>pThr<\\e1> Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pThr","object":"peptidyl-prolyl cis\/trans-isomerase A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we demonstrate that <e2>GENE-Y<\\e2> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer\/<e1>CHEMICAL<\\e1> Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer\/pThr Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification"}
{"PMID":23231502,"re_id":3,"annotated sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (<e2>Pin1<\\e2> , an enzyme that catalyzes the conversion of the peptide bond of pSer\/<e1>pThr<\\e1> Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"pThr","object":"Pin1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (<e2>GENE-Y<\\e2> , an enzyme that catalyzes the conversion of the peptide bond of pSer\/<e1>CHEMICAL<\\e1> Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (Pin1 , an enzyme that catalyzes the conversion of the peptide bond of pSer\/pThr Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification"}
{"PMID":23231502,"re_id":4,"annotated sentence":"Here, we demonstrate that <e2>peptidyl-prolyl cis\/trans-isomerase A1<\\e2> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer\/pThr-<e1>Pro<\\e1> moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Pro","object":"peptidyl-prolyl cis\/trans-isomerase A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we demonstrate that <e2>GENE-Y<\\e2> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer\/pThr-<e1>CHEMICAL<\\e1> moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer\/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification"}
{"PMID":23231502,"re_id":5,"annotated sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (<e2>Pin1<\\e2> , an enzyme that catalyzes the conversion of the peptide bond of pSer\/pThr-<e1>Pro<\\e1> moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Pro","object":"Pin1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (<e2>GENE-Y<\\e2> , an enzyme that catalyzes the conversion of the peptide bond of pSer\/pThr-<e1>CHEMICAL<\\e1> moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification","sentence":"Here, we demonstrate that peptidyl-prolyl cis\/trans-isomerase A1 (Pin1 , an enzyme that catalyzes the conversion of the peptide bond of pSer\/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification"}
{"PMID":23238783,"re_id":0,"annotated sentence":"These results suggest that <e2>CYP2B6<\\e2> genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of <e1>bupropion<\\e1>  The bupropion metabolic ratio appears to detect known differences in CYP2B6 activity associated with genetic polymorphism, across different ethnic groups","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bupropion","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e2>GENE-Y<\\e2> genotype is the most important patient variable for predicting the level of GENE-Y activity in women, when measured by the metabolism of <e1>CHEMICAL<\\e1>  The CHEMICAL metabolic ratio appears to detect known differences in GENE-Y activity associated with genetic polymorphism, across different ethnic groups","sentence":"These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of bupropion  The bupropion metabolic ratio appears to detect known differences in CYP2B6 activity associated with genetic polymorphism, across different ethnic groups"}
{"PMID":23238783,"re_id":1,"annotated sentence":"These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of <e2>CYP2B6<\\e2> activity in women, when measured by the metabolism of <e1>bupropion<\\e1>  The bupropion metabolic ratio appears to detect known differences in CYP2B6 activity associated with genetic polymorphism, across different ethnic groups","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bupropion","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that GENE-Y genotype is the most important patient variable for predicting the level of <e2>GENE-Y<\\e2> activity in women, when measured by the metabolism of <e1>CHEMICAL<\\e1>  The CHEMICAL metabolic ratio appears to detect known differences in GENE-Y activity associated with genetic polymorphism, across different ethnic groups","sentence":"These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of bupropion  The bupropion metabolic ratio appears to detect known differences in CYP2B6 activity associated with genetic polymorphism, across different ethnic groups"}
{"PMID":23238783,"re_id":2,"annotated sentence":"The <e1>bupropion<\\e1> metabolic ratio appears to detect known differences in <e2>CYP2B6<\\e2> activity associated with genetic polymorphism, across different ethnic groups","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bupropion","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> metabolic ratio appears to detect known differences in <e2>GENE-Y<\\e2> activity associated with genetic polymorphism, across different ethnic groups","sentence":"The bupropion metabolic ratio appears to detect known differences in CYP2B6 activity associated with genetic polymorphism, across different ethnic groups"}
{"PMID":23238783,"re_id":3,"annotated sentence":"To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using <e1>bupropion<\\e1> (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a <e2>CYP2B6<\\e2> probe substrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bupropion","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To identify important covariates associated with interindividual variation in GENE-Y activity in vivo, we evaluated these effects in healthy volunteers using <e1>CHEMICAL<\\e1> (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a <e2>GENE-Y<\\e2> probe substrate","sentence":"To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using bupropion (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a CYP2B6 probe substrate"}
{"PMID":23238783,"re_id":4,"annotated sentence":"To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using bupropion (<e1>Wellbutrin SR<\\e1> GlaxoSmithKline, Research Triangle Park, NC) as a <e2>CYP2B6<\\e2> probe substrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Wellbutrin SR","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To identify important covariates associated with interindividual variation in GENE-Y activity in vivo, we evaluated these effects in healthy volunteers using bupropion (<e1>CHEMICAL<\\e1> GlaxoSmithKline, Research Triangle Park, NC) as a <e2>GENE-Y<\\e2> probe substrate","sentence":"To identify important covariates associated with interindividual variation in CYP2B6 activity in vivo, we evaluated these effects in healthy volunteers using bupropion (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a CYP2B6 probe substrate"}
{"PMID":23238783,"re_id":5,"annotated sentence":"The influence of sex, ethnicity, and <e2>CYP2B6<\\e2> genotype on <e1>bupropion<\\e1> metabolism as an index of hepatic CYP2B6 activity in humans","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bupropion","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The influence of sex, ethnicity, and <e2>GENE-Y<\\e2> genotype on <e1>CHEMICAL<\\e1> metabolism as an index of hepatic GENE-Y activity in humans","sentence":"The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans"}
{"PMID":23238784,"re_id":0,"annotated sentence":"The <e2>CYP3A4<\\e2> activity could be induced 2-fold by <e1>rifampicin<\\e1>  whereas CYP2C9 activity remained equally high","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rifampicin","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> activity could be induced 2-fold by <e1>CHEMICAL<\\e1>  whereas CYP2C9 activity remained equally high","sentence":"The CYP3A4 activity could be induced 2-fold by rifampicin  whereas CYP2C9 activity remained equally high"}
{"PMID":23238784,"re_id":1,"annotated sentence":"The CYP3A4 activity could be induced 2-fold by <e1>rifampicin<\\e1>  whereas <e2>CYP2C9<\\e2> activity remained equally high","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rifampicin","object":"CYP2C9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The CYP3A4 activity could be induced 2-fold by <e1>CHEMICAL<\\e1>  whereas <e2>GENE-Y<\\e2> activity remained equally high","sentence":"The CYP3A4 activity could be induced 2-fold by rifampicin  whereas CYP2C9 activity remained equally high"}
{"PMID":23247008,"re_id":0,"annotated sentence":"<e2>Mammalian ALDH1B1<\\e2>  another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing <e1>acetaldehyde<\\e1> but has a tissue distribution and pattern of activity distinct from that of ALDH2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetaldehyde","object":"Mammalian ALDH1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2>  another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing <e1>CHEMICAL<\\e1> but has a tissue distribution and pattern of activity distinct from that of ALDH2","sentence":"Mammalian ALDH1B1  another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing acetaldehyde but has a tissue distribution and pattern of activity distinct from that of ALDH2"}
{"PMID":23247008,"re_id":1,"annotated sentence":"Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with <e2>ALDH2<\\e2>  is also capable of metabolizing <e1>acetaldehyde<\\e1> but has a tissue distribution and pattern of activity distinct from that of ALDH2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acetaldehyde","object":"ALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with <e2>GENE-Y<\\e2>  is also capable of metabolizing <e1>CHEMICAL<\\e1> but has a tissue distribution and pattern of activity distinct from that of GENE-Y","sentence":"Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with ALDH2  is also capable of metabolizing acetaldehyde but has a tissue distribution and pattern of activity distinct from that of ALDH2"}
{"PMID":23247009,"re_id":0,"annotated sentence":"<e1>Beta-glucogallin<\\e1> reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of <e2>aldose reductase<\\e2> in murine macrophages and ocular tissues","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Beta-glucogallin","object":"aldose reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of <e2>GENE-Y<\\e2> in murine macrophages and ocular tissues","sentence":"Beta-glucogallin reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of aldose reductase in murine macrophages and ocular tissues"}
{"PMID":23247009,"re_id":1,"annotated sentence":"<e1>Beta-glucogallin<\\e1> (BGG), a recently described <e2>AR<\\e2> inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Beta-glucogallin","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (BGG), a recently described <e2>GENE-Y<\\e2> inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis)","sentence":"Beta-glucogallin (BGG), a recently described AR inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis)"}
{"PMID":23247009,"re_id":2,"annotated sentence":"Beta-glucogallin (<e1>BGG<\\e1> , a recently described <e2>AR<\\e2> inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BGG","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Beta-glucogallin (<e1>CHEMICAL<\\e1> , a recently described <e2>GENE-Y<\\e2> inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis)","sentence":"Beta-glucogallin (BGG , a recently described AR inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis)"}
{"PMID":23247009,"re_id":3,"annotated sentence":"In this study, we found that <e1>BGG<\\e1> showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited <e2>AR<\\e2> activity as measured by a decrease in sorbitol accumulation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BGG","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we found that <e1>CHEMICAL<\\e1> showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited <e2>GENE-Y<\\e2> activity as measured by a decrease in sorbitol accumulation","sentence":"In this study, we found that BGG showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited AR activity as measured by a decrease in sorbitol accumulation"}
{"PMID":23247009,"re_id":4,"annotated sentence":"In addition, <e1>BGG<\\e1> mediated inhibition of <e2>AR<\\e2> prevented LPS-induced activation of JNK and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BGG","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> mediated inhibition of <e2>GENE-Y<\\e2> prevented LPS-induced activation of JNK and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis","sentence":"In addition, BGG mediated inhibition of AR prevented LPS-induced activation of JNK and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis"}
{"PMID":23247009,"re_id":5,"annotated sentence":"In addition, <e1>BGG<\\e1> mediated inhibition of AR prevented LPS-induced activation of <e2>JNK<\\e2> and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BGG","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> mediated inhibition of AR prevented LPS-induced activation of <e2>GENE-N<\\e2> and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis","sentence":"In addition, BGG mediated inhibition of AR prevented LPS-induced activation of JNK and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis"}
{"PMID":23247009,"re_id":6,"annotated sentence":"In addition, <e1>BGG<\\e1> mediated inhibition of AR prevented LPS-induced activation of JNK and <e2>p38<\\e2> and lowered ROS levels, which could inhibit LPS-induced apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BGG","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> mediated inhibition of AR prevented LPS-induced activation of JNK and <e2>GENE-N<\\e2> and lowered ROS levels, which could inhibit LPS-induced apoptosis","sentence":"In addition, BGG mediated inhibition of AR prevented LPS-induced activation of JNK and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis"}
{"PMID":23247009,"re_id":7,"annotated sentence":"<e2>Aldose reductase<\\e2> (AR) catalyzes the reduction of toxic lipid <e1>aldehydes<\\e1> to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"aldehydes","object":"Aldose reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (AR) catalyzes the reduction of toxic lipid <e1>CHEMICAL<\\e1> to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)","sentence":"Aldose reductase (AR) catalyzes the reduction of toxic lipid aldehydes to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)"}
{"PMID":23247009,"re_id":8,"annotated sentence":"Aldose reductase (<e2>AR<\\e2>  catalyzes the reduction of toxic lipid <e1>aldehydes<\\e1> to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"aldehydes","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aldose reductase (<e2>GENE-Y<\\e2>  catalyzes the reduction of toxic lipid <e1>CHEMICAL<\\e1> to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)","sentence":"Aldose reductase (AR  catalyzes the reduction of toxic lipid aldehydes to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)"}
{"PMID":23247009,"re_id":9,"annotated sentence":"<e2>Aldose reductase<\\e2> (AR) catalyzes the reduction of toxic lipid aldehydes to their <e1>alcohol<\\e1> products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alcohol","object":"Aldose reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (AR) catalyzes the reduction of toxic lipid aldehydes to their <e1>CHEMICAL<\\e1> products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)","sentence":"Aldose reductase (AR) catalyzes the reduction of toxic lipid aldehydes to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)"}
{"PMID":23247009,"re_id":10,"annotated sentence":"Aldose reductase (<e2>AR<\\e2>  catalyzes the reduction of toxic lipid aldehydes to their <e1>alcohol<\\e1> products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alcohol","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aldose reductase (<e2>GENE-Y<\\e2>  catalyzes the reduction of toxic lipid aldehydes to their <e1>CHEMICAL<\\e1> products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)","sentence":"Aldose reductase (AR  catalyzes the reduction of toxic lipid aldehydes to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)"}
{"PMID":23249624,"re_id":0,"annotated sentence":"Mechanisms limiting distribution of the <e2>threonine-protein kinase B-RaF<\\e2> V600E) inhibitor <e1>dabrafenib<\\e1> to the brain: implications for the treatment of melanoma brain metastases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dabrafenib","object":"threonine-protein kinase B-RaF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mechanisms limiting distribution of the <e2>GENE-Y<\\e2> V600E) inhibitor <e1>CHEMICAL<\\e1> to the brain: implications for the treatment of melanoma brain metastases","sentence":"Mechanisms limiting distribution of the threonine-protein kinase B-RaF V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases"}
{"PMID":23249624,"re_id":1,"annotated sentence":"Mechanisms limiting distribution of the threonine-protein kinase B-RaF(<e2>V600E<\\e2>  inhibitor <e1>dabrafenib<\\e1> to the brain: implications for the treatment of melanoma brain metastases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dabrafenib","object":"V600E","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Mechanisms limiting distribution of the threonine-protein kinase B-RaF(<e2>GENE-N<\\e2>  inhibitor <e1>CHEMICAL<\\e1> to the brain: implications for the treatment of melanoma brain metastases","sentence":"Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E  inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases"}
{"PMID":23249624,"re_id":2,"annotated sentence":"Further, compared with <e1>vemurafenib<\\e1>  another <e2>BRAF<\\e2> V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vemurafenib","object":"BRAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, compared with <e1>CHEMICAL<\\e1>  another <e2>GENE-Y<\\e2> V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose","sentence":"Further, compared with vemurafenib  another BRAF V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose"}
{"PMID":23249624,"re_id":3,"annotated sentence":"Further, compared with <e1>vemurafenib<\\e1>  another BRAF(<e2>V600E<\\e2>  inhibitor, dabrafenib showed greater brain penetration with a similar dose","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vemurafenib","object":"V600E","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further, compared with <e1>CHEMICAL<\\e1>  another BRAF(<e2>GENE-N<\\e2>  inhibitor, dabrafenib showed greater brain penetration with a similar dose","sentence":"Further, compared with vemurafenib  another BRAF(V600E  inhibitor, dabrafenib showed greater brain penetration with a similar dose"}
{"PMID":23249624,"re_id":4,"annotated sentence":"In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that <e1>dabrafenib<\\e1> is an avid substrate for both <e2>P-gp<\\e2> and BCRP","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dabrafenib","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that <e1>CHEMICAL<\\e1> is an avid substrate for both <e2>GENE-N<\\e2> and BCRP","sentence":"In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that dabrafenib is an avid substrate for both P-gp and BCRP"}
{"PMID":23249624,"re_id":5,"annotated sentence":"In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that <e1>dabrafenib<\\e1> is an avid substrate for both P-gp and <e2>BCRP<\\e2>  Directional flux studies revealed greater transport in the basolateral to apical direction with corrected efflux ratios greater than 2 for both P-gp and Bcrp1 transfected cell lines","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dabrafenib","object":"BCRP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that <e1>CHEMICAL<\\e1> is an avid substrate for both P-gp and <e2>GENE-Y<\\e2>  Directional flux studies revealed greater transport in the basolateral to apical direction with corrected efflux ratios greater than 2 for both P-gp and Bcrp1 transfected cell lines","sentence":"In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that dabrafenib is an avid substrate for both P-gp and BCRP  Directional flux studies revealed greater transport in the basolateral to apical direction with corrected efflux ratios greater than 2 for both P-gp and Bcrp1 transfected cell lines"}
{"PMID":23250811,"re_id":0,"annotated sentence":"This study explored whether <e1>curcumin<\\e1> improves colonic inflammation in a rat colitis model through inhibition of the <e2>TLR4<\\e2> NF-\u03baB signaling pathway and IL-27 expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study explored whether <e1>CHEMICAL<\\e1> improves colonic inflammation in a rat colitis model through inhibition of the <e2>GENE-Y<\\e2> NF-\u03baB signaling pathway and IL-27 expression","sentence":"This study explored whether curcumin improves colonic inflammation in a rat colitis model through inhibition of the TLR4 NF-\u03baB signaling pathway and IL-27 expression"}
{"PMID":23250811,"re_id":1,"annotated sentence":"This study explored whether <e1>curcumin<\\e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4\/<e2>NF-\u03baB<\\e2> signaling pathway and IL-27 expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study explored whether <e1>CHEMICAL<\\e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4\/<e2>GENE-N<\\e2> signaling pathway and IL-27 expression","sentence":"This study explored whether curcumin improves colonic inflammation in a rat colitis model through inhibition of the TLR4\/NF-\u03baB signaling pathway and IL-27 expression"}
{"PMID":23250811,"re_id":2,"annotated sentence":"This study explored whether <e1>curcumin<\\e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4\/NF-\u03baB signaling pathway and <e2>IL-27<\\e2> expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"IL-27","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study explored whether <e1>CHEMICAL<\\e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4\/NF-\u03baB signaling pathway and <e2>GENE-Y<\\e2> expression","sentence":"This study explored whether curcumin improves colonic inflammation in a rat colitis model through inhibition of the TLR4\/NF-\u03baB signaling pathway and IL-27 expression"}
{"PMID":23250811,"re_id":3,"annotated sentence":"Compared with the untreated colitis group, the <e1>curcumin<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of <e2>NF-\u03baB<\\e2> mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compared with the untreated colitis group, the <e1>CHEMICAL<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of <e2>GENE-N<\\e2> mRNA, IL-27 mRNA, TLR4 protein, GENE-N p65 protein, and IL-27 p28 protein (p < 0.05)","sentence":"Compared with the untreated colitis group, the curcumin treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)"}
{"PMID":23250811,"re_id":4,"annotated sentence":"Compared with the untreated colitis group, the <e1>curcumin<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, <e2>IL-27<\\e2> mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"IL-27","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with the untreated colitis group, the <e1>CHEMICAL<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, <e2>GENE-Y<\\e2> mRNA, TLR4 protein, NF-\u03baB p65 protein, and GENE-Y p28 protein (p < 0.05)","sentence":"Compared with the untreated colitis group, the curcumin treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)"}
{"PMID":23250811,"re_id":5,"annotated sentence":"Compared with the untreated colitis group, the <e1>curcumin<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, <e2>TLR4<\\e2> protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with the untreated colitis group, the <e1>CHEMICAL<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, <e2>GENE-Y<\\e2> protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)","sentence":"Compared with the untreated colitis group, the curcumin treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)"}
{"PMID":23250811,"re_id":6,"annotated sentence":"Compared with the untreated colitis group, the <e1>curcumin<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, <e2>NF-\u03baB<\\e2> p65 protein, and IL-27 p28 protein (p < 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compared with the untreated colitis group, the <e1>CHEMICAL<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of GENE-N mRNA, IL-27 mRNA, TLR4 protein, <e2>GENE-N<\\e2> p65 protein, and IL-27 p28 protein (p < 0.05)","sentence":"Compared with the untreated colitis group, the curcumin treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)"}
{"PMID":23250811,"re_id":7,"annotated sentence":"Compared with the untreated colitis group, the <e1>curcumin<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB <e2>p65<\\e2> protein, and IL-27 p28 protein (p < 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with the untreated colitis group, the <e1>CHEMICAL<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB <e2>GENE-Y<\\e2> protein, and IL-27 p28 protein (p < 0.05)","sentence":"Compared with the untreated colitis group, the curcumin treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)"}
{"PMID":23250811,"re_id":8,"annotated sentence":"Compared with the untreated colitis group, the <e1>curcumin<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and <e2>IL-27<\\e2> p28 protein (p < 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"IL-27","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with the untreated colitis group, the <e1>CHEMICAL<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, GENE-Y mRNA, TLR4 protein, NF-\u03baB p65 protein, and <e2>GENE-Y<\\e2> p28 protein (p < 0.05)","sentence":"Compared with the untreated colitis group, the curcumin treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)"}
{"PMID":23250811,"re_id":9,"annotated sentence":"Compared with the untreated colitis group, the <e1>curcumin<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 <e2>p28<\\e2> protein (p < 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"p28","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with the untreated colitis group, the <e1>CHEMICAL<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 <e2>GENE-Y<\\e2> protein (p < 0.05)","sentence":"Compared with the untreated colitis group, the curcumin treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)"}
{"PMID":23250811,"re_id":10,"annotated sentence":"Compared with the untreated colitis group, the <e1>curcumin<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, <e2>myeloperoxidase<\\e2> activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"myeloperoxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with the untreated colitis group, the <e1>CHEMICAL<\\e1> treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, <e2>GENE-Y<\\e2> activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)","sentence":"Compared with the untreated colitis group, the curcumin treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)"}
{"PMID":23250811,"re_id":11,"annotated sentence":"<e1>Curcumin<\\e1> improves TNBS-induced colitis in rats by inhibiting <e2>IL-27<\\e2> expression via the TLR4\/NF-\u03baB signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Curcumin","object":"IL-27","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> improves TNBS-induced colitis in rats by inhibiting <e2>GENE-Y<\\e2> expression via the TLR4\/NF-\u03baB signaling pathway","sentence":"Curcumin improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4\/NF-\u03baB signaling pathway"}
{"PMID":23250811,"re_id":12,"annotated sentence":"<e1>Curcumin<\\e1> improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the <e2>TLR4<\\e2> NF-\u03baB signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Curcumin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the <e2>GENE-Y<\\e2> NF-\u03baB signaling pathway","sentence":"Curcumin improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4 NF-\u03baB signaling pathway"}
{"PMID":23250811,"re_id":13,"annotated sentence":"<e1>Curcumin<\\e1> improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4\/<e2>NF-\u03baB<\\e2> signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Curcumin","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4\/<e2>GENE-N<\\e2> signaling pathway","sentence":"Curcumin improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4\/NF-\u03baB signaling pathway"}
{"PMID":23250811,"re_id":14,"annotated sentence":"There was no significant difference in <e2>TLR4<\\e2>  NF-\u03baB, and IL-27 mRNA and proteins between <e1>curcumin<\\e1> treated and sulfasalazine-treated groups","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was no significant difference in <e2>GENE-Y<\\e2>  NF-\u03baB, and IL-27 mRNA and proteins between <e1>CHEMICAL<\\e1> treated and sulfasalazine-treated groups","sentence":"There was no significant difference in TLR4  NF-\u03baB, and IL-27 mRNA and proteins between curcumin treated and sulfasalazine-treated groups"}
{"PMID":23250811,"re_id":15,"annotated sentence":"There was no significant difference in TLR4, <e2>NF-\u03baB<\\e2>  and IL-27 mRNA and proteins between <e1>curcumin<\\e1> treated and sulfasalazine-treated groups","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"There was no significant difference in TLR4, <e2>GENE-N<\\e2>  and IL-27 mRNA and proteins between <e1>CHEMICAL<\\e1> treated and sulfasalazine-treated groups","sentence":"There was no significant difference in TLR4, NF-\u03baB  and IL-27 mRNA and proteins between curcumin treated and sulfasalazine-treated groups"}
{"PMID":23250811,"re_id":16,"annotated sentence":"There was no significant difference in TLR4, NF-\u03baB, and <e2>IL-27<\\e2> mRNA and proteins between <e1>curcumin<\\e1> treated and sulfasalazine-treated groups","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"IL-27","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was no significant difference in TLR4, NF-\u03baB, and <e2>GENE-Y<\\e2> mRNA and proteins between <e1>CHEMICAL<\\e1> treated and sulfasalazine-treated groups","sentence":"There was no significant difference in TLR4, NF-\u03baB, and IL-27 mRNA and proteins between curcumin treated and sulfasalazine-treated groups"}
{"PMID":23250811,"re_id":17,"annotated sentence":"There was no significant difference in <e2>TLR4<\\e2>  NF-\u03baB, and IL-27 mRNA and proteins between curcumin-treated and <e1>sulfasalazine<\\e1> treated groups","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulfasalazine","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was no significant difference in <e2>GENE-Y<\\e2>  NF-\u03baB, and IL-27 mRNA and proteins between curcumin-treated and <e1>CHEMICAL<\\e1> treated groups","sentence":"There was no significant difference in TLR4  NF-\u03baB, and IL-27 mRNA and proteins between curcumin-treated and sulfasalazine treated groups"}
{"PMID":23250811,"re_id":18,"annotated sentence":"There was no significant difference in TLR4, <e2>NF-\u03baB<\\e2>  and IL-27 mRNA and proteins between curcumin-treated and <e1>sulfasalazine<\\e1> treated groups","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulfasalazine","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"There was no significant difference in TLR4, <e2>GENE-N<\\e2>  and IL-27 mRNA and proteins between curcumin-treated and <e1>CHEMICAL<\\e1> treated groups","sentence":"There was no significant difference in TLR4, NF-\u03baB  and IL-27 mRNA and proteins between curcumin-treated and sulfasalazine treated groups"}
{"PMID":23250811,"re_id":19,"annotated sentence":"There was no significant difference in TLR4, NF-\u03baB, and <e2>IL-27<\\e2> mRNA and proteins between curcumin-treated and <e1>sulfasalazine<\\e1> treated groups","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sulfasalazine","object":"IL-27","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was no significant difference in TLR4, NF-\u03baB, and <e2>GENE-Y<\\e2> mRNA and proteins between curcumin-treated and <e1>CHEMICAL<\\e1> treated groups","sentence":"There was no significant difference in TLR4, NF-\u03baB, and IL-27 mRNA and proteins between curcumin-treated and sulfasalazine treated groups"}
{"PMID":23250811,"re_id":20,"annotated sentence":"The anti-inflammatory actions of <e1>curcumin<\\e1> on colitis may involve inhibition of the <e2>TLR4<\\e2> NF-\u03baB signaling pathway and of IL-27 expression.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The anti-inflammatory actions of <e1>CHEMICAL<\\e1> on colitis may involve inhibition of the <e2>GENE-Y<\\e2> NF-\u03baB signaling pathway and of IL-27 expression.","sentence":"The anti-inflammatory actions of curcumin on colitis may involve inhibition of the TLR4 NF-\u03baB signaling pathway and of IL-27 expression."}
{"PMID":23250811,"re_id":21,"annotated sentence":"The anti-inflammatory actions of <e1>curcumin<\\e1> on colitis may involve inhibition of the TLR4\/<e2>NF-\u03baB<\\e2> signaling pathway and of IL-27 expression.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The anti-inflammatory actions of <e1>CHEMICAL<\\e1> on colitis may involve inhibition of the TLR4\/<e2>GENE-N<\\e2> signaling pathway and of IL-27 expression.","sentence":"The anti-inflammatory actions of curcumin on colitis may involve inhibition of the TLR4\/NF-\u03baB signaling pathway and of IL-27 expression."}
{"PMID":23250811,"re_id":22,"annotated sentence":"The anti-inflammatory actions of <e1>curcumin<\\e1> on colitis may involve inhibition of the TLR4\/NF-\u03baB signaling pathway and of <e2>IL-27<\\e2> expression.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"curcumin","object":"IL-27","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The anti-inflammatory actions of <e1>CHEMICAL<\\e1> on colitis may involve inhibition of the TLR4\/NF-\u03baB signaling pathway and of <e2>GENE-Y<\\e2> expression.","sentence":"The anti-inflammatory actions of curcumin on colitis may involve inhibition of the TLR4\/NF-\u03baB signaling pathway and of IL-27 expression."}
{"PMID":23256725,"re_id":0,"annotated sentence":"Central and peripheral administration of <e2>kisspeptin<\\e2> stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a <e1>gonadotrophin releasing hormone<\\e1> (GnRH) antagonist abolishes this effect","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"gonadotrophin releasing hormone","object":"kisspeptin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Central and peripheral administration of <e2>GENE-N<\\e2> stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a <e1>CHEMICAL<\\e1> (GnRH) antagonist abolishes this effect","sentence":"Central and peripheral administration of kisspeptin stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone (GnRH) antagonist abolishes this effect"}
{"PMID":23256725,"re_id":1,"annotated sentence":"Central and peripheral administration of <e2>kisspeptin<\\e2> stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone (<e1>GnRH<\\e1>  antagonist abolishes this effect","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GnRH","object":"kisspeptin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Central and peripheral administration of <e2>GENE-N<\\e2> stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone (<e1>CHEMICAL<\\e1>  antagonist abolishes this effect","sentence":"Central and peripheral administration of kisspeptin stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone (GnRH  antagonist abolishes this effect"}
{"PMID":23260346,"re_id":0,"annotated sentence":"Several inhibitors of <e2>Lp-PLA(2)<\\e2> have been described, including <e1>darapladib<\\e1>  which is currently in phase 3 clinical development for the treatment of atherosclerosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"darapladib","object":"Lp-PLA(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Several inhibitors of <e2>GENE-Y<\\e2> have been described, including <e1>CHEMICAL<\\e1>  which is currently in phase 3 clinical development for the treatment of atherosclerosis","sentence":"Several inhibitors of Lp-PLA(2) have been described, including darapladib  which is currently in phase 3 clinical development for the treatment of atherosclerosis"}
{"PMID":23260346,"re_id":1,"annotated sentence":"We show that both <e1>darapladib<\\e1> and a novel class of structurally distinct carbamate inhibitors inactivate <e2>Lp-PLA(2)<\\e2> in mouse tissues and human cell lines with high selectivity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"darapladib","object":"Lp-PLA(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We show that both <e1>CHEMICAL<\\e1> and a novel class of structurally distinct carbamate inhibitors inactivate <e2>GENE-Y<\\e2> in mouse tissues and human cell lines with high selectivity","sentence":"We show that both darapladib and a novel class of structurally distinct carbamate inhibitors inactivate Lp-PLA(2) in mouse tissues and human cell lines with high selectivity"}
{"PMID":23260346,"re_id":2,"annotated sentence":"We show that both darapladib and a novel class of structurally distinct <e1>carbamate<\\e1> inhibitors inactivate <e2>Lp-PLA(2)<\\e2> in mouse tissues and human cell lines with high selectivity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbamate","object":"Lp-PLA(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We show that both darapladib and a novel class of structurally distinct <e1>CHEMICAL<\\e1> inhibitors inactivate <e2>GENE-Y<\\e2> in mouse tissues and human cell lines with high selectivity","sentence":"We show that both darapladib and a novel class of structurally distinct carbamate inhibitors inactivate Lp-PLA(2) in mouse tissues and human cell lines with high selectivity"}
{"PMID":23260350,"re_id":0,"annotated sentence":"Identification of <e1>benzofuran<\\e1> central cores for the inhibition of <e2>leukotriene A(4) hydrolase<\\e2>  Leukotrienes (LT's) are known to play a physiological role in inflammatory immune response","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzofuran","object":"leukotriene A(4) hydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Identification of <e1>CHEMICAL<\\e1> central cores for the inhibition of <e2>GENE-Y<\\e2>  Leukotrienes (LT's) are known to play a physiological role in inflammatory immune response","sentence":"Identification of benzofuran central cores for the inhibition of leukotriene A(4) hydrolase  Leukotrienes (LT's) are known to play a physiological role in inflammatory immune response"}
{"PMID":23260350,"re_id":1,"annotated sentence":"This paper describes the identification and synthesis of substituted <e1>benzofurans<\\e1> as <e2>LTH(4)H<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzofurans","object":"LTH(4)H","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This paper describes the identification and synthesis of substituted <e1>CHEMICAL<\\e1> as <e2>GENE-Y<\\e2> inhibitors","sentence":"This paper describes the identification and synthesis of substituted benzofurans as LTH(4)H inhibitors"}
{"PMID":23260350,"re_id":2,"annotated sentence":"<e1>Benzofuran<\\e1> 28 showed dose responsive target engagement and provides a useful tool to explore a <e2>LTA(4)H<\\e2> inhibitor for the treatment of inflammatory diseases, such as asthma and inflammatory bowel disease (IBD).","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Benzofuran","object":"LTA(4)H","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> 28 showed dose responsive target engagement and provides a useful tool to explore a <e2>GENE-Y<\\e2> inhibitor for the treatment of inflammatory diseases, such as asthma and inflammatory bowel disease (IBD).","sentence":"Benzofuran 28 showed dose responsive target engagement and provides a useful tool to explore a LTA(4)H inhibitor for the treatment of inflammatory diseases, such as asthma and inflammatory bowel disease (IBD)."}
{"PMID":23260350,"re_id":3,"annotated sentence":"Leukotriene A(4) hydrolase (<e2>LTA(4)H<\\e2>  is a cystolic enzyme that stereospecifically catalyzes the transformation of <e1>LTA(4)<\\e1> to LTB(4)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"LTA(4)","object":"LTA(4)H","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Leukotriene A(4) hydrolase (<e2>CHEMICALH<\\e2>  is a cystolic enzyme that stereospecifically catalyzes the transformation of <e1>CHEMICAL<\\e1> to LTB(4)","sentence":"Leukotriene A(4) hydrolase (LTA(4)H  is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to LTB(4)"}
{"PMID":23260350,"re_id":4,"annotated sentence":"<e2>Leukotriene A(4) hydrolase<\\e2> (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of <e1>LTA(4)<\\e1> to LTB(4)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"LTA(4)","object":"Leukotriene A(4) hydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CHEMICALH) is a cystolic enzyme that stereospecifically catalyzes the transformation of <e1>CHEMICAL<\\e1> to LTB(4)","sentence":"Leukotriene A(4) hydrolase (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to LTB(4)"}
{"PMID":23260350,"re_id":5,"annotated sentence":"Leukotriene A(4) hydrolase (<e2>LTA(4)H<\\e2>  is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to <e1>LTB(4)<\\e1>  LTB(4) is a known pro-inflammatory mediator","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"LTB(4)","object":"LTA(4)H","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Leukotriene A(4) hydrolase (<e2>GENE-Y<\\e2>  is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to <e1>CHEMICAL<\\e1>  CHEMICAL is a known pro-inflammatory mediator","sentence":"Leukotriene A(4) hydrolase (LTA(4)H  is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to LTB(4)  LTB(4) is a known pro-inflammatory mediator"}
{"PMID":23260350,"re_id":6,"annotated sentence":"<e2>Leukotriene A(4) hydrolase<\\e2> (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to <e1>LTB(4)<\\e1>  LTB(4) is a known pro-inflammatory mediator","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"LTB(4)","object":"Leukotriene A(4) hydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to <e1>CHEMICAL<\\e1>  CHEMICAL is a known pro-inflammatory mediator","sentence":"Leukotriene A(4) hydrolase (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to LTB(4)  LTB(4) is a known pro-inflammatory mediator"}
{"PMID":23261590,"re_id":0,"annotated sentence":"In addition, we found that <e1>neoechinulin A<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator <e2>tumour necrosis factor-\u03b1<\\e2> (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"tumour necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we found that <e1>CHEMICAL<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator <e2>GENE-Y<\\e2> (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells","sentence":"In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells"}
{"PMID":23261590,"re_id":1,"annotated sentence":"In addition, we found that <e1>neoechinulin A<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (<e2>TNF-\u03b1<\\e2> , interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we found that <e1>CHEMICAL<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (<e2>GENE-Y<\\e2> , interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells","sentence":"In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1 , interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells"}
{"PMID":23261590,"re_id":2,"annotated sentence":"In addition, we found that <e1>neoechinulin A<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), <e2>interleukin-1\u03b2<\\e2> (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"interleukin-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we found that <e1>CHEMICAL<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), <e2>GENE-Y<\\e2> (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells","sentence":"In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells"}
{"PMID":23261590,"re_id":3,"annotated sentence":"In addition, we found that <e1>neoechinulin A<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (<e2>IL-1\u03b2<\\e2> , interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"IL-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we found that <e1>CHEMICAL<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (<e2>GENE-Y<\\e2> , interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells","sentence":"In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2 , interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells"}
{"PMID":23261590,"re_id":4,"annotated sentence":"In addition, we found that <e1>neoechinulin A<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), <e2>interleukin-6<\\e2> (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"interleukin-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we found that <e1>CHEMICAL<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), <e2>GENE-Y<\\e2> (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells","sentence":"In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells"}
{"PMID":23261590,"re_id":5,"annotated sentence":"In addition, we found that <e1>neoechinulin A<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (<e2>IL-6<\\e2> , and prostaglandin E2 (PGE2) in activated BV-2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"IL-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we found that <e1>CHEMICAL<\\e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (<e2>GENE-Y<\\e2> , and prostaglandin E2 (PGE2) in activated BV-2 cells","sentence":"In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6 , and prostaglandin E2 (PGE2) in activated BV-2 cells"}
{"PMID":23261590,"re_id":6,"annotated sentence":"<e1>Neoechinulin A<\\e1> suppresses <e2>amyloid-\u03b2<\\e2> oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Neoechinulin A","object":"amyloid-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppresses <e2>GENE-Y<\\e2> oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity","sentence":"Neoechinulin A suppresses amyloid-\u03b2 oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity"}
{"PMID":23261590,"re_id":7,"annotated sentence":"The molecular mechanism studies suggested that <e1>neoechinulin A<\\e1> may block the phosphorylation of <e2>mitogen-activated protein kinase<\\e2> (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"mitogen-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The molecular mechanism studies suggested that <e1>CHEMICAL<\\e1> may block the phosphorylation of <e2>GENE-N<\\e2> (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits","sentence":"The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits"}
{"PMID":23261590,"re_id":8,"annotated sentence":"The molecular mechanism studies suggested that <e1>neoechinulin A<\\e1> may block the phosphorylation of mitogen-activated protein kinase (<e2>MAPK<\\e2>  molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The molecular mechanism studies suggested that <e1>CHEMICAL<\\e1> may block the phosphorylation of mitogen-activated protein kinase (<e2>GENE-N<\\e2>  molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits","sentence":"The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK  molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits"}
{"PMID":23261590,"re_id":9,"annotated sentence":"The molecular mechanism studies suggested that <e1>neoechinulin A<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule <e2>p38<\\e2>  apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The molecular mechanism studies suggested that <e1>CHEMICAL<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule <e2>GENE-N<\\e2>  apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits","sentence":"The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38  apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits"}
{"PMID":23261590,"re_id":10,"annotated sentence":"The molecular mechanism studies suggested that <e1>neoechinulin A<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, <e2>apoptosis signal-regulating kinase 1<\\e2> (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"apoptosis signal-regulating kinase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The molecular mechanism studies suggested that <e1>CHEMICAL<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, <e2>GENE-Y<\\e2> (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits","sentence":"The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits"}
{"PMID":23261590,"re_id":11,"annotated sentence":"The molecular mechanism studies suggested that <e1>neoechinulin A<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (<e2>ASK-1<\\e2>  and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"ASK-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The molecular mechanism studies suggested that <e1>CHEMICAL<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (<e2>GENE-Y<\\e2>  and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits","sentence":"The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1  and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits"}
{"PMID":23261590,"re_id":12,"annotated sentence":"The molecular mechanism studies suggested that <e1>neoechinulin A<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of <e2>nuclear factor-\u03baB<\\e2> (NF-\u03baB) p65 and p50 subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"nuclear factor-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The molecular mechanism studies suggested that <e1>CHEMICAL<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of <e2>GENE-N<\\e2> (NF-\u03baB) p65 and p50 subunits","sentence":"The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits"}
{"PMID":23261590,"re_id":13,"annotated sentence":"The molecular mechanism studies suggested that <e1>neoechinulin A<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (<e2>NF-\u03baB<\\e2>  p65 and p50 subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The molecular mechanism studies suggested that <e1>CHEMICAL<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (<e2>GENE-N<\\e2>  p65 and p50 subunits","sentence":"The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB  p65 and p50 subunits"}
{"PMID":23261590,"re_id":14,"annotated sentence":"The molecular mechanism studies suggested that <e1>neoechinulin A<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) <e2>p65<\\e2> and p50 subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The molecular mechanism studies suggested that <e1>CHEMICAL<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) <e2>GENE-Y<\\e2> and p50 subunits","sentence":"The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits"}
{"PMID":23261590,"re_id":15,"annotated sentence":"The molecular mechanism studies suggested that <e1>neoechinulin A<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and <e2>p50<\\e2> subunits","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"p50","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The molecular mechanism studies suggested that <e1>CHEMICAL<\\e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and <e2>GENE-Y<\\e2> subunits","sentence":"The molecular mechanism studies suggested that neoechinulin A may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits"}
{"PMID":23261590,"re_id":16,"annotated sentence":"In this study, focus was given to evaluate the ability of <e1>neoechinulin A<\\e1>  an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric <e2>amyloid-\u03b2 1-42<\\e2> (A\u03b242)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"amyloid-\u03b2 1-42","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, focus was given to evaluate the ability of <e1>CHEMICAL<\\e1>  an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric <e2>GENE-Y<\\e2> (A\u03b242)","sentence":"In this study, focus was given to evaluate the ability of neoechinulin A  an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 (A\u03b242)"}
{"PMID":23261590,"re_id":17,"annotated sentence":"In this study, focus was given to evaluate the ability of <e1>neoechinulin A<\\e1>  an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 (<e2>A\u03b242<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"neoechinulin A","object":"A\u03b242","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, focus was given to evaluate the ability of <e1>CHEMICAL<\\e1>  an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 (<e2>GENE-Y<\\e2> ","sentence":"In this study, focus was given to evaluate the ability of neoechinulin A  an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 (A\u03b242 "}
{"PMID":23261590,"re_id":18,"annotated sentence":"In this study, focus was given to evaluate the ability of neoechinulin A, an <e1>indole<\\e1> alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric <e2>amyloid-\u03b2 1-42<\\e2> (A\u03b242)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indole","object":"amyloid-\u03b2 1-42","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, focus was given to evaluate the ability of neoechinulin A, an <e1>CHEMICAL<\\e1> alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric <e2>GENE-Y<\\e2> (A\u03b242)","sentence":"In this study, focus was given to evaluate the ability of neoechinulin A, an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 (A\u03b242)"}
{"PMID":23261590,"re_id":19,"annotated sentence":"In this study, focus was given to evaluate the ability of neoechinulin A, an <e1>indole<\\e1> alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 (<e2>A\u03b242<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indole","object":"A\u03b242","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, focus was given to evaluate the ability of neoechinulin A, an <e1>CHEMICAL<\\e1> alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 (<e2>GENE-Y<\\e2> ","sentence":"In this study, focus was given to evaluate the ability of neoechinulin A, an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 (A\u03b242 "}
{"PMID":23261590,"re_id":20,"annotated sentence":"<e1>Neoechinulin A<\\e1> treatment significantly inhibited the generation of reactive oxygen and nitrogen species in <e2>A\u03b242<\\e2> activated BV-2 microglia cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Neoechinulin A","object":"A\u03b242","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment significantly inhibited the generation of reactive oxygen and nitrogen species in <e2>GENE-Y<\\e2> activated BV-2 microglia cells","sentence":"Neoechinulin A treatment significantly inhibited the generation of reactive oxygen and nitrogen species in A\u03b242 activated BV-2 microglia cells"}
{"PMID":23261645,"re_id":0,"annotated sentence":"<e1>Jaspamide<\\e1> also inhibited other channels including <e2>Cav1.2<\\e2>  Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Jaspamide","object":"Cav1.2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also inhibited other channels including <e2>GENE-N<\\e2>  Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected","sentence":"Jaspamide also inhibited other channels including Cav1.2  Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected"}
{"PMID":23261645,"re_id":1,"annotated sentence":"<e1>Jaspamide<\\e1> also inhibited other channels including Cav1.2, <e2>Cav3.2<\\e2>  and HCN2; however, the Kv11.1 (hERG) channel was minimally affected","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Jaspamide","object":"Cav3.2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also inhibited other channels including Cav1.2, <e2>GENE-N<\\e2>  and HCN2; however, the Kv11.1 (hERG) channel was minimally affected","sentence":"Jaspamide also inhibited other channels including Cav1.2, Cav3.2  and HCN2; however, the Kv11.1 (hERG) channel was minimally affected"}
{"PMID":23261645,"re_id":2,"annotated sentence":"<e1>Jaspamide<\\e1> also inhibited other channels including Cav1.2, Cav3.2, and <e2>HCN2<\\e2>  however, the Kv11.1 (hERG) channel was minimally affected","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Jaspamide","object":"HCN2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also inhibited other channels including Cav1.2, Cav3.2, and <e2>GENE-N<\\e2>  however, the Kv11.1 (hERG) channel was minimally affected","sentence":"Jaspamide also inhibited other channels including Cav1.2, Cav3.2, and HCN2  however, the Kv11.1 (hERG) channel was minimally affected"}
{"PMID":23262271,"re_id":0,"annotated sentence":"Among the isolated compounds, <e1>trans-dihydromorin<\\e1> (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant <e2>tyrosinase<\\e2> inhibition activities","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"trans-dihydromorin","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the isolated compounds, <e1>CHEMICAL<\\e1> (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant <e2>GENE-Y<\\e2> inhibition activities","sentence":"Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant tyrosinase inhibition activities"}
{"PMID":23262271,"re_id":1,"annotated sentence":"Among the isolated compounds, trans-dihydromorin (8), <e1>oxyresveratrol<\\e1> (9), and steppogenin (12) were found to exhibit significant <e2>tyrosinase<\\e2> inhibition activities","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"oxyresveratrol","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the isolated compounds, trans-dihydromorin (8), <e1>CHEMICAL<\\e1> (9), and steppogenin (12) were found to exhibit significant <e2>GENE-Y<\\e2> inhibition activities","sentence":"Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant tyrosinase inhibition activities"}
{"PMID":23262271,"re_id":2,"annotated sentence":"Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and <e1>steppogenin<\\e1> (12) were found to exhibit significant <e2>tyrosinase<\\e2> inhibition activities","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"steppogenin","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and <e1>CHEMICAL<\\e1> (12) were found to exhibit significant <e2>GENE-Y<\\e2> inhibition activities","sentence":"Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant tyrosinase inhibition activities"}
{"PMID":23264615,"re_id":0,"annotated sentence":"<e1>Cortisol<\\e1> and IFNT stimulated endometrial <e2>HSD11B1<\\e2> expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cortisol","object":"HSD11B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and IFNT stimulated endometrial <e2>GENE-Y<\\e2> expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium","sentence":"Cortisol and IFNT stimulated endometrial HSD11B1 expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium"}
{"PMID":23264615,"re_id":1,"annotated sentence":"<e1>Cortisol<\\e1> and IFNT stimulated endometrial HSD11B1 expression and activity, increased endometrial <e2>PTGS2<\\e2> activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cortisol","object":"PTGS2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and IFNT stimulated endometrial HSD11B1 expression and activity, increased endometrial <e2>GENE-Y<\\e2> activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium","sentence":"Cortisol and IFNT stimulated endometrial HSD11B1 expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium"}
{"PMID":23264615,"re_id":2,"annotated sentence":"In study 1, cyclic ewes received vehicle, cortisol, <e1>PF 915275<\\e1> (PF; a selective inhibitor of <e2>HSD11B1<\\e2> , cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PF 915275","object":"HSD11B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In study 1, cyclic ewes received vehicle, cortisol, <e1>CHEMICAL<\\e1> (PF; a selective inhibitor of <e2>GENE-Y<\\e2> , cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus","sentence":"In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1 , cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus"}
{"PMID":23264615,"re_id":3,"annotated sentence":"In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, <e1>meloxicam<\\e1> (a selective inhibitor of <e2>PTGS2<\\e2> , cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"meloxicam","object":"PTGS2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, <e1>CHEMICAL<\\e1> (a selective inhibitor of <e2>GENE-Y<\\e2> , cortisol and CHEMICAL, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus","sentence":"In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2 , cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus"}
{"PMID":23264615,"re_id":4,"annotated sentence":"The primary aim of these studies was to test the hypothesis that <e2>HSD11B1<\\e2> derived <e1>cortisol<\\e1> has a biological role in endometrial function and conceptus development during early pregnancy in sheep","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisol","object":"HSD11B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The primary aim of these studies was to test the hypothesis that <e2>GENE-Y<\\e2> derived <e1>CHEMICAL<\\e1> has a biological role in endometrial function and conceptus development during early pregnancy in sheep","sentence":"The primary aim of these studies was to test the hypothesis that HSD11B1 derived cortisol has a biological role in endometrial function and conceptus development during early pregnancy in sheep"}
{"PMID":23264615,"re_id":5,"annotated sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce <e1>prostaglandins<\\e1> (PG) via <e2>PG synthase 2<\\e2> (PTGS2) and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandins","object":"PG synthase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce <e1>CHEMICAL<\\e1> (PG) via <e2>GENE-Y<\\e2> (PTGS2) and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1)","sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1)"}
{"PMID":23264615,"re_id":6,"annotated sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce <e1>prostaglandins<\\e1> (PG) via PG synthase 2 (<e2>PTGS2<\\e2>  and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandins","object":"PTGS2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce <e1>CHEMICAL<\\e1> (PG) via PG synthase 2 (<e2>GENE-Y<\\e2>  and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1)","sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2  and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1)"}
{"PMID":23264615,"re_id":7,"annotated sentence":"These results suggest that <e2>HSD11B1<\\e2> derived <e1>cortisol<\\e1> mediates, in part, actions of ovarian progesterone and the conceptus on endometrial function and support the hypothesis that IFNT, PG, and cortisol coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisol","object":"HSD11B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e2>GENE-Y<\\e2> derived <e1>CHEMICAL<\\e1> mediates, in part, actions of ovarian progesterone and the conceptus on endometrial function and support the hypothesis that IFNT, PG, and CHEMICAL coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.","sentence":"These results suggest that HSD11B1 derived cortisol mediates, in part, actions of ovarian progesterone and the conceptus on endometrial function and support the hypothesis that IFNT, PG, and cortisol coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep."}
{"PMID":23264615,"re_id":8,"annotated sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and <e1>cortisol<\\e1> via <e2>hydroxysteroid (11-\u03b2) dehydrogenase 1<\\e2> (HSD11B1)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisol","object":"hydroxysteroid (11-\u03b2) dehydrogenase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and <e1>CHEMICAL<\\e1> via <e2>GENE-Y<\\e2> (HSD11B1)","sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1)"}
{"PMID":23264615,"re_id":9,"annotated sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and <e1>cortisol<\\e1> via hydroxysteroid (11-\u03b2) dehydrogenase 1 (<e2>HSD11B1<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisol","object":"HSD11B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and <e1>CHEMICAL<\\e1> via hydroxysteroid (11-\u03b2) dehydrogenase 1 (<e2>GENE-Y<\\e2> ","sentence":"During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1 "}
{"PMID":23265491,"re_id":0,"annotated sentence":"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean <e1>isoflavone<\\e1> increased gene expression of <e2>heme oxygenase-1<\\e2> (HO-1), a major antioxidative stress enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"isoflavone","object":"heme oxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean <e1>CHEMICAL<\\e1> increased gene expression of <e2>GENE-Y<\\e2> (HO-1), a major antioxidative stress enzyme","sentence":"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean isoflavone increased gene expression of heme oxygenase-1 (HO-1), a major antioxidative stress enzyme"}
{"PMID":23265491,"re_id":1,"annotated sentence":"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean <e1>isoflavone<\\e1> increased gene expression of heme oxygenase-1 (<e2>HO-1<\\e2> , a major antioxidative stress enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"isoflavone","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean <e1>CHEMICAL<\\e1> increased gene expression of heme oxygenase-1 (<e2>GENE-Y<\\e2> , a major antioxidative stress enzyme","sentence":"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean isoflavone increased gene expression of heme oxygenase-1 (HO-1 , a major antioxidative stress enzyme"}
{"PMID":23265543,"re_id":0,"annotated sentence":"Overall, higher alcohol production was reduced by <e1>ammonium<\\e1> supplementation, and this can be correlated with a general downregulation of genes encoding <e2>decarboxylases<\\e2> and dehydrogenases of the Ehrlich pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ammonium","object":"decarboxylases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Overall, higher alcohol production was reduced by <e1>CHEMICAL<\\e1> supplementation, and this can be correlated with a general downregulation of genes encoding <e2>GENE-N<\\e2> and dehydrogenases of the Ehrlich pathway","sentence":"Overall, higher alcohol production was reduced by ammonium supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and dehydrogenases of the Ehrlich pathway"}
{"PMID":23265543,"re_id":1,"annotated sentence":"Overall, higher alcohol production was reduced by <e1>ammonium<\\e1> supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and <e2>dehydrogenases<\\e2> of the Ehrlich pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ammonium","object":"dehydrogenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Overall, higher alcohol production was reduced by <e1>CHEMICAL<\\e1> supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and <e2>GENE-N<\\e2> of the Ehrlich pathway","sentence":"Overall, higher alcohol production was reduced by ammonium supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and dehydrogenases of the Ehrlich pathway"}
{"PMID":23265892,"re_id":0,"annotated sentence":"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (<e1>SCH 900229<\\e1> , a potent, <e2>PS1<\\e2> selective \u03b3-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SCH 900229","object":"PS1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (<e1>CHEMICAL<\\e1> , a potent, <e2>GENE-Y<\\e2> selective \u03b3-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease","sentence":"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (SCH 900229 , a potent, PS1 selective \u03b3-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease"}
{"PMID":23265892,"re_id":1,"annotated sentence":"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (<e1>SCH 900229<\\e1> , a potent, PS1-selective <e2>\u03b3-secretase<\\e2> inhibitor and clinical candidate for the treatment of Alzheimer's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SCH 900229","object":"\u03b3-secretase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (<e1>CHEMICAL<\\e1> , a potent, PS1-selective <e2>GENE-N<\\e2> inhibitor and clinical candidate for the treatment of Alzheimer's disease","sentence":"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (SCH 900229 , a potent, PS1-selective \u03b3-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease"}
{"PMID":23265892,"re_id":2,"annotated sentence":"Structure activity relationship studies of <e1>tricyclic bispyran sulfone<\\e1> <e2>\u03b3-secretase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tricyclic bispyran sulfone","object":"\u03b3-secretase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Structure activity relationship studies of <e1>CHEMICAL<\\e1> <e2>GENE-N<\\e2> inhibitors","sentence":"Structure activity relationship studies of tricyclic bispyran sulfone \u03b3-secretase inhibitors"}
{"PMID":23266505,"re_id":0,"annotated sentence":"In this study, aldosterone (<e1>ALD<\\e1> -induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of <e2>calpain<\\e2> signaling were clarified","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ALD","object":"calpain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, aldosterone (<e1>CHEMICAL<\\e1> -induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of <e2>GENE-N<\\e2> signaling were clarified","sentence":"In this study, aldosterone (ALD -induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of calpain signaling were clarified"}
{"PMID":23266505,"re_id":1,"annotated sentence":"<e1>ALD<\\e1> increased <e2>calpain<\\e2> expression and caspase-3 activity and promoted Bid cleavage","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ALD","object":"calpain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increased <e2>GENE-N<\\e2> expression and caspase-3 activity and promoted Bid cleavage","sentence":"ALD increased calpain expression and caspase-3 activity and promoted Bid cleavage"}
{"PMID":23266505,"re_id":2,"annotated sentence":"<e1>ALD<\\e1> increased calpain expression and <e2>caspase-3<\\e2> activity and promoted Bid cleavage","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ALD","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased calpain expression and <e2>GENE-Y<\\e2> activity and promoted Bid cleavage","sentence":"ALD increased calpain expression and caspase-3 activity and promoted Bid cleavage"}
{"PMID":23266505,"re_id":3,"annotated sentence":"Activation of an apoptotic signal transduction pathway involved in the upregulation of <e2>calpain<\\e2> and apoptosis-inducing factor in <e1>aldosterone<\\e1> induced primary cultured cardiomyocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"aldosterone","object":"calpain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Activation of an apoptotic signal transduction pathway involved in the upregulation of <e2>GENE-N<\\e2> and apoptosis-inducing factor in <e1>CHEMICAL<\\e1> induced primary cultured cardiomyocytes","sentence":"Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and apoptosis-inducing factor in aldosterone induced primary cultured cardiomyocytes"}
{"PMID":23266505,"re_id":4,"annotated sentence":"Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and <e2>apoptosis-inducing factor<\\e2> in <e1>aldosterone<\\e1> induced primary cultured cardiomyocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"aldosterone","object":"apoptosis-inducing factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and <e2>GENE-Y<\\e2> in <e1>CHEMICAL<\\e1> induced primary cultured cardiomyocytes","sentence":"Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and apoptosis-inducing factor in aldosterone induced primary cultured cardiomyocytes"}
{"PMID":23266505,"re_id":5,"annotated sentence":"The upregulation of <e2>calpain<\\e2>  tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of <e1>ALD<\\e1>  Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ALD","object":"calpain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The upregulation of <e2>GENE-N<\\e2>  tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of <e1>CHEMICAL<\\e1>  Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin","sentence":"The upregulation of calpain  tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of ALD  Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin"}
{"PMID":23266505,"re_id":6,"annotated sentence":"The upregulation of calpain, <e2>tBid<\\e2> and caspase-3 activity were further inhibited by treatment with EGTA in the presence of <e1>ALD<\\e1>  Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ALD","object":"tBid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The upregulation of calpain, <e2>GENE-Y<\\e2> and caspase-3 activity were further inhibited by treatment with EGTA in the presence of <e1>CHEMICAL<\\e1>  Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin","sentence":"The upregulation of calpain, tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of ALD  Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin"}
{"PMID":23266505,"re_id":7,"annotated sentence":"The upregulation of calpain, tBid and <e2>caspase-3<\\e2> activity were further inhibited by treatment with EGTA in the presence of <e1>ALD<\\e1>  Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ALD","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The upregulation of calpain, tBid and <e2>GENE-Y<\\e2> activity were further inhibited by treatment with EGTA in the presence of <e1>CHEMICAL<\\e1>  Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin","sentence":"The upregulation of calpain, tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of ALD  Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin"}
{"PMID":23266505,"re_id":8,"annotated sentence":"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the <e1>ALD<\\e1> induced increase of <e2>calpain<\\e2> and AIF levels.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ALD","object":"calpain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of CHEMICAL but reversed the <e1>CHEMICAL<\\e1> induced increase of <e2>GENE-N<\\e2> and AIF levels.","sentence":"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the ALD induced increase of calpain and AIF levels."}
{"PMID":23266505,"re_id":9,"annotated sentence":"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the <e1>ALD<\\e1> induced increase of calpain and <e2>AIF<\\e2> levels.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ALD","object":"AIF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of CHEMICAL but reversed the <e1>CHEMICAL<\\e1> induced increase of calpain and <e2>GENE-Y<\\e2> levels.","sentence":"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the ALD induced increase of calpain and AIF levels."}
{"PMID":23266505,"re_id":10,"annotated sentence":"In this study, <e1>aldosterone<\\e1> (ALD)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of <e2>calpain<\\e2> signaling were clarified","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"aldosterone","object":"calpain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, <e1>CHEMICAL<\\e1> (ALD)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of <e2>GENE-N<\\e2> signaling were clarified","sentence":"In this study, aldosterone (ALD)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of calpain signaling were clarified"}
{"PMID":23266505,"re_id":11,"annotated sentence":"The upregulation of <e2>calpain<\\e2>  tBid and caspase-3 activity were further inhibited by treatment with <e1>EGTA<\\e1> in the presence of ALD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EGTA","object":"calpain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The upregulation of <e2>GENE-N<\\e2>  tBid and caspase-3 activity were further inhibited by treatment with <e1>CHEMICAL<\\e1> in the presence of ALD","sentence":"The upregulation of calpain  tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of ALD"}
{"PMID":23266505,"re_id":12,"annotated sentence":"The upregulation of calpain, <e2>tBid<\\e2> and caspase-3 activity were further inhibited by treatment with <e1>EGTA<\\e1> in the presence of ALD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EGTA","object":"tBid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The upregulation of calpain, <e2>GENE-Y<\\e2> and caspase-3 activity were further inhibited by treatment with <e1>CHEMICAL<\\e1> in the presence of ALD","sentence":"The upregulation of calpain, tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of ALD"}
{"PMID":23266505,"re_id":13,"annotated sentence":"The upregulation of calpain, tBid and <e2>caspase-3<\\e2> activity were further inhibited by treatment with <e1>EGTA<\\e1> in the presence of ALD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EGTA","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The upregulation of calpain, tBid and <e2>GENE-Y<\\e2> activity were further inhibited by treatment with <e1>CHEMICAL<\\e1> in the presence of ALD","sentence":"The upregulation of calpain, tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of ALD"}
{"PMID":23266505,"re_id":14,"annotated sentence":"Additionally, <e2>AIF<\\e2> levels in the cytosol decreased due to <e1>EGTA<\\e1> but not due to calpeptin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EGTA","object":"AIF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e2>GENE-Y<\\e2> levels in the cytosol decreased due to <e1>CHEMICAL<\\e1> but not due to calpeptin","sentence":"Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin"}
{"PMID":23266505,"re_id":15,"annotated sentence":"Furthermore, treatment with <e1>spironoclactone<\\e1> not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of <e2>calpain<\\e2> and AIF levels.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"spironoclactone","object":"calpain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, treatment with <e1>CHEMICAL<\\e1> not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of <e2>GENE-N<\\e2> and AIF levels.","sentence":"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and AIF levels."}
{"PMID":23266505,"re_id":16,"annotated sentence":"Furthermore, treatment with <e1>spironoclactone<\\e1> not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and <e2>AIF<\\e2> levels.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"spironoclactone","object":"AIF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, treatment with <e1>CHEMICAL<\\e1> not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and <e2>GENE-Y<\\e2> levels.","sentence":"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and AIF levels."}
{"PMID":23270965,"re_id":0,"annotated sentence":"Furthermore, compared with control groups, the plaque endothelium level of <e2>p75(NTR)<\\e2> was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by <e1>SFO<\\e1> HD","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SFO","object":"p75(NTR)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, compared with control groups, the plaque endothelium level of <e2>GENE-Y<\\e2> was 3-fold increased and the liver level of GENE-Y was 17.4-fold increased by <e1>CHEMICAL<\\e1> HD","sentence":"Furthermore, compared with control groups, the plaque endothelium level of p75(NTR) was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by SFO HD"}
{"PMID":23270965,"re_id":1,"annotated sentence":"Furthermore, compared with control groups, the plaque endothelium level of p75(NTR) was 3-fold increased and the liver level of <e2>p75(NTR)<\\e2> was 17.4-fold increased by <e1>SFO<\\e1> HD","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SFO","object":"p75(NTR)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, compared with control groups, the plaque endothelium level of GENE-Y was 3-fold increased and the liver level of <e2>GENE-Y<\\e2> was 17.4-fold increased by <e1>CHEMICAL<\\e1> HD","sentence":"Furthermore, compared with control groups, the plaque endothelium level of p75(NTR) was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by SFO HD"}
{"PMID":23270965,"re_id":2,"annotated sentence":"Meanwhile, the serum level of KC (a functional homolog of <e2>IL-8<\\e2> and the main proinflammatory alpha chemokine in mice) in apoE(-\/-) mice was up to 357pg\/ml in <e1>SFO<\\e1> HD treated group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SFO","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Meanwhile, the serum level of KC (a functional homolog of <e2>GENE-N<\\e2> and the main proinflammatory alpha chemokine in mice) in apoE(-\/-) mice was up to 357pg\/ml in <e1>CHEMICAL<\\e1> HD treated group","sentence":"Meanwhile, the serum level of KC (a functional homolog of IL-8 and the main proinflammatory alpha chemokine in mice) in apoE(-\/-) mice was up to 357pg\/ml in SFO HD treated group"}
{"PMID":23270965,"re_id":3,"annotated sentence":"Meanwhile, the serum level of KC (a functional homolog of IL-8 and the main proinflammatory <e2>alpha chemokine<\\e2> in mice) in apoE(-\/-) mice was up to 357pg\/ml in <e1>SFO<\\e1> HD treated group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SFO","object":"alpha chemokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Meanwhile, the serum level of KC (a functional homolog of IL-8 and the main proinflammatory <e2>GENE-N<\\e2> in mice) in apoE(-\/-) mice was up to 357pg\/ml in <e1>CHEMICAL<\\e1> HD treated group","sentence":"Meanwhile, the serum level of KC (a functional homolog of IL-8 and the main proinflammatory alpha chemokine in mice) in apoE(-\/-) mice was up to 357pg\/ml in SFO HD treated group"}
{"PMID":23270965,"re_id":4,"annotated sentence":"Thus, <e1>SFO<\\e1> contributes to the instability of atherosclerotic plaque in apoE(-\/-) mice through activating <e2>p75(NTR)<\\e2> and IL-8 and cell apoptosis in plaque.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SFO","object":"p75(NTR)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> contributes to the instability of atherosclerotic plaque in apoE(-\/-) mice through activating <e2>GENE-Y<\\e2> and IL-8 and cell apoptosis in plaque.","sentence":"Thus, SFO contributes to the instability of atherosclerotic plaque in apoE(-\/-) mice through activating p75(NTR) and IL-8 and cell apoptosis in plaque."}
{"PMID":23270965,"re_id":5,"annotated sentence":"Thus, <e1>SFO<\\e1> contributes to the instability of atherosclerotic plaque in apoE(-\/-) mice through activating p75(NTR) and <e2>IL-8<\\e2> and cell apoptosis in plaque.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SFO","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, <e1>CHEMICAL<\\e1> contributes to the instability of atherosclerotic plaque in apoE(-\/-) mice through activating p75(NTR) and <e2>GENE-N<\\e2> and cell apoptosis in plaque.","sentence":"Thus, SFO contributes to the instability of atherosclerotic plaque in apoE(-\/-) mice through activating p75(NTR) and IL-8 and cell apoptosis in plaque."}
{"PMID":23273219,"re_id":0,"annotated sentence":"\u03b2-Amyloid aggregation results showed that all compounds exhibited remarkable <e2>A\u03b2<\\e2> fibril aggregation inhibition activity with a nearly similar potential as the reference compound <e1>rifampicin<\\e1>  which makes them promising anti-Alzheimer drug candidates","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rifampicin","object":"A\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"\u03b2-Amyloid aggregation results showed that all compounds exhibited remarkable <e2>GENE-Y<\\e2> fibril aggregation inhibition activity with a nearly similar potential as the reference compound <e1>CHEMICAL<\\e1>  which makes them promising anti-Alzheimer drug candidates","sentence":"\u03b2-Amyloid aggregation results showed that all compounds exhibited remarkable A\u03b2 fibril aggregation inhibition activity with a nearly similar potential as the reference compound rifampicin  which makes them promising anti-Alzheimer drug candidates"}
{"PMID":23273219,"re_id":1,"annotated sentence":"To develop new drugs for treatment of Alzheimer's disease, a group of <e1>N'-2-(4-Benzylpiperidin-\/piperazin-1-yl)acylhydrazones<\\e1> was designed, synthesized and tested for their ability to inhibit <e2>acetylcholinesterase<\\e2>  butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N'-2-(4-Benzylpiperidin-\/piperazin-1-yl)acylhydrazones","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To develop new drugs for treatment of Alzheimer's disease, a group of <e1>CHEMICAL<\\e1> was designed, synthesized and tested for their ability to inhibit <e2>GENE-Y<\\e2>  butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42)","sentence":"To develop new drugs for treatment of Alzheimer's disease, a group of N'-2-(4-Benzylpiperidin-\/piperazin-1-yl)acylhydrazones was designed, synthesized and tested for their ability to inhibit acetylcholinesterase  butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42)"}
{"PMID":23273219,"re_id":2,"annotated sentence":"To develop new drugs for treatment of Alzheimer's disease, a group of <e1>N'-2-(4-Benzylpiperidin-\/piperazin-1-yl)acylhydrazones<\\e1> was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, <e2>butyrylcholinesterase<\\e2> and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N'-2-(4-Benzylpiperidin-\/piperazin-1-yl)acylhydrazones","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To develop new drugs for treatment of Alzheimer's disease, a group of <e1>CHEMICAL<\\e1> was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, <e2>GENE-Y<\\e2> and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42)","sentence":"To develop new drugs for treatment of Alzheimer's disease, a group of N'-2-(4-Benzylpiperidin-\/piperazin-1-yl)acylhydrazones was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42)"}
{"PMID":23273219,"re_id":3,"annotated sentence":"Synthesis, molecular modeling and evaluation of novel <e1>N'-2-(4-benzylpiperidin-\/piperazin-1-yl)acylhydrazone<\\e1> derivatives as dual inhibitors for <e2>cholinesterases<\\e2> and A\u03b2 aggregation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N'-2-(4-benzylpiperidin-\/piperazin-1-yl)acylhydrazone","object":"cholinesterases","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis, molecular modeling and evaluation of novel <e1>CHEMICAL<\\e1> derivatives as dual inhibitors for <e2>GENE-Y<\\e2> and A\u03b2 aggregation","sentence":"Synthesis, molecular modeling and evaluation of novel N'-2-(4-benzylpiperidin-\/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and A\u03b2 aggregation"}
{"PMID":23273219,"re_id":4,"annotated sentence":"Synthesis, molecular modeling and evaluation of novel <e1>N'-2-(4-benzylpiperidin-\/piperazin-1-yl)acylhydrazone<\\e1> derivatives as dual inhibitors for cholinesterases and <e2>A\u03b2<\\e2> aggregation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N'-2-(4-benzylpiperidin-\/piperazin-1-yl)acylhydrazone","object":"A\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis, molecular modeling and evaluation of novel <e1>CHEMICAL<\\e1> derivatives as dual inhibitors for cholinesterases and <e2>GENE-Y<\\e2> aggregation","sentence":"Synthesis, molecular modeling and evaluation of novel N'-2-(4-benzylpiperidin-\/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and A\u03b2 aggregation"}
{"PMID":23274771,"re_id":0,"annotated sentence":"Furthermore, <e1>DOX<\\e1> treated WT and p65(-\/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of <e2>p65<\\e2> positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of I\u03baB\u03b1-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DOX","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> treated WT and GENE-Y(-\/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of <e2>GENE-Y<\\e2> positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of I\u03baB\u03b1-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter","sentence":"Furthermore, DOX treated WT and p65(-\/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of p65 positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of I\u03baB\u03b1-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter"}
{"PMID":23274894,"re_id":0,"annotated sentence":"G6PC2: A Negative Regulator of Basal <e1>Glucose<\\e1> Stimulated <e2>Insulin<\\e2> Secretion","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Glucose","object":"Insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"G6PC2: A Negative Regulator of Basal <e1>CHEMICAL<\\e1> Stimulated <e2>GENE-Y<\\e2> Secretion","sentence":"G6PC2: A Negative Regulator of Basal Glucose Stimulated Insulin Secretion"}
{"PMID":23274894,"re_id":1,"annotated sentence":"G6pc2 deletion resulted in a leftward shift in the dose-response curve for <e1>glucose<\\e1> stimulated <e2>insulin<\\e2> secretion (GSIS)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"G6pc2 deletion resulted in a leftward shift in the dose-response curve for <e1>CHEMICAL<\\e1> stimulated <e2>GENE-N<\\e2> secretion (GSIS)","sentence":"G6pc2 deletion resulted in a leftward shift in the dose-response curve for glucose stimulated insulin secretion (GSIS)"}
{"PMID":23274894,"re_id":2,"annotated sentence":"These data suggest that <e2>G6pc2<\\e2> represents a novel, negative regulator of basal GSIS that acts by hydrolyzing <e1>glucose-6-phosphate<\\e1>  thereby reducing glycolytic flux.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glucose-6-phosphate","object":"G6pc2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that <e2>GENE-Y<\\e2> represents a novel, negative regulator of basal GSIS that acts by hydrolyzing <e1>CHEMICAL<\\e1>  thereby reducing glycolytic flux.","sentence":"These data suggest that G6pc2 represents a novel, negative regulator of basal GSIS that acts by hydrolyzing glucose-6-phosphate  thereby reducing glycolytic flux."}
{"PMID":23277230,"re_id":0,"annotated sentence":"<e1>Fisetin<\\e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma <e2>insulin<\\e2>  The treatment also improved the antioxidant status in pancreas as well as plasma of diabetic rats indicating the antioxidant potential of fisetin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Fisetin","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma <e2>GENE-N<\\e2>  The treatment also improved the antioxidant status in pancreas as well as plasma of diabetic rats indicating the antioxidant potential of fisetin","sentence":"Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin  The treatment also improved the antioxidant status in pancreas as well as plasma of diabetic rats indicating the antioxidant potential of fisetin"}
{"PMID":23277230,"re_id":1,"annotated sentence":"<e1>Fisetin<\\e1> treatment showed a significant decline in the levels of blood glucose, <e2>glycosylated hemoglobin<\\e2> (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fisetin","object":"glycosylated hemoglobin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment showed a significant decline in the levels of blood glucose, <e2>GENE-N<\\e2> (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin","sentence":"Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin"}
{"PMID":23277230,"re_id":2,"annotated sentence":"<e1>Fisetin<\\e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (<e2>HbA1c<\\e2> , NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fisetin","object":"HbA1c","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (<e2>GENE-N<\\e2> , NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin","sentence":"Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c , NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin"}
{"PMID":23277230,"re_id":3,"annotated sentence":"<e1>Fisetin<\\e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), <e2>NF-kB<\\e2> p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fisetin","object":"NF-kB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), <e2>GENE-N<\\e2> p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin","sentence":"Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin"}
{"PMID":23277230,"re_id":4,"annotated sentence":"<e1>Fisetin<\\e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB <e2>p65<\\e2> unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fisetin","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB <e2>GENE-Y<\\e2> unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin","sentence":"Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin"}
{"PMID":23277230,"re_id":5,"annotated sentence":"<e1>Fisetin<\\e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and <e2>IL-1\u03b2<\\e2> (plasma), serum nitric oxide (NO) with an elevation in plasma insulin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fisetin","object":"IL-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and <e2>GENE-Y<\\e2> (plasma), serum nitric oxide (NO) with an elevation in plasma insulin","sentence":"Fisetin treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin"}
{"PMID":23290487,"re_id":0,"annotated sentence":"Next to <e2>Glut-4<\\e2>  the predominant protein influencing <e1>glucose<\\e1> metabolism is PPAR\u03b1 and \u03b3 whose expressions were also positively modulated","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glucose","object":"Glut-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Next to <e2>GENE-Y<\\e2>  the predominant protein influencing <e1>CHEMICAL<\\e1> metabolism is PPAR\u03b1 and \u03b3 whose expressions were also positively modulated","sentence":"Next to Glut-4  the predominant protein influencing glucose metabolism is PPAR\u03b1 and \u03b3 whose expressions were also positively modulated"}
{"PMID":23291323,"re_id":0,"annotated sentence":"Absorption and secretion of <e1>fluoride<\\e1> increase at acid pH levels, possibly because of its non-ionized state at these pHs and\/or because of participation of a F(-)\/H(+) cotransporter or a <e2>F(-)\/OH(-) antiporter<\\e2>  The results also suggest transcellular participation of mechanisms involved in transport of Cl(-) and of an active transport in the secretory direction","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"fluoride","object":"F(-)\/OH(-) antiporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorption and secretion of <e1>CHEMICAL<\\e1> increase at acid pH levels, possibly because of its non-ionized state at these pHs and\/or because of participation of a F(-)\/H(+) cotransporter or a <e2>GENE-N<\\e2>  The results also suggest transcellular participation of mechanisms involved in transport of Cl(-) and of an active transport in the secretory direction","sentence":"Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and\/or because of participation of a F(-)\/H(+) cotransporter or a F(-)\/OH(-) antiporter  The results also suggest transcellular participation of mechanisms involved in transport of Cl(-) and of an active transport in the secretory direction"}
{"PMID":23291323,"re_id":1,"annotated sentence":"Absorption and secretion of <e1>fluoride<\\e1> increase at acid pH levels, possibly because of its non-ionized state at these pHs and\/or because of participation of a <e2>F(-)\/H(+) cotransporter<\\e2> or a F(-)\/OH(-) antiporter","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"fluoride","object":"F(-)\/H(+) cotransporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Absorption and secretion of <e1>CHEMICAL<\\e1> increase at acid pH levels, possibly because of its non-ionized state at these pHs and\/or because of participation of a <e2>GENE-N<\\e2> or a F(-)\/OH(-) antiporter","sentence":"Absorption and secretion of fluoride increase at acid pH levels, possibly because of its non-ionized state at these pHs and\/or because of participation of a F(-)\/H(+) cotransporter or a F(-)\/OH(-) antiporter"}
{"PMID":23291559,"re_id":0,"annotated sentence":"<e2>KCNK1<\\e2>  a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after <e1>phenobarbital<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenobarbital","object":"KCNK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2>  a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after <e1>CHEMICAL<\\e1> treatment","sentence":"KCNK1  a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after phenobarbital treatment"}
{"PMID":23291559,"re_id":1,"annotated sentence":"KCNK1, a member of the family of two-pore <e2>K(+) ion channels<\\e2>  is specifically induced in the livers of male mice after <e1>phenobarbital<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenobarbital","object":"K(+) ion channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"KCNK1, a member of the family of two-pore <e2>GENE-N<\\e2>  is specifically induced in the livers of male mice after <e1>CHEMICAL<\\e1> treatment","sentence":"KCNK1, a member of the family of two-pore K(+) ion channels  is specifically induced in the livers of male mice after phenobarbital treatment"}
{"PMID":23291559,"re_id":2,"annotated sentence":"Here, we have determined the molecular mechanism of this male-specific activation of the <e2>Kcnk1<\\e2> gene and characterized KCNK1 as a <e1>phenobarbital<\\e1> inducible antihyperplasia factor","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenobarbital","object":"Kcnk1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we have determined the molecular mechanism of this male-specific activation of the <e2>GENE-Y<\\e2> gene and characterized KCNK1 as a <e1>CHEMICAL<\\e1> inducible antihyperplasia factor","sentence":"Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized KCNK1 as a phenobarbital inducible antihyperplasia factor"}
{"PMID":23291559,"re_id":3,"annotated sentence":"Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized <e2>KCNK1<\\e2> as a <e1>phenobarbital<\\e1> inducible antihyperplasia factor","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenobarbital","object":"KCNK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized <e2>GENE-Y<\\e2> as a <e1>CHEMICAL<\\e1> inducible antihyperplasia factor","sentence":"Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized KCNK1 as a phenobarbital inducible antihyperplasia factor"}
{"PMID":23291559,"re_id":4,"annotated sentence":"Upon activation by <e1>phenobarbital<\\e1>  <e2>nuclear receptor<\\e2> CAR binds the 97-bp response element (-2441\/-2345) within the Kcnk1 promoter","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenobarbital","object":"nuclear receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Upon activation by <e1>CHEMICAL<\\e1>  <e2>GENE-N<\\e2> CAR binds the 97-bp response element (-2441\/-2345) within the Kcnk1 promoter","sentence":"Upon activation by phenobarbital  nuclear receptor CAR binds the 97-bp response element (-2441\/-2345) within the Kcnk1 promoter"}
{"PMID":23291559,"re_id":5,"annotated sentence":"Upon activation by <e1>phenobarbital<\\e1>  nuclear receptor <e2>CAR<\\e2> binds the 97-bp response element (-2441\/-2345) within the Kcnk1 promoter","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenobarbital","object":"CAR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon activation by <e1>CHEMICAL<\\e1>  nuclear receptor <e2>GENE-Y<\\e2> binds the 97-bp response element (-2441\/-2345) within the Kcnk1 promoter","sentence":"Upon activation by phenobarbital  nuclear receptor CAR binds the 97-bp response element (-2441\/-2345) within the Kcnk1 promoter"}
{"PMID":23291559,"re_id":6,"annotated sentence":"These results indicate that <e1>phenobarbital<\\e1> treatment induces <e2>KCNK1<\\e2> to elicit a male-specific and growth-suppressing signal","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"phenobarbital","object":"KCNK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> treatment induces <e2>GENE-Y<\\e2> to elicit a male-specific and growth-suppressing signal","sentence":"These results indicate that phenobarbital treatment induces KCNK1 to elicit a male-specific and growth-suppressing signal"}
{"PMID":23291630,"re_id":0,"annotated sentence":"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of <e1>navitoclax<\\e1>  a selective inhibitor of both <e2>BCL-2<\\e2> and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"navitoclax","object":"BCL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of <e1>CHEMICAL<\\e1>  a selective inhibitor of both <e2>GENE-Y<\\e2> and GENE-Y-like 1 (BCL-X(L)), which has shown clinical efficacy in some GENE-Y-dependent hematological cancers","sentence":"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax  a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers"}
{"PMID":23291630,"re_id":1,"annotated sentence":"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of <e1>navitoclax<\\e1>  a selective inhibitor of both BCL-2 and <e2>BCL-2-like 1<\\e2> (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"navitoclax","object":"BCL-2-like 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of <e1>CHEMICAL<\\e1>  a selective inhibitor of both BCL-2 and <e2>GENE-Y<\\e2> (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers","sentence":"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax  a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers"}
{"PMID":23291630,"re_id":2,"annotated sentence":"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of <e1>navitoclax<\\e1>  a selective inhibitor of both BCL-2 and BCL-2-like 1 (<e2>BCL-X(L)<\\e2> , which has shown clinical efficacy in some BCL-2-dependent hematological cancers","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"navitoclax","object":"BCL-X(L)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of <e1>CHEMICAL<\\e1>  a selective inhibitor of both BCL-2 and BCL-2-like 1 (<e2>GENE-Y<\\e2> , which has shown clinical efficacy in some BCL-2-dependent hematological cancers","sentence":"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax  a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L) , which has shown clinical efficacy in some BCL-2-dependent hematological cancers"}
{"PMID":23291630,"re_id":3,"annotated sentence":"Here we report the re-engineering of <e1>navitoclax<\\e1> to create a highly potent, orally bioavailable and <e2>BCL-2<\\e2> selective inhibitor, ABT-199","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"navitoclax","object":"BCL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we report the re-engineering of <e1>CHEMICAL<\\e1> to create a highly potent, orally bioavailable and <e2>GENE-Y<\\e2> selective inhibitor, ABT-199","sentence":"Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2 selective inhibitor, ABT-199"}
{"PMID":23291630,"re_id":4,"annotated sentence":"Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and <e2>BCL-2<\\e2> selective inhibitor, <e1>ABT-199<\\e1>  This compound inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ABT-199","object":"BCL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and <e2>GENE-Y<\\e2> selective inhibitor, <e1>CHEMICAL<\\e1>  This compound inhibits the growth of GENE-Y-dependent tumors in vivo and spares human platelets","sentence":"Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2 selective inhibitor, ABT-199  This compound inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets"}
{"PMID":23291630,"re_id":5,"annotated sentence":"<e1>ABT-199<\\e1>  a potent and selective <e2>BCL-2<\\e2> inhibitor, achieves antitumor activity while sparing platelets","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ABT-199","object":"BCL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a potent and selective <e2>GENE-Y<\\e2> inhibitor, achieves antitumor activity while sparing platelets","sentence":"ABT-199  a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets"}
{"PMID":23293129,"re_id":0,"annotated sentence":"Cotreatments of 5, 10 and 20 \u00b5g\/mL concentrations of MEP with <e1>aflatoxin B(1)<\\e1> decreased the frequencies of SCE and the malondialdehyde level and increased amount of <e2>superoxide dismutase<\\e2>  glutathione and glutathione peroxidase which were decreased by aflatoxin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"aflatoxin B(1)","object":"superoxide dismutase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cotreatments of 5, 10 and 20 \u00b5g\/mL concentrations of MEP with <e1>CHEMICAL<\\e1> decreased the frequencies of SCE and the malondialdehyde level and increased amount of <e2>GENE-N<\\e2>  glutathione and glutathione peroxidase which were decreased by aflatoxin","sentence":"Cotreatments of 5, 10 and 20 \u00b5g\/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase  glutathione and glutathione peroxidase which were decreased by aflatoxin"}
{"PMID":23293129,"re_id":1,"annotated sentence":"Cotreatments of 5, 10 and 20 \u00b5g\/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and <e2>glutathione peroxidase<\\e2> which were decreased by <e1>aflatoxin<\\e1>  The data obtained from this work have clearly shown that MEP has significant antigenotoxic effects which are thought to be partly due to the antioxidant activities and antioxidant inducing capability of MEP","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aflatoxin","object":"glutathione peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cotreatments of 5, 10 and 20 \u00b5g\/mL concentrations of MEP with CHEMICAL B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and <e2>GENE-N<\\e2> which were decreased by <e1>CHEMICAL<\\e1>  The data obtained from this work have clearly shown that MEP has significant antigenotoxic effects which are thought to be partly due to the antioxidant activities and antioxidant inducing capability of MEP","sentence":"Cotreatments of 5, 10 and 20 \u00b5g\/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and glutathione peroxidase which were decreased by aflatoxin  The data obtained from this work have clearly shown that MEP has significant antigenotoxic effects which are thought to be partly due to the antioxidant activities and antioxidant inducing capability of MEP"}
{"PMID":23298258,"re_id":0,"annotated sentence":"<e1>All-trans retinoic acid<\\e1> protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating <e2>collagen 8A2<\\e2>  As a therapeutic or chemopreventative agent for various cancers, all-trans retinoic acid (atRA) has been reported to inhibit growth, induce apoptosis or cause differentiation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"All-trans retinoic acid","object":"collagen 8A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating <e2>GENE-Y<\\e2>  As a therapeutic or chemopreventative agent for various cancers, all-trans retinoic acid (atRA) has been reported to inhibit growth, induce apoptosis or cause differentiation","sentence":"All-trans retinoic acid protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating collagen 8A2  As a therapeutic or chemopreventative agent for various cancers, all-trans retinoic acid (atRA) has been reported to inhibit growth, induce apoptosis or cause differentiation"}
{"PMID":23298698,"re_id":0,"annotated sentence":"Local <e1>PGE2<\\e1> administration prevented the increase of airway <e2>IL-13<\\e2> and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PGE2","object":"IL-13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Local <e1>CHEMICAL<\\e1> administration prevented the increase of airway <e2>GENE-Y<\\e2> and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline","sentence":"Local PGE2 administration prevented the increase of airway IL-13 and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline"}
{"PMID":23298698,"re_id":1,"annotated sentence":"Local <e1>PGE2<\\e1> administration prevented the increase of airway IL-13 and <e2>osteopontin<\\e2> and kept lung plasmacytoid dendritic cell counts close to baseline","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PGE2","object":"osteopontin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Local <e1>CHEMICAL<\\e1> administration prevented the increase of airway IL-13 and <e2>GENE-Y<\\e2> and kept lung plasmacytoid dendritic cell counts close to baseline","sentence":"Local PGE2 administration prevented the increase of airway IL-13 and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline"}
{"PMID":23298698,"re_id":2,"annotated sentence":"Lung inflammation, <e2>IL-4<\\e2> production, and airway mast cell activity were also prevented under this early short-term treatment with <e1>PGE2<\\e1>  Interestingly, a Th2 response was already committed on day 5 of exposure to HDM","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PGE2","object":"IL-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Lung inflammation, <e2>GENE-Y<\\e2> production, and airway mast cell activity were also prevented under this early short-term treatment with <e1>CHEMICAL<\\e1>  Interestingly, a Th2 response was already committed on day 5 of exposure to HDM","sentence":"Lung inflammation, IL-4 production, and airway mast cell activity were also prevented under this early short-term treatment with PGE2  Interestingly, a Th2 response was already committed on day 5 of exposure to HDM"}
{"PMID":23298863,"re_id":0,"annotated sentence":"The IC50 values for <e2>Gli1<\\e2> mRNA inhibition in the tumor and skin by <e1>TAK-441<\\e1> were estimated to be 0.0457 and 0.113 \u03bcg\/ml, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAK-441","object":"Gli1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The IC50 values for <e2>GENE-Y<\\e2> mRNA inhibition in the tumor and skin by <e1>CHEMICAL<\\e1> were estimated to be 0.0457 and 0.113 \u03bcg\/ml, respectively","sentence":"The IC50 values for Gli1 mRNA inhibition in the tumor and skin by TAK-441 were estimated to be 0.0457 and 0.113 \u03bcg\/ml, respectively"}
{"PMID":23298863,"re_id":1,"annotated sentence":"6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (<e1>TAK-441<\\e1>  is a potent, selective <e2>hedgehog<\\e2> signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAK-441","object":"hedgehog","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (<e1>CHEMICAL<\\e1>  is a potent, selective <e2>GENE-N<\\e2> signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer","sentence":"6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (TAK-441  is a potent, selective hedgehog signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer"}
{"PMID":23298863,"re_id":2,"annotated sentence":"Pharmacokinetic and pharmacodynamic modeling of <e2>hedgehog<\\e2> inhibitor <e1>TAK-441<\\e1> for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAK-441","object":"hedgehog","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pharmacokinetic and pharmacodynamic modeling of <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice","sentence":"Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice"}
{"PMID":23298863,"re_id":3,"annotated sentence":"Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor <e1>TAK-441<\\e1> for the inhibition of <e2>Gli1<\\e2> messenger RNA expression and antitumor efficacy in xenografted tumor model mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TAK-441","object":"Gli1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor <e1>CHEMICAL<\\e1> for the inhibition of <e2>GENE-Y<\\e2> messenger RNA expression and antitumor efficacy in xenografted tumor model mice","sentence":"Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice"}
{"PMID":23301860,"re_id":0,"annotated sentence":"An amphiphile with branched <e1>poly(ethylene glycol)<\\e1> architecture also activated the <e2>lectin<\\e2> pathway but only through L-ficolin recognition","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"poly(ethylene glycol)","object":"lectin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"An amphiphile with branched <e1>CHEMICAL<\\e1> architecture also activated the <e2>GENE-N<\\e2> pathway but only through L-ficolin recognition","sentence":"An amphiphile with branched poly(ethylene glycol) architecture also activated the lectin pathway but only through L-ficolin recognition"}
{"PMID":23301897,"re_id":0,"annotated sentence":"In addition, the new compound <e1>perviridicin B<\\e1> (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant <e2>NF-\u03baB<\\e2> (p65) inhibitory activity in an ELISA assay.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"perviridicin B","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, the new compound <e1>CHEMICAL<\\e1> (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant <e2>GENE-N<\\e2> (p65) inhibitory activity in an ELISA assay.","sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (p65) inhibitory activity in an ELISA assay."}
{"PMID":23301897,"re_id":1,"annotated sentence":"In addition, the new compound <e1>perviridicin B<\\e1> (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (<e2>p65<\\e2>  inhibitory activity in an ELISA assay.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"perviridicin B","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, the new compound <e1>CHEMICAL<\\e1> (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (<e2>GENE-Y<\\e2>  inhibitory activity in an ELISA assay.","sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (p65  inhibitory activity in an ELISA assay."}
{"PMID":23301897,"re_id":2,"annotated sentence":"In addition, the new compound perviridicin B (2), three known <e1>rocaglate<\\e1> derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant <e2>NF-\u03baB<\\e2> (p65) inhibitory activity in an ELISA assay.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rocaglate","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, the new compound perviridicin B (2), three known <e1>CHEMICAL<\\e1> derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant <e2>GENE-N<\\e2> (p65) inhibitory activity in an ELISA assay.","sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (p65) inhibitory activity in an ELISA assay."}
{"PMID":23301897,"re_id":3,"annotated sentence":"In addition, the new compound perviridicin B (2), three known <e1>rocaglate<\\e1> derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (<e2>p65<\\e2>  inhibitory activity in an ELISA assay.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rocaglate","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, the new compound perviridicin B (2), three known <e1>CHEMICAL<\\e1> derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (<e2>GENE-Y<\\e2>  inhibitory activity in an ELISA assay.","sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (p65  inhibitory activity in an ELISA assay."}
{"PMID":23301897,"re_id":4,"annotated sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known <e1>sesquiterpene<\\e1>  2-oxaisodauc-5-en-12-al (17), showed significant <e2>NF-\u03baB<\\e2> (p65) inhibitory activity in an ELISA assay.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sesquiterpene","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known <e1>CHEMICAL<\\e1>  2-oxaisodauc-5-en-12-al (17), showed significant <e2>GENE-N<\\e2> (p65) inhibitory activity in an ELISA assay.","sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene  2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (p65) inhibitory activity in an ELISA assay."}
{"PMID":23301897,"re_id":5,"annotated sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known <e1>sesquiterpene<\\e1>  2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (<e2>p65<\\e2>  inhibitory activity in an ELISA assay.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sesquiterpene","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known <e1>CHEMICAL<\\e1>  2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (<e2>GENE-Y<\\e2>  inhibitory activity in an ELISA assay.","sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene  2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (p65  inhibitory activity in an ELISA assay."}
{"PMID":23301897,"re_id":6,"annotated sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, <e1>2-oxaisodauc-5-en-12-al<\\e1> (17), showed significant <e2>NF-\u03baB<\\e2> (p65) inhibitory activity in an ELISA assay.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-oxaisodauc-5-en-12-al","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, <e1>CHEMICAL<\\e1> (17), showed significant <e2>GENE-N<\\e2> (p65) inhibitory activity in an ELISA assay.","sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (p65) inhibitory activity in an ELISA assay."}
{"PMID":23301897,"re_id":7,"annotated sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, <e1>2-oxaisodauc-5-en-12-al<\\e1> (17), showed significant NF-\u03baB (<e2>p65<\\e2>  inhibitory activity in an ELISA assay.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-oxaisodauc-5-en-12-al","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, <e1>CHEMICAL<\\e1> (17), showed significant NF-\u03baB (<e2>GENE-Y<\\e2>  inhibitory activity in an ELISA assay.","sentence":"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB (p65  inhibitory activity in an ELISA assay."}
{"PMID":23305850,"re_id":0,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2<\\e2> target genes in response to NRF2 inducers (<e1>sulforaphane<\\e1>  tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sulforaphane","object":"NRF2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>GENE-Y<\\e2> target genes in response to GENE-Y inducers (<e1>CHEMICAL<\\e1>  tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane  tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":1,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to <e2>NRF2<\\e2> inducers (<e1>sulforaphane<\\e1>  tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sulforaphane","object":"NRF2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported GENE-Y target genes in response to <e2>GENE-Y<\\e2> inducers (<e1>CHEMICAL<\\e1>  tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane  tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":2,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (<e1>sulforaphane<\\e1>  tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the <e2>aldo-keto reductase (AKR) 1C1<\\e2> is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sulforaphane","object":"aldo-keto reductase (AKR) 1C1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (<e1>CHEMICAL<\\e1>  tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the <e2>GENE-Y<\\e2> is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane  tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":3,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2<\\e2> target genes in response to NRF2 inducers (sulforaphane, <e1>tert-butylhydroquinone<\\e1>  cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tert-butylhydroquinone","object":"NRF2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>GENE-Y<\\e2> target genes in response to GENE-Y inducers (sulforaphane, <e1>CHEMICAL<\\e1>  cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone  cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":4,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to <e2>NRF2<\\e2> inducers (sulforaphane, <e1>tert-butylhydroquinone<\\e1>  cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tert-butylhydroquinone","object":"NRF2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported GENE-Y target genes in response to <e2>GENE-Y<\\e2> inducers (sulforaphane, <e1>CHEMICAL<\\e1>  cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone  cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":5,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, <e1>tert-butylhydroquinone<\\e1>  cinnamic aldehyde, and hydrogen peroxide) showed that the <e2>aldo-keto reductase (AKR) 1C1<\\e2> is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tert-butylhydroquinone","object":"aldo-keto reductase (AKR) 1C1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, <e1>CHEMICAL<\\e1>  cinnamic aldehyde, and hydrogen peroxide) showed that the <e2>GENE-Y<\\e2> is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone  cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":6,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2<\\e2> target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, <e1>cinnamic aldehyde<\\e1>  and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cinnamic aldehyde","object":"NRF2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>GENE-Y<\\e2> target genes in response to GENE-Y inducers (sulforaphane, tert-butylhydroquinone, <e1>CHEMICAL<\\e1>  and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde  and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":7,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to <e2>NRF2<\\e2> inducers (sulforaphane, tert-butylhydroquinone, <e1>cinnamic aldehyde<\\e1>  and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cinnamic aldehyde","object":"NRF2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported GENE-Y target genes in response to <e2>GENE-Y<\\e2> inducers (sulforaphane, tert-butylhydroquinone, <e1>CHEMICAL<\\e1>  and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde  and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":8,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, <e1>cinnamic aldehyde<\\e1>  and hydrogen peroxide) showed that the <e2>aldo-keto reductase (AKR) 1C1<\\e2> is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cinnamic aldehyde","object":"aldo-keto reductase (AKR) 1C1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, <e1>CHEMICAL<\\e1>  and hydrogen peroxide) showed that the <e2>GENE-Y<\\e2> is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde  and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":9,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2<\\e2> target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and <e1>hydrogen peroxide<\\e1>  showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"hydrogen peroxide","object":"NRF2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>GENE-Y<\\e2> target genes in response to GENE-Y inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and <e1>CHEMICAL<\\e1>  showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide  showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":10,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to <e2>NRF2<\\e2> inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and <e1>hydrogen peroxide<\\e1>  showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"hydrogen peroxide","object":"NRF2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported GENE-Y target genes in response to <e2>GENE-Y<\\e2> inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and <e1>CHEMICAL<\\e1>  showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide  showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":11,"annotated sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and <e1>hydrogen peroxide<\\e1>  showed that the <e2>aldo-keto reductase (AKR) 1C1<\\e2> is highly inducible by all treatments","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"hydrogen peroxide","object":"aldo-keto reductase (AKR) 1C1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and <e1>CHEMICAL<\\e1>  showed that the <e2>GENE-Y<\\e2> is highly inducible by all treatments","sentence":"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide  showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments"}
{"PMID":23305850,"re_id":12,"annotated sentence":"The treatment of U937 cells with <e2>NRF2<\\e2> inducers including <e1>sulforaphane<\\e1> effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sulforaphane","object":"NRF2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The treatment of U937 cells with <e2>GENE-Y<\\e2> inducers including <e1>CHEMICAL<\\e1> effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3","sentence":"The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3"}
{"PMID":23305850,"re_id":13,"annotated sentence":"The treatment of U937 cells with NRF2 inducers including <e1>sulforaphane<\\e1> effectively elevated the expression of <e2>AKR1B1, 1B10, 1C1, 1C2, and 1C3<\\e2>  Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sulforaphane","object":"AKR1B1, 1B10, 1C1, 1C2, and 1C3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The treatment of U937 cells with NRF2 inducers including <e1>CHEMICAL<\\e1> effectively elevated the expression of <e2>GENE-N<\\e2>  Whereas, the levels of both the basal and CHEMICAL-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells","sentence":"The treatment of U937 cells with NRF2 inducers including sulforaphane effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3  Whereas, the levels of both the basal and sulforaphane-inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells"}
{"PMID":23305850,"re_id":14,"annotated sentence":"Whereas, the levels of both the basal and <e1>sulforaphane<\\e1> inducible expression of <e2>AKR1C1<\\e2> were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sulforaphane","object":"AKR1C1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Whereas, the levels of both the basal and <e1>CHEMICAL<\\e1> inducible expression of <e2>GENE-Y<\\e2> were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells","sentence":"Whereas, the levels of both the basal and sulforaphane inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells"}
{"PMID":23313376,"re_id":0,"annotated sentence":"<e1>PTE<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (<e2>Bax<\\e2>  Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PTE","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (<e2>GENE-Y<\\e2>  Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","sentence":"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax  Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27"}
{"PMID":23313376,"re_id":1,"annotated sentence":"<e1>PTE<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, <e2>Bak<\\e2>  cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PTE","object":"Bak","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, <e2>GENE-Y<\\e2>  cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","sentence":"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak  cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27"}
{"PMID":23313376,"re_id":2,"annotated sentence":"<e1>PTE<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic <e2>Cytochrome c<\\e2>  and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PTE","object":"Cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic <e2>GENE-Y<\\e2>  and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","sentence":"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c  and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27"}
{"PMID":23313376,"re_id":3,"annotated sentence":"<e1>PTE<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved <e2>Caspase3<\\e2>  and cyclin-dependent kinase inhibitors such as p21 and p27","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PTE","object":"Caspase3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved <e2>GENE-Y<\\e2>  and cyclin-dependent kinase inhibitors such as p21 and p27","sentence":"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3  and cyclin-dependent kinase inhibitors such as p21 and p27"}
{"PMID":23313376,"re_id":4,"annotated sentence":"<e1>PTE<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as <e2>p21<\\e2> and p27","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PTE","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as <e2>GENE-Y<\\e2> and p27","sentence":"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27"}
{"PMID":23313376,"re_id":5,"annotated sentence":"<e1>PTE<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and <e2>p27<\\e2>  PTE, used in combination with a known JAK2\/STAT3 inhibitor, AG490, further decreased the viability of osteosarcoma cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PTE","object":"p27","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and <e2>GENE-Y<\\e2>  CHEMICAL, used in combination with a known JAK2\/STAT3 inhibitor, AG490, further decreased the viability of osteosarcoma cells","sentence":"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27  PTE, used in combination with a known JAK2\/STAT3 inhibitor, AG490, further decreased the viability of osteosarcoma cells"}
{"PMID":23313376,"re_id":6,"annotated sentence":"<e1>Pterostilbene<\\e1> exerts antitumor activity against human osteosarcoma cells by inhibiting the <e2>JAK2<\\e2> STAT3 signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pterostilbene","object":"JAK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> exerts antitumor activity against human osteosarcoma cells by inhibiting the <e2>GENE-Y<\\e2> STAT3 signaling pathway","sentence":"Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2 STAT3 signaling pathway"}
{"PMID":23313376,"re_id":7,"annotated sentence":"<e1>Pterostilbene<\\e1> exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2\/<e2>STAT3<\\e2> signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pterostilbene","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2\/<e2>GENE-Y<\\e2> signaling pathway","sentence":"Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2\/STAT3 signaling pathway"}
{"PMID":23313376,"re_id":8,"annotated sentence":"Furthermore, <e1>PTE<\\e1> treatment directly inhibited the phosphorylation of <e2>JAK2<\\e2> at Tyr 1007 and the downstream activation of STAT3","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PTE","object":"JAK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> treatment directly inhibited the phosphorylation of <e2>GENE-Y<\\e2> at Tyr 1007 and the downstream activation of STAT3","sentence":"Furthermore, PTE treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of STAT3"}
{"PMID":23313376,"re_id":9,"annotated sentence":"Furthermore, <e1>PTE<\\e1> treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of <e2>STAT3<\\e2>  PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PTE","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of <e2>GENE-Y<\\e2>  CHEMICAL also down-regulated the expression of GENE-Y target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","sentence":"Furthermore, PTE treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of STAT3  PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27"}
{"PMID":23313376,"re_id":10,"annotated sentence":"<e1>PTE<\\e1> also down-regulated the expression of <e2>STAT3<\\e2> target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PTE","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also down-regulated the expression of <e2>GENE-Y<\\e2> target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","sentence":"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27"}
{"PMID":23313376,"re_id":11,"annotated sentence":"<e1>PTE<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins <e2>Bcl-xL<\\e2> and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PTE","object":"Bcl-xL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins <e2>GENE-Y<\\e2> and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","sentence":"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27"}
{"PMID":23313376,"re_id":12,"annotated sentence":"<e1>PTE<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and <e2>Mcl-1<\\e2>  leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PTE","object":"Mcl-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and <e2>GENE-Y<\\e2>  leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27","sentence":"PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1  leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27"}
{"PMID":23313376,"re_id":13,"annotated sentence":"PTE, used in combination with a known <e2>JAK2<\\e2> STAT3 inhibitor, <e1>AG490<\\e1>  further decreased the viability of osteosarcoma cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AG490","object":"JAK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PTE, used in combination with a known <e2>GENE-Y<\\e2> STAT3 inhibitor, <e1>CHEMICAL<\\e1>  further decreased the viability of osteosarcoma cells","sentence":"PTE, used in combination with a known JAK2 STAT3 inhibitor, AG490  further decreased the viability of osteosarcoma cells"}
{"PMID":23313376,"re_id":14,"annotated sentence":"PTE, used in combination with a known JAK2\/<e2>STAT3<\\e2> inhibitor, <e1>AG490<\\e1>  further decreased the viability of osteosarcoma cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AG490","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PTE, used in combination with a known JAK2\/<e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  further decreased the viability of osteosarcoma cells","sentence":"PTE, used in combination with a known JAK2\/STAT3 inhibitor, AG490  further decreased the viability of osteosarcoma cells"}
{"PMID":23313376,"re_id":15,"annotated sentence":"Taken together, <e1>PTE<\\e1> is a potent inhibitor of osteosarcoma cell growth that targets the <e2>JAK2<\\e2> STAT3 signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PTE","object":"JAK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, <e1>CHEMICAL<\\e1> is a potent inhibitor of osteosarcoma cell growth that targets the <e2>GENE-Y<\\e2> STAT3 signaling pathway","sentence":"Taken together, PTE is a potent inhibitor of osteosarcoma cell growth that targets the JAK2 STAT3 signaling pathway"}
{"PMID":23313376,"re_id":16,"annotated sentence":"Taken together, <e1>PTE<\\e1> is a potent inhibitor of osteosarcoma cell growth that targets the JAK2\/<e2>STAT3<\\e2> signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PTE","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, <e1>CHEMICAL<\\e1> is a potent inhibitor of osteosarcoma cell growth that targets the JAK2\/<e2>GENE-Y<\\e2> signaling pathway","sentence":"Taken together, PTE is a potent inhibitor of osteosarcoma cell growth that targets the JAK2\/STAT3 signaling pathway"}
{"PMID":23313376,"re_id":17,"annotated sentence":"These data suggest that inhibition of <e2>JAK2<\\e2> STAT3 signaling is a novel mechanism of action for <e1>PTE<\\e1> during therapeutic intervention in osteosarcoma cancers.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PTE","object":"JAK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that inhibition of <e2>GENE-Y<\\e2> STAT3 signaling is a novel mechanism of action for <e1>CHEMICAL<\\e1> during therapeutic intervention in osteosarcoma cancers.","sentence":"These data suggest that inhibition of JAK2 STAT3 signaling is a novel mechanism of action for PTE during therapeutic intervention in osteosarcoma cancers."}
{"PMID":23313376,"re_id":18,"annotated sentence":"These data suggest that inhibition of JAK2\/<e2>STAT3<\\e2> signaling is a novel mechanism of action for <e1>PTE<\\e1> during therapeutic intervention in osteosarcoma cancers.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PTE","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that inhibition of JAK2\/<e2>GENE-Y<\\e2> signaling is a novel mechanism of action for <e1>CHEMICAL<\\e1> during therapeutic intervention in osteosarcoma cancers.","sentence":"These data suggest that inhibition of JAK2\/STAT3 signaling is a novel mechanism of action for PTE during therapeutic intervention in osteosarcoma cancers."}
{"PMID":23313557,"re_id":0,"annotated sentence":"In Alexander cells, only when they were transfected with FXR+RXR, <e1>GW4064<\\e1> caused up-regulation of <e2>SHP<\\e2> and OST\u03b2, and a down-regulation of CYP27A1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GW4064","object":"SHP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In Alexander cells, only when they were transfected with FXR+RXR, <e1>CHEMICAL<\\e1> caused up-regulation of <e2>GENE-Y<\\e2> and OST\u03b2, and a down-regulation of CYP27A1","sentence":"In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OST\u03b2, and a down-regulation of CYP27A1"}
{"PMID":23313557,"re_id":1,"annotated sentence":"In Alexander cells, only when they were transfected with FXR+RXR, <e1>GW4064<\\e1> caused up-regulation of SHP and <e2>OST\u03b2<\\e2>  and a down-regulation of CYP27A1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GW4064","object":"OST\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In Alexander cells, only when they were transfected with FXR+RXR, <e1>CHEMICAL<\\e1> caused up-regulation of SHP and <e2>GENE-Y<\\e2>  and a down-regulation of CYP27A1","sentence":"In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OST\u03b2  and a down-regulation of CYP27A1"}
{"PMID":23313557,"re_id":2,"annotated sentence":"Moreover, GCs have a synergistic effect on <e1>GW4064<\\e1> induced <e2>FXR<\\e2> activation, whereas chenodeoxycholate and GW4064 have an additive effect","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"GW4064","object":"FXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, GCs have a synergistic effect on <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> activation, whereas chenodeoxycholate and CHEMICAL have an additive effect","sentence":"Moreover, GCs have a synergistic effect on GW4064 induced FXR activation, whereas chenodeoxycholate and GW4064 have an additive effect"}
{"PMID":23313557,"re_id":3,"annotated sentence":"In Alexander cells, only when they were transfected with FXR+RXR, <e1>GW4064<\\e1> caused up-regulation of SHP and OST\u03b2, and a down-regulation of <e2>CYP27A1<\\e2>  GCs had the opposite effect on these genes, both in the absence and in the presence of FXR expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GW4064","object":"CYP27A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In Alexander cells, only when they were transfected with FXR+RXR, <e1>CHEMICAL<\\e1> caused up-regulation of SHP and OST\u03b2, and a down-regulation of <e2>GENE-Y<\\e2>  GCs had the opposite effect on these genes, both in the absence and in the presence of FXR expression","sentence":"In Alexander cells, only when they were transfected with FXR+RXR, GW4064 caused up-regulation of SHP and OST\u03b2, and a down-regulation of CYP27A1  GCs had the opposite effect on these genes, both in the absence and in the presence of FXR expression"}
{"PMID":23313794,"re_id":0,"annotated sentence":"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) <e1>PhIP<\\e1> at the doses of 10mg\/kg and\/or 15mg\/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and <e2>c-jun<\\e2> expression relative to control","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PhIP","object":"c-jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With the elevated doses of CHEMICAL, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) <e1>CHEMICAL<\\e1> at the doses of 10mg\/kg and\/or 15mg\/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and <e2>GENE-Y<\\e2> expression relative to control","sentence":"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg\/kg and\/or 15mg\/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control"}
{"PMID":23313794,"re_id":1,"annotated sentence":"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) <e1>PhIP<\\e1> at the doses of 10mg\/kg and\/or 15mg\/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced <e2>c-fos<\\e2> and c-jun expression relative to control","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PhIP","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With the elevated doses of CHEMICAL, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) <e1>CHEMICAL<\\e1> at the doses of 10mg\/kg and\/or 15mg\/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced <e2>GENE-Y<\\e2> and c-jun expression relative to control","sentence":"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg\/kg and\/or 15mg\/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control"}
{"PMID":23313794,"re_id":2,"annotated sentence":"The data indicated that <e1>PhIP<\\e1> could cause stomach injury, oxidative stress in rat stomachs as well as the activation of <e2>c-fos<\\e2> and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PhIP","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The data indicated that <e1>CHEMICAL<\\e1> could cause stomach injury, oxidative stress in rat stomachs as well as the activation of <e2>GENE-Y<\\e2> and c-jun and inactivation of p16, which may play a role in the pathogenesis of CHEMICAL-associated stomach cancer.","sentence":"The data indicated that PhIP could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer."}
{"PMID":23313794,"re_id":3,"annotated sentence":"The data indicated that <e1>PhIP<\\e1> could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and <e2>c-jun<\\e2> and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PhIP","object":"c-jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The data indicated that <e1>CHEMICAL<\\e1> could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and <e2>GENE-Y<\\e2> and inactivation of p16, which may play a role in the pathogenesis of CHEMICAL-associated stomach cancer.","sentence":"The data indicated that PhIP could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer."}
{"PMID":23313794,"re_id":4,"annotated sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <e1>PhIP<\\e1> (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased <e2>catalase<\\e2> (CAT) activity compared with the control","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PhIP","object":"catalase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that (1) 15mg\/kg body weight CHEMICAL induced obvious histopathological changes in gastric mucosa; (2) <e1>CHEMICAL<\\e1> (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased <e2>GENE-Y<\\e2> (CAT) activity compared with the control","sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control"}
{"PMID":23313794,"re_id":5,"annotated sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <e1>PhIP<\\e1> (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (<e2>CAT<\\e2>  activity compared with the control","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PhIP","object":"CAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that (1) 15mg\/kg body weight CHEMICAL induced obvious histopathological changes in gastric mucosa; (2) <e1>CHEMICAL<\\e1> (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (<e2>GENE-Y<\\e2>  activity compared with the control","sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT  activity compared with the control"}
{"PMID":23313794,"re_id":6,"annotated sentence":"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) <e1>PhIP<\\e1> at the doses of 10mg\/kg and\/or 15mg\/kg significantly inhibited <e2>p16<\\e2> mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PhIP","object":"p16","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With the elevated doses of CHEMICAL, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) <e1>CHEMICAL<\\e1> at the doses of 10mg\/kg and\/or 15mg\/kg significantly inhibited <e2>GENE-Y<\\e2> mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control","sentence":"With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg\/kg and\/or 15mg\/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control"}
{"PMID":23313794,"re_id":7,"annotated sentence":"The data indicated that <e1>PhIP<\\e1> could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of <e2>p16<\\e2>  which may play a role in the pathogenesis of PhIP-associated stomach cancer.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PhIP","object":"p16","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The data indicated that <e1>CHEMICAL<\\e1> could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of <e2>GENE-Y<\\e2>  which may play a role in the pathogenesis of CHEMICAL-associated stomach cancer.","sentence":"The data indicated that PhIP could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of p16  which may play a role in the pathogenesis of PhIP-associated stomach cancer."}
{"PMID":23313794,"re_id":8,"annotated sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <e1>PhIP<\\e1> (10 and\/or 15mg\/kg) significantly decreased <e2>superoxide dismutase<\\e2> (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PhIP","object":"superoxide dismutase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results showed that (1) 15mg\/kg body weight CHEMICAL induced obvious histopathological changes in gastric mucosa; (2) <e1>CHEMICAL<\\e1> (10 and\/or 15mg\/kg) significantly decreased <e2>GENE-N<\\e2> (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control","sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control"}
{"PMID":23313794,"re_id":9,"annotated sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <e1>PhIP<\\e1> (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (<e2>SOD<\\e2>  and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PhIP","object":"SOD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results showed that (1) 15mg\/kg body weight CHEMICAL induced obvious histopathological changes in gastric mucosa; (2) <e1>CHEMICAL<\\e1> (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (<e2>GENE-N<\\e2>  and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control","sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD  and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control"}
{"PMID":23313794,"re_id":10,"annotated sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <e1>PhIP<\\e1> (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and <e2>glutathioneperoxidase<\\e2> (GPx) activities, while increased catalase (CAT) activity compared with the control","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PhIP","object":"glutathioneperoxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results showed that (1) 15mg\/kg body weight CHEMICAL induced obvious histopathological changes in gastric mucosa; (2) <e1>CHEMICAL<\\e1> (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and <e2>GENE-N<\\e2> (GPx) activities, while increased catalase (CAT) activity compared with the control","sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control"}
{"PMID":23313794,"re_id":11,"annotated sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) <e1>PhIP<\\e1> (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (<e2>GPx<\\e2>  activities, while increased catalase (CAT) activity compared with the control","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PhIP","object":"GPx","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results showed that (1) 15mg\/kg body weight CHEMICAL induced obvious histopathological changes in gastric mucosa; (2) <e1>CHEMICAL<\\e1> (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (<e2>GENE-N<\\e2>  activities, while increased catalase (CAT) activity compared with the control","sentence":"The results showed that (1) 15mg\/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and\/or 15mg\/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx  activities, while increased catalase (CAT) activity compared with the control"}
{"PMID":23314320,"re_id":0,"annotated sentence":"military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective <e2>acetylcholinesterase<\\e2> reactivator, <e1>1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate<\\e1> (MMB-4)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective <e2>GENE-Y<\\e2> reactivator, <e1>CHEMICAL<\\e1> (MMB-4)","sentence":"military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective acetylcholinesterase reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate (MMB-4)"}
{"PMID":23314320,"re_id":1,"annotated sentence":"military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective <e2>acetylcholinesterase<\\e2> reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate (<e1>MMB-4<\\e1> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MMB-4","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective <e2>GENE-Y<\\e2> reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate (<e1>CHEMICAL<\\e1> ","sentence":"military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective acetylcholinesterase reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate (MMB-4 "}
{"PMID":23315277,"re_id":0,"annotated sentence":"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to <e1>SiO(2)<\\e1> NPs, the messenger RNA level of apoptotic genes (<e2>caspase-3<\\e2> and caspase-9) were upregulated in a dose-dependent manner","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SiO(2)","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to <e1>CHEMICAL<\\e1> NPs, the messenger RNA level of apoptotic genes (<e2>GENE-Y<\\e2> and caspase-9) were upregulated in a dose-dependent manner","sentence":"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to SiO(2) NPs, the messenger RNA level of apoptotic genes (caspase-3 and caspase-9) were upregulated in a dose-dependent manner"}
{"PMID":23315277,"re_id":1,"annotated sentence":"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to <e1>SiO(2)<\\e1> NPs, the messenger RNA level of apoptotic genes (caspase-3 and <e2>caspase-9<\\e2>  were upregulated in a dose-dependent manner","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SiO(2)","object":"caspase-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to <e1>CHEMICAL<\\e1> NPs, the messenger RNA level of apoptotic genes (caspase-3 and <e2>GENE-Y<\\e2>  were upregulated in a dose-dependent manner","sentence":"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to SiO(2) NPs, the messenger RNA level of apoptotic genes (caspase-3 and caspase-9  were upregulated in a dose-dependent manner"}
{"PMID":23315277,"re_id":2,"annotated sentence":"Moreover, activities of <e2>caspase-3<\\e2> and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to <e1>SiO(2)<\\e1> NPs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SiO(2)","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, activities of <e2>GENE-Y<\\e2> and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to <e1>CHEMICAL<\\e1> NPs","sentence":"Moreover, activities of caspase-3 and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to SiO(2) NPs"}
{"PMID":23315277,"re_id":3,"annotated sentence":"Moreover, activities of caspase-3 and <e2>caspase-9<\\e2> enzymes were also significantly higher in both kinds of cells exposed to <e1>SiO(2)<\\e1> NPs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SiO(2)","object":"caspase-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, activities of caspase-3 and <e2>GENE-Y<\\e2> enzymes were also significantly higher in both kinds of cells exposed to <e1>CHEMICAL<\\e1> NPs","sentence":"Moreover, activities of caspase-3 and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to SiO(2) NPs"}
{"PMID":23315644,"re_id":0,"annotated sentence":"The mouse <e2>CYP2J<\\e2> subfamily includes members that have wide tissue distribution and are active in the metabolism of <e1>arachidonic acid<\\e1> (AA), linoleic acid (LA), and other lipids and xenobiotics","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"CYP2J","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The mouse <e2>GENE-N<\\e2> subfamily includes members that have wide tissue distribution and are active in the metabolism of <e1>CHEMICAL<\\e1> (AA), linoleic acid (LA), and other lipids and xenobiotics","sentence":"The mouse CYP2J subfamily includes members that have wide tissue distribution and are active in the metabolism of arachidonic acid (AA), linoleic acid (LA), and other lipids and xenobiotics"}
{"PMID":23315644,"re_id":1,"annotated sentence":"The mouse <e2>CYP2J<\\e2> subfamily includes members that have wide tissue distribution and are active in the metabolism of arachidonic acid (AA), <e1>linoleic acid<\\e1> (LA), and other lipids and xenobiotics","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"linoleic acid","object":"CYP2J","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The mouse <e2>GENE-N<\\e2> subfamily includes members that have wide tissue distribution and are active in the metabolism of arachidonic acid (AA), <e1>CHEMICAL<\\e1> (LA), and other lipids and xenobiotics","sentence":"The mouse CYP2J subfamily includes members that have wide tissue distribution and are active in the metabolism of arachidonic acid (AA), linoleic acid (LA), and other lipids and xenobiotics"}
{"PMID":23316965,"re_id":0,"annotated sentence":"Particularly, the effects of <e1>doxycycline<\\e1> used as a non selective <e2>MMP<\\e2> inhibitor in experimental and clinical studies will be discussed.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"doxycycline","object":"MMP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Particularly, the effects of <e1>CHEMICAL<\\e1> used as a non selective <e2>GENE-N<\\e2> inhibitor in experimental and clinical studies will be discussed.","sentence":"Particularly, the effects of doxycycline used as a non selective MMP inhibitor in experimental and clinical studies will be discussed."}
{"PMID":23318471,"re_id":0,"annotated sentence":"Functional and biochemical studies indicated that <e1>TES<\\e1> signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the <e2>androgen receptor<\\e2> and culminated in enhanced production of cGMP and microvascular vasodilation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TES","object":"androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Functional and biochemical studies indicated that <e1>CHEMICAL<\\e1> signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the <e2>GENE-Y<\\e2> and culminated in enhanced production of cGMP and microvascular vasodilation","sentence":"Functional and biochemical studies indicated that TES signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation"}
{"PMID":23318471,"re_id":1,"annotated sentence":"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by <e1>peroxynitrite<\\e1> formed from <e2>xanthine oxidase<\\e2> generated superoxide and NO","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"peroxynitrite","object":"xanthine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by <e1>CHEMICAL<\\e1> formed from <e2>GENE-Y<\\e2> generated superoxide and NO","sentence":"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from xanthine oxidase generated superoxide and NO"}
{"PMID":23318471,"re_id":2,"annotated sentence":"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from <e2>xanthine oxidase<\\e2> generated <e1>superoxide<\\e1> and NO","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"superoxide","object":"xanthine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from <e2>GENE-Y<\\e2> generated <e1>CHEMICAL<\\e1> and NO","sentence":"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from xanthine oxidase generated superoxide and NO"}
{"PMID":23318471,"re_id":3,"annotated sentence":"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from <e2>xanthine oxidase<\\e2> generated superoxide and <e1>NO<\\e1>  This response was associated with activation of the PI3 kinase-Akt signaling cascade initiated by activation of the androgen receptor","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"NO","object":"xanthine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from <e2>GENE-Y<\\e2> generated superoxide and <e1>CHEMICAL<\\e1>  This response was associated with activation of the PI3 kinase-Akt signaling cascade initiated by activation of the androgen receptor","sentence":"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from xanthine oxidase generated superoxide and NO  This response was associated with activation of the PI3 kinase-Akt signaling cascade initiated by activation of the androgen receptor"}
{"PMID":23318471,"re_id":4,"annotated sentence":"As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and <e2>xanthine oxidase<\\e2> was identified as the likely source of <e1>TES<\\e1> stimulated superoxide production","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"TES","object":"xanthine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As predicted, CHEMICAL enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and <e2>GENE-Y<\\e2> was identified as the likely source of <e1>CHEMICAL<\\e1> stimulated superoxide production","sentence":"As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and xanthine oxidase was identified as the likely source of TES stimulated superoxide production"}
{"PMID":23318471,"re_id":5,"annotated sentence":"As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and <e2>xanthine oxidase<\\e2> was identified as the likely source of TES-stimulated <e1>superoxide<\\e1> production","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"superoxide","object":"xanthine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., CHEMICAL and nitic oxide), and <e2>GENE-Y<\\e2> was identified as the likely source of TES-stimulated <e1>CHEMICAL<\\e1> production","sentence":"As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and xanthine oxidase was identified as the likely source of TES-stimulated superoxide production"}
{"PMID":23318726,"re_id":0,"annotated sentence":"<e1>Butein<\\e1> also increased <e2>heme oxygenase-1<\\e2> (HO-1) protein expression and HO activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Butein","object":"heme oxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also increased <e2>GENE-Y<\\e2> (HO-1) protein expression and HO activity","sentence":"Butein also increased heme oxygenase-1 (HO-1) protein expression and HO activity"}
{"PMID":23318726,"re_id":1,"annotated sentence":"<e1>Butein<\\e1> also increased heme oxygenase-1 (<e2>HO-1<\\e2>  protein expression and HO activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Butein","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also increased heme oxygenase-1 (<e2>GENE-Y<\\e2>  protein expression and HO activity","sentence":"Butein also increased heme oxygenase-1 (HO-1  protein expression and HO activity"}
{"PMID":23318726,"re_id":2,"annotated sentence":"<e1>Butein<\\e1> also increased heme oxygenase-1 (HO-1) protein expression and <e2>HO<\\e2> activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Butein","object":"HO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also increased heme oxygenase-1 (GENE-Y-1) protein expression and <e2>GENE-Y<\\e2> activity","sentence":"Butein also increased heme oxygenase-1 (HO-1) protein expression and HO activity"}
{"PMID":23318726,"re_id":3,"annotated sentence":"Furthermore, <e1>butein<\\e1> treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of <e2>antioxidant response elements<\\e2> (AREs)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"butein","object":"antioxidant response elements","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of <e2>GENE-N<\\e2> (AREs)","sentence":"Furthermore, butein treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of antioxidant response elements (AREs)"}
{"PMID":23318726,"re_id":4,"annotated sentence":"Furthermore, <e1>butein<\\e1> treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of antioxidant response elements (<e2>AREs<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"butein","object":"AREs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of antioxidant response elements (<e2>GENE-N<\\e2> ","sentence":"Furthermore, butein treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of antioxidant response elements (AREs "}
{"PMID":23318726,"re_id":5,"annotated sentence":"Furthermore, <e1>butein<\\e1> treatment caused nuclear accumulation of <e2>nuclear factor-E2-related factor 2<\\e2> (Nrf2) and increased the promoter activity of antioxidant response elements (AREs)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"butein","object":"nuclear factor-E2-related factor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> treatment caused nuclear accumulation of <e2>GENE-Y<\\e2> (Nrf2) and increased the promoter activity of antioxidant response elements (AREs)","sentence":"Furthermore, butein treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of antioxidant response elements (AREs)"}
{"PMID":23318726,"re_id":6,"annotated sentence":"Furthermore, <e1>butein<\\e1> treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (<e2>Nrf2<\\e2>  and increased the promoter activity of antioxidant response elements (AREs)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"butein","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (<e2>GENE-Y<\\e2>  and increased the promoter activity of antioxidant response elements (AREs)","sentence":"Furthermore, butein treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2  and increased the promoter activity of antioxidant response elements (AREs)"}
{"PMID":23318726,"re_id":7,"annotated sentence":"Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced <e1>butein<\\e1> induced <e2>HO-1<\\e2> expression, and butein treatment led to increased JNK phosphorylation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"butein","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> expression, and CHEMICAL treatment led to increased JNK phosphorylation","sentence":"Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced butein induced HO-1 expression, and butein treatment led to increased JNK phosphorylation"}
{"PMID":23318726,"re_id":8,"annotated sentence":"Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced butein-induced HO-1 expression, and <e1>butein<\\e1> treatment led to increased <e2>JNK<\\e2> phosphorylation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"butein","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment of HDP cells with a c-Jun NH2-terminal kinase (GENE-N) inhibitor also reduced CHEMICAL-induced HO-1 expression, and <e1>CHEMICAL<\\e1> treatment led to increased <e2>GENE-N<\\e2> phosphorylation","sentence":"Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced butein-induced HO-1 expression, and butein treatment led to increased JNK phosphorylation"}
{"PMID":23322769,"re_id":0,"annotated sentence":"Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor <e1>manumycin A<\\e1> caused elevation of <e2>ApoA-I<\\e2> secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"manumycin A","object":"ApoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor <e1>CHEMICAL<\\e1> caused elevation of <e2>GENE-Y<\\e2> secretion from hepatocytes and from transgenic mice expressing hGENE-Y and cholesterol ester transfer protein transgenes","sentence":"Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor manumycin A caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes"}
{"PMID":23322769,"re_id":1,"annotated sentence":"Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor <e1>manumycin A<\\e1> caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing <e2>hApoA-I<\\e2> and cholesterol ester transfer protein transgenes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"manumycin A","object":"hApoA-I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor <e1>CHEMICAL<\\e1> caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing <e2>GENE-Y<\\e2> and cholesterol ester transfer protein transgenes","sentence":"Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor manumycin A caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes"}
{"PMID":23322769,"re_id":2,"annotated sentence":"Repression of <e2>farnesyltransferase<\\e2> (FNTA) by siRNA and the enzyme inhibitor <e1>manumycin A<\\e1> caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"manumycin A","object":"farnesyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Repression of <e2>GENE-Y<\\e2> (FNTA) by siRNA and the enzyme inhibitor <e1>CHEMICAL<\\e1> caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes","sentence":"Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor manumycin A caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes"}
{"PMID":23322769,"re_id":3,"annotated sentence":"Repression of farnesyltransferase (<e2>FNTA<\\e2>  by siRNA and the enzyme inhibitor <e1>manumycin A<\\e1> caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"manumycin A","object":"FNTA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Repression of farnesyltransferase (<e2>GENE-Y<\\e2>  by siRNA and the enzyme inhibitor <e1>CHEMICAL<\\e1> caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes","sentence":"Repression of farnesyltransferase (FNTA  by siRNA and the enzyme inhibitor manumycin A caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes"}
{"PMID":23325562,"re_id":0,"annotated sentence":"Interestingly, <e1>ursolic acid<\\e1> increased the phosphorylation of <e2>AMPK<\\e2> and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> increased the phosphorylation of <e2>GENE-N<\\e2> and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas CHEMICAL attenuated the phosphorylation of AKT and mTOR in HepG2 cells","sentence":"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells"}
{"PMID":23325562,"re_id":1,"annotated sentence":"Interestingly, <e1>ursolic acid<\\e1> increased the phosphorylation of AMPK and <e2>coenzyme A carboxylase<\\e2> and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"coenzyme A carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> increased the phosphorylation of AMPK and <e2>GENE-N<\\e2> and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas CHEMICAL attenuated the phosphorylation of AKT and mTOR in HepG2 cells","sentence":"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells"}
{"PMID":23325562,"re_id":2,"annotated sentence":"Interestingly, <e1>ursolic acid<\\e1> increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of <e2>GSK3\u03b2<\\e2> at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"GSK3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of <e2>GENE-Y<\\e2> at inactive form serine 9, whereas CHEMICAL attenuated the phosphorylation of AKT and mTOR in HepG2 cells","sentence":"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells"}
{"PMID":23325562,"re_id":3,"annotated sentence":"Activation of <e2>AMP-activated Protein Kinase<\\e2> and Phosphorylation of Glycogen Synthase Kinase3 \u03b2 Mediate <e1>Ursolic Acid<\\e1> Induced Apoptosis in HepG2 Liver Cancer Cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ursolic Acid","object":"AMP-activated Protein Kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Activation of <e2>GENE-N<\\e2> and Phosphorylation of Glycogen Synthase Kinase3 \u03b2 Mediate <e1>CHEMICAL<\\e1> Induced Apoptosis in HepG2 Liver Cancer Cells","sentence":"Activation of AMP-activated Protein Kinase and Phosphorylation of Glycogen Synthase Kinase3 \u03b2 Mediate Ursolic Acid Induced Apoptosis in HepG2 Liver Cancer Cells"}
{"PMID":23325562,"re_id":4,"annotated sentence":"Activation of AMP-activated Protein Kinase and Phosphorylation of <e2>Glycogen Synthase Kinase3 \u03b2<\\e2> Mediate <e1>Ursolic Acid<\\e1> Induced Apoptosis in HepG2 Liver Cancer Cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ursolic Acid","object":"Glycogen Synthase Kinase3 \u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of AMP-activated Protein Kinase and Phosphorylation of <e2>GENE-Y<\\e2> Mediate <e1>CHEMICAL<\\e1> Induced Apoptosis in HepG2 Liver Cancer Cells","sentence":"Activation of AMP-activated Protein Kinase and Phosphorylation of Glycogen Synthase Kinase3 \u03b2 Mediate Ursolic Acid Induced Apoptosis in HepG2 Liver Cancer Cells"}
{"PMID":23325562,"re_id":5,"annotated sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of <e2>PARP<\\e2> and caspase 3 induced by <e1>ursolic acid<\\e1> in HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"PARP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of <e2>GENE-N<\\e2> and caspase 3 induced by <e1>CHEMICAL<\\e1> in HepG2 cells","sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":6,"annotated sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and <e2>caspase 3<\\e2> induced by <e1>ursolic acid<\\e1> in HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and <e2>GENE-Y<\\e2> induced by <e1>CHEMICAL<\\e1> in HepG2 cells","sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":7,"annotated sentence":"Furthermore, proteosomal inhibitor <e1>MG132<\\e1> suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased <e2>AEG-1<\\e2> induced by ursolic acid in HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MG132","object":"AEG-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, proteosomal inhibitor <e1>CHEMICAL<\\e1> suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased <e2>GENE-Y<\\e2> induced by ursolic acid in HepG2 cells","sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":8,"annotated sentence":"Furthermore, proteosomal inhibitor MG132 suppressed <e2>AMPK<\\e2> activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by <e1>ursolic acid<\\e1> in HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, proteosomal inhibitor MG132 suppressed <e2>GENE-N<\\e2> activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by <e1>CHEMICAL<\\e1> in HepG2 cells","sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":9,"annotated sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, <e2>GSK3\u03b2<\\e2> phosphorylation, cleaved PARP and deceased AEG-1 induced by <e1>ursolic acid<\\e1> in HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"GSK3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, <e2>GENE-Y<\\e2> phosphorylation, cleaved PARP and deceased AEG-1 induced by <e1>CHEMICAL<\\e1> in HepG2 cells","sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":10,"annotated sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased <e2>AEG-1<\\e2> induced by <e1>ursolic acid<\\e1> in HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"AEG-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased <e2>GENE-Y<\\e2> induced by <e1>CHEMICAL<\\e1> in HepG2 cells","sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":11,"annotated sentence":"Overall, our findings suggest that <e1>ursolic acid<\\e1> induced apoptosis in HepG2 cells via <e2>AMPK<\\e2> activation and GSK3\u03b2 phosphorylation as a potent chemopreventive agent","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Overall, our findings suggest that <e1>CHEMICAL<\\e1> induced apoptosis in HepG2 cells via <e2>GENE-N<\\e2> activation and GSK3\u03b2 phosphorylation as a potent chemopreventive agent","sentence":"Overall, our findings suggest that ursolic acid induced apoptosis in HepG2 cells via AMPK activation and GSK3\u03b2 phosphorylation as a potent chemopreventive agent"}
{"PMID":23325562,"re_id":12,"annotated sentence":"Overall, our findings suggest that <e1>ursolic acid<\\e1> induced apoptosis in HepG2 cells via AMPK activation and <e2>GSK3\u03b2<\\e2> phosphorylation as a potent chemopreventive agent","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"GSK3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Overall, our findings suggest that <e1>CHEMICAL<\\e1> induced apoptosis in HepG2 cells via AMPK activation and <e2>GENE-Y<\\e2> phosphorylation as a potent chemopreventive agent","sentence":"Overall, our findings suggest that ursolic acid induced apoptosis in HepG2 cells via AMPK activation and GSK3\u03b2 phosphorylation as a potent chemopreventive agent"}
{"PMID":23325562,"re_id":13,"annotated sentence":"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas <e1>ursolic acid<\\e1> attenuated the phosphorylation of <e2>AKT<\\e2> and mTOR in HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, CHEMICAL increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas <e1>CHEMICAL<\\e1> attenuated the phosphorylation of <e2>GENE-N<\\e2> and mTOR in HepG2 cells","sentence":"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells"}
{"PMID":23325562,"re_id":14,"annotated sentence":"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas <e1>ursolic acid<\\e1> attenuated the phosphorylation of AKT and <e2>mTOR<\\e2> in HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, CHEMICAL increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas <e1>CHEMICAL<\\e1> attenuated the phosphorylation of AKT and <e2>GENE-Y<\\e2> in HepG2 cells","sentence":"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells"}
{"PMID":23325562,"re_id":15,"annotated sentence":"Conversely, AMPK inhibitor <e1>compound C<\\e1> or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and <e2>caspase 3<\\e2> induced by ursolic acid in HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"compound C","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Conversely, AMPK inhibitor <e1>CHEMICAL<\\e1> or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and <e2>GENE-Y<\\e2> induced by ursolic acid in HepG2 cells","sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":16,"annotated sentence":"Conversely, <e2>AMPK<\\e2> inhibitor <e1>compound C<\\e1> or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"compound C","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Conversely, <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells","sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":17,"annotated sentence":"Conversely, AMPK inhibitor compound C or <e2>GSK3\u03b2<\\e2> inhibitor <e1>SB216763<\\e1> blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB216763","object":"GSK3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Conversely, AMPK inhibitor compound C or <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells","sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":18,"annotated sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor <e1>SB216763<\\e1> blocked the cleavages of PARP and <e2>caspase 3<\\e2> induced by ursolic acid in HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB216763","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor <e1>CHEMICAL<\\e1> blocked the cleavages of PARP and <e2>GENE-Y<\\e2> induced by ursolic acid in HepG2 cells","sentence":"Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":19,"annotated sentence":"Furthermore, proteosomal inhibitor <e1>MG132<\\e1> suppressed <e2>AMPK<\\e2> activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MG132","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, proteosomal inhibitor <e1>CHEMICAL<\\e1> suppressed <e2>GENE-N<\\e2> activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells","sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":20,"annotated sentence":"Furthermore, proteosomal inhibitor <e1>MG132<\\e1> suppressed AMPK activation, <e2>GSK3\u03b2<\\e2> phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MG132","object":"GSK3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, proteosomal inhibitor <e1>CHEMICAL<\\e1> suppressed AMPK activation, <e2>GENE-Y<\\e2> phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells","sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells"}
{"PMID":23325562,"re_id":21,"annotated sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased <e2>AEG-1<\\e2> induced by <e1>ursolic acid<\\e1> in HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ursolic acid","object":"AEG-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased <e2>GENE-Y<\\e2> induced by <e1>CHEMICAL<\\e1> in HepG2 cells","sentence":"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells"}
{"PMID":23327877,"re_id":0,"annotated sentence":"Uptake of the radiolabeled model substrates <e1>estradiol 17\u03b2-glucuronide<\\e1>  estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>OATP1B1<\\e2> or OATP1B3","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"estradiol 17\u03b2-glucuronide","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Uptake of the radiolabeled model substrates <e1>CHEMICAL<\\e1>  estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>GENE-Y<\\e2> or OATP1B3","sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide  estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3"}
{"PMID":23327877,"re_id":1,"annotated sentence":"Uptake of the radiolabeled model substrates <e1>estradiol 17\u03b2-glucuronide<\\e1>  estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>OATP1B3<\\e2>  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"estradiol 17\u03b2-glucuronide","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Uptake of the radiolabeled model substrates <e1>CHEMICAL<\\e1>  estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>GENE-Y<\\e2>  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates","sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide  estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates"}
{"PMID":23327877,"re_id":2,"annotated sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, <e1>estrone 3-sulfate<\\e1>  and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>OATP1B1<\\e2> or OATP1B3","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"estrone 3-sulfate","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, <e1>CHEMICAL<\\e1>  and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>GENE-Y<\\e2> or OATP1B3","sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate  and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3"}
{"PMID":23327877,"re_id":3,"annotated sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, <e1>estrone 3-sulfate<\\e1>  and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>OATP1B3<\\e2>  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"estrone 3-sulfate","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, <e1>CHEMICAL<\\e1>  and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>GENE-Y<\\e2>  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates","sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate  and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates"}
{"PMID":23327877,"re_id":4,"annotated sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and <e1>dehydroepiandrosterone sulfate<\\e1> (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>OATP1B1<\\e2> or OATP1B3","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dehydroepiandrosterone sulfate","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and <e1>CHEMICAL<\\e1> (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>GENE-Y<\\e2> or OATP1B3","sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3"}
{"PMID":23327877,"re_id":5,"annotated sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and <e1>dehydroepiandrosterone sulfate<\\e1> (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>OATP1B3<\\e2>  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dehydroepiandrosterone sulfate","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and <e1>CHEMICAL<\\e1> (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>GENE-Y<\\e2>  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates","sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates"}
{"PMID":23327877,"re_id":6,"annotated sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (<e1>DHEAS<\\e1>  was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>OATP1B1<\\e2> or OATP1B3","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DHEAS","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (<e1>CHEMICAL<\\e1>  was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>GENE-Y<\\e2> or OATP1B3","sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS  was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3"}
{"PMID":23327877,"re_id":7,"annotated sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (<e1>DHEAS<\\e1>  was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>OATP1B3<\\e2>  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DHEAS","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (<e1>CHEMICAL<\\e1>  was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>GENE-Y<\\e2>  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates","sentence":"Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS  was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3  Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates"}
{"PMID":23327877,"re_id":8,"annotated sentence":"Compound 6 stimulated OATP1B3-mediated <e1>estradiol 17\u03b2-glucuronide<\\e1> uptake by increasing the apparent affinity of <e2>OATP1B3<\\e2> for its substrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"estradiol 17\u03b2-glucuronide","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compound 6 stimulated GENE-Y-mediated <e1>CHEMICAL<\\e1> uptake by increasing the apparent affinity of <e2>GENE-Y<\\e2> for its substrate","sentence":"Compound 6 stimulated OATP1B3-mediated estradiol 17\u03b2-glucuronide uptake by increasing the apparent affinity of OATP1B3 for its substrate"}
{"PMID":23327877,"re_id":9,"annotated sentence":"Compound 6 stimulated <e2>OATP1B3<\\e2> mediated <e1>estradiol 17\u03b2-glucuronide<\\e1> uptake by increasing the apparent affinity of OATP1B3 for its substrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"estradiol 17\u03b2-glucuronide","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compound 6 stimulated <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> uptake by increasing the apparent affinity of GENE-Y for its substrate","sentence":"Compound 6 stimulated OATP1B3 mediated estradiol 17\u03b2-glucuronide uptake by increasing the apparent affinity of OATP1B3 for its substrate"}
{"PMID":23327877,"re_id":10,"annotated sentence":"Transport by <e2>OATP1B1<\\e2> and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several <e1>quercetin<\\e1> derivatives","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"quercetin","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Transport by <e2>GENE-Y<\\e2> and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several <e1>CHEMICAL<\\e1> derivatives","sentence":"Transport by OATP1B1 and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several quercetin derivatives"}
{"PMID":23327877,"re_id":11,"annotated sentence":"Transport by OATP1B1 and <e2>OATP1B3<\\e2> enhances the cytotoxicity of epigallocatechin 3-O-gallate and several <e1>quercetin<\\e1> derivatives","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"quercetin","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Transport by OATP1B1 and <e2>GENE-Y<\\e2> enhances the cytotoxicity of epigallocatechin 3-O-gallate and several <e1>CHEMICAL<\\e1> derivatives","sentence":"Transport by OATP1B1 and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several quercetin derivatives"}
{"PMID":23327877,"re_id":12,"annotated sentence":"Transport by <e2>OATP1B1<\\e2> and OATP1B3 enhances the cytotoxicity of <e1>epigallocatechin 3-O-gallate<\\e1> and several quercetin derivatives","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"epigallocatechin 3-O-gallate","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Transport by <e2>GENE-Y<\\e2> and OATP1B3 enhances the cytotoxicity of <e1>CHEMICAL<\\e1> and several quercetin derivatives","sentence":"Transport by OATP1B1 and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several quercetin derivatives"}
{"PMID":23327877,"re_id":13,"annotated sentence":"Transport by OATP1B1 and <e2>OATP1B3<\\e2> enhances the cytotoxicity of <e1>epigallocatechin 3-O-gallate<\\e1> and several quercetin derivatives","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"epigallocatechin 3-O-gallate","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Transport by OATP1B1 and <e2>GENE-Y<\\e2> enhances the cytotoxicity of <e1>CHEMICAL<\\e1> and several quercetin derivatives","sentence":"Transport by OATP1B1 and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several quercetin derivatives"}
{"PMID":23327877,"re_id":14,"annotated sentence":"Cytotoxicity assays demonstrated that <e1>epigallocatechin 3-O-gallate<\\e1> (EGCG) and most of compounds 1-6 killed preferentially <e2>OATP<\\e2> expressing CHO cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"epigallocatechin 3-O-gallate","object":"OATP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cytotoxicity assays demonstrated that <e1>CHEMICAL<\\e1> (EGCG) and most of compounds 1-6 killed preferentially <e2>GENE-N<\\e2> expressing CHO cells","sentence":"Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate (EGCG) and most of compounds 1-6 killed preferentially OATP expressing CHO cells"}
{"PMID":23327877,"re_id":15,"annotated sentence":"Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate (<e1>EGCG<\\e1>  and most of compounds 1-6 killed preferentially <e2>OATP<\\e2> expressing CHO cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"EGCG","object":"OATP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate (<e1>CHEMICAL<\\e1>  and most of compounds 1-6 killed preferentially <e2>GENE-N<\\e2> expressing CHO cells","sentence":"Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate (EGCG  and most of compounds 1-6 killed preferentially OATP expressing CHO cells"}
{"PMID":23327877,"re_id":16,"annotated sentence":"EGCG, 1, and 3 were the most potent cytotoxic compounds, with <e1>EGCG<\\e1> and 3 selectively killing <e2>OATP1B3<\\e2> expressing cells","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"EGCG","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICAL, 1, and 3 were the most potent cytotoxic compounds, with <e1>CHEMICAL<\\e1> and 3 selectively killing <e2>GENE-Y<\\e2> expressing cells","sentence":"EGCG, 1, and 3 were the most potent cytotoxic compounds, with EGCG and 3 selectively killing OATP1B3 expressing cells"}
{"PMID":23327993,"re_id":0,"annotated sentence":"The TXM peptides were effective in inhibiting <e1>AuF<\\e1> induced <e2>MAPK<\\e2>  JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AuF","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The TXM peptides were effective in inhibiting <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2>  JNK and p38(GENE-N) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation","sentence":"The TXM peptides were effective in inhibiting AuF induced MAPK  JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation"}
{"PMID":23327993,"re_id":1,"annotated sentence":"The TXM peptides were effective in inhibiting <e1>AuF<\\e1> induced MAPK, <e2>JNK<\\e2> and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AuF","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The TXM peptides were effective in inhibiting <e1>CHEMICAL<\\e1> induced MAPK, <e2>GENE-N<\\e2> and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation","sentence":"The TXM peptides were effective in inhibiting AuF induced MAPK, JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation"}
{"PMID":23327993,"re_id":2,"annotated sentence":"The TXM peptides were effective in inhibiting <e1>AuF<\\e1> induced MAPK, JNK and <e2>p38<\\e2> MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AuF","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The TXM peptides were effective in inhibiting <e1>CHEMICAL<\\e1> induced MAPK, JNK and <e2>GENE-N<\\e2> MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation","sentence":"The TXM peptides were effective in inhibiting AuF induced MAPK, JNK and p38 MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation"}
{"PMID":23327993,"re_id":3,"annotated sentence":"The TXM peptides were effective in inhibiting <e1>AuF<\\e1> induced MAPK, JNK and p38(<e2>MAPK<\\e2>  phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AuF","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The TXM peptides were effective in inhibiting <e1>CHEMICAL<\\e1> induced GENE-N, JNK and p38(<e2>GENE-N<\\e2>  phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation","sentence":"The TXM peptides were effective in inhibiting AuF induced MAPK, JNK and p38(MAPK  phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation"}
{"PMID":23327993,"re_id":4,"annotated sentence":"The Trx mimetics peptides (TXM) protected insulinoma INS 832\/13 cells from oxidative stress induced by selectively inhibiting <e2>TrxR<\\e2> with <e1>auranofin<\\e1> (AuF)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"auranofin","object":"TrxR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The Trx mimetics peptides (TXM) protected insulinoma INS 832\/13 cells from oxidative stress induced by selectively inhibiting <e2>GENE-N<\\e2> with <e1>CHEMICAL<\\e1> (AuF)","sentence":"The Trx mimetics peptides (TXM) protected insulinoma INS 832\/13 cells from oxidative stress induced by selectively inhibiting TrxR with auranofin (AuF)"}
{"PMID":23327993,"re_id":5,"annotated sentence":"The Trx mimetics peptides (TXM) protected insulinoma INS 832\/13 cells from oxidative stress induced by selectively inhibiting <e2>TrxR<\\e2> with auranofin (<e1>AuF<\\e1> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AuF","object":"TrxR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The Trx mimetics peptides (TXM) protected insulinoma INS 832\/13 cells from oxidative stress induced by selectively inhibiting <e2>GENE-N<\\e2> with auranofin (<e1>CHEMICAL<\\e1> ","sentence":"The Trx mimetics peptides (TXM) protected insulinoma INS 832\/13 cells from oxidative stress induced by selectively inhibiting TrxR with auranofin (AuF "}
{"PMID":23330542,"re_id":0,"annotated sentence":"Since the original discovery of <e1>azoles<\\e1> analogs as <e2>PXR<\\e2> antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"azoles","object":"PXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since the original discovery of <e1>CHEMICAL<\\e1> analogs as <e2>GENE-Y<\\e2> antagonists, we have preliminarily defined an important GENE-Y antagonist pharmacophore and developed less-toxic GENE-Y antagonists","sentence":"Since the original discovery of azoles analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists"}
{"PMID":23330542,"re_id":1,"annotated sentence":"Since the original discovery of <e1>azoles<\\e1> analogs as PXR antagonists, we have preliminarily defined an important <e2>PXR<\\e2> antagonist pharmacophore and developed less-toxic PXR antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"azoles","object":"PXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since the original discovery of <e1>CHEMICAL<\\e1> analogs as GENE-Y antagonists, we have preliminarily defined an important <e2>GENE-Y<\\e2> antagonist pharmacophore and developed less-toxic GENE-Y antagonists","sentence":"Since the original discovery of azoles analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists"}
{"PMID":23330542,"re_id":2,"annotated sentence":"Since the original discovery of <e1>azoles<\\e1> analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic <e2>PXR<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"azoles","object":"PXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since the original discovery of <e1>CHEMICAL<\\e1> analogs as GENE-Y antagonists, we have preliminarily defined an important GENE-Y antagonist pharmacophore and developed less-toxic <e2>GENE-Y<\\e2> antagonists","sentence":"Since the original discovery of azoles analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists"}
{"PMID":23333261,"re_id":0,"annotated sentence":"Moreover, <e1>curcumin<\\e1> alleviated <e2>Sim2<\\e2> expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"curcumin","object":"Sim2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> alleviated <e2>GENE-Y<\\e2> expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia","sentence":"Moreover, curcumin alleviated Sim2 expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia"}
{"PMID":23333261,"re_id":1,"annotated sentence":"Moreover, <e1>curcumin<\\e1> alleviated Sim2 expression, and reversely raised <e2>Drebrin<\\e2> expression in neurons treated with hyperglycaemia","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"curcumin","object":"Drebrin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> alleviated Sim2 expression, and reversely raised <e2>GENE-Y<\\e2> expression in neurons treated with hyperglycaemia","sentence":"Moreover, curcumin alleviated Sim2 expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia"}
{"PMID":23333261,"re_id":2,"annotated sentence":"It was found that expression of <e2>Sim2<\\e2> protein in cortical neurons was increased in <e1>streptozotocin<\\e1> induced diabetes mellitus rat model","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"streptozotocin","object":"Sim2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It was found that expression of <e2>GENE-Y<\\e2> protein in cortical neurons was increased in <e1>CHEMICAL<\\e1> induced diabetes mellitus rat model","sentence":"It was found that expression of Sim2 protein in cortical neurons was increased in streptozotocin induced diabetes mellitus rat model"}
{"PMID":23333577,"re_id":0,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of <e2>p21<\\e2> WAF1\/CIP1) and p53","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of <e2>GENE-Y<\\e2> WAF1\/CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21 WAF1\/CIP1) and p53"}
{"PMID":23333577,"re_id":1,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(<e2>WAF1<\\e2> CIP1) and p53","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"WAF1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(<e2>GENE-Y<\\e2> CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1 CIP1) and p53"}
{"PMID":23333577,"re_id":2,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/<e2>CIP1<\\e2>  and p53","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"CIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/<e2>GENE-Y<\\e2>  and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1  and p53"}
{"PMID":23333577,"re_id":3,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and <e2>p53<\\e2>  Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and <e2>GENE-Y<\\e2>  CHEMICAL was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53  Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway"}
{"PMID":23333577,"re_id":4,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of <e2>cyclin D1<\\e2>  cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"cyclin D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of <e2>GENE-Y<\\e2>  cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1  cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53"}
{"PMID":23333577,"re_id":5,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, <e2>cyclin E<\\e2>  cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"cyclin E","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, <e2>GENE-Y<\\e2>  cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E  cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53"}
{"PMID":23333577,"re_id":6,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, <e2>cyclin A<\\e2>  cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"cyclin A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, <e2>GENE-Y<\\e2>  cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A  cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53"}
{"PMID":23333577,"re_id":7,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, <e2>cyclin dependent kinase 2<\\e2> (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"cyclin dependent kinase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, <e2>GENE-Y<\\e2> (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53"}
{"PMID":23333577,"re_id":8,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (<e2>CDK2<\\e2> , CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"CDK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (<e2>GENE-Y<\\e2> , CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2 , CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53"}
{"PMID":23333577,"re_id":9,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), <e2>CDK4<\\e2>  c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"CDK4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), <e2>GENE-Y<\\e2>  c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4  c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53"}
{"PMID":23333577,"re_id":10,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, <e2>c-Myc<\\e2>  and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"c-Myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, <e2>GENE-Y<\\e2>  and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc  and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53"}
{"PMID":23333577,"re_id":11,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and <e2>retinoblastoma protein<\\e2> (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"retinoblastoma protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and <e2>GENE-Y<\\e2> (pRb), and the upregulation of p21(WAF1\/CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1\/CIP1) and p53"}
{"PMID":23333577,"re_id":12,"annotated sentence":"<e1>Pinosylvin<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (<e2>pRb<\\e2> , and the upregulation of p21(WAF1\/CIP1) and p53","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"pRb","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (<e2>GENE-Y<\\e2> , and the upregulation of p21(WAF1\/CIP1) and p53","sentence":"Pinosylvin inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb , and the upregulation of p21(WAF1\/CIP1) and p53"}
{"PMID":23333577,"re_id":13,"annotated sentence":"<e1>Pinosylvin<\\e1> was also found to attenuate the activation of proteins involved in f<e2>ocal adhesion kinase<\\e2> (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"ocal adhesion kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was also found to attenuate the activation of proteins involved in f<e2>GENE-Y<\\e2> (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","sentence":"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway"}
{"PMID":23333577,"re_id":14,"annotated sentence":"<e1>Pinosylvin<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (<e2>FAK<\\e2> \/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"FAK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (<e2>GENE-Y<\\e2> \/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","sentence":"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK \/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway"}
{"PMID":23333577,"re_id":15,"annotated sentence":"<e1>Pinosylvin<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/<e2>c-Src<\\e2> extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"c-Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/<e2>GENE-Y<\\e2> extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","sentence":"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway"}
{"PMID":23333577,"re_id":16,"annotated sentence":"<e1>Pinosylvin<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/<e2>extracellular signal-regulated kinase<\\e2> (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"extracellular signal-regulated kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/<e2>GENE-N<\\e2> (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","sentence":"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway"}
{"PMID":23333577,"re_id":17,"annotated sentence":"<e1>Pinosylvin<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (<e2>ERK<\\e2>  signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (<e2>GENE-N<\\e2>  signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","sentence":"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK  signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway"}
{"PMID":23333577,"re_id":18,"annotated sentence":"<e1>Pinosylvin<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and <e2>phosphoinositide 3-kinase<\\e2> (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"phosphoinositide 3-kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and <e2>GENE-N<\\e2> (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","sentence":"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway"}
{"PMID":23333577,"re_id":19,"annotated sentence":"<e1>Pinosylvin<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (<e2>PI3K<\\e2> \/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (<e2>GENE-N<\\e2> \/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","sentence":"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K \/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway"}
{"PMID":23333577,"re_id":20,"annotated sentence":"<e1>Pinosylvin<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/<e2>Akt<\\e2>  glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/<e2>GENE-N<\\e2>  glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway","sentence":"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt  glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway"}
{"PMID":23333577,"re_id":21,"annotated sentence":"<e1>Pinosylvin<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ <e2>glycogen synthase kinase 3\u03b2<\\e2> (GSK-3\u03b2) signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"glycogen synthase kinase 3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ <e2>GENE-Y<\\e2> (GSK-3\u03b2) signaling pathway","sentence":"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway"}
{"PMID":23333577,"re_id":22,"annotated sentence":"<e1>Pinosylvin<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (<e2>GSK-3\u03b2<\\e2>  signaling pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pinosylvin","object":"GSK-3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (<e2>GENE-Y<\\e2>  signaling pathway","sentence":"Pinosylvin was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)\/c-Src\/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)\/Akt\/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2  signaling pathway"}
{"PMID":23333577,"re_id":23,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of <e2>\u03b2-catenin<\\e2>  one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"\u03b2-catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of <e2>GENE-Y<\\e2>  one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of GENE-Y-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin  one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc"}
{"PMID":23333577,"re_id":24,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of <e2>PI3K<\\e2> Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of <e2>GENE-N<\\e2> Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc"}
{"PMID":23333577,"re_id":25,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/<e2>Akt<\\e2> GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/<e2>GENE-N<\\e2> GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc"}
{"PMID":23333577,"re_id":26,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/<e2>GSK-3\u03b2<\\e2> signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"GSK-3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/<e2>GENE-Y<\\e2> signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc"}
{"PMID":23333577,"re_id":27,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of <e2>\u03b2-catenin<\\e2> mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"\u03b2-catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of GENE-Y, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of <e2>GENE-Y<\\e2> mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc"}
{"PMID":23333577,"re_id":28,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including <e2>BMP4<\\e2>  ID2, survivin, cyclin D1, MMP7, and c-Myc","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"BMP4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including <e2>GENE-Y<\\e2>  ID2, survivin, cyclin D1, MMP7, and c-Myc","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4  ID2, survivin, cyclin D1, MMP7, and c-Myc"}
{"PMID":23333577,"re_id":29,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, <e2>ID2<\\e2>  survivin, cyclin D1, MMP7, and c-Myc","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"ID2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, <e2>GENE-Y<\\e2>  survivin, cyclin D1, MMP7, and c-Myc","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2  survivin, cyclin D1, MMP7, and c-Myc"}
{"PMID":23333577,"re_id":30,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, <e2>survivin<\\e2>  cyclin D1, MMP7, and c-Myc","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"survivin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, <e2>GENE-Y<\\e2>  cyclin D1, MMP7, and c-Myc","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin  cyclin D1, MMP7, and c-Myc"}
{"PMID":23333577,"re_id":31,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, <e2>cyclin D1<\\e2>  MMP7, and c-Myc","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"cyclin D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, <e2>GENE-Y<\\e2>  MMP7, and c-Myc","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1  MMP7, and c-Myc"}
{"PMID":23333577,"re_id":32,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, <e2>MMP7<\\e2>  and c-Myc","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"MMP7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, <e2>GENE-Y<\\e2>  and c-Myc","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7  and c-Myc"}
{"PMID":23333577,"re_id":33,"annotated sentence":"Subsequently, <e1>pinosylvin<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and <e2>c-Myc<\\e2>  These findings demonstrate that the anti-proliferative activity of pinosylvin might be associated with the cell cycle arrest and downregulation of cell proliferation regulating signaling pathways in human colorectal cancer cells.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"c-Myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequently, <e1>CHEMICAL<\\e1> suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and <e2>GENE-Y<\\e2>  These findings demonstrate that the anti-proliferative activity of CHEMICAL might be associated with the cell cycle arrest and downregulation of cell proliferation regulating signaling pathways in human colorectal cancer cells.","sentence":"Subsequently, pinosylvin suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K\/Akt\/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc  These findings demonstrate that the anti-proliferative activity of pinosylvin might be associated with the cell cycle arrest and downregulation of cell proliferation regulating signaling pathways in human colorectal cancer cells."}
{"PMID":23333577,"re_id":34,"annotated sentence":"Suppression of <e2>Src<\\e2> ERK and GSK-3\/\u03b2-catenin signaling by <e1>pinosylvin<\\e1> inhibits the growth of human colorectal cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Suppression of <e2>GENE-Y<\\e2> ERK and GSK-3\/\u03b2-catenin signaling by <e1>CHEMICAL<\\e1> inhibits the growth of human colorectal cancer cells","sentence":"Suppression of Src ERK and GSK-3\/\u03b2-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells"}
{"PMID":23333577,"re_id":35,"annotated sentence":"Suppression of Src\/<e2>ERK<\\e2> and GSK-3\/\u03b2-catenin signaling by <e1>pinosylvin<\\e1> inhibits the growth of human colorectal cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Suppression of Src\/<e2>GENE-N<\\e2> and GSK-3\/\u03b2-catenin signaling by <e1>CHEMICAL<\\e1> inhibits the growth of human colorectal cancer cells","sentence":"Suppression of Src\/ERK and GSK-3\/\u03b2-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells"}
{"PMID":23333577,"re_id":36,"annotated sentence":"Suppression of Src\/ERK and <e2>GSK-3<\\e2> \u03b2-catenin signaling by <e1>pinosylvin<\\e1> inhibits the growth of human colorectal cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"GSK-3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Suppression of Src\/ERK and <e2>GENE-N<\\e2> \u03b2-catenin signaling by <e1>CHEMICAL<\\e1> inhibits the growth of human colorectal cancer cells","sentence":"Suppression of Src\/ERK and GSK-3 \u03b2-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells"}
{"PMID":23333577,"re_id":37,"annotated sentence":"Suppression of Src\/ERK and GSK-3\/<e2>\u03b2-catenin<\\e2> signaling by <e1>pinosylvin<\\e1> inhibits the growth of human colorectal cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pinosylvin","object":"\u03b2-catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Suppression of Src\/ERK and GSK-3\/<e2>GENE-Y<\\e2> signaling by <e1>CHEMICAL<\\e1> inhibits the growth of human colorectal cancer cells","sentence":"Suppression of Src\/ERK and GSK-3\/\u03b2-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells"}
{"PMID":23337256,"re_id":0,"annotated sentence":"However, recent clinical studies have shown that a single low-dose injection of <e1>ketamine<\\e1>  an <e2>N-methyl d-aspartate receptor<\\e2> (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ketamine","object":"N-methyl d-aspartate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, recent clinical studies have shown that a single low-dose injection of <e1>CHEMICAL<\\e1>  an <e2>GENE-N<\\e2> (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting","sentence":"However, recent clinical studies have shown that a single low-dose injection of ketamine  an N-methyl d-aspartate receptor (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting"}
{"PMID":23337256,"re_id":1,"annotated sentence":"However, recent clinical studies have shown that a single low-dose injection of <e1>ketamine<\\e1>  an N-methyl d-aspartate receptor (<e2>NMDAR<\\e2>  antagonist, has rapid antidepressant effects that are observed within hours and are long lasting","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ketamine","object":"NMDAR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, recent clinical studies have shown that a single low-dose injection of <e1>CHEMICAL<\\e1>  an N-methyl d-aspartate receptor (<e2>GENE-N<\\e2>  antagonist, has rapid antidepressant effects that are observed within hours and are long lasting","sentence":"However, recent clinical studies have shown that a single low-dose injection of ketamine  an N-methyl d-aspartate receptor (NMDAR  antagonist, has rapid antidepressant effects that are observed within hours and are long lasting"}
{"PMID":23339625,"re_id":0,"annotated sentence":"4.\u2002Administration of a single dose of <e1>DEX-P<\\e1> showed a temporal increase in <e2>CYP3A<\\e2> activity in both tissues and the induction ratios reached maximum values at 12\u2009h after DEX-P administration","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX-P","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"4.\u2002Administration of a single dose of <e1>CHEMICAL<\\e1> showed a temporal increase in <e2>GENE-N<\\e2> activity in both tissues and the induction ratios reached maximum values at 12\u2009h after CHEMICAL administration","sentence":"4.\u2002Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12\u2009h after DEX-P administration"}
{"PMID":23339625,"re_id":1,"annotated sentence":"4.\u2002Administration of a single dose of DEX-P showed a temporal increase in <e2>CYP3A<\\e2> activity in both tissues and the induction ratios reached maximum values at 12\u2009h after <e1>DEX-P<\\e1> administration","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX-P","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"4.\u2002Administration of a single dose of CHEMICAL showed a temporal increase in <e2>GENE-N<\\e2> activity in both tissues and the induction ratios reached maximum values at 12\u2009h after <e1>CHEMICAL<\\e1> administration","sentence":"4.\u2002Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12\u2009h after DEX-P administration"}
{"PMID":23339625,"re_id":2,"annotated sentence":"Time-dependent changes in hepatic and intestinal induction of <e2>cytochrome P450 3A<\\e2> after administration of <e1>dexamethasone<\\e1> to rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"dexamethasone","object":"cytochrome P450 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Time-dependent changes in hepatic and intestinal induction of <e2>GENE-N<\\e2> after administration of <e1>CHEMICAL<\\e1> to rats","sentence":"Time-dependent changes in hepatic and intestinal induction of cytochrome P450 3A after administration of dexamethasone to rats"}
{"PMID":23339625,"re_id":3,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal <e2>cytochrome P450 3A<\\e2> (CYP3A) in rats using <e1>dexamethasone 21-phosphate<\\e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"dexamethasone 21-phosphate","object":"cytochrome P450 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal <e2>GENE-N<\\e2> (CYP3A) in rats using <e1>CHEMICAL<\\e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively"}
{"PMID":23339625,"re_id":4,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A<\\e2>  in rats using <e1>dexamethasone 21-phosphate<\\e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"dexamethasone 21-phosphate","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>GENE-N<\\e2>  in rats using <e1>CHEMICAL<\\e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to GENE-N, respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A  in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively"}
{"PMID":23339625,"re_id":5,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using <e1>dexamethasone 21-phosphate<\\e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to <e2>CYP3A<\\e2>  respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"dexamethasone 21-phosphate","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (GENE-N) in rats using <e1>CHEMICAL<\\e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to <e2>GENE-N<\\e2>  respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A  respectively"}
{"PMID":23339625,"re_id":6,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal <e2>cytochrome P450 3A<\\e2> (CYP3A) in rats using dexamethasone 21-phosphate (<e1>DEX-P<\\e1>  and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX-P","object":"cytochrome P450 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal <e2>GENE-N<\\e2> (CYP3A) in rats using dexamethasone 21-phosphate (<e1>CHEMICAL<\\e1>  and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P  and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively"}
{"PMID":23339625,"re_id":7,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A<\\e2>  in rats using dexamethasone 21-phosphate (<e1>DEX-P<\\e1>  and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX-P","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>GENE-N<\\e2>  in rats using dexamethasone 21-phosphate (<e1>CHEMICAL<\\e1>  and midazolam (MDZ) as an inducer and a substrate to GENE-N, respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A  in rats using dexamethasone 21-phosphate (DEX-P  and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively"}
{"PMID":23339625,"re_id":8,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (<e1>DEX-P<\\e1>  and midazolam (MDZ) as an inducer and a substrate to <e2>CYP3A<\\e2>  respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX-P","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (GENE-N) in rats using dexamethasone 21-phosphate (<e1>CHEMICAL<\\e1>  and midazolam (MDZ) as an inducer and a substrate to <e2>GENE-N<\\e2>  respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P  and midazolam (MDZ) as an inducer and a substrate to CYP3A  respectively"}
{"PMID":23339625,"re_id":9,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and <e1>midazolam<\\e1> (MDZ) as an inducer and a substrate to <e2>CYP3A<\\e2>  respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"midazolam","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (GENE-N) in rats using dexamethasone 21-phosphate (DEX-P) and <e1>CHEMICAL<\\e1> (MDZ) as an inducer and a substrate to <e2>GENE-N<\\e2>  respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A  respectively"}
{"PMID":23339625,"re_id":10,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<e1>MDZ<\\e1>  as an inducer and a substrate to <e2>CYP3A<\\e2>  respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MDZ","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (GENE-N) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<e1>CHEMICAL<\\e1>  as an inducer and a substrate to <e2>GENE-N<\\e2>  respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ  as an inducer and a substrate to CYP3A  respectively"}
{"PMID":23339625,"re_id":11,"annotated sentence":"3.\u2002<e2>CYP3A<\\e2> induction in the liver increased depending on the dose of <e1>DEX-P<\\e1>  whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX-P","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"3.\u2002<e2>GENE-N<\\e2> induction in the liver increased depending on the dose of <e1>CHEMICAL<\\e1>  whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of CHEMICAL","sentence":"3.\u2002CYP3A induction in the liver increased depending on the dose of DEX-P  whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P"}
{"PMID":23339625,"re_id":12,"annotated sentence":"3.\u2002<e2>CYP3A<\\e2> induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of <e1>DEX-P<\\e1>  4.\u2002Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12\u2009h after DEX-P administration","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX-P","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"3.\u2002<e2>GENE-N<\\e2> induction in the liver increased depending on the dose of CHEMICAL, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of <e1>CHEMICAL<\\e1>  4.\u2002Administration of a single dose of CHEMICAL showed a temporal increase in GENE-N activity in both tissues and the induction ratios reached maximum values at 12\u2009h after CHEMICAL administration","sentence":"3.\u2002CYP3A induction in the liver increased depending on the dose of DEX-P, whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of DEX-P  4.\u2002Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12\u2009h after DEX-P administration"}
{"PMID":23339625,"re_id":13,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using <e1>dexamethasone 21-phosphate<\\e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to <e2>CYP3A<\\e2>  respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dexamethasone 21-phosphate","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (GENE-N) in rats using <e1>CHEMICAL<\\e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to <e2>GENE-N<\\e2>  respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A  respectively"}
{"PMID":23339625,"re_id":14,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (<e1>DEX-P<\\e1>  and midazolam (MDZ) as an inducer and a substrate to <e2>CYP3A<\\e2>  respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DEX-P","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (GENE-N) in rats using dexamethasone 21-phosphate (<e1>CHEMICAL<\\e1>  and midazolam (MDZ) as an inducer and a substrate to <e2>GENE-N<\\e2>  respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P  and midazolam (MDZ) as an inducer and a substrate to CYP3A  respectively"}
{"PMID":23339625,"re_id":15,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal <e2>cytochrome P450 3A<\\e2> (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and <e1>midazolam<\\e1> (MDZ) as an inducer and a substrate to CYP3A, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"midazolam","object":"cytochrome P450 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal <e2>GENE-N<\\e2> (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and <e1>CHEMICAL<\\e1> (MDZ) as an inducer and a substrate to CYP3A, respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively"}
{"PMID":23339625,"re_id":16,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A<\\e2>  in rats using dexamethasone 21-phosphate (DEX-P) and <e1>midazolam<\\e1> (MDZ) as an inducer and a substrate to CYP3A, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"midazolam","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>GENE-N<\\e2>  in rats using dexamethasone 21-phosphate (DEX-P) and <e1>CHEMICAL<\\e1> (MDZ) as an inducer and a substrate to GENE-N, respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A  in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively"}
{"PMID":23339625,"re_id":17,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and <e1>midazolam<\\e1> (MDZ) as an inducer and a substrate to <e2>CYP3A<\\e2>  respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"midazolam","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (GENE-N) in rats using dexamethasone 21-phosphate (DEX-P) and <e1>CHEMICAL<\\e1> (MDZ) as an inducer and a substrate to <e2>GENE-N<\\e2>  respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A  respectively"}
{"PMID":23339625,"re_id":18,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A<\\e2>  in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<e1>MDZ<\\e1>  as an inducer and a substrate to CYP3A, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"MDZ","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>GENE-N<\\e2>  in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<e1>CHEMICAL<\\e1>  as an inducer and a substrate to GENE-N, respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A  in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ  as an inducer and a substrate to CYP3A, respectively"}
{"PMID":23339625,"re_id":19,"annotated sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<e1>MDZ<\\e1>  as an inducer and a substrate to <e2>CYP3A<\\e2>  respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"MDZ","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (GENE-N) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<e1>CHEMICAL<\\e1>  as an inducer and a substrate to <e2>GENE-N<\\e2>  respectively","sentence":"Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ  as an inducer and a substrate to CYP3A  respectively"}
{"PMID":23344961,"re_id":0,"annotated sentence":"Altogether, our findings support a model in which Top2\u03b2 deficiency promotes <e1>CPT<\\e1> induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and <e2>p53<\\e2> accumulation.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CPT","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Altogether, our findings support a model in which Top2\u03b2 deficiency promotes <e1>CHEMICAL<\\e1> induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and <e2>GENE-Y<\\e2> accumulation.","sentence":"Altogether, our findings support a model in which Top2\u03b2 deficiency promotes CPT induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and p53 accumulation."}
{"PMID":23344961,"re_id":1,"annotated sentence":"To explore the molecular basis for CPT hypersensitivity in Top2\u03b2-deficient cells, we found that upon <e1>CPT<\\e1> exposure, the <e2>RNA polymerase II large subunit<\\e2> (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2\u03b2-deficient cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CPT","object":"RNA polymerase II large subunit","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To explore the molecular basis for CHEMICAL hypersensitivity in Top2\u03b2-deficient cells, we found that upon <e1>CHEMICAL<\\e1> exposure, the <e2>GENE-N<\\e2> (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2\u03b2-deficient cells","sentence":"To explore the molecular basis for CPT hypersensitivity in Top2\u03b2-deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2\u03b2-deficient cells"}
{"PMID":23344961,"re_id":2,"annotated sentence":"To explore the molecular basis for CPT hypersensitivity in Top2\u03b2-deficient cells, we found that upon <e1>CPT<\\e1> exposure, the RNA polymerase II large subunit (<e2>RNAP LS<\\e2>  became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2\u03b2-deficient cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CPT","object":"RNAP LS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To explore the molecular basis for CHEMICAL hypersensitivity in Top2\u03b2-deficient cells, we found that upon <e1>CHEMICAL<\\e1> exposure, the RNA polymerase II large subunit (<e2>GENE-N<\\e2>  became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas GENE-N remained depleted without recovery in Top2\u03b2-deficient cells","sentence":"To explore the molecular basis for CPT hypersensitivity in Top2\u03b2-deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (RNAP LS  became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2\u03b2-deficient cells"}
{"PMID":23344961,"re_id":3,"annotated sentence":"To explore the molecular basis for CPT hypersensitivity in Top2\u03b2-deficient cells, we found that upon <e1>CPT<\\e1> exposure, the RNA polymerase II large subunit (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas <e2>RNAP LS<\\e2> remained depleted without recovery in Top2\u03b2-deficient cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CPT","object":"RNAP LS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To explore the molecular basis for CHEMICAL hypersensitivity in Top2\u03b2-deficient cells, we found that upon <e1>CHEMICAL<\\e1> exposure, the RNA polymerase II large subunit (GENE-N) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas <e2>GENE-N<\\e2> remained depleted without recovery in Top2\u03b2-deficient cells","sentence":"To explore the molecular basis for CPT hypersensitivity in Top2\u03b2-deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2\u03b2-deficient cells"}
{"PMID":23344961,"re_id":4,"annotated sentence":"Altogether, our findings support a model in which Top2\u03b2 deficiency promotes <e1>CPT<\\e1> induced apoptosis in quiescent non-S-phase cells, possibly due to <e2>RNAP LS<\\e2> depletion and p53 accumulation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CPT","object":"RNAP LS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Altogether, our findings support a model in which Top2\u03b2 deficiency promotes <e1>CHEMICAL<\\e1> induced apoptosis in quiescent non-S-phase cells, possibly due to <e2>GENE-N<\\e2> depletion and p53 accumulation.","sentence":"Altogether, our findings support a model in which Top2\u03b2 deficiency promotes CPT induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and p53 accumulation."}
{"PMID":23344961,"re_id":5,"annotated sentence":"Second, <e1>ICRF-187<\\e1>  a <e2>Top2<\\e2> catalytic inhibitor known to deplete Top2\u03b2, specifically sensitized MEFs to CPT","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ICRF-187","object":"Top2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Second, <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> catalytic inhibitor known to deplete GENE-Y\u03b2, specifically sensitized MEFs to CPT","sentence":"Second, ICRF-187  a Top2 catalytic inhibitor known to deplete Top2\u03b2, specifically sensitized MEFs to CPT"}
{"PMID":23344961,"re_id":6,"annotated sentence":"Second, <e1>ICRF-187<\\e1>  a Top2 catalytic inhibitor known to deplete <e2>Top2\u03b2<\\e2>  specifically sensitized MEFs to CPT","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ICRF-187","object":"Top2\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Second, <e1>CHEMICAL<\\e1>  a Top2 catalytic inhibitor known to deplete <e2>GENE-Y<\\e2>  specifically sensitized MEFs to CPT","sentence":"Second, ICRF-187  a Top2 catalytic inhibitor known to deplete Top2\u03b2  specifically sensitized MEFs to CPT"}
{"PMID":23348500,"re_id":0,"annotated sentence":"<e1>NCFP<\\e1> binds to the CPPHA site on mGlu5 and potentiates <e2>mGlu5<\\e2> mediated responses in both recombinant and native systems","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NCFP","object":"mGlu5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> binds to the CPPHA site on GENE-Y and potentiates <e2>GENE-Y<\\e2> mediated responses in both recombinant and native systems","sentence":"NCFP binds to the CPPHA site on mGlu5 and potentiates mGlu5 mediated responses in both recombinant and native systems"}
{"PMID":23349501,"re_id":0,"annotated sentence":"Dietary <e1>EPA<\\e1> DHA treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving <e2>insulin<\\e2> sensitivity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"EPA","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Dietary <e1>CHEMICAL<\\e1> DHA treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving <e2>GENE-N<\\e2> sensitivity","sentence":"Dietary EPA DHA treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving insulin sensitivity"}
{"PMID":23349501,"re_id":1,"annotated sentence":"Notably, <e1>17-HDHA<\\e1> treatment reduced adipose tissue expression of inflammatory cytokines, increased <e2>adiponectin<\\e2> expression and improved glucose tolerance parallel to insulin sensitivity in obese mice","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"17-HDHA","object":"adiponectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Notably, <e1>CHEMICAL<\\e1> treatment reduced adipose tissue expression of inflammatory cytokines, increased <e2>GENE-Y<\\e2> expression and improved glucose tolerance parallel to insulin sensitivity in obese mice","sentence":"Notably, 17-HDHA treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice"}
{"PMID":23349501,"re_id":2,"annotated sentence":"Notably, <e1>17-HDHA<\\e1> treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression and improved glucose tolerance parallel to <e2>insulin<\\e2> sensitivity in obese mice","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"17-HDHA","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Notably, <e1>CHEMICAL<\\e1> treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression and improved glucose tolerance parallel to <e2>GENE-N<\\e2> sensitivity in obese mice","sentence":"Notably, 17-HDHA treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice"}
{"PMID":23349501,"re_id":3,"annotated sentence":"Dietary EPA\/<e1>DHA<\\e1> treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving <e2>insulin<\\e2> sensitivity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DHA","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Dietary EPA\/<e1>CHEMICAL<\\e1> treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving <e2>GENE-N<\\e2> sensitivity","sentence":"Dietary EPA\/DHA treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving insulin sensitivity"}
{"PMID":23349501,"re_id":4,"annotated sentence":"Notably, <e1>17-HDHA<\\e1> treatment reduced adipose tissue expression of inflammatory <e2>cytokines<\\e2>  increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"17-HDHA","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Notably, <e1>CHEMICAL<\\e1> treatment reduced adipose tissue expression of inflammatory <e2>GENE-N<\\e2>  increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice","sentence":"Notably, 17-HDHA treatment reduced adipose tissue expression of inflammatory cytokines  increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice"}
{"PMID":23350847,"re_id":0,"annotated sentence":"We describe the discovery of several <e1>pyrrolopyrazines<\\e1> as potent and selective <e2>Syk<\\e2> inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrrolopyrazines","object":"Syk","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We describe the discovery of several <e1>CHEMICAL<\\e1> as potent and selective <e2>GENE-Y<\\e2> inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies","sentence":"We describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies"}
{"PMID":23350847,"re_id":1,"annotated sentence":"<e1>Pyrrolopyrazines<\\e1> as Selective <e2>Spleen Tyrosine Kinase<\\e2> Inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pyrrolopyrazines","object":"Spleen Tyrosine Kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> as Selective <e2>GENE-Y<\\e2> Inhibitors","sentence":"Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors"}
{"PMID":23354070,"re_id":0,"annotated sentence":"We describe here the isolation and biochemical characterization of the marine natural <e1>sesquiterpene<\\e1> palinurin as a <e2>GSK-3\u03b2<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sesquiterpene","object":"GSK-3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We describe here the isolation and biochemical characterization of the marine natural <e1>CHEMICAL<\\e1> palinurin as a <e2>GENE-Y<\\e2> inhibitor","sentence":"We describe here the isolation and biochemical characterization of the marine natural sesquiterpene palinurin as a GSK-3\u03b2 inhibitor"}
{"PMID":23354070,"re_id":1,"annotated sentence":"We describe here the isolation and biochemical characterization of the marine natural sesquiterpene <e1>palinurin<\\e1> as a <e2>GSK-3\u03b2<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"palinurin","object":"GSK-3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We describe here the isolation and biochemical characterization of the marine natural sesquiterpene <e1>CHEMICAL<\\e1> as a <e2>GENE-Y<\\e2> inhibitor","sentence":"We describe here the isolation and biochemical characterization of the marine natural sesquiterpene palinurin as a GSK-3\u03b2 inhibitor"}
{"PMID":23354070,"re_id":2,"annotated sentence":"Experimental studies performed for characterizing the inhibitory mechanism indicate that <e2>GSK-3\u03b2<\\e2> inhibition by <e1>palinurin<\\e1> cannot be competed out by ATP nor peptide substrate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"palinurin","object":"GSK-3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Experimental studies performed for characterizing the inhibitory mechanism indicate that <e2>GENE-Y<\\e2> inhibition by <e1>CHEMICAL<\\e1> cannot be competed out by ATP nor peptide substrate","sentence":"Experimental studies performed for characterizing the inhibitory mechanism indicate that GSK-3\u03b2 inhibition by palinurin cannot be competed out by ATP nor peptide substrate"}
{"PMID":23354070,"re_id":3,"annotated sentence":"Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of <e1>palinurin<\\e1> leads to <e2>GSK-3\u03b2<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"palinurin","object":"GSK-3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of <e1>CHEMICAL<\\e1> leads to <e2>GENE-Y<\\e2> inhibition","sentence":"Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of palinurin leads to GSK-3\u03b2 inhibition"}
{"PMID":23357976,"re_id":0,"annotated sentence":"<e2>Type 2 11\u03b2-hydroxysteroid dehydrogenase<\\e2> encoded by the HSD11B2 gene converts <e1>cortisol<\\e1> to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisol","object":"Type 2 11\u03b2-hydroxysteroid dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> encoded by the HSD11B2 gene converts <e1>CHEMICAL<\\e1> to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids","sentence":"Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the HSD11B2 gene converts cortisol to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids"}
{"PMID":23357976,"re_id":1,"annotated sentence":"Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the <e2>HSD11B2<\\e2> gene converts <e1>cortisol<\\e1> to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisol","object":"HSD11B2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the <e2>GENE-Y<\\e2> gene converts <e1>CHEMICAL<\\e1> to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids","sentence":"Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the HSD11B2 gene converts cortisol to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids"}
{"PMID":23357976,"re_id":2,"annotated sentence":"<e2>Type 2 11\u03b2-hydroxysteroid dehydrogenase<\\e2> encoded by the HSD11B2 gene converts cortisol to inactive <e1>cortisone<\\e1>  and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisone","object":"Type 2 11\u03b2-hydroxysteroid dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> encoded by the HSD11B2 gene converts cortisol to inactive <e1>CHEMICAL<\\e1>  and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids","sentence":"Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the HSD11B2 gene converts cortisol to inactive cortisone  and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids"}
{"PMID":23357976,"re_id":3,"annotated sentence":"Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the <e2>HSD11B2<\\e2> gene converts cortisol to inactive <e1>cortisone<\\e1>  and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisone","object":"HSD11B2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the <e2>GENE-Y<\\e2> gene converts cortisol to inactive <e1>CHEMICAL<\\e1>  and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids","sentence":"Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the HSD11B2 gene converts cortisol to inactive cortisone  and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids"}
{"PMID":23358258,"re_id":0,"annotated sentence":"A series of <e1>xanthine<\\e1> derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of <e2>dipeptidyl peptidase 4<\\e2> (DPP-4) for the treatment of type 2 diabetes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"xanthine","object":"dipeptidyl peptidase 4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> derivatives in which a methylene was inserted at position 8 of CHEMICAL scaffold was synthesized and evaluated as inhibitors of <e2>GENE-Y<\\e2> (DPP-4) for the treatment of type 2 diabetes","sentence":"A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4) for the treatment of type 2 diabetes"}
{"PMID":23358258,"re_id":1,"annotated sentence":"A series of <e1>xanthine<\\e1> derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (<e2>DPP-4<\\e2>  for the treatment of type 2 diabetes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"xanthine","object":"DPP-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> derivatives in which a methylene was inserted at position 8 of CHEMICAL scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (<e2>GENE-Y<\\e2>  for the treatment of type 2 diabetes","sentence":"A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4  for the treatment of type 2 diabetes"}
{"PMID":23358258,"re_id":2,"annotated sentence":"A series of xanthine derivatives in which a methylene was inserted at position 8 of <e1>xanthine<\\e1> scaffold was synthesized and evaluated as inhibitors of <e2>dipeptidyl peptidase 4<\\e2> (DPP-4) for the treatment of type 2 diabetes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"xanthine","object":"dipeptidyl peptidase 4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of CHEMICAL derivatives in which a methylene was inserted at position 8 of <e1>CHEMICAL<\\e1> scaffold was synthesized and evaluated as inhibitors of <e2>GENE-Y<\\e2> (DPP-4) for the treatment of type 2 diabetes","sentence":"A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4) for the treatment of type 2 diabetes"}
{"PMID":23358258,"re_id":3,"annotated sentence":"A series of xanthine derivatives in which a methylene was inserted at position 8 of <e1>xanthine<\\e1> scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (<e2>DPP-4<\\e2>  for the treatment of type 2 diabetes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"xanthine","object":"DPP-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of CHEMICAL derivatives in which a methylene was inserted at position 8 of <e1>CHEMICAL<\\e1> scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (<e2>GENE-Y<\\e2>  for the treatment of type 2 diabetes","sentence":"A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4  for the treatment of type 2 diabetes"}
{"PMID":23360412,"re_id":0,"annotated sentence":"The activity of the human nasal mucosa microsomes was inhibited by <e1>8-methoxypsoralen<\\e1>  a known <e2>CYP2A<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"8-methoxypsoralen","object":"CYP2A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The activity of the human nasal mucosa microsomes was inhibited by <e1>CHEMICAL<\\e1>  a known <e2>GENE-N<\\e2> inhibitor","sentence":"The activity of the human nasal mucosa microsomes was inhibited by 8-methoxypsoralen  a known CYP2A inhibitor"}
{"PMID":23362262,"re_id":0,"annotated sentence":"<e1>PP242<\\e1> induced reversal of <e2>deptor<\\e2> suppression by TGF\u03b2 was associated with a significant inhibition of TGF\u03b2-stimulated protein synthesis and hypertrophy","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PP242","object":"deptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced reversal of <e2>GENE-Y<\\e2> suppression by TGF\u03b2 was associated with a significant inhibition of TGF\u03b2-stimulated protein synthesis and hypertrophy","sentence":"PP242 induced reversal of deptor suppression by TGF\u03b2 was associated with a significant inhibition of TGF\u03b2-stimulated protein synthesis and hypertrophy"}
{"PMID":23362262,"re_id":1,"annotated sentence":"Using the <e2>mTOR<\\e2> inhibitor <e1>PP242,<\\e1> we found that TGF\u03b2-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PP242,","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> we found that TGF\u03b2-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression","sentence":"Using the mTOR inhibitor PP242, we found that TGF\u03b2-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression"}
{"PMID":23374869,"re_id":0,"annotated sentence":"Based on recent reports that the small molecules, <e1>isatin<\\e1> and phthalimide, are suitable scaffolds for the design of high potency <e2>monoamine oxidase<\\e2> (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"isatin","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Based on recent reports that the small molecules, <e1>CHEMICAL<\\e1> and phthalimide, are suitable scaffolds for the design of high potency <e2>GENE-N<\\e2> (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues","sentence":"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues"}
{"PMID":23374869,"re_id":1,"annotated sentence":"Based on recent reports that the small molecules, <e1>isatin<\\e1> and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (<e2>MAO<\\e2>  inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"isatin","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Based on recent reports that the small molecules, <e1>CHEMICAL<\\e1> and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (<e2>GENE-N<\\e2>  inhibitors, the present study examines the GENE-N inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues","sentence":"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO  inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues"}
{"PMID":23374869,"re_id":2,"annotated sentence":"Based on recent reports that the small molecules, isatin and <e1>phthalimide<\\e1>  are suitable scaffolds for the design of high potency <e2>monoamine oxidase<\\e2> (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phthalimide","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Based on recent reports that the small molecules, isatin and <e1>CHEMICAL<\\e1>  are suitable scaffolds for the design of high potency <e2>GENE-N<\\e2> (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues","sentence":"Based on recent reports that the small molecules, isatin and phthalimide  are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues"}
{"PMID":23374869,"re_id":3,"annotated sentence":"Based on recent reports that the small molecules, isatin and <e1>phthalimide<\\e1>  are suitable scaffolds for the design of high potency monoamine oxidase (<e2>MAO<\\e2>  inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phthalimide","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Based on recent reports that the small molecules, isatin and <e1>CHEMICAL<\\e1>  are suitable scaffolds for the design of high potency monoamine oxidase (<e2>GENE-N<\\e2>  inhibitors, the present study examines the GENE-N inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues","sentence":"Based on recent reports that the small molecules, isatin and phthalimide  are suitable scaffolds for the design of high potency monoamine oxidase (MAO  inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues"}
{"PMID":23374869,"re_id":4,"annotated sentence":"In most instances, C6-substituted <e1>phthalides<\\e1> exhibit <e2>MAO-B<\\e2> specific inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phthalides","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In most instances, C6-substituted <e1>CHEMICAL<\\e1> exhibit <e2>GENE-Y<\\e2> specific inhibition","sentence":"In most instances, C6-substituted phthalides exhibit MAO-B specific inhibition"}
{"PMID":23374869,"re_id":5,"annotated sentence":"The results also show that the binding modes of representative <e1>phthalides<\\e1> are reversible and competitive at both <e2>MAO<\\e2> isoforms","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phthalides","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results also show that the binding modes of representative <e1>CHEMICAL<\\e1> are reversible and competitive at both <e2>GENE-N<\\e2> isoforms","sentence":"The results also show that the binding modes of representative phthalides are reversible and competitive at both MAO isoforms"}
{"PMID":23374869,"re_id":6,"annotated sentence":"Inhibition of <e2>monoamine oxidase<\\e2> by <e1>phthalide<\\e1> analogues","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phthalide","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1> analogues","sentence":"Inhibition of monoamine oxidase by phthalide analogues"}
{"PMID":23374869,"re_id":7,"annotated sentence":"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the <e2>MAO<\\e2> inhibitory properties of a series of <e1>phthalide<\\e1> [2-benzofuran-1(3H)-one] analogues","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phthalide","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (GENE-N) inhibitors, the present study examines the <e2>GENE-N<\\e2> inhibitory properties of a series of <e1>CHEMICAL<\\e1> [2-benzofuran-1(3H)-one] analogues","sentence":"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues"}
{"PMID":23374869,"re_id":8,"annotated sentence":"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the <e2>MAO<\\e2> inhibitory properties of a series of phthalide [<e1>2-benzofuran-1(3H)-one<\\e1>  analogues","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-benzofuran-1(3H)-one","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (GENE-N) inhibitors, the present study examines the <e2>GENE-N<\\e2> inhibitory properties of a series of phthalide [<e1>CHEMICAL<\\e1>  analogues","sentence":"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one  analogues"}
{"PMID":23375228,"re_id":0,"annotated sentence":"A novel class of <e1>quinoxalines<\\e1> has been discovered as antagonists of the <e2>IgG<\\e2> FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"quinoxalines","object":"IgG","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A novel class of <e1>CHEMICAL<\\e1> has been discovered as antagonists of the <e2>GENE-N<\\e2> FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.","sentence":"A novel class of quinoxalines has been discovered as antagonists of the IgG FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen."}
{"PMID":23375228,"re_id":1,"annotated sentence":"A novel class of <e1>quinoxalines<\\e1> has been discovered as antagonists of the IgG:<e2>FcRn<\\e2> protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"quinoxalines","object":"FcRn","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A novel class of <e1>CHEMICAL<\\e1> has been discovered as antagonists of the IgG:<e2>GENE-Y<\\e2> protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.","sentence":"A novel class of quinoxalines has been discovered as antagonists of the IgG:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen."}
{"PMID":23375813,"re_id":0,"annotated sentence":"Guided by the <e2>acetylcholinesterase<\\e2> inhibiting activity, the <e1>bisindole alkaloid<\\e1> 3'-R\/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bisindole alkaloid","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Guided by the <e2>GENE-Y<\\e2> inhibiting activity, the <e1>CHEMICAL<\\e1> 3'-R\/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory","sentence":"Guided by the acetylcholinesterase inhibiting activity, the bisindole alkaloid 3'-R\/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory"}
{"PMID":23375813,"re_id":1,"annotated sentence":"Guided by the <e2>acetylcholinesterase<\\e2> inhibiting activity, the bisindole alkaloid <e1>3'-R\/S-hydroxyvoacamine<\\e1> was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"3'-R\/S-hydroxyvoacamine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Guided by the <e2>GENE-Y<\\e2> inhibiting activity, the bisindole alkaloid <e1>CHEMICAL<\\e1> was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory","sentence":"Guided by the acetylcholinesterase inhibiting activity, the bisindole alkaloid 3'-R\/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory"}
{"PMID":23375813,"re_id":2,"annotated sentence":"<e1>3'-R\/S-Hydroxyvoacamine<\\e1>  a potent <e2>acetylcholinesterase<\\e2> inhibitor from Tabernaemontana divaricata","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"3'-R\/S-Hydroxyvoacamine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a potent <e2>GENE-Y<\\e2> inhibitor from Tabernaemontana divaricata","sentence":"3'-R\/S-Hydroxyvoacamine  a potent acetylcholinesterase inhibitor from Tabernaemontana divaricata"}
{"PMID":23376140,"re_id":0,"annotated sentence":"<e1>Cadmium<\\e1> activates <e2>NADPH oxidase<\\e2>  ROS produced by this oxidase activates Src, enable that in turn, transactivates EGFR that activates Stat3 in tyrosine, allowing its dimerization","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cadmium","object":"NADPH oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> activates <e2>GENE-N<\\e2>  ROS produced by this oxidase activates Src, enable that in turn, transactivates EGFR that activates Stat3 in tyrosine, allowing its dimerization","sentence":"Cadmium activates NADPH oxidase  ROS produced by this oxidase activates Src, enable that in turn, transactivates EGFR that activates Stat3 in tyrosine, allowing its dimerization"}
{"PMID":23376140,"re_id":1,"annotated sentence":"However, after 12h <e1>CdCl2<\\e1> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in <e2>p53<\\e2> activation and the pro-apoptotic protein Bax.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CdCl2","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, after 12h <e1>CHEMICAL<\\e1> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in <e2>GENE-Y<\\e2> activation and the pro-apoptotic protein Bax.","sentence":"However, after 12h CdCl2 treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in p53 activation and the pro-apoptotic protein Bax."}
{"PMID":23376140,"re_id":2,"annotated sentence":"However, after 12h <e1>CdCl2<\\e1> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in p53 activation and the pro-apoptotic protein <e2>Bax<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CdCl2","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, after 12h <e1>CHEMICAL<\\e1> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in p53 activation and the pro-apoptotic protein <e2>GENE-Y<\\e2> ","sentence":"However, after 12h CdCl2 treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in p53 activation and the pro-apoptotic protein Bax "}
{"PMID":23376140,"re_id":3,"annotated sentence":"However, after 12h <e1>CdCl2<\\e1> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of <e2>metallothionein-II<\\e2> production, and an increase in p53 activation and the pro-apoptotic protein Bax.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CdCl2","object":"metallothionein-II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, after 12h <e1>CHEMICAL<\\e1> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of <e2>GENE-Y<\\e2> production, and an increase in p53 activation and the pro-apoptotic protein Bax.","sentence":"However, after 12h CdCl2 treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in p53 activation and the pro-apoptotic protein Bax."}
{"PMID":23376161,"re_id":0,"annotated sentence":"<e1>Catalpol<\\e1> also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of I\u03baB\u03b1 and the nuclear localization of <e2>NF-\u03baB<\\e2>  Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by catalpol treatment, through dual action of reducing ROS itself and inhibiting NADPH oxidase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of I\u03baB\u03b1 and the nuclear localization of <e2>GENE-N<\\e2>  Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by catalpol treatment, through dual action of reducing ROS itself and inhibiting NADPH oxidase activity","sentence":"Catalpol also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of I\u03baB\u03b1 and the nuclear localization of NF-\u03baB  Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by catalpol treatment, through dual action of reducing ROS itself and inhibiting NADPH oxidase activity"}
{"PMID":23376161,"re_id":1,"annotated sentence":"<e1>Catalpol<\\e1> also suppressed AGE-induced phosphorylation of <e2>mitogen activated protein (MAP) kinases<\\e2>  degradation of I\u03baB\u03b1 and the nuclear localization of NF-\u03baB","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"mitogen activated protein (MAP) kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also suppressed AGE-induced phosphorylation of <e2>GENE-N<\\e2>  degradation of I\u03baB\u03b1 and the nuclear localization of NF-\u03baB","sentence":"Catalpol also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases  degradation of I\u03baB\u03b1 and the nuclear localization of NF-\u03baB"}
{"PMID":23376161,"re_id":2,"annotated sentence":"<e1>Catalpol<\\e1> also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of <e2>I\u03baB\u03b1<\\e2> and the nuclear localization of NF-\u03baB","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"I\u03baB\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of <e2>GENE-Y<\\e2> and the nuclear localization of NF-\u03baB","sentence":"Catalpol also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of I\u03baB\u03b1 and the nuclear localization of NF-\u03baB"}
{"PMID":23376161,"re_id":3,"annotated sentence":"Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by <e1>catalpol<\\e1> treatment, through dual action of reducing ROS itself and inhibiting <e2>NADPH oxidase<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"catalpol","object":"NADPH oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by <e1>CHEMICAL<\\e1> treatment, through dual action of reducing ROS itself and inhibiting <e2>GENE-N<\\e2> activity","sentence":"Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by catalpol treatment, through dual action of reducing ROS itself and inhibiting NADPH oxidase activity"}
{"PMID":23376161,"re_id":4,"annotated sentence":"Our findings indicate that <e1>catalpol<\\e1> suppresses AGE-mediated inflammation by inhibiting ROS production and <e2>NF-\u03baB<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"catalpol","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our findings indicate that <e1>CHEMICAL<\\e1> suppresses AGE-mediated inflammation by inhibiting ROS production and <e2>GENE-N<\\e2> activity","sentence":"Our findings indicate that catalpol suppresses AGE-mediated inflammation by inhibiting ROS production and NF-\u03baB activity"}
{"PMID":23376161,"re_id":5,"annotated sentence":"<e1>Catalpol<\\e1> reduced the expression of pro-inflammatory mediates, such as <e2>monocyte chemotactic protein-1<\\e2> (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"monocyte chemotactic protein-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the expression of pro-inflammatory mediates, such as <e2>GENE-Y<\\e2> (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)","sentence":"Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)"}
{"PMID":23376161,"re_id":6,"annotated sentence":"<e1>Catalpol<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (<e2>MCP-1<\\e2> , tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"MCP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (<e2>GENE-Y<\\e2> , tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)","sentence":"Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1 , tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)"}
{"PMID":23376161,"re_id":7,"annotated sentence":"<e1>Catalpol<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), <e2>tumor necrosis factor-\u03b1<\\e2> (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"tumor necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), <e2>GENE-Y<\\e2> (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)","sentence":"Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)"}
{"PMID":23376161,"re_id":8,"annotated sentence":"<e1>Catalpol<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (<e2>TNF-\u03b1<\\e2> , inducible NO synthase (iNOS), and receptor for AGE (RAGE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (<e2>GENE-Y<\\e2> , inducible NO synthase (iNOS), and receptor for AGE (RAGE)","sentence":"Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1 , inducible NO synthase (iNOS), and receptor for AGE (RAGE)"}
{"PMID":23376161,"re_id":9,"annotated sentence":"<e1>Catalpol<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), <e2>inducible NO synthase<\\e2> (iNOS), and receptor for AGE (RAGE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"inducible NO synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), <e2>GENE-Y<\\e2> (iNOS), and receptor for AGE (RAGE)","sentence":"Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)"}
{"PMID":23376161,"re_id":10,"annotated sentence":"<e1>Catalpol<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (<e2>iNOS<\\e2> , and receptor for AGE (RAGE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (<e2>GENE-Y<\\e2> , and receptor for AGE (RAGE)","sentence":"Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS , and receptor for AGE (RAGE)"}
{"PMID":23376161,"re_id":11,"annotated sentence":"<e1>Catalpol<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and <e2>receptor for AGE<\\e2> (RAGE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"receptor for AGE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and <e2>GENE-Y<\\e2> (RAGE)","sentence":"Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)"}
{"PMID":23376161,"re_id":12,"annotated sentence":"<e1>Catalpol<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (<e2>RAGE<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Catalpol","object":"RAGE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (<e2>GENE-Y<\\e2> ","sentence":"Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE "}
{"PMID":23376161,"re_id":13,"annotated sentence":"Promoter and electromobility shift assays showed that transcriptional activation of <e2>NF-\u03baB<\\e2> was significantly reduced by <e1>catalpol<\\e1> treatment, while AP-1 was not","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"catalpol","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Promoter and electromobility shift assays showed that transcriptional activation of <e2>GENE-N<\\e2> was significantly reduced by <e1>CHEMICAL<\\e1> treatment, while AP-1 was not","sentence":"Promoter and electromobility shift assays showed that transcriptional activation of NF-\u03baB was significantly reduced by catalpol treatment, while AP-1 was not"}
{"PMID":23381968,"re_id":0,"annotated sentence":"In this study, we assessed the effects of <e1>clopidogrel<\\e1> and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with <e2>CYP2B6<\\e2> polymorphisms in humans","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clopidogrel","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we assessed the effects of <e1>CHEMICAL<\\e1> and clarithromycin, known GENE-Y and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with <e2>GENE-Y<\\e2> polymorphisms in humans","sentence":"In this study, we assessed the effects of clopidogrel and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans"}
{"PMID":23381968,"re_id":1,"annotated sentence":"In this study, we assessed the effects of <e1>clopidogrel<\\e1> and clarithromycin, known <e2>CYP2B6<\\e2> and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clopidogrel","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we assessed the effects of <e1>CHEMICAL<\\e1> and clarithromycin, known <e2>GENE-Y<\\e2> and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with GENE-Y polymorphisms in humans","sentence":"In this study, we assessed the effects of clopidogrel and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans"}
{"PMID":23381968,"re_id":2,"annotated sentence":"In this study, we assessed the effects of <e1>clopidogrel<\\e1> and clarithromycin, known CYP2B6 and <e2>CYP3A<\\e2> inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clopidogrel","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, we assessed the effects of <e1>CHEMICAL<\\e1> and clarithromycin, known CYP2B6 and <e2>GENE-N<\\e2> inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans","sentence":"In this study, we assessed the effects of clopidogrel and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans"}
{"PMID":23381968,"re_id":3,"annotated sentence":"In this study, we assessed the effects of clopidogrel and <e1>clarithromycin<\\e1>  known <e2>CYP2B6<\\e2> and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clarithromycin","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we assessed the effects of clopidogrel and <e1>CHEMICAL<\\e1>  known <e2>GENE-Y<\\e2> and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with GENE-Y polymorphisms in humans","sentence":"In this study, we assessed the effects of clopidogrel and clarithromycin  known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans"}
{"PMID":23381968,"re_id":4,"annotated sentence":"In this study, we assessed the effects of clopidogrel and <e1>clarithromycin<\\e1>  known CYP2B6 and <e2>CYP3A<\\e2> inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clarithromycin","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, we assessed the effects of clopidogrel and <e1>CHEMICAL<\\e1>  known CYP2B6 and <e2>GENE-N<\\e2> inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans","sentence":"In this study, we assessed the effects of clopidogrel and clarithromycin  known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans"}
{"PMID":23384446,"re_id":0,"annotated sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by <e1>cyclopiazonic acid<\\e1> (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial <e2>SERCA<\\e2> pump","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyclopiazonic acid","object":"SERCA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by <e1>CHEMICAL<\\e1> (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial <e2>GENE-N<\\e2> pump","sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump"}
{"PMID":23384446,"re_id":1,"annotated sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (<e1>CPA<\\e1> , which promotes store-operated Ca(2+) entry by inhibiting the endothelial <e2>SERCA<\\e2> pump","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CPA","object":"SERCA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (<e1>CHEMICAL<\\e1> , which promotes store-operated Ca(2+) entry by inhibiting the endothelial <e2>GENE-N<\\e2> pump","sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA , which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump"}
{"PMID":23384446,"re_id":2,"annotated sentence":"Potentiation was prevented by catalase, the catalase\/superoxide dismutase mimetic manganese porphyrin and the <e2>NADPH oxidase<\\e2> inhibitor <e1>apocynin<\\e1>  By contrast in aortic rings, that exhibited negligible EDHF-type responses, endothelium-dependent NO-mediated relaxations evoked by CPA and ACh were unaffected by arsenite","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"apocynin","object":"NADPH oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Potentiation was prevented by catalase, the catalase\/superoxide dismutase mimetic manganese porphyrin and the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1>  By contrast in aortic rings, that exhibited negligible EDHF-type responses, endothelium-dependent NO-mediated relaxations evoked by CPA and ACh were unaffected by arsenite","sentence":"Potentiation was prevented by catalase, the catalase\/superoxide dismutase mimetic manganese porphyrin and the NADPH oxidase inhibitor apocynin  By contrast in aortic rings, that exhibited negligible EDHF-type responses, endothelium-dependent NO-mediated relaxations evoked by CPA and ACh were unaffected by arsenite"}
{"PMID":23384446,"re_id":3,"annotated sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the <e2>G protein-coupled receptor<\\e2> agonist <e1>acetylcholine<\\e1> (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"acetylcholine","object":"G protein-coupled receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1> (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump","sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump"}
{"PMID":23384446,"re_id":4,"annotated sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the <e2>G protein-coupled receptor<\\e2> agonist acetylcholine (<e1>ACh<\\e1>  and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"ACh","object":"G protein-coupled receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the <e2>GENE-N<\\e2> agonist acetylcholine (<e1>CHEMICAL<\\e1>  and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump","sentence":"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh  and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump"}
{"PMID":23384446,"re_id":5,"annotated sentence":"Our results suggest that arsenite can potentiate EDHF-type relaxations via a mechanism that is dependent on hydrogen peroxide, thus demonstrating that dismutation of the <e1>superoxide<\\e1> anion generated by <e2>NADPH oxidase<\\e2> can potentially offset loss of NO bioavailability under conditions of reduced eNOS activity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"superoxide","object":"NADPH oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our results suggest that arsenite can potentiate EDHF-type relaxations via a mechanism that is dependent on hydrogen peroxide, thus demonstrating that dismutation of the <e1>CHEMICAL<\\e1> anion generated by <e2>GENE-N<\\e2> can potentially offset loss of NO bioavailability under conditions of reduced eNOS activity","sentence":"Our results suggest that arsenite can potentiate EDHF-type relaxations via a mechanism that is dependent on hydrogen peroxide, thus demonstrating that dismutation of the superoxide anion generated by NADPH oxidase can potentially offset loss of NO bioavailability under conditions of reduced eNOS activity"}
{"PMID":23386390,"re_id":0,"annotated sentence":"The <e2>hemoglobin A1c<\\e2> (HbA1c) of all patients improved significantly from 8.1\u00b11.2% to 7.6\u00b11.1% after 12 weeks of add-on therapy with <e1>sitagliptin<\\e1> (p<0.01), and the insulin dosage was reduced from 27.3\u00b115.8 U\/day to 24.5\u00b116.5 U\/day (p<0.001)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sitagliptin","object":"hemoglobin A1c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> (HbA1c) of all patients improved significantly from 8.1\u00b11.2% to 7.6\u00b11.1% after 12 weeks of add-on therapy with <e1>CHEMICAL<\\e1> (p<0.01), and the insulin dosage was reduced from 27.3\u00b115.8 U\/day to 24.5\u00b116.5 U\/day (p<0.001)","sentence":"The hemoglobin A1c (HbA1c) of all patients improved significantly from 8.1\u00b11.2% to 7.6\u00b11.1% after 12 weeks of add-on therapy with sitagliptin (p<0.01), and the insulin dosage was reduced from 27.3\u00b115.8 U\/day to 24.5\u00b116.5 U\/day (p<0.001)"}
{"PMID":23386390,"re_id":1,"annotated sentence":"The hemoglobin A1c (<e2>HbA1c<\\e2>  of all patients improved significantly from 8.1\u00b11.2% to 7.6\u00b11.1% after 12 weeks of add-on therapy with <e1>sitagliptin<\\e1> (p<0.01), and the insulin dosage was reduced from 27.3\u00b115.8 U\/day to 24.5\u00b116.5 U\/day (p<0.001)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"sitagliptin","object":"HbA1c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The hemoglobin A1c (<e2>GENE-Y<\\e2>  of all patients improved significantly from 8.1\u00b11.2% to 7.6\u00b11.1% after 12 weeks of add-on therapy with <e1>CHEMICAL<\\e1> (p<0.01), and the insulin dosage was reduced from 27.3\u00b115.8 U\/day to 24.5\u00b116.5 U\/day (p<0.001)","sentence":"The hemoglobin A1c (HbA1c  of all patients improved significantly from 8.1\u00b11.2% to 7.6\u00b11.1% after 12 weeks of add-on therapy with sitagliptin (p<0.01), and the insulin dosage was reduced from 27.3\u00b115.8 U\/day to 24.5\u00b116.5 U\/day (p<0.001)"}
{"PMID":23386390,"re_id":2,"annotated sentence":"Add-on therapy with the <e2>DPP-4<\\e2> inhibitor <e1>sitagliptin<\\e1> improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sitagliptin","object":"DPP-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Add-on therapy with the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus","sentence":"Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus"}
{"PMID":23386702,"re_id":0,"annotated sentence":"Diclofenac-\u03b2-d-glucuronide, <e1>clopidogrel-\u03b2-d-glucuronide<\\e1>  ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited <e2>hCES1<\\e2>  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"clopidogrel-\u03b2-d-glucuronide","object":"hCES1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Diclofenac-\u03b2-d-glucuronide, <e1>CHEMICAL<\\e1>  ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited <e2>GENE-Y<\\e2>  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2","sentence":"Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide  ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited hCES1  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2"}
{"PMID":23386702,"re_id":1,"annotated sentence":"Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, <e1>ibuprofen-\u03b2-d-glucuronide<\\e1>  (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited <e2>hCES1<\\e2>  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ibuprofen-\u03b2-d-glucuronide","object":"hCES1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, <e1>CHEMICAL<\\e1>  (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited <e2>GENE-Y<\\e2>  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2","sentence":"Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide  (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited hCES1  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2"}
{"PMID":23386702,"re_id":2,"annotated sentence":"Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, <e1>(R)-naproxen-\u03b2-d-glucuronide<\\e1>  and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited <e2>hCES1<\\e2>  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(R)-naproxen-\u03b2-d-glucuronide","object":"hCES1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, <e1>CHEMICAL<\\e1>  and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited <e2>GENE-Y<\\e2>  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2","sentence":"Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide  and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited hCES1  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2"}
{"PMID":23386702,"re_id":3,"annotated sentence":"Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and <e1>(S)-naproxen-\u03b2-d-glucuronide<\\e1> selectively inhibited <e2>hCES1<\\e2>  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(S)-naproxen-\u03b2-d-glucuronide","object":"hCES1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and <e1>CHEMICAL<\\e1> selectively inhibited <e2>GENE-Y<\\e2>  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2","sentence":"Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited hCES1  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2"}
{"PMID":23386702,"re_id":4,"annotated sentence":"Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to <e1>acyl glucuronides<\\e1> due to the potential inhibition of <e2>hCESs<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"hCESs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to <e1>CHEMICAL<\\e1> due to the potential inhibition of <e2>GENE-N<\\e2> ","sentence":"Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to acyl glucuronides due to the potential inhibition of hCESs "}
{"PMID":23386702,"re_id":5,"annotated sentence":"Objective: This study explores the ability of <e1>acyl glucuronides<\\e1> to act as substrates or inhibitors of <e2>human carboxylesterases 1<\\e2> (hCES1) and 2 (hCES2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"human carboxylesterases 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Objective: This study explores the ability of <e1>CHEMICAL<\\e1> to act as substrates or inhibitors of <e2>GENE-Y<\\e2> (hCES1) and 2 (hCES2)","sentence":"Objective: This study explores the ability of acyl glucuronides to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (hCES2)"}
{"PMID":23386702,"re_id":6,"annotated sentence":"Objective: This study explores the ability of <e1>acyl glucuronides<\\e1> to act as substrates or inhibitors of human carboxylesterases 1 (<e2>hCES1<\\e2>  and 2 (hCES2)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"hCES1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Objective: This study explores the ability of <e1>CHEMICAL<\\e1> to act as substrates or inhibitors of human carboxylesterases 1 (<e2>GENE-Y<\\e2>  and 2 (hCES2)","sentence":"Objective: This study explores the ability of acyl glucuronides to act as substrates or inhibitors of human carboxylesterases 1 (hCES1  and 2 (hCES2)"}
{"PMID":23386702,"re_id":7,"annotated sentence":"Objective: This study explores the ability of <e1>acyl glucuronides<\\e1> to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (<e2>hCES2<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"hCES2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Objective: This study explores the ability of <e1>CHEMICAL<\\e1> to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (<e2>GENE-Y<\\e2> ","sentence":"Objective: This study explores the ability of acyl glucuronides to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (hCES2 "}
{"PMID":23386702,"re_id":8,"annotated sentence":"Reversible inhibition of <e2>human carboxylesterases<\\e2> by <e1>acyl glucuronides<\\e1>  Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"human carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Reversible inhibition of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1>  Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively","sentence":"Reversible inhibition of human carboxylesterases by acyl glucuronides  Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively"}
{"PMID":23386702,"re_id":9,"annotated sentence":"<e1>Diclofenac-\u03b2-d-glucuronide<\\e1>  clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited <e2>hCES1<\\e2>  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Diclofenac-\u03b2-d-glucuronide","object":"hCES1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited <e2>GENE-Y<\\e2>  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2","sentence":"Diclofenac-\u03b2-d-glucuronide  clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited hCES1  with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2"}
{"PMID":23386702,"re_id":10,"annotated sentence":"<e2>Carboxylesterases<\\e2> hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting <e1>alcohols<\\e1>  amines, and thiols, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"alcohols","object":"Carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting <e1>CHEMICAL<\\e1>  amines, and thiols, respectively","sentence":"Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols  amines, and thiols, respectively"}
{"PMID":23386702,"re_id":11,"annotated sentence":"<e2>Uridine 5'-diphosphate- glucuronosyltransferases<\\e2> are colocalized with carboxylesterases and have the potential to further metabolize <e1>carboxylic acids<\\e1> to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"carboxylic acids","object":"Uridine 5'-diphosphate- glucuronosyltransferases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> are colocalized with carboxylesterases and have the potential to further metabolize <e1>CHEMICAL<\\e1> to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases","sentence":"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases"}
{"PMID":23386702,"re_id":12,"annotated sentence":"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with <e2>carboxylesterases<\\e2> and have the potential to further metabolize <e1>carboxylic acids<\\e1> to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"carboxylic acids","object":"carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with <e2>GENE-N<\\e2> and have the potential to further metabolize <e1>CHEMICAL<\\e1> to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with GENE-N","sentence":"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases"}
{"PMID":23386702,"re_id":13,"annotated sentence":"<e2>Carboxylesterases<\\e2> hydrolyze <e1>esters<\\e1>  amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"esters","object":"Carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> hydrolyze <e1>CHEMICAL<\\e1>  amides, and thioCHEMICAL to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively","sentence":"Carboxylesterases hydrolyze esters  amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively"}
{"PMID":23386702,"re_id":14,"annotated sentence":"<e2>Uridine 5'-diphosphate- glucuronosyltransferases<\\e2> are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to <e1>acyl glucuronides<\\e1>  but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"Uridine 5'-diphosphate- glucuronosyltransferases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to <e1>CHEMICAL<\\e1>  but it is currently unknown if CHEMICAL, being esters, also interact with carboxylesterases","sentence":"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides  but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases"}
{"PMID":23386702,"re_id":15,"annotated sentence":"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with <e2>carboxylesterases<\\e2> and have the potential to further metabolize carboxylic acids to <e1>acyl glucuronides<\\e1>  but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with <e2>GENE-N<\\e2> and have the potential to further metabolize carboxylic acids to <e1>CHEMICAL<\\e1>  but it is currently unknown if CHEMICAL, being esters, also interact with GENE-N","sentence":"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides  but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases"}
{"PMID":23386702,"re_id":16,"annotated sentence":"<e2>Uridine 5'-diphosphate- glucuronosyltransferases<\\e2> are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if <e1>acyl glucuronides<\\e1>  being esters, also interact with carboxylesterases","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"Uridine 5'-diphosphate- glucuronosyltransferases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to CHEMICAL, but it is currently unknown if <e1>CHEMICAL<\\e1>  being esters, also interact with carboxylesterases","sentence":"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides  being esters, also interact with carboxylesterases"}
{"PMID":23386702,"re_id":17,"annotated sentence":"<e2>Carboxylesterases<\\e2> hydrolyze esters, <e1>amides<\\e1>  and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amides","object":"Carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> hydrolyze esters, <e1>CHEMICAL<\\e1>  and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively","sentence":"Carboxylesterases hydrolyze esters, amides  and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively"}
{"PMID":23386702,"re_id":18,"annotated sentence":"Objective: This study explores the ability of <e1>acyl glucuronides<\\e1> to act as substrates or inhibitors of <e2>human carboxylesterases 1<\\e2> (hCES1) and 2 (hCES2)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"human carboxylesterases 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Objective: This study explores the ability of <e1>CHEMICAL<\\e1> to act as substrates or inhibitors of <e2>GENE-Y<\\e2> (hCES1) and 2 (hCES2)","sentence":"Objective: This study explores the ability of acyl glucuronides to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (hCES2)"}
{"PMID":23386702,"re_id":19,"annotated sentence":"Objective: This study explores the ability of <e1>acyl glucuronides<\\e1> to act as substrates or inhibitors of human carboxylesterases 1 (<e2>hCES1<\\e2>  and 2 (hCES2)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"hCES1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Objective: This study explores the ability of <e1>CHEMICAL<\\e1> to act as substrates or inhibitors of human carboxylesterases 1 (<e2>GENE-Y<\\e2>  and 2 (hCES2)","sentence":"Objective: This study explores the ability of acyl glucuronides to act as substrates or inhibitors of human carboxylesterases 1 (hCES1  and 2 (hCES2)"}
{"PMID":23386702,"re_id":20,"annotated sentence":"Objective: This study explores the ability of <e1>acyl glucuronides<\\e1> to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (<e2>hCES2<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"hCES2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Objective: This study explores the ability of <e1>CHEMICAL<\\e1> to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (<e2>GENE-Y<\\e2> ","sentence":"Objective: This study explores the ability of acyl glucuronides to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (hCES2 "}
{"PMID":23386702,"re_id":21,"annotated sentence":"<e2>Carboxylesterases<\\e2> hydrolyze esters, amides, and <e1>thioesters<\\e1> to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"thioesters","object":"Carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> hydrolyze esters, amides, and <e1>CHEMICAL<\\e1> to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively","sentence":"Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively"}
{"PMID":23386702,"re_id":22,"annotated sentence":"Methods: The stability of six <e1>acyl glucuronides<\\e1> in the presence of <e2>hCES1<\\e2>  hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"hCES1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methods: The stability of six <e1>CHEMICAL<\\e1> in the presence of <e2>GENE-Y<\\e2>  hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated","sentence":"Methods: The stability of six acyl glucuronides in the presence of hCES1  hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated"}
{"PMID":23386702,"re_id":23,"annotated sentence":"Methods: The stability of six <e1>acyl glucuronides<\\e1> in the presence of hCES1, <e2>hCES2<\\e2>  and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"acyl glucuronides","object":"hCES2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methods: The stability of six <e1>CHEMICAL<\\e1> in the presence of hCES1, <e2>GENE-Y<\\e2>  and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated","sentence":"Methods: The stability of six acyl glucuronides in the presence of hCES1, hCES2  and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated"}
{"PMID":23386702,"re_id":24,"annotated sentence":"<e2>Carboxylesterases<\\e2> hydrolyze esters, amides, and thioesters to produce <e1>carboxylic acids<\\e1> and resulting alcohols, amines, and thiols, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"carboxylic acids","object":"Carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> hydrolyze esters, amides, and thioesters to produce <e1>CHEMICAL<\\e1> and resulting alcohols, amines, and thiols, respectively","sentence":"Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively"}
{"PMID":23386702,"re_id":25,"annotated sentence":"<e2>Carboxylesterases<\\e2> hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, <e1>amines<\\e1>  and thiols, respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"amines","object":"Carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, <e1>CHEMICAL<\\e1>  and thiols, respectively","sentence":"Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines  and thiols, respectively"}
{"PMID":23386702,"re_id":26,"annotated sentence":"<e2>Carboxylesterases<\\e2> hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and <e1>thiols<\\e1>  respectively","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"thiols","object":"Carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and <e1>CHEMICAL<\\e1>  respectively","sentence":"Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols  respectively"}
{"PMID":23391485,"re_id":0,"annotated sentence":"Our results showed that low dose <e1>BPA<\\e1> and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of <e2>Oct4<\\e2> and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BPA","object":"Oct4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results showed that low dose <e1>CHEMICAL<\\e1> and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of <e2>GENE-Y<\\e2> and Nanog proteins, while only CHEMICAL could downregulate the expression of E-cadherin protein","sentence":"Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein"}
{"PMID":23391485,"re_id":1,"annotated sentence":"Our results showed that low dose <e1>BPA<\\e1> and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and <e2>Nanog<\\e2> proteins, while only BPA could downregulate the expression of E-cadherin protein","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BPA","object":"Nanog","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results showed that low dose <e1>CHEMICAL<\\e1> and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and <e2>GENE-Y<\\e2> proteins, while only CHEMICAL could downregulate the expression of E-cadherin protein","sentence":"Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein"}
{"PMID":23391485,"re_id":2,"annotated sentence":"Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only <e1>BPA<\\e1> could downregulate the expression of <e2>E-cadherin<\\e2> protein","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPA","object":"E-cadherin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results showed that low dose CHEMICAL and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only <e1>CHEMICAL<\\e1> could downregulate the expression of <e2>GENE-Y<\\e2> protein","sentence":"Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein"}
{"PMID":23393220,"re_id":0,"annotated sentence":"Given these findings, a unified PK model including the inhibition of <e2>MAO-A<\\e2>  and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood <e1>harmaline<\\e1>  5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of <e2>GENE-Y<\\e2>  and CYP2D6-catalyzed 5-MeO-DMT metabolism by CHEMICAL was developed to describe blood <e1>CHEMICAL<\\e1>  5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A  and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline  5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":1,"annotated sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and <e2>CYP2D6<\\e2> catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood <e1>harmaline<\\e1>  5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and <e2>GENE-Y<\\e2> catalyzed 5-MeO-DMT metabolism by CHEMICAL was developed to describe blood <e1>CHEMICAL<\\e1>  5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-GENE-Y mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6 catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline  5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":2,"annotated sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood <e1>harmaline<\\e1>  5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-<e2>CYP2D6<\\e2> mouse models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and GENE-Y-catalyzed 5-MeO-DMT metabolism by CHEMICAL was developed to describe blood <e1>CHEMICAL<\\e1>  5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-<e2>GENE-Y<\\e2> mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline  5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":3,"annotated sentence":"Our recent study has demonstrated that coadministration of <e2>monoamine oxidase A<\\e2> (MAO-A) inhibitor <e1>harmaline<\\e1> (5 mg\/kg) increases systemic exposure to 5-MeO-DMT (2 mg\/kg) and active metabolite bufotenine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"monoamine oxidase A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our recent study has demonstrated that coadministration of <e2>GENE-Y<\\e2> (MAO-A) inhibitor <e1>CHEMICAL<\\e1> (5 mg\/kg) increases systemic exposure to 5-MeO-DMT (2 mg\/kg) and active metabolite bufotenine","sentence":"Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg\/kg) increases systemic exposure to 5-MeO-DMT (2 mg\/kg) and active metabolite bufotenine"}
{"PMID":23393220,"re_id":4,"annotated sentence":"Our recent study has demonstrated that coadministration of monoamine oxidase A (<e2>MAO-A<\\e2>  inhibitor <e1>harmaline<\\e1> (5 mg\/kg) increases systemic exposure to 5-MeO-DMT (2 mg\/kg) and active metabolite bufotenine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our recent study has demonstrated that coadministration of monoamine oxidase A (<e2>GENE-Y<\\e2>  inhibitor <e1>CHEMICAL<\\e1> (5 mg\/kg) increases systemic exposure to 5-MeO-DMT (2 mg\/kg) and active metabolite bufotenine","sentence":"Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A  inhibitor harmaline (5 mg\/kg) increases systemic exposure to 5-MeO-DMT (2 mg\/kg) and active metabolite bufotenine"}
{"PMID":23393220,"re_id":5,"annotated sentence":"Our data revealed that inhibition of <e2>MAO-A<\\e2> mediated metabolic elimination by <e1>harmaline<\\e1> (2, 5, and 15 mg\/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg\/kg) at all dose combinations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our data revealed that inhibition of <e2>GENE-Y<\\e2> mediated metabolic elimination by <e1>CHEMICAL<\\e1> (2, 5, and 15 mg\/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg\/kg) at all dose combinations","sentence":"Our data revealed that inhibition of MAO-A mediated metabolic elimination by harmaline (2, 5, and 15 mg\/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg\/kg) at all dose combinations"}
{"PMID":23393220,"re_id":6,"annotated sentence":"Pharmacokinetic Interactions between <e2>Monoamine Oxidase A<\\e2> Inhibitor <e1>Harmaline<\\e1> and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Harmaline","object":"Monoamine Oxidase A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacokinetic Interactions between <e2>GENE-Y<\\e2> Inhibitor <e1>CHEMICAL<\\e1> and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status","sentence":"Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status"}
{"PMID":23393220,"re_id":7,"annotated sentence":"The in vivo inhibitory effect of <e1>harmaline<\\e1> on <e2>CYP2D6<\\e2> catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The in vivo inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2> catalyzed bufotenine formation was confirmed by in vitro study using purified GENE-Y","sentence":"The in vivo inhibitory effect of harmaline on CYP2D6 catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6"}
{"PMID":23393220,"re_id":8,"annotated sentence":"The in vivo inhibitory effect of <e1>harmaline<\\e1> on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified <e2>CYP2D6<\\e2>  Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The in vivo inhibitory effect of <e1>CHEMICAL<\\e1> on GENE-Y-catalyzed bufotenine formation was confirmed by in vitro study using purified <e2>GENE-Y<\\e2>  Given these findings, a unified PK model including the inhibition of MAO-A- and GENE-Y-catalyzed 5-MeO-DMT metabolism by CHEMICAL was developed to describe blood CHEMICAL, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-GENE-Y mouse models","sentence":"The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6  Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":9,"annotated sentence":"Given these findings, a unified PK model including the inhibition of <e2>MAO-A<\\e2>  and CYP2D6-catalyzed 5-MeO-DMT metabolism by <e1>harmaline<\\e1> was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of <e2>GENE-Y<\\e2>  and CYP2D6-catalyzed 5-MeO-DMT metabolism by <e1>CHEMICAL<\\e1> was developed to describe blood CHEMICAL, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A  and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":10,"annotated sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and <e2>CYP2D6<\\e2> catalyzed 5-MeO-DMT metabolism by <e1>harmaline<\\e1> was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and <e2>GENE-Y<\\e2> catalyzed 5-MeO-DMT metabolism by <e1>CHEMICAL<\\e1> was developed to describe blood CHEMICAL, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-GENE-Y mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6 catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":11,"annotated sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by <e1>harmaline<\\e1> was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-<e2>CYP2D6<\\e2> mouse models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"harmaline","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and GENE-Y-catalyzed 5-MeO-DMT metabolism by <e1>CHEMICAL<\\e1> was developed to describe blood CHEMICAL, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-<e2>GENE-Y<\\e2> mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":12,"annotated sentence":"Given these findings, a unified PK model including the inhibition of <e2>MAO-A<\\e2>  and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, <e1>5-MeO-DMT<\\e1>  and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-MeO-DMT","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of <e2>GENE-Y<\\e2>  and CYP2D6-catalyzed CHEMICAL metabolism by harmaline was developed to describe blood harmaline, <e1>CHEMICAL<\\e1>  and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A  and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT  and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":13,"annotated sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and <e2>CYP2D6<\\e2> catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, <e1>5-MeO-DMT<\\e1>  and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-MeO-DMT","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and <e2>GENE-Y<\\e2> catalyzed CHEMICAL metabolism by harmaline was developed to describe blood harmaline, <e1>CHEMICAL<\\e1>  and bufotenine PK profiles in both wild-type and Tg-GENE-Y mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6 catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT  and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":14,"annotated sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, <e1>5-MeO-DMT<\\e1>  and bufotenine PK profiles in both wild-type and Tg-<e2>CYP2D6<\\e2> mouse models","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-MeO-DMT","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and GENE-Y-catalyzed CHEMICAL metabolism by harmaline was developed to describe blood harmaline, <e1>CHEMICAL<\\e1>  and bufotenine PK profiles in both wild-type and Tg-<e2>GENE-Y<\\e2> mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT  and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":15,"annotated sentence":"The in vivo inhibitory effect of harmaline on <e2>CYP2D6<\\e2> catalyzed <e1>bufotenine<\\e1> formation was confirmed by in vitro study using purified CYP2D6","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bufotenine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The in vivo inhibitory effect of harmaline on <e2>GENE-Y<\\e2> catalyzed <e1>CHEMICAL<\\e1> formation was confirmed by in vitro study using purified GENE-Y","sentence":"The in vivo inhibitory effect of harmaline on CYP2D6 catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6"}
{"PMID":23393220,"re_id":16,"annotated sentence":"The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed <e1>bufotenine<\\e1> formation was confirmed by in vitro study using purified <e2>CYP2D6<\\e2>  Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"bufotenine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The in vivo inhibitory effect of harmaline on GENE-Y-catalyzed <e1>CHEMICAL<\\e1> formation was confirmed by in vitro study using purified <e2>GENE-Y<\\e2>  Given these findings, a unified PK model including the inhibition of MAO-A- and GENE-Y-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and CHEMICAL PK profiles in both wild-type and Tg-GENE-Y mouse models","sentence":"The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6  Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":17,"annotated sentence":"Given these findings, a unified PK model including the inhibition of <e2>MAO-A<\\e2>  and CYP2D6-catalyzed <e1>5-MeO-DMT<\\e1> metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-MeO-DMT","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of <e2>GENE-Y<\\e2>  and CYP2D6-catalyzed <e1>CHEMICAL<\\e1> metabolism by harmaline was developed to describe blood harmaline, CHEMICAL, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A  and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":18,"annotated sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and <e2>CYP2D6<\\e2> catalyzed <e1>5-MeO-DMT<\\e1> metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-MeO-DMT","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and <e2>GENE-Y<\\e2> catalyzed <e1>CHEMICAL<\\e1> metabolism by harmaline was developed to describe blood harmaline, CHEMICAL, and bufotenine PK profiles in both wild-type and Tg-GENE-Y mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6 catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23393220,"re_id":19,"annotated sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed <e1>5-MeO-DMT<\\e1> metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-<e2>CYP2D6<\\e2> mouse models","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-MeO-DMT","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and GENE-Y-catalyzed <e1>CHEMICAL<\\e1> metabolism by harmaline was developed to describe blood harmaline, CHEMICAL, and bufotenine PK profiles in both wild-type and Tg-<e2>GENE-Y<\\e2> mouse models","sentence":"Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models"}
{"PMID":23395981,"re_id":0,"annotated sentence":"In addition, <e1>ethanol<\\e1> induced degradation of <e2>DNA methyltransferases<\\e2> (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"DNA methyltransferases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induced degradation of <e2>GENE-N<\\e2> (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","sentence":"In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway"}
{"PMID":23395981,"re_id":1,"annotated sentence":"In addition, <e1>ethanol<\\e1> induced degradation of DNA methyltransferases (<e2>DNMT-<\\e2> , DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"DNMT-","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induced degradation of DNA methyltransferases (<e2>GENE-Y<\\e2> , GENE-Y3a, and GENE-Y3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","sentence":"In addition, ethanol induced degradation of DNA methyltransferases (DNMT- , DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway"}
{"PMID":23395981,"re_id":2,"annotated sentence":"In addition, <e1>ethanol<\\e1> induced degradation of DNA methyltransferases (DNMT-1, <e2>DNMT-3a<\\e2>  and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"DNMT-3a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induced degradation of DNA methyltransferases (DNMT-1, <e2>GENE-Y<\\e2>  and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","sentence":"In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a  and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway"}
{"PMID":23395981,"re_id":3,"annotated sentence":"In addition, <e1>ethanol<\\e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and <e2>DNMT-3b<\\e2> , as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"DNMT-3b","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and <e2>GENE-Y<\\e2> , as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","sentence":"In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b , as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway"}
{"PMID":23395981,"re_id":4,"annotated sentence":"In addition, <e1>ethanol<\\e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the <e2>methyl CpG-binding proteins<\\e2> (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"methyl CpG-binding proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the <e2>GENE-N<\\e2> (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","sentence":"In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway"}
{"PMID":23395981,"re_id":5,"annotated sentence":"In addition, <e1>ethanol<\\e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (<e2>MeCP-2<\\e2>  MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"MeCP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (<e2>GENE-Y<\\e2>  MBD-2 and MBD-3), in MEF cells by the proteasomal pathway","sentence":"In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2  MBD-2 and MBD-3), in MEF cells by the proteasomal pathway"}
{"PMID":23395981,"re_id":6,"annotated sentence":"In addition, <e1>ethanol<\\e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, <e2>MBD-2<\\e2> and MBD-3), in MEF cells by the proteasomal pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"MBD-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, <e2>GENE-Y<\\e2> and MBD-3), in MEF cells by the proteasomal pathway","sentence":"In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway"}
{"PMID":23395981,"re_id":7,"annotated sentence":"In addition, <e1>ethanol<\\e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and <e2>MBD-3<\\e2> , in MEF cells by the proteasomal pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethanol","object":"MBD-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and <e2>GENE-Y<\\e2> , in MEF cells by the proteasomal pathway","sentence":"In addition, ethanol induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3 , in MEF cells by the proteasomal pathway"}
{"PMID":23397055,"re_id":0,"annotated sentence":"The <e2>A2A adenosine receptor<\\e2> agonist CGS21680 (<e1>C23H29N7O6.HCl.xH2O<\\e1>  (0.001-0.1 \u03bcM) did not alter NE oxidation currents","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"C23H29N7O6.HCl.xH2O","object":"A2A adenosine receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> agonist CGS21680 (<e1>CHEMICAL<\\e1>  (0.001-0.1 \u03bcM) did not alter NE oxidation currents","sentence":"The A2A adenosine receptor agonist CGS21680 (C23H29N7O6.HCl.xH2O  (0.001-0.1 \u03bcM) did not alter NE oxidation currents"}
{"PMID":23397055,"re_id":1,"annotated sentence":"Adenosine and N(6)-cyclopentyl-adenosine (<e1>CPA<\\e1>  <e2>A1R<\\e2> agonist) constricted MVs but not MAs","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"CPA","object":"A1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adenosine and N(6)-cyclopentyl-adenosine (<e1>CHEMICAL<\\e1>  <e2>GENE-Y<\\e2> agonist) constricted MVs but not MAs","sentence":"Adenosine and N(6)-cyclopentyl-adenosine (CPA  A1R agonist) constricted MVs but not MAs"}
{"PMID":23397055,"re_id":2,"annotated sentence":"<e1>Adenosine<\\e1> and N(6)-cyclopentyl-adenosine (CPA, <e2>A1R<\\e2> agonist) constricted MVs but not MAs","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Adenosine","object":"A1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and N(6)-cyclopentyl-adenosine (CPA, <e2>GENE-Y<\\e2> agonist) constricted MVs but not MAs","sentence":"Adenosine and N(6)-cyclopentyl-adenosine (CPA, A1R agonist) constricted MVs but not MAs"}
{"PMID":23397055,"re_id":3,"annotated sentence":"Adenosine and <e1>N(6)-cyclopentyl-adenosine<\\e1> (CPA, <e2>A1R<\\e2> agonist) constricted MVs but not MAs","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"N(6)-cyclopentyl-adenosine","object":"A1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adenosine and <e1>CHEMICAL<\\e1> (CPA, <e2>GENE-Y<\\e2> agonist) constricted MVs but not MAs","sentence":"Adenosine and N(6)-cyclopentyl-adenosine (CPA, A1R agonist) constricted MVs but not MAs"}
{"PMID":23397055,"re_id":4,"annotated sentence":"The <e2>A2A adenosine receptor<\\e2> agonist <e1>CGS21680<\\e1> (C23H29N7O6.HCl.xH2O) (0.001-0.1 \u03bcM) did not alter NE oxidation currents","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"CGS21680","object":"A2A adenosine receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> (C23H29N7O6.HCl.xH2O) (0.001-0.1 \u03bcM) did not alter NE oxidation currents","sentence":"The A2A adenosine receptor agonist CGS21680 (C23H29N7O6.HCl.xH2O) (0.001-0.1 \u03bcM) did not alter NE oxidation currents"}
{"PMID":23402364,"re_id":0,"annotated sentence":"Nitric oxide products of <e1>VP-16<\\e1> displayed significantly diminished <e2>topoisomerase II<\\e2> dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"VP-16","object":"topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nitric oxide products of <e1>CHEMICAL<\\e1> displayed significantly diminished <e2>GENE-Y<\\e2> dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells","sentence":"Nitric oxide products of VP-16 displayed significantly diminished topoisomerase II dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells"}
{"PMID":23402841,"re_id":0,"annotated sentence":"The values of mean corpuscular hemoglobin concentration and mean corpuscular <e2>hemoglobin<\\e2> increased in the <e1>STX<\\e1> group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"STX","object":"hemoglobin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The values of mean corpuscular GENE-N concentration and mean corpuscular <e2>GENE-N<\\e2> increased in the <e1>CHEMICAL<\\e1> group","sentence":"The values of mean corpuscular hemoglobin concentration and mean corpuscular hemoglobin increased in the STX group"}
{"PMID":23402841,"re_id":1,"annotated sentence":"The values of mean corpuscular <e2>hemoglobin<\\e2> concentration and mean corpuscular hemoglobin increased in the <e1>STX<\\e1> group","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"STX","object":"hemoglobin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The values of mean corpuscular <e2>GENE-N<\\e2> concentration and mean corpuscular GENE-N increased in the <e1>CHEMICAL<\\e1> group","sentence":"The values of mean corpuscular hemoglobin concentration and mean corpuscular hemoglobin increased in the STX group"}
{"PMID":23403203,"re_id":0,"annotated sentence":"Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator <e1>BAPTA-AM<\\e1> prevented downregulation of <e2>Cx43<\\e2> and inhibition of GJIC","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BAPTA-AM","object":"Cx43","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator <e1>CHEMICAL<\\e1> prevented downregulation of <e2>GENE-Y<\\e2> and inhibition of GJIC","sentence":"Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of Cx43 and inhibition of GJIC"}
{"PMID":23403203,"re_id":1,"annotated sentence":"Taken together, these findings indicate that <e1>antofine<\\e1> induces Cx43 gap junction disassembly by the <e2>PKC\u03b2<\\e2> signaling pathway","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"antofine","object":"PKC\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, these findings indicate that <e1>CHEMICAL<\\e1> induces Cx43 gap junction disassembly by the <e2>GENE-Y<\\e2> signaling pathway","sentence":"Taken together, these findings indicate that antofine induces Cx43 gap junction disassembly by the PKC\u03b2 signaling pathway"}
{"PMID":23403203,"re_id":2,"annotated sentence":"Levels of <e2>Cx43<\\e2> protein were also decreased in a dose- and time-dependent manner following <e1>antofine<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"antofine","object":"Cx43","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Levels of <e2>GENE-Y<\\e2> protein were also decreased in a dose- and time-dependent manner following <e1>CHEMICAL<\\e1> treatment","sentence":"Levels of Cx43 protein were also decreased in a dose- and time-dependent manner following antofine treatment"}
{"PMID":23403203,"re_id":3,"annotated sentence":"Co-treatment of astrocytes with <e1>antofine<\\e1> and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of <e2>Cx43<\\e2> and inhibition of GJIC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"antofine","object":"Cx43","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Co-treatment of astrocytes with <e1>CHEMICAL<\\e1> and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of <e2>GENE-Y<\\e2> and inhibition of GJIC","sentence":"Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of Cx43 and inhibition of GJIC"}
{"PMID":23403203,"re_id":4,"annotated sentence":"Moreover, co-treatment with <e1>antofine<\\e1> and a specific PKC\u03b2 inhibitor prevented endocytosis of gap junctions, downregulation of <e2>Cx43<\\e2>  and inhibition of GJIC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"antofine","object":"Cx43","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, co-treatment with <e1>CHEMICAL<\\e1> and a specific PKC\u03b2 inhibitor prevented endocytosis of gap junctions, downregulation of <e2>GENE-Y<\\e2>  and inhibition of GJIC","sentence":"Moreover, co-treatment with antofine and a specific PKC\u03b2 inhibitor prevented endocytosis of gap junctions, downregulation of Cx43  and inhibition of GJIC"}
{"PMID":23410005,"re_id":0,"annotated sentence":"Our previous work, built on the early pioneering multikinase inhibitor <e1>LY294002<\\e1>  resulted in the only <e2>PI3K<\\e2> vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LY294002","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our previous work, built on the early pioneering multikinase inhibitor <e1>CHEMICAL<\\e1>  resulted in the only <e2>GENE-N<\\e2> vascular-targeted GENE-N inhibitor prodrug, SF1126, which has now completed Phase I clinical trials","sentence":"Our previous work, built on the early pioneering multikinase inhibitor LY294002  resulted in the only PI3K vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials"}
{"PMID":23410005,"re_id":1,"annotated sentence":"Our previous work, built on the early pioneering multikinase inhibitor <e1>LY294002<\\e1>  resulted in the only PI3K vascular-targeted <e2>PI3K<\\e2> inhibitor prodrug, SF1126, which has now completed Phase I clinical trials","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LY294002","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our previous work, built on the early pioneering multikinase inhibitor <e1>CHEMICAL<\\e1>  resulted in the only GENE-N vascular-targeted <e2>GENE-N<\\e2> inhibitor prodrug, SF1126, which has now completed Phase I clinical trials","sentence":"Our previous work, built on the early pioneering multikinase inhibitor LY294002  resulted in the only PI3K vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials"}
{"PMID":23410005,"re_id":2,"annotated sentence":"Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only <e2>PI3K<\\e2> vascular-targeted PI3K inhibitor prodrug, <e1>SF1126<\\e1>  which has now completed Phase I clinical trials","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SF1126","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only <e2>GENE-N<\\e2> vascular-targeted GENE-N inhibitor prodrug, <e1>CHEMICAL<\\e1>  which has now completed Phase I clinical trials","sentence":"Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3K vascular-targeted PI3K inhibitor prodrug, SF1126  which has now completed Phase I clinical trials"}
{"PMID":23410005,"re_id":3,"annotated sentence":"Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3K vascular-targeted <e2>PI3K<\\e2> inhibitor prodrug, <e1>SF1126<\\e1>  which has now completed Phase I clinical trials","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SF1126","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only GENE-N vascular-targeted <e2>GENE-N<\\e2> inhibitor prodrug, <e1>CHEMICAL<\\e1>  which has now completed Phase I clinical trials","sentence":"Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3K vascular-targeted PI3K inhibitor prodrug, SF1126  which has now completed Phase I clinical trials"}
{"PMID":23410005,"re_id":4,"annotated sentence":"This work resulted in the discovery of the <e1>5-morpholino-7H-thieno[3,2-b]pyran-7-one<\\e1> system as the foundation of a new compound class of potential <e2>PI3K<\\e2> inhibitors having improved potency toward PI3K","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-morpholino-7H-thieno[3,2-b]pyran-7-one","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This work resulted in the discovery of the <e1>CHEMICAL<\\e1> system as the foundation of a new compound class of potential <e2>GENE-N<\\e2> inhibitors having improved potency toward GENE-N","sentence":"This work resulted in the discovery of the 5-morpholino-7H-thieno[3,2-b]pyran-7-one system as the foundation of a new compound class of potential PI3K inhibitors having improved potency toward PI3K"}
{"PMID":23410005,"re_id":5,"annotated sentence":"This work resulted in the discovery of the <e1>5-morpholino-7H-thieno[3,2-b]pyran-7-one<\\e1> system as the foundation of a new compound class of potential PI3K inhibitors having improved potency toward <e2>PI3K<\\e2>  The synthesis and cancer stem cell-based activity of these compounds are reported herein.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-morpholino-7H-thieno[3,2-b]pyran-7-one","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This work resulted in the discovery of the <e1>CHEMICAL<\\e1> system as the foundation of a new compound class of potential GENE-N inhibitors having improved potency toward <e2>GENE-N<\\e2>  The synthesis and cancer stem cell-based activity of these compounds are reported herein.","sentence":"This work resulted in the discovery of the 5-morpholino-7H-thieno[3,2-b]pyran-7-one system as the foundation of a new compound class of potential PI3K inhibitors having improved potency toward PI3K  The synthesis and cancer stem cell-based activity of these compounds are reported herein."}
{"PMID":23410005,"re_id":6,"annotated sentence":"Synthesis and cancer stem cell-based activity of substituted <e1>5-morpholino-7H-thieno[3,2-b]pyran-7-ones<\\e1> designed as next generation <e2>PI3K<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-morpholino-7H-thieno[3,2-b]pyran-7-ones","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Synthesis and cancer stem cell-based activity of substituted <e1>CHEMICAL<\\e1> designed as next generation <e2>GENE-N<\\e2> inhibitors","sentence":"Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors"}
{"PMID":23410798,"re_id":0,"annotated sentence":"Spiro heterocycles as potential inhibitors of <e2>SIRT1<\\e2>  Pd\/C-mediated synthesis of novel <e1>N-indolylmethyl spiroindoline-3,2'-quinazolines<\\e1>  Novel N-indolylmethyl substituted spiroindoline-3,2'-quinazolines were designed as potential inhibitiors of SIRT1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-indolylmethyl spiroindoline-3,2'-quinazolines","object":"SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Spiro heterocycles as potential inhibitors of <e2>GENE-Y<\\e2>  Pd\/C-mediated synthesis of novel <e1>CHEMICAL<\\e1>  Novel N-indolylmethyl substituted spiroindoline-3,2'-quinazolines were designed as potential inhibitiors of GENE-Y","sentence":"Spiro heterocycles as potential inhibitors of SIRT1  Pd\/C-mediated synthesis of novel N-indolylmethyl spiroindoline-3,2'-quinazolines  Novel N-indolylmethyl substituted spiroindoline-3,2'-quinazolines were designed as potential inhibitiors of SIRT1"}
{"PMID":23410798,"re_id":1,"annotated sentence":"Novel <e1>N-indolylmethyl substituted spiroindoline-3,2'-quinazolines<\\e1> were designed as potential inhibitiors of <e2>SIRT1<\\e2>  These compounds were synthesized in good yields by using Pd\/C-Cu mediated coupling-cyclization strategy as a key step involving the reaction of 1-(prop-2-ynyl)-1'H-spiro[indoline-3,2'-quinazoline]-2,4'(3'H)-dione with 2-iodoanilides","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-indolylmethyl substituted spiroindoline-3,2'-quinazolines","object":"SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel <e1>CHEMICAL<\\e1> were designed as potential inhibitiors of <e2>GENE-Y<\\e2>  These compounds were synthesized in good yields by using Pd\/C-Cu mediated coupling-cyclization strategy as a key step involving the reaction of 1-(prop-2-ynyl)-1'H-spiro[indoline-3,2'-quinazoline]-2,4'(3'H)-dione with 2-iodoanilides","sentence":"Novel N-indolylmethyl substituted spiroindoline-3,2'-quinazolines were designed as potential inhibitiors of SIRT1  These compounds were synthesized in good yields by using Pd\/C-Cu mediated coupling-cyclization strategy as a key step involving the reaction of 1-(prop-2-ynyl)-1'H-spiro[indoline-3,2'-quinazoline]-2,4'(3'H)-dione with 2-iodoanilides"}
{"PMID":23411172,"re_id":0,"annotated sentence":"Furthermore, the up-regulation of <e2>IL-12<\\e2> and TNF-\u03b1 was found in the <e1>procyanidin<\\e1> trimers-treated cells in the presence of OVA","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"procyanidin","object":"IL-12","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the up-regulation of <e2>GENE-N<\\e2> and TNF-\u03b1 was found in the <e1>CHEMICAL<\\e1> trimers-treated cells in the presence of OVA","sentence":"Furthermore, the up-regulation of IL-12 and TNF-\u03b1 was found in the procyanidin trimers-treated cells in the presence of OVA"}
{"PMID":23411172,"re_id":1,"annotated sentence":"Furthermore, the up-regulation of IL-12 and <e2>TNF-\u03b1<\\e2> was found in the <e1>procyanidin<\\e1> trimers-treated cells in the presence of OVA","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"procyanidin","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the up-regulation of IL-12 and <e2>GENE-N<\\e2> was found in the <e1>CHEMICAL<\\e1> trimers-treated cells in the presence of OVA","sentence":"Furthermore, the up-regulation of IL-12 and TNF-\u03b1 was found in the procyanidin trimers-treated cells in the presence of OVA"}
{"PMID":23411172,"re_id":2,"annotated sentence":"A significant decrease in <e2>HLA-DR<\\e2> expression was observed in the AP and fractionated <e1>procyanidin<\\e1> treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"procyanidin","object":"HLA-DR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A significant decrease in <e2>GENE-N<\\e2> expression was observed in the AP and fractionated <e1>CHEMICAL<\\e1> treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed","sentence":"A significant decrease in HLA-DR expression was observed in the AP and fractionated procyanidin treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed"}
{"PMID":23411172,"re_id":3,"annotated sentence":"Apple <e1>polyphenols<\\e1> suppress antigen presentation of <e2>ovalbumin<\\e2> by THP-1-derived dendritic cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"polyphenols","object":"ovalbumin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Apple <e1>CHEMICAL<\\e1> suppress antigen presentation of <e2>GENE-N<\\e2> by THP-1-derived dendritic cells","sentence":"Apple polyphenols suppress antigen presentation of ovalbumin by THP-1-derived dendritic cells"}
{"PMID":23411246,"re_id":0,"annotated sentence":"In relation to zinc bioavailability, <e2>\u03b1-CPPs<\\e2>  \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased <e1>zinc<\\e1> uptake","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"zinc","object":"\u03b1-CPPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In relation to CHEMICAL bioavailability, <e2>GENE-N<\\e2>  \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased <e1>CHEMICAL<\\e1> uptake","sentence":"In relation to zinc bioavailability, \u03b1-CPPs  \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased zinc uptake"}
{"PMID":23411246,"re_id":1,"annotated sentence":"In relation to zinc bioavailability, \u03b1-CPPs, <e2>\u03b2-CPPs<\\e2>  \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased <e1>zinc<\\e1> uptake","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"zinc","object":"\u03b2-CPPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In relation to CHEMICAL bioavailability, \u03b1-CPPs, <e2>GENE-N<\\e2>  \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased <e1>CHEMICAL<\\e1> uptake","sentence":"In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs  \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased zinc uptake"}
{"PMID":23411246,"re_id":2,"annotated sentence":"In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs, <e2>\u03b1(s1)-CN<\\e2> 64-74)4P and \u03b2-CN(1-25)4P increased <e1>zinc<\\e1> uptake","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"zinc","object":"\u03b1(s1)-CN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In relation to CHEMICAL bioavailability, \u03b1-CPPs, \u03b2-CPPs, <e2>GENE-Y<\\e2> 64-74)4P and \u03b2-CN(1-25)4P increased <e1>CHEMICAL<\\e1> uptake","sentence":"In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs, \u03b1(s1)-CN 64-74)4P and \u03b2-CN(1-25)4P increased zinc uptake"}
{"PMID":23411246,"re_id":3,"annotated sentence":"In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and <e2>\u03b2-CN<\\e2> 1-25)4P increased <e1>zinc<\\e1> uptake","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"zinc","object":"\u03b2-CN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In relation to CHEMICAL bioavailability, \u03b1-CPPs, \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and <e2>GENE-Y<\\e2> 1-25)4P increased <e1>CHEMICAL<\\e1> uptake","sentence":"In relation to zinc bioavailability, \u03b1-CPPs, \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and \u03b2-CN 1-25)4P increased zinc uptake"}
{"PMID":23411272,"re_id":0,"annotated sentence":"It has been reported that oligomeric <e1>procyanidins<\\e1> of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and <e2>insulin<\\e2> potentiating activities","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"procyanidins","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It has been reported that oligomeric <e1>CHEMICAL<\\e1> of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and <e2>GENE-Y<\\e2> potentiating activities","sentence":"It has been reported that oligomeric procyanidins of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and insulin potentiating activities"}
{"PMID":23414235,"re_id":0,"annotated sentence":"A new inhibitor of <e2>VEGF receptor tyrosine kinases<\\e2>  <e1>vegfrecine<\\e1> (1), was isolated from the culture broth of Streptomyces sp","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vegfrecine","object":"VEGF receptor tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A new inhibitor of <e2>GENE-N<\\e2>  <e1>CHEMICAL<\\e1> (1), was isolated from the culture broth of Streptomyces sp","sentence":"A new inhibitor of VEGF receptor tyrosine kinases  vegfrecine (1), was isolated from the culture broth of Streptomyces sp"}
{"PMID":23414235,"re_id":1,"annotated sentence":"<e1>Vegfrecine<\\e1>  an Inhibitor of <e2>VEGF Receptor Tyrosine Kinases<\\e2> Isolated from the Culture Broth of Streptomyces sp","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Vegfrecine","object":"VEGF Receptor Tyrosine Kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  an Inhibitor of <e2>GENE-N<\\e2> Isolated from the Culture Broth of Streptomyces sp","sentence":"Vegfrecine  an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp"}
{"PMID":23414340,"re_id":0,"annotated sentence":"Although <e2>thioredoxin reductase<\\e2> (TRR) inhibitors (<e1>aurothioglucose<\\e1> and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aurothioglucose","object":"thioredoxin reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although <e2>GENE-N<\\e2> (TRR) inhibitors (<e1>CHEMICAL<\\e1> and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction","sentence":"Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction"}
{"PMID":23414340,"re_id":1,"annotated sentence":"Although thioredoxin reductase (<e2>TRR<\\e2>  inhibitors (<e1>aurothioglucose<\\e1> and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aurothioglucose","object":"TRR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although thioredoxin reductase (<e2>GENE-N<\\e2>  inhibitors (<e1>CHEMICAL<\\e1> and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat GENE-N plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction","sentence":"Although thioredoxin reductase (TRR  inhibitors (aurothioglucose and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction"}
{"PMID":23414340,"re_id":2,"annotated sentence":"Although <e2>thioredoxin reductase<\\e2> (TRR) inhibitors (aurothioglucose and <e1>Sb(III)<\\e1>  inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sb(III)","object":"thioredoxin reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although <e2>GENE-N<\\e2> (TRR) inhibitors (aurothioglucose and <e1>CHEMICAL<\\e1>  inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction","sentence":"Although thioredoxin reductase (TRR) inhibitors (aurothioglucose and Sb(III)  inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction"}
{"PMID":23414340,"re_id":3,"annotated sentence":"Although thioredoxin reductase (<e2>TRR<\\e2>  inhibitors (aurothioglucose and <e1>Sb(III)<\\e1>  inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sb(III)","object":"TRR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although thioredoxin reductase (<e2>GENE-N<\\e2>  inhibitors (aurothioglucose and <e1>CHEMICAL<\\e1>  inhibited cytosolic DMAs(V) reduction, recombinant rat GENE-N plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction","sentence":"Although thioredoxin reductase (TRR  inhibitors (aurothioglucose and Sb(III)  inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction"}
{"PMID":23414340,"re_id":4,"annotated sentence":"Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect <e2>methyltransferase<\\e2> inhibitor periodate-oxidized <e1>adenosine<\\e1> was without effect","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"adenosine","object":"methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect <e2>GENE-N<\\e2> inhibitor periodate-oxidized <e1>CHEMICAL<\\e1> was without effect","sentence":"Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect methyltransferase inhibitor periodate-oxidized adenosine was without effect"}
{"PMID":23414340,"re_id":5,"annotated sentence":"Although <e2>glutathione S-transferase omega 1<\\e2> (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze <e1>DMAs(V)<\\e1> reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DMAs(V)","object":"glutathione S-transferase omega 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although <e2>GENE-Y<\\e2> (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze <e1>CHEMICAL<\\e1> reduction, their role in CHEMICAL reduction in vivo, or in cell extracts is uncertain","sentence":"Although glutathione S-transferase omega 1 (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain"}
{"PMID":23414340,"re_id":6,"annotated sentence":"Although glutathione S-transferase omega 1 (GSTO1) and <e2>arsenic methyltransferase<\\e2> have been shown or thought to catalyze <e1>DMAs(V)<\\e1> reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DMAs(V)","object":"arsenic methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although glutathione S-transferase omega 1 (GSTO1) and <e2>GENE-Y<\\e2> have been shown or thought to catalyze <e1>CHEMICAL<\\e1> reduction, their role in CHEMICAL reduction in vivo, or in cell extracts is uncertain","sentence":"Although glutathione S-transferase omega 1 (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze DMAs(V) reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain"}
{"PMID":23414802,"re_id":0,"annotated sentence":"In this study, a novel series of <e1>2-hydroxydiarylamide<\\e1> derivatives were synthesized and evaluated for inhibiting <e2>TMPRSS4<\\e2> serine protease activity and suppressing cancer cell invasion","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-hydroxydiarylamide","object":"TMPRSS4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, a novel series of <e1>CHEMICAL<\\e1> derivatives were synthesized and evaluated for inhibiting <e2>GENE-Y<\\e2> serine protease activity and suppressing cancer cell invasion","sentence":"In this study, a novel series of 2-hydroxydiarylamide derivatives were synthesized and evaluated for inhibiting TMPRSS4 serine protease activity and suppressing cancer cell invasion"}
{"PMID":23414802,"re_id":1,"annotated sentence":"In this study, a novel series of <e1>2-hydroxydiarylamide<\\e1> derivatives were synthesized and evaluated for inhibiting TMPRSS4 <e2>serine protease<\\e2> activity and suppressing cancer cell invasion","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-hydroxydiarylamide","object":"serine protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, a novel series of <e1>CHEMICAL<\\e1> derivatives were synthesized and evaluated for inhibiting TMPRSS4 <e2>GENE-N<\\e2> activity and suppressing cancer cell invasion","sentence":"In this study, a novel series of 2-hydroxydiarylamide derivatives were synthesized and evaluated for inhibiting TMPRSS4 serine protease activity and suppressing cancer cell invasion"}
{"PMID":23414802,"re_id":2,"annotated sentence":"Discovery of novel <e1>2-hydroxydiarylamide<\\e1> derivatives as <e2>TMPRSS4<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2-hydroxydiarylamide","object":"TMPRSS4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery of novel <e1>CHEMICAL<\\e1> derivatives as <e2>GENE-Y<\\e2> inhibitors","sentence":"Discovery of novel 2-hydroxydiarylamide derivatives as TMPRSS4 inhibitors"}
{"PMID":23416143,"re_id":0,"annotated sentence":"Consumption of <e1>alcohol<\\e1> for 8weeks induced severe liver damage with increases in prognostic indicators such as <e2>aspartate transaminase<\\e2>  alanine transaminase in serum whereas co-administration of CNF suppressed their increases","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"alcohol","object":"aspartate transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Consumption of <e1>CHEMICAL<\\e1> for 8weeks induced severe liver damage with increases in prognostic indicators such as <e2>GENE-N<\\e2>  alanine transaminase in serum whereas co-administration of CNF suppressed their increases","sentence":"Consumption of alcohol for 8weeks induced severe liver damage with increases in prognostic indicators such as aspartate transaminase  alanine transaminase in serum whereas co-administration of CNF suppressed their increases"}
{"PMID":23416143,"re_id":1,"annotated sentence":"Consumption of <e1>alcohol<\\e1> for 8weeks induced severe liver damage with increases in prognostic indicators such as aspartate transaminase, <e2>alanine transaminase<\\e2> in serum whereas co-administration of CNF suppressed their increases","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"alcohol","object":"alanine transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Consumption of <e1>CHEMICAL<\\e1> for 8weeks induced severe liver damage with increases in prognostic indicators such as aspartate transaminase, <e2>GENE-N<\\e2> in serum whereas co-administration of CNF suppressed their increases","sentence":"Consumption of alcohol for 8weeks induced severe liver damage with increases in prognostic indicators such as aspartate transaminase, alanine transaminase in serum whereas co-administration of CNF suppressed their increases"}
{"PMID":23416143,"re_id":2,"annotated sentence":"Chronic consumption of <e1>alcohol<\\e1> also stimulated abrupt increases in pro-inflammatory cytokines such as <e2>nuclear factor (NF)-\u03baB<\\e2>  tumor necrosis factor (TNF)-\u03b1 and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"alcohol","object":"nuclear factor (NF)-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Chronic consumption of <e1>CHEMICAL<\\e1> also stimulated abrupt increases in pro-inflammatory cytokines such as <e2>GENE-N<\\e2>  tumor necrosis factor (TNF)-\u03b1 and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently","sentence":"Chronic consumption of alcohol also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB  tumor necrosis factor (TNF)-\u03b1 and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently"}
{"PMID":23416143,"re_id":3,"annotated sentence":"Chronic consumption of <e1>alcohol<\\e1> also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB, <e2>tumor necrosis factor (TNF)-\u03b1<\\e2> and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"alcohol","object":"tumor necrosis factor (TNF)-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Chronic consumption of <e1>CHEMICAL<\\e1> also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB, <e2>GENE-Y<\\e2> and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently","sentence":"Chronic consumption of alcohol also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB, tumor necrosis factor (TNF)-\u03b1 and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently"}
{"PMID":23416143,"re_id":4,"annotated sentence":"Chronic consumption of <e1>alcohol<\\e1> also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB, tumor necrosis factor (TNF)-\u03b1 and <e2>interleukin (IL)-1\u03b2<\\e2> in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"alcohol","object":"interleukin (IL)-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Chronic consumption of <e1>CHEMICAL<\\e1> also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB, tumor necrosis factor (TNF)-\u03b1 and <e2>GENE-Y<\\e2> in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently","sentence":"Chronic consumption of alcohol also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB, tumor necrosis factor (TNF)-\u03b1 and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently"}
{"PMID":23418087,"re_id":0,"annotated sentence":"<e2>DNA methyltransferase 3a<\\e2> expression was increased in all <e1>BPA<\\e1> males and BPA 0.5 females and reduced in BPA 200 females","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BPA","object":"DNA methyltransferase 3a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> expression was increased in all <e1>CHEMICAL<\\e1> males and CHEMICAL 0.5 females and reduced in CHEMICAL 200 females","sentence":"DNA methyltransferase 3a expression was increased in all BPA males and BPA 0.5 females and reduced in BPA 200 females"}
{"PMID":23418087,"re_id":1,"annotated sentence":"<e2>DNA methyltransferase 3a<\\e2> expression was increased in all BPA males and <e1>BPA<\\e1> 0.5 females and reduced in BPA 200 females","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BPA","object":"DNA methyltransferase 3a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> expression was increased in all CHEMICAL males and <e1>CHEMICAL<\\e1> 0.5 females and reduced in CHEMICAL 200 females","sentence":"DNA methyltransferase 3a expression was increased in all BPA males and BPA 0.5 females and reduced in BPA 200 females"}
{"PMID":23418087,"re_id":2,"annotated sentence":"<e2>DNA methyltransferase 3a<\\e2> expression was increased in all BPA males and BPA 0.5 females and reduced in <e1>BPA<\\e1> 200 females","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BPA","object":"DNA methyltransferase 3a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> expression was increased in all CHEMICAL males and CHEMICAL 0.5 females and reduced in <e1>CHEMICAL<\\e1> 200 females","sentence":"DNA methyltransferase 3a expression was increased in all BPA males and BPA 0.5 females and reduced in BPA 200 females"}
{"PMID":23418087,"re_id":3,"annotated sentence":"The <e1>calcium<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (<e2>PLB<\\e2> , phospho-PLB, and calsequestrin 2 are important for contraction and relaxation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"calcium","object":"PLB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium CHEMICAL exchanger-1, phospholamban (<e2>GENE-Y<\\e2> , phospho-GENE-Y, and calsequestrin 2 are important for contraction and relaxation","sentence":"The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB , phospho-PLB, and calsequestrin 2 are important for contraction and relaxation"}
{"PMID":23418087,"re_id":4,"annotated sentence":"The <e1>calcium<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), <e2>phospho-PLB<\\e2>  and calsequestrin 2 are important for contraction and relaxation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"calcium","object":"phospho-PLB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium CHEMICAL exchanger-1, phospholamban (PLB), <e2>GENE-Y<\\e2>  and calsequestrin 2 are important for contraction and relaxation","sentence":"The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB  and calsequestrin 2 are important for contraction and relaxation"}
{"PMID":23418087,"re_id":5,"annotated sentence":"The <e1>calcium<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and <e2>calsequestrin 2<\\e2> are important for contraction and relaxation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"calcium","object":"calsequestrin 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium CHEMICAL exchanger-1, phospholamban (PLB), phospho-PLB, and <e2>GENE-Y<\\e2> are important for contraction and relaxation","sentence":"The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation"}
{"PMID":23418087,"re_id":6,"annotated sentence":"The <e1>calcium<\\e1> homeostasis proteins <e2>sarcoendoplasmic reticulum ATPase 2a<\\e2> (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"calcium","object":"sarcoendoplasmic reticulum ATPase 2a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> homeostasis proteins <e2>GENE-Y<\\e2> (SERCA2a), sodium CHEMICAL exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation","sentence":"The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation"}
{"PMID":23418087,"re_id":7,"annotated sentence":"The <e1>calcium<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (<e2>SERCA2a<\\e2> , sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"calcium","object":"SERCA2a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (<e2>GENE-Y<\\e2> , sodium CHEMICAL exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation","sentence":"The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a , sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation"}
{"PMID":23418087,"re_id":8,"annotated sentence":"The <e1>calcium<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), <e2>sodium calcium exchanger-1<\\e2>  phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"calcium","object":"sodium calcium exchanger-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), <e2>sodium CHEMICAL exchanger-1<\\e2>  phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation","sentence":"The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1  phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation"}
{"PMID":23418087,"re_id":9,"annotated sentence":"The <e1>calcium<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, <e2>phospholamban<\\e2> (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"calcium","object":"phospholamban","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium CHEMICAL exchanger-1, <e2>GENE-Y<\\e2> (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation","sentence":"The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation"}
{"PMID":23418674,"re_id":0,"annotated sentence":"The results suggested that both the <e1>EtOAc<\\e1> extract and berberine were able to activate <e2>PPAR\u03b1\/\u03b2\/\u03b3<\\e2>  and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"EtOAc","object":"PPAR\u03b1\/\u03b2\/\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results suggested that both the <e1>CHEMICAL<\\e1> extract and berberine were able to activate <e2>GENE-N<\\e2>  and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine","sentence":"The results suggested that both the EtOAc extract and berberine were able to activate PPAR\u03b1\/\u03b2\/\u03b3  and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine"}
{"PMID":23418674,"re_id":1,"annotated sentence":"The results suggested that both the EtOAc extract and <e1>berberine<\\e1> were able to activate <e2>PPAR\u03b1\/\u03b2\/\u03b3<\\e2>  and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"berberine","object":"PPAR\u03b1\/\u03b2\/\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results suggested that both the EtOAc extract and <e1>CHEMICAL<\\e1> were able to activate <e2>GENE-N<\\e2>  and Rhizoma Coptis contains potential natural agonists of PPARs besides CHEMICAL","sentence":"The results suggested that both the EtOAc extract and berberine were able to activate PPAR\u03b1\/\u03b2\/\u03b3  and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine"}
{"PMID":23418674,"re_id":2,"annotated sentence":"The results suggested that both the EtOAc extract and berberine were able to activate <e2>PPAR\u03b1\/\u03b2\/\u03b3<\\e2>  and Rhizoma Coptis contains potential natural agonists of PPARs besides <e1>berberine<\\e1>  In conclusion, the developed HTS assay is a simple, rapid, stable, and specific method for the screening of PPARs natural agonists.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"berberine","object":"PPAR\u03b1\/\u03b2\/\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results suggested that both the EtOAc extract and CHEMICAL were able to activate <e2>GENE-N<\\e2>  and Rhizoma Coptis contains potential natural agonists of PPARs besides <e1>CHEMICAL<\\e1>  In conclusion, the developed HTS assay is a simple, rapid, stable, and specific method for the screening of PPARs natural agonists.","sentence":"The results suggested that both the EtOAc extract and berberine were able to activate PPAR\u03b1\/\u03b2\/\u03b3  and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine  In conclusion, the developed HTS assay is a simple, rapid, stable, and specific method for the screening of PPARs natural agonists."}
{"PMID":23418674,"re_id":3,"annotated sentence":"The results suggested that both the EtOAc extract and berberine were able to activate PPAR\u03b1\/\u03b2\/\u03b3, and Rhizoma Coptis contains potential natural agonists of <e2>PPARs<\\e2> besides <e1>berberine<\\e1>  In conclusion, the developed HTS assay is a simple, rapid, stable, and specific method for the screening of PPARs natural agonists.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"berberine","object":"PPARs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results suggested that both the EtOAc extract and CHEMICAL were able to activate PPAR\u03b1\/\u03b2\/\u03b3, and Rhizoma Coptis contains potential natural agonists of <e2>GENE-N<\\e2> besides <e1>CHEMICAL<\\e1>  In conclusion, the developed HTS assay is a simple, rapid, stable, and specific method for the screening of GENE-N natural agonists.","sentence":"The results suggested that both the EtOAc extract and berberine were able to activate PPAR\u03b1\/\u03b2\/\u03b3, and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine  In conclusion, the developed HTS assay is a simple, rapid, stable, and specific method for the screening of PPARs natural agonists."}
{"PMID":23419638,"re_id":0,"annotated sentence":"Similarly, <e1>pelargonidin<\\e1> induced the expression of <e2>CYP1A1<\\e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD), the most potent activator of AhR","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pelargonidin","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, <e1>CHEMICAL<\\e1> induced the expression of <e2>GENE-Y<\\e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD), the most potent activator of AhR","sentence":"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD), the most potent activator of AhR"}
{"PMID":23419638,"re_id":1,"annotated sentence":"Similarly, pelargonidin induced the expression of <e2>CYP1A1<\\e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM <e1>2,3,7,8-tetrachlorodibenzodioxin<\\e1> (TCDD), the most potent activator of AhR","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2,3,7,8-tetrachlorodibenzodioxin","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, pelargonidin induced the expression of <e2>GENE-Y<\\e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM <e1>CHEMICAL<\\e1> (TCDD), the most potent activator of AhR","sentence":"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD), the most potent activator of AhR"}
{"PMID":23419638,"re_id":2,"annotated sentence":"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM <e1>2,3,7,8-tetrachlorodibenzodioxin<\\e1> (TCDD), the most potent activator of <e2>AhR<\\e2>  CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2,3,7,8-tetrachlorodibenzodioxin","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM <e1>CHEMICAL<\\e1> (TCDD), the most potent activator of <e2>GENE-Y<\\e2>  CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","sentence":"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD), the most potent activator of AhR  CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme"}
{"PMID":23419638,"re_id":3,"annotated sentence":"Similarly, pelargonidin induced the expression of <e2>CYP1A1<\\e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (<e1>TCDD<\\e1> , the most potent activator of AhR","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, pelargonidin induced the expression of <e2>GENE-Y<\\e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (<e1>CHEMICAL<\\e1> , the most potent activator of AhR","sentence":"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD , the most potent activator of AhR"}
{"PMID":23419638,"re_id":4,"annotated sentence":"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (<e1>TCDD<\\e1> , the most potent activator of <e2>AhR<\\e2>  CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (<e1>CHEMICAL<\\e1> , the most potent activator of <e2>GENE-Y<\\e2>  CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of CHEMICAL potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","sentence":"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD , the most potent activator of AhR  CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme"}
{"PMID":23419638,"re_id":5,"annotated sentence":"<e2>CYP1A1<\\e2> and CYP1A2 mRNAs were also increased by <e1>pelargonidin<\\e1> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pelargonidin","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and CYP1A2 mRNAs were also increased by <e1>CHEMICAL<\\e1> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in GENE-Y protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of GENE-Y enzyme","sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme"}
{"PMID":23419638,"re_id":6,"annotated sentence":"CYP1A1 and <e2>CYP1A2<\\e2> mRNAs were also increased by <e1>pelargonidin<\\e1> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pelargonidin","object":"CYP1A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CYP1A1 and <e2>GENE-Y<\\e2> mRNAs were also increased by <e1>CHEMICAL<\\e1> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme"}
{"PMID":23419638,"re_id":7,"annotated sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by <e1>pelargonidin<\\e1> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in <e2>CYP1A1<\\e2> protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pelargonidin","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GENE-Y and CYP1A2 mRNAs were also increased by <e1>CHEMICAL<\\e1> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in <e2>GENE-Y<\\e2> protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of GENE-Y enzyme","sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme"}
{"PMID":23419638,"re_id":8,"annotated sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by <e1>pelargonidin<\\e1> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of <e2>CYP1A1<\\e2> enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pelargonidin","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GENE-Y and CYP1A2 mRNAs were also increased by <e1>CHEMICAL<\\e1> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in GENE-Y protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of <e2>GENE-Y<\\e2> enzyme","sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme"}
{"PMID":23419638,"re_id":9,"annotated sentence":"<e2>CYP1A1<\\e2> and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <e1>TCDD<\\e1> potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <e1>CHEMICAL<\\e1> potency) and the increase in GENE-Y protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of GENE-Y enzyme","sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme"}
{"PMID":23419638,"re_id":10,"annotated sentence":"CYP1A1 and <e2>CYP1A2<\\e2> mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <e1>TCDD<\\e1> potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"CYP1A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CYP1A1 and <e2>GENE-Y<\\e2> mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <e1>CHEMICAL<\\e1> potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme"}
{"PMID":23419638,"re_id":11,"annotated sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <e1>TCDD<\\e1> potency) and the increase in <e2>CYP1A1<\\e2> protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GENE-Y and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <e1>CHEMICAL<\\e1> potency) and the increase in <e2>GENE-Y<\\e2> protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of GENE-Y enzyme","sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme"}
{"PMID":23419638,"re_id":12,"annotated sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <e1>TCDD<\\e1> potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of <e2>CYP1A1<\\e2> enzyme","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GENE-Y and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <e1>CHEMICAL<\\e1> potency) and the increase in GENE-Y protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of <e2>GENE-Y<\\e2> enzyme","sentence":"CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme"}
{"PMID":23419638,"re_id":13,"annotated sentence":"<e1>Pelargonidin<\\e1> activates the <e2>AhR<\\e2> and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Pelargonidin","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> activates the <e2>GENE-Y<\\e2> and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T","sentence":"Pelargonidin activates the AhR and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T"}
{"PMID":23419638,"re_id":14,"annotated sentence":"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, <e1>pelargonidin<\\e1> can bind to and activate the <e2>AhR<\\e2> and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pelargonidin","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Overall, although most anthocyanidins had no effects on GENE-Y-CYP1A1 signaling, <e1>CHEMICAL<\\e1> can bind to and activate the <e2>GENE-Y<\\e2> and GENE-Y-dependent gene expression, and CHEMICAL and delphinidin inhibit the CYP1A1 catalytic activity.","sentence":"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity."}
{"PMID":23419638,"re_id":15,"annotated sentence":"<e2>AhR<\\e2> dependent reporter gene expression in transfected HepG2 cells was increased by <e1>pelargonidin<\\e1> in a concentration-dependent manner at 24h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"pelargonidin","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> dependent reporter gene expression in transfected HepG2 cells was increased by <e1>CHEMICAL<\\e1> in a concentration-dependent manner at 24h","sentence":"AhR dependent reporter gene expression in transfected HepG2 cells was increased by pelargonidin in a concentration-dependent manner at 24h"}
{"PMID":23419638,"re_id":16,"annotated sentence":"Enzyme kinetic analyses using human liver microsomes revealed inhibition of <e2>CYP1A1<\\e2> activity by <e1>delphinidin<\\e1> (IC50 78 \u03bcM) and pelargonidin (IC50 33 \u03bcM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"delphinidin","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Enzyme kinetic analyses using human liver microsomes revealed inhibition of <e2>GENE-Y<\\e2> activity by <e1>CHEMICAL<\\e1> (IC50 78 \u03bcM) and pelargonidin (IC50 33 \u03bcM)","sentence":"Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 \u03bcM) and pelargonidin (IC50 33 \u03bcM)"}
{"PMID":23419638,"re_id":17,"annotated sentence":"Enzyme kinetic analyses using human liver microsomes revealed inhibition of <e2>CYP1A1<\\e2> activity by delphinidin (IC50 78 \u03bcM) and <e1>pelargonidin<\\e1> (IC50 33 \u03bcM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pelargonidin","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Enzyme kinetic analyses using human liver microsomes revealed inhibition of <e2>GENE-Y<\\e2> activity by delphinidin (IC50 78 \u03bcM) and <e1>CHEMICAL<\\e1> (IC50 33 \u03bcM)","sentence":"Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 \u03bcM) and pelargonidin (IC50 33 \u03bcM)"}
{"PMID":23419638,"re_id":18,"annotated sentence":"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and <e1>pelargonidin<\\e1> and delphinidin inhibit the <e2>CYP1A1<\\e2> catalytic activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pelargonidin","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Overall, although most anthocyanidins had no effects on AhR-GENE-Y signaling, CHEMICAL can bind to and activate the AhR and AhR-dependent gene expression, and <e1>CHEMICAL<\\e1> and delphinidin inhibit the <e2>GENE-Y<\\e2> catalytic activity.","sentence":"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity."}
{"PMID":23419638,"re_id":19,"annotated sentence":"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and <e1>delphinidin<\\e1> inhibit the <e2>CYP1A1<\\e2> catalytic activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"delphinidin","object":"CYP1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Overall, although most anthocyanidins had no effects on AhR-GENE-Y signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and <e1>CHEMICAL<\\e1> inhibit the <e2>GENE-Y<\\e2> catalytic activity.","sentence":"Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity."}
{"PMID":23422569,"re_id":0,"annotated sentence":"Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of <e1>resveratrol<\\e1> while PPAR\u03b1 inhibition prevented the effects of this <e2>SIRT1<\\e2> activator","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of <e1>CHEMICAL<\\e1> while PPAR\u03b1 inhibition prevented the effects of this <e2>GENE-Y<\\e2> activator","sentence":"Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of resveratrol while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator"}
{"PMID":23422569,"re_id":1,"annotated sentence":"SIRT1 co-precipitated with PPAR\u03b1 and <e1>nicotinamide<\\e1> increased the acetylation of the PPAR\u03b1 coactivator <e2>PGC-1\u03b1<\\e2>  which was suppressed by resveratrol","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"nicotinamide","object":"PGC-1\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SIRT1 co-precipitated with PPAR\u03b1 and <e1>CHEMICAL<\\e1> increased the acetylation of the PPAR\u03b1 coactivator <e2>GENE-Y<\\e2>  which was suppressed by resveratrol","sentence":"SIRT1 co-precipitated with PPAR\u03b1 and nicotinamide increased the acetylation of the PPAR\u03b1 coactivator PGC-1\u03b1  which was suppressed by resveratrol"}
{"PMID":23422569,"re_id":2,"annotated sentence":"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of <e2>SIRT1<\\e2> (<e1>nicotinamide<\\e1>  sirtinol, EX527) in aorta segments isolated from young Wistar rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicotinamide","object":"SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether dysregulation of GENE-Y promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1>  sirtinol, EX527) in aorta segments isolated from young Wistar rats","sentence":"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide  sirtinol, EX527) in aorta segments isolated from young Wistar rats"}
{"PMID":23422569,"re_id":3,"annotated sentence":"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of <e2>SIRT1<\\e2> (nicotinamide, <e1>sirtinol<\\e1>  EX527) in aorta segments isolated from young Wistar rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sirtinol","object":"SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether dysregulation of GENE-Y promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of <e2>GENE-Y<\\e2> (nicotinamide, <e1>CHEMICAL<\\e1>  EX527) in aorta segments isolated from young Wistar rats","sentence":"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol  EX527) in aorta segments isolated from young Wistar rats"}
{"PMID":23422569,"re_id":4,"annotated sentence":"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of <e2>SIRT1<\\e2> (nicotinamide, sirtinol, <e1>EX527<\\e1>  in aorta segments isolated from young Wistar rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EX527","object":"SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To determine whether dysregulation of GENE-Y promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of <e2>GENE-Y<\\e2> (nicotinamide, sirtinol, <e1>CHEMICAL<\\e1>  in aorta segments isolated from young Wistar rats","sentence":"To determine whether dysregulation of SIRT1 promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527  in aorta segments isolated from young Wistar rats"}
{"PMID":23422569,"re_id":5,"annotated sentence":"Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the <e2>NADPH oxidase<\\e2> inhibitor <e1>apocynin<\\e1> or superoxide dismutase","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"apocynin","object":"NADPH oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> or superoxide dismutase","sentence":"Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor apocynin or superoxide dismutase"}
{"PMID":23422569,"re_id":6,"annotated sentence":"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced <e2>NADPH oxidase<\\e2> activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by <e1>resveratrol<\\e1>  Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of resveratrol while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"NADPH oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced <e2>GENE-N<\\e2> activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by <e1>CHEMICAL<\\e1>  Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of CHEMICAL while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator","sentence":"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol  Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of resveratrol while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator"}
{"PMID":23422569,"re_id":7,"annotated sentence":"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits <e2>p22(phox)<\\e2> and NOX4, which were prevented by <e1>resveratrol<\\e1>  Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of resveratrol while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"p22(phox)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits <e2>GENE-Y<\\e2> and NOX4, which were prevented by <e1>CHEMICAL<\\e1>  Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of CHEMICAL while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator","sentence":"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol  Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of resveratrol while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator"}
{"PMID":23422569,"re_id":8,"annotated sentence":"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and <e2>NOX4<\\e2>  which were prevented by <e1>resveratrol<\\e1>  Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of resveratrol while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"NOX4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and <e2>GENE-Y<\\e2>  which were prevented by <e1>CHEMICAL<\\e1>  Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of CHEMICAL while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator","sentence":"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4  which were prevented by resveratrol  Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of resveratrol while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator"}
{"PMID":23422569,"re_id":9,"annotated sentence":"SIRT1 co-precipitated with PPAR\u03b1 and nicotinamide increased the acetylation of the PPAR\u03b1 coactivator <e2>PGC-1\u03b1<\\e2>  which was suppressed by <e1>resveratrol<\\e1>  In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"resveratrol","object":"PGC-1\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SIRT1 co-precipitated with PPAR\u03b1 and nicotinamide increased the acetylation of the PPAR\u03b1 coactivator <e2>GENE-Y<\\e2>  which was suppressed by <e1>CHEMICAL<\\e1>  In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype","sentence":"SIRT1 co-precipitated with PPAR\u03b1 and nicotinamide increased the acetylation of the PPAR\u03b1 coactivator PGC-1\u03b1  which was suppressed by resveratrol  In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype"}
{"PMID":23422569,"re_id":10,"annotated sentence":"To determine whether dysregulation of SIRT1 promotes <e2>NADPH oxidase<\\e2> dependent production of reactive <e1>oxygen<\\e1> species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"oxygen","object":"NADPH oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To determine whether dysregulation of SIRT1 promotes <e2>GENE-N<\\e2> dependent production of reactive <e1>CHEMICAL<\\e1> species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats","sentence":"To determine whether dysregulation of SIRT1 promotes NADPH oxidase dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats"}
{"PMID":23422569,"re_id":11,"annotated sentence":"Inhibition of <e2>SIRT1<\\e2> significantly increased vascular <e1>superoxide<\\e1> production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"superoxide","object":"SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> significantly increased vascular <e1>CHEMICAL<\\e1> production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol","sentence":"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol"}
{"PMID":23422872,"re_id":0,"annotated sentence":"This is described in a case study of the expedited review and approval of <e1>peramivir<\\e1>  a novel <e2>neuraminidase<\\e2> inhibitor, in Japan in the context of the emergence of new strain of influenza in 2009","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"peramivir","object":"neuraminidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This is described in a case study of the expedited review and approval of <e1>CHEMICAL<\\e1>  a novel <e2>GENE-N<\\e2> inhibitor, in Japan in the context of the emergence of new strain of influenza in 2009","sentence":"This is described in a case study of the expedited review and approval of peramivir  a novel neuraminidase inhibitor, in Japan in the context of the emergence of new strain of influenza in 2009"}
{"PMID":23423570,"re_id":0,"annotated sentence":"In conclusion, <e2>IL-8<\\e2> production and neutrophil infiltration are increased in high-<e1>glucose<\\e1> environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e2>GENE-Y<\\e2> production and neutrophil infiltration are increased in high-<e1>CHEMICAL<\\e1> environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin","sentence":"In conclusion, IL-8 production and neutrophil infiltration are increased in high-glucose environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin"}
{"PMID":23423570,"re_id":1,"annotated sentence":"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-<e1>glucose<\\e1> environment enhanced <e2>IL-8<\\e2> production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-<e1>CHEMICAL<\\e1> environment enhanced <e2>GENE-Y<\\e2> production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes","sentence":"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-glucose environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes"}
{"PMID":23423570,"re_id":2,"annotated sentence":"High-<e1>glucose<\\e1> environment enhanced oxidative stress and increased <e2>interleukin-8<\\e2> secretion from keratinocytes: New insights on impaired diabetic wound healing","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"interleukin-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"High-<e1>CHEMICAL<\\e1> environment enhanced oxidative stress and increased <e2>GENE-Y<\\e2> secretion from keratinocytes: New insights on impaired diabetic wound healing","sentence":"High-glucose environment enhanced oxidative stress and increased interleukin-8 secretion from keratinocytes: New insights on impaired diabetic wound healing"}
{"PMID":23423713,"re_id":0,"annotated sentence":"Upon co-exposure to <e1>V(5+)<\\e1> and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the <e2>Cyp1a1<\\e2>  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"V(5+)","object":"Cyp1a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to <e1>CHEMICAL<\\e1> and TCDD, CHEMICAL significantly potentiated the TCDD-mediated induction of the <e2>GENE-Y<\\e2>  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":1,"annotated sentence":"Upon co-exposure to <e1>V(5+)<\\e1> and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, <e2>Cyp1a2<\\e2>  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"V(5+)","object":"Cyp1a2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to <e1>CHEMICAL<\\e1> and TCDD, CHEMICAL significantly potentiated the TCDD-mediated induction of the Cyp1a1, <e2>GENE-Y<\\e2>  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":2,"annotated sentence":"Upon co-exposure to <e1>V(5+)<\\e1> and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and <e2>Cyp1b1<\\e2> mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"V(5+)","object":"Cyp1b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to <e1>CHEMICAL<\\e1> and TCDD, CHEMICAL significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and <e2>GENE-Y<\\e2> mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":3,"annotated sentence":"Upon co-exposure to V(5+) and <e1>TCDD<\\e1>  V(5+) significantly potentiated the TCDD-mediated induction of the <e2>Cyp1a1<\\e2>  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Cyp1a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to V(5+) and <e1>CHEMICAL<\\e1>  V(5+) significantly potentiated the CHEMICAL-mediated induction of the <e2>GENE-Y<\\e2>  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD  V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":4,"annotated sentence":"Upon co-exposure to V(5+) and <e1>TCDD<\\e1>  V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, <e2>Cyp1a2<\\e2>  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Cyp1a2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to V(5+) and <e1>CHEMICAL<\\e1>  V(5+) significantly potentiated the CHEMICAL-mediated induction of the Cyp1a1, <e2>GENE-Y<\\e2>  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD  V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":5,"annotated sentence":"Upon co-exposure to V(5+) and <e1>TCDD<\\e1>  V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and <e2>Cyp1b1<\\e2> mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Cyp1b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to V(5+) and <e1>CHEMICAL<\\e1>  V(5+) significantly potentiated the CHEMICAL-mediated induction of the Cyp1a1, Cyp1a2, and <e2>GENE-Y<\\e2> mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD  V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":6,"annotated sentence":"Upon co-exposure to V(5+) and TCDD, <e1>V(5+)<\\e1> significantly potentiated the TCDD-mediated induction of the <e2>Cyp1a1<\\e2>  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"V(5+)","object":"Cyp1a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to CHEMICAL and TCDD, <e1>CHEMICAL<\\e1> significantly potentiated the TCDD-mediated induction of the <e2>GENE-Y<\\e2>  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":7,"annotated sentence":"Upon co-exposure to V(5+) and TCDD, <e1>V(5+)<\\e1> significantly potentiated the TCDD-mediated induction of the Cyp1a1, <e2>Cyp1a2<\\e2>  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"V(5+)","object":"Cyp1a2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to CHEMICAL and TCDD, <e1>CHEMICAL<\\e1> significantly potentiated the TCDD-mediated induction of the Cyp1a1, <e2>GENE-Y<\\e2>  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":8,"annotated sentence":"Upon co-exposure to V(5+) and TCDD, <e1>V(5+)<\\e1> significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and <e2>Cyp1b1<\\e2> mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"V(5+)","object":"Cyp1b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to CHEMICAL and TCDD, <e1>CHEMICAL<\\e1> significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and <e2>GENE-Y<\\e2> mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":9,"annotated sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the <e1>TCDD<\\e1> mediated induction of the <e2>Cyp1a1<\\e2>  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Cyp1a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to V(5+) and CHEMICAL, V(5+) significantly potentiated the <e1>CHEMICAL<\\e1> mediated induction of the <e2>GENE-Y<\\e2>  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD mediated induction of the Cyp1a1  Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":10,"annotated sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the <e1>TCDD<\\e1> mediated induction of the Cyp1a1, <e2>Cyp1a2<\\e2>  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Cyp1a2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to V(5+) and CHEMICAL, V(5+) significantly potentiated the <e1>CHEMICAL<\\e1> mediated induction of the Cyp1a1, <e2>GENE-Y<\\e2>  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD mediated induction of the Cyp1a1, Cyp1a2  and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":11,"annotated sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the <e1>TCDD<\\e1> mediated induction of the Cyp1a1, Cyp1a2, and <e2>Cyp1b1<\\e2> mRNA, protein, and catalytic activity levels at 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Cyp1b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon co-exposure to V(5+) and CHEMICAL, V(5+) significantly potentiated the <e1>CHEMICAL<\\e1> mediated induction of the Cyp1a1, Cyp1a2, and <e2>GENE-Y<\\e2> mRNA, protein, and catalytic activity levels at 24\u00a0h","sentence":"Upon co-exposure to V(5+) and TCDD, V(5+) significantly potentiated the TCDD mediated induction of the Cyp1a1, Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h"}
{"PMID":23423713,"re_id":12,"annotated sentence":"<e1>V(5+)<\\e1> also increased <e2>serum hemoglobin<\\e2> (Hb) levels in animals treated for 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"V(5+)","object":"serum hemoglobin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also increased <e2>GENE-N<\\e2> (Hb) levels in animals treated for 24\u00a0h","sentence":"V(5+) also increased serum hemoglobin (Hb) levels in animals treated for 24\u00a0h"}
{"PMID":23423713,"re_id":13,"annotated sentence":"<e1>V(5+)<\\e1> also increased serum hemoglobin (<e2>Hb<\\e2>  levels in animals treated for 24\u00a0h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"V(5+)","object":"Hb","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also increased serum hemoglobin (<e2>GENE-N<\\e2>  levels in animals treated for 24\u00a0h","sentence":"V(5+) also increased serum hemoglobin (Hb  levels in animals treated for 24\u00a0h"}
{"PMID":23423713,"re_id":14,"annotated sentence":"In vitro, V(5+) decreased the <e1>TCDD<\\e1> mediated induction of <e2>Cyp1a1<\\e2> mRNA, protein, and catalytic activity levels","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Cyp1a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro, V(5+) decreased the <e1>CHEMICAL<\\e1> mediated induction of <e2>GENE-Y<\\e2> mRNA, protein, and catalytic activity levels","sentence":"In vitro, V(5+) decreased the TCDD mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels"}
{"PMID":23423713,"re_id":15,"annotated sentence":"Furthermore, V(5+) significantly inhibited the <e1>TCDD<\\e1> induced <e2>AhR<\\e2> dependent luciferase activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, V(5+) significantly inhibited the <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> dependent luciferase activity","sentence":"Furthermore, V(5+) significantly inhibited the TCDD induced AhR dependent luciferase activity"}
{"PMID":23423713,"re_id":16,"annotated sentence":"Upon treatment of isolated hepatocytes with Hb alone or in the presence of <e1>TCDD<\\e1>  there was an increase in the <e2>AhR<\\e2> dependent luciferase activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon treatment of isolated hepatocytes with Hb alone or in the presence of <e1>CHEMICAL<\\e1>  there was an increase in the <e2>GENE-Y<\\e2> dependent luciferase activity","sentence":"Upon treatment of isolated hepatocytes with Hb alone or in the presence of TCDD  there was an increase in the AhR dependent luciferase activity"}
{"PMID":23423713,"re_id":17,"annotated sentence":"In vitro, <e1>V(5+)<\\e1> decreased the TCDD-mediated induction of <e2>Cyp1a1<\\e2> mRNA, protein, and catalytic activity levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"V(5+)","object":"Cyp1a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro, <e1>CHEMICAL<\\e1> decreased the TCDD-mediated induction of <e2>GENE-Y<\\e2> mRNA, protein, and catalytic activity levels","sentence":"In vitro, V(5+) decreased the TCDD-mediated induction of Cyp1a1 mRNA, protein, and catalytic activity levels"}
{"PMID":23423713,"re_id":18,"annotated sentence":"Furthermore, <e1>V(5+)<\\e1> significantly inhibited the TCDD-induced <e2>AhR<\\e2> dependent luciferase activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"V(5+)","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> significantly inhibited the TCDD-induced <e2>GENE-Y<\\e2> dependent luciferase activity","sentence":"Furthermore, V(5+) significantly inhibited the TCDD-induced AhR dependent luciferase activity"}
{"PMID":23429912,"re_id":0,"annotated sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>TCDD<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of <e2>Lgr5<\\e2>  a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Lgr5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In support of the hypothesis that CHEMICAL decreases canonical Wnt signaling, we identify inhibitory effects of CHEMICAL on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>CHEMICAL<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of <e2>GENE-Y<\\e2>  a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by CHEMICAL","sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5  a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD"}
{"PMID":23429912,"re_id":1,"annotated sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>TCDD<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a <e2>RSPO receptor<\\e2> that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"RSPO receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In support of the hypothesis that CHEMICAL decreases canonical Wnt signaling, we identify inhibitory effects of CHEMICAL on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>CHEMICAL<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a <e2>GENE-Y<\\e2> that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by CHEMICAL","sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD"}
{"PMID":23429912,"re_id":2,"annotated sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>TCDD<\\e1> on prostatic bud formation: (1) expression of <e2>R-spondins<\\e2> (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"R-spondins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In support of the hypothesis that CHEMICAL decreases canonical Wnt signaling, we identify inhibitory effects of CHEMICAL on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>CHEMICAL<\\e1> on prostatic bud formation: (1) expression of <e2>GENE-N<\\e2> (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by CHEMICAL","sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD"}
{"PMID":23429912,"re_id":3,"annotated sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>TCDD<\\e1> on prostatic bud formation: (1) expression of R-spondins (<e2>Rspo2<\\e2> and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Rspo2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In support of the hypothesis that CHEMICAL decreases canonical Wnt signaling, we identify inhibitory effects of CHEMICAL on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>CHEMICAL<\\e1> on prostatic bud formation: (1) expression of R-spondins (<e2>GENE-Y<\\e2> and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by CHEMICAL","sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD"}
{"PMID":23429912,"re_id":4,"annotated sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>TCDD<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and <e2>Rspo3<\\e2>  that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Rspo3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In support of the hypothesis that CHEMICAL decreases canonical Wnt signaling, we identify inhibitory effects of CHEMICAL on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>CHEMICAL<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and <e2>GENE-Y<\\e2>  that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by CHEMICAL","sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3  that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD"}
{"PMID":23429912,"re_id":5,"annotated sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>TCDD<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of <e2>Lef1<\\e2>  Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Lef1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In support of the hypothesis that CHEMICAL decreases canonical Wnt signaling, we identify inhibitory effects of CHEMICAL on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>CHEMICAL<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of <e2>GENE-Y<\\e2>  Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by CHEMICAL","sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1  Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD"}
{"PMID":23429912,"re_id":6,"annotated sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>TCDD<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, <e2>Tcf1<\\e2>  and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Tcf1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In support of the hypothesis that CHEMICAL decreases canonical Wnt signaling, we identify inhibitory effects of CHEMICAL on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>CHEMICAL<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, <e2>GENE-Y<\\e2>  and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by CHEMICAL","sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1  and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD"}
{"PMID":23429912,"re_id":7,"annotated sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>TCDD<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and <e2>Wif1<\\e2>  established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Wif1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In support of the hypothesis that CHEMICAL decreases canonical Wnt signaling, we identify inhibitory effects of CHEMICAL on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of <e1>CHEMICAL<\\e1> on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and <e2>GENE-Y<\\e2>  established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by CHEMICAL","sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1  established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD"}
{"PMID":23429912,"re_id":8,"annotated sentence":"<e1>TCDD<\\e1> inhibition of canonical <e2>wnt<\\e2> signaling disrupts prostatic bud formation in mouse urogenital sinus","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"wnt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibition of canonical <e2>GENE-N<\\e2> signaling disrupts prostatic bud formation in mouse urogenital sinus","sentence":"TCDD inhibition of canonical wnt signaling disrupts prostatic bud formation in mouse urogenital sinus"}
{"PMID":23429912,"re_id":9,"annotated sentence":"Thus, the <e1>TCDD<\\e1> induced reduction in canonical <e2>Wnt<\\e2> signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Wnt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, the <e1>CHEMICAL<\\e1> induced reduction in canonical <e2>GENE-N<\\e2> signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway","sentence":"Thus, the TCDD induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway"}
{"PMID":23429912,"re_id":10,"annotated sentence":"Thus, the <e1>TCDD<\\e1> induced reduction in canonical Wnt signaling is associated with a decrease in activators (<e2>Rspo2<\\e2> and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Rspo2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, the <e1>CHEMICAL<\\e1> induced reduction in canonical Wnt signaling is associated with a decrease in activators (<e2>GENE-Y<\\e2> and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway","sentence":"Thus, the TCDD induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway"}
{"PMID":23429912,"re_id":11,"annotated sentence":"Thus, the <e1>TCDD<\\e1> induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and <e2>Rspo3<\\e2>  rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Rspo3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, the <e1>CHEMICAL<\\e1> induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and <e2>GENE-Y<\\e2>  rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway","sentence":"Thus, the TCDD induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3  rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway"}
{"PMID":23429912,"re_id":12,"annotated sentence":"Thus, the <e1>TCDD<\\e1> induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (<e2>Dkk1<\\e2> and Dkk2) of the pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Dkk1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, the <e1>CHEMICAL<\\e1> induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (<e2>GENE-Y<\\e2> and Dkk2) of the pathway","sentence":"Thus, the TCDD induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway"}
{"PMID":23429912,"re_id":13,"annotated sentence":"Thus, the <e1>TCDD<\\e1> induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and <e2>Dkk2<\\e2>  of the pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Dkk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, the <e1>CHEMICAL<\\e1> induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and <e2>GENE-Y<\\e2>  of the pathway","sentence":"Thus, the TCDD induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2  of the pathway"}
{"PMID":23429912,"re_id":14,"annotated sentence":"This study focuses on determining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and\/or RSPO3 is capable of rescuing the inhibitory effects of <e1>TCDD<\\e1> on canonical <e2>Wnt<\\e2> signaling and prostatic bud formation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Wnt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study focuses on determining whether treatment of CHEMICAL-exposed UGS organ cultures with RSPO2 and\/or RSPO3 is capable of rescuing the inhibitory effects of <e1>CHEMICAL<\\e1> on canonical <e2>GENE-N<\\e2> signaling and prostatic bud formation","sentence":"This study focuses on determining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and\/or RSPO3 is capable of rescuing the inhibitory effects of TCDD on canonical Wnt signaling and prostatic bud formation"}
{"PMID":23429912,"re_id":15,"annotated sentence":"We discovered that each RSPO alone or in combination partially rescues <e1>TCDD<\\e1> inhibition of both canonical <e2>Wnt<\\e2> signaling and prostatic bud formation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Wnt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We discovered that each RSPO alone or in combination partially rescues <e1>CHEMICAL<\\e1> inhibition of both canonical <e2>GENE-N<\\e2> signaling and prostatic bud formation.","sentence":"We discovered that each RSPO alone or in combination partially rescues TCDD inhibition of both canonical Wnt signaling and prostatic bud formation."}
{"PMID":23429912,"re_id":16,"annotated sentence":"In support of the hypothesis that <e1>TCDD<\\e1> decreases canonical <e2>Wnt<\\e2> signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TCDD","object":"Wnt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In support of the hypothesis that <e1>CHEMICAL<\\e1> decreases canonical <e2>GENE-N<\\e2> signaling, we identify inhibitory effects of CHEMICAL on multiple components of the canonical GENE-N signaling pathway in the UGS that temporally coincide with the inhibitory effect of CHEMICAL on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical GENE-N signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical GENE-N target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical GENE-N signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical GENE-N signaling, is not increased by CHEMICAL","sentence":"In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD"}
{"PMID":23435367,"re_id":0,"annotated sentence":"Luciferase reporter assays showed that transcription of <e2>FDX1<\\e2> was synergistically activated by the NR5A family and <e1>8Br-cAMP<\\e1> treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"8Br-cAMP","object":"FDX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Luciferase reporter assays showed that transcription of <e2>GENE-Y<\\e2> was synergistically activated by the NR5A family and <e1>CHEMICAL<\\e1> treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN","sentence":"Luciferase reporter assays showed that transcription of FDX1 was synergistically activated by the NR5A family and 8Br-cAMP treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN"}
{"PMID":23435367,"re_id":1,"annotated sentence":"These results indicate transcription of <e2>FDX1<\\e2> is regulated by the NR5A family and <e1>cAMP<\\e1> signaling, and participates in steroid hormone production in ovarian granulosa cells.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cAMP","object":"FDX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate transcription of <e2>GENE-Y<\\e2> is regulated by the NR5A family and <e1>CHEMICAL<\\e1> signaling, and participates in steroid hormone production in ovarian granulosa cells.","sentence":"These results indicate transcription of FDX1 is regulated by the NR5A family and cAMP signaling, and participates in steroid hormone production in ovarian granulosa cells."}
{"PMID":23435367,"re_id":2,"annotated sentence":"Ferredoxin 1 (<e2>FDX1<\\e2>  adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid<\\e1> hormone synthesis in mammalian tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"steroid","object":"FDX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ferredoxin 1 (<e2>GENE-Y<\\e2>  adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>CHEMICAL<\\e1> hormone synthesis in mammalian tissues","sentence":"Ferredoxin 1 (FDX1  adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues"}
{"PMID":23435367,"re_id":3,"annotated sentence":"Ferredoxin 1 (FDX1; <e2>adrenodoxin<\\e2>  is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid<\\e1> hormone synthesis in mammalian tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"steroid","object":"adrenodoxin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ferredoxin 1 (FDX1; <e2>GENE-Y<\\e2>  is an iron-sulfur protein that is involved in various metabolic processes, including <e1>CHEMICAL<\\e1> hormone synthesis in mammalian tissues","sentence":"Ferredoxin 1 (FDX1; adrenodoxin  is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues"}
{"PMID":23435367,"re_id":4,"annotated sentence":"<e2>Ferredoxin 1<\\e2> (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid<\\e1> hormone synthesis in mammalian tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"steroid","object":"Ferredoxin 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>CHEMICAL<\\e1> hormone synthesis in mammalian tissues","sentence":"Ferredoxin 1 (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues"}
{"PMID":23435367,"re_id":5,"annotated sentence":"Ferredoxin 1 (<e2>FDX1<\\e2>  adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid hormone<\\e1> synthesis in mammalian tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"steroid hormone","object":"FDX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ferredoxin 1 (<e2>GENE-Y<\\e2>  adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>CHEMICAL<\\e1> synthesis in mammalian tissues","sentence":"Ferredoxin 1 (FDX1  adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues"}
{"PMID":23435367,"re_id":6,"annotated sentence":"Ferredoxin 1 (FDX1; <e2>adrenodoxin<\\e2>  is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid hormone<\\e1> synthesis in mammalian tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"steroid hormone","object":"adrenodoxin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ferredoxin 1 (FDX1; <e2>GENE-Y<\\e2>  is an iron-sulfur protein that is involved in various metabolic processes, including <e1>CHEMICAL<\\e1> synthesis in mammalian tissues","sentence":"Ferredoxin 1 (FDX1; adrenodoxin  is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues"}
{"PMID":23435367,"re_id":7,"annotated sentence":"<e2>Ferredoxin 1<\\e2> (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid hormone<\\e1> synthesis in mammalian tissues","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"steroid hormone","object":"Ferredoxin 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>CHEMICAL<\\e1> synthesis in mammalian tissues","sentence":"Ferredoxin 1 (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues"}
{"PMID":23435367,"re_id":8,"annotated sentence":"These results indicate transcription of <e2>FDX1<\\e2> is regulated by the NR5A family and cAMP signaling, and participates in <e1>steroid<\\e1> hormone production in ovarian granulosa cells.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"steroid","object":"FDX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate transcription of <e2>GENE-Y<\\e2> is regulated by the NR5A family and cAMP signaling, and participates in <e1>CHEMICAL<\\e1> hormone production in ovarian granulosa cells.","sentence":"These results indicate transcription of FDX1 is regulated by the NR5A family and cAMP signaling, and participates in steroid hormone production in ovarian granulosa cells."}
{"PMID":23435910,"re_id":0,"annotated sentence":"Furthermore, <e1>sinapic acid<\\e1> reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of <e2>type I collagen<\\e2> mRNA and histological analysis of collagen in liver tissue","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sinapic acid","object":"type I collagen","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of <e2>GENE-N<\\e2> mRNA and histological analysis of collagen in liver tissue","sentence":"Furthermore, sinapic acid reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of type I collagen mRNA and histological analysis of collagen in liver tissue"}
{"PMID":23435910,"re_id":1,"annotated sentence":"Additionally, the expression of hepatic fibrosis-related factors such as <e2>\u03b1-smooth muscle actin<\\e2> and transforming growth factor-\u03b21 (TGF-\u03b21), were reduced in rats treated with <e1>sinapic acid<\\e1>  Sinapic acid exhibited strong scavenging activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sinapic acid","object":"\u03b1-smooth muscle actin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, the expression of hepatic fibrosis-related factors such as <e2>GENE-Y<\\e2> and transforming growth factor-\u03b21 (TGF-\u03b21), were reduced in rats treated with <e1>CHEMICAL<\\e1>  Sinapic acid exhibited strong scavenging activity","sentence":"Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and transforming growth factor-\u03b21 (TGF-\u03b21), were reduced in rats treated with sinapic acid  Sinapic acid exhibited strong scavenging activity"}
{"PMID":23435910,"re_id":2,"annotated sentence":"Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and <e2>transforming growth factor-\u03b21<\\e2> (TGF-\u03b21), were reduced in rats treated with <e1>sinapic acid<\\e1>  Sinapic acid exhibited strong scavenging activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sinapic acid","object":"transforming growth factor-\u03b21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and <e2>GENE-Y<\\e2> (TGF-\u03b21), were reduced in rats treated with <e1>CHEMICAL<\\e1>  Sinapic acid exhibited strong scavenging activity","sentence":"Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and transforming growth factor-\u03b21 (TGF-\u03b21), were reduced in rats treated with sinapic acid  Sinapic acid exhibited strong scavenging activity"}
{"PMID":23435910,"re_id":3,"annotated sentence":"Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and transforming growth factor-\u03b21 (<e2>TGF-\u03b21<\\e2> , were reduced in rats treated with <e1>sinapic acid<\\e1>  Sinapic acid exhibited strong scavenging activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sinapic acid","object":"TGF-\u03b21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and transforming growth factor-\u03b21 (<e2>GENE-Y<\\e2> , were reduced in rats treated with <e1>CHEMICAL<\\e1>  Sinapic acid exhibited strong scavenging activity","sentence":"Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and transforming growth factor-\u03b21 (TGF-\u03b21 , were reduced in rats treated with sinapic acid  Sinapic acid exhibited strong scavenging activity"}
{"PMID":23435910,"re_id":4,"annotated sentence":"In conclusion, we find that <e1>sinapic acid<\\e1> exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress <e2>TGF-\u03b21<\\e2> and its ability to attenuate activation of hepatic stellate cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sinapic acid","object":"TGF-\u03b21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, we find that <e1>CHEMICAL<\\e1> exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress <e2>GENE-Y<\\e2> and its ability to attenuate activation of hepatic stellate cells","sentence":"In conclusion, we find that sinapic acid exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress TGF-\u03b21 and its ability to attenuate activation of hepatic stellate cells"}
{"PMID":23435915,"re_id":0,"annotated sentence":"<e1>Genistin<\\e1> decreased <e2>myosin light chain kinase<\\e2> (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Genistin","object":"myosin light chain kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased <e2>GENE-Y<\\e2> (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects","sentence":"Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects"}
{"PMID":23435915,"re_id":1,"annotated sentence":"<e1>Genistin<\\e1> decreased myosin light chain kinase (<e2>MLCK<\\e2>  protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Genistin","object":"MLCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased myosin light chain kinase (<e2>GENE-Y<\\e2>  protein contents and GENE-Y mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of GENE-Y contents and inhibition of GENE-Y activity are involved in the genistin-induced inhibitory effects","sentence":"Genistin decreased myosin light chain kinase (MLCK  protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects"}
{"PMID":23435915,"re_id":2,"annotated sentence":"<e1>Genistin<\\e1> decreased myosin light chain kinase (MLCK) protein contents and <e2>MLCK<\\e2> mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Genistin","object":"MLCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased myosin light chain kinase (GENE-Y) protein contents and <e2>GENE-Y<\\e2> mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of GENE-Y contents and inhibition of GENE-Y activity are involved in the genistin-induced inhibitory effects","sentence":"Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects"}
{"PMID":23435915,"re_id":3,"annotated sentence":"<e1>Genistin<\\e1> decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-<e2>ATPase<\\e2> activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Genistin","object":"ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-<e2>GENE-N<\\e2> activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects","sentence":"Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects"}
{"PMID":23435915,"re_id":4,"annotated sentence":"Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of <e2>MLCK<\\e2> contents and inhibition of MLCK activity are involved in the <e1>genistin<\\e1> induced inhibitory effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"genistin","object":"MLCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Genistin decreased myosin light chain kinase (GENE-Y) protein contents and GENE-Y mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of <e2>GENE-Y<\\e2> contents and inhibition of GENE-Y activity are involved in the <e1>CHEMICAL<\\e1> induced inhibitory effects","sentence":"Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin induced inhibitory effects"}
{"PMID":23435915,"re_id":5,"annotated sentence":"Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of <e2>MLCK<\\e2> activity are involved in the <e1>genistin<\\e1> induced inhibitory effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"genistin","object":"MLCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Genistin decreased myosin light chain kinase (GENE-Y) protein contents and GENE-Y mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of GENE-Y contents and inhibition of <e2>GENE-Y<\\e2> activity are involved in the <e1>CHEMICAL<\\e1> induced inhibitory effects","sentence":"Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin induced inhibitory effects"}
{"PMID":23439561,"re_id":0,"annotated sentence":"<e2>Cycloxygenase-2<\\e2> (COX-2)-derived <e1>prostaglandin E2<\\e1> (PGE2) has been shown to be important in esophageal tumorigenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin E2","object":"Cycloxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (COX-2)-derived <e1>CHEMICAL<\\e1> (PGE2) has been shown to be important in esophageal tumorigenesis","sentence":"Cycloxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) has been shown to be important in esophageal tumorigenesis"}
{"PMID":23439561,"re_id":1,"annotated sentence":"Cycloxygenase-2 (<e2>COX-2<\\e2> -derived <e1>prostaglandin E2<\\e1> (PGE2) has been shown to be important in esophageal tumorigenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandin E2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cycloxygenase-2 (<e2>GENE-Y<\\e2> -derived <e1>CHEMICAL<\\e1> (PGE2) has been shown to be important in esophageal tumorigenesis","sentence":"Cycloxygenase-2 (COX-2 -derived prostaglandin E2 (PGE2) has been shown to be important in esophageal tumorigenesis"}
{"PMID":23439561,"re_id":2,"annotated sentence":"We conclude that <e2>mPGES1<\\e2> mediates acid-induced increase in <e1>PGE2<\\e1> production and cell proliferation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE2","object":"mPGES1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that <e2>GENE-Y<\\e2> mediates acid-induced increase in <e1>CHEMICAL<\\e1> production and cell proliferation","sentence":"We conclude that mPGES1 mediates acid-induced increase in PGE2 production and cell proliferation"}
{"PMID":23439561,"re_id":3,"annotated sentence":"<e2>Cycloxygenase-2<\\e2> (COX-2)-derived prostaglandin E2 (<e1>PGE2<\\e1>  has been shown to be important in esophageal tumorigenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE2","object":"Cycloxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (COX-2)-derived prostaglandin E2 (<e1>CHEMICAL<\\e1>  has been shown to be important in esophageal tumorigenesis","sentence":"Cycloxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2  has been shown to be important in esophageal tumorigenesis"}
{"PMID":23439561,"re_id":4,"annotated sentence":"Cycloxygenase-2 (<e2>COX-2<\\e2> -derived prostaglandin E2 (<e1>PGE2<\\e1>  has been shown to be important in esophageal tumorigenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cycloxygenase-2 (<e2>GENE-Y<\\e2> -derived prostaglandin E2 (<e1>CHEMICAL<\\e1>  has been shown to be important in esophageal tumorigenesis","sentence":"Cycloxygenase-2 (COX-2 -derived prostaglandin E2 (PGE2  has been shown to be important in esophageal tumorigenesis"}
{"PMID":23439561,"re_id":5,"annotated sentence":"We have shown that <e2>COX-2<\\e2> mediates acid-induced <e1>PGE2<\\e1> production","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have shown that <e2>GENE-Y<\\e2> mediates acid-induced <e1>CHEMICAL<\\e1> production","sentence":"We have shown that COX-2 mediates acid-induced PGE2 production"}
{"PMID":23439661,"re_id":0,"annotated sentence":"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (<e1>GSK2251052<\\e1>  is a novel boron-containing antibiotic that inhibits <e2>bacterial leucyl tRNA synthetase<\\e2>  and that has been in development for the treatment of serious Gram-negative infections","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GSK2251052","object":"bacterial leucyl tRNA synthetase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (<e1>CHEMICAL<\\e1>  is a novel boron-containing antibiotic that inhibits <e2>GENE-N<\\e2>  and that has been in development for the treatment of serious Gram-negative infections","sentence":"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052  is a novel boron-containing antibiotic that inhibits bacterial leucyl tRNA synthetase  and that has been in development for the treatment of serious Gram-negative infections"}
{"PMID":23439661,"re_id":1,"annotated sentence":"<e1>(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole<\\e1> (GSK2251052) is a novel boron-containing antibiotic that inhibits <e2>bacterial leucyl tRNA synthetase<\\e2>  and that has been in development for the treatment of serious Gram-negative infections","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole","object":"bacterial leucyl tRNA synthetase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (GSK2251052) is a novel boron-containing antibiotic that inhibits <e2>GENE-N<\\e2>  and that has been in development for the treatment of serious Gram-negative infections","sentence":"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing antibiotic that inhibits bacterial leucyl tRNA synthetase  and that has been in development for the treatment of serious Gram-negative infections"}
{"PMID":23439661,"re_id":2,"annotated sentence":"A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor <e1>4-methylpyrazole<\\e1> provided strong evidence that <e2>alcohol dehydrogenase<\\e2>  potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-methylpyrazole","object":"alcohol dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor <e1>CHEMICAL<\\e1> provided strong evidence that <e2>GENE-N<\\e2>  potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite.","sentence":"A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor 4-methylpyrazole provided strong evidence that alcohol dehydrogenase  potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite."}
{"PMID":23444334,"re_id":0,"annotated sentence":"The treatment of mice with <e1>Fe-NTA<\\e1> alone enhances <e2>ornithine decarboxylase<\\e2> activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Fe-NTA","object":"ornithine decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The treatment of mice with <e1>CHEMICAL<\\e1> alone enhances <e2>GENE-Y<\\e2> activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls","sentence":"The treatment of mice with Fe-NTA alone enhances ornithine decarboxylase activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls"}
{"PMID":23446230,"re_id":0,"annotated sentence":"Moreover, overexpressed CYP2J2 and <e1>EETs<\\e1> inhibited <e2>Ang II<\\e2> induced macrophage migration in a VSMC-macrophage coculture system","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EETs","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, overexpressed CYP2J2 and <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> induced macrophage migration in a VSMC-macrophage coculture system","sentence":"Moreover, overexpressed CYP2J2 and EETs inhibited Ang II induced macrophage migration in a VSMC-macrophage coculture system"}
{"PMID":23446230,"re_id":1,"annotated sentence":"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and <e1>EETs<\\e1> markedly suppressed <e2>Ang II<\\e2> induced inflammatory cytokine expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EETs","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and <e1>CHEMICAL<\\e1> markedly suppressed <e2>GENE-Y<\\e2> induced inflammatory cytokine expression","sentence":"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and EETs markedly suppressed Ang II induced inflammatory cytokine expression"}
{"PMID":23446230,"re_id":2,"annotated sentence":"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and <e1>EETs<\\e1> markedly suppressed Ang II-induced inflammatory <e2>cytokine<\\e2> expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EETs","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and <e1>CHEMICAL<\\e1> markedly suppressed Ang II-induced inflammatory <e2>GENE-N<\\e2> expression","sentence":"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and EETs markedly suppressed Ang II-induced inflammatory cytokine expression"}
{"PMID":23446230,"re_id":3,"annotated sentence":"<e2>Cytochrome P450 epoxygenase 2J2<\\e2> (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids (<e1>EETs<\\e1> , which possess various beneficial effects on the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"EETs","object":"Cytochrome P450 epoxygenase 2J2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids (<e1>CHEMICAL<\\e1> , which possess various beneficial effects on the cardiovascular system","sentence":"Cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids (EETs , which possess various beneficial effects on the cardiovascular system"}
{"PMID":23446230,"re_id":4,"annotated sentence":"Cytochrome P450 epoxygenase 2J2 (<e2>CYP2J2<\\e2>  metabolizes arachidonic acids to form epoxyeicosatrienoic acids (<e1>EETs<\\e1> , which possess various beneficial effects on the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"EETs","object":"CYP2J2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cytochrome P450 epoxygenase 2J2 (<e2>GENE-Y<\\e2>  metabolizes arachidonic acids to form epoxyeicosatrienoic acids (<e1>CHEMICAL<\\e1> , which possess various beneficial effects on the cardiovascular system","sentence":"Cytochrome P450 epoxygenase 2J2 (CYP2J2  metabolizes arachidonic acids to form epoxyeicosatrienoic acids (EETs , which possess various beneficial effects on the cardiovascular system"}
{"PMID":23446230,"re_id":5,"annotated sentence":"However, whether increasing <e1>EETs<\\e1> production by <e2>CYP2J2<\\e2> overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"EETs","object":"CYP2J2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, whether increasing <e1>CHEMICAL<\\e1> production by <e2>GENE-Y<\\e2> overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown","sentence":"However, whether increasing EETs production by CYP2J2 overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown"}
{"PMID":23446230,"re_id":6,"annotated sentence":"<e2>Cytochrome P450 epoxygenase 2J2<\\e2> (CYP2J2) metabolizes <e1>arachidonic acids<\\e1> to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acids","object":"Cytochrome P450 epoxygenase 2J2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CYP2J2) metabolizes <e1>CHEMICAL<\\e1> to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system","sentence":"Cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system"}
{"PMID":23446230,"re_id":7,"annotated sentence":"Cytochrome P450 epoxygenase 2J2 (<e2>CYP2J2<\\e2>  metabolizes <e1>arachidonic acids<\\e1> to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acids","object":"CYP2J2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cytochrome P450 epoxygenase 2J2 (<e2>GENE-Y<\\e2>  metabolizes <e1>CHEMICAL<\\e1> to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system","sentence":"Cytochrome P450 epoxygenase 2J2 (CYP2J2  metabolizes arachidonic acids to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system"}
{"PMID":23446230,"re_id":8,"annotated sentence":"<e2>Cytochrome P450 epoxygenase 2J2<\\e2> (CYP2J2) metabolizes arachidonic acids to form <e1>epoxyeicosatrienoic acids<\\e1> (EETs), which possess various beneficial effects on the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"epoxyeicosatrienoic acids","object":"Cytochrome P450 epoxygenase 2J2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CYP2J2) metabolizes arachidonic acids to form <e1>CHEMICAL<\\e1> (EETs), which possess various beneficial effects on the cardiovascular system","sentence":"Cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system"}
{"PMID":23446230,"re_id":9,"annotated sentence":"Cytochrome P450 epoxygenase 2J2 (<e2>CYP2J2<\\e2>  metabolizes arachidonic acids to form <e1>epoxyeicosatrienoic acids<\\e1> (EETs), which possess various beneficial effects on the cardiovascular system","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"epoxyeicosatrienoic acids","object":"CYP2J2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cytochrome P450 epoxygenase 2J2 (<e2>GENE-Y<\\e2>  metabolizes arachidonic acids to form <e1>CHEMICAL<\\e1> (EETs), which possess various beneficial effects on the cardiovascular system","sentence":"Cytochrome P450 epoxygenase 2J2 (CYP2J2  metabolizes arachidonic acids to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system"}
{"PMID":23453039,"re_id":0,"annotated sentence":"The expression of <e2>regucalcin<\\e2> is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by <e1>streptozotocin<\\e1> administration in vivo","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"streptozotocin","object":"regucalcin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of <e2>GENE-Y<\\e2> is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by <e1>CHEMICAL<\\e1> administration in vivo","sentence":"The expression of regucalcin is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by streptozotocin administration in vivo"}
{"PMID":23453071,"re_id":0,"annotated sentence":"Previously, we have found that <e1>BRN-103<\\e1>  a nicotinamide derivative, inhibits vascular endothelial growth factor (<e2>VEGF<\\e2> -mediated angiogenesis signaling in human endothelial cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BRN-103","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Previously, we have found that <e1>CHEMICAL<\\e1>  a nicotinamide derivative, inhibits vascular endothelial growth factor (<e2>GENE-Y<\\e2> -mediated angiogenesis signaling in human endothelial cells","sentence":"Previously, we have found that BRN-103  a nicotinamide derivative, inhibits vascular endothelial growth factor (VEGF -mediated angiogenesis signaling in human endothelial cells"}
{"PMID":23453071,"re_id":1,"annotated sentence":"Previously, we have found that <e1>BRN-103<\\e1>  a nicotinamide derivative, inhibits <e2>vascular endothelial growth factor<\\e2> (VEGF)-mediated angiogenesis signaling in human endothelial cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BRN-103","object":"vascular endothelial growth factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Previously, we have found that <e1>CHEMICAL<\\e1>  a nicotinamide derivative, inhibits <e2>GENE-Y<\\e2> (VEGF)-mediated angiogenesis signaling in human endothelial cells","sentence":"Previously, we have found that BRN-103  a nicotinamide derivative, inhibits vascular endothelial growth factor (VEGF)-mediated angiogenesis signaling in human endothelial cells"}
{"PMID":23453071,"re_id":2,"annotated sentence":"Previously, we have found that BRN-103, a <e1>nicotinamide<\\e1> derivative, inhibits vascular endothelial growth factor (<e2>VEGF<\\e2> -mediated angiogenesis signaling in human endothelial cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicotinamide","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Previously, we have found that BRN-103, a <e1>CHEMICAL<\\e1> derivative, inhibits vascular endothelial growth factor (<e2>GENE-Y<\\e2> -mediated angiogenesis signaling in human endothelial cells","sentence":"Previously, we have found that BRN-103, a nicotinamide derivative, inhibits vascular endothelial growth factor (VEGF -mediated angiogenesis signaling in human endothelial cells"}
{"PMID":23453071,"re_id":3,"annotated sentence":"Previously, we have found that BRN-103, a <e1>nicotinamide<\\e1> derivative, inhibits <e2>vascular endothelial growth factor<\\e2> (VEGF)-mediated angiogenesis signaling in human endothelial cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicotinamide","object":"vascular endothelial growth factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Previously, we have found that BRN-103, a <e1>CHEMICAL<\\e1> derivative, inhibits <e2>GENE-Y<\\e2> (VEGF)-mediated angiogenesis signaling in human endothelial cells","sentence":"Previously, we have found that BRN-103, a nicotinamide derivative, inhibits vascular endothelial growth factor (VEGF)-mediated angiogenesis signaling in human endothelial cells"}
{"PMID":23453071,"re_id":4,"annotated sentence":"Furthermore, <e1>BRN-250<\\e1> inhibited the <e2>VEGF<\\e2> induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BRN-250","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> inhibited the <e2>GENE-Y<\\e2> induced phosphorylation and intracellular tyrosine kinase activity of GENE-Y receptor 2 (GENE-YR2) and the activation of its downstream AKT pathway","sentence":"Furthermore, BRN-250 inhibited the VEGF induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway"}
{"PMID":23453071,"re_id":5,"annotated sentence":"Furthermore, <e1>BRN-250<\\e1> inhibited the VEGF-induced phosphorylation and intracellular <e2>tyrosine kinase<\\e2> activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BRN-250","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> inhibited the VEGF-induced phosphorylation and intracellular <e2>GENE-N<\\e2> activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway","sentence":"Furthermore, BRN-250 inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway"}
{"PMID":23453071,"re_id":6,"annotated sentence":"Furthermore, <e1>BRN-250<\\e1> inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of <e2>VEGF receptor 2<\\e2> (VEGFR2) and the activation of its downstream AKT pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BRN-250","object":"VEGF receptor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of <e2>GENE-Y<\\e2> (VEGFR2) and the activation of its downstream AKT pathway","sentence":"Furthermore, BRN-250 inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway"}
{"PMID":23453071,"re_id":7,"annotated sentence":"Furthermore, <e1>BRN-250<\\e1> inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (<e2>VEGFR2<\\e2>  and the activation of its downstream AKT pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BRN-250","object":"VEGFR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (<e2>GENE-Y<\\e2>  and the activation of its downstream AKT pathway","sentence":"Furthermore, BRN-250 inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2  and the activation of its downstream AKT pathway"}
{"PMID":23453071,"re_id":8,"annotated sentence":"Furthermore, <e1>BRN-250<\\e1> inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream <e2>AKT<\\e2> pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BRN-250","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream <e2>GENE-N<\\e2> pathway","sentence":"Furthermore, BRN-250 inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway"}
{"PMID":23454149,"re_id":0,"annotated sentence":"Gelatin zymography showed that <e1>DMBT<\\e1> inhibited secretion and activity of <e2>MMP-9<\\e2>  Western blotting demonstrated that DMBT effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and p-Akt","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gelatin zymography showed that <e1>CHEMICAL<\\e1> inhibited secretion and activity of <e2>GENE-Y<\\e2>  Western blotting demonstrated that CHEMICAL effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and p-Akt","sentence":"Gelatin zymography showed that DMBT inhibited secretion and activity of MMP-9  Western blotting demonstrated that DMBT effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and p-Akt"}
{"PMID":23454149,"re_id":1,"annotated sentence":"Western blotting demonstrated that <e1>DMBT<\\e1> effectively suppressed the expression of <e2>VEGF<\\e2>  p-VEGFR-2, p-EGFR, and p-Akt","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Western blotting demonstrated that <e1>CHEMICAL<\\e1> effectively suppressed the expression of <e2>GENE-N<\\e2>  p-GENE-NR-2, p-EGFR, and p-Akt","sentence":"Western blotting demonstrated that DMBT effectively suppressed the expression of VEGF  p-VEGFR-2, p-EGFR, and p-Akt"}
{"PMID":23454149,"re_id":2,"annotated sentence":"Western blotting demonstrated that <e1>DMBT<\\e1> effectively suppressed the expression of VEGF, <e2>p-VEGFR-2<\\e2>  p-EGFR, and p-Akt","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"p-VEGFR-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blotting demonstrated that <e1>CHEMICAL<\\e1> effectively suppressed the expression of VEGF, <e2>GENE-Y<\\e2>  p-EGFR, and p-Akt","sentence":"Western blotting demonstrated that DMBT effectively suppressed the expression of VEGF, p-VEGFR-2  p-EGFR, and p-Akt"}
{"PMID":23454149,"re_id":3,"annotated sentence":"Western blotting demonstrated that <e1>DMBT<\\e1> effectively suppressed the expression of VEGF, p-VEGFR-2, <e2>p-EGFR<\\e2>  and p-Akt","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"p-EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blotting demonstrated that <e1>CHEMICAL<\\e1> effectively suppressed the expression of VEGF, p-VEGFR-2, <e2>GENE-Y<\\e2>  and p-Akt","sentence":"Western blotting demonstrated that DMBT effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR  and p-Akt"}
{"PMID":23454149,"re_id":4,"annotated sentence":"Western blotting demonstrated that <e1>DMBT<\\e1> effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and <e2>p-Akt<\\e2>  These results suggested that DMBT could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of Akt pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"p-Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Western blotting demonstrated that <e1>CHEMICAL<\\e1> effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and <e2>GENE-N<\\e2>  These results suggested that CHEMICAL could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of Akt pathway","sentence":"Western blotting demonstrated that DMBT effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and p-Akt  These results suggested that DMBT could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of Akt pathway"}
{"PMID":23454149,"re_id":5,"annotated sentence":"Inhibition of angiogenesis and invasion by <e1>DMBT<\\e1> is mediated by downregulation of VEGF and MMP-9 through <e2>Akt<\\e2> pathway in MDA-MB-231 breast cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of angiogenesis and invasion by <e1>CHEMICAL<\\e1> is mediated by downregulation of VEGF and MMP-9 through <e2>GENE-N<\\e2> pathway in MDA-MB-231 breast cancer cells","sentence":"Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells"}
{"PMID":23454149,"re_id":6,"annotated sentence":"Inhibition of angiogenesis and invasion by <e1>DMBT<\\e1> is mediated by downregulation of <e2>VEGF<\\e2> and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of angiogenesis and invasion by <e1>CHEMICAL<\\e1> is mediated by downregulation of <e2>GENE-N<\\e2> and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells","sentence":"Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells"}
{"PMID":23454149,"re_id":7,"annotated sentence":"Inhibition of angiogenesis and invasion by <e1>DMBT<\\e1> is mediated by downregulation of VEGF and <e2>MMP-9<\\e2> through Akt pathway in MDA-MB-231 breast cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of angiogenesis and invasion by <e1>CHEMICAL<\\e1> is mediated by downregulation of VEGF and <e2>GENE-Y<\\e2> through Akt pathway in MDA-MB-231 breast cancer cells","sentence":"Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells"}
{"PMID":23454149,"re_id":8,"annotated sentence":"These results suggested that <e1>DMBT<\\e1> could inhibit invasion and angiogenesis by downregulation of <e2>VEGF<\\e2> nd MMP-9, resulting from the inhibition of Akt pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results suggested that <e1>CHEMICAL<\\e1> could inhibit invasion and angiogenesis by downregulation of <e2>GENE-N<\\e2> nd MMP-9, resulting from the inhibition of Akt pathway","sentence":"These results suggested that DMBT could inhibit invasion and angiogenesis by downregulation of VEGF nd MMP-9, resulting from the inhibition of Akt pathway"}
{"PMID":23454149,"re_id":9,"annotated sentence":"These results suggested that <e1>DMBT<\\e1> could inhibit invasion and angiogenesis by downregulation of VEGFand <e2>MMP-9<\\e2>  resulting from the inhibition of Akt pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggested that <e1>CHEMICAL<\\e1> could inhibit invasion and angiogenesis by downregulation of VEGFand <e2>GENE-Y<\\e2>  resulting from the inhibition of Akt pathway","sentence":"These results suggested that DMBT could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9  resulting from the inhibition of Akt pathway"}
{"PMID":23454149,"re_id":10,"annotated sentence":"These results suggested that <e1>DMBT<\\e1> could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of <e2>Akt<\\e2> pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DMBT","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results suggested that <e1>CHEMICAL<\\e1> could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of <e2>GENE-N<\\e2> pathway","sentence":"These results suggested that DMBT could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of Akt pathway"}
{"PMID":23458730,"re_id":0,"annotated sentence":"Concentration-dependent inhibitory effects of <e1>baicalin<\\e1> on the metabolism of dextromethorphan, a dual probe of <e2>CYP2D<\\e2> and CYP3A, in rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"baicalin","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Concentration-dependent inhibitory effects of <e1>CHEMICAL<\\e1> on the metabolism of dextromethorphan, a dual probe of <e2>GENE-N<\\e2> and CYP3A, in rats","sentence":"Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats"}
{"PMID":23458730,"re_id":1,"annotated sentence":"Concentration-dependent inhibitory effects of <e1>baicalin<\\e1> on the metabolism of dextromethorphan, a dual probe of CYP2D and <e2>CYP3A<\\e2>  in rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"baicalin","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Concentration-dependent inhibitory effects of <e1>CHEMICAL<\\e1> on the metabolism of dextromethorphan, a dual probe of CYP2D and <e2>GENE-N<\\e2>  in rats","sentence":"Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A  in rats"}
{"PMID":23458730,"re_id":2,"annotated sentence":"The activity of <e2>CYP3A<\\e2> in excised liver samples from rats following multiple <e1>baicalin<\\e1> treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"baicalin","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The activity of <e2>GENE-N<\\e2> in excised liver samples from rats following multiple <e1>CHEMICAL<\\e1> treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of CHEMICAL had no obvious effect on the activity of CYP2D","sentence":"The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D"}
{"PMID":23458730,"re_id":3,"annotated sentence":"Taken together, these data demonstrate that <e1>baicalin<\\e1> inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic <e2>CYP2D<\\e2> and CYP3A activities.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"baicalin","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, these data demonstrate that <e1>CHEMICAL<\\e1> inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic <e2>GENE-N<\\e2> and CYP3A activities.","sentence":"Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities."}
{"PMID":23458730,"re_id":4,"annotated sentence":"Taken together, these data demonstrate that <e1>baicalin<\\e1> inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and <e2>CYP3A<\\e2> activities.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"baicalin","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, these data demonstrate that <e1>CHEMICAL<\\e1> inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and <e2>GENE-N<\\e2> activities.","sentence":"Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities."}
{"PMID":23458730,"re_id":5,"annotated sentence":"In the current study, we reveal the inhibitory effects of <e1>baicalin<\\e1> on the metabolism of dextromethorphan (DXM), a dual probe substrate of <e2>CYP2D<\\e2> and CYP3A, in rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"baicalin","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the current study, we reveal the inhibitory effects of <e1>CHEMICAL<\\e1> on the metabolism of dextromethorphan (DXM), a dual probe substrate of <e2>GENE-N<\\e2> and CYP3A, in rats","sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats"}
{"PMID":23458730,"re_id":6,"annotated sentence":"In the current study, we reveal the inhibitory effects of <e1>baicalin<\\e1> on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and <e2>CYP3A<\\e2>  in rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"baicalin","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the current study, we reveal the inhibitory effects of <e1>CHEMICAL<\\e1> on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and <e2>GENE-N<\\e2>  in rats","sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A  in rats"}
{"PMID":23458730,"re_id":7,"annotated sentence":"Lineweaver-Burk plots demonstrated that <e1>baicalin<\\e1> inhibited the activities of <e2>CYP2D<\\e2> and CYP3A in a non-competitive manner in rat liver microsomes (RLMs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"baicalin","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Lineweaver-Burk plots demonstrated that <e1>CHEMICAL<\\e1> inhibited the activities of <e2>GENE-N<\\e2> and CYP3A in a non-competitive manner in rat liver microsomes (RLMs)","sentence":"Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs)"}
{"PMID":23458730,"re_id":8,"annotated sentence":"Lineweaver-Burk plots demonstrated that <e1>baicalin<\\e1> inhibited the activities of CYP2D and <e2>CYP3A<\\e2> in a non-competitive manner in rat liver microsomes (RLMs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"baicalin","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Lineweaver-Burk plots demonstrated that <e1>CHEMICAL<\\e1> inhibited the activities of CYP2D and <e2>GENE-N<\\e2> in a non-competitive manner in rat liver microsomes (RLMs)","sentence":"Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs)"}
{"PMID":23458730,"re_id":9,"annotated sentence":"Concentration-dependent inhibitory effects of baicalin on the metabolism of <e1>dextromethorphan<\\e1>  a dual probe of <e2>CYP2D<\\e2> and CYP3A, in rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dextromethorphan","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Concentration-dependent inhibitory effects of baicalin on the metabolism of <e1>CHEMICAL<\\e1>  a dual probe of <e2>GENE-N<\\e2> and CYP3A, in rats","sentence":"Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan  a dual probe of CYP2D and CYP3A, in rats"}
{"PMID":23458730,"re_id":10,"annotated sentence":"Concentration-dependent inhibitory effects of baicalin on the metabolism of <e1>dextromethorphan<\\e1>  a dual probe of CYP2D and <e2>CYP3A<\\e2>  in rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dextromethorphan","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Concentration-dependent inhibitory effects of baicalin on the metabolism of <e1>CHEMICAL<\\e1>  a dual probe of CYP2D and <e2>GENE-N<\\e2>  in rats","sentence":"Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan  a dual probe of CYP2D and CYP3A  in rats"}
{"PMID":23458730,"re_id":11,"annotated sentence":"Taken together, these data demonstrate that baicalin inhibits the metabolism of <e1>DXM<\\e1> in a concentration-dependent manner in rats, possibly through inhibiting hepatic <e2>CYP2D<\\e2> and CYP3A activities.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DXM","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, these data demonstrate that baicalin inhibits the metabolism of <e1>CHEMICAL<\\e1> in a concentration-dependent manner in rats, possibly through inhibiting hepatic <e2>GENE-N<\\e2> and CYP3A activities.","sentence":"Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities."}
{"PMID":23458730,"re_id":12,"annotated sentence":"Taken together, these data demonstrate that baicalin inhibits the metabolism of <e1>DXM<\\e1> in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and <e2>CYP3A<\\e2> activities.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DXM","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, these data demonstrate that baicalin inhibits the metabolism of <e1>CHEMICAL<\\e1> in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and <e2>GENE-N<\\e2> activities.","sentence":"Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities."}
{"PMID":23458730,"re_id":13,"annotated sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of <e1>dextromethorphan<\\e1> (DXM), a dual probe substrate of <e2>CYP2D<\\e2> and CYP3A, in rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dextromethorphan","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of <e1>CHEMICAL<\\e1> (DXM), a dual probe substrate of <e2>GENE-N<\\e2> and CYP3A, in rats","sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats"}
{"PMID":23458730,"re_id":14,"annotated sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of <e1>dextromethorphan<\\e1> (DXM), a dual probe substrate of CYP2D and <e2>CYP3A<\\e2>  in rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"dextromethorphan","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of <e1>CHEMICAL<\\e1> (DXM), a dual probe substrate of CYP2D and <e2>GENE-N<\\e2>  in rats","sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A  in rats"}
{"PMID":23458730,"re_id":15,"annotated sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (<e1>DXM<\\e1> , a dual probe substrate of <e2>CYP2D<\\e2> and CYP3A, in rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DXM","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (<e1>CHEMICAL<\\e1> , a dual probe substrate of <e2>GENE-N<\\e2> and CYP3A, in rats","sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM , a dual probe substrate of CYP2D and CYP3A, in rats"}
{"PMID":23458730,"re_id":16,"annotated sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (<e1>DXM<\\e1> , a dual probe substrate of CYP2D and <e2>CYP3A<\\e2>  in rats","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"DXM","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (<e1>CHEMICAL<\\e1> , a dual probe substrate of CYP2D and <e2>GENE-N<\\e2>  in rats","sentence":"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM , a dual probe substrate of CYP2D and CYP3A  in rats"}
{"PMID":23465612,"re_id":0,"annotated sentence":"The structure-activity relationship of a series of <e1>dihydroisoquinoline<\\e1> <e2>BACE-1<\\e2> inhibitors is described","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydroisoquinoline","object":"BACE-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The structure-activity relationship of a series of <e1>CHEMICAL<\\e1> <e2>GENE-Y<\\e2> inhibitors is described","sentence":"The structure-activity relationship of a series of dihydroisoquinoline BACE-1 inhibitors is described"}
{"PMID":23465612,"re_id":1,"annotated sentence":"Structure-based design of novel <e1>dihydroisoquinoline<\\e1> <e2>BACE-1<\\e2> inhibitors that do not engage the catalytic aspartates","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydroisoquinoline","object":"BACE-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Structure-based design of novel <e1>CHEMICAL<\\e1> <e2>GENE-Y<\\e2> inhibitors that do not engage the catalytic aspartates","sentence":"Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates"}
{"PMID":23466229,"re_id":0,"annotated sentence":"The modification of the inhibitor scaffold of 1 and 2 from a <e1>dihydroquinolinone<\\e1> core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent <e2>KAT II<\\e2> inhibitors with excellent physicochemical properties","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydroquinolinone","object":"KAT II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The modification of the inhibitor scaffold of 1 and 2 from a <e1>CHEMICAL<\\e1> core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent <e2>GENE-Y<\\e2> inhibitors with excellent physicochemical properties","sentence":"The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent KAT II inhibitors with excellent physicochemical properties"}
{"PMID":23466229,"re_id":1,"annotated sentence":"The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a <e1>tetrahydropyrazolopyridinone<\\e1> core led to discovery of a new series of potent <e2>KAT II<\\e2> inhibitors with excellent physicochemical properties","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tetrahydropyrazolopyridinone","object":"KAT II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a <e1>CHEMICAL<\\e1> core led to discovery of a new series of potent <e2>GENE-Y<\\e2> inhibitors with excellent physicochemical properties","sentence":"The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent KAT II inhibitors with excellent physicochemical properties"}
{"PMID":23466229,"re_id":2,"annotated sentence":"The structure-based design, synthesis, and biological evaluation of a new <e1>pyrazole<\\e1> series of irreversible <e2>KAT II<\\e2> inhibitors are described herein","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrazole","object":"KAT II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The structure-based design, synthesis, and biological evaluation of a new <e1>CHEMICAL<\\e1> series of irreversible <e2>GENE-Y<\\e2> inhibitors are described herein","sentence":"The structure-based design, synthesis, and biological evaluation of a new pyrazole series of irreversible KAT II inhibitors are described herein"}
{"PMID":23466229,"re_id":3,"annotated sentence":"<e1>PF-04859989<\\e1> as a template for structure-based drug design: identification of new pyrazole series of irreversible <e2>KAT II<\\e2> inhibitors with improved lipophilic efficiency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PF-04859989","object":"KAT II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> as a template for structure-based drug design: identification of new pyrazole series of irreversible <e2>GENE-Y<\\e2> inhibitors with improved lipophilic efficiency","sentence":"PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency"}
{"PMID":23466229,"re_id":4,"annotated sentence":"PF-04859989 as a template for structure-based drug design: identification of new <e1>pyrazole<\\e1> series of irreversible <e2>KAT II<\\e2> inhibitors with improved lipophilic efficiency","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrazole","object":"KAT II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PF-04859989 as a template for structure-based drug design: identification of new <e1>CHEMICAL<\\e1> series of irreversible <e2>GENE-Y<\\e2> inhibitors with improved lipophilic efficiency","sentence":"PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency"}
{"PMID":23466232,"re_id":0,"annotated sentence":"Structure-activity relationship studies indicated that <e1>5-(p-toluenesulfonylamino)phthalimide<\\e1> moiety is a favorable scaffold to exert the <e2>\u03b1-glucosidase<\\e2> inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-(p-toluenesulfonylamino)phthalimide","object":"\u03b1-glucosidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Structure-activity relationship studies indicated that <e1>CHEMICAL<\\e1> moiety is a favorable scaffold to exert the <e2>GENE-N<\\e2> inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities.","sentence":"Structure-activity relationship studies indicated that 5-(p-toluenesulfonylamino)phthalimide moiety is a favorable scaffold to exert the \u03b1-glucosidase inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities."}
{"PMID":23466232,"re_id":1,"annotated sentence":"Several members of a new family of non-sugar-type <e2>\u03b1-glycosidase<\\e2> inhibitors, bearing a <e1>5-(p-toluenesulfonylamino)phthalimide<\\e1> moiety and various substituent at the N2 position, were synthesized and their activities were investigated","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-(p-toluenesulfonylamino)phthalimide","object":"\u03b1-glycosidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Several members of a new family of non-sugar-type <e2>GENE-N<\\e2> inhibitors, bearing a <e1>CHEMICAL<\\e1> moiety and various substituent at the N2 position, were synthesized and their activities were investigated","sentence":"Several members of a new family of non-sugar-type \u03b1-glycosidase inhibitors, bearing a 5-(p-toluenesulfonylamino)phthalimide moiety and various substituent at the N2 position, were synthesized and their activities were investigated"}
{"PMID":23466232,"re_id":2,"annotated sentence":"A new series of <e1>N2-substituted-5-(p-toluenesulfonylamino)phthalimide<\\e1> analogues as <e2>\u03b1-glucosidase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N2-substituted-5-(p-toluenesulfonylamino)phthalimide","object":"\u03b1-glucosidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A new series of <e1>CHEMICAL<\\e1> analogues as <e2>GENE-N<\\e2> inhibitors","sentence":"A new series of N2-substituted-5-(p-toluenesulfonylamino)phthalimide analogues as \u03b1-glucosidase inhibitors"}
{"PMID":23473681,"re_id":0,"annotated sentence":"We previously employed a chemical genomic strategy to identify a novel small molecule, <e1>MAC13243<\\e1>  as a likely inhibitor of the <e2>bacterial lipoprotein<\\e2> targeting chaperone, LolA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MAC13243","object":"bacterial lipoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We previously employed a chemical genomic strategy to identify a novel small molecule, <e1>CHEMICAL<\\e1>  as a likely inhibitor of the <e2>GENE-N<\\e2> targeting chaperone, LolA","sentence":"We previously employed a chemical genomic strategy to identify a novel small molecule, MAC13243  as a likely inhibitor of the bacterial lipoprotein targeting chaperone, LolA"}
{"PMID":23473681,"re_id":1,"annotated sentence":"We previously employed a chemical genomic strategy to identify a novel small molecule, <e1>MAC13243<\\e1>  as a likely inhibitor of the bacterial lipoprotein targeting <e2>chaperone<\\e2>  LolA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MAC13243","object":"chaperone","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We previously employed a chemical genomic strategy to identify a novel small molecule, <e1>CHEMICAL<\\e1>  as a likely inhibitor of the bacterial lipoprotein targeting <e2>GENE-N<\\e2>  LolA","sentence":"We previously employed a chemical genomic strategy to identify a novel small molecule, MAC13243  as a likely inhibitor of the bacterial lipoprotein targeting chaperone  LolA"}
{"PMID":23473681,"re_id":2,"annotated sentence":"We previously employed a chemical genomic strategy to identify a novel small molecule, <e1>MAC13243<\\e1>  as a likely inhibitor of the bacterial lipoprotein targeting chaperone, <e2>LolA<\\e2>  Here, we report on the degradation of MAC13243 into the active species, S-(4-chlorobenzyl)isothiourea","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MAC13243","object":"LolA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We previously employed a chemical genomic strategy to identify a novel small molecule, <e1>CHEMICAL<\\e1>  as a likely inhibitor of the bacterial lipoprotein targeting chaperone, <e2>GENE-N<\\e2>  Here, we report on the degradation of CHEMICAL into the active species, S-(4-chlorobenzyl)isothiourea","sentence":"We previously employed a chemical genomic strategy to identify a novel small molecule, MAC13243  as a likely inhibitor of the bacterial lipoprotein targeting chaperone, LolA  Here, we report on the degradation of MAC13243 into the active species, S-(4-chlorobenzyl)isothiourea"}
{"PMID":23473804,"re_id":0,"annotated sentence":"Thus, in 158N cells, the ability of <e1>oxysterols<\\e1> to trigger a mode of cell death by apoptosis involving <e2>GSK-3<\\e2> and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxysterols","object":"GSK-3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, in 158N cells, the ability of <e1>CHEMICAL<\\e1> to trigger a mode of cell death by apoptosis involving <e2>GENE-N<\\e2> and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.","sentence":"Thus, in 158N cells, the ability of oxysterols to trigger a mode of cell death by apoptosis involving GSK-3 and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains."}
{"PMID":23473804,"re_id":1,"annotated sentence":"Thus, in 158N cells, the ability of <e1>oxysterols<\\e1> to trigger a mode of cell death by apoptosis involving GSK-3 and <e2>caspase-3<\\e2> activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oxysterols","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, in 158N cells, the ability of <e1>CHEMICAL<\\e1> to trigger a mode of cell death by apoptosis involving GSK-3 and <e2>GENE-Y<\\e2> activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.","sentence":"Thus, in 158N cells, the ability of oxysterols to trigger a mode of cell death by apoptosis involving GSK-3 and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains."}
{"PMID":23473804,"re_id":2,"annotated sentence":"To this end, 158N murine oligodendrocytes were treated with <e1>7KC<\\e1> or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving <e2>Mcl-1<\\e2>  and caspase-3 activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"7KC","object":"Mcl-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To this end, 158N murine oligodendrocytes were treated with <e1>CHEMICAL<\\e1> or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving <e2>GENE-Y<\\e2>  and caspase-3 activation","sentence":"To this end, 158N murine oligodendrocytes were treated with 7KC or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1  and caspase-3 activation"}
{"PMID":23473804,"re_id":3,"annotated sentence":"To this end, 158N murine oligodendrocytes were treated with <e1>7KC<\\e1> or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and <e2>caspase-3<\\e2> activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"7KC","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To this end, 158N murine oligodendrocytes were treated with <e1>CHEMICAL<\\e1> or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and <e2>GENE-Y<\\e2> activation","sentence":"To this end, 158N murine oligodendrocytes were treated with 7KC or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and caspase-3 activation"}
{"PMID":23473804,"re_id":4,"annotated sentence":"To this end, 158N murine oligodendrocytes were treated with 7KC or <e1>7\u03b2OHC<\\e1> inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving <e2>Mcl-1<\\e2>  and caspase-3 activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"7\u03b2OHC","object":"Mcl-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To this end, 158N murine oligodendrocytes were treated with 7KC or <e1>CHEMICAL<\\e1> inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving <e2>GENE-Y<\\e2>  and caspase-3 activation","sentence":"To this end, 158N murine oligodendrocytes were treated with 7KC or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1  and caspase-3 activation"}
{"PMID":23473804,"re_id":5,"annotated sentence":"To this end, 158N murine oligodendrocytes were treated with 7KC or <e1>7\u03b2OHC<\\e1> inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and <e2>caspase-3<\\e2> activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"7\u03b2OHC","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To this end, 158N murine oligodendrocytes were treated with 7KC or <e1>CHEMICAL<\\e1> inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and <e2>GENE-Y<\\e2> activation","sentence":"To this end, 158N murine oligodendrocytes were treated with 7KC or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation\/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and caspase-3 activation"}
{"PMID":23474889,"re_id":0,"annotated sentence":"This inhibition was blocked when mice were pretreated with the selective <e2>H3R<\\e2> agonist <e1>R-(alpha)-methyl-histamine<\\e1> (10\u00a0mg\/kg)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"R-(alpha)-methyl-histamine","object":"H3R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This inhibition was blocked when mice were pretreated with the selective <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> (10\u00a0mg\/kg)","sentence":"This inhibition was blocked when mice were pretreated with the selective H3R agonist R-(alpha)-methyl-histamine (10\u00a0mg\/kg)"}
{"PMID":23478800,"re_id":0,"annotated sentence":"Subsequent analysis revealed that <e1>cucurbitacin I<\\e1> strongly activates <e2>RhoA<\\e2> and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cucurbitacin I","object":"RhoA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Subsequent analysis revealed that <e1>CHEMICAL<\\e1> strongly activates <e2>GENE-N<\\e2> and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers","sentence":"Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers"}
{"PMID":23478800,"re_id":1,"annotated sentence":"Subsequent analysis revealed that <e1>cucurbitacin I<\\e1> strongly activates RhoA and the <e2>Rho<\\e2> effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cucurbitacin I","object":"Rho","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Subsequent analysis revealed that <e1>CHEMICAL<\\e1> strongly activates GENE-NA and the <e2>GENE-N<\\e2> effector GENE-N kinase (ROCK) in breast cancer cells and induces the formation of stress fibers","sentence":"Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers"}
{"PMID":23478800,"re_id":2,"annotated sentence":"Subsequent analysis revealed that <e1>cucurbitacin I<\\e1> strongly activates RhoA and the Rho effector <e2>Rho kinase<\\e2> (ROCK) in breast cancer cells and induces the formation of stress fibers","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cucurbitacin I","object":"Rho kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Subsequent analysis revealed that <e1>CHEMICAL<\\e1> strongly activates RhoA and the Rho effector <e2>GENE-N<\\e2> (ROCK) in breast cancer cells and induces the formation of stress fibers","sentence":"Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers"}
{"PMID":23478800,"re_id":3,"annotated sentence":"Subsequent analysis revealed that <e1>cucurbitacin I<\\e1> strongly activates RhoA and the Rho effector Rho kinase (<e2>ROCK<\\e2>  in breast cancer cells and induces the formation of stress fibers","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cucurbitacin I","object":"ROCK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Subsequent analysis revealed that <e1>CHEMICAL<\\e1> strongly activates RhoA and the Rho effector Rho kinase (<e2>GENE-N<\\e2>  in breast cancer cells and induces the formation of stress fibers","sentence":"Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK  in breast cancer cells and induces the formation of stress fibers"}
{"PMID":23478800,"re_id":4,"annotated sentence":"Lastly, we found that <e2>RhoA<\\e2> activation by <e1>cucurbitacin I<\\e1> is mediated by reactive oxygen species (ROS)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cucurbitacin I","object":"RhoA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Lastly, we found that <e2>GENE-N<\\e2> activation by <e1>CHEMICAL<\\e1> is mediated by reactive oxygen species (ROS)","sentence":"Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS)"}
{"PMID":23478800,"re_id":5,"annotated sentence":"The ROS scavenger <e1>N-acetyl l-cysteine<\\e1> and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on <e2>Rac1<\\e2> activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"N-acetyl l-cysteine","object":"Rac1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ROS scavenger <e1>CHEMICAL<\\e1> and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on <e2>GENE-Y<\\e2> activation","sentence":"The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation"}
{"PMID":23478800,"re_id":6,"annotated sentence":"<e1>Cucurbitacin I<\\e1> inhibits <e2>rac1<\\e2> activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cucurbitacin I","object":"rac1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1","sentence":"Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1"}
{"PMID":23478800,"re_id":7,"annotated sentence":"Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of <e1>cucurbitacin I<\\e1> on <e2>Rac1<\\e2> activation by heregulin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cucurbitacin I","object":"Rac1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2> activation by heregulin","sentence":"Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin"}
{"PMID":23478800,"re_id":8,"annotated sentence":"The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of <e1>cucurbitacin I<\\e1> on <e2>Rac1<\\e2> activation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cucurbitacin I","object":"Rac1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2> activation","sentence":"The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation"}
{"PMID":23478800,"re_id":9,"annotated sentence":"Moreover, they established that the inhibitory effect of <e1>cucurbitacin I<\\e1> on <e2>Rac1<\\e2> activity involves the alteration of the balance between Rho and Rac.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cucurbitacin I","object":"Rac1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, they established that the inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2> activity involves the alteration of the balance between Rho and Rac.","sentence":"Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac."}
{"PMID":23478800,"re_id":10,"annotated sentence":"Here we found that the anticancer agent <e1>cucurbitacin I<\\e1>  a <e2>Jak2<\\e2> inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cucurbitacin I","object":"Jak2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Here we found that the anticancer agent <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells","sentence":"Here we found that the anticancer agent cucurbitacin I  a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells"}
{"PMID":23478800,"re_id":11,"annotated sentence":"Here we found that the anticancer agent <e1>cucurbitacin I<\\e1>  a Jak2 inhibitor, reduced the activation of <e2>Rac1<\\e2> and motility in response to the ErbB3 ligand heregulin in breast cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cucurbitacin I","object":"Rac1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we found that the anticancer agent <e1>CHEMICAL<\\e1>  a Jak2 inhibitor, reduced the activation of <e2>GENE-Y<\\e2> and motility in response to the ErbB3 ligand heregulin in breast cancer cells","sentence":"Here we found that the anticancer agent cucurbitacin I  a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells"}
{"PMID":23479389,"re_id":0,"annotated sentence":"The major ingredient of ginger, <e1>[6]-gingerol<\\e1>  could inhibit <e2>angiotensin II type 1 receptor<\\e2> activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"[6]-gingerol","object":"angiotensin II type 1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The major ingredient of ginger, <e1>CHEMICAL<\\e1>  could inhibit <e2>GENE-Y<\\e2> activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.","sentence":"The major ingredient of ginger, [6]-gingerol  could inhibit angiotensin II type 1 receptor activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system."}
{"PMID":23479389,"re_id":1,"annotated sentence":"<e1>[6]-Gingerol<\\e1> derived from Zingiber officinale Roscoe (ginger) was identified as a novel <e2>angiotensin II type 1 receptor<\\e2> antagonist, with an IC50 value of 8.173 \u00b5M","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"[6]-Gingerol","object":"angiotensin II type 1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> derived from Zingiber officinale Roscoe (ginger) was identified as a novel <e2>GENE-Y<\\e2> antagonist, with an IC50 value of 8.173 \u00b5M","sentence":"[6]-Gingerol derived from Zingiber officinale Roscoe (ginger) was identified as a novel angiotensin II type 1 receptor antagonist, with an IC50 value of 8.173 \u00b5M"}
{"PMID":23479389,"re_id":2,"annotated sentence":"<e1>[6]-gingerol<\\e1>  a novel <e2>AT\u2081<\\e2> antagonist for the treatment of cardiovascular disease","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"[6]-gingerol","object":"AT\u2081","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a novel <e2>GENE-Y<\\e2> antagonist for the treatment of cardiovascular disease","sentence":"[6]-gingerol  a novel AT\u2081 antagonist for the treatment of cardiovascular disease"}
{"PMID":23481236,"re_id":0,"annotated sentence":"Saturated <e1>palmitic and stearic acids<\\e1> increased ceramides, up-regulated <e2>PTP1B<\\e2>  and had AKt and PTP1B phosphorylation at Ser 50 impaired","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"palmitic and stearic acids","object":"PTP1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Saturated <e1>CHEMICAL<\\e1> increased ceramides, up-regulated <e2>GENE-Y<\\e2>  and had AKt and GENE-Y phosphorylation at Ser 50 impaired","sentence":"Saturated palmitic and stearic acids increased ceramides, up-regulated PTP1B  and had AKt and PTP1B phosphorylation at Ser 50 impaired"}
{"PMID":23481236,"re_id":1,"annotated sentence":"Saturated <e1>palmitic and stearic acids<\\e1> increased ceramides, up-regulated PTP1B, and had <e2>AKt<\\e2> and PTP1B phosphorylation at Ser 50 impaired","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"palmitic and stearic acids","object":"AKt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Saturated <e1>CHEMICAL<\\e1> increased ceramides, up-regulated PTP1B, and had <e2>GENE-N<\\e2> and PTP1B phosphorylation at Ser 50 impaired","sentence":"Saturated palmitic and stearic acids increased ceramides, up-regulated PTP1B, and had AKt and PTP1B phosphorylation at Ser 50 impaired"}
{"PMID":23481236,"re_id":2,"annotated sentence":"Saturated <e1>palmitic and stearic acids<\\e1> increased ceramides, up-regulated PTP1B, and had AKt and <e2>PTP1B<\\e2> phosphorylation at Ser 50 impaired","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"palmitic and stearic acids","object":"PTP1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Saturated <e1>CHEMICAL<\\e1> increased ceramides, up-regulated GENE-Y, and had AKt and <e2>GENE-Y<\\e2> phosphorylation at Ser 50 impaired","sentence":"Saturated palmitic and stearic acids increased ceramides, up-regulated PTP1B, and had AKt and PTP1B phosphorylation at Ser 50 impaired"}
{"PMID":23481236,"re_id":3,"annotated sentence":"Cells were also evaluated in the presence of <e1>wortmannin<\\e1>  an inhibitor of <e2>phosphatidylinositol 3-kinases<\\e2> and thus AKt (0-100 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wortmannin","object":"phosphatidylinositol 3-kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cells were also evaluated in the presence of <e1>CHEMICAL<\\e1>  an inhibitor of <e2>GENE-N<\\e2> and thus AKt (0-100 nM)","sentence":"Cells were also evaluated in the presence of wortmannin  an inhibitor of phosphatidylinositol 3-kinases and thus AKt (0-100 nM)"}
{"PMID":23481236,"re_id":4,"annotated sentence":"Cells were also evaluated in the presence of <e1>wortmannin<\\e1>  an inhibitor of phosphatidylinositol 3-kinases and thus <e2>AKt<\\e2> (0-100 nM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"wortmannin","object":"AKt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cells were also evaluated in the presence of <e1>CHEMICAL<\\e1>  an inhibitor of phosphatidylinositol 3-kinases and thus <e2>GENE-N<\\e2> (0-100 nM)","sentence":"Cells were also evaluated in the presence of wortmannin  an inhibitor of phosphatidylinositol 3-kinases and thus AKt (0-100 nM)"}
{"PMID":23481236,"re_id":5,"annotated sentence":"Only FFAs that increased <e1>ceramides<\\e1> caused impairment of <e2>AKt<\\e2> and PTP1B phosphorylation at Ser 50","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ceramides","object":"AKt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Only FFAs that increased <e1>CHEMICAL<\\e1> caused impairment of <e2>GENE-N<\\e2> and PTP1B phosphorylation at Ser 50","sentence":"Only FFAs that increased ceramides caused impairment of AKt and PTP1B phosphorylation at Ser 50"}
{"PMID":23481236,"re_id":6,"annotated sentence":"Only FFAs that increased <e1>ceramides<\\e1> caused impairment of AKt and <e2>PTP1B<\\e2> phosphorylation at Ser 50","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ceramides","object":"PTP1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Only FFAs that increased <e1>CHEMICAL<\\e1> caused impairment of AKt and <e2>GENE-Y<\\e2> phosphorylation at Ser 50","sentence":"Only FFAs that increased ceramides caused impairment of AKt and PTP1B phosphorylation at Ser 50"}
{"PMID":23487168,"re_id":0,"annotated sentence":"Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly <e1>telmisartan<\\e1>  are partial agonists at <e2>peroxisome proliferator-activated receptor-\u03b3<\\e2>  All of these properties are comprehensively reviewed in this article","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"telmisartan","object":"peroxisome proliferator-activated receptor-\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly <e1>CHEMICAL<\\e1>  are partial agonists at <e2>GENE-Y<\\e2>  All of these properties are comprehensively reviewed in this article","sentence":"Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan  are partial agonists at peroxisome proliferator-activated receptor-\u03b3  All of these properties are comprehensively reviewed in this article"}
{"PMID":23487168,"re_id":1,"annotated sentence":"Although generally highly specific for <e2>angiotensin II type 1 receptors<\\e2>  some ARBs, particularly <e1>telmisartan<\\e1>  are partial agonists at peroxisome proliferator-activated receptor-\u03b3","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"telmisartan","object":"angiotensin II type 1 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although generally highly specific for <e2>GENE-Y<\\e2>  some ARBs, particularly <e1>CHEMICAL<\\e1>  are partial agonists at peroxisome proliferator-activated receptor-\u03b3","sentence":"Although generally highly specific for angiotensin II type 1 receptors  some ARBs, particularly telmisartan  are partial agonists at peroxisome proliferator-activated receptor-\u03b3"}
{"PMID":23489521,"re_id":0,"annotated sentence":"A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma <e1>glucose<\\e1> improved with <e2>insulin<\\e2> detemir without an increased incidence of hypoglycaemia","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A head-to-head comparison between GENE-Y detemir and NPH GENE-Y in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma <e1>CHEMICAL<\\e1> improved with <e2>GENE-Y<\\e2> detemir without an increased incidence of hypoglycaemia","sentence":"A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma glucose improved with insulin detemir without an increased incidence of hypoglycaemia"}
{"PMID":23489628,"re_id":0,"annotated sentence":"In this study, we employed virtual screening and chemical synthesis to identify a series of <e1>N-(thiophen-2-yl) benzamide<\\e1> derivatives as potent <e2>BRAF<\\e2> V600E) inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-(thiophen-2-yl) benzamide","object":"BRAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we employed virtual screening and chemical synthesis to identify a series of <e1>CHEMICAL<\\e1> derivatives as potent <e2>GENE-Y<\\e2> V600E) inhibitors","sentence":"In this study, we employed virtual screening and chemical synthesis to identify a series of N-(thiophen-2-yl) benzamide derivatives as potent BRAF V600E) inhibitors"}
{"PMID":23489628,"re_id":1,"annotated sentence":"In this study, we employed virtual screening and chemical synthesis to identify a series of <e1>N-(thiophen-2-yl) benzamide<\\e1> derivatives as potent BRAF(<e2>V600E<\\e2>  inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-(thiophen-2-yl) benzamide","object":"V600E","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, we employed virtual screening and chemical synthesis to identify a series of <e1>CHEMICAL<\\e1> derivatives as potent BRAF(<e2>GENE-N<\\e2>  inhibitors","sentence":"In this study, we employed virtual screening and chemical synthesis to identify a series of N-(thiophen-2-yl) benzamide derivatives as potent BRAF(V600E  inhibitors"}
{"PMID":23489628,"re_id":2,"annotated sentence":"Identification and synthesis of <e1>N-(thiophen-2-yl) benzamide<\\e1> derivatives as <e2>BRAF<\\e2> V600E) inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-(thiophen-2-yl) benzamide","object":"BRAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Identification and synthesis of <e1>CHEMICAL<\\e1> derivatives as <e2>GENE-Y<\\e2> V600E) inhibitors","sentence":"Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF V600E) inhibitors"}
{"PMID":23489628,"re_id":3,"annotated sentence":"Identification and synthesis of <e1>N-(thiophen-2-yl) benzamide<\\e1> derivatives as BRAF(<e2>V600E<\\e2>  inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-(thiophen-2-yl) benzamide","object":"V600E","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Identification and synthesis of <e1>CHEMICAL<\\e1> derivatives as BRAF(<e2>GENE-N<\\e2>  inhibitors","sentence":"Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E  inhibitors"}
{"PMID":23493374,"re_id":0,"annotated sentence":"Methylation-specific PCR and bisulfite sequencing identified methylation of this <e1>CpG<\\e1> ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in <e2>DNA methyl transferase 3a<\\e2> concentrations noted with advancing postnatal age (PN14 vs PN3)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CpG","object":"DNA methyl transferase 3a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methylation-specific PCR and bisulfite sequencing identified methylation of this <e1>CHEMICAL<\\e1> ((m)CHEMICAL) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in <e2>GENE-Y<\\e2> concentrations noted with advancing postnatal age (PN14 vs PN3)","sentence":"Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3)"}
{"PMID":23493374,"re_id":1,"annotated sentence":"Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG (<e1>(m)CpG<\\e1>  island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in <e2>DNA methyl transferase 3a<\\e2> concentrations noted with advancing postnatal age (PN14 vs PN3)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"(m)CpG","object":"DNA methyl transferase 3a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG (<e1>CHEMICAL<\\e1>  island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in <e2>GENE-Y<\\e2> concentrations noted with advancing postnatal age (PN14 vs PN3)","sentence":"Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ((m)CpG  island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3)"}
{"PMID":23493374,"re_id":2,"annotated sentence":"5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that <e1>(m)CpGs<\\e1> inhibit <e2>glut3<\\e2> transcription","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(m)CpGs","object":"glut3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"5'-flanking region of GENE-Y-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that <e1>CHEMICAL<\\e1> inhibit <e2>GENE-Y<\\e2> transcription","sentence":"5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription"}
{"PMID":23493374,"re_id":3,"annotated sentence":"Separate <e1>5-aza-2'-deoxycytidine<\\e1> pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting <e2>Mecp2<\\e2> and Creb1 separately or together depleting Mecp2 and\/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-aza-2'-deoxycytidine","object":"Mecp2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Separate <e1>CHEMICAL<\\e1> pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting <e2>GENE-Y<\\e2> and Creb1 separately or together depleting GENE-Y and\/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells","sentence":"Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and\/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells"}
{"PMID":23493374,"re_id":4,"annotated sentence":"Separate <e1>5-aza-2'-deoxycytidine<\\e1> pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and <e2>Creb1<\\e2> separately or together depleting Mecp2 and\/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-aza-2'-deoxycytidine","object":"Creb1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Separate <e1>CHEMICAL<\\e1> pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and <e2>GENE-Y<\\e2> separately or together depleting Mecp2 and\/or GENE-Y binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells","sentence":"Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and\/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells"}
{"PMID":23493374,"re_id":5,"annotated sentence":"Separate 5-aza-2'-deoxycytidine pretreatment or in combination with <e1>trichostatin A<\\e1> reduced (m)CpG and specific small interference RNAs targeting <e2>Mecp2<\\e2> and Creb1 separately or together depleting Mecp2 and\/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"trichostatin A","object":"Mecp2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Separate 5-aza-2'-deoxycytidine pretreatment or in combination with <e1>CHEMICAL<\\e1> reduced (m)CpG and specific small interference RNAs targeting <e2>GENE-Y<\\e2> and Creb1 separately or together depleting GENE-Y and\/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells","sentence":"Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and\/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells"}
{"PMID":23493374,"re_id":6,"annotated sentence":"Separate 5-aza-2'-deoxycytidine pretreatment or in combination with <e1>trichostatin A<\\e1> reduced (m)CpG and specific small interference RNAs targeting Mecp2 and <e2>Creb1<\\e2> separately or together depleting Mecp2 and\/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"trichostatin A","object":"Creb1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Separate 5-aza-2'-deoxycytidine pretreatment or in combination with <e1>CHEMICAL<\\e1> reduced (m)CpG and specific small interference RNAs targeting Mecp2 and <e2>GENE-Y<\\e2> separately or together depleting Mecp2 and\/or GENE-Y binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells","sentence":"Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and\/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells"}
{"PMID":23494186,"re_id":0,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ezetimibe","object":"LDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":23494186,"re_id":1,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bile acid","object":"LDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":23494186,"re_id":2,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fibrates","object":"LDL","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":23495205,"re_id":0,"annotated sentence":"The most potent in\u2005vitro DASI discovered is an <e1>imidazole<\\e1> derivative with IC50 values against <e2>aromatase<\\e2> and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5\u2005nM, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imidazole","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most potent in\u2005vitro DASI discovered is an <e1>CHEMICAL<\\e1> derivative with IC50 values against <e2>GENE-Y<\\e2> and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5\u2005nM, respectively","sentence":"The most potent in\u2005vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5\u2005nM, respectively"}
{"PMID":23495205,"re_id":1,"annotated sentence":"The most potent in\u2005vitro DASI discovered is an <e1>imidazole<\\e1> derivative with IC50 values against aromatase and <e2>steroid sulfatase<\\e2> in a JEG-3 cell preparation of 0.2 and 2.5\u2005nM, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"imidazole","object":"steroid sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most potent in\u2005vitro DASI discovered is an <e1>CHEMICAL<\\e1> derivative with IC50 values against aromatase and <e2>GENE-Y<\\e2> in a JEG-3 cell preparation of 0.2 and 2.5\u2005nM, respectively","sentence":"The most potent in\u2005vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5\u2005nM, respectively"}
{"PMID":23495205,"re_id":2,"annotated sentence":"The parent <e1>phenol<\\e1> of this compound inhibits <e2>aromatase<\\e2> with an IC50 value of 0.028\u2005nM in the same assay.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phenol","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The parent <e1>CHEMICAL<\\e1> of this compound inhibits <e2>GENE-Y<\\e2> with an IC50 value of 0.028\u2005nM in the same assay.","sentence":"The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028\u2005nM in the same assay."}
{"PMID":23495205,"re_id":3,"annotated sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (<e1>F<\\e1>  Cl, Br) derivatives are first-generation dual <e2>aromatase<\\e2> and sulfatase inhibitors (DASIs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"F","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (<e1>CHEMICAL<\\e1>  Cl, Br) derivatives are first-generation dual <e2>GENE-Y<\\e2> and sulfatase inhibitors (DASIs)","sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F  Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)"}
{"PMID":23495205,"re_id":4,"annotated sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (<e1>F<\\e1>  Cl, Br) derivatives are first-generation dual aromatase and <e2>sulfatase<\\e2> inhibitors (DASIs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"F","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (<e1>CHEMICAL<\\e1>  Cl, Br) derivatives are first-generation dual aromatase and <e2>GENE-Y<\\e2> inhibitors (DASIs)","sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F  Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)"}
{"PMID":23495205,"re_id":5,"annotated sentence":"Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual <e2>Aromatase<\\e2> Sulfatase Inhibitor <e1>4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate<\\e1>  4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate","object":"Aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual <e2>GENE-Y<\\e2> Sulfatase Inhibitor <e1>CHEMICAL<\\e1>  CHEMICAL and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)","sentence":"Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate  4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)"}
{"PMID":23495205,"re_id":6,"annotated sentence":"Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-<e2>Sulfatase<\\e2> Inhibitor <e1>4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate<\\e1>  4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate","object":"Sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-<e2>GENE-Y<\\e2> Inhibitor <e1>CHEMICAL<\\e1>  CHEMICAL and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)","sentence":"Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate  4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)"}
{"PMID":23495205,"re_id":7,"annotated sentence":"<e1>4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate<\\e1> and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual <e2>aromatase<\\e2> and sulfatase inhibitors (DASIs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual <e2>GENE-Y<\\e2> and sulfatase inhibitors (DASIs)","sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)"}
{"PMID":23495205,"re_id":8,"annotated sentence":"<e1>4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate<\\e1> and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and <e2>sulfatase<\\e2> inhibitors (DASIs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and <e2>GENE-Y<\\e2> inhibitors (DASIs)","sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)"}
{"PMID":23495205,"re_id":9,"annotated sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, <e1>Cl<\\e1>  Br) derivatives are first-generation dual <e2>aromatase<\\e2> and sulfatase inhibitors (DASIs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cl","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, <e1>CHEMICAL<\\e1>  Br) derivatives are first-generation dual <e2>GENE-Y<\\e2> and sulfatase inhibitors (DASIs)","sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl  Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)"}
{"PMID":23495205,"re_id":10,"annotated sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, <e1>Cl<\\e1>  Br) derivatives are first-generation dual aromatase and <e2>sulfatase<\\e2> inhibitors (DASIs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Cl","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, <e1>CHEMICAL<\\e1>  Br) derivatives are first-generation dual aromatase and <e2>GENE-Y<\\e2> inhibitors (DASIs)","sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl  Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)"}
{"PMID":23495205,"re_id":11,"annotated sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, <e1>Br<\\e1>  derivatives are first-generation dual <e2>aromatase<\\e2> and sulfatase inhibitors (DASIs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Br","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, <e1>CHEMICAL<\\e1>  derivatives are first-generation dual <e2>GENE-Y<\\e2> and sulfatase inhibitors (DASIs)","sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br  derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)"}
{"PMID":23495205,"re_id":12,"annotated sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, <e1>Br<\\e1>  derivatives are first-generation dual aromatase and <e2>sulfatase<\\e2> inhibitors (DASIs)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Br","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, <e1>CHEMICAL<\\e1>  derivatives are first-generation dual aromatase and <e2>GENE-Y<\\e2> inhibitors (DASIs)","sentence":"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br  derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)"}
{"PMID":23497227,"re_id":0,"annotated sentence":"A series of <e1>pyrido-quinazolines<\\e1> have been synthesised, characterised and tested for their in vitro <e2>EGFR<\\e2> tyrosine kinase inhibitory activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrido-quinazolines","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> have been synthesised, characterised and tested for their in vitro <e2>GENE-Y<\\e2> tyrosine kinase inhibitory activity","sentence":"A series of pyrido-quinazolines have been synthesised, characterised and tested for their in vitro EGFR tyrosine kinase inhibitory activity"}
{"PMID":23497227,"re_id":1,"annotated sentence":"A series of <e1>pyrido-quinazolines<\\e1> have been synthesised, characterised and tested for their in vitro EGFR <e2>tyrosine kinase<\\e2> inhibitory activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrido-quinazolines","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of <e1>CHEMICAL<\\e1> have been synthesised, characterised and tested for their in vitro EGFR <e2>GENE-N<\\e2> inhibitory activity","sentence":"A series of pyrido-quinazolines have been synthesised, characterised and tested for their in vitro EGFR tyrosine kinase inhibitory activity"}
{"PMID":23497227,"re_id":2,"annotated sentence":"Synthesis and in vitro evaluation of <e1>N-Aryl pyrido-quinazolines<\\e1> derivatives as potent <e2>EGFR<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"N-Aryl pyrido-quinazolines","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and in vitro evaluation of <e1>CHEMICAL<\\e1> derivatives as potent <e2>GENE-Y<\\e2> inhibitors","sentence":"Synthesis and in vitro evaluation of N-Aryl pyrido-quinazolines derivatives as potent EGFR inhibitors"}
{"PMID":23500382,"re_id":0,"annotated sentence":"In the in vitro assay, <e1>kinsenoside<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), <e2>lactic dehydrogenase<\\e2> (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kinsenoside","object":"lactic dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the in vitro assay, <e1>CHEMICAL<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), <e2>GENE-N<\\e2> (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","sentence":"In the in vitro assay, kinsenoside (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system"}
{"PMID":23500382,"re_id":1,"annotated sentence":"In the in vitro assay, <e1>kinsenoside<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (<e2>LDH<\\e2> , superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kinsenoside","object":"LDH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the in vitro assay, <e1>CHEMICAL<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (<e2>GENE-N<\\e2> , superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","sentence":"In the in vitro assay, kinsenoside (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH , superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system"}
{"PMID":23500382,"re_id":2,"annotated sentence":"In the in vitro assay, <e1>kinsenoside<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), <e2>superoxide dismutase<\\e2> (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kinsenoside","object":"superoxide dismutase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the in vitro assay, <e1>CHEMICAL<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), <e2>GENE-N<\\e2> (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","sentence":"In the in vitro assay, kinsenoside (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system"}
{"PMID":23500382,"re_id":3,"annotated sentence":"In the in vitro assay, <e1>kinsenoside<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (<e2>SOD<\\e2> , and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kinsenoside","object":"SOD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the in vitro assay, <e1>CHEMICAL<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (<e2>GENE-N<\\e2> , and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","sentence":"In the in vitro assay, kinsenoside (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD , and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system"}
{"PMID":23500382,"re_id":4,"annotated sentence":"In the in vitro assay, <e1>kinsenoside<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and <e2>catalase<\\e2> (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kinsenoside","object":"catalase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the in vitro assay, <e1>CHEMICAL<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and <e2>GENE-Y<\\e2> (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","sentence":"In the in vitro assay, kinsenoside (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system"}
{"PMID":23500382,"re_id":5,"annotated sentence":"In the in vitro assay, <e1>kinsenoside<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (<e2>CAT<\\e2> ) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kinsenoside","object":"CAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the in vitro assay, <e1>CHEMICAL<\\e1> (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (<e2>GENE-Y<\\e2> ) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system","sentence":"In the in vitro assay, kinsenoside (20 and 50\u03bcg\/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT ) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system"}
{"PMID":23500382,"re_id":6,"annotated sentence":"The vascular protective effects of <e1>kinsenoside<\\e1> were speculated to be attributed to oxidative stress inhibition and the reduction of <e2>nuclear factor kappa B<\\e2> (NF-\u03baB) mRNA expression levels in high glucose conditions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kinsenoside","object":"nuclear factor kappa B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The vascular protective effects of <e1>CHEMICAL<\\e1> were speculated to be attributed to oxidative stress inhibition and the reduction of <e2>GENE-N<\\e2> (NF-\u03baB) mRNA expression levels in high glucose conditions","sentence":"The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-\u03baB) mRNA expression levels in high glucose conditions"}
{"PMID":23500382,"re_id":7,"annotated sentence":"The vascular protective effects of <e1>kinsenoside<\\e1> were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (<e2>NF-\u03baB<\\e2>  mRNA expression levels in high glucose conditions","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"kinsenoside","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The vascular protective effects of <e1>CHEMICAL<\\e1> were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (<e2>GENE-N<\\e2>  mRNA expression levels in high glucose conditions","sentence":"The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-\u03baB  mRNA expression levels in high glucose conditions"}
{"PMID":23500545,"re_id":0,"annotated sentence":"<e1>Cholesterol<\\e1> uptake from <e2>lipoproteins<\\e2>  intracellular vesicle transport and lipid transfer are also modified by oxysterols","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Cholesterol","object":"lipoproteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> uptake from <e2>GENE-N<\\e2>  intracellular vesicle transport and lipid transfer are also modified by oxysterols","sentence":"Cholesterol uptake from lipoproteins  intracellular vesicle transport and lipid transfer are also modified by oxysterols"}
{"PMID":23500772,"re_id":0,"annotated sentence":"Activation of <e2>ALDH2<\\e2> with <e1>ethanol<\\e1> attenuates diabetes induced myocardial injury in rats","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ethanol","object":"ALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>GENE-Y<\\e2> with <e1>CHEMICAL<\\e1> attenuates diabetes induced myocardial injury in rats","sentence":"Activation of ALDH2 with ethanol attenuates diabetes induced myocardial injury in rats"}
{"PMID":23500772,"re_id":1,"annotated sentence":"This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with <e2>ALDH2<\\e2> activator <e1>ethanol<\\e1> (EtOH)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ethanol","object":"ALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study assessed changes in myocardial GENE-Y expression in the diabetic rat, in particular the diabetic rat pretreated with <e2>GENE-Y<\\e2> activator <e1>CHEMICAL<\\e1> (EtOH)","sentence":"This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with ALDH2 activator ethanol (EtOH)"}
{"PMID":23500772,"re_id":2,"annotated sentence":"This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with <e2>ALDH2<\\e2> activator ethanol (<e1>EtOH<\\e1> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"EtOH","object":"ALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study assessed changes in myocardial GENE-Y expression in the diabetic rat, in particular the diabetic rat pretreated with <e2>GENE-Y<\\e2> activator ethanol (<e1>CHEMICAL<\\e1> ","sentence":"This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with ALDH2 activator ethanol (EtOH "}
{"PMID":23500772,"re_id":3,"annotated sentence":"Compared with DM8W group, <e2>SOD<\\e2> and ALDH2 in <e1>EtOH<\\e1> DM8W group was increased, MDA was decreased","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"EtOH","object":"SOD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Compared with DM8W group, <e2>GENE-N<\\e2> and ALDH2 in <e1>CHEMICAL<\\e1> DM8W group was increased, MDA was decreased","sentence":"Compared with DM8W group, SOD and ALDH2 in EtOH DM8W group was increased, MDA was decreased"}
{"PMID":23500772,"re_id":4,"annotated sentence":"Compared with DM8W group, SOD and <e2>ALDH2<\\e2> in <e1>EtOH<\\e1> DM8W group was increased, MDA was decreased","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"EtOH","object":"ALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with DM8W group, SOD and <e2>GENE-Y<\\e2> in <e1>CHEMICAL<\\e1> DM8W group was increased, MDA was decreased","sentence":"Compared with DM8W group, SOD and ALDH2 in EtOH DM8W group was increased, MDA was decreased"}
{"PMID":23500772,"re_id":5,"annotated sentence":"HbA1c level in DM12W group was higher than in DM4W group, <e2>HbA1c<\\e2> level in <e1>EtOH<\\e1> DM8W group was lower than in DM8W group","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EtOH","object":"HbA1c","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GENE-N level in DM12W group was higher than in DM4W group, <e2>GENE-N<\\e2> level in <e1>CHEMICAL<\\e1> DM8W group was lower than in DM8W group","sentence":"HbA1c level in DM12W group was higher than in DM4W group, HbA1c level in EtOH DM8W group was lower than in DM8W group"}
{"PMID":23500776,"re_id":0,"annotated sentence":"<e2>EROD<\\e2> activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to <e1>polycyclic aromatic hydrocarbons<\\e1>  Little is known in terms of multi-matrix cytochrome P450 activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, PAH)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"polycyclic aromatic hydrocarbons","object":"EROD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to <e1>CHEMICAL<\\e1>  Little is known in terms of multi-matrix cytochrome P450 activity induction under repeated oral exposure to planar halogenated and CHEMICAL (PHH, PAH)","sentence":"EROD activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to polycyclic aromatic hydrocarbons  Little is known in terms of multi-matrix cytochrome P450 activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, PAH)"}
{"PMID":23500776,"re_id":1,"annotated sentence":"Little is known in terms of multi-matrix <e2>cytochrome P450<\\e2> activity induction under repeated oral exposure to planar <e1>halogenated and polycyclic aromatic hydrocarbons<\\e1> (PHH, PAH)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"halogenated and polycyclic aromatic hydrocarbons","object":"cytochrome P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Little is known in terms of multi-matrix <e2>GENE-N<\\e2> activity induction under repeated oral exposure to planar <e1>CHEMICAL<\\e1> (PHH, PAH)","sentence":"Little is known in terms of multi-matrix cytochrome P450 activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, PAH)"}
{"PMID":23500776,"re_id":2,"annotated sentence":"Little is known in terms of multi-matrix <e2>cytochrome P450<\\e2> activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, <e1>PAH<\\e1> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"PAH","object":"cytochrome P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Little is known in terms of multi-matrix <e2>GENE-N<\\e2> activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, <e1>CHEMICAL<\\e1> ","sentence":"Little is known in terms of multi-matrix cytochrome P450 activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, PAH "}
{"PMID":23506741,"re_id":0,"annotated sentence":"A novel <e1>benzo[d]imidazole<\\e1> derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of <e2>NLRP3<\\e2> inflammasome","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzo[d]imidazole","object":"NLRP3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A novel <e1>CHEMICAL<\\e1> derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of <e2>GENE-Y<\\e2> inflammasome","sentence":"A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome"}
{"PMID":23506741,"re_id":1,"annotated sentence":"Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of <e2>caspase-1<\\e2> in peritoneal macrophages were detected in <e1>Fc11a<\\e1> 2-treated mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a","object":"caspase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of <e2>GENE-Y<\\e2> in peritoneal macrophages were detected in <e1>CHEMICAL<\\e1> 2-treated mice","sentence":"Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a 2-treated mice"}
{"PMID":23506741,"re_id":2,"annotated sentence":"The mechanism of action of <e1>Fc11a-2<\\e1> was related to the inhibition of the cleavage of <e2>pro-caspase-1<\\e2>  pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"pro-caspase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism of action of <e1>CHEMICAL<\\e1> was related to the inhibition of the cleavage of <e2>GENE-Y<\\e2>  pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome","sentence":"The mechanism of action of Fc11a-2 was related to the inhibition of the cleavage of pro-caspase-1  pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome"}
{"PMID":23506741,"re_id":3,"annotated sentence":"The mechanism of action of <e1>Fc11a-2<\\e1> was related to the inhibition of the cleavage of pro-caspase-1, <e2>pro-IL-1\u03b2<\\e2> and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"pro-IL-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism of action of <e1>CHEMICAL<\\e1> was related to the inhibition of the cleavage of pro-caspase-1, <e2>GENE-Y<\\e2> and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome","sentence":"The mechanism of action of Fc11a-2 was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome"}
{"PMID":23506741,"re_id":4,"annotated sentence":"The mechanism of action of <e1>Fc11a-2<\\e1> was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and <e2>pro-IL-18<\\e2> which in turn suppressed the activation of NLRP3 inflammasome","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"pro-IL-18","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism of action of <e1>CHEMICAL<\\e1> was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and <e2>GENE-Y<\\e2> which in turn suppressed the activation of NLRP3 inflammasome","sentence":"The mechanism of action of Fc11a-2 was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome"}
{"PMID":23506741,"re_id":5,"annotated sentence":"The mechanism of action of <e1>Fc11a-2<\\e1> was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of <e2>NLRP3<\\e2> inflammasome","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"NLRP3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism of action of <e1>CHEMICAL<\\e1> was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of <e2>GENE-Y<\\e2> inflammasome","sentence":"The mechanism of action of Fc11a-2 was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome"}
{"PMID":23506741,"re_id":6,"annotated sentence":"Taken together, our results demonstrate the ability of <e1>Fc11a-2<\\e1> to inhibit <e2>NLRP3<\\e2> inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"NLRP3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, our results demonstrate the ability of <e1>CHEMICAL<\\e1> to inhibit <e2>GENE-Y<\\e2> inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.","sentence":"Taken together, our results demonstrate the ability of Fc11a-2 to inhibit NLRP3 inflammasome activation and its potential use in the treatment of inflammatory bowel diseases."}
{"PMID":23506741,"re_id":7,"annotated sentence":"In addition, the disease activity index, histopathologic scores and <e2>myeloperoxidase<\\e2> activity were also significantly reduced by <e1>Fc11a-2<\\e1> treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"myeloperoxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, the disease activity index, histopathologic scores and <e2>GENE-N<\\e2> activity were also significantly reduced by <e1>CHEMICAL<\\e1> treatment","sentence":"In addition, the disease activity index, histopathologic scores and myeloperoxidase activity were also significantly reduced by Fc11a-2 treatment"}
{"PMID":23506741,"re_id":8,"annotated sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory <e2>cytokines<\\e2> in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by <e1>Fc11a-2<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory <e2>GENE-N<\\e2> in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by <e1>CHEMICAL<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in CHEMICAL-treated mice","sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by Fc11a-2  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice"}
{"PMID":23506741,"re_id":9,"annotated sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including <e2>TNF-\u03b1<\\e2>  IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by <e1>Fc11a-2<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including <e2>GENE-Y<\\e2>  IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by <e1>CHEMICAL<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in CHEMICAL-treated mice","sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1  IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by Fc11a-2  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice"}
{"PMID":23506741,"re_id":10,"annotated sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, <e2>IL-1\u03b2<\\e2>  IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by <e1>Fc11a-2<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"IL-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, <e2>GENE-Y<\\e2>  IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by <e1>CHEMICAL<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in CHEMICAL-treated mice","sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2  IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by Fc11a-2  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice"}
{"PMID":23506741,"re_id":11,"annotated sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, <e2>IL-18<\\e2>  IL-17A and IFN-\u03b3, were markedly suppressed by <e1>Fc11a-2<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"IL-18","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, <e2>GENE-Y<\\e2>  IL-17A and IFN-\u03b3, were markedly suppressed by <e1>CHEMICAL<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in CHEMICAL-treated mice","sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18  IL-17A and IFN-\u03b3, were markedly suppressed by Fc11a-2  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice"}
{"PMID":23506741,"re_id":12,"annotated sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, <e2>IL-17A<\\e2> and IFN-\u03b3, were markedly suppressed by <e1>Fc11a-2<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"IL-17A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, <e2>GENE-Y<\\e2> and IFN-\u03b3, were markedly suppressed by <e1>CHEMICAL<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in CHEMICAL-treated mice","sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by Fc11a-2  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice"}
{"PMID":23506741,"re_id":13,"annotated sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and <e2>IFN-\u03b3<\\e2>  were markedly suppressed by <e1>Fc11a-2<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fc11a-2","object":"IFN-\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and <e2>GENE-Y<\\e2>  were markedly suppressed by <e1>CHEMICAL<\\e1>  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in CHEMICAL-treated mice","sentence":"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3  were markedly suppressed by Fc11a-2  Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice"}
{"PMID":23517912,"re_id":0,"annotated sentence":"We also observed that <e1>fisetin<\\e1> efficiently suppressed the phosphorylation of <e2>Akt<\\e2>  S6K1 and mTORC1 in adipose tissue","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We also observed that <e1>CHEMICAL<\\e1> efficiently suppressed the phosphorylation of <e2>GENE-N<\\e2>  S6K1 and mTORC1 in adipose tissue","sentence":"We also observed that fisetin efficiently suppressed the phosphorylation of Akt  S6K1 and mTORC1 in adipose tissue"}
{"PMID":23517912,"re_id":1,"annotated sentence":"We also observed that <e1>fisetin<\\e1> efficiently suppressed the phosphorylation of Akt, <e2>S6K1<\\e2> and mTORC1 in adipose tissue","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"S6K1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We also observed that <e1>CHEMICAL<\\e1> efficiently suppressed the phosphorylation of Akt, <e2>GENE-Y<\\e2> and mTORC1 in adipose tissue","sentence":"We also observed that fisetin efficiently suppressed the phosphorylation of Akt, S6K1 and mTORC1 in adipose tissue"}
{"PMID":23517912,"re_id":2,"annotated sentence":"We also observed that <e1>fisetin<\\e1> efficiently suppressed the phosphorylation of Akt, S6K1 and <e2>mTORC1<\\e2> in adipose tissue","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"mTORC1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We also observed that <e1>CHEMICAL<\\e1> efficiently suppressed the phosphorylation of Akt, S6K1 and <e2>GENE-N<\\e2> in adipose tissue","sentence":"We also observed that fisetin efficiently suppressed the phosphorylation of Akt, S6K1 and mTORC1 in adipose tissue"}
{"PMID":23517912,"re_id":3,"annotated sentence":"Collectively, these results suggest that inhibition of <e2>mTORC1<\\e2> signaling by <e1>fisetin<\\e1> prevents adipocyte differentiation of 3T3-L1 preadipocytes and obesity in HFD-fed mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"mTORC1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Collectively, these results suggest that inhibition of <e2>GENE-N<\\e2> signaling by <e1>CHEMICAL<\\e1> prevents adipocyte differentiation of 3T3-L1 preadipocytes and obesity in HFD-fed mice","sentence":"Collectively, these results suggest that inhibition of mTORC1 signaling by fisetin prevents adipocyte differentiation of 3T3-L1 preadipocytes and obesity in HFD-fed mice"}
{"PMID":23517912,"re_id":4,"annotated sentence":"<e1>Fisetin<\\e1> treatment of preadipocytes reduced the phosphorylation of <e2>S6K1<\\e2> and mTORC1 in a time- and concentration-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fisetin","object":"S6K1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment of preadipocytes reduced the phosphorylation of <e2>GENE-Y<\\e2> and mTORC1 in a time- and concentration-dependent manner","sentence":"Fisetin treatment of preadipocytes reduced the phosphorylation of S6K1 and mTORC1 in a time- and concentration-dependent manner"}
{"PMID":23517912,"re_id":5,"annotated sentence":"<e1>Fisetin<\\e1> treatment of preadipocytes reduced the phosphorylation of S6K1 and <e2>mTORC1<\\e2> in a time- and concentration-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Fisetin","object":"mTORC1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment of preadipocytes reduced the phosphorylation of S6K1 and <e2>GENE-N<\\e2> in a time- and concentration-dependent manner","sentence":"Fisetin treatment of preadipocytes reduced the phosphorylation of S6K1 and mTORC1 in a time- and concentration-dependent manner"}
{"PMID":23517912,"re_id":6,"annotated sentence":"To further our understanding of how <e1>fisetin<\\e1> negatively regulates <e2>mTORC1<\\e2> signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in fisetin-treated TSC2-knockdown cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"mTORC1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To further our understanding of how <e1>CHEMICAL<\\e1> negatively regulates <e2>GENE-N<\\e2> signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in CHEMICAL-treated TSC2-knockdown cells","sentence":"To further our understanding of how fisetin negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in fisetin-treated TSC2-knockdown cells"}
{"PMID":23517912,"re_id":7,"annotated sentence":"The results suggested that <e1>fisetin<\\e1> treatment inhibits <e2>mTORC1<\\e2> activity in an Akt-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"mTORC1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results suggested that <e1>CHEMICAL<\\e1> treatment inhibits <e2>GENE-N<\\e2> activity in an Akt-dependent manner","sentence":"The results suggested that fisetin treatment inhibits mTORC1 activity in an Akt-dependent manner"}
{"PMID":23517912,"re_id":8,"annotated sentence":"The results suggested that <e1>fisetin<\\e1> treatment inhibits mTORC1 activity in an <e2>Akt<\\e2> dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results suggested that <e1>CHEMICAL<\\e1> treatment inhibits mTORC1 activity in an <e2>GENE-N<\\e2> dependent manner","sentence":"The results suggested that fisetin treatment inhibits mTORC1 activity in an Akt dependent manner"}
{"PMID":23517912,"re_id":9,"annotated sentence":"Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of <e1>fisetin<\\e1> on <e2>mTOR<\\e2>  The inhibitory effect of fisetin on adipogenesis is dependent of mTOR activity, suggesting that fisetin inhibits adipogenesis and the accumulation of intracellular triglycerides during adipocyte differentiation by targeting mTORC1 signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fisetin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2>  The inhibitory effect of CHEMICAL on adipogenesis is dependent of GENE-Y activity, suggesting that CHEMICAL inhibits adipogenesis and the accumulation of intracellular triglycerides during adipocyte differentiation by targeting GENE-YC1 signaling","sentence":"Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of fisetin on mTOR  The inhibitory effect of fisetin on adipogenesis is dependent of mTOR activity, suggesting that fisetin inhibits adipogenesis and the accumulation of intracellular triglycerides during adipocyte differentiation by targeting mTORC1 signaling"}
{"PMID":23519392,"re_id":0,"annotated sentence":"<e1>Amprenavir<\\e1> mediated <e2>PXR<\\e2> activation stimulated the expression of several key intestinal genes involved in lipid homeostasis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Amprenavir","object":"PXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> mediated <e2>GENE-Y<\\e2> activation stimulated the expression of several key intestinal genes involved in lipid homeostasis","sentence":"Amprenavir mediated PXR activation stimulated the expression of several key intestinal genes involved in lipid homeostasis"}
{"PMID":23519392,"re_id":1,"annotated sentence":"<e1>Amprenavir<\\e1> efficiently activated <e2>PXR<\\e2> and induced PXR target gene expression in vitro and in vivo","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Amprenavir","object":"PXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> efficiently activated <e2>GENE-Y<\\e2> and induced GENE-Y target gene expression in vitro and in vivo","sentence":"Amprenavir efficiently activated PXR and induced PXR target gene expression in vitro and in vivo"}
{"PMID":23519392,"re_id":2,"annotated sentence":"<e1>Amprenavir<\\e1> efficiently activated PXR and induced <e2>PXR<\\e2> target gene expression in vitro and in vivo","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Amprenavir","object":"PXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> efficiently activated GENE-Y and induced <e2>GENE-Y<\\e2> target gene expression in vitro and in vivo","sentence":"Amprenavir efficiently activated PXR and induced PXR target gene expression in vitro and in vivo"}
{"PMID":23519392,"re_id":3,"annotated sentence":"Pregnane X Receptor Mediates Dyslipidemia Induced by the <e2>HIV Protease<\\e2> Inhibitor <e1>Amprenavir<\\e1> in Mice","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Amprenavir","object":"HIV Protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pregnane X Receptor Mediates Dyslipidemia Induced by the <e2>GENE-N<\\e2> Inhibitor <e1>CHEMICAL<\\e1> in Mice","sentence":"Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice"}
{"PMID":23519392,"re_id":4,"annotated sentence":"In the present study, we identified <e1>amprenavir<\\e1>  a widely used HIV PI, as a potent <e2>PXR<\\e2> selective agonist","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"amprenavir","object":"PXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the present study, we identified <e1>CHEMICAL<\\e1>  a widely used HIV PI, as a potent <e2>GENE-Y<\\e2> selective agonist","sentence":"In the present study, we identified amprenavir  a widely used HIV PI, as a potent PXR selective agonist"}
{"PMID":23521080,"re_id":0,"annotated sentence":"One exception is <e1>tranexamic acid<\\e1> (TXA), which, as a lysine mimetic, inhibits binding of <e2>plasminogen<\\e2> to fibrin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranexamic acid","object":"plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One exception is <e1>CHEMICAL<\\e1> (TXA), which, as a lysine mimetic, inhibits binding of <e2>GENE-Y<\\e2> to fibrin","sentence":"One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to fibrin"}
{"PMID":23521080,"re_id":1,"annotated sentence":"One exception is <e1>tranexamic acid<\\e1> (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to <e2>fibrin<\\e2>  However, the daily dose of TXA is high due to its modest potency and pharmacokinetic properties","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tranexamic acid","object":"fibrin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One exception is <e1>CHEMICAL<\\e1> (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to <e2>GENE-N<\\e2>  However, the daily dose of TXA is high due to its modest potency and pharmacokinetic properties","sentence":"One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to fibrin  However, the daily dose of TXA is high due to its modest potency and pharmacokinetic properties"}
{"PMID":23521080,"re_id":2,"annotated sentence":"One exception is tranexamic acid (<e1>TXA<\\e1> , which, as a lysine mimetic, inhibits binding of <e2>plasminogen<\\e2> to fibrin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TXA","object":"plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One exception is tranexamic acid (<e1>CHEMICAL<\\e1> , which, as a lysine mimetic, inhibits binding of <e2>GENE-Y<\\e2> to fibrin","sentence":"One exception is tranexamic acid (TXA , which, as a lysine mimetic, inhibits binding of plasminogen to fibrin"}
{"PMID":23521080,"re_id":3,"annotated sentence":"One exception is tranexamic acid (<e1>TXA<\\e1> , which, as a lysine mimetic, inhibits binding of plasminogen to <e2>fibrin<\\e2>  However, the daily dose of TXA is high due to its modest potency and pharmacokinetic properties","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TXA","object":"fibrin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One exception is tranexamic acid (<e1>CHEMICAL<\\e1> , which, as a lysine mimetic, inhibits binding of plasminogen to <e2>GENE-N<\\e2>  However, the daily dose of CHEMICAL is high due to its modest potency and pharmacokinetic properties","sentence":"One exception is tranexamic acid (TXA , which, as a lysine mimetic, inhibits binding of plasminogen to fibrin  However, the daily dose of TXA is high due to its modest potency and pharmacokinetic properties"}
{"PMID":23521080,"re_id":4,"annotated sentence":"One exception is tranexamic acid (TXA), which, as a <e1>lysine<\\e1> mimetic, inhibits binding of <e2>plasminogen<\\e2> to fibrin","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lysine","object":"plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One exception is tranexamic acid (TXA), which, as a <e1>CHEMICAL<\\e1> mimetic, inhibits binding of <e2>GENE-Y<\\e2> to fibrin","sentence":"One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to fibrin"}
{"PMID":23521080,"re_id":5,"annotated sentence":"One exception is tranexamic acid (TXA), which, as a <e1>lysine<\\e1> mimetic, inhibits binding of plasminogen to <e2>fibrin<\\e2>  However, the daily dose of TXA is high due to its modest potency and pharmacokinetic properties","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"lysine","object":"fibrin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"One exception is tranexamic acid (TXA), which, as a <e1>CHEMICAL<\\e1> mimetic, inhibits binding of plasminogen to <e2>GENE-N<\\e2>  However, the daily dose of TXA is high due to its modest potency and pharmacokinetic properties","sentence":"One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to fibrin  However, the daily dose of TXA is high due to its modest potency and pharmacokinetic properties"}
{"PMID":23521080,"re_id":6,"annotated sentence":"Coupling this computational technique with a high-quality low-throughput screen identified <e1>5-(4-piperidyl)-3-isoxazolol<\\e1> (4-PIOL) as a potent <e2>plasminogen<\\e2> binding inhibitor with the potential for the treatment of various bleeding disorders","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-(4-piperidyl)-3-isoxazolol","object":"plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coupling this computational technique with a high-quality low-throughput screen identified <e1>CHEMICAL<\\e1> (4-PIOL) as a potent <e2>GENE-Y<\\e2> binding inhibitor with the potential for the treatment of various bleeding disorders","sentence":"Coupling this computational technique with a high-quality low-throughput screen identified 5-(4-piperidyl)-3-isoxazolol (4-PIOL) as a potent plasminogen binding inhibitor with the potential for the treatment of various bleeding disorders"}
{"PMID":23521080,"re_id":7,"annotated sentence":"Coupling this computational technique with a high-quality low-throughput screen identified 5-(4-piperidyl)-3-isoxazolol (<e1>4-PIOL<\\e1>  as a potent <e2>plasminogen<\\e2> binding inhibitor with the potential for the treatment of various bleeding disorders","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"4-PIOL","object":"plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coupling this computational technique with a high-quality low-throughput screen identified 5-(4-piperidyl)-3-isoxazolol (<e1>CHEMICAL<\\e1>  as a potent <e2>GENE-Y<\\e2> binding inhibitor with the potential for the treatment of various bleeding disorders","sentence":"Coupling this computational technique with a high-quality low-throughput screen identified 5-(4-piperidyl)-3-isoxazolol (4-PIOL  as a potent plasminogen binding inhibitor with the potential for the treatment of various bleeding disorders"}
{"PMID":23522834,"re_id":0,"annotated sentence":"Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of <e1>dihydropteridinone<\\e1> based <e2>Plk-2<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydropteridinone","object":"Plk-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Polo-like kinase-2 (GENE-Y) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of <e1>CHEMICAL<\\e1> based <e2>GENE-Y<\\e2> inhibitors","sentence":"Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of dihydropteridinone based Plk-2 inhibitors"}
{"PMID":23523949,"re_id":0,"annotated sentence":"<e1>Crocin<\\e1> (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of <e2>caspase 3<\\e2> and release of cytochrome c to the cytosol induced by DZN","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Crocin","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of <e2>GENE-Y<\\e2> and release of cytochrome c to the cytosol induced by DZN","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN"}
{"PMID":23523949,"re_id":1,"annotated sentence":"RESULTS: <e1>DZN<\\e1> induced histophatological damages and elevated the level of cardiac marker <e2>CK-MB<\\e2>  These effects were associated with increased MDA level, lower level of reduced GSH and induction of apoptosis through elevation of Bax\/Bcl2 ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation caspase 3 in cardiac tissue","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DZN","object":"CK-MB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> induced histophatological damages and elevated the level of cardiac marker <e2>GENE-N<\\e2>  These effects were associated with increased MDA level, lower level of reduced GSH and induction of apoptosis through elevation of Bax\/Bcl2 ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation caspase 3 in cardiac tissue","sentence":"RESULTS: DZN induced histophatological damages and elevated the level of cardiac marker CK-MB  These effects were associated with increased MDA level, lower level of reduced GSH and induction of apoptosis through elevation of Bax\/Bcl2 ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation caspase 3 in cardiac tissue"}
{"PMID":23523949,"re_id":2,"annotated sentence":"Crocin (25 and 50mg\/kg) or <e1>vitamin E<\\e1> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of <e2>caspase 3<\\e2> and release of cytochrome c to the cytosol induced by DZN","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vitamin E","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Crocin (25 and 50mg\/kg) or <e1>CHEMICAL<\\e1> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of <e2>GENE-Y<\\e2> and release of cytochrome c to the cytosol induced by DZN","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN"}
{"PMID":23523949,"re_id":3,"annotated sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of <e2>Bax<\\e2> Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by <e1>DZN<\\e1>  In summary, DZN induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DZN","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of <e2>GENE-Y<\\e2> Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by <e1>CHEMICAL<\\e1>  In summary, CHEMICAL induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN  In summary, DZN induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure"}
{"PMID":23523949,"re_id":4,"annotated sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of <e2>caspase 3<\\e2> and release of cytochrome c to the cytosol induced by <e1>DZN<\\e1>  In summary, DZN induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DZN","object":"caspase 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of <e2>GENE-Y<\\e2> and release of cytochrome c to the cytosol induced by <e1>CHEMICAL<\\e1>  In summary, CHEMICAL induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN  In summary, DZN induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure"}
{"PMID":23523949,"re_id":5,"annotated sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of <e2>cytochrome c<\\e2> to the cytosol induced by <e1>DZN<\\e1>  In summary, DZN induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DZN","object":"cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of <e2>GENE-Y<\\e2> to the cytosol induced by <e1>CHEMICAL<\\e1>  In summary, CHEMICAL induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN  In summary, DZN induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure"}
{"PMID":23523949,"re_id":6,"annotated sentence":"<e1>Crocin<\\e1> (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and <e2>CK-MB<\\e2>  increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Crocin","object":"CK-MB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and <e2>GENE-N<\\e2>  increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB  increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN"}
{"PMID":23523949,"re_id":7,"annotated sentence":"<e1>Crocin<\\e1> (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of <e2>Bax<\\e2> Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Crocin","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of <e2>GENE-Y<\\e2> Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN"}
{"PMID":23523949,"re_id":8,"annotated sentence":"<e1>Crocin<\\e1> (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/<e2>Bcl2<\\e2> ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Crocin","object":"Bcl2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/<e2>GENE-Y<\\e2> ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN"}
{"PMID":23523949,"re_id":9,"annotated sentence":"<e1>Crocin<\\e1> (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of <e2>cytochrome c<\\e2> to the cytosol induced by DZN","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Crocin","object":"cytochrome c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of <e2>GENE-Y<\\e2> to the cytosol induced by DZN","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN"}
{"PMID":23523949,"re_id":10,"annotated sentence":"Crocin (25 and 50mg\/kg) or <e1>vitamin E<\\e1> improved histopathological damages, decreased MDA and <e2>CK-MB<\\e2>  increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vitamin E","object":"CK-MB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Crocin (25 and 50mg\/kg) or <e1>CHEMICAL<\\e1> improved histopathological damages, decreased MDA and <e2>GENE-N<\\e2>  increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB  increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN"}
{"PMID":23523949,"re_id":11,"annotated sentence":"Crocin (25 and 50mg\/kg) or <e1>vitamin E<\\e1> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of <e2>Bax<\\e2> Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vitamin E","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Crocin (25 and 50mg\/kg) or <e1>CHEMICAL<\\e1> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of <e2>GENE-Y<\\e2> Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN"}
{"PMID":23523949,"re_id":12,"annotated sentence":"Crocin (25 and 50mg\/kg) or <e1>vitamin E<\\e1> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/<e2>Bcl2<\\e2> ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vitamin E","object":"Bcl2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Crocin (25 and 50mg\/kg) or <e1>CHEMICAL<\\e1> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/<e2>GENE-Y<\\e2> ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN"}
{"PMID":23523949,"re_id":13,"annotated sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/<e2>Bcl2<\\e2> ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by <e1>DZN<\\e1>  In summary, DZN induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DZN","object":"Bcl2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/<e2>GENE-Y<\\e2> ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by <e1>CHEMICAL<\\e1>  In summary, CHEMICAL induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure","sentence":"Crocin (25 and 50mg\/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax\/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN  In summary, DZN induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure"}
{"PMID":23528251,"re_id":0,"annotated sentence":"<e1>Phenobarbital<\\e1> (PB), a typical <e2>CAR<\\e2> activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Phenobarbital","object":"CAR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (PB), a typical <e2>GENE-Y<\\e2> activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a","sentence":"Phenobarbital (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a"}
{"PMID":23528251,"re_id":1,"annotated sentence":"<e1>Phenobarbital<\\e1> (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including <e2>erythropoietin<\\e2>  heme oxygenase-1 and vascular endothelial growth factor-a","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Phenobarbital","object":"erythropoietin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including <e2>GENE-Y<\\e2>  heme oxygenase-1 and vascular endothelial growth factor-a","sentence":"Phenobarbital (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin  heme oxygenase-1 and vascular endothelial growth factor-a"}
{"PMID":23528251,"re_id":2,"annotated sentence":"<e1>Phenobarbital<\\e1> (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, <e2>heme oxygenase-1<\\e2> and vascular endothelial growth factor-a","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Phenobarbital","object":"heme oxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, <e2>GENE-Y<\\e2> and vascular endothelial growth factor-a","sentence":"Phenobarbital (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a"}
{"PMID":23528251,"re_id":3,"annotated sentence":"<e1>Phenobarbital<\\e1> (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and <e2>vascular endothelial growth factor-a<\\e2>  PB induced an accumulation of nuclear HIF-1\u03b1 and an increase in the HIF-responsive element-mediated transactivation in HepG2 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Phenobarbital","object":"vascular endothelial growth factor-a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and <e2>GENE-Y<\\e2>  PB induced an accumulation of nuclear HIF-1\u03b1 and an increase in the HIF-responsive element-mediated transactivation in HepG2 cells","sentence":"Phenobarbital (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a  PB induced an accumulation of nuclear HIF-1\u03b1 and an increase in the HIF-responsive element-mediated transactivation in HepG2 cells"}
{"PMID":23528251,"re_id":4,"annotated sentence":"<e1>Cobalt chloride<\\e1>  a typical <e2>HIF<\\e2> activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cobalt chloride","object":"HIF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a typical <e2>GENE-N<\\e2> activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver","sentence":"Cobalt chloride  a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver"}
{"PMID":23528251,"re_id":5,"annotated sentence":"<e1>Cobalt chloride<\\e1>  a typical HIF activator, induced the gene expression of CAR-target genes, including <e2>cyp2b9<\\e2> and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cobalt chloride","object":"cyp2b9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a typical HIF activator, induced the gene expression of CAR-target genes, including <e2>GENE-Y<\\e2> and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver","sentence":"Cobalt chloride  a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver"}
{"PMID":23528251,"re_id":6,"annotated sentence":"<e1>Cobalt chloride<\\e1>  a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and <e2>cyp2b10<\\e2>  an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Cobalt chloride","object":"cyp2b10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and <e2>GENE-Y<\\e2>  an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver","sentence":"Cobalt chloride  a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10  an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver"}
{"PMID":23530018,"re_id":0,"annotated sentence":"Sixteen of 34 <e1>CGPs<\\e1> inhibited <e2>MRP1<\\e2> mediated E217\u03b2G uptake by >50% (IC50's 0.7-7.6 \u03bcM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CGPs","object":"MRP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sixteen of 34 <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> mediated E217\u03b2G uptake by >50% (IC50's 0.7-7.6 \u03bcM)","sentence":"Sixteen of 34 CGPs inhibited MRP1 mediated E217\u03b2G uptake by >50% (IC50's 0.7-7.6 \u03bcM)"}
{"PMID":23530018,"re_id":1,"annotated sentence":"When tested in the intact cells, only 4 of 16 <e1>CGPs<\\e1> (at 10 \u03bcM) inhibited <e2>MRP1<\\e2> mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CGPs","object":"MRP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When tested in the intact cells, only 4 of 16 <e1>CHEMICAL<\\e1> (at 10 \u03bcM) inhibited <e2>GENE-Y<\\e2> mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%","sentence":"When tested in the intact cells, only 4 of 16 CGPs (at 10 \u03bcM) inhibited MRP1 mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%"}
{"PMID":23530018,"re_id":2,"annotated sentence":"These five <e1>CGPs<\\e1> also inhibited [(3)H]E217\u03b2G uptake by <e2>MRP4<\\e2>  In contrast, their effects on MRP2 varied with two (V-4, V-6) inhibiting E217\u03b2G transport (IC50's 2.0, 9.2 \u03bcM), two (V-3, III-1) stimulating transport (>2-fold), while CGP I-5 had no effect","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CGPs","object":"MRP4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These five <e1>CHEMICAL<\\e1> also inhibited [(3)H]E217\u03b2G uptake by <e2>GENE-Y<\\e2>  In contrast, their effects on MRP2 varied with two (V-4, V-6) inhibiting E217\u03b2G transport (IC50's 2.0, 9.2 \u03bcM), two (V-3, III-1) stimulating transport (>2-fold), while CGP I-5 had no effect","sentence":"These five CGPs also inhibited [(3)H]E217\u03b2G uptake by MRP4  In contrast, their effects on MRP2 varied with two (V-4, V-6) inhibiting E217\u03b2G transport (IC50's 2.0, 9.2 \u03bcM), two (V-3, III-1) stimulating transport (>2-fold), while CGP I-5 had no effect"}
{"PMID":23530018,"re_id":3,"annotated sentence":"Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of <e1>[(3)H]estradiol glucuronide<\\e1> (E217\u03b2G) (a prototypical <e2>MRP<\\e2> substrate) into MRP-enriched inside-out membrane vesicles","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[(3)H]estradiol glucuronide","object":"MRP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of <e1>CHEMICAL<\\e1> (E217\u03b2G) (a prototypical <e2>GENE-N<\\e2> substrate) into GENE-N-enriched inside-out membrane vesicles","sentence":"Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (E217\u03b2G) (a prototypical MRP substrate) into MRP-enriched inside-out membrane vesicles"}
{"PMID":23530018,"re_id":4,"annotated sentence":"Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (<e1>E217\u03b2G<\\e1>  (a prototypical <e2>MRP<\\e2> substrate) into MRP-enriched inside-out membrane vesicles","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"E217\u03b2G","object":"MRP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (<e1>CHEMICAL<\\e1>  (a prototypical <e2>GENE-N<\\e2> substrate) into GENE-N-enriched inside-out membrane vesicles","sentence":"Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (E217\u03b2G  (a prototypical MRP substrate) into MRP-enriched inside-out membrane vesicles"}
{"PMID":23530018,"re_id":5,"annotated sentence":"Sixteen of 34 CGPs inhibited <e2>MRP1<\\e2> mediated <e1>E217\u03b2G<\\e1> uptake by >50% (IC50's 0.7-7.6 \u03bcM)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"E217\u03b2G","object":"MRP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sixteen of 34 CGPs inhibited <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> uptake by >50% (IC50's 0.7-7.6 \u03bcM)","sentence":"Sixteen of 34 CGPs inhibited MRP1 mediated E217\u03b2G uptake by >50% (IC50's 0.7-7.6 \u03bcM)"}
{"PMID":23530018,"re_id":6,"annotated sentence":"When tested in the intact cells, only 4 of 16 CGPs (at 10 \u03bcM) inhibited <e2>MRP1<\\e2> mediated <e1>calcein<\\e1> efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"calcein","object":"MRP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When tested in the intact cells, only 4 of 16 CGPs (at 10 \u03bcM) inhibited <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%","sentence":"When tested in the intact cells, only 4 of 16 CGPs (at 10 \u03bcM) inhibited MRP1 mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%"}
{"PMID":23530018,"re_id":7,"annotated sentence":"These five CGPs also inhibited <e1>[(3)H]E217\u03b2G<\\e1> uptake by <e2>MRP4<\\e2>  In contrast, their effects on MRP2 varied with two (V-4, V-6) inhibiting E217\u03b2G transport (IC50's 2.0, 9.2 \u03bcM), two (V-3, III-1) stimulating transport (>2-fold), while CGP I-5 had no effect","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[(3)H]E217\u03b2G","object":"MRP4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These five CGPs also inhibited <e1>CHEMICAL<\\e1> uptake by <e2>GENE-Y<\\e2>  In contrast, their effects on MRP2 varied with two (V-4, V-6) inhibiting E217\u03b2G transport (IC50's 2.0, 9.2 \u03bcM), two (V-3, III-1) stimulating transport (>2-fold), while CGP I-5 had no effect","sentence":"These five CGPs also inhibited [(3)H]E217\u03b2G uptake by MRP4  In contrast, their effects on MRP2 varied with two (V-4, V-6) inhibiting E217\u03b2G transport (IC50's 2.0, 9.2 \u03bcM), two (V-3, III-1) stimulating transport (>2-fold), while CGP I-5 had no effect"}
{"PMID":23531031,"re_id":0,"annotated sentence":"Results: Our results demonstrate that treatment with <e1>LBH589<\\e1> leads to <e2>NIS<\\e2> RNA expression as shown by RT-PCR and luciferase assay, and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"LBH589","object":"NIS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results: Our results demonstrate that treatment with <e1>CHEMICAL<\\e1> leads to <e2>GENE-Y<\\e2> RNA expression as shown by RT-PCR and luciferase assay, and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors","sentence":"Results: Our results demonstrate that treatment with LBH589 leads to NIS RNA expression as shown by RT-PCR and luciferase assay, and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors"}
{"PMID":23531031,"re_id":1,"annotated sentence":"Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the <e2>histone deacetylase<\\e2> inhibitor <e1>LBH589<\\e1>  After treatment, we evaluated the expression and function of NIS","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"LBH589","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1>  After treatment, we evaluated the expression and function of NIS","sentence":"Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the histone deacetylase inhibitor LBH589  After treatment, we evaluated the expression and function of NIS"}
{"PMID":23531488,"re_id":0,"annotated sentence":"Using a transient heterologous cell expression system, we find that the transport activities of the <e2>short OATP2B1<\\e2> variant towards substrates <e1>estrone sulfate<\\e1> and rosuvastatin are similar to the well-characterized full length variant","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"estrone sulfate","object":"short OATP2B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using a transient heterologous cell expression system, we find that the transport activities of the <e2>GENE-Y<\\e2> variant towards substrates <e1>CHEMICAL<\\e1> and rosuvastatin are similar to the well-characterized full length variant","sentence":"Using a transient heterologous cell expression system, we find that the transport activities of the short OATP2B1 variant towards substrates estrone sulfate and rosuvastatin are similar to the well-characterized full length variant"}
{"PMID":23531488,"re_id":1,"annotated sentence":"Using a transient heterologous cell expression system, we find that the transport activities of the <e2>short OATP2B1<\\e2> variant towards substrates estrone sulfate and <e1>rosuvastatin<\\e1> are similar to the well-characterized full length variant","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"rosuvastatin","object":"short OATP2B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using a transient heterologous cell expression system, we find that the transport activities of the <e2>GENE-Y<\\e2> variant towards substrates estrone sulfate and <e1>CHEMICAL<\\e1> are similar to the well-characterized full length variant","sentence":"Using a transient heterologous cell expression system, we find that the transport activities of the short OATP2B1 variant towards substrates estrone sulfate and rosuvastatin are similar to the well-characterized full length variant"}
{"PMID":23532634,"re_id":0,"annotated sentence":"In four (10\u00a0%) patients the peak <e2>ACTH<\\e2> stimulated <e1>cortisol<\\e1> values were lower than 18\u00a0\u03bcg\/dL","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisol","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In four (10\u00a0%) patients the peak <e2>GENE-Y<\\e2> stimulated <e1>CHEMICAL<\\e1> values were lower than 18\u00a0\u03bcg\/dL","sentence":"In four (10\u00a0%) patients the peak ACTH stimulated cortisol values were lower than 18\u00a0\u03bcg\/dL"}
{"PMID":23532634,"re_id":1,"annotated sentence":"<e2>ACTH<\\e2> stimulated peak <e1>cortisol<\\e1>  delta cortisol, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cortisol","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> stimulated peak <e1>CHEMICAL<\\e1>  delta CHEMICAL, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover","sentence":"ACTH stimulated peak cortisol  delta cortisol, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover"}
{"PMID":23532634,"re_id":2,"annotated sentence":"<e2>ACTH<\\e2> stimulated peak cortisol, <e1>delta cortisol<\\e1>  and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"delta cortisol","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> stimulated peak cortisol, <e1>CHEMICAL<\\e1>  and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover","sentence":"ACTH stimulated peak cortisol, delta cortisol  and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover"}
{"PMID":23532634,"re_id":3,"annotated sentence":"<e2>ACTH<\\e2> stimulated peak cortisol, delta cortisol, and <e1>delta DHEA<\\e1> S levels are decreased during hyperthyroidism, probably due to increased turnover","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"delta DHEA","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> stimulated peak cortisol, delta cortisol, and <e1>CHEMICAL<\\e1> S levels are decreased during hyperthyroidism, probably due to increased turnover","sentence":"ACTH stimulated peak cortisol, delta cortisol, and delta DHEA S levels are decreased during hyperthyroidism, probably due to increased turnover"}
{"PMID":23532918,"re_id":0,"annotated sentence":"Synthesis and in Vitro Characterisation of <e1>Ifenprodil<\\e1> Based Fluorescein Conjugates as <e2>GluN1<\\e2> GluN2B N-Methyl-D-aspartate Receptor Antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Ifenprodil","object":"GluN1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and in Vitro Characterisation of <e1>CHEMICAL<\\e1> Based Fluorescein Conjugates as <e2>GENE-Y<\\e2> GluN2B N-Methyl-D-aspartate Receptor Antagonists","sentence":"Synthesis and in Vitro Characterisation of Ifenprodil Based Fluorescein Conjugates as GluN1 GluN2B N-Methyl-D-aspartate Receptor Antagonists"}
{"PMID":23532918,"re_id":1,"annotated sentence":"Synthesis and in Vitro Characterisation of <e1>Ifenprodil<\\e1> Based Fluorescein Conjugates as GluN1\/<e2>GluN2B<\\e2> N-Methyl-D-aspartate Receptor Antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Ifenprodil","object":"GluN2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and in Vitro Characterisation of <e1>CHEMICAL<\\e1> Based Fluorescein Conjugates as GluN1\/<e2>GENE-Y<\\e2> N-Methyl-D-aspartate Receptor Antagonists","sentence":"Synthesis and in Vitro Characterisation of Ifenprodil Based Fluorescein Conjugates as GluN1\/GluN2B N-Methyl-D-aspartate Receptor Antagonists"}
{"PMID":23532918,"re_id":2,"annotated sentence":"Synthesis and in Vitro Characterisation of <e1>Ifenprodil<\\e1> Based Fluorescein Conjugates as GluN1\/GluN2B <e2>N-Methyl-D-aspartate Receptor<\\e2> Antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Ifenprodil","object":"N-Methyl-D-aspartate Receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Synthesis and in Vitro Characterisation of <e1>CHEMICAL<\\e1> Based Fluorescein Conjugates as GluN1\/GluN2B <e2>GENE-N<\\e2> Antagonists","sentence":"Synthesis and in Vitro Characterisation of Ifenprodil Based Fluorescein Conjugates as GluN1\/GluN2B N-Methyl-D-aspartate Receptor Antagonists"}
{"PMID":23532918,"re_id":3,"annotated sentence":"Synthesis and in Vitro Characterisation of Ifenprodil-Based <e1>Fluorescein<\\e1> Conjugates as <e2>GluN1<\\e2> GluN2B N-Methyl-D-aspartate Receptor Antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Fluorescein","object":"GluN1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and in Vitro Characterisation of Ifenprodil-Based <e1>CHEMICAL<\\e1> Conjugates as <e2>GENE-Y<\\e2> GluN2B N-Methyl-D-aspartate Receptor Antagonists","sentence":"Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1 GluN2B N-Methyl-D-aspartate Receptor Antagonists"}
{"PMID":23532918,"re_id":4,"annotated sentence":"Synthesis and in Vitro Characterisation of Ifenprodil-Based <e1>Fluorescein<\\e1> Conjugates as GluN1\/<e2>GluN2B<\\e2> N-Methyl-D-aspartate Receptor Antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Fluorescein","object":"GluN2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and in Vitro Characterisation of Ifenprodil-Based <e1>CHEMICAL<\\e1> Conjugates as GluN1\/<e2>GENE-Y<\\e2> N-Methyl-D-aspartate Receptor Antagonists","sentence":"Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1\/GluN2B N-Methyl-D-aspartate Receptor Antagonists"}
{"PMID":23532918,"re_id":5,"annotated sentence":"Synthesis and in Vitro Characterisation of Ifenprodil-Based <e1>Fluorescein<\\e1> Conjugates as GluN1\/GluN2B <e2>N-Methyl-D-aspartate Receptor<\\e2> Antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Fluorescein","object":"N-Methyl-D-aspartate Receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Synthesis and in Vitro Characterisation of Ifenprodil-Based <e1>CHEMICAL<\\e1> Conjugates as GluN1\/GluN2B <e2>GENE-N<\\e2> Antagonists","sentence":"Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1\/GluN2B N-Methyl-D-aspartate Receptor Antagonists"}
{"PMID":23532918,"re_id":6,"annotated sentence":"<e1>Ifenprodil<\\e1>  known as the <e2>GluNR2B<\\e2> antagonist of reference, was chosen as the template for the elaboration of probes","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Ifenprodil","object":"GluNR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  known as the <e2>GENE-Y<\\e2> antagonist of reference, was chosen as the template for the elaboration of probes","sentence":"Ifenprodil  known as the GluNR2B antagonist of reference, was chosen as the template for the elaboration of probes"}
{"PMID":23534442,"re_id":0,"annotated sentence":"<e1>Nitrooxy<\\e1> derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective <e2>COX-2<\\e2> inhibitors in in vitro experimental models","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Nitrooxy","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective <e2>GENE-Y<\\e2> inhibitors in in vitro experimental models","sentence":"Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models"}
{"PMID":23534442,"re_id":1,"annotated sentence":"Novel analgesic\/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as <e2>cyclooxygenase-2<\\e2> inhibiting <e1>nitric oxide<\\e1> donors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nitric oxide","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel analgesic\/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as <e2>GENE-Y<\\e2> inhibiting <e1>CHEMICAL<\\e1> donors","sentence":"Novel analgesic\/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors"}
{"PMID":23534442,"re_id":2,"annotated sentence":"Novel analgesic\/anti-inflammatory agents: <e1>1,5-diarylpyrrole nitrooxyalkyl ethers<\\e1> and related compounds as <e2>cyclooxygenase-2<\\e2> inhibiting nitric oxide donors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,5-diarylpyrrole nitrooxyalkyl ethers","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel analgesic\/anti-inflammatory agents: <e1>CHEMICAL<\\e1> and related compounds as <e2>GENE-Y<\\e2> inhibiting nitric oxide donors","sentence":"Novel analgesic\/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors"}
{"PMID":23534442,"re_id":3,"annotated sentence":"New classes of <e1>pyrrole<\\e1> derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as <e2>COX-2<\\e2> selective inhibitors and NO donors were synthesized and are herein reported","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyrrole","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"New classes of <e1>CHEMICAL<\\e1> derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as <e2>GENE-Y<\\e2> selective inhibitors and NO donors were synthesized and are herein reported","sentence":"New classes of pyrrole derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported"}
{"PMID":23534442,"re_id":4,"annotated sentence":"New classes of pyrrole-derived <e1>nitrooxyalkyl<\\e1> inverse esters, carbonates, and ethers (7-10) as <e2>COX-2<\\e2> selective inhibitors and NO donors were synthesized and are herein reported","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nitrooxyalkyl","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"New classes of pyrrole-derived <e1>CHEMICAL<\\e1> inverse esters, carbonates, and ethers (7-10) as <e2>GENE-Y<\\e2> selective inhibitors and NO donors were synthesized and are herein reported","sentence":"New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported"}
{"PMID":23534442,"re_id":5,"annotated sentence":"New classes of pyrrole-derived nitrooxyalkyl inverse <e1>esters<\\e1>  carbonates, and ethers (7-10) as <e2>COX-2<\\e2> selective inhibitors and NO donors were synthesized and are herein reported","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"esters","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"New classes of pyrrole-derived nitrooxyalkyl inverse <e1>CHEMICAL<\\e1>  carbonates, and ethers (7-10) as <e2>GENE-Y<\\e2> selective inhibitors and NO donors were synthesized and are herein reported","sentence":"New classes of pyrrole-derived nitrooxyalkyl inverse esters  carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported"}
{"PMID":23534442,"re_id":6,"annotated sentence":"New classes of pyrrole-derived nitrooxyalkyl inverse esters, <e1>carbonates<\\e1>  and ethers (7-10) as <e2>COX-2<\\e2> selective inhibitors and NO donors were synthesized and are herein reported","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbonates","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"New classes of pyrrole-derived nitrooxyalkyl inverse esters, <e1>CHEMICAL<\\e1>  and ethers (7-10) as <e2>GENE-Y<\\e2> selective inhibitors and NO donors were synthesized and are herein reported","sentence":"New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates  and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported"}
{"PMID":23534442,"re_id":7,"annotated sentence":"New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and <e1>ethers<\\e1> (7-10) as <e2>COX-2<\\e2> selective inhibitors and NO donors were synthesized and are herein reported","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethers","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and <e1>CHEMICAL<\\e1> (7-10) as <e2>GENE-Y<\\e2> selective inhibitors and NO donors were synthesized and are herein reported","sentence":"New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported"}
{"PMID":23535327,"re_id":0,"annotated sentence":"Synthesis and structure-activity relationship of <e1>pyripyropene A<\\e1> derivatives as potent and selective <e2>acyl-CoA:cholesterol acyltransferase 2<\\e2> (ACAT2) inhibitors: Part 2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyripyropene A","object":"acyl-CoA:cholesterol acyltransferase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and structure-activity relationship of <e1>CHEMICAL<\\e1> derivatives as potent and selective <e2>GENE-Y<\\e2> (ACAT2) inhibitors: Part 2","sentence":"Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: Part 2"}
{"PMID":23535327,"re_id":1,"annotated sentence":"Synthesis and structure-activity relationship of <e1>pyripyropene A<\\e1> derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (<e2>ACAT2<\\e2>  inhibitors: Part 2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"pyripyropene A","object":"ACAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and structure-activity relationship of <e1>CHEMICAL<\\e1> derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (<e2>GENE-Y<\\e2>  inhibitors: Part 2","sentence":"Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2  inhibitors: Part 2"}
{"PMID":23535516,"re_id":0,"annotated sentence":"Blockade of <e2>JAK<\\e2> and ERK pathways with <e1>AG490<\\e1> and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-\u03b1-MSH","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"AG490","object":"JAK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of <e2>GENE-N<\\e2> and ERK pathways with <e1>CHEMICAL<\\e1> and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-\u03b1-MSH","sentence":"Blockade of JAK and ERK pathways with AG490 and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-\u03b1-MSH"}
{"PMID":23535516,"re_id":1,"annotated sentence":"Blockade of JAK and <e2>ERK<\\e2> pathways with AG490 and <e1>U0126<\\e1>  respectively, abrogated the myocardial infarct size reduction by NDP-\u03b1-MSH","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U0126","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of JAK and <e2>GENE-N<\\e2> pathways with AG490 and <e1>CHEMICAL<\\e1>  respectively, abrogated the myocardial infarct size reduction by NDP-\u03b1-MSH","sentence":"Blockade of JAK and ERK pathways with AG490 and U0126  respectively, abrogated the myocardial infarct size reduction by NDP-\u03b1-MSH"}
{"PMID":23536521,"re_id":0,"annotated sentence":"A decrease in <e2>ADA<\\e2> activity was observed when the slices were exposed to <e1>organoselenium<\\e1> at the concentrations of 1, 10 and 30 \u00b5M","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"organoselenium","object":"ADA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A decrease in <e2>GENE-Y<\\e2> activity was observed when the slices were exposed to <e1>CHEMICAL<\\e1> at the concentrations of 1, 10 and 30 \u00b5M","sentence":"A decrease in ADA activity was observed when the slices were exposed to organoselenium at the concentrations of 1, 10 and 30 \u00b5M"}
{"PMID":23538162,"re_id":0,"annotated sentence":"Taken together, our results suggested that <e1>Rg1<\\e1> protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent <e2>ERK<\\e2> phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Rg1","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, our results suggested that <e1>CHEMICAL<\\e1> protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent <e2>GENE-N<\\e2> phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades","sentence":"Taken together, our results suggested that Rg1 protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades"}
{"PMID":23538162,"re_id":1,"annotated sentence":"Activating <e2>glucocorticoid receptor<\\e2> ERK signaling pathway contributes to <e1>ginsenoside Rg1<\\e1> protection against \u03b2-amyloid peptide-induced human endothelial cells apoptosis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ginsenoside Rg1","object":"glucocorticoid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activating <e2>GENE-Y<\\e2> ERK signaling pathway contributes to <e1>CHEMICAL<\\e1> protection against \u03b2-amyloid peptide-induced human endothelial cells apoptosis","sentence":"Activating glucocorticoid receptor ERK signaling pathway contributes to ginsenoside Rg1 protection against \u03b2-amyloid peptide-induced human endothelial cells apoptosis"}
{"PMID":23538162,"re_id":2,"annotated sentence":"Activating glucocorticoid receptor-<e2>ERK<\\e2> signaling pathway contributes to <e1>ginsenoside Rg1<\\e1> protection against \u03b2-amyloid peptide-induced human endothelial cells apoptosis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ginsenoside Rg1","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Activating glucocorticoid receptor-<e2>GENE-N<\\e2> signaling pathway contributes to <e1>CHEMICAL<\\e1> protection against \u03b2-amyloid peptide-induced human endothelial cells apoptosis","sentence":"Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against \u03b2-amyloid peptide-induced human endothelial cells apoptosis"}
{"PMID":23538162,"re_id":3,"annotated sentence":"Taken together, our results suggested that <e1>Rg1<\\e1> protected against <e2>A\u03b225-35<\\e2> induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rg1","object":"A\u03b225-35","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, our results suggested that <e1>CHEMICAL<\\e1> protected against <e2>GENE-Y<\\e2> induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades","sentence":"Taken together, our results suggested that Rg1 protected against A\u03b225-35 induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades"}
{"PMID":23538162,"re_id":4,"annotated sentence":"Taken together, our results suggested that <e1>Rg1<\\e1> protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating <e2>HIF-1\u03b1<\\e2> initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rg1","object":"HIF-1\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, our results suggested that <e1>CHEMICAL<\\e1> protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating <e2>GENE-Y<\\e2> initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades","sentence":"Taken together, our results suggested that Rg1 protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades"}
{"PMID":23538162,"re_id":5,"annotated sentence":"Activating glucocorticoid receptor-ERK signaling pathway contributes to <e1>ginsenoside Rg1<\\e1> protection against <e2>\u03b2-amyloid peptide<\\e2> induced human endothelial cells apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ginsenoside Rg1","object":"\u03b2-amyloid peptide","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activating glucocorticoid receptor-ERK signaling pathway contributes to <e1>CHEMICAL<\\e1> protection against <e2>GENE-Y<\\e2> induced human endothelial cells apoptosis","sentence":"Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against \u03b2-amyloid peptide induced human endothelial cells apoptosis"}
{"PMID":23538162,"re_id":6,"annotated sentence":"These data provided a novel insight to the mechanisms of <e1>Rg1<\\e1> rotective effects on <e2>A\u03b225-35<\\e2> induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rg1","object":"A\u03b225-35","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data provided a novel insight to the mechanisms of <e1>CHEMICAL<\\e1> rotective effects on <e2>GENE-Y<\\e2> induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.","sentence":"These data provided a novel insight to the mechanisms of Rg1 rotective effects on A\u03b225-35 induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it."}
{"PMID":23538162,"re_id":7,"annotated sentence":"<e1>Rg1<\\e1> attenuated the <e2>A\u03b225-35<\\e2> associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1\u03b1 expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rg1","object":"A\u03b225-35","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> attenuated the <e2>GENE-Y<\\e2> associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1\u03b1 expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination","sentence":"Rg1 attenuated the A\u03b225-35 associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1\u03b1 expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination"}
{"PMID":23538162,"re_id":8,"annotated sentence":"<e1>Rg1<\\e1> attenuated the A\u03b225-35-associated mitochondrial apoptotic events, accompanied by inhibiting <e2>HIF-1\u03b1<\\e2> expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rg1","object":"HIF-1\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> attenuated the A\u03b225-35-associated mitochondrial apoptotic events, accompanied by inhibiting <e2>GENE-Y<\\e2> expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination","sentence":"Rg1 attenuated the A\u03b225-35-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1\u03b1 expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination"}
{"PMID":23538162,"re_id":9,"annotated sentence":"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or <e2>p-ERK<\\e2> inhibitor <e1>U0126<\\e1> rather than estrogen receptor \u03b1 antagonist ICI 82,780","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"U0126","object":"p-ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> rather than estrogen receptor \u03b1 antagonist ICI 82,780","sentence":"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780"}
{"PMID":23538162,"re_id":10,"annotated sentence":"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than <e2>estrogen receptor \u03b1<\\e2> antagonist <e1>ICI 82,780<\\e1>  Taken together, our results suggested that Rg1 protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ICI 82,780","object":"estrogen receptor \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  Taken together, our results suggested that Rg1 protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades","sentence":"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780  Taken together, our results suggested that Rg1 protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades"}
{"PMID":23538162,"re_id":11,"annotated sentence":"These protective effects were abolished by <e2>glucocorticoid receptor<\\e2> (GR) antagonist <e1>RU486<\\e1> or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"RU486","object":"glucocorticoid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These protective effects were abolished by <e2>GENE-Y<\\e2> (GR) antagonist <e1>CHEMICAL<\\e1> or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780","sentence":"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780"}
{"PMID":23538162,"re_id":12,"annotated sentence":"These protective effects were abolished by glucocorticoid receptor (<e2>GR<\\e2>  antagonist <e1>RU486<\\e1> or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"RU486","object":"GR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These protective effects were abolished by glucocorticoid receptor (<e2>GENE-Y<\\e2>  antagonist <e1>CHEMICAL<\\e1> or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780","sentence":"These protective effects were abolished by glucocorticoid receptor (GR  antagonist RU486 or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780"}
{"PMID":23539296,"re_id":0,"annotated sentence":"Here, we have now found that activation of <e2>p38<\\e2> MAPK by <e1>anisomycin<\\e1> potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anisomycin","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Here, we have now found that activation of <e2>GENE-N<\\e2> MAPK by <e1>CHEMICAL<\\e1> potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes","sentence":"Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes"}
{"PMID":23539296,"re_id":1,"annotated sentence":"Here, we have now found that activation of p38 <e2>MAPK<\\e2> by <e1>anisomycin<\\e1> potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anisomycin","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Here, we have now found that activation of p38 <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1> potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes","sentence":"Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes"}
{"PMID":23539296,"re_id":2,"annotated sentence":"Here, we have now found that activation of p38 MAPK by <e1>anisomycin<\\e1> potentiated induction of <e2>CYP2B6<\\e2> mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anisomycin","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we have now found that activation of p38 MAPK by <e1>CHEMICAL<\\e1> potentiated induction of <e2>GENE-Y<\\e2> mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes","sentence":"Here, we have now found that activation of p38 MAPK by anisomycin potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes"}
{"PMID":23539296,"re_id":3,"annotated sentence":"siRNA knockdown of p38 MAPK abrogated the ability of <e1>anisomycin<\\e1> to synergistically induce <e2>CYP2B6<\\e2> mRNA","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anisomycin","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"siRNA knockdown of p38 MAPK abrogated the ability of <e1>CHEMICAL<\\e1> to synergistically induce <e2>GENE-Y<\\e2> mRNA","sentence":"siRNA knockdown of p38 MAPK abrogated the ability of anisomycin to synergistically induce CYP2B6 mRNA"}
{"PMID":23539296,"re_id":4,"annotated sentence":"In addition to <e2>CYP2B6<\\e2>  <e1>anisomycin<\\e1> co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anisomycin","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to <e2>GENE-Y<\\e2>  <e1>CHEMICAL<\\e1> co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs","sentence":"In addition to CYP2B6  anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs"}
{"PMID":23539296,"re_id":5,"annotated sentence":"In addition to CYP2B6, <e1>anisomycin<\\e1> co-treatment potentiated an increase in <e2>CYP2A7<\\e2> and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anisomycin","object":"CYP2A7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to CYP2B6, <e1>CHEMICAL<\\e1> co-treatment potentiated an increase in <e2>GENE-Y<\\e2> and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs","sentence":"In addition to CYP2B6, anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs"}
{"PMID":23539296,"re_id":6,"annotated sentence":"In addition to CYP2B6, <e1>anisomycin<\\e1> co-treatment potentiated an increase in CYP2A7 and <e2>CYP2C9<\\e2> mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"anisomycin","object":"CYP2C9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to CYP2B6, <e1>CHEMICAL<\\e1> co-treatment potentiated an increase in CYP2A7 and <e2>GENE-Y<\\e2> mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs","sentence":"In addition to CYP2B6, anisomycin co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs"}
{"PMID":23541436,"re_id":0,"annotated sentence":"FCEO significantly inhibited <e1>nitric oxide<\\e1> (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of <e2>inducible nitric oxide synthase<\\e2> (iNOS) and cyclooxygenase (COX)-2, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nitric oxide","object":"inducible nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"FCEO significantly inhibited <e1>CHEMICAL<\\e1> (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of <e2>inducible CHEMICAL synthase<\\e2> (iNOS) and cyclooxygenase (COX)-2, respectively","sentence":"FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2, respectively"}
{"PMID":23541436,"re_id":1,"annotated sentence":"FCEO significantly inhibited <e1>nitric oxide<\\e1> (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (<e2>iNOS<\\e2>  and cyclooxygenase (COX)-2, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nitric oxide","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"FCEO significantly inhibited <e1>CHEMICAL<\\e1> (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible CHEMICAL synthase (<e2>GENE-Y<\\e2>  and cyclooxygenase (COX)-2, respectively","sentence":"FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS  and cyclooxygenase (COX)-2, respectively"}
{"PMID":23541436,"re_id":2,"annotated sentence":"FCEO significantly inhibited nitric oxide (<e1>NO<\\e1>  and prostaglandin E2 (PGE2) by suppressing the protein expression of <e2>inducible nitric oxide synthase<\\e2> (iNOS) and cyclooxygenase (COX)-2, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NO","object":"inducible nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"FCEO significantly inhibited nitric oxide (<e1>CHEMICAL<\\e1>  and prostaglandin E2 (PGE2) by suppressing the protein expression of <e2>GENE-Y<\\e2> (iCHEMICALS) and cyclooxygenase (COX)-2, respectively","sentence":"FCEO significantly inhibited nitric oxide (NO  and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2, respectively"}
{"PMID":23541436,"re_id":3,"annotated sentence":"FCEO significantly inhibited nitric oxide (<e1>NO<\\e1>  and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (<e2>iNOS<\\e2>  and cyclooxygenase (COX)-2, respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NO","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"FCEO significantly inhibited nitric oxide (<e1>CHEMICAL<\\e1>  and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (<e2>iCHEMICALS<\\e2>  and cyclooxygenase (COX)-2, respectively","sentence":"FCEO significantly inhibited nitric oxide (NO  and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS  and cyclooxygenase (COX)-2, respectively"}
{"PMID":23541436,"re_id":4,"annotated sentence":"FCEO significantly inhibited nitric oxide (NO) and <e1>prostaglandin E2<\\e1> (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and <e2>cyclooxygenase (COX)-2<\\e2>  respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prostaglandin E2","object":"cyclooxygenase (COX)-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"FCEO significantly inhibited nitric oxide (NO) and <e1>CHEMICAL<\\e1> (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and <e2>GENE-Y<\\e2>  respectively","sentence":"FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2  respectively"}
{"PMID":23541436,"re_id":5,"annotated sentence":"FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 (<e1>PGE2<\\e1>  by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and <e2>cyclooxygenase (COX)-2<\\e2>  respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PGE2","object":"cyclooxygenase (COX)-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 (<e1>CHEMICAL<\\e1>  by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and <e2>GENE-Y<\\e2>  respectively","sentence":"FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 (PGE2  by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2  respectively"}
{"PMID":23541637,"re_id":0,"annotated sentence":"<e1>Aldosterone<\\e1> induced <e2>ENaC<\\e2> and basal Na(+)\/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Aldosterone","object":"ENaC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> and basal Na(+)\/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells","sentence":"Aldosterone induced ENaC and basal Na(+)\/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells"}
{"PMID":23541637,"re_id":1,"annotated sentence":"<e1>Aldosterone<\\e1> induced ENaC and basal <e2>Na(+)\/K(+)-ATPase<\\e2> trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Aldosterone","object":"Na(+)\/K(+)-ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced ENaC and basal <e2>GENE-N<\\e2> trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells","sentence":"Aldosterone induced ENaC and basal Na(+)\/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells"}
{"PMID":23541637,"re_id":2,"annotated sentence":"<e1>Aldosterone<\\e1> also induces the rapid phosphorylation of <e2>Protein Kinase D1<\\e2> (PKD1)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Aldosterone","object":"Protein Kinase D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also induces the rapid phosphorylation of <e2>GENE-Y<\\e2> (PKD1)","sentence":"Aldosterone also induces the rapid phosphorylation of Protein Kinase D1 (PKD1)"}
{"PMID":23541637,"re_id":3,"annotated sentence":"<e1>Aldosterone<\\e1> also induces the rapid phosphorylation of Protein Kinase D1 (<e2>PKD1<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Aldosterone","object":"PKD1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also induces the rapid phosphorylation of Protein Kinase D1 (<e2>GENE-Y<\\e2> ","sentence":"Aldosterone also induces the rapid phosphorylation of Protein Kinase D1 (PKD1 "}
{"PMID":23542513,"re_id":0,"annotated sentence":"Thus, we found that <e1>5HHMF<\\e1> enhances <e2>heme oxygenase-1<\\e2> (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"heme oxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, we found that <e1>CHEMICAL<\\e1> enhances <e2>GENE-Y<\\e2> (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation","sentence":"Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation"}
{"PMID":23542513,"re_id":1,"annotated sentence":"Thus, we found that <e1>5HHMF<\\e1> enhances heme oxygenase-1 (<e2>HO-1<\\e2>  expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, we found that <e1>CHEMICAL<\\e1> enhances heme oxygenase-1 (<e2>GENE-Y<\\e2>  expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation","sentence":"Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1  expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation"}
{"PMID":23542513,"re_id":2,"annotated sentence":"Thus, we found that <e1>5HHMF<\\e1> enhances heme oxygenase-1 (HO-1) expression via <e2>nuclear factor-erythroid 2-related factor 2<\\e2> (Nrf2) activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"nuclear factor-erythroid 2-related factor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, we found that <e1>CHEMICAL<\\e1> enhances heme oxygenase-1 (HO-1) expression via <e2>GENE-Y<\\e2> (Nrf2) activation","sentence":"Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation"}
{"PMID":23542513,"re_id":3,"annotated sentence":"Thus, we found that <e1>5HHMF<\\e1> enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (<e2>Nrf2<\\e2>  activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, we found that <e1>CHEMICAL<\\e1> enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (<e2>GENE-Y<\\e2>  activation","sentence":"Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2  activation"}
{"PMID":23542513,"re_id":4,"annotated sentence":"In addition, <e1>cobalt protoporphyrin<\\e1> (CoPP), a specific <e2>HO-1<\\e2> inducer, predominantly suppressed LPS-induced NO production","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"cobalt protoporphyrin","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> (CoPP), a specific <e2>GENE-Y<\\e2> inducer, predominantly suppressed LPS-induced NO production","sentence":"In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production"}
{"PMID":23542513,"re_id":5,"annotated sentence":"In addition, cobalt protoporphyrin (<e1>CoPP<\\e1> , a specific <e2>HO-1<\\e2> inducer, predominantly suppressed LPS-induced NO production","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CoPP","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, cobalt protoporphyrin (<e1>CHEMICAL<\\e1> , a specific <e2>GENE-Y<\\e2> inducer, predominantly suppressed LPS-induced NO production","sentence":"In addition, cobalt protoporphyrin (CoPP , a specific HO-1 inducer, predominantly suppressed LPS-induced NO production"}
{"PMID":23542513,"re_id":6,"annotated sentence":"<e1>5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone<\\e1> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and <e2>Nrf-2<\\e2> dependent heme oxygenase-1 induction","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone","object":"Nrf-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and <e2>GENE-Y<\\e2> dependent heme oxygenase-1 induction","sentence":"5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and Nrf-2 dependent heme oxygenase-1 induction"}
{"PMID":23542513,"re_id":7,"annotated sentence":"<e1>5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone<\\e1> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and Nrf-2-dependent <e2>heme oxygenase-1<\\e2> induction","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone","object":"heme oxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and Nrf-2-dependent <e2>GENE-Y<\\e2> induction","sentence":"5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and Nrf-2-dependent heme oxygenase-1 induction"}
{"PMID":23542513,"re_id":8,"annotated sentence":"Further, <e1>5HHMF<\\e1> increased specific DNA-binding activity of <e2>Nrf2<\\e2>  and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, <e1>CHEMICAL<\\e1> increased specific DNA-binding activity of <e2>GENE-Y<\\e2>  and transient knockdown with GENE-Y siRNA subsequently reversed CHEMICAL-induced NO inhibition, which was followed by suppression of HO-1 activity","sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2  and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity"}
{"PMID":23542513,"re_id":9,"annotated sentence":"Further, <e1>5HHMF<\\e1> increased specific DNA-binding activity of Nrf2, and transient knockdown with <e2>Nrf2<\\e2> siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, <e1>CHEMICAL<\\e1> increased specific DNA-binding activity of GENE-Y, and transient knockdown with <e2>GENE-Y<\\e2> siRNA subsequently reversed CHEMICAL-induced NO inhibition, which was followed by suppression of HO-1 activity","sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity"}
{"PMID":23542513,"re_id":10,"annotated sentence":"Further, <e1>5HHMF<\\e1> increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of <e2>HO-1<\\e2> activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, <e1>CHEMICAL<\\e1> increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed CHEMICAL-induced NO inhibition, which was followed by suppression of <e2>GENE-Y<\\e2> activity","sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity"}
{"PMID":23542513,"re_id":11,"annotated sentence":"Further, 5HHMF increased specific DNA-binding activity of <e2>Nrf2<\\e2>  and transient knockdown with Nrf2 siRNA subsequently reversed <e1>5HHMF<\\e1> induced NO inhibition, which was followed by suppression of HO-1 activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, CHEMICAL increased specific DNA-binding activity of <e2>GENE-Y<\\e2>  and transient knockdown with GENE-Y siRNA subsequently reversed <e1>CHEMICAL<\\e1> induced NO inhibition, which was followed by suppression of HO-1 activity","sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2  and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF induced NO inhibition, which was followed by suppression of HO-1 activity"}
{"PMID":23542513,"re_id":12,"annotated sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with <e2>Nrf2<\\e2> siRNA subsequently reversed <e1>5HHMF<\\e1> induced NO inhibition, which was followed by suppression of HO-1 activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, CHEMICAL increased specific DNA-binding activity of GENE-Y, and transient knockdown with <e2>GENE-Y<\\e2> siRNA subsequently reversed <e1>CHEMICAL<\\e1> induced NO inhibition, which was followed by suppression of HO-1 activity","sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF induced NO inhibition, which was followed by suppression of HO-1 activity"}
{"PMID":23542513,"re_id":13,"annotated sentence":"Taken together, our findings indicate that <e1>5HHMF<\\e1> suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of <e2>Nrf2<\\e2> dependent HO-1 activity.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, our findings indicate that <e1>CHEMICAL<\\e1> suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of <e2>GENE-Y<\\e2> dependent HO-1 activity.","sentence":"Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2 dependent HO-1 activity."}
{"PMID":23542513,"re_id":14,"annotated sentence":"Taken together, our findings indicate that <e1>5HHMF<\\e1> suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent <e2>HO-1<\\e2> activity.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, our findings indicate that <e1>CHEMICAL<\\e1> suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent <e2>GENE-Y<\\e2> activity.","sentence":"Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent HO-1 activity."}
{"PMID":23542513,"re_id":15,"annotated sentence":"Taken together, our findings indicate that 5HHMF suppresses <e1>NO<\\e1> production through modulation of iNOS, consequently suppressing <e2>NF-\u03baB<\\e2> activity and induction of Nrf2-dependent HO-1 activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NO","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, our findings indicate that 5HHMF suppresses <e1>CHEMICAL<\\e1> production through modulation of iCHEMICALS, consequently suppressing <e2>GENE-N<\\e2> activity and induction of Nrf2-dependent HO-1 activity.","sentence":"Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent HO-1 activity."}
{"PMID":23542513,"re_id":16,"annotated sentence":"Taken together, our findings indicate that 5HHMF suppresses <e1>NO<\\e1> production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of <e2>Nrf2<\\e2> dependent HO-1 activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NO","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, our findings indicate that 5HHMF suppresses <e1>CHEMICAL<\\e1> production through modulation of iCHEMICALS, consequently suppressing NF-\u03baB activity and induction of <e2>GENE-Y<\\e2> dependent HO-1 activity.","sentence":"Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2 dependent HO-1 activity."}
{"PMID":23542513,"re_id":17,"annotated sentence":"Taken together, our findings indicate that 5HHMF suppresses <e1>NO<\\e1> production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent <e2>HO-1<\\e2> activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NO","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, our findings indicate that 5HHMF suppresses <e1>CHEMICAL<\\e1> production through modulation of iCHEMICALS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent <e2>GENE-Y<\\e2> activity.","sentence":"Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent HO-1 activity."}
{"PMID":23542513,"re_id":18,"annotated sentence":"In addition, <e1>5HHMF<\\e1> blocked LPS-induced phosphorylation of <e2>I\u03baB<\\e2>  resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"I\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> blocked LPS-induced phosphorylation of <e2>GENE-N<\\e2>  resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression","sentence":"In addition, 5HHMF blocked LPS-induced phosphorylation of I\u03baB  resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression"}
{"PMID":23542513,"re_id":19,"annotated sentence":"In addition, <e1>5HHMF<\\e1> blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of <e2>nuclear factor-\u03baB<\\e2> (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"nuclear factor-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of <e2>GENE-N<\\e2> (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression","sentence":"In addition, 5HHMF blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression"}
{"PMID":23542513,"re_id":20,"annotated sentence":"In addition, <e1>5HHMF<\\e1> blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (<e2>NF-\u03baB<\\e2>  subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (<e2>GENE-N<\\e2>  subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression","sentence":"In addition, 5HHMF blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB  subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression"}
{"PMID":23542513,"re_id":21,"annotated sentence":"In addition, <e1>5HHMF<\\e1> blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely <e2>p65<\\e2> and p50, which are important molecules involved in the regulation of iNOS expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely <e2>GENE-Y<\\e2> and p50, which are important molecules involved in the regulation of iNOS expression","sentence":"In addition, 5HHMF blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression"}
{"PMID":23542513,"re_id":22,"annotated sentence":"In addition, <e1>5HHMF<\\e1> blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and <e2>p50<\\e2>  which are important molecules involved in the regulation of iNOS expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"p50","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and <e2>GENE-Y<\\e2>  which are important molecules involved in the regulation of iNOS expression","sentence":"In addition, 5HHMF blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and p50  which are important molecules involved in the regulation of iNOS expression"}
{"PMID":23542513,"re_id":23,"annotated sentence":"In this study, we found that <e1>5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone<\\e1> (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of <e2>inducible NO synthase<\\e2> (iNOS) in BV2 microglia","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone","object":"inducible NO synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we found that <e1>CHEMICAL<\\e1> (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of <e2>GENE-Y<\\e2> (iNOS) in BV2 microglia","sentence":"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia"}
{"PMID":23542513,"re_id":24,"annotated sentence":"In this study, we found that <e1>5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone<\\e1> (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (<e2>iNOS<\\e2>  in BV2 microglia","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we found that <e1>CHEMICAL<\\e1> (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (<e2>GENE-Y<\\e2>  in BV2 microglia","sentence":"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS  in BV2 microglia"}
{"PMID":23542513,"re_id":25,"annotated sentence":"<e1>Pyrrolidine dithiocarbamate<\\e1> (PDTC), a specific <e2>NF-\u03baB<\\e2> inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pyrrolidine dithiocarbamate","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (PDTC), a specific <e2>GENE-N<\\e2> inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing GENE-N activity","sentence":"Pyrrolidine dithiocarbamate (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity"}
{"PMID":23542513,"re_id":26,"annotated sentence":"<e1>Pyrrolidine dithiocarbamate<\\e1> (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced <e2>iNOS<\\e2> expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pyrrolidine dithiocarbamate","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced <e2>GENE-Y<\\e2> expression, which indirectly suggested that 5HHMF downregulated GENE-Y expression by suppressing NF-\u03baB activity","sentence":"Pyrrolidine dithiocarbamate (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity"}
{"PMID":23542513,"re_id":27,"annotated sentence":"Pyrrolidine dithiocarbamate (<e1>PDTC<\\e1> , a specific <e2>NF-\u03baB<\\e2> inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PDTC","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pyrrolidine dithiocarbamate (<e1>CHEMICAL<\\e1> , a specific <e2>GENE-N<\\e2> inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing GENE-N activity","sentence":"Pyrrolidine dithiocarbamate (PDTC , a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity"}
{"PMID":23542513,"re_id":28,"annotated sentence":"Pyrrolidine dithiocarbamate (<e1>PDTC<\\e1> , a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced <e2>iNOS<\\e2> expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PDTC","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pyrrolidine dithiocarbamate (<e1>CHEMICAL<\\e1> , a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced <e2>GENE-Y<\\e2> expression, which indirectly suggested that 5HHMF downregulated GENE-Y expression by suppressing NF-\u03baB activity","sentence":"Pyrrolidine dithiocarbamate (PDTC , a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity"}
{"PMID":23542513,"re_id":29,"annotated sentence":"Pyrrolidine dithiocarbamate (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that <e1>5HHMF<\\e1> downregulated <e2>iNOS<\\e2> expression by suppressing NF-\u03baB activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pyrrolidine dithiocarbamate (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced GENE-Y expression, which indirectly suggested that <e1>CHEMICAL<\\e1> downregulated <e2>GENE-Y<\\e2> expression by suppressing NF-\u03baB activity","sentence":"Pyrrolidine dithiocarbamate (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity"}
{"PMID":23542513,"re_id":30,"annotated sentence":"Pyrrolidine dithiocarbamate (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that <e1>5HHMF<\\e1> downregulated iNOS expression by suppressing <e2>NF-\u03baB<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pyrrolidine dithiocarbamate (PDTC), a specific GENE-N inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that <e1>CHEMICAL<\\e1> downregulated iNOS expression by suppressing <e2>GENE-N<\\e2> activity","sentence":"Pyrrolidine dithiocarbamate (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-\u03baB activity"}
{"PMID":23542513,"re_id":31,"annotated sentence":"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (<e1>5HHMF<\\e1>  from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of <e2>inducible NO synthase<\\e2> (iNOS) in BV2 microglia","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"inducible NO synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (<e1>CHEMICAL<\\e1>  from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of <e2>GENE-Y<\\e2> (iNOS) in BV2 microglia","sentence":"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF  from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia"}
{"PMID":23542513,"re_id":32,"annotated sentence":"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (<e1>5HHMF<\\e1>  from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (<e2>iNOS<\\e2>  in BV2 microglia","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (<e1>CHEMICAL<\\e1>  from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (<e2>GENE-Y<\\e2>  in BV2 microglia","sentence":"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF  from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS  in BV2 microglia"}
{"PMID":23542513,"re_id":33,"annotated sentence":"<e1>5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone<\\e1> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via <e2>NF-\u03baB<\\e2> suppression and Nrf-2-dependent heme oxygenase-1 induction","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via <e2>GENE-N<\\e2> suppression and Nrf-2-dependent heme oxygenase-1 induction","sentence":"5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and Nrf-2-dependent heme oxygenase-1 induction"}
{"PMID":23542513,"re_id":34,"annotated sentence":"In contrast, <e1>zinc protoporphyrin<\\e1> (ZnPP), a specific <e2>HO-1<\\e2> inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zinc protoporphyrin","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1> (ZnPP), a specific <e2>GENE-Y<\\e2> inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production","sentence":"In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production"}
{"PMID":23542513,"re_id":35,"annotated sentence":"In contrast, zinc protoporphyrin (<e1>ZnPP<\\e1> , a specific <e2>HO-1<\\e2> inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ZnPP","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, zinc protoporphyrin (<e1>CHEMICAL<\\e1> , a specific <e2>GENE-Y<\\e2> inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production","sentence":"In contrast, zinc protoporphyrin (ZnPP , a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production"}
{"PMID":23542513,"re_id":36,"annotated sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed <e1>5HHMF<\\e1> induced NO inhibition, which was followed by suppression of <e2>HO-1<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, CHEMICAL increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed <e1>CHEMICAL<\\e1> induced NO inhibition, which was followed by suppression of <e2>GENE-Y<\\e2> activity","sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF induced NO inhibition, which was followed by suppression of HO-1 activity"}
{"PMID":23542513,"re_id":37,"annotated sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced <e1>NO<\\e1> inhibition, which was followed by suppression of <e2>HO-1<\\e2> activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NO","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced <e1>CHEMICAL<\\e1> inhibition, which was followed by suppression of <e2>GENE-Y<\\e2> activity","sentence":"Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity"}
{"PMID":23542513,"re_id":38,"annotated sentence":"Taken together, our findings indicate that <e1>5HHMF<\\e1> suppresses NO production through modulation of iNOS, consequently suppressing <e2>NF-\u03baB<\\e2> activity and induction of Nrf2-dependent HO-1 activity.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5HHMF","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, our findings indicate that <e1>CHEMICAL<\\e1> suppresses NO production through modulation of iNOS, consequently suppressing <e2>GENE-N<\\e2> activity and induction of Nrf2-dependent HO-1 activity.","sentence":"Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent HO-1 activity."}
{"PMID":23543413,"re_id":0,"annotated sentence":"We confirm the correlation between higher <e2>hCTR1<\\e2> levels and higher <e1>Pt<\\e1> drug uptake in tumor cells sensitive to the drug","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Pt","object":"hCTR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We confirm the correlation between higher <e2>GENE-Y<\\e2> levels and higher <e1>CHEMICAL<\\e1> drug uptake in tumor cells sensitive to the drug","sentence":"We confirm the correlation between higher hCTR1 levels and higher Pt drug uptake in tumor cells sensitive to the drug"}
{"PMID":23543413,"re_id":1,"annotated sentence":"It has been claimed that <e2>hCTR1<\\e2>  the human high affinity copper transporter, is the major entry pathway for <e1>cDDP<\\e1> and related drugs via a mechanism that mimics copper","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cDDP","object":"hCTR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It has been claimed that <e2>GENE-Y<\\e2>  the human high affinity copper transporter, is the major entry pathway for <e1>CHEMICAL<\\e1> and related drugs via a mechanism that mimics copper","sentence":"It has been claimed that hCTR1  the human high affinity copper transporter, is the major entry pathway for cDDP and related drugs via a mechanism that mimics copper"}
{"PMID":23543413,"re_id":2,"annotated sentence":"It has been claimed that hCTR1, the <e2>human high affinity copper transporter<\\e2>  is the major entry pathway for <e1>cDDP<\\e1> and related drugs via a mechanism that mimics copper","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"cDDP","object":"human high affinity copper transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It has been claimed that hCTR1, the <e2>GENE-N<\\e2>  is the major entry pathway for <e1>CHEMICAL<\\e1> and related drugs via a mechanism that mimics copper","sentence":"It has been claimed that hCTR1, the human high affinity copper transporter  is the major entry pathway for cDDP and related drugs via a mechanism that mimics copper"}
{"PMID":23550028,"re_id":0,"annotated sentence":"Taken together, our study for the first time suggests that <e1>2-hydroxy-3-methylanthraquinone<\\e1> is able to enhance apoptosis of U937 cells, at least in part, through activation of <e2>p-p38MAPK<\\e2> and downregulation of p-ERK1\/2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2-hydroxy-3-methylanthraquinone","object":"p-p38MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, our study for the first time suggests that <e1>CHEMICAL<\\e1> is able to enhance apoptosis of U937 cells, at least in part, through activation of <e2>GENE-N<\\e2> and downregulation of p-ERK1\/2","sentence":"Taken together, our study for the first time suggests that 2-hydroxy-3-methylanthraquinone is able to enhance apoptosis of U937 cells, at least in part, through activation of p-p38MAPK and downregulation of p-ERK1\/2"}
{"PMID":23550028,"re_id":1,"annotated sentence":"Our results showed that <e1>2-hydroxy-3-methylanthraquinone<\\e1> decreased phosphorylation-ERK1\/2 (p-ERK1\/2), and increased <e2>p-p38MAPK<\\e2>  but did not affect expressions of p-JNK1\/2 in U937 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2-hydroxy-3-methylanthraquinone","object":"p-p38MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our results showed that <e1>CHEMICAL<\\e1> decreased phosphorylation-ERK1\/2 (p-ERK1\/2), and increased <e2>GENE-N<\\e2>  but did not affect expressions of p-JNK1\/2 in U937 cells","sentence":"Our results showed that 2-hydroxy-3-methylanthraquinone decreased phosphorylation-ERK1\/2 (p-ERK1\/2), and increased p-p38MAPK  but did not affect expressions of p-JNK1\/2 in U937 cells"}
{"PMID":23550028,"re_id":2,"annotated sentence":"Moreover, treatment of U937 cells with <e1>2-hydroxy-3-methylanthraquinone<\\e1> resulted in activation of <e2>caspase-3<\\e2>  Furthermore, PD98059 (ERK1\/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"2-hydroxy-3-methylanthraquinone","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, treatment of U937 cells with <e1>CHEMICAL<\\e1> resulted in activation of <e2>GENE-Y<\\e2>  Furthermore, PD98059 (ERK1\/2 inhibitor) significantly enhanced CHEMICAL-induced apoptosis in U937 cells, whereas GENE-Y inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells","sentence":"Moreover, treatment of U937 cells with 2-hydroxy-3-methylanthraquinone resulted in activation of caspase-3  Furthermore, PD98059 (ERK1\/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells"}
{"PMID":23550028,"re_id":3,"annotated sentence":"Furthermore, PD98059 (ERK1\/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or <e1>SB203580<\\e1> (<e2>p-p38MAPK<\\e2> inhibitor), decreased apoptosis in U937 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB203580","object":"p-p38MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, PD98059 (ERK1\/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or <e1>CHEMICAL<\\e1> (<e2>GENE-N<\\e2> inhibitor), decreased apoptosis in U937 cells","sentence":"Furthermore, PD98059 (ERK1\/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells"}
{"PMID":23550066,"re_id":0,"annotated sentence":"<e1>ThioTEPA<\\e1> (<e2>CYP2B6<\\e2> inhibitor, 25 \u03bcM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 \u03bcM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ThioTEPA","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> inhibitor, 25 \u03bcM) and the monoclonal antibody against GENE-Y but not troleandomycin (CYP3A4 inhibitor, 25 \u03bcM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations","sentence":"ThioTEPA (CYP2B6 inhibitor, 25 \u03bcM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 \u03bcM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations"}
{"PMID":23550066,"re_id":1,"annotated sentence":"ThioTEPA (CYP2B6 inhibitor, 25 \u03bcM) and the monoclonal antibody against CYP2B6 but not <e1>troleandomycin<\\e1> (<e2>CYP3A4<\\e2> inhibitor, 25 \u03bcM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"troleandomycin","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"ThioTEPA (CYP2B6 inhibitor, 25 \u03bcM) and the monoclonal antibody against CYP2B6 but not <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> inhibitor, 25 \u03bcM) or the monoclonal antibody against GENE-Y inhibited ketamine N-demethylation at clinically relevant concentrations","sentence":"ThioTEPA (CYP2B6 inhibitor, 25 \u03bcM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 \u03bcM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations"}
{"PMID":23550066,"re_id":2,"annotated sentence":"The intrinsic clearance for both <e1>ketamine<\\e1> enantiomers by the high affinity enzyme in HLMs with <e2>CYP2B6*1<\\e2> *1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1\/*6 genotype and CYP2B6*6\/*6 genotype","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ketamine","object":"CYP2B6*1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The intrinsic clearance for both <e1>CHEMICAL<\\e1> enantiomers by the high affinity enzyme in HLMs with <e2>GENE-Y<\\e2> *1 genotype were at least 2-fold and 6-fold higher, respectively, than those for GENE-Y\/*6 genotype and CYP2B6*6\/*6 genotype","sentence":"The intrinsic clearance for both ketamine enantiomers by the high affinity enzyme in HLMs with CYP2B6*1 *1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1\/*6 genotype and CYP2B6*6\/*6 genotype"}
{"PMID":23550066,"re_id":3,"annotated sentence":"The <e2>CYP2B6*6<\\e2> Allele Significantly Alters the N-demethylation of <e1>Ketamine<\\e1> Enantiomers In Vitro","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Ketamine","object":"CYP2B6*6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> Allele Significantly Alters the N-demethylation of <e1>CHEMICAL<\\e1> Enantiomers In Vitro","sentence":"The CYP2B6*6 Allele Significantly Alters the N-demethylation of Ketamine Enantiomers In Vitro"}
{"PMID":23550066,"re_id":4,"annotated sentence":"<e1>Ketamine<\\e1> is primarily metabolized to norketamine by hepatic <e2>cytochrome P450 (CYP) 2B6<\\e2> and CYP3A4-mediated N-demethylation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Ketamine","object":"cytochrome P450 (CYP) 2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is primarily metabolized to norketamine by hepatic <e2>GENE-Y<\\e2> and CYP3A4-mediated N-demethylation","sentence":"Ketamine is primarily metabolized to norketamine by hepatic cytochrome P450 (CYP) 2B6 and CYP3A4-mediated N-demethylation"}
{"PMID":23550066,"re_id":5,"annotated sentence":"<e1>Ketamine<\\e1> is primarily metabolized to norketamine by hepatic cytochrome P450 (CYP) 2B6 and <e2>CYP3A4<\\e2> mediated N-demethylation","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Ketamine","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is primarily metabolized to norketamine by hepatic cytochrome P450 (CYP) 2B6 and <e2>GENE-Y<\\e2> mediated N-demethylation","sentence":"Ketamine is primarily metabolized to norketamine by hepatic cytochrome P450 (CYP) 2B6 and CYP3A4 mediated N-demethylation"}
{"PMID":23550066,"re_id":6,"annotated sentence":"These results indicate a major role of <e2>CYP2B6<\\e2> in <e1>ketamine<\\e1> N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ketamine","object":"CYP2B6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate a major role of <e2>GENE-Y<\\e2> in <e1>CHEMICAL<\\e1> N-demethylation in vitro and a significant impact of the GENE-Y*6 allele on enzyme-CHEMICAL binding and catalytic activity.","sentence":"These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity."}
{"PMID":23550066,"re_id":7,"annotated sentence":"These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the <e2>CYP2B6*6<\\e2> allele on enzyme-<e1>ketamine<\\e1> binding and catalytic activity.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ketamine","object":"CYP2B6*6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate a major role of CYP2B6 in CHEMICAL N-demethylation in vitro and a significant impact of the <e2>GENE-Y<\\e2> allele on enzyme-<e1>CHEMICAL<\\e1> binding and catalytic activity.","sentence":"These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity."}
{"PMID":23550066,"re_id":8,"annotated sentence":"The <e2>CYP2B6*6<\\e2> allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in <e1>ketamine<\\e1> metabolism","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ketamine","object":"CYP2B6*6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in <e1>CHEMICAL<\\e1> metabolism","sentence":"The CYP2B6*6 allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in ketamine metabolism"}
{"PMID":23550066,"re_id":9,"annotated sentence":"We examined the N-demethylation of individual <e1>ketamine<\\e1> enantiomers using human liver microsomes (HLMs) genotyped for the <e2>CYP2B6*6<\\e2> allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"ketamine","object":"CYP2B6*6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We examined the N-demethylation of individual <e1>CHEMICAL<\\e1> enantiomers using human liver microsomes (HLMs) genotyped for the <e2>GENE-Y<\\e2> allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant","sentence":"We examined the N-demethylation of individual ketamine enantiomers using human liver microsomes (HLMs) genotyped for the CYP2B6*6 allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant"}
{"PMID":23551063,"re_id":0,"annotated sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>HFC<\\e1> glucuronidation catalysts were <e2>UGT1A10<\\e2> followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HFC","object":"UGT1A10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>CHEMICAL<\\e1> glucuronidation catalysts were <e2>GENE-Y<\\e2> followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs","sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs"}
{"PMID":23551063,"re_id":1,"annotated sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>HFC<\\e1> glucuronidation catalysts were UGT1A10 followed by <e2>UGT1A6<\\e2> >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HFC","object":"UGT1A6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>CHEMICAL<\\e1> glucuronidation catalysts were UGT1A10 followed by <e2>GENE-Y<\\e2> >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M GENE-Y was about 10 times better catalyst than the other recombinant UGTs","sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs"}
{"PMID":23551063,"re_id":2,"annotated sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>HFC<\\e1> glucuronidation catalysts were UGT1A10 followed by UGT1A6 ><e2>UGT1A7<\\e2> >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HFC","object":"UGT1A7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>CHEMICAL<\\e1> glucuronidation catalysts were UGT1A10 followed by UGT1A6 ><e2>GENE-Y<\\e2> >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs","sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs"}
{"PMID":23551063,"re_id":3,"annotated sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>HFC<\\e1> glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 ><e2>UGT2A1<\\e2>  whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HFC","object":"UGT2A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>CHEMICAL<\\e1> glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 ><e2>GENE-Y<\\e2>  whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs","sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1  whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs"}
{"PMID":23551063,"re_id":4,"annotated sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>HFC<\\e1> glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M <e2>UGT1A6<\\e2> was about 10 times better catalyst than the other recombinant UGTs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HFC","object":"UGT1A6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>CHEMICAL<\\e1> glucuronidation catalysts were UGT1A10 followed by GENE-Y >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M <e2>GENE-Y<\\e2> was about 10 times better catalyst than the other recombinant UGTs","sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs"}
{"PMID":23551063,"re_id":5,"annotated sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>HFC<\\e1> glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant <e2>UGTs<\\e2>  The activities of UGTs 1A3, 1A8, 1A9, 2B4 and 2B7 were low, whereas UGT1A1 and UGT2B17 exhibited no HFC glucuronidation activity","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HFC","object":"UGTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active <e1>CHEMICAL<\\e1> glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant <e2>GENE-N<\\e2>  The activities of GENE-N 1A3, 1A8, 1A9, 2B4 and 2B7 were low, whereas UGT1A1 and UGT2B17 exhibited no CHEMICAL glucuronidation activity","sentence":"4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs  The activities of UGTs 1A3, 1A8, 1A9, 2B4 and 2B7 were low, whereas UGT1A1 and UGT2B17 exhibited no HFC glucuronidation activity"}
{"PMID":23551063,"re_id":6,"annotated sentence":"A high throughput assay for the glucuronidation of <e1>7-hydroxy-4-trifluoromethylcoumarin<\\e1> by recombinant <e2>human UDP-glucuronosyltransferases<\\e2> and liver microsomes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"7-hydroxy-4-trifluoromethylcoumarin","object":"human UDP-glucuronosyltransferases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A high throughput assay for the glucuronidation of <e1>CHEMICAL<\\e1> by recombinant <e2>GENE-N<\\e2> and liver microsomes","sentence":"A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes"}
{"PMID":23551063,"re_id":7,"annotated sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both <e1>HFC<\\e1> and UDP-glucuronic acid than the other <e2>UGTs<\\e2>  5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HFC","object":"UGTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both <e1>CHEMICAL<\\e1> and UDP-glucuronic acid than the other <e2>GENE-N<\\e2>  5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed CHEMICAL glucuronidation at high rates","sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs  5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates"}
{"PMID":23551063,"re_id":8,"annotated sentence":"<e2>UGT1A6<\\e2> exhibited a significantly higher Vmax and Km values toward both <e1>HFC<\\e1> and UDP-glucuronic acid than the other UGTs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HFC","object":"UGT1A6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> exhibited a significantly higher Vmax and Km values toward both <e1>CHEMICAL<\\e1> and UDP-glucuronic acid than the other UGTs","sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs"}
{"PMID":23551063,"re_id":9,"annotated sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and <e1>UDP<\\e1> glucuronic acid than the other <e2>UGTs<\\e2>  5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"UDP","object":"UGTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and <e1>CHEMICAL<\\e1> glucuronic acid than the other <e2>GENE-N<\\e2>  5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates","sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP glucuronic acid than the other UGTs  5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates"}
{"PMID":23551063,"re_id":10,"annotated sentence":"<e2>UGT1A6<\\e2> exhibited a significantly higher Vmax and Km values toward both HFC and <e1>UDP<\\e1> glucuronic acid than the other UGTs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"UDP","object":"UGT1A6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> exhibited a significantly higher Vmax and Km values toward both HFC and <e1>CHEMICAL<\\e1> glucuronic acid than the other UGTs","sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP glucuronic acid than the other UGTs"}
{"PMID":23551063,"re_id":11,"annotated sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-<e1>glucuronic acid<\\e1> than the other <e2>UGTs<\\e2>  5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glucuronic acid","object":"UGTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-<e1>CHEMICAL<\\e1> than the other <e2>GENE-N<\\e2>  5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates","sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs  5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates"}
{"PMID":23551063,"re_id":12,"annotated sentence":"<e2>UGT1A6<\\e2> exhibited a significantly higher Vmax and Km values toward both HFC and UDP-<e1>glucuronic acid<\\e1> than the other UGTs","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"glucuronic acid","object":"UGT1A6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> exhibited a significantly higher Vmax and Km values toward both HFC and UDP-<e1>CHEMICAL<\\e1> than the other UGTs","sentence":"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs"}
{"PMID":23551063,"re_id":13,"annotated sentence":"2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of <e1>7-hydroxy-4-trifluoromethylcoumarin<\\e1> (HFC) for several <e2>UGTs<\\e2>  3.\u2002 We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"7-hydroxy-4-trifluoromethylcoumarin","object":"UGTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of <e1>CHEMICAL<\\e1> (HFC) for several <e2>GENE-N<\\e2>  3.\u2002 We have used this method to screen 11 recombinant human GENE-N for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes","sentence":"2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs  3.\u2002 We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes"}
{"PMID":23551063,"re_id":14,"annotated sentence":"2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (<e1>HFC<\\e1>  for several <e2>UGTs<\\e2>  3.\u2002 We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HFC","object":"UGTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (<e1>CHEMICAL<\\e1>  for several <e2>GENE-N<\\e2>  3.\u2002 We have used this method to screen 11 recombinant human GENE-N for CHEMICAL glucuronidation activity and studied the reaction kinetics with the most active enzymes","sentence":"2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC  for several UGTs  3.\u2002 We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes"}
{"PMID":23551063,"re_id":15,"annotated sentence":"3.\u2002 We have used this method to screen 11 recombinant <e2>human UGTs<\\e2> for <e1>HFC<\\e1> glucuronidation activity and studied the reaction kinetics with the most active enzymes","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"HFC","object":"human UGTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"3.\u2002 We have used this method to screen 11 recombinant <e2>GENE-N<\\e2> for <e1>CHEMICAL<\\e1> glucuronidation activity and studied the reaction kinetics with the most active enzymes","sentence":"3.\u2002 We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes"}
{"PMID":23551329,"re_id":0,"annotated sentence":"In PFC, <e1>DEX<\\e1> caused activation of <e2>AKT<\\e2>  augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2\/Bax protein ratio, as well Bcl-2 translocation to mitochondria","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In PFC, <e1>CHEMICAL<\\e1> caused activation of <e2>GENE-N<\\e2>  augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2\/Bax protein ratio, as well Bcl-2 translocation to mitochondria","sentence":"In PFC, DEX caused activation of AKT  augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2\/Bax protein ratio, as well Bcl-2 translocation to mitochondria"}
{"PMID":23551329,"re_id":1,"annotated sentence":"In PFC, <e1>DEX<\\e1> caused activation of AKT, augmentation of pro-survival <e2>Bcl-2<\\e2> protein and enhanced Bcl-2\/Bax protein ratio, as well Bcl-2 translocation to mitochondria","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In PFC, <e1>CHEMICAL<\\e1> caused activation of AKT, augmentation of pro-survival <e2>GENE-Y<\\e2> protein and enhanced GENE-Y\/Bax protein ratio, as well GENE-Y translocation to mitochondria","sentence":"In PFC, DEX caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2\/Bax protein ratio, as well Bcl-2 translocation to mitochondria"}
{"PMID":23551329,"re_id":2,"annotated sentence":"In PFC, <e1>DEX<\\e1> caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced <e2>Bcl-2<\\e2> Bax protein ratio, as well Bcl-2 translocation to mitochondria","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In PFC, <e1>CHEMICAL<\\e1> caused activation of AKT, augmentation of pro-survival GENE-Y protein and enhanced <e2>GENE-Y<\\e2> Bax protein ratio, as well GENE-Y translocation to mitochondria","sentence":"In PFC, DEX caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2 Bax protein ratio, as well Bcl-2 translocation to mitochondria"}
{"PMID":23551329,"re_id":3,"annotated sentence":"In PFC, <e1>DEX<\\e1> caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2\/<e2>Bax<\\e2> protein ratio, as well Bcl-2 translocation to mitochondria","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In PFC, <e1>CHEMICAL<\\e1> caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2\/<e2>GENE-Y<\\e2> protein ratio, as well Bcl-2 translocation to mitochondria","sentence":"In PFC, DEX caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2\/Bax protein ratio, as well Bcl-2 translocation to mitochondria"}
{"PMID":23551329,"re_id":4,"annotated sentence":"Results of RT-PCR analysis showed decrease of <e2>p53<\\e2> mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in <e1>DEX<\\e1> treated rats","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results of RT-PCR analysis showed decrease of <e2>GENE-Y<\\e2> mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in <e1>CHEMICAL<\\e1> treated rats","sentence":"Results of RT-PCR analysis showed decrease of p53 mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in DEX treated rats"}
{"PMID":23552101,"re_id":0,"annotated sentence":"<e2>PIP5K1B<\\e2> encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate <e1>phosphatidylinositol-4,5-bisphosphate<\\e1> [PI(4,5)P2]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phosphatidylinositol-4,5-bisphosphate","object":"PIP5K1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate <e1>CHEMICAL<\\e1> [PI(4,5)P2]","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]"}
{"PMID":23552101,"re_id":1,"annotated sentence":"PIP5K1B encodes <e2>phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I<\\e2> (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate <e1>phosphatidylinositol-4,5-bisphosphate<\\e1> [PI(4,5)P2]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phosphatidylinositol-4,5-bisphosphate","object":"phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PIP5K1B encodes <e2>GENE-Y<\\e2> (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate <e1>CHEMICAL<\\e1> [PI(4,5)P2]","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]"}
{"PMID":23552101,"re_id":2,"annotated sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (<e2>pip5k1\u03b2<\\e2> , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate <e1>phosphatidylinositol-4,5-bisphosphate<\\e1> [PI(4,5)P2]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phosphatidylinositol-4,5-bisphosphate","object":"pip5k1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (<e2>GENE-Y<\\e2> , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate <e1>CHEMICAL<\\e1> [PI(4,5)P2]","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2 , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]"}
{"PMID":23552101,"re_id":3,"annotated sentence":"<e2>PIP5K1B<\\e2> encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [<e1>PI(4,5)P2<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PI(4,5)P2","object":"PIP5K1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [<e1>CHEMICAL<\\e1> ","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2 "}
{"PMID":23552101,"re_id":4,"annotated sentence":"PIP5K1B encodes <e2>phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I<\\e2> (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [<e1>PI(4,5)P2<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PI(4,5)P2","object":"phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PIP5K1B encodes <e2>GENE-Y<\\e2> (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [<e1>CHEMICAL<\\e1> ","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2 "}
{"PMID":23552101,"re_id":5,"annotated sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (<e2>pip5k1\u03b2<\\e2> , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [<e1>PI(4,5)P2<\\e1> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PI(4,5)P2","object":"pip5k1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (<e2>GENE-Y<\\e2> , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [<e1>CHEMICAL<\\e1> ","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2 , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2 "}
{"PMID":23552101,"re_id":6,"annotated sentence":"Accordingly, loss of <e2>pip5k1\u03b2<\\e2> function in FRDA cells was accompanied by decreased <e1>PI(4,5)P2<\\e1> levels and was shown instrumental for destabilization of the actin network and delayed cell spreading","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PI(4,5)P2","object":"pip5k1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Accordingly, loss of <e2>GENE-Y<\\e2> function in FRDA cells was accompanied by decreased <e1>CHEMICAL<\\e1> levels and was shown instrumental for destabilization of the actin network and delayed cell spreading","sentence":"Accordingly, loss of pip5k1\u03b2 function in FRDA cells was accompanied by decreased PI(4,5)P2 levels and was shown instrumental for destabilization of the actin network and delayed cell spreading"}
{"PMID":23552101,"re_id":7,"annotated sentence":"<e2>PIP5K1B<\\e2> encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates <e1>phosphatidylinositol 4-phosphate<\\e1> [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phosphatidylinositol 4-phosphate","object":"PIP5K1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> encodes CHEMICAL 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates <e1>CHEMICAL<\\e1> [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]"}
{"PMID":23552101,"re_id":8,"annotated sentence":"PIP5K1B encodes <e2>phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I<\\e2> (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates <e1>phosphatidylinositol 4-phosphate<\\e1> [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phosphatidylinositol 4-phosphate","object":"phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PIP5K1B encodes <e2>CHEMICAL 5-kinase \u03b2 type I<\\e2> (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates <e1>CHEMICAL<\\e1> [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]"}
{"PMID":23552101,"re_id":9,"annotated sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (<e2>pip5k1\u03b2<\\e2> , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates <e1>phosphatidylinositol 4-phosphate<\\e1> [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"phosphatidylinositol 4-phosphate","object":"pip5k1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PIP5K1B encodes CHEMICAL 5-kinase \u03b2 type I (<e2>GENE-Y<\\e2> , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates <e1>CHEMICAL<\\e1> [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2 , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]"}
{"PMID":23552101,"re_id":10,"annotated sentence":"<e2>PIP5K1B<\\e2> encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [<e1>PI(4)P<\\e1>  to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PI(4)P","object":"PIP5K1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [<e1>CHEMICAL<\\e1>  to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P  to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]"}
{"PMID":23552101,"re_id":11,"annotated sentence":"PIP5K1B encodes <e2>phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I<\\e2> (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [<e1>PI(4)P<\\e1>  to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PI(4)P","object":"phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PIP5K1B encodes <e2>GENE-Y<\\e2> (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [<e1>CHEMICAL<\\e1>  to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P  to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]"}
{"PMID":23552101,"re_id":12,"annotated sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (<e2>pip5k1\u03b2<\\e2> , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [<e1>PI(4)P<\\e1>  to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PI(4)P","object":"pip5k1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (<e2>GENE-Y<\\e2> , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [<e1>CHEMICAL<\\e1>  to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]","sentence":"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2 , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P  to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]"}
{"PMID":23552263,"re_id":0,"annotated sentence":"Regarding <e2>urease<\\e2> inhibition, <e1>n-butanol<\\e1> was the most potent fraction (IC50: 97 \u00b5g\/mL)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"n-butanol","object":"urease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Regarding <e2>GENE-N<\\e2> inhibition, <e1>CHEMICAL<\\e1> was the most potent fraction (IC50: 97 \u00b5g\/mL)","sentence":"Regarding urease inhibition, n-butanol was the most potent fraction (IC50: 97 \u00b5g\/mL)"}
{"PMID":23552851,"re_id":0,"annotated sentence":"Treatment of A549 and H1299 cells with <e1>dioscin<\\e1> caused a dose-dependent increase in ERK1\/2 and <e2>JNK1\/2<\\e2> activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"dioscin","object":"JNK1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment of A549 and H1299 cells with <e1>CHEMICAL<\\e1> caused a dose-dependent increase in ERK1\/2 and <e2>GENE-N<\\e2> activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR","sentence":"Treatment of A549 and H1299 cells with dioscin caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR"}
{"PMID":23552851,"re_id":1,"annotated sentence":"Treatment of A549 and H1299 cells with <e1>dioscin<\\e1> caused a dose-dependent increase in <e2>ERK1\/2<\\e2> and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"dioscin","object":"ERK1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment of A549 and H1299 cells with <e1>CHEMICAL<\\e1> caused a dose-dependent increase in <e2>GENE-N<\\e2> and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR","sentence":"Treatment of A549 and H1299 cells with dioscin caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR"}
{"PMID":23552851,"re_id":2,"annotated sentence":"Meanwhile, autophagy was detected as early as 12\u00a0h after an exposure to low-dose <e1>dioscin<\\e1>  as indicated by an up-regulated expression of <e2>LC3-II<\\e2> and beclin-1 proteins","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"dioscin","object":"LC3-II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Meanwhile, autophagy was detected as early as 12\u00a0h after an exposure to low-dose <e1>CHEMICAL<\\e1>  as indicated by an up-regulated expression of <e2>GENE-Y<\\e2> and beclin-1 proteins","sentence":"Meanwhile, autophagy was detected as early as 12\u00a0h after an exposure to low-dose dioscin  as indicated by an up-regulated expression of LC3-II and beclin-1 proteins"}
{"PMID":23552851,"re_id":3,"annotated sentence":"Meanwhile, autophagy was detected as early as 12\u00a0h after an exposure to low-dose <e1>dioscin<\\e1>  as indicated by an up-regulated expression of LC3-II and <e2>beclin-1<\\e2> proteins","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"dioscin","object":"beclin-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Meanwhile, autophagy was detected as early as 12\u00a0h after an exposure to low-dose <e1>CHEMICAL<\\e1>  as indicated by an up-regulated expression of LC3-II and <e2>GENE-Y<\\e2> proteins","sentence":"Meanwhile, autophagy was detected as early as 12\u00a0h after an exposure to low-dose dioscin  as indicated by an up-regulated expression of LC3-II and beclin-1 proteins"}
{"PMID":23552851,"re_id":4,"annotated sentence":"Treatment of A549 and H1299 cells with <e1>dioscin<\\e1> caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased <e2>PI3K<\\e2> expression and decreased phosphorylation of Akt and mTOR","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dioscin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment of A549 and H1299 cells with <e1>CHEMICAL<\\e1> caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased <e2>GENE-N<\\e2> expression and decreased phosphorylation of Akt and mTOR","sentence":"Treatment of A549 and H1299 cells with dioscin caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR"}
{"PMID":23552851,"re_id":5,"annotated sentence":"Treatment of A549 and H1299 cells with <e1>dioscin<\\e1> caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of <e2>Akt<\\e2> and mTOR","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dioscin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment of A549 and H1299 cells with <e1>CHEMICAL<\\e1> caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of <e2>GENE-N<\\e2> and mTOR","sentence":"Treatment of A549 and H1299 cells with dioscin caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR"}
{"PMID":23552851,"re_id":6,"annotated sentence":"Treatment of A549 and H1299 cells with <e1>dioscin<\\e1> caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and <e2>mTOR<\\e2>  Taken together, this study demonstrated for the first time that autophagy occurred earlier than apoptosis during dioscin-induced human lung cancer cell line apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dioscin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment of A549 and H1299 cells with <e1>CHEMICAL<\\e1> caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and <e2>GENE-N<\\e2>  Taken together, this study demonstrated for the first time that autophagy occurred earlier than apoptosis during CHEMICAL-induced human lung cancer cell line apoptosis","sentence":"Treatment of A549 and H1299 cells with dioscin caused a dose-dependent increase in ERK1\/2 and JNK1\/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR  Taken together, this study demonstrated for the first time that autophagy occurred earlier than apoptosis during dioscin-induced human lung cancer cell line apoptosis"}
{"PMID":23557706,"re_id":0,"annotated sentence":"High <e1>glucose<\\e1> (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates <e2>mTOR<\\e2>  HG also increases the levels of Nox4 and Nox1 and NADPH oxidase activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"glucose","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"High <e1>CHEMICAL<\\e1> (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates <e2>GENE-Y<\\e2>  HG also increases the levels of Nox4 and Nox1 and NADPH oxidase activity","sentence":"High glucose (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates mTOR  HG also increases the levels of Nox4 and Nox1 and NADPH oxidase activity"}
{"PMID":23557706,"re_id":1,"annotated sentence":"Pharmacological doses of the <e2>mTOR<\\e2> inhibitor <e1>rapamycin<\\e1> reduce albuminura in diabetes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rapamycin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological doses of the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> reduce albuminura in diabetes","sentence":"Pharmacological doses of the mTOR inhibitor rapamycin reduce albuminura in diabetes"}
{"PMID":23557706,"re_id":2,"annotated sentence":"High <e1>glucose<\\e1> (HG) induces apoptosis of podocytes, inhibits <e2>AMPK<\\e2> activation, inactivates tuberin and activates mTOR","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucose","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"High <e1>CHEMICAL<\\e1> (HG) induces apoptosis of podocytes, inhibits <e2>GENE-N<\\e2> activation, inactivates tuberin and activates mTOR","sentence":"High glucose (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates mTOR"}
{"PMID":23557706,"re_id":3,"annotated sentence":"High <e1>glucose<\\e1> (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates <e2>tuberin<\\e2> and activates mTOR","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"glucose","object":"tuberin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"High <e1>CHEMICAL<\\e1> (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates <e2>GENE-Y<\\e2> and activates mTOR","sentence":"High glucose (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates mTOR"}
{"PMID":23557706,"re_id":4,"annotated sentence":"Inhibition of <e2>mTOR<\\e2> by low dose <e1>rapamycin<\\e1> decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rapamycin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> by low dose <e1>CHEMICAL<\\e1> decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis","sentence":"Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis"}
{"PMID":23557706,"re_id":5,"annotated sentence":"Inhibition of mTOR by low dose <e1>rapamycin<\\e1> decreases HG-induced <e2>Nox4<\\e2> and Nox1, NADPH oxidase activity and podocyte apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rapamycin","object":"Nox4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of mTOR by low dose <e1>CHEMICAL<\\e1> decreases HG-induced <e2>GENE-Y<\\e2> and Nox1, NADPH oxidase activity and podocyte apoptosis","sentence":"Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis"}
{"PMID":23557706,"re_id":6,"annotated sentence":"Inhibition of mTOR by low dose <e1>rapamycin<\\e1> decreases HG-induced Nox4 and <e2>Nox1<\\e2>  NADPH oxidase activity and podocyte apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rapamycin","object":"Nox1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of mTOR by low dose <e1>CHEMICAL<\\e1> decreases HG-induced Nox4 and <e2>GENE-Y<\\e2>  NADPH oxidase activity and podocyte apoptosis","sentence":"Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1  NADPH oxidase activity and podocyte apoptosis"}
{"PMID":23557706,"re_id":7,"annotated sentence":"Inhibition of mTOR by low dose <e1>rapamycin<\\e1> decreases HG-induced Nox4 and Nox1, <e2>NADPH oxidase<\\e2> activity and podocyte apoptosis","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rapamycin","object":"NADPH oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of mTOR by low dose <e1>CHEMICAL<\\e1> decreases HG-induced Nox4 and Nox1, <e2>GENE-N<\\e2> activity and podocyte apoptosis","sentence":"Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis"}
{"PMID":23557706,"re_id":8,"annotated sentence":"Inhibition of <e2>mTOR<\\e2> by small dose of <e1>rapamycin<\\e1> reduces podocyte apoptosis, attenuates glomerular injury and albuminuria","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rapamycin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> by small dose of <e1>CHEMICAL<\\e1> reduces podocyte apoptosis, attenuates glomerular injury and albuminuria","sentence":"Inhibition of mTOR by small dose of rapamycin reduces podocyte apoptosis, attenuates glomerular injury and albuminuria"}
{"PMID":23563205,"re_id":0,"annotated sentence":"Correlation between activation of <e2>PPAR\u03b3<\\e2> and resistin downregulation in a mouse adipocyte cell line by a series of <e1>thiazolidinediones<\\e1>  The present study shows significant correlations between the EC50 for PPAR\u03b3 activation in a reporter gene cell line and resistin downregulation in mouse adipocytes, and between the IC50 for resistin downregulation and the already published minimum effective dose for antihyperglycemic activity in a mouse model","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"thiazolidinediones","object":"PPAR\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Correlation between activation of <e2>GENE-Y<\\e2> and resistin downregulation in a mouse adipocyte cell line by a series of <e1>CHEMICAL<\\e1>  The present study shows significant correlations between the EC50 for GENE-Y activation in a reporter gene cell line and resistin downregulation in mouse adipocytes, and between the IC50 for resistin downregulation and the already published minimum effective dose for antihyperglycemic activity in a mouse model","sentence":"Correlation between activation of PPAR\u03b3 and resistin downregulation in a mouse adipocyte cell line by a series of thiazolidinediones  The present study shows significant correlations between the EC50 for PPAR\u03b3 activation in a reporter gene cell line and resistin downregulation in mouse adipocytes, and between the IC50 for resistin downregulation and the already published minimum effective dose for antihyperglycemic activity in a mouse model"}
{"PMID":23563205,"re_id":1,"annotated sentence":"Correlation between activation of PPAR\u03b3 and <e2>resistin<\\e2> downregulation in a mouse adipocyte cell line by a series of <e1>thiazolidinediones<\\e1>  The present study shows significant correlations between the EC50 for PPAR\u03b3 activation in a reporter gene cell line and resistin downregulation in mouse adipocytes, and between the IC50 for resistin downregulation and the already published minimum effective dose for antihyperglycemic activity in a mouse model","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"thiazolidinediones","object":"resistin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Correlation between activation of PPAR\u03b3 and <e2>GENE-Y<\\e2> downregulation in a mouse adipocyte cell line by a series of <e1>CHEMICAL<\\e1>  The present study shows significant correlations between the EC50 for PPAR\u03b3 activation in a reporter gene cell line and GENE-Y downregulation in mouse adipocytes, and between the IC50 for GENE-Y downregulation and the already published minimum effective dose for antihyperglycemic activity in a mouse model","sentence":"Correlation between activation of PPAR\u03b3 and resistin downregulation in a mouse adipocyte cell line by a series of thiazolidinediones  The present study shows significant correlations between the EC50 for PPAR\u03b3 activation in a reporter gene cell line and resistin downregulation in mouse adipocytes, and between the IC50 for resistin downregulation and the already published minimum effective dose for antihyperglycemic activity in a mouse model"}
{"PMID":23564313,"re_id":0,"annotated sentence":"In addition, <e1>vinblastine<\\e1> induces the DNA-binding activities of the transcription factor <e2>NF-\u03baB<\\e2>  HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induces the DNA-binding activities of the transcription factor <e2>GENE-N<\\e2>  HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins","sentence":"In addition, vinblastine induces the DNA-binding activities of the transcription factor NF-\u03baB  HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins"}
{"PMID":23564313,"re_id":1,"annotated sentence":"In addition, <e1>vinblastine<\\e1> induces the DNA-binding activities of the transcription factor NF-\u03baB, <e2>HSF1<\\e2>  AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"HSF1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induces the DNA-binding activities of the transcription factor NF-\u03baB, <e2>GENE-Y<\\e2>  AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins","sentence":"In addition, vinblastine induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1  AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins"}
{"PMID":23564313,"re_id":2,"annotated sentence":"In addition, <e1>vinblastine<\\e1> induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, <e2>AP-1<\\e2>  and ATF-2, together with the expression of HSP70 and Bax proteins","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"AP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, <e2>GENE-Y<\\e2>  and ATF-2, together with the expression of HSP70 and Bax proteins","sentence":"In addition, vinblastine induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1  and ATF-2, together with the expression of HSP70 and Bax proteins"}
{"PMID":23564313,"re_id":3,"annotated sentence":"In addition, <e1>vinblastine<\\e1> induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and <e2>ATF-2<\\e2>  together with the expression of HSP70 and Bax proteins","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"ATF-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and <e2>GENE-Y<\\e2>  together with the expression of HSP70 and Bax proteins","sentence":"In addition, vinblastine induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2  together with the expression of HSP70 and Bax proteins"}
{"PMID":23564313,"re_id":4,"annotated sentence":"In addition, <e1>vinblastine<\\e1> induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of <e2>HSP70<\\e2> and Bax proteins","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"HSP70","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of <e2>GENE-N<\\e2> and Bax proteins","sentence":"In addition, vinblastine induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins"}
{"PMID":23564313,"re_id":5,"annotated sentence":"In addition, <e1>vinblastine<\\e1> induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and <e2>Bax<\\e2> proteins","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and <e2>GENE-Y<\\e2> proteins","sentence":"In addition, vinblastine induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins"}
{"PMID":23564313,"re_id":6,"annotated sentence":"Also, <e1>vinblastine<\\e1> enhances the phosphorylation of <e2>Ras homologous protein A<\\e2>  the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"Ras homologous protein A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, <e1>CHEMICAL<\\e1> enhances the phosphorylation of <e2>GENE-Y<\\e2>  the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1","sentence":"Also, vinblastine enhances the phosphorylation of Ras homologous protein A  the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1"}
{"PMID":23564313,"re_id":7,"annotated sentence":"Also, <e1>vinblastine<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of <e2>apoptosis signal-regulating kinase 1<\\e2>  c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"apoptosis signal-regulating kinase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, <e1>CHEMICAL<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of <e2>GENE-Y<\\e2>  c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1","sentence":"Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1  c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1"}
{"PMID":23564313,"re_id":8,"annotated sentence":"Also, <e1>vinblastine<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, <e2>c-jun-N-terminal kinase<\\e2>  p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"c-jun-N-terminal kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Also, <e1>CHEMICAL<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, <e2>GENE-N<\\e2>  p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1","sentence":"Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase  p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1"}
{"PMID":23564313,"re_id":9,"annotated sentence":"Also, <e1>vinblastine<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, <e2>p38<\\e2>  inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Also, <e1>CHEMICAL<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, <e2>GENE-N<\\e2>  inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1","sentence":"Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38  inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1"}
{"PMID":23564313,"re_id":10,"annotated sentence":"Also, <e1>vinblastine<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, <e2>inhibitor of kappaB\u03b1<\\e2> (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"inhibitor of kappaB\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, <e1>CHEMICAL<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, <e2>GENE-Y<\\e2> (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1","sentence":"Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1"}
{"PMID":23564313,"re_id":11,"annotated sentence":"Also, <e1>vinblastine<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (<e2>I\u03baB\u03b1<\\e2>  kinase, and inositol requiring enzyme 1\u03b1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"I\u03baB\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, <e1>CHEMICAL<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (<e2>GENE-Y<\\e2>  kinase, and inositol requiring enzyme 1\u03b1","sentence":"Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1  kinase, and inositol requiring enzyme 1\u03b1"}
{"PMID":23564313,"re_id":12,"annotated sentence":"Also, <e1>vinblastine<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) <e2>kinase<\\e2>  and inositol requiring enzyme 1\u03b1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Also, <e1>CHEMICAL<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating GENE-N 1, c-jun-N-terminal GENE-N, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) <e2>GENE-N<\\e2>  and inositol requiring enzyme 1\u03b1","sentence":"Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase  and inositol requiring enzyme 1\u03b1"}
{"PMID":23564313,"re_id":13,"annotated sentence":"Also, <e1>vinblastine<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and <e2>inositol requiring enzyme 1\u03b1<\\e2>  In addition, vinblastine induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"vinblastine","object":"inositol requiring enzyme 1\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, <e1>CHEMICAL<\\e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and <e2>GENE-Y<\\e2>  In addition, CHEMICAL induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins","sentence":"Also, vinblastine enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1  In addition, vinblastine induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins"}
{"PMID":23567950,"re_id":0,"annotated sentence":"In further evaluation, the representative compound <e1>N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide<\\e1> (3b) exhibited potent pro-apoptotic activity, through <e2>RhoB<\\e2> activation, in HeLa cells.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide","object":"RhoB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In further evaluation, the representative compound <e1>CHEMICAL<\\e1> (3b) exhibited potent pro-apoptotic activity, through <e2>GENE-Y<\\e2> activation, in HeLa cells.","sentence":"In further evaluation, the representative compound N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide (3b) exhibited potent pro-apoptotic activity, through RhoB activation, in HeLa cells."}
{"PMID":23570914,"re_id":0,"annotated sentence":"To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative <e2>Nrf2<\\e2> activator, <e1>caffeic acid phenethyl ester<\\e1>  and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"caffeic acid phenethyl ester","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate GENE-Y and related antioxidant proteins in bleomycin-treated fibroblasts using a putative <e2>GENE-Y<\\e2> activator, <e1>CHEMICAL<\\e1>  and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance","sentence":"To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester  and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance"}
{"PMID":23570914,"re_id":1,"annotated sentence":"In a cell-based model, <e1>bleomycin<\\e1> suppressed Nrf2 activation via <e2>extracellular signal-related kinase<\\e2> phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bleomycin","object":"extracellular signal-related kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In a cell-based model, <e1>CHEMICAL<\\e1> suppressed Nrf2 activation via <e2>GENE-N<\\e2> phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion","sentence":"In a cell-based model, bleomycin suppressed Nrf2 activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion"}
{"PMID":23570914,"re_id":2,"annotated sentence":"To confirm this novel mechanism of <e1>bleomycin<\\e1> induced fibrogenesis, we attempted to upregulate <e2>Nrf2<\\e2> and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"bleomycin","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To confirm this novel mechanism of <e1>CHEMICAL<\\e1> induced fibrogenesis, we attempted to upregulate <e2>GENE-Y<\\e2> and related antioxidant proteins in CHEMICAL-treated fibroblasts using a putative GENE-Y activator, caffeic acid phenethyl ester, and the results showed that CHEMICAL-induced fibroblast proliferation and collagen content were attenuated through improved redox balance","sentence":"To confirm this novel mechanism of bleomycin induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance"}
{"PMID":23570914,"re_id":3,"annotated sentence":"Treatment of C57 BL\/6 mice with <e1>bleomycin<\\e1> increased fibroblast viability and collagen production and significantly downregulated <e2>Nrf2<\\e2>  In addition, prominent oxidative stress was indicated by changes in superoxide dismutase, catalase activity, and glutathione and thiobarbituric acid-reactive substance levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bleomycin","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment of C57 BL\/6 mice with <e1>CHEMICAL<\\e1> increased fibroblast viability and collagen production and significantly downregulated <e2>GENE-N<\\e2>  In addition, prominent oxidative stress was indicated by changes in superoxide dismutase, catalase activity, and glutathione and thiobarbituric acid-reactive substance levels","sentence":"Treatment of C57 BL\/6 mice with bleomycin increased fibroblast viability and collagen production and significantly downregulated Nrf2  In addition, prominent oxidative stress was indicated by changes in superoxide dismutase, catalase activity, and glutathione and thiobarbituric acid-reactive substance levels"}
{"PMID":23570914,"re_id":4,"annotated sentence":"In a cell-based model, <e1>bleomycin<\\e1> suppressed <e2>Nrf2<\\e2> activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"bleomycin","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In a cell-based model, <e1>CHEMICAL<\\e1> suppressed <e2>GENE-Y<\\e2> activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion","sentence":"In a cell-based model, bleomycin suppressed Nrf2 activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion"}
{"PMID":23574017,"re_id":0,"annotated sentence":"The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic <e2>CYP3A<\\e2> subfamily-mediated metabolism (21.9% decrease) of <e1>doxorubicin<\\e1>  These results might have broader implications to understand the altered pharmacokinetics and\/or pharmacologic effects of doxorubicin via biliary excretion and hepatic metabolism in experimental and clinical estrogen-induced cholestasis.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"doxorubicin","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic <e2>GENE-N<\\e2> subfamily-mediated metabolism (21.9% decrease) of <e1>CHEMICAL<\\e1>  These results might have broader implications to understand the altered pharmacokinetics and\/or pharmacologic effects of CHEMICAL via biliary excretion and hepatic metabolism in experimental and clinical estrogen-induced cholestasis.","sentence":"The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic CYP3A subfamily-mediated metabolism (21.9% decrease) of doxorubicin  These results might have broader implications to understand the altered pharmacokinetics and\/or pharmacologic effects of doxorubicin via biliary excretion and hepatic metabolism in experimental and clinical estrogen-induced cholestasis."}
{"PMID":23574017,"re_id":1,"annotated sentence":"<e1>Doxorubicin<\\e1> is mainly excreted into the bile via <e2>P-glycoprotein<\\e2> (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Doxorubicin","object":"P-glycoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is mainly excreted into the bile via <e2>GENE-N<\\e2> (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily","sentence":"Doxorubicin is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily"}
{"PMID":23574017,"re_id":2,"annotated sentence":"<e1>Doxorubicin<\\e1> is mainly excreted into the bile via P-glycoprotein (<e2>P-gp<\\e2>  and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Doxorubicin","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is mainly excreted into the bile via P-glycoprotein (<e2>GENE-N<\\e2>  and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily","sentence":"Doxorubicin is mainly excreted into the bile via P-glycoprotein (P-gp  and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily"}
{"PMID":23574017,"re_id":3,"annotated sentence":"<e1>Doxorubicin<\\e1> is mainly excreted into the bile via P-glycoprotein (P-gp) and <e2>multidrug resistance-associated protein 2<\\e2> (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Doxorubicin","object":"multidrug resistance-associated protein 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is mainly excreted into the bile via P-glycoprotein (P-gp) and <e2>GENE-Y<\\e2> (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily","sentence":"Doxorubicin is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily"}
{"PMID":23574017,"re_id":4,"annotated sentence":"<e1>Doxorubicin<\\e1> is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (<e2>Mrp2<\\e2>  in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Doxorubicin","object":"Mrp2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (<e2>GENE-Y<\\e2>  in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily","sentence":"Doxorubicin is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2  in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily"}
{"PMID":23574017,"re_id":5,"annotated sentence":"<e1>Doxorubicin<\\e1> is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via <e2>cytochrome P450 (CYP) 3A<\\e2> subfamily","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Doxorubicin","object":"cytochrome P450 (CYP) 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via <e2>GENE-N<\\e2> subfamily","sentence":"Doxorubicin is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily"}
{"PMID":23578390,"re_id":0,"annotated sentence":"Exposure of cells to 4mM <e1>NaF<\\e1> for 24h induced <e2>caspase-3<\\e2> activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"NaF","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exposure of cells to 4mM <e1>CHEMICAL<\\e1> for 24h induced <e2>GENE-Y<\\e2> activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent","sentence":"Exposure of cells to 4mM NaF for 24h induced caspase-3 activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent"}
{"PMID":23578390,"re_id":1,"annotated sentence":"<e1>Fluoride<\\e1> treatment also increased phosphorylation of <e2>JNK<\\e2> and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Fluoride","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment also increased phosphorylation of <e2>GENE-N<\\e2> and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with GENE-N or ERK inhibitors, respectively","sentence":"Fluoride treatment also increased phosphorylation of JNK and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively"}
{"PMID":23578390,"re_id":2,"annotated sentence":"<e1>Fluoride<\\e1> treatment also increased phosphorylation of JNK and <e2>ERK<\\e2>  but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Fluoride","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment also increased phosphorylation of JNK and <e2>GENE-N<\\e2>  but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or GENE-N inhibitors, respectively","sentence":"Fluoride treatment also increased phosphorylation of JNK and ERK  but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively"}
{"PMID":23578607,"re_id":0,"annotated sentence":"<e1>6-DHSG<\\e1> was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of <e2>glutathione-S-transferase<\\e2> (GST)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"6-DHSG","object":"glutathione-S-transferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> was metabolised by GSH to form a GSH conjugate (GS-CHEMICAL) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of <e2>GENE-N<\\e2> (GST)","sentence":"6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (GST)"}
{"PMID":23578607,"re_id":1,"annotated sentence":"<e1>6-DHSG<\\e1> was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (<e2>GST<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"6-DHSG","object":"GST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> was metabolised by GSH to form a GSH conjugate (GS-CHEMICAL) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (<e2>GENE-N<\\e2> ","sentence":"6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (GST "}
{"PMID":23578607,"re_id":2,"annotated sentence":"6-DHSG was metabolised by GSH to form a GSH conjugate (<e1>GS-6-DHSG<\\e1>  in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of <e2>glutathione-S-transferase<\\e2> (GST)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"GS-6-DHSG","object":"glutathione-S-transferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"6-DHSG was metabolised by GSH to form a GSH conjugate (<e1>CHEMICAL<\\e1>  in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of <e2>GENE-N<\\e2> (GST)","sentence":"6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG  in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (GST)"}
{"PMID":23578607,"re_id":3,"annotated sentence":"6-DHSG was metabolised by GSH to form a GSH conjugate (<e1>GS-6-DHSG<\\e1>  in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (<e2>GST<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"GS-6-DHSG","object":"GST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"6-DHSG was metabolised by GSH to form a GSH conjugate (<e1>CHEMICAL<\\e1>  in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (<e2>GENE-N<\\e2> ","sentence":"6-DHSG was metabolised by GSH to form a GSH conjugate (GS-6-DHSG  in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (GST "}
{"PMID":23578688,"re_id":0,"annotated sentence":"A series of <e1>carbamoylmethylene<\\e1> linked prodrugs of 1 (BMS-582949), a clinical <e2>p38\u03b1<\\e2> inhibitor, were synthesized and evaluated","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbamoylmethylene","object":"p38\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> linked prodrugs of 1 (BMS-582949), a clinical <e2>GENE-Y<\\e2> inhibitor, were synthesized and evaluated","sentence":"A series of carbamoylmethylene linked prodrugs of 1 (BMS-582949), a clinical p38\u03b1 inhibitor, were synthesized and evaluated"}
{"PMID":23578688,"re_id":1,"annotated sentence":"A series of carbamoylmethylene linked prodrugs of 1 (<e1>BMS-582949<\\e1> , a clinical <e2>p38\u03b1<\\e2> inhibitor, were synthesized and evaluated","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-582949","object":"p38\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of carbamoylmethylene linked prodrugs of 1 (<e1>CHEMICAL<\\e1> , a clinical <e2>GENE-Y<\\e2> inhibitor, were synthesized and evaluated","sentence":"A series of carbamoylmethylene linked prodrugs of 1 (BMS-582949 , a clinical p38\u03b1 inhibitor, were synthesized and evaluated"}
{"PMID":23578688,"re_id":2,"annotated sentence":"Synthesis and evaluation of <e1>carbamoylmethylene<\\e1> linked prodrugs of BMS-582949, a clinical <e2>p38\u03b1<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbamoylmethylene","object":"p38\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and evaluation of <e1>CHEMICAL<\\e1> linked prodrugs of BMS-582949, a clinical <e2>GENE-Y<\\e2> inhibitor","sentence":"Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38\u03b1 inhibitor"}
{"PMID":23578688,"re_id":3,"annotated sentence":"Synthesis and evaluation of carbamoylmethylene linked prodrugs of <e1>BMS-582949<\\e1>  a clinical <e2>p38\u03b1<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BMS-582949","object":"p38\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and evaluation of carbamoylmethylene linked prodrugs of <e1>CHEMICAL<\\e1>  a clinical <e2>GENE-Y<\\e2> inhibitor","sentence":"Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949  a clinical p38\u03b1 inhibitor"}
{"PMID":23578952,"re_id":0,"annotated sentence":"Here we studied the effects of the recently developed <e2>monoacylglycerol lipase<\\e2> inhibitor <e1>JZL184<\\e1> on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"JZL184","object":"monoacylglycerol lipase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we studied the effects of the recently developed <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses","sentence":"Here we studied the effects of the recently developed monoacylglycerol lipase inhibitor JZL184 on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses"}
{"PMID":23579178,"re_id":0,"annotated sentence":"Mechanisms of Glucose Lowering of <e2>Dipeptidyl Peptidase-4<\\e2> Inhibitor <e1>Sitagliptin<\\e1> When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sitagliptin","object":"Dipeptidyl Peptidase-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mechanisms of Glucose Lowering of <e2>GENE-Y<\\e2> Inhibitor <e1>CHEMICAL<\\e1> When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study","sentence":"Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study"}
{"PMID":23580446,"re_id":0,"annotated sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of <e2>p21<\\e2> WAF1\/CIP1) and upregulation of cyclinB1, since these effects were prevented by <e1>rofecoxib<\\e1> a selective COX-2 inhibitor) and rescued by exogenous PGE2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of <e2>GENE-Y<\\e2> WAF1\/CIP1) and upregulation of cyclinB1, since these effects were prevented by <e1>CHEMICAL<\\e1> a selective COX-2 inhibitor) and rescued by exogenous PGE2","sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21 WAF1\/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib a selective COX-2 inhibitor) and rescued by exogenous PGE2"}
{"PMID":23580446,"re_id":1,"annotated sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(<e2>WAF1<\\e2> CIP1) and upregulation of cyclinB1, since these effects were prevented by <e1>rofecoxib<\\e1> a selective COX-2 inhibitor) and rescued by exogenous PGE2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"WAF1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(<e2>GENE-Y<\\e2> CIP1) and upregulation of cyclinB1, since these effects were prevented by <e1>CHEMICAL<\\e1> a selective COX-2 inhibitor) and rescued by exogenous PGE2","sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1 CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib a selective COX-2 inhibitor) and rescued by exogenous PGE2"}
{"PMID":23580446,"re_id":2,"annotated sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1\/<e2>CIP1<\\e2>  and upregulation of cyclinB1, since these effects were prevented by <e1>rofecoxib<\\e1> a selective COX-2 inhibitor) and rescued by exogenous PGE2","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"CIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1\/<e2>GENE-Y<\\e2>  and upregulation of cyclinB1, since these effects were prevented by <e1>CHEMICAL<\\e1> a selective COX-2 inhibitor) and rescued by exogenous PGE2","sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1\/CIP1  and upregulation of cyclinB1, since these effects were prevented by rofecoxib a selective COX-2 inhibitor) and rescued by exogenous PGE2"}
{"PMID":23580446,"re_id":3,"annotated sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1\/CIP1) and upregulation of <e2>cyclinB1<\\e2>  since these effects were prevented by <e1>rofecoxib<\\e1> a selective COX-2 inhibitor) and rescued by exogenous PGE2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"cyclinB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1\/CIP1) and upregulation of <e2>GENE-Y<\\e2>  since these effects were prevented by <e1>CHEMICAL<\\e1> a selective COX-2 inhibitor) and rescued by exogenous PGE2","sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1\/CIP1) and upregulation of cyclinB1  since these effects were prevented by rofecoxib a selective COX-2 inhibitor) and rescued by exogenous PGE2"}
{"PMID":23580446,"re_id":4,"annotated sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1\/CIP1) and upregulation of cyclinB1, since these effects were prevented by <e1>rofecoxib<\\e1> a selective <e2>COX-2<\\e2> inhibitor) and rescued by exogenous PGE2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Platelet-induced GENE-Y-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1\/CIP1) and upregulation of cyclinB1, since these effects were prevented by <e1>CHEMICAL<\\e1> a selective <e2>GENE-Y<\\e2> inhibitor) and rescued by exogenous PGE2","sentence":"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1\/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib a selective COX-2 inhibitor) and rescued by exogenous PGE2"}
{"PMID":23580446,"re_id":5,"annotated sentence":"<e2>Cyclooxygenase(COX)-2<\\e2> derived <e1>prostanoids<\\e1> can influence several processes that are linked to carcinogenesis","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostanoids","object":"Cyclooxygenase(COX)-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> derived <e1>CHEMICAL<\\e1> can influence several processes that are linked to carcinogenesis","sentence":"Cyclooxygenase(COX)-2 derived prostanoids can influence several processes that are linked to carcinogenesis"}
{"PMID":23580446,"re_id":6,"annotated sentence":"Platelet-induced <e2>COX-2<\\e2> dependent <e1>PGE2<\\e1> synthesis in HT29 cells was involved in downregulation of p21(WAF1\/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PGE2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Platelet-induced <e2>GENE-Y<\\e2> dependent <e1>CHEMICAL<\\e1> synthesis in HT29 cells was involved in downregulation of p21(WAF1\/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective GENE-Y inhibitor) and rescued by exogenous CHEMICAL","sentence":"Platelet-induced COX-2 dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1\/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2"}
{"PMID":23582273,"re_id":0,"annotated sentence":"Synthesis and antitumor activity of <e1>1,3,4-oxadiazole<\\e1> possessing 1,4-benzodioxan moiety as a novel class of potent <e2>methionine aminopeptidase type II<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,3,4-oxadiazole","object":"methionine aminopeptidase type II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and antitumor activity of <e1>CHEMICAL<\\e1> possessing 1,4-benzodioxan moiety as a novel class of potent <e2>GENE-Y<\\e2> inhibitors","sentence":"Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors"}
{"PMID":23582273,"re_id":1,"annotated sentence":"Synthesis and antitumor activity of 1,3,4-oxadiazole possessing <e1>1,4-benzodioxan<\\e1> moiety as a novel class of potent <e2>methionine aminopeptidase type II<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,4-benzodioxan","object":"methionine aminopeptidase type II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and antitumor activity of 1,3,4-oxadiazole possessing <e1>CHEMICAL<\\e1> moiety as a novel class of potent <e2>GENE-Y<\\e2> inhibitors","sentence":"Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors"}
{"PMID":23583257,"re_id":0,"annotated sentence":"Such model of <e2>Nox4<\\e2> activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme, i.e., its potential redox regulation, and could also define new therapeutic targets in diseases in which <e1>quinones<\\e1> and Nox4 are implicated.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"quinones","object":"Nox4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Such model of <e2>GENE-Y<\\e2> activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme, i.e., its potential redox regulation, and could also define new therapeutic targets in diseases in which <e1>CHEMICAL<\\e1> and GENE-Y are implicated.","sentence":"Such model of Nox4 activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme, i.e., its potential redox regulation, and could also define new therapeutic targets in diseases in which quinones and Nox4 are implicated."}
{"PMID":23583257,"re_id":1,"annotated sentence":"<e2>Nox4<\\e2> oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific <e1>quinone<\\e1> derivatives could modulate this activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"quinone","object":"Nox4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific <e1>CHEMICAL<\\e1> derivatives could modulate this activity","sentence":"Nox4 oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific quinone derivatives could modulate this activity"}
{"PMID":23583257,"re_id":2,"annotated sentence":"Nox4 <e2>oxidase<\\e2> activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific <e1>quinone<\\e1> derivatives could modulate this activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"quinone","object":"oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Nox4 <e2>GENE-N<\\e2> activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific <e1>CHEMICAL<\\e1> derivatives could modulate this activity","sentence":"Nox4 oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific quinone derivatives could modulate this activity"}
{"PMID":23583257,"re_id":3,"annotated sentence":"In fact, we demonstrated a significant stimulation of <e2>Nox4<\\e2> activity by 4 <e1>quinone<\\e1> derivatives (AA-861, tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"quinone","object":"Nox4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In fact, we demonstrated a significant stimulation of <e2>GENE-Y<\\e2> activity by 4 <e1>CHEMICAL<\\e1> derivatives (AA-861, tBuBHQ, tBuBQ, and duroCHEMICAL) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines","sentence":"In fact, we demonstrated a significant stimulation of Nox4 activity by 4 quinone derivatives (AA-861, tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines"}
{"PMID":23583257,"re_id":4,"annotated sentence":"In fact, we demonstrated a significant stimulation of <e2>Nox4<\\e2> activity by 4 quinone derivatives (<e1>AA-861<\\e1>  tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AA-861","object":"Nox4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In fact, we demonstrated a significant stimulation of <e2>GENE-Y<\\e2> activity by 4 quinone derivatives (<e1>CHEMICAL<\\e1>  tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines","sentence":"In fact, we demonstrated a significant stimulation of Nox4 activity by 4 quinone derivatives (AA-861  tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines"}
{"PMID":23583257,"re_id":5,"annotated sentence":"In fact, we demonstrated a significant stimulation of <e2>Nox4<\\e2> activity by 4 quinone derivatives (AA-861, <e1>tBuBHQ<\\e1>  tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tBuBHQ","object":"Nox4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In fact, we demonstrated a significant stimulation of <e2>GENE-Y<\\e2> activity by 4 quinone derivatives (AA-861, <e1>CHEMICAL<\\e1>  tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines","sentence":"In fact, we demonstrated a significant stimulation of Nox4 activity by 4 quinone derivatives (AA-861, tBuBHQ  tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines"}
{"PMID":23583257,"re_id":6,"annotated sentence":"In fact, we demonstrated a significant stimulation of <e2>Nox4<\\e2> activity by 4 quinone derivatives (AA-861, tBuBHQ, <e1>tBuBQ<\\e1>  and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"tBuBQ","object":"Nox4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In fact, we demonstrated a significant stimulation of <e2>GENE-Y<\\e2> activity by 4 quinone derivatives (AA-861, tBuBHQ, <e1>CHEMICAL<\\e1>  and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines","sentence":"In fact, we demonstrated a significant stimulation of Nox4 activity by 4 quinone derivatives (AA-861, tBuBHQ, tBuBQ  and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines"}
{"PMID":23583257,"re_id":7,"annotated sentence":"In fact, we demonstrated a significant stimulation of <e2>Nox4<\\e2> activity by 4 quinone derivatives (AA-861, tBuBHQ, tBuBQ, and <e1>duroquinone<\\e1>  observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"duroquinone","object":"Nox4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In fact, we demonstrated a significant stimulation of <e2>GENE-Y<\\e2> activity by 4 quinone derivatives (AA-861, tBuBHQ, tBuBQ, and <e1>CHEMICAL<\\e1>  observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines","sentence":"In fact, we demonstrated a significant stimulation of Nox4 activity by 4 quinone derivatives (AA-861, tBuBHQ, tBuBQ, and duroquinone  observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines"}
{"PMID":23583806,"re_id":0,"annotated sentence":"<e1>Allicin<\\e1> treatment showed reduced production of pro-inflammatory cytokines and NO and increased <e2>HO-1<\\e2> activity","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Allicin","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment showed reduced production of pro-inflammatory cytokines and NO and increased <e2>GENE-Y<\\e2> activity","sentence":"Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity"}
{"PMID":23583806,"re_id":1,"annotated sentence":"<e1>Allicin<\\e1> treatment showed reduced production of pro-inflammatory <e2>cytokines<\\e2> and NO and increased HO-1 activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Allicin","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment showed reduced production of pro-inflammatory <e2>GENE-N<\\e2> and NO and increased HO-1 activity","sentence":"Allicin treatment showed reduced production of pro-inflammatory cytokines and NO and increased HO-1 activity"}
{"PMID":23583884,"re_id":0,"annotated sentence":"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that <e1>TCDD<\\e1> up-regulated the expression and secretion of <e2>tumor necrosis factor-alpha<\\e2> (TNF-\u03b1) in a time-dependent manner in cultured HAPI microglial cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"tumor necrosis factor-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that <e1>CHEMICAL<\\e1> up-regulated the expression and secretion of <e2>GENE-Y<\\e2> (TNF-\u03b1) in a time-dependent manner in cultured HAPI microglial cells","sentence":"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that TCDD up-regulated the expression and secretion of tumor necrosis factor-alpha (TNF-\u03b1) in a time-dependent manner in cultured HAPI microglial cells"}
{"PMID":23583884,"re_id":1,"annotated sentence":"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that <e1>TCDD<\\e1> up-regulated the expression and secretion of tumor necrosis factor-alpha (<e2>TNF-\u03b1<\\e2>  in a time-dependent manner in cultured HAPI microglial cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that <e1>CHEMICAL<\\e1> up-regulated the expression and secretion of tumor necrosis factor-alpha (<e2>GENE-Y<\\e2>  in a time-dependent manner in cultured HAPI microglial cells","sentence":"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that TCDD up-regulated the expression and secretion of tumor necrosis factor-alpha (TNF-\u03b1  in a time-dependent manner in cultured HAPI microglial cells"}
{"PMID":23583884,"re_id":2,"annotated sentence":"<e1>TCDD<\\e1> also caused a fast (within 30min as judged by the increase in its mRNA level) activation of <e2>cytosolic phospholipase A2<\\e2> (cPLA2)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"cytosolic phospholipase A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also caused a fast (within 30min as judged by the increase in its mRNA level) activation of <e2>GENE-Y<\\e2> (cPLA2)","sentence":"TCDD also caused a fast (within 30min as judged by the increase in its mRNA level) activation of cytosolic phospholipase A2 (cPLA2)"}
{"PMID":23583884,"re_id":3,"annotated sentence":"<e1>TCDD<\\e1> also caused a fast (within 30min as judged by the increase in its mRNA level) activation of cytosolic phospholipase A2 (<e2>cPLA2<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"cPLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also caused a fast (within 30min as judged by the increase in its mRNA level) activation of cytosolic phospholipase A2 (<e2>GENE-Y<\\e2> ","sentence":"TCDD also caused a fast (within 30min as judged by the increase in its mRNA level) activation of cytosolic phospholipase A2 (cPLA2 "}
{"PMID":23583884,"re_id":4,"annotated sentence":"This initial action was accompanied by up-regulation of <e2>cyclooxygenase-2<\\e2> (COX-2), an important inflammation marker within 1h after <e1>TCDD<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This initial action was accompanied by up-regulation of <e2>GENE-Y<\\e2> (COX-2), an important inflammation marker within 1h after <e1>CHEMICAL<\\e1> treatment","sentence":"This initial action was accompanied by up-regulation of cyclooxygenase-2 (COX-2), an important inflammation marker within 1h after TCDD treatment"}
{"PMID":23583884,"re_id":5,"annotated sentence":"This initial action was accompanied by up-regulation of cyclooxygenase-2 (<e2>COX-2<\\e2> , an important inflammation marker within 1h after <e1>TCDD<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This initial action was accompanied by up-regulation of cyclooxygenase-2 (<e2>GENE-Y<\\e2> , an important inflammation marker within 1h after <e1>CHEMICAL<\\e1> treatment","sentence":"This initial action was accompanied by up-regulation of cyclooxygenase-2 (COX-2 , an important inflammation marker within 1h after TCDD treatment"}
{"PMID":23583884,"re_id":6,"annotated sentence":"Further, <e1>TCDD<\\e1> exposure could induce phosphorylation- and ubiquitination-dependent degradation of <e2>I\u043aB\u03b1<\\e2>  and the translocation of NF-\u03baB p65 from the cytosol to the nucleus in this microglial cell line","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"I\u043aB\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further, <e1>CHEMICAL<\\e1> exposure could induce phosphorylation- and ubiquitination-dependent degradation of <e2>GENE-Y<\\e2>  and the translocation of NF-\u03baB p65 from the cytosol to the nucleus in this microglial cell line","sentence":"Further, TCDD exposure could induce phosphorylation- and ubiquitination-dependent degradation of I\u043aB\u03b1  and the translocation of NF-\u03baB p65 from the cytosol to the nucleus in this microglial cell line"}
{"PMID":23583884,"re_id":7,"annotated sentence":"Thus, the <e2>NF-\u03baB<\\e2> signaling pathway can be activated after <e1>TCDD<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, the <e2>GENE-N<\\e2> signaling pathway can be activated after <e1>CHEMICAL<\\e1> treatment","sentence":"Thus, the NF-\u03baB signaling pathway can be activated after TCDD treatment"}
{"PMID":23583884,"re_id":8,"annotated sentence":"However, Ca(2+) blockers also obviously attenuated <e2>NF-\u03baB<\\e2> activation and transnuclear transport induced by <e1>TCDD<\\e1>  In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and NF-\u03baB activation induced by TCDD can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, Ca(2+) blockers also obviously attenuated <e2>GENE-N<\\e2> activation and transnuclear transport induced by <e1>CHEMICAL<\\e1>  In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and GENE-N activation induced by CHEMICAL can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.","sentence":"However, Ca(2+) blockers also obviously attenuated NF-\u03baB activation and transnuclear transport induced by TCDD  In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and NF-\u03baB activation induced by TCDD can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells."}
{"PMID":23583884,"re_id":9,"annotated sentence":"In concert with these results, we highlighted that the secretion of pro-inflammatory <e2>cytokine<\\e2> and NF-\u03baB activation induced by <e1>TCDD<\\e1> can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In concert with these results, we highlighted that the secretion of pro-inflammatory <e2>GENE-N<\\e2> and NF-\u03baB activation induced by <e1>CHEMICAL<\\e1> can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.","sentence":"In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and NF-\u03baB activation induced by TCDD can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells."}
{"PMID":23583884,"re_id":10,"annotated sentence":"In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and <e2>NF-\u03baB<\\e2> activation induced by <e1>TCDD<\\e1> can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCDD","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and <e2>GENE-N<\\e2> activation induced by <e1>CHEMICAL<\\e1> can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.","sentence":"In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and NF-\u03baB activation induced by TCDD can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells."}
{"PMID":23584948,"re_id":0,"annotated sentence":"<e1>Vandetanib<\\e1> (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and <e2>epidermal growth-factor receptors<\\e2>  It is the first systemic drug with demonstrated anti-tumor benefits in advanced MTC, and it has recently been approved for locally advanced or metastatic MTC by the United States Food and Drug Administration (April 2011) and the European Medicines Agency (February 2012)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Vandetanib","object":"epidermal growth-factor receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and <e2>GENE-Y<\\e2>  It is the first systemic drug with demonstrated anti-tumor benefits in advanced MTC, and it has recently been approved for locally advanced or metastatic MTC by the United States Food and Drug Administration (April 2011) and the European Medicines Agency (February 2012)","sentence":"Vandetanib (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors  It is the first systemic drug with demonstrated anti-tumor benefits in advanced MTC, and it has recently been approved for locally advanced or metastatic MTC by the United States Food and Drug Administration (April 2011) and the European Medicines Agency (February 2012)"}
{"PMID":23584948,"re_id":1,"annotated sentence":"<e1>Vandetanib<\\e1> (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral <e2>tyrosine kinase<\\e2> inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Vandetanib","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral <e2>GENE-N<\\e2> inhibitor that selectively inhibits signalling mediated by growth-factor receptor GENE-N RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors","sentence":"Vandetanib (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors"}
{"PMID":23584948,"re_id":2,"annotated sentence":"<e1>Vandetanib<\\e1> (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by <e2>growth-factor receptor tyrosine kinase<\\e2> RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Vandetanib","object":"growth-factor receptor tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by <e2>GENE-N<\\e2> RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors","sentence":"Vandetanib (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors"}
{"PMID":23584948,"re_id":3,"annotated sentence":"<e1>Vandetanib<\\e1> (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase <e2>RET<\\e2> (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Vandetanib","object":"RET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase <e2>GENE-Y<\\e2> (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors","sentence":"Vandetanib (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors"}
{"PMID":23584948,"re_id":4,"annotated sentence":"Vandetanib (<e1>Caprelsa<\\e1> \u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and <e2>epidermal growth-factor receptors<\\e2>  It is the first systemic drug with demonstrated anti-tumor benefits in advanced MTC, and it has recently been approved for locally advanced or metastatic MTC by the United States Food and Drug Administration (April 2011) and the European Medicines Agency (February 2012)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Caprelsa","object":"epidermal growth-factor receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Vandetanib (<e1>CHEMICAL<\\e1> \u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and <e2>GENE-Y<\\e2>  It is the first systemic drug with demonstrated anti-tumor benefits in advanced MTC, and it has recently been approved for locally advanced or metastatic MTC by the United States Food and Drug Administration (April 2011) and the European Medicines Agency (February 2012)","sentence":"Vandetanib (Caprelsa \u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors  It is the first systemic drug with demonstrated anti-tumor benefits in advanced MTC, and it has recently been approved for locally advanced or metastatic MTC by the United States Food and Drug Administration (April 2011) and the European Medicines Agency (February 2012)"}
{"PMID":23584948,"re_id":5,"annotated sentence":"Vandetanib (<e1>Caprelsa<\\e1> \u00ae), AstraZeneca) is a once-daily oral <e2>tyrosine kinase<\\e2> inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Caprelsa","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Vandetanib (<e1>CHEMICAL<\\e1> \u00ae), AstraZeneca) is a once-daily oral <e2>GENE-N<\\e2> inhibitor that selectively inhibits signalling mediated by growth-factor receptor GENE-N RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors","sentence":"Vandetanib (Caprelsa \u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors"}
{"PMID":23585058,"re_id":0,"annotated sentence":"Chelation of calcium ions by BAPTA-AM or blockade of <e2>ERK1\/2<\\e2> activation by <e1>UO126<\\e1> also prevented the NMDA effects","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"UO126","object":"ERK1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Chelation of calcium ions by BAPTA-AM or blockade of <e2>GENE-N<\\e2> activation by <e1>CHEMICAL<\\e1> also prevented the NMDA effects","sentence":"Chelation of calcium ions by BAPTA-AM or blockade of ERK1\/2 activation by UO126 also prevented the NMDA effects"}
{"PMID":23585058,"re_id":1,"annotated sentence":"Thus prolonged activation of NMDA receptors in hippocampal neurons reduced <e2>GABAR \u03b4 subunit<\\e2> expression through <e1>Ca2+<\\e1> entry and at least in part by ERK1\/2 activation.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Ca2+","object":"GABAR \u03b4 subunit","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus prolonged activation of NMDA receptors in hippocampal neurons reduced <e2>GENE-Y<\\e2> expression through <e1>CHEMICAL<\\e1> entry and at least in part by ERK1\/2 activation.","sentence":"Thus prolonged activation of NMDA receptors in hippocampal neurons reduced GABAR \u03b4 subunit expression through Ca2+ entry and at least in part by ERK1\/2 activation."}
{"PMID":23597450,"re_id":0,"annotated sentence":"Promoter assay revealed that <e1>prunetin<\\e1> inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of <e2>iNOS<\\e2> and COX-2 at the transcriptional level","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prunetin","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Promoter assay revealed that <e1>CHEMICAL<\\e1> inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of <e2>GENE-Y<\\e2> and COX-2 at the transcriptional level","sentence":"Promoter assay revealed that prunetin inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of iNOS and COX-2 at the transcriptional level"}
{"PMID":23597450,"re_id":1,"annotated sentence":"Promoter assay revealed that <e1>prunetin<\\e1> inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of iNOS and <e2>COX-2<\\e2> at the transcriptional level","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prunetin","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Promoter assay revealed that <e1>CHEMICAL<\\e1> inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of iNOS and <e2>GENE-Y<\\e2> at the transcriptional level","sentence":"Promoter assay revealed that prunetin inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of iNOS and COX-2 at the transcriptional level"}
{"PMID":23597450,"re_id":2,"annotated sentence":"Anti-inflammatory effect of <e1>prunetin<\\e1> via the suppression of <e2>NF-\u03baB<\\e2> pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prunetin","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Anti-inflammatory effect of <e1>CHEMICAL<\\e1> via the suppression of <e2>GENE-N<\\e2> pathway","sentence":"Anti-inflammatory effect of prunetin via the suppression of NF-\u03baB pathway"}
{"PMID":23597450,"re_id":3,"annotated sentence":"In addition, <e1>prunetin<\\e1> inhibits <e2>NF-\u03baB<\\e2> dependent inflammatory responses by modulating I\u03baB kinase (IKK)-inhibitor \u03baB\u03b1 (I\u03baB\u03b1)-NF-\u03baB signaling","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prunetin","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> inhibits <e2>GENE-N<\\e2> dependent inflammatory responses by modulating I\u03baB kinase (IKK)-inhibitor \u03baB\u03b1 (I\u03baB\u03b1)-GENE-N signaling","sentence":"In addition, prunetin inhibits NF-\u03baB dependent inflammatory responses by modulating I\u03baB kinase (IKK)-inhibitor \u03baB\u03b1 (I\u03baB\u03b1)-NF-\u03baB signaling"}
{"PMID":23597450,"re_id":4,"annotated sentence":"Consistent with these results, <e1>prunetin<\\e1> significantly reduced serum levels of inflammatory <e2>cytokines<\\e2> and mortality in mice challenged with lipopolysaccharide","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prunetin","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Consistent with these results, <e1>CHEMICAL<\\e1> significantly reduced serum levels of inflammatory <e2>GENE-N<\\e2> and mortality in mice challenged with lipopolysaccharide","sentence":"Consistent with these results, prunetin significantly reduced serum levels of inflammatory cytokines and mortality in mice challenged with lipopolysaccharide"}
{"PMID":23600432,"re_id":0,"annotated sentence":"Introduction: 5-Lipoxygenase (<e2>5-LO<\\e2>  is a crucial enzyme of the <e1>arachidonic acid<\\e1> (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"5-LO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Introduction: 5-Lipoxygenase (<e2>GENE-Y<\\e2>  is a crucial enzyme of the <e1>CHEMICAL<\\e1> (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the GENE-Y-activating protein","sentence":"Introduction: 5-Lipoxygenase (5-LO  is a crucial enzyme of the arachidonic acid (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein"}
{"PMID":23600432,"re_id":1,"annotated sentence":"Introduction: <e2>5-Lipoxygenase<\\e2> (5-LO) is a crucial enzyme of the <e1>arachidonic acid<\\e1> (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"5-Lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Introduction: <e2>GENE-Y<\\e2> (5-LO) is a crucial enzyme of the <e1>CHEMICAL<\\e1> (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein","sentence":"Introduction: 5-Lipoxygenase (5-LO) is a crucial enzyme of the arachidonic acid (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein"}
{"PMID":23600800,"re_id":0,"annotated sentence":"The reduction of <e2>P2X3<\\e2> expression levels was reversed by the proteasomal inhibitor <e1>MG-132<\\e1>  Moreover, neuronal CASK\/P2X3 interaction was upregulated by NGF signaling and downregulated by P2X3 agonist-induced desensitization","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MG-132","object":"P2X3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reduction of <e2>GENE-Y<\\e2> expression levels was reversed by the proteasomal inhibitor <e1>CHEMICAL<\\e1>  Moreover, neuronal CASK\/GENE-Y interaction was upregulated by NGF signaling and downregulated by GENE-Y agonist-induced desensitization","sentence":"The reduction of P2X3 expression levels was reversed by the proteasomal inhibitor MG-132  Moreover, neuronal CASK\/P2X3 interaction was upregulated by NGF signaling and downregulated by P2X3 agonist-induced desensitization"}
{"PMID":23601990,"re_id":0,"annotated sentence":"A series of <e1>phosphorylated flavonoids<\\e1> were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic <e2>cholesterol esterase<\\e2> (CEase) and acetylcholinesterase (AChE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphorylated flavonoids","object":"cholesterol esterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic <e2>GENE-Y<\\e2> (CEase) and acetylcholinesterase (AChE)","sentence":"A series of phosphorylated flavonoids were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (AChE)"}
{"PMID":23601990,"re_id":1,"annotated sentence":"A series of <e1>phosphorylated flavonoids<\\e1> were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (<e2>CEase<\\e2>  and acetylcholinesterase (AChE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphorylated flavonoids","object":"CEase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (<e2>GENE-Y<\\e2>  and acetylcholinesterase (AChE)","sentence":"A series of phosphorylated flavonoids were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase  and acetylcholinesterase (AChE)"}
{"PMID":23601990,"re_id":2,"annotated sentence":"A series of <e1>phosphorylated flavonoids<\\e1> were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and <e2>acetylcholinesterase<\\e2> (AChE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphorylated flavonoids","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and <e2>GENE-Y<\\e2> (AChE)","sentence":"A series of phosphorylated flavonoids were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (AChE)"}
{"PMID":23601990,"re_id":3,"annotated sentence":"A series of <e1>phosphorylated flavonoids<\\e1> were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (<e2>AChE<\\e2> ","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphorylated flavonoids","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (<e2>GENE-Y<\\e2> ","sentence":"A series of phosphorylated flavonoids were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (AChE "}
{"PMID":23601990,"re_id":4,"annotated sentence":"The results showed that most of the synthesized compounds exhibited nanomolar potency against <e2>CEase<\\e2>  much better than the parent <e1>flavonoids<\\e1>  Furthermore, these phosphorylated flavonoids demonstrated good to high selectivity for CEase over AChE, which only showed micromolar potency inhibition of AChE","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"flavonoids","object":"CEase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that most of the synthesized compounds exhibited nanomolar potency against <e2>GENE-Y<\\e2>  much better than the parent <e1>CHEMICAL<\\e1>  Furthermore, these phosphorylated CHEMICAL demonstrated good to high selectivity for GENE-Y over AChE, which only showed micromolar potency inhibition of AChE","sentence":"The results showed that most of the synthesized compounds exhibited nanomolar potency against CEase  much better than the parent flavonoids  Furthermore, these phosphorylated flavonoids demonstrated good to high selectivity for CEase over AChE, which only showed micromolar potency inhibition of AChE"}
{"PMID":23601990,"re_id":5,"annotated sentence":"Furthermore, these <e1>phosphorylated flavonoids<\\e1> demonstrated good to high selectivity for <e2>CEase<\\e2> over AChE, which only showed micromolar potency inhibition of AChE","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphorylated flavonoids","object":"CEase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, these <e1>CHEMICAL<\\e1> demonstrated good to high selectivity for <e2>GENE-Y<\\e2> over AChE, which only showed micromolar potency inhibition of AChE","sentence":"Furthermore, these phosphorylated flavonoids demonstrated good to high selectivity for CEase over AChE, which only showed micromolar potency inhibition of AChE"}
{"PMID":23601990,"re_id":6,"annotated sentence":"Furthermore, these <e1>phosphorylated flavonoids<\\e1> demonstrated good to high selectivity for CEase over <e2>AChE<\\e2>  which only showed micromolar potency inhibition of AChE","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphorylated flavonoids","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, these <e1>CHEMICAL<\\e1> demonstrated good to high selectivity for CEase over <e2>GENE-Y<\\e2>  which only showed micromolar potency inhibition of GENE-Y","sentence":"Furthermore, these phosphorylated flavonoids demonstrated good to high selectivity for CEase over AChE  which only showed micromolar potency inhibition of AChE"}
{"PMID":23601990,"re_id":7,"annotated sentence":"Furthermore, these <e1>phosphorylated flavonoids<\\e1> demonstrated good to high selectivity for CEase over AChE, which only showed micromolar potency inhibition of <e2>AChE<\\e2>  The most selective and potent inhibitor of CEase (3e) had IC50 value of 0.72\u00a0nM and 11800-fold selectivity for CEase over AChE","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphorylated flavonoids","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, these <e1>CHEMICAL<\\e1> demonstrated good to high selectivity for CEase over GENE-Y, which only showed micromolar potency inhibition of <e2>GENE-Y<\\e2>  The most selective and potent inhibitor of CEase (3e) had IC50 value of 0.72\u00a0nM and 11800-fold selectivity for CEase over GENE-Y","sentence":"Furthermore, these phosphorylated flavonoids demonstrated good to high selectivity for CEase over AChE, which only showed micromolar potency inhibition of AChE  The most selective and potent inhibitor of CEase (3e) had IC50 value of 0.72\u00a0nM and 11800-fold selectivity for CEase over AChE"}
{"PMID":23601990,"re_id":8,"annotated sentence":"The structure-activity relationships revealed that the free <e1>hydroxyl<\\e1> group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of <e2>CEase<\\e2>  The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of CEase.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"hydroxyl","object":"CEase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The structure-activity relationships revealed that the free <e1>CHEMICAL<\\e1> group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of <e2>GENE-Y<\\e2>  The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of GENE-Y.","sentence":"The structure-activity relationships revealed that the free hydroxyl group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of CEase  The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of CEase."}
{"PMID":23601990,"re_id":9,"annotated sentence":"The structure-activity relationships revealed that the free hydroxyl group at position 5 and <e1>phosphate<\\e1> group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of <e2>CEase<\\e2>  The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of CEase.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphate","object":"CEase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The structure-activity relationships revealed that the free hydroxyl group at position 5 and <e1>CHEMICAL<\\e1> group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of <e2>GENE-Y<\\e2>  The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of GENE-Y.","sentence":"The structure-activity relationships revealed that the free hydroxyl group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of CEase  The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of CEase."}
{"PMID":23601990,"re_id":10,"annotated sentence":"The structure-activity relationships revealed that the free hydroxyl group at position 5 and phosphate group at position 7 of the <e1>phosphorylated flavonoids<\\e1> are favorable to the inhibition of <e2>CEase<\\e2>  The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of CEase.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphorylated flavonoids","object":"CEase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The structure-activity relationships revealed that the free hydroxyl group at position 5 and phosphate group at position 7 of the <e1>CHEMICAL<\\e1> are favorable to the inhibition of <e2>GENE-Y<\\e2>  The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of GENE-Y.","sentence":"The structure-activity relationships revealed that the free hydroxyl group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of CEase  The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of CEase."}
{"PMID":23601990,"re_id":11,"annotated sentence":"Synthesis and biological evaluation of <e1>phosphorylated flavonoids<\\e1> as potent and selective inhibitors of <e2>cholesterol esterase<\\e2>  A series of phosphorylated flavonoids were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (AChE)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"phosphorylated flavonoids","object":"cholesterol esterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and biological evaluation of <e1>CHEMICAL<\\e1> as potent and selective inhibitors of <e2>GENE-Y<\\e2>  A series of CHEMICAL were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic GENE-Y (CEase) and acetylcholinesterase (AChE)","sentence":"Synthesis and biological evaluation of phosphorylated flavonoids as potent and selective inhibitors of cholesterol esterase  A series of phosphorylated flavonoids were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (AChE)"}
{"PMID":23605695,"re_id":0,"annotated sentence":"<e1>Pasireotide<\\e1> (Signifor(\u00ae)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of <e2>corticotropin<\\e2> from the pituitary adenoma in patients with Cushing's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Pasireotide","object":"corticotropin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Signifor(\u00ae)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of <e2>GENE-Y<\\e2> from the pituitary adenoma in patients with Cushing's disease","sentence":"Pasireotide (Signifor(\u00ae)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease"}
{"PMID":23605695,"re_id":1,"annotated sentence":"Pasireotide (<e1>Signifor<\\e1> \u00ae)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of <e2>corticotropin<\\e2> from the pituitary adenoma in patients with Cushing's disease","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Signifor","object":"corticotropin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pasireotide (<e1>CHEMICAL<\\e1> \u00ae)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of <e2>GENE-Y<\\e2> from the pituitary adenoma in patients with Cushing's disease","sentence":"Pasireotide (Signifor \u00ae)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease"}
{"PMID":23609606,"re_id":0,"annotated sentence":"No effects were observed when <e1>fenclozic acid<\\e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major <e2>human cytochrome P450<\\e2> enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fenclozic acid","object":"human cytochrome P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"No effects were observed when <e1>CHEMICAL<\\e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major <e2>GENE-N<\\e2> enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells","sentence":"No effects were observed when fenclozic acid was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells"}
{"PMID":23609606,"re_id":1,"annotated sentence":"No effects were observed when <e1>fenclozic acid<\\e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary <e2>efflux transporters<\\e2> BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fenclozic acid","object":"efflux transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"No effects were observed when <e1>CHEMICAL<\\e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary <e2>GENE-N<\\e2> BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells","sentence":"No effects were observed when fenclozic acid was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells"}
{"PMID":23609606,"re_id":2,"annotated sentence":"No effects were observed when <e1>fenclozic acid<\\e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters <e2>BSEP<\\e2> and MRP2 or mitochondrial toxicity to THLE or HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fenclozic acid","object":"BSEP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"No effects were observed when <e1>CHEMICAL<\\e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters <e2>GENE-Y<\\e2> and MRP2 or mitochondrial toxicity to THLE or HepG2 cells","sentence":"No effects were observed when fenclozic acid was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells"}
{"PMID":23609606,"re_id":3,"annotated sentence":"No effects were observed when <e1>fenclozic acid<\\e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and <e2>MRP2<\\e2> or mitochondrial toxicity to THLE or HepG2 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"fenclozic acid","object":"MRP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"No effects were observed when <e1>CHEMICAL<\\e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and <e2>GENE-Y<\\e2> or mitochondrial toxicity to THLE or HepG2 cells","sentence":"No effects were observed when fenclozic acid was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells"}
{"PMID":23612487,"re_id":0,"annotated sentence":"<e1>Sphingosine-1-phosphate<\\e1> promotes the nuclear translocation of \u03b2-catenin and thereby induces <e2>osteoprotegerin<\\e2> gene expression in osteoblast-like cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Sphingosine-1-phosphate","object":"osteoprotegerin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> promotes the nuclear translocation of \u03b2-catenin and thereby induces <e2>GENE-N<\\e2> gene expression in osteoblast-like cell lines","sentence":"Sphingosine-1-phosphate promotes the nuclear translocation of \u03b2-catenin and thereby induces osteoprotegerin gene expression in osteoblast-like cell lines"}
{"PMID":23612487,"re_id":1,"annotated sentence":"<e1>S1P<\\e1> increased the amount of <e2>osteoprotegerin<\\e2> at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S1P","object":"osteoprotegerin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increased the amount of <e2>GENE-N<\\e2> at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization","sentence":"S1P increased the amount of osteoprotegerin at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization"}
{"PMID":23612487,"re_id":2,"annotated sentence":"These findings suggest that <e1>S1P<\\e1> activates the <e2>PI3K<\\e2> Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S1P","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> activates the <e2>GENE-N<\\e2> Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","sentence":"These findings suggest that S1P activates the PI3K Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively."}
{"PMID":23612487,"re_id":3,"annotated sentence":"These findings suggest that <e1>S1P<\\e1> activates the PI3K\/<e2>Akt<\\e2> signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S1P","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> activates the PI3K\/<e2>GENE-N<\\e2> signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","sentence":"These findings suggest that S1P activates the PI3K\/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively."}
{"PMID":23612487,"re_id":4,"annotated sentence":"These findings suggest that <e1>S1P<\\e1> activates the PI3K\/Akt signaling pathway leading to the promotion of nuclear translocation of <e2>\u03b2-catenin<\\e2> in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S1P","object":"\u03b2-catenin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> activates the PI3K\/Akt signaling pathway leading to the promotion of nuclear translocation of <e2>GENE-N<\\e2> in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","sentence":"These findings suggest that S1P activates the PI3K\/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively."}
{"PMID":23612487,"re_id":5,"annotated sentence":"These findings suggest that <e1>S1P<\\e1> activates the PI3K\/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of <e2>osteoptotegerin<\\e2> and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S1P","object":"osteoptotegerin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> activates the PI3K\/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of <e2>GENE-N<\\e2> and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","sentence":"These findings suggest that S1P activates the PI3K\/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively."}
{"PMID":23612487,"re_id":6,"annotated sentence":"These findings suggest that <e1>S1P<\\e1> activates the PI3K\/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including <e2>alkaline phosphatase<\\e2>  probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S1P","object":"alkaline phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> activates the PI3K\/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including <e2>GENE-N<\\e2>  probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","sentence":"These findings suggest that S1P activates the PI3K\/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase  probably relating to the inhibition of osteoclast formation and the mineralization, respectively."}
{"PMID":23612487,"re_id":7,"annotated sentence":"<e1>S1P<\\e1> activated <e2>phosphatidylinositol 3-kinase<\\e2> (PI3K)\/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S1P","object":"phosphatidylinositol 3-kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> activated <e2>GENE-N<\\e2> (PI3K)\/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells","sentence":"S1P activated phosphatidylinositol 3-kinase (PI3K)\/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells"}
{"PMID":23612487,"re_id":8,"annotated sentence":"<e1>S1P<\\e1> activated phosphatidylinositol 3-kinase (<e2>PI3K<\\e2> \/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S1P","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> activated phosphatidylinositol 3-kinase (<e2>GENE-N<\\e2> \/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells","sentence":"S1P activated phosphatidylinositol 3-kinase (PI3K \/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells"}
{"PMID":23612487,"re_id":9,"annotated sentence":"<e1>S1P<\\e1> activated phosphatidylinositol 3-kinase (PI3K)\/<e2>Akt<\\e2> signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"S1P","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> activated phosphatidylinositol 3-kinase (PI3K)\/<e2>GENE-N<\\e2> signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells","sentence":"S1P activated phosphatidylinositol 3-kinase (PI3K)\/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells"}
{"PMID":23612487,"re_id":10,"annotated sentence":"<e1>S1P<\\e1> activated phosphatidylinositol 3-kinase (PI3K)\/Akt signaling, leading to the inhibition of <e2>glycogen synthase kinase-3\u03b2<\\e2> and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"S1P","object":"glycogen synthase kinase-3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> activated phosphatidylinositol 3-kinase (PI3K)\/Akt signaling, leading to the inhibition of <e2>GENE-N<\\e2> and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells","sentence":"S1P activated phosphatidylinositol 3-kinase (PI3K)\/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin\/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells"}
{"PMID":23614730,"re_id":0,"annotated sentence":"Results: The administration of <e1>prallethrin<\\e1> 1.6% w\/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, <e2>hemoglobin<\\e2>  packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72\u2009h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48\u2009h to return to normal after 72\u2009h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"prallethrin","object":"hemoglobin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results: The administration of <e1>CHEMICAL<\\e1> 1.6% w\/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, <e2>GENE-N<\\e2>  packed cell volume, platelets, mean corpuscular volume, and mean corpuscular GENE-N in rats after 24, 48, and 72\u2009h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48\u2009h to return to normal after 72\u2009h","sentence":"Results: The administration of prallethrin 1.6% w\/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, hemoglobin  packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72\u2009h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48\u2009h to return to normal after 72\u2009h"}
{"PMID":23614730,"re_id":1,"annotated sentence":"Results: The administration of <e1>prallethrin<\\e1> 1.6% w\/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, hemoglobin, packed cell volume, platelets, mean corpuscular volume, and mean corpuscular <e2>hemoglobin<\\e2> in rats after 24, 48, and 72\u2009h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48\u2009h to return to normal after 72\u2009h","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"prallethrin","object":"hemoglobin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results: The administration of <e1>CHEMICAL<\\e1> 1.6% w\/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, GENE-N, packed cell volume, platelets, mean corpuscular volume, and mean corpuscular <e2>GENE-N<\\e2> in rats after 24, 48, and 72\u2009h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48\u2009h to return to normal after 72\u2009h","sentence":"Results: The administration of prallethrin 1.6% w\/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, hemoglobin, packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72\u2009h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48\u2009h to return to normal after 72\u2009h"}
{"PMID":23615073,"re_id":0,"annotated sentence":"Result showed that <e1>vitamin C<\\e1> treatment resulted in markedly reduced <e2>c-Rel<\\e2> nuclear translocation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vitamin C","object":"c-Rel","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Result showed that <e1>CHEMICAL<\\e1> treatment resulted in markedly reduced <e2>GENE-Y<\\e2> nuclear translocation","sentence":"Result showed that vitamin C treatment resulted in markedly reduced c-Rel nuclear translocation"}
{"PMID":23615073,"re_id":1,"annotated sentence":"All these results demonstrate that <e1>vitamin C<\\e1> prevents CS(E)-induced <e2>NF-\u03baB<\\e2> activation and thus it could be used for the prevention of CS-induced inflammatory diseases.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vitamin C","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"All these results demonstrate that <e1>CHEMICAL<\\e1> prevents CS(E)-induced <e2>GENE-N<\\e2> activation and thus it could be used for the prevention of CS-induced inflammatory diseases.","sentence":"All these results demonstrate that vitamin C prevents CS(E)-induced NF-\u03baB activation and thus it could be used for the prevention of CS-induced inflammatory diseases."}
{"PMID":23615073,"re_id":2,"annotated sentence":"It is possible that <e1>vitamin C<\\e1>  an antioxidant, may prevent cigarette smoke (CS)-induced <e2>NF-\u03baB<\\e2> activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of c-Rel\/p50 in alveolar epithelial cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vitamin C","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is possible that <e1>CHEMICAL<\\e1>  an antioxidant, may prevent cigarette smoke (CS)-induced <e2>GENE-N<\\e2> activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of c-Rel\/p50 in alveolar epithelial cells","sentence":"It is possible that vitamin C  an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of c-Rel\/p50 in alveolar epithelial cells"}
{"PMID":23615073,"re_id":3,"annotated sentence":"It is possible that <e1>vitamin C<\\e1>  an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of <e2>I-\u03baB\u03b5<\\e2> and nuclear translocation of c-Rel\/p50 in alveolar epithelial cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vitamin C","object":"I-\u03baB\u03b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It is possible that <e1>CHEMICAL<\\e1>  an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of <e2>GENE-Y<\\e2> and nuclear translocation of c-Rel\/p50 in alveolar epithelial cells","sentence":"It is possible that vitamin C  an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of c-Rel\/p50 in alveolar epithelial cells"}
{"PMID":23615073,"re_id":4,"annotated sentence":"We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding, <e2>I-\u03baB\u03b5<\\e2> degradation and c-Rel nuclear translocation in cells pretreated with <e1>vitamin C<\\e1>  To further validate the result, we examined sub-cellular distribution of c-Rel in lungs of CS-exposed guinea pigs treated or untreated with vitamin C","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"vitamin C","object":"I-\u03baB\u03b5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding, <e2>GENE-Y<\\e2> degradation and c-Rel nuclear translocation in cells pretreated with <e1>CHEMICAL<\\e1>  To further validate the result, we examined sub-cellular distribution of c-Rel in lungs of CS-exposed guinea pigs treated or untreated with CHEMICAL","sentence":"We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding, I-\u03baB\u03b5 degradation and c-Rel nuclear translocation in cells pretreated with vitamin C  To further validate the result, we examined sub-cellular distribution of c-Rel in lungs of CS-exposed guinea pigs treated or untreated with vitamin C"}
{"PMID":23615073,"re_id":5,"annotated sentence":"<e1>Vitamin C<\\e1> forestalls cigarette smoke induced <e2>NF-\u03baB<\\e2> activation in alveolar epithelial cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Vitamin C","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> forestalls cigarette smoke induced <e2>GENE-N<\\e2> activation in alveolar epithelial cells","sentence":"Vitamin C forestalls cigarette smoke induced NF-\u03baB activation in alveolar epithelial cells"}
{"PMID":23618901,"re_id":0,"annotated sentence":"Suppression of <e2>T\u03b2R1<\\e2> by the pharmacological inhibitor (<e1>SB431542<\\e1>  markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by T\u03b2R1 siRNA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB431542","object":"T\u03b2R1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Suppression of <e2>GENE-Y<\\e2> by the pharmacological inhibitor (<e1>CHEMICAL<\\e1>  markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by GENE-Y siRNA","sentence":"Suppression of T\u03b2R1 by the pharmacological inhibitor (SB431542  markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by T\u03b2R1 siRNA"}
{"PMID":23618901,"re_id":1,"annotated sentence":"Suppression of T\u03b2R1 by the pharmacological inhibitor (<e1>SB431542<\\e1>  markedly reduced <e2>VEGF<\\e2> release by HFL-1 in response to CSE and this effect was confirmed by T\u03b2R1 siRNA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"SB431542","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Suppression of T\u03b2R1 by the pharmacological inhibitor (<e1>CHEMICAL<\\e1>  markedly reduced <e2>GENE-Y<\\e2> release by HFL-1 in response to CSE and this effect was confirmed by T\u03b2R1 siRNA","sentence":"Suppression of T\u03b2R1 by the pharmacological inhibitor (SB431542  markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by T\u03b2R1 siRNA"}
{"PMID":23619386,"re_id":0,"annotated sentence":"<e1>Rapamycin<\\e1> inhibits <e2>proteinase<\\e2> and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rapamycin","object":"proteinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-N<\\e2> and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations","sentence":"Rapamycin inhibits proteinase and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations"}
{"PMID":23619386,"re_id":1,"annotated sentence":"<e1>Rapamycin<\\e1> inhibits proteinase and selected <e2>peptidase<\\e2> activities of the catalytic core proteasome at low micromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rapamycin","object":"peptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits proteinase and selected <e2>GENE-N<\\e2> activities of the catalytic core proteasome at low micromolar concentrations","sentence":"Rapamycin inhibits proteinase and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations"}
{"PMID":23619386,"re_id":2,"annotated sentence":"<e1>Rapamycin<\\e1> inhibits proteinase and selected peptidase activities of the catalytic core <e2>proteasome<\\e2> at low micromolar concentrations","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Rapamycin","object":"proteasome","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits proteinase and selected peptidase activities of the catalytic core <e2>GENE-N<\\e2> at low micromolar concentrations","sentence":"Rapamycin inhibits proteinase and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations"}
{"PMID":23620436,"re_id":0,"annotated sentence":"<e1>MNU<\\e1> induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high <e2>MGMT<\\e2> staining","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MNU","object":"MGMT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high <e2>GENE-N<\\e2> staining","sentence":"MNU induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high MGMT staining"}
{"PMID":23620436,"re_id":1,"annotated sentence":"<e1>MNU<\\e1> induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of <e2>E-cadherin<\\e2>  and high MGMT staining","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MNU","object":"E-cadherin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of <e2>GENE-Y<\\e2>  and high MGMT staining","sentence":"MNU induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin  and high MGMT staining"}
{"PMID":23623751,"re_id":0,"annotated sentence":"<e1>Methylphenidate<\\e1> increased <e2>DAT<\\e2> Vmax in SHR mPFC and decreased DAT Vmax in WKY OFC","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Methylphenidate","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased <e2>GENE-Y<\\e2> Vmax in SHR mPFC and decreased GENE-Y Vmax in WKY OFC","sentence":"Methylphenidate increased DAT Vmax in SHR mPFC and decreased DAT Vmax in WKY OFC"}
{"PMID":23623751,"re_id":1,"annotated sentence":"Thus, the increase in mPFC <e2>DAT<\\e2> function was an SHR-specific long term consequence of <e1>methylphenidate<\\e1> treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"methylphenidate","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, the increase in mPFC <e2>GENE-Y<\\e2> function was an SHR-specific long term consequence of <e1>CHEMICAL<\\e1> treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration.","sentence":"Thus, the increase in mPFC DAT function was an SHR-specific long term consequence of methylphenidate treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration."}
{"PMID":23623751,"re_id":2,"annotated sentence":"<e1>Methylphenidate<\\e1>  an inhibitor of <e2>dopamine and norepinephrine transporters<\\e2> (DAT and NET, respectively), is a standard treatment for ADHD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Methylphenidate","object":"dopamine and norepinephrine transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  an inhibitor of <e2>GENE-N<\\e2> (DAT and NET, respectively), is a standard treatment for ADHD","sentence":"Methylphenidate  an inhibitor of dopamine and norepinephrine transporters (DAT and NET, respectively), is a standard treatment for ADHD"}
{"PMID":23623751,"re_id":3,"annotated sentence":"<e1>Methylphenidate<\\e1>  an inhibitor of dopamine and norepinephrine transporters (<e2>DAT<\\e2> and NET, respectively), is a standard treatment for ADHD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Methylphenidate","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an inhibitor of dopamine and norepinephrine transporters (<e2>GENE-Y<\\e2> and NET, respectively), is a standard treatment for ADHD","sentence":"Methylphenidate  an inhibitor of dopamine and norepinephrine transporters (DAT and NET, respectively), is a standard treatment for ADHD"}
{"PMID":23623751,"re_id":4,"annotated sentence":"<e1>Methylphenidate<\\e1>  an inhibitor of dopamine and norepinephrine transporters (DAT and <e2>NET<\\e2>  respectively), is a standard treatment for ADHD","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Methylphenidate","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an inhibitor of dopamine and norepinephrine transporters (DAT and <e2>GENE-Y<\\e2>  respectively), is a standard treatment for ADHD","sentence":"Methylphenidate  an inhibitor of dopamine and norepinephrine transporters (DAT and NET  respectively), is a standard treatment for ADHD"}
{"PMID":23623751,"re_id":5,"annotated sentence":"<e1>Methylphenidate<\\e1> increased DAT Vmax in SHR mPFC and decreased <e2>DAT<\\e2> Vmax in WKY OFC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Methylphenidate","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> increased GENE-Y Vmax in SHR mPFC and decreased <e2>GENE-Y<\\e2> Vmax in WKY OFC","sentence":"Methylphenidate increased DAT Vmax in SHR mPFC and decreased DAT Vmax in WKY OFC"}
{"PMID":23623751,"re_id":6,"annotated sentence":"Also, <e1>methylphenidate<\\e1> decreased <e2>DAT<\\e2> Km in WIS OFC","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"methylphenidate","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, <e1>CHEMICAL<\\e1> decreased <e2>GENE-Y<\\e2> Km in WIS OFC","sentence":"Also, methylphenidate decreased DAT Km in WIS OFC"}
{"PMID":23625750,"re_id":0,"annotated sentence":"In the <e1>IB-MECA<\\e1> group, <e2>\u03b1-amylase<\\e2> activity was decreased with statistically high significance compared to group I","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"IB-MECA","object":"\u03b1-amylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the <e1>CHEMICAL<\\e1> group, <e2>GENE-N<\\e2> activity was decreased with statistically high significance compared to group I","sentence":"In the IB-MECA group, \u03b1-amylase activity was decreased with statistically high significance compared to group I"}
{"PMID":23625750,"re_id":1,"annotated sentence":"The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the <e2>adenosine A3 receptor<\\e2> agonist <e1>IB-MECA<\\e1> (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75\u00a0mg\/kg b.w","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"IB-MECA","object":"adenosine A3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75\u00a0mg\/kg b.w","sentence":"The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the adenosine A3 receptor agonist IB-MECA (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75\u00a0mg\/kg b.w"}
{"PMID":23625750,"re_id":2,"annotated sentence":"The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the <e2>adenosine A3 receptor<\\e2> agonist IB-MECA <e1>(1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide<\\e1> at a dose of 0.75\u00a0mg\/kg b.w","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"(1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide","object":"adenosine A3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the <e2>GENE-Y<\\e2> agonist IB-MECA <e1>CHEMICAL<\\e1> at a dose of 0.75\u00a0mg\/kg b.w","sentence":"The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the adenosine A3 receptor agonist IB-MECA (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75\u00a0mg\/kg b.w"}
{"PMID":23625750,"re_id":3,"annotated sentence":"The effects of the <e2>adenosine A3 receptor<\\e2> agonist <e1>IB-MECA<\\e1> on sodium taurocholate-induced experimental acute pancreatitis","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"IB-MECA","object":"adenosine A3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> on sodium taurocholate-induced experimental acute pancreatitis","sentence":"The effects of the adenosine A3 receptor agonist IB-MECA on sodium taurocholate-induced experimental acute pancreatitis"}
{"PMID":23625750,"re_id":4,"annotated sentence":"The use of <e2>A3 receptor<\\e2> agonist <e1>IB-MECA<\\e1> attenuates EAP","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"IB-MECA","object":"A3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The use of <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> attenuates EAP","sentence":"The use of A3 receptor agonist IB-MECA attenuates EAP"}
{"PMID":23628509,"re_id":0,"annotated sentence":"The data show that <e1>CP[c]Ph<\\e1> is less potent at inducing <e2>CYP1A<\\e2> gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CP[c]Ph","object":"CYP1A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The data show that <e1>CHEMICAL<\\e1> is less potent at inducing <e2>GENE-N<\\e2> gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist","sentence":"The data show that CP[c]Ph is less potent at inducing CYP1A gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist"}
{"PMID":23628509,"re_id":1,"annotated sentence":"The data show that CP[c]Ph is less potent at inducing <e2>CYP1A<\\e2> gene expression in rainbow trout than <e1>benzo[a]pyrene<\\e1> (B[a]P), a well-known Ah-receptor agonist","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"benzo[a]pyrene","object":"CYP1A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The data show that CP[c]Ph is less potent at inducing <e2>GENE-N<\\e2> gene expression in rainbow trout than <e1>CHEMICAL<\\e1> (B[a]P), a well-known Ah-receptor agonist","sentence":"The data show that CP[c]Ph is less potent at inducing CYP1A gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist"}
{"PMID":23628509,"re_id":2,"annotated sentence":"The data show that CP[c]Ph is less potent at inducing <e2>CYP1A<\\e2> gene expression in rainbow trout than benzo[a]pyrene (<e1>B[a]P<\\e1> , a well-known Ah-receptor agonist","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"B[a]P","object":"CYP1A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The data show that CP[c]Ph is less potent at inducing <e2>GENE-N<\\e2> gene expression in rainbow trout than benzo[a]pyrene (<e1>CHEMICAL<\\e1> , a well-known Ah-receptor agonist","sentence":"The data show that CP[c]Ph is less potent at inducing CYP1A gene expression in rainbow trout than benzo[a]pyrene (B[a]P , a well-known Ah-receptor agonist"}
{"PMID":23628509,"re_id":3,"annotated sentence":"Interestingly, the <e1>CP[c]Ph<\\e1> dependent up-regulation of <e2>CYP1A<\\e2> mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"CP[c]Ph","object":"CYP1A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, the <e1>CHEMICAL<\\e1> dependent up-regulation of <e2>GENE-N<\\e2> mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes","sentence":"Interestingly, the CP[c]Ph dependent up-regulation of CYP1A mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes"}
{"PMID":23628509,"re_id":4,"annotated sentence":"<e1>CP[c]Ph<\\e1> has, comparably to B[a]P, a potential to repress expression of <e2>tumor suppressor p53<\\e2>  in the head kidney of rainbow trout","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"CP[c]Ph","object":"tumor suppressor p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has, comparably to B[a]P, a potential to repress expression of <e2>GENE-Y<\\e2>  in the head kidney of rainbow trout","sentence":"CP[c]Ph has, comparably to B[a]P, a potential to repress expression of tumor suppressor p53  in the head kidney of rainbow trout"}
{"PMID":23628509,"re_id":5,"annotated sentence":"CP[c]Ph has, comparably to <e1>B[a]P<\\e1>  a potential to repress expression of <e2>tumor suppressor p53<\\e2>  in the head kidney of rainbow trout","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"B[a]P","object":"tumor suppressor p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CP[c]Ph has, comparably to <e1>CHEMICAL<\\e1>  a potential to repress expression of <e2>GENE-Y<\\e2>  in the head kidney of rainbow trout","sentence":"CP[c]Ph has, comparably to B[a]P  a potential to repress expression of tumor suppressor p53  in the head kidney of rainbow trout"}
{"PMID":23628791,"re_id":0,"annotated sentence":"Combined treatment of <e1>Mn<\\e1> and DA further augments cell toxicity, ROS production and <e2>JNK<\\e2> phosphorylation in LRRK2 deficient cells compared to controls","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Mn","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Combined treatment of <e1>CHEMICAL<\\e1> and DA further augments cell toxicity, ROS production and <e2>GENE-N<\\e2> phosphorylation in LRRK2 deficient cells compared to controls","sentence":"Combined treatment of Mn and DA further augments cell toxicity, ROS production and JNK phosphorylation in LRRK2 deficient cells compared to controls"}
{"PMID":23629516,"re_id":0,"annotated sentence":"<e2>Type I deiodinase<\\e2>  liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by <e1>TCPP<\\e1>  while TDCPP induced CYP3A37 and CYP2H1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCPP","object":"Type I deiodinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2>  liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by <e1>CHEMICAL<\\e1>  while TDCPP induced CYP3A37 and CYP2H1","sentence":"Type I deiodinase  liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP  while TDCPP induced CYP3A37 and CYP2H1"}
{"PMID":23629516,"re_id":1,"annotated sentence":"Type I deiodinase, <e2>liver fatty-acid binding protein<\\e2> and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by <e1>TCPP<\\e1>  while TDCPP induced CYP3A37 and CYP2H1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCPP","object":"liver fatty-acid binding protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Type I deiodinase, <e2>GENE-Y<\\e2> and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by <e1>CHEMICAL<\\e1>  while TDCPP induced CYP3A37 and CYP2H1","sentence":"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP  while TDCPP induced CYP3A37 and CYP2H1"}
{"PMID":23629516,"re_id":2,"annotated sentence":"Type I deiodinase, liver fatty-acid binding protein and <e2>cytochrome P450 (CYP) 3A37<\\e2> mRNA levels were significantly induced by <e1>TCPP<\\e1>  while TDCPP induced CYP3A37 and CYP2H1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TCPP","object":"cytochrome P450 (CYP) 3A37","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Type I deiodinase, liver fatty-acid binding protein and <e2>GENE-Y<\\e2> mRNA levels were significantly induced by <e1>CHEMICAL<\\e1>  while TDCPP induced CYP3A37 and CYP2H1","sentence":"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP  while TDCPP induced CYP3A37 and CYP2H1"}
{"PMID":23629516,"re_id":3,"annotated sentence":"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while <e1>TDCPP<\\e1> induced <e2>CYP3A37<\\e2> and CYP2H1","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TDCPP","object":"CYP3A37","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> and CYP2H1","sentence":"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while TDCPP induced CYP3A37 and CYP2H1"}
{"PMID":23629516,"re_id":4,"annotated sentence":"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while <e1>TDCPP<\\e1> induced CYP3A37 and <e2>CYP2H1<\\e2>  Chemical analysis of egg contents at incubation days 0, 5, 11, 18, and 19 revealed that >92% of the injected TCPP or TDCPP concentration was detectable up to day 5; however, <1% was detected by day 19","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TDCPP","object":"CYP2H1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while <e1>CHEMICAL<\\e1> induced CYP3A37 and <e2>GENE-Y<\\e2>  Chemical analysis of egg contents at incubation days 0, 5, 11, 18, and 19 revealed that >92% of the injected TCPP or CHEMICAL concentration was detectable up to day 5; however, <1% was detected by day 19","sentence":"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while TDCPP induced CYP3A37 and CYP2H1  Chemical analysis of egg contents at incubation days 0, 5, 11, 18, and 19 revealed that >92% of the injected TCPP or TDCPP concentration was detectable up to day 5; however, <1% was detected by day 19"}
{"PMID":23631499,"re_id":0,"annotated sentence":"The results showed that administration of <e1>AlCl3<\\e1> resulted in a significant elevation in the levels of <e2>AchE<\\e2> activity, CRP, NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"AchE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that administration of <e1>CHEMICAL<\\e1> resulted in a significant elevation in the levels of <e2>GENE-Y<\\e2> activity, CRP, NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level","sentence":"The results showed that administration of AlCl3 resulted in a significant elevation in the levels of AchE activity, CRP, NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level"}
{"PMID":23631499,"re_id":1,"annotated sentence":"The results showed that administration of <e1>AlCl3<\\e1> resulted in a significant elevation in the levels of AchE activity, <e2>CRP<\\e2>  NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"CRP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that administration of <e1>CHEMICAL<\\e1> resulted in a significant elevation in the levels of AchE activity, <e2>GENE-Y<\\e2>  NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level","sentence":"The results showed that administration of AlCl3 resulted in a significant elevation in the levels of AchE activity, CRP  NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level"}
{"PMID":23631499,"re_id":2,"annotated sentence":"The results showed that administration of <e1>AlCl3<\\e1> resulted in a significant elevation in the levels of AchE activity, CRP, <e2>NF-\u03baB<\\e2>  and MCP-1 accompanied with a significant depletion in the Ach level","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results showed that administration of <e1>CHEMICAL<\\e1> resulted in a significant elevation in the levels of AchE activity, CRP, <e2>GENE-N<\\e2>  and MCP-1 accompanied with a significant depletion in the Ach level","sentence":"The results showed that administration of AlCl3 resulted in a significant elevation in the levels of AchE activity, CRP, NF-\u03baB  and MCP-1 accompanied with a significant depletion in the Ach level"}
{"PMID":23631499,"re_id":3,"annotated sentence":"The results showed that administration of <e1>AlCl3<\\e1> resulted in a significant elevation in the levels of AchE activity, CRP, NF-\u03baB, and <e2>MCP-1<\\e2> accompanied with a significant depletion in the Ach level","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"AlCl3","object":"MCP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results showed that administration of <e1>CHEMICAL<\\e1> resulted in a significant elevation in the levels of AchE activity, CRP, NF-\u03baB, and <e2>GENE-Y<\\e2> accompanied with a significant depletion in the Ach level","sentence":"The results showed that administration of AlCl3 resulted in a significant elevation in the levels of AchE activity, CRP, NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level"}
{"PMID":23632081,"re_id":0,"annotated sentence":"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of <e1>serotonin<\\e1>  possibly by facilitating the interaction of serotonin with transport-ready conformations of <e2>SERT<\\e2> when concentrations of serotonin were low and rate limiting","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"serotonin","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of <e1>CHEMICAL<\\e1>  possibly by facilitating the interaction of CHEMICAL with transport-ready conformations of <e2>GENE-Y<\\e2> when concentrations of CHEMICAL were low and rate limiting","sentence":"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin  possibly by facilitating the interaction of serotonin with transport-ready conformations of SERT when concentrations of serotonin were low and rate limiting"}
{"PMID":23632081,"re_id":1,"annotated sentence":"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of <e1>serotonin<\\e1> with transport-ready conformations of <e2>SERT<\\e2> when concentrations of serotonin were low and rate limiting","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"serotonin","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of CHEMICAL, possibly by facilitating the interaction of <e1>CHEMICAL<\\e1> with transport-ready conformations of <e2>GENE-Y<\\e2> when concentrations of CHEMICAL were low and rate limiting","sentence":"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of serotonin with transport-ready conformations of SERT when concentrations of serotonin were low and rate limiting"}
{"PMID":23632081,"re_id":2,"annotated sentence":"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of serotonin with transport-ready conformations of <e2>SERT<\\e2> when concentrations of <e1>serotonin<\\e1> were low and rate limiting","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"serotonin","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of CHEMICAL, possibly by facilitating the interaction of CHEMICAL with transport-ready conformations of <e2>GENE-Y<\\e2> when concentrations of <e1>CHEMICAL<\\e1> were low and rate limiting","sentence":"In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of serotonin, possibly by facilitating the interaction of serotonin with transport-ready conformations of SERT when concentrations of serotonin were low and rate limiting"}
{"PMID":23636303,"re_id":0,"annotated sentence":"In the local presence into the LC of the <e2>\u03b12-adrenoceptor<\\e2> antagonist <e1>RS79948<\\e1> (1\u00a0\u03bcM), systemic citalopram increased NA in the LC (Emax\u2009=\u2009157\u2009\u00b1\u200925\u00a0%) and PFC (Emax\u2009=\u2009175\u2009\u00b1\u200924\u00a0%)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"RS79948","object":"\u03b12-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the local presence into the LC of the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> (1\u00a0\u03bcM), systemic citalopram increased NA in the LC (Emax\u2009=\u2009157\u2009\u00b1\u200925\u00a0%) and PFC (Emax\u2009=\u2009175\u2009\u00b1\u200924\u00a0%)","sentence":"In the local presence into the LC of the \u03b12-adrenoceptor antagonist RS79948 (1\u00a0\u03bcM), systemic citalopram increased NA in the LC (Emax\u2009=\u2009157\u2009\u00b1\u200925\u00a0%) and PFC (Emax\u2009=\u2009175\u2009\u00b1\u200924\u00a0%)"}
{"PMID":23636303,"re_id":1,"annotated sentence":"Local LC citalopram effect was abolished by LC presence of the <e2>5-HT3<\\e2> receptor antagonist <e1>MDL72222<\\e1> (1\u00a0\u03bcM) but not the 5-HT1\/2 receptor antagonist methiothepin (1\u00a0\u03bcM)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"MDL72222","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Local LC citalopram effect was abolished by LC presence of the <e2>GENE-Y<\\e2> receptor antagonist <e1>CHEMICAL<\\e1> (1\u00a0\u03bcM) but not the 5-HT1\/2 receptor antagonist methiothepin (1\u00a0\u03bcM)","sentence":"Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1\u00a0\u03bcM) but not the 5-HT1\/2 receptor antagonist methiothepin (1\u00a0\u03bcM)"}
{"PMID":23636303,"re_id":2,"annotated sentence":"Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1\u00a0\u03bcM) but not the <e2>5-HT1\/2<\\e2> receptor antagonist <e1>methiothepin<\\e1> (1\u00a0\u03bcM)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methiothepin","object":"5-HT1\/2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1\u00a0\u03bcM) but not the <e2>GENE-N<\\e2> receptor antagonist <e1>CHEMICAL<\\e1> (1\u00a0\u03bcM)","sentence":"Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1\u00a0\u03bcM) but not the 5-HT1\/2 receptor antagonist methiothepin (1\u00a0\u03bcM)"}
{"PMID":23639362,"re_id":0,"annotated sentence":"Additionally, <e1>MPTP<\\e1> significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in <e2>Bax<\\e2> expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MPTP","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in <e2>GENE-Y<\\e2> expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment","sentence":"Additionally, MPTP significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment"}
{"PMID":23639362,"re_id":1,"annotated sentence":"Additionally, <e1>MPTP<\\e1> significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-<e2>caspase-3<\\e2> expression, whereas these were inhibited by CRE or EB treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"MPTP","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-<e2>GENE-Y<\\e2> expression, whereas these were inhibited by CRE or EB treatment","sentence":"Additionally, MPTP significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment"}
{"PMID":23639362,"re_id":2,"annotated sentence":"Additionally, <e1>MPTP<\\e1> significantly down-regulated <e2>Bcl-2<\\e2> expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"MPTP","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> significantly down-regulated <e2>GENE-Y<\\e2> expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment","sentence":"Additionally, MPTP significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment"}
{"PMID":23639738,"re_id":0,"annotated sentence":"<e2>Cholesterol esterase<\\e2> (CE) induced surface erosion of poly(ethylene carbonate) (<e1>PEC<\\e1>  and drug release from PEC under mild physiological environment was investigated","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PEC","object":"Cholesterol esterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CE) induced surface erosion of poly(ethylene carbonate) (<e1>CHEMICAL<\\e1>  and drug release from CHEMICAL under mild physiological environment was investigated","sentence":"Cholesterol esterase (CE) induced surface erosion of poly(ethylene carbonate) (PEC  and drug release from PEC under mild physiological environment was investigated"}
{"PMID":23639738,"re_id":1,"annotated sentence":"Cholesterol esterase (<e2>CE<\\e2>  induced surface erosion of poly(ethylene carbonate) (<e1>PEC<\\e1>  and drug release from PEC under mild physiological environment was investigated","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"PEC","object":"CE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cholesterol esterase (<e2>GENE-Y<\\e2>  induced surface erosion of poly(ethylene carbonate) (<e1>CHEMICAL<\\e1>  and drug release from CHEMICAL under mild physiological environment was investigated","sentence":"Cholesterol esterase (CE  induced surface erosion of poly(ethylene carbonate) (PEC  and drug release from PEC under mild physiological environment was investigated"}
{"PMID":23639738,"re_id":2,"annotated sentence":"<e2>Cholesterol esterase<\\e2> (CE) induced surface erosion of <e1>poly(ethylene carbonate)<\\e1> (PEC) and drug release from PEC under mild physiological environment was investigated","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"poly(ethylene carbonate)","object":"Cholesterol esterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CE) induced surface erosion of <e1>CHEMICAL<\\e1> (PEC) and drug release from PEC under mild physiological environment was investigated","sentence":"Cholesterol esterase (CE) induced surface erosion of poly(ethylene carbonate) (PEC) and drug release from PEC under mild physiological environment was investigated"}
{"PMID":23639738,"re_id":3,"annotated sentence":"Cholesterol esterase (<e2>CE<\\e2>  induced surface erosion of <e1>poly(ethylene carbonate)<\\e1> (PEC) and drug release from PEC under mild physiological environment was investigated","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"poly(ethylene carbonate)","object":"CE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cholesterol esterase (<e2>GENE-Y<\\e2>  induced surface erosion of <e1>CHEMICAL<\\e1> (PEC) and drug release from PEC under mild physiological environment was investigated","sentence":"Cholesterol esterase (CE  induced surface erosion of poly(ethylene carbonate) (PEC) and drug release from PEC under mild physiological environment was investigated"}
{"PMID":23642478,"re_id":0,"annotated sentence":"A series of <e1>benzenesulfonamides<\\e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2>  from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzenesulfonamides","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, <e2>GENE-Y<\\e2>  from Saccharomyces cerevisiae, ScCA","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1  from Saccharomyces cerevisiae, ScCA"}
{"PMID":23642478,"re_id":1,"annotated sentence":"A series of <e1>benzenesulfonamides<\\e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, <e2>ScCA<\\e2>  Some of these compounds were low nanomolar or subnanomolar ScCA inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting ScCA over hCA II","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzenesulfonamides","object":"ScCA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, <e2>GENE-Y<\\e2>  Some of these compounds were low nanomolar or subnanomolar GENE-Y inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting GENE-Y over hCA II","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA  Some of these compounds were low nanomolar or subnanomolar ScCA inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting ScCA over hCA II"}
{"PMID":23642478,"re_id":2,"annotated sentence":"A series of <e1>benzenesulfonamides<\\e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the <e2>\u03b2-carbonic anhydrase<\\e2> (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzenesulfonamides","object":"\u03b2-carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the <e2>GENE-Y<\\e2> (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA"}
{"PMID":23642478,"re_id":3,"annotated sentence":"A series of <e1>benzenesulfonamides<\\e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benzenesulfonamides","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of <e1>CHEMIGENE-NL<\\e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1) from Saccharomyces cerevisiae, ScGENE-N","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA  EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA"}
{"PMID":23642478,"re_id":4,"annotated sentence":"A series of benzenesulfonamides incorporating <e1>cyanoacrylamide<\\e1> moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2>  from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyanoacrylamide","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of benzenesulfonamides incorporating <e1>CHEMICAL<\\e1> moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, <e2>GENE-Y<\\e2>  from Saccharomyces cerevisiae, ScCA","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1  from Saccharomyces cerevisiae, ScCA"}
{"PMID":23642478,"re_id":5,"annotated sentence":"A series of benzenesulfonamides incorporating <e1>cyanoacrylamide<\\e1> moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, <e2>ScCA<\\e2>  Some of these compounds were low nanomolar or subnanomolar ScCA inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting ScCA over hCA II","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyanoacrylamide","object":"ScCA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of benzenesulfonamides incorporating <e1>CHEMICAL<\\e1> moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, <e2>GENE-Y<\\e2>  Some of these compounds were low nanomolar or subnanomolar GENE-Y inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting GENE-Y over hCA II","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA  Some of these compounds were low nanomolar or subnanomolar ScCA inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting ScCA over hCA II"}
{"PMID":23642478,"re_id":6,"annotated sentence":"A series of benzenesulfonamides incorporating <e1>cyanoacrylamide<\\e1> moieties (tyrphostine analogs) were assayed as inhibitors of the <e2>\u03b2-carbonic anhydrase<\\e2> (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyanoacrylamide","object":"\u03b2-carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of benzenesulfonamides incorporating <e1>CHEMICAL<\\e1> moieties (tyrphostine analogs) were assayed as inhibitors of the <e2>GENE-Y<\\e2> (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA"}
{"PMID":23642478,"re_id":7,"annotated sentence":"A series of benzenesulfonamides incorporating <e1>cyanoacrylamide<\\e1> moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyanoacrylamide","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of benzenesulfonamides incorporating <e1>CHEMIGENE-NL<\\e1> moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1) from Saccharomyces cerevisiae, ScGENE-N","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA  EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA"}
{"PMID":23642478,"re_id":8,"annotated sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>tyrphostine<\\e1> analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, <e2>EC 4.2.1.1<\\e2>  from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tyrphostine","object":"EC 4.2.1.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>CHEMICAL<\\e1> analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, <e2>GENE-Y<\\e2>  from Saccharomyces cerevisiae, ScCA","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1  from Saccharomyces cerevisiae, ScCA"}
{"PMID":23642478,"re_id":9,"annotated sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>tyrphostine<\\e1> analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, <e2>ScCA<\\e2>  Some of these compounds were low nanomolar or subnanomolar ScCA inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting ScCA over hCA II","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tyrphostine","object":"ScCA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>CHEMICAL<\\e1> analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, <e2>GENE-Y<\\e2>  Some of these compounds were low nanomolar or subnanomolar GENE-Y inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting GENE-Y over hCA II","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA  Some of these compounds were low nanomolar or subnanomolar ScCA inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting ScCA over hCA II"}
{"PMID":23642478,"re_id":10,"annotated sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>tyrphostine<\\e1> analogs) were assayed as inhibitors of the <e2>\u03b2-carbonic anhydrase<\\e2> (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tyrphostine","object":"\u03b2-carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>CHEMICAL<\\e1> analogs) were assayed as inhibitors of the <e2>GENE-Y<\\e2> (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA"}
{"PMID":23642478,"re_id":11,"annotated sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>tyrphostine<\\e1> analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (<e2>CA<\\e2>  EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"tyrphostine","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>CHEMIGENE-NL<\\e1> analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (<e2>GENE-N<\\e2>  EC 4.2.1.1) from Saccharomyces cerevisiae, ScGENE-N","sentence":"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA  EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA"}
{"PMID":23642478,"re_id":12,"annotated sentence":"<e1>Benzenesulfonamides<\\e1> incorporating cyanoacrylamide moieties strongly inhibit <e2>Saccharomyces cerevisiae \u03b2-carbonic anhydrase<\\e2>  A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Benzenesulfonamides","object":"Saccharomyces cerevisiae \u03b2-carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> incorporating cyanoacrylamide moieties strongly inhibit <e2>GENE-Y<\\e2>  A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","sentence":"Benzenesulfonamides incorporating cyanoacrylamide moieties strongly inhibit Saccharomyces cerevisiae \u03b2-carbonic anhydrase  A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA"}
{"PMID":23642478,"re_id":13,"annotated sentence":"Benzenesulfonamides incorporating <e1>cyanoacrylamide<\\e1> moieties strongly inhibit <e2>Saccharomyces cerevisiae \u03b2-carbonic anhydrase<\\e2>  A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyanoacrylamide","object":"Saccharomyces cerevisiae \u03b2-carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Benzenesulfonamides incorporating <e1>CHEMICAL<\\e1> moieties strongly inhibit <e2>GENE-Y<\\e2>  A series of benzenesulfonamides incorporating CHEMICAL moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA","sentence":"Benzenesulfonamides incorporating cyanoacrylamide moieties strongly inhibit Saccharomyces cerevisiae \u03b2-carbonic anhydrase  A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA"}
{"PMID":23643730,"re_id":0,"annotated sentence":"<e1>Juglone<\\e1>  isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of <e2>AR<\\e2> expression in human prostate cancer LNCaP cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Juglone","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of <e2>GENE-Y<\\e2> expression in human prostate cancer LNCaP cells","sentence":"Juglone  isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of AR expression in human prostate cancer LNCaP cells"}
{"PMID":23643730,"re_id":1,"annotated sentence":"Moreover, we found that <e1>juglone<\\e1> significantly inhibited the expression levels of <e2>androgen receptor<\\e2> (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"juglone","object":"androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, we found that <e1>CHEMICAL<\\e1> significantly inhibited the expression levels of <e2>GENE-Y<\\e2> (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)","sentence":"Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)"}
{"PMID":23643730,"re_id":2,"annotated sentence":"Moreover, we found that <e1>juglone<\\e1> significantly inhibited the expression levels of androgen receptor (<e2>AR<\\e2>  and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"juglone","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, we found that <e1>CHEMICAL<\\e1> significantly inhibited the expression levels of androgen receptor (<e2>GENE-Y<\\e2>  and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of GENE-Y and PSA genes with and\/or without dihydrotestosterone (DHT)","sentence":"Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR  and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)"}
{"PMID":23643730,"re_id":3,"annotated sentence":"Moreover, we found that <e1>juglone<\\e1> significantly inhibited the expression levels of androgen receptor (AR) and <e2>prostate-specific antigen<\\e2> (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"juglone","object":"prostate-specific antigen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, we found that <e1>CHEMICAL<\\e1> significantly inhibited the expression levels of androgen receptor (AR) and <e2>GENE-Y<\\e2> (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)","sentence":"Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)"}
{"PMID":23643730,"re_id":4,"annotated sentence":"Moreover, we found that <e1>juglone<\\e1> significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (<e2>PSA<\\e2>  in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"juglone","object":"PSA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, we found that <e1>CHEMICAL<\\e1> significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (<e2>GENE-Y<\\e2>  in a dose-dependent manner, as well as abrogated up-regulation of AR and GENE-Y genes with and\/or without dihydrotestosterone (DHT)","sentence":"Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA  in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)"}
{"PMID":23643730,"re_id":5,"annotated sentence":"Moreover, we found that <e1>juglone<\\e1> significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of <e2>AR<\\e2> and PSA genes with and\/or without dihydrotestosterone (DHT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"juglone","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, we found that <e1>CHEMICAL<\\e1> significantly inhibited the expression levels of androgen receptor (GENE-Y) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of <e2>GENE-Y<\\e2> and PSA genes with and\/or without dihydrotestosterone (DHT)","sentence":"Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)"}
{"PMID":23643730,"re_id":6,"annotated sentence":"Moreover, we found that <e1>juglone<\\e1> significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and <e2>PSA<\\e2> genes with and\/or without dihydrotestosterone (DHT)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"juglone","object":"PSA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, we found that <e1>CHEMICAL<\\e1> significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (GENE-Y) in a dose-dependent manner, as well as abrogated up-regulation of AR and <e2>GENE-Y<\\e2> genes with and\/or without dihydrotestosterone (DHT)","sentence":"Moreover, we found that juglone significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and\/or without dihydrotestosterone (DHT)"}
{"PMID":23643730,"re_id":7,"annotated sentence":"Take together, our results demonstrated that <e1>juglone<\\e1> might induce the apoptosis in LNCaP cell via down-regulation of <e2>AR<\\e2> expression","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"juglone","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Take together, our results demonstrated that <e1>CHEMICAL<\\e1> might induce the apoptosis in LNCaP cell via down-regulation of <e2>GENE-Y<\\e2> expression","sentence":"Take together, our results demonstrated that juglone might induce the apoptosis in LNCaP cell via down-regulation of AR expression"}
{"PMID":23643883,"re_id":0,"annotated sentence":"In addition, pretreatment with <e1>Z-Val-Ala-Asp-fluoromethylketone<\\e1> (Z-VAD-fmk), a broad spectrum of <e2>caspase<\\e2> inhibitor, could not rescue apoptotic cells from ClpP toxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Z-Val-Ala-Asp-fluoromethylketone","object":"caspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, pretreatment with <e1>CHEMICAL<\\e1> (Z-VAD-fmk), a broad spectrum of <e2>GENE-N<\\e2> inhibitor, could not rescue apoptotic cells from ClpP toxicity","sentence":"In addition, pretreatment with Z-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk), a broad spectrum of caspase inhibitor, could not rescue apoptotic cells from ClpP toxicity"}
{"PMID":23643883,"re_id":1,"annotated sentence":"In addition, pretreatment with Z-Val-Ala-Asp-fluoromethylketone (<e1>Z-VAD-fmk<\\e1> , a broad spectrum of <e2>caspase<\\e2> inhibitor, could not rescue apoptotic cells from ClpP toxicity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Z-VAD-fmk","object":"caspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, pretreatment with Z-Val-Ala-Asp-fluoromethylketone (<e1>CHEMICAL<\\e1> , a broad spectrum of <e2>GENE-N<\\e2> inhibitor, could not rescue apoptotic cells from ClpP toxicity","sentence":"In addition, pretreatment with Z-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk , a broad spectrum of caspase inhibitor, could not rescue apoptotic cells from ClpP toxicity"}
{"PMID":23643933,"re_id":0,"annotated sentence":"Among these differentially expressed lncRNAs, the greatest change was noted for <e2>uc002mbe.2<\\e2>  which had more than 300 folds induction upon <e1>TSA<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TSA","object":"uc002mbe.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among these differentially expressed lncRNAs, the greatest change was noted for <e2>GENE-Y<\\e2>  which had more than 300 folds induction upon <e1>CHEMICAL<\\e1> treatment","sentence":"Among these differentially expressed lncRNAs, the greatest change was noted for uc002mbe.2  which had more than 300 folds induction upon TSA treatment"}
{"PMID":23643933,"re_id":1,"annotated sentence":"<e1>TSA<\\e1> selectively induced <e2>uc002mbe.2<\\e2> in four studied HCC cell lines","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TSA","object":"uc002mbe.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> selectively induced <e2>GENE-Y<\\e2> in four studied HCC cell lines","sentence":"TSA selectively induced uc002mbe.2 in four studied HCC cell lines"}
{"PMID":23643933,"re_id":2,"annotated sentence":"The <e1>TSA<\\e1> induced <e2>uc002mbe.2<\\e2> expression was positively correlated with the apoptotic effect of TSA in HCC cells","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"TSA","object":"uc002mbe.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> expression was positively correlated with the apoptotic effect of CHEMICAL in HCC cells","sentence":"The TSA induced uc002mbe.2 expression was positively correlated with the apoptotic effect of TSA in HCC cells"}
{"PMID":23643933,"re_id":3,"annotated sentence":"Considerable attention has focused on the antitumor effect of <e2>histone deacetylase<\\e2> inhibitor (<e1>Trichostatin A<\\e1>  TSA) as well as the coding gene expression-induced apoptosis of cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Trichostatin A","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Considerable attention has focused on the antitumor effect of <e2>GENE-N<\\e2> inhibitor (<e1>CHEMICAL<\\e1>  TSA) as well as the coding gene expression-induced apoptosis of cancer cells","sentence":"Considerable attention has focused on the antitumor effect of histone deacetylase inhibitor (Trichostatin A  TSA) as well as the coding gene expression-induced apoptosis of cancer cells"}
{"PMID":23643933,"re_id":4,"annotated sentence":"Considerable attention has focused on the antitumor effect of <e2>histone deacetylase<\\e2> inhibitor (Trichostatin A, <e1>TSA<\\e1>  as well as the coding gene expression-induced apoptosis of cancer cells","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"TSA","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Considerable attention has focused on the antitumor effect of <e2>GENE-N<\\e2> inhibitor (Trichostatin A, <e1>CHEMICAL<\\e1>  as well as the coding gene expression-induced apoptosis of cancer cells","sentence":"Considerable attention has focused on the antitumor effect of histone deacetylase inhibitor (Trichostatin A, TSA  as well as the coding gene expression-induced apoptosis of cancer cells"}
{"PMID":23644411,"re_id":0,"annotated sentence":"RESULTS: Fractionated bulb extracts and the two isolated <e1>steroidal glycoalkaloids<\\e1> (1) and (2) induced NO production and <e2>TGF-\u03b2 receptor I<\\e2> mRNA expression in fibroblast cell culture","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"steroidal glycoalkaloids","object":"TGF-\u03b2 receptor I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Fractionated bulb extracts and the two isolated <e1>CHEMICAL<\\e1> (1) and (2) induced NO production and <e2>GENE-Y<\\e2> mRNA expression in fibroblast cell culture","sentence":"RESULTS: Fractionated bulb extracts and the two isolated steroidal glycoalkaloids (1) and (2) induced NO production and TGF-\u03b2 receptor I mRNA expression in fibroblast cell culture"}
{"PMID":25225185,"re_id":0,"annotated sentence":"Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, <e1>brexpiprazole<\\e1> displayed less efficacy at <e2>D2 receptors<\\e2>  In the hippocampus, brexpiprazole acted as a full agonist at 5-HT1A receptors on pyramidal neurons","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"brexpiprazole","object":"D2 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, <e1>CHEMICAL<\\e1> displayed less efficacy at <e2>GENE-Y<\\e2>  In the hippocampus, CHEMICAL acted as a full agonist at 5-HT1A receptors on pyramidal neurons","sentence":"Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, brexpiprazole displayed less efficacy at D2 receptors  In the hippocampus, brexpiprazole acted as a full agonist at 5-HT1A receptors on pyramidal neurons"}
{"PMID":25225185,"re_id":1,"annotated sentence":"In the DRN, <e1>brexpiprazole<\\e1> completely inhibited the firing of 5-HT neurons via <e2>5-HT1A<\\e2> agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug\/kg, respectively)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"brexpiprazole","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the DRN, <e1>CHEMICAL<\\e1> completely inhibited the firing of 5-HT neurons via <e2>GENE-Y<\\e2> agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug\/kg, respectively)","sentence":"In the DRN, brexpiprazole completely inhibited the firing of 5-HT neurons via 5-HT1A agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug\/kg, respectively)"}
{"PMID":25225185,"re_id":2,"annotated sentence":"In the DRN, brexpiprazole completely inhibited the firing of 5-HT neurons via <e2>5-HT1A<\\e2> agonism and was more potent than <e1>aripiprazole<\\e1> (ED50 = 230 and 700 mug\/kg, respectively)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"aripiprazole","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the DRN, brexpiprazole completely inhibited the firing of 5-HT neurons via <e2>GENE-Y<\\e2> agonism and was more potent than <e1>CHEMICAL<\\e1> (ED50 = 230 and 700 mug\/kg, respectively)","sentence":"In the DRN, brexpiprazole completely inhibited the firing of 5-HT neurons via 5-HT1A agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug\/kg, respectively)"}
{"PMID":25225185,"re_id":3,"annotated sentence":"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential <e2>5-HT2A<\\e2> receptor agonist <e1>DOI<\\e1> (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug\/kg), demonstrating 5-HT2A antagonistic action","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"DOI","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential <e2>GENE-Y<\\e2> receptor agonist <e1>CHEMICAL<\\e1> (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug\/kg), demonstrating GENE-Y antagonistic action","sentence":"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential 5-HT2A receptor agonist DOI (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug\/kg), demonstrating 5-HT2A antagonistic action"}
{"PMID":25225185,"re_id":4,"annotated sentence":"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential <e2>5-HT2A<\\e2> receptor agonist DOI (<e1>2,5-dimethoxy-4-iodoamphetamine<\\e1>  on norepinephrine neuronal firing (ED50 = 110 mug\/kg), demonstrating 5-HT2A antagonistic action","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"2,5-dimethoxy-4-iodoamphetamine","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential <e2>GENE-Y<\\e2> receptor agonist DOI (<e1>CHEMICAL<\\e1>  on norepinephrine neuronal firing (ED50 = 110 mug\/kg), demonstrating GENE-Y antagonistic action","sentence":"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential 5-HT2A receptor agonist DOI (2,5-dimethoxy-4-iodoamphetamine  on norepinephrine neuronal firing (ED50 = 110 mug\/kg), demonstrating 5-HT2A antagonistic action"}
{"PMID":25225185,"re_id":5,"annotated sentence":"Brexpiprazole reversed the inhibitory effect of the DA agonist <e1>apomorphine<\\e1> on VTA DA neurons (ED50 = 61 mug\/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on <e2>D2 receptors<\\e2>  Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, brexpiprazole displayed less efficacy at D2 receptors","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"apomorphine","object":"D2 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Brexpiprazole reversed the inhibitory effect of the DA agonist <e1>CHEMICAL<\\e1> on VTA DA neurons (ED50 = 61 mug\/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on <e2>GENE-Y<\\e2>  Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, brexpiprazole displayed less efficacy at GENE-Y","sentence":"Brexpiprazole reversed the inhibitory effect of the DA agonist apomorphine on VTA DA neurons (ED50 = 61 mug\/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on D2 receptors  Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, brexpiprazole displayed less efficacy at D2 receptors"}
{"PMID":25225185,"re_id":6,"annotated sentence":"In the hippocampus, <e1>brexpiprazole<\\e1> acted as a full agonist at <e2>5-HT1A<\\e2> receptors on pyramidal neurons","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"brexpiprazole","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the hippocampus, <e1>CHEMICAL<\\e1> acted as a full agonist at <e2>GENE-Y<\\e2> receptors on pyramidal neurons","sentence":"In the hippocampus, brexpiprazole acted as a full agonist at 5-HT1A receptors on pyramidal neurons"}
{"PMID":25225185,"re_id":7,"annotated sentence":"In the lateral geniculate nucleus, <e1>brexpiprazole<\\e1> displayed <e2>alpha1B-adrenoceptor<\\e2> antagonistic action","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"brexpiprazole","object":"alpha1B-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the lateral geniculate nucleus, <e1>CHEMICAL<\\e1> displayed <e2>GENE-Y<\\e2> antagonistic action","sentence":"In the lateral geniculate nucleus, brexpiprazole displayed alpha1B-adrenoceptor antagonistic action"}
{"PMID":2530096,"re_id":0,"annotated sentence":"The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a <e2>5-HT1A<\\e2> selective agonist, <e1>8-hydroxy-2-(di-n-propylamino)tetralin<\\e1>  was inactive","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"8-hydroxy-2-(di-n-propylamino)tetralin","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a <e2>GENE-Y<\\e2> selective agonist, <e1>CHEMICAL<\\e1>  was inactive","sentence":"The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a 5-HT1A selective agonist, 8-hydroxy-2-(di-n-propylamino)tetralin  was inactive"}
{"PMID":2530096,"re_id":1,"annotated sentence":"The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective <e2>5-HT2<\\e2> antagonist, <e1>ritanserin<\\e1>  These results suggest that the beneficial effect of minaprine on cycloheximide-induced amnesia may be related not only to cholinergic but also serotonergic neuronal systems (5-HT2 receptors).","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ritanserin","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1>  These results suggest that the beneficial effect of minaprine on cycloheximide-induced amnesia may be related not only to cholinergic but also serotonergic neuronal systems (GENE-N receptors).","sentence":"The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective 5-HT2 antagonist, ritanserin  These results suggest that the beneficial effect of minaprine on cycloheximide-induced amnesia may be related not only to cholinergic but also serotonergic neuronal systems (5-HT2 receptors)."}
{"PMID":2568212,"re_id":0,"annotated sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>histamine H1-receptor<\\e2> antagonists <e1>terfenadine<\\e1>  astemizole, loratadine, and acrivastine are reviewed","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"terfenadine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>GENE-Y<\\e2> antagonists <e1>CHEMICAL<\\e1>  astemizole, loratadine, and acrivastine are reviewed","sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating histamine H1-receptor antagonists terfenadine  astemizole, loratadine, and acrivastine are reviewed"}
{"PMID":2568212,"re_id":1,"annotated sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>histamine H1-receptor<\\e2> antagonists terfenadine, <e1>astemizole<\\e1>  loratadine, and acrivastine are reviewed","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"astemizole","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>GENE-Y<\\e2> antagonists terfenadine, <e1>CHEMICAL<\\e1>  loratadine, and acrivastine are reviewed","sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating histamine H1-receptor antagonists terfenadine, astemizole  loratadine, and acrivastine are reviewed"}
{"PMID":2568212,"re_id":2,"annotated sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>histamine H1-receptor<\\e2> antagonists terfenadine, astemizole, <e1>loratadine<\\e1>  and acrivastine are reviewed","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"loratadine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>GENE-Y<\\e2> antagonists terfenadine, astemizole, <e1>CHEMICAL<\\e1>  and acrivastine are reviewed","sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating histamine H1-receptor antagonists terfenadine, astemizole, loratadine  and acrivastine are reviewed"}
{"PMID":2568212,"re_id":3,"annotated sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>histamine H1-receptor<\\e2> antagonists terfenadine, astemizole, loratadine, and <e1>acrivastine<\\e1> are reviewed","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"acrivastine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>GENE-Y<\\e2> antagonists terfenadine, astemizole, loratadine, and <e1>CHEMICAL<\\e1> are reviewed","sentence":"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating histamine H1-receptor antagonists terfenadine, astemizole, loratadine, and acrivastine are reviewed"}
{"PMID":2568212,"re_id":4,"annotated sentence":"<e1>Terfenadine<\\e1> and astemizole are chemically unrelated to <e2>histamine H1-receptor<\\e2> antagonists such as diphenhydramine and chlorpheniramine","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Terfenadine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and astemizole are chemically unrelated to <e2>GENE-Y<\\e2> antagonists such as diphenhydramine and chlorpheniramine","sentence":"Terfenadine and astemizole are chemically unrelated to histamine H1-receptor antagonists such as diphenhydramine and chlorpheniramine"}
{"PMID":2568212,"re_id":5,"annotated sentence":"Terfenadine and <e1>astemizole<\\e1> are chemically unrelated to <e2>histamine H1-receptor<\\e2> antagonists such as diphenhydramine and chlorpheniramine","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"astemizole","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Terfenadine and <e1>CHEMICAL<\\e1> are chemically unrelated to <e2>GENE-Y<\\e2> antagonists such as diphenhydramine and chlorpheniramine","sentence":"Terfenadine and astemizole are chemically unrelated to histamine H1-receptor antagonists such as diphenhydramine and chlorpheniramine"}
{"PMID":2568212,"re_id":6,"annotated sentence":"Terfenadine and astemizole are chemically unrelated to <e2>histamine H1-receptor<\\e2> antagonists such as <e1>diphenhydramine<\\e1> and chlorpheniramine","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"diphenhydramine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Terfenadine and astemizole are chemically unrelated to <e2>GENE-Y<\\e2> antagonists such as <e1>CHEMICAL<\\e1> and chlorpheniramine","sentence":"Terfenadine and astemizole are chemically unrelated to histamine H1-receptor antagonists such as diphenhydramine and chlorpheniramine"}
{"PMID":2568212,"re_id":7,"annotated sentence":"Terfenadine and astemizole are chemically unrelated to <e2>histamine H1-receptor<\\e2> antagonists such as diphenhydramine and <e1>chlorpheniramine<\\e1>  Loratadine is structurally related to the antihistamine azatadine, and acrivastine is a side-chain-reduced metabolite of the antihistamine triprolidine","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"chlorpheniramine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Terfenadine and astemizole are chemically unrelated to <e2>GENE-Y<\\e2> antagonists such as diphenhydramine and <e1>CHEMICAL<\\e1>  Loratadine is structurally related to the antihistamine azatadine, and acrivastine is a side-chain-reduced metabolite of the antihistamine triprolidine","sentence":"Terfenadine and astemizole are chemically unrelated to histamine H1-receptor antagonists such as diphenhydramine and chlorpheniramine  Loratadine is structurally related to the antihistamine azatadine, and acrivastine is a side-chain-reduced metabolite of the antihistamine triprolidine"}
{"PMID":2568748,"re_id":0,"annotated sentence":"<e1>Esmolol<\\e1>  a unique cardioselective <e2>beta 1-adrenergic receptor<\\e2> blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Esmolol","object":"beta 1-adrenergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a unique cardioselective <e2>GENE-Y<\\e2> blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy","sentence":"Esmolol  a unique cardioselective beta 1-adrenergic receptor blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy"}
{"PMID":2833901,"re_id":0,"annotated sentence":"Felodipine and the <e1>p-chloro<\\e1> analogue inhibited the actin-activated <e2>Mg2+-ATPase<\\e2> activity of smooth muscle myosin (IC50 = 25.1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"Mg2+-ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Felodipine and the <e1>CHEMICAL<\\e1> analogue inhibited the actin-activated <e2>GENE-N<\\e2> activity of smooth muscle myosin (IC50 = 25.1 microM)","sentence":"Felodipine and the p-chloro analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle myosin (IC50 = 25.1 microM)"}
{"PMID":2833901,"re_id":1,"annotated sentence":"Felodipine and the <e1>p-chloro<\\e1> analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle <e2>myosin<\\e2> (IC50 = 25.1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"myosin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Felodipine and the <e1>CHEMICAL<\\e1> analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle <e2>GENE-N<\\e2> (IC50 = 25.1 microM)","sentence":"Felodipine and the p-chloro analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle myosin (IC50 = 25.1 microM)"}
{"PMID":2833901,"re_id":2,"annotated sentence":"Similarly, <e1>felodipine<\\e1> and the p-chloro analogue blocked <e2>myosin<\\e2> filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"myosin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Similarly, <e1>CHEMICAL<\\e1> and the p-chloro analogue blocked <e2>GENE-N<\\e2> filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not","sentence":"Similarly, felodipine and the p-chloro analogue blocked myosin filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not"}
{"PMID":2833901,"re_id":3,"annotated sentence":"Similarly, felodipine and the <e1>p-chloro<\\e1> analogue blocked <e2>myosin<\\e2> filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"myosin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Similarly, felodipine and the <e1>CHEMICAL<\\e1> analogue blocked <e2>GENE-N<\\e2> filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not","sentence":"Similarly, felodipine and the p-chloro analogue blocked myosin filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not"}
{"PMID":2833901,"re_id":4,"annotated sentence":"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine <e2>Ca2+ channel<\\e2> blocker <e1>felodipine<\\e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"Ca2+ channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine <e2>GENE-N<\\e2> blocker <e1>CHEMICAL<\\e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies","sentence":"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies"}
{"PMID":2833901,"re_id":5,"annotated sentence":"Again, inhibition of the actin-activated <e2>myosin<\\e2> Mg2+-ATPase and myosin filament assembly by <e1>felodipine<\\e1> and the p-chloro analogue could be reversed by raising the calmodulin concentration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"myosin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Again, inhibition of the actin-activated <e2>GENE-N<\\e2> Mg2+-ATPase and GENE-N filament assembly by <e1>CHEMICAL<\\e1> and the p-chloro analogue could be reversed by raising the calmodulin concentration","sentence":"Again, inhibition of the actin-activated myosin Mg2+-ATPase and myosin filament assembly by felodipine and the p-chloro analogue could be reversed by raising the calmodulin concentration"}
{"PMID":2833901,"re_id":6,"annotated sentence":"Again, inhibition of the actin-activated myosin <e2>Mg2+-ATPase<\\e2> and myosin filament assembly by <e1>felodipine<\\e1> and the p-chloro analogue could be reversed by raising the calmodulin concentration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"Mg2+-ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Again, inhibition of the actin-activated myosin <e2>GENE-N<\\e2> and myosin filament assembly by <e1>CHEMICAL<\\e1> and the p-chloro analogue could be reversed by raising the calmodulin concentration","sentence":"Again, inhibition of the actin-activated myosin Mg2+-ATPase and myosin filament assembly by felodipine and the p-chloro analogue could be reversed by raising the calmodulin concentration"}
{"PMID":2833901,"re_id":7,"annotated sentence":"Again, inhibition of the actin-activated myosin Mg2+-ATPase and <e2>myosin<\\e2> filament assembly by <e1>felodipine<\\e1> and the p-chloro analogue could be reversed by raising the calmodulin concentration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"myosin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Again, inhibition of the actin-activated GENE-N Mg2+-ATPase and <e2>GENE-N<\\e2> filament assembly by <e1>CHEMICAL<\\e1> and the p-chloro analogue could be reversed by raising the calmodulin concentration","sentence":"Again, inhibition of the actin-activated myosin Mg2+-ATPase and myosin filament assembly by felodipine and the p-chloro analogue could be reversed by raising the calmodulin concentration"}
{"PMID":2833901,"re_id":8,"annotated sentence":"Again, inhibition of the actin-activated <e2>myosin<\\e2> Mg2+-ATPase and myosin filament assembly by felodipine and the <e1>p-chloro<\\e1> analogue could be reversed by raising the calmodulin concentration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"myosin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Again, inhibition of the actin-activated <e2>GENE-N<\\e2> Mg2+-ATPase and GENE-N filament assembly by felodipine and the <e1>CHEMICAL<\\e1> analogue could be reversed by raising the calmodulin concentration","sentence":"Again, inhibition of the actin-activated myosin Mg2+-ATPase and myosin filament assembly by felodipine and the p-chloro analogue could be reversed by raising the calmodulin concentration"}
{"PMID":2833901,"re_id":9,"annotated sentence":"Again, inhibition of the actin-activated myosin <e2>Mg2+-ATPase<\\e2> and myosin filament assembly by felodipine and the <e1>p-chloro<\\e1> analogue could be reversed by raising the calmodulin concentration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"Mg2+-ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Again, inhibition of the actin-activated myosin <e2>GENE-N<\\e2> and myosin filament assembly by felodipine and the <e1>CHEMICAL<\\e1> analogue could be reversed by raising the calmodulin concentration","sentence":"Again, inhibition of the actin-activated myosin Mg2+-ATPase and myosin filament assembly by felodipine and the p-chloro analogue could be reversed by raising the calmodulin concentration"}
{"PMID":2833901,"re_id":10,"annotated sentence":"Again, inhibition of the actin-activated myosin Mg2+-ATPase and <e2>myosin<\\e2> filament assembly by felodipine and the <e1>p-chloro<\\e1> analogue could be reversed by raising the calmodulin concentration","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"myosin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Again, inhibition of the actin-activated GENE-N Mg2+-ATPase and <e2>GENE-N<\\e2> filament assembly by felodipine and the <e1>CHEMICAL<\\e1> analogue could be reversed by raising the calmodulin concentration","sentence":"Again, inhibition of the actin-activated myosin Mg2+-ATPase and myosin filament assembly by felodipine and the p-chloro analogue could be reversed by raising the calmodulin concentration"}
{"PMID":2833901,"re_id":11,"annotated sentence":"These observations suggest that some of the pharmacological actions of <e1>felodipine<\\e1> on smooth muscle may involve inhibition of <e2>calmodulin-dependent enzymes<\\e2> which are functionally involved in the regulation of smooth muscle contraction.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"calmodulin-dependent enzymes","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These observations suggest that some of the pharmacological actions of <e1>CHEMICAL<\\e1> on smooth muscle may involve inhibition of <e2>GENE-N<\\e2> which are functionally involved in the regulation of smooth muscle contraction.","sentence":"These observations suggest that some of the pharmacological actions of felodipine on smooth muscle may involve inhibition of calmodulin-dependent enzymes which are functionally involved in the regulation of smooth muscle contraction."}
{"PMID":2833901,"re_id":12,"annotated sentence":"The <e2>cAMP phosphodiesterase<\\e2> was inhibited completely by <e1>felodipine<\\e1> and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"cAMP phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> was inhibited completely by <e1>CHEMICAL<\\e1> and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively","sentence":"The cAMP phosphodiesterase was inhibited completely by felodipine and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively"}
{"PMID":2833901,"re_id":13,"annotated sentence":"The <e2>cAMP phosphodiesterase<\\e2> was inhibited completely by felodipine and the <e1>p-chloro<\\e1> analogue with IC50 values of 3.7 and 1.5 microM respectively","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"cAMP phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> was inhibited completely by felodipine and the <e1>CHEMICAL<\\e1> analogue with IC50 values of 3.7 and 1.5 microM respectively","sentence":"The cAMP phosphodiesterase was inhibited completely by felodipine and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively"}
{"PMID":2833901,"re_id":14,"annotated sentence":"<e1>Felodipine<\\e1> and the p-chloro analogue inhibited the basal (Ca2+\/calmodulin-independent) activity of <e2>cAMP phosphodiesterase<\\e2> as well as the calmodulin-stimulated activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felodipine","object":"cAMP phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and the p-chloro analogue inhibited the basal (Ca2+\/calmodulin-independent) activity of <e2>GENE-N<\\e2> as well as the calmodulin-stimulated activity","sentence":"Felodipine and the p-chloro analogue inhibited the basal (Ca2+\/calmodulin-independent) activity of cAMP phosphodiesterase as well as the calmodulin-stimulated activity"}
{"PMID":2833901,"re_id":15,"annotated sentence":"<e1>Felodipine<\\e1> and the p-chloro analogue inhibited the basal (Ca2+\/calmodulin-independent) activity of cAMP phosphodiesterase as well as the <e2>calmodulin<\\e2> stimulated activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felodipine","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and the p-chloro analogue inhibited the basal (Ca2+\/GENE-Y-independent) activity of cAMP phosphodiesterase as well as the <e2>GENE-Y<\\e2> stimulated activity","sentence":"Felodipine and the p-chloro analogue inhibited the basal (Ca2+\/calmodulin-independent) activity of cAMP phosphodiesterase as well as the calmodulin stimulated activity"}
{"PMID":2833901,"re_id":16,"annotated sentence":"Felodipine and the <e1>p-chloro<\\e1> analogue inhibited the basal (Ca2+\/calmodulin-independent) activity of <e2>cAMP phosphodiesterase<\\e2> as well as the calmodulin-stimulated activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"cAMP phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Felodipine and the <e1>CHEMICAL<\\e1> analogue inhibited the basal (Ca2+\/calmodulin-independent) activity of <e2>GENE-N<\\e2> as well as the calmodulin-stimulated activity","sentence":"Felodipine and the p-chloro analogue inhibited the basal (Ca2+\/calmodulin-independent) activity of cAMP phosphodiesterase as well as the calmodulin-stimulated activity"}
{"PMID":2833901,"re_id":17,"annotated sentence":"Felodipine and the <e1>p-chloro<\\e1> analogue inhibited the basal (Ca2+\/calmodulin-independent) activity of cAMP phosphodiesterase as well as the <e2>calmodulin<\\e2> stimulated activity","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Felodipine and the <e1>CHEMICAL<\\e1> analogue inhibited the basal (Ca2+\/GENE-Y-independent) activity of cAMP phosphodiesterase as well as the <e2>GENE-Y<\\e2> stimulated activity","sentence":"Felodipine and the p-chloro analogue inhibited the basal (Ca2+\/calmodulin-independent) activity of cAMP phosphodiesterase as well as the calmodulin stimulated activity"}
{"PMID":2833901,"re_id":18,"annotated sentence":"Calmodulin was relatively ineffective in preventing inhibition of <e2>cAMP phosphodiesterase<\\e2> by <e1>felodipine<\\e1> and the p-chloro analogue","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"cAMP phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Calmodulin was relatively ineffective in preventing inhibition of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1> and the p-chloro analogue","sentence":"Calmodulin was relatively ineffective in preventing inhibition of cAMP phosphodiesterase by felodipine and the p-chloro analogue"}
{"PMID":2833901,"re_id":19,"annotated sentence":"Calmodulin was relatively ineffective in preventing inhibition of <e2>cAMP phosphodiesterase<\\e2> by felodipine and the <e1>p-chloro<\\e1> analogue","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"cAMP phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Calmodulin was relatively ineffective in preventing inhibition of <e2>GENE-N<\\e2> by felodipine and the <e1>CHEMICAL<\\e1> analogue","sentence":"Calmodulin was relatively ineffective in preventing inhibition of cAMP phosphodiesterase by felodipine and the p-chloro analogue"}
{"PMID":2833901,"re_id":20,"annotated sentence":"<e1>Felodipine<\\e1> and the p-chloro analogue inhibited Ca2+\/calmodulin-dependent <e2>caldesmon kinase<\\e2> with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felodipine","object":"caldesmon kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and the p-chloro analogue inhibited Ca2+\/calmodulin-dependent <e2>GENE-N<\\e2> with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition","sentence":"Felodipine and the p-chloro analogue inhibited Ca2+\/calmodulin-dependent caldesmon kinase with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition"}
{"PMID":2833901,"re_id":21,"annotated sentence":"Felodipine and the <e1>p-chloro<\\e1> analogue inhibited Ca2+\/calmodulin-dependent <e2>caldesmon kinase<\\e2> with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"caldesmon kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Felodipine and the <e1>CHEMICAL<\\e1> analogue inhibited Ca2+\/calmodulin-dependent <e2>GENE-N<\\e2> with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition","sentence":"Felodipine and the p-chloro analogue inhibited Ca2+\/calmodulin-dependent caldesmon kinase with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition"}
{"PMID":2833901,"re_id":22,"annotated sentence":"Similarly, <e1>felodipine<\\e1> and the p-chloro analogue inhibited <e2>myosin light chain kinase<\\e2> activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"myosin light chain kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, <e1>CHEMICAL<\\e1> and the p-chloro analogue inhibited <e2>GENE-Y<\\e2> activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate","sentence":"Similarly, felodipine and the p-chloro analogue inhibited myosin light chain kinase activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate"}
{"PMID":2833901,"re_id":23,"annotated sentence":"Effects of <e1>felodipine<\\e1> (a dihydropyridine <e2>calcium channel<\\e2> blocker) and analogues on calmodulin-dependent enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"calcium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effects of <e1>CHEMICAL<\\e1> (a dihydropyridine <e2>GENE-N<\\e2> blocker) and analogues on calmodulin-dependent enzymes","sentence":"Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes"}
{"PMID":2833901,"re_id":24,"annotated sentence":"Effects of felodipine (a <e1>dihydropyridine<\\e1> <e2>calcium channel<\\e2> blocker) and analogues on calmodulin-dependent enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydropyridine","object":"calcium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effects of felodipine (a <e1>CHEMICAL<\\e1> <e2>GENE-N<\\e2> blocker) and analogues on calmodulin-dependent enzymes","sentence":"Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes"}
{"PMID":2833901,"re_id":25,"annotated sentence":"Similarly, felodipine and the <e1>p-chloro<\\e1> analogue inhibited <e2>myosin light chain kinase<\\e2> activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"p-chloro","object":"myosin light chain kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similarly, felodipine and the <e1>CHEMICAL<\\e1> analogue inhibited <e2>GENE-Y<\\e2> activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate","sentence":"Similarly, felodipine and the p-chloro analogue inhibited myosin light chain kinase activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate"}
{"PMID":2833901,"re_id":26,"annotated sentence":"<e1>Felodipine<\\e1> and the p-chloro analogue inhibited the actin-activated <e2>Mg2+-ATPase<\\e2> activity of smooth muscle myosin (IC50 = 25.1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felodipine","object":"Mg2+-ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and the p-chloro analogue inhibited the actin-activated <e2>GENE-N<\\e2> activity of smooth muscle myosin (IC50 = 25.1 microM)","sentence":"Felodipine and the p-chloro analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle myosin (IC50 = 25.1 microM)"}
{"PMID":2833901,"re_id":27,"annotated sentence":"<e1>Felodipine<\\e1> and the p-chloro analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle <e2>myosin<\\e2> (IC50 = 25.1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Felodipine","object":"myosin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and the p-chloro analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle <e2>GENE-N<\\e2> (IC50 = 25.1 microM)","sentence":"Felodipine and the p-chloro analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle myosin (IC50 = 25.1 microM)"}
{"PMID":2855105,"re_id":0,"annotated sentence":"In all patients <e1>loperamide<\\e1> induced a significant fall in plasma <e2>ACTH<\\e2> levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In all patients <e1>CHEMICAL<\\e1> induced a significant fall in plasma <e2>GENE-Y<\\e2> levels","sentence":"In all patients loperamide induced a significant fall in plasma ACTH levels"}
{"PMID":2855105,"re_id":1,"annotated sentence":"<e1>Loperamide<\\e1> is a peripheral opiate agonist able to inhibit <e2>ACTH<\\e2> secretion","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Loperamide","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a peripheral opiate agonist able to inhibit <e2>GENE-Y<\\e2> secretion","sentence":"Loperamide is a peripheral opiate agonist able to inhibit ACTH secretion"}
{"PMID":2855105,"re_id":2,"annotated sentence":"CRH caused a rise in plasma ACTH after both loperamide (from 30 +\/- 16.6 to a peak of 108 +\/- 31 pmol\/l) and placebo (from 98.5 +\/- 47 to 211 +\/- 61.7 pmol\/l): the interaction between treatments and time was significant, and the first phase of <e2>CRH<\\e2> induced ACTH secretion was significantly lower after <e1>loperamide<\\e1>  These data demonstrate that loperamide differently modifies the stimulatory action of LVP and CRH on ACTH secretion: namely, LVP and loperamide act in an additive manner, while CRH and loperamide interact in a non additive way","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"CRH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GENE-Y caused a rise in plasma ACTH after both CHEMICAL (from 30 +\/- 16.6 to a peak of 108 +\/- 31 pmol\/l) and placebo (from 98.5 +\/- 47 to 211 +\/- 61.7 pmol\/l): the interaction between treatments and time was significant, and the first phase of <e2>GENE-Y<\\e2> induced ACTH secretion was significantly lower after <e1>CHEMICAL<\\e1>  These data demonstrate that CHEMICAL differently modifies the stimulatory action of LVP and GENE-Y on ACTH secretion: namely, LVP and CHEMICAL act in an additive manner, while GENE-Y and CHEMICAL interact in a non additive way","sentence":"CRH caused a rise in plasma ACTH after both loperamide (from 30 +\/- 16.6 to a peak of 108 +\/- 31 pmol\/l) and placebo (from 98.5 +\/- 47 to 211 +\/- 61.7 pmol\/l): the interaction between treatments and time was significant, and the first phase of CRH induced ACTH secretion was significantly lower after loperamide  These data demonstrate that loperamide differently modifies the stimulatory action of LVP and CRH on ACTH secretion: namely, LVP and loperamide act in an additive manner, while CRH and loperamide interact in a non additive way"}
{"PMID":2855105,"re_id":3,"annotated sentence":"CRH caused a rise in plasma ACTH after both loperamide (from 30 +\/- 16.6 to a peak of 108 +\/- 31 pmol\/l) and placebo (from 98.5 +\/- 47 to 211 +\/- 61.7 pmol\/l): the interaction between treatments and time was significant, and the first phase of CRH-induced <e2>ACTH<\\e2> secretion was significantly lower after <e1>loperamide<\\e1>  These data demonstrate that loperamide differently modifies the stimulatory action of LVP and CRH on ACTH secretion: namely, LVP and loperamide act in an additive manner, while CRH and loperamide interact in a non additive way","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"loperamide","object":"ACTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CRH caused a rise in plasma GENE-Y after both CHEMICAL (from 30 +\/- 16.6 to a peak of 108 +\/- 31 pmol\/l) and placebo (from 98.5 +\/- 47 to 211 +\/- 61.7 pmol\/l): the interaction between treatments and time was significant, and the first phase of CRH-induced <e2>GENE-Y<\\e2> secretion was significantly lower after <e1>CHEMICAL<\\e1>  These data demonstrate that CHEMICAL differently modifies the stimulatory action of LVP and CRH on GENE-Y secretion: namely, LVP and CHEMICAL act in an additive manner, while CRH and CHEMICAL interact in a non additive way","sentence":"CRH caused a rise in plasma ACTH after both loperamide (from 30 +\/- 16.6 to a peak of 108 +\/- 31 pmol\/l) and placebo (from 98.5 +\/- 47 to 211 +\/- 61.7 pmol\/l): the interaction between treatments and time was significant, and the first phase of CRH-induced ACTH secretion was significantly lower after loperamide  These data demonstrate that loperamide differently modifies the stimulatory action of LVP and CRH on ACTH secretion: namely, LVP and loperamide act in an additive manner, while CRH and loperamide interact in a non additive way"}
{"PMID":2855368,"re_id":0,"annotated sentence":"A <e1>naloxone-steroid hybrid azine<\\e1> with selective and long-acting opioid antagonism at <e2>delta receptors<\\e2> in vitro","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"naloxone-steroid hybrid azine","object":"delta receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A <e1>CHEMICAL<\\e1> with selective and long-acting opioid antagonism at <e2>GENE-Y<\\e2> in vitro","sentence":"A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro"}
{"PMID":2877081,"re_id":0,"annotated sentence":"Actions of <e1>nizatidine<\\e1>  a selective <e2>histamine H2-receptor<\\e2> antagonist, on gastric acid secretion in dogs, rats and frogs","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"nizatidine","object":"histamine H2-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Actions of <e1>CHEMICAL<\\e1>  a selective <e2>GENE-N<\\e2> antagonist, on gastric acid secretion in dogs, rats and frogs","sentence":"Actions of nizatidine  a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs"}
{"PMID":2877081,"re_id":1,"annotated sentence":"<e1>Nizatidine<\\e1> (LY139037), a selective <e2>histamine H2-receptor<\\e2> antagonist, is a potent inhibitor of gastric acid secretion","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Nizatidine","object":"histamine H2-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (LY139037), a selective <e2>GENE-N<\\e2> antagonist, is a potent inhibitor of gastric acid secretion","sentence":"Nizatidine (LY139037), a selective histamine H2-receptor antagonist, is a potent inhibitor of gastric acid secretion"}
{"PMID":2877081,"re_id":2,"annotated sentence":"Nizatidine (<e1>LY139037<\\e1> , a selective <e2>histamine H2-receptor<\\e2> antagonist, is a potent inhibitor of gastric acid secretion","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"LY139037","object":"histamine H2-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Nizatidine (<e1>CHEMICAL<\\e1> , a selective <e2>GENE-N<\\e2> antagonist, is a potent inhibitor of gastric acid secretion","sentence":"Nizatidine (LY139037 , a selective histamine H2-receptor antagonist, is a potent inhibitor of gastric acid secretion"}
{"PMID":2886642,"re_id":0,"annotated sentence":"<e1>ORF 17583<\\e1>  a <e2>histamine H2-receptor<\\e2> antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg\/kg intraduodenal; 3.4 mg\/kg p.o.; and 0.21 mg\/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg\/kg p.o","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ORF 17583","object":"histamine H2-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg\/kg intraduodenal; 3.4 mg\/kg p.o.; and 0.21 mg\/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg\/kg p.o","sentence":"ORF 17583  a histamine H2-receptor antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg\/kg intraduodenal; 3.4 mg\/kg p.o.; and 0.21 mg\/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg\/kg p.o"}
{"PMID":2886642,"re_id":1,"annotated sentence":"Effects of <e1>ORF 17583<\\e1>  other <e2>histamine H2-receptor<\\e2> antagonists and omeprazole on gastric acid secretory states in rats and dogs","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ORF 17583","object":"histamine H2-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effects of <e1>CHEMICAL<\\e1>  other <e2>GENE-N<\\e2> antagonists and omeprazole on gastric acid secretory states in rats and dogs","sentence":"Effects of ORF 17583  other histamine H2-receptor antagonists and omeprazole on gastric acid secretory states in rats and dogs"}
{"PMID":3345199,"re_id":0,"annotated sentence":"<e2>Acetylcholinesterase<\\e2> (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by <e1>oximes<\\e1> due to dealkylation of the soman-enzyme complex","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oximes","object":"Acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by <e1>CHEMICAL<\\e1> due to dealkylation of the soman-enzyme complex","sentence":"Acetylcholinesterase (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex"}
{"PMID":3345199,"re_id":1,"annotated sentence":"Acetylcholinesterase (<e2>AChE<\\e2>  inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by <e1>oximes<\\e1> due to dealkylation of the soman-enzyme complex","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oximes","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetylcholinesterase (<e2>GENE-Y<\\e2>  inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by <e1>CHEMICAL<\\e1> due to dealkylation of the soman-enzyme complex","sentence":"Acetylcholinesterase (AChE  inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex"}
{"PMID":3345199,"re_id":2,"annotated sentence":"The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of <e1>soman<\\e1> inhibited, solubilized <e2>AChE<\\e2> from human erythrocytes was investigated in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"soman","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of <e1>CHEMICAL<\\e1> inhibited, solubilized <e2>GENE-Y<\\e2> from human erythrocytes was investigated in vitro","sentence":"The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of soman inhibited, solubilized AChE from human erythrocytes was investigated in vitro"}
{"PMID":3345199,"re_id":3,"annotated sentence":"<e2>Acetylcholinesterase<\\e2> (AChE) inhibited by the <e1>organophosphate<\\e1> soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"organophosphate","object":"Acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (AChE) inhibited by the <e1>CHEMICAL<\\e1> soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex","sentence":"Acetylcholinesterase (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex"}
{"PMID":3345199,"re_id":4,"annotated sentence":"Acetylcholinesterase (<e2>AChE<\\e2>  inhibited by the <e1>organophosphate<\\e1> soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"organophosphate","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetylcholinesterase (<e2>GENE-Y<\\e2>  inhibited by the <e1>CHEMICAL<\\e1> soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex","sentence":"Acetylcholinesterase (AChE  inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex"}
{"PMID":3345199,"re_id":5,"annotated sentence":"<e2>Acetylcholinesterase<\\e2> (AChE) inhibited by the organophosphate <e1>soman<\\e1> (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"soman","object":"Acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (AChE) inhibited by the organophosphate <e1>CHEMICAL<\\e1> (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the CHEMICAL-enzyme complex","sentence":"Acetylcholinesterase (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex"}
{"PMID":3345199,"re_id":6,"annotated sentence":"Acetylcholinesterase (<e2>AChE<\\e2>  inhibited by the organophosphate <e1>soman<\\e1> (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"soman","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetylcholinesterase (<e2>GENE-Y<\\e2>  inhibited by the organophosphate <e1>CHEMICAL<\\e1> (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the CHEMICAL-enzyme complex","sentence":"Acetylcholinesterase (AChE  inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex"}
{"PMID":3345199,"re_id":7,"annotated sentence":"<e2>Acetylcholinesterase<\\e2> (AChE) inhibited by the organophosphate soman (<e1>1,2,2-trimethyl-propylmethylphosphonofluoridate<\\e1>  rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,2,2-trimethyl-propylmethylphosphonofluoridate","object":"Acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (AChE) inhibited by the organophosphate soman (<e1>CHEMICAL<\\e1>  rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex","sentence":"Acetylcholinesterase (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate  rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex"}
{"PMID":3345199,"re_id":8,"annotated sentence":"Acetylcholinesterase (<e2>AChE<\\e2>  inhibited by the organophosphate soman (<e1>1,2,2-trimethyl-propylmethylphosphonofluoridate<\\e1>  rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"1,2,2-trimethyl-propylmethylphosphonofluoridate","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetylcholinesterase (<e2>GENE-Y<\\e2>  inhibited by the organophosphate soman (<e1>CHEMICAL<\\e1>  rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex","sentence":"Acetylcholinesterase (AChE  inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate  rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex"}
{"PMID":3345199,"re_id":9,"annotated sentence":"Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of <e1>soman<\\e1> inhibited <e2>human acetylcholinesterase<\\e2> in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"soman","object":"human acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> in vitro","sentence":"Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of soman inhibited human acetylcholinesterase in vitro"}
{"PMID":3345199,"re_id":10,"annotated sentence":"If the effectors were added after 5 min of aging they increased the activity of <e1>soman<\\e1> inhibited <e2>AChE<\\e2>  but to a considerably smaller extent than HI 6","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"soman","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"If the effectors were added after 5 min of aging they increased the activity of <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2>  but to a considerably smaller extent than HI 6","sentence":"If the effectors were added after 5 min of aging they increased the activity of soman inhibited AChE  but to a considerably smaller extent than HI 6"}
{"PMID":3440035,"re_id":0,"annotated sentence":"Pharmacological properties of <e1>lorglumide<\\e1> as a member of a new class of <e2>cholecystokinin<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"lorglumide","object":"cholecystokinin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological properties of <e1>CHEMICAL<\\e1> as a member of a new class of <e2>GENE-Y<\\e2> antagonists","sentence":"Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists"}
{"PMID":3440035,"re_id":1,"annotated sentence":"The most potent compound, <e1>D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid<\\e1> (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent <e2>CCK<\\e2> antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid","object":"CCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most potent compound, <e1>CHEMICAL<\\e1> (lorglumide, CR 1409), has a great affinity for the pancreatic GENE-Y receptors and is a competitive, specific and potent <e2>GENE-Y<\\e2> antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the GENE-Y-induced amylase secretion of isolated pancreatic acini","sentence":"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini"}
{"PMID":3440035,"re_id":2,"annotated sentence":"Derivatives of <e1>5-(dipentylamino)-5-oxo-pentanoic acid<\\e1> are a new class of non-peptide cholecystokinin (<e2>CCK<\\e2>  antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"5-(dipentylamino)-5-oxo-pentanoic acid","object":"CCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Derivatives of <e1>CHEMICAL<\\e1> are a new class of non-peptide cholecystokinin (<e2>GENE-Y<\\e2>  antagonists","sentence":"Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK  antagonists"}
{"PMID":3440035,"re_id":3,"annotated sentence":"Derivatives of <e1>5-(dipentylamino)-5-oxo-pentanoic acid<\\e1> are a new class of non-peptide <e2>cholecystokinin<\\e2> (CCK) antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"5-(dipentylamino)-5-oxo-pentanoic acid","object":"cholecystokinin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Derivatives of <e1>CHEMICAL<\\e1> are a new class of non-peptide <e2>GENE-Y<\\e2> (CCK) antagonists","sentence":"Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists"}
{"PMID":3440035,"re_id":4,"annotated sentence":"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (<e1>lorglumide<\\e1>  CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent <e2>CCK<\\e2> antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"lorglumide","object":"CCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (<e1>CHEMICAL<\\e1>  CR 1409), has a great affinity for the pancreatic GENE-Y receptors and is a competitive, specific and potent <e2>GENE-Y<\\e2> antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the GENE-Y-induced amylase secretion of isolated pancreatic acini","sentence":"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide  CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini"}
{"PMID":3440035,"re_id":5,"annotated sentence":"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, <e1>CR 1409<\\e1> , has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent <e2>CCK<\\e2> antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"CR 1409","object":"CCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, <e1>CHEMICAL<\\e1> , has a great affinity for the pancreatic GENE-Y receptors and is a competitive, specific and potent <e2>GENE-Y<\\e2> antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the GENE-Y-induced amylase secretion of isolated pancreatic acini","sentence":"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409 , has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini"}
{"PMID":3440035,"re_id":6,"annotated sentence":"none","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"lorglumide","object":"CCK-8","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":3828735,"re_id":0,"annotated sentence":"The activation may be accelerated by an acute inflammatory process provoked by <e1>oleate<\\e1>  which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma <e2>fibrinogen<\\e2> level which was observed in all during the period.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"oleate","object":"fibrinogen","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The activation may be accelerated by an acute inflammatory process provoked by <e1>CHEMICAL<\\e1>  which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma <e2>GENE-N<\\e2> level which was observed in all during the period.","sentence":"The activation may be accelerated by an acute inflammatory process provoked by oleate  which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma fibrinogen level which was observed in all during the period."}
{"PMID":3828735,"re_id":1,"annotated sentence":"In vitro studies, however, revealed that <e1>EO<\\e1> inhibits <e2>fibrin<\\e2> clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"EO","object":"fibrin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In vitro studies, however, revealed that <e1>CHEMICAL<\\e1> inhibits <e2>GENE-N<\\e2> clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro","sentence":"In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro"}
{"PMID":6146346,"re_id":0,"annotated sentence":"The efficacy of <e1>astemizole<\\e1>  a new, long acting, oral <e2>histamine H1-receptor<\\e2> antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"astemizole","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The efficacy of <e1>CHEMICAL<\\e1>  a new, long acting, oral <e2>GENE-Y<\\e2> antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982","sentence":"The efficacy of astemizole  a new, long acting, oral histamine H1-receptor antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982"}
{"PMID":6146346,"re_id":1,"annotated sentence":"<e1>Astemizole<\\e1>  a potent <e2>histamine H1-receptor<\\e2> antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Astemizole","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a potent <e2>GENE-Y<\\e2> antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels","sentence":"Astemizole  a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels"}
{"PMID":6227474,"re_id":0,"annotated sentence":"Selective precipitation of cytosol receptors with 36% <e1>(NH4)2SO4<\\e1> reduced <e2>CBG<\\e2> concentrations to negligible levels","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(NH4)2SO4","object":"CBG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective precipitation of cytosol receptors with 36% <e1>CHEMICAL<\\e1> reduced <e2>GENE-Y<\\e2> concentrations to negligible levels","sentence":"Selective precipitation of cytosol receptors with 36% (NH4)2SO4 reduced CBG concentrations to negligible levels"}
{"PMID":6374639,"re_id":0,"annotated sentence":"Although inhibition of <e2>LH<\\e2> release can be achieved by <e1>estrogen<\\e1> and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"estrogen","object":"LH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although inhibition of <e2>GENE-N<\\e2> release can be achieved by <e1>CHEMICAL<\\e1> and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an GENE-NRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the GENE-N responsiveness to GENE-NRH.","sentence":"Although inhibition of LH release can be achieved by estrogen and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH."}
{"PMID":6374639,"re_id":1,"annotated sentence":"Although inhibition of <e2>LH<\\e2> release can be achieved by estrogen and <e1>progestins<\\e1>  an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"progestins","object":"LH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although inhibition of <e2>GENE-N<\\e2> release can be achieved by estrogen and <e1>CHEMICAL<\\e1>  an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an GENE-NRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the GENE-N responsiveness to GENE-NRH.","sentence":"Although inhibition of LH release can be achieved by estrogen and progestins  an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH."}
{"PMID":7582530,"re_id":0,"annotated sentence":"The results of this study suggest that <e1>noradrenaline<\\e1> predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an <e2>alphalD-adrenoceptor<\\e2> ","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"noradrenaline","object":"alphalD-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results of this study suggest that <e1>CHEMICAL<\\e1> predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an <e2>GENE-Y<\\e2> ","sentence":"The results of this study suggest that noradrenaline predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an alphalD-adrenoceptor "}
{"PMID":7678677,"re_id":0,"annotated sentence":"<e1>Alprenolol<\\e1> and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of <e2>beta-adrenoceptor<\\e2> blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Alprenolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of <e2>GENE-N<\\e2> blockade","sentence":"Alprenolol and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of beta-adrenoceptor blockade"}
{"PMID":7678677,"re_id":1,"annotated sentence":"Alprenolol and <e1>BAAM<\\e1> at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of <e2>beta-adrenoceptor<\\e2> blockade","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"BAAM","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Alprenolol and <e1>CHEMICAL<\\e1> at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of <e2>GENE-N<\\e2> blockade","sentence":"Alprenolol and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of beta-adrenoceptor blockade"}
{"PMID":7678677,"re_id":2,"annotated sentence":"Alprenolol and BAAM also caused surmountable antagonism of <e1>isoprenaline<\\e1> responses, and this <e2>beta 1-adrenoceptor<\\e2> antagonism was slowly reversible","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"isoprenaline","object":"beta 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Alprenolol and BAAM also caused surmountable antagonism of <e1>CHEMICAL<\\e1> responses, and this <e2>GENE-Y<\\e2> antagonism was slowly reversible","sentence":"Alprenolol and BAAM also caused surmountable antagonism of isoprenaline responses, and this beta 1-adrenoceptor antagonism was slowly reversible"}
{"PMID":7678677,"re_id":3,"annotated sentence":"We conclude that <e1>alprenolol<\\e1> and BAAM are competitive slowly reversible <e2>beta 1-adrenoceptor<\\e2> antagonists on rat left atria.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"alprenolol","object":"beta 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that <e1>CHEMICAL<\\e1> and BAAM are competitive slowly reversible <e2>GENE-Y<\\e2> antagonists on rat left atria.","sentence":"We conclude that alprenolol and BAAM are competitive slowly reversible beta 1-adrenoceptor antagonists on rat left atria."}
{"PMID":7678677,"re_id":4,"annotated sentence":"We conclude that alprenolol and <e1>BAAM<\\e1> are competitive slowly reversible <e2>beta 1-adrenoceptor<\\e2> antagonists on rat left atria.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"BAAM","object":"beta 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that alprenolol and <e1>CHEMICAL<\\e1> are competitive slowly reversible <e2>GENE-Y<\\e2> antagonists on rat left atria.","sentence":"We conclude that alprenolol and BAAM are competitive slowly reversible beta 1-adrenoceptor antagonists on rat left atria."}
{"PMID":7678677,"re_id":5,"annotated sentence":"<e1>Alprenolol<\\e1> and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the <e2>beta 1-adrenoceptors<\\e2> of rat left atria","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Alprenolol","object":"beta 1-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the <e2>GENE-Y<\\e2> of rat left atria","sentence":"Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria"}
{"PMID":7678677,"re_id":6,"annotated sentence":"Alprenolol and <e1>bromoacetylalprenololmenthane<\\e1> are competitive slowly reversible antagonists at the <e2>beta 1-adrenoceptors<\\e2> of rat left atria","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"bromoacetylalprenololmenthane","object":"beta 1-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Alprenolol and <e1>CHEMICAL<\\e1> are competitive slowly reversible antagonists at the <e2>GENE-Y<\\e2> of rat left atria","sentence":"Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria"}
{"PMID":7678677,"re_id":7,"annotated sentence":"<e1>Alprenolol<\\e1> and BAAM also caused surmountable antagonism of isoprenaline responses, and this <e2>beta 1-adrenoceptor<\\e2> antagonism was slowly reversible","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Alprenolol","object":"beta 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and BAAM also caused surmountable antagonism of isoprenaline responses, and this <e2>GENE-Y<\\e2> antagonism was slowly reversible","sentence":"Alprenolol and BAAM also caused surmountable antagonism of isoprenaline responses, and this beta 1-adrenoceptor antagonism was slowly reversible"}
{"PMID":7678677,"re_id":8,"annotated sentence":"Alprenolol and <e1>BAAM<\\e1> also caused surmountable antagonism of isoprenaline responses, and this <e2>beta 1-adrenoceptor<\\e2> antagonism was slowly reversible","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"BAAM","object":"beta 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Alprenolol and <e1>CHEMICAL<\\e1> also caused surmountable antagonism of isoprenaline responses, and this <e2>GENE-Y<\\e2> antagonism was slowly reversible","sentence":"Alprenolol and BAAM also caused surmountable antagonism of isoprenaline responses, and this beta 1-adrenoceptor antagonism was slowly reversible"}
{"PMID":7680751,"re_id":0,"annotated sentence":"In HEK-293 cells stably transfected with this receptor, <e1>serotonin<\\e1> elicits a potent stimulation of <e2>adenylyl cyclase<\\e2> activity, which is blocked by antipsychotic and antidepressant drugs","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"serotonin","object":"adenylyl cyclase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In HEK-293 cells stably transfected with this receptor, <e1>CHEMICAL<\\e1> elicits a potent stimulation of <e2>GENE-N<\\e2> activity, which is blocked by antipsychotic and antidepressant drugs","sentence":"In HEK-293 cells stably transfected with this receptor, serotonin elicits a potent stimulation of adenylyl cyclase activity, which is blocked by antipsychotic and antidepressant drugs"}
{"PMID":7711211,"re_id":0,"annotated sentence":"Both <e1>5 alpha-NET<\\e1> and 3 beta,5 alpha-NET blocked the <e2>PR<\\e2> down-regulation induced by P4 as assessed by Western and Northern blot methods","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5 alpha-NET","object":"PR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both <e1>CHEMICAL<\\e1> and 3 beta,CHEMICAL blocked the <e2>GENE-Y<\\e2> down-regulation induced by P4 as assessed by Western and Northern blot methods","sentence":"Both 5 alpha-NET and 3 beta,5 alpha-NET blocked the PR down-regulation induced by P4 as assessed by Western and Northern blot methods"}
{"PMID":7711211,"re_id":1,"annotated sentence":"Both 5 alpha-NET and <e1>3 beta,5 alpha-NET<\\e1> blocked the <e2>PR<\\e2> down-regulation induced by P4 as assessed by Western and Northern blot methods","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"3 beta,5 alpha-NET","object":"PR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both 5 alpha-NET and <e1>CHEMICAL<\\e1> blocked the <e2>GENE-Y<\\e2> down-regulation induced by P4 as assessed by Western and Northern blot methods","sentence":"Both 5 alpha-NET and 3 beta,5 alpha-NET blocked the PR down-regulation induced by P4 as assessed by Western and Northern blot methods"}
{"PMID":7711211,"re_id":2,"annotated sentence":"The inhibition of UG synthesis and <e2>PR<\\e2> down-regulation by <e1>5 alpha-NET<\\e1> and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"5 alpha-NET","object":"PR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibition of UG synthesis and <e2>GENE-Y<\\e2> down-regulation by <e1>CHEMICAL<\\e1> and 3 beta,CHEMICAL indicates that these NET metabolites possess antiprogestational properties.","sentence":"The inhibition of UG synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties."}
{"PMID":7711211,"re_id":3,"annotated sentence":"As determined by Western and Northern blot analyses, <e1>5 alpha-NET<\\e1> inhibited the P4-induced <e2>UG<\\e2> gene expression in a dose-dependent manner","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5 alpha-NET","object":"UG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As determined by Western and Northern blot analyses, <e1>CHEMICAL<\\e1> inhibited the P4-induced <e2>GENE-Y<\\e2> gene expression in a dose-dependent manner","sentence":"As determined by Western and Northern blot analyses, 5 alpha-NET inhibited the P4-induced UG gene expression in a dose-dependent manner"}
{"PMID":7711211,"re_id":4,"annotated sentence":"The estrogenic agent <e1>3 beta,5 alpha-NET<\\e1> and estradiol at a dose of 1.0 mg also inhibited the <e2>UG<\\e2> gene expression induced by P4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"3 beta,5 alpha-NET","object":"UG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The estrogenic agent <e1>CHEMICAL<\\e1> and estradiol at a dose of 1.0 mg also inhibited the <e2>GENE-Y<\\e2> gene expression induced by P4","sentence":"The estrogenic agent 3 beta,5 alpha-NET and estradiol at a dose of 1.0 mg also inhibited the UG gene expression induced by P4"}
{"PMID":7711211,"re_id":5,"annotated sentence":"The estrogenic agent 3 beta,5 alpha-NET and <e1>estradiol<\\e1> at a dose of 1.0 mg also inhibited the <e2>UG<\\e2> gene expression induced by P4","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"estradiol","object":"UG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The estrogenic agent 3 beta,5 alpha-NET and <e1>CHEMICAL<\\e1> at a dose of 1.0 mg also inhibited the <e2>GENE-Y<\\e2> gene expression induced by P4","sentence":"The estrogenic agent 3 beta,5 alpha-NET and estradiol at a dose of 1.0 mg also inhibited the UG gene expression induced by P4"}
{"PMID":7711211,"re_id":6,"annotated sentence":"The inhibition of <e2>UG<\\e2> synthesis and PR down-regulation by <e1>5 alpha-NET<\\e1> and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"5 alpha-NET","object":"UG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibition of <e2>GENE-Y<\\e2> synthesis and PR down-regulation by <e1>CHEMICAL<\\e1> and 3 beta,CHEMICAL indicates that these NET metabolites possess antiprogestational properties.","sentence":"The inhibition of UG synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties."}
{"PMID":7711211,"re_id":7,"annotated sentence":"The inhibition of <e2>UG<\\e2> synthesis and PR down-regulation by 5 alpha-NET and <e1>3 beta,5 alpha-NET<\\e1> indicates that these NET metabolites possess antiprogestational properties.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"3 beta,5 alpha-NET","object":"UG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibition of <e2>GENE-Y<\\e2> synthesis and PR down-regulation by 5 alpha-NET and <e1>CHEMICAL<\\e1> indicates that these NET metabolites possess antiprogestational properties.","sentence":"The inhibition of UG synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties."}
{"PMID":7711211,"re_id":8,"annotated sentence":"The inhibition of UG synthesis and <e2>PR<\\e2> down-regulation by 5 alpha-NET and <e1>3 beta,5 alpha-NET<\\e1> indicates that these NET metabolites possess antiprogestational properties.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"3 beta,5 alpha-NET","object":"PR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibition of UG synthesis and <e2>GENE-Y<\\e2> down-regulation by 5 alpha-NET and <e1>CHEMICAL<\\e1> indicates that these NET metabolites possess antiprogestational properties.","sentence":"The inhibition of UG synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties."}
{"PMID":7711211,"re_id":9,"annotated sentence":"The inhibition of <e2>UG<\\e2> synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these <e1>NET<\\e1> metabolites possess antiprogestational properties.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NET","object":"UG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibition of <e2>GENE-Y<\\e2> synthesis and PR down-regulation by 5 alpha-CHEMICAL and 3 beta,5 alpha-CHEMICAL indicates that these <e1>CHEMICAL<\\e1> metabolites possess antiprogestational properties.","sentence":"The inhibition of UG synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties."}
{"PMID":7711211,"re_id":10,"annotated sentence":"The inhibition of UG synthesis and <e2>PR<\\e2> down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these <e1>NET<\\e1> metabolites possess antiprogestational properties.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NET","object":"PR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibition of UG synthesis and <e2>GENE-Y<\\e2> down-regulation by 5 alpha-CHEMICAL and 3 beta,5 alpha-CHEMICAL indicates that these <e1>CHEMICAL<\\e1> metabolites possess antiprogestational properties.","sentence":"The inhibition of UG synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties."}
{"PMID":7768269,"re_id":0,"annotated sentence":"Doses of dimethocaine (1.7 mg\/kg) and cocaine (0.3 mg\/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the <e2>dopamine D1 receptor<\\e2> antagonist <e1>SCH 39166<\\e1> ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg\/kg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SCH 39166","object":"dopamine D1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Doses of dimethocaine (1.7 mg\/kg) and cocaine (0.3 mg\/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg\/kg)","sentence":"Doses of dimethocaine (1.7 mg\/kg) and cocaine (0.3 mg\/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg\/kg)"}
{"PMID":7768269,"re_id":1,"annotated sentence":"Doses of dimethocaine (1.7 mg\/kg) and cocaine (0.3 mg\/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the <e2>dopamine D1 receptor<\\e2> antagonist SCH 39166 (<e1>(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine<\\e1>  and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg\/kg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine","object":"dopamine D1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Doses of dimethocaine (1.7 mg\/kg) and cocaine (0.3 mg\/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the <e2>GENE-Y<\\e2> antagonist SCH 39166 (<e1>CHEMICAL<\\e1>  and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg\/kg)","sentence":"Doses of dimethocaine (1.7 mg\/kg) and cocaine (0.3 mg\/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine  and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg\/kg)"}
{"PMID":7768269,"re_id":2,"annotated sentence":"Doses of dimethocaine (1.7 mg\/kg) and cocaine (0.3 mg\/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the <e2>dopamine D2 receptor<\\e2> antagonist <e1>raclopride<\\e1> (both at 0.003-0.03 mg\/kg)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"raclopride","object":"dopamine D2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Doses of dimethocaine (1.7 mg\/kg) and cocaine (0.3 mg\/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (both at 0.003-0.03 mg\/kg)","sentence":"Doses of dimethocaine (1.7 mg\/kg) and cocaine (0.3 mg\/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg\/kg)"}
{"PMID":7832763,"re_id":0,"annotated sentence":"<e1>Indomethacin<\\e1> inhibited both <e2>hCOX-1<\\e2> and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"hCOX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited both <e2>GENE-Y<\\e2> and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2","sentence":"Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2"}
{"PMID":7832763,"re_id":1,"annotated sentence":"<e1>Indomethacin<\\e1> inhibited both hCOX-1 and <e2>hCOX-2<\\e2>  whereas NS-398 and Dup-697 selectively inhibited hCOX-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"hCOX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited both hCOX-1 and <e2>GENE-Y<\\e2>  whereas NS-398 and Dup-697 selectively inhibited GENE-Y","sentence":"Indomethacin inhibited both hCOX-1 and hCOX-2  whereas NS-398 and Dup-697 selectively inhibited hCOX-2"}
{"PMID":7832763,"re_id":2,"annotated sentence":"Indomethacin inhibited both hCOX-1 and hCOX-2, whereas <e1>NS-398<\\e1> and Dup-697 selectively inhibited <e2>hCOX-2<\\e2>  Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2, as did indomethacin on both enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NS-398","object":"hCOX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Indomethacin inhibited both hCOX-1 and GENE-Y, whereas <e1>CHEMICAL<\\e1> and Dup-697 selectively inhibited <e2>GENE-Y<\\e2>  Both CHEMICAL and Dup-697 exhibited time-dependent inactivation of GENE-Y, as did indomethacin on both enzymes","sentence":"Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2  Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2, as did indomethacin on both enzymes"}
{"PMID":7832763,"re_id":3,"annotated sentence":"Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and <e1>Dup-697<\\e1> selectively inhibited <e2>hCOX-2<\\e2>  Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2, as did indomethacin on both enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dup-697","object":"hCOX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Indomethacin inhibited both hCOX-1 and GENE-Y, whereas NS-398 and <e1>CHEMICAL<\\e1> selectively inhibited <e2>GENE-Y<\\e2>  Both NS-398 and CHEMICAL exhibited time-dependent inactivation of GENE-Y, as did indomethacin on both enzymes","sentence":"Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2  Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2, as did indomethacin on both enzymes"}
{"PMID":7832763,"re_id":4,"annotated sentence":"Both <e1>NS-398<\\e1> and Dup-697 exhibited time-dependent inactivation of <e2>hCOX-2<\\e2>  as did indomethacin on both enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"NS-398","object":"hCOX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both <e1>CHEMICAL<\\e1> and Dup-697 exhibited time-dependent inactivation of <e2>GENE-Y<\\e2>  as did indomethacin on both enzymes","sentence":"Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2  as did indomethacin on both enzymes"}
{"PMID":7832763,"re_id":5,"annotated sentence":"Both NS-398 and <e1>Dup-697<\\e1> exhibited time-dependent inactivation of <e2>hCOX-2<\\e2>  as did indomethacin on both enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dup-697","object":"hCOX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both NS-398 and <e1>CHEMICAL<\\e1> exhibited time-dependent inactivation of <e2>GENE-Y<\\e2>  as did indomethacin on both enzymes","sentence":"Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2  as did indomethacin on both enzymes"}
{"PMID":7832763,"re_id":6,"annotated sentence":"Both NS-398 and Dup-697 exhibited time-dependent inactivation of <e2>hCOX-2<\\e2>  as did <e1>indomethacin<\\e1> on both enzymes","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"indomethacin","object":"hCOX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both NS-398 and Dup-697 exhibited time-dependent inactivation of <e2>GENE-Y<\\e2>  as did <e1>CHEMICAL<\\e1> on both enzymes","sentence":"Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2  as did indomethacin on both enzymes"}
{"PMID":7832763,"re_id":7,"annotated sentence":"The competitive inhibitor of <e2>hCOX-1<\\e2>  <e1>mefenamic acid<\\e1>  also displayed competitive inhibition of hCOX-2","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mefenamic acid","object":"hCOX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The competitive inhibitor of <e2>GENE-Y<\\e2>  <e1>CHEMICAL<\\e1>  also displayed competitive inhibition of hCOX-2","sentence":"The competitive inhibitor of hCOX-1  mefenamic acid  also displayed competitive inhibition of hCOX-2"}
{"PMID":7832763,"re_id":8,"annotated sentence":"The competitive inhibitor of hCOX-1, <e1>mefenamic acid<\\e1>  also displayed competitive inhibition of <e2>hCOX-2<\\e2>  These results demonstrate the ability to generate selective non-steroidal anti-inflammatory drugs (NSAIDs), which could provide useful improvement therapeutically in the treatment of chronic inflammatory disease.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"mefenamic acid","object":"hCOX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The competitive inhibitor of hCOX-1, <e1>CHEMICAL<\\e1>  also displayed competitive inhibition of <e2>GENE-Y<\\e2>  These results demonstrate the ability to generate selective non-steroidal anti-inflammatory drugs (NSAIDs), which could provide useful improvement therapeutically in the treatment of chronic inflammatory disease.","sentence":"The competitive inhibitor of hCOX-1, mefenamic acid  also displayed competitive inhibition of hCOX-2  These results demonstrate the ability to generate selective non-steroidal anti-inflammatory drugs (NSAIDs), which could provide useful improvement therapeutically in the treatment of chronic inflammatory disease."}
{"PMID":7832763,"re_id":9,"annotated sentence":"The enzyme <e2>cyclo-oxygenase<\\e2> catalyses the oxygenation of arachidonic acid, leading to the formation of <e1>prostaglandins<\\e1>  Recently two forms of cyclo-oxygenase have been described: a constitutive (COX-1) enzyme present in most cells and tissues, and an inducible (COX-2) isoenzyme observed in many cells in response to pro-inflammatory cytokines","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"prostaglandins","object":"cyclo-oxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The enzyme <e2>GENE-N<\\e2> catalyses the oxygenation of arachidonic acid, leading to the formation of <e1>CHEMICAL<\\e1>  Recently two forms of GENE-N have been described: a constitutive (COX-1) enzyme present in most cells and tissues, and an inducible (COX-2) isoenzyme observed in many cells in response to pro-inflammatory cytokines","sentence":"The enzyme cyclo-oxygenase catalyses the oxygenation of arachidonic acid, leading to the formation of prostaglandins  Recently two forms of cyclo-oxygenase have been described: a constitutive (COX-1) enzyme present in most cells and tissues, and an inducible (COX-2) isoenzyme observed in many cells in response to pro-inflammatory cytokines"}
{"PMID":7832763,"re_id":10,"annotated sentence":"The enzyme <e2>cyclo-oxygenase<\\e2> catalyses the oxygenation of <e1>arachidonic acid<\\e1>  leading to the formation of prostaglandins","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"cyclo-oxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The enzyme <e2>GENE-N<\\e2> catalyses the oxygenation of <e1>CHEMICAL<\\e1>  leading to the formation of prostaglandins","sentence":"The enzyme cyclo-oxygenase catalyses the oxygenation of arachidonic acid  leading to the formation of prostaglandins"}
{"PMID":7832763,"re_id":11,"annotated sentence":"<e2>hCOX-1<\\e2> had a specific activity of 18.8 mumol of O2\/mg with a Km of 13.8 microM for <e1>arachidonate<\\e1> and Vmax","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonate","object":"hCOX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> had a specific activity of 18.8 mumol of O2\/mg with a Km of 13.8 microM for <e1>CHEMICAL<\\e1> and Vmax","sentence":"hCOX-1 had a specific activity of 18.8 mumol of O2\/mg with a Km of 13.8 microM for arachidonate and Vmax"}
{"PMID":7832763,"re_id":12,"annotated sentence":"of 1500 nmol of O2\/nmol of enzyme, whereas <e2>hCOX-2<\\e2> had a specific activity of 12.2 mumol of O2\/mg with a Km of 8.7 microM for <e1>arachidonate<\\e1> and a Vmax","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonate","object":"hCOX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"of 1500 nmol of O2\/nmol of enzyme, whereas <e2>GENE-Y<\\e2> had a specific activity of 12.2 mumol of O2\/mg with a Km of 8.7 microM for <e1>CHEMICAL<\\e1> and a Vmax","sentence":"of 1500 nmol of O2\/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2\/mg with a Km of 8.7 microM for arachidonate and a Vmax"}
{"PMID":7885191,"re_id":0,"annotated sentence":"The channel activators <e1>avermectin<\\e1> and moxidectin usually retain their inhibitory potency in the <e2>Rdl<\\e2> subunit mutants","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"avermectin","object":"Rdl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The channel activators <e1>CHEMICAL<\\e1> and moxidectin usually retain their inhibitory potency in the <e2>GENE-Y<\\e2> subunit mutants","sentence":"The channel activators avermectin and moxidectin usually retain their inhibitory potency in the Rdl subunit mutants"}
{"PMID":7885191,"re_id":1,"annotated sentence":"The channel activators avermectin and <e1>moxidectin<\\e1> usually retain their inhibitory potency in the <e2>Rdl<\\e2> subunit mutants","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"moxidectin","object":"Rdl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The channel activators avermectin and <e1>CHEMICAL<\\e1> usually retain their inhibitory potency in the <e2>GENE-Y<\\e2> subunit mutants","sentence":"The channel activators avermectin and moxidectin usually retain their inhibitory potency in the Rdl subunit mutants"}
{"PMID":7906055,"re_id":0,"annotated sentence":"<e1>Agmatine<\\e1>  locally synthesized, is an endogenous agonist at <e2>imidazoline receptors<\\e2>  a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Agmatine","object":"imidazoline receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  locally synthesized, is an endogenous agonist at <e2>GENE-N<\\e2>  a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter.","sentence":"Agmatine  locally synthesized, is an endogenous agonist at imidazoline receptors  a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter."}
{"PMID":7912539,"re_id":0,"annotated sentence":"Both <e1>BRL<\\e1> and SAL produced a significant increase in postural finger tremor in keeping with <e2>beta 2-adrenoceptor<\\e2> stimulation, and this response was totally abolished by pretreatment with N20","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"BRL","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both <e1>CHEMICAL<\\e1> and SAL produced a significant increase in postural finger tremor in keeping with <e2>GENE-Y<\\e2> stimulation, and this response was totally abolished by pretreatment with N20","sentence":"Both BRL and SAL produced a significant increase in postural finger tremor in keeping with beta 2-adrenoceptor stimulation, and this response was totally abolished by pretreatment with N20"}
{"PMID":7912539,"re_id":1,"annotated sentence":"Both BRL and <e1>SAL<\\e1> produced a significant increase in postural finger tremor in keeping with <e2>beta 2-adrenoceptor<\\e2> stimulation, and this response was totally abolished by pretreatment with N20","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"SAL","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both BRL and <e1>CHEMICAL<\\e1> produced a significant increase in postural finger tremor in keeping with <e2>GENE-Y<\\e2> stimulation, and this response was totally abolished by pretreatment with N20","sentence":"Both BRL and SAL produced a significant increase in postural finger tremor in keeping with beta 2-adrenoceptor stimulation, and this response was totally abolished by pretreatment with N20"}
{"PMID":7912539,"re_id":2,"annotated sentence":"Cardiac effects of the <e2>beta 3-adrenoceptor<\\e2> agonist <e1>BRL35135<\\e1> in man","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"BRL35135","object":"beta 3-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cardiac effects of the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> in man","sentence":"Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man"}
{"PMID":7912539,"re_id":3,"annotated sentence":"The aim of the present study was to evaluate the cardiac effects of the <e2>beta 3-adrenoceptor<\\e2> agonist <e1>BRL35135<\\e1>  and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"BRL35135","object":"beta 3-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The aim of the present study was to evaluate the cardiac effects of the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1>  and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man","sentence":"The aim of the present study was to evaluate the cardiac effects of the beta 3-adrenoceptor agonist BRL35135  and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man"}
{"PMID":7912539,"re_id":4,"annotated sentence":"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective <e2>beta 2-adrenoceptor<\\e2> agonist <e1>salbutamol<\\e1> 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"salbutamol","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors","sentence":"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors"}
{"PMID":7912539,"re_id":5,"annotated sentence":"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective <e2>beta 2-adrenoceptor<\\e2> agonist salbutamol 8 mg (<e1>SAL<\\e1> , after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"SAL","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective <e2>GENE-Y<\\e2> agonist salbutamol 8 mg (<e1>CHEMICAL<\\e1> , after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors","sentence":"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL , after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors"}
{"PMID":7912539,"re_id":6,"annotated sentence":"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), <e1>bisoprolol<\\e1> 5 mg (B5) as a selective <e2>beta 1-adrenoceptor<\\e2> antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"bisoprolol","object":"beta 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), <e1>CHEMICAL<\\e1> 5 mg (B5) as a selective <e2>GENE-Y<\\e2> antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors","sentence":"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors"}
{"PMID":7929150,"re_id":0,"annotated sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by <e1>acetazolamide<\\e1>  ethoxzolamide, and cyanate, <e2>CA V<\\e2> is very similar to CA II","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA V","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In catalytic properties, mouse GENE-Y is closest to CA I; however, in inhibition by <e1>CHEMICAL<\\e1>  ethoxzolamide, and cyanate, <e2>GENE-Y<\\e2> is very similar to CA II","sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide  ethoxzolamide, and cyanate, CA V is very similar to CA II"}
{"PMID":7929150,"re_id":1,"annotated sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by <e1>acetazolamide<\\e1>  ethoxzolamide, and cyanate, CA V is very similar to <e2>CA II<\\e2>  Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by <e1>CHEMICAL<\\e1>  ethoxzolamide, and cyanate, CA V is very similar to <e2>GENE-Y<\\e2>  Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway","sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide  ethoxzolamide, and cyanate, CA V is very similar to CA II  Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway"}
{"PMID":7929150,"re_id":2,"annotated sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, <e1>ethoxzolamide<\\e1>  and cyanate, <e2>CA V<\\e2> is very similar to CA II","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethoxzolamide","object":"CA V","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In catalytic properties, mouse GENE-Y is closest to CA I; however, in inhibition by acetazolamide, <e1>CHEMICAL<\\e1>  and cyanate, <e2>GENE-Y<\\e2> is very similar to CA II","sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide  and cyanate, CA V is very similar to CA II"}
{"PMID":7929150,"re_id":3,"annotated sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, <e1>ethoxzolamide<\\e1>  and cyanate, CA V is very similar to <e2>CA II<\\e2>  Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"ethoxzolamide","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, <e1>CHEMICAL<\\e1>  and cyanate, CA V is very similar to <e2>GENE-Y<\\e2>  Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway","sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide  and cyanate, CA V is very similar to CA II  Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway"}
{"PMID":7929150,"re_id":4,"annotated sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and <e1>cyanate<\\e1>  <e2>CA V<\\e2> is very similar to CA II","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyanate","object":"CA V","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In catalytic properties, mouse GENE-Y is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and <e1>CHEMICAL<\\e1>  <e2>GENE-Y<\\e2> is very similar to CA II","sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate  CA V is very similar to CA II"}
{"PMID":7929150,"re_id":5,"annotated sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and <e1>cyanate<\\e1>  CA V is very similar to <e2>CA II<\\e2>  Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"cyanate","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and <e1>CHEMICAL<\\e1>  CA V is very similar to <e2>GENE-Y<\\e2>  Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway","sentence":"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate  CA V is very similar to CA II  Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway"}
{"PMID":7944828,"re_id":0,"annotated sentence":"It is concluded that <e1>D-1997<\\e1> contracts the canine basilar artery by stimulating <e2>5-HT1-like receptors<\\e2> unrelated to either the 5-HT1A or 5-HT1B receptor subtypes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"D-1997","object":"5-HT1-like receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is concluded that <e1>CHEMICAL<\\e1> contracts the canine basilar artery by stimulating <e2>GENE-N<\\e2> unrelated to either the 5-HT1A or 5-HT1B receptor subtypes","sentence":"It is concluded that D-1997 contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the 5-HT1A or 5-HT1B receptor subtypes"}
{"PMID":7944828,"re_id":1,"annotated sentence":"It is concluded that <e1>D-1997<\\e1> contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the <e2>5-HT1A<\\e2> or 5-HT1B receptor subtypes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"D-1997","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It is concluded that <e1>CHEMICAL<\\e1> contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the <e2>GENE-Y<\\e2> or 5-HT1B receptor subtypes","sentence":"It is concluded that D-1997 contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the 5-HT1A or 5-HT1B receptor subtypes"}
{"PMID":7944828,"re_id":2,"annotated sentence":"It is concluded that <e1>D-1997<\\e1> contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the 5-HT1A or <e2>5-HT1B<\\e2> receptor subtypes","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"D-1997","object":"5-HT1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It is concluded that <e1>CHEMICAL<\\e1> contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the 5-HT1A or <e2>GENE-Y<\\e2> receptor subtypes","sentence":"It is concluded that D-1997 contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the 5-HT1A or 5-HT1B receptor subtypes"}
{"PMID":7944828,"re_id":3,"annotated sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the <e2>beta-adrenoceptor<\\e2> blocker with high affinity for 5-HT1A and 5-HT1B binding sites <e1>(+\/-)-pindolol<\\e1> (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"(+\/-)-pindolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the <e2>GENE-N<\\e2> blocker with high affinity for 5-HT1A and 5-HT1B binding sites <e1>CHEMICAL<\\e1> (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)","sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)"}
{"PMID":7944828,"re_id":4,"annotated sentence":"<e1>2-(2-Aminoethyl)-quinoline<\\e1> (D-1997): a novel agonist at <e2>5-hydroxytryptamine1-like receptors<\\e2> in the canine basilar artery","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"2-(2-Aminoethyl)-quinoline","object":"5-hydroxytryptamine1-like receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (D-1997): a novel agonist at <e2>GENE-N<\\e2> in the canine basilar artery","sentence":"2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery"}
{"PMID":7944828,"re_id":5,"annotated sentence":"2-(2-Aminoethyl)-quinoline (<e1>D-1997<\\e1> : a novel agonist at <e2>5-hydroxytryptamine1-like receptors<\\e2> in the canine basilar artery","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"D-1997","object":"5-hydroxytryptamine1-like receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"2-(2-Aminoethyl)-quinoline (<e1>CHEMICAL<\\e1> : a novel agonist at <e2>GENE-N<\\e2> in the canine basilar artery","sentence":"2-(2-Aminoethyl)-quinoline (D-1997 : a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery"}
{"PMID":7944828,"re_id":6,"annotated sentence":"In contrast, the <e1>D-1997<\\e1> induced responses were potently and concentration-dependently antagonized by the mixed <e2>5-HT1-like<\\e2> and 5-HT2 receptor antagonist methiothepin (0.01-1 microM)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"D-1997","object":"5-HT1-like","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the <e1>CHEMICAL<\\e1> induced responses were potently and concentration-dependently antagonized by the mixed <e2>GENE-N<\\e2> and 5-HT2 receptor antagonist methiothepin (0.01-1 microM)","sentence":"In contrast, the D-1997 induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and 5-HT2 receptor antagonist methiothepin (0.01-1 microM)"}
{"PMID":7944828,"re_id":7,"annotated sentence":"In contrast, the <e1>D-1997<\\e1> induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and <e2>5-HT2 receptor<\\e2> antagonist methiothepin (0.01-1 microM)","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"D-1997","object":"5-HT2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the <e1>CHEMICAL<\\e1> induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and <e2>GENE-N<\\e2> antagonist methiothepin (0.01-1 microM)","sentence":"In contrast, the D-1997 induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and 5-HT2 receptor antagonist methiothepin (0.01-1 microM)"}
{"PMID":7944828,"re_id":8,"annotated sentence":"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed <e2>5-HT1-like<\\e2> and 5-HT2 receptor antagonist <e1>methiothepin<\\e1> (0.01-1 microM)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methiothepin","object":"5-HT1-like","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed <e2>GENE-N<\\e2> and 5-HT2 receptor antagonist <e1>CHEMICAL<\\e1> (0.01-1 microM)","sentence":"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and 5-HT2 receptor antagonist methiothepin (0.01-1 microM)"}
{"PMID":7944828,"re_id":9,"annotated sentence":"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and <e2>5-HT2 receptor<\\e2> antagonist <e1>methiothepin<\\e1> (0.01-1 microM)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methiothepin","object":"5-HT2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> (0.01-1 microM)","sentence":"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and 5-HT2 receptor antagonist methiothepin (0.01-1 microM)"}
{"PMID":7944828,"re_id":10,"annotated sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the <e2>5-HT2 receptor<\\e2> antagonist <e1>ketanserin<\\e1> (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ketanserin","object":"5-HT2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)","sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)"}
{"PMID":7944828,"re_id":11,"annotated sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the <e2>5-HT3<\\e2> and 5-HT4 receptor antagonist ICS205930 (<e1>tropisetron<\\e1>  0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tropisetron","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the <e2>GENE-N<\\e2> and 5-HT4 receptor antagonist ICS205930 (<e1>CHEMICAL<\\e1>  0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)","sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron  0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)"}
{"PMID":7944828,"re_id":12,"annotated sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and <e2>5-HT4<\\e2> receptor antagonist ICS205930 (<e1>tropisetron<\\e1>  0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tropisetron","object":"5-HT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and <e2>GENE-Y<\\e2> receptor antagonist ICS205930 (<e1>CHEMICAL<\\e1>  0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)","sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron  0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)"}
{"PMID":7944828,"re_id":13,"annotated sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the <e2>5-HT1A<\\e2> receptor antagonist <e1>spiroxatrine<\\e1> (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"spiroxatrine","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the <e2>GENE-Y<\\e2> receptor antagonist <e1>CHEMICAL<\\e1> (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for GENE-Y and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)","sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)"}
{"PMID":7944828,"re_id":14,"annotated sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the <e2>alpha 1-adrenoceptor<\\e2> antagonist <e1>prazosin<\\e1> (0.01-1 microM)","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"prazosin","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> (0.01-1 microM)","sentence":"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+\/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)"}
{"PMID":7986344,"re_id":0,"annotated sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its <e2>proline-42-to-alanine<\\e2> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and <e1>2'-cytidine monophosphate<\\e1> (2'CMP) inhibitor binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'-cytidine monophosphate","object":"proline-42-to-alanine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its <e2>GENE-N<\\e2> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and <e1>CHEMICAL<\\e1> (2'CMP) inhibitor binding","sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding"}
{"PMID":7986344,"re_id":1,"annotated sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (<e2>Pro42Ala<\\e2>  have been studied by monitoring tyrosine burial and <e1>2'-cytidine monophosphate<\\e1> (2'CMP) inhibitor binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'-cytidine monophosphate","object":"Pro42Ala","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (<e2>GENE-N<\\e2>  have been studied by monitoring tyrosine burial and <e1>CHEMICAL<\\e1> (2'CMP) inhibitor binding","sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala  have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding"}
{"PMID":7986344,"re_id":2,"annotated sentence":"The refolding kinetics of guanidine-denatured disulfide-intact <e2>bovine pancreatic ribonuclease A<\\e2> (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and <e1>2'-cytidine monophosphate<\\e1> (2'CMP) inhibitor binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'-cytidine monophosphate","object":"bovine pancreatic ribonuclease A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The refolding kinetics of guanidine-denatured disulfide-intact <e2>GENE-Y<\\e2> (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and <e1>CHEMICAL<\\e1> (2'CMP) inhibitor binding","sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding"}
{"PMID":7986344,"re_id":3,"annotated sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A<\\e2>  and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and <e1>2'-cytidine monophosphate<\\e1> (2'CMP) inhibitor binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'-cytidine monophosphate","object":"RNase A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>GENE-Y<\\e2>  and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and <e1>CHEMICAL<\\e1> (2'CMP) inhibitor binding","sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A  and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding"}
{"PMID":7986344,"re_id":4,"annotated sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its <e2>proline-42-to-alanine<\\e2> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP<\\e1>  inhibitor binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'CMP","object":"proline-42-to-alanine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its <e2>GENE-N<\\e2> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>CHEMICAL<\\e1>  inhibitor binding","sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP  inhibitor binding"}
{"PMID":7986344,"re_id":5,"annotated sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (<e2>Pro42Ala<\\e2>  have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP<\\e1>  inhibitor binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'CMP","object":"Pro42Ala","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (<e2>GENE-N<\\e2>  have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>CHEMICAL<\\e1>  inhibitor binding","sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala  have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP  inhibitor binding"}
{"PMID":7986344,"re_id":6,"annotated sentence":"The refolding kinetics of guanidine-denatured disulfide-intact <e2>bovine pancreatic ribonuclease A<\\e2> (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP<\\e1>  inhibitor binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'CMP","object":"bovine pancreatic ribonuclease A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The refolding kinetics of guanidine-denatured disulfide-intact <e2>GENE-Y<\\e2> (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>CHEMICAL<\\e1>  inhibitor binding","sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP  inhibitor binding"}
{"PMID":7986344,"re_id":7,"annotated sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A<\\e2>  and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP<\\e1>  inhibitor binding","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'CMP","object":"RNase A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>GENE-Y<\\e2>  and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>CHEMICAL<\\e1>  inhibitor binding","sentence":"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A  and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP  inhibitor binding"}
{"PMID":7986344,"re_id":8,"annotated sentence":"The folding rate for wild-type <e2>RNase A<\\e2> is faster in the presence of the inhibitor <e1>2'CMP<\\e1> than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"2'CMP","object":"RNase A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The folding rate for wild-type <e2>GENE-Y<\\e2> is faster in the presence of the inhibitor <e1>CHEMICAL<\\e1> than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by CHEMICAL","sentence":"The folding rate for wild-type RNase A is faster in the presence of the inhibitor 2'CMP than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP"}
{"PMID":8052854,"re_id":0,"annotated sentence":"The anti-inflammatory drugs <e1>sodium salicylate<\\e1> and aspirin inhibited the activation of <e2>NF-kappa B<\\e2>  which further explains the mechanism of action of these drugs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"sodium salicylate","object":"NF-kappa B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The anti-inflammatory drugs <e1>CHEMICAL<\\e1> and aspirin inhibited the activation of <e2>GENE-N<\\e2>  which further explains the mechanism of action of these drugs","sentence":"The anti-inflammatory drugs sodium salicylate and aspirin inhibited the activation of NF-kappa B  which further explains the mechanism of action of these drugs"}
{"PMID":8052854,"re_id":1,"annotated sentence":"The anti-inflammatory drugs sodium salicylate and <e1>aspirin<\\e1> inhibited the activation of <e2>NF-kappa B<\\e2>  which further explains the mechanism of action of these drugs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aspirin","object":"NF-kappa B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The anti-inflammatory drugs sodium salicylate and <e1>CHEMICAL<\\e1> inhibited the activation of <e2>GENE-N<\\e2>  which further explains the mechanism of action of these drugs","sentence":"The anti-inflammatory drugs sodium salicylate and aspirin inhibited the activation of NF-kappa B  which further explains the mechanism of action of these drugs"}
{"PMID":8052854,"re_id":2,"annotated sentence":"<e1>Sodium salicylate<\\e1> and aspirin also inhibited <e2>NF-kappa B<\\e2> dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sodium salicylate","object":"NF-kappa B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and aspirin also inhibited <e2>GENE-N<\\e2> dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","sentence":"Sodium salicylate and aspirin also inhibited NF-kappa B dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells."}
{"PMID":8052854,"re_id":3,"annotated sentence":"<e1>Sodium salicylate<\\e1> and aspirin also inhibited NF-kappa B-dependent transcription from the <e2>Ig kappa<\\e2> enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Sodium salicylate","object":"Ig kappa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and aspirin also inhibited NF-kappa B-dependent transcription from the <e2>GENE-Y<\\e2> enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","sentence":"Sodium salicylate and aspirin also inhibited NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells."}
{"PMID":8052854,"re_id":4,"annotated sentence":"Sodium salicylate and <e1>aspirin<\\e1> also inhibited <e2>NF-kappa B<\\e2> dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aspirin","object":"NF-kappa B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sodium salicylate and <e1>CHEMICAL<\\e1> also inhibited <e2>GENE-N<\\e2> dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","sentence":"Sodium salicylate and aspirin also inhibited NF-kappa B dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells."}
{"PMID":8052854,"re_id":5,"annotated sentence":"Sodium salicylate and <e1>aspirin<\\e1> also inhibited NF-kappa B-dependent transcription from the <e2>Ig kappa<\\e2> enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"aspirin","object":"Ig kappa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sodium salicylate and <e1>CHEMICAL<\\e1> also inhibited NF-kappa B-dependent transcription from the <e2>GENE-Y<\\e2> enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","sentence":"Sodium salicylate and aspirin also inhibited NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells."}
{"PMID":8263811,"re_id":0,"annotated sentence":"These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to <e1>clonidine<\\e1> and endogenous clonidine-displacing substance(s), and may serve as markers of <e2>imidazoline receptors<\\e2> in humans.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"clonidine","object":"imidazoline receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to <e1>CHEMICAL<\\e1> and endogenous CHEMICAL-displacing substance(s), and may serve as markers of <e2>GENE-N<\\e2> in humans.","sentence":"These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to clonidine and endogenous clonidine-displacing substance(s), and may serve as markers of imidazoline receptors in humans."}
{"PMID":8600944,"re_id":0,"annotated sentence":"<e1>DEX<\\e1> enhanced the ratio <e2>IFN-gamma<\\e2> IL-4 (mean +\/- SEM: control, 28.7 +\/- 17.6; with 10-7 M DEX, 55.0 +\/- 27.5, P<0.005)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX","object":"IFN-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> enhanced the ratio <e2>GENE-Y<\\e2> IL-4 (mean +\/- SEM: control, 28.7 +\/- 17.6; with 10-7 M CHEMICAL, 55.0 +\/- 27.5, P<0.005)","sentence":"DEX enhanced the ratio IFN-gamma IL-4 (mean +\/- SEM: control, 28.7 +\/- 17.6; with 10-7 M DEX, 55.0 +\/- 27.5, P<0.005)"}
{"PMID":8600944,"re_id":1,"annotated sentence":"<e1>DEX<\\e1> enhanced the ratio IFN-gamma\/<e2>IL-4<\\e2> (mean +\/- SEM: control, 28.7 +\/- 17.6; with 10-7 M DEX, 55.0 +\/- 27.5, P<0.005)","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX","object":"IL-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> enhanced the ratio IFN-gamma\/<e2>GENE-Y<\\e2> (mean +\/- SEM: control, 28.7 +\/- 17.6; with 10-7 M CHEMICAL, 55.0 +\/- 27.5, P<0.005)","sentence":"DEX enhanced the ratio IFN-gamma\/IL-4 (mean +\/- SEM: control, 28.7 +\/- 17.6; with 10-7 M DEX, 55.0 +\/- 27.5, P<0.005)"}
{"PMID":8600944,"re_id":2,"annotated sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers <e1>DEX<\\e1> inhibited IL-2 production partially and enhanced <e2>IL-2R alpha<\\e2> expression and proliferation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"DEX","object":"IL-2R alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and GENE-Y expression and proliferation; 1) In low IL-2 producers CHEMICAL blocked IL-2 production and decreased GENE-Y expression and proliferation; 2) In high IL-2 producers <e1>CHEMICAL<\\e1> inhibited IL-2 production partially and enhanced <e2>GENE-Y<\\e2> expression and proliferation","sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation"}
{"PMID":8600944,"re_id":3,"annotated sentence":"Dexamethasone (<e1>DEX<\\e1>  inhibited the anti-<e2>CD3<\\e2> induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"CD3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Dexamethasone (<e1>CHEMICAL<\\e1>  inhibited the anti-<e2>GENE-N<\\e2> induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested","sentence":"Dexamethasone (DEX  inhibited the anti-CD3 induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested"}
{"PMID":8600944,"re_id":4,"annotated sentence":"Dexamethasone (<e1>DEX<\\e1>  inhibited the anti-CD3-induced production of <e2>IL-4<\\e2>  IL-5 and IFN-gamma in all 20 clones tested","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"IL-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (<e1>CHEMICAL<\\e1>  inhibited the anti-CD3-induced production of <e2>GENE-Y<\\e2>  IL-5 and IFN-gamma in all 20 clones tested","sentence":"Dexamethasone (DEX  inhibited the anti-CD3-induced production of IL-4  IL-5 and IFN-gamma in all 20 clones tested"}
{"PMID":8600944,"re_id":5,"annotated sentence":"Dexamethasone (<e1>DEX<\\e1>  inhibited the anti-CD3-induced production of IL-4, <e2>IL-5<\\e2> and IFN-gamma in all 20 clones tested","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"IL-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (<e1>CHEMICAL<\\e1>  inhibited the anti-CD3-induced production of IL-4, <e2>GENE-Y<\\e2> and IFN-gamma in all 20 clones tested","sentence":"Dexamethasone (DEX  inhibited the anti-CD3-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested"}
{"PMID":8600944,"re_id":6,"annotated sentence":"Dexamethasone (<e1>DEX<\\e1>  inhibited the anti-CD3-induced production of IL-4, IL-5 and <e2>IFN-gamma<\\e2> in all 20 clones tested","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"IFN-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dexamethasone (<e1>CHEMICAL<\\e1>  inhibited the anti-CD3-induced production of IL-4, IL-5 and <e2>GENE-Y<\\e2> in all 20 clones tested","sentence":"Dexamethasone (DEX  inhibited the anti-CD3-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested"}
{"PMID":8600944,"re_id":7,"annotated sentence":"<e1>GCS<\\e1> therapy results in reduced mRNA expression of <e2>interleukin-4<\\e2> (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GCS","object":"interleukin-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> therapy results in reduced mRNA expression of <e2>GENE-Y<\\e2> (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma","sentence":"GCS therapy results in reduced mRNA expression of interleukin-4 (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma"}
{"PMID":8600944,"re_id":8,"annotated sentence":"<e1>GCS<\\e1> therapy results in reduced mRNA expression of interleukin-4 (<e2>IL-4<\\e2>  and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GCS","object":"IL-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> therapy results in reduced mRNA expression of interleukin-4 (<e2>GENE-Y<\\e2>  and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma","sentence":"GCS therapy results in reduced mRNA expression of interleukin-4 (IL-4  and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma"}
{"PMID":8600944,"re_id":9,"annotated sentence":"<e1>GCS<\\e1> therapy results in reduced mRNA expression of interleukin-4 (IL-4) and <e2>IL-5<\\e2> in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GCS","object":"IL-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> therapy results in reduced mRNA expression of interleukin-4 (IL-4) and <e2>GENE-Y<\\e2> in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma","sentence":"GCS therapy results in reduced mRNA expression of interleukin-4 (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma"}
{"PMID":8600944,"re_id":10,"annotated sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers <e1>DEX<\\e1> blocked <e2>IL-2<\\e2> production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on GENE-Y production and GENE-YR alpha expression and proliferation; 1) In low GENE-Y producers <e1>CHEMICAL<\\e1> blocked <e2>GENE-Y<\\e2> production and decreased GENE-YR alpha expression and proliferation; 2) In high GENE-Y producers CHEMICAL inhibited GENE-Y production partially and enhanced GENE-YR alpha expression and proliferation","sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation"}
{"PMID":8600944,"re_id":11,"annotated sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers <e1>DEX<\\e1> blocked IL-2 production and decreased <e2>IL-2R alpha<\\e2> expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"IL-2R alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and GENE-Y expression and proliferation; 1) In low IL-2 producers <e1>CHEMICAL<\\e1> blocked IL-2 production and decreased <e2>GENE-Y<\\e2> expression and proliferation; 2) In high IL-2 producers CHEMICAL inhibited IL-2 production partially and enhanced GENE-Y expression and proliferation","sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation"}
{"PMID":8600944,"re_id":12,"annotated sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers <e1>DEX<\\e1> inhibited <e2>IL-2<\\e2> production partially and enhanced IL-2R alpha expression and proliferation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"IL-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on GENE-Y production and GENE-YR alpha expression and proliferation; 1) In low GENE-Y producers CHEMICAL blocked GENE-Y production and decreased GENE-YR alpha expression and proliferation; 2) In high GENE-Y producers <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> production partially and enhanced GENE-YR alpha expression and proliferation","sentence":"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation"}
{"PMID":8600944,"re_id":13,"annotated sentence":"In conclusion, the production of <e2>IL-4<\\e2> and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by <e1>DEX<\\e1> than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"IL-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, the production of <e2>GENE-Y<\\e2> and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by <e1>CHEMICAL<\\e1> than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma","sentence":"In conclusion, the production of IL-4 and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by DEX than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma"}
{"PMID":8600944,"re_id":14,"annotated sentence":"In conclusion, the production of IL-4 and <e2>IL-5<\\e2> by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by <e1>DEX<\\e1> than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"IL-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, the production of IL-4 and <e2>GENE-Y<\\e2> by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by <e1>CHEMICAL<\\e1> than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma","sentence":"In conclusion, the production of IL-4 and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by DEX than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma"}
{"PMID":8600944,"re_id":15,"annotated sentence":"In conclusion, the production of IL-4 and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by <e1>DEX<\\e1> than that of <e2>IFN-gamma<\\e2>  which may account for the therapeutic effects of glucocorticosteroids in patients with asthma","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"DEX","object":"IFN-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, the production of IL-4 and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by <e1>CHEMICAL<\\e1> than that of <e2>GENE-Y<\\e2>  which may account for the therapeutic effects of glucocorticosteroids in patients with asthma","sentence":"In conclusion, the production of IL-4 and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by DEX than that of IFN-gamma  which may account for the therapeutic effects of glucocorticosteroids in patients with asthma"}
{"PMID":8600944,"re_id":16,"annotated sentence":"In vitro studies with blood-derived T cells, however, show inhibition of all three <e2>cytokines<\\e2> by <e1>GCS<\\e1>  We studied the effects of GCS on T cells from BAL in vitro, namely Th0-, Th1, and Th2-like clones; and we compared BAL- with blood-derived clones","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"GCS","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In vitro studies with blood-derived T cells, however, show inhibition of all three <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1>  We studied the effects of CHEMICAL on T cells from BAL in vitro, namely Th0-, Th1, and Th2-like clones; and we compared BAL- with blood-derived clones","sentence":"In vitro studies with blood-derived T cells, however, show inhibition of all three cytokines by GCS  We studied the effects of GCS on T cells from BAL in vitro, namely Th0-, Th1, and Th2-like clones; and we compared BAL- with blood-derived clones"}
{"PMID":8600944,"re_id":17,"annotated sentence":"<e1>Dexamethasone<\\e1> (DEX) inhibited the anti-<e2>CD3<\\e2> induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dexamethasone","object":"CD3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (DEX) inhibited the anti-<e2>GENE-N<\\e2> induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested","sentence":"Dexamethasone (DEX) inhibited the anti-CD3 induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested"}
{"PMID":8600944,"re_id":18,"annotated sentence":"<e1>Dexamethasone<\\e1> (DEX) inhibited the anti-CD3-induced production of <e2>IL-4<\\e2>  IL-5 and IFN-gamma in all 20 clones tested","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dexamethasone","object":"IL-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (DEX) inhibited the anti-CD3-induced production of <e2>GENE-Y<\\e2>  IL-5 and IFN-gamma in all 20 clones tested","sentence":"Dexamethasone (DEX) inhibited the anti-CD3-induced production of IL-4  IL-5 and IFN-gamma in all 20 clones tested"}
{"PMID":8600944,"re_id":19,"annotated sentence":"<e1>Dexamethasone<\\e1> (DEX) inhibited the anti-CD3-induced production of IL-4, <e2>IL-5<\\e2> and IFN-gamma in all 20 clones tested","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dexamethasone","object":"IL-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (DEX) inhibited the anti-CD3-induced production of IL-4, <e2>GENE-Y<\\e2> and IFN-gamma in all 20 clones tested","sentence":"Dexamethasone (DEX) inhibited the anti-CD3-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested"}
{"PMID":8600944,"re_id":20,"annotated sentence":"<e1>Dexamethasone<\\e1> (DEX) inhibited the anti-CD3-induced production of IL-4, IL-5 and <e2>IFN-gamma<\\e2> in all 20 clones tested","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"Dexamethasone","object":"IFN-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (DEX) inhibited the anti-CD3-induced production of IL-4, IL-5 and <e2>GENE-Y<\\e2> in all 20 clones tested","sentence":"Dexamethasone (DEX) inhibited the anti-CD3-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested"}
{"PMID":8636122,"re_id":0,"annotated sentence":"Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific <e2>CB1<\\e2> antagonist <e1>SR 141716A<\\e1>  The antagonist SR 141716A has a high specificity for the central CB1 cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SR 141716A","object":"CB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Structural features of the central cannabinoid GENE-Y receptor involved in the binding of the specific <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  The antagonist CHEMICAL has a high specificity for the central GENE-Y cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships","sentence":"Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A  The antagonist SR 141716A has a high specificity for the central CB1 cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships"}
{"PMID":8667211,"re_id":0,"annotated sentence":"Histamine and <e1>Ca<\\e1> added to NSAIDs amplified the activating effect of the latter on <e2>CA II<\\e2>  Association of PGE2 or acetazolamide to NSAIDs reduced NSAID-induced activation of CA I and CA II","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Ca","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Histamine and <e1>CHEMICAL<\\e1> added to NSAIDs amplified the activating effect of the latter on <e2>GENE-Y<\\e2>  Association of PGE2 or acetazolamide to NSAIDs reduced NSAID-induced activation of CA I and GENE-Y","sentence":"Histamine and Ca added to NSAIDs amplified the activating effect of the latter on CA II  Association of PGE2 or acetazolamide to NSAIDs reduced NSAID-induced activation of CA I and CA II"}
{"PMID":8667211,"re_id":1,"annotated sentence":"<e1>Indomethacin<\\e1> abolished the inhibitory effect of acetazolamide on <e2>CA I<\\e2> and CA II","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"CA I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> abolished the inhibitory effect of acetazolamide on <e2>GENE-Y<\\e2> and GENE-YI","sentence":"Indomethacin abolished the inhibitory effect of acetazolamide on CA I and CA II"}
{"PMID":8667211,"re_id":2,"annotated sentence":"<e1>Indomethacin<\\e1> abolished the inhibitory effect of acetazolamide on CA I and <e2>CA II<\\e2>  Our data imply that between CA and cyclooxygenase there is an inverse relationship, CA activation being accompanied by reduction of cyclooxygenase activity, a reduction achieved by the pH modifications induced by CA activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"Indomethacin","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> abolished the inhibitory effect of acetazolamide on CA I and <e2>GENE-Y<\\e2>  Our data imply that between CA and cyclooxygenase there is an inverse relationship, CA activation being accompanied by reduction of cyclooxygenase activity, a reduction achieved by the pH modifications induced by CA activation","sentence":"Indomethacin abolished the inhibitory effect of acetazolamide on CA I and CA II  Our data imply that between CA and cyclooxygenase there is an inverse relationship, CA activation being accompanied by reduction of cyclooxygenase activity, a reduction achieved by the pH modifications induced by CA activation"}
{"PMID":8667211,"re_id":3,"annotated sentence":"Association of PGE2 or <e1>acetazolamide<\\e1> to NSAIDs reduced NSAID-induced activation of <e2>CA I<\\e2> and CA II","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Association of PGE2 or <e1>CHEMICAL<\\e1> to NSAIDs reduced NSAID-induced activation of <e2>GENE-Y<\\e2> and GENE-YI","sentence":"Association of PGE2 or acetazolamide to NSAIDs reduced NSAID-induced activation of CA I and CA II"}
{"PMID":8667211,"re_id":4,"annotated sentence":"Association of PGE2 or <e1>acetazolamide<\\e1> to NSAIDs reduced NSAID-induced activation of CA I and <e2>CA II<\\e2>  Indomethacin abolished the inhibitory effect of acetazolamide on CA I and CA II","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Association of PGE2 or <e1>CHEMICAL<\\e1> to NSAIDs reduced NSAID-induced activation of CA I and <e2>GENE-Y<\\e2>  Indomethacin abolished the inhibitory effect of CHEMICAL on CA I and GENE-Y","sentence":"Association of PGE2 or acetazolamide to NSAIDs reduced NSAID-induced activation of CA I and CA II  Indomethacin abolished the inhibitory effect of acetazolamide on CA I and CA II"}
{"PMID":8667211,"re_id":5,"annotated sentence":"Indomethacin abolished the inhibitory effect of <e1>acetazolamide<\\e1> on <e2>CA I<\\e2> and CA II","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Indomethacin abolished the inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2> and GENE-YI","sentence":"Indomethacin abolished the inhibitory effect of acetazolamide on CA I and CA II"}
{"PMID":8667211,"re_id":6,"annotated sentence":"Indomethacin abolished the inhibitory effect of <e1>acetazolamide<\\e1> on CA I and <e2>CA II<\\e2>  Our data imply that between CA and cyclooxygenase there is an inverse relationship, CA activation being accompanied by reduction of cyclooxygenase activity, a reduction achieved by the pH modifications induced by CA activation","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"acetazolamide","object":"CA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Indomethacin abolished the inhibitory effect of <e1>CHEMICAL<\\e1> on CA I and <e2>GENE-Y<\\e2>  Our data imply that between CA and cyclooxygenase there is an inverse relationship, CA activation being accompanied by reduction of cyclooxygenase activity, a reduction achieved by the pH modifications induced by CA activation","sentence":"Indomethacin abolished the inhibitory effect of acetazolamide on CA I and CA II  Our data imply that between CA and cyclooxygenase there is an inverse relationship, CA activation being accompanied by reduction of cyclooxygenase activity, a reduction achieved by the pH modifications induced by CA activation"}
{"PMID":8667211,"re_id":7,"annotated sentence":"Previous studies by this research team proved that vasodilating <e1>prostaglandins<\\e1> (PGs) E1, E2 and I2 inhibit <e2>carbonic anhydrase<\\e2> (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prostaglandins","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previous studies by this research team proved that vasodilating <e1>CHEMICAL<\\e1> (PGs) E1, E2 and I2 inhibit <e2>GENE-N<\\e2> (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs","sentence":"Previous studies by this research team proved that vasodilating prostaglandins (PGs) E1, E2 and I2 inhibit carbonic anhydrase (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs"}
{"PMID":8667211,"re_id":8,"annotated sentence":"Previous studies by this research team proved that vasodilating <e1>prostaglandins<\\e1> (PGs) E1, E2 and I2 inhibit carbonic anhydrase (<e2>CA<\\e2>  in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"prostaglandins","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previous studies by this research team proved that vasodilating <e1>CHEMIGENE-NL<\\e1> (PGs) E1, E2 and I2 inhibit carbonic anhydrase (<e2>GENE-N<\\e2>  in vitro and in vivo, which suggested involvement of GENE-N in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs","sentence":"Previous studies by this research team proved that vasodilating prostaglandins (PGs) E1, E2 and I2 inhibit carbonic anhydrase (CA  in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs"}
{"PMID":8667211,"re_id":9,"annotated sentence":"Previous studies by this research team proved that vasodilating prostaglandins (<e1>PGs<\\e1>  E1, E2 and I2 inhibit <e2>carbonic anhydrase<\\e2> (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PGs","object":"carbonic anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previous studies by this research team proved that vasodilating prostaglandins (<e1>CHEMICAL<\\e1>  E1, E2 and I2 inhibit <e2>GENE-N<\\e2> (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of CHEMICAL","sentence":"Previous studies by this research team proved that vasodilating prostaglandins (PGs  E1, E2 and I2 inhibit carbonic anhydrase (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs"}
{"PMID":8667211,"re_id":10,"annotated sentence":"Previous studies by this research team proved that vasodilating prostaglandins (<e1>PGs<\\e1>  E1, E2 and I2 inhibit carbonic anhydrase (<e2>CA<\\e2>  in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"PGs","object":"CA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Previous studies by this research team proved that vasodilating prostaglandins (<e1>CHEMIGENE-NL<\\e1>  E1, E2 and I2 inhibit carbonic anhydrase (<e2>GENE-N<\\e2>  in vitro and in vivo, which suggested involvement of GENE-N in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of CHEMIGENE-NL","sentence":"Previous studies by this research team proved that vasodilating prostaglandins (PGs  E1, E2 and I2 inhibit carbonic anhydrase (CA  in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs"}
{"PMID":8799556,"re_id":0,"annotated sentence":"<e1>(+)-Tamsulosin<\\e1>  (-)-tamsulosin, SL 89,0591, Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(+)-Tamsulosin","object":"human alpha 1D adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  (-)-tamsulosin, SL 89,0591, Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>GENE-Y<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069","sentence":"(+)-Tamsulosin  (-)-tamsulosin, SL 89,0591, Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069"}
{"PMID":8799556,"re_id":1,"annotated sentence":"(+)-Tamsulosin, <e1>(-)-tamsulosin<\\e1>  SL 89,0591, Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(-)-tamsulosin","object":"human alpha 1D adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(+)-Tamsulosin, <e1>CHEMICAL<\\e1>  SL 89,0591, Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>GENE-Y<\\e2>  The following rank order was obtained: prazosin = CHEMICAL > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069","sentence":"(+)-Tamsulosin, (-)-tamsulosin  SL 89,0591, Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069"}
{"PMID":8799556,"re_id":2,"annotated sentence":"(+)-Tamsulosin, (-)-tamsulosin, <e1>SL 89,0591<\\e1>  Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SL 89,0591","object":"human alpha 1D adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(+)-Tamsulosin, (-)-tamsulosin, <e1>CHEMICAL<\\e1>  Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>GENE-Y<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > CHEMICAL = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069","sentence":"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591  Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069"}
{"PMID":8799556,"re_id":3,"annotated sentence":"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, <e1>Rec 15\/2739<\\e1>  SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Rec 15\/2739","object":"human alpha 1D adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, <e1>CHEMICAL<\\e1>  SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>GENE-Y<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > CHEMICAL > RS 17053 = SNAP 1069","sentence":"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15\/2739  SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069"}
{"PMID":8799556,"re_id":4,"annotated sentence":"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15\/2739, <e1>SNAP 1069<\\e1> and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"SNAP 1069","object":"human alpha 1D adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15\/2739, <e1>CHEMICAL<\\e1> and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>GENE-Y<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = CHEMICAL","sentence":"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069"}
{"PMID":8799556,"re_id":5,"annotated sentence":"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15\/2739, SNAP 1069 and <e1>RS 17053<\\e1> appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"RS 17053","object":"human alpha 1D adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15\/2739, SNAP 1069 and <e1>CHEMICAL<\\e1> appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>GENE-Y<\\e2>  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > CHEMICAL = SNAP 1069","sentence":"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15\/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned human alpha 1D adrenoceptors  The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15\/2739 > RS 17053 = SNAP 1069"}
{"PMID":8836655,"re_id":0,"annotated sentence":"These results suggest that <e1>epinastine<\\e1>  although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional <e2>5-HT1-like receptor<\\e2>  located to sensory nerves.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"epinastine","object":"5-HT1-like receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1>  although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional <e2>GENE-N<\\e2>  located to sensory nerves.","sentence":"These results suggest that epinastine  although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor  located to sensory nerves."}
{"PMID":8836655,"re_id":1,"annotated sentence":"These results suggest that <e1>epinastine<\\e1>  although identified as a 5-HT antagonist, acts as a <e2>5-HT1<\\e2> agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"epinastine","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results suggest that <e1>CHEMICAL<\\e1>  although identified as a 5-HT antagonist, acts as a <e2>GENE-N<\\e2> agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional GENE-N-like receptor, located to sensory nerves.","sentence":"These results suggest that epinastine  although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional 5-HT1-like receptor, located to sensory nerves."}
{"PMID":8836655,"re_id":2,"annotated sentence":"Pretreatment of the tissues with combined <e2>5-HT1<\\e2> 5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of <e1>epinastine<\\e1> on the noncholinergic contraction","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"epinastine","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment of the tissues with combined <e2>GENE-N<\\e2> 5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of <e1>CHEMICAL<\\e1> on the noncholinergic contraction","sentence":"Pretreatment of the tissues with combined 5-HT1 5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction"}
{"PMID":8836655,"re_id":3,"annotated sentence":"Pretreatment of the tissues with combined 5-HT1\/<e2>5-HT2<\\e2> antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of <e1>epinastine<\\e1> on the noncholinergic contraction","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"epinastine","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment of the tissues with combined 5-HT1\/<e2>GENE-N<\\e2> antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of <e1>CHEMICAL<\\e1> on the noncholinergic contraction","sentence":"Pretreatment of the tissues with combined 5-HT1\/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction"}
{"PMID":8836655,"re_id":4,"annotated sentence":"Pretreatment of the tissues with combined <e2>5-HT1<\\e2> 5-HT2 antagonists, <e1>methysergide<\\e1> (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methysergide","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment of the tissues with combined <e2>GENE-N<\\e2> 5-HT2 antagonists, <e1>CHEMICAL<\\e1> (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction","sentence":"Pretreatment of the tissues with combined 5-HT1 5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction"}
{"PMID":8836655,"re_id":5,"annotated sentence":"Pretreatment of the tissues with combined 5-HT1\/<e2>5-HT2<\\e2> antagonists, <e1>methysergide<\\e1> (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methysergide","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment of the tissues with combined 5-HT1\/<e2>GENE-N<\\e2> antagonists, <e1>CHEMICAL<\\e1> (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction","sentence":"Pretreatment of the tissues with combined 5-HT1\/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction"}
{"PMID":8836655,"re_id":6,"annotated sentence":"Pretreatment of the tissues with combined <e2>5-HT1<\\e2> 5-HT2 antagonists, methysergide (1 microM) or <e1>methiothepin<\\e1> (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methiothepin","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment of the tissues with combined <e2>GENE-N<\\e2> 5-HT2 antagonists, methysergide (1 microM) or <e1>CHEMICAL<\\e1> (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction","sentence":"Pretreatment of the tissues with combined 5-HT1 5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction"}
{"PMID":8836655,"re_id":7,"annotated sentence":"Pretreatment of the tissues with combined 5-HT1\/<e2>5-HT2<\\e2> antagonists, methysergide (1 microM) or <e1>methiothepin<\\e1> (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"methiothepin","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment of the tissues with combined 5-HT1\/<e2>GENE-N<\\e2> antagonists, methysergide (1 microM) or <e1>CHEMICAL<\\e1> (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction","sentence":"Pretreatment of the tissues with combined 5-HT1\/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction"}
{"PMID":8836655,"re_id":8,"annotated sentence":"Pretreatment with <e1>tropisetron<\\e1> (1 microM), a <e2>5-HT3<\\e2> antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tropisetron","object":"5-HT3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment with <e1>CHEMICAL<\\e1> (1 microM), a <e2>GENE-N<\\e2> antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect","sentence":"Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect"}
{"PMID":8836655,"re_id":9,"annotated sentence":"Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, <e1>ketanserin<\\e1> (10 microM), a <e2>5-HT2<\\e2> antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"ketanserin","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, <e1>CHEMICAL<\\e1> (10 microM), a <e2>GENE-N<\\e2> antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect","sentence":"Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect"}
{"PMID":8836655,"re_id":10,"annotated sentence":"Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, <e1>thioperamide<\\e1> (10 microM), a <e2>histamine H3<\\e2> antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"thioperamide","object":"histamine H3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, <e1>CHEMICAL<\\e1> (10 microM), a <e2>GENE-Y<\\e2> antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect","sentence":"Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect"}
{"PMID":8836655,"re_id":11,"annotated sentence":"<e1>Chlorpheniramine<\\e1> (10 microM), another <e2>histamine H1 receptor<\\e2> antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"Chlorpheniramine","object":"histamine H1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (10 microM), another <e2>GENE-Y<\\e2> antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction","sentence":"Chlorpheniramine (10 microM), another histamine H1 receptor antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction"}
{"PMID":8894610,"re_id":0,"annotated sentence":"(+\/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of <e2>alpha 1B-adrenoceptors<\\e2> by treatment with <e1>chlorethylclonidine<\\e1>  which is an indication that the (+\/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"chlorethylclonidine","object":"alpha 1B-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(+\/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of <e2>GENE-Y<\\e2> by treatment with <e1>CHEMICAL<\\e1>  which is an indication that the (+\/-)-tamsulosin-sensitive subtype belongs to a class resistant to CHEMICAL","sentence":"(+\/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine  which is an indication that the (+\/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine"}
{"PMID":8894610,"re_id":1,"annotated sentence":"These results indicate that the positive inotropic effect, mediated via (+\/-)-tamsulosin- and <e1>oxymetazoline<\\e1> sensitive subtype of <e2>alpha 1-adrenoceptors<\\e2>  is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"oxymetazoline","object":"alpha 1-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results indicate that the positive inotropic effect, mediated via (+\/-)-tamsulosin- and <e1>CHEMICAL<\\e1> sensitive subtype of <e2>GENE-N<\\e2>  is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.","sentence":"These results indicate that the positive inotropic effect, mediated via (+\/-)-tamsulosin- and oxymetazoline sensitive subtype of alpha 1-adrenoceptors  is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates."}
{"PMID":8894610,"re_id":2,"annotated sentence":"<e1>Phenylephrine<\\e1> elicited a concentration-dependent positive inotropic effect via <e2>alpha 1-adrenoceptors<\\e2> in the presence of either (+\/-)-bupranolol or S(-)-timolol","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Phenylephrine","object":"alpha 1-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> elicited a concentration-dependent positive inotropic effect via <e2>GENE-N<\\e2> in the presence of either (+\/-)-bupranolol or S(-)-timolol","sentence":"Phenylephrine elicited a concentration-dependent positive inotropic effect via alpha 1-adrenoceptors in the presence of either (+\/-)-bupranolol or S(-)-timolol"}
{"PMID":8894610,"re_id":3,"annotated sentence":"(+\/-)-Tamsulosin effectively antagonized the positive inotropic effect of <e1>phenylephrine<\\e1> even after inactivation of <e2>alpha 1B-adrenoceptors<\\e2> by treatment with chlorethylclonidine, which is an indication that the (+\/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"phenylephrine","object":"alpha 1B-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(+\/-)-Tamsulosin effectively antagonized the positive inotropic effect of <e1>CHEMICAL<\\e1> even after inactivation of <e2>GENE-Y<\\e2> by treatment with chlorethylclonidine, which is an indication that the (+\/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine","sentence":"(+\/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+\/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine"}
{"PMID":8894610,"re_id":4,"annotated sentence":"The influence of <e1>(+\/-)-tamsulosin<\\e1>  a selective <e2>alpha 1A-adrenoceptor<\\e2> antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(+\/-)-tamsulosin","object":"alpha 1A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The influence of <e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another GENE-Y ligand oxymetazoline in the rabbit ventricular myocardium","sentence":"The influence of (+\/-)-tamsulosin  a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium"}
{"PMID":8894610,"re_id":5,"annotated sentence":"These results indicate that the positive inotropic effect, mediated via <e1>(+\/-)-tamsulosin<\\e1>  and oxymetazoline-sensitive subtype of <e2>alpha 1-adrenoceptors<\\e2>  is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(+\/-)-tamsulosin","object":"alpha 1-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results indicate that the positive inotropic effect, mediated via <e1>CHEMICAL<\\e1>  and oxymetazoline-sensitive subtype of <e2>GENE-N<\\e2>  is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.","sentence":"These results indicate that the positive inotropic effect, mediated via (+\/-)-tamsulosin  and oxymetazoline-sensitive subtype of alpha 1-adrenoceptors  is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates."}
{"PMID":8894610,"re_id":6,"annotated sentence":"<e1>(+\/-)-Tamsulosin<\\e1> effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of <e2>alpha 1B-adrenoceptors<\\e2> by treatment with chlorethylclonidine, which is an indication that the (+\/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(+\/-)-Tamsulosin","object":"alpha 1B-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of <e2>GENE-Y<\\e2> by treatment with chlorethylclonidine, which is an indication that the (+\/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine","sentence":"(+\/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of alpha 1B-adrenoceptors by treatment with chlorethylclonidine, which is an indication that the (+\/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine"}
{"PMID":8894610,"re_id":7,"annotated sentence":"<e1>(+\/-)-tamsulosin<\\e1>  an <e2>alpha 1A-adrenoceptor<\\e2> antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(+\/-)-tamsulosin","object":"alpha 1A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart","sentence":"(+\/-)-tamsulosin  an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart"}
{"PMID":8894610,"re_id":8,"annotated sentence":"<e1>(+\/-)-Tamsulosin<\\e1>  over the range of concentrations at which it antagonized the positive inotropic effect mediated by <e2>alpha 1-adrenoceptors<\\e2>  did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"(+\/-)-Tamsulosin","object":"alpha 1-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  over the range of concentrations at which it antagonized the positive inotropic effect mediated by <e2>GENE-N<\\e2>  did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine","sentence":"(+\/-)-Tamsulosin  over the range of concentrations at which it antagonized the positive inotropic effect mediated by alpha 1-adrenoceptors  did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine"}
{"PMID":8925876,"re_id":0,"annotated sentence":"The potency of the antipsychotic drug, <e1>risperidone<\\e1>  to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and <e2>alpha 1B-adrenoceptor<\\e2> mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"risperidone","object":"alpha 1B-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potency of the antipsychotic drug, <e1>CHEMICAL<\\e1>  to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and <e2>GENE-Y<\\e2> mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists","sentence":"The potency of the antipsychotic drug, risperidone  to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists"}
{"PMID":8925876,"re_id":1,"annotated sentence":"The potency of the antipsychotic drug, <e1>risperidone<\\e1>  to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of <e2>alpha 1-adrenoceptor<\\e2> subtype-discriminating antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"risperidone","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The potency of the antipsychotic drug, <e1>CHEMICAL<\\e1>  to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of <e2>GENE-N<\\e2> subtype-discriminating antagonists","sentence":"The potency of the antipsychotic drug, risperidone  to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists"}
{"PMID":8925876,"re_id":2,"annotated sentence":"The potency of the antipsychotic drug, <e1>risperidone<\\e1>  to antagonize <e2>alpha 1A-adrenoceptor<\\e2> mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"risperidone","object":"alpha 1A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potency of the antipsychotic drug, <e1>CHEMICAL<\\e1>  to antagonize <e2>GENE-Y<\\e2> mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists","sentence":"The potency of the antipsychotic drug, risperidone  to antagonize alpha 1A-adrenoceptor mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists"}
{"PMID":9003761,"re_id":0,"annotated sentence":"TREK-1 currents are insensitive to pharmacological agents that block <e2>TWIK-1<\\e2> activity such as <e1>quinine<\\e1> and quinidine","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinine","object":"TWIK-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TREK-1 currents are insensitive to pharmacological agents that block <e2>GENE-Y<\\e2> activity such as <e1>CHEMICAL<\\e1> and quinidine","sentence":"TREK-1 currents are insensitive to pharmacological agents that block TWIK-1 activity such as quinine and quinidine"}
{"PMID":9003761,"re_id":1,"annotated sentence":"TREK-1 currents are insensitive to pharmacological agents that block <e2>TWIK-1<\\e2> activity such as quinine and <e1>quinidine<\\e1>  Extensive inhibitions of TREK-1 activity are observed after activation of protein kinases A and C","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"quinidine","object":"TWIK-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TREK-1 currents are insensitive to pharmacological agents that block <e2>GENE-Y<\\e2> activity such as quinine and <e1>CHEMICAL<\\e1>  Extensive inhibitions of TREK-1 activity are observed after activation of protein kinases A and C","sentence":"TREK-1 currents are insensitive to pharmacological agents that block TWIK-1 activity such as quinine and quinidine  Extensive inhibitions of TREK-1 activity are observed after activation of protein kinases A and C"}
{"PMID":9040115,"re_id":0,"annotated sentence":"Conversely, opioid antagonists such as naloxone and <e1>naltrexone<\\e1> (which bind to non-selectively <e2>opioid receptors<\\e2>  have been shown to decrease alcohol consumption under various experimental conditions","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"naltrexone","object":"opioid receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Conversely, opioid antagonists such as naloxone and <e1>CHEMICAL<\\e1> (which bind to non-selectively <e2>GENE-N<\\e2>  have been shown to decrease alcohol consumption under various experimental conditions","sentence":"Conversely, opioid antagonists such as naloxone and naltrexone (which bind to non-selectively opioid receptors  have been shown to decrease alcohol consumption under various experimental conditions"}
{"PMID":9040115,"re_id":1,"annotated sentence":"none","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"alcohol","object":"beta-endorphin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":9040115,"re_id":2,"annotated sentence":"Conversely, opioid antagonists such as <e1>naloxone<\\e1> and naltrexone (which bind to non-selectively <e2>opioid receptors<\\e2>  have been shown to decrease alcohol consumption under various experimental conditions","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"naloxone","object":"opioid receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Conversely, opioid antagonists such as <e1>CHEMICAL<\\e1> and naltrexone (which bind to non-selectively <e2>GENE-N<\\e2>  have been shown to decrease alcohol consumption under various experimental conditions","sentence":"Conversely, opioid antagonists such as naloxone and naltrexone (which bind to non-selectively opioid receptors  have been shown to decrease alcohol consumption under various experimental conditions"}
{"PMID":9231746,"re_id":0,"annotated sentence":"We have examined the effect of dihydropyridine <e2>Ca2+-channel<\\e2> blockers <e1>felodipine<\\e1> and nicardipine on CaMPDE","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"Ca2+-channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have examined the effect of dihydropyridine <e2>GENE-N<\\e2> blockers <e1>CHEMICAL<\\e1> and nicardipine on CaMPDE","sentence":"We have examined the effect of dihydropyridine Ca2+-channel blockers felodipine and nicardipine on CaMPDE"}
{"PMID":9231746,"re_id":1,"annotated sentence":"We have examined the effect of dihydropyridine <e2>Ca2+-channel<\\e2> blockers felodipine and <e1>nicardipine<\\e1> on CaMPDE","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicardipine","object":"Ca2+-channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have examined the effect of dihydropyridine <e2>GENE-N<\\e2> blockers felodipine and <e1>CHEMICAL<\\e1> on CaMPDE","sentence":"We have examined the effect of dihydropyridine Ca2+-channel blockers felodipine and nicardipine on CaMPDE"}
{"PMID":9231746,"re_id":2,"annotated sentence":"The results suggest that the 63-kDa (<e2>PDE 1B1<\\e2>  and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by <e1>felodipine<\\e1> and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"PDE 1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that the 63-kDa (<e2>GENE-Y<\\e2>  and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by <e1>CHEMICAL<\\e1> and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","sentence":"The results suggest that the 63-kDa (PDE 1B1  and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other"}
{"PMID":9231746,"re_id":3,"annotated sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (<e2>PDE 1A2<\\e2>  CaMPDE isozymes are inhibited by <e1>felodipine<\\e1> and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"PDE 1A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (<e2>GENE-Y<\\e2>  CaMPDE isozymes are inhibited by <e1>CHEMICAL<\\e1> and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2  CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other"}
{"PMID":9231746,"re_id":4,"annotated sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) <e2>CaMPDE<\\e2> isozymes are inhibited by <e1>felodipine<\\e1> and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"felodipine","object":"CaMPDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) <e2>GENE-N<\\e2> isozymes are inhibited by <e1>CHEMICAL<\\e1> and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other"}
{"PMID":9231746,"re_id":5,"annotated sentence":"The results suggest that the 63-kDa (<e2>PDE 1B1<\\e2>  and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and <e1>nicardipine<\\e1> by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicardipine","object":"PDE 1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that the 63-kDa (<e2>GENE-Y<\\e2>  and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and <e1>CHEMICAL<\\e1> by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","sentence":"The results suggest that the 63-kDa (PDE 1B1  and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other"}
{"PMID":9231746,"re_id":6,"annotated sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (<e2>PDE 1A2<\\e2>  CaMPDE isozymes are inhibited by felodipine and <e1>nicardipine<\\e1> by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicardipine","object":"PDE 1A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (<e2>GENE-Y<\\e2>  CaMPDE isozymes are inhibited by felodipine and <e1>CHEMICAL<\\e1> by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2  CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other"}
{"PMID":9231746,"re_id":7,"annotated sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) <e2>CaMPDE<\\e2> isozymes are inhibited by felodipine and <e1>nicardipine<\\e1> by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"nicardipine","object":"CaMPDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) <e2>GENE-N<\\e2> isozymes are inhibited by felodipine and <e1>CHEMICAL<\\e1> by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other","sentence":"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other"}
{"PMID":9231746,"re_id":8,"annotated sentence":"Felodipine and nicardipine have similar affinities for 60-kDa <e2>CaMPDE<\\e2> isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by <e1>dihydropyridine<\\e1> Ca2+-channel blockers.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydropyridine","object":"CaMPDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Felodipine and nicardipine have similar affinities for 60-kDa <e2>GENE-N<\\e2> isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by <e1>CHEMICAL<\\e1> Ca2+-channel blockers.","sentence":"Felodipine and nicardipine have similar affinities for 60-kDa CaMPDE isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by dihydropyridine Ca2+-channel blockers."}
{"PMID":9231746,"re_id":9,"annotated sentence":"Felodipine and nicardipine have similar affinities for 60-kDa CaMPDE isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by <e1>dihydropyridine<\\e1> <e2>Ca2+-channel<\\e2> blockers.","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydropyridine","object":"Ca2+-channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Felodipine and nicardipine have similar affinities for 60-kDa CaMPDE isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by <e1>CHEMICAL<\\e1> <e2>GENE-N<\\e2> blockers.","sentence":"Felodipine and nicardipine have similar affinities for 60-kDa CaMPDE isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by dihydropyridine Ca2+-channel blockers."}
{"PMID":9231746,"re_id":10,"annotated sentence":"We have examined the effect of <e1>dihydropyridine<\\e1> <e2>Ca2+-channel<\\e2> blockers felodipine and nicardipine on CaMPDE","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"dihydropyridine","object":"Ca2+-channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have examined the effect of <e1>CHEMICAL<\\e1> <e2>GENE-N<\\e2> blockers felodipine and nicardipine on CaMPDE","sentence":"We have examined the effect of dihydropyridine Ca2+-channel blockers felodipine and nicardipine on CaMPDE"}
{"PMID":9399012,"re_id":0,"annotated sentence":"These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that <e1>zolmitriptan<\\e1> blocks elevations of <e2>calcitonin-gene-related peptide<\\e2> in jugular venous blood during electrical stimulation of the trigeminal ganglion","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"zolmitriptan","object":"calcitonin-gene-related peptide","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that <e1>CHEMICAL<\\e1> blocks elevations of <e2>GENE-N<\\e2> in jugular venous blood during electrical stimulation of the trigeminal ganglion","sentence":"These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that zolmitriptan blocks elevations of calcitonin-gene-related peptide in jugular venous blood during electrical stimulation of the trigeminal ganglion"}
{"PMID":9399012,"re_id":1,"annotated sentence":"Zolmitriptan (Zomig; formerly <e1>311C90<\\e1>  is a novel <e2>5-hydroxytryptamine (5HT)1B\/1D<\\e2> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"311C90","object":"5-hydroxytryptamine (5HT)1B\/1D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Zolmitriptan (Zomig; formerly <e1>CHEMICAL<\\e1>  is a novel <e2>GENE-N<\\e2> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura","sentence":"Zolmitriptan (Zomig; formerly 311C90  is a novel 5-hydroxytryptamine (5HT)1B\/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura"}
{"PMID":9399012,"re_id":2,"annotated sentence":"Pre-clinical pharmacology of <e1>zolmitriptan<\\e1> (Zomig; formerly 311C90), a centrally and peripherally acting <e2>5HT1B\/1D<\\e2> agonist for migraine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"zolmitriptan","object":"5HT1B\/1D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pre-clinical pharmacology of <e1>CHEMICAL<\\e1> (Zomig; formerly 311C90), a centrally and peripherally acting <e2>GENE-N<\\e2> agonist for migraine","sentence":"Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B\/1D agonist for migraine"}
{"PMID":9399012,"re_id":3,"annotated sentence":"<e1>Zolmitriptan<\\e1> (Zomig; formerly 311C90) is a novel <e2>5-hydroxytryptamine (5HT)1B\/1D<\\e2> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Zolmitriptan","object":"5-hydroxytryptamine (5HT)1B\/1D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (Zomig; formerly 311C90) is a novel <e2>GENE-N<\\e2> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura","sentence":"Zolmitriptan (Zomig; formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B\/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura"}
{"PMID":9399012,"re_id":4,"annotated sentence":"Pre-clinical pharmacology of zolmitriptan (<e1>Zomig<\\e1>  formerly 311C90), a centrally and peripherally acting <e2>5HT1B\/1D<\\e2> agonist for migraine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Zomig","object":"5HT1B\/1D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pre-clinical pharmacology of zolmitriptan (<e1>CHEMICAL<\\e1>  formerly 311C90), a centrally and peripherally acting <e2>GENE-N<\\e2> agonist for migraine","sentence":"Pre-clinical pharmacology of zolmitriptan (Zomig  formerly 311C90), a centrally and peripherally acting 5HT1B\/1D agonist for migraine"}
{"PMID":9399012,"re_id":5,"annotated sentence":"Pre-clinical pharmacology of zolmitriptan (Zomig; formerly <e1>311C90<\\e1> , a centrally and peripherally acting <e2>5HT1B\/1D<\\e2> agonist for migraine","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"311C90","object":"5HT1B\/1D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pre-clinical pharmacology of zolmitriptan (Zomig; formerly <e1>CHEMICAL<\\e1> , a centrally and peripherally acting <e2>GENE-N<\\e2> agonist for migraine","sentence":"Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90 , a centrally and peripherally acting 5HT1B\/1D agonist for migraine"}
{"PMID":9399012,"re_id":6,"annotated sentence":"Zolmitriptan (<e1>Zomig<\\e1>  formerly 311C90) is a novel <e2>5-hydroxytryptamine (5HT)1B\/1D<\\e2> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura","re_type_id":"CPR:5","lable_positive":"None","re_type":"None","subject":"Zomig","object":"5-hydroxytryptamine (5HT)1B\/1D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Zolmitriptan (<e1>CHEMICAL<\\e1>  formerly 311C90) is a novel <e2>GENE-N<\\e2> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura","sentence":"Zolmitriptan (Zomig  formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B\/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura"}
{"PMID":9480923,"re_id":0,"annotated sentence":"Treatment of Rat-2 fibroblast cells with <e1>C2-ceramide<\\e1> caused the stimulation of <e2>c-fos SRE<\\e2> dependent reporter gene activity in a dose- and time-dependent manner by transient transfection analysis","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"C2-ceramide","object":"c-fos SRE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment of Rat-2 fibroblast cells with <e1>CHEMICAL<\\e1> caused the stimulation of <e2>GENE-N<\\e2> dependent reporter gene activity in a dose- and time-dependent manner by transient transfection analysis","sentence":"Treatment of Rat-2 fibroblast cells with C2-ceramide caused the stimulation of c-fos SRE dependent reporter gene activity in a dose- and time-dependent manner by transient transfection analysis"}
{"PMID":9480923,"re_id":1,"annotated sentence":"Next, we examined the role of Rho family GTPases in the <e1>ceramide<\\e1> induced signalling to <e2>SRE<\\e2> activation","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ceramide","object":"SRE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Next, we examined the role of Rho family GTPases in the <e1>CHEMICAL<\\e1> induced signalling to <e2>GENE-N<\\e2> activation","sentence":"Next, we examined the role of Rho family GTPases in the ceramide induced signalling to SRE activation"}
{"PMID":9480923,"re_id":2,"annotated sentence":"By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, <e1>C2-ceramide<\\e1> induced <e2>SRE<\\e2> activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"C2-ceramide","object":"SRE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus","sentence":"By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA, C2-ceramide induced SRE activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus"}
{"PMID":9480923,"re_id":3,"annotated sentence":"Exogenous <e1>C2-ceramide<\\e1> activates <e2>c-fos serum response element<\\e2> via Rac-dependent signalling pathway","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"C2-ceramide","object":"c-fos serum response element","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exogenous <e1>CHEMICAL<\\e1> activates <e2>GENE-N<\\e2> via Rac-dependent signalling pathway","sentence":"Exogenous C2-ceramide activates c-fos serum response element via Rac-dependent signalling pathway"}
{"PMID":9480923,"re_id":4,"annotated sentence":"In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the <e1>C2-ceramide<\\e1> induced <e2>SRE<\\e2> activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"C2-ceramide","object":"SRE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> activation selectively, implying a critical role of cPLA2 in CHEMICAL-induced signalling to nucleus","sentence":"In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus"}
{"PMID":9480923,"re_id":5,"annotated sentence":"Together, our findings suggest the critical role of 'Rac and subsequent activation of <e2>phospholipase A2<\\e2>  in <e1>ceramide<\\e1> signalling to nucleus.","re_type_id":"CPR:3","lable_positive":"None","re_type":"None","subject":"ceramide","object":"phospholipase A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Together, our findings suggest the critical role of 'Rac and subsequent activation of <e2>GENE-Y<\\e2>  in <e1>CHEMICAL<\\e1> signalling to nucleus.","sentence":"Together, our findings suggest the critical role of 'Rac and subsequent activation of phospholipase A2  in ceramide signalling to nucleus."}
{"PMID":9480923,"re_id":6,"annotated sentence":"Consistent with these results, the translocation of cPLA2 protein as well as the release of <e1>arachidonic acid<\\e1>  a principal product of <e2>phospholipase A2<\\e2>  was rapidly induced by the addition of C2-ceramide in a Rac-dependent manner","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"arachidonic acid","object":"phospholipase A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Consistent with these results, the translocation of cPLA2 protein as well as the release of <e1>CHEMICAL<\\e1>  a principal product of <e2>GENE-Y<\\e2>  was rapidly induced by the addition of C2-ceramide in a Rac-dependent manner","sentence":"Consistent with these results, the translocation of cPLA2 protein as well as the release of arachidonic acid  a principal product of phospholipase A2  was rapidly induced by the addition of C2-ceramide in a Rac-dependent manner"}
{"PMID":9633680,"re_id":0,"annotated sentence":"Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of <e2>AADC<\\e2> (carbidopa or <e1>benserazide<\\e1> , and inhibitors of COMT will also enter clinical use","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"benserazide","object":"AADC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Because gastric GENE-Y and COMT degrade levodopa, the drug is given with inhibitors of <e2>GENE-Y<\\e2> (carbidopa or <e1>CHEMICAL<\\e1> , and inhibitors of COMT will also enter clinical use","sentence":"Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or benserazide , and inhibitors of COMT will also enter clinical use"}
{"PMID":9633680,"re_id":1,"annotated sentence":"Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of <e2>AADC<\\e2> (<e1>carbidopa<\\e1> or benserazide), and inhibitors of COMT will also enter clinical use","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"carbidopa","object":"AADC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Because gastric GENE-Y and COMT degrade levodopa, the drug is given with inhibitors of <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1> or benserazide), and inhibitors of COMT will also enter clinical use","sentence":"Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use"}
{"PMID":9633680,"re_id":2,"annotated sentence":"<e1>Levodopa<\\e1> is absorbed in the small bowel and is rapidly catabolized by <e2>aromatic-L-amino-acid decarboxylase<\\e2> (AADC) and catechol-O-methyltransferase (COMT)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Levodopa","object":"aromatic-L-amino-acid decarboxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is absorbed in the small bowel and is rapidly catabolized by <e2>GENE-Y<\\e2> (AADC) and catechol-O-methyltransferase (COMT)","sentence":"Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT)"}
{"PMID":9633680,"re_id":3,"annotated sentence":"<e1>Levodopa<\\e1> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (<e2>AADC<\\e2>  and catechol-O-methyltransferase (COMT)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Levodopa","object":"AADC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (<e2>GENE-Y<\\e2>  and catechol-O-methyltransferase (COMT)","sentence":"Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC  and catechol-O-methyltransferase (COMT)"}
{"PMID":9633680,"re_id":4,"annotated sentence":"<e1>Levodopa<\\e1> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and <e2>catechol-O-methyltransferase<\\e2> (COMT)","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Levodopa","object":"catechol-O-methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and <e2>GENE-Y<\\e2> (COMT)","sentence":"Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT)"}
{"PMID":9633680,"re_id":5,"annotated sentence":"<e1>Levodopa<\\e1> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (<e2>COMT<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"Levodopa","object":"COMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (<e2>GENE-Y<\\e2> ","sentence":"Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT "}
{"PMID":9633680,"re_id":6,"annotated sentence":"Because gastric <e2>AADC<\\e2> and COMT degrade <e1>levodopa<\\e1>  the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"levodopa","object":"AADC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Because gastric <e2>GENE-Y<\\e2> and COMT degrade <e1>CHEMICAL<\\e1>  the drug is given with inhibitors of GENE-Y (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use","sentence":"Because gastric AADC and COMT degrade levodopa  the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use"}
{"PMID":9633680,"re_id":7,"annotated sentence":"Because gastric AADC and <e2>COMT<\\e2> degrade <e1>levodopa<\\e1>  the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"levodopa","object":"COMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Because gastric AADC and <e2>GENE-Y<\\e2> degrade <e1>CHEMICAL<\\e1>  the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of GENE-Y will also enter clinical use","sentence":"Because gastric AADC and COMT degrade levodopa  the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use"}
{"PMID":9666414,"re_id":0,"annotated sentence":"Two mechanisms of action have been identified for <e1>A77 1726<\\e1>  inhibition of <e2>dihydroorotate dehydrogenase<\\e2> (DHODH) and inhibition of tyrosine kinases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"A77 1726","object":"dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two mechanisms of action have been identified for <e1>CHEMICAL<\\e1>  inhibition of <e2>GENE-Y<\\e2> (DHODH) and inhibition of tyrosine kinases","sentence":"Two mechanisms of action have been identified for A77 1726  inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of tyrosine kinases"}
{"PMID":9666414,"re_id":1,"annotated sentence":"Two mechanisms of action have been identified for <e1>A77 1726<\\e1>  inhibition of dihydroorotate dehydrogenase (<e2>DHODH<\\e2>  and inhibition of tyrosine kinases","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"A77 1726","object":"DHODH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two mechanisms of action have been identified for <e1>CHEMICAL<\\e1>  inhibition of dihydroorotate dehydrogenase (<e2>GENE-Y<\\e2>  and inhibition of tyrosine kinases","sentence":"Two mechanisms of action have been identified for A77 1726  inhibition of dihydroorotate dehydrogenase (DHODH  and inhibition of tyrosine kinases"}
{"PMID":9666414,"re_id":2,"annotated sentence":"Two mechanisms of action have been identified for <e1>A77 1726<\\e1>  inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of <e2>tyrosine kinases<\\e2>  DHODH inhibition occurs at lower concentrations of A77 1726 than that of tyrosine kinases and is currently considered the major mode of action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"A77 1726","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Two mechanisms of action have been identified for <e1>CHEMICAL<\\e1>  inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of <e2>GENE-N<\\e2>  DHODH inhibition occurs at lower concentrations of CHEMICAL than that of GENE-N and is currently considered the major mode of action","sentence":"Two mechanisms of action have been identified for A77 1726  inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of tyrosine kinases  DHODH inhibition occurs at lower concentrations of A77 1726 than that of tyrosine kinases and is currently considered the major mode of action"}
{"PMID":9666414,"re_id":3,"annotated sentence":"<e2>DHODH<\\e2> inhibition occurs at lower concentrations of <e1>A77 1726<\\e1> than that of tyrosine kinases and is currently considered the major mode of action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"A77 1726","object":"DHODH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibition occurs at lower concentrations of <e1>CHEMICAL<\\e1> than that of tyrosine kinases and is currently considered the major mode of action","sentence":"DHODH inhibition occurs at lower concentrations of A77 1726 than that of tyrosine kinases and is currently considered the major mode of action"}
{"PMID":9666414,"re_id":4,"annotated sentence":"DHODH inhibition occurs at lower concentrations of <e1>A77 1726<\\e1> than that of <e2>tyrosine kinases<\\e2> and is currently considered the major mode of action","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"A77 1726","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"DHODH inhibition occurs at lower concentrations of <e1>CHEMICAL<\\e1> than that of <e2>GENE-N<\\e2> and is currently considered the major mode of action","sentence":"DHODH inhibition occurs at lower concentrations of A77 1726 than that of tyrosine kinases and is currently considered the major mode of action"}
{"PMID":9722550,"re_id":0,"annotated sentence":"The purified <e2>phosphodiester alpha-GlcNAcase<\\e2> has a specific activity of 498 micromol of <e1>[3H]GlcNAc-alpha-phosphomannose-alpha-methyl<\\e1> cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]GlcNAc-alpha-phosphomannose-alpha-methyl","object":"phosphodiester alpha-GlcNAcase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purified <e2>GENE-Y<\\e2> has a specific activity of 498 micromol of <e1>CHEMICAL<\\e1> cleaved per h per mg of protein using 0.5 mM CHEMICAL as substrate","sentence":"The purified phosphodiester alpha-GlcNAcase has a specific activity of 498 micromol of [3H]GlcNAc-alpha-phosphomannose-alpha-methyl cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate"}
{"PMID":9722550,"re_id":1,"annotated sentence":"The purified <e2>phosphodiester alpha-GlcNAcase<\\e2> has a specific activity of 498 micromol of [3H]GlcNAc-alpha-phosphomannose-alpha-methyl cleaved per h per mg of protein using 0.5 mM <e1>[3H]GlcNAc-alpha-phosphomannose-alpha-methyl<\\e1> as substrate","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"[3H]GlcNAc-alpha-phosphomannose-alpha-methyl","object":"phosphodiester alpha-GlcNAcase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purified <e2>GENE-Y<\\e2> has a specific activity of 498 micromol of CHEMICAL cleaved per h per mg of protein using 0.5 mM <e1>CHEMICAL<\\e1> as substrate","sentence":"The purified phosphodiester alpha-GlcNAcase has a specific activity of 498 micromol of [3H]GlcNAc-alpha-phosphomannose-alpha-methyl cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate"}
{"PMID":9722550,"re_id":2,"annotated sentence":"<e2>N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase<\\e2> (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the <e1>mannose 6-phosphate<\\e1> determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"mannose 6-phosphate","object":"N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the <e1>CHEMICAL<\\e1> determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome","sentence":"N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome"}
{"PMID":9722550,"re_id":3,"annotated sentence":"N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (<e2>EC 3.1.4.45<\\e2>  phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the <e1>mannose 6-phosphate<\\e1> determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"mannose 6-phosphate","object":"EC 3.1.4.45","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (<e2>GENE-Y<\\e2>  phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the <e1>CHEMICAL<\\e1> determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome","sentence":"N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45  phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome"}
{"PMID":9722550,"re_id":4,"annotated sentence":"N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45; <e2>phosphodiester alpha-GlcNAcase<\\e2>  catalyzes the second step in the synthesis of the <e1>mannose 6-phosphate<\\e1> determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"mannose 6-phosphate","object":"phosphodiester alpha-GlcNAcase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45; <e2>GENE-Y<\\e2>  catalyzes the second step in the synthesis of the <e1>CHEMICAL<\\e1> determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome","sentence":"N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45; phosphodiester alpha-GlcNAcase  catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome"}
{"PMID":9732824,"re_id":0,"annotated sentence":"Both the <e2>5 alpha-reductase<\\e2> inhibitor <e1>finasteride<\\e1> and alpha 1-adrenoceptor antagonists (e.g","re_type_id":"CPR:4","lable_positive":"None","re_type":"None","subject":"finasteride","object":"5 alpha-reductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> and alpha 1-adrenoceptor antagonists (e.g","sentence":"Both the 5 alpha-reductase inhibitor finasteride and alpha 1-adrenoceptor antagonists (e.g"}
{"PMID":9732824,"re_id":1,"annotated sentence":"none","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"alfuzosin","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":9732824,"re_id":2,"annotated sentence":"none","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"doxazosin","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":9732824,"re_id":3,"annotated sentence":"none","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"prazosin","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":9732824,"re_id":4,"annotated sentence":"none","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"tamsulosin","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":9732824,"re_id":5,"annotated sentence":"none","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"terazosin","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":9928259,"re_id":0,"annotated sentence":"In another experiment, <e1>cyanopindolol<\\e1>  an antagonist of the <e2>serotonin terminal autoreceptor<\\e2>  also prolonged the clearance of 5-HT from the CA3 region","re_type_id":"CPR:6","lable_positive":"None","re_type":"None","subject":"cyanopindolol","object":"serotonin terminal autoreceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In another experiment, <e1>CHEMICAL<\\e1>  an antagonist of the <e2>GENE-N<\\e2>  also prolonged the clearance of 5-HT from the CA3 region","sentence":"In another experiment, cyanopindolol  an antagonist of the serotonin terminal autoreceptor  also prolonged the clearance of 5-HT from the CA3 region"}
{"PMID":9928259,"re_id":1,"annotated sentence":"From these data, it is inferred that both the <e2>SERT<\\e2> and NET contribute to the active clearance of exogenously applied <e1>5-HT<\\e1> in the dentate gyrus","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-HT","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"From these data, it is inferred that both the <e2>GENE-Y<\\e2> and NET contribute to the active clearance of exogenously applied <e1>CHEMICAL<\\e1> in the dentate gyrus","sentence":"From these data, it is inferred that both the SERT and NET contribute to the active clearance of exogenously applied 5-HT in the dentate gyrus"}
{"PMID":9928259,"re_id":2,"annotated sentence":"From these data, it is inferred that both the SERT and <e2>NET<\\e2> contribute to the active clearance of exogenously applied <e1>5-HT<\\e1> in the dentate gyrus","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-HT","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"From these data, it is inferred that both the SERT and <e2>GENE-Y<\\e2> contribute to the active clearance of exogenously applied <e1>CHEMICAL<\\e1> in the dentate gyrus","sentence":"From these data, it is inferred that both the SERT and NET contribute to the active clearance of exogenously applied 5-HT in the dentate gyrus"}
{"PMID":9928259,"re_id":3,"annotated sentence":"These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of <e1>5-HT<\\e1> uptake through an effect on the <e2>serotonin transporter<\\e2> ","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-HT","object":"serotonin transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of <e1>CHEMICAL<\\e1> uptake through an effect on the <e2>GENE-Y<\\e2> ","sentence":"These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of 5-HT uptake through an effect on the serotonin transporter "}
{"PMID":9928259,"re_id":4,"annotated sentence":"These and other data have generated a working hypothesis that activation of the terminal <e2>serotonin autoreceptor<\\e2> enhances the kinetics of <e1>5-HT<\\e1> uptake through an effect on the serotonin transporter.","re_type_id":"CPR:9","lable_positive":"None","re_type":"None","subject":"5-HT","object":"serotonin autoreceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These and other data have generated a working hypothesis that activation of the terminal <e2>GENE-N<\\e2> enhances the kinetics of <e1>CHEMICAL<\\e1> uptake through an effect on the serotonin transporter.","sentence":"These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of 5-HT uptake through an effect on the serotonin transporter."}